



# DRUGS OF CHOICE 1960-1961

---

**Walter Modell, M D , Editor**

*Director, Clinical Pharmacology, and Associate Professor of  
Pharmacology, Cornell University Medical College, Attending  
Physician, New York Veterans Administration Hospital, Associate  
Visiting Physician Bellevue Hospital Member, Poison Control  
Advisory Board of New York City, Member, Revision Committee,  
United States Pharmacopoeia XVI, Editor, Clinical  
Pharmacology and Therapeutics*

---

**The C. V. Mosby Company**  
*St Louis 1960*

1960 1961 EDITION  
COPYRIGHT © 1960 BY  
THE C V MOSBY COMPANY

*All rights reserved*

*1958 1959 edition copyrighted 1958*

*Printed in the United States of America*

*Library of Congress Catalog Card Number 58 6889*

*Distributed in Great Britain by Henry Kimpton, London*

# CONTRIBUTORS

**THOMAS P ALMY MD**

*Professor of Medicine Cornell University Medical College Director of Second  
(Cornell) Medical Division Bellevue Hospital New York N Y*

**JOSEPH F ARTUSIO Jr MD**

*Professor of Anesthesiology in Surgery and Professor of Anesthesiology in Obstetrics  
and Gynecology Cornell University Medical College Anesthesiologist in Chief  
New York Hospital New York N Y*

**ALVAN L BARACH MD**

*Clinical Professor of Medicine College of Physicians and Surgeons Columbia  
University Associate Attending Physician Presbyterian Hospital New York N Y*

**DAVID PRESWICK BARR MD LL.D Sc.D**

*Professor (Emeritus) of Medicine Cornell University Medical College Consulting  
Physician to the New York Hospital New York N Y*

**WILLIAM B BEAN MD**

*Professor and Head of the Department of Internal Medicine College of Medicine State  
University of Iowa Physician in Chief University Hospitals Iowa City Senior Medical  
Consultant Veterans Administration Hospitals Iowa City and Des Moines Iowa*

**HYLAN A BICKERMAN MD**

*Associate Clinical Professor of Medicine College of Physicians and Surgeons Columbia  
University Visiting Physician Columbia University Research Division Goldwater  
Memorial Hospital New York N Y*

**JOHN J BONICA MD**

*Director of the Department of Anesthesiology and Pain Clinic Tacoma General  
Hospital and Pierce County Hospital Clinical Associate in Anatomy and Consultant  
to the Department of Anesthesiology University of Washington School of Medicine  
Senior Consultant in Anesthesiology Madigan Army Hospital and American Lake  
Veterans Administration Hospital Tacoma Wash*

**KEEN CATTELL Ph.D MD**

*Professor (Emeritus) of Pharmacology Cornell University Medical College  
New York N Y*

**CHOWDHURY MB DPhil**

*School of Tropical Medicine Calcutta India*



**LEIGHTON E CLUFF MD**

*Associate Professor of Medicine and Head Division of Infectious Disease and Allergy  
Department of Medicine The Johns Hopkins University School of Medicine  
Physician The Johns Hopkins Hospital Baltimore Md*

**WILLIAM DAMESHEK, MD**

*Professor of Medicine Tufts University School of Medicine Senior Physician and  
Chief of Hematology New England Center Hospital Editor in Chief Blood The  
Journal of Hematology Boston Mass*

**M EDWARD DAVIS MD**

*Joseph Bolivar DeLee Professor and Chairman of the Department of Obstetrics and  
Gynecology University of Chicago Chief Chicago Lying in Hospital Chicago Ill*

**ALAN K DONE MD**

*Assistant Professor of Pediatrics Stanford University School of Medicine  
Stanford Calif*

**FRDERICK R FRANK MD DSc (Med)**

*Assistant Professor of Medicine School of Medicine University of Pittsburgh  
Pittsburgh Pa*

**DALE G FRIEND MD**

*Assistant Professor of Medicine Harvard Medical School Clinical Pharmacologist  
Peter Bent Brigham Hospital Boston Mass*

**NICHOLAS W FUGO PhD, MD**

*Associate Professor of Obstetrics and Gynecology University of Chicago and Chicago  
Lying in Hospital Chicago Ill*

**JAMES T HAMLIN III, MD**

*Research Fellow in Medicine Harvard Medical School and Assistant in Medicine,  
Peter Bent Brigham Hospital Boston Mass*

**ROBERT G HEATH MD**

*Professor and Chairman of the Department of Psychiatry and Neurology Tulane  
University School of Medicine Senior Visiting Physician Charity Hospital of  
Louisiana New Orleans La*

**CHARLES H HEIDER MD**

*Department of Internal Medicine Hahnemann Medical College and Hospital of  
Philadelphia Philadelphia Pa*

**PAUL H HOCH MD**

*Commissioner of Mental Hygiene State of New York Professor of Clinical  
Psychiatry College of Physicians and Surgeons Columbia University New York N Y*

**ALBERT H HOLLAND Jr MD**

*Formerly Medical Director Food and Drug Administration Washington D C*

**SIBLEY W HOOBLER MD**

*Professor of Internal Medicine University of Michigan Medical School  
Director of the Hypertension Unit University of Michigan Hospital Ann Arbor Mich*

# CONTRIBUTORS

DAVID A KARNOFSKY, MD

Member Sloan Kettering Institute Associate Professor of Medicine Cornell University Medical College Attending Physician Chemotherapy Service D Medicine Memorial and James Ewing Hospitals New York N Y

B H KEAN MD

Associate Professor of Clinical Medicine (Tropical Medicine) Cornell University Medical College New York N Y

CHESTER S KEEFER MD

Professor of Medicine Boston University School of Medicine Physician in Chief Massachusetts Memorial Hospitals Boston Mass

HERBERT S KUPPERMAN Ph.D MD

Associate Professor of Medicine New York University Bellevue Medical Center New York N Y

LOUIS LASAGNA MD

Associate Professor of Medicine and Associate Professor of Pharmacology and Experimental Therapeutics Johns Hopkins University School of Medicine Baltimore Md

DONALD D LATHROP MD

Assistant in Psychiatry Department of Psychiatry and Neurology Louisiana State University School of Medicine New Orleans La

IRVING H LEOPOLD MD

Professor and Chairman Department of Ophthalmology The Graduate School of Medicine University of Pennsylvania Director of Research and Attending Surgeon Wills Eye Hospital Philadelphia Pa

ROBERT LICH Jr MD MS (Path)

Professor and Chairman of the Section on Urology Department of Surgery University of Louisville School of Medicine Louisville Ky

T A LOOMIS Ph.D MD

Professor of Pharmacology School of Medicine University of Washington Seattle Wash

WILLIAM McFARLAND MD

Commander U S Navy Head Department of Clinical Hematology National Naval Medical Center Bethesda Md

PAUL L McLAIN MD

Professor of Physiology and Pharmacology School of Medicine University of Pittsburgh Pittsburgh Pa

LOYD C MILLER Ph.D

Director of Revision Pharmacopoeia of the United States New York N Y

WIS C. MILLS MD

Associate Professor of Medicine Hahnemann Medical College and Hospital of Philadelphia Philadelphia Pa

**WALTER MODELL, M D**

*Associate Professor of Pharmacology, Cornell University Medical College, Attending Physician New York Veterans Administration Hospital, Associate Visiting Physician, Bellevue Hospital, Member, Poison Control Advisory Board of New York City, Member, Revision Committee, United States Pharmacopeia XVI, Editor, Clinical Pharmacology and Therapeutics, New York, N Y*

**JOHN H. MOYER M D**

*Professor of Medicine and Chairman of the Department of Internal Medicine, Hahnemann Medical College and Hospital, Philadelphia, Pa*

**PHILIP B PRICE, M D**

*Dean University of Utah College of Medicine, Salt Lake City, Utah*

**TRACY JACKSON PUTNAM, M D**

*Formerly Professor of Neurology, Harvard Medical School, Chief of the Department of Neurosurgery, Cedars of Lebanon Hospital, Los Angeles, Calif*

**GEORGE G RFADER, M D**

*Professor of Medicine, Cornell University Medical College, New York, N Y*

**WILLIAM H SAUNDERS, M D**

*Associate Professor of Otolaryngology, University Hospital, Ohio State University, Columbus Ohio*

**EDWARD B SCHLESINGER, M D**

*Attending Neurological Surgeon, Columbia Presbyterian Medical Center, Assistant Professor of Clinical Neurological Surgery, College of Physicians and Surgeons, Columbia University New York, N Y*

**PAUL K SMITH Ph D**

*Professor of Pharmacology and Executive Officer, School of Medicine, The George Washington University Consultant in Therapeutics, District of Columbia General Hospital and The George Washington University Hospital Member, Tri-Service Motion Sickness Committee, Washington, D C*

**HERMAN STEINBERG, M D.**

*Instructor in Medicine, Cornell University Medical College, New York, N Y*

**MARION B SULZBERGER, M D**

*Associate Professor of Medicine, New York College of Podiatric Medicine, New York College of Podiatric Medicine, New York, N Y*

**JOHN H TALBOTT, M D**

*Associate Professor of Medicine, Hahnemann Medical College and Hospital, Philadelphia, Pa*

**WILLIAM L WILSON, M D**

*Assistant Professor of Medicine Hahnemann Medical College and Hospital of Philadelphia, Philadelphia, Pa*

HOW I CAN MAKE A PATIENT VOMIT, and how  
I can purge or sweat him, are matters which  
a druggist's shopboy can tell me offhand  
When, however, I must use one sort of medicine  
in preference to another, requires an  
informant of a different kind—a man  
*who has no little practice in the arena of*  
his profession

—SYDENHAM (1624-1689)



## PREFACE TO 1960-1961 EDITION

The warm reception given *Drugs of Choice*, 1958-1959 proved that members of the medical profession recognize the present urgent need for authoritative and unbiased information on the choice of a particular drug for a particular clinical situation. This was gratifying to the thirty-seven contributors who gave their time to make an up-to-date book of this type possible. A well-timed revision is, however, essential if the book is to remain useful by being sufficiently up to date.

After thoughtful consideration, a two-year interval was selected for the revision period. A shorter period would be too brief for substantial experience with the drugs introduced in the interval and there would be too few new drugs to merit a new edition, whereas a longer period would allow the current edition to become badly dated long before a new one was available.

In the present book there are eight new chapters. The Physical and Chemical Considerations in the Choice of Drugs, The Choice of a Local Antiseptic, The Choice of Drugs for Viral, Spirochetal, and Rickettsial Infections, The Choice of an Anorexiant, The Choice of Drugs in General Medical Practice, The Choice of Sedatives and Tranquilizers in General Medical Practice, The Choice of an Antidote, and The Choice of Drugs for Otolaryngologic Disorders.

In order to provide fresh insights and a forum for different points of view, it was originally planned to change the authorship of a few chapters, especially those on controversial issues, in each edition, consequently, three chapters in this edition are written by new authors. Thirteen new names will be found in the list of eminent contributors, the total now stands at forty-seven.

In this edition, a single alphabetically arranged all-inclusive Drug Index is used in preference to the separate specialized lists of drugs which followed the individual chapters in the original book. Drugs not mentioned or evaluated in the text are likely to be found in the Drug Index, but they will not appear in the general subject index, which includes page references for only those drugs described in the text.

Failure to discuss a new drug in the text may be interpreted to mean that the drug was introduced too recently to provide experience for a substantial opinion. Failure to discuss an older drug may be interpreted to mean that it is not a drug of choice and, in the author's opinion is not of sufficient importance to merit discussion.

WALTER MOELLER, M.D.



## PREFACE TO 1958-1959 EDITION

---

This book is a practical guide to the selection of the best drug for a particular therapeutic problem. Due to the extremely fertile mating of the synthetic chemist and the pharmaceutical manufacturer, drugs appear on the market almost too quickly to learn the names to say nothing of distinguishing which are the same drugs with different proprietary names. It is a Herculean job to learn enough about them to evaluate their relative therapeutic merits. Yet the choice of a drug will determine whether the patient will receive the most judicious therapy.

There are real advantages in choosing the best drug for the clinical problem at the outset of treatment. For the seriously ill patient, time may be precious, and, if the first choice is the best drug for the situation, that irretrievable commodity is not wasted. Something short of the best may provide incomplete relief, no relief at all, untoward effects, or disaster. The patient is likely to assume, and perhaps he also has the right to expect, that his physician will provide the optimum drug for his condition the first time he writes a prescription. It is understandable that, having endured a period of unsatisfactory treatment, the patient may be reluctant to continue with an obviously trial and error process. For his part, it is not feasible for the physician to plead that there is no other way of determining the best drug.

A bad initial impression of a drug often leads to enduring and unshakable prejudice and causes the physician to avoid using it in situations in which it is eminently useful and safe. Nothing is more likely to lead to a bad first impression than ignorance of uses, limitations, and dangers, and, conversely, nothing is more likely to lead to appropriate first impressions of new drugs than the knowledge which enables the physician to select the best drug for the therapeutic target, that is to say, the *drug of choice*. Yet there is almost nowhere for the physician to turn for the kind of help he needs, certainly no place where unbiased, authoritative, and definitive information bearing on this problem is brought together and made easily available. This volume is designed to satisfy this need by bringing together knowledge which is presently spread through the various specialties and, if published at all, published separately.

It is a volume of expert *opinion* designed to provide the American physician with a comprehensive source of clear, concise, authoritative, and practical answers to the continually recurring question of which drug in a rapidly changing scene is, at the critical moment, the drug of choice for an actual therapeutic problem. Many experts and educators in medicine have participated in the preparation of this book.



Each was requested to express his own *opinion* of the drugs in current use in his field, based on his specialized knowledge and experience. Controversy was avoided because, to be fairly explored, controversy *must be considered in great detail*. Such discussions in the usual format of the review article often leave the reader still seeking the clear and definitive answer. This we wish to avoid. Although the existence of controversy may be indicated, the issues will not be argued here since such argument would defeat our purpose.

Each day the drug manufacturer bombards his target through the mails with a barrage of attractive and eminently readable but far from disinterested literature which he regularly follows up with the attack direct by his detail man. Here, the physician has his troubles, for although he may know that the drug house is perhaps the least likely source of disinterested opinion on the choice of drugs, it is understandably difficult for him, without authoritative support, to stand firm against this well organized campaign.

The physician who reads the literature will find that the early reports on new drugs tend to be sanguine, the possibilities for utility emphasized, and the limitations minimized, for otherwise there would seem to be no reason to write about or to introduce a new drug. Too often, the first hopes are not borne out by later experience and, at best, require considerable revision and modification. Most drugs need time and experience for final evaluation, it is the very rare exception to this rule which, like penicillin, from the very beginning can be established as both eminently useful and safe.

Most chapters are divided into several major sections, each section contains a concise discussion of clinical conditions in which the drugs under consideration are used, a consideration of the several drugs, and the nature of the available data which make one or another the more desirable. Each section also contains a view of what the future holds and what is lacking in drug therapy in the particular area. Each section has a list of selected references which provided the data on which the opinions expressed are based.

Many drugs have more than one action and more than one sphere of clinical application. In each of these the same drug may be relatively more or less effective, more or less dangerous, more or less important. Since relative utility may vary with the clinical application, the same drug may be discussed in several sections of the book. While this also reduces cross reference to an endurable minimum, at the same time it provides a satisfactory compromise between repetition and convenience. Drug mixtures are not often considered, not only because their number, with variations on the same theme, is so great as to be overwhelming, but also because their unique virtues are elusive difficult to evaluate. There are very few mixtures indeed whose effects cannot be duplicated by the separate use of the constituents where a special function is performed by a mixture, it is here considered. Biologicals are not considered since they do not fall within the scope of this book.

Finally following each chapter there is an extensive but not necessarily complete alphabetically arranged Drug Index of the drugs commonly used for the disturbances under consideration, including a capsule account of the drug, the

dosage forms in which it is available, and, as far as practical, their proprietary names and fabricators

The Drug Indexes have been compiled by the editorial staff, therefore, the Drug Index *will not help the reader make his choice*. Recommendations of authors are to be found only in the text itself. The Drug Index is an up-to-date and representative list of drugs in common use, limited in size by practical considerations. Many obsolete and obviously irrational medicaments have been excluded, but many drugs with limited utility are included simply because they are still being used. When the number of proprietary names for a single drug was so large as to make their complete listing a stupendous as well as an entirely unrewarding undertaking, many of the proprietary names were omitted. Even so, the Drug Index for some chapters may seem overwhelmingly long. Where this is so, it is merely a reflection of the situation which confronts the practicing physician every time he is faced with the problem of choosing a drug in that area.

There are instances in which the drugs listed in the Drug Index are not mentioned in the text. It should be assumed that the use of these drugs is not recommended, that they are either of insufficient merit to warrant space and effort required for a statement, or, as in the case of new and untried drugs, that at the time of the writing there were insufficient clinical data available for a definite opinion on their utility.

There is no indication that the present birth rate of new drugs will diminish, no likelihood that a moratorium will be called. Complicating matters still further is the fact that many new drugs are still being explored for yet more suggestive actions and, as in the case of the phenothiazine compounds which were recently introduced only for their antihistamine action, new therapeutic uses are being continually proposed. It is to be expected, therefore, that the appearance of drugs and reports yet to come regarding accumulating experience with those already introduced will provide ample material for revision on a regular basis.

The editor of any collaborative book, for the most part, exploits the authority, the knowledge, and the talents of others. His only justification is the purpose and the value of the end product. I would therefore, like to thank the eminent collaborators of *Drugs of Choice*. None of them had the time to spare, they found the time because they agreed with me that such a book was needed. I am grateful to Dr. Margaret Garrett for her assistance in proofreading.

I wish to thank Dr. David P. Barr for his encouragement when my part in the undertaking seemed beyond me. I also wish to express my gratitude to the late Frank A. Volk, of The C. V. Mosby Company, whose enthusiasm for the project was both gratifying and helpful. I owe the Sydenham statement which opens the book to the kindness of Dr. William B. Bean.

WALTER MODELL, M.D.

New York



# CONTENTS

---

<i>Chapter 1</i>	
PRINCIPLES OF THE CHOICE OF DRUGS ( <i>Walter Modell M D</i> )	23
<i>Chapter 2</i>	
THE PHYSICAL AND CHEMICAL CONSIDERATIONS IN THE CHOICE OF DRUGS ( <i>Lloyd C Miller Ph D and Albert H Holland Jr M D</i> )	40
<i>Chapter 3</i>	
THE CHOICE OF DRUGS FOR CHILDREN ( <i>Alan A Done M D</i> )	47
<i>Chapter 4</i>	
THE CHOICE OF AGENTS TO ADJUST AND MAINTAIN INTERNAL HOMEOSTASIS ( <i>Poul L McLean M D and Frederick R Franke M D D Sc [Med]</i> )	54
<i>Chapter 5</i>	
THE CHOICE OF A DIURETIC ( <i>Walter Modell M D</i> )	85
<i>Chapter 6</i>	
THE CHOICE OF DRUGS FOR NUTRITIONAL DISORDERS ( <i>William B Bean M D</i> )	106
<i>Chapter 7</i>	
THE CHOICE OF A LOCAL ANTISEPTIC ( <i>Philip B Price M D</i> )	129
<i>Chapter 8</i>	
THE CHOICE OF AN ANTIBACTERIAL AGENT ( <i>Chester S Keefer M D</i> )	141
<i>Chapter 9</i>	
THE CHOICE OF DRUGS FOR VIRAL SPIROCHETAL AND RICKETTSIAL INFECTIONS ( <i>Leghion F Cluff M D</i> )	164
<i>Chapter 10</i>	
THE CHOICE OF DRUGS FOR STIMULATION OF MENTAL AND PHYSICAL ACTIVITY ( <i>Robert G Heath M D and Donald D Lathrop M D</i> )	178
<i>Chapter 11</i>	
THE CHOICE OF A STIMULANT TO VITAL MEDULLARY CENTERS ( <i>McKeen Cattell Ph D M D</i> )	192

## Chapter 12

- THE CHOICE OF DRUGS FOR THE RELIEF OF PAIN (*John J. Bonica M.D.*) 196

## Chapter 13

- THE CHOICE OF AN ANESTHETIC (*Joseph F. Artusio Jr. M.D.*) 244

## Chapter 14

- THE CHOICE OF SEDATIVES AND TRANQUILIZERS IN GENERAL MEDICAL PRACTICE (*Dale G. Friend M.D. and James T. Hamlin III M.D.*) 267

## Chapter 15

- THE CHOICE OF SEDATIVES AND TRANQUILIZERS FOR PSYCHIATRIC DISORDERS (*Paul H. Hoch M.D.*) 273

## Chapter 16

- THE CHOICE OF A HYPNOTIC (*Louis Lasagna M.D.*) 287

## Chapter 17

- THE CHOICE OF AN ANTICONVULSANT (*Tracy Jackson Putnam M.D.*) 293

## Chapter 18

- THE CHOICE OF A SKELETAL MUSCLE RELAXANT (*Edward B. Schlesinger M.D.*) 306

## Chapter 19

- THE CHOICE OF AN AGENT FOR DISTURBANCES IN EQUILIBRIUM (*Paul A. Smith Ph.D.*) 311

## Chapter 20

- THE CHOICE OF AN ANTIEMETIC AGENT (*John H. Moyer M.D. and William L. Wilson M.D.*) 324

## Chapter 21

- THE CHOICE OF AN ANOREXIANT (*Walter Modell M.D. and George G. Reader M.D.*) 341

## Chapter 22

- THE CHOICE OF DRUGS FOR GASTROINTESTINAL DISTURBANCES (*Thomas P. Almy M.D. and Herman Steinberg M.D.*) 352

## Chapter 23

- THE CHOICE OF DRUGS FOR INTESTINAL PARASITISM (*B. H. Kean M.D. and A. B. Chowdhury M.D. D.Phil.*) 379

## Chapter 24

- THE CHOICE OF DRUGS FOR DISEASES OF THE HEART (*Walter Modell M.D.*) 392

## Chapter 25

- THE CHOICE OF DRUGS IN THE TREATMENT OF HYPERTENSION  
(Sibley W. Hoobler M.D.) 437

## Chapter 26

- THE CHOICE OF VASOCONSTRICTOR DRUGS FOR HYPOTENSION  
AND SHOCK (John H. Moyer M.D. and Leatt C. Mills M.D.) 458

## Chapter 27

- THE CHOICE OF VASODILATOR DRUGS FOR THE TREATMENT OF  
PERIPHERAL VASCULAR DISTURBANCES (John H. Moyer M.D. and  
Charles H. Heider M.D.) 481

## Chapter 28

- THE CHOICE OF ANTITUSSIVE AGENTS (Hylan A. Bickerman M.D.) 493

## Chapter 29

- THE CHOICE OF ANTIALLERGIC AGENTS (Hylan A. Bickerman M.D.  
and Allan L. Barach M.D.) 516

## Chapter 30

- THE CHOICE OF DRUGS IN CERTAIN DISORDERS OF METABOLISM  
(George G. Reader M.D.) 541

## Chapter 31

- THE CHOICE OF DRUGS IN ENDOCRINE DYSFUNCTION (Herbert S.  
Kupperman M.D.) 553

## Chapter 32

- THE CHOICE OF AN ANTIARTHRITIC AGENT (John H. Talbott M.D.) 589

## Chapter 33

- THE CHOICE OF DRUGS FOR CANCER AND ALLIED DISEASES (David  
A. Kornofsky M.D.) 604

## Chapter 34

- THE CHOICE OF DRUGS FOR HEMATOLOGIC DISORDERS (William  
McFarland M.D. and William Dameshek M.D.) 629

## Chapter 35

- THE CHOICE OF DRUGS AFFECTING THE COAGULATION OF BLOOD  
(T. A. Loomis Ph.D. M.D.) 649

## Chapter 36

- THE CHOICE OF DRUGS IN OBSTETRICS AND GYNECOLOGY (M.  
Edward Davis M.D. and Nicholas W. Fugo Ph.D. M.D.) 662

## Chapter 37

- THE CHOICE OF DRUGS FOR UROLOGIC DISORDERS (Robert Lach  
Jr. M.D., M.S. [Path.]) 689

## Chapter 12

- THE CHOICE OF DRUGS FOR THE RELIEF OF PAIN (*John J Bonica M D*) 196

## Chapter 13

- THE CHOICE OF AN ANESTHETIC (*Joseph F Artusio Jr M D*) 244

## Chapter 14

- THE CHOICE OF SEDATIVES AND TRANQUILIZERS IN GENERAL MEDICAL PRACTICE (*Dale G Friend M D and James T Hanlin III M D*) 262 •

## Chapter 15

- THE CHOICE OF SEDATIVES AND TRANQUILIZERS FOR PSYCHIATRIC DISORDERS (*Paul H Hoch M D*) 273 •

## Chapter 16

- THE CHOICE OF A HYPNOTIC (*Louis Lasagna M D*) 287

## Chapter 17

- THE CHOICE OF AN ANTICONVULSANT (*Tracy Jackson Putnam M D*) 293

## Chapter 18

- THE CHOICE OF A SKELETAL MUSCLE RELAXANT (*Edward B Schlesinger M D*) 306

## Chapter 19

- THE CHOICE OF AN AGENT FOR DISTURBANCES IN EQUILIBRIUM (*Paul K Smith Ph D*) 311

## Chapter 20

- THE CHOICE OF AN ANTIEMETIC AGENT (*John H Moyer M D and William L Wilson M D*) 324 •

## Chapter 21

- THE CHOICE OF AN ANOREXIANT (*Walter Modell M D and George C Reader M D*) 341

## Chapter 22

- THE CHOICE OF DRUGS FOR GASTROINTESTINAL DISTURBANCES (*Thomas P Almy M D and Herman Steinberg M D*) 352

## Chapter 23

- THE CHOICE OF DRUGS FOR INTESTINAL PARASITISM (*B H Kean M D and A B Chowdhury M D D Phil*) 379

## Chapter 24

- THE CHOICE OF DRUGS FOR DISEASES OF THE HEART (*Walter Modell M D*) 392 /

## Chapter 25

- THE CHOICE OF DRUGS IN THE TREATMENT OF HYPERTENSION  
(Sibley W. Hoobler M.D.) 437

## Chapter 26

- THE CHOICE OF VASOCONSTRICTOR DRUGS FOR HYPOTENSION  
AND SHOCK (John H. Moyer M.D. and Lewis C. Mills M.D.) 458

## Chapter 27

- THE CHOICE OF VASODILATOR DRUGS FOR THE TREATMENT OF  
PERIPHERAL VASCULAR DISTURBANCES (John H. Moyer M.D. and  
Charles H. Heider M.D.) 481

## Chapter 28

- THE CHOICE OF ANTITUSSIVE AGENTS (Hylan A. Eckerman M.D.) 493

## Chapter 29

- THE CHOICE OF ANTIALLERGIC AGENTS (Hylan A. Eckerman M.D.  
and Alvan L. Barach M.D.) 516

## Chapter 30

- THE CHOICE OF DRUGS IN CERTAIN DISORDERS OF METABOLISM  
(George G. Reader M.D.) 541

## Chapter 31

- THE CHOICE OF DRUGS IN ENDOCRINE DYSFUNCTION (Herbert S.  
Kupferman M.D.) 555

## Chapter 32

- THE CHOICE OF AN ANTIARTHRITIC AGENT (John H. Talbott M.D.) 589

## Chapter 33

- THE CHOICE OF DRUGS FOR CANCER AND ALLIED DISEASES (David  
A. Karnofsky M.D.) 604

## Chapter 34

- THE CHOICE OF DRUGS FOR HEMATOLOGIC DISORDERS (William  
McFarland M.D. and William Dameshek M.D.) 629

## Chapter 35

- THE CHOICE OF DRUGS AFFECTING THE COAGULATION OF BLOOD  
(T. A. Loomis Ph.D. M.D.) 649

## Chapter 36

- THE CHOICE OF DRUGS IN OBSTETRICS AND GYNECOLOGY (M.  
Eduard Davis M.D. and Nicholas W. Fugo Ph.D. M.D.) 662

## Chapter 37

- THE CHOICE OF DRUGS FOR UROLOGIC DISORDERS (Robert Lach  
Jr. M.D. M.S. {Path.}) 689



*Chapter 38*

THE CHOICE OF DRUGS FOR OPHTHALMIC USE (*Irving H Leopold MD*) 699

*Chapter 39*

THE CHOICE OF DRUGS FOR OTOLARYNGOLOGIC DISORDERS (*William H Saunders MD*) 716

*Chapter 40*

THE CHOICE OF DERMATOLOGIC DRUGS (*Marion B Sulzberger MD*) 726

*Chapter 41*

THE CHOICE OF DRUGS FOR THE TREATMENT OF POISONING (*Alan K Done MD*) 774

*Chapter 42*

THE CHOICE OF A DIAGNOSTIC AGENT (*David Preswick Barr MD LL.D Sc.D Walter Modell MD Sibley B Hoobler MD Thomas P Almy MD and Herman Steinberg MD M Eduard Davis MD and Nicholas W Fugo Ph.D MD Robert Lich Jr MD MS [Path] Irving H Leopold MD*) 795

*Drug Index*

813

DRUGS OF

CHOICE 1960-1961



## PRINCIPLES OF THE CHOICE OF DRUGS

*Walter Modell, M D*

---

### INTRODUCTION

To judge whether a drug is useful in a specific clinical setting or, where there is more than one drug available to decide which is preferable requires two kinds of pharmacologic information (1) data obtained through studies in the laboratory and (2) data developed through studies in man

### ESSENTIAL PHARMACOLOGIC INFORMATION

In the choice of a drug the laboratory investigations which supply information and the proper interpretation of the data they provide are basic because knowledge about the actions of a drug, its potency, and its toxic effects gives the initial clue to its therapeutic potential and its safe use. Most of the important drugs in modern use have come by way of the laboratory, for example, penicillin, only a few old ones like digitalis, which came into medicine by way of an accident or the herb doctor, survive.

#### Bearing of Experimental Data on Clinical Utility of Drugs

This is an appropriate place to make clear that there is no conflict between the data of the laboratory and the clinic. If properly selected, laboratory findings are more often directly applicable to the clinical situation than many clinicians admit. That a disparity should sometimes seem to exist generally arises through neglect of pertinent laboratory data or through their improper interpretation.

Chemists and drug manufacturers have an understandable tendency to make assumptions of drug utility where there is only superficial evidence that clinical requisites are satisfied. The newspapers too, especially the Sunday supplements, have a special passion for disclosing undigested information on drugs which have a suggestive design of pharmacologic action and for presenting them forthwith as having unquestioned clinical utility.

Such publicity frequently is followed by public pressure on the medical profession to make premature use of poorly tested drugs. More often than otherwise, trial of these drugs in man fails dismally to fulfill the unwarranted predictions made

for them or even remotely to satisfy the need for which they appeared to be suited. Too often, such failures are interpreted as evidence of lack of compatibility between laboratory data and clinical application and as implying that the former are of limited utility in the evaluation of drugs for man.

It is of the utmost importance to realize that it is the initial observation of the pharmacologic properties of new drugs in the laboratory animal which gives the clue to utility as well as makes possible their safe exploration in man. Thus the animal, the experiment, and, in fact, the pharmacology laboratory are basic to progress in therapeutics.

The pharmacologic properties of drugs as seen in the animal are likely to apply to man when laboratory experiments are carefully analyzed and applied only to those clinical situations which really correspond. Although species differences are sometimes very striking, it is often possible to avoid this disparity by the choice of the appropriate laboratory animal. When appropriate associations are regularly made *there will be far less time and effort lost in the futile trial of drugs which do not apply to the conditions for which they are tested.* The well designed laboratory investigation should provide precise information essential for determining the applicability of a drug to clinical problems, the physiologic functions altered by the drug, the nature of toxic reactions, and the likelihood of species differences in relation to drug tolerance as well as pharmacodynamic action.

The nature and extent of the physiologic dysfunction in man to be rectified by therapy must be borne in mind and compared with that in the experimental animal in which the drug was tested, or a mismatch will inevitably result. Notable examples of such mismatches can be cited. Respiratory stimulation can be induced in the cat with several drugs, but it may not be automatically assumed that these drugs will stimulate clinical depression of respiration. In fact, respiratory stimulants in clinical use do not produce the same striking stimulation of the depressed respiratory center seen in the laboratory animal. That clinical depression of respiration continues despite decreased oxygen and increased carbon dioxide content of the blood, both excellent stimulants of the reactive center, is strong evidence that the respiratory center is not only depressed but also resistive to stimulation. The reason why the respiratory analeptics now in use are disappointing is not that the respiratory center of the normal cat is different from that of man, but that the respiratory center examined in the laboratory is different from that in the clinical situation (see Chapter 11).

The pharmacologic actions of drugs can usually be trimmed down to very simple and precise terms since fundamentally drugs either stimulate or depress some physiologic function. These include toxic and undesirable actions as well as potentially useful effects. When drug actions seen in the animal are analyzed on such a basis, one can compare the experimental and clinical setting to decide whether there is sufficient similarity between them to hope for clinical utility. A drug which anesthetizes a normal animal is very likely to anesthetize a patient because the physiologic setting in both is similar, e.g., the central nervous system of the patient is usually as normal as that of the cat before the anesthesia. The action of antidotes in the poisoned animal is also likely to correspond with that in man because the type of action called for and the setting are much the same in both.

## PRINCIPLES OF THE CHOICE OF DRUGS

There are, of course, instances of disease or dysfunction in man for which there is no laboratory duplicate against which to test a drug. However, when the clinical situations with their physiologic dysfunctions are carefully evaluated, comparable laboratory-induced states in animals are usually possible. Sometimes the association between laboratory and clinical states can be made out of piecemeal consideration of the disturbance in man. Where it is a fact that there is no laboratory counterpart, the deficiency on the part of the laboratory must be reckoned with, and in such a case it may be that only evaluation in the patient will provide information on clinical utility. In any event, a careful and precise analysis of the disturbance caused by disease as well as that of the situation in which a drug is examined is essential if the findings in the latter are to be applicable to the needs of the former.

### The Nature of Chemical Relationships of Drugs to Clinical Use

Our understanding of structure activity relationships of many drugs has progressed to a point where the pharmacologist can often design a chemical structure and predict its pharmacologic action and toxic effects with amazing assurance. The genius of the synthetic chemist is such that he plies the pharmacologist with new drugs with interesting and challenging actions. His ability to make these new drugs threatens our present capacity for their careful clinical evaluation.

In considering new drugs, knowledge of previously investigated congeners is important as a basis for speculation and prognostication. It is equally important to recall that new drugs may or may not have all the particularized actions of the mother substance, in the transformation, they may have lost some facets of action or gained entirely new ones. It is important to recognize that some new drugs are inferior to the old ones which they were supposed to displace, alterations are not invariably improvements. Despite our highly developed talent for predicting the pharmacologic actions of freshly synthesized drugs, only examination in the animal and long trial in man tell the complete story. Sometimes the full potential for harm as well as the limit of utility is realized only after two or three years of clinical use.

### Patterns of Drug Action

The parameters of drug action provide the practical considerations which determine whether a drug with an attractive pharmacodynamic design will prove useful. Potency, curve of action, characteristics of absorption, elimination, all play a decisive role in determining where a drug may be used and, in the end, whether despite eminently desirable pharmacologic actions, it can be used well or at all. This is to say, not only are pharmacodynamic effects important, but even when drugs possess the most desirable of actions, administration by an acceptable route in the circumstances which exist must be feasible and the desired effects must be obtainable within an acceptable period and maintainable at a desirable level for a period of time long enough and last long enough.

**Potency**—The potency of a drug, namely, the amount by weight necessary to produce an effect, is of obvious practical importance since it determines the absolute amount which will have to be given to induce an effect, but beyond this it is not a very telling bit of information. *Provided it is possible to produce equal intensity of effects with other drugs, absolute potency per se is not an outstanding determinant in drug choice.* For example, since it is possible to reproduce all the effects of 1 mg of digitoxin on the heart with digitalis leaf, which is  $\frac{1}{4}$  000 as potent merely by giving a 1 Gm dose, the difference in absolute potency provides in itself no basis for a choice between them.

In some instances, potency of drugs is so expressed in the literature as to be come truly misleading. For example, there are barbiturate drugs for which the average hypnotic dose for man is appreciably smaller than that of the usual barbiturate less than the common capsule containing 100 mg. Such a barbiturate has been advertised as being safer than others of which more has to be used for similar effect. The implication here is that the smaller absolute dose is less likely to cause difficulties. On the other hand less potent barbiturates which require more drug per hypnotic dose than the usual 100 mg have been advertised as being preferable because a larger than usual amount is required for toxic effects. The implication here is that difficulties are not so likely to be encountered because a larger than usual amount of drug is needed to cause toxicity. Obviously, both arguments cannot be correct but what is more important is that *both are wrong.* Yet the fallacies in these cynical claims have escaped many, and few are sensitive to the fact that relative potency is not nearly as important as relative difference in therapeutic ratio.

Relative potency has more meaning when it implies that more can be accomplished with one drug than another that is to say, when one drug has a higher ceiling of action than another. Thus even though both drugs have qualitatively similar actions on the heart it is possible to produce effects on the heart with quinidine which cannot be duplicated with any dose of quinine. It is the higher ceiling of action of quinidine that makes it more potent than quinine in cardiac arrhythmias not the difference in absolute dosage required to duplicate some effects.

**Untoward Reactions**—There are two categories of untoward reactions (1) those which can be related to dosage and to a large extent anticipated i.e. toxic reactions and (2) those caused by infinitesimal doses and largely unpredictable i.e. allergic reactions.

**Toxic Reactions**—It is a characteristic of the clinically safer drugs that there is not only a reasonably predictable toxic dose but also that before this is reached there is a range in which such reactions are rare and when they do occur, are not serious. Larger doses of course tend to produce both a higher incidence of toxic reactions and more intense or serious reactions. Finally, there is a dosage range in which serious reaction or fatality may be anticipated.

Often the aim of new additions to a series of related drugs is to reduce relative toxicity by the chemical alteration. The ancestry of the drug is highly suggestive of what the possibilities are and until experience proves otherwise, knowledge of toxic reactions which have occurred with one member should be taken to indicate that such a potential resides in new and related members of the same group of

## PRINCIPLES OF THE CHOICE OF DRUGS

For example, Nirvanol, a hydantoinate which was used many years ago in England for chorea, was followed so regularly by fever and a skin eruption that its reaction, called Nirvanol sickness, was literally a part of treatment and without it therapeutic effects were not anticipated. It was to be expected, therefore, that in another hydantoinate Dilantin introduced many years later, there would be similar toxic potential. The reason that Nirvanol was discarded and Dilantin has continued in clinical use is that the differences in structure though small significantly separate the anticonvulsant and toxic effects. Dilantin can usually be employed without untoward effects, but it is equally noteworthy that the change in chemical structure did not entirely eliminate the reactions. On the other hand, it has been shown that Mesantoin, another congener of Nirvanol, produces its pharmacologic effects through biotransformation to Nirvanol. It is not surprising, therefore, that they should be similar toxicologically as well as therapeutically.

Unfortunately, statistical expressions of toxicity and safety with drugs do not necessarily apply to the individual he may deviate markedly from the average patient. For him, only careful observation will supply the necessary safeguard against serious reaction. An especially useful characteristic of some drugs, e.g. the digitalis glycosides, is the well timed development of minor toxic symptoms they should never be considered as they are by some a nuisance. When they appear they serve as a clear warning that further administration of the drug to a particular patient may end in disaster while prompt cessation will be relatively uneventful. On the other hand drugs like the coumarin anticoagulants which produce few if any minor toxic symptoms and whose first reactions are relatively serious ones, are treacherous regardless of therapeutic ratio because they fail to provide a warning that poisoning is developing.

**ALLERGIC REACTIONS**—Allergic reactions may develop without warning and these and new ones of the same series should be treated with due consideration for this propensity.

Too often there is no way of testing for such a potential in a particular drug. A history of allergic reaction to an older drug in a particular patient is a strong suggestion to proceed with caution with related drugs. A tainted heredity in patient as well as drug should never be ignored.

**The Curve of Action**—This is the curve of intensity of pharmacologic action of a drug described during its development, maintenance, and dissipation. It is of great practical importance in the choice and the regimen of use of drugs, it capsule account of how long it takes for effects to develop and how long they persist. It indicates whether a drug may or may not be useful for emergency maintenance. It provides the information basic to dosage scheduling. Its components should therefore be examined. The development of drug action in the depends on several aspects of absorption: rate, extent, and site of administration.

**RATE OF ABSORPTION**—The rate of absorption determines when a drug begins its pharmacologic action at the site of its action. Rate of absorption depends on when after administration a concentration of a useful, effective level is reached. It is not possible to say nothing of a useful, effective level must be reached.



very rapid absorption or by intravenous injection circumvent the process of absorption entirely. On the other hand, where slow development of action is acceptable, the rate of absorption is a matter of less importance in the choice of drugs.

**EXTENT OF ABSORPTION**—The extent of absorption is important in relation to the amount of drug that must be administered as well as in the choice of a drug. Obviously, where a drug is completely absorbed from the gastrointestinal tract as in the case of digitoxin absorption is not a factor in the choice, whereas ouabain, which is not absorbed from the gastrointestinal tract, would never be chosen for oral administration. The extent of absorption relates to the dosage necessary to produce desired effects. Dosage of poorly absorbed drug has to be large enough to make up for the proportion of the total which will not be absorbed. Irregularity in absorption may make dosage uncertain and may even make the use of the drug unsafe.

**SITE OF ABSORPTION**—The site of absorption is important in determining the suitability of drugs because (1) in a particular patient it may not be reasonable to expect absorption from the site of administration (e.g., oral administration in a patient who is vomiting or subcutaneous administration in an area of massive edema) (2) the drug may be destroyed at the site of administration (e.g., by gastric acid) before appreciable absorption can take place, (3) absorption may not develop rapidly enough at the site of administration.

**INTERMEDIARY PROCESSES**—There are many examples of latency in action. Digitoxin may be injected intravenously, yet even though all the drug appears immediately in the blood stream, many hours elapse before full development of action. Obviously, some intermediary process or processes are involved in such delayed drug actions, these may include changes in the nature of the drug to prepare it for its action, cellular penetration, development of secondary reactions, and others. This fact is of practical importance because, if unexpected results due to cumulation are to be avoided, sufficient time must elapse between one dose and another to permit full development of action. To the extent that these processes delay the development of action, they influence the curve of drug action, the routine of dosage, and the choice of drugs.

**ELIMINATION**—Once a drug appears in the blood stream by whatever means of absorption or from whatever site, processes of elimination begin. Sometimes these operate in force almost at once so that, as in the case of epinephrine, if a dose is injected intravenously slowly, the peak effect may be appreciably lower than when the same dose is injected rapidly. Similarly, drugs absorbed very slowly in the intestinal tract, or whose absorption is retarded by food or some deliberate device, may also lose effectiveness. On the other hand digitoxin is excreted so slowly that elimination does not significantly alter the development of the curve of action.

The means by which the effects of drugs are dissipated are varied and are not known for all drugs. Some are destroyed or altered in the body, some are eliminated either unaltered or changed in the urine, some in the feces, some by expiration. It is conceivable that serious defects in an organ of elimination may alter the curve of action by delaying elimination. However, significant deviations from the usual curve of action for particular drugs are usually caused only by far-advanced disease of the organ of elimination. Characteristic deviations of this kind have been used for diagnostic tests but are also the basis for the choice of drugs.

**The Therapeutic Ratio**—The physical amount of a drug which will produce a pharmacodynamic effect has special significance in relation to the amount of the same drug which will produce untoward effects under the same circumstances, for its ultimate usefulness in clinical medicine probably depends on its therapeutic ratio—the relationship between therapeutic and toxic potency. Whether or not a drug is safe as well as useful depends largely on how well these two categories of drug action can be segregated in terms of dosage.

The therapeutic ratio is a far more realistic indicator of drug safety and utility than absolute potency or absolute toxicity. For the therapist, it weighs the effects he seeks against the untoward reactions he fears. It is a mathematic expression of this therapeutic attitude, becoming more favorable as the gap between the therapeutic effectiveness and toxicity widens.

It is interesting that in the case of the barbiturate drugs the therapeutic ratio is virtually the same for all members of this large series of drugs, the more potent as well as the weaker members. This is to say, as much more is required of the weaker barbiturates for therapeutic effects as for toxic effects and, conversely, in the case of the more potent barbiturates, proportionately smaller amounts are required for both toxic and therapeutic effects, therefore, there are no barbiturates which have advantages in terms of relative safety. Their important and realistic differences lie in other aspects of their parameters of action. Uniformity of the therapeutic ratio in a series of congeners applies to some groups but is by no means invariable. When chemical changes bring about significant improvements in the therapeutic ratio, they provide us with safer new drugs. But there are other possibilities in the case of new drugs: absolute potency may rise or fall, absolute toxicity may rise or fall, new facets of action, therapeutic or toxic, may appear or old ones may disappear; the therapeutic ratio may fall or remain unchanged; new drugs are not necessarily superior to the old and they may be worse—one has to find out which in each case.

### Dosage

It is the opinion of outstanding therapists that improper dosage with the proper drug is at least as common a reason for therapeutic failure as the application of an improper drug. Token effects of drugs are useless, while enthusiasm as the only governor of the dosage regimen leads to disaster.

Dosage may be insufficient through the physician's timidity or the patient's tolerance, excessive through the physician's exuberance or the patient's sensitivity. To obtain from a drug all that it may provide, the dosage must be tailored to suit the patient as well as his disease. Dosage is an individual matter depending not only on the potency and toxicity of the drug, but also on the urgency of the condition, the mode of elimination of the drug, the influence of the patient's disease on reactivity and elimination, whether the effect desired is to be sustained, intermittent, or occasional, and the physical inconvenience of repeated dosing where sustained effects are desired. Finally, there is an unpredictable and to a large extent an incalculable factor—the patient's constitutional tolerance or hypersensitivity to the drug—which plays a vital role in determining safety as well as dosage for him but which can be estimated only after he is exposed to the drug.

As already indicated the dose of a drug which may be used implies a consideration of the amount necessary to induce a useful therapeutic effect in the face of the danger of inducing untoward effects on the one hand, and, on the other, that of failing to relieve the condition in good time. The probability of the therapeutic utility of a dosage scheme depends on the nature of its compromise between safety and pharmacologic action.

**The Average Dose**—This term is really a misnomer and is not what it seems to mean—a mathematic average of all the doses given, rather it is the dose given the average patient. As it is now used, it usually signifies the probably safe dose with which to start the trial with the drug in the usual patient. Actually, it is a dose calculated to induce a relatively low incidence of untoward effects in an untested patient and burdened by this limitation, a practical probability of useful effects.

The ratio between the two is variable, depending on the nature of the drug. True toxic (not including allergic) reactions to penicillin occur very rarely. An extremely large number of units (25,000,000 in some cases) have been given without untoward effect. As a result, the average dose of penicillin tends to be generous and is likely to be followed by a very high incidence of satisfactory results. Another antibiotic streptomycin, may be followed by about 10 to 15 per cent of vestibular disturbances. In this case, the average dose with an eye fixed on toxic effects, tends to be conservative and as a consequence, the average dose of streptomycin is not as frequently effective as the average dose of penicillin.

**Dosage Schedule**—The dosage schedule is just as important as the individual dose because it has the same potential for making treatment either ineffectual or excessive. If it provides the drug faster than the patient can excrete or destroy it, regardless of how small the individual dose may be, excessive effects will eventually develop. If it supplies the drug slowly so that the patient eliminates it faster than it can cumulate a therapeutic level may never be achieved. Thus, depending on the need and the way a drug is administered, cumulation and failure to cumulate can both be either desirable or disastrous.

The duration of effects provided by the dosage schedule will often determine the success with a drug. When the patient requires continued drug action, as the patient with heart failure requires digitalis a system of dosage must be provided to supply this need. On the other hand, in the patient with episodic asthmatic attacks, continued epinephrine action might end in disaster while occasional use may add up to therapeutic success.

**Potency as a Basis of the Choice of a Drug**—It has already been stated that absolute potency, hence absolute dosage, is not as important as biologic potency and biologic dosage in terms of what can be expected from a drug. What a drug will accomplish is obviously more significant than how much, by weight, is needed to do it. What real difference does it make if one can accomplish precisely the same thing with twice as much of one drug as another? In a sense, the now almost completely outmoded system of unitage has advantages over the absolute doses we use for our highly purified drugs. It is a dynamic method and has implications of dose effect relationships not inherent in the absolute dosage system.

Another consideration relating to dosage which has a high priority rating in

determining choice is the therapeutic ratio. This contains the answer to the question whether one drug or another used in the way dictated by biologic potency, pharmacologic actions, and the clinical condition is the safer.

The parameters of its action indicate precisely how a drug has to be manipulated to induce and sustain a particular pharmacologic effect, that is to say, the route of administration, the size of the individual dose, and the dosage regimen. The difficulties which attend this accomplishment in the case of one drug as compared with another are important practical elements in the choice between them.

## PRINCIPLES IN DRUG EVALUATION

It is a shopworn medical maxim usually blandly stated with little thought for its implications that "each new patient is yet another experiment in therapy." It should be so, of course, but rarely is more than lip service paid this statement.

The clinical experiment involves a rigorous discipline and for proper performance sometimes demands even more skill, insight, knowledge, and, above all, patience than the proper laboratory experiment. The discussion of the principles of the clinical experiment which follows may be useful to the practicing physician, not so much as the basis of his evaluations of new drugs as for the examination of reports on new drugs.

The program for the evaluation of the clinical effects of drugs must be designed in such a way as to eliminate or take account of all forces other than the drug itself which may influence the response to treatment. This involves (1) the resolution of forces extraneous to issues at hand, (2) the resolution of psychic factors in the response to medical care, (3) the selection of the proper subjects for the evaluation, (4) the selection of the proper dosage for the evaluation of the drug under consideration, (5) the utilization of appropriate controls, (6) the determination of the sensitivity of the method, and (7) the selection of the best method for the collection of data. Data collected with these precautions must then be subjected to analysis, often statistical, to determine their significance.

**Resolution of External Forces**—The resolution of external forces deals with such diverse influences on the state of the patient's well-being as the course of his illness, changes in weather, and the turn of world affairs. All may affect the responses of a patient to an inquiry regarding his reaction to treatment, for all may influence his physical well-being as well as his sense of well-being. Since there are chance occurrences the possibility that they may influence results may be eliminated through the randomization of medication. This implies that in clinical evaluation some control has to be used to provide a basis for comparison—another active drug and, preferably, also a placebo.

**Resolution of Psychic Forces**—The importance of psychic forces on the course of disease has been stressed mercilessly in recent literature. The patient's desire to get well and his response to the fact that he is receiving accredited attention and reassurance—the so-called placebo effects of treatment—tend to provide the illusion of effects from medication itself and to make it difficult to distinguish the difference between the specific effects of the medication and the inevitable nonspecific effects of the fact of receiving treatment, that is, the placebo effect inherent in the treatment.

ment Sometimes the distinction can be made only after long study, prolonged periods of treatment, and large numbers of properly controlled comparisons

Confronted with reports of good and even dramatic results from new drugs, it is well to recall that dramatic cures have been reported after the ministrations of modern as well as ancient witch doctors, Christian Scientists, naturopaths and a Canadian twist of the foot by Dr. Locke. Think also of the regimens which were once espoused by the medical profession which, like the protein hydrolysates for peptic ulcer, are now somewhere in limbo while the peptic ulcer still awaits satisfactory medical treatment.

**RESOLUTION OF UNCONTROLLABLE BIAS**—The attitude of the physician as well as of the patient is important in shaping responses to treatment. Both are usually hopeful; they desire that the medication do the job.

The physician wants to do good because that is his function in life. His recent experience with such new drugs as the antibiotics, cortisone, and anticonvulsants has given him a realistic basis for an optimistic attitude toward new medication. The patient is usually hopeful for more selfish but nonetheless persuasive reasons. On the other hand, there are patients who for reasons of their own want to suffer, to remain invalids, to receive special attention. This attitude may induce negative responses to medication.

The physician's knowledge of the medication he is prescribing is exceedingly important in the clinical experiment, for, regardless of how much he tries, if he knows what he is prescribing, in one way or another he will communicate his feelings about the medication to the patient. If he has deep concern over the untoward possibilities of the new and poorly understood medication he is using, he will communicate his concern to the patient; if he is bursting with enthusiasm, he will communicate this attitude. It has been shown that knowledge of participation in an experiment also distorts patient response; subjects who know they are being observed often tend to be tolerant to discomforts.

How to deal with bias is one of the great problems of the discipline of drug evaluation. It would appear to be a practical impossibility for the practicing physician because he cannot and should not be blind to the medication he is giving his patients. He writes his own prescriptions and must know what danger signals to look for. In the clinical evaluations of drugs, ignorance of the medication provides a useful way of eliminating bias, for getting at the truth. A well recognized procedure is to make placebo and medication identical in appearance to use both but to keep physician and patient ignorant of what is in use both at the time it is prescribed and when the patient is being questioned. This has been aptly called the double blind procedure.

**THE DOUBLE BLIND AND THE ALL-BLIND**—Much has been written in recent years about the double blind technique. It is my stand that while the technique must be applied in virtually all instances of drug evaluations in man, the blindness must begin and end at the proper time and that double blindness does not ensure valid results in otherwise poorly designed studies, and, in general, that it is no cure for myopia or astigmatism in drug evaluation.

Double blindness is nothing more than one device in the methodology of studying drugs in man; it is not a complete method in its own right. This is an im-

portant practical matter, for the application of the double-blind technique has been used to whitewash otherwise seriously deficient methods of drug evaluation. The double blind procedure has been mentioned in the titles of papers as if its use *proved the validity of the conclusions. Nothing could be further from the truth.* It merely ensures the removal of bias and identifies placebo forces in shaping responses, in no way does it guarantee that the data so accumulated are otherwise untainted and can be used for definitive conclusions without further analysis.

**Appropriate Subjects**—The argument that the patient for whom the medication is intended is the best subject for its evaluation seems to be a truism. Yet there are situations in which he might make the worst subject for drug evaluation. For example, the very suggestive patient with anxiety symptoms may react with such wide swings to both placebo and treatment as to make it utterly impossible to demonstrate differences between sedative and placebo actions. On the other hand, because of the highly specific nature of the drug action which relieves it without producing serious central depression the influence of drugs on myalgia can only be studied in patients who experience it spontaneously.

Highly suggestive, very labile and very phlegmatic patients, patients who have such high regard for the physician that they try to show their appreciation for his efforts by responding positively to all he does and, conversely, those who feel that only by overstating their case will they get full value from their physicians make poor subjects and tend to reduce the sensitivity of methods used in the evaluation of drugs. The proper subject for an evaluation varies with the type of drug effect under examination, the nature of the dysfunction to be influenced by the drug, and the sensitivity of the method necessary to demonstrate a drug action in man.

**Appropriate Dosage**—If dosage is too low regardless of the pharmacologic actions of a drug, clinical evaluation in man will reveal no difference between the drug and placebo, dosage so high as to produce undesirable effects may obscure therapeutic merit and discourage further examination of the drug. A body of previous experience with the drugs as well as its congeners, often in the form of a pilot study, must be used as a basis of ensuring the use of the best dose or series of doses for the evaluation. There is no such thing as an evaluation of a drug without a control, for a control is merely a basis of comparison, and therefore, every statement about a drug implies a control. Consequently, there are no uncontrolled studies merely studies with appropriate controls and studies with inappropriate controls.

**Appropriate Controls**—In the animal littermates provide the classic controls so that sex, age, weight, as well as constitutional features are identical in treated and control animals. All that is required is the proper purchase order to get quantity as well as quality in control. This is not the case in the clinical experiment. The identical twin who serves as a control for his brother is a once in a lifetime coincidence. If alternate cases are used for control the treated patient may be a young thin bachelor and the alternate patient an obese elderly woman who has borne a dozen offspring. They may come from different economic and cultural environments. The influence of these differences on the effects seen and reported after treatment may be enormous. Satisfactory matches for purposes of control are rarely available and only large numbers suffice as a substitute. The subject may serve as his own control by alternating periods of treatment with periods of placebo.

medication. But this procedure must be carefully scrutinized, since the patient's illness may change in such a way during the study as to shape the results.

Yet, since no valid comparison can be made without them, appropriate controls must somehow be provided. Where a large number of patients are available, alternate cases are likely to equalize the effects of extraneous influences and may, therefore, be used for control. Where patients are few in number, the only recourse is to have each patient serve as his own control through the use of both drug and placebo in each case. With randomization of medications and a sufficient number of trials in each patient, it is often possible to rule out progression of disease as an influence in the total response of the patient to treatment. For experimental use no control is more precarious than the so-called 'historic control' that is a recollection of previous experience. Yet in the case of exceedingly rare diseases this may be the only control possible and it is also the basis of the physician's own method of accumulating experiential knowledge.

**Collection of the Data**—The collection of data is a critical matter in all scientific investigations. Here the training, skills, and acuity of the scientist are of first importance. In some studies in medicine, observations can be made by objective clinical findings, x-ray, electrocardiogram, changes in temperature, weight and other means. When they reflect the action of drugs, such data simplify the problems in drug evaluation. Unfortunately, not all drug effects can be measured directly. Many drugs are used for the relief of symptoms, and their effects, as expressed by the subjective responses of patients, are not so easily reduced to objective data as clinical responses which can be recorded by x-ray or thermometer.

In the evaluation of drugs influencing the pain experience, for example, the patient is the only observer of the effectiveness of the treatment. There are many other areas of drug evaluation in which the patient's subjective experiences must be used as the basis of measuring the differences between the actions of drugs. The difficulties in collecting responsible data may profoundly influence the method as well as the validity of the conclusions the data seem to indicate.

The patient is asked to recount his experiences, evaluate them, eliminate extraneous forces and wipe out his bias and his desire to get better or worse. He is asked to obliterate the total effect of all these influences during the period of treatment from the effects of the medication itself. There are few scientific investigations in which so critical a part as the collection, storage, and interpretation of observations is left in the hands of an interested, biased and untrained assistant—in this case, the subject himself.

Responses to treatment should be collected immediately after the experience. Unfortunately this is not always possible. Yet, if the subject has to wait before reporting matters may be further confused, for he cannot help having his recollections colored by more recent events than by those farther back—what happened two days ago against two hours ago. Report cards which the patients fill out every night summarizing the day's experience have a theoretic advantage over responses gathered after longer periods of treatment. Postal cards which patients mail to the physician every night are still better because they provide assurance that the card was filled out at the end of the day stated. In order to ensure fresh and uncolored responses it has been found advantageous in some studies to question the subjects by phone each night. The most accurate data are those accumulated by an on-the-

## PRINCIPLES OF THE CHOICE OF DRUGS

spot observer This, however, imposes a heavy burden on those who are examining drugs in man

**Sensitivity of Method**—Devices for measurement must always be examined to make certain they have the requisite ability to discriminate The physician is satisfied with the examining room scales to weigh a patient, but the chemist on an analytic balance which is sensitive to differences of fractions of milligrams The same is true in clinical evaluations The method itself must, in fact, be precise if it is to be fairly stated that the results it yields are reliable The ability of method of drug evaluation to distinguish positive from negative or indifferent responses can be established by demonstrating positive responses with drugs of known activity Sensitivity can be shown by the increments in dosage which the method can distinguish

**Statistical Significance**—Often one reads that a difference was found but it was not proved to be significant or that there was a trend which was not significant This is an unworthy way of approaching data Only significant data have merit and nonsignificant data may not be used to suggest a possibility If a difference is not significant it is not a real difference and regardless of qualification should not be stated as one

Because of great variability in disease expression to individual differences, and to influences of extraneous forces the proof of the conclusions in drug evaluation often must rest on a statistical demonstration Great difficulties often attend the accumulation of adequate numbers of cases especially of the more unusual diseases Only statistical analysis can indicate the validity of the significance of differences found in data and the likelihood that they can be reproduced in the patient who receives the drug for therapy

The most efficient way to design a study for clinical evaluation is to deal with statistical problems at the outset to apply a method which can be predicted to supply valid data with the amount of material available the type of control which, for want of better may have to be used and the method of collecting data to which the physician is reduced Failure to take account of this problem in the design often ends with mountains of data which do not answer the questions posed

It cannot be gainsaid that the statistician has come into the act The details of his designs are often highly technical matters it is my practice therefore, to consult a statistician at the beginning of a study as well as at its conclusion Statistical analysis however, does not examine the data itself It merely examines differences indicated by the data Statistical prognostication is based on the assumption that data used were worthy of collection It must be emphasized, therefore that regardless of statistical considerations in all other aspects the design of the method also be such that it ensures the quality of the data Without the latter the statistical analysis may well provide statistically significant but nonetheless erroneous conclusions

**Interpretation of the Data.**\*—It is convenient to consider the design of a study for clinical evaluation in terms of a balance which is used to weigh the evidence for or against a particular pharmacodynamic or therapeutic effect of a drug



as compared with chance occurrence. Which way the balance swings, i.e., whether drug action is favored or not, depends, of course, on the relative weight of the evidence in one or the other pan. Whether the swing is meaningful or misleading depends on whether the weight which swings it is due to a specific action of the drug or to any of a myriad of forces which influence man's behavior and his mental, physical, and visceral activity. When such a model is used, one way to prevent swings of the balance by factors other than the intrinsic pharmacodynamic action of the drug itself is to accept and spread their influence equally on both sides of the balance, thereby causing no disturbance in balance by their weight. This is precisely what is attempted by the control devices of double blindness and randomization: they merely prevent chance and erroneous swings of the balance.

What is not often taken into account in clinical evaluations is how much weight is necessary to make the balance swing at all, that is, the basic sensitivity of the method. Whatever the original sensitivity, consider what is done with it in the usual design for clinical evaluation. Consider that such a balance is not empty at the outset of the evaluation, merely in balance on both sides of the balance one places equally placebo action of drugs, bias, and influence of diverse extraneous factors, such as weather, political events, family stresses, and a number of other vagaries of human experience that tend to mold or alter man's functional state and his response to drugs. It is to be emphasized that these are not removed as interferences; they are permitted to remain. They are merely spread equally over both pans of the balance by the process of randomization and by the control of double blindness. The balance is thereby deadweighted with a large amount of material which is immaterial to the specific problem at hand. No matter how sensitive originally, such a procedure makes the balance less sensitive, just as an analytic balance, sensitive to a fraction of a milligram under usual conditions, is no longer swung out of balance by milligrams when dead weighted with several kilograms on each pan (Fig. 1).

Ultimately, therefore, the sensitivity of a method of clinical evaluation is a function of the relative weight of the pharmacodynamic force under investigation and the weight of the nonessential interfering forces which are treated by equalizing them: the greater the former with respect to the latter, the more sensitive the method, and, vice versa, when the latter becomes relatively heavier, the method becomes proportionately less sensitive. The extent to which dead weighting the balance grossly desensitizes the balance can lead to erroneous interpretations in the sense that the balance indicates no differences whenever it is used to weigh what it is no longer competent to detect.

Of the factors already discussed, some are subject to choice, such as the proper dosage range and subjects and the appropriate control. Other factors may be modified. The removal of the patient from the home to a constant environment in the hospital may sometimes reduce the extraneous variables. The collection of data on the spot, rather than placing it in the hands of the subject himself, reduces the treachery of patient recall. Finally, there remain some irreducible disturbances which can be neither removed nor modified, that is, bias, placebo actions, and the residual extraneous forces. For these there remain the double blind control and the process of randomization to spread the prejudicial factors equally, so that none of them swings the balance in either direction.

## HOW TO SELECT THE BEST DRUG

By some means or other, the practicing physician must decide which of the drugs available or suggested for a particular purpose is the best. It is his obligation to make this decision, but in doing so he must be wary of the prejudiced advice served to him by the drug manufacturer. He is again advised that the drug

# PRINCIPLES OF THE CHOICE OF DRUGS

manufacturer will tell him little but the superiority of his product. For there is a large volume on an antibiotic published by its manufacturer in which expression "untoward effects" and the word "toxicity" do not appear at all. He must listen to unbiased voices as well as try to make substantial estimates of drug utility on his own. Many fine, original, even classic observations have been made by the physician in the conduct of his regular practice. Although they are of great value, today they often cannot cover enough ground. The busy practitioner rarely has the time or the opportunity to conduct the rigorous experiment in office or at the bedside and usually has to depend on the recommendations of experts he can trust. The best source of such unbiased expert opinion is the medical literature.




Fig. 1.—Diagrammatic representation of experimental designs for clinical evaluation. Left: excessive dead weighting to prevent chance occurrence from swinging the balance reduces sensitivity to the extent that drug effects do not swing balance and, hence, cannot be measured. Right: reduced dead weighting through appropriate design makes it possible to measure pharmacodynamic effects of same intensity with same balance. (From Modell, W., and Houde, W. Evaluation of Drugs J. A. M. A. 167: 2090, 1958)

In the literature the early papers on new drugs tend to give little comparative information, that is, in terms of superiority of particular drugs over others in the same field. It often happens that toxic propensities of a drug are brought to light only after considerable clinical experience. The physician has to wait for the review article which usually is the best source of comparative information. Since there is a considerable delay between the introduction of drugs and the publication of the review article, the physician is regularly faced with the problem of considering a new drug about which he can get little definitive information. How is he to come to a decision when the need is immediate? Usually, it is, the chemical structure, and the pharmacologic group to which the drug belongs. Experiences with older drugs in the same group are also helpful.

is likely to be a satisfactory literature on these related compounds which will provide information for prognostication. Although the intent with new drugs is to eliminate or reduce the defects of the older relations, genealogic studies of the older drugs usually have an important bearing on the new. It is a good thing to bear in mind that a new drug may not be better than the older one it is designed to replace. Sometimes it may even be worse.

A new drug is never introduced on the American drug market without some publication in medical journals of studies of its pharmacologic properties, for without it the Government does not permit its sale. While the drug manufacturer is unlikely to offer any unfavorable reports if nowhere else this reference may be obtained from him. Information on some of the parameters of drug action is likely to be found here. The ability of the parameters of action as well as the pharmacologic actions themselves to suit the therapeutic needs, and the characteristics of dosage form the basis of the choice of a drug, the basis for trying a new drug in preference to continuing with the old.

Do not use a new drug in combination with other drugs. No plan of investigation is more certain to obscure the merits or disadvantages of the new drug.

## THE CHOICE OF A PLACEBO

A word must be said about the choice of the ubiquitous medicament, the placebo, if only because there has been so much recent talk about it that clarification is necessary. There is nothing really profound about it and it is just as old as the art of medicine. There are two major areas for the use of the placebo: the experiment and the patient.

Placebo is used in the clinical experiment for a nontherapeutic function—to deal with psychic responses in drug evaluation. It is contrived and administered to duplicate in appearance and in mode of application the drug under investigation so that the subject does not know when medication is being switched. In this way the physician may learn whether a particular form of therapy provides something more than placebo relief. It may be used in general practice to determine whether the drug or the act of its administration is making the patient better—or worse.

The second use of placebo is in treatment. Many patients will have negative reactions to their visit to the physician if they do not come away with a prescription for medication; such patients require and benefit from placebo. Under these particular conditions the placebo serves as a symbol of medical treatment and is in fact treatment. It may be given while waiting for the diagnosis essential to definitive treatment or even simply because the patient demands medication.

The potency of placebo may be a blinding phenomenon. The physician must be wary of the assumption that a strong positive placebo reaction provides a diagnosis of psychogenic origin or that a negative reaction to placebo proves the presence of organic disease. Serious somatic disease may respond well to placebo while psychic distress may resist it. It should be an inviolate rule therefore not to permit the result with placebo to alter the routine of a thorough physical examination and a complete diagnostic work up.

Despite its effectiveness in particular instances, placebo should never be a substitute for rational medication and well considered therapy in addition to an equal

placebo effect, the latter will help in areas not touched by placebo, will produce more enduring results, and can cure where placebo cannot

In choosing a placebo, the physician has two choices—the "pure," a tablet made of an inert material such as lactose, and the "impure," a harmless but inappropriate medication. The most compelling argument against the former is that patients who have discovered the fact have interpreted it as dishonesty rather than treatment. Since this interpretation harms the patient and threatens his relationship with his physician, there is an understandable tendency to use a placebo which the average patient cannot interpret as "dishonest."

I would argue endlessly that there is no taint of dishonesty in the well considered use of placebo, but I cannot gainsay the embarrassments of discovery. The "impure" placebo eliminates them. But if the patient becomes better after a poly-vitamin capsule,\* the temptation is great to attribute the results to the vitamins, however inappropriate they may be for the condition. The "impure" placebo, therefore, threatens the physician's intellectual fortitude for he may be deluded that results are due to the *contents of the tablet* rather than the *act of taking the tablet*.

I would argue also that the physician should always take pains to know when he is giving a placebo. Only then will he make the fullest use of the placebo. Only then will he be in a position to fashion the placebo which best suits the immediate needs and the attitudes of the patient to the physician and the taking of medication. Only then can he decide whether the placebo should be solid or liquid, capsule or tablet, tasteless or repugnant, odorless or malodorous administered orally or by injection, given three times a day or once a week for maximum placebo effect.

Beyond this accomplishment, when the physician uses the placebo expertly he will also be an accomplished and perceptive therapist, for he will be exploiting the only *universal medicament* as well as distinguishing the actions of others.

## SELECTED REFERENCES

- Beecher, Henry K. Appraisal of Drugs Intended to Alter Subjective Responses, Symptoms, J A M A 158 399, 1955  
 Beecher, Henry K. The Powerful Placebo, J A M A 159 1602, 1955  
 von Felsinger, John M., Lasagna, Louis, and Beecher, Henry K. Drug-Induced Mood Changes in Man, J A M A 157 1113, 1955  
 Fischer, H. K., and Dlin, B. M. The Dynamics of Placebo Therapy, Am J M Sc 232 504, 1956  
 Gaddum, J. H. Clinical Pharmacology, Proc Roy Soc Med 47 11, 1954  
 Harris, S. C., and Worley, R. C. Evaluation of a New Analgesic, J Appl Physiol 7 183, 1954  
 Jellinek, E. M. Clinical Tests on Comparative Effectiveness of Analgesic Drugs, Biometrics Bull 2 87, 1946  
 Lasagna, Louis, Mosteller, Frederick, von Felsinger, John M., and Beecher, Henry K. A  
 Modell, .  
 Modell, .  
 Shapiro, .  
 J A M A 160 30, 1956  
 Travell, Janet. Assessment of Drugs for Therapeutic Efficacy, Am J Phys Med 34 129, 1955

\*It is of interest that even this placebo may be dangerous. There are recent reports of serious consequences of the suppression of early signs of pernicious anemia by the small doses of antianemic materials in such mixtures.

## THE PHYSICAL AND CHEMICAL CONSIDERATIONS IN THE CHOICE OF DRUGS

Lloyd C. Miller, Ph.D., and

Albert H. Holland, Jr., M.D.

---

### INTRODUCTION

Physicians in the United States are offered a greater variety of forms of the same drugs than physicians anywhere else in the world. This circumstance is a development of the keen and extensive competition under a free enterprise system in a highly diversified industry. Although it is impossible for the busy practitioner to be intimately acquainted with the practical aspects of pharmaceutical chemistry, he should have some knowledge of the important physical and chemical characteristics of drugs that relate to any differences of significance upon which rests a basis for the choice of one form of a drug over another form of the same drug.

The purity and composition of drugs is guaranteed in part by the standards set by *The United States Pharmacopeia*, *The National Formulary*, and *New and Nonofficial Drugs*. Compliance with these standards is supervised to a degree limited by a small budget by the Food and Drug Administration of the Federal government. However, in the case of such new drugs for which official standards have not been set by the U.S.P. or N.F., the reliability of the pharmaceutical manufacturer becomes an especially important matter. When a drug is prescribed the reliability of the manufacturer is therefore at stake. In addition, there may be two or more brands (with entirely different brand names) of the same drug. How much good research, quality control, and effort does the manufacturer expend to protect the integrity of his line of merchandise? Brand named drugs carry the same implications of quality as brand named merchandise in other commercial fields. This is of importance to the physician for he too assumes considerable responsibility when he prescribes a specific product.

One cannot engage in a discussion of the meaning and importance of brand names without a consideration of patent rights. There are some who view patents and patent rights as providing an unjustifiable monopoly, particularly so in the case of medicines. The granting of a patent is a reward for the disclosure of an invention and provides the recipient with a protected period for profit.

by exploiting his own invention. Patent rights thereby provide motivation and incentive for originality and advancements which have contributed to the great progress made in the development of entirely new drugs as well as for more effective and more convenient forms of older ones.

## FACTORS INFLUENCING ORAL ABSORPTION

The remarkable extent to which chemical and physical factors can deprive patients especially the acutely ill of the benefits of medication is scantily appreciated. Since the stomach is not primarily an organ of absorption, drugs must generally pass from it to the small intestine even to begin to undergo absorption. This is particularly true of those drugs that are insoluble in acids, e.g., the barbiturates. Others are unstable in acid, e.g., all of the penicillins except the phenoxymethyl derivative. Thus prompt passage into the upper intestine favors absorption.

However, satisfactory passage from the stomach does not insure full absorption. Indeed, an extensive series of experiments has shown that for riboflavin, as a typical constituent of multivitamin tablets and for *p*-aminosalicylic acid, full absorption depends upon how promptly the constituent goes into solution. This rather reasonable conclusion is not easily put to critical test, but published evidence strongly suggests that plain tablets ought to disintegrate promptly after ingestion. Thus there has been a sharp reduction in the disintegration time limits for tablets now allowed under the U.S.P. standards as compared with earlier revisions. This represents abandonment of the once prevailing concept that prompt disintegration is a virtue only for analgesics and other drugs needed for the "fast relief" so freely promised in popular advertising.

An argument held against short disintegration times when pharmacopeial limits were first imposed was that tablets tend to "case harden" on storage and failing the test would face discard. Since the drug content was still up to standard there was little inclination on the part of manufacturers to regard this as simply another form of deterioration. Yet when absorption is poor, the patient obviously gets little benefit and the physician's plan of therapy goes awry.

There is a recorded instance, however, of a small but ethical drug firm's having voluntarily recalled all outstanding stocks of a lot of simple uncoated sulfadiazine tablets that had become so hard as to pass through the entire gastrointestinal tract intact.

The greatest risk is with special coatings and a recent study showed that a disturbingly high proportion of enteric coated tablets supplied on contract to a government hospital were excreted whole. Fecal examinations in healthy students revealed that intact tablets or insoluble fragments were recovered up to 48 hours after ingestion. The percentage of recovered tablets showed a high degree of correlation with prolonged *in vitro* disintegration by the U.S.P. test for enteric coated tablets.

These facts suggest that physicians ought to instruct the nursing personnel to look for excreted intact tablets when medication appears to fail or proves less effective than expected.

**Physiologic Availability of Liquid and Solid Dosage Forms**—Among new drugs for use orally the solid forms outnumber the liquid 2 to 1. The greater convenience of the solid forms to patients is doubtless an important factor in their popularity. However convenience may come, to an undetermined extent, at the expense of sure availability of the active ingredient. A liquid medicine enters the fluid milieu of the stomach with no delay or loss beyond what may be adsorbed on the mucous membranes en route, in reaching and leaving the stomach. It therefore is the form most available by mouth.

**Tablets and Capsules**—New drugs for oral use are often first introduced in capsules for the pharmacetic reason that thereby the problems of disintegration stability taste etc. are bypassed. Later, when solutions to these problems lead to suitable tablet forms the tablet forms are generally used because they are less costly to produce. Despite this fact, capsules may still be continued if for no other reason than the fact that they lend themselves to closer identification with the maker by color coding banding or name imprinting. The extra cost of this advantage to the producer is passed on to the patient.

The hard shelled capsules are the most convenient form for extemporaneous dispensing by the pharmacist in filling prescriptions calling for sizes not available from the producer. Generally the drug is not distributed in pure form without diluents so that the pharmacist may be obliged to crush regular tablets to a powder to fill the capsules. Soft capsules require special machinery that forms and fills the capsule in a single operation.

Capsule shells both hard and soft consist almost entirely of gelatin suitably plasticized. These normally digest promptly in the stomach thereby making the capsule contents available for absorption only slightly less quickly than is a liquid medicament.

**Enteric Coated and Other Delayed Absorption Dosage Forms**—The irritation to the gastric mucosa from readily soluble drugs taken by mouth is manifested by symptoms ranging from mild distress to severe vomiting. Long ago this problem suggested finding a means of keeping the drug from dissolving until it had passed through the pylorus. Though time honored, this approach merely begs the issue in being more nearly analogous to symptomatic relief than to outright cure. It leaves unanswered the question of whether simply transporting the drug beyond the point where the patient feels or shows ill effects from the irritation is in keeping with the principle of *nolo nocere* (do no harm to the patient). Nevertheless the potential benefit from a simple drug such as ammonium chloride which causes intense irritation to the average stomach is sufficiently great to justify its use in a form intended to resist dissolution until it has reached the intestine.

There are however other valid reasons for delaying the action of a drug until it has passed beyond the pylorus e.g., to avoid its destruction by the acid of gastric juice or to protract the period of its absorption as a means of avoiding an exaggerated pharmacodynamic effect such as flushing of the skin produced by rapid absorption of nicotinic acid derivatives.

Until recently the best means of achieving delayed absorption was by applying an enteric coating to a tablet or capsule. These coatings consisted of acid insoluble alkali soluble substances such as various natural gums, waxes etc. in

cluding shellac particularly and synthetics such as phenyl salicylate (salol) and cellulose acetate phthalate. In general, these substances are quite insoluble in an acid milieu but are sufficiently soluble in the intestinal fluid to serve the intended purposes although, in fact, the latter fluid is never very strongly alkaline. As stated by Dragstedt in 1958, the very number of these substances in use is "something of a mute testimonial to the fact that none has been found to be uniformly successful" [These include such proprietary preparations as Emplet, Encoat, Enerel, Enseal, Entertab, Keracote. Ed.]

Another pharmaceutical approach has been to use hygroscopic substances such as powdered elm bark and agar. Incorporated in the coating of a tablet, these take up enough moisture from the stomach contents to initiate a disruptive process that proceeds slowly enough, in theory at least for the tablets to have passed out of the stomach before the coating breaks down.

A fairly recent and promising development depends upon forming complexes of the drugs with ion-exchange resins. Claims for these complexes include improved taste characteristics and increased stability. The resins used are generally styrene divinylbenzene copolymers appropriately treated to create an affinity for either cations or anions. Thus a cation exchange resin is used to complex amphetamine in such a way that the drug is released to its surroundings over an extended period of time. The advantages claimed for these complexes include increased stability and greater certainty of action by circumventing most of the batch-to-batch variation that can occur in the application of enteric coatings. In time, important economies in cost should be apparent. However, as yet, production experience with the resin complexes is relatively limited.

Physicians, in considering the use of delayed absorption dosage forms, should be aware that the difficulties faced by the pharmacist in making suitable delayed-absorption preparations are compounded by the physiologic variations normally observed in the emptying time of the human stomach. [These include such proprietary preparations as Durabond, Dura Tab, Extentab, Gradumet, Repetab, Spacetab, Spansule. Ed.]

Except for study made possible by such rare accidents as that which gave Beaumont the injured Alexis St. Martin in 1819 long before full advantage could be taken of the opportunity, x-ray examination has been the method of choice in following the fate of ingested medicine and tablets in particular. Nearly always conducted on normal subjects, such studies have shown invariably that, because of individual variation, the time required for insoluble tablets to leave the stomach is remarkably unpredictable. In some subjects all tablets taken have left the stomach within 30 minutes, while in others similar tablets are retained for hours, even after eating a full meal. The pattern for any single individual is fairly reproducible.

The popular belief that only liquids pass through the pyloric sphincter is, of course, untenable. Fairly large tablets readily leave the stomach intact *provided* they are brought near the pylorus. The force of gravity can be drawn upon to hasten passage from the stomach, especially if persons in bed are placed on their right sides. In tests of this point, Gruber and his associates have shown that enteric-coated tablets passed out of the stomach quickly in each of several subjects



who turned on their right sides after having lain on the opposite sides for 6 hours, during which time the tablets remained in the lower curvature of the stomach. Blood analysis confirmed the lack of absorption of the tablet contents. Hence, for tablets that disintegrate but slowly or not until leaving the stomach, as is intended for those that are enteric coated, the tablet contents may be unavailable for hours.

## CHOICE BETWEEN FORMS OF THE SAME DRUG

The choice between two or more chemical forms of a drug depends upon both pharmaceutical expediency and the intended route of administration. Few students of medicine can take time to inquire into the pharmaceutical aspects of organic chemistry and to inform themselves of the elements that profoundly influence the performance of the drugs they prescribe. Therefore, they must rely upon the decisions made by others for pharmaceuticals provided in finished form.

**Simple Salts**—Different salts of the same drug rarely differ pharmacologically, the differences are usually based on physical properties. For physiologic as well as for chemical reasons, hydrochlorides are by far the most frequent choice of the available salt-forming inorganic radicals. For the same reasons, sodium is the most favored cation. Of the drugs recognized in the U.S.P., the hydrochlorides outrank the sulfates, the next nearest in frequency, nearly 4 to 1, and the sodium salts are in even greater preponderance. The bromide and iodide salts are never chosen over the chloride except by necessity both because these halogens are not inert pharmacologically and because they are more expensive. Ionic fluorine is used only in inorganic form as a specific prophylactic against dental caries, however, organically substituted in the structure of the drug principle, it may enhance pharmacologic activity remarkably.

For pharmaceutical reasons, the phosphate ion and various forms of sulfonates are used, for example, methanedisulfonate, ethanedisulfonate, and camphorsulfonate. The phosphate salts of the antimalaria drugs of the quinoline and acridine type were chosen because of better tolerance and greater efficacy after extensive comparisons in research conducted during the period from 1942 to 1946 as a military necessity. The choice of organic acid radicals is dictated by chemical and pharmaceutical attributes. Salt combinations with the monocarboxylic acids are generally insoluble in water and lend themselves to repository preparations. Those of the dicarboxylic acids (above oxalic, which is too toxic to use) confer water solubility if one of the carboxyl groups is left free, a notable example is the water soluble hydrocortisone sodium succinate.

Pharmaceutical chemists choose from the salts on the basis of convenience including cost of raw materials, ease of crystallization, stability, and such physical factors as hygroscopicity and flow characteristics of the resulting solid drug. The pharmacologist takes into account elements of toxicity which lead him to select sodium over potassium and those organic radicals that are readily excreted or metabolized.

For parenteral preparations, solubility and stability in solution are paramount considerations, and an objectionable taste poses no problem. In contrast, for oral preparations, taste is important, and often a taste problem is eliminated by finding

a water insoluble form of the drug in question. A good example is the antibiotic chloramphenicol, the hydrochloride of which is very soluble and bitter whereas the palmitate is so insoluble as to be tasteless.

**The Importance of Solubility**—Solubility is relative, of course, and as the term is used here has reference to water and body fluids as the solvents. The degree of solubility has important implications. Codeine phosphate is sufficiently more soluble than the sulfate to be the form of choice for parenteral solutions. This gives the phosphate an over all advantage, since it is equally suitable for all other applications, and accounts for its being the only salt of codeine recognized in the *United States Pharmacopeia*.

The preparation of soluble derivatives of today's complex molecules severely taxes the ingenuity of the chemist who works with synthetics. Where he has not yet succeeded, the pharmacist may be called upon to compromise as in the case of Mephyton Sterile Emulsion (sterile phytonadione emulsion, USP). This is the only sterile oil in-water emulsion recognized for intravenous use. The compromise was dictated by the need for a promptly effective form of this vitally important antidote to an overshooting of the mark in anticoagulant therapy. More recently Konakion has appeared to provide the same drug dispersed finely enough in an aqueous medium to give the appearance of a true solution.

The antibiotics and steroids which as a class are characterized by relatively large molecules, present several solubility problems. Not the least of these have been the difficulties with tetracycline which is practically insoluble in water above pH 3. The synthesis of Syntetrim, a substituted tetracycline, N-(pyrrolidinomethyl) tetracycline, is welcome since the new derivative is 2,500 times more soluble than tetracycline at the pH of body fluids. On the other hand, the relatively great solubility of the sodium and potassium salts of penicillin was a serious drawback because of rapid absorption from an injection site and prompt excretion. This was overcome first by the discovery of the procaine salt which is soluble in water to the extent of only about 6 mg per milliliter. Hundreds of other salts of simple and complex amine bases with penicillin have been prepared and examined of which benzathine penicillin and procaine penicillin have survived as the forms of choice for intramuscular use. Modifications of the acidic moiety of penicillin have yielded phenoxymethyl penicillin, which has remarkable stability to acid and thus has advantages over benzyl penicillin. The forms of penicillin recognized in the USP include two distinct penicillin molecules phenoxymethyl penicillin and benzyl penicillin (penicillin G), the potassium salt of the former and four salts of the latter i.e., sodium, potassium, procaine, and benzathine. The sodium and the potassium salts are virtually indistinguishable, but each of the two other forms has attributes which give it distinctive advantages.

**Aerosol Mists**—Pulmonary inhalation of drugs as a route of administration doubtless began with steam inhalation which is described in ancient medical records and is still useful. However, with drug steam vapors, the particle size is seldom small enough for the drug to penetrate beyond the trachea. Mists of particles 10 to 30 microns in radius that are obtained in "atomizers" may reach the bronchioles, but a reduction in radius to 3 to 10 microns is necessary to reach the alveolar sacs. Such particles are attained by use of nebulizers based on the Venturi

principle of passing a jet of air or gas across the top of a vertical tube, generally of capillary bore, immersed in a solution of the medicament. Making the jet stream of the drug solution impinge on a baffle subdivides the particles still further. This form of medication has gained great impetus as the result of ready availability of suitable propellents, for example, the inert gases, argon and nitrogen, and the fluorohydrocarbons, such as Freon, which liquefy under low pressures. This makes possible the modern form of aerosol packing of drugs that yield metered amounts of drug charged vapor on release. Fairly accurate metering of single bursts of vapor is highly important in dosage control. An additional attribute is the convenience of a compact, nonspillable package.

Such risk as exists from overdosage in using the aerosol packages can be prevented only by educating the patient to limit the number of applications. Responsibility for this should be assumed by both the physician, in prescribing, and the pharmacist, in dispensing the aerosol dosage forms.

Comparative studies show that the cardiovascular side effects of isoproterenol hydrochloride are less following aerosol administration than after sublingual dosage, both of which compare favorably with subcutaneous injection. The metered aerosols seem certain to replace the long-familiar dropper bottles of liquid inhalants or "nose drops" for administering the potent bronchodilators and those antibiotics of use in the local treatment of respiratory tract infections.

## SELECTED REFERENCES

- Blythe, R. H., Grass, G. M., and MacDonnell, D. R. The Formulation and Evaluation of  
Chapman, J. A. M. A. 191 206, 1959  
Dragstedt, J. A. M. A. 168 1652, 1958  
Gruber, Charles M., Jr., Ridolfo, Anthony S., and Griffith, Richard S. An Enteric Com-  
pression Coating. III. In Vivo Studies With Nitrocin Tablets, J. Am. Pharm. A  
Scient. Ed. 47 867, 1958  
Jarowski, Charles I. Superior Medicinals Achieved by Simple Chemical Modification. Tr.  
New York Acad. Sc. (Series II) 21 290, 1959  
Lazarus, J., and Cooper, J. Oral Prolonged Action Medicaments. Their Pharmaceutical  
Control and Therapeutic Aspects, J. Pharm. & Pharmacol. 11 257, 1959

## THE CHOICE OF DRUGS FOR CHILDREN

Alan K. Done, M.D

---

### INTRODUCTION

The effect of any drug is dependent upon an *interaction* between the drug and the recipient. Since individuals may differ markedly in biochemical make up, it is not surprising that there is striking variability in the response to drugs, even among adults. When the factor of immaturity is introduced, physiologic and biochemical differences are accentuated to the extent that the response to drugs can be predicted from adult experience only with considerable reservation. Indeed, the realization that children are not simply miniature adults with respect to reaction to disease or response to drugs is a *sine qua non* of successful pediatric practice.

### FACTORS IN DRUG SELECTION IN CHILDREN

A number of special problems enter into the proper selection of drugs for children. Among these are (1) the effects of immaturity on therapeutic response and toxicity, (2) difficulties in evaluating the effects of drugs, (3) the possibility of affecting growth adversely, and (4) difficulties in administration. Immaturity poses additional problems in that it may alter appreciably the response to disease and this, in turn, may influence the indications for, or response to, drug therapy. In general, the younger the child the more influential the factors listed above.

Once a drug has been selected, there is the problem of deciding upon dosage and the route and frequency of administration. The small size of the child is a major, though not the only, problem here. Some of the factors which apply to selection of the drug apply as well to the establishment of a safe and adequate dosage schedule.

**Immaturity and the Response to Drugs**—That the infant, especially during the neonatal period, differs from the mature individual with regard to functions of organs and tissues is becoming increasingly apparent. Recent and current investigations are uncovering more and more examples of incompletely developed enzyme systems, inadequacies in organ functions, and qualitative, as well as quantitative, differences in metabolic pathways in the infant as compared with the older child or adult. Some of these factors have obvious implications in terms of the treatment of children, while the therapeutic significance of others is, as yet, obscure. Un

fortunately, studies which are performed preparatory to the release of a drug for marketing seldom include observations on very young animals. However well the action and toxicity of a drug may have been delineated in the mature animal there is no assurance that a similar reaction will occur in the immature organism.

Immaturity may influence the response to treatment either directly through altered sensitivity to a drug or indirectly through a deficient ability to detoxify and/or excrete the medication. Because little specific information is available, it is possible at this time only to enumerate instances wherein immaturity has been observed to be associated with an altered response or there are strong theoretic reasons for supposing that such an altered response might occur. There is no question that additional study and observation will reveal the problem to extend far beyond these isolated examples, particularly with the development of new, more potent drugs. The possibility that immaturity may influence response should be considered in the selection of medications for children. Lack of specific knowledge on this point is a distinct contraindication to the use of any drug, at least in the newborn or premature infant and perhaps in older infants as well. As Kretschmer so aptly stated: "It is imperative that the pharmacology of an agent be investigated in the laboratory with the use of fetal and neonatal animals and only when this specific information is gathered should it be administered to infants."<sup>\*</sup>

**ALTERED SENSITIVITY**—Infants and young children are more susceptible than older individuals to the development of particular types of toxicity. Generally speaking they are more prone to develop dangerous disturbances in *acid base equilibrium* in response to drugs with this potential effect. For example, overdosage with salicylates not uncommonly leads to the development of metabolic acidosis in younger children, a complication which is rarely seen in adults even with comparable blood levels of salicylate.<sup>†</sup> Serious depletion of sodium and/or potassium from the use of diuretics is more likely to occur in younger children than in older individuals.

Children seem to be particularly susceptible to *stimulation of the central nervous system* by drugs. Delirium and/or convulsions occur rather commonly in children in response to toxic doses of drugs which rarely produce these manifestations in adults (e.g., salicylates, antihistaminics, amphetamine and related compounds, aminophylline and atropine). The feeling of many that children are more sensitive than adults to *central nervous system depressants* is not well substantiated although under certain circumstances the effects of drug induced depression are more likely to be deleterious. Dangers inherent in the production of respiratory depression in the face of acid base disturbances are discussed under "Influence of Disease."

**LIMITED ABILITY TO DETOXYFY AND/OR ELIMINATE**—There is considerable evidence that kidney function is not fully developed during early infancy.<sup>‡</sup> Con-

<sup>\*</sup>Kretschmer's commentary on the therapeutic implications of immaturity is recommended reading for anyone concerned with the drug treatment of children.

<sup>†</sup>Barnett and Vesterdal in an excellent review, discuss the application of knowledge concerning renal function in infancy to some of the clinical conditions where the knowledge

sequently, administration to the newborn or very young infant of a drug which depends upon the kidneys for elimination may result in higher blood levels which persist for a longer period of time. For example, because of decreased excretion penicillin can be given to infants in smaller doses at less frequent intervals to achieve comparable blood and tissue levels.

Recent experiments by Jondorf and associates and by Brown and Zuelzer have indicated that newborn animals may be deficient in the ability to form glucuronides with various compounds. Glucuronide conjugation is a major process in the inactivation of a number of well known drugs such as barbiturates, various phenolic compounds, antipyrine, sulfisoxazole (Gantisin) and chloramphenicol (Chloromycetin). It is to be expected that the administration to newborn infants of these and other compounds which depend upon glucuronide conjugation for detoxification may result in a more intense and prolonged therapeutic effect. It may also result in the accumulation of toxic levels of the drug or of other materials which must compete with the drug for glucuronide conjugation. Deaths have occurred in premature infants coincident with the administration of large doses of chloramphenicol (Chloromycetin). Presumably inadequate glucuronide conjugation and/or urinary excretion of the drug were responsible for its accumulation in the blood of these infants. (Doses of chloramphenicol 25 and 50 mg per kilogram per day in premature and full term infants respectively are said to be safe and are far below those received by the infants who died.) Sulfisoxazole (Gantisin) interferes with glucuronide conjugation and protein binding of bilirubin and its use has been associated with the development of jaundice and kernicterus in premature infants.

**Evaluation of Drug Effects**—Considerable difficulty may be encountered in determining when a child has received an optimal dose of a drug or in detecting the early development of toxicity. The infant or young child may be unable to report, or to describe accurately, subjective changes. In addition, some of the commonly used objective 'end points' (e.g. pulse and respiratory rates, blood pressure, activity, clarity of mentation) tend to be less predictable, and therefore sensitive, or may be obscured in the disturbed uncooperative child. From a practical standpoint, difficulty in assessing the adequacy of response or the development of toxicity in the child is tantamount to a lowering of the therapeutic index (ratio of toxic to therapeutic dose) of a variety of drugs. The possibility that this may be a problem in the individual case should be taken into account in choosing a drug and in following the course of therapy.

The use of digitalis serves as an excellent illustration of this point. The signs of digitalis intoxication (anorexia, nausea, and cerebral disturbance) are not easily recognizable in infants. Consequently, intoxication may not become apparent until severe. For this reason, when it becomes necessary either to adjust digitalis dosage or to 'push' digitalization in the infant, a more rapid preparation such as digoxin offers some advantage since it is obvious that any toxicity encountered be of short duration.

**Influences on Growth**—This is of course a problem in drug therapy that does not exist in the adult. The possibility of affecting growth should be an important consideration in the child only with respect to treatment with hormonal drugs. The long term administration of cortisone

compounds may result in inhibition of growth and osseous development. The sex hormones, particularly those which are androgenic (e.g., testosterone), although capable of stimulating growth, may result in an actual reduction of *ultimate* (mature) height. Adult stature is dependent not only on the rate of growth, but also on the age at which growth stops due to closure of epiphyses. Since androgens accelerate epiphyseal closure, the advantage of achieving an immediate growth spurt may be overshadowed by an eventual stunting of growth. Whether newer anabolic agents with diminished androgenic potency will promote growth but not early closure of epiphyses is doubtful. If, in spite of the above, continued androgen therapy for a child is decided upon, periodic x-ray examinations should be obtained to permit early detection of a disproportionate advance in skeletal maturation\*. If this occurs therapy either should be discontinued or reduced, unless the indications for treatment are impellent.

**Administration of Drugs**—Difficulties in administration may, by limiting the available routes by which a drug can be given, influence the choice of medications for a child. Vomiting occurs commonly in children as a nonspecific response to illness and may preclude the use of the oral route of administration. With few exceptions, however, the oral route is preferable from the standpoint of safety, avoidance of psychic trauma, and the preservation of rapport for future visits. The giving of pills to a struggling child or one too young to swallow them may result in aspiration. Similarly, the oral administration of oily or irritant medications may, under these circumstances, result in aspiration and the development of a chemical or lipid pneumonitis.

Drugs for oral administration should be made as palatable as possible. Distasteful powdered medications may be mixed with jam, jelly, honey, applesauce, or sugar, liquids can be masked with flavored syrups. Pleasantly flavored medications for pediatric use are being marketed with increasing frequency. However, their palatability increases the likelihood that they will be ingested accidentally in toxic amounts. It is safer to render potentially toxic drugs palatable at the time of administration than to tempt children by storing flavored preparations in the home.

Where oral medication is not feasible, some drugs can be administered by rectum. However, it must be determined beforehand that the substance in question is absorbable by this route. This route should not be used in the presence of diarrhea. The medication can be suspended in 1 or 2 ounces of water or starch solution and introduced through a catheter or with a bulb syringe. The buttocks then should be held or taped together to prevent evacuation. In general, the rectal dose is approximately twice the oral dose, though the assumption that this holds for all drugs is neither justified nor safe.

Parenteral administration of drugs may be necessary in some instances, but the advantages should be weighed against the psychic (and physical) trauma entailed by injections.

\* See also [1] for finding that a dose of 5 mg of testosterone per day was as effective as [2].

## INFLUENCE OF DISEASE

Certain characteristics of the childhood response to disease should be considered in selecting drugs for infants and children

**Narrow Margin for Error**—There is a *greater tendency for the dissemination or rapid progression of infection in children*. That is to say, there is a lesser margin for error in selecting the correct antibacterial drug and dosage schedule initially. Inappropriate or inadequate treatment with an antibiotic or chemotherapeutic agent may, through the loss of valuable time permit progression of the infection and the development of dangerous complications. Errors of this type are usually related to a failure to establish the correct etiologic diagnosis

It is neither practical nor rational however to delay antibacterial therapy pending availability of bacteriologic data in the child in whom such treatment seems definitely indicated. A satisfactory alternative is to "cover" the likely diagnostic possibilities with appropriate smears and/or cultures (nasopharyngeal, blood, spinal fluid, stool etc., as indicated in the particular case) prior to institution of treatment. The agent then selected should provide therapeutic coverage for the likely etiologic possibilities. This is particularly important in circumstances where it is not possible to obtain bacteriologic studies. At times, it is wise to institute treatment on the basis of epidemiological information. For example, if a child has meningococcemia and a sibling is found to be ill it is only sensible that treatment should not be denied the latter until the culture is reported or the clinical picture has become definable (and perhaps, irreversible). If and when cultures indicate that an inappropriate antibiotic was selected and/or it becomes obvious that the clinical course is not being affected favorably therapy should be changed accordingly.

Adequate coverage of etiologic possibilities and the prompt institution of indicated changes in the therapeutic program are particularly critical in such serious childhood infections as meningitis, osteomyelitis, pyelonephritis, septicemia, and in any infection in the newborn infant.

**Disturbances in Internal Homeostasis**—In the infant and young child, *fluid balance and acid-base equilibrium are disturbed more easily* and by a wider variety of abnormal circumstances than in the adult. Vomiting, diarrhea, fever, excessive sweating, and hyperpnea, each of which may result in the loss of substantial amounts of fluid, are seen as specific or nonspecific manifestations of illness far more commonly and to a greater degree in children than in adults. This problem is complicated further by the fact that maintenance of an adequate fluid intake is often difficult in the child who is ill and anorectic. Thus, dehydration, albeit subtle at times, is a relatively frequent occurrence in sick children and may result in significantly reduced renal function, particularly in infants.

Under these circumstances, the administration of a potentially toxic drug which is eliminated by the kidneys may be followed by hazardous accumulation. Furthermore, the potential deleterious effects of a drug on acid base equilibrium may be enhanced. For example, the administration of salicylate in usual therapeutic doses to a dehydrated infant or young child may lead to dangerous intoxication. Higher blood levels of salicylate may occur and, with or without this factor, acidosis is more likely to develop.



The production of respiratory depression by drugs may aggravate disturbances in acid base equilibrium in the child. Not only is respiratory compensation eliminated, but respiratory acidosis may be superimposed. For this reason, potentially depressant drugs, such as paregoric, should be used with extreme caution in the infant with severe diarrhea. Similarly, opiates should be used with caution in infants subjected to prolonged fluid deprivation incident to surgery.

## DOSAGE CONSIDERATIONS

There are few drugs for which adequate data are available concerning optimal doses for children. Consequently, various formulas, usually based on age or weight have been devised for calculating pediatric doses from those known to be effective in adults. However, these rules are not applicable to patients of all sizes. For example, the usually recommended digitalizing dose of digoxin ranges from 0.02 to 0.06 mg per kilogram, within this range, the younger the child, the higher the dose per kilogram of body weight. In small children, sulfadiazine is used commonly in doses of 200 mg per kilogram in the treatment of severe infections, in a 70 Kg adult, this would amount, on the basis of body weight, to a dose of 14 Gm.

*Table 1 Determination of Children's Doses From Adult Doses on the Basis of Body Surface Area*

Weight		Surface Area (Sq Meters)	Fraction of Adult Dose*
Kg	Lb		
2	4.4	0.15	0.09
4	8.8	0.25	0.14
6	13.2	0.33	0.19
8	17.6	0.40	0.23
10	22.0	0.46	0.27
15	33.0	0.63	0.36
20	44.0	0.83	0.48
25	55.0	0.95	0.55
30	66.0	1.08	0.62
35	77.0	1.20	0.69
40	88.0	1.30	0.75
45	99.0	1.40	0.81
50	110.0	1.51	0.87
55	121.0	1.58	0.91

\*Based on average adult surface area of 1.73 sq M

Crawford and associates, Snively, and others have noted that many of the fundamental physiologic processes such as water, electrolyte and caloric requirements, plasma volume, oxygen consumption, and glomerular filtration are essentially constant when compared on the basis of body surface area. The studies of Crawford and co-workers suggest that the calculation of dosage in terms of surface area offers the advantages of greater simplicity and accuracy than calculations based on body weight or age. Although there is some doubt as to the validity of body surface area as a unit of physiologic function, its application to the calculation of drug doses, other factors being equal, eliminates the need for using different dosage standards in various age groups\*. For example the average digitalizing dose of

\*Snively presents an illuminating discussion of the use of body surface area as a dosage criterion for fluid therapy from the standpoints of theory and clinical application. Oliver and associates have challenged the acceptance of surface area as a unit of physiologic function.

digitoxin is 0.75 mg per square meter of body surface area, regardless of the age or size of the individual. However, the observations cited in the section "Immaturity and the Response to Drugs" suggest that neither weight nor body surface area is a sufficient criterion for the accurate administration of drugs to infants. In the latter, it is imperative that the physician know whether immaturity poses problems other than the small size of the individual before any dosage criterion is employed. When available, experimentally determined or clinically established doses are to be preferred to those calculated on the basis of adult dose, regardless of the method of calculation.

Table 1 presents figures for estimating childhood doses of drugs from adult doses on the basis of body surface area.

It should be emphasized that no method of calculating doses provides for individual variations in response or obviates the necessity for careful clinical appraisal of appropriateness of dosage.

SELECTED REFERENCES

Barnett H. L., and Vesterdal, J. The Physiologic and Clinical Significance of Immaturity of Kidney Function. *Am J Med* 23: 66, 1957.

Brown, A. K., and Zuelzer, W. Conjugating System. *Am J Med* 23: 66, 1957.

Crawford, J. D., Terry M. tion by Application. *Am J Med* 23: 66, 1957.

Goodman, L. S., and Gilman. *Pharmacology*. New York, 1955. The Macmillan Co.

Jondorf, W. R., Maickel, R. P. and Brodie, B. B. Inability of Newborn Mice and Guinea Pigs to Metabolize Drugs, *Biochem Pharmacol* 1: 352, 1959.

Kre. *Am J Med* 23: 66, 1957.

Kre. *Am J Med* 23: 66, 1957.

Leis. *Am J Med* 23: 66, 1957.

Nadas, A. S., Rudolph, A. M., and Reinhold, J. D. L. The Use of Digitalis in Infants and Children. *New England J Med* 248: 98, 1953.

Nelson, W. E. *Textbook of Pediatrics*, ed. 6. Philadelphia, 1954, W. B. Saunders Co.

Neter, E., and Karzon, D. T. Pediatric Dosages and Routes of Administration of Antibiotics, *Am J Med* 23: 66, 1957.

Snively, V. D. T. *Am J Med* 23: 66, 1957.

Sobel, E. *Am J Med* 23: 66, 1957.

Unna, K. R., Glaser, K., Lipton, E., and Patterson, P. R. Dosage of Drugs in Infants and Children. I. Atropine, *Pediatrics* 6: 197, 1950.

Wallace, W. M. The Use of Salicylates in Pediatrics, *Quart Rev Pediat* 9: 135, 1954.

## THE CHOICE OF AGENTS TO ADJUST AND MAINTAIN INTERNAL HOMEOSTASIS

*Paul L. McLain, M.D., and*

*Frederick R. Franke, M.D., D.Sc. (Med.)*

### INTRODUCTION

The concept of internal homeostasis, first clearly enunciated by Claude Bernard, is now thoroughly entrenched in medical thinking. Indeed, the preservation of a cellular environment consistent with normal function may well be considered the ultimate purpose of most physiologic mechanisms, and the restoration or maintenance of such conditions the ultimate aim of most if not all therapy. Sober a view, however valid, is rather esoteric, but there is an area of practical therapeutics which bears directly on the problem, namely, that pertaining to the maintenance and repair of the various body fluids. The present chapter is restricted largely to this latter field.

The following brief review of fluid distribution and composition in the human body is presented as a background for discussion of specific therapeutic measures.

**The Fluid Compartments**—Many valid considerations support the concept that body fluids occupy three major compartments, separated from each other by cellular membranes which are, in general, freely permeable to water and to many organic and inorganic solutes, nearly impermeable to particles of the dimensions of proteins, and somewhat selectively permeable to certain critical ions such as  $\text{Na}^+$ ,  $\text{K}^+$ ,  $\text{Mg}^{++}$ , and  $\text{Cl}^-$ . The three compartments are designated respectively as cellular, comprising the fluid of the cells themselves, interstitial, consisting of fluid immediately surrounding the cells, and vascular, comprising the fluid of blood plasma. The term extracellular fluid is often employed and includes both interstitial and vascular fluids. It is important to realize that all fluid exchange between the organism and its environment must be mediated through the vascular compartment, the avenues for such exchange being the skin, the lungs, the gut, the kidneys. Similarly, the only avenue of exchange between the cellular and vascular compartments is the interstitial fluid. Thus, the integrity of the cellular fluid is guarded from environmental onslaught by two "buffer states."

**Volume of Body Fluid**—The volumes of fluid in the several compartments are relatively constant, and the methods available yield clinically

useful results. One of the chief determinants is body size, especially the lean body mass, and there is apparently a notable difference between the sexes. A frequently quoted working estimate for a 70 Kg man places the volume of the vascular compartment (expressed as plasma water) at 3 liters, that of the interstitial compartment at 14 liters, and that of the cellular compartment at 29 liters. According to this estimate, the total body water is about 660 ml per kilogram of body weight. One must not confuse the vascular fluid compartment with the total blood volume, since the latter includes about 45 per cent of cellular material whose fluid correctly belongs to the cellular compartment.

**Composition of Body Fluids**—The body fluids are essentially solutions of electrolytes in which the opposing ionic charges are balanced. Each fluid compartment of the body has a distinctive solute pattern, which is apparently determined by the relative diffusibility of the various materials through the several separating membranes. It is generally held that the final distribution of ions at equilibrium on the two sides of a membrane is in accord with the Donnan theorem, which states, in effect, that the concentration products of the diffusible anions and cations on opposite sides of the membrane are equal. The presence of large numbers of poorly diffusible ions, such as the protein anions in plasma and cellular fluid, results in differences among the compartments in their total electrolyte concentrations. Thus, the total electrolyte concentration of plasma is about 310 mEq per liter, that of interstitial fluid about 300, and that of cellular fluid about 390 (Table 2). In general, the greater the concentration of nondiffusible ions, the greater is the total electrolyte concentration.

*Table 2 Normal Electrolyte Patterns of the Body Fluids\**

	<i>Plasma (mEq/Liter)</i>	<i>Interstitial Fluid (mEq/Liter)</i>	<i>Intracellular Fluid (mEq/Liter)</i>
<b>Cations</b>			
Na <sup>+</sup>	142	138	14 (?)
K <sup>+</sup>	5	5	157
Ca <sup>++</sup>	5	5	—
Mg <sup>++</sup>	3	3	26
Totals	155	151	197
<b>Anions</b>			
Cl <sup>-</sup>	103	108	—
HCO <sub>3</sub> <sup>-</sup>	27	27	10
HPO <sub>4</sub> <sup>-</sup>	2	2	110
SO <sub>4</sub> <sup>-</sup>	1	1	1
Organic Acids	6	6	—
Protein	16	2	74
Totals	155	146	195

Note. Apparent imbalance of total anions and cations results from uncertainty of some of the analyses.

\*After Bland, J. H. *The Clinical Use of Fluid and Electrolyte*, W. B. Saunders Co., 1952.

Excepting its relatively great protein content, plasma has virtually the same chemical composition as does interstitial fluid. This fact is of great practical importance because it permits inferences concerning the composition of interstitial fluid from chemical analysis of plasma, a much more accessible fluid. In both, the

major cation is  $\text{Na}^+$ , and the major anions are  $\text{Cl}$  and  $\text{HCO}_3^-$ . Both fluids contain small concentrations of  $\text{K}^+$ ,  $\text{Ca}^{++}$ ,  $\text{Mg}^{++}$ ,  $\text{HPO}_4^{--}$ ,  $\text{SO}_4^{--}$ , and anionic organic material. Both contain small concentrations of nonelectrolytes, the most impressive of which, quantitatively, are phospholipids, cholesterol, neutral fat, and glucose.

Cellular fluid differs markedly from extracellular. Here, the chief cation is  $\text{K}^+$ , while only small amounts of  $\text{Na}^+$  are ordinarily found, and  $\text{Mg}^{++}$  is much more prominent than in plasma or interstitial fluid. Among the anions,  $\text{Cl}$  is conspicuous by its scarcity, its place being taken largely by  $\text{HPO}_4^{--}$ . The concentration of  $\text{HCO}_3^-$  is lower than in extracellular fluid, that of  $\text{SO}_4^{--}$  about the same. The protein concentration of cells is, of course, greater than that of plasma, and far exceeds that of interstitial fluid.

**Dynamics of Body Fluids**—Again with the exception of protein differences the striking feature of comparison among the various fluids is the tendency of  $\text{Na}^+$  and  $\text{Cl}$  to remain extracellular while  $\text{K}^+$  and  $\text{Mg}^{++}$  become concentrated within the cells. The cause and full significance of this distribution are not understood, but for all practical purposes one may consider that the capillary membrane is freely permeable to these ions while the cell has some mechanism, whether or not it be a property of the membrane, which normally keeps it nearly free of  $\text{Na}^+$  and  $\text{Cl}$ . The property just described, often called selective permeability, is impaired when cells are damaged or killed. Under these conditions the segregation of  $\text{Na}^+$  and  $\text{K}^+$  into separate compartments disappears.

**DIFFUSION**—While the fluid compartments are anatomically distinct, physiologically they form a sort of continuum subject to massive exchanges of materials, especially water. Several kinds of forces are active in producing shifts of water, ions, and nonelectrolytes among the fluid spaces. Perhaps the most important of these is *diffusion*, the migration of a particle species in response to a concentration gradient. Diffusion across membranes can occur, of course, only if the membrane is permeable to the ions or molecules in question. In general, a material which is diffusible (i.e. to which the membrane is permeable) will tend to move in the direction of the lower concentration of that particular material until the concentrations on each side of the membrane are equal. At this point, rates of diffusion are equal in the two directions, and migration apparently ceases. In the case of the body fluids, as noted above, the equilibrium state is not that of equal concentrations of all diffusible ions because of the restraining effects of the undiffusible ions such as proteins.

**OSMOSIS**—Materials in solution, even when they are rather freely diffusible, are responsible for movement of water across membranes by the process called *osmosis*. Strictly, osmosis is diffusion of water rather than of solute. It depends upon the fact that, in relation to the body membranes, body water is much more diffusible than any of the materials normally dissolved in it. If, therefore, unequal total concentrations of solutes exist on opposite sides of a membrane, the same must be true of water. Water then diffuses in the direction of the greater solute concentration because that is the direction of the lower water concentration. In the case of diffusible solutes, the water diffusion has the greater velocity, and there will be some exchange of solute in the opposite direction before equilibrium is attained. Nondiffusible solutes, on the other hand, are trapped on one side of the

## AGENTS TO ADJUST AND MAINTAIN INTERNAL HOMEOSTASIS

membrane, and water transfer is the only means of approaching equilibrium. In general, the osmotic activity of dissolved material depends upon the total particle concentration of the solute or solutes present. In this regard, ions are the equivalent of molecules. When the system is in equilibrium the osmotic activities of the three fluid compartments of the body are nearly equal, i.e., the vascular, interstitial and cellular fluids are isotonic, each with the others.

**HYDROSTATIC PRESSURE**—Since diffusion across membranes depends upon the random contact of particles with the membrane, forces which increase the likelihood of such contact will increase the rate of diffusion. *Hydrostatic pressure* is such a force and it operates especially between the vascular and interstitial fluid compartments. The blood pressure in the capillaries has an important influence on the diffusion of vascular fluid into the interstitial space. This effect is not balanced by any comparable hydrostatic pressure in the tissues, but the osmotic effect of the plasma colloids, tending to effect diffusion of water from the interstitial into the vascular compartment, is of comparable magnitude and, in fact, often exceeds the blood or plasma hydrostatic pressure. The balance of these opposing forces determines the direction of fluid exchange at any point in the vascular tree where such exchange is possible.

The mechanisms of fluid and solute exchange thus far considered are purely physical. There are situations, however, in which material is transferred from one compartment to another against a concentration gradient. Such is the case, for example, in the exclusion of  $\text{Na}^+$  and  $\text{Cl}^-$  from cells and in the intracellular accumulation of  $\text{K}^+$  and  $\text{Mg}^{++}$ . Maintenance of concentrations in opposition to physical gradients is assumed to require metabolic work which in the cases mentioned, is performed by the cells. The details of this cellular operation can only be surmised at present and are not essential to practical application of the result.

**BUFFER SYSTEMS**—Another important property of the body fluids, intimately related to their chemical constitution, is reaction or hydrogen ion concentration. Through a series of so called buffer systems, the extracellular fluids are normally maintained in a slightly alkaline state not far from neutrality ( $\text{pH } 7.36-7.41$ ). The chief characteristic of a buffer system is its ability to withstand the addition of relatively large amounts of acid or alkali with only a small shift in final reaction or pH. This effect depends upon the ionization characteristics of weak acids and their salts, whereby both the undissociated molecule and the anion exist simultaneously in the fluid. A typical body buffer system comprises  $\text{NaHCO}_3$  and  $\text{H}_2\text{CO}_3$ . The  $\text{NaHCO}_3$  provides the ion  $\text{HCO}_3^-$ , which, with the undissociated acid, makes up the requisite combination. Addition of a strong acid to a solution containing these two substances has the effect of increasing the concentration of nonionized  $\text{H}_2\text{CO}_3$  at the expense of the  $\text{HCO}_3^-$ . The actual change of pH is much smaller than that which would occur in the absence of the buffer system.

In addition to the bicarbonate system, body fluids are buffered by phosphate and protein systems which operate in a similar manner. Proteins are highly important buffer constituents of blood and cells. Two or more sets of buffers interact in such a manner that the final pH corresponds to the final concentration ratio of any of the buffer pairs. It is possible, therefore, to estimate pH from analyses for a single buffer pair, such as  $\text{HCO}_3^-$  and  $\text{H}_2\text{CO}_3$ . The relationship is expressed by the

the following form of the familiar Henderson Hasselbach equation

$$\text{pH} = 6.1 + \log \frac{[\text{HCO}_3^-]}{[\text{H}^+ \text{CO}_2]}$$

There is ample evidence that the volume, composition, and reaction of the body fluids are important to the organism. They are normally maintained within remarkably narrow limits, and serious dislocations are attended by some danger. Abnormalities in volume may be estimated by dilution methods, but are, in practice, often inferred from clinical data and from the results of physical and chemical analysis of the blood and plasma. Reaction may be measured, calculated, or simply inferred. Rational therapy directed toward the body fluids must, of course, take cognizance of the abnormalities known or assumed to exist, and is based upon the principles here considered.

## CLINICAL APPLICATIONS

Internal homeostasis is dependent upon adequate intake of electrolytes and water (which are usually consumed in excess of actual needs), balanced by selective excretion. Water loss is partitioned, in the main, between skin and lungs on the one hand and the kidneys on the other. Under ordinary conditions, extrarenal excretion of water occurs without important loss of electrolytes. It is an important factor in the regulation of body temperature and is markedly altered by environmental conditions and by disease. Urine volume varies so as to complement extrarenal water loss in balancing the intake. The kidneys also assume the major role in electrolyte excretion and conservation. Urinary output is regulated by a complex system of receptors and effectors which include the hypothalamus and posterior pituitary.

### Disturbances in Homeostasis

Abnormalities of the body fluids may be classified, for the sake of convenience, into two broad categories: those of volume or distribution, the effects of which are predominantly mechanical, and those of composition, with chiefly chemical or metabolic consequences. The distinction is somewhat artificial, since volume and composition are not independent variables. However, there is justification for considering one or the other factor as dominant in many clinical situations.

**Disturbances in Volume**—Abnormalities in volume may, of course, be in either direction and tend to distribute themselves, albeit unevenly, among all the fluid compartments. The cellular compartment is remarkably well protected against large variations in volume and is, in any case, relatively inaccessible to examination. The extracellular volume is much more labile and not infrequently undergoes significant changes, with readily recognizable results.

**DECREASE IN EXTRACELLULAR FLUID VOLUME**—Independent alterations of vascular and interstitial volumes do not long persist because the capillary membrane is freely permeable to water and most solutes, and large gradients may be developed rapidly. It is possible, however, to have in effect an almost pure or uncomplicated depletion of the vascular compartment for a long enough period to produce serious trouble. The most obvious example of this condition occurs with sud-

den and severe hemorrhage. If the vascular volume is decreased beyond the ability of the organism to compensate by vasoconstriction, venous return to the heart is impaired and cardiac output falls. The critical result of this sequence is diminution of oxygen delivery to the tissues. It should be emphasized that these events may occur without anemia and, indeed, with a normal amount of circulating hemoglobin. The defect is primarily one of circulating volume, it may be aggravated, of course, by co existing hemoglobin deficiency. If defective oxygenation of the tissues is allowed to persist, irreversible changes occur which make restoration of function difficult or impossible.

**Causes** In general, significant reduction in vascular fluid volume is apt to be a part of the clinical syndrome usually referred to as "shock." In such conditions, the plasma volume may be reduced with little change in the actual red cell volume. Extensive burns, crushing trauma, and intestinal obstruction are offenders in this respect. Of course, the dynamic effects of low blood or plasma volume are evident whether or not there are co existing abnormalities in the other fluid compartments.

When plasma volume is reduced some depletion of interstitial volume almost certainly occurs within a short time. Consequently, from the standpoint of fluid balance, the extracellular compartments are properly considered together. The clinical states mentioned above actually reduce the volume of the entire extracellular space. Moreover, the changes may not be properly distributed to bring into prominence the mechanical effects upon the circulation which are so characteristic of severe blood or plasma loss. Thus dehydration, as from excessive sweating, water deprivation, diuresis, or diarrhea, may seriously deplete the extracellular, or even the intracellular, fluid without inducing circulatory collapse.

Shocklike states, associated with hypotension, favor transfer of fluids from the interstitial into the vascular compartment. Extensive vasodilation may produce a relative hypovolemia, with the general dynamic phenomena of reduced blood volume, but without actual loss of fluid from the vascular circuit. Under such conditions (e.g., in so called neurogenic shock), decrease in interstitial volume may occur while plasma volume actually increases.

Water loss, both renal and extrarenal, derives immediately from the extracellular fluid compartment. In order to maintain internal homeostasis water loss to the environment is followed immediately by adjustments in the other compartments to protect the body against marked changes in a single compartment. Thus, loss from the extracellular fluid is compensated by release of water from the cells because of the resultant increased osmolarity of the extracellular fluid, loss of potassium from cells causes even greater cellular dehydration.

Dehydration is one of the most common and important causes of volume defect and, depending upon its rapidity of development, may be considered either acute or chronic. Clinically it is seen in subjects whose water intake is markedly decreased. This status may be self-imposed as in the psychotic or aged, associated with infection, brain injury, pain, drugs, and sedatives, or related to physician dictum as frequently seen in pre- and postoperative fluid restriction. As the body solutes become more concentrated, subjective and objective manifestations occur. Thirst is a frequent complaint, increasing as urine volume decreases and its specific



gravity rises. Mental changes such as lassitude and apathy develop going on to disorientation, confusion and even mania. Signs of dryness are seen in the condition of the tongue and mucous membranes, poor tissue turgor and soft muscles and eyeballs. Decreased blood pressure, rapid pulse and even peripheral circulatory failure may develop.

**INCREASE IN EXTRACELLULAR FLUID VOLUME**—Plethora occurs as an isolated phenomenon chiefly in response to overenthusiastic fluid therapy. Excessive intake of water or hypotonic solutions of crystalloids will produce a primary increase in plasma volume which is soon shared by the interstitial spaces. Hypertonic solutions or more particularly colloid solutions (including plasma and blood) can on the other hand induce sufficiently high blood volumes to embarrass the circulation with little immediate effect on the interstitial compartment.

Excessive oral water intake with properly functioning renal and adaptive mechanisms will not produce positive water balance and retention. The kidneys rapidly excrete the water so that loss equals intake and with overwhelming intake excretion may be so massive as to result in a decrease in body weight.

More commonly excess of extracellular fluid is the result of some circulatory or renal deficiency which interferes with proper elimination of water. In disease states associated with oliguria or anuria, water overloading which cannot be met by increased excretion through insensible routes results in increased total body water, both extra- and intracellular. The effect is then that of sodium and potassium dilution with water intoxication. Subjective and objective signs of excessive hydration are related to the increased volume of water and also to its excess in relation to sodium content. The manifestations may be associated either with increased intracranial pressure, dilution of electrolytes or excretion of water excess. The first two conditions produce headache, papilledema, vomiting, muscular cramps or twitchings, respiratory changes and convulsions while water excess is partly relieved by vomiting, diarrhea and excessive salivation. Hypertensive encephalopathy and the central changes of eclampsia may be due to water intoxication. Vascular engorgement results in pressure elevation, skin edema and the excretion of low gravity, low chloride urine. Blood analyses may show dilution of solutes and cellular elements.

#### Disturbances in Composition —

**RELATION BETWEEN VOLUME AND COMPOSITION**—In the maintenance of the internal environment of the body, water content and sodium concentration are interdependent although a deficit of one without a corresponding deficit of the other may well occur. The demand of a known amount of sodium for a certain amount of water is well established. Changes in electrolyte pattern and concentrations of specific ions may be more important in their effect on body well-being than even changes in water volume. Examples of this occur in such states as severe hyponatremia or acidosis. Certainly changes in volume and extracellular fluid composition are met with changes in intracellular volume and composition. Present concepts relating to sodium retention as the background for the development of congestive failure indicate the complexity of the interrelationship between volume and composition. The problem of acid-base balance further complicates the fluid

position, concentration, and regional distribution are present simultaneously, and therapy may have to be aimed at the one which seems clinically the most important

**ALTERATION IN ELECTROLYTE PATTERN**—Paleochemistry would seem to indicate the evolutionary relationship of our extracellular fluid with marine ancestry. Particularly suggestive is the similarity of sodium concentration in extracellular fluid and sea water, although total ionic concentrations are different. The fluid compartments of the body have been reconstructed experimentally from data on the intact organism by dilution techniques, isotope dilution and turnover techniques, balance studies, and analysis of tissue samples. Such information now enables us to estimate the composition of body fluids in both health and disease. Bicolumnar diagrammatic representation of cations and anions making up the total ionic composition of the extra- and intracellular fluid is common practice and is used clinically as an aid in diagnosis and therapy. Clinical inferences as to specific ion content may be made from analysis of extracellular sodium, potassium, chlorides, and bicarbonate, and therapy is guided by serial determinations to estimate intracellular change.

**Specific Important Ions** While sodium is the predominant extracellular cation, chloride is the main anion and, although their concentrations are not identical, they are associated in a proportion of 3:2. Since chloride determinations are more available and perhaps generally more accurate than those of sodium, chloride analysis may serve as a guide to changes in both ions. In disease states, the proportion may be disturbed, so there are limitations to the evaluation of body fluids and required therapy by this method.

Sodium is maintained at a constant level despite alterations in intake chiefly by tubular reabsorption of the filtered ion. Adrenal corticosteroids, possibly a specific one, aldosterone, control this function in association with the anterior pituitary and higher brain centers.

Ingested potassium, which is perhaps more incompletely absorbed than sodium, enters the intracellular fluid, where its concentration is some 15 to 20 times the extracellular, or it may be excreted by way of the skin, intestinal tract, or urine. Since growth, repair, and glycogenesis require potassium, its intracellular importance is obvious. Regulatory mechanisms keep the low extracellular potassium levels relatively constant, but intracellular potassium may be decreased considerably. The adrenal corticosteroids which facilitate tubular reabsorption of sodium increase tubular secretion or markedly limit tubular reabsorption of potassium.

In general, chloride is maintained by the same factors which regulate sodium. In disease or stress, the effect of adrenal cortical hormones is probably more upon sodium than upon chloride. Vitamin D and the parathyroid hormone regulate calcium and phosphorus metabolism either by increasing absorption of ingested calcium or by increasing excretion of inorganic phosphorus from the body. Regulation of magnesium is poorly understood at present but elevations are associated with renal failure and diabetic coma, while depletion is associated with vasomotor depression, respiratory failure, and hypothyroidism.

**Alterations in Acid-Base Balance** Since metabolism produces sufficient acid to alter seriously the buffer system guarding body pH, this system must maintain its integrity for the protection of the internal environment. Studies on the status of any buffer system such as, for example, that of bicarbonate are valid for that

system in intracellular as well as extracellular compartments. To maintain the constancy of pH with continuously acid producing metabolism, elimination of relatively strong acids neutralized by the buffer system must take place. This is accomplished by excretion of free organic acids in acid urine as well as monobasic phosphates as buffer pairs. The latter are in salt to acid ratios which are smaller than those of the ultrafiltrate from which the urine was formed, so that base is conserved. Ammonium salts of these acids and ammonium ion formed from ammonia remove both the anion and cation (hydrogen ion) of the original acid. Alkali cations are further conserved by the tubular excretion of hydrogen ions, which further acidifies urine. By such action, which is essentially elimination of stronger acids than those neutralized, the buffer system ratios, and hence the pH, are kept constant. Carbonic acid is eliminated by way of the lungs as carbon dioxide, in alkalosis, bicarbonate may be excreted by the urine with the excess cation, and chloride is retained.

Bicarbonate makes up approximately one-fifth of the anions, protein one tenth, and chloride the remainder. As long as buffer salts are available, carbon dioxide, being constantly produced by metabolism, serves as an inexhaustible source of reserve bicarbonate. No such reserve of chloride is available but total anion concentration is adjusted by the ability of the body to convert carbon dioxide to bicarbonate and to excrete carbon dioxide by ventilation or bicarbonate in the urine. Sodium makes up approximately nine tenths of the total cation and is roughly proportional to the sum of the bicarbonate and chloride anions except in disease, when the other anions (organic acids, sulfate, phosphate) may be in excess of normal.

*Clinical States Commonly Associated With Ion Defects* <sup>1</sup> Starvation occurs in clinical conditions which interfere with the intake of foodstuffs. Loss of weight is associated with loss of body substance, mainly fat stores and tissue protein. Nitrogenous wastes as well as acetone bodies tend to accumulate with this process, and potassium is released from cells. As potassium enters the extracellular fluid, its excretion is increased but considerable conservation takes place so that sodium excretion is markedly diminished. Late effects include increases in extracellular volume, decreased protein levels and lowered cholesterol.

<sup>2</sup> Vomiting leads essentially to dehydration and starvation, with the added effect of loss of electrolyte in the vomitus. Large quantities of sodium, potassium, and chloride are lost in this way, as well as large volumes of body water. Metabolic alkalosis occurs, with chloride loss disproportionately greater than sodium loss compensated by retention of carbon dioxide, increase in bicarbonate, and resultant rise in pH.

<sup>3</sup> Diarrhea is similar to vomiting except that the loss of electrolytes in liquid stools includes bicarbonate in addition to sodium and potassium. Metabolic acidosis therefore occurs and may be increased by starvation, renal failure, and hyperchloremia. Dehydration may be so severe that normal or elevated plasma electrolyte concentrations may be observed despite marked body depletion.

Sweating as seen in fever states or elevated environmental temperatures incurs losses of sodium, chloride, and potassium beyond the renal excretion of these substances and may produce important deficits.

Kidney malfunction may exaggerate volume deficits of any type if the reabsorptive capacity of the tubules is impaired. Conservation of sodium and chloride usually persists even in advanced kidney disease so that deficits in these ions do not usually occur. Chronic renal disease may occasionally be associated with potassium loss. Renal loss of phosphate may occur under unusual conditions as may deficits of calcium and protein.

Excesses of sodium and chloride occur frequently in patients with normal excretory apparatus and are seen for example in premenstrual fluid retention. Since sodium excretion may be based upon several previous days' intake, warm weather weight changes may be associated with relative sodium retention. Disease of the kidneys, endocrines and central nervous system are associated with salt retention, edema and congestive failure. Salt retention and edema may also develop during certain stages of hepatic cirrhosis and the toxemias of pregnancy. The underlying cause here may be specifically related to excessive tubular reabsorption of sodium (and therefore chloride) because of excessive adrenal cortical or some related function.

Excesses of potassium like those of sodium are related to volume changes. Hyperkalemia may be a manifestation of dehydration rather than of increase in total potassium. Extracellular increase in potassium such as may occur in anoxia, diabetic coma and diarrhea is rapidly disposed of by the kidneys so that persistent elevations are seen usually in association with anuria or oliguria. An increase in total potassium would occur only in kidney disease or some disturbance of excretion such as adrenal insufficiency. Cellular potassium increase at the expense of extracellular potassium may occur in periodic paralysis with insulin or glucose therapy or cell repair. Muscular and neurological function may be altered by potassium variation. The former is commonly detected in the electrocardiogram. Since the electrocardiogram reflects cellular potassium, the typical effects of hyperkalemia in the trace may precede or lag those of extracellular potassium by some 24 hours.

Acid base disturbances may be of the metabolic type, usually associated with a primary disturbance of the bicarbonate buffer system, or the respiratory type associated with alteration of carbonic acid elimination. In these disturbances protective mechanisms may maintain the pH but associated changes in volume and composition of body fluids frequently occur. Much of the symptomatology may therefore be due to loss of body water and sodium as previously discussed. Metabolic alkalosis due to alkali retention is not commonly seen but is produced when excess bicarbonate is given. Related to it is sodium retention, so that fluid retention and edema may also be present. Metabolic alkalosis due to acid loss is frequently seen in prolonged and severe vomiting with loss of hydrochloric acid; related to this is dehydration. Loss of extracellular fluid may be so marked as to keep electrolyte concentrations deceptively high. Metabolic acidosis is observed more frequently than alkalosis and may be due either to retention of acid or to alkali loss. In the former, carbon dioxide combining power decreases as buffer salts react with stronger acids produced by altered metabolism. Excretion of acid depletes sodium and with this decrease in sodium extracellular fluid volume decreases. Characteristically, electrolyte analysis reveals increase in organic acids, reduction of bicarbonate, compensatory loss of carbonic acid with hyperventilation and reduction of chloride. Metabolic acidosis may be due to alkali loss because of inability of

the kidney to conserve base or from severe loss of lower intestinal tract secretions. Here loss of chloride and fluid is accompanied by dehydration. Critical acid may be present with relatively little change in carbon dioxide combining power because of fluid loss, but the loss of alkali may be such that only a slight further progression of acidosis can be overwhelming. Respiratory alkalosis may be in any clinical condition characterized by marked hyperventilation. Here respiration of bicarbonate takes place, with resultant decrease in carbon dioxide combining power which may be mistaken for acidosis. With this type of alkalosis, urine is alkaline and follows the pH of the plasma. Respiratory acidosis is seen when carbon dioxide accumulates due to pulmonary disease. With this type of acidosis, the alkali reserve rises to accommodate to the carbon dioxide excess. A possible false interpretation of alkalosis may be avoided by demonstration of a high urine or decreased serum pH.

**ALTERATIONS IN COLLOID PATTERN**—Plasma colloid depletion, by diminishing the colloidal osmotic activity of the plasma, may upset the normal balance of forces controlling the exchange of fluid between the vascular and interstitial compartments. Specifically, this defect leaves the hydrostatic pressure in the capillaries relatively unopposed, and favors transfer of fluid from the plasma into the interstitial compartment. The edema of hypoproteinemia has been generally attributed to such an effect. A similar result would follow from excessive leakage of proteins from plasma into the interstitial fluid. Normally, a small amount of such protein leakage is known to occur, but the colloid is prevented from accumulating in the interstitial fluid by virtue of the lymphatic drainage. Should the lymphatics be blocked or otherwise rendered nonfunctional, the rising colloidal osmotic activity of the interstitial fluid, especially in view of the low hydrostatic pressures of the tissues, would favor edema formation at the expense of plasma water.

**ALTERATIONS IN RESPIRATORY FUNCTION OF THE BLOOD**—The importance of homeostasis of adequate oxygenation of the tissues requires no discussion, nor does the relationship of hemoglobin concentration or oxygen carrying power of blood to the entire process of cellular respiration. The most important defect in this area is anemia, which, of course, has numerous causes. The effect of anemia may be produced by intoxicants which, like carbon monoxide or methemoglobin formers, render the hemoglobin incapable of carrying the normal oxygen load. Enzymic poisons such as the cyanides, prevent the uptake of oxygen by the tissues even from normally oxygenated blood.

Hemoglobin excess is not of itself harmful, but mechanical difficulties may result from a severe polycythemia. Polycythemia may be associated with increased normal, or diminished blood volume, and the effects of these are not related to the excess of cells. If, however, there is a marked increase of red cell volume relative to plasma volume, the viscosity of the blood is increased in proportion to this excess. While it is possible that high viscosity may result in sluggish circulation through the capillaries, the viscosity change associated with moderate polycythemia is probably of little importance.

## GENERAL PHARMACOLOGIC CONSIDERATIONS

In general, the rational treatment of fluid imbalance is directed toward the spe-

been implied, the abnormalities are usually multiple, although one may predominate in a given situation. The major therapeutic objectives constitute the primary subdivisions of this section. Extensive advice of a specific nature is included in the many excellent monographs available and cannot be included here.

**Fluid Replacement**—Replacement therapy is designed to restore the normal physicochemical environment of the cells and the normal volume relationships of the fluid compartments of the body. The plan of therapy is based upon some sort of estimate, preferably both qualitative and quantitative, of the existing state of the body fluids. Decision as to how much of what kind of fluid to administer requires, in addition to certain laboratory aids, no little clinical knowledge and judgment, since estimates of abnormalities in volume and/or composition are, at best, imprecise. It is important, in other words, to know how various clinical entities generally affect the fluid balance. In addition, the clinical situation introduces the element of time and dictates whether the treatment must be immediate and heroic or may be expectant and conservative. Similar considerations will affect decisions regarding the route of administration.

The greatest danger in connection with fluid therapy is overdoing it. This possibility exists both for fluid volume and for certain specific constituents. Accordingly, experienced clinicians do not attempt a complete correction of estimated deficits within the first 24 hours of treatment, especially when the deficits are thought to be great. The implication is not, of course, that large volumes may not be given within a short time when indicated, as, for example, in severe hemorrhage or advanced dehydration, but that the first estimate of total requirement may be in serious error, and that certain physiologic mechanisms may be overtaxed. The only safe guide in the course of fluid therapy is the response of the patient, assessed by his clinical progress and the results of timely laboratory examination of his blood and urine.

It is well to remember that the administration of large quantities of fluid parenterally may result, inadvertently, in giving too much of some particular constituent of the solution. Each liter of 0.9 per cent sodium chloride solution, for example, contains 9 Gm of salt, including about 155 mEq of sodium. This is a considerable fraction of the average daily sodium turnover. Several liters of such a fluid might be administered in the course of 24 hours, and under conditions of impaired sodium excretion. Special caution must be exercised in the administration of solutions containing potassium because of its marked toxicity on the heart. While less often given in dangerous quantities, the magnesium ion, likewise, is far from innocuous.

The hazards of overloading the circulatory apparatus have already been mentioned. In general, solutions of crystalloids are better tolerated from this standpoint than are the colloidal "plasma expanders" because the former readily escape from the vascular tree into the interstitial spaces. Blood and plasma infusion have their special dangers, such as incompatibility, nonspecific febrile reactions, and homologous serum hepatitis, in addition to the possible effects of excessive volume per se.

**Reduction of Edema**—Therapeutic relief from edema is most efficiently provided when the factors underlying its production are adequately modified. Causes

related to lymphatic or venous obstruction, trauma, capillary permeability, increased capillary pressure, and congestive heart failure are not within the scope of the present discussion but must be evaluated before proper therapy can be provided. Consideration must be given to multiple factors.

Hypoproteinemia may be produced from exogenous or endogenous causes, and massive parenteral therapy directed toward the latter without consideration and care of the former is inefficient. Plasma given for hypoproteinemia will only slowly raise total protein levels above the critical minimum for edema at a rate of about 0.1 Gm per cent per unit of administered plasma.

The problem of simple overhydration as a cause of edema can readily be met by fluid restriction, but here prevention is a better approach. Water intoxication in patients with renal disease although relatively rare, may be treated in some situations by only minor restriction in fluids or, in the case of anuria, may require maintenance by replacement only of fluid lost by insensible routes.

Edema caused by sodium retention must be approached in a similar way. Therapy aimed at the underlying mechanism of the sodium retention is most important whether this be a simple problem such as excessive sodium intake or a complex situation such as nephrosis. Sodium retention may be handled by reduction of sodium intake below excretion. Here in addition to dietary regimens which are frequently unpalatable and objectionable, methods to prevent absorption of available sodium are in vogue. Excretion of sodium can be hastened by diuretic therapy which brings into use time honored, simple agents and newer, complex, oral and injectable preparations. Dialysis and the use of mechanical measures to remove excesses are now mainly limited to research centers with biochemical laboratories of unusual merit. Overtreatment with diuretic agents is a hazard that must be guarded against. Injectable diuretics may be unnecessary with present oral enzyme system competitors which, with adequate sodium restriction, keep the patient dry. This avoids the problem of repeated visits to the physician as well as the danger of local reaction or infection. Unsuspected hyponatremia with increasing edema and mental aberrations may develop in the patient on prolonged sodium removal therapy. When this condition is present, continued therapy can result in a therapeutic paradox. Hypochloremic alkalosis is another clinical complication of overzealous or uncontrolled therapy. Observation and reevaluation of the patient are needed to prevent insidious development of these dangers.

**Restoration of Acid Base Balance**—Both metabolic and respiratory acid base disturbances are associated with profound changes in extracellular and intracellular balance as well as with altered renal and extrarenal compensatory mechanisms. Complex chemical analyses and calculations as to the alkali reserve, the hydrogen ion concentration, body fluid electrolyte pattern and volume give considerable information as to specific losses and therapeutic needs but sometimes fail to provide essential information as to the status of intracellular potassium and intracellular reaction. Such a specific need as water replacement may not be suggested by these studies yet demands immediate care. Therapy must be based upon fundamental knowledge of the biophysical change and directed toward rational reestablishment.

lishment of the steady state. Experience in clinical appraisal of the situation from history and physical examination may be more important than isolated laboratory data. In addition to replacement therapy, the causative factors in production of the depletion must be successfully managed as, for example, the diarrhea of pseudo-membranous colitis. Intelligent fluid therapy demands evaluation of the whole patient. Modification of calculated deficit replacement should be made in the light of such factors as the risk of producing congestive failure and hypertension or the exaggeration of acidosis or circulatory failure.

**METABOLIC ALKALOSIS**—Metabolic alkalosis due to increased alkali intake is relatively rare and may have sodium retention edema as its main feature. The chief therapeutic need may be the removal of excess sodium. Metabolic alkalosis from acid loss, as seen in severe vomiting or gastric suction with direct loss of chloride anion, requires different replacement therapy from that associated with the potassium loss incident to gastrointestinal damage. In situations of potassium deficit, sodium may also be needed although as potassium is replaced intracellularly sodium leaves the cells. Hypochloremic alkalosis as sometimes seen in chronic mercurial therapy, may be met by the use of ammonium chloride. Ammonium chloride is frequently used to potentiate the mercurial effect and may be even considered prophylactic against this type of alkalosis.

**METABOLIC ACIDOSIS**—Metabolic acidosis can be due to ingestion and/or retention of organic acids such as salicylic or boric with resultant decrease in available cations. Such cases may need temporary anion relief by means of the artificial kidney. Acid retention of diabetes requires proper administration of insulin with precautions to avoid hypoglycemia, as well as replacement of water and sodium. Metabolic acidosis of renal failure is associated with alkali loss and retention of fixed anions. Cases of acute renal failure may be brought toward normal by the use of such agents as corticosteroids and antibiotics. In both acute and chronic renal failure acidosis may be relieved by sodium lactate or bicarbonate, but here the danger of hypertension and vascular overload is considerable. Again temporary use of the artificial kidney may be indicated in anuria caused by acute nephritis or exacerbations of chronic renal disease.

**RESPIRATORY ALKALOSIS**—Respiratory alkalosis related to hyperventilation is best relieved by therapy directed toward the etiology, which may vary from profound psychoneurosis to severe central nervous system trauma. Fever, brain tumor or inflammation, salicylate therapy or simple habit may be factors. Rebreathing or increasing carbon dioxide content of inspired air provides relief.

**RESPIRATORY ACIDOSIS**—Respiratory acidosis caused by chronic pulmonary disease taxes the skill of the most experienced therapist and brings into use digitalization, bronchial dilators, diuretics, antibiotics, corticosteroids, oxygen and even patient re-education in the use of accessory respiratory muscles. Carbonic anhydrase inhibitors may have some usefulness here. The associated hypochloremia and elevated combining power must not be confused with metabolic alkalosis, for the wrong therapy could be fatal. Oxygen administration is potentially dangerous as it may produce coma or fatal apnea by relief of the anoxia which in these patients may be the only stimulus to the fatigued respiratory center.



## AGENTS FOR ADJUSTING AND MAINTAINING INTERNAL HOMEOSTASIS

### For Expansion of the Vascular Fluid Volume

**Colloidal Fluids.**—For restoration of low blood or plasma volume, fluids containing colloids have the obvious advantage that they tend to persist longer within the blood vessels than do solutions of crystalloids. Hence, the repletion of volume, while by no means permanent, has a duration which is practically satisfactory, requiring a minimum of active interference and a minimum of material. Perhaps the most "physiologic" of such replacement fluids are blood and its derivatives.

**WHOLE BLOOD.**—For replacement of actual blood loss, whole blood affords the most complete answer. It is a serious mistake, however, to assume that no other replacement fluid is of real value. The greater the depletion of red cell volume, the more urgent is the indication for whole blood transfusion which, at one and the same time, restores both volume and respiratory value to the circulation. When blood transfusion is considered primarily for replacement of red cells (i.e., when the blood volume is normal in the presence of anemia), one must weigh the possibility of producing a temporary hypervolemia of serious proportions. When anemia exists with evidence of vascular engorgement and high plasma volume, the use of packed erythrocytes may be considered. The precautions for blood transfusion form a special topic beyond the scope of this discussion.

**PLASMA.**—In situations where restoration of circulating volume is the primary objective, infusion of plasma (normal human plasma), is as effective as that of whole blood. Indeed, there are conditions such as hemoconcentration where, temporarily at least, the introduction of red cells might be considered undesirable. The normal plasma proteins insure adequate retention of the fluid in the circulation.

Plasma may be more readily available than whole blood because it is more readily preserved especially in the lyophilized form. Furthermore, the technique of pooling the plasmas of several donors reduces the probability of agglutination reactions involving the recipient's cells, and typing is not necessary. Many clinicians prefer to avoid plasma infusions because of the possibility of transmitting to the patient the virus of serum hepatitis. Processing methods have been described which seem practically to eliminate this hazard, but they are not, as yet, generally employed.

**PLASMA SUBSTITUTES.**—The practical disadvantages of plasma for infusion have inspired a continuing search for other colloid materials which might be used in its place. Many such substances have been tried, experimentally and in the clinic, and the choice among them is not always clearly defined. Each of the plasma substitutes has some potential or actual disadvantage which must be weighed against its possible usefulness in a given clinical situation. While studies on experimental animals continue to yield valuable information concerning the virtues as well as the hazards of these materials, such studies indicate significant species differences and have at best only a provisional quantitative applicability to man. The necessity for carefully controlled human studies is therefore apparent. These are accumulating but are still incomplete.

In general, plasma substitutes may be categorized as solutions of protein or solutions of relatively inert, nonprotein material of large molecular size.

*Protein Solutions* Solutions of proteins, provided they are not antigenic, may be employed with excellent results as so called volume expanders. In addition solutions of plasma proteins may be used to replace protein deficits. Solution of *serum albumin* (normal human serum albumin) of 25 per cent concentration is an excellent volume expander. High cost is practically its only disadvantage. The danger of serum hepatitis does not exist with this preparation. The conventional 25 per cent solution is of course much more concentrated than is the albumin fraction of plasma and has a correspondingly greater restraining power against fluid loss from the circulation. Its efficacy as a means of increasing circulatory volume is approximately 5 times that of plasma; hence, it must be administered conservatively. At the same time it affords an excellent means of increasing the plasma protein concentration. The USP product is obtained from human blood. Purified bovine albumin is available but is sufficiently antigenic that in its present state of development it is best avoided.

*Modified human globin* prepared from red cells discarded in the preparation of plasma has received some attention as a plasma substitute. It is administered in 4 or 8 per cent concentration preferably in isotonic saline. The material has also great potential value for protein replenishment. Further clinical evaluation is required.

A rival protein is *gelatin* (gelatin solution special intravenous 6 per cent in isotonic sodium chloride solution). Recent investigations indicate that this preparation may be given safely and satisfactorily for the restoration and maintenance of vascular volume. The material is pyrogen free and rarely produces allergic reactions. The 6 per cent solution is said to be equivalent volumetrically to plasma. Disadvantages include interference with typing and cross matching of the recipient's blood and the fact that the solutions gel at room temperature. Both of these objections are readily circumvented at least in hospital practice. Gelatin of course, is valueless for the purpose of restoring plasma proteins. While gelatin may occasionally produce temporary lesions of renal tubules, most human studies indicate that it is not apt to impair renal function.

Among many other proteins which have been proposed as plasma substitutes two *modified gelatins* known respectively as *modified fluid gelatin* and *oxypolygelatin* show special promise. Both of these materials are fluid at ordinary temperatures. Neither has produced clinical reactions attributable to its antigenicity. Modified fluid gelatin is administered in 3 per cent, oxypolygelatin in 5 per cent concentration in physiologic saline solution. It is possible that when controlled by adequate clinical experience they may be judged as preferable to the parent gelatin.

*Nonprotein Colloid Solutions* Completely removed from the category of animal derivatives are certain polymers of high molecular weight which have received intensive scrutiny as plasma substitutes. While these materials are quite satisfactory as volume expanders, accumulating experience indicates that they are not completely devoid of risk. The potential difficulties concern chiefly the blood and the kidneys and the hazards seem to increase with the molecular weight of the polymer and with the frequency of administration.

The greatest experience has accrued to the dextrans. *Dextran* is a generic term applied to a series of branched polysaccharides composed of glucose units.

Commercially, it is prepared from beet sugar by bacterial hydrolysis. The average molecular weight of the marketed product is about 75,000, but each lot represents a spectrum of molecular weights which may be quite broad. A 6 per cent solution in isotonic sodium chloride is recommended as the approximate osmotic equivalent of plasma. Dextran is somewhat antigenic, and a low incidence (under 10 per cent) of allergic reactions may be expected. It seems now to be clearly established that this material even when used conservatively, may cause prolongation of bleeding time in almost half of the recipients. While clinical bleeding tendency following dextran infusion has been reported relatively rarely, the hazard deserves attention. The mechanism of this hemostatic defect is not known but some interference with platelet activity has been suggested. The effect is temporary. Coagulation time apparently is not prolonged. Reversible depression of renal tubular function has also been reported in connection with the use of dextran both in animals and in human beings. It is difficult to assess the clinical significance of this observation; obviously, the material should be used with caution when kidneys are known to be diseased.

Another useful substance is *polyvinylpyrrolidone* (PVP), a high polymer product obtained from the reaction of ammonia, formaldehyde, and acetylene subjected to high pressure. It appears that polyvinylpyrrolidone may share, perhaps to a less marked degree, the potential disadvantages described for the dextrans. In addition, because of the fact that it is metabolically inert, PVP is known to persist in the tissues for many months following a single infusion. Significant functional defects resulting from such prolonged storage have not been described for human beings. Polyvinylpyrrolidone is used as a 3.5 per cent solution in isotonic sodium chloride.

Russian investigators have reported success with a glucose polymer, *polyglucin* as a substitute for blood or plasma in the management of traumatic or burn shock. More information is needed about this preparation, but it seems promising.

**Solutions of Crystalloids**—Solutions of crystalloids, usually based upon sodium chloride or glucose, have a long and honorable history in the emergency management of reduced blood volume. The poor retention of such solutions within the vascular tree is a notorious disadvantage but one which may be offset on occasion by the ready availability and general safety of these materials. Their value for repair of the extracellular fluid is considered in another section.

In general, such solutions must be pyrogen free, nontoxic, and approximately isotonic with red cells. Sodium chloride solutions of 0.85 or 0.9 per cent concentration and glucose solutions of 5 per cent are equally efficacious for temporary volume replacement, and the more elaborate solutions, such as Ringer's, Locke's, Tyrode's, and their innumerable modifications, have no special advantage if restoration of volume is the only concern. Because crystalloid solutions leak out of the circulation rapidly, relatively large quantities may be required to restore the circulatory dynamics to normal. For the same reason these solutions cannot be used with total disregard of the state of the interstitial fluid.

**Summary**—The ideal replacement for blood loss is properly matched whole blood. However, it is not always possible or expedient to employ blood where replacement of circulating volume rather than hemoglobin is the immediate concern. Theoretically, at least, plasma would be the ideal solution for such problems were

the possibility of transmitting the virus of hepatitis a negligible factor. While plasma substitutes are perhaps physiologically inferior to plasma, they offer the advantages of low cost, ease of storage, and freedom from the danger of hepatitis. Of the substitutes the colloids are preferable to the crystalloids but the latter should not be forgotten.

### For Expansion of the Interstitial (Extracellular) Fluid Volume

Clinical situations characterized by volume depletion of the extracellular fluid differ from those considered in the preceding section because as a rule the accompanying low plasma (vascular) volume is not the critical feature. While the vascular compartment is depleted along with the interstitial, the latter is generally the object of major concern. Replacement of extracellular fluid is usually accomplished by the administration of various solutions of crystalloids, the choice depending upon the nature of the fluid abnormality, i.e., upon what component of the extracellular fluid is most needed to restore balance. In his therapeutic diligence the physician should not forget the virtues of fluids taken by mouth.

**Isotonic Solutions**—Because some salt depletion is always associated with water losses of the magnitude requiring parenteral replacement, by far the greatest reliance is placed upon isotonic solutions of the major electrolytes found in the extracellular fluid.

**ISOTONIC SALINE**—The simplest of these is 0.9 per cent sodium chloride solution containing approximately 155 mEq per liter each of  $\text{Na}^+$  and  $\text{Cl}^-$ . It will be noted that as the normal levels of  $\text{Na}^+$  and  $\text{Cl}^-$  in extracellular fluid are approximately 142 and 110 mEq per liter, respectively, isotonic sodium chloride solution is not ionically perfect, neither is it too badly distorted. In the presence of normal or at least adequate kidney function there is no cause for concern about the apparent chloride excess. The ions being readily diffusible, isotonic saline quickly reaches the interstitial fluid when given intravenously. It is nonirritating and is therefore equally suitable for subcutaneous administration. It is probably the solution of choice for extracellular fluid replacement when (1) there is no reason to suspect marked hypertonicity of the interstitial fluid, (2) there is no known or suspected deficit of specific ions such as  $\text{Ca}^{++}$  or  $\text{K}^+$ , and (3) there is no serious concern about the acid-base balance of the body.

**BALANCED SOLUTIONS**—The more elaborate saline solutions, sometimes called balanced solutions, reflect an attempt more closely to imitate the chemical anatomy of normal plasma.

**Ringer's Solution**—The best known is called Ringer's solution, although very few of the popular varieties follow the original Ringer formula. Ringer's solutions contain  $\text{K}^+$  and  $\text{Ca}^{++}$  in addition to  $\text{Na}^+$  and  $\text{Cl}^-$ . The potassium and calcium are supplied only in physiologic concentrations which would be ineffective for replacing deficits of these ions.

Ringer's solution contains per liter

$\text{NaCl}$	8.6 Gm	(145 mEq each of $\text{Na}^+$ and $\text{Cl}^-$ )
$\text{KCl}$	0.3 Gm	(4 mEq each of $\text{K}^+$ and $\text{Cl}^-$ )
$\text{CaCl}_2$	0.33 Gm	(6 mEq each of $\text{Ca}^{++}$ and $\text{Cl}^-$ )

**Lactated Ringer's Solution** "Plain Ringer's" fluids of the type just described contain more chloride than does the normal extracellular fluid and, while electrically neutral, tend to have a slight acidifying effect in the body. There is some theoretical justification, therefore, for including an excess of sodium over chloride, as is done in lactated Ringer's solution, which has the following composition per liter

NaCl	6.0 Gm	(103 mEq	each of Na <sup>+</sup> and Cl <sup>-</sup> )
KCl	0.3 Gm	(4 mEq	each of K <sup>+</sup> and Cl <sup>-</sup> )
CaCl <sub>2</sub>	0.2 Gm	(36 mEq	each of Ca <sup>++</sup> and Cl <sup>-</sup> )
Na lactate	3.1 Gm	(27.7 mEq	each of Na <sup>+</sup> and lactate)

**ISOTONIC DEXTROSE**—Isotonic dextrose solution (dextrose injection 5 per cent) is recommended where 'pure water deficiency' is thought to exist. In such cases, there is evidence that water loss has greatly exceeded salt loss, with resulting hypertonicity of the tissue fluids, and electrolyte replacement is not indicated. So far as the electrolytes of extracellular fluid are concerned, the dextrose solution has the effect of a hypotonic replacement fluid.

**DEXTROSE AND SODIUM CHLORIDE**—Isotonic solutions are frequently employed as the vehicles for specific substances which one desires to introduce. The combination of 0.9 per cent sodium chloride with appropriate amounts of glucose, potassium chloride, calcium chloride, sodium bicarbonate, etc., is a very common and accepted practice. A favorite formula for rehydration in the presence of salt loss is 5 per cent glucose in 0.9 per cent sodium chloride solution (dextrose and sodium chloride injection). While this solution is not isotonic with red cells, the electrolyte effect on extracellular fluids is the same as with ordinary isotonic saline solution, and the glucose has some value as a nutrient.

**Hypertonic Solutions**—Where salt has been lost in excess of water, replacement of the electrolytes is indicated. For this purpose, hypertonic solutions may be employed. A 3 per cent sodium chloride solution, containing 513 mEq each of Na<sup>+</sup> and Cl<sup>-</sup>, is recommended. Stronger solutions of sodium chloride may be used, but the concentration should not exceed 5 per cent.

### For the Reduction of Interstitial or Intracellular Volume

Greater difficulty may be encountered in the removal of excesses of water or of retained electrolytes than in the replacement of deficits. This is due in part to the difficulty of assessing clinically the cause of the fluid retention as well as to the multitude of available agents. Edema due to cardiac failure per se does not fall within the scope of this discussion, and cardiovascular agents and diuretics which are essential in this area are discussed elsewhere (Chapter 5). Fluid accumulation may also be related to inflammation or allergy, venous or lymphatic obstruction, or nutritional disturbance. The problem of colloid osmotic pressure, capillary blood pressure, and hypoproteinemia has been discussed, as regards the renal factor, retention of water and sodium chloride is of prime importance. For this reason, measures aimed at water or sodium depletion are used. In some instances, as in the nephritic, water retention may be due to simple water overload. Here water intake, which includes all dietary water, may need to be drastically reduced so as to balance that excreted. Success here may depend upon less than 0.5 liter difference per day.

**Increase in Salt Excretion**—Agents used to increase renal excretion of sodium and chloride include the various diuretic preparations presented elsewhere (Chapter 5). Several deserve repeated mention.

**WATER DIURESIS**—Water diuresis, while favorably reported by some, has potential danger. In theory patients who have excesses of electrolytes may have fluid depletion. In such patients, water administration, either orally or parenterally, results in decreased tubular resorption as well as increased glomerular filtration and excretion of the excessive sodium. However, many subjects do not have this relative fluid deficit, and water administration results in severe intoxication.

**MERCURIAL DIURETICS**—Mercurial diuretics remain among the most effective agents, particularly when used parenterally and with ammonium chloride. The effect is attributed to the inability of the tubules to reabsorb sodium and chloride in the presence of mercury. Decreased effectiveness in the presence of hypochloremic alkalosis suggests that the main action may be upon the chloride ion rather than upon sodium.

**CARBONIC ANHYDRASE INHIBITORS**—Carbonic anhydrase inhibitors are currently popular clinically, and new preparations are frequent in this group. They are often ineffective for therapy of the acute condition but useful to keep the patient edema free after adequate treatment with other agents.

**THIAZIDE DERIVATIVES**—Chlorothiazide, hydrochlorothiazide, flumethiazide and associated substances are thought to have diuretic action resembling a combination of carbonic anhydrase inhibition as well as mercurial-like blockage of sodium chloride resorption. Great usefulness of these preparations is related to oral effectiveness and minor toxicity.

**UREA**—Urea remains an effective diuretic when given in daily doses of 40 to 50 Gm. as a 40 per cent solution in water or carbonated beverages. Success requires raising the nonprotein nitrogen to 80 to 90 mg. per 100 ml., which causes an increased urine flow and salt loss by interfering with filtrate reabsorption.

**Removal of Salt From Gastrointestinal Tract**—Depletion of sodium by way of the gastrointestinal tract has been attempted for years, with unpredictable and usually unsuccessful results, by the use of severe catharsis, continuous colonic irrigation or intestinal lavage. A more effective approach is the sodium binding action of the cation exchange resins which prevents intestinal transfer of the cation and results in fecal elimination. Dialysis by means of the artificial kidney is another method of removing sodium when the kidney has temporarily lost its excretory function.

**Salt Restriction**—Restriction of dietary sodium chloride gives variable results depending upon such factors as previous excesses, the degree of renal or cardiac improvement afforded by other measures, and the adjuvant use of active methods to facilitate sodium excretion.

### For Adjustment of Ionic Balance

Therapy for adjusting ionic balance must be guided by consideration of the multiple regulatory mechanisms of the body and the fact that one area of deficit cannot be adjusted without alterations of intra- and extracellular fluid volume,

concentration, ion ratio, and even distribution of the ion deficit being corrected. Undue burden must not be placed on the regulatory mechanisms themselves lest replacement cause even more deficit. Since the amount of the deficiency is not accurately known, the therapist must cautiously and gradually attempt replacement, frequently assessing the clinical status to ensure that a therapeutic paradox has not resulted. With the exception of conditions such as intestinal obstruction or surgery, severe nausea, vomiting, or hemorrhage, the oral administration of ions for replacement is preferred over the parenteral route. The latter has definite disadvantages, such as the possible production of pyrogenic reactions or circulatory insufficiency.

#### Sodium Depletion —

**ISOTONIC SALINE** —Isotonic sodium chloride solution is a time honored replacement fluid and has been previously discussed. In addition to providing sodium it is excellent for replacement of body water, particularly when kidney function does not create a potential problem in sodium retention. Sodium chloride is potentially an acidifying salt. In the majority of instances of sodium depletion, 0.9 per cent sodium chloride solution would appear to be the agent of choice. It must be given in amounts adequate to replace the sodium deficiency with care not to disturb volume.

**HYPERTONIC SALINE** —Hypertonic sodium chloride solution may be indicated in advanced extracellular sodium depletion. Care must be exercised at all times to avoid overloading hypertension, and congestive failure. Total quantity as well as speed of administration must be considered. Use should perhaps be restricted to cases where dehydration is not a problem as a concentrating effect is desired. In some instances it may even be desirable to restrict water. Prepared solutions vary in concentration from 2 to 5 per cent. A greater hazard is associated with the more concentrated solutions.

**HYPOTONIC SALINE WITH DEXTROSE** —Hypotonic sodium chloride solution with dextrose is an efficient agent to replace water and maintain sodium at normal levels. For continued parenteral fluid therapy, it is prophylactic in that it provides water and also sodium in quantity sufficient neither to overload nor to diminish extracellular content. Commercially available solutions contain 0.425 per cent sodium chloride and 2.5 per cent dextrose.

**ORAL SALT REPLACEMENT** —Oral agents to replenish sodium loss may be given as simple oral milk feedings or by intubation with constant drip through a small plastic tube. Isotonic sodium chloride solution or a saline solution, made by dissolving 5 Gm of sodium chloride (1 large teaspoonful) and 2.5 Gm of sodium bicarbonate in 1000 ml of water, may be administered in this way. Enteric coated tablets of sodium chloride are available, but even when taken with large quantities of water they frequently produce nausea and vomiting.

**Potassium Depletion** —With all preparations of potassium, the danger of hyperkalemia is present. Even small amounts of potassium by mouth may be catastrophic in the presence of kidney failure.

**POTASSIUM CHLORIDE** —Potassium chloride is the most commonly used preparation at present. It may be obtained commercially in the concentration of 80 mEq of potassium per liter in 5 per cent dextrose, or in half normal sodium chloride

solution Vials containing 20 ml of sterile 15 per cent potassium chloride solution are available commercially each vial contains 40 mEq of potassium These vials may be added to proper solutions of sodium chloride or dextrose to produce excellent replacement solutions Unless the potassium deficit is severe, replacement can be obtained with less danger of cardiac arrest by using concentrations of 40 mEq per liter When concentrations of 80 mEq per liter are used the rate of injection should not exceed 10 ml per minute When potassium is being replaced intracellularly the simultaneous use of sodium chloride carries a potential danger of increasing the potassium deficit because the administered sodium may enter the cells more readily than the administered potassium

**POTASSIUM PHOSPHATE**—Potassium phosphate solution is commonly prepared by the addition of a commercially available ampule (20 ml containing 60 mEq of potassium) to 1 000 ml of 5 per cent dextrose which results in a buffered solution at a relatively safe concentration Some authorities feel that this preparation is to be preferred for specific intracellular potassium deficiency not associated with alkalosis since the potassium is supplied with its usual intracellular anion

**POTASSIUM ACETATE**—Potassium acetate solutions may be prepared by adding 1 or 2 ampules (20 ml containing 40 mEq of potassium) to 1 000 ml of 5 per cent dextrose solution This solution has the advantage in acidosis with retention of phosphate or chloride ions of providing potassium with an anion that can be easily metabolized

#### BALANCED SOLUTIONS —

*Darrow's Solution* Balanced electrolyte solutions are typified by Darrow's solution which contains in each liter

KCl	2.7 Gm	(35 mEq each of K and Cl)
NaCl	4.0 Gm	(69 mEq each of Na and Cl)
Na lactate	4.4 Gm	(53 mEq each of Na and lactate)

This preparation is used particularly in the treatment of infantile diarrhea associated with metabolic acidosis and intracellular potassium deficiency

*Elkinton's Solution* A high potassium low sodium solution designed by Elkinton is useful in therapy of metabolic alkalosis associated with intracellular potassium deficiency This solution contains in each liter

$K_2HPO_4$	3.2 Gm	(37 mEq each of K and $HPO_4$ )
$KH_2PO_4$	0.7 Gm	(5 mEq each of K and $H_2PO_4$ )
KCl	3.0 Gm	(40 mEq each of K and Cl)
NaCl	4.2 Gm	(72 mEq each of Na and Cl)

Elkinton's solution may be approximated by adding 60 mEq of buffered potassium phosphate and 80 mEq of potassium chloride to 1 liter of isotonic sodium chloride and 1 liter of 5 per cent dextrose in water The low sodium content of this solution may facilitate the replacement of the abnormal intracellular sodium by the administered potassium

Incorporation of serum proteins in a balanced solution of electrolytes has been recommended recently for extracellular fluid repair especially in pediatric practice

**ORAL POTASSIUM REPLACEMENT**—Oral potassium preparations are available which supply potassium as chloride or gluconate in liquid or tablet form Fruit



juices generally are high in potassium and provide an excellent vehicle for even additional amounts of potassium chloride, with the exception of tomato juice they are very low in sodium. Dialyzed milk is also high in potassium and relatively low in sodium.

**Calcium Deficiency**—Abnormalities in calcium metabolism are related to variations in absorption, distribution and excretion of this cation. Regulation of these factors is very complex and involves diet, renal function, parathyroid activity, the state of the gastrointestinal tract, and the acid base balance of the body. Tetany due to hypocalcemia may be associated with low intake of calcium and/or vitamin D, hypoparathyroidism, intestinal diseases, as sprue, with low assimilation of calcium, increased serum alkalinity from any cause including hyperventilation and excesses of certain chemicals such as citrates and phosphates.

**CALCIUM GLUCONATE**—Calcium gluconate (90 per cent calcium) may be given by oral, intramuscular, or intravenous routes, the latter being the most common. Sterile 10 per cent solution is available commercially, and this concentration may be given slowly by vein or even intramuscularly. The intramuscular route has the disadvantage of local irritation. To make a 0.3 per cent solution which can be administered slowly for prolonged effect 30 ml of 10 per cent solution may be diluted in 1,000 ml of isotonic saline.

**CALCIUM CHLORIDE**—Calcium chloride (27 per cent calcium) is freely soluble in water and is used commonly for oral administration. It is locally irritating and should not be injected into tissues. If given intravenously, the concentration should not exceed 5 per cent of the salt, and the rate should be less than 2 ml per minute in order to avoid systolic cardiac arrest. Orally the average daily dose is about 8 Gm; milk is a good vehicle. The acidifying nature of the chloride may support the calcium effect against tetany.

**CALCIUM LACTATE**—Calcium lactate (13 per cent calcium) is an excellent preparation for oral calcium administration and is well tolerated. As much as 4 Gm daily may be administered.

**CALCIUM PHOSPHATE**—Dibasic calcium phosphate and tribasic calcium phosphate may be useful as antacids but also serve to supply calcium and phosphorus. The total daily dose is 8 Gm. Mixtures of the dibasic phosphate and gluconate are frequently used as antepartum dietary supplements, vitamin D in varying amounts is incorporated in many of these preparations.

**CALCIUM CARBONATE**—Precipitated calcium carbonate (40 per cent calcium) is suitable only for oral use. It serves as a gastric antacid and may be converted into a soluble salt with consequent absorption in the lower bowel.

**Magnesium Abnormalities**—Although magnesium is an important cation in intracellular metabolism, little is known specifically about its quantitative relationships. Magnesium deficits are associated with chronic renal disease and massive diuresis. Symptoms and signs are described as hyperirritability, nausea, vomiting, convulsions and tetany. Magnesium excess is associated with advanced renal disease and decreased urine output. Central nervous system depression, with stupor and hyporeflexia, is an important manifestation.

**MAGNESIUM SULFATE**—Magnesium sulfate is commonly used parenterally by slow intravenous administration of 10 ml of 25 per cent solution, the 20 or 25 per

cent solutions may also be given intramuscularly. Magnesium is employed in the management of eclamptic convulsions, seizures related to local cerebral edema, tetanus, and other states which call for depression of the central nervous system. Duration of action is short, and small repeated doses may be indicated.

Occasionally, the inclusion of magnesium in therapy directed toward restoration of fluid balance has resulted in dramatic improvement in the clinical state, but the indications for such therapy are not clearly defined.

### For Adjustment of Acid Base Balance

In the treatment of acidosis or alkalosis, one may have to give attention to specific ion adjustments as well as to the more general problem of body reaction. For example, metabolic acidosis may be associated with sodium depletion or hyperchloremia requiring special attention in the therapeutic plan.

#### Acidosis.—

**ISOTONIC SODIUM LACTATE SOLUTION**—Isotonic sodium lactate solution (1% molar) provides the necessary sodium for combination with bicarbonate in acidosis. The lactate is readily metabolized to provide energy. This is true for levorotatory sodium lactate, but commercial racemic preparations may be excreted before the metabolic effect takes place. Sodium lactate solutions are not affected by boiling or high temperatures. Vials of hypertonic solution are also available and may be used to prepare isotonic solutions by appropriate dilution.

**HYPERTONIC SODIUM LACTATE SOLUTION**—Hypertonic sodium lactate solution (molar) may be used in cases of severe acidosis when body water is not depleted and fluid restriction may be desirable. Here great care must be observed to prevent vascular overload; the usual commercially available solutions must be diluted with at least equal parts of water before use.

**ISOTONIC SODIUM BICARBONATE SOLUTION**—Isotonic sodium bicarbonate solution (1.3 per cent) is available commercially. Sterilization of the solution may drive off important quantities of carbon dioxide. Again isotonic solutions may be prepared by dilution of the hypertonic solution. The usefulness of bicarbonate in therapy of acidosis can be questioned on the basis that low  $\text{HCO}_3^-$  is related to retention of fixed anion rather than to a true deficit or unavailability of the bicarbonate.

**HYPERTONIC SODIUM BICARBONATE SOLUTION**—Hypertonic sodium bicarbonate solution is available in vials containing 40 mEq. These vials may be added to other solutions to obtain the desired concentration of sodium bicarbonate. The prepared 7.5 per cent solution of sodium bicarbonate must be diluted with equal parts or more of water before administration. This form again has the advantage of an alkalizing action when fluid intake is markedly restricted. It must be given slowly because of the danger of producing hypertension and congestive failure.

**SODIUM BICARBONATE ORAL**—Oral agents for therapy of systemic acidosis include sodium bicarbonate tablets. Since metabolic acidosis is a problem in volume, composition and acid base balance, oral medication usually is less effective than parenteral therapy. By the time oral agents can be tolerated, the acidosis usually has been well compensated.

### Alkalosis —

**AMMONIUM CHLORIDE SOLUTION** —Ammonium chloride solution (2 per cent) may be used in patients with severe alkalosis due to specific chloride loss, as in pyloric stenosis. With liver and kidney disease the organism may not be able to dispose of or metabolize the ammonium ion, so alkalosis in this type of patient is best treated by other means. Ammonium chloride,  $\frac{1}{8}$  molar, in isotonic saline solution, may be a safer form for parenteral administration. This is also a hypertonic solution, but with conversion of  $\text{NH}_4^+$  to urea it is isotonic in effect.

**AMMONIUM CHLORIDE, ORAL** —Ammonium chloride enteric coated tablets (0.5 Gm) may be considered prophylactic acidifiers when used in conjunction with mercurial diuretics. Here disproportionate chloride loss could result in therapeutic alkalosis.

## DESIGN FOR USE OF AGENTS FOR ADJUSTING AND MAINTAINING INTERNAL HOMEOSTASIS

While fluid and electrolyte replacement therapy is not an exact science, the best results are obtained with the least danger when some rational plan is followed. As with other forms of treatment, a reasonably accurate estimate of the clinical situation is a necessary prerequisite. Three types of information should be sought: (1) evidence that a threat to internal homeostasis does in fact exist, (2) the nature of the defect or excess, (3) roughly, the amount of the defect or excess. Four types of abnormalities may be encountered, involving (1) volume, (2) osmotic relationships, (3) specific ions, and (4) acid base relationships. Two or more of these categories may, and often do, exist simultaneously.

### Fluid Therapy

#### Estimate of the Fluid Imbalance —

**ABNORMALITIES OF VOLUME** —In practice, decision as to the presence of a significant volume defect is largely one of clinical judgment. It is possible, of course, to estimate plasma and extracellular fluid volumes by special laboratory procedures. However, such estimates are costly, time consuming, and sufficiently inconvenient to place them among the tools of the investigator rather than the practitioner. Fortunately, the clinical features of overhydration and underhydration are a sufficiently safe guide in most instances. A careful history and a painstaking physical examination will usually permit a fairly shrewd guess, not only as to the existence of a volume abnormality but also as to its nature and extent.

Among the simpler and more rapid laboratory tests, some reliance may be placed upon the hematocrit and upon the color and specific gravity of the urine (the latter provided renal function may be assumed as approximately normal). Hemoconcentration usually points to a volume deficit, though there are some striking exceptions. The same is true of elevated plasma protein concentration (rapidly estimated from the specific gravity of properly collected plasma or serum). Similarly, scanty urine of high color and high specific gravity is suggestive of dehydration. However, none of these indices has any real quantitative significance. If one has prior knowledge of the patient, changes in body weight may afford important clues as to massive gain or loss of water.

Since a quantitative estimate of volume abnormality is difficult to achieve simply and rapidly, a practically useful first approximation may be obtained from the following rough relationships (Hardy)

Mild dehydration	volume deficit 4 per cent of body weight
Moderate dehydration	volume deficit 6 per cent of body weight
Severe dehydration	volume deficit 8 per cent of body weight

The degree of dehydration is based upon clinical observation, and the tentative estimate of fluid deficit is made accordingly

**OSMOTIC ABNORMALITIES**—When the body loses markedly hypotonic or hypertonic fluids in large volumes, the remaining extracellular fluid is left with an excess or deficit of dissolved material, and the normal osmotic relationships between cells and their environment are disturbed. This condition leads to hydration or dehydration of the intracellular fluid and perhaps to other cellular changes as well. While osmotic defects may often be inferred from purely clinical data, the definitive diagnosis rests upon the chemical analysis of plasma

While the total electrolyte concentration of plasma, which must be accepted as an index to the state of the interstitial fluid as well, is normally about 310 mEq per liter (155 mEq each of cations and anions), it is not necessary to make a complete chemical analysis of plasma in order to divine the presence of osmolar abnormalities. In fact, a very reliable decision on this point requires only two relatively simple determinations, namely, plasma chloride and plasma bicarbonate, the latter being estimated from the carbon dioxide-combining power of the plasma. If the sum of  $\text{Cl}^-$  and  $\text{HCO}_3^-$ , the most labile of the plasma anions, lies between 125 and 135 mEq per liter, the total osmolarity of the plasma (and interstitial fluid) may be considered within normal limits. The average normal sum is 130 mEq per liter (Table 3). Plasma sodium gives valuable confirmatory information, but this analysis may not be readily available. The normal  $\text{Na}^+$  of plasma is close to 142 mEq per liter. Since  $\text{Na}^+$  is the chief cation of extracellular fluid, its concentration is significant with respect to total ion concentration.

**ABNORMALITIES OF SPECIFIC IONS**—The electrolyte structure of extracellular fluid is based upon  $\text{Na}^+$ ,  $\text{Cl}^-$ , and  $\text{HCO}_3^-$ . However, there are other important ions to which attention must frequently be directed. Of these,  $\text{K}^+$  and  $\text{Ca}^{++}$  are perhaps the most troublesome. Adequate chemical methods are available for their estimation, and no other method for detecting abnormalities of these materials is at all reliable. It is rarely necessary to analyze for  $\text{Mg}^{++}$ .

Table 3 Normal Electrolyte Pattern of Plasma\*

Cations	mEq./Liter	Anions	mEq./Liter
$\text{Na}^+$	142	$\text{Cl}^-$	103
$\text{K}^+$	5	$\text{HCO}_3^-$	27
$\text{Ca}^{++}$	5	$\text{HPO}_4^{--}$	2
$\text{Mg}^{++}$	3	$\text{SO}_4^{--}$	1
		Organic Acids	6
		Protein	16
Totals	155		155

\*After Gamble, J. L. Chemical Anatomy, Physiology and Pathology of Extracellular Fluid, Harvard University Press, 1949

**ACID BASE BALANCE**—The only certain method of diagnosing disturbances of the acid base balance is by measuring the pH of the blood. This is frequently awkward or impractical, and in untrained hands may give very misleading results. Besides, owing to the efficiency of the blood buffers, the pH may be within normal limits when the buffer systems themselves are nearly exhausted. Inferences regarding the acid base balance of the body may be drawn from the clinical examination together with certain aspects of the blood chemistry.

As indicated in the introductory section, blood pH may be calculated from analysis for  $\text{HCO}_3^-$  and for  $\text{H}_2\text{CO}_3$ . However, these observations require that the blood samples be handled anaerobically, a matter simpler in theory than in practice. Hence, the more crude and incomplete carbon dioxide combining power of plasma (or serum) is still applied extensively to the problem. With all of its admitted faults, this method gives information of value.

The carbon dioxide combining power affords an estimate of plasma bicarbonate under conditions of "physiologic" carbon dioxide tension (about 40 mm Hg). Indirectly, this quantity reflects the amount of plasma cation not already combined with or matched by anions of acids stronger than carbonic, i.e., the amount available for immediate neutralization of strong acids. Obviously, this measurement does not include all of the blood buffers. Furthermore, it neutralizes short term effects of respiration upon the anion distribution in the plasma.

The average normal carbon dioxide combining power of plasma is about 60 volumes per cent, representing 27 mEq of  $\text{HCO}_3^-$  per liter. (To convert volumes per cent  $\text{CO}_2$  into milliequivalents of  $\text{HCO}_3^-$  per liter of plasma, divide the former by 2.22.) In general, values less than 20 mEq per liter indicate a significant trend toward acidosis, while values above 30 mEq per liter have the opposite implication. There are important exceptions. Hyperventilation may induce alkalosis with low plasma bicarbonate secondary to excessive pulmonary excretion of carbon dioxide. In such cases, compensatory mechanisms include renal excretion of sodium while chloride is retained, and the latter component of plasma is elevated. Conversely, inadequate pulmonary ventilation leads to so called respiratory acidosis, with retention of carbon dioxide, elevated plasma bicarbonate, and depressed levels of plasma chloride. For these reasons, respiratory function must always be considered in the interpretation of plasma electrolyte concentrations.

Table 4 Conversion of Gravimetric Concentrations of Plasma Electrolytes to Combining Equivalents\*

Element	Atomic Weight	Conversion Factor (mg % $\times$ Factor = mEq/Liter)
Na	23	0.435
K	39	0.256
Ca	40	0.500
Mg	24	0.833
Cl	35	0.286

\*One equivalent (= 1000 milliequivalents) is equal to 1 gram atomic weight divided by the valence. The general formula for conversion of mg per cent to mEq per liter is

$$\text{mEq per liter} = \frac{\text{mg per cent} \times 10 \times \text{valence}}{\text{atomic weight}}$$

**Plan of Therapy**—It has been emphasized that fluid therapy should be systematic and tailored to the specific indications presented by the patient. This does not mean that treatment must be delayed until the laboratory reports are available. In fact, one may institute therapy based upon the clinical state alone and make later modifications according to clinical response and laboratory data.

A safe general rule is to direct initial therapy toward volume replacement. There are several reasons for the recommended starting point. *First*, volume deficit, especially if severe, imposes a very serious physiologic strain upon the organism and cries for immediate correction. *Second*, a satisfactory approximation of the volume deficit can be made from clinical observation, and no harm can result from immediate administration of isotonic fluids. *Third*, the initial laboratory data may fail to reveal specific ion deficits because they are masked by hemoconcentration, while excesses will be corrected by volume replacement. Finally, in adults at least, the body buffers will frequently be adequate for correction of acid base imbalance once the volume and osmolarity of the body fluids are brought within normal limits.

If an early decision can be made regarding osmotic abnormalities, their correction can be incorporated with the adjustment of fluid volume. Osmotic imbalance may be strongly suggested by the history. In any event, the chloride and bicarbonate concentrations of plasma may be ascertained before volume replacement has progressed very far and from these an estimate of osmolar deficiency or excess is available as indicated in a preceding section. As volume correction continues, additional analyses of blood and urine will dictate whether or not measures should be taken to correct abnormalities of specific ions or of fluid reaction.

Estimating requirements prior to the beginning of treatment is at best a form of guessing. Hence, therapy must be controlled as it progresses and modified accordingly. If the conservative plan of slight undercorrection is followed at each stage of treatment, the necessary modifications are readily made. One must expect that the correction of severe fluid imbalance will require several days. For following the progress of therapy, primary reliance is once more upon the clinical response of the patient. However, this should be supported by periodic laboratory studies so that one may know whether the treatment is actually accomplishing what is intended. Eventually, a regimen must be established which will maintain internal homeostasis. Data obtained during the active correction of abnormalities will indicate what one may expect from the patient's physiologic mechanisms and will be generally helpful in devising a maintenance schedule.

It has been assumed in this discussion that fluids are to be administered parenterally. The necessity for good products (free from pyrogens and bacterial contamination) and for good technique is obvious and will not be considered further. A few precautions may be worthy of summary. In general, intravenous infusions should be given slowly, particularly if they contain colloids. It is difficult to be specific on this point because there are wide differences among patients as to tolerance and among solutions as to the actual risks involved. However, barring those situations in which a rapid repletion of blood volume is essential to restore circulation, there seems to be little indication for haste in administration, and a rate of 1 liter per hour should rarely be exceeded. For large volume deficits, a much slower rate, say 250 ml per hour, is preferable. There is much merit in the recommenda-

tion (Hardy) that the entire estimated requirement for the 24 hour period be administered during the usual waking hours as a continuous infusion. Special care must be exercised when therapeutic concentrations of potassium are administered. Potassium in high concentration is very toxic to the heart and should be infused slowly and under constant supervision. Calcium, on the other hand may be administered with much less danger of untoward effect. If markedly hypertonic solutions are indicated, they must be given by vein because they are irritating and their introduction into the tissues may cause sloughing. Markedly hypotonic solutions should not be administered parenterally.

### Control of Fluid Excess

The same type of information should be sought for proper therapy of excesses in fluid volume as for replacement of deficits. New drugs for removing excess body water are appearing constantly. However, restriction of water intake is frequently the proper course, particularly in the semianuric patient or in those subjected to zealous overtreatment with parenteral fluids.

Restriction of sodium or use of the multitude of agents advocated to aid in its excretion should not be considered until all possible causes for edema and hypotonicity have been investigated. Relief of fluid excess may depend upon correction of hypoproteinemia secondary to liver disease, kidney damage, or improper nutrition. Similarly, one must be careful about treating hypotonicity by the administration of sodium chloride unless salt depletion is truly present. Otherwise, the use of sodium chloride particularly hypertonic sodium chloride may be harmful. Sodium depletion or water intoxication should be confirmed before sodium chloride is given in such instances.

### Control of Electrolyte Excess

Sodium and chloride excess can be treated by decreasing the intake of these substances or by aiding their renal and/or extrarenal excretion. This type of control is essentially the therapy of congestive heart failure and is presented elsewhere. It includes restriction of sodium, removal by dialysis or exchange resins, and forced excretion by the use of diuretics.

Excess of potassium, as manifested by increased concentration in extracellular fluid, presents serious problems in control and, if not corrected, may result in cardiac standstill. These excesses may be treated by any or all of the following methods:

- 1 Where hyperkalemia is associated with water loss, expansion of the volume of body fluids by the administration of fluids which contain no potassium is effective.

- 2 Removal of extracellular potassium may be accomplished by a number of processes including intracellular transfer. Here therapy of existing dehydration or abnormal carbohydrate metabolism is important. Potassium may also be removed by improving urinary excretion. Proper treatment of any cause of impaired renal function as congestive failure or kidney disease, is of course, essential. Similarly, potassium may be removed by gastrointestinal and/or peritoneal lavage, by exchange resins, and by the use of the artificial kidney. The latter method is con

stantly being improved, and its use, while now restricted, may soon become commonplace

3 Antagonism of potassium may be attempted by the use of calcium salts and digitalis. Sodium chloride may also be considered an antagonist but is less beneficial in this respect. The use of potassium in treating digitalis toxicity is probably more effective than the reverse.

In summary, excess of electrolytes can be treated by restriction of intake and by attempts to increase excretion. Potassium excesses are poorly withstood by the body and their excretion or transfer must be promptly undertaken. In cases of temporary loss of excretory ability, vivodialysis should be considered.

## RATIONAL BASIS FOR NEW AGENTS FOR ADJUSTING AND MAINTAINING INTERNAL HOMEOSTASIS

**Blood and Plasma Substitutes**—It is generally agreed that all currently available blood and plasma substitutes are inferior to the natural material. The criteria for an ideal volume expander have been repeatedly stated, but in essence they amount to a description of the properties of plasma. What is needed is a material which maintains increased circulatory volume for an extended period, but which has no immediate or remote ill effects upon the organism. Low cost, ready availability, uniformity, and stability in storage are important additional considerations.

Since blood and plasma must always be obtained from human donors, they will probably never be available in unlimited quantities, and stockpiling for war or disaster would remain a problem even if the materials could be stored indefinitely. However, extension of the useful life of bank blood is worthy of continued serious study. As for plasma, the lyophilized product keeps well, and the logical goal would seem to be a sure way to inactivate the virus of hepatitis without rendering the plasma unsuitable in other respects.

Regardless of progress, or the lack thereof, toward the objectives just mentioned, search for better plasma substitutes than are now at hand will undoubtedly continue if only because one cannot visualize having a comfortable supply of plasma. Since there are satisfactory substitutes, the need is perhaps not critical, but one would like to hope for nonantigenic and otherwise nontoxic synthetic or semisynthetic colloids which approach the plasma proteins not only in their oncotic properties but in their metabolic behavior.

**Repair and Replacement Fluids**—In the area of materials for replacement or adjustment of body fluids the need would appear to be for improved methods of assessing the chemical status of the patient rather than for better correctional agents. Where fluid imbalance results from endocrine imbalance, as is the case with diabetes mellitus or Addison's disease, cheaper, safer, and more efficient drugs to combat the underlying metabolic lesion may, of course, be envisioned.

**Drugs**—Recent biophysical investigations have resulted in better understanding of the mechanisms which control fluid balance. This is especially true in relation to the corticosteroids and their effects on metabolism. As more information is obtained regarding the role of hormones in controlling fluid balance, congestive failure, hypertension, and kidney function, newer preparations in this area may be expected. These preparations may be of prophylactic value rather than specifically



on (Hardy) that the entire estimated requirement for the 24 hour period be administered during the usual waking hours as a continuous infusion. Special care must be exercised when therapeutic concentrations of potassium are administered. Potassium in high concentration is very toxic to the heart and should be infused slowly and under constant supervision. Calcium, on the other hand, may be administered with much less danger of untoward effect. If markedly hypertonic solutions are indicated, they must be given by vein because they are irritating and their introduction into the tissues may cause sloughing. Markedly hypotonic solutions should not be administered parenterally.

### Control of Fluid Excess

The same type of information should be sought for proper therapy of excesses of fluid volume as for replacement of deficits. New drugs for removing excess body water are appearing constantly. However, restriction of water intake is frequently the proper course, particularly in the semianuric patient or in those subjected to dialysis or treatment with parenteral fluids.

Restriction of sodium or use of the multitude of agents advocated to aid in its excretion should not be considered until all possible causes for edema and hypotonicity have been investigated. Relief of fluid excess may depend upon correction of hypoproteinemia secondary to liver disease, kidney damage, or improper nutrition. Similarly, one must be careful about treating hypotonicity by the administration of sodium chloride unless salt depletion is truly present. Otherwise, the use of sodium chloride, particularly hypertonic sodium chloride, may be harmful. Sodium depletion or water intoxication should be confirmed before sodium chloride is given in such instances.

### Control of Electrolyte Excess

Sodium and chloride excess can be treated by decreasing the intake of these substances or by aiding their renal and/or extrarenal excretion. This type of control is essentially the therapy of congestive heart failure and is presented elsewhere. It includes restriction of sodium, removal by dialysis or exchange resins, and forced excretion by the use of diuretics.

Excess of potassium, as manifested by increased concentration in extracellular fluid, presents serious problems in control and, if not corrected, may result in cardiac standstill. These excesses may be treated by any or all of the following methods:

- 1 Where hyperkalemia is associated with water loss, expansion of the volume of body fluids by the administration of fluids which contain no potassium is effective.
- 2 Removal of extracellular potassium may be accomplished by a number of processes including intracellular transfer. Here therapy of existing dehydration and abnormal carbohydrate metabolism is important. Potassium may also be removed by improving urinary excretion. Proper treatment of any cause of impaired renal function, as congestive failure or kidney disease, is, of course, essential. Similarly, potassium may be removed by gastrointestinal and/or peritoneal lavage, by exchange resins, and by the use of the artificial kidney. The latter method is con-

stantly being improved, and its use, while now restricted, may soon become commonplace

3 Antagonism of potassium may be attempted by the use of calcium salts and digitalis. Sodium chloride may also be considered an antagonist but is less beneficial in this respect. The use of potassium in treating digitalis toxicity is probably more effective than the reverse.

In summary, excess of electrolytes can be treated by restriction of intake and by attempts to increase excretion. Potassium excesses are poorly withstood by the body and their excretion or transfer must be promptly undertaken. In cases of temporary loss of excretory ability, hemodialysis should be considered.

## RATIONAL BASIS FOR NEW AGENTS FOR ADJUSTING AND MAINTAINING INTERNAL HOMEOSTASIS

**Blood and Plasma Substitutes**—It is generally agreed that all currently available blood and plasma substitutes are inferior to the natural material. The criteria for an ideal volume expander have been repeatedly stated, but in essence they amount to a description of the properties of plasma. What is needed is a material which maintains increased circulatory volume for an extended period, but which has no immediate or remote ill effects upon the organism. Low cost, ready availability, uniformity and stability in storage are important additional considerations.

Since blood and plasma must always be obtained from human donors, they will probably never be available in unlimited quantities and stockpiling for war or disaster would remain a problem even if the materials could be stored indefinitely. However, extension of the useful life of bank blood is worthy of continued serious study. As for plasma, the lyophilized product keeps well, and the logical goal would seem to be a sure way to inactivate the virus of hepatitis without rendering the plasma unsuitable in other respects.

Regardless of progress, or the lack thereof, toward the objectives just mentioned, search for better plasma substitutes than are now at hand will undoubtedly continue, if only because one cannot visualize having a comfortable supply of plasma. Since there are satisfactory substitutes, the need is perhaps not critical, but one would like to hope for nonantigenic and otherwise nontoxic synthetic or semisynthetic colloids which approach the plasma proteins not only in their oncotic properties but in their metabolic behavior.

**Repair and Replacement Fluids**—In the area of materials for replacement or adjustment of body fluids the need would appear to be for improved methods of assessing the chemical status of the patient rather than for better correctional agents. Where fluid imbalance results from endocrine imbalance, as is the case with diabetes mellitus or Addison's disease, cheaper, safer, and more efficient drugs to combat the underlying metabolic lesion may of course be envisioned.

**Drugs**—Recent biophysical investigations have resulted in better understanding of the mechanisms which control fluid balance. This is especially true in relation to the corticosteroids and their effects on metabolism. As more information is obtained regarding the role of hormones in controlling fluid balance, congestive failure, hypertension, and kidney function, newer preparations in this area may be expected. These preparations may be of prophylactic value rather than specifically

curative in effect At present, aldosterone and its antagonists, as well as serotonin, are undergoing extensive study Enzyme systems and their controls are fertile areas for new preparations for control of the internal environment

## SELECTED REFERENCES

- Adolph, E F The Metabolism and Distribution of Water in Body and Tissues, *Physiol Rev* 13 336, 1933
- Bard, Philip Medical Physiology, St Louis, 1956, The C V Mosby Co, pp 332 339, 743 779, 808 810
- Bland, J H The Clinical Use of Fluid and Electrolyte, Philadelphia, 1952, W B Saunders Co
- Danowski, T S, and Elkinton, J R Exchanges of Potassium Related to Organs and Systems, *Pharmacol Rev* 3 42, 1951
- Darrow, D C, and Pratt, E L Fluid Therapy, Relation to Tissue Composition and the Expenditure of Water and Electrolyte, *J A M A* 143 365, 1950
- Drill, V A Pharmacology in Medicine, A Collaborative Textbook, New York, 1958, McGraw-Hill Book Co, pp 535 618
- Elkinton, J R, and Danowski, T S The Body Fluids, Baltimore, 1955, Williams & Wilkins Co
- Goodman, L S Therapeutics, New York, 1956, W B Saunders Co
- Guyton, A C Textbook of Medical Physiology, Philadelphia, 1955, W B Saunders Co
- Gamble, W F Extracellular Fluid, Cambridge, 1955, Cambridge University Press
- Gropper, A H Fluid Expanders, *Internat Abstr Surg* 93 541, 1952
- Hardy, J D Fluid Therapy, Philadelphia, 1954, Lea & Febiger
- Mollison, P L Blood Transfusion in Clinical Medicine, Springfield, Ill, 1956, Charles C Thomas, Publisher
- Moyer, C A Fluid Balance, A Clinical Manual, Chicago, 1952, The Year Book Publishers, Inc
- Overman, R R Sodium, Potassium and Chloride Alterations in Disease, *Physiol Rev* 31 285, 1951
- Schmidt, R H Calcium, Magnesium, and Potassium Transport and Regulation of Calcium, *Physiol Rev* 15 297, 1935
- Sjostrand, A Regulation of Water and Electrolyte Balance in Regulating the Internal Environment, New York, 1955, McGraw-Hill Book Co
- Technical Manual, Department of Commerce, No 67040, 1955
- Weisberg, H F Water, Electrolyte and Acid Base Balance, Baltimore, 1953, Williams & Wilkins Co
- Wiggers C J The Physiology of Shock, New York, 1950, Commonwealth Fund

## THE CHOICE OF A DIURETIC

*Walter Modell, M.D.*

---

### INTRODUCTION

Reviews have appeared from time to time in an attempt to summarize a mountainous literature on diuretics, and of a large list the reader is referred to a full historical and clinical account by Vogl, one on the more technical aspects of diuretics by Pitts and Sartorius and one on the more recent literature by Modell. The clinical experiences and the several drugs which are available or under investigation will be considered separately.

The diuretics are discussed in this unconventional position in a systematized consideration of drugs and their therapeutic uses to emphasize their fundamental therapeutic function which, as indicated in the preceding chapter is, in fact, to relieve symptoms due to internal derangements of electrolyte and fluid. Their more obvious effect of increasing the rate of urine flow is actually the consequence of their tendency to rearrange internal electrolyte relationships. The urgently needed therapeutic effect of improving the excretory function of a failing kidney or increasing the rate of excretion of toxic materials in poisoning is so rarely an attribute of these drugs which superficially seem to stimulate renal activity as to be an outstanding therapeutic paradox.

There are, of course, a number of clinical conditions in which their pharmacologic actions are useful. Of these, the relief of the edema, particularly that of congestive heart failure, is by far the most important. They are also used in the ascites of cirrhosis, the nephrotic syndrome, and the edema of pregnancy. Glaucoma, hyperpotassemia, bromide intoxication, the anginal syndrome, epilepsy, migraine, hypertension, and premenstrual depression provide highly specialized uses for diuretics in conditions in which edema is not present or at least not definitely established. Despite the apparent dissimilarity of these conditions, in all the usefulness of the diuretic as a therapeutic agent depends on its capacity to rearrange internal water and electrolyte relationships.

### CLINICAL APPLICATIONS

#### Edema

The edema of heart disease provides the most important use for diuretic agents. The practice has been to reserve diuretics for severe cases of congestive failure in

which digitalis is insufficient. There is clinical evidence, however, that some diuretics provide relief more promptly and are more dependable than digitalis, and as a result there is an increasing tendency to use diuretics along with digitalis at the outset of treatment.

Although diuretics are used with good results in what are commonly designated the right sided and the left sided forms of heart failure and the regimens for treatment are much the same, indications and urgency are often quite different and the character of action and result are also somewhat different. Separate discussion is therefore profitable.

**Right-Sided Heart Failure**—This form is the more commonly recognized manifestation of heart failure even though there is reason to believe that the left sided form may be an equally frequent, or even the more frequent, clinical syndrome. The difference in rate of recognition may be largely due to the fact that the signs of right sided failure are easily noticed since they are largely external, being expressed as ankle edema which mounts up the legs and thighs, with characteristic pitting quality. In this situation a large diuresis, sometimes inducing a loss of 10 pounds or more overnight, is an emphatic demonstration to patient and physician of the need and utility of a diuretic. The question of the need for treatment of the edema rarely arises in this situation, more often the only question is that of the choice of the diuretic to be used in those cases in which digitalis alone is not sufficiently effective.

**Left Sided Heart Failure**—This form of cardiac edema provides much more subtle indication. It is far less frequently of the pulmonary type. In such cases, only those clinicians who are willing to rest their case entirely on symptoms—dyspnea on exertion, modest orthopnea, angina decubitus—will see the indication for diuretics.

That the use of such potent diuretics as the mercurials may produce only a modest diuresis also tends to weaken the faith of some in the existence of edema or the propriety of the therapy. Yet in a large number of cases with hypertension or mitral stenosis, the subsequent development of full blown signs of left sided heart failure will provide the proof that the initial symptoms without detectable signs were the forerunners of the later unmistakable developments. The fact remains that clinically imperceptible amounts of fluid in the pulmonary bed, in the interstitial spaces rather than in the alveoli, may interfere perceptibly with respiration. There is the additional fact that when this fluid is removed by the action of diuretics, the very small diuresis provides great relief and comfort, significantly increases the ability of the patient to perform, and often effectively prevents the subsequent development of pulmonary edema. This early subtle form of left sided heart failure tends to be overlooked and untreated while the full fledged forms of pulmonary edema usually present no question of the need for treatment.

The mercurial diuretics have long been recognized as of outstanding value in the treatment and prophylaxis of frank pulmonary edema, paroxysmal nocturnal dyspnea, etc., but, unfortunately, less commonly for the earlier stages. Even for the patient with only dyspnea on effort and no râles, the mercurials, rather than

less potent diuretics, are more likely to provide a large measure of relief and to be the most effective in prophylaxis

**ANGINA DECUBITUS**—The relief provided by mercurial diuretics to patients with the anginal syndrome, especially angina decubitus, a manifestation of left sided heart failure, was reported by Gold some years ago and has since been confirmed by others. Further experience is necessary to establish criteria for the selection of suitable patients with the anginal syndrome for this treatment. Until then, the only patients with anginal pain for whom this form of therapy can be prescribed with reasonable assurance of benefit are those with angina decubitus

**Pulmonary Disease**—In chronic pulmonary disease of a variety of types, cor pulmonale may result. It has been suggested that in those cases with respiratory acidosis and congestive heart failure, there may be a large diuretic response to acetazolamide (and presumably, the other carbonic anhydrase inhibitors) and a salutary effect on accumulated plasma bicarbonate which makes it the diuretic of preference in this highly specialized type of edema

**Refractory Edema of Heart Disease**—This is a term with inconstant implications, changing largely in inverse relation to the effectiveness of measures applied. With the advent of modern diuretics, the incidence of refractory edema has diminished markedly. Recently refractory cardiac edema was defined as that which a daily routine of 2 ml doses of mercurial diuretics together with digitalis and salt-poor diet failed to relieve. By such standards Rubin and associates state that it now occurs in less than 1 per cent of patients with congestive heart failure

**AMINOPHYLLINE**—Vogl and Esserman claim that the addition of aminophylline to a regimen with mercurial diuretics is useful in "intractable" failure. Their use of the term is inappropriate for they admit that "complete lack of response to mercurial diuretics has never been demonstrated". Their data show that the patients in their study were inadequately treated with mercurial diuretics. The utility of the method requires confirmation

**EXCHANGE RESINS**—There is the suggestion in the literature that the resins may act to potentiate mercurial diuretics especially in those cases in which a hydrogen exchange resin is used to the extent of inducing a degree of hyperchloremic acidosis. The degree to which this method is useful has not yet been established, but there are significant implications in the fact that the use of the resins has tended to decrease with the increase in experience with them

**AMMONIUM CHLORIDE**—Ammonium chloride may synergize with mercurial diuretics, and the statement has been made that it may reverse refractory heart failure due to hypochloremia. However much ammonium chloride may assist in the action of the mercurial diuretics it does not appear to provide a consistent answer to the problem of resistance to them

**ACETAZOLAMIDE (DIAMOX)**—Rubin and associates used Diamox in the management of edema refractory to mercurial diuretics but found that only after it was combined with relatively large doses of ammonium chloride, so that a degree of hyperchloremic acidosis developed, was the lost vigor restored to the mercurials. These findings probably apply also to the more recently introduced carbonic anhydrase inhibitors

**ACTH AND CORTISONE**—The late Dr. Scheinm and his co-workers described cases of otherwise refractory edema in which, following the use of corticotropin

(ACTH) and cortisone, sodium excretion and diuresis returned spontaneously in some while in others there was restored responsiveness to mercurial diuretics. The authors were unable to describe the type of patient with resistant edema who is likely to respond to this form of therapy. This paradoxical phenomenon lacks not only explanation but also confirmation. It is possible, however, that recent findings of materials which antagonize aldosterone have some bearing on it.

**PERITONEAL DIALYSIS**—Leiter describes peritoneal dialysis as a means of removing sodium. This procedure is followed by diuresis in some patients with resistant cardiac edema, but the physical factors involved in its application seem to have limited its utilization.

**SOUTHEY TUBES**—A plea for the use of this device has been made by Fiese and Thayer, who claim that it is more sound physiologically than diuretics in that it removes edema per se and does not act through the diuresis of a particular electrolyte. There is the possibility, however, that should it be used more extensively electrolyte disturbances would develop in some cases just as they do after paracentesis.

**DIET**—Diets with low salt content have long been used in combination with diuretics, especially for resistant cases. Iseri and associates have described satisfactory results in this state with diets containing as little as 50 mg of sodium. The Council on Food and Nutrition of the American Medical Association has issued a warning about the possibilities of salt depletion syndromes resulting from such diets in combination with potent diuretic agents.

**Nephrotic Syndrome**—Since the report in 1941 by Tyson of fatalities following the use of mercurial diuretics in children with the nephrotic syndrome this condition has been an accepted contraindication to their use even though the danger has not been confirmed by others. As a consequence little is to be found in the recent literature on the utility of the mercurial diuretics in this condition.

**ACTH AND CORTISONE**—Good results in the therapy of the nephrotic syndrome with these agents have been reported by many. Some argue that in many cases in which diuresis is induced there are signs of improvement in renal function along with the relief of edema and that this may well indicate a salutary effect on the basic disease process. Striking improvements are often short lived and some times associated with disagreeable or more serious reactions. Some writers express doubt as to whether the ultimate course of the syndrome is permanently or significantly influenced by this therapy.

**RESINS**—There are reports that the exchange resins may remove edema in the nephrotic syndrome, but there are also warnings against the possibility of electrolyte disturbance and the induction of other forms of renal dysfunction.

**ALBUMIN**—Concentrated human albumin, especially salt poor serum albumin, produces a diuresis in patients with the nephrotic syndrome but there is no evidence that this alters the glomerular filtration rate or the eventual course of the disease.

**Cirrhotic Edema**—The edema of cirrhosis, chiefly ascites, has been relatively resistant to diuretic therapy, and a specialized mechanism of edema formation has been suggested. There is some question regarding the practical value of diuretics in cirrhosis and as matters stand none of our current therapies appears to be either potent or uniformly effective in this condition.

On the other hand sodium is retained with this form of edema and any device which produces a negative sodium balance will to a degree, cause a diuresis. Rigid restriction of sodium in the diet is said to result in protein sparing, reduced rate of ascites formation, and reduced need for abdominal tapping. Hilton states that patients with cirrhosis who fail to respond to the mercurial diuretics, often exhibit satisfactory results if ammonium chloride is given along with it. Salt poor albumin in conjunction with the mercurial diuretics and low sodium diet have also been shown to be effective. Others have reported diuresis after the exchange resins, but opinion on their utility is mixed.

**Edema of Pregnancy**—Salt poor albumin has been reported to relieve edema in patients with toxemia of pregnancy. Brown and Sutherland state that ammonium chloride produced increases in sodium excretion with relief of the edema and other symptoms of pregnancy. While mercurials were even more effective these authors suggest caution when they are used during pregnancy.

### Removal of Nonedematous Fluid

**Glaucoma**—Carbonic anhydrase facilitates the formation of intraocular fluid and therefore it is not surprising that acetazolamide and the newer carbonic anhydrase inhibitors, ethoxzolamide and dichlorophenamide were found to lower intraocular pressure in glaucoma. Both oral and intravenous administration are effective but there is no report on local application. Some state that the effect on intraocular pressure is short lived and that refractoriness soon develops. The best results which may sometimes be dramatic are more likely to occur in acute glaucoma while protracted therapy for chronic glaucoma is apt to be uncertain. Supplemental use of miotic drugs is suggested.

### Electrolyte Derangements

**Hypo and Hyperpotassemia**—Exchange resins have been suggested as the basis of the treatment of hypo and hyperpotassemia although no reports of their successful use in the clinical conditions have been made. Because it accelerates potassium excretion Diamox has been suggested for hyperpotassemia. More recently dichlorophenamide, a new carbonic anhydrase inhibitor, has been used to treat respiratory acidosis.

**Bromide Intoxication**—In 1941 Bodansky and Modell reported that mercurial and xanthine diuretics markedly accelerated the renal excretion of the bromide ion. This finding has been successfully applied to the treatment of bromide poisoning.

### Unknown Mechanism of Action

**Hypertension**—It is held by some that the removal of sodium stores has a beneficial effect on the course of hypertension. A treatment for hypertension based on this hypothesis has been described in which diuretics are used to accelerate the excretion of sodium. It must be added that whereas this has not been confirmed it may also have a bearing on the established effectiveness of chlorothiazide in hypertension. See Chapter 25 for further details.



**Epilepsy**—Bergstrom and associates and Merlis report diminution of epileptic seizures with the use of acetazolamide (*Diamox*), but the former suggest that this action of drug is of limited value. No adequate explanation has yet been offered for this effect.

**Migraine**—Foldes recently reported on an 'antiretentional therapy' for migraine in which he postulated cerebral edema and for which he suggests that diuretic therapy can be used for both prophylaxis and treatment. This novel concept is without confirmation.

**Premenstrual Tension**—The demonstration of premenstrual retention of salt and water has led to trial of salt restriction as well as diuretics. It is difficult to distinguish between pharmacodynamic and psychologic aspects of relief in this condition and a well controlled study is needed to establish diuresis as a useful therapy for premenstrual tension.

## THE PHARMACOLOGIC BASIS OF DIURETIC THERAPY

Diuretic drugs are almost always used for the removal of extracellular fluid. Regardless of the nature or the site of their action, if diuretics are to accomplish this they must induce a negative sodium balance. Since this action is never specific for sodium alone but to a varying degree involves other ions as well, diuresis also constitutes a variable threat to electrolyte homeostasis. It appears not to matter greatly what the precise nature of the diuretic device is, restriction of sodium in the diet, mercury inhibiting salt resorption in the renal tubule, acetazolamide depressing hydration of carbon dioxide exchange resins drawing salt from the food in the intestinal tract or water diuresis all may and sometimes do induce clinically evident electrolyte disturbances. Combinations of these devices are even more likely to do this. Electrolyte disturbances have also been reported after paracentesis. It is interesting to note that there is now evidence suggesting that the too free use of water together with potent diuretics may be an important cause of electrolyte disturbances.

**Dangers of Diuretic Therapy**—The two major dangers of diuretic therapy are electrolyte disturbances and toxic reactions due to the specific nature of the drugs rather than as a consequence of diuresis. That a threat to electrolyte homeostasis is inherent in the mechanism of effective diuresis has already been explained. The danger is a real one only in so far as the therapist fails to recognize this quality of the diuretic procedure. The danger of specific drug intoxication from the diuretic is a possibility of course, as with all drugs. Since this is an individual matter, it will be considered in relation to the particular agents in the appropriate sections.

Reaction of the prostate, with acute prostatic shutdown due to excessive diuresis is a danger which should be considered before the regimen is written for the elderly male patient.

## THE DIURETICS

### Diet

Diet affects the flow of urine for precisely the same reason as most diuretics, namely there is diuresis to the degree that the restriction of sodium intake results

in a negative sodium balance. This physiologic fact was recognized more than 70 years ago. Its recent resurgence comes as part of a routine rather than as the sole measure in the treatment of edema. Occasionally, however, one may observe a satisfactory diuresis produced by salt restriction alone.

The choice of the patient in whom dietary restriction alone is likely to be a practical measure may be based on the difference it makes in his sodium balance. This depends largely on two factors: (1) the customary salt intake of the patient and (2) the rate at which his kidney excretes sodium.

Whereas the average American consumes about 10 Gm. of salt daily, there are many who customarily take considerably more, and in the latter the restriction of salt is more likely to induce significant alterations in salt balance. It is a practical matter, therefore, to examine the patient's usual diet carefully and to base one's anticipation on it. The ability of the kidney to excrete salt is, to a degree, also reflected in the relation of edema accumulation to the patient's customary diet. Should a patient accumulate edema on a relatively low salt intake, it indicates markedly reduced renal capacity for salt elimination, and while salt restriction is also indicated, it does not offer much hope that this measure alone, even though very stringently applied, will be especially effective in reducing edema. Details and explanations of this limitation are to be found in an excellent review by Danowski.

The chief disadvantage of the low salt regimen is its impalatability for most patients. Early willingness to cooperate often quickly changes to obstinate resistance, and unfortunately, there are no safe and satisfactorily salty salt substitutes.

The Karell diet, as modified by Gold, is 2 quarts of milk as the sole article of the diet with an equal amount of water daily. It contains a bit more than 2 Gm. of salt. It is not therefore unusually low in sodium content. Others have used diets containing as little as 50 mg. of sodium daily, and the rice diet recommended by Kempner contains about 150 mg. of sodium. The virtues of the milk diet are convenience and assurance: milk is one of the easiest articles of diet to get under any circumstances. No cook or restaurateur is likely to add salt to it; its salt content is never likely to exceed that provided by the cow. It is the item of food par excellence, therefore, for those who use the restaurant as well as for the emergency situation. The unopened egg is likewise an article of diet to which it may safely be assumed that no salt has been added.

Under all but carefully controlled conditions, it must be assumed, no matter how vigorous the denials, that a so-called low salt diet contains approximately the same amount of salt as the average diet supplied by the same purveyor of food. This negative attitude is based on unhappy experiences that led me to doubt my best friends under this particular set of circumstances. But it is one which leads to better results in the therapy of edema.

## Water

Water as the basis of a systematic treatment of edema was reintroduced by Schemm in 1942. Water diuresis is not a self-limiting process and, like other diuretics, when used excessively, may induce hyponatremia and tissue dehydration.

The case for water as a clinical diuretic reposes on what may well be called

the demonstration of a feat by Schemm, namely, that considerable amounts of edema can be removed by large amounts of water, i.e., from 6 to 8 liters daily, especially when the diet has an acid ash. The practical limitations of such a dreary method are obvious. Perhaps the major contribution of this demonstration of the diuretic capacity of water is that it has emphasized the undesirability of limiting water intake of patients with edema. It should also be recalled that excessive use of water together with diuretics has been implicated as a cause of serious electrolyte imbalance.

It must be pointed out, also, that there are areas in this country in which tap water contains so much sodium that it may aggravate the dropsical state of the patient with heart disease.

### Ammonium Chloride

Ammonium chloride has been used in the treatment of edema for its own diuretic action as well as for its enhancement of the action of the mercurial and xanthine diuretics. Within a few days after ammonium chloride is administered, it becomes ineffective as a diuretic. Despite this self-limiting protective device to conserve base, ammonium chloride may sometimes cause acidosis.

The enhancement of the mercurial diuretics is a more practical action. It has been shown that 8 Gm of ammonium chloride given for 2 days may double the effect of Mercuhydrin in some cases. This action appears to be more useful when smaller doses of the mercurial are used than with the usual 2 ml doses. This has variously been attributed to the effect of relative acidosis and the influence of the chloride ion.

Ammonium nitrate and calcium chloride, acid forming diuretics with much the same uses and limitations, are less frequently used. A recent paper by Luckey and his co-workers suggests, however, that there are instances of ammonia intoxication after ammonium chloride which can be prevented by the use of calcium chloride.

### Osmotic Diuretics

The use of osmotic diuretics, e.g., urea, has declined steadily since the advent of new, modern, more potent, and more dependable diuretics. Older work has indicated that while these agents may induce a degree of salt loss, as a rule this is not very large, and the diuresis, beyond that induced by the water ingested along with the osmotic agent, is very small indeed. Inasmuch as salt retention is the major problem in most instances in which diuretics are required, these observations provide little incentive for a search for new osmotic diuretics.

### Xanthine Diuretics

Although drugs of this large group have long been known to exhibit diuretic activity and are still widely used for this purpose, their position in the therapy of edema is definitely secondary to that of the mercurials. Special merits, in addition to their diuretic action, have been attached by some to the xanthines in the treatment of congestive heart failure, although this is not supported by proof. Investi-

gations on the effect of aminophylline on the cerebral circulation have indicated that therapeutic doses in man may cause constriction of the cerebral vessels and a degree of cerebral anoxia. Gastrointestinal distress is very common after the oral use of all xanthine diuretics.

Vogl and Esserman recommend aminophylline as a supplement to mercury diuretics in intractable congestive heart failure, but a study in which the combination was subjected to precise measurements does not support this contention.

**Administration**—Studies have shown that the rectal retention enema is the most effective nonparenteral route of administration of xanthine diuretics. There are wide variations in blood levels after the administration of tablets and suppositories. Others also have found the oral route less effective than the parenteral, while, by the intramuscular route, aminophylline produced local discomfort.

**Newer Xanthine Diuretics**—Whereas Pearson reported it to be a feeble diuretic, Cholelyl (choline theophyllinate) has been recommended by others for the treatment of congestive heart failure as well as for the anginal syndrome. Negligible gastrointestinal irritation has been claimed and these claims have provided material for a polemic in the columns of the *Journal of the American Medical Association*.

**Summary**—The reasons for the present inferior position of the xanthine drugs in the therapy of edema may be briefly listed: (1) They are not as effective as the mercurials. (2) They are not as dependable as the mercurials. (3) Given by mouth, effective doses cause a high incidence of gastrointestinal distress and are relatively ineffectual, nor is this materially improved when similar doses are given by suppository. (4) When they are given intravenously, fatalities as well as less serious immediate reactions have been reported. (5) When they are given intramuscularly local discomfort is common. These considerations do not, however vitiate whatever uses they may exert due to other pharmacodynamic actions which they possess.

### Mercurial Diuretics

In a recent editorial, the mercurial diuretics were called "the greatest advance in the treatment of chronic congestive failure since Withering." There are suggestions that in the relief of some aspects of cardiac edema they may sometimes surpass digitalis as well as all other diuretics now in common use. Despite publication of an increasing number of toxic reactions, the mercurial diuretics retain their position of pre-eminence and, as a matter of fact their use has increased through introduction of new forms and the extension of therapeutic usefulness to such important areas as the prophylaxis of pulmonary edema, asthma complicated by heart disease, cirrhosis of the liver, and bromide poisoning. The experience of most physicians with these agents in the treatment of cardiac edema is so large and general that it will not be reviewed here.

**Untoward Reactions**—The older literature contains many accounts of patients who have received several hundreds of injections of mercurial diuretics without special incident or renal injury and with long continued effectiveness. There are also patients who have reacted badly, some after the first dose of the mercurials, but in most instances after a period of salutary results. In view of the potency of

the demonstration of a feat by Schemm, namely, that considerable amounts of edema can be removed by large amounts of water, i.e., from 6 to 8 liters daily, especially when the diet has an acid ash. The practical limitations of such a dreary method are obvious. Perhaps the major contribution of this demonstration of the diuretic capacity of water is that it has emphasized the undesirability of limiting water intake of patients with edema. It should also be recalled that excessive use of water together with diuretics has been implicated as a cause of serious electrolyte unbalance.

It must be pointed out, also, that there are areas in this country in which tap water contains so much sodium that it may aggravate the dropsical state of the patient with heart disease.

### Ammonium Chloride

Ammonium chloride has been used in the treatment of edema for its own diuretic action as well as for its enhancement of the action of the mercurial and xanthine diuretics. Within a few days after ammonium chloride is administered, it becomes ineffective as a diuretic. Despite this self limiting protective device to conserve base ammonium chloride may sometimes cause acidosis.

The enhancement of the mercurial diuretics is a more practical action. It has been shown that 8 Gm of ammonium chloride given for 2 days may double the effect of Mercuhydrin in some cases. This action appears to be more useful when smaller doses of the mercurial are used than with the usual 2 ml doses. This has variously been attributed to the effect of relative acidosis and the influence of the chloride ion.

Ammonium nitrate and calcium chloride, acid forming diuretics with much the same uses and limitations are less frequently used. A recent paper by Luckey and his co-workers suggests, however, that there are instances of ammonia intoxication after ammonium chloride which can be prevented by the use of calcium chloride.

### Osmotic Diuretics

The use of osmotic diuretics, e.g., urea, has declined steadily since the advent of new modern more potent, and more dependable diuretics. Older work has indicated that while these agents may induce a degree of salt loss, as a rule this is not very large, and the diuresis, beyond that induced by the water ingested along with the osmotic agent is very small indeed. Inasmuch as salt retention is the major problem in most instances in which diuretics are required these observations provide little incentive for a search for new osmotic diuretics.

### Xanthine Diuretics

Although drugs of this large group have long been known to exhibit diuretic activity and are still widely used for this purpose, their position in the therapy of edema is definitely secondary to that of the mercurials. Special merits, in addition to their  
Investment of the treat

gations on the effect of aminophylline on the cerebral circulation have indicated that therapeutic doses in man may cause constriction of the cerebral vessels and a degree of cerebral anoxia. Gastrointestinal distress is very common after the oral use of all xanthine diuretics.

Vogl and Esserman recommend aminophylline as a supplement to mercury diuretics in intractable congestive heart failure but a study in which the combination was subjected to precise measurements does not support this contention.

**Administration**—Studies have shown that the rectal retention enema is the most effective nonparenteral route of administration of xanthine diuretics. There are wide variations in blood levels after the administration of tablets and suppositories. Others also have found the oral route less effective than the parenteral while by the intramuscular route aminophylline produced local discomfort.

**Newer Xanthine Diuretics.**—Whereas Pearson reported it to be a feeble diuretic, Choledyl (choline theophyllinate) has been recommended by others for the treatment of congestive heart failure as well as for the anginal syndrome. Negligible gastrointestinal irritation has been claimed and these claims have provided material for a polemic in the columns of the *Journal of the American Medical Association*.

**Summary**—The reasons for the present inferior position of the xanthine drugs in the therapy of edema may be briefly listed: (1) They are not as effective as the mercurials. (2) They are not as dependable as the mercurials. (3) Given by mouth effective doses cause a high incidence of gastrointestinal distress and are relatively ineffectual, nor is this materially improved when similar doses are given by suppository. (4) When they are given intravenously fatalities as well as less serious immediate reactions have been reported. (5) When they are given intramuscularly, local discomfort is common. These considerations do not however vitiate whatever uses they may exert due to other pharmacodynamic actions which they possess.

## Mercurial Diuretics

In a recent editorial, the mercurial diuretics were called "the greatest advance in the treatment of chronic congestive failure since Withering." There are suggestions that in the relief of some aspects of cardiac edema they may sometimes surpass digitalis as well as all other diuretics now in common use. Despite publication of an increasing number of toxic reactions, the mercurial diuretics retain their position of pre-eminence and as a matter of fact their use has increased through introduction of new forms and the extension of therapeutic usefulness to such important areas as the prophylaxis of pulmonary edema, asthma complicated by heart disease, cirrhosis of the liver, and bromide poisoning. The experience of most physicians with these agents in the treatment of cardiac edema is so large and general that it will not be reviewed here.

**Untoward Reactions**—The older literature contains many accounts of patients who have received several hundreds of injections of mercurial diuretics without special incident or renal injury and with long continued effectiveness. There are also patients who have reacted badly, some after the first dose of the mercurials but in most instances after a period of salutary results. In view of the potency of

the drugs as well as their wide scale use, this is not surprising. Since the reactions to mercurials have already been well described, the present account will consider only briefly statements in the literature which appear to add something to the already well known picture.

1. **DIGITALIS REINTOXICATION**—There is the now almost classic view that when mercurial diuretics act to release large amounts of fluid locked in the tissue interstices, there is also liberated such digitalis as may have been fixed in the fluid, and that in the already well digitalized patient, this supplement of digitalis may sometimes be sufficient to induce symptoms of digitalis intoxication. This view, however attractive or presumably reasonable, has never been supported by substantial evidence. It may now be assumed that the *coup de grâce* was delivered by a publication by St. George et al. These investigators demonstrated that the digitoxin content in edema fluids of well digitalized patients with ascites or pleural effusion was so small that redigitalization through its mobilization is not conceivable.

**ELECTROLYTE DISTURBANCES**—Because of an increased interest in problems of electrolyte balance as well as the fact that the mercurial diuretics have been combined with devices for enhancing the negative sodium balance and have been used with increasing vigor in resistant cases, electrolyte disturbances have attracted the greatest part of the recent attention devoted to diuretic reactions. Several varieties of electrolyte disturbance have been described: hypochloremic alkalosis, hypotensive alkalosis, hyponatremia with hypervolemia and with hypovolemia.

**OTHER REACTIONS**—Brown has reviewed the subject of reactions to mercurial diuretics and has grouped them into toxic and allergic reactions. In addition to the symptoms attributable to electrolyte disturbances, he lists chills, fever, malaise, muscular aching, nausea, erythema, chest pain, vomiting, dyspnea, tetany, and allergic reactions.

**PREVENTION OF REACTIONS**—Means of avoiding reactions is a matter of some interest. Caution has been advised against the excessive use of mercurials in general and more specifically against excessive diuresis. Modell has shown that muscle cramps developing after the use of mercurial diuretics may be correlated directly with the extent of diuresis and, presumably, transient electrolyte imbalance, rather than with the dose of mercury injected, and also that a diuresis which exceeds that producing a weight loss of 2 pounds markedly increases the incidence of cramps.

**Skin Tests**—Brown points out that skin tests are usually of little value in avoiding reactions. Patients who have a history of allergic reaction to some mercurial diuretics may tolerate others, but this is not invariably the case. Where previous allergic reactions have been severe, recourse to another type of diuretic is the safest procedure.

**Specific Antidotes**—A few specific methods of combating toxicity of mercurials have been suggested. While dimercaprol (BAL) has been shown clearly to reduce the acute toxicity of the mercurials, there is no good evidence that this also applies to the later toxic effects in which the concentration of mercury in the tissues is very low. The fact that latent reactions occur after mercaptomerin, a monothiol, also suggests that the dithiol BAL may be of little value in this respect. Magnesium sulfate to prevent ventricular fibrillation has been reported as useless. The hope that ascorbic acid might provide an antidote has not been substantiated by clinical trials.

Cohn reports that some symptoms of hypersensitivity can be prevented by the concomitant use of antihistamine drugs

*Mode of Administration* Fatality after the intravenous injection of mercurial diuretics is now unheard of largely it may be assumed, because that route has been abandoned in favor of the intramuscular While the latter is unquestionably the safer, there seems to be no reason why in a hypersensitive patient serious reaction or fatality may not develop after mercurials are injected into the muscle

*Mercury Resistance*—Responsiveness to the organic mercurials sometimes decreases significantly after a longer or shorter period of satisfactory reactivity Rarely is mercury resistance encountered at the outset of the use of the organic mercurials and absolute pharmacologic tolerance may be considered outside the range of normal variability More often than not clinical resistance develops in urgently ill patients A variety of circumstances especially electrolyte disturbances have been examined and suggested as an explanation for this state

Sometimes but not invariably ammonium chloride will restore responsiveness which continues for a period and once more ammonium chloride is needed Diamox and ammonium or calcium chloride comprise the most recent attack on the problem and a favorable report is considered in more detail in another section as is the suggestion that aminophylline is a most effective agent A recent report that pyridoxine may be used to overcome mercury fastness lacks confirmation as well as basis

*Self Administration*—Self administration of diuretics is economically desirable for the patient and also makes possible an ideal in treatment—the daily balancing of water and salt metabolism

*SUBCUTANEOUS*—There are reports of the satisfactory subcutaneous self administration of mercaptoproterin and of meralluride Mergamate is another mercurial recently reported as effective and satisfactory by subcutaneous injection Confirmation is awaited

*RECTAL*—Salyrgan (mersalyl) and Mercuzanthin (mercuophylline) were administered in suppository form in previous years but were discontinued largely because of a high incidence of proctitis Reports on satisfactory results with Mercuhydrin suppositories without rectal or colonic reactions have not been confirmed by a substantial experience

*ORAL*—Whereas all organic mercurials have long been known to be effective when administered by mouth there are sharp limitations to this convenient route of administration due mainly to a high incidence of distressing symptoms, especially the gastrointestinal In this connection it is well to recall that most bioassays of the potency of the oral diuretics in man consider only diuretic potency and fail to take into account undesirable effects in the gastrointestinal tract which develop only after continued use

*Neohydrin (Chlormerodrin)* At the time of this writing this drug is the most widely used oral mercurial diuretic Good results as well as economic advantages have been reported but such good results are not obtained in severe cases There are also reports of gastric distress from continued use

*Mercurital and Mergurate* These are reported to be effective oral diuretics able to replace parenteral therapy completely However, information is not avail



able concerning the extent of congestive failure in the patients or the duration of treatment or development of toxicity

#### Newer Mercurial Diuretics.—

**MERCAPTOMERIN (DIUCARDYN, THIOMERIN)**—The introduction of a monothiol group into an organic mercurial seems not to interfere significantly with diuretic potency of, at least some, mercurial diuretics e.g., mercaptomerin, whereas it reduces acute cardiac toxicity and local irritant action and therefore, may be administered subcutaneously. Satisfactory clinical results with mercaptomerin in the treatment of congestive heart failure have been reported by many.

The question which needs to be settled is whether mercaptomerin is superior to the standard mercurials in terms of reduction of toxic reactions. There are clinical reports that mercaptomerin is not without disadvantages but there are yet no clear statements of clinical superiority or inferiority to the other established organic mercurials. The best evidence indicates that they are all of about equal potency and tendency to latent reaction. Mercaptomerin does have the advantage of subcutaneous acceptability.

**DICURIN (MERETHIOXYLLINE)**—This drug has been introduced recently and is usually sold in a mixture containing procaine. It appears to be about as effective as most of the mercurial diuretics now on the market, but statements of lessened irritativeness must be considered not yet established.

**CUMERTILIN (MERCUMATILIN)**—This has been reported to be about as effective by parenteral injection as others in common use and to be potent orally as well as intramuscularly.

**Summary**—The mercurial diuretics are the injectable diuretics of choice since they are the most potent as well as the most dependable. Their toxicity is not an important consideration either by comparison with other diuretics or in relation to the seriousness of the conditions in which they provide such excellent relief. Those now on the market differ little from one another and there appears to be slight basis for special preference other than that of local reaction. Unfortunately, the oral and rectal preparations have not answered the problem of self-administration for patients who require mercurial diuretics, a compromise solution is provided by the subcutaneous administration of mercaptomerin and meralluride.

#### Exchange Resins

Although it has long been used in industry, the principle of ion exchange has been applied only recently to the treatment of edema. The attractiveness of the concept of removing the salt from the diet after the palate has been satisfied, the early reports of minimal toxicity, the desire for a substitute for the salt poor diet and a complement to mercurial diuretics led to widespread trial. As a result of these trials however the drugs are far less used than when first introduced.

**Types**—There are two types of ion exchange resins, the cation exchangers and the anion exchangers. The cation exchangers are the sulfonic acid resins. The anion exchangers are the carboxylic resins. The sulfonic acid resins have the greater capacity for exchange in the medium existing in the gastrointestinal tract. Diverse opinions will be found with no large body of



the resin to remove sodium from the intestinal tract is considerably decreased when the salt ingested is limited, yet the low salt diet cannot be avoided because the exchanger can rarely be taken in amounts large enough to produce a useful effect with average salt ingestion. Thus the resins turn out to be a nearly complete failure, they have not served to eliminate the nuisance and tastelessness of the usual salt poor cardiac diet and at the same time, they are far less effective than the standard diuretics. As a result, the exchange resin plays a minor role in the therapy of edema. Special indications for the resins, such as the treatment of hypo- and hyperpotassemia may provide a continuing use for them.

### Carbonic Anhydrase Inhibitors

**Acetazolamide (Diamox) and Its Congeners**—Although there are now a large number of drugs which are known to inhibit the activity of carbonic anhydrase only one acetazolamide (*Diamox*), has been widely used as a diuretic. At the time of this writing other carbonic anhydrase inhibitors belonging to the same chemical series as *Diamox* are under active investigation. *Dimate* has been reported to be too feeble to be of real value. *Dichlorophenamide (Daranide)* and *ethoxzolamide (Cardrase)* have been recently introduced into the commercial drug market but do not appear to have any special advantages over *Diamox*. The subject of carbonic anhydrase inhibition is relatively new and is being actively investigated. It may be assumed that many views now expressed will be modified.

What can be said of *Diamox* applies to the other carbonic anhydrase inhibitors now available. The extent to which carbonic anhydrase inhibition develops depends on the dose and the concentration of *Diamox* in the plasma. However, there are sharp limitations to the diuretic action of *Diamox*. When *Diamox* is given around the clock or in large single daily doses, alkalinization of the urine and diuresis ceases after 3 to 4 days. The daily ceiling dose has been established to be approximately 500 mg. On the other hand doses smaller than 250 mg per day are not likely to be effective by mouth although they may be so when given intravenously.

The action of carbonic anhydrase is not restricted to the renal tubule for it is a ubiquitous enzyme whose functions in all the tissues in which it is found are not understood. No organ or tissue has been shown to have a special affinity for the inhibitor and effects exerted elsewhere than on the kidney are now being studied. The utility of *Diamox* in glaucoma through decrease in intraocular fluid formation and in epilepsy through an ill understood mechanism, are discussed in another section. Effects on pancreatic secretion, saliva, the cerebrospinal fluid, and red blood cells have not as yet been demonstrated to have any clinical importance.

**EFFECT ON ELECTROLYTE BALANCE**—The development of *Diamox* action is followed by a rise in urinary pH with increased excretion of bicarbonate, sodium and potassium and a decrease in chloride and ammonia excretion, and titratable acidity of the urine. There appears to be little change in phosphate excretion. When these electrolyte alterations are uncompensated, hyperchloremic acidosis develops.

Schwartz and Reiman reported that *Diamox* is not likely to cause serious acidosis because its effect on serum bicarbonate tends to limit its ability to increase the excretion of base. A self limiting action has also been reported by others who

opinion preponderantly supporting the clinical utility or preferability of either the sulfonic or the carboxylic resin, nor have combinations of carboxylic and sulfonic resins proved particularly advantageous.

The nonspecific character of cation exchange results in removal of other ions than sodium, potassium in particular, and, to overcome this, exchangers have been made which release potassium. This combination, unfortunately, still further decreases the sodium removal capacity of the exchangers and provides a new danger, that of hyperpotassemia. Depletion of calcium and magnesium is also possible, but usually minimal, so that no addition of these minerals is made to the exchangers. Dock and Frank point out that there is, nevertheless, a distinct risk of gradual demineralization of bone in patients on a steady diet of exchangers over a period of years. They mention two cases of tetany.

At present, the most acceptable resins are mixtures of ammonium or hydrogen exchangers with potassium exchangers in a 2:1 or 3:1 ratio. Mixtures of anion and cation exchange resins have been suggested for special instances, such as renal disease.

**Effects on Electrolyte Balance**—The fundamental action of the resin, to exchange one ion for another, is, unfortunately, not highly selective, and ions removed as well as those provided in exchange may cause disturbances of electrolyte homeostasis. There is the possibility of producing hyperchloremic acidosis as well as hypopotassemia. Some discount the importance of such possibilities, pointing out that adaptive reactions of the intestinal tract prevent the depletion of sodium by the resins, that there is no evidence of depletion of sodium stores through the continued use of the resins, and that the fecal sodium excretion diminishes with the continued use of resins. Coincidentally with this, however, there is a tendency for fecal potassium to increase and, in patients receiving the resins for prolonged periods, for the potassium removed to exceed that of the sodium. Danowski and associates state that after 6 months' use there may be danger of hyponatremia and hypocalcemia. They believe that if the resins are to be effective, liberalization of the diet is not possible and that prolonged therapy may lead also to potassium deficit and acidosis. Others report negative sodium balance in patients on low sodium diet and a tendency to hyperchloremic acidosis which is greater in renal disease.

**Other Toxic Effects**—Casts have been found in the urine of patients with out renal insufficiency, which led to a warning regarding their use in renal disease of any severity.

It has been said that patients with severe hepatic disease tolerate the resins poorly. Highly specialized toxic effects have been reported in patients with cirrhosis: drowsiness, apathy, weakness, slurring of speech, disorientation, and tremor.

**Summary**—The theoretic advantages of the cation exchange resins are often overbalanced by realistic disadvantages such as impotence, necessitating large doses and rigid salt restriction for significant effects; unpleasant texture, making ingestion of the necessary large amounts difficult; and irritant action, making gastrointestinal difficulties common after usage. The addition of potassium decreases the likelihood of hypopotassemia but considerably decreases exchange effectiveness. The ability of

## ACTH and Cortisone

The action of ACTH and cortisone derivatives to induce diuresis has already been discussed in the sections on refractory cardiac edema and the treatment of the nephrotic syndrome

## Chlorothiazide (Diuril) and Its Congeners

Chlorothiazide is attracting more attention in the current literature, medical seminars and symposia than any other recent diuretic. If everything claimed for it is true it is a major addition to the drugs available for cardiovascular disease as well as for all forms of edema. This orally effective agent is now recommended as a diuretic. A discussion of the use of this drug in the treatment of hypertension will be found in Chapter 25. Whereas other newer drugs closely related to it are now in use there is no evidence that they are pharmacologically different and for that reason chlorothiazide the best known member will be discussed as the prototype.

It is perhaps important to emphasize at this point that most of the statements of its actions and effects, uses and lack of danger come as the result of studies conducted by investigators in selected rather than the usual run of cases. It has been made available on the commercial drug market only recently so that there are few published experiences on its effects, uses, or dangers in the hands of the practitioner. This statement is not made to dampen interest in an extremely interesting agent. If the drug proves to be as effective in the hands of the practitioner as it seems to be in the minds of its promoters, it will easily survive this expression of the need for caution. The statement is made merely to prevent the disaster that befalls useful drugs which are introduced on the heels of exaggerated claims and which because they fail to live up to them are dismissed as entirely without merit. It is, I think, permissible to repeat at this time, when there seems to be almost nothing but unequivocal enthusiasm for chlorothiazide, that the true utility of a drug can be determined and its proper exploitation developed only after the broad experience made possible by general use, and, further, that the full potential for dangers of drugs is usually not established until after several years of trial. With these basic reservations it is only fair to state my opinion that chlorothiazide not only is a most interesting diuretic but also appears to have advantages over all other oral diuretics now in use.

The mode of action of chlorothiazide is unique in that it exerts two actions, each characteristic of an entirely different type of diuretic. On the one hand, it has potent carbonic anhydrase activity and therefore, acts in the same way as acetazolamide (Diamox) and, on the other hand like mercurial diuretics it acts directly on the renal tubule to depress salt resorption, although on a different transport system. This combination of actions seems to have a peculiar advantage in that the tendency of the former to retain chloride and lose bicarbonate leading to hyperchloremic acidosis is cancelled by the latter action which induces chloride loss and otherwise leads to hypochloremic alkalosis.

The drug is well absorbed from the gastrointestinal tract and is commonly given orally in doses of 0.5 Gm twice a day. The effects of such doses develop quickly and disappear almost completely within 12 to 15 hours.

found that despite continued use, diuresis soon diminishes and within 2 to 5 days urine returns to its pretreatment composition, and, in addition, this corresponds with the appearance of hyperchloremia. The action of Diamox to increase potassium excretion has led to the suggestion that it be used in hyperpotassemia.

**Toxic Reactions**—Serious toxic reactions thus far have been relatively rare. In those subjects with renal disease and acidosis Diamox seems to be without much effect. The earliest reports contained accounts of paresthesias, lassitude and drowsiness. These symptoms usually disappear even though the drug is continued. Although carbonic anhydrase inhibition produces hyperchloremic acidosis and accelerates the excretion of potassium serious reactions due to this action are uncommon in man apparently because of the self limiting nature of the drug. Febrile reactions have been reported.

The close chemical relationship of Diamox and the sulfonamides suggest the possibility of related toxic reactions. At this early date in the clinical experience with Diamox cases of agranulocytosis, renal lesions similar to those after sulfonamides, and thrombocytopenia have already been published.

**SUMMARY**—Friedberg and associates and others report a satisfactory experience with Diamox in patients with congestive failure. On the other hand Reiman and co workers were disappointed because half of their patients failed to lose edema. Diamox is not as potent as the mercurial diuretics nor can it be substituted for them. It is an effective oral diuretic however and may be used as an adjunct to the mercurial diuretics. Because of its self limiting action, Diamox is usually given for 2 or 3 days and discontinued for the remainder of the week to permit readjustment of electrolyte and restoration of activity. At the present time there is no evidence of superiority of any of the three available drugs of this series. Cardrase, Diamox and Daranide. The differences in absolute potency can be made up by adjustment in dosage so that for all practical purposes they are equally useful.

**Methazolamide (Neptazane)**—In view of the current and growing interest in the extreme effectiveness of chlorothiazide and its many effective new congeners by the oral route interest in the carbonic anhydrase inhibitors in the treatment of edema has subsided considerably whereas the interest in their utility in glaucoma has grown substantially. Thus there is a new carbonic anhydrase inhibitor methazolamide (Neptazane) which undoubtedly has the diuretic actions of the others but which is advertised only for its utility in glaucoma.

#### **Pyrimidine Dione or Amino Uracil Diuretics**

A number of amino uracil also called pyrimidine dione drugs exert diuretic activity when given by mouth. Some members of the amino uracil group are also strongly emetic. One member of this group Mictine (aminometradine), has been reported to be significantly less emetic than others in the group. It is a relatively mild diuretic but clinical experience with the drug is still too small to evaluate its position as an oral material. **Roliton** (amisometradine), a new Mictine like drug is too recent an addition for comment other than that there is yet no evidence of superiority over Mictine despite the fact that Roliton was introduced to replace Mictine. The general impression however, is that it is a relatively feeble diuretic.

## Combinations

Combinations of diuretic devices are used either because the edema attacked is relatively resistant to any one measure or because the urgency of the situation calls for relatively rapid relief. It is to be borne in mind that the continued use of combined measures to increase and prolong the negative salt balance is the more likely therapy to induce electrolyte disturbance syndromes. It is essential, therefore, that the combination of measures used to relieve edema be altered as the nature and extent of the edema alters and responds to the treatment, and that blood electrolyte levels be followed as therapy progresses.

## New Diuretics Under Investigation

It is perhaps of more than passing interest that an ability to exert a diuresis has recently been added to the multitudinous pharmacologic accomplishments of the so called tranquilizer, chlorpromazine (Thorazine). How this action is developed is not clear nor is its record as a clinical diuretic outstanding. Other phenothiazine congeners remain to be tested, and until there is a clear picture of their clinical value as diuretics no recommendation regarding their use can be made.

Perhaps the most exciting new possibility is an entirely new approach to the problem that of aldosterone inhibition. There is evidence that spiro lactone, an aldosterone like structure antagonizes the action of aldosterone on sodium resorption in the renal tubule. The first clinical trials with spiro lactone indicate that it also induces diuresis in patients with edema. At this time only a small experience has been reported, but this drug, or one similar to it, may provide, as well as a new approach, entirely new diuretic actions and, with them, clear advantages over the old diuretics.

Trials with triazines have been reported from time to time, none of them very impressive as yet. A recent one, amanozine, has been reported as superior to the others but this drug has not yet been subjected to sufficient clinical trial for a firm opinion.

## THE DESIGN FOR DIURESIS

Only therapy which takes into account (1) the nature of the fluid or electrolyte to be removed, (2) the ease with which it can be done in the specific case with the agents available, (3) the need for speed in its removal, and (4) the setting in which it will be done (whether the home or the hospital where sodium intake can realistically be controlled) will provide the greatest likelihood of success with diuretics.

If edema is recognized in its least threatening stages, the measures for its removal will be the simplest, the disorders of water and salt balance incident to its removal will be the most modest, and the success will be satisfactory without either danger or discomfort. If therapy is delayed until heroic measures are the only ones which will provide sufficient relief in time, the nature of the necessary diuretic action is such that a degree of distress due to diuresis alone is inevitable, and, the


Specific toxic effects have not been described in detail in man although hypopotassemia, more easy to prevent than to control when established, is well recognized as a danger of chlorothiazide. Skin rashes have also been reported and more recently it has been pointed out that, in the treatment of alcoholics with cirrhotic edema, there is a real danger of precipitating hepatic coma. It is well to remember that the drug is related to the sulfonamides and there is, therefore, a possibility of bone marrow depression and, at this early date, cases of agranulocytosis and thrombocytopenia have been reported. The reduction of blood pressure in hypertension is an effect of chlorothiazide which has not been explained, but which may, if it induces precipitous depression of blood pressure, be a source of serious difficulty in some patients with heart disease. Furthermore, there is the experience that this agent enhances the hypotensive actions of drugs commonly used in the treatment of hypertension. In patients receiving such drugs for hypertension there appears to be a realistic danger in the careless use of chlorothiazide.

Such a new and patently attractive drug may present the physician with a serious problem of choice. Chlorothiazide appears to be a generally more desirable diuretic than acetazolamide (Diamox). It can be given for longer periods without the development of tolerance, while tolerance very quickly limits the utility of Diamox. It is claimed that, unlike other diuretics, it is effective in patients using corticosteroids. Unless the amino-uracils, xanthines, and oral mercurials, it causes little gastric distress.

Chlorothiazide's negative features lie chiefly in what we do not yet know about it. Like every effective drug it must have dangers, disadvantages and limitations. These are not yet recounted in the literature on chlorothiazide, we have yet to discover them. The extent to which it can replace or reduce the need for injections of mercurial diuretics in patients with advanced congestive failure and its effectiveness in stubborn edemas remain to be established. We know nothing of the incidence of allergic or hypersensitivity reactions. We know nothing of the effects of truly long term use (i.e., usage comparable to the experience with mercurials for 10 or more years without ill effect). Already, however, the propensity of chlorothiazide to induce hypopotassemia is well recognized, and it is usual to attempt to control it, not always effectively though, with potassium chloride or orange juice. Bone marrow depression and other blood dyscrasias have been reported. This is not surprising in view of the close relationship to the sulfonamides. In addition pancreatitis has been reported as a complication.

Because of its apparent advantages I would choose chlorothiazide if I desired an oral diuretic. I recommend that all who use it consider its undetermined limitations and dangers. I advise that anyone unwilling to follow both the literature and the patient carefully use another oral diuretic. It may be of interest that the manufacturers of Diuril are now purveying hydrochlorothiazide, which seems to have no practical advantage over chlorothiazide. The tremendous success of

ment on their relative effectiveness. It is a certainty, however, that there will be more of them.





In choosing the proper diuretic it should be decided whether or not to use a parenteral mercurial diuretic rather than how long to try the others before succumbing to its unquestioned superiority. In general, the oral diuretics are far more useful in maintenance therapy than for the initial treatment of the edema.

**Dosage**—Dosage is better considered in terms of biologic effect than in absolute amounts. Where time permits, a less than average dose, say 0.5 ml, of a mercurial diuretic can be used to test the patient's response to the drug. In such a case, a dose can be adjusted which will induce an average diuresis of from 1.5 to 2 pounds. A larger diuresis is likely to cause cramps or other symptoms due to transient electrolyte disturbance. Where the time is short, the 2 ml dose may be used at the outset. In some relatively resistant cases 3 ml of a mercurial may be a minimal effective dose. In a few instances 2 ml has to be given twice a day before diuresis develops. The latter dosages are rarely required and should be administered only after it is clear that the more than usual dosage is both essential and likely to be effective. Whatever the diuretic used may be once the edema is satisfactorily relieved a dosage schedule should be established which maintains the patient in a state of normal hydration.

### RATIONAL BASIS FOR NEW DIURETICS

The potency of diuretics presently available is adequate for all common needs indeed, many of the fears about them are based on reactions due to the more than requisite response to some of these agents at the hands of the indiscriminating. The qualities to be sought in new diuretics are listed here. No available diuretic of adequate potency by the route generally recommended for its use possesses all of these qualities.

- 1 Sustained rather than abrupt violent action
- 2 Reduced capacity for electrolyte upheaval
- 3 Convenience of administration, self administration (oral, rectal or subcutaneous)
- 4 Decreased toxicity (systemic and local irritant action especially of the gastrointestinal tract)
- 5 Effectiveness where others are ineffectual or contraindicated
- 6 Applicability in cases with a history of allergic reaction to other diuretics

In evaluating new diuretics, look for specific data on these issues and remember that early enthusiasms for new diuretics often are not supported by subsequent trials in man. Such discrepancies may arise from the fact that the responses of many animals differ from those in man, in addition, clinical evaluation is determined in the patient with congestive heart failure, a condition which cannot be duplicated in the animal, and bio assay of diuretics in the patient with congestive heart failure usually provides answers which apply much more to potency than to long continued utility.

### SELECTED REFERENCES

- Arnold, W. P. Medical Uses of Ion Exchange Resins, New England J. Med. 245: 331, 1951  
 Bell, A. L., Smith, C. N. and Andrae, E. Effects of the Carbonic Anhydrase Inhibitor 6063 (Diamox) on Respiration and Electrolyte Metabolism of Patients With Re

small in comparison with the danger of the clinical condition, the danger of reaction will increase

The aim of the design should be to bring about a normal state of interstitial hydration. I deplore the use of the term "dehydration" because it leads to implications of desiccation. Tissues properly treated by diuretics are neither dry nor wet, they are normally hydrated. The ideal therapeutic program is one which provides a daily salt and water balance, rather than the more commonly weekly or semimonthly salt-and water statement.

Diet is a matter of the first importance. Since patients with cardiac edema will probably sooner or later have to accept the salt poor diet, they would be well advised if they decided to do it sooner. For those who have difficulty with the diet, the inevitable day can be deferred by the use of diuretics or doses more potent than would otherwise be necessary.

Oral diuretics are desirable but, unfortunately, they are often impotent for the purpose or irritant to the patient's stomach. Oral diuretics are most likely to be of practical and continued utility in cases in which a modest diuretic action is satisfactory. Such results are sometimes obtainable with small doses of Neohydrin. If larger doses are necessary, gastrointestinal distress is likely to arise sooner or later, at which time the problem of therapy will have to be faced and solved in a different way. Because unpleasant effects are less common, Diamox is a useful diuretic. Unfortunately, its effectiveness is brief and, although it returns after a waiting period, some other diuretic often has to be used between periods of Diamox therapy. The xanthine diuretics cause gastrointestinal disturbances too frequently, even when used in suppository form, to be of value in any but the most unusual case. Resins usually provide too many difficulties to justify their relatively small contribution to the relief of edema. It may sometimes be possible to reduce the number of injections necessary by the supplemental use of oral diuretics, but, if the patient is not resistant to mercurial diuretics, this help is not required. The most recent agent, chlorothiazide (Diuril) seems to be the oral diuretic of choice.

The mercurial diuretics are still by all odds the most effective and the most dependable diuretic agents we have today. The undesirable results which have caused concern come from the fact that they are very effective rather than because of any defect. Their use orally or rectally, as already indicated, has serious limitations. No one organic mercurial diuretic is preferable in terms of effectiveness or decreased likelihood to induce electrolyte imbalance.

Digitalis is indicated in virtually all cases of edema of heart disease. In a large number, however, especially those with a normal sinus rhythm and those with an element of left sided heart failure, the benefits of the digitalis are not likely to be great enough to be easily discernible, while in many with advanced congestive failure the mercurial diuretic clearly provides more relief than the digitalis used in the combination.

Where cardiac patients, like diabetic patients, will inject a diuretic subcutaneously, frequent injections of relatively smaller doses of mercurial diuretics are both economical and feasible, and a frequent balancing of salt-and water intake and output may be achieved. For such patients mercaptopimerin or meralluride may be used.

# THE CHOICE OF DRUGS FOR NUTRITIONAL DISORDERS

William B Bean, M D

## INTRODUCTION

No animal can survive long when his diet consists of pure protein, fat, carbohydrate, and the necessary minerals. Man shares with many living creatures along the evolutionary scale the ability to live on plant foods or the tissues of other animals. These contain innumerable materials in addition to the three basic food constituents. Even a cursory view of the history of man's food and food habits shows there are no such things as good or bad tissues, or good or bad foods, or good or bad habits. Individual persons and whole nations have thrived on many different diets. Food customs provide a good illustration of Henning's dictum that there is nothing on earth which is not as much beloved by one group of people as it is detested by another. When given a wide variety of foods, man may not have always chosen the best diet, but he has managed to survive.

The medical puzzles introduced by the discovery of vitamins, their complex interrelationships, and the central position of food in human ecology highlight the difficult problem of nutrition. Dietary deficiencies have analogies with other diseases where replacement therapy of an inherent deficiency is essential for survival. For example, certain lesions reduce or abolish the supply of hormones. The resulting metabolic irregularities may be corrected by supplying extracted or synthesized hormones, thus keeping the person not only alive but in good health. The use of insulin in diabetes and the use of steroid hormones in Addison's disease are examples. Dietary deficiencies are not inherent, but represent failures to balance supply and demand. Vitamins are used in therapy to pay back a debt. *Replacement* rather than *replacement* therapy.

The appearance of clinical indications for employing vitamins and related accessory food factors as drugs signifies that a serious breakdown has occurred in the orderly processes leading to proper nutrition. There are many avenues which man may develop the clinical phenomena we recognize as pernicious anemia may result from an inborn error leading to a functional disturbance as in pernicious anemia. A basically similar disease may be produced by a tapeworm harbored in the upper reaches of the small intestine. The tape-

- Bodansky, O, and Modell, W The Differential Excretion of Bromide and Chloride Ions and Its Role in Bromide Retention, *J Pharmacol & Exper Therap* 73 51, 1941
- Brown, E A The Question of Reactions to Mercurial Diuretics, *Ann Allergy* 13 131, 1955
- Council on Foods and Nutrition Nutritional Implications of Sodium Restriction, *J A M A* 149 1317, 1952
- Danowski, T S Low Sodium Diets—Physiologic Adaptation and Clinical Usefulness, *J A M A* 168 1886, 1958
- Dixon, L R, Kim, Y S, and Vander Veer, J B Clinical Experience With Chlorothiazide (Diuril), With Particular Emphasis on Untoward Responses, *Am J M Sc* 236 533, 1958
- Dock, W, and Frank, N R Cation Exchangers Their Use and Hazards As Aids in Managing Edema, *Am Heart J* 40 638 1950
- Fiese, M J, and Thayer, J M Value of Southey Leech Tubes in Rapid Relief of Massive Edema, *Arch Int Med* 85 132, 1950
- Ford, R V, and Spurr, C L Electrolyte Excretion Patterns Due to Chlorothiazide, a New Osmotic Diuretic, *Am J Med* 1957
- Carbonic Acid Failure, *J Med* 603, 1947
- Heidorn, G H, and Schemm, F Steroids in the Therapy
- Hollister, J M, Lubash, G D, E H Refractory Edema
- Mercurial Diuretics, *Am Heart J* 50 629, 1950
- Iseri, L T, Boyle, A J, and Myers, G B Water and Electrolyte Balance During Recovery From Severe Congestive Failure on a 50 Milligram Sodium Diet, *Am Heart J* 40 706 1950
- Johnson, D H, and Cornish, A L Acute Pancreatitis in Patients Receiving Chlorothiazide, *J A M A* 170 2054, 1959
- Lester, L Intractable Edema Clinical Therapeutic Implications, *New York J Med* 48 624 1948
- Liddle, G W Aldosterone Antagonists, *A M A Arch Int Med* 102 998, 1958
- Mackie, J E, Stormont, J M, Hollister, R M, and Davidson, C S Production of Hepatic Coma by Chlorothiazide and Its Prevention by Antibiotics, *New England J Med* 259 1151, 1958
- Merrill, A J, and Wilson, J Continuous ACTH Therapy of the Nephrotic Syndrome, *Am J Med* 16 600, 1954
- Minor, R W, editor Conference on Ion Exchange Resins in Medicine and Biological Research, *A M A Arch Int Med* 109 649, 1959
- Model, 1956
- Model, 39, 1959
- Model, talis and Mer 6 358, 1947
- Moyer, 0 2048, 1959
- Pitts, Med 24 745, 1958
- Pitts R F, Kruck, F, Lozano, R, Taylor, D W, Heidenreich, O P A, and Kessler, R H Studies on the Mechanism of Diuretic Action of Chlorothiazide, *J Pharmacol & Exper Med* 123 89, 1958
- Pitts, R te of Diuretics,
- Rubin, A c Management
- Rubin, A in Congestive Failure 13 655, 1956
- S: C. S. N. A. C. F. S. R. U. J. A. 1950, 1950
- Sch
- Sch
- Sch
- Vog
- Zuc
- 1950, 1950

supply system. A man's entire need for vitamin K can be supplied by the action of enteric organisms if bile is available to promote its absorption.

The nutritional needs of man are subject to adaptive changes so that a requirement may diminish under certain circumstances and may increase under others. This is important in different parts of the world where the economic and educational status, climate, land, and customs provide peculiar diets for Arab and Eskimo, for Bushman and New Yorker. Evolutionary forces may have led to the survival of certain groups fittest to thrive on particular and peculiar foods. Influences of another kind are far more important in clinical medicine where organic diseases, neurosis, food fads, and even unwise therapeutic diets may provoke or precipitate actual deficiency diseases.

The age of the biochemist, enzyme chemist, and animal nutrition expert is now with us. The past saw much reluctance on the part of those in basic science to tackle the problems of clinical medicine. Under the impact of laboratory research this has changed, and once the change came it continued with accelerating speed. The trend of neglect has been reversed so completely that laboratory scientists have far outstripped the clinician in knowledge and understanding of many biologic and biochemical problems relating to nutrition. Thus we are in the remarkable and uneasy situation of having a great many vitamins whose function in man is not known but is inferred by gross extrapolation from known or suspected biologic functions in lower organisms or from *in vitro* studies.

There is vast perplexity in the clinical diagnosis and treatment of most vitamin deficiencies. In a large population group, for instance inmates of a prison, eating the same poor diet several different deficiency diseases may develop; many persons however will have no lesions or illness. A sign usually attributed to a specific B vitamin deficiency may respond to the administration of another vitamin. One vitamin may increase the absorption of another, facilitate its metabolic function, or have a sparing action. On the other hand if given in large amounts one vitamin may indeed increase the need for another. It must be assumed that all tissues require all essential vitamins but one vitamin becomes a limiting factor in producing symptoms of disease or even death before another one equally deficient in the food causes perceptible trouble. Since the B complex vitamins occur in natural foods together and since the potential pathologic response of tissues and organs is limited it is not surprising that several deficiencies produce similar lesions or that several different vitamins may produce clinical improvement of one lesion. We do not yet understand many of these complexities.

Before leaving the general problems of the need of various nutrients let us consider another element which makes the problem of daily requirements and hypothetically optimal levels of intake exasperatingly difficult. In our laboratory we have measured specific vitamin content of several natural foods and of whole diet. The vitamin and mineral content of an egg, a potato or a piece of steak may vary greatly from that of an apparently identical specimen. In spite of what nutrition tables tell us about the vitamin values of various foods the following factors are others need consideration when we try to estimate how much of a special vitamin goes into the tissues of our patients and ourselves. For food plants alone species, variety, and genetic make up of the plant, (2) phys

gets the vitamin B<sub>12</sub>, the host little or none. Rarely, clinical vitamin B<sub>12</sub> deficiency occurs when the diet has been very poor for a long time. Alcoholism may be complicated by secondary deficiency diseases, though most cases of hyperchromic, macrocytic anemia in cirrhosis are not the result of B<sub>12</sub> deficiency. Finally, and not least important, diseases may produce secondary malnutrition in many ways. Total gastrectomy, removing intrinsic factor, usually yields this kind of anemia if the patient survives long enough. A blind pouch of bowel or a short circuit may result in a B<sub>12</sub> deficiency, iron deficiency anemia, pellagra, or sometimes apparent good health. These are the main kinds of processes by which the illnesses of under-nutrition are produced. Obesity, the opposite form of malnutrition, rarely requires drugs in therapy.

There is hardly a field of clinical medicine where the questions of dosage, "requirement," and therapy have more uncertain answers than in nutrition. While nutritional deficiency diseases and the many diseases which interfere with nutrition are the proper concern of the physician, clinical science has been relatively sterile in this field. The serious perplexities, the long years of study, the inability to arrange short, neat, readily controlled tests, and the many reports of casual slipshod experiments masquerading as research have left clinical nutrition far behind other fields of scientific medicine. This vacuum attracts the quack and the zealot who gull the ignorant from opposite motives.

Living organisms require many contributions from their environment: oxygen, constantly, sunlight and warmth, regularly, and then a host of minerals, energy materials, and preformed compounds which must be supplied to permit life to make its continual homeokinetic adjustments. A clear rank order of the urgency of the several requirements exists. Thus oxygen lack is fatal in minutes, deprivation of warmth is fatal in hours, of water in days, of calories and some minerals in weeks, of certain trace minerals, B complex vitamins, and ascorbic acid in months, and of fat-soluble vitamins and vitamin B<sub>12</sub> in months or years.

Barring an easy solution of the problem is the fact that not only do the needs of the organism vary with growth, age, size, activity, pregnancy, lactation, intercurrent disease and other influences but there are variations in time, secular trends, and a host of ecological relations scarcely investigated and little understood. There are genetically determined variations in requirements which make each man different from every other man. Of the approximately 60 different essential nutrients, any person may have some needs high, some low, and some moderate. Requirements may be related to other factors, such as nonfat calories to thiamine. One-way substitution may be possible, e.g., tryptophan may serve as a precursor for niacin though the reverse exchange does not operate. We do not know what determines the choice of metabolic pathways for tryptophan when niacin is in short supply. Many complex organic compounds can be made by microorganisms living in peace and symbiosis in our enteric canals, though ruminants have a much better arrangement in their alimentary brewing vats. Biosynthesis in the foregut of ruminants occurs where it is a real help since the products of fermentation must run the gauntlet of those parts of the gut where absorption is active. In man biosynthesis in the cecum and colon are almost biologic afterthoughts although they may have some utility. Vitamin K is an example of a completely self-sufficient do-it-yourself

may stalk latent beriberi. Deficiency of the B complex vitamins which occur together in nature may produce signs and symptoms singly or in clusters. Kaleidoscopic patterns emerge in a population group or even a family exposed to the same foods. Thus may result from different actual intake or variable specific requirements or metabolic peculiarities—the genotrophic individualities of Roger Williams. Which are important or how they work, we do not know.

### Fat-Soluble Vitamins

The fat soluble vitamins of clinical concern are vitamins A, D, and K. Vitamin E, long the cross-eyed stepchild, may be admitted to a seat of honor at the table if its advocacy is taken from the hands of medical mythologists and restored to legitimacy. Oral therapy with fat soluble vitamins is preferable unless sprue exists or bile is blocked or diverted from the gut.

**Vitamin A**—Deficiency of the carotinoid vitamin A, said to be common in parts of the Orient, is very rare here. The liver is tenacious of its stores. Animals made deficient of vitamin A have defective vision, metaplasia and atrophy of epithelial tissues, and a disorder in the growth and remodeling of bones. In man it has not been possible to separate the hypoplasia and increased keratinization of the epidermis of vitamin A deficiency from those of starvation. Affections of the eye may progress from night blindness through dryness, thickening, and roughening of the lackluster bulbar conjunctivae, to Bitot's spots, impaired sensation in the cornea and sclera, reduced vision in good light, photophobia, edema, opacification and ulceration of the cornea and the final ruin of panophthalmia.

The treatment of vitamin A deficiency is to prescribe vitamin A. This trism contains the essence of all vitamin therapy. Fifty thousand to one hundred thousand units of pure vitamin A or potent extract of fish liver containing this amount should be given daily. The sheet anchor of all vitamin therapy is to get the patient over the hump with vitamins, restore his depleted stocks with concentrates, and then provide and sustain an ample diet. This is easy to say but may be hard or impossible to do. Vitamin A deficiency develops slowly and responds with equal slowness so that therapy may have to continue for half a year or more. It is not an emergency problem.

**Vitamin D**—Vitamin D is the generic term for a group of related sterols which prevent or cure rickets. When there is enough exposure to sunlight, a unique form of biosynthesis may occur in the skin if it is not too heavily pigmented. The mechanisms by which vitamin D aids in the absorption of calcium from the gut and helps deposit it as phosphate or carbonate in osteoid and cartilage matrix is a flagrant mystery. But when vitamin D is inadequate, membranous bones and the shafts of long bones produce too much uncalcified bone. Osteoid develops without lime salts, the soft rib cage becomes an inadequate bellows and the long bones warp and bow. Cartilage cells without calcium salts fail to mature. They accumulate and are distorted. Later degeneration and efforts at repair by vascularization complete the sorry condition. Only within limits can the fully developed process be reversed.

In severe rickets 20,000 units of vitamin D are given by mouth each day. Clinical and x-ray changes indicate progress. After convalescence is established,

properties, mineral, organic, microbacterial elements of the soil on which it is grown, (3) sunlight, length of daylight, season of the year, as well as the growing time, (4) general climate and altitude, (5) ground moisture, rainfall, (6) the time and method of harvesting and whether the plant is picked green or ripe, (7) the exact state of the food in collecting, transporting, and storing, (8) the processing, refrigerating, drying, as well as bacterial contamination, oxidation, spoiling, (9) milling, bleaching, mixing, homogenizing, chemical treatment and chemical preservatives, (10) methods of distribution, storage, packaging, exposure to heat, moisture, light, and the duration of standing before ultimate sale, (11) similar factors with reference to home storage, freezing, canning, (12) the preparation of the food including heating, freezing, thawing, drying, cooking, standing after cooking, disposal of cooking water, (13) method of serving and, finally, (14) eating.

The effect of variation of these factors is suspected and in a few cases measured, but for the most part it is unknown. To such manifold variations in the vitamin or mineral content of standard items of food we must add the intricate and still not clearly understood processes of digestion, absorption, and assimilation. Perhaps the confusion may be epitomized by the unhappy thought that even the word "vitamin" is a misnomer.

## CLINICAL APPLICATIONS

A vitamin is an organic chemical compound, of simple structure (e.g., niacin) or complex structure (e.g., cyanocobalamin) existing in natural plant or animal foodstuffs, essential for the normal reproduction, growth, and metabolism of higher forms of animal life. Unlike hormones which they much resemble, the host is unable to synthesize them or at least enough of them for its requirements. What is a vitamin for one species can be manufactured by another. Ascorbic acid is a vitamin for man and guinea pigs, but not for dogs or rats, which may startle the cynic. Water-soluble vitamins, whose function we suspect by data from laboratory observations, are active in enzyme systems which govern energy transfers in the busy metabolic housekeeping which is coterminous with, or may be defined as, life. Vitamins are active in very small amounts, how small we now appreciate in the example of the vitamin B<sub>12</sub>, of which a day's supply is only about  $\frac{1}{60}$  billionth of the body weight of the host.

A vitamin, if a drug at all, is not one in the ordinary sense, though vitamins may have independent pharmacologic reactions and all can be poisons if given long enough at excessive levels. Though vitamins have been used for an extravagant array of ills and ails not related to a lowered stock in the tissues, their undisputed use is to correct a deficiency. If any genuine virtue resides in other uses, it will be winnowed out of our present vogue of therapeutic faddism which, replacing an equally excessive therapeutic nihilism, has overreached itself.

The proper use of vitamins is an individual problem. In some instances there is but a single deficiency and a single vitamin will correct it. Scurvy responds to vitamin C. In other situations the clinical signs may suggest that only one vitamin is seriously deficient, but there may be gross dietary deficiencies of several factors causing humoral faults and upsetting some normal functions but not recognizable by any sign as another specific vitamin deficiency syndrome. With clinical pellagra,



no certain connection as yet between any of the muscular dystrophies, hemorrhagic disorders, or disturbances of fertility and gestation in human beings and such signs of vitamin E deficiency in animals. However, the negative aspects of Horwitt's studies where a vitamin E free diet has been given to many subjects for periods of many months should make us skeptical. For the time being, vitamin E, though probably essential and perhaps very important has not been defined in terms of its role in clinical medicine.

### Water-Soluble Vitamins

**Thiamine**—Thiamine was called vitamin B<sub>1</sub> because it was the first element discovered in what was thought to be a single water-soluble vitamin. It is the eldest of the numerous progeny, perhaps with more siblings to come. Many reactions are catalyzed by thiamine-containing enzymes, the majority having to do with the breakdown of pyruvic acid and alpha-ketoglutaric acid. The biochemical and physiologic lesions of beriberi result from disturbances in carbohydrate metabolism. Thiamine requirement is influenced by carbohydrate intake and total calorie expenditure. Deficiency of thiamine leads to beriberi. Records from China suggest that it may have existed more than 2000 years B.C. Clinical beriberi may be a dry variety, peripheral neuropathy without cardiac complications or it may be wet beriberi with edema, cardiovascular symptoms, and peripheral neuropathy. It has been suggested that peripheral neuritis may incapacitate a person and thus prevent exercise which might precipitate heart failure. The mechanism by which a disturbance in pyruvate metabolism produces a cardiovascular disorder is not known. High cardiac output, fast blood flow, wide-open arterial circuits, relaxed vasomotor tone, warm flushed skin, pounding pulse, high pulse pressure, capillary pulsation and pistol shot sounds characterize wet beriberi. It may end fatally with severe peripheral edema, dyspnea and orthopnea. Both the high output failure of wet beriberi and the peripheral neuropathy of thiamine deficiency have become very rare in this country during the last ten years. The improved economy of the country and the restoration to flour of some of the thiamine removed in the milling process probably account for this trend.

Thiamine shares with other water soluble vitamins the tendency to be excreted in the urine when it is given in large quantities. For this reason, several doses of 5 mg with meals and at bedtime are satisfactory except in critically ill patients where parenteral injection of 50 to 100 mg may be necessary even though much of this will be lost in the urine. If there is any doubt, employment of thiamine both methods is satisfactory. As soon as convalescence is established, a good nutritious diet together with supplementation of other B complex vitamins is necessary for proper therapy. The neuropathy may fail to respond if the nerve is dead, but therapy for months with 5 mg daily may be associated with some improvement.

**Riboflavin**—The first demonstration of the relationship between biological functions and vitamins followed rapidly after Warburg and Christian discovered their flavoprotein enzyme. This was followed shortly by the separation, identification and synthesis of the prosthetic group. It had long been known that the disease resembled pellagra but in which skin lesions were

3 teaspoonfuls of cod-liver oil a day may be substituted. Sometimes refractory rickets occurs in older children and heroic doses up to one million units a day may be needed, but the hazard of a toxic reaction is great. Of all the compounds having vitamin D activity, only  $D_2$  (calciferol) and  $D_3$  (activated 7-hydrocholesterol) have any real clinical application.

**Vitamin K**—Deficiency of vitamin K does not occur in healthy persons, even on a diet devoid of the vitamin, because of biosynthesis in the alimentary tract. Clinical difficulty with vitamin K deficiency develops when fat-soluble material cannot be absorbed. This occurs notably in obstructive jaundice where bile does not reach the alimentary canal or in disease of the parenchymal cells of the liver where vitamin K is unable to play its part in the fabrication of prothrombin. As a late stage in sprue or idiopathic steatorrhea, vitamin K deficiency may occur from failure of absorption. At the present time, the commonest cause of the deficiency is the therapeutic employment of a direct antagonist of vitamin K, Dicumarol. There is nothing specific about bleeding which occurs as a result of prothrombin deficiency induced by an inadequate supply of vitamin K. The first thing that is noticed may be massive hemorrhage, or bleeding may begin insidiously with ecchymotic specks or most trivial purpura. The use of wide spectrum antibiotics for a long period of time may eliminate bacteria which manufacture vitamin K, but clinical difficulty has been encountered only rarely in such circumstances. Where vitamin K deficiency is caused by lack of bile in the alimentary canal, 2 mg of vitamin K orally with 1 or 2 Gm bile salts daily may prevent or correct the deficiency. Vitamin K has been given prophylactically, 2 mg of menadione daily, in the last ten days of pregnancy in an attempt to avoid hemorrhagic diseases of the newborn, but evidence for its value is in dispute. Phytonadione (Mephyton,  $K_1$ ) is available as a 5 per cent aqueous emulsion in 1 per cent lecithin. A 50 mg dose is administered intravenously over a period of 2 minutes. If bleeding is less severe, two 5 mg tablets may be given orally. Vitamin K is not effective against the hemorrhagic diathesis induced by heparin but only where Dicumarol has been given or the prothrombin time is low because of an inadequate supply of vitamin K.

**Vitamin E**—Like most vitamins, vitamin E has been used enthusiastically but uncritically in a great variety of diseases for which there is no specific cure but for which there have been innumerable forms of treatment. The evidence that it does any good in such circumstances is lacking. The testimony is enormous. No field of therapy is strewn with more wreckage of outmoded and futile effort than that of vitamin E. Happily the recent flurry of using vitamin E for nonspecific ulcers and sundry kinds of heart failure has gone the way of puppy-dog fat and unicorn's horns.

Actual vitamin E deficiency in man has been recognized only recently on the basis of the work of Gyorgy, Gordon Woodruff, and their associates. Vitamin E deficiency has been sought in patients having difficulty with fat absorption, especially in patients with atresia of the bile ducts, or obstruction or fistulas, sprue, idiopathic steatorrhea, and cystic fibrosis of the pancreas. A syndrome is beginning to emerge. It is characterized by very poor absorption of vitamin A and other fats, low levels of serum cholesterol, creatinuria, and decreased resistance to peroxide hemolysis. All abnormalities are corrected by vitamin E therapy. There is

nicotinic acid amide by mouth 3 times a day with meals is usually adequate, but doses 3 or 4 times this high may be given safely. If patients are gravely ill and cannot eat, intravenous or intramuscular injections of 50 mg should be made at least 5 times a day, an effort being made to spread doses. Supplementary vitamin tablets containing all the B complex vitamins should be given as soon as the patient can eat. Additional concentrates include brewer's yeast up to 3 tablespoonfuls by mouth 4 times a day. Supplementary feeding with egg-nog and milk shakes is helpful. Crude liver extract was used formerly but has no role now that purified preparations are available.

Other materials can be used in the treatment of pellagra but they are of importance only in experimental demonstration. Cozymase, the actual enzyme containing nicotinamide, may induce improvement in pellagrous glossitis in minutes. Nicotinic acid amide and nicotinic acid take from many minutes up to a few hours. Tryptophan is somewhat slower than nicotinic acid in producing its effects. It usually takes 1 to 3 days before definite improvement occurs. Improvement has followed ACTH, though the specificity of this response is most uncertain. Diet and yeast take several days to several weeks to effect satisfactory therapeutic response. Local therapy for the painful dermatitis, glossitis, and diarrhea is not necessary. If the diarrhea fails to respond to ample quantities of nicotinic acid it is an indication that the patient is moribund and will respond to nothing.

**Pyridoxine (Vitamin B<sub>6</sub>)**—The only established role of pyridoxine in therapy so far occurs in infants. The heat required to sterilize canned baby formulas destroys a large part of the pyridoxine in the milk. Infants fed such formulas may develop irritability, colic, and convulsions. This has been observed during the third month of life. Most of the infants have appeared well nourished and well developed and have not had feeding problems.

This disorder can be corrected by adding 2 mg pyridoxine a day to the baby's formula of a liquid diet. In the acute condition, 5 mg of pyridoxine hydrochloride may be given intramuscularly at the beginning of difficulty and thereafter a supplement of 2 mg a day by mouth. Now that the nature of this trouble is well recognized there should be no further difficulty since the deficiency in the formula is easy to correct.

In spite of the demonstration that a clinical and metabolic disorder can be produced by a pyridoxine antagonist, pyridoxine has not proved useful in treating patients who have developed similar signs and symptoms while eating a normal diet.

There is suggestive evidence that at times there may be an unusual requirement for pyridoxine during pregnancy. Satisfactory balance studies have not been reported.

**Folic Acid**—Partial solution of the folic acid mystery, while not disclosing all the secrets of the vitamin sphinx, is clarifying several problems. A major biochemical function of pteroylglutamic acid is its enzyme action in fostering the synthesis of purines, pyrimidines, and certain amino acids by the incorporation of single carbon units. Perhaps the only function of para aminobenzoic acid is in the synthesis of pteroylglutamic acid. Under the influence of ascorbic acid free folic acid is converted into folinic acid, perhaps with the assistance of vitamin B<sub>12</sub>. Folinic acid acts in enzyme systems to liberate and transfer methyl and amino acid groups

sent Only after nicotinic acid became available could the situation be studied experimentally Sebrell and Butler made a series of classic observations on patients with induced riboflavin deficiency They developed angular stomatitis and greasy desquamation of the nasolabial folds The complete picture with angular stomatitis fissuring of the vermilion border of the lips crusting and desquamation of the mucous membranes magenta tongue and sometimes patchy redness and scaling on the scrotum have emerged The evidence is against an etiologic association of riboflavin deficiency and vascularization of the healthy cornea There is some variation in the rate of response to riboflavin but it is much slower than the response of clinical manifestations in beriberi or pellagra

It is preferable to give riboflavin in 2 to 5 mg tablets by mouth with meals More is retained when a 2 mg tablet is given after each meal than when a larger total is given in a single dose Vitamin supplements may be helpful but a well balanced diet is essential

**Niacin and Pellagra**—Nicotinic acid or closely related compounds are essential to the metabolic activity of all living cells The only known function is in the coenzymes containing nicotinic acid which catalyze almost fifty different chemical reactions One of the blights of contemporary investigation is the lack of any rational idea or any inspiration to gain a clue about how disordered chemical functions lead to the gross changes in function and structure which characterize the advanced states of malnutrition Most B complex vitamins function in enzyme systems transferring energy Whatever increases the requirements for oxidation therefore is likely to aggravate precipitate or hasten the advent of deficiency diseases But this tells us nothing of alternative metabolic pathways detour mechanisms for bypassing obstacles or finer homeokinetic adjustments which go on beyond our sight and understanding

Tryptophan and its role of treatment and prevention of pellagra illustrate the solution of a vexing puzzle which had plagued nutrition experts for some time The quantity of nicotinic acid in various diets did not have the expected reciprocal relationship to the risk of developing pellagra Sometimes pellagra was common in a population using a diet which contained more nicotinic acid than in another population using a diet with less nicotinic acid Among the possible reasons was a hypothetical toxic material requiring extra nicotinic acid to counteract it or a substitute which could pinch hit for nicotinic acid in the diet The observations of Krehl and his colleagues that tryptophan might be converted to nicotinic acid not only through biosynthesis of intestinal microorganisms but also in the body revived Goldberger's old and forgotten observation that tryptophan might be an important therapeutic agent in pellagra

**TREATMENT**—In our experience in this country today, it is uncommon for pellagra to result from a poor diet alone Usually there is some primary disease Therapy should follow two independent lines simultaneously A search for an underlying disease should be made If one is found which is correctible it should be treated appropriately Obstructive lesions along the alimentary canal require surgical correction or palliation Where metabolism is high efforts should be made to reduce it Alcoholism should be treated appropriately Specific therapy for pellagra should proceed as soon as the diagnosis is made For an adult, 100 mg

B<sub>12</sub> facilitates the transfer of single carbon fragments, helps form nucleosides and nucleotides, and seems to have some role in the activation of S S groups. On the other hand folic acid to be active must undergo metabolic conversion through folinic acid to a still incompletely defined active substance. This reaction is facilitated by ascorbic acid but inhibited by aminopterin and other folic acid antagonists. There is some evidence but not final proof that vitamin B<sub>12</sub> may facilitate these reactions.

Pernicious anemia, produced by a deficiency of vitamin B<sub>12</sub> because of inadequate intrinsic factor, is treated with B<sub>12</sub> parenterally. Fish tapeworm anemia is caused by deficiency of vitamin B<sub>12</sub> which results from absorption, utilization, or an inactivation of B<sub>12</sub> by the tapeworm and perhaps by some inactivation of intrinsic factor. In order to cause these reactions the worm must be fairly high in the alimentary canal. If a vermifuge is successful in eliminating the worm spontaneous recovery develops slowly and is speeded up by parenteral or oral vitamin B<sub>12</sub>. Nutritional megaloblastic anemia is caused by a primary deficiency of vitamin B<sub>12</sub> and a secondary deficiency of folic acid. Treatment with folic acid or B<sub>12</sub> is satisfactory. The pernicious anemia of pregnancy results from a metabolic abnormality in enzymatic action of folic acid. Large doses of folic acid correct the difficulty. Refractory megaloblastic anemias are caused by a metabolic abnormality in the enzyme function of folinic acid and may be corrected by large doses of folic acid. The megaloblastic anemia of sprue seems to come from a primary dietary deficiency of folic acid and a secondary deficiency of vitamin B<sub>12</sub>. Late in the disease organic lesions of the alimentary canal lead to deficiencies in many substances which are water soluble as well as fat soluble. Megaloblastic anemias from blind pouches, fistulas, and mechanical lesions of the alimentary canal usually result from an abnormality of folic acid metabolism associated with a deranged microflora of the gut. They respond to folic acid surgical correction of the lesion or broad spectrum antibiotics.

When vitamin B<sub>12</sub> is needed several priming doses of 100 mcg should be injected. A satisfactory maintenance program then is 50 mcg a month by parenteral injection. There is no advantage in using expensive oral preparations with intrinsic factor.

**Biotin and Pantothenic Acid**—Experimental efforts to produce biotin deficiency and one possible example of spontaneous biotin deficiency in a man addicted to raw eggs have been reported, but the problem remains in doubt. We do not know the role of biotin in man or its function in metabolic economy and we are not sure of specific signs of a deficiency.

Studies of the function of pantothenic acid in health and disease have been underway in our Metabolism Unit for more than 10 years. There is much to suggest that pantothenic acid has many essential functions in human nutrition and metabolism among which seem to be an intimate role in the maintenance of potassium and perhaps other electrolytes, a suggestive function in the regulation of steroid hormones manufactured by the adrenal cortex, a possible role in maintenance of normal secretion of gastric juice and many suggestive functions in maintenance of carbohydrate metabolism. It will take many years of painstaking studies to obtain conclusive evidence on these points.

from simple compounds to help form purine and pyrimidine rings. Under the influence of vitamin B<sub>12</sub> the addition of pentose or pentose phosphate yields precursors for the nucleosides and nucleotides. When methyl or formate is available, the process goes on to the formation of nucleic acid. Decreased intake of pteroyl glutamic acid is rarely the single cause of deficiency though it seems to be a factor in the anemias of pregnancy and of sprue. There may be inborn errors in enzymes required for its absorption though no disorder analogous to vitamin B<sub>12</sub> deficiency or pernicious anemia is known. In sprue, the pernicious anemia of pregnancy, and in megaloblastic anemias refractory to liver extract and vitamin B<sub>12</sub>, folic acid in doses of 5 mg., 3 times a day with meals, ordinarily is effective. In some cases the response will not be complete until vitamin B<sub>12</sub> is added. Rarely larger doses of folic acid will be needed.

**Vitamin B<sub>12</sub>.**—Vitamin B<sub>12</sub> has come to be accepted not only as the extrinsic factor of Castle but as the erythrocyte maturing factor of the liver. Its relation to folic acid has not been resolved in all aspects. In the normal person an enzymatic process occurs in the course of digestion which liberates vitamin B<sub>12</sub> from its intimate binding with foodstuffs and facilitates its absorption. In a person with *pernicious anemia, intrinsic factor is not made by the stomach in adequate amounts*. Thus little or no vitamin B<sub>12</sub> can be absorbed. Since the liver can retain its supply for months, and occasionally even for years, signs of pernicious anemia may take a long time to develop. Conversely, in a patient in whom pernicious anemia has been corrected by adequate doses of vitamin B<sub>12</sub>, it may be months or years before a relapse occurs after maintenance with vitamin B<sub>12</sub> has been discontinued. Even after the blood has been restored to normal with vitamin B<sub>12</sub>, the defect in the stomach and the histopathologic alteration of other cells still persists. This can be demonstrated by Schilling's test for the absorption of radioactive vitamin B<sub>12</sub> which is inadequate or absent in a person with pernicious anemia regardless of the state of the blood. This is important in the separation of patients with posterolateral column disease into those who develop combined sclerosis because of inadequate B<sub>12</sub> absorbing mechanisms and those who do not. Since the neurologic manifestations of pernicious anemia may appear before any alteration in the blood, this test is helpful in discovering those who should respond to B<sub>12</sub> and those who will not respond.

Other mechanisms producing vitamin B<sub>12</sub> deficiency include infestation with fish tapeworm, various enteric anastomoses, short cuts and blind loops of bowel, and protracted severe dietary deficiency of vitamin B<sub>12</sub> and various B complex vitamins. The clinical disease is the same. It responds to adequate doses of vitamin B<sub>12</sub> which may have to be given parenterally, or orally with intrinsic factor. Probably all persons who have had a total gastrectomy may develop pernicious anemia. Since such an operation usually is done for cancer of the stomach, there are relatively few who survive long enough for vitamin B<sub>12</sub> deficiency to appear.

If folic acid is given without vitamin B<sub>12</sub>, therapeutically or by self-medication with vitamin pills, devastating manifestations of combined system disease may occur.

When vitamin B<sub>12</sub> is absorbed from the alimentary canal it does its metabolic work immediately without further change. Its connection with folic acid, folinic acid, and ascorbic acid in hematopoiesis is not completely understood. Vitamin

a 1 to 2 per cent solution in physiologic saline. In spite of its acidity it need not be buffered or neutralized for intravenous injection. Divided doses are advisable when it is given by mouth. The emphasis should be on a generally nutritious diet and the correction of any intercurrent disease. During convalescence 100 mg of ascorbic acid with each meal and later 25 mg with meals restore the depletion.

In severely injured or burned patients, sometime in shock, and after extensive surgical operations, vitamin C may disappear from the plasma. It is customary to give large doses to correct this laboratory finding, but there is little convincing evidence that the therapy helps, or the low level in the blood does specific harm. Treating a laboratory datum is unsatisfactory therapy.

## GENERAL PHARMACOLOGIC CONSIDERATIONS

It is not surprising that vitamins and closely related chemical compounds have pharmacologic actions separate from their function as vitamins. Vitamins are poisons if used to excess. The same is true of water, oxygen, or calories. In our shotgun approach to therapy, almost every disease with unknown cause or unsatisfactory treatment has had a trial with vitamin therapy. Even the enthusiasm of the naive investigator cannot identify any specific cures in what has been an unhappy chaos of credulity. Vitamins are essential to life but their administration by unusual routes or in large quantities may be associated with anaphylactic shock, either mild, serious, or fatal. Now that the blood level of tranquilizers is so often high the vitamin as placebo may be on the decline in autotherapy.

### Niacin

One of the great shocks which occurred in the early days of the employment of nicotinic acid in the treatment of pellagra was the discovery that it produced intense and sometimes unpleasant vasodilatation. Since this had never been observed in experimental animals, it came as a complete surprise to those who tested the compound on themselves before giving it to persons with pellagra.

Niacin administered orally or parenterally in sufficient doses produces a characteristic train of symptoms. Within less than a minute after intravenous administration of 20 mg, a sensation of heat occurs in the skin. It begins in the face and spreads over the chest, neck, and upper arms. Sometimes the entire body becomes affected. It may be particularly disagreeable in the perianal region. The sensation of heat merges into a sensation of stinging and tingling of the skin. Occasionally actual pain occurs. At the same time there may be a sensation of fullness and throbbing in the head. Extensive studies to identify the precise chemical structure of the compound responsible for producing this symptom were reported in 1939. It was found that only those molecules which contained the specific configuration of 3-carboxy-pyridine had the flushing and vasodilating property. Thus sodium, ammonium, and ethylnicotinate, and nicotinic acid produced flushing. It was not 1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-22-23-24-25-26-27-28-29-30-31-32-33-34-35-36-37-38-39-40-41-42-43-44-45-46-47-48-49-50-51-52-53-54-55-56-57-58-59-60-61-62-63-64-65-66-67-68-69-70-71-72-73-74-75-76-77-78-79-80-81-82-83-84-85-86-87-88-89-90-91-92-93-94-95-96-97-98-99-100-101-102-103-104-105-106-107-108-109-110-111-112-113-114-115-116-117-118-119-120-121-122-123-124-125-126-127-128-129-130-131-132-133-134-135-136-137-138-139-140-141-142-143-144-145-146-147-148-149-150-151-152-153-154-155-156-157-158-159-160-161-162-163-164-165-166-167-168-169-170-171-172-173-174-175-176-177-178-179-180-181-182-183-184-185-186-187-188-189-190-191-192-193-194-195-196-197-198-199-200-201-202-203-204-205-206-207-208-209-210-211-212-213-214-215-216-217-218-219-220-221-222-223-224-225-226-227-228-229-230-231-232-233-234-235-236-237-238-239-240-241-242-243-244-245-246-247-248-249-250-251-252-253-254-255-256-257-258-259-260-261-262-263-264-265-266-267-268-269-270-271-272-273-274-275-276-277-278-279-280-281-282-283-284-285-286-287-288-289-290-291-292-293-294-295-296-297-298-299-300-301-302-303-304-305-306-307-308-309-310-311-312-313-314-315-316-317-318-319-320-321-322-323-324-325-326-327-328-329-330-331-332-333-334-335-336-337-338-339-340-341-342-343-344-345-346-347-348-349-350-351-352-353-354-355-356-357-358-359-360-361-362-363-364-365-366-367-368-369-370-371-372-373-374-375-376-377-378-379-380-381-382-383-384-385-386-387-388-389-390-391-392-393-394-395-396-397-398-399-400-401-402-403-404-405-406-407-408-409-410-411-412-413-414-415-416-417-418-419-420-421-422-423-424-425-426-427-428-429-430-431-432-433-434-435-436-437-438-439-440-441-442-443-444-445-446-447-448-449-450-451-452-453-454-455-456-457-458-459-460-461-462-463-464-465-466-467-468-469-470-471-472-473-474-475-476-477-478-479-480-481-482-483-484-485-486-487-488-489-490-491-492-493-494-495-496-497-498-499-500-501-502-503-504-505-506-507-508-509-510-511-512-513-514-515-516-517-518-519-520-521-522-523-524-525-526-527-528-529-530-531-532-533-534-535-536-537-538-539-540-541-542-543-544-545-546-547-548-549-550-551-552-553-554-555-556-557-558-559-560-561-562-563-564-565-566-567-568-569-570-571-572-573-574-575-576-577-578-579-580-581-582-583-584-585-586-587-588-589-590-591-592-593-594-595-596-597-598-599-600-601-602-603-604-605-606-607-608-609-610-611-612-613-614-615-616-617-618-619-620-621-622-623-624-625-626-627-628-629-630-631-632-633-634-635-636-637-638-639-640-641-642-643-644-645-646-647-648-649-650-651-652-653-654-655-656-657-658-659-660-661-662-663-664-665-666-667-668-669-670-671-672-673-674-675-676-677-678-679-680-681-682-683-684-685-686-687-688-689-690-691-692-693-694-695-696-697-698-699-700-701-702-703-704-705-706-707-708-709-710-711-712-713-714-715-716-717-718-719-720-721-722-723-724-725-726-727-728-729-730-731-732-733-734-735-736-737-738-739-740-741-742-743-744-745-746-747-748-749-750-751-752-753-754-755-756-757-758-759-760-761-762-763-764-765-766-767-768-769-770-771-772-773-774-775-776-777-778-779-780-781-782-783-784-785-786-787-788-789-790-791-792-793-794-795-796-797-798-799-800-801-802-803-804-805-806-807-808-809-810-811-812-813-814-815-816-817-818-819-820-821-822-823-824-825-826-827-828-829-830-831-832-833-834-835-836-837-838-839-840-841-842-843-844-845-846-847-848-849-850-851-852-853-854-855-856-857-858-859-860-861-862-863-864-865-866-867-868-869-870-871-872-873-874-875-876-877-878-879-880-881-882-883-884-885-886-887-888-889-890-891-892-893-894-895-896-897-898-899-900-901-902-903-904-905-906-907-908-909-910-911-912-913-914-915-916-917-918-919-920-921-922-923-924-925-926-927-928-929-930-931-932-933-934-935-936-937-938-939-940-941-942-943-944-945-946-947-948-949-950-951-952-953-954-955-956-957-958-959-960-961-962-963-964-965-966-967-968-969-970-971-972-973-974-975-976-977-978-979-980-981-982-983-984-985-986-987-988-989-990-991-992-993-994-995-996-997-998-999-1000-1001-1002-1003-1004-1005-1006-1007-1008-1009-1010-1011-1012-1013-1014-1015-1016-1017-1018-1019-1020-1021-1022-1023-1024-1025-1026-1027-1028-1029-1030-1031-1032-1033-1034-1035-1036-1037-1038-1039-1040-1041-1042-1043-1044-1045-1046-1047-1048-1049-1050-1051-1052-1053-1054-1055-1056-1057-1058-1059-1060-1061-1062-1063-1064-1065-1066-1067-1068-1069-1070-1071-1072-1073-1074-1075-1076-1077-1078-1079-1080-1081-1082-1083-1084-1085-1086-1087-1088-1089-1090-1091-1092-1093-1094-1095-1096-1097-1098-1099-1100-1101-1102-1103-1104-1105-1106-1107-1108-1109-1110-1111-1112-1113-1114-1115-1116-1117-1118-1119-1120-1121-1122-1123-1124-1125-1126-1127-1128-1129-1130-1131-1132-1133-1134-1135-1136-1137-1138-1139-1140-1141-1142-1143-1144-1145-1146-1147-1148-1149-1150-1151-1152-1153-1154-1155-1156-1157-1158-1159-1160-1161-1162-1163-1164-1165-1166-1167-1168-1169-1170-1171-1172-1173-1174-1175-1176-1177-1178-1179-1180-1181-1182-1183-1184-1185-1186-1187-1188-1189-1190-1191-1192-1193-1194-1195-1196-1197-1198-1199-1200-1201-1202-1203-1204-1205-1206-1207-1208-1209-1210-1211-1212-1213-1214-1215-1216-1217-1218-1219-1220-1221-1222-1223-1224-1225-1226-1227-1228-1229-1230-1231-1232-1233-1234-1235-1236-1237-1238-1239-1240-1241-1242-1243-1244-1245-1246-1247-1248-1249-1250-1251-1252-1253-1254-1255-1256-1257-1258-1259-1260-1261-1262-1263-1264-1265-1266-1267-1268-1269-1270-1271-1272-1273-1274-1275-1276-1277-1278-1279-1280-1281-1282-1283-1284-1285-1286-1287-1288-1289-1290-1291-1292-1293-1294-1295-1296-1297-1298-1299-1300-1301-1302-1303-1304-1305-1306-1307-1308-1309-1310-1311-1312-1313-1314-1315-1316-1317-1318-1319-1320-1321-1322-1323-1324-1325-1326-1327-1328-1329-1330-1331-1332-1333-1334-1335-1336-1337-1338-1339-1340-1341-1342-1343-1344-1345-1346-1347-1348-1349-1350-1351-1352-1353-1354-1355-1356-1357-1358-1359-1360-1361-1362-1363-1364-1365-1366-1367-1368-1369-1370-1371-1372-1373-1374-1375-1376-1377-1378-1379-1380-1381-1382-1383-1384-1385-1386-1387-1388-1389-1390-1391-1392-1393-1394-1395-1396-1397-1398-1399-1400-1401-1402-1403-1404-1405-1406-1407-1408-1409-1410-1411-1412-1413-1414-1415-1416-1417-1418-1419-1420-1421-1422-1423-1424-1425-1426-1427-1428-1429-1430-1431-1432-1433-1434-1435-1436-1437-1438-1439-1440-1441-1442-1443-1444-1445-1446-1447-1448-1449-1450-1451-1452-1453-1454-1455-1456-1457-1458-1459-1460-1461-1462-1463-1464-1465-1466-1467-1468-1469-1470-1471-1472-1473-1474-1475-1476-1477-1478-1479-1480-1481-1482-1483-1484-1485-1486-1487-1488-1489-1490-1491-1492-1493-1494-1495-1496-1497-1498-1499-1500-1501-1502-1503-1504-1505-1506-1507-1508-1509-1510-1511-1512-1513-1514-1515-1516-1517-1518-1519-1520-1521-1522-1523-1524-1525-1526-1527-1528-1529-1530-1531-1532-1533-1534-1535-1536-1537-1538-1539-1540-1541-1542-1543-1544-1545-1546-1547-1548-1549-1550-1551-1552-1553-1554-1555-1556-1557-1558-1559-1560-1561-1562-1563-1564-1565-1566-1567-1568-1569-1570-1571-1572-1573-1574-1575-1576-1577-1578-1579-1580-1581-1582-1583-1584-1585-1586-1587-1588-1589-1590-1591-1592-1593-1594-1595-1596-1597-1598-1599-1600-1601-1602-1603-1604-1605-1606-1607-1608-1609-1610-1611-1612-1613-1614-1615-1616-1617-1618-1619-1620-1621-1622-1623-1624-1625-1626-1627-1628-1629-1630-1631-1632-1633-1634-1635-1636-1637-1638-1639-1640-1641-1642-1643-1644-1645-1646-1647-1648-1649-1650-1651-1652-1653-1654-1655-1656-1657-1658-1659-1660-1661-1662-1663-1664-1665-1666-1667-1668-1669-1670-1671-1672-1673-1674-1675-1676-1677-1678-1679-1680-1681-1682-1683-1684-1685-1686-1687-1688-1689-1690-1691-1692-1693-1694-1695-1696-1697-1698-1699-1700-1701-1702-1703-1704-1705-1706-1707-1708-1709-1710-1711-1712-1713-1714-1715-1716-1717-1718-1719-1720-1721-1722-1723-1724-1725-1726-1727-1728-1729-1730-1731-1732-1733-1734-1735-1736-1737-1738-1739-1740-1741-1742-1743-1744-1745-1746-1747-1748-1749-1750-1751-1752-1753-1754-1755-1756-1757-1758-1759-1760-1761-1762-1763-1764-1765-1766-1767-1768-1769-1770-1771-1772-1773-1774-1775-1776-1777-1778-1779-1780-1781-1782-1783-1784-1785-1786-1787-1788-1789-1790-1791-1792-1793-1794-1795-1796-1797-1798-1799-1800-1801-1802-1803-1804-1805-1806-1807-1808-1809-1810-1811-1812-1813-1814-1815-1816-1817-1818-1819-1820-1821-1822-1823-1824-1825-1826-1827-1828-1829-1830-1831-1832-1833-1834-1835-1836-1837-1838-1839-1840-1841-1842-1843-1844-1845-1846-1847-1848-1849-1850-1851-1852-1853-1854-1855-1856-1857-1858-1859-1860-1861-1862-1863-1864-1865-1866-1867-1868-1869-1870-1871-1872-1873-1874-1875-1876-1877-1878-1879-1880-1881-1882-1883-1884-1885-1886-1887-1888-1889-1890-1891-1892-1893-1894-1895-1896-1897-1898-1899-1900-1901-1902-1903-1904-1905-1906-1907-1908-1909-1910-1911-1912-1913-1914-1915-1916-1917-1918-1919-1920-1921-1922-1923-1924-1925-1926-1927-1928-1929-1930-1931-1932-1933-1934-1935-1936-1937-1938-1939-1940-1941-1942-1943-1944-1945-1946-1947-1948-1949-1950-1951-1952-1953-1954-1955-1956-1957-1958-1959-1960-1961-1962-1963-1964-1965-1966-1967-1968-1969-1970-1971-1972-1973-1974-1975-1976-1977-1978-1979-1980-1981-1982-1983-1984-1985-1986-1987-1988-1989-1990-1991-1992-1993-1994-1995-1996-1997-1998-1999-2000-2001-2002-2003-2004-2005-2006-2007-2008-2009-2010-2011-2012-2013-2014-2015-2016-2017-2018-2019-2020-2021-2022-2023-2024-2025-2026-2027-2028-2029-2030-2031-2032-2033-2034-2035-2036-2037-2038-2039-2040-2041-2042-2043-2044-2045-2046-2047-2048-2049-2050-2051-2052-2053-2054-2055-2056-2057-2058-2059-2060-2061-2062-2063-2064-2065-2066-2067-2068-2069-2070-2071-2072-2073-2074-2075-2076-2077-2078-2079-2080-2081-2082-2083-2084-2085-2086-2087-2088-2089-2090-2091-2092-2093-2094-2095-2096-2097-2098-2099-2100-2101-2102-2103-2104-2105-2106-2107-2108-2109-2110-2111-2112-2113-2114-2115-2116-2117-2118-2119-2120-2121-2122-2123-2124-2125-2126-2127-2128-2129-2130-2131-2132-2133-2134-2135-2136-2137-2138-2139-2140-2141-2142-2143-2144-2145-2146-2147-2148-2149-2150-2151-2152-2153-2154-2155-2156-2157-2158-2159-2160-2161-2162-2163-2164-2165-2166-2167-2168-2169-2170-2171-2172-2173-2174-2175-2176-2177-2178-2179-2180-2181-2182-2183-2184-2185-2186-2187-2188-2189-2190-2191-2192-2193-2194-2195-2196-2197-2198-2199-2200-2201-2202-2203-2204-2205-2206-2207-2208-2209-2210-2211-2212-2213-2214-2215-2216-2217-2218-2219-2220-2221-2222-2223-2224-2225-2226-2227-2228-2229-2230-2231-2232-2233-2234-2235-2236-2237-2238-2239-2240-2241-2242-2243-2244-2245-2246-2247-2248-2249-2250-2251-2252-2253-2254-2255-2256-2257-2258-2259-2260-2261-2262-2263-2264-2265-2266-2267-2268-2269-2270-2271-2272-2273-2274-2275-2276-2277-2278-2279-2280-2281-2282-2283-2284-2285-2286-2287-2288-2289-2290-2291-2292-2293-2294-2295-2296-2297-2298-2299-2300-2301-2302-2303-2304-2305-2306-2307-2308-2309-2310-2311-2312-2313-2314-2315-2316-2317-2318-2319-2320-2321-2322-2323-2324-2325-2326-2327-2328-2329-2330-2331-2332-2333-2334-2335-2336-2337-2338-2339-2340-2341-2342-2343-2344-2345-2346-2347-2348-2349-2350-2351-2352-2353-2354-2355-2356-2357-2358-2359-2360-2361-2362-2363-2364-2365-2366-2367-2368-2369-2370-2371-2372-2373-2374-2375-2376-2377-2378-2379-2380-2381-2382-2383-2384-2385-2386-2387-2388-2389-2390-2391-2392-2393-2394-2395-2396-2397-2398-2399-2400-2401-2402-2403-2404-2405-2406-2407-2408-2409-2410-2411-2412-2413-2414-2415-2416-2417-2418-2419-2420-2421-2422-2423-2424-2425-2426-2427-2428-2429-2430-2431-2432-2433-2434-2435-2436-2437-2438-2439-2440-2441-2442-2443-2444-2445-2446-2447-2448-2449-2450-2451-2452-2453-2454-2455-2456-2457-2458-2459-2460-2461-2462-2463-2464-2465-2466-2467-2468-2469-2470-2471-2472-2473-2474-2475-2476-2477-2478-2479-2480-2481-2482-2483-2484-2485-2486-2487-2488-2489-2490-2491-2492-2493-2494-2495-2496-2497-2498-2499-2500-2501-2502-2503-2504-2505-2506-2507-2508-2509-2510-2511-2512-25

At the present time there is no known justification for the employment of pantothenic acid or biotin in human nutrition though inclusion of such materials in vitamin capsules for the treatment of severe undernutrition does not have any known contraindications

**Ascorbic Acid**—The slow working of the human intellect is illustrated in the long lag from the early clinical and folk knowledge of antiscorbutic foods and the circumstances under which scurvy might arise to the final isolation and synthesis of ascorbic acid. Over 200 years ago James Lind summarized his medical experiences in the British Navy in his treatise on 'The Scurvy'. He expounded its cause, described its cure, illustrated its prevention and defined the disease and the treatment. As an example of the ponderous movement of bureaucracy, the Lords of the British admiralty adopted Lind's recommendations as official doctrine for the Royal Navy, after a lapse of only 40 years, but an even more ponderous delay occurred in the 125 years which were needed before students of chemistry and physiology finally came round to the isolation and synthesis of ascorbic acid.

During the last two decades many of the obscure functions of ascorbic acid have been clarified *in vitro* but not the mechanism of its function in man. In naturally occurring or induced ascorbic acid deficiency in man the first change is the keratinization of perifollicular papules. After 3 or 4 months, erythema and finally bleeding into the hair follicles produces the classical punctate hemorrhage found chiefly in the lower extremities but sometimes over the entire body. Bleeding then occurs subcutaneously, first with easy bruising then purpuric blotches involving large portions of the skin appear and finally very extensive hemorrhage occurs in and about joints, sometimes dissecting widely along fascial planes. It may produce the same induration and swelling one sees in hemophilia although the ultimate contractures do not occur since the disease either responds to therapy or is fatal. It is not a chronic disease. In severe scurvy the gums become swollen, friable, and bleed easily on mild trauma, with hematomas, necrosis, infection, and sloughing. The oral lesions are severe only when oral hygiene is poor. They do not occur in an edentulous person afflicted with scurvy. Wound healing is delayed.

In infants and growing children, lesions of the bone produce characteristic subperiosteal hemorrhages and ultimately, deformity of the ribs. In the wrists and ankles and at the end of other long bones a dense white line extends across the shaft as revealed in x ray examination. It is caused by a deposition of calcium in the matrix. Rarefaction of the adjoining bone emphasizes the abnormality. Anemia may occur in children and adults who have scurvy. The work of May and his associates has helped clarify the relationship of ascorbic acid and folic acid in scurvy although the story is not yet completely told and we need more information in certain areas. The pathologic physiology is a defect in connective tissue. The teeth, bone, and blood vessels are the major sites of characteristic lesions.

With our present day emphasis on tomatoes and citrus fruits, and generally ample diet, scurvy is extremely rare in this country except in recluses who eat erratically according to whim and circumstance.

When clinical scurvy occurs in an adult, it may be necessary to give as much as 2 Gm. of ascorbic acid a day, preferably by mouth, although sometimes the mouth is so sore that swallowing is very difficult. It may be given intravenously as



## Hypervitaminosis D

Although intoxication with vitamin D occasionally occurs in therapy for rickets, particularly in refractory cases, most information about the effects of massive doses of vitamin D has accrued from patients given huge quantities of calciferol in the treatment of arthritis. Relatively small doses have been fatal more commonly in children than in adults.

The underlying pathologic effect is the precipitation of calcium in various tissues. As a result of calcification in the kidneys, renal failure may occur with its characteristic train of symptoms. Under certain circumstances the bones are demineralized apparently in order to supply the *extravagant demands for calcium* produced by such large amounts of vitamin D. The histopathology is the same in young and old. Calcinosi may affect literally any tissue or organ of the body—the joints with their synovial membranes, the alveoli of the lung, parathyroid glands, heart muscle, the kidneys and the renal pelvis, skin, lymph nodes, pancreas, various arteries, the lining wall of the stomach, and even the cornea and conjunctiva. At first the bones may show accelerated calcification in the provisional zone of calcification. Then comes thickening of periosteum. Finally the cartilage itself is deformed. Ultimately there may be demineralization of the bones.

In contradistinction to the osteoporosis produced by parathormone, that produced by hypervitaminosis D does not lead to the replacement of the demineralized areas by fibrous tissue. Based on experimental work, the initial renal lesion begins with actual deposition of calcium in the lining membrane in the cells of the distal tubules. An inflammatory reaction follows, and later, obstruction with degeneration and ultimately failure of the nephron to function take place. Inflammation which spreads rapidly throughout the kidney may increase the speed of destruction. In addition to uremia, occasionally hypertension and its attendant signs and symptoms have resulted.

There is a dramatic variability in the amount of extra vitamin D required to produce intoxication. It has been reported in one instance that 400 units a day have led to lesions which proved fatal. In rare cases no more than 2 weeks of excessive therapy is necessary to produce discrete calcification. The manifestations of hypervitaminosis D result from an enhancement of the usual action of the vitamin which increases the absorption of calcium from the alimentary canal and increases the urinary excretion of phosphorus. In less severe cases the appetite is lost and nausea, vomiting and diarrhea may occur. There may be weakness, malaise, occasionally polyuria, headache, various disturbances in cutaneous sensation, patchy brown pigmentation of the skin and renal insufficiency.

Nobody seems to have any good ideas as to the mechanism by which calcification takes place. The best speculation is that damage to the cell occurs. Then under certain unusual conditions of hydrogen ion concentration and perhaps actual mechanical interference with membrane function, the abnormal deposit of calcium occurs. But the physicochemical state required for this deposition is not understood. In animals calcium may be deposited in spite of the fact that the serum calcium is normal or even low. The role of the parathyroids is not clear. It is unusual for any additional difficulty to be caused by exposure to sunlight or by large amounts of dietary calcium. Other factors, however, such as the susceptibility of the indi-

published in a review of 1944. The method has promise in studying vitamin function in man.

### Pharmacologic and Pathologic Actions of Vitamin A

**Carotenemia**—Carotene is an example of a vitamin precursor more complex than the vitamin, vitamin A being carotene divided in half. Carotenemia is a state of increased carotene in the blood. The condition is common when very high levels of carotene exist in the diet. It may occur in young children eating an overabundance of carrots and related foods and occasionally in diabetics for reasons unknown.

Carotene is one of the normal constituents of the human skin. There is more in women than in men. It is high in the skin of castrates and is reduced to normal levels after appropriate sex hormone therapy. In carotenemia the skin may be discolored with a canary or sulfur color but the sclera are white and the mucous membranes are normal except for the palate which may be yellow. The axillae, the palms, the soles, and the nasolabial folds are the most intensively discolored areas in carotenemia.

**Hypervitaminosis A**—From ancient times Eskimos have known that polar bear liver eaten or fed to their dogs produced an acute prostrating illness which might end in death. Kane, an Arctic explorer 110 years ago, described examples of severe illness occurring in semistarved Eskimos who feasted on polar bear liver. Only in relatively recent times has it been recognized that the cause of the toxic effects of large amounts of polar bear liver were the enormous quantities of vitamin A it contained. The vitamin A content of the polar bear liver is 18,000 units per gram. If one managed to eat a pound of polar bear liver, he would receive in the neighborhood of 8,000,000 units. It has been recognized for 30 years that excessive doses of vitamin A in experimental animals produce diarrhea, loss of appetite, unkempt fur, decalcification and spontaneous fracture of bones, scurvylike hemorrhages, and a variety of lesions in the internal organs. The typical lesions result from an acceleration of the constant remodeling process which takes place during the maturation of bones. In vitamin A toxicity more is resorbed than is laid down. Periosteal new bone may be deposited along the shafts of the long bones where it should not occur at all. While most cases of vitamin A intoxication have occurred in infants and children, it may also occur in adults. Caffey has described the features of chronic vitamin A intoxication and presented some excellent photographs of the lesions.

Occasionally an acute intoxication analogous to poisoning from eating polar bear liver may occur when a child swallows the entire contents of a 2 ounce bottle of vitamin A concentrate. Headache, hyperirritability, and sometimes a mild exfoliation of the skin occur. In addition to Caffey's thorough review of toxicity in children, Shaw and Niccoli have reported hypervitaminosis A in a man. His main complaints were hepatomegaly and a greasy, odorous skin, but he had bone and joint pain, alteration of the mucous membranes of the lips, weakness, loss of weight and appetite. Unless the disease is recognized and vitamin A intake is stopped, it may go on to death. Usually it is recognized before this occurs. This is a classical example of iatrogenic disease or suicidal or "do-it yourself" disease.

Table 5

Vitamin Group	Common Name	Chemical Name and Properties	Biological Function	Clinical Deficiency Signs	Average Daily Allowance <sup>a</sup> for Normal Adult Per Kg Body Weight	Therapeutic Dose/Day
Vitamin A	Vitamin A	3,7-dimethyl 9 (2',3',6'-trimethyl)cyclohexen 1-yl) 2,4,6,8-nonatetraen-1-ol Solubility fat soluble Color and form pale crystals that melt into a thick, yellow oil Stability readily oxidizable but heat stable in air free containers	Unknown, appears to be needed for growth and integrity of certain epithelial tissues	Night blindness skin lesions metaplasia of epithelial tissues of respiratory tract, c, e, and genitourinary tract	45 $\pm$ 5 mcg vitamin A or beta carotene	50 000 to 100 000 units of vitamin A
Vitamin B <sub>1</sub>	Thiamine	2-methyl 5(4-methyl 5 $\beta$ -hydroxyethylthiazolium chloride) methyl 6-aminopyrimidine hydrochloride Heat stable white crystal freely soluble in water	The active form of thiamine is phosphorylated thiamine or cocarboxylase which is essential in decarboxylation of pyruvic acid with liberation of energy for muscle contraction	Dry beriberi, peripheral neuritis, peripheral neuropathy generally beginning in the feet, later in the hands with sensory changes first, motor changes subsequently, ultimately producing paralysis and contracture unless treatment intervenes. Wet beriberi includes in addition to neuropathy, cardiovascular symptoms of high output failure and edema	20 $\pm$ 5 mcg	10 to 50 mg daily in divided doses parenterally or by mouth
Vitamin B <sub>2</sub>	Riboflavin	6,7-dimethyl 9 (D 1'-ribityl) isovaloxazine Deteriorates in solution and on exposure to light but relatively stable to heat and oxygen Occurs as orange yellow crystals sparingly soluble in water	An essential constituent of flavoprotein coenzymes, its phosphorylated form along with nicotinic acid enzymes is an element in the chain of reactions transporting hydrogen from metabolites to the blood stream to combine with oxygen	Angular stomatitis, cheilosis, glossitis, possibly seborrheic dermatitis, and scrotal skin lesions	25 $\pm$ 5 mcg	2 to 10 mg in divided doses orally or parenterally

vidual and the underlying disease for which vitamin D might have been given, as well as the age and the endocrine status of the patient all have an influence

In some persons with injured muscle a chronic pericardial lesion, or arteriosclerosis, calcium may be deposited. Eventually, true bone may be formed. Myositis ossificans seems to depend on an initial disturbance in tissue calcification although the mechanism here is not vitamin D intoxication.

## THE SEVERAL DRUGS

A description of the various vitamins is given in Table 5 together with additional information. When using pure vitamins it is not known that one brand has an advantage over another as long as they meet the specifications of purity and strength required by law.

Many concentrates and crude preparations are excellent sources of vitamins. Thus fish liver oils are good sources of vitamin A. There are other sources of vitamin D. Whole brewer's yeast is an excellent source of protein and B complex vitamins, is relatively cheap and though unpalatable is an excellent supplement for those who have B complex deficiencies.

Polyvitamin tablets and capsules vary considerably in the number of constituents they contain and in the concentration of different ones as well as in the number of minerals and sometimes the concentrates of vitamin rich material. When these are to be used as supplements in the presence of severe malnutrition or actual vitamin deficiency diseases one should be careful to study the contents and not waste money on those with fancy labels and relatively small quantities of vitamins. A careful study of the list of ingredients reveals that many things are put in for which there is no known function in human metabolism. Some are almost certainly important; others are not.

Physicians are well advised to prescribe vitamin preparations manufactured by ethical pharmaceutical concerns since the actual ingredients of the tablet or capsule are likely to be reflected accurately in the label. This is certainly not true of many preparations on the market which not only may contain much less but cost much more. A physician should never prescribe just vitamins; he should know the contents of various capsules and he should not be beguiled into believing that vitamins really correct old age, pregnancy infections or any other trouble that comes along in spite of extensive advertising claims and innuendoes.

## A DESIGN FOR THE USE OF VITAMINS

*The employment of vitamins as specific therapeutic agents is indicated when a clinically recognized deficiency syndrome exists. It may have been produced by an intercurrent disease, by a food fad or phobia, or by the willful choice of an inadequate diet. But for the most part it comes from socioeconomic breakdown in which the demand for food has outreached the supply because of poverty, ignorance, overpopulation, war or famine. There is no proper design for the use of drugs in therapy in nutrition. The need for drugs means that prevention has failed. Prevention—a good diet for everyone—would do away with the need for using any drugs at all. We hardly hope to see the establishment of a utopian condition*

Table 5—Cont'd

Vitamin Group	Common Name	Chemical Name and Properties	Biological Function	Clinical Deficiency Signs	Average Daily Allowance, Adult Per Kg Body Weight	Therapeutic Dose/Day
Vitamin B <sub>2</sub>	Cyanocobalamin	$C_{64}H_{88}O_{14}N_{14}PCo$	Involved in stimulating the effect of folic acid on nuclear protein synthesis, metabolism, transmethylation, and conversion of carbohydrates to fat	Maturation arrest with hyperchromic macrocytic anemia and sometimes combined neurosis of spinal cord, probably has some role in peripheral nerve function	Probably less than 0.01 mg	10 to 50 mcg/day and then maintenance 50 mcg/month parentally
Vitamin C	Ascorbic acid	2,3-enediol L gulono-1,4-lactone	Somehow connected with the formation of connective tissue framework of the body and the protein matrix of osseous tissue and dentine, connected with metabolism of phenylalanine and tyrosine and integrity of the adrenal cortex, may have some role in biologic function of folic acid, its conversion to folic acid, absorption of iron, and some still unknown function in cell metabolism and in respiration	Infantile scurvy with failure of growth and disorderly bone formation Adult scurvy with perifollicular hemorrhages, bleeding into joints, muscles, subcutaneous tissue, gingivitis, necrosis with infarction of mucous membrane of gums, general debility, inadequate wound healing	$1 \pm 0.25$ mg	1 to 2 Gm by mouth or parenterally during acute stage, and 100 mg during convalescence
Vitamin D	Vitamin D	9,10 seco-5,7,10(10),22-cholatrietraen 3B-ol Soluble in fat solvents, sparingly in vegetable oils Fine colorless needles In proper am- ples ergocalciferol is stable 6-12 months under refrigeration	Promotes absorption, retention, and balance of calcium and phosphorus perhaps by aiding in converting organic to inorganic phosphorus at site of lime salt precipitation in bone formations	Rickets with deformities of skull, ribs, pelvis, bowing of long bones, and in adults, osteomalacia with generalized rarefaction of bones, weakened bones with deformity and muscle weakness Occasionally hypocalcemic tetany	Adult requirement unknown	20,000 units vitamin D and in very severe cases up to 1,000,000 during acute stage
Vitamin K	Vitamin K	2 methyl-3-phytyl-1,4 naphthoquinone Fat soluble yellow oil stable to heat, air, and moisture, sensitive to light, alkali, and reducing agents	Stimulates synthesis of prothrombin in the liver but is not incorporated in the prothrombin molecule	Bleeding in association with low blood prothrombin	Adult requirement unknown	10 to 25 mg of menadiolone bisulfite parentally

Vitamin D <sub>2</sub>	Pyridoxine	Pantothenic acid	Biotin	Folic acid	
Nicotinic acid amide Unusually stable to heat, air, light, and alkali	2 methyl 3 hydroxy 4,5 bis hydroxymethyl pyridine White crystalline plates stable to heat, acid and alkalis, destroyed by light	D(+) N (2 4 d hydroxy 3 3 dimethylbutyryl) $\beta$ alanine Pale yellow oil stable in neutral solutions but sensitive to heat, acids and bases	Hexahydro-2 oxo 1 thieno [3 4] imidazole 4 valeric acid Long colorless needles Heat stable but readily oxidized some what unstable in presence of acid and alkali benzoyl	N [4 (((2 amino-4 hydroxy 6 pteridinyl)methyl) amino) benzoyl] glutamic acid Brilliant yellow crystals sparingly soluble in water Deteriorates on exposure to sunlight when stored at room temperature and when exposed to heat in acid medium	In its phosphorylated forms as codehydrogenase I and II, it is concerned with hydro gen transport in same sys tem as riboflavin Concerned with protein me tabolism and fat metabo lism Codecarboxylase phosphory lated pyridoxal is concerned with removal of CO <sub>2</sub> from amino acids functions in transamination as well as conversion of tryptophan to niacin Presumably connected with acetylation in many systems is active in phosphorylated form probably as coenzyme A and has some influence on pyruvic acid oxidation is related to the integrity of the adrenal cortex and may be important in ant body formation Unknown may be concerned with transamination protein synthesis, and CO <sub>2</sub> fixation Unknown
				Maturational arrest with megaloblastic anemia and hyper chromic macrocytic red cells in peripheral smear class ically seen in certain forms of malnutrition and in anemia the pernicious anemia of pregnancy	50 to 500 mg / day orally or parenterally
				Unknown	Unknown
				Unknown	Unknown



in which each person in the entire population of the world would get a diet providing enough of each required factor too much of none. The precise intake would be highly individualized to suit measured needs. No rational man believes that in society as we know it such a state of affairs will ever be possible. Thus prevention at the earliest breach in the dike is a desideratum marvelous to contemplate but foolish to expect.

Failing in prevention the next stage in the employment of vitamins as drugs would be to seek out persons whose diet is unbalanced whose calorie supply is adequate or more nearly adequate than the supply of vitamins particularly B complex vitamins. Here if anywhere we need sensitive laboratory tests to detect specific vitamin deficiencies in the humoral stage before functional derangements become established, and long before the morphologic hallmark of a specific vitamin deficiency disease is apparent. It is a commentary on the state of our ignorance or perhaps the unrealistic hope for such tests that we get very little aid from them. *Neither tests of the excretion of vitamins in the urine nor tests of their level in the blood nor the effect of a load test can give us the information we need about past dietary experience.* Tests reflect with fair accuracy the recent past of a given individual. But a few good meals may disguise a long famine. The notoriously uncertain history of eating experience and patterns is helpful within very narrow limits. Thus we are a long way from being able to discover vitamin deficiencies in their incipient stages. Even when we go back over the history of someone who has been studied carefully during the development of a deficiency we find signs and symptoms so nonspecific that they would not identify such persons in a large group. The actual circumstances in which political, economic and geographic factors conspire to produce malnutrition are such that the resources of society and medicine also are at a low ebb and cannot provide even the modest aids we have in early detection or delayed prevention.

Another concern in our own present economic and geographic status is the question of the legitimate use of vitamins and vitamin mixtures in clinical practice today. Lacking the absolutes we like to have as to indications for specific therapy, the answer depends upon our philosophy. Should we accept the vitamin capsule or polytherapeutic tablet for a miscellany of nonspecific complaints in a throng of complaining patients? Should the public be encouraged or permitted to use at random or with compulsive regularity the ubiquitous vitamin capsule, following the do it yourself principle of self diagnosis and self treatment, naively hoping to avoid the usual unpleasant corollary of self medication namely self sacrifice? Partly to be doing something partly to remove the pressure and relieve himself of his guilty feelings of incompetence or impotence but mainly because of unhappy ignorance the physician may use vitamins by default. *I don't know what to do. Vitamins won't hurt. Let's try some vitamins.* The body reacts to large doses of vitamins as it does to poisons by eliminating them in the urine or by inactivation or by chemical decomposition. We do not yet know whether large amounts of a single element of the B complex produces imbalances. We do know that fat soluble vitamins A and D if taken too long in large doses produce serious and even fatal intoxication or chronic illness.

Thus we are faced with a dilemma in the use of vitamins as drugs. They are needed in high doses when a specific deficiency syndrome is diagnosed. We are



takes to kill the bacterium), and the interfering or inhibiting effects of grease, proteins, fluid, soap, and other substances that may be present

From a practical standpoint, the prime purpose of antiseptics is to prevent or limit infections. Surgical technique can never be perfect so as to eliminate completely the entry of microorganisms into the body, even in "clean" operations. Fortunately, healthy tissues can take care of large numbers of bacteria without clinical signs of infection. However, if the tissues are damaged or have a poor blood supply or if foreign material is also present, infection is apt to ensue. Thus, another set of influential variable factors comes into play, complicating the "clinical evaluation" of antiseptics.

Historically, the main factors affecting general acceptance or outmoding of antiseptics have been irrational ones—prejudice, convention, fashion, or sheer convenience. The old lime and soda method of hand disinfection had much to commend it, but it produced an unpleasant odor and so never became popular. Bichloride of mercury hand soaks, once used almost universally, were gradually abandoned when other agents were introduced which did not darken the nails or roughen the skin. Organic preparations of mercury and silver had their day, but were gradually discarded for reasons that are not entirely clear except that they became unfashionable. The present vogue of hexachlorophene soaps and detergents for preoperative hand scrubs rests largely upon considerations of convenience and timesaving.

Clearly, then, reliable evaluation of local antiseptics is a difficult task. It can not be done precisely, it should not be done dogmatically. The following attempt at assessment is based on a critical review of most of the extensive literature on the subject, ample clinical experience with each of the agents discussed and many years spent in testing them in the experimental laboratory.

## SKIN DISINFECTION

**Nature of the Problem**—It is not possible to sterilize skin without destroying it although it is possible to reduce the number of bacteria present. The surgeon is compelled, therefore, always to operate with hands that cannot be fully disinfected, and to make incisions through skin that cannot be rendered entirely germ-free. It becomes a matter of prime importance to know which antiseptics are most effective.

The skin is an irregularly pitted, ridged, and creased epidermal surface that normally is watertight and forms an effective barrier against bacterial invasion. Bacteria are found in large numbers on the surface, on and under loosely attached flakes of keratin; some microorganisms may be detected in hair pits and mouths of sebaceous ducts but few if any can be demonstrated in or between the living cells of normal skin.

The cutaneous flora is composed of transient and resident bacteria. Transients vary tremendously in number and kind. Virulent germs as well as saprophytes may be present. Most extraneous microorganisms that get on the skin soon disappear from the surface or can be easily removed or killed. Vast numbers can usually be found, however, under nails, between the toes, in the perineal breast and axillary folds, on the scalp, in the umbilicus, and on other areas that tend to



tate or roughen the skin, penetrate the epidermis so as to be absorbed systemically, or produce sensitivity. Of secondary but practical importance are considerations of availability of the agent, economy in use, and the absence of unpleasant characteristics such as a disagreeable odor or permanent skin staining.

Medical students often ask why, if rubber gloves are to be worn anyhow, it is necessary to disinfect the hands at all. Unfortunately, many operators do not appear to know the answer themselves. First, without preliminary hand preparation, it is almost impossible to "gown and glove" without serious breaks in aseptic technique. Second, under rubber gloves, hands that have not been disinfected soon develop abnormally large bacterial populations. Pathogens present participate fully in that increase. A situation is thus created which permits dangerous spillage of bacteria through any tear or puncture hole in the glove. Third, tears, puncture holes, and leaky patches in gloves occur more frequently than is generally recognized. On my own service, where everyone was well alerted to these dangers, I found on occasion that as many as 20 per cent of the gloves used by the operating team had leaks in them by the time they were returned to the Central Surgical Supply Department. Fourth, forearms of operators are not covered by impervious rubber but by a cloth sleeve through which underlying bacteria pass readily wherever and whenever the fabric becomes wet with sweat, saline, or blood.

No way has been found to prevent an increase of the cutaneous bacterial flora under rubber gloves. The best that can be done is to reduce the flora to relatively small size before putting on gloves, and then between operations to degerm the hands again by appropriate washing in alcohol or some other suitable antiseptic solution.

**Soap**—Soap is a feeble antiseptic. A cake of nonmedicated soap will sterilize itself quickly after use, but per se it is relatively ineffective in disinfecting the skin.

Its great value lies in its detergent action, especially when washing is combined with mechanical friction. Whenever the skin is rubbed or brushed with soap and warm water, grease, fats, dirt, and loose keratin come away, and with them most of the transient and a small portion of the resident bacterial flora.

For preoperative scrubs, a preliminary toilet of the nails is recommended, followed by a 7 minute wash, using soap, a good nylon bristle brush, and running water, not neglecting any area between the finger tips and a level well above the elbows. That procedure can be counted upon to remove all grease and dirt, all contaminating bacteria and about half of the resident flora. Then the hands and arms should be dried with a sterile towel so that the following antiseptic solution will not be diluted and weakened by water left on the skin.

Tests show that it makes little difference whether the detergent used is cake soap, liquid soap or tincture of green soap. If the tap water used is very hard, a synthetic detergent may be preferable, but its degerming action will not be greater than that of ordinary soap used with soft water. Medicated soaps (except those containing hexachlorophene) possess no advantage over nonmedicated, they are more expensive, and occasionally are found to be irritating. Pure soap is rarely irritating to the skin if it is not used in a too concentrated liquid form.

**Hexachlorophene**—Hexachlorophene is one of the few known antiseptics that do not lose their antibacterial potency in the presence of soap. The combination

organisms (which are "transients") placed on the hands are nearly all removed (above 98 per cent of them) by simple washing for a minute with soap under the tap, but to remove *all* of them with certainty requires 7 to 8 minutes of scrubbing with brush, soap and water.

Residents form the stable bacterial population of the skin. They live and multiply there. Some of them die there, many are rubbed off or are washed off. Under ordinary conditions of life increases tend to balance losses, so that on the same person the total number of resident microorganisms remains fairly constant. Washing removes them slowly, and antiseptics are less effective against them than against transients. In most persons the resident flora is composed largely of staphylococci of low pathogenicity, but some pathogens are almost always present also. Prolonged or frequent exposure of the skin to large numbers of pathogenic bacteria may alter the ordinary composition of the resident flora and increase its potential infectiousness.

Some persons habitually carry a much larger flora than do others, but it is not possible simply by looking at the skin to say whether its flora is large or small. Some of the largest counts ever recorded have come from smooth, grossly clean, almost hairless skin of young women. The rate at which the flora is reduced by scrubbing also varies with different individuals. In general, the higher the initial flora, the slower the rate of reduction.

In addition to the flora just described, there is a reservoir of bacteria hidden deeply in the skin. The superficial resident flora comes off in washings at a regular rate, whereas the deep bacteria begin to appear in washings in appreciable numbers only after 15 or more minutes of scrubbing. It is possible that many of these deep-lying bacteria come from sebaceous ducts.

The distribution of bacteria on skin is found to be uneven, and contiguous areas may show different sized counts, but no constant or definite pattern has been discerned. On the average exposed skin has a resident flora approximately equal to that of skin ordinarily covered by clothing. The hands, arms, abdomen, back, thighs and the dorsum of the feet all have counts of about the same size.

After the cutaneous bacterial flora has been reduced by scrubbing or by antiseptics, regeneration occurs, probably following a growth curve similar to that seen in cultures. Re-establishment of the usual flora requires from one to several days, depending upon the thoroughness with which the skin has been degermed. Under rubber gloves and impervious dressings, regeneration takes place much more rapidly.

## ANTISEPTICS USED TO DISINFECT THE HANDS

**General Considerations**—It is important in preparation for operation that the hands be scrubbed thoroughly so as to remove all dirt, grease, and natural fats, otherwise the antiseptic cannot make maximal contact with the cutaneous bacteria. Tests have shown that about 7 minutes of conscientious scrubbing with brush, soap, and warm water are required, on the average, to eradicate virtually all fats from the hands and arms.

Hand antiseptics should be both bacteriologically effective and harmless to the skin. Since they may be applied several times a day to the same pair of hands and arms, they should not, even with prolonged and frequent use, injure or irri-

the stronger solutions, because it spreads evenly, wets efficiently and because it is almost completely innocuous on the healthy skin (it happens to contain some unusual, irritating, denaturing substance).

Solutions of alcohol exposed in an open basin for periods of time lose strength because the alcohol (95 per cent) fraction evaporates and leaves the water fraction.

Timing is important also. Washing the hands and arms with 70 per cent (by weight) alcohol has a degerming effect equivalent to 20 minutes of scrubbing. Washing for 3 minutes will be as effective, but 20 minutes of scrubbing. If, in addition, one rubs the skin with a washcloth while washing in the alcohol the degerming rate will be increased.

In the light of these considerations, the following routine is suggested as a preoperative routine.

Trim and clean the fingernails

Scrub under running water with nonmedicated soap (or soap, if desired) and a good brush, for 7 minutes (longer if hands are greasy and dirty)

Dry with a sterile towel

Rinse briefly in 95 per cent (commercial) alcohol to remove soap. (The small amount of this stronger alcohol solution next basin will help maintain its strength.)

Wash for 3 full minutes in 70 per cent (by weight) alcohol, gently but thoroughly with gauze or a washcloth.

Dry with a second sterile towel

Put on gown and gloves

This procedure is not unduly time consuming, is not hard on the skin, and can be relied upon to reduce the cutaneous bacterial flora far more than any other simple routine known to the author.

The same basin of alcohol may be used by a succession of operations. At the end of the day the used alcohol can be salvaged by filtering it and bringing it back to its original strength with the aid of an alcoholometer and appropriate dilution.

**Isopropyl Alcohol**—Isopropyl alcohol degerms the skin full strength, perhaps even a little better than, ethyl alcohol. Solutions 70 per cent or stronger are recommended. In contradistinction to ethyl alcohol, the germicidal action increases with the concentration, so that full strength is somewhat more effective than 70 per cent.

Since isopropyl alcohol is nonpotable, it may be obtained readily in a purified form, and without the annoying restrictions and taxes ordinarily associated with ethyl alcohol. However, since isopropyl solutions are more irritating to the skin than equivalent ethyl alcohol solutions, they are more apt to cause dryness of the skin if used frequently. Repeated washing in isopropyl alcohol leaves the hands rough and slightly scaly, with an uncomfortable feeling of dryness.

is a happy one. Hexachlorophene itself is virtually insoluble in pure water, but the alkaline soap keeps it in solution. Consequently, hexachlorophene combined with soap and other detergents has been recommended for surgical preparation of hands and the field of operation.

Highly favorable reports have been published by Traub and co workers Udinski, Seastone, and others. Walter introduced a combination of a synthetic detergent with 3 per cent hexachlorophene, which, it is claimed, is even more effective than the soap preparations. It has been asserted that persons who operate regularly need not scrub in the old-fashioned manner, nor do they need to soak the hands in antiseptic solutions; instead it is necessary only to lather the hands and arms for 2 or 3 minutes with hexachlorophene soap. It has been alleged that washing with G-11 soap once a day will not only reduce the cutaneous bacterial flora to a very low level but will keep it persistently low.

These glowing recommendations, together with the desire of many surgeons for a quick, easy method of preparing for operation, have resulted in wholesale adoption of hexachlorophene soap or pHisoHex in operating rooms all over the country, where they have tended to replace the conventional scrub and alcohol wash.

It is only natural that the initial enthusiastic reports about hexachlorophene should have been followed by more critical re-evaluations. Several have been published. These warnings are reinforced by a recent increase in incidence of infections in 'clean cases' in many hospitals. In my opinion, the blame must be placed both upon overuse and undue reliance on antibiotics in surgical cases and upon the unreliability of the short hexachlorophene scrub.

Hexachlorophene does not disinfect the skin quickly, as alcohol does, but only slowly over the course of several days. This slow degerming action is attributed to a film of the agent left on the hands and arms after washing with the medicated soap. It is possible to reduce the bacterial flora of the skin to about 5 per cent of its usual size, but to achieve this desired effect it is necessary to use G-11 soap exclusively and frequently (several times each day) for 4 to 5 days. A single brief scrub with hexachlorophene soap or with pHisoHex is not significantly more effective than a scrub of equal length using ordinary soap.

Furthermore, it has been demonstrated that at least some people have bacterial populations that are more resistant to this slow effect of hexachlorophene than others are. Even in the case of those persons whose cutaneous bacterial flora has been shown by appropriate tests to be sensitive to hexachlorophene, it has been shown that an occasional wash with G-11 soap cannot be relied upon to keep the hands free from infectious germs, either under rubber gloves or in ordinary conditions of life.

**Ethyl Alcohol**—Ethyl alcohol is probably the most effective and satisfactory hand disinfectant available.

The concentration is important. Strengths between 70 per cent by weight (approximately 80 per cent by volume when prepared at room temperature) and 92 per cent by weight (commercial alcohol, 95 per cent by volume) are all about equally effective against the bacterial flora of skin. For routine use 70 per cent by weight is recommended because, volume for volume, it is less expensive than

sore throat, may contribute an abnormally large number of pathogenic bacteria to the existing flora. Yet, the person preparing the field of operation is expected to disinfect the skin surface quickly and thoroughly—quickly because the surgical team is in a hurry and the crowded operating room schedule demands it, and thoroughly because the cutaneous surface is exposed during the operation and is not effectively sealed off, as hands are with rubber gloves.

However, the skin of the patient will usually tolerate stronger and harsher antiseptic solutions as a single application than is permissible on hands which must be disinfected repeatedly, day after day. Even so, one is limited, of course, to *antiseptics that do not harm the patient's skin*.

In using these stronger antiseptics, reaction time (between the chemical and the bacterial flora) cannot be ignored. There is no such thing as instantaneous disinfection by means of an antiseptic. Generally speaking, the longer the antiseptic has to act, the more effective it will be. However, the contact between bacteria and the bactericidal agent can be augmented and the rate of disinfection of skin can in consequence be increased by using gauze friction to apply the antiseptic. The spray method of applying antiseptic solutions is not recommended.

The old-fashioned custom of applying disinfectants to the operative site a day or two before surgery and wrapping the part in sterile dressings or sterile towels is bacteriologically useless and psychologically bad.

**Soap**—The uses and limitations of soap as an adjunct in skin disinfection are discussed in the previous section on Antiseptics Used to Disinfect the Hands.

Soap is useful in preparation of the patient's skin for operation, but, generally speaking it does not have as large a role as in hand disinfection. Washing the field of operation in the operating room prior to surgery is sloppy, and may be dangerous if sterile drapes become wet as a result. It is better to wash the area ahead of time and have it reach the operating table grossly clean and dry.

**Hexachlorophene**—The peculiar properties of this disinfecting agent have also been described in the foregoing section. A single wash with hexachlorophene soap or pHisoHex immediately before operation does not accomplish much bacteriologically. There is a place for hexachlorophene, however, in preparation of the field of elective operations, especially in areas of the body not easily disinfected by ordinary means—such areas as hands, feet, face, and perineum. If those regions can be washed 3 or 4 times a day for 4 or 5 days prior to operation, they will come to surgery already pretty well disinfected. The instructed patient can carry out this regimen himself at home. It is not necessary to keep the part wrapped during this preoperative period.

**Ethyl and Isopropyl Alcohols**—Ethyl alcohol, 70 per cent by weight, and isopropyl alcohol, 70 per cent or stronger, are both superlative preparations for disinfection of the operative field, whether for major surgical procedures in the operating room or for minor office or ward procedures such as needle punctures. Seventy per cent ethyl alcohol is not a good fat solvent, however, and should not be relied upon to do the work of a detergent. Full strength isopropyl alcohol is more effective from that standpoint.

The importance of the time factor must be kept in mind. Undue haste inevitably decreases the bactericidal effect of the antiseptic and increases the risk of subsequent infection.

A peculiarity of Zephiran is that its antiseptic action can be effectively neutralized by soap. Even traces of soap regularly found on the skin of cleanly persons are sufficient to act as an antidote to Zephiran in aqueous solution. Another characteristic of the compound is that extremely small amounts of it in culture media may inhibit growth of bacterial colonies to a degree that is thoroughly misleading to the unwary investigator.

If Zephiran is to be used, care should be taken to remove all soap from the skin first. It is not sufficient just to rinse off visible suds with water. Even thorough washing with water will not ensure elimination of all the soap clinging to the skin surface. However, 40 to 70 per cent alcohol solutions are excellent, readily available soap solvents.

Even when the epidermal surface has been rendered soap free by a preliminary wash with alcohol, 1:1000 aqueous Zephiran solution is a relatively weak skin antiseptic. Tincture of Zephiran (1:1000) is more effective, though no better than plain 70 per cent alcohol which is much less expensive. Indeed, a considerable portion of the degerming effect of tincture of Zephiran is attributable to the activity of the alcohol-acetone solvent.

Zephiran in 1:1000 solution is harmless on healthy skin except in extremely rare instances.

It has become customary in some hospitals to prepare for operation by washing the hands with hexachlorophene soap and then washing in aqueous Zephiran solution before putting on gloves. The poor logic of such a procedure should be obvious. Many persons who follow that routine assume that the Zephiran will have an immediate antiseptic effect and will continue to depress the cutaneous bacterial flora during the period that gloves are being worn. Such is not the case. Not only is the antiseptic neutralized by the soap abundantly present on the skin under these circumstances, but even when there is no soap present, Zephiran will not prevent the multiplication of skin bacteria that seems always to take place under rubber gloves.

Zephiran is one of a number of quaternary ammonium compounds. They are all similar in skin antiseptic qualities. Of those tested by the author (Phemerol, Ceepryn, and Diaparene Chloride), none has been found superior to Zephiran as a skin antiseptic.

## ANTISEPTICS USED TO DISINFECT THE FIELD OF OPERATION

**Special Considerations.**—The problem of disinfecting the patient's skin for surgical procedures differs in several important respects from that of hand disinfection. For one thing, the patient's skin is not subjected to prolonged preliminary scrubbing as hands are. Although the patient's skin may appear grossly clean, it invariably harbors a large bacterial flora, both transients and residents (including some pathogens), and this flora is protected to some extent by extraneous oils and natural fats when the antiseptic is applied. In some instances this bacterial flora will be abnormally large. That will happen if the ward prep (preliminary washing and shaving) has excoriated or scratched the surface. That will also be the case if there is a nearby infection, a draining sinus, or a colostomy seeding the operative site with contaminating organisms. Even a distant infection such as a



defect, however, of causing mild to serious burns on the skin of an unacceptably large proportion of patients even when care is taken to wash away with alcohol much of the mahogany colored coat as a final step before draping.

The preparation formerly known as half strength tincture of iodine (pre 1947 tincture of iodine diluted with equal parts of 95 per cent alcohol) has about half the skin disinfectant power of the parent solution, but it is even more apt to produce burns, in my experience because the high alcoholic content evaporates rapidly leaving streaks and rims of highly concentrated iodine on the skin and it is at these areas under the drapes that painful burns are apt to occur.

Modern iodine tincture which contains 2 per cent iodine, 24 per cent potassium iodide and 44 to 50 per cent alcohol, is a more satisfactory preparation than any of those mentioned above.

Superior to all of them, however, in my opinion is a preparation of 2 per cent iodine in 70 per cent (by weight) alcohol. This solution spreads evenly, dries slowly, does not burn the skin and rarely causes the patient discomfort of any sort. Quantitative bacteriologic tests in my laboratory show this preparation of iodine to be more effective in reducing the cutaneous flora than any other antiseptic tested.

These newer preparations of iodine deserve a larger place of usefulness in present day operating rooms.

**Povidone-Iodine**—Povidone iodine (Betadine, Isodine), recently introduced as a topical antiseptic is a water soluble complex of polyvinylpyrrolidone and iodine which on contact with skin or mucous membranes tends to break down and release inorganic iodine slowly. The slight residual stain on skin is readily washed away with water. It is said that povidone iodine rarely irritates skin and that in the use of this preparation the toxicity of iodine is reduced. For topical application a 10 per cent solution containing 1 per cent free iodine is available.

In vitro tests against a variety of pathogenic organisms commonly found on skin and in wounds show that povidone iodine is effectively antimicrobial even in the presence of serum and blood. The effectiveness and relative value of the agent as a skin antiseptic under conditions of actual use have yet to be demonstrated, however.

**Acrizane Chloride**—This is the name given to a new antiseptic 9 para-hexyl oxyphenol 9 chloro-10 methyl acridine. It has been recommended in 1:200 and 1:1,000 concentrations in aqueous or alcohol acetone solutions. Acrizane colors the skin intensely yellow and the stain may spread to dressings, drapes and bed clothes. For this reason it may not be popular with hospital administrators. It is not irritating to skin.

Tests show that both aqueous and alcoholic solutions even of the 1:1,000 concentration are highly effective skin antiseptics. A limited trial on my surgical service gave thoroughly satisfactory clinical results.

**Chemical Detergents**.—These substances have only slight skin antiseptic action. Even as adjuncts to skin disinfection their usefulness is limited to the occasional necessity of removing adhesive tape marks, heavy grease or oil, paint, tar, etc.

In the days of drop ether anesthesia a conventional step in preparation of the field of operation was to wash the area with an ether sponge. The elimination of

**Zephiran**—The value and hazards of this agent are described in the foregoing section on Antiseptics Used to Disinfect the Hands

Aqueous 1:1,000 Zephiran solution can be used safely around the eyes, but, because of its feeble antiseptic qualities, it is not recommended for skin disinfection elsewhere

Tinted tincture of Zephiran, 1:1,000 strength, is a relatively good skin antiseptic, however, if properly used. The stain is not objectionable and enables the operator to make sure that no part of the operative field has been missed by the antiseptic.

The following routine is preferred to all others on my own surgical service as the standard method of preparing the field of operation

Wash with alcohol  
Wash with Zephiran  
Wash with alcohol  
Wash with Zephiran  
Wash with alcohol

The alcohol used is either 70 per cent ethyl alcohol by weight, or 70 per cent iso propyl alcohol, the Zephiran, 1:1,000 stained tincture. The alcohol not only removes all soap which might interfere with action of the Zephiran, but it has powerful antiseptic activity of its own. The Zephiran has, under these conditions, an antiseptic value about equal to that of the alcohol, and the stain ensures that there will be no skip areas. The number of alterations forces the person applying the antiseptics to spend at least 3 to 5 minutes going through the routine, thus giving the germicides time to act. This procedure does not harm even delicate skin, reduces the cutaneous flora very effectively, and does not appear to interfere in any way with subsequent healing of the incision.

**Iodine**—Iodine has long been considered one of the best, if not the best, of all skin antiseptics from a purely bacteriologic standpoint, and rightly so. The chief reason it has been largely displaced by other agents in preoperative skin preparation is that it so often burned or irritated the patient's skin. However, this was largely the fault of the preparations used. It is only the occasional patient that is sensitive to topical application of iodine when applied in proper concentration.

Iodine, in contradistinction to mercurials and some other chemicals, and alcohol fully reinforce each other's antiseptic activity on skin.

Aqueous solutions of iodine should be used with some caution, especially the more concentrated preparations. Lugol's solution (iodine 5, potassium iodide 10, distilled water q s ad 100), for example, may be dangerous if used on large areas of skin. Three subjects in my laboratory, one after the other, who washed their hands and arms in the solution to test its antiseptic effects were all badly burned, and one of them had to be hospitalized for systemic symptoms of iodism. However, Gershenfeld and others recommend a 2 per cent water solution of iodine iodide (iodine solution) and consider it a superior antiseptic.

Strong iodine tincture, previous to 1947 called 'tincture of iodine,' contains 7 per cent iodine and 5 per cent potassium iodide in 83 to 88 per cent alcohol. It is a powerfully effective skin antiseptic, even though it evaporates quickly and thus has a relatively brief time in which to exert its bactericidal action. It has the

tions directly to wounds known to be infected with types of bacteria that are specifically sensitive to those agents. That may be indicated especially in wounds and infections that are intractable to ordinary methods of treatment. A good example is the treatment of certain stubborn infections with bacitracin. This agent is not inhibited by pus, blood, or broken down tissue, or inactivated by penicillinase producers.

## SELECTED REFERENCES

- Surface II Hexachlorophene  
Lippincott Co  
J Surg 94 938 1957  
in New York Acad Sc 53  
172, 1950
- Klarmann, E. G. The Role of Antagonisms in Evaluation of Antiseptics, Ann N Y Acad Sc 53 123, 1950
- Price, P. B. The Bacteriology of Normal Skin, a New Quantitative Test Applied to a Study of the Bacterial Flora and the Disinfectant Action of Mechanical Cleansing J Infect Dis 63 301, 1938
- Price, P. B. Re Evaluation of Ethyl Alcohol as a Germicide Arch Surg 60 492, 1950
- Price, P. B. Benzalkonium Chloride (Zephiran Chloride) as a Skin Disinfectant, Arch Surg 61 23, 1950
- Price, P. B. Fallacy of a Current Surgical Fad—the 3 Minute Scrub With Hexachlorophene Soap, Ann Surg 154 476, 1951
- Price, P. B., and Wilson, B. L. Acrizane Chloride, a Promising New Skin Antiseptic, Am Surgeon 19 792, 1953
- Seastone, C. V. Observations on the Use of G 11 in the Surgical Scrub, Surg Gynec & Obst 84 355, 1947
- Traub, E. F., Newhall, C. A., and Fuller, J. R. Value of a New Compound (Dihydroxy . . . . .) to Reduce the Bacterial Flora of Human . . . . .
- Udinski, . . . . . Daily Use of a Soap Containing New Jersey 42 15 1945
- Walter C. . . . . York 1948, The Macmillan Co

that step was no loss from a bacteriologic standpoint. Ether on a sponge is not even an efficient detergent for the skin.

Acetone is an effective detergent and a fairly good antiseptic but it is somewhat injurious to skin.

Carbon tetrachloride is a feeble antiseptic and is toxic as well.

Chloroform and xylene have antiseptic actions comparable to that of alcohol but both substances are so irritating and harmful to skin that their use should be avoided if possible.

## THE USE OF ANTISEPTICS IN WOUNDS

**Special Considerations**—Closed wounds are usually uninfected wounds. In deed the most effective way to control and eliminate infection in an open wound is to convert it to a closed wound. The habit of painting with an antiseptic the suture line of a freshly closed incision is a useless possibly harmful gesture.

Open wounds are always infected to a greater or lesser degree. The consideration of prime importance is not the presence of bacteria on the surface of the wound but rather the invasion of the body by those organisms. Chronic wounds lined with granulation and fibrous tissue present a pretty effective barrier to bacterial penetration into underlying tissues; on the other hand fresh wounds including burns in which there has not been time for the body to build up its defenses are subject to rapid and sometimes disastrous bacterial invasion. It is in such situations that appropriate antibiotics given systemically may play an effective and decisive role.

Local antiseptics have a very limited usefulness in wounds. Mechanical measures such as the removal of all foreign bodies and necrotic tissue, free drainage and mild irrigations with physiologic salt solution, avoidance of poor circulation and congestion and rest are generally much more important than topical drugs. When antiseptics are used the chances are that they will be largely inactivated by serum, blood, pus, necrotic tissue and dilution.

**Specific Local Antiseptics**—Ether recommended half a century ago by Staige Davis appears to clean granulating surfaces well and is not painful to the patient but is of little bacteriologic significance.

Dakin's solution (buffered aqueous solution of sodium hypochlorite) was introduced during World War I as an antiseptic irrigant for wounds. It proved to be less effective in combatting infection and less innocuous to wounds than was originally thought. It is no longer used to any extent neither is it recommended.

The application of caustics and strong chemical germicides to wounds is an old old story and in general a sad one. Substances like alcohol, iodine, mercurials and silver nitrate do more harm than good.

Some substances not strongly germicidal themselves have the effect of antiseptics because they can change the environment so that it becomes unsuitable for growth of specific organisms. Examples are the application of oxidizing agents (hydrogen peroxide or activated zinc peroxide) for anaerobic infections, and more questionably the use of acetic acid solution for pyocyanus infections.

In selected cases it is rational and useful to apply selected antibiotic prepara-

are useful and have clinical application because so many are histiotoxic. The antibiotics which are clinically most useful are penicillin, streptomycin, tetracycline, oxytetracycline (Terramycin), chlortetracycline (Aureomycin), chloramphenicol (Chloromycetin), bacitracin, polymyxin B (Aerospirin), neomycin, erythromycin, novobiocin, oleandomycin, and spiramycin. [Griseofulvin is considered in the chapter on The Choice of Dermatologic Drugs. Ed.]

The bacterial spectrum and the sensitivity of various microorganisms to the different antibiotics varies enormously, but in general, antibiotics fall into patterns of activity that have been designated as narrow- or broad spectrum antibiotics. Organisms have been designated as sensitive or insensitive. Infections have been classified as being resistant or susceptible.

There are four major antibiotics—penicillin, streptomycin, tetracycline, and chloramphenicol. All of these antibiotics are widely used and, when they are properly selected and exhibited, they are capable of controlling the majority of bacterial infections. In addition to these four major antibiotics, there are a number of minor antibiotics which are less active but nevertheless important therapeutic agents because when they are selected and used in patients with infections which are resistant to the major antibiotics or in patients who are hypersensitive to them, they are beneficial and often lifesaving. They include those listed in Table 11.

**Mode of Action**—It is now recognized that antibiotics like penicillin are bacteriostatic in low and bactericidal in higher concentrations, and that microorganisms are killed only when they are exposed to a high concentration of antibiotic during the active growth phase of multiplication. While many very careful studies have been made to determine the mechanism of action of penicillin, the mode of action has not been completely solved. Several mechanisms have been suggested, to wit, that penicillin prevents the entrance of some essential nutrient factor into the bacterial cell and probably blocks the retention of others already present. It has been postulated that penicillin may be directly related to its ability to produce excessive dehydrogenation of sulfhydryl bearing compounds. It is of the utmost importance that efforts be devoted to determining the mode of action of all antibiotics because to elucidate the mode of attack of a chemical molecule on a bacterium might lead to the design of a molecule that works as well or better and is far more effective and easier to make. It has been postulated that the efficacy of all antibiotics is due to the molecule of the antibiotic being very but not quite like that of the normal and essential foodstuff of the bacterium so that when it is taken in it "jams the works" and kills the organism.

**Selection of Antibiotics**—One of the problems facing every doctor when he is confronted with a patient suffering from an infection is to establish a clinical and bacteriologic diagnosis. He will want to know whether the infection is susceptible to any of the available antibiotics and, if so, which one he should choose. There is a wide variety of agents to choose from, but the main object is to select the agent that will produce a positive effect in the shortest period of time.

There are three broad classes of antibiotics in general use and a number with special and limited use. The three common ones are penicillin, streptomycin, and the tetracyclines. All of the others have a place, but the indications for their use are more limited. They include those listed in Table 6.

## THE CHOICE OF AN ANTIBACTERIAL AGENT

*Chester S. Keefer, M.D.*

---

### INTRODUCTION

The development of new therapeutic weapons for the war against disease is clearly the most revolutionary factor in modern clinical practice. It has altered profoundly the ways in which millions of people are treated when ill. It has changed medicine and its practice in all of its aspects almost beyond recognition. These revolutionary changes in medicine have created new possibilities for health and longevity which would have seemed fantastic even as recently as twenty five years ago. This revolutionary force in medicine and especially in the field of antibacterial agents is now advancing with amazing swiftness so that we now make in years the advances whose past analogues required decades or even centuries.

Physicians now have available a wide variety of highly potent and highly effective chemicals for the prevention and treatment of infectious disease. New antibacterial agents are being discovered and applied. Some have broad application others are limited. The scene shifts from year to year as experience accumulates. New problems are created and new methods of attacking them are required. The choice of an antibacterial agent will depend upon many considerations but in general it can be said that one chooses an antibacterial agent that will bring the infection under control in the shortest period of time so as to save life and to shorten the course of the disease.

For the treatment of most bacterial infections then there are a variety of anti-infective agents. These are often subdivided into the antibiotics, the antituberculosis drugs, and other chemotherapeutic agents such as the sulfonamides. In this chapter a discussion of the choice of antibiotics and other antibacterial agents will be presented.

### ANTIBIOTICS

**General Characteristics**—The discovery, development and production of antibiotics for the treatment of infectious diseases constitutes one of the greatest advances of all time in medical therapeutics. A wide variety of antimicrobial agents have been isolated from bacteria, plants, animal tissues, and fungi, but only a few

the site and nature of the infection. The aim of treatment is to bring about recovery and control of infection in the shortest period of time and with the least inconvenience to the patient.

**ORAL PENICILLIN**—A variety of dosage forms of penicillin are available for oral administration. The sodium or potassium crystalline salts of penicillin G, penicillin combined with Benemid, Bicillin and penicillin V are the common preparations. The crystalline salts are combined with a buffer for the purpose of enhancing the stability and to increase the acid neutralizing capacity when exposed to the gastric juice. Buffered preparations are not essential for a satisfactory therapeutic result.

Penicillin combined with Benemid is used for the purpose of delaying the excretion of penicillin. With this preparation it is possible to obtain plasma concentrations of the antibiotic which are comparable to those that are seen following the injections of the same amount parenterally. Bicillin is absorbed more slowly than the crystalline salts and plasma concentrations of penicillin are detectable for a longer period of time.

Penicillin V is another salt of penicillin which is given by mouth. It is absorbed more slowly than crystalline penicillin G so that plasma concentrations reach their peak somewhat later and remain higher for a slightly longer period of time. Biologically, penicillin V is no more effective than other forms of penicillin.

More and more penicillin of all forms is being given by mouth. It is well tolerated and it is as effective. It is convenient and decreases nursing care and the discomfort arising from injections. The incidence of serious hypersensitivity is lower. The important point with oral preparations is the dosage schedule. The therapeutic results following oral therapy are comparable in every way to parenteral therapy.

While dosage schedules vary from one patient to another and from one disease to another, when crystalline penicillin is used by mouth it is well that 3 to 5 times the minimum effective parenteral dose be used. When penicillin is used with Benemid, much less need be given because comparable plasma levels may be obtained with the same amount of penicillin as that given intramuscularly.

**PROCAINE PENICILLIN G**—This is the most widely used parenteral dosage form of penicillin. The preparation is relatively insoluble in water and is absorbed slowly from the site of injection. Thus 1 or 2 injections daily will insure plasma concentrations of penicillin throughout the 24 hour period. For example, following the injection of 1 ml containing 300 000 units of procaine penicillin, maximum plasma concentrations are reached within 1 to 2 hours. The concentration then decreases slowly over a period of 24 hours. Maximum plasma concentration following a single injection of aqueous crystalline penicillin G occurs within 10 to 15 minutes after injection and is always greater than that following a similar amount of procaine penicillin G, but penicillin disappears from the blood more rapidly because the aqueous sodium penicillin G is absorbed more rapidly.

Following the injection of 300 000 units of aqueous penicillin G, the plasma concentration is usually about the same at the end of 1 hour as at the end of 12 hours following the same dose of procaine penicillin.

Sodium or potassium penicillin G is often combined with procaine penicillin to give higher concentrations of penicillin as well as a 24 hour

Table 6 Antibiotics in General Use

Wide Use	Limited Use
Penicillin	Bacitracin
Streptomycin and Dihydrostreptomycin	Carbomycin
Tetracyclines	Cycloserine
Tetracycline	Chloramphenicol
Oxytetracycline	Erythromycin
Chlortetracycline	Fumagillin
N (Pyrrolidinomethyl) tetracycline	Kanamycin
Demethylchlortetracycline	Neomycin
	Novobiocin
	Nystatin
	Oleandomycin and Triacetyleandomycin
	Polymyxin B
	Ristocetin
	Spiromycin
	Vancomycin
	Viomycin

It is well, then, to be familiar with the action and practical application of the various antibiotics so that the most effective one may be selected.

**Penicillin**—Penicillin G continues to be the most widely used of all antibiotics. It is the most potent and the least toxic. It is available in a variety of dosage forms and it is bactericidal. With the exception of an increasing number of strains of staphylococci, practically all microorganisms which were originally sensitive to penicillin remain sensitive so that penicillin continues to be the antibiotic of choice for the treatment of all patients with gram positive coccal infections except the *Streptococcus faecalis* and the resistant staphylococci. The one exception in so far as the patient is concerned is hypersensitivity to penicillin. Further, it is the drug of choice for the treatment of gonorrhea and syphilis and of yaws (See Table 7).

Table 7 Diseases in Which Penicillin Is the Antibacterial Agent of Choice

All gram positive bacterial infections including
All sensitive strains of staphylococci
Pneumococcal infections
Hemolytic streptococci
Nonhemolytic streptococci
Anthrax
Actinomycosis
Tetanus
Diphtheria
Clostridial infections
Fusospirochetal diseases
Gonorrhea
Syphilis
Yaws

**DOSAGE FORMS**—The commonest dosage forms are (1) crystalline penicillin G for oral use, (2) sodium or potassium salts of penicillin G for injection in aqueous solution, (3) procaine penicillin G suspended in water or aluminum stearate, (4) crystalline penicillin combined with Benemid to delay excretion, (5) combinations of aqueous soluble and procaine penicillin and (6) penicillin V.

The selection of a dosage form will depend upon the individual patient and



Table 8 Diseases in Which Streptomycin and Dihydrostreptomycin Are the Antibiotics of Choice

---



---

Tuberculosis—combined with isoniazid or P A S
Tularemia
All gram negative bacterial infections due to sensitive strains
<i>H. influenzae</i> —combined with sulfadiazine
<i>K. pneumoniae</i> —combined with sulfadiazine
Granuloma inguinale
Plague—combined with sulfadiazine

---

used for the treatment of *H. influenzae* meningitis it is well to combine its use with sulfadiazine in order to delay the emergence of resistant strains. *Klebsiella pneumoniae* infections and mixed infections of the peritoneum are also treated with streptomycin. The dosage and duration of treatment should be guided by the clinical response and the severity of the infection. Optimum therapy should be employed for 7 to 14 days or before resistant organisms emerge.

**CONCENTRATION AND DOSAGE**—Following intramuscular injection streptomycin diffuses freely into the blood stream and lymphatics and can be detected in the peritoneal and pleural fluid, the aqueous humor, and the bile. It diffuses into soft tissues and into abscesses.

Streptomycin is excreted in the urine and in the bile. At least 60 to 80 per cent of the streptomycin injected may be recovered in the urine within 24 hours.

For intrathecal injection a single injection of 25 to 50 mg every 24 hours is usually adequate.

Streptomycin may be used locally by inhalation in solution in infections of the ear or the conjunctivae or in the pleural or peritoneal cavity.

The reactions to streptomycin are discussed under Side Reactions to Antibacterial Agents.

In short streptomycin and dihydrostreptomycin are the antibiotics of choice in the treatment of tuberculosis, tularemia, and gram negative bacillary infections sensitive to the antibiotic. Other infections listed in Table 8 also respond.

**The Tetracyclines** Tetracycline, Oxytetracycline, Chlortetracycline—These three antibiotics can be considered together because tetracycline is essentially the basic chemical structure for oxytetracycline and for chlortetracycline. All three are equal in their biologic activity; all three are useful in the same infections and cross resistance of organisms is common. The incidence of side reactions may differ from one agent to another, but nausea, vomiting, and diarrhea may be observed with any one of them.

Tetracycline diffuses into the cerebrospinal fluid in greater amounts than the other two, but it has no demonstrable effects on the central nervous system in that it is not antispasmodic or anticonvulsant and it is not a sedative.

The tetracyclines are classified as broad spectrum antibiotics because of their range of activity. They are bacteriostatic in their action and do not kill microorganisms directly unless the ratio of the concentration of antibiotic to the initial number of bacterial cells is very high. All three agents are more histotoxic than penicillin or streptomycin. These agents, when used alone or in combination with other agents, are highly effective and play a most important role in supplementing penicillin and streptomycin in the war against infections.

concentration in the plasma. The combination is usually 100 000 units of the crystalline salt and 300 000 units of procaine penicillin per milliliter.

**PROCAINE PENICILLIN IN ALUMINUM MONOSTEARATE**—Procaine penicillin G suspended in oil and aluminum monostearate is absorbed more slowly and uniformly than procaine penicillin G alone. When this preparation is used the maximum penicillin levels are lower than when other preparations are injected but the plasma concentrations persist for a longer period of time. The usual amount injected is 300 000 to 600 000 units or more and under these circumstances penicillin may be found in the plasma for 3 to 5 days.

**AQUEOUS SOLUBLE PENICILLIN**—The sodium and potassium salts of penicillin G for injection in aqueous solution are used widely in all acute infections susceptible to its action. They are absorbed rapidly so that maximum plasma concentrations develop within 15 to 30 minutes after injection and then depending upon the dosage employed disappear within a period of 3 to 6 hours.

Aqueous soluble penicillin can be given intramuscularly intravenously intrathecally or into the serous cavities, depending upon the need and the site of infection. Dosage schedules are planned so that the maximum therapeutic effect is obtained in the shortest period of time.

The dosage schedules have varied widely and often 300 000 to 500 000 units or more of aqueous penicillin are injected every 3 to 6 hours, depending upon the severity of the infection.

Penicillin G is often used as an inhalant in chronic pulmonary infections and it is incorporated into troches for its local effect in the mouth and throat. Finally it is combined with various ointment bases for local application to the skin or conjunctivae.

In short a wide variety of dosage forms of penicillin are available for selection and application. The reactions to penicillin vary with individuals and with previous experience with the agent. These are discussed under Side Reactions to Antibacterial Agents.

**Streptomycin and Dihydrostreptomycin**—Streptomycin and dihydrostreptomycin are used most widely for the treatment of tuberculosis. Usually they are combined in equal amounts in order to reduce the incidence of neurotoxicity of the eighth cranial nerve and as a rule they are administered with isonicotinic acid hydrazide and/or para aminosalicylic acid in order to delay the emergence of resistant strains of tubercle bacilli.

**MODES OF ADMINISTRATION**—These antibiotics are administered intramuscularly topically and orally. The oral route is used only when a local effect in the intestinal flora is desired but this route is not used for the treatment of systemic infections because very little is absorbed from the gastrointestinal tract. For all systemic infections in which these antibiotics are used the intramuscular route is employed. For the management of meningitis, both the intramuscular and intrathecal route are employed. In empyema direct injection into the pleural cavity is desirable.

**CLINICAL INDICATIONS**—Streptomycin or dihydrostreptomycin is the antibiotic of choice in the treatment of tuberculosis, tularemia, *Hemophilus influenzae* infections—especially meningitis, urinary tract infections due to gram negative bacilli and all forms of bacterial meningitis due to gram negative microorganisms. When it is

good evidence that chloramphenicol diffuses into the tissues and is excreted in the bile and the urine. Small amounts appear in the cerebrospinal fluid. Most of the drug administered by mouth is recovered from the urine within 24 hours although most of it is in an inactive form of the drug. Enough of the active drug appears in the urine, however, to render it bacteriostatic to susceptible organisms.

Chloramphenicol is active against gram positive as well as gram negative organisms but its main effect is upon gram negative bacteria. It resembles streptomycin in its bacterial spectrum but it is very much less active against the tubercle bacillus. The action against the typhoid bacillus and the rickettsial organisms is striking. Some activity is present against psittacosis, lymphogranuloma venereum and Newcastle virus when its potency is tested in vitro.

**CLINICAL USES**—Chloramphenicol has been highly effective in the management of a variety of medical and surgical infections due to staphylococci. The most striking results have been observed in the treatment of typhoid fever, the rickettsial diseases, brucellosis, urinary tract infections and penicillin resistant staphylococcal infections. Also, favorable results have been observed in some cases of primary atypical pneumonia and *H. influenzae* infections. (Table 10)

*Table 10 Diseases in Which Chloramphenicol Is the Drug of Choice*

**Toxicity**—In general it can be said that chloramphenicol is well tolerated and produces few side effects. Hypersensitivity of the serum sickness type has not been reported. Abdominal cramps, vasomotor reactions such as coolness of the skin and weakness of the legs have been recorded.

The most undesirable side effect of chloramphenicol has been the development of some form of blood dyscrasia in a few patients. Leukopenia, agranulocytosis, thrombopenic purpura, and aplastic anemia have been reported. Prolonged treatment and repeated courses of treatment are predisposing factors.

However, blood disorders have been reported after a few days of treatment in occasional patients. One of the rules of administration should be that the patient is followed closely and the blood should be examined repeatedly for any significant change. Discontinuing treatment at the first sign of leukopenia is usually followed by recovery.

**Bacitracin**—This antibiotic is derived from a strain of *Bacillus subtilis*. It is a polypeptide and has the same general bacterial spectrum as penicillin. It can be administered locally or parenterally and it is used in cases of penicillin insensitive infections, especially staphylococcal infections of wounds of the meninges and of the endocardium. It is most frequently used topically in various forms of ointment. It is soluble in water or physiologic salt solution and when given intramuscularly it is dissolved in 2 per cent procaine solution in physiologic saline in order to decrease the local pain at the site of injection.

*Table 9 Diseases in Which the Tetracyclines Are the Antibacterial Agents of Choice*

All mixed bacterial infections due to susceptible organisms
Wound infections
Respiratory infections
Peritonitis
•
•
•
due to sensitive organisms
Rickettsial diseases psittacosis and lymphogranuloma venereum
Primary atypical pneumonia
Brucellosis

**MODE OF ADMINISTRATION**—The tetracyclines are usually given by mouth. They are absorbed from the gastrointestinal tract, and the plasma concentrations reach their peak within 2 to 4 hours. When 1 Gm. is given at intervals of every 4 to 6 hours, the plasma concentrations remain within a predictable range of 5 to 20 mcg. per milliliter of plasma.

They are excreted in the urine, and after a single dose they may be detected in the urine from 1 to 24 hours later.

Solutions are available for intravenous administration or for topical application.

**CLINICAL USES**—These agents have very wide use and application in a wide variety of bacterial and rickettsial diseases. They are used in all cases of bacterial infection when a patient is sensitive to penicillin or when the organisms are resistant to other antibiotics. They are also used widely and extensively as a temporary cover for the treatment of infections until the bacteriologic diagnosis can be established or when it is impossible to establish such a diagnosis.

As a rule, then, the most logical use of the broad spectrum antibiotics is in the treatment of gram negative bacillary infections and the rickettsial diseases and of all gram positive infections resistant to penicillin and in the treatment of all patients with sensitive bacterial infections who are hypersensitive to other antibiotics. The diseases in which the tetracyclines are most useful are listed in Table 9 and the side reactions are discussed in the section devoted to reactions.

[Two new forms of tetracycline N (pyrrolidinomethyl) tetracycline (Syntetrin) which is said to be 2,500 times as soluble as the older forms and demethylchlorotetracycline (Declomycin) have just been introduced. Although they may well have special merits, there has been insufficient experience with them for an opinion at this time. Ed.]

**Chloramphenicol (Chloromycetin)**—This antibiotic is produced by either chemical synthesis or fermentation. Originally it was derived from fermentation using *Streptomyces* as the mold. It contains a nitro group and a dichloroacetic acid residue with nonionic chloride. It was the first broad spectrum antibiotic to be isolated as well as to be synthesized.

**MODE OF ADMINISTRATION**—Chloramphenicol is a crystalline agent which is usually given by mouth. It is absorbed rapidly from the enteric tract, and the maximum plasma concentration following a single dose is reached within 2 hours. It gradually decreases over a period of 8 hours and none of the drug is found after 24 hours. Plasma concentrations are related to dosage and to time. There is

the agent must be discontinued if the injury is appreciable. In many cases the drug has been lifesaving and renal injury has been minimal or absent.

**Cycloserine (Seromycin)**—This antibiotic has been used most widely for the treatment of tuberculosis although it has had therapeutic trials in other infections as well. When it is employed in tuberculosis it is generally combined with isoniazid. Both agents are active and useful in treatment of streptomycin resistant tuberculosis. Cycloserine has very little therapeutic effect or application in other bacterial infections and its use should be reserved for patients with tuberculosis resistant to streptomycin and other antituberculostatic drugs.

**Carbomycin (Magnamycin)**—This antibiotic is produced from *Streptomyces halstedii*. It consists of two biologically active components which are equally effective against microorganisms but have somewhat different pharmacologic properties in that one component is absorbed from the gastrointestinal tract more rapidly than the other. Carbomycin also has been isolated from a strain of *Streptomyces hydropiscus*.

**BACTERIAL SPECTRUM**—Carbomycin is a narrow spectrum antibiotic with a bacterial spectrum resembling erythromycin that is it is most active against gram positive organisms but demonstrates little activity against gram negative organisms. It has some activity against rickettsiae and psittacosis. Organisms become resistant to it slowly and in the fashion of penicillin resistance. There is no cross resistance with other antibiotics except erythromycin. Erythromycin is more active and more potent than carbomycin but there is cross resistance between the two. They have similar empirical chemical formulae and similar absorption and excretion patterns.

Inasmuch as carbomycin and erythromycin are identical in most respects although they are not chemically the same the one may be used for the same indications as the other. (See Erythromycin.)

**Erythromycin**—This is an antibiotic elaborated from *Streptomyces erythreus* and it is produced in crystalline form from its basic compound. It is relatively insoluble in water (2 mg per milliliter) but highly soluble in alcohol and in organic solvents.

Erythromycin is active in a slightly alkaline medium and is not affected by substances which are known to inhibit penicillin, streptomycin or the sulfonamides. It has a moderately broad spectrum of activity but gram positive organisms including *Staphylococcus aureus* are highly sensitive to erythromycin. Group A hemolytic streptococci and pneumococci are most sensitive and *Escherichia coli*, *Proteus* and *Pseudomonas* are all quite resistant.

**MODE OF ADMINISTRATION**—The usual mode of administration is by mouth since it is readily absorbed from the intestinal tract. The plasma concentration can be correlated with the dosage, and peak concentrations are reached within 1 to 2 hours after each dose and decline rapidly so that the agent is no longer detected after 4 to 6 hours. Only small amounts are formed in the urine. The usual dosage is 250 to 500 mg every 6 hours.

**CLINICAL USE**—Erythromycin is most valuable in the treatment of diseases due to penicillin resistant *Staphylococcus aureus* infections and in the management of pneumococcal and hemolytic streptococcal infections in people who are hypersensitive to penicillin. It is not the drug of choice for the treatment of these in

Bacitracin is absorbed very slowly from the gastrointestinal tract so that very little reaches the tissues when it is given by this route. Intestinal bacteria including *Clostridia* and gram-positive organisms such as staphylococci and enterococci are inhibited in their growth when it is given by mouth.

Following intramuscular injection, this antibiotic appears in the blood and tissues but very little diffuses into the cerebrospinal fluid. It is excreted slowly, mainly by the kidneys, but, in contrast to penicillin, the plasma concentrations may continue elevated for several hours following a single injection.

Table 11 Uses of Narrow Spectrum Antibiotics

Bacitracin	Used locally for treatment of wounds and superficial infections of the skin and to reduce bacterial flora of gastrointestinal tract Used systemically for treatment of resistant staphylococcal infections Incidence of hypersensitivity is low and bacterial resistance develops very slowly	
Erythromycin		
Neomycin	reduce the bacterial flora of the gastrointestinal tract Used systemically in treatment of staphylococcal infections resistant to other antibiotics	
Polymyxin B		1050
Oleandomycin		
Triacetyloleandomycin		in
Novobiocin		Also Pro
Spiramycin		
Viomycin	Used in treatment of cases of streptomycin resistant tuberculosis used combined with INH	
Cycloserine	Used in treatment of streptomycin resistant tuberculosis, usually combined with INH	
Isonicotinic Hydrazide (INH)	Used in combination with PAS or streptomycin or dihydrostreptomycin in treatment of tuberculosis	
Para amino Salicylic Acid (PAS)	Used with streptomycin or dihydrostreptomycin or with INH in the treatment of tuberculosis	
Pyrazinamide	Used only for treatment of tuberculosis	
Kanamycin	Used only for treatment of other antibiotic resistant staphylococcal infections urinary tract infections	
Vancomycin	Effective against staphylococcus intravenous route only	

**CLINICAL APPLICATION**—Bacitracin has been used most widely and most successfully in the topical therapy of wound infections caused by *Staphylococcus aureus* and other gram positive bacteria particularly those microorganisms which are insensitive to other antibiotics. This antibiotic should be used locally for the treatment of all penicillin-insensitive infections of wounds and systemically for penicillin-resistant staphylococcal infections including meningitis and endocarditis. The intramuscular dose is 15,000 to 20,000 units given 4 times a day.

**Toxicity**—A limiting factor in the systemic or parenteral use of bacitracin is the risk of renal damage. This is a variable manifestation but one that must be considered. It is the one area which must be watched for signs of toxicity and

In view of the high incidence of toxicity neomycin is not an antibiotic with a high priority and it should not be selected as the first drug to be employed in any systemic infection

When it is used the oral dosage is 2 Gm every 6 hours and the parenteral dosage is 0.5 Gm every 6 hours

**Polymyxin B (Aerosporin)**—This antibiotic is derived from the micro organism *Bacillus polymyxin*. It is a polypeptide and its main effect is against gram negative bacilli. So far it is one of the most powerful antibiotics against these organisms although strains of *Proteus* are highly resistant

Polymyxin is not absorbed from the gastrointestinal tract but it eliminates sensitive organisms from the bowel when given by mouth. When it is administered parenterally the intramuscular route is used and the total daily dose should not exceed 0.2 to 0.5 Gm. The time interval between doses is 8 to 12 hours.

Following parenteral injection the antibiotic is absorbed but disappears rapidly from the plasma. It does not diffuse into the bile or cerebrospinal fluid and it cannot be detected in the urine in biologically active form.

**Toxicity**—A limiting factor in the use of polymyxin is its nephrotoxicity and its effects upon the nervous system. In a certain number of patients beginning on the fourth or fifth day proteinuria or oliguria with or without nitrogen retention may appear. The incidence of renal damage varies with the preparation with dosage and with the individual.

The signs of nephrotoxicity are those of paresthesias or numbness about the muzzle area. The signs are temporary and usually disappear promptly with the withdrawal of the antibiotic.

The most striking clinical results have been obtained in *Pseudomonas aeruginosa* infections especially bacteremia and in meningitis. In the case of meningitis the antibiotic is given intrathecally in small dosages.

In *Pseudomonas* infections of the urinary tract with systemic symptoms polymyxin should be used with the understanding of its toxicity.

**Oleandomycin (Matromycin)**—This antibiotic is derived from *Streptomyces antibioticus* and has been used most extensively in combination with tetracycline (Sivomycin) for the treatment of penicillin resistant staphylococcal infections. Oleandomycin is most active against gram positive bacteria but it has some effect against *Neisseria*, *Hemophilus* and *Brucella*. Also mycobacteria rickettsiae and some of the large viruses are inhibited slightly by its action. It is active against staphylococci that are resistant to other antibiotics but resistance develops with increasing concentrations of the antibiotic. It has been used successfully in the treatment of staphylococcal infections including enterocolitis and in bacterial pneumonias in children. Likewise it has been effective in the treatment of gonorrhea soft tissue infections and donovanosis.

It is given by mouth and the side effects are infrequent. Absorption from the gastrointestinal tract is prompt and plasma concentrations of the antibiotic capable of inhibiting the growth of sensitive bacteria can be obtained with doses of 300 to 500 mg given in divided doses 3 to 4 times a day.

The parenteral use of oleandomycin is under experimental study in staphylococcal infections.

fections if patients can take penicillin without reaction since penicillin is more active.

One of the interesting features of the agent is the rapidity with which resistant strains of staphylococci emerge after exposure to erythromycin either in vitro or in the management of patients. There is some experimental evidence to indicate that the emergence of resistant strains may be delayed or diminished when organisms are exposed to mixtures of either penicillin or streptomycin, realizing of course, that the original organisms are sensitive to both antibiotics at the start. In any event, when erythromycin is given optimum doses should be employed for a short time and precautions taken against cross infection.

This antibiotic is well tolerated and there are few if any side effects. The evidence of hypersensitivity is exceedingly low.

**Fumagillin**—This antibiotic was first isolated as an antiphage agent from *Aspergillus* sp. numbered H3. It was capable of inhibiting *Staphylococcus aureus* 209 bacteriophage but has no antiviral activity in vivo against viruses of poliomyelitis or influenza. It has little or no activity against bacteria or fungi but it has been useful in the treatment of amebiasis in asymptomatic and mildly symptomatic patients. It is the first antibiotic having a direct effect in *Entamoeba histolytica* and in many cases it has been of considerable merit in the treatment of intestinal amebiasis. It is poorly absorbed from the intestine and has a low index of toxicity. It is given orally in gelatin capsules and dosage schedules vary from 5 m. daily for 5 days to 50 mg. daily in divided doses for 7 days.

Signs of toxicity have been anorexia, nausea and vomiting, abdominal pain, drowsiness, diarrhea, vascular exanthems with desquamation and neutropenia.

**Kanamycin (Kantrex)**—This antibiotic has been under clinical trial for the treatment of staphylococcal infections which are resistant to other antibiotics. It is also being studied for the treatment of tuberculosis and urinary tract infections. It resembles neomycin in its bacterial activity but it is less toxic. It is readily absorbed when given by mouth and it may be given intramuscularly when necessary. [Ototoxicity has recently been reported. Fd.]

**Neomycin**—Neomycin is a powerful bactericidal antibiotic with a broad spectrum. It is active against a wide variety of gram positive and gram negative bacteria, but because of its toxicity it has a limited application. It can be administered orally or parenterally or used locally in superficial wounds. Absorption from the intestinal tract is poor. This is one of the reasons that it is given orally for its local effect in reducing the bacterial flora of the intestinal tract prior to surgical operations on the large bowel as well as for nonspecific forms of diarrhea. When neomycin is given by mouth in amounts of 2 Gm. every 6 hours, the plasma concentration is only about one eighth as high as that which follows the intramuscular injection of only 0.5 Gm. every 6 hours.

The two signs of toxicity are renal injury and damage to the eighth cranial nerve. The infections which have responded most often are *Proteus vulgaris* infections of the urinary tract or of wounds, penicillin resistant staphylococcal infections and other antibiotic insensitive infections. It has been used most widely as an agent to reduce the bacterial flora of the intestinal tract and in nonspecific diarrhea.



*vitro*, and it shows no cross resistance with any other useful antibiotic. The development of resistant strains of staphylococci under treatment has not been observed.

Vancomycin is poorly absorbed from the intestinal tract and it is too irritating to be used intramuscularly; therefore it must be given intravenously for systemic infections. Following oral use gram positive organisms are eliminated from the stools, but the gram negative organisms continue to thrive. After intravenous doses of 500 mg, effective plasma concentrations of the drug can be maintained for 12 hours; therefore 2 daily doses are usually adequate. The drug diffuses well into the tissues and high concentrations appear in the urine.

The most favorable results have been reported in staphylococcal infections and in enterococcal endocarditis.

Side effects have included chills, fever, skin rashes and phlebitis at the site of injection. Granular casts have been observed in the urine during treatment but renal insufficiency has not been observed.

**Viomycin**—This antibiotic has limited use for the treatment of tuberculosis. It can be employed in patients who have become resistant to streptomycin and isoniazid. It is generally agreed that it is less potent than other agents and should not be used in patients who have a streptomycin INH sensitive infection. However, as a second or third line of defense it can be a useful agent in the treatment of relapsing tuberculosis due to organisms which are resistant to the more popular antibacterial drugs.

The recommended dosage is 2 Gm injected intramuscularly every third day, preferably in combination with isoniazid or P.A.S. It should not be given as a companion with streptomycin because both drugs have an effect on the eighth cranial nerve and an additive toxic effect may occur.

Intermittent therapy reduces the hazards of allergy and of eighth cranial nerve damage. Also the disturbances in the plasma electrolytes that were reported are less frequent.

## THIOL SULFONAMIDES

The sulfonamides are exceedingly valuable agents in the treatment of a wide variety of infections and they have a wide application. By careful selection of the proper sulfonamide many infections can be controlled.

The limiting factors in the use of the sulfonamides are their side effects and the availability of antibiotics which in most infections are more active and effective. The three most widely used and useful sulfonamides are sulfadiazine, sulfamerazine and sulfisoxazole (Gantrisin).

All the sulfonamides can be given by mouth and with the exception of sulfaguanidine, sulfathalidine and succinylsulfathiazole, they are absorbed rapidly from the gastrointestinal tract. Plasma concentrations of 5 to 10 mg per milliliter are usually adequate for the management of most infections.

The two side effects which are most important are skin rashes with fever and renal lesions leading to oliguria and anemia. The various side effects are discussed in the section on Side Reactions.

[Recent studies have indicated that oleandomycin is relatively impotent and that in the form in which it is generally used a mixture with tetracycline (Sig mamycin), most if not all the therapeutic effects are produced by the tetracycline. More recently, however, triactyloleandomycin has been promoted and apparently used with more effect. Ed.]

**Novobiocin (Cathomycin, Albamycin)**—Novobiocin is produced from *Streptomyces spheroides*. It is characterized as a potent narrow spectrum bactericidal antibiotic which is most active against staphylococci, including those resistant to other antibiotics, and against some strains of *Proteus vulgaris* and *Streptococcus faecalis*. It is more active against gram positive bacteria than gram negative organisms but is less potent than other antibiotics.

It is usually given by mouth in capsule form in doses of 1 to 2 Gm a day. It is well tolerated and causes very few side effects. About 5 per cent of patients become sensitized to novobiocin when it is given for a period of 7 days or longer, the main features being fever and a skin eruption.

Novobiocin is often combined with penicillin in order to broaden the spectrum of activity since novobiocin is effective against some organisms that are not susceptible to the action of penicillin alone.

Following oral administration novobiocin is absorbed promptly from the gastrointestinal tract and it is excreted slowly over a period of 24 hours. Adequate plasma concentrations of the drug can be obtained with doses of 250 mg given 4 times daily.

Novobiocin is a useful agent for the treatment of staphylococcal infections, some cases of *Proteus vulgaris* infections and enterococcal infections. It is effective in other gram positive infections but less potent than other antibiotics.

**Ristocetin (Spontin)**—This antibiotic is active against Gram positive bacteria and particularly against staphylococci. When compared with vancomycin it is somewhat less active on a weight for weight basis. Staphylococci develop resistance to ristocetin very slowly and it shows no cross resistance with other antibiotics.

It is not absorbed from the gastrointestinal tract and it is too irritating to be given intramuscularly. The intravenous route must be used for the treatment of systemic infections. It has been effective in the treatment of pneumococcal, enterococcal and staphylococcal infections. In general the agent is well tolerated except for local irritation at the site of injection. Daily doses of 2 to 4 Gm or more in 2 to 4 injections are usually required in severe staphylococcal infections.

The drawbacks to the use of this antibiotic aside from the local irritating effects have been serious hematologic complications in some cases. It is well then to reserve this antibiotic for the treatment of serious and life threatening staphylococcal infections in which other antibiotics have failed.

**Spiromycin**—This is an antibiotic with a narrow bacterial spectrum and resembles novobiocin and erythromycin in its scope of activity. Only a relatively small number of patients have been treated with it in the United States and it is not generally available.

**Vancomycin (Vancocin)**—This is a bactericidal drug most effective against the staphylococci which are almost universally susceptible. Resistance of staphylococci develops very slowly and with difficulty from exposures to vancomycin in

Streptomycin and dihydrostreptomycin have been discussed elsewhere. The other useful drugs in the treatment of tuberculosis are presented here.

**Para Aminosalicic Acid, Sodium Para-Aminosalicic Acid**—While this drug may be used alone for the treatment of tuberculosis, it is practically always used as a companion of streptomycin. This agent interferes with the oxygen metabolism of the tubercle bacillus and is bacteriostatic against bovine and human strains as well as BCG. This effect can be demonstrated *in vitro* and *in vivo*.

When used alone, tubercle bacilli become resistant to it after several months. When used in combination with streptomycin, there is a delay in the appearance of resistance to each of the two drugs. So, for practical purposes when it is used, it is combined with streptomycin or with isoniazid.

PAS has two limiting factors—the gastrointestinal irritation and allergic reactions. Also, in order to obtain an optimal effect, it is necessary to give between 12 and 20 Gm a day.

**DOSAGE**—The minimum effective dose of PAS is 8 Gm a day. However, wide clinical experience has shown that the best results are obtained with doses ranging from 16 to 20 Gm a day. If the sodium salt is used in patients who tolerate this salt better than PAS, then a dose 25 per cent greater should be used.

The drug is given in divided doses, 4 times a day, usually with or after meals. In this way it is better tolerated.

The gastrointestinal symptoms are those of irritation and manifest themselves as anorexia, heartburn, and soft stools.

Allergic reactions are shown by skin eruptions, fever, and occasionally localized pulmonary edema with eosinophilia.

At present, PAS is usually combined with isoniazid rather than streptomycin. It is agreed, however, that isoniazid as a companion of streptomycin is superior.

#### Isoniazid and Related Compounds—

**ISONIAZID (ISONICOTINIC ACID HYDRAZIDE, INH)**—This agent is a potent tuberculostatic agent which is similar to streptomycin. It has the added advantage that it can be taken by mouth. It is absorbed readily and diffuses into the cerebrospinal fluid in therapeutic concentrations. It is therefore of great importance in the treatment of miliary tuberculosis and meningitis.

It has the disadvantage when it is given alone that tubercle bacilli become resistant to it in the same way as to streptomycin, but when it is combined with streptomycin the emergence of resistant strains is greatly delayed and the therapeutic action of the combination is sustained for a long period of time. Dosage schedules vary from 3 to 5 mg per kilogram of body weight to as much as 10 mg per kilogram when meningitis is present.

In high doses, convulsions may be observed. Toxic psychoses and peripheral neuritis and leukopenia have been reported, but especially when very high doses have been given.

**IPRONIAZID (ISOPROPYL ISONICOTINIC ACID HYDRAZIDE)**—This drug was used before isoniazid. The therapeutic effects of the two agents are similar, and there is cross resistance to the two drugs.

It is rarely used today because of its toxicity. It tends to produce toxic psychoses and disturbing and harassing withdrawal symptoms. The difference in

### Choice of Sulfonamides.—

**SULFADIAZINE AND SULFAMERAZINE** —These are the two sulfonamides of choice for the treatment of all cases of meningococcic meningitis meningococcic sepsis, and bacillary dysentery

**SULFAPYRIDINE** —Since dermatitis herpetiformis may be controlled by sulfa pyridine it should be used in all cases

**SULFAQUANIDINE** —This sulfonamide is highly effective in the treatment of some types of bacillary dysentery and in reducing the bacterial flora of the intestinal tract of patients who are being prepared for surgical procedures on the large intestine Other sulfonamides such as succinylsulfathiazole and sulfathalidine are equally effective for the same type of surgical procedure

**SULFISOXAZOLE (GANTRISIN** — This sulfonamide is widely used for the treatment of urinary tract infections because it is more soluble than either sulfadiazine or sulfamerazine It is readily absorbed from the gastrointestinal tract and is distributed in body water and does not enter cells It is acetylated to about 30 or 35 per cent but the acetylated form is more soluble in water than the other absorbable sulfonamides In view of the fact that it does not diffuse into cells the plasma concentration of Gantrisin is about three times that of other sulfonamides when equal amounts are given

**SULFAMETHOXYPYRIDAZINE (KYNEX MIDICEL)** —This sulfonamide is well absorbed and slowly excreted The blood levels become high after a single oral dose and when as little as 0.5 Gm is given every 12 hours there is a tendency to accumulate during a period of 7 days and there is very little fluctuation between doses It is well tolerated and usually no untoward effects are encountered although very recently accounts of serious adverse effects have been reported This agent may be most useful in the management of urinary tract infections and when prolonged treatment or prophylaxis is required

[There is insufficient evidence based on carefully controlled clinical experience to make a statement regarding the special merits if any of sulfadimethoxine (Madribon Madriqid) Ed]

**SUMMARY** —In short the sulfonamides are most useful in the control of meningococcic and Shigella infections and in all urinary tract infections due to Gram negative bacteria Further they are exceedingly valuable in reducing the bacterial flora of the intestinal tract in preparation for surgical operations

### TUBERCULOSTATIC DRUGS

There are available at present a number of tuberculostatic drugs which are highly effective for the treatment of tuberculosis Certainly, the physician is in a stronger position today when he is faced with the problem of treatment of tuberculosis than at any time in the past When he combines the best methods of the past with the new advances in chemotherapy and surgery as indicated, the patient benefits enormously

In general it can be said that tuberculosis is treated with a combination of drugs This is done for several reasons to reduce toxicity, to delay the emergence of resistant strains of tubercle bacilli and to achieve additive effects

systemic infections Experience with nitrofurans in urinary tract infections and elsewhere are discussed in appropriate chapters of this book Ed ]

## SIDE REACTIONS TO ANTIBACTERIAL AGENTS

**Toxicity, General Comments**—In the choice of any antibacterial agent it is necessary to be familiar with the toxic and harmful side effects which may be encountered The margin between toxic concentrations and therapeutic effects varies from one agent to another and in some instances it is very narrow indeed

When possible, these toxic and harmful side effects should be avoided at all costs because they may add an additional burden to the patient, especially to the resistance of an infant or an elderly person or to a person with a depression of resistance due to complicating diseases

**Superinfection**—One of the hazards of antibacterial therapy is the risk of superinfection by insensitive or resistant microorganisms This problem has been studied extensively by Weinstein and many others Briefly stated, the situation is as follows Following the use of antibacterial agents there is a profound alteration and disturbance of the normal bacterial equilibrium Some organisms are suppressed while others overgrow and predominate In many patients this alteration in the bacterial flora is unattended by any illness or signs of a superinfection, but any disturbance in equilibrium may cause serious illness in small infants, in elderly people, or in debilitated individuals

It is particularly noticeable that following the use of the broad spectrum antibiotics there is a suppression of the growth of the predominant natural flora of the respiratory and gastrointestinal tract There soon appears a group of organisms which are insensitive to treatment, namely, *Pseudomonas pyocyanea*, *Proteus* Can dida These organisms are usually of very low virulence in the presence of normal host resistance, but they can be invasive and cause serious illness in infants and debilitated individuals

Weinstein found that superinfection was most often encountered in children under 3 years of age who had received one of the broad spectrum antibiotics The organs most often involved were those usually affected by the primary infection and the organisms responsible for the superinfection were more difficult to treat following the use of broad spectrum antibiotics than following the use of the narrow spectrum bactericidal antibiotics The common sites for reinfection were the respiratory tract, the middle ear, and the intestinal tract

Superinfections tend to occur most often on the fourth to fifth day after initiation of chemotherapy, they are often more protracted than the initial infection and are occasionally fatal

Alexander has directed attention to the fact that the rising incidence of meningitis due to *Proteus* and *Ps pyocyanea* is a consequence of the use of broad spectrum antibiotics

Forms of superinfection or hazardous side effects of antibiotic therapy, usually of the broad spectrum variety, are staphylococcus enterocolitis, monilial colitis, and pseudomembranous enterocolitis

It is well established that following the use of antibiotics, usually the broad spectrum ones, diarrhea may be a striking and troublesome feature In some,

the toxicity between the two drugs may be due not only to the difference in the chemical formula but also to the difference in the rate of absorption and the higher plasma concentrations that are observed when iproniazid is administered

**PYRAZINAMIDE**—This drug is pyrazine carboxamide and is a derivative of nicotinic acid. Organisms become resistant to it at about the same rate as to INH. Also, INH is more effective and less toxic. One of the undesirable side effects is jaundice. The dosage schedule is 2.8 Gm a day usually given in 700 mg doses, 4 times a day.

**The Sulfones**—The sulfones have been used widely in the treatment of leprosy. Basically, all of these compounds are derivatives of diaminodiphenyl sulfone. They are Promin, Promizole, sulphethrone and hydroxyethyl sulfone. Promin has been studied extensively in experimental tuberculosis in guinea pigs and is highly effective. Promizole has been used widely in the treatment of milary tuberculosis in infants and children and has been found to decrease the likelihood of relapse in milary tuberculosis and tuberculous meningitis.

**Thiosemicarbazone (Amithiozone)**—This chemical is more toxic and less effective in the treatment of tuberculosis than other available agents.

**Drugs of Choice**—The drugs of choice for the treatment of tuberculosis, then may be listed as follows. The first choice is streptomycin or dihydrostreptomycin with INH. The second choice is INH and P.A.S. Then cycloserine and INH, and viomycin and INH, and pyrazinamide and INH may be used as a means of defense.

**Dosage Schedules**—A wide variety of dosage schedules are recommended for the treatment of tuberculosis, and various patterns of treatment have been studied and are still being investigated. The selection of agents, the dosage schedules, and the duration of treatment require critical judgment and careful assessment of the individual patient—to include the location of the lesion and the general condition of the patient. In the management of tuberculosis every detail must be considered and every patient assessed as a special and individual problem. The patient must be followed carefully and regularly for a lifetime. Therefore, the dosage schedules given here are presented as guide lines. It is generally agreed that neither streptomycin nor isoniazid should be used alone because of the more rapid development of resistant strains.

**STREPTOMYCIN**—The dose is 1 Gm every 2 to 3 days except in fulminating infections when 1 Gm a day should be used.

**DIHYDROSTREPTOMYCIN**—Dosage is the same as for streptomycin.

Five tenths gram of each may be used in combination instead of 1 Gm of either streptomycin or dihydrostreptomycin.

**P.A.S.**—Eight to twenty grams a day should be given in 4 divided doses. When sodium salts are used 25 per cent more drug by weight should be used.

**ISONIAZID**—The dose of INH is 3 to 5 mg per kilogram of body weight, or 150 to 300 mg a day. It is given in divided doses 2 or 3 times a day, usually by mouth. It may be injected intramuscularly when patients are unable to take it by mouth. This mode of administration may be useful in patients with meningitis.

[There has not yet been sufficient experience with tinclobisomium chloride (Triburon) and furaltadone (Altafur) for a valid opinion on their usefulness in

other sulfonamides. Local application in the form of ointments to irritated skin induces high degrees of allergy and is undesirable. In any event, when sulfonamides are used, one should be on the alert to detect reactions, especially fever and skin eruptions.

**PENICILLIN**—Penicillin is the least toxic of all the antibiotics. However, because of its widespread use the incidence of hypersensitivity or allergic reactions is increasing in frequency. Some general principles are established and can be stated as follows. The various penicillins tend to cross react in allergic patients, and the incidence of allergic reactions with various dosage forms is least when penicillin is given by mouth, greater with crystalline penicillin given by injection, greater still with procaine penicillin given by injection, and greatest of all when applied locally to inflamed skin in the form of ointments. The procaine present in procaine penicillin rarely causes any reactions.

The commonest reactions to penicillin are fever, skin rashes, urticaria, and serum sickness' syndrome, although acute shock or anaphylactic reactions may be observed if penicillin is accidentally injected into a vein in an allergic patient. An infrequent reaction is a polyarthritides.

One may observe eosinophilia without other signs of hypersensitivity, and when penicillin is used locally in the mouth, dryness and soreness of the tongue are often a complaint. Black tongue is an occasional feature.

Convulsions and coma may be observed following the injection of penicillin intrathecally, and if this route of administration is used, not more than 5,000 to 15,000 units should be injected in a 24 hour period.

[The utility of penicillinase (Neutrapen) in the treatment of penicillin reactions has not yet been established. Ed.]

**STREPTOMYCIN**—There are two common reactions following streptomycin—hypersensitive reactions and neurologic complications such as vertigo, tinnitus, and deafness. The hypersensitive reactions are not serious, but they tend to be relatively frequent, perhaps because streptomycin is used for treatment of tuberculosis and is given for protracted periods of time.

The three symptoms referable to the eighth cranial nerve following streptomycin are tinnitus, vertigo and deafness. They are infrequent now that the dosage of streptomycin and the frequency of its administration for the treatment of tuberculosis have been decreased. The symptoms may be mild or severe. They may be transitory and disappear with discontinuing the antibiotic. Occasionally the labyrinthine disturbance and the deafness are permanent.

**THE TETRACYCLINES**—These antibiotics are usually well tolerated and the incidence of hypersensitive reactions is low, the common symptoms being fever and skin rashes. Inasmuch as these agents are closely related chemically, they probably cross react in allergic patients.

The chief side effects of these agents are nausea, vomiting, diarrhea, and epigastric distress. Some patients complain of a metallic taste in the mouth and lose the sense of smell. Pruritus of the anus or scrotum and vaginitis may be most troublesome and annoying.

The most troublesome side effect is diarrhea which may be due to one of several factors. First, the direct irritative effect of the antibiotic on the intestinal

*Micrococcus pyogenes* is cultured in pure culture, in others no micrococci are found. The problem is a complex one because antibiotic resistant strains of *M. pyogenes* may be present, along with the normal intestinal flora, and produce no symptoms. On the other hand, when they occur in large numbers or in pure culture, they may be associated with the systemic reactions and the diarrhea that has been so clearly described by Finland. Micrococcic enteritis is a reversible disease and often can be treated adequately with erythromycin, novobiocin, or neomycin.

Pseudomembranous enteritis or enterocolitis is a more serious disease and may exist with or without *M. pyogenes* in the intestine and with or without previous antibiotic therapy. The relation between *M. pyogenes* and pseudomembranous enteritis or enterocolitis remains unclear. When *M. pyogenes* is present in the stools of these patients, then suppression may be followed by improvement. This subject has been studied and reviewed by Finland, Deany, and others.

**Allergy and Other Reactions**—One of the common problems concerned with the use of antibacterial agents is the undesirable side reactions which may follow. They vary with the drug used and with the individual. It is necessary to be familiar with the types of reaction that may occur so that they may be recognized and treated. Allergic reactions to drugs have been discussed briefly but clearly in a paper by Lowell in which he has made many practical points.

The subject is a broad one and there are many gaps in our knowledge concerning the various reactions which are observed. Lowell has summarized the types of reactions into allergic, probably allergic, and possibly or doubtfully allergic. They are listed in Table 12.

Table 12 List of Allergic or Possibly Allergic Reactions to Drugs\*

(A) Allergic	(B) Probably Allergic	(C) Possibly or Doubtfully Allergic
1 Rash usually maculopapular but variable and often associated with fever	1 Fever alone	1 Leucopenia
2 Urticaria and angioneurotic edema	2 Purpura (often not thrombocytopenic)	2 Anemia
3 "Serum disease" syndrome	3 Granulocytopenia	3 Nephritis or nephrosis
4 Exfoliative dermatitis	4 Necrotizing angitis (including polyarteritis)	4 Hepatitis
5 Eosinophilia	5 Syndrome simulating disseminated lupus erythematosus	5 Aplastic anemia
6 Acute allergic or "anaphylactic" shock, asthma and urticaria, in combination or singly		6 Acute hemolytic anemia
		7 Peripheral neuritis
		8 Fibrinous pneumonia

\*From Lowell: Allergic Reactions to Drugs. *The Practitioner* 178: 673, 1957.

The various reactions to antibacterial agents will be summarized here.

**THE SULFONAMIDES**—The sulfonamides tend to produce reactions in a moderate number of patients who receive them. The commonest types of reaction are fever and a skin eruption. The skin eruption is usually maculopapular in type but other skin reactions such as urticaria, angioneurotic edema, and exfoliative dermatitis may occur. Serum sickness syndrome, purpura, granulocytopenia, necrotizing angitis, anemia, nephrosis, and hepatitis are seen less often.

It is generally acknowledged that sulfathiazole, or all sulfonamides that are hydrolyzed to sulfathiazole, cause rashes and other reactions more often than the



other sulfonamides. Local application in the form of ointments to irritated skin induces high degrees of allergy and is undesirable. In any event, when sulfonamides are used one should be on the alert to detect reactions, especially fever and skin eruptions.

**PENICILLIN**—Penicillin is the least toxic of all the antibiotics. However, because of its widespread use the incidence of hypersensitivity or allergic reactions is increasing in frequency. Some general principles are established and can be stated as follows. The various penicillins tend to cross react in allergic patients, and the incidence of allergic reactions with various dosage forms is least when penicillin is given by mouth, greater with crystalline penicillin given by injection, greater still with procaine penicillin given by injection, and greatest of all when applied locally to inflamed skin in the form of ointments. The procaine present in procaine penicillin rarely causes any reactions.

The commonest reactions to penicillin are fever, skin rashes, urticaria, and serum sickness syndrome, although acute shock or anaphylactic reactions may be observed if penicillin is accidentally injected into a vein in an allergic patient. An infrequent reaction is a polyarthritus.

One may observe eosinophilia without other signs of hypersensitivity, and when penicillin is used locally in the mouth dryness and soreness of the tongue are often a complaint. Black tongue is an occasional feature.

Convulsions and coma may be observed following the injection of penicillin intrathecally, and if this route of administration is used, not more than 5,000 to 15,000 units should be injected in a 24 hour period.

[The utility of penicillinase (Neutrapen) in the treatment of penicillin reactions has not yet been established. Ed.]

**STREPTOMYCIN**—There are two common reactions following streptomycin—hypersensitive reactions and neurologic complications such as vertigo, tinnitus and deafness. The hypersensitive reactions are not serious but they tend to be relatively frequent, perhaps because streptomycin is used for treatment of tuberculosis and is given for protracted periods of time.

The three symptoms referable to the eighth cranial nerve following streptomycin are tinnitus, vertigo and deafness. They are infrequent now that the dosage of streptomycin and the frequency of its administration for the treatment of tuberculosis have been decreased. The symptoms may be mild or severe. They may be transitory and disappear with discontinuing the antibiotic. Occasionally the labyrinthine disturbance and the deafness are permanent.

**THE TETRACYCLINES**—These antibiotics are usually well tolerated and the incidence of hypersensitive reactions is low, the common symptoms being fever and skin rashes. Inasmuch as these agents are closely related chemically, they probably cross react in allergic patients.

The chief side effects of these agents are nausea, vomiting, diarrhea and epigastric distress. Some patients complain of a metallic taste in the mouth and lose the sense of smell. Pruritus of the anus or scrotum and vaginitis may be most troublesome and annoying.

The most troublesome side effect is diarrhea which may be due to one of several factors. First, the direct irritative effect of the antibiotic on the intestinal

mucosa second a change in the bacterial flora with a superinfection with tetracycline resistant staphylococci and/or moniliasis and finally a severe form of diarrhea caused by pseudomembranous colitis which may appear independent of antibiotic therapy but which is seen today most often in patients who have received antibiotic therapy

It is desirable in every case to establish the cause of diarrhea in order to institute proper treatment. When diarrhea is caused by the direct action of the drug the dosage schedule has usually been greater than 1 Gm. a day, and therefore the reduction of the total dosage or discontinuance of the antibiotic is an effective measure of control.

When staphylococcic diarrhea is present the stools commonly contain a pure culture of staphylococci which are resistant to the antibiotic that is being used. The superinfection may be controlled by stopping the antibiotic and by giving either novobiocin or erythromycin.

When the monilia predominate nystatin should be used.

**GILORAMPHENICOL.**—This antibiotic is well tolerated and the incidence of reactions is low. Skin rashes and fever have been reported. Lower abdominal cramps and discomfort, nausea, vomiting and diarrhea occur in occasional patients.

Because of the occasional occurrence of aplastic anemia or agranulocytosis which may be fatal there has been a tendency to use this drug less than other antibiotics. When it is used the patient should be followed carefully and leukocyte and erythrocyte counts done regularly.

**BACITRACIN.**—The chief problem in using this antibiotic is the occurrence of renal insufficiency. Albuminuria and nitrogen retention may occur. Other side effects are infrequent although skin eruptions, tinnitus, nausea and vomiting and occasional disturbances in taste are noticeable.

**CARBOXYMycin AND ERYTHROMycin.** These two antibiotics are closely related in their action against bacteria and often show cross resistance. They are well tolerated and the incidence of reactions is very low. Occasional skin rashes have been recorded. Otherwise few if any side reactions have been noted.

**NEOMycin.** The one drawback to using this antibiotic systemically is the high incidence of side effects. It is well tolerated when used locally or when given by mouth because very little is absorbed.

The side effects recorded have been renal irritation with proteinuria and cylindruria, renal insufficiency, dizziness and tinnitus, numbness of the hands and feet or face and low grade fever.

**NOVOBIOCIN.**—The side reactions of novobiocin are limited to skin rashes although rare cases of leukopenia have been recorded.

**NYSTATIN.**—This agent is usually combined with one of the tetracyclines and given by mouth. Side effects are few and those which are recorded consist of flatulence, nausea, diarrhea and diaphoresis. Systemic reactions are not recorded.

**OLEANDOMycin.**—This antibiotic is well tolerated and is used most often in combination with tetracycline (Sigmamycin). It is given by mouth and readily absorbed from the gastrointestinal tract. Apparently triacetyloleandomycin is to be preferred.

**POLYMYXIN B (AEROSPORIN)**—The side effects of polymyxin B consist of renal irritation with albuminuria, cylindruria and nitrogen retention, fever, vertigo, and paresthesia of the fifth cranial nerve, especially around the mouth

**SPIROMYCIN**—The side effects of this agent are minimal and are usually mild gastrointestinal symptoms

**TRIACETYLOLEANDOMYCIN**—It may be that this agent accomplishes what was hoped for with oleandomycin. Much more experience is needed. [Ed.]

**VANCOMYCIN**—Very few toxic reactions have been reported, but not many patients have been treated

**VIOMYCIN**—This antituberculostatic agent causes eighth cranial nerve lesions and allergic manifestations. Vestibular disturbances and impaired hearing may result from prolonged use

**CYCLOSERINE (SEROMYCIN)**—This antibiotic is used for the treatment of tuberculosis and is usually combined with isoniazid. The significant side effects are referable to the nervous system. Personality changes, convulsions, and hyperreflexia are the features observed. These irritative phenomena are related to the total dosage, the plasma concentration, and the pre-existing convulsive tendencies and/or personality disorders of the patient. They appear most often when the dosage has been more than 1 Gm per day, and they are more frequent when the entire dose is given at one time rather than being divided.

When it is combined with isoniazid, it should be recalled that this agent alone may cause signs of central nervous system stimulation. Doses of 0.5 Gm of cycloserine divided in two doses and isoniazid in dosage of 4 mg per kilogram of body weight may be utilized without signs of drug toxicity.

**PARA AMINOSALICYLIC ACID—PAS**—The two most important side effects following the use of PAS are gastrointestinal symptoms and the development of hypersensitivity in some patients. Anorexia, indigestion, and loose stools are the common gastrointestinal complaints, and skin rashes and fever the common allergic features.

**ISONICOTINIC HYDRAZIDE—INH**—When large doses are used, symptoms of central nervous system irritation may be observed. Hyperreflexia and convulsions may occur in high dosage.

## SELECTED REFERENCES

- Bunn, P. A., Canarile, L., and Eastman, G. Pharmacologic Properties of Various Antimicrobial Agents With Particular Reference to Common Dosage Scheduling, New York J Med 55 3607, 1955
- Dowling, H. F. Mixtures of Antibiotics J A M A 164 44, 1957
- Finland, M. Antimicrobial Treatment for Viral and Related Infections New England J Med 247 417 1952
- "Endocarditis J A M A 166 364 1958
- M. Cross Resistance to Antibiotics in or Erythromycin in Vitro Proc Soc Abinations, New England J Med 256
- lococci, South M J 49 1173 1950
- Antibiotics on the in Vitro Emergence of Staphylococcus Resistant to Novobiocin, AM & CT 4 35 1957
- Lin, F., and Corbett, L. L.

mucosa second a change in the bacterial flora with a superinfection with tetracycline resistant staphylococci and or moniliasis and finally a severe form of diarrhea caused by pseudomembranous colitis which may appear independent of antibiotic therapy but which is seen today most often in patients who have received antibiotic therapy

It is desirable in every case to establish the cause of diarrhea in order to institute proper treatment. When diarrhea is caused by the direct action of the drug the dosage schedule has usually been greater than 1 Gm. a day, and therefore the reduction of the total dosage or discontinuance of the antibiotic is an effective measure of control.

When staphylococcal diarrhea is present the stools commonly contain a pure culture of staphylococci which are resistant to the antibiotic that is being used. The superinfection may be controlled by stopping the antibiotic and by giving either novobiocin or erythromycin.

When the monilia predominate nystatin should be used.

**CHLORAMPHENICOL**—This antibiotic is well tolerated and the incidence of reactions is low. Skin rashes and fever have been reported. Lower abdominal cramps and discomfort, nausea, vomiting, and diarrhea occur in occasional patients.

Because of the occasional occurrence of aplastic anemia or agranulocytosis which may be fatal there has been a tendency to use this drug less than other antibiotics. When it is used the patient should be followed carefully and leukocyte and erythrocyte counts done regularly.

**BACITRACIN**—The chief problem in using this antibiotic is the occurrence of renal insufficiency. Albuminuria and nitrogen retention may occur. Other side effects are infrequent although skin eruptions, tinnitus, nausea and vomiting and occasional disturbances in taste are noticeable.

**CARBOXYMycin AND ERYTHROMycin**—These two antibiotics are closely related in their action against bacteria and often show cross resistance. They are well tolerated and the incidence of reactions is very low. Occasional skin rashes have been recorded. Otherwise few if any side reactions have been noted.

**NEOMycin**—The one drawback to using this antibiotic systemically is the high incidence of side effects. It is well tolerated when used locally or when given by mouth because very little is absorbed.

The side effects recorded have been renal irritation with proteinuria and cylindruria, renal insufficiency, dizziness and tinnitus, numbness of the hands and feet or face, and low grade fever.

**NOVOBIOCIN**—The side reactions of novobiocin are limited to skin rashes although rare cases of leukopenia have been recorded.

**NYSTATIN**—This agent is usually combined with one of the tetracyclines and given by mouth. Side effects are few and those which are recorded consist of flatulence, nausea, diarrhea and diaphoresis. Systemic reactions are not recorded.

**OLEANDOMycin**—This antibiotic is well tolerated and is used most often in combination with tetracycline (Sigmamycin). It is given by mouth and readily absorbed from the gastrointestinal tract. Apparently triacetyloleandomycin is to be preferred.

## THE CHOICE OF DRUGS FOR VIRAL, SPIROCHETAL, AND RICKETTSIAL INFECTIONS

*Leighton E. Cluff, M.D.*

---

### INTRODUCTION

Several microbial diseases, such as smallpox and typhus, once played an important role in the political, military, economic, and social life of nations but have become medical oddities in many parts of the world. The decreased significance of these infections is attributable largely to improved standards of public health, associated with effective control of the dissemination of microorganisms, better methods of sanitation, elimination of vectors of disease, prophylactic immunization, and rising standards of living and education. Chemotherapeutic agents and antibiotics have had an impact upon some of these infections and have been at least partly responsible for the changed spectrum of microbial disease.

The pestilences of the past have been replaced by infections not appreciably affected by therapy, and, although a few bacterial diseases are involved, the infections resistant to drug treatment are caused largely by viruses. It is fortunate, in this respect, that many of the virus infections which are a serious threat to life, including epidemic influenza, poliomyelitis, smallpox, and rabies, are being controlled by vaccination. Although occasionally effectively prevented by immunization, the rickettsial and spirochetal infections are often vulnerable to antibiotic treatment and, therefore, successfully met. Despite these advances in prophylaxis and treatment of infection, we have yet to understand the means of preventing or treating the commonest of all human infections—the “common cold.” This is illustrative of the fact that the infections presently most difficult to deal with are those in which man is the principal natural reservoir and the disease is spread from person to person by direct contact or by the respiratory route. Interruption of the spread of infection can then be accomplished primarily by immunization, and, when this is unsuccessful, the disease may continue to occur. Treatment of an infection such as syphilis with drugs has occasionally been an effective means of preventing spread to other persons, but this has not been a uniform experience. Spread of infection becomes less serious, however, when the disease is benign or when an effective therapeutic agent is available. For example, we often encourage the transmission of common contagious diseases such as rubella, rubeola, and

- Lowell, F C Allergic Reactions to Drugs Practitioner 178 673, 1957
- MacLeod, C M Interactions of Host, Microbe and Chemotherapeutic Agent, Bull New York Acad Med 31 427, 1955
- Marshall, E A, Jr The Dosage Schedule of Chemotherapeutic Agents, Pharmacol Rev 4 83 1952
- Martí Ibanex, F The Next Half Century in Antibiotic Medicine and Its Impact on the History of the Clinical Case History, Antibiotics Annual 1955 1956, p 3
- Modell, Walter The Comparative Effectiveness and Selection of Sulfonamides and Antibiotics, Pharmacology in Medicine, ed 2, New York, 1958 McGraw Hill
- Perry, H O, and Winkelman R A Adverse Reactions to Sulfamethoxypyridazine (Synex), J A M A 169 127, 1959
- Salvaggio, J and Gonzalez, F Severe Toxic Reactions Associated With Sulfamethoxypyridazine (Synex) Ann Int. Med 51 60, 1959
- Stone, R L, Boniece, W S, and Culbertson, C G A Comparison of the in Vitro and in Vivo Effects of Erythromycin, Penicillin and Oxytetracycline Against Resistant Staphylococci Antibiotics and Chemotherapy 3 17, 1953
- Wier J A Present Status of the Treatment of Tuberculosis, J A M A 162 471, 1956
- Wynn O, Smith G N, Hobby, G L, Oginsky, E L., and Iratt, R Symposium on the Mode of Action of Antibiotics, Bact Rev 17 17, 1953

observed after institution of treatment may be unrelated to the therapy. Fig 2 illustrates an instance of Q fever where defervescence occurred without antibiotic treatment and before confirmation of the diagnosis by serologic test was possible.

Syphilis is an example of an infection frequently unassociated with significant illness during the acute primary disease but is followed by serious late complications. A few of the rickettsial infections may be relapsing in character. In an acute infection that is asymptomatic or characterized by spontaneous recovery, the danger of recrudescence or late complications may, in certain instances, demand treatment. On the other hand, if relapses and late sequelae do not present a problem, as in Q fever, treatment following spontaneous recovery is not necessary. An




Fig 2—The course of untreated Q fever in a butcher, showing rapid spontaneous defervescence

awareness of the natural history of the infection when no specific therapy is given will obviously determine to a large degree the appropriate use of drugs.

Antimicrobial drugs have limited effectiveness in the treatment of irreversible

lished, as illustrated by the failure of penicillin in the treatment of once impaired hepatic function has become evident. These facts are of importance in considering the application of antibiotics in the treatment of infection.

**A Design for the Use of Nonspecific Therapy**—Fever, shock, respiratory difficulty, cardiac failure, and other manifestations of infection are not controllable

varicella from child to child to 'get it over with,' and we may make little effort to vaccinate exposed persons to Q fever, since the disease is so susceptible to treatment with several antibiotics. These considerations condition one's expectations from newer drugs which will undoubtedly become available in the future for treating infections, particularly those due to viruses. Although drugs might be successful in treating infection, they may abort the development of effective immunity or have no particular influence upon the occurrence of disease.

Prophylactic use of antibiotics has been successful in certain instances, but the impracticality of widespread use of such a measure is clearly evident. In the rickettsial diseases, prophylactic antibiotics may only prolong the incubation period of the infection but not prevent the illness.

The broad generalizations made above in no way negate the importance of drug treatment of infectious disease. The armamentarium in antibiotics now available has saved lives and significantly reduced the seriousness of many infections, but their use has not eliminated the necessity of considering the ecologic relationships in microbial disease.

## CLINICAL APPLICATIONS

Selection of an antibiotic or other chemotherapeutic agent in the treatment of an infection is dependent upon a correct diagnosis. There is no generally effective drug that can be selected indiscriminately in the therapy of an undiagnosed infection. The microbiologic laboratory has played an important part in the diagnosis of bacterial diseases but has yet to become very useful in identification of the microorganisms responsible for viral, rickettsial, or spirochetal infections. Demonstration of *Treponema pallidum* in the primary chancre of syphilis and inclusion bodies in varicella are two of the very few examples of those instances where the microorganisms can be readily identified.

It is evident that for a specific drug to be maximally effective in the treatment of infection, it is best given early in the course of disease. This fact is such that serologic tests are of little value in directing the therapy of infection. Furthermore, the many serologic tests now available for diagnostic purposes provide a discriminating clinical impression for selection of the appropriate chemotherapeutic test. Demonstration of serum antibody, however, is frequently the only method available for finally establishing a correct diagnosis and categorizing the infection characteristics and epidemiology of disease.

Fortunately, many viral, spirochetal, and rickettsial infections have distinctive clinical and epidemiologic characteristics that facilitate their recognition. Poliomyelitis, for example, may be unrecognized when it occurs sporadically. When it occurs in an epidemic, identification of the infection is greatly facilitated. Clinical experience, interest, and a high index of suspicion are, therefore, of great importance in the diagnosis of these infections.

Evaluation of the effectiveness of a drug in the treatment of infection must include an understanding of the natural course of the infection. Many of the viral, rickettsial, and spirochetal infections are self-limited and every may occur spontaneously and rapidly. When this happens, the



pyretics When aspirin (acetylsalicylic acid) is given as an antipyretic, it should be administered at regular intervals and in doses sufficient to reduce the temperature without necessarily rendering the patient afebrile Aspirin in a dosage of 0.3 to 0.6 Gm given every 3 to 4 hours will ordinarily accomplish the desired effect The adrenal corticosteroids may reduce the fever of infection but should never be used solely for this purpose

Vascular collapse with hypotension is observed occasionally in many severe infections, and its treatment is little different from that used in other forms of nonhemorrhagic shock Although blood transfusions are not ordinarily necessary, in the rickettsial infections hypoproteinemia and electrolyte disturbance are common, and blood or plasma, as well as electrolyte infusions, has been said to be of value

Norepinephrine is a useful drug for maintenance of blood pressure in the vascular collapse associated with infection and should be given as an intravenous infusion of 5 per cent glucose and 0.85 per cent NaCl containing 4 to 8 mg norepinephrine per liter The rate of administration will be determined largely by the response of the patient's blood pressure Adrenal insufficiency is probably a rare complication of viral rickettsial and spirochetal infections, but the adrenal corticosteroids can have a beneficial influence upon the vascular collapse seen in these diseases Preparations are available for parenteral and oral administration, but in the presence of shock intravenous therapy is usually necessary Hydrocortisone may be given intravenously in an infusion of glucose and saline containing 100 mg or more of the drug Prednisone or prednisolone may be given orally in a dosage of 25 to 50 mg or more per 24 hours Combined use of corticosteroids and vasopressor agents, such as norepinephrine, may be more effective than either agent alone in controlling vascular collapse The pharmacologic action of corticosteroids in restoring normal vascular tone in the shock of infection is not known Inhibition of the injurious effect of certain microbial toxins and reduction of inflammation by the hormones may be important mechanisms, but their influence upon electrolyte metabolism and their demonstrated action upon vascular reactivity may also be responsible for correcting hypotension The place of adrenal steroids in the management of infections, however, has not yet been completely established It is of course, important to be alert to more specific causes of shock in infection particularly that attributable to myocardial or respiratory failure

Respiratory insufficiency and cyanosis can develop in several of the infections under consideration They are attributable to pneumonia and bronchitis observed in psittacosis, primary atypical pneumonia, Q fever, influenza, and varicella or they are attributable to respiratory paralysis as observed in poliomyelitis Embarrassment of pulmonary function may develop from bronchial obstruction, disturbance of alveolocapillary gas diffusion, or from weakness of the muscles of respiration Bronchial obstruction is not commonly observed in the pulmonary involvement associated with viral, spirochetal, and rickettsial infections unless bronchial asthma develops or there is secondary bacterial infection Bronchodilators such as aminophylline or epinephrine may be effective in alleviating bronchial obstruction, but the inhalation of moisture laden air (steam) is particularly useful in facilitating the removal of thick bronchial secretions and relieving cough in tracheitis, as may

entirely by specific antibiotic therapy. It is, therefore, necessary in considering the treatment of choice in infection to employ drugs of value in the management of these manifestations or complications. Many of the symptomatic remedies are discussed separately elsewhere and will not be considered.

Fever is a constant occurrence in most viral, rickettsial, and spirochetal infections but is rarely of sufficient magnitude to require the use of antipyretics. Artificial reduction of fever, however, may be desirable in the patient who could be




Fig. 3—Abrupt, severe, and transient hypothermia in a patient with miliary tuberculosis following a single oral dose of aspirin.

adversely affected by high temperature. Administration of antipyretics to febrile patients may be followed occasionally by an abrupt fall in temperature producing transient hypothermia (Fig. 3). Their intermittent use, therefore, can result in a hectic febrile course leading to repeated chills and exhaustion. Sporadic use of antipyretics is undesirable, not only because of the possible production of chills and hypothermia but also because changes in the febrile pattern may eliminate a most important criterion of diagnosis and prognosis.

Salicylates, particularly aspirin, are most frequently used for control of fever in infection, although the adrenal corticosteroids also have been in vogue as anti-

prove incomplete or inadequate. Relapse of infection or failure to prevent the occurrence of disease after administration of a bacteriostatic antibiotic has been observed in rickettsial infections and is illustrative of the inadequacy of such treatment. Unfortunately, however, reliance must be placed at present upon rickettsiostatic drugs for the specific therapy of these infections, since no rickettsiocidal antibiotic is available. Penicillin has little, if any, action upon rickettsiae but is of value in treatment of many of the spirochetal infections.




Fig 4—The effect of hydrocortisone upon the fever in a patient with mumps orchitis associated with prompt alleviation of testicular pain

**Prophylaxis**—Antibiotics have been used excessively in the prophylaxis or prevention of infection. Their administration for this purpose, however, is circumscribed and is indicated and effective only in specific instances. The rapidly accumulating evidence illustrates clearly the inadvisability of the indiscriminate use of antibiotics for prophylaxis.

Penicillin will prevent the development of syphilis in the exposed person, but if the dosage of the drug is inadequate the infection may be aborted but not eliminated. Ordinarily 1 to 2 million units of procaine or benzathine penicillin G will protect against the development of syphilis, but the exposed person must be followed closely with serologic tests during the 6 months after contact with the infected subject. Whether or not the administration of tetracycline or penicillin will prevent the development of psittacosis or lymphopathia venereum after exposure is not known, and the influence of prophylactic antibiotics upon other spirochetal infections has not been assessed.

be observed in varicella and influenza. Tachypnea and cyanosis attributable to alveolar involvement are occasionally seen in primary atypical pneumonia, influenza pneumonia, varicella and other virus and rickettsial infections. Oxygen, of course, is a useful adjunctive treatment in patients with these infections, but will not aid in the resolution of the disease process. Adrenal corticosteroids have been useful agents in some instances of diffuse pulmonary infection without apparent harm. It has been suggested, however, that varicella developing in the person receiving adrenal steroids may be very severe. The beneficial effect of cortisone upon the pneumonia due to viral and rickettsial infections, however, has not yet been conclusively demonstrated. Maintenance of the respiratory toilet and use of the artificial respirator are of primary importance in relieving the disturbed pulmonary function associated with poliomyelitis.

The adrenal corticosteroids undoubtedly have a nonspecific but important place in the management of many infections. The potentially deleterious influence of these hormones in microbial diseases has been repeatedly stressed, however, and their eventual role in treatment has yet to be defined. There can be no question about the use of adrenal steroids in the presence of adrenocortical insufficiency, but the hormone dosage required to significantly change the course of an infection far exceeds that used for replacement therapy. In those infections for which effective specific antimicrobial drugs are available, cortisone has been found to be a useful therapeutic adjunct in relieving the symptoms of infection and in ameliorating complications. When no specific antimicrobial agent is available, however, the possible adverse effects of steroids upon the infection must be weighed against the beneficial influence of the hormones upon symptoms or complications of the disease.

Mumps orchitis can frequently be dramatically relieved with corticosteroids. Initiation of cortisone treatment is followed by prompt defervescence and alleviation of testicular pain (Fig. 4). Interstitial keratitis and eighth cranial nerve deafness developing in congenital or late syphilis do not respond to antibiotic treatment, but the administration of adrenal steroids may be accompanied by the clearing of the keratitis and the return of hearing. Similarly, the nerve deafness rarely observed in persons convalescing from influenza has improved with corticosteroid therapy. Severe fulminant hepatitis has been reported to respond favorably to cortisone treatment, but the beneficial influence of this therapy is inconstant. Other manifestations of viral, rickettsial, and spirochetal infection have been treated with corticosteroids but the effectiveness of such therapy has not been established.

**A Design for the Use of Specific Antibiotics**—Drugs which suppress microbial multiplication must be differentiated from drugs capable of killing microorganisms. Virtually all antibiotics have both bacteriostatic and bactericidal activity, but achievable therapeutic blood levels of the antibiotics commonly referred to as broad spectrums are principally bacteriostatic. Penicillin is the one drug available which can be administered in almost unlimited quantity and is usually bactericidal against those organisms it is capable of affecting. The distinction between these types of antimicrobial agents is important, since killing of the microorganism by the drug can eradicate infection independent of mechanisms of host resistance, whereas suppression of the infection may not eliminate the disease if host defenses

4 Gm a day The occurrence of serious reactions to sulfonamides, such as periarthritis nodosa, drug fever, dermatitis medicamentosa, and hematologic disorders, may eventually lead to the uniform acceptance of tetracycline as the drug of choice in this infection

The sulfonamides and tetracycline drugs are effective in the treatment of trachoma as they are in psittacosis and lymphopathia venereum The dosage of these drugs in trachoma is the same as in the latter two virus infections Tetracycline has one demonstrated superiority over sulfonamide in the treatment of this infection, namely, its greater effect in treatment of the infection by topical application as an ointment to the eye

Although reports have appeared from time to time indicating that the bacteriostatic antibiotics, such as tetracycline, are effective in shortening the illness associated with primary atypical pneumonia, herpes zoster, infectious hepatitis, and infectious mononucleosis, there is insufficient evidence to enable a recommendation of these drugs in treatment of virus infections except psittacosis, lymphopathia venereum, and trachoma There are no drugs of demonstrated value in the specific treatment of rabies, poliomyelitis, influenza, or other virus diseases Therefore, reliance must be placed upon biologicals such as antiserum and vaccines, and upon drugs for control of symptoms in these infections

The bacteriostatic antibiotics, particularly chloramphenicol but also tetracycline, are effective in treatment of the rickettsial infections, including Rocky Mountain spotted fever typhus, Q fever, and rickettsialpox The usual dosage of these drugs in adults is 3 to 4 Gm per day in 3 to 4 divided doses In children the dosage may be correspondingly reduced, depending upon the weight of the patient As a general rule 25 mg per kilogram of body weight can be administered This treatment is most effective when begun early in the course of illness when the mortality rate from the infections can be eliminated and the duration of disease shortened to about one sixth of that observed in the untreated person It is desirable that treatment be continued until the patient is symptomatically improved and the temperature has been normal for 2 or more days Relapse of infection is uncommon if specific treatment is begun early and continued long enough, but in scrub typhus recrudescence of fever may appear 5 to 8 days after discontinuing the antibiotic Reinstitution of therapy is followed again by prompt recovery Antibiotics other than chloramphenicol and tetracycline have not been demonstrated to be effective in the rickettsial infections

Many of the antibiotics have a bactericidal or bacteriostatic action upon the spirochetes responsible for syphilis, Weil's disease relapsing fever, and rat bite fever

Chloramphenicol, tetracycline, and erythromycin have a treponemicidal effect, but penicillin is generally considered the drug of choice in the treatment of syphilis The depot, or long acting penicillin preparations are most frequently used primarily because of their greater ease of administration, but also because they are known to be effective in antisyphilitic therapy

Early syphilis can be treated adequately with 4 to 6 million units of procaine penicillin given in divided daily doses over a period of 8 to 10 days Intramuscular benzathine penicillin G can be given as a single dose of 2.5 million units and has the advantage of providing effective therapy with one injection, but it is not

The ineffectiveness of prophylaxis with a rickettsiostatic antibiotic such as tetracycline in preventing the emergence of disease in volunteers exposed to *Coxiella burnetii* has been described. Although illness did not appear in the exposed persons while the drug was given, withdrawal of the antibiotic was followed by development of Q fever. The incubation period of the disease was merely prolonged. A similar example of the ineffectiveness of bacteriostatic antibiotics in preventing the occurrence of tularemia in volunteers has been described. In the latter circumstance, however, complete suppression of the infection was possible when bactericidal streptomycin was used as the prophylactic agent. It is probable that a rickettsiocidal drug would be equally effective in the prevention of Q fever.

The administration of antibiotics or sulfonamides to patients with virus infections in an attempt to prevent secondary bacterial infection has been a common practice but is usually ineffective and cannot be condoned. Antibiotics cannot prevent the development of all bacterial infections although prophylaxis directed against specific infections, such as those due to group A Streptococcus, Pneumococcus, and Shigella may be successful. The incidence of secondary infection is probably not changed, but the invading bacteria will be commonly resistant to chemotherapy in virus infections treated with prophylactic antibiotics.

Controlled studies of the use of antibiotics to prevent secondary bacterial infection in patients with measles and poliomyelitis have shown no decrease in the occurrence of bacterial complications, but the secondary infections were almost uniformly attributable to antibiotic resistant *Pseudomonas pyocyanea*, *Staphylococcus aureus*, and *Haemophilus influenzae*. Bacterial infections in patients with poliomyelitis who did not receive prophylactic antibiotics were most often attributable to antibiotic sensitive pneumococci and beta hemolytic streptococci.

When it is desirable to prevent the appearance of group A streptococcal or pneumococcal infections in patients with virus disease, particularly of the respiratory tract, small doses of procaine penicillin G (300 000 units) or oral penicillin G (600,000 units) may be given each day. This prophylactic treatment, however, must not be given with the expectation of preventing all secondary bacterial infections. Preferably, the secondary infection should be treated appropriately when and if it occurs.

**Specific Treatment**—Psittacosis, lymphopathia venereum, and trachoma are notable exceptions to the rule that virus infections are not susceptible to antibiotic therapy. Many of the available antibiotics are effective in the treatment of psittacosis including penicillin given in large doses. The tetracyclines are the preferred drugs, however, in this disease, and 2 to 4 Gm given by mouth in 4 divided doses every 24 hours will ordinarily eliminate the infection. Treatment should be continued until the patient has been afebrile for 3 to 4 days.

The acute manifestations of lymphopathia venereum usually respond to treatment with sulfonamides although resolution of the infection may not occur for 1 to 2 weeks after beginning therapy. Four grams of sulfadiazine per day, given in divided doses, is the accepted drug schedule for the disease. Other absorbable sulfonamides are probably as effective as sulfadiazine, but they have been used less frequently. Bacteriostatic antibiotics, such as tetracycline and chloramphenicol, are also effective in treatment of lymphopathia venereum, in divided doses of 2 to

The classical treatment of rat-bite fever (caused by *Spirillum minus*) is with arsenical preparations. Recent experience, however, indicates that penicillin and tetracycline may be the drugs of choice in this infection. Five million units of penicillin, or 3 to 4 Gm of tetracycline, given every day is usually effective in controlling the disease.

Relapsing fever is a relatively infrequent disease in the United States and occurs predominantly in the western part of the country. Treatment of this infection with 2 to 4 Gm of tetracycline per day is usually effective.

## GENERAL PHARMACOLOGIC CONSIDERATIONS AND THE VARIOUS DRUGS

Antibiotics have the impressive property of affecting viable cells differentially. Although toxic in therapeutic doses for susceptible microorganisms, they have little influence upon the host's tissues. This is particularly true with penicillin, as this antibiotic can be administered to man by various routes in extremely large amounts without deleterious effects. All other antibiotics and sulfonamides, however, show a narrower difference between the toxic dose for man and the toxic dose for susceptible microorganisms. These latter drugs, therefore, can be administered only in certain well defined amounts.

The microorganisms susceptible to the bacteriostatic action of sulfonamides are usually the same irrespective of the type of sulfonamide derivative tested although the potency of the various drugs may differ appreciably. Similarly, the untoward effects of treatment with sulfonamide derivatives tend to be the same, but the toxicity, solubility, and elimination of one as compared to another may be quite different. Selection of a sulfonamide as an antibacterial drug, therefore, will depend upon consideration of its antimicrobial potential and its relative toxicity and absorbability from the gastrointestinal tract. Sulfadiazine is the agent usually recommended in treatment of trachoma and lymphopathia venereum, largely because there has been a more extensive experience with this drug than with any other in treatment of these infections.

The antimicrobial action of sulfonamides is dependent upon their ability to compete with the microorganism for para aminobenzoic acid. The effect of sulfonamides is limited in the presence of pus and other tissue fluids and at low pH, and for this reason topically applied sulfonamides in trachoma have less effect than do the tetracycline drugs.

The untoward reactions to sulfonamides observed in some patients are characterized by granulocytopenia, crystalluria, hematuria, nephritis, dermatitis, and other manifestations of hypersensitivity. Granulocytopenia is the commonest reaction observed and it is important for the person receiving these drugs to be examined frequently for depression of the blood neutrophils.

Penicillin is a bactericidal and bacteriostatic antibiotic produced by certain strains of the mold *Penicillium*, but it has also been synthesized. Penicillin G (benzyl) and penicillin V (phenoxymethyl) are most active and commercially available as the potassium salt. The pharmacologic action of penicillin as an antimicrobial is determined by the drug's ability to interfere with the incorporation of a nucleotide into the cell wall, resulting in cell lysis or impairment of cell multi-

recommended for routine treatment. Oral administration is not an acceptable means of giving penicillin in the treatment of syphilis. A 6 months' follow-up examination of the patient with adequately treated early syphilis should include a serologic test. If there is no appreciable decrease in titer, retreatment is probably necessary.

Late latent syphilis detectable only by a positive serologic test, rarely results in neurosyphilis, but cardiovascular lesions and gummas may occur. Treatment of the previously untreated patient with a positive serologic test is, therefore, mandatory. The dose of penicillin and its method of administration are the same in late latent syphilis as in early syphilis, but failure of the serologic titer to return to negative does not have the same significance, and retreatment after 6 to 12 months may not be necessary.

Late syphilis, associated with gummas, cardiovascular lesions, paresis, optic atrophy, meningitis, Charcot joints, etc., should be treated with large doses of penicillin. The response to antibiotic treatment of some of these manifestations of late syphilis, however, is negligible. This is particularly the case in those situations accompanied by destructive changes without appreciable inflammatory reaction, as seen in tabes, optic atrophy, and Charcot joints. In these conditions fever therapy combined with penicillin may be desirable although not generally used at present.

One million units of procaine penicillin administered daily or given every other day, for 12 to 20 injections is the preferred treatment in late syphilis. Herxheimer reactions associated with fever, or precipitation of vascular accidents in syphilitic aortitis may appear within a few hours after beginning treatment of late syphilis. These reactions, however, are infrequent except in paresis, in which 50 per cent of the patients may temporarily show increasing agitation and confusion after the onset of therapy.

Syphilis in pregnancy should always be treated with penicillin, even if treatment had been previously given, unless the serologic test is negative. The drug should be given in the first trimester of pregnancy if possible. The infant born of a mother who has been treated for syphilis should be followed by serologic tests at 1 and 6 months of age.

Congenital syphilis in the newborn should be treated with procaine penicillin in a dosage of 200,000 units per kilogram of body weight, or approximately 15 million units, given in divided doses for 8 to 10 days. Interstitial keratitis and syphilitic hydrarthrosis respond poorly, if at all, to penicillin therapy.

The administration of penicillin or tetracycline early in the course of experimentally produced Weil's disease is effective in controlling the infection. Treatment of the naturally occurring disease in man, however, is usually of little benefit probably because recognition of the illness and onset of therapy in the human being is often deferred. Nevertheless, penicillin and tetracycline are the drugs of choice in Weil's disease. Penicillin may be given in a dose of 5 to 10 million units a day, and the tetracycline may be given in a dose of 2 to 4 Gm per day. There is no predictable response to this therapy, and treatment should be continued for the duration of the acute illness.

Leptospirosis meningitis is often a self-limited form of benign 'aseptic' or lymphocytic meningitis which does not ordinarily require specific treatment. Other forms of leptospirosis are also usually self limited infections.



The viral and rickettsial infections are associated with intracellular parasitism. Few of the antibiotics and chemotherapeutic drugs have demonstrated activity on microorganisms found within cells, and this would be expected to limit the effectiveness of these agents in treatment of viral and rickettsial diseases. However, the rapidity with which tetracycline and chloramphenicol produce recovery in psittacosis, lymphopathia venereum, trachoma, and the rickettsial infections suggests that these antibiotics may have the ability to penetrate cells and exert their antimicrobial action. Studies of the effect of chloramphenicol upon *Rickettsia tsutsugamushi* infecting cells in tissue culture supports this suggestion by illustrating a rapid disappearance of viable organisms from the cells and a reduction in infective titer.

## RATIONAL BASIS FOR NEW DRUGS

It can only be hoped that in the near future drugs such as the antibiotics will be developed for treatment of virus infections. The impact of antiviral agents, if as effective as antibacterial drugs, would significantly alter our concern about infectious diseases. The possibility that drug resistant variants of viruses, rickettsiae, and spirochetes might appear could prove as difficult as the problem currently produced by the staphylococci. It is not unlikely, however, that ways will be found to interfere with the parasitism by viruses, dependent as these organisms are upon an intracellular habitat. Means of altering the susceptibility of cells to invasion by viruses could provide the means for preventing as well as treating infection. If it becomes necessary to depend exclusively upon antiviral drugs, it is unlikely that prevention of infection will be possible, and such drugs may have little or no impact upon the incidence of infection. Methods of increasing host resistance to viral invasion will be required to control the occurrence of the common cold, grippe, and other acute respiratory infections. Acquired immunity to these commonly occurring virus infections is ordinarily of short duration and the great variety of pathogenic strains renders it almost impossible to provide much protection by the techniques of vaccination. Newer concepts for the control of virus disease will most certainly have to evolve.

The variability of host resistance to rickettsial infection, illustrated by relapsing disease in scrub typhus, and the inability to provide effective prophylaxis against Q fever with bacteriostatic antibiotics indicate the desirability of finding rickettsiocidal drugs. It is very likely that such agents will be synthesized or uncovered but it is disappointing in the several years since the discovery of penicillin that practically no other bactericidal antibiotics with low toxicity have been produced. Streptomycin and bacitracin are two of the bactericidal drugs other than penicillin, but they have limited usefulness, and their toxicity is of such magnitude as to preclude administration in large doses over long periods of time.

The inability of bactericidal drugs to affect significantly the clinical course of leptospiral infections such as Weil's disease illustrates the problem presented by microbial diseases which continue to progress after reaching a certain point even though the microorganism is eradicated. The future approach to this problem will necessitate efforts to understand and control the host's response to infection. This is partly responsible for the high level of interest in adrenal corticosteroids in

plication Penicillin is active primarily against rapidly growing microorganisms

The amount of penicillin which can be safely administered to a human being is limited more by the cation of the salt than by the drug's toxicity One million units of potassium penicillin contains about 0.2 Gm potassium, and this dose of the cation can restrict significantly the use of penicillin in the patient with renal insufficiency Nevertheless, the most frequent untoward reactions to penicillin are attributable to drug hypersensitivity, characterized by serum sickness, fever, arthralgia, and, rarely, anaphylaxis

The three tetracycline antibiotics presently used widely are oxytetracycline (Terramycin), chlortetracycline (Aureomycin), and tetracycline (Achromycin, Steclin, Panmycin, Tetracylin, etc.) These drugs are bacteriostatic and have identical antibacterial actions They are products of the molds *Streptomyces* and can be converted one into the other by chemical manipulation Selection of one drug is determined largely empirically, but also by their varying toxic effects

Tetracycline antibiotics affect a wide spectrum of bacteria, but their most impressive therapeutic effect has been demonstrated in the treatment of rickettsial infections, lymphopathia venereum, trachoma, and psittacosis Although commonly used, these antibiotics are not usually the preferred drugs in treatment of other microbial infections

The toxic effects of tetracycline are observed primarily in the gastrointestinal tract, producing diarrhea, nausea, and vomiting Rarely, more serious complications may arise, including staphylococcal or monilial enterocolitis and pneumonia These secondary infections in patients given tetracycline are believed to follow alteration of the normal bacterial flora by the drugs and replacement by antibiotic-resistant bacteria or fungi

Chloramphenicol is an antibiotic elaborated by *Streptomyces venezuelae* but is now produced commercially by chemical synthesis It is a bacteriostatic drug with about the same antibacterial spectrum as tetracycline, although it has a more impressive effect in salmonella and staphylococcal infections Chloramphenicol has been used widely in the treatment of rickettsial infections where it is considered the drug of choice

Chloramphenicol interferes with protein synthesis by the microorganism, and this action is probably responsible for its bacteriostatic effect The drug produces fewer gastrointestinal side effects, and secondary resistant bacterial infection in patients receiving chloramphenicol have been reported less frequently than with tetracycline Chloramphenicol has been responsible for a few serious toxic reactions characterized by aplastic anemia and death This complication restricted the use of the antibiotic for several years, but it is now being used more often Aplastic anemia may arise from toxic suppression of the bone marrow by excessive dosage of the drug, but it has also been observed when the antibiotic was given in small doses, which is possibly attributable to a hypersensitivity reaction

The appearance of resistant mutants among microorganisms susceptible to the antibacterial action of antibiotics has not been observed with viruses, spirochetes, and rickettsiae although it is probable that such variants might develop Therefore, development of resistant organisms does not require the elaboration needed in considering the antibiotics of choice in bacterial infection

## THE CHOICE OF DRUGS FOR STIMULATION OF MENTAL AND PHYSICAL ACTIVITY

*Robert G Heath, M D , and*

*Donald D Lathrop, M D*

---

### INTRODUCTION

This discussion will be concerned with a number of compounds that are used primarily for the purpose of stimulating mental activity, some also stimulate physical activity. An ideal stimulant drug would produce elevation of mood and feeling and enhance efficiency of thought without undesirable side effects. At present, no such ideal preparation exists. However, a number of preparations, though falling far short of this ideal goal, are employed for this purpose. The stimulant drugs most extensively used over the years fall into two main categories: the sympathomimetic amines and the piperidine derivatives. In addition, there are less frequently used and less effective central stimulants which have been evaluated over prolonged periods. Recently, the amine oxidase inhibitors have been introduced as useful central stimulants. None of these compounds is free of undesirable side effects and with all there is a real question as to their effectiveness in actually fulfilling the desired goal. In this respect, one must be very careful in evaluating their worth. The reader will note that we devote relatively little space to some new drugs which are being widely advertised. In the interest of safety, a certain amount of conservatism is indicated. Although experience with the new 'anti-depressant' drugs is somewhat limited, there is sufficient evidence to warrant caution in prescribing any of the avalanche of these new drugs.

### CLINICAL APPLICATIONS

Stimulant drugs are employed in the treatment of a large number of clinical disorders. Their principal, positive clinical effect is to ward off fatigue through inducing a state of wakefulness. They also frequently induce euphoria. Complications can and do result from this response and, in addition, undesirable physiologic side effects sometimes can occur. In no instance can their effect be considered curative. The degree of symptomatic improvement which they induce is greater in the treatment of some disorders than of others. Their use is purely empiric and their effectiveness in all conditions is unpredictable. The clinical

the treatment of infection. These drugs have the capacity for altering inflammation, metabolism, and other responses to microbial invasion, even though they exert no influence upon the microorganism. Further understanding of the mode of action of these hormones in infection may provide the means of controlling disease, and the antibiotics can then be used selectively for eradication of the causative microbes.

## SELECTED REFERENCES

- Beerman, H., Schamberg, I. L., Nicholas, L., and Greenberg, M. S. Syphilis. Review of the Recent Literature. *A M A Arch Int Med* 101:952, 1958.
- Bozeman, F. M., Hopps, H. E., Danauskas, J. X., Jackson, L. B., and Smadel, J. E. Study on the Growth of *Rickettsiae*. I. A Tissue Culture System for Quantitative Estima-
- Carter, A.
- Finland, M. Management of Acute Respiratory Infections and Influenza, *New England J Med* 247:557, 1952.
- Jawetz, E. Problems of Antimicrobial Therapy, *Ann Rev Med* 5:1, 1954.
- Kass, E. H., and Finland, M. Adrenocortical Hormones in the Management of Infection, *Ann Rev Med* 8:1, 1957.
- Klatskin, G. Leptospirosis, *Yale J Biol & Med* 27:243, 1955.
- McCrumb, F. R., Jr., Snyder, M. J., and Woodward, T. E. Studies on Human Infection With *Pasteurella Tularensis*. The Prophylaxis of Clinical Disease.
- Meyer, K. F., and Eddle, B. Chemotherapy of Tetra-cyclone, *Chlc Chemother* 5:289, 1955.
- Petersdorf, R. G., and Bennett, I. L., Jr. Treatment of Mumps Orchitis With Adrenal Hormones. Report of 23 Cases With Note on Hepatic Involvement in Mumps, 99:222, 1957.
- Smadel, J. E., Adair, C. V., and Gauld, R. L. Aseptic meningitis, a Disease of Diverse Etiology. *Int Med* 99:675, 1953.
- Smadel, J. E., Leon, J. E. Chemo-cyclin in the Treatment of Patients. *Med* 68:12, 1948.
- Tigeritt, W. D., and Woodward, T. E. Tr A Am Physicians 69:98, 1956.
- Med 43:287, 1955.
- Bacterial Complications of Measles, 99:222, 1957.
- ms Occurring During Chemotherapy 99:222, 1957.
- ing Factors, *New England J Med* 251:247, 1954.
- Woodward, T. E., and Wisseman, C. L. Chloromycetin (Chloramphenicol), Antibiotic Monographs, No. 8, New York, 1958, Medical Encyclopedia, Inc.

for themselves. It is in this group that the stimulant drugs are especially contra indicated. The consumption of sympathomimetic amines or amine oxidase inhibitors for prolonged periods will sometimes precipitate decompensating overt psychotic symptoms in this group. Patients with true psychotic depression do not obtain the desired amelioration in their mood disorder from the stimulating drugs. Rather, these drugs tend to produce increased agitation in this group. Marsilid in some instances is an exception in this regard although it too, usually fails to induce improvement in psychotic depression. A small number of cases have been reported in which a dramatic decrease in psychotic depressive symptoms occurs following its administration.

**The Neuroses**—Stimulant drugs are widely used in treating a number of the symptoms of neurotic patients. Since their principal desirable effect is to increase productiveness through delaying onset of awareness of fatigue, these drugs produce the greatest symptomatic improvement in those patients whose predominant psychological pattern of adaptation is such that they must perform and please in order to feel secure. The groups who gain the most symptomatic benefit are, therefore, the classical obsessive and the neurotic or reactive depressive patients.

These over all diagnostic categories in themselves are quite broad and the establishment of a classic diagnosis is not sufficient indication for treatment with stimulant drugs. Before prescribing the stimulant drugs for a neurotic patient, the physician should be somewhat familiar with the patient's psychodynamics or patterns of adapting to life situations. Reactive depressions, for example, occur for a number of reasons. Most normal individuals will react to the death of a person they love very much with normal grief presenting symptoms resembling depression. Stimulant drugs would be ineffective in such a situation and their prolonged usage could produce undesirable effects. On the other hand, the insecure person who is depressed because he feels unloved and rejected unless performing at a very high level would gain relief from the increased production which these drugs could induce. One however, must always be cognizant of the fact that inefficient or neurotic patterns must ultimately be resolved through psychotherapy. The drug effects, at best, are temporary, and the pre existing faulty patterns will be present after the drug effects disappear or when tachyphylaxis develops as it does with all of these compounds. For temporary alleviation of specific neurotic symptoms Dextedrine is the drug of choice. Several relatively new drugs currently are used for treatment of mild and severe depression. These include 2 dimethylamino ethanol tartrate (Deaner), captodiamine (Suvren), orphenadrine (Disipal), mepazine (Pacatal), imipramine HCl (Tofranil), and the amine oxidase inhibitors—iproniazid (Marsilid), isocarboxazid (Marplan), nialamide (Niamid),  $\beta$  phenyl isopropyl hydrazine HCl (Catron), and phenelzine dihydrogen sulfate (Nardil). None of these compounds in the hands of the practitioner, has proved as dramatically successful and free of side effects as hoped for on the basis of enthusiastic preliminary studies. Only time and wide experience will provide us with a sober evaluation of these new compounds.

**Obesity**—Obesity is a complicated symptom and a manifestation of multiple etiological factors. Certain stimulant drugs are useful in curbing the appetite of those individuals in whom the symptom is a manifestation of a neurotic pattern. They are of no value in those patients who are obese because of an underlying

syndromes for which treatment with stimulant drugs is most widely advocated and the rationale for their use in each instance will be briefly described

**The Functional Psychoses**—The group of functional psychoses would include predominantly schizophrenia and manic depressive psychosis. Schizophrenia is not well defined and authorities in the field differ widely in their criteria for making this diagnosis. All however, would agree that the majority of patients with psychosis exclusive of those with demonstrable cellular disease would fall into this category. Differences exist in regard to the incidence of manic depressive psychosis. Some authorities include manic depressive disorders in the category of schizophrenia. There are well established clinical psychologic and physiologic data to indicate an over all impairment of physiologic and psychologic levels of awareness in psychotic patients. Virtually all manifest demonstrable retardation in motor activity as determined by clinical motor tests. There are impairment and fragmentation in their thought processes. There are disturbances in association and affectivity. The psychotics have impairment of reality testing and exhibit autism. Even more fundamentally they display an inability to integrate feelings of pleasure, and their concept of themselves in the social scheme is defective.

The nature of these symptoms is such as to suggest that a stimulant drug to enhance pleasurable feelings and produce an over all heightening in level of psychologic awareness is indicated. However all of the popular stimulant drugs have been widely employed in the treatment of psychosis without significant effect. On the contrary most of the stimulant drugs especially the sympathomimetic amines and amine oxidase inhibitors such as iproniazid have been reported to cause an exacerbation of some psychotic symptoms particularly overt schizophrenic symptoms i.e. delusions hallucinations and symptoms resulting from excitement in the manic patient. It long has been known that Sodium Amytal is of some value in causing a temporary remission of certain psychotic symptoms particularly catatonia. Its hypnotic effects however tend to limit its usefulness for this purpose. When administered in conjunction with a stimulant drug the hypnotic effects are somewhat combated without obliteration of its temporary normalizing effect. Thus there is a limited indication for the use of stimulant drugs as an adjunct to Sodium Amytal for the purpose of temporarily ameliorating psychotic symptoms in psychotic patients. When used alone however, they are of no real value and, in fact there is some evidence that they are contraindicated in the treatment of this major disorder.

There is a large group of patients considered by many authorities to be basically schizophrenic whose symptoms are not sufficiently severe to warrant their hospitalization. They have been categorized by many persons as pseudoneurotic schizophrenics. They present symptoms which resemble those of the neurotic patient but they are more disorganized than the classic neurotic patients and display fundamental symptoms of schizophrenia which are extremely difficult for the physician who is not especially trained in psychiatric diagnosis to detect. Since one of the most prominent symptoms is a persisting pleasure deficiency, the doctor is apt to be tempted to prescribe stimulant drugs which can produce euphoria for this group. Patients with this disorder, in an effort to overcome their deficiency are constantly searching for relief and are prone to prescribe the stimulant drugs

accurately evaluated. The results of these studies suggest that the effectiveness of these compounds is minimal at best. The drug of choice in the treatment of depressive reactions in the aged is *Dexedrine* in low doses. When agitation is also present the stimulant drugs combined with a sedative or tranquilizer are more effective. *Metrazol* and *pipradrol* also reportedly have been used effectively. None of these compounds has been shown to produce a specific effect, however, since there has been no statistically valid improvement in memory, orientation or general strength with any of these compounds which is over and above that noted in control patients subjected to a good ward routine.

**Alcoholism**—Stimulant drugs have been used to alleviate the psychic pain of hang over in the alcoholic. These drugs do not counteract or aid in the elimination of alcohol in the system but through their central stimulant effects do relieve some of the morning after effects. It has been reported that the drugs will help to prevent alcoholic excess in some patients. For prevention of excessive drinking they are most effective in patients who are drinking to relieve symptoms of the pain of reactive depression. The rationale for their effect in this condition has been described under *The Neuroses*. The drug of choice for reviving the unconscious drunk is *methylphenidate* administered intravenously. For hang over effects *Dexedrine* or a *chlorpromazine* *Dexedrine* combination orally is recommended. The time honored remedy of caffeine in the form of coffee is likewise of merit in combating acute alcoholic effects as well as morning after' hang over.

**Neurologic Disorders**—These compounds have proved useful as adjuncts in the treatment of a large number of neurologic disorders.

**PARKINSONISM**—*Dexedrine* and *pipradrol* have proved of value in the treatment of Parkinsonism in conjunction with the antispasmodic drugs. Their greatest usefulness is in the relief of muscular rigidity and oculogyric crisis. *Dexedrine* is the drug of choice.

**NARCOLEPSY**—The group of stimulant drugs are the only effective medication for the relief of this symptom and results are by and large quite gratifying. Quite favorable results have been reported with the use of *methylphenidate*, *Dexedrine* and recently with *pipradrol*. Unusually large doses are required—up to thirty times the usual therapeutic level. There is no way of predicting adequate dosage. Because of tachyphylaxis a gradual increase in the dosage level is usually required.

**SPASTIC DISORDERS**—*Dexedrine* is the first stimulant drug reported to be effective in the treatment of spastic disorders. Recently *pipradrol* has been reported as effective in the relief of spasmodic torticollis, blepharospasm and tics. *Dexedrine* and *pipradrol* are drugs of choice.

**EPILEPSY**—*Dexedrine* is reported to be of value in the control of petit mal seizures in some patients. The value of the stimulant drugs as adjuncts to the conventional anticonvulsant medications, however, is extremely limited, and at present they are used only on rare occasions to produce increased alertness in patients where this is indicated.

**Pharmacologic Depression**—Stimulant drugs have been used to combat acute depression due to overdosage of sedative and hypnotic drugs. More recently they have been used in combination with sedatives and tranquilizers to prevent excessive drowsiness in patients taking these medications over prolonged periods.

**metabolic disorder** The sympathomimetic amines, particularly Dexedrine and Preludin are the drugs of choice. They are effective temporarily probably because of mild peripheral physiologic effects on the smooth musculature of the alimentary tract as well as for central stimulating or psychologic reasons. The principal psychologic factor involved in overeating is a feeling of being unloved. Such feelings are derived from the patient's interpersonal relationships during childhood—usually the relationship between mother and child. These persons feel insecure in love relationships with others and are overly sensitive to rejection. In the adaptation of the child, first and closest love relationships are closely interwoven with the intake of food. In the faulty adaptive pattern of the adult, intake of food becomes a substitute for love and security. Patients with obesity problems are subject to reactive depression.

**Behavioral Problems in Children**—Although the discovery that amphetamine may sometimes produce "normalization" in both hyperactive and hypoactive children was made almost twenty years ago, there is still no adequate explanation for this effect. Nevertheless, in hyperactive and aggressively noisy children—children inclined toward antisocial acting out—as well as in quiet and withdrawn children, the stimulant drugs may exert a salubrious effect. Where withdrawal is a manifestation of schizophrenia or where acting out is a manifestation of a psychopathic personality, an unfavorable result may be expected. However, in the much larger group of children whose motor behavior is either markedly below or markedly above the norm, the stimulant drugs tend to normalize. Present data suggest that the sympathomimetic amines, either Dexedrine or amphetamine, are the drugs of choice in the management of behavioral patterns in children. However, limited data suggest that pipradrol might be equally effective.

Several reports indicate that the stimulant drugs may be of value in the symptomatic treatment of enuresis in children. Psychiatric studies have indicated consistently that bed wetting most frequently occurs when the child is in deep and usually dreamless sleep—occasionally it is associated with a simple, wishful dream, the commonest dream content being that he is at the toilet. The rationale for use of the stimulant drugs is that through prevention of deep sleep, enuresis will not occur. Since bed wetting is an emotional problem involving the parent-child relationship, the value of stimulant drugs is highly questionable. They may help temporarily in relieving the symptoms, but as in most situations, the consequences of the undesirable effects of the loss of the restorative qualities of the deep sleep must be weighed against the value of the temporary amelioration of the symptom. Pipradrol and Dexedrine are most commonly advocated as drugs of choice.

**Geriatric Problems**—Virtually all groups of stimulant drugs have been advocated as useful in the management of patients with cerebral damage resulting from age, i.e., senility and cerebral arteriosclerosis. In these patients there is actual cell damage and the rationale for the use of stimulant drugs is that they might improve the functioning of remaining cells, thereby lessening or removing compensating behavioral symptoms. Despite many rather glowing reports of the effectiveness of a number of compounds, one's optimism must be guarded. Recently, a number of excellent control studies have been reported where the effects of good ward management and the additional attention and enthusiasm on the part of the staff that surrounds the introduction of a new compound have been more



gesics such as aspirin and phenacetin. For migraine, caffeine is synergistic with ergot alkaloids. Caffeine appears to constrict cerebral blood vessels and thus reduce the cerebral blood flow. In hypertensive individuals the cerebrospinal pressure may fall somewhat. Dexedrine, also in combination with analgesics, has been found to be useful in the treatment of tension headaches. It is recommended particularly for treatment of those patients in whom there is a prominent depressive component to the underlying personality.

**Stimulants as an Adjunct in Psychiatric Interview**—The use of stimulant drugs to assist in psychiatric interview has a long and colorful history. Physicians have used drugs which alter the state of consciousness in an attempt to obtain more information both from natural and supernatural sources. In modern psychiatric practice the use of stimulant drugs is intended to facilitate release of repressed and suppressed material.

In hysterical amnesia the stimulant may result in immediate relief from amnesia, often with a very dramatic abreaction and release of tension. Stimulant drugs have the distinct advantage over the hypnotic drugs because they do not foster postinterview drug amnesia. Administration of stimulants may also be useful in the differential diagnosis of certain psychiatric disorders. In schizophrenic patients, catatonic features become more intense. Manic patients show an intensification of mania, and depressed patients with underlying agitated features become severely agitated.

The drug of choice for the purpose of psychiatric interview is methamphetamine. Where the blood pressure is not severely elevated (above 200 systolic/120 diastolic) 20 mg of the drug is given intravenously in 1 ml of solution. There may be an immediate effect characterized by marked increase in the flow of speech, intensification of underlying feelings, aggravation of delusions and hallucinations, and free verbalization of these experiences. The maximum effect is usually reached within 15 minutes and may last for 1 or 2 hours. It is often worth while to follow the use of the stimulant drug with a sedative such as Sodium Amytal (1 Gm) intravenously. Frequently, this sedative phase of the interview will bring forth additional information as the patient lapses into a more relaxed state.

It is usually not wise to use this procedure on outpatients, since severe emotional reactions may ensue. When possible, it should be done early in the day so that the large dose of stimulant will not interfere with the patient's ability to sleep. It is often worth while to prescribe a sedative at bedtime following this procedure.

Dexedrine and amphetamine may also be used for this purpose, but in our experience methamphetamine gives excellent results without severe side reactions. It is likely also that pipradrol and methylphenidate may be useful for this purpose, but they have not received adequate trial to date.

**Psychologic Reaction to Physiologic States**—The frequently encountered problems of premenstrual tension, nausea and vomiting in pregnancy, and menstrual pausal syndromes have been studied extensively from both the physiologic and emotional points of view. Regardless of one's orientation, there seems to be no reason to doubt that there is an emotional component to each of these conditions. In many persons who are predisposed to reactive depression, there is a psychological element of loss of love involved in these conditions. In the hysterical patient, the

The management of acute depression due to overdosage of sedative and hypnotic drugs is certainly controversial. There have been a large number of articles extolling the virtues of almost every conceivable kind of treatment. There is a recent report containing convincing evidence that analeptics such as Metrazol, Coramine, amphetamine, and caffeine are without value and may even increase the hazard of narcosis by causing convulsions, cardiac irregularity, and vomiting. If anoxia has been a prominent part of the patient's clinical course, analeptics are contra-indicated. Supportive management has been found to produce better results than supportive management plus analeptics in a large group of patients. In milder cases of poisoning, where anoxia has not supervened, there may be some value to giving stimulant drugs. Although they do not hasten the metabolism of the sedative, they may raise the level of consciousness sufficiently to prevent aspiration and permit the patient to attend to some of his own needs. Of course, the danger of adding vomiting and convulsions to the already overburdened central nervous system is involved inevitably. We do not recommend a drug of choice here because we feel supportive treatment is preferred management.

The use of stimulants in combination with sedatives, hypnotics, tranquilizers, antihistaminics, and anesthetics is becoming ever more popular. A large number of such preparations are available and the variety of combinations is limited only by the imagination of the pharmaceutical manufacturers. The physician who desires to individualize his treatment will find that Dexedrine or methamphetamine will serve admirably to counteract depression or drowsiness in most instances. Occasionally, as in the treatment of upper respiratory and allergic disorders, ephedrine (25 mg, 2 or 3 times daily) will be the drug of choice to serve as a stimulant.

For those who prefer proprietary preparations, we recommend selecting one that seems preferable and becoming familiar with its use rather than attempting to follow nuances of the recommendations of the manufacturers. A combination of chlorpromazine and Dexedrine (Thora Dex) which is available in two dosage forms (chlorpromazine 10 mg, Dexedrine 2 mg; chlorpromazine 25 mg, Dexedrine 5 mg) has been found most convenient in our hands when combined therapy is indicated. There have been reports of good results with combinations of chlorpromazine or reserpine with pipradrol or methylphenidate but we have found the chlorpromazine Dexedrine combination to be more convenient for general use.

**Headaches**—The vast majority of headache problems confronting the physician are of the tension type. Tension headaches are a response to intrapsychic (i.e. faulty patterns based on faulty learning) as well as extrapsychic stresses (i.e. realistic external problems). Not uncommonly, there is an element of depression involved. Furthermore, the sufferer frequently finds that tension headaches interfere with his ability to perform his regular duties, which leads to exasperation and frequently to intensification of the head pains. Likewise, in migraine headaches there is an undeniable association between the emotional state and the occurrence of attacks. The headaches associated with hypertension are due primarily to the increase in spinal fluid pressure but in some instances also to the emotional state of the individual.

The drug of choice in the symptomatic treatment of headaches of these types is caffeine. For tension headaches, it is usually given in combination with anal-

The observation that usage of drugs which increase the level of amines in the body sometimes leads to psychotic behavior is most provocative. Employment of the amphetamine preparations on rare occasions will do this. Also there are reports of overt psychotic symptoms being brought on in some patients through use of the amine oxidase inhibitor, iproniazid. With this compound it can be presumed that amine levels in the body are increased by virtue of the inhibition of the enzyme which normally would metabolize amines. These observations suggest that disturbances in amine metabolism may be an important factor in endogenous psychosis. The present stimulant drugs have their greatest worth when an extended but self limited period of wakefulness is necessary. They are also of considerable value in the treatment of narcolepsy. In both situations, the temporary sympathomimetic effect can serve a useful purpose. Allowance must be made for an adequate period of convalescence to combat the accumulative fatigue in these circumstances.

The prescribing of current popular stimulant drugs presents a great temptation to the physician. The drugs produce an immediate effect which is apt to give the physician a false feeling of gratification that he is able to work quick magic with his patients. It is necessary for the physician to be aware that these effects at best are temporary and that present drugs do not provide an adequate substitute or short cut for thorough work up and the time consuming process of gaining an understanding of his patient which is essential to resolve the basic underlying pathology.

## THE SYMPATHOMIMETIC DRUGS

**Sympathomimetic Amines**—The first major group of chemicals to be considered are the sympathomimetic amines. Of these, four are important clinically: amphetamine, dextroamphetamine, methamphetamine, and mephentermine. Although ephedrine historically is important for its central and peripheral stimulating properties it rarely is used now solely for these effects. The four derivatives listed above possess the desirable central stimulating properties of ephedrine with much less tendency to produce the undesirable peripheral stimulant effects.

Amphetamine is a racemic compound while dextroamphetamine is the dextro rotary form. The latter is about twice as potent a central stimulant as the former. Methamphetamine is a more potent cortical stimulant than amphetamine, its central action being more rapid in onset and more prolonged. It is slightly less active on the peripheral system. Mephentermine is a mild central stimulant and has a potent pressor effect. The mechanism of central stimulating action of these drugs is not known. They are known to inhibit amine oxidase and this is believed to be the basis for their sympathomimetic action.

**Amine Oxidase Inhibitors**—Because of enthusiastic early reports of the effectiveness of iproniazid as an 'antidepressant', a number of compounds in this category have been marketed recently. Since there are many and varied types of compounds which can inhibit amine oxidase it is likely that we will see even more compounds with this function appearing in the future. Efforts are directed toward finding an amine oxidase inhibitor with high antidepressant activity and low or absent toxicity. Although antidepressant compounds are classified as amine oxidase inhibitors it is a highly speculative assumption that a causal rela-

No drug has been found to be invariably effective in the treatment of these conditions. However, there is adequate rationale for the use of stimulant drugs in their management. The drugs of choice are Dexedrine, amphetamine and methamphetamine. They are most commonly used in combination with a sedative, such as amobarbital, an analgesic such as aspirin, or a tranquilizer, such as chlorpromazine. Again the physician will do well to familiarize himself with the combination of these drugs which is most appealing to him. Excellent results can be obtained with any of these compounds if they are given at the appropriate time in adequate dosages.

**PREMENSTRUAL TENSION**—For premenstrual tension it is recommended that the drug be started 1 to 2 days before the expected onset of the symptoms. Dexedrine is the drug of choice.

**NAUSEA AND VOMITING OF PREGNANCY**—In the management of nausea and vomiting of pregnancy, Dexedrine in combination with chlorpromazine is often effective. The antiemetic effect of chlorpromazine together with the antidepressant effect of Dexedrine often results in relief of this symptom. Use of combinations of chlorpromazine and pipradrol have also been reported but appear to possess no particular advantage over the chlorpromazine-Dexedrine compound.

**MENOPAUSAL SYNDROME**—Similarly in the menopausal syndrome where the symptoms are mild and especially when mild depressive symptoms predominate the use of Dexedrine, amphetamine or methamphetamine alone or in combination with sedatives and tranquilizers sometimes produces gratifying results.

## GENERAL PHARMACOLOGIC CONSIDERATIONS

The need for an ideal stimulant drug is greatest in the field of psychiatry. In the field of mental and nervous disorders the greatest single need is for a compound which will induce a basic feeling of true pleasure. On the basis of clinical observations as well as from physiologic studies a compound that fulfills this function is likely to be effective in the treatment of the psychoses. Some existing compounds including sedatives as well as stimulants do produce a type of euphoria. This however is a quite different phenomenon from the inducement of a real pleasure feeling and existing compounds are not effective in alleviating psychoses. An ideal pleasure inducing compound should be effective in alleviating emergency emotional responses such as fear and rage and logically therefore would improve an individual's rational thought processes.

The stimulant drugs which are considered in this presentation are stimulants only in rather specific areas. Most are primarily sympathomimetic and those which are preferred and most widely used possess the quality of stimulating central nervous system activity with a lesser degree of peripheral autonomic effect. Their principal central effect is to increase wakefulness which they do quite adequately. This however is not a wholly desirable effect. It results in delaying but not eliminating fatigue. Thus the letdown effects after discontinuation of the medication are quite marked because of cumulative fatigue. One cannot prolong the inevitable fatigue by continuing to take these medications since tachyphylaxis develops and the drug gradually loses its effect. Prolonged usage because of cumulative excessive fatigue will often lead to muddled inefficient thinking and poor performance.

Practically nothing is known of the mechanism of action of these drugs, and we may only speculate that since they have in common the piperidine ring this may be the pharmacologic common denominator. Pipradrol has been demonstrated to intensify electrical activity in subcortical structures.

**Pentyleneetetrazol**—This drug is a tetrazol derivative, known also as Metrazol and Cardiazol. It affects primarily the rostral brain stem but has a lesser cortical stimulant effect.

**Caffeine**—Caffeine, a member of the xanthine family, stimulates the cortex and brain stem in addition to its familiar cardiovascular effects.

## A DESIGN FOR THE USE OF DRUGS FOR STIMULATION

**Sympathomimetic Amines**—For general use, Dexedrine or methamphetamine may be started at 2.5 mg, 2 or 3 times a day. Most patients will tolerate a starting dose of 5 mg, 2 or 3 times a day. The time of administration of the drug is determined by the effects desired and by the appearance of side effects. In most cases of depression a dose should be taken on arising in the morning when depression tends to be most severe. In the same patients, a late afternoon dose may aggravate insomnia, if this occurs, a morning and noon dose only should be given. In obesity, when appetite control is desired, medication given 30 to 60 minutes before meals is most satisfactory. Sustained release preparations give the physician the greatest advantage in appetite control since the patient can take a capsule early in the morning and then forget his appetite instead of forgetting to take his medication for the remainder of the day.

If the desired effect is not obtained in 3 to 5 days at 5 mg, 3 times a day, increase one dose by 2.5 mg. Repeat this procedure until maximum benefit or intolerable side effects occur. When appetite suppression is not desired give with or after meals. If insomnia occurs, give the afternoon dose earlier or decrease it.

The dose of amphetamine required to produce equivalent central stimulation is about twice that of Dexedrine. However, the same initial regimen may be used in order to avoid undue side effects. Since all of these drugs are tachyphylactic smaller initial doses and gradual increase will produce few severe side reactions. This also will make occasional readjustment of dosage necessary.

These drugs are convenient to use because they are rapid in onset of action (15 to 30 minutes) and brief in duration of action (4 to 6 hours).

Higher doses than might be expected will be tolerated by children with behavioral disorders. The regular starting regimen outlined above for adults may be used. In narcolepsy, tremendous doses may be required ranging up to 30 times the average dose required for treatment of other conditions.

**Amine Oxidase Inhibitors**—Isocarboxazid (Marplan) like its precursor iproniazid (Marsild), may be given in a single daily dosage or divided dosage. Start Marplan at 30 mg daily and level off to 10 to 20 mg daily in 3 to 4 weeks.

Iproniazid (Marsild) should be given in a single dose. In mild depression begin with 50 mg a day and reduce to the minimum effective level as soon as possible (2 to 4 weeks on the average). In severe depression or in regressed psychosis the initial dosage is 150 mg daily until improvement occurs and then the dosage should be reduced to the minimum effective level (25 to 30 mg daily).

tionship exists between inhibition of amine oxidase and mood elevation. Such a relationship has never been clearly demonstrated and it indeed, may be a paradoxical side effect of some of these compounds which results in mood elevation in some patients. Further investigation into the mode of action of these compounds is indicated.

These drugs cause an accumulation of serotonin and norepinephrine and inhibit detoxification of various drugs by the liver (barbiturates, amphetamines and aminopyrines). Complications and side effects include psychotic reaction, orthostatic hypotension, edema, hypochromic anemia, constipation, dizziness, diaphoresis, impotence, delay in micturition, insomnia, restlessness, tremulousness, dry mouth, etc. Hepatocellular necrosis resulting in jaundice and rarely, in death, has been reported with Marsilid. This is an imposing list of complications but it is worthy of note that severe complications are relatively uncommon and usually accompany high dosage levels and prolonged administration. Unquestionably these drugs have produced some dramatic results. Before their usefulness can be finally judged, however, further evaluation is required. When they are used it must be under careful medical supervision.

Iproniazid (Marsilid), a potent amine oxidase inhibitor, causes an accumulation of serotonin and norepinephrine and inhibits detoxification of various drugs by the liver (barbiturates, amphetamines and aminopyrines). Complications and side effects include psychotic reaction, hypotension, edema, hypochromic anemia, vitamin B<sub>6</sub> deficiency syndrome, constipation, dizziness, diaphoresis and hepatocellular necrosis resulting in jaundice and rarely in death. This is an imposing list of complications, but it is worthy of note that the incidence of fatal complications is extremely rare and the others listed usually follow administration of the drug in high doses for prolonged periods. On the positive side, this drug recently has been heralded as a real pharmacologic advancement in so far as the treatment of depressive symptoms is concerned. Before its effects can be finally judged, this compound requires further evaluation and when it is employed it demands thorough familiarity and conscientious medical supervision.

Imipramine HCl—Tofranil is structurally related to the phenothiazines. It is speculated that it exerts an antidepressant effect by virtue of sensitization of central adrenergic synapses. This remains to be proved.

Side effects include orthostatic hypotension, dryness of mouth, tachycardia, constipation and occasionally visual disturbances.

As with the other new drugs, caution and close surveillance are required when this compound is employed.

Deanol—Deanol (Deaner) is believed to be a precursor to acetylcholine. It is speculated that its particular stimulant action in the central nervous system is related to the ease of penetration of deanol base across the blood brain barrier. Because of its physiologic action it is low in toxicity. Accumulated clinical evidence, however, suggests that this preparation is quite ineffective.

Piperidine Derivatives—Two chemically related compounds which have become popular recently as mental and physical stimulants are piperidine derivatives. These drugs, which have had wide clinical trial, are pipradrol (Meratran) and methylphenidate HCl (Ritalin).

dose may be increased or decreased depending upon results in the individual. Or doses of 60 to 90 mg a day are not uncommon. In fact, as with the other drug dosage may be safely increased until desired results are obtained or side effects become intolerable. When the drug is given intravenously, 0.2 mg per pound is recommended starting dose.

#### Other Drugs —

**CAFFEINE** —Caffeine is often given intramuscularly for acute conditions, 0.5 Gm being the usual dose. Oral medication is used commonly in combination with other drugs or in beverages, the average dose is 0.15 to 0.5 Gm.

**PENTYLENETETRAZOL** —Pentylenetetrazol (Metrazol, Cardiazol) when given orally is prescribed in tablets containing 0.1 or 0.2 Gm. A reasonable starting dose is 0.2 Gm, 3 times daily. When given to elderly patients, the drug may be expected not to produce significant effects in less than 90 days. However, it is often possible to increase the dose by 0.1 Gm a day after about 2 weeks if the patient does not appear ashen, tremulous, or excited. When used intravenously for activation of epileptogenic foci, a 10 per cent solution is injected slowly. Normal subjects activate, i.e., become anxious and tremulous after an average of 3.5 ml, and the epileptic patients show electroencephalographic changes at an average of 2.3 ml.

**IMIPRAMINE** —Imipramine (Tofranil) may be started intramuscularly in hospitalized patients at 100 mg daily in divided doses. This may be increased in increments of 25 mg daily up to 300 mg per day if necessary to obtain the desired response. Dosage for outpatients is 200 mg daily. Maintenance dosage varies from 50 mg to 150 mg daily.

Complications and side effects are similar to those described under amine oxidase inhibitors. Glaucoma is also a contraindication.

**DEANOL** —Deanol (Deaner) may be used for mild depressions. Begin with 50 mg daily in single dosage. Side effects include headache, constipation, overstimulation, and insomnia. These are relieved by reduction of dosage or temporary suspension of treatment. Effects are seen in 1 to 3 weeks at which time a minimum maintenance dosage of 10 to 25 mg daily may be instituted.

### RATIONAL BASIS FOR THE DEVELOPMENT OF NEW STIMULANT DRUGS

As emphasized throughout this discussion, the sympathomimetic effect as produced by presently popular stimulant drugs, is a nonspecific action in the treatment of a number of clinical entities. As evidenced by recent research, it is becoming more apparent that psychotic behavior which is numerically the greatest indication for a satisfactory stimulant is a manifestation of a faulty metabolic process. The essential requirement for a drug to meet the needs in this area is that it will satisfactorily correct the endogenous defect. This will require considerable research into the nature of the disorder. The compound that fulfills this need will be perhaps better classified as 'corrective' rather than 'stimulant'.

### SELECTED REFERENCES

Allin, T. G., Jr., and Fogge, R. C. *The Use of Azacyclonol and Pipradrol in General Practice*. Internat. Record Med. & G. P. Clin. 169: 222, 1956.

Vitamin B complex containing pyridoxine should be given simultaneously. The blood pressure should be checked frequently and the dosage reduced or the drug stopped if hypotension becomes severe. Warn patients to avoid postural hypotension. Edema can be controlled with diuretics. Watch obese patients for weight gain as this drug often stimulates appetite dramatically.

Phenelzine dihydrogen sulfate (Nardil) is started at 15 mg, 3 times a day with meals. Look for a response in 2 to 3 days, but maintain dosage until maximum response is gained, usually less than 6 weeks. Maintenance dosage should be around 15 mg.

$\beta$  Phenylisopropyl hydrazine HCl (Catron) is started at 12 mg daily in the morning for 1 to 2 weeks. When a response occurs, reduce to minimal maintenance level, about 3 mg daily.

Nialamide (Niamid) may be started at 75 mg daily in single or divided dosage. After 7 to 10 days, raise or lower the dosage depending upon response. Maintenance dosage is 12.5 to 25 mg daily.

With all of these drugs, the use of minimal maintenance dose is essential to reduce side effects. Often a regime of one half tablet on even days and a whole tablet on odd days will be sufficient.

Patients must be warned about orthostatic hypotension. If hypotension becomes severe, stop the drug. Edema can be controlled with diuretics. Obese patients must be watched for weight gain as this often accompanies administration of these medications. Serial liver function tests have been recommended but appear to be of little value since altered liver function has not correlated with the occurrence of complications. Jaundice may subside with discontinuance of the drug and has subsided with continuance of the drug. Continued drug administration in the presence of jaundice, however, is not recommended.

Contraindications to these drugs are impaired hepatic or renal function, epilepsy, and electroconvulsive therapy. They should be used with great caution with sedatives, hypnotics, narcotics, alcohol, and local and general anesthetics.

#### Piperidine Derivatives—

**PIPRADROL.**—Pipradrol (Meratran) should be started generally at 1 mg, 2 or 3 times a day. If the patient tolerates this well and the desired results are not obtained within a week, increase to 2.5 mg, 2 or 3 times a day. There are reports of initial cryptic weight loss of a few pounds as well as other side effects. Weight usually will tend to stabilize and many side effects decrease or disappear by the end of a week. Some persons are capable of tolerating higher dosage without side effects and some seemingly have a higher threshold for the effects of the medication. Therefore if dosage up to 2.5 mg, 3 times a day, does not produce satisfactory results, it is worth while before discarding this drug as ineffective to increase 2.5 mg a day each week until the desired results are obtained or undesirable side effects occur. In spastic disorders and in narcolepsy, very large doses (5 to 30 times the usual dose) may be required.

**METHYLPHENIDATE.**—Methylphenidate (Ritalin) may be given in 5, 10, or 20 mg tablets. An average oral starting dose is 10 mg, 2 or 4 times a day. Observe the patient for several days then adjust the dosage by adding 5 or 10 mg a day. Some patients will require only 5 mg, 2 or 4 times a day, and the



## THE CHOICE OF A STIMULANT TO VITAL MEDULLARY CENTERS

McKeen Cattell, Ph D, M D

---

### INTRODUCTION

The rational use of therapeutic agents for the stimulation of medullary functions *requires consideration*, not only of the limitations of the drugs presently available for clinical use, but perhaps more important, of the therapeutic effects to be expected from such symptomatic therapy. Here consideration will be limited to drugs which stimulate two medullary centers namely, the respiratory center and the vasomotor center. The choice of a drug to produce emesis, which involves another function centered in the medulla is discussed elsewhere.

### CLINICAL APPLICATIONS

Man and other warm blooded animals are endowed with effective regulatory mechanisms for respiratory and vasomotor control, two functions which are essential to life. It is important from the standpoint of achieving rational drug therapy to consider the status of these regulatory mechanisms in the clinical conditions in which the objective is to restore a failing respiration or peripheral circulation. Here we are concerned with the contribution which could reasonably be expected from drugs which stimulate the medullary centers controlling these functions.

**Respiratory Stimulants**—In general drugs which stimulate respiration under normal conditions are not effective when the center is depressed to an extent reducing external respiration below the needs of the body. This is presumably due at least in part to the fact that under such circumstances carbon dioxide, the natural stimulus to the respiratory center, accumulates in the body. Carbon dioxide is the most effective stimulant known and it is therefore not surprising that under these circumstances drugs may fail to call forth a further response. It can be shown experimentally in an animal severely depressed that respiratory stimulants produce no effect short of convulsive doses.

**Vasomotor Stimulants**—Drugs which stimulate the vasomotor center cause a rise in the blood pressure and are generally classed as circulatory stimulants. It is worth while to consider what one can hope to accomplish by the use of circulatory stimulants. Excluding those drugs which improve cardiac function we have to

- Andren, H E Treatment of Depression With Meratran and Electroshock, Dis Nerv System  
16 275, 1955
- Barrabee, P, Wingate, J H, Phillips, B D, and Greenblatt, M Effects of L Glutavite  
Compared with Metrazol and Vitamins on Aged Female Psychotic Patients, Post  
grad Med 19 485, 1956
- Bradley, C Benzedrine and Dexedrine in the Treatment of Children's Behavior Disorders,  
Pediatrics 5 24, 1950
- Cohen, S Clinical Evaluation of Ritalin, Dis Nerv System 17- 392, 1956
- Newman, H W, and Newman, E J Failure of Dexedrine and Caffeine as Practical An  
tagonists of the Depressant Effect of Ethyl Alcohol in Man, Quart J Alcohol 17  
406, 1956
- Rosner, B S, Fierman, L B, and Kramer, J F Clinical Evaluation of Meratran and Tren  
quel on a Chronic Psychotic Population, Am J Psychiat 113 993, 1957
- Rudolf, G de M The Treatment of Depression With Methylamphetamine, J Ment Sc  
102 358 1956
- Symposium on the Biochemical and Clinical Aspects of Marsilid and Other Monoamine  
Oxidase Inhibitors, J Clin & Exper Psychopath 19 (suppl to No 2) 1958
- Tennent, J J Experiences With Metrazol in Psychoses With Cerebral Arteriosclerosis,  
Psychiatric Quart 30 249, 1956

tral stimulants results from respiratory depression. The secondary respiratory depression limits the use of stimulants to acute emergencies and precludes their administration over a long period of time.

## DESIGN FOR USE OF DRUGS FOR MEDULLARY STIMULATION

In view of the pharmacologic and physiologic considerations which have been briefly reviewed in this chapter, it is apparent that *medullary stimulants* have but very limited therapeutic application.

**Artificial Respiration**—The most direct approach for the correction of an inadequate respiratory exchange is to apply artificial respiration. When this is done, the addition of carbon dioxide to the inspired air serves to maintain a high level in the blood and tissues and thus provides an effective respiratory stimulus and, in case of hyperventilation, prevents the carbon dioxide tension from falling to unphysiologic levels. This is accomplished by employing a mixture of 7 per cent  $\text{CO}_2$  and 93 per cent  $\text{O}_2$ .

**Caffeine**—Probably the most widely used and generally useful central nervous system stimulant is caffeine. In addition to its action on the higher centers it has a definite effect on the respiratory center and probably to a slight extent on the vasoconstrictor center. Whatever the cause of the central depression, if not too severe, caffeine can be expected to temporarily improve the general alertness of a depressed patient. Such symptomatic therapy cannot be regarded as lifesaving but the use of caffeine is favored by its relative freedom from side effects. However, since too vigorous treatment can readily induce a further depression the single dose of caffeine should not exceed 1 Gm, and, if it is to be repeated, the second dose should be given only after the elapse of several hours.

**Other Medullary Stimulants**—Other medullary stimulants, such as picrotoxin and pentylenetetrazol, may be useful in antagonizing the depressant effects of sedative drugs, such as the barbiturates. Specific blocking agents, such as levallorphan (Lorfan) and nalorphine (Nalline), provide the most effective treatment for respiratory depression caused by morphine and certain other opiates. These compounds are not medullary stimulants and their use is considered in Chapter 12.

At the present time we have no drugs which are employed clinically for stimulation of the vasomotor center. The same ends are accomplished when indicated by a variety of drugs which belong to the group of sympathomimetic agents and which cause constriction by a direct action on the blood vessels. These are discussed in Chapters 26 and 27 on vasoconstrictor and vasodilator drugs.

## RATIONAL BASIS FOR NEW DRUGS TO COUNTERACT DEPRESSION OF MEDULLARY FUNCTION

Since, at best, medullary stimulants cannot do more than relieve a symptom consequent to some bodily disorder or to the direct action of a toxic agent, this therapeutic approach has extremely limited applications. It is doubtful that even an ideal medullary stimulant could be expected to contribute appreciably to the therapy of respiratory or vasomotor depression. Rather, therapy should be directed toward the removal of the cause of the depression. In this direction progress is

consider only those agents which bring about a constriction of the peripheral vessels by either a direct or a central action and thus cause an increase in the arterial pressure. When the pressure falls from any cause, the sensory endings in the carotid sinus are stimulated and a reflex vasoconstriction ensues. Even in an advanced state of shock or peripheral vascular failure, this mechanism is operative. Thus the vasomotor center continues to function normally during advanced failure with very low blood pressure, at which time the arterioles are maximally constricted.

Effective stimulants of the vasoconstrictor center are not available, but even if they were it is doubtful that they would be useful under these conditions. There is the further consideration that whenever arteriolar constriction occurs the blood flow through the organ supplied is decreased. Although this results in a rise in blood pressure and an increased flow of blood to the heart and brain which may improve temporarily the apparent condition of the patient, it does so at the expense of worsening the fundamental difficulty—an inadequate supply of blood to the tissues. In other words, the blood pressure is raised at the expense of blood flow.

**SYMPATHOMIMETIC AMINES**—The physiologic considerations described above are also pertinent to the rational use of peripherally acting vasoconstrictors. It is important to note that they do not necessarily constitute a contraindication to the use of vasoconstrictor agents to combat an *acute* drop in blood pressure as, for example, that resulting from influences mediated through the central nervous system or from the blocking of the sympathetic innervation during spinal anesthesia. It has for example been shown experimentally in dogs that norepinephrine added to a dextrose saline infusion during the first hour after an otherwise fatal hemorrhage greatly increased the number of animals surviving the period and increased survival time after replacing the blood. To tide over a temporary period of low blood pressure before the advent of peripheral vascular failure a number of sympathomimetic amines are available such as phenylephrine (Neo Synephrine) and norepinephrine (levarterenol Levophed).

## GENERAL PHARMACOLOGIC CONSIDERATIONS

The actions of respiratory and vasomotor stimulants are not confined to the medulla but extend in varying degree to all parts of the central nervous system. Indeed it is probable that their value depends in part upon the general improvement which may be induced in central functions and the reflection of this stimulant effect on the medulla. Ephedrine probably acts through this mechanism.

The effectiveness of medullary stimulants is determined by the state of the centers the functions of which it is desired to improve. As indicated above, if the circulation or respiration is depressed by other than central mechanisms, little can be expected from the use of drugs. On the other hand, if the condition is a result of some toxic agent acting on the center, such as a barbiturate, and the depression is not too great, improvement may result from the use of such drugs as picrotoxin and pentylenetetrazol (Metrazol, Cardiazol).

It is well to bear in mind two unfortunate pharmacologic properties of central stimulants, which limit the amount which can be administered. In large doses they cause convulsions which must of course be avoided, and, further, initial stimulation is followed by depression. The fatal outcome from excessive doses of cen-

## THE CHOICE OF DRUGS FOR THE RELIEF OF PAIN

*John J. Bonica, M.D.*

---

### INTRODUCTION

The usual introductory remarks justifying a writing are hardly necessary in presenting a discussion on the management of pain, for reflection emphasizes that this task has been for centuries, and still remains, a difficult clinical problem which confronts every practitioner of the healing arts. In fact, the existence of pain and possibilities for its management probably constitute the most ancient reasons for the existence of the physician, for pain is as old as mankind. As the records of every race are examined, one finds testimonials to the omnipresence of pain, and as long as pain has existed there have been efforts to find means of controlling it. Its management has for all times taxed the diagnostic acumen and therapeutic skill of physicians.

The monumental achievements of medicine during the last quarter century have made possible prevention or elimination of a great deal of suffering. The great strides taken by all branches of surgery and anesthesia have made it possible to remove the cause of the pain or to interrupt its pathways in circumstances which previously precluded surgical intervention. Moreover, the development of many systemic analgesics, local and general anesthetics, and other agents has provided the physician with a huge arsenal filled with pain relieving remedies. These, together with the great progress made in psychosomatic medicine and psychiatry, physiatry, roentgen therapy, orthopedics, and all other medical services, have greatly enhanced the effectiveness of the physician's efforts in relieving pain. Yet despite these advances, the management of pain remains one of the most difficult and often vexing phases of medical practice, not only because it is the leading symptom of many diseases and therefore constitutes one of the most frequent reasons for patients seeking counsel of their physician, but also because often it is a complex and distressing problem. It is obvious, therefore, that the proper management of pain constitutes (from the patient's standpoint at least) the most important obligation, one of the main objectives, and the crowning achievement of every physician.

### THE NATURE OF PAIN

In order to understand some of the principles in managing patients with pain and the proper therapeutic application of various drugs, some insight into the

being made in the synthesis of compounds which block the action of toxic agents. A better understanding of the factors contributing to failure of nerve centers in disease would contribute to the solution of this problem.

### SELECTED REFERENCES

- Bard, Philip, editor. Medical Physiology, St. Louis, 1956, The C. V. Mosby Co.
- Dale, H. H., and Evans, C. L. Effects on the Circulation of Changes in the Carbon Dioxide Content of the Blood, *J. Physiol.* 56: 125, 1922.
- Drill, V. A., editor. Pharmacology in Medicine, New York, 1954, McGraw Hill Book Co., Inc.
- Eckenhoff, J. E., Schmidt, C. F., Driggs, R. D., and Kety, S. S. A Status Report on Analeptics. *J. A. M. A.* 139: 790, 1949.
- Gilmore, J. P. Effectiveness of Levarterenol During Hemorrhagic Hypotension, *Am. J. Physiol.* 195: 473, 1958.
- Goodman, L., and Gilman, A. Pharmacological Basis of Therapeutics, New York, 1956, Little, Brown, & Co.
- Liljestrand, H. *Acta Med. Scand.* 2: 623, 1951.
- Watts, J. Poisoning Com.

## THE CHOICE OF DRUGS FOR THE RELIEF OF PAIN

*John J. Bonica, M D*

---

### INTRODUCTION

The usual introductory remarks justifying a writing are hardly necessary in presenting a discussion on the management of pain, for reflection emphasizes that this task has been for centuries, and still remains, a difficult clinical problem which confronts every practitioner of the healing arts. In fact, the existence of pain and possibilities for its management probably constitute the most ancient reasons for the existence of the physician, for pain is as old as mankind. As the records of every race are examined, one finds testimonials to the omnipresence of pain, and as long as pain has existed there have been efforts to find means of controlling it. Its management has for all times taxed the diagnostic acumen and therapeutic skill of physicians.

The monumental achievements of medicine during the last quarter century have made possible prevention or elimination of a great deal of suffering. The great strides taken by all branches of surgery and anesthesia have made it possible to remove the cause of the pain or to interrupt its pathways in circumstances which previously precluded surgical intervention. Moreover, the development of many systemic analgesics, local and general anesthetics, and other agents has provided the physician with a huge arsenal filled with pain relieving remedies, these, together with the great progress made in psychosomatic medicine and psychiatry, physiatry, roentgen therapy, orthopedics, and all other medical services, have greatly enhanced the effectiveness of the physician's efforts in relieving pain. Yet despite these advances, the management of pain remains one of the most difficult and often vexing phases of medical practice, not only because it is the leading symptom of many diseases and therefore constitutes one of the most frequent reasons for patients' seeking counsel of their physician, but also because often it is a complex and distressing problem. It is obvious, therefore, that the proper management of pain constitutes (from the patient's standpoint at least) the most important obligation one of the main objectives, and the crowning achievement of every physician.

### THE NATURE OF PAIN

In order to understand some of the principles in managing patients with pain and the proper therapeutic application of various drugs some insight into the

nature of pain is essential. The scope of this book and limitation of space permit only mention of the most important aspects. A more detailed dissertation may be found in other books by the author and others.

Although people know what is meant by the word pain, many have great difficulty in defining it. This is so because pain is a highly personal affair entirely subjective in nature and a complex physiopsychologic phenomenon which almost defies enquiry. Aristotle considered pain as a 'qualé' or passion of the soul, a state of feeling, the antithetic experience from pleasure, and the epitome of unpleasantness, together with pleasure, these were the main normal driving forces that guided man's actions. This concept was accepted until the middle of the nineteenth century, when scientists began to consider pain as a sensation. Presently a number of authorities believe pain to be composed of two parts—the perception of pain and the reaction to pain. Perception of pain is a neurophysiologic process which has special structural, functional, and perceptual properties and is accomplished by means of relatively simple and primitive neural receptive and conductive mechanisms. It is measurable and constant, although it can be modified by drugs and psychic factors and completely obviated by interruption of its pathways by chemical (nerve block) or surgical means.

On the other hand, the reaction to pain is a complex physiopsychologic process which involves the cognitive functions of the individual. It represents the emotional and physiologic expressions resulting from the perception of pain; it is what the individual feels, thinks, and does about the pain he perceives. The pattern of reaction depends, in part, upon what sensation means to the individual in the light of his past life experience, his attitude toward it, his judgment, mood, emotional status, and will, the state of his nervous system and the various cerebral processes, the presence or absence of anxiety, and many other factors. Obviously, the reaction to pain is different for each individual, indeed, with the passing of time and the accumulation of life experience, it is never exactly the same for an individual from one time to another.

Although this artificial dichotomy of the pain experience has proved useful in studying and understanding it, it is doubtful that there is such a thing as a pure sensation of pain separate and distinct from the influence of reaction. For one thing, the processing of the psychic reaction to the original stimulus probably begins before awareness of the sensation has been achieved. There are many who firmly believe that the essential part of pain is awareness and no other sensation or experience can be termed pain unless it is felt as such. The obvious conclusion is that the "qualé" or feeling state, i.e., the patient's complaints, and his physical and mental responses are the manifestations of the reactions and are the most relevant aspect of the pain experience—certainly to the patient. This is one of the most important and fundamental facts about pain; it must be accepted with its full implications if one is to be successful in managing patients with intractable pain. The importance of the reaction or the affective component of pain from a therapeutic standpoint will be emphasized further in the discussion of the addictive analgesics, the hypnotics, and the placebo.

The origin of pain may be a stimulus in the somatic or visceral structures of the body and acting on the peripheral part of the nervous system or it may be in the central nervous system and projected to a distant part of the body, as is found



in the pain of the thalamic syndrome, in the painful aura of sensory epileptiform seizures, or in the conversion type of pain in hysteria. Here we are primarily concerned with pain of peripheral origin, because it is this type which is most frequently encountered by the practitioner and the one which is manageable with drugs.




Fig 5—A simplified schematic diagram which illustrates the three relays of nervous elements involved in the conduction of pain from the periphery to the brain. A peripheral, B connecting, and C central neurons. It should be noted that the neuron conducting pain from the viscera passes through the central nervous system in association with sympathetic fibers and will thus pass through the prevertebral and paravertebral sympathetic ganglionic chain. However, these fibers are constituents of the spinal nerves having their cell bodies in the posterior root ganglion and entering the central nervous system via the posterior root as do sensory fibers from other structures. The secondary neurons form the spinothalamic tract, which in this diagram is represented by one neuron for the sake of clarity. The central neurons take origin in the thalamus wherein they synapse with the secondary neuron and end in the cerebral cortex. (From Bonica, J. J. *Management of Pain*, Philadelphia 1953, Lea & Febiger.)

The nervous pathways for pain arising in the somatic and visceral structures may be said to be organized into three distinct units or relays: the first relay, the peripheral sensory neurons, the second relay, the connector (internuncial) neurons, and the third relay, the central sensory neurons as depicted in Fig 5.

Although pain sensation is probably also integrated in the mesencephalon and thalamus, the cortex is the highest level of such integration which results in the

nature of pain is essential. The scope of this book and limitation of space permit only mention of the most important aspects. A more detailed dissertation may be found in other books by the author and others.

Although people know what is meant by the word pain, many have great difficulty in defining it. This is so because pain is a highly personal affair entirely subjective in nature and a complex physiopsychologic phenomenon which almost defies enquiry. Aristotle considered pain as a 'quale' or passion of the soul, a state of feeling, the antithetic experience from pleasure, and the epitome of unpleasantness together with pleasure, these were the main normal driving forces that guided man's actions. This concept was accepted until the middle of the nineteenth century, when scientists began to consider pain as a sensation. Presently a number of authorities believe pain to be composed of two parts—the perception of pain and the reaction to pain. Perception of pain is a neurophysiologic process which has special structural, functional, and perceptual properties and is accomplished by means of relatively simple and primitive neural receptive and conductive mechanisms. It is measurable and constant, although it can be modified by drugs and psychic factors and completely obviated by interruption of its pathways by chemical (nerve block) or surgical means.

On the other hand, the reaction to pain is a complex physiopsychologic process which involves the cognitive functions of the individual. It represents the emotional and physiologic expressions resulting from the perception of pain, it is what the individual feels, thinks, and does about the pain he perceives. The pattern of reaction depends, in part, upon what sensation means to the individual in the light of his past life experience, his attitude toward it, his judgment, mood, emotional status, and will, the state of his nervous system and the various cerebral processes, the presence or absence of anxiety, and many other factors. Obviously, the reaction to pain is different for each individual, indeed, with the passing of time and the accumulation of life experience, it is never exactly the same for an individual from one time to another.

Although this artificial dichotomy of the pain experience has proved useful in studying and understanding it, it is doubtful that there is such a thing as a pure sensation of pain separate and distinct from the influence of reaction. For one thing, the processing of the psychic reaction to the original stimulus probably begins before awareness of the sensation has been achieved. There are many who firmly believe that the essential part of pain is awareness and no other sensation or experience can be termed pain unless it is felt as such. The obvious conclusion is that the 'quale' or feeling state, i.e., the patient's complaints, and his physical and mental responses are the manifestations of the reactions and are the most relevant aspect of the pain experience—certainly to the patient. This is one of the most important and fundamental facts about pain, it must be accepted with its full implications if one is to be successful in managing patients with intractable pain. The importance of the reaction or the affective component of pain from a therapeutic standpoint will be emphasized further in the discussion of the addictive analgesics, the hypnotics, and the placebo.

The origin of pain may be a stimulus in the somatic or visceral structures of the body and acting on the peripheral part of the nervous system, or it may be in the central nervous system and projected to a distant part of the body, as is found

or widespread disease. Moreover, the intensity of pain is not generally increased by the summation of neural impulses from noxious stimulation at different sites. Patients with long standing pain do not get accustomed to it, but rather seem to become more 'sensitive' to it and suffer more with the passing of time. Protracted pain no matter whether moderate or severe, produces physical and psychologic depletions which vary widely between individuals and may be evidence of basic personality differences.

General debility, malnutrition, fatigue, anxiety, and mental turmoil lower the reaction threshold still more so that the pain is more severe and more difficult to treat. Lack of sleep is particularly important in this respect. Patients with chronic suffering have a gradual but complete alteration in their attitude to their environment. Consequently, they have no other interest and the pain in fact becomes a consuming problem which completely dominates their lives. In such cases interruption of pain pathways with consequent complete abolition of pain perception cannot be expected to solve the problem entirely. In many instances the problem is much more complicated and necessitates a long term application of psychotherapeutic and rehabilitative measures as well.

## METHODS OF PAIN CONTROL

From what has been said, it is apparent that there is need for orientation regarding the totally functioning human being in the evaluation of such a complex phenomenon as pain. It is essential that the physician make an intelligent appraisal of the patient with pain in order to make a diagnosis of the over all disease and that he understand the underlying pain mechanisms and formulate a systematic plan for relief that will provide the best results.

From the standpoint of approaches to treatment it is desirable to differentiate that which is primarily structural, primarily physiologic, and primarily psychologic. When there is a significant psychic factor, as in many psychophysiologic disorders, or when there is pain related to personality factors but without demonstrable physiologic changes, the treatment of the psychologic problem becomes paramount. In these cases it is essential that one treat the underlying psychophysiologic condition and the fundamental methods of psychiatric management must be considered. A discussion of psychiatric technique is beyond the scope of this chapter, but the importance of this method in managing patients with severe intractable pain cannot be overemphasized. An excellent dissertation on this subject has been written by Ripley.

Now let us focus our attention on patients with pain of structural etiology and altered physiologic function without structural change. Although psychologic support is very useful in helping these patients, the main treatment is directed to the elimination of the primary disease. This may be accomplished medically by means of drugs (antibiotics, antispasmodics, spasmolytics [curare], vasodilators, vasoconstrictors, etc.), by surgical extirpation of the lesion, or by physical methods (roentgen therapy, physical therapy, etc.). In such patients with pain due to self limiting medical diseases or due to disorders which indicate surgical extirpation the solution of the pain problem is usually clear cut and relatively simple. However, in patients with protracted pain, the cause or mechanism of which cannot be

normal apperception of pain. The very complex intercommunications between the postcentral gyrus, where are concentrated the thalamocortical projections and other parts of the cortex results in an intimate functional relationship among these various parts. This relationship makes possible the mobilization of all sorts of associations based upon past experience and judgments so that the individual is able to evaluate the particular sensation. It is here that the sensation is converted into a painful experience by incredibly complex physiopsychologic mechanisms. Sensation becomes perception. Percepts are further elaborated into concepts. Concepts cluster together to form ideas and ideational constellations, and all of these events undergo mnemonic engrammatization, i.e., formation of memory traces which in part form the basis of the reaction to the sensation. Here occurs the formulation of the individual reactions to the perception or appreciation of pain. Moreover, it is here that the appreciation of the stimulus is further modified by the state of activity of other cortical centers, particularly those located in the frontal lobe, so that the appreciation is aggravated or inhibited.

### Some Characteristics of Pain

Noxious stimulation produces pain which differs in its characteristics according to the structures involved. The characteristics of pain of special interest to the clinician include quality, intensity, duration and extension. Noxious stimulation of superficial somatic structures (skin, subcutaneous tissues) produces pain which has a sharp quality, is well localized and is felt quickly. Pain induced by noxious stimuli applied to the deep soma (fascia, periosteum, tendon, subcutaneous tissue) is duller and more diffuse than cutaneous pain. Pain resulting from application of pain stimuli to viscera is usually described as a dull, aching, sickening discomfort which the patient has difficulty in localizing because it is diffuse and is not so rapidly perceived.

There are several other important characteristics of pain which must be kept in mind. Pain is rarely constant in intensity for a protracted period. The brief, severe, lancinating pain of trigeminal neuralgia is an extreme example; the pain of carcinomatosis is notoriously waxing and waning. In addition to intrinsic mechanical and chemical factors which may cause the pain to become more or less severe, environmental changes may be important. Pain is generally worse at night because the distractions and mood modifying effects of the day's activities are not present. When the patient is quiet in bed he becomes preoccupied with his condition.

There is no constant necessary or proportionate relationship between the perception of pain and the reaction to that perception. The obvious inference of great clinical importance is that the intensity of pain or amount of suffering experienced by the patient is independent of the size of the lesion. Perhaps the paramount factor in determining the intensity of pain and suffering is the significance of its source. If there is no worry or other distressing implication regarding its source, pain is comparatively well tolerated.

Another characteristic of pain is that when two or more sources of pain stimuli exist coincidentally, perception of pain is monopolized by the most intense. A point of great clinical significance when treating patients with metastatic lesions

When the decision has been made, it is important to inform the patient and, if circumstances warrant, also his family about the plan of treatment. A general outline of the procedures, the effects that may be expected, and what may be accomplished must be explained in detail.

Since persistent pain exacts a heavy price in the form of physical and mental depletions, it is most important to provide complete relief at the earliest possible date. Although the systemic analgesics are most frequently used in treating severe, intractable pain, it must be realized that they seldom completely relieve pain, but merely make it more tolerable. For this reason it is important to consider the early use of some method to interrupt pain pathways before tolerance and addiction to analgesics develop.

All patients who experience severe, chronic pain require psychologic support and moral encouragement. The first positive step in relief of intractable suffering occurs when a physician manifests his responsibility and willingness to properly discharge his obligation for the care of the patient. In addition to the benefits made possible by modern science, the physician should bring to the patient a sympathetic understanding, kindness, cheerfulness, and reassurance. Since patients are quick to sense an attitude of defeatism or lack of interest, the physician should do all he can to instill into the patient confidence and a sense of security based upon the conviction that all will be done to relieve his suffering. The general practitioner, by virtue of the proper rapport and confidence which he has cultivated in the patient, is best qualified to carry out this phase of management.

Measures to support the patient physically are also essential, not only to compensate for physiologic depletions, but also because malnourished patients do not tolerate pain as well as those in good physical condition. The diet should be high in proteins, vitamins, and calories. If anemia is present in spite of proper therapy, transfusions should be given. In addition, good hygiene and competent nursing care together with rest and sufficient sleep are necessary.

## PRINCIPLES OF THE CONTROL OF THE SEVERAL VARIETIES OF PAIN

### Neuralgias

Neuralgia is a broad descriptive term that is frequently indiscriminately employed for any pain. Its use should be restricted to the literal connotation—nerve pain—that is, pain with a segmental or peripheral nerve distribution. It is usually a symptomatic expression of an inflammatory, mechanical, circulatory, toxic, degenerative or neoplastic neuropathy, radiculopathy, or myelopathy. It may be the first and only manifestation of the pathologic process, although in many instances it is accompanied by hyperesthesia and hyperalgesia or diminution of sensations and other neurologic symptomatology, which at first may be of such minimal degree as to escape the attention of all but the most careful examiner. The chronicity of the pain and its persistence until the cause is removed make it mandatory that these cases be studied carefully and the cause ascertained and removed, if possible. Occasionally the neuralgia constitutes the entire clinical syndrome without any apparent etiologic basis or structural changes. In such instances it is necessary to direct the entire treatment to the elimination of

ascertained or eliminated, the problem is often very difficult from a therapeutic, as well as from a diagnostic, standpoint. Such cases require a well planned attack that is based upon fundamental principles which must be followed if good results are to be achieved.

In such instances the diagnosis and localization of the source of pain usually require a thorough detailed examination and a correct interpretation of medical, neurologic, radiologic and laboratory data. It becomes immediately apparent that proper management of such patients requires a great deal of time and effort, more than some practitioners are willing to spend, but unless the physician is willing to devote the necessary time to the problem, he cannot hope to achieve optimal results. In fact, he may do more harm than good.

In taking the history of the pain three phases or periods should be considered: onset, course, and present status. The location and distribution, the quality, the intensity or severity, and the duration of the first pain should be ascertained. The characteristics of the pain at the time of examination should be determined. The patient should be asked how these pains compare with those experienced at the onset and during the course of the disease. The patient should be asked what circumstances or conditions have aggravated or relieved the pain and what effect emotional disturbances, movement of the part, and other activities have had on the severity, quality, and distribution of the pain. What has been done and what drugs have been taken to relieve the pain and what have been the effects of these? What time of day is the pain least? What postures have relieved or aggravated the pain? In the event that associated sensory, motor, or autonomic disturbances are still present, these should be investigated.

After a diagnosis has been made and the mechanism of pain is determined, it is essential to map out carefully the best course of treatment, i.e., the use of procedures which are most likely to produce optimal and certain results. In determining what procedure or procedures are to be used it is necessary to consider many factors. The cause of the pain, its site, type, and mechanism, its intensity, and its probable duration must be taken into account. In addition, it is essential to consider the nature of the disease causing the pain and the age of the patient, his physical and mental status, his life expectancy, and his obligations to his family and the community. In deciding the form of treatment of pain, the methods which are locally available and practical under the circumstances must frequently be considered; however, the physician should not hesitate to recommend a form of pain control available elsewhere if it is clearly superior to the methods available locally. In case of doubt it is advisable to explain the advantages, disadvantages, and limitation of each of the methods and to let the patient and his family make the decision. In special circumstances it is necessary to consider the reactions of the family toward the problem. The physician has the obligation of selecting a method or methods most likely to produce results.

Frequently, management of the pain problem requires application of several therapeutic methods. There has been as yet relatively little clinical exploitation of a multiphasic approach to pain control by applying several well chosen combinations of therapeutic methods, each specific for certain desired effects. This is usually much more effective and far more satisfactory than alteration of the reaction with addictive analgesics.

The myofascial pain syndrome with trigger mechanisms constitutes one of the most common causes of disability of the shoulder girdle, low back, neck, and lower extremity in people over the age of 30 years. These conditions are best treated by ethyl chloride spray or infiltration of the trigger area. Nonaddictive analgesics alone or in combination with small doses of sedatives or even mild narcotic analgesics may be used in conjunction with the injection therapy and physical therapy which are necessary for cure. The same form of treatment should be employed in the management of simple sprains, fractures, tendinitis, tenosynovitis, and other minor musculoskeletal disorders. Whenever these conditions become chronic and are associated with persistent pain, the continuous use of addictive analgesics should be avoided.

### Pain Due to Peripheral Vascular Insufficiency

Peripheral circulatory insufficiency is often accompanied by pain, the severity of which depends on the degree of insufficiency and duration of its onset and mechanism of the pain. Sudden obstruction of a major artery frequently produces severe ischemic pain which requires large doses of narcotic analgesics administered intravenously or intramuscularly. A still better method of management is the use of continuous epidural block which if properly executed, not only provides complete relief of pain but also produces sympathetic interruption. The latter effect may relieve the spasm of the collateral arteries that frequently accompanies such disorders as traumatic segmentary vasospasm, embolism, thrombosis, laceration and other affections of the peripheral arterial tree.

Pain associated with such chronic vasospastic disorders as Raynaud's disease, postfrostbite syndrome, postpoliomyelitis syndrome and acrocyanosis is best managed by avoiding conditions which aggravate the spasm. In addition it may be necessary to employ nonaddictive analgesics and small doses of sedatives and tranquilizing agents in order to eliminate psychic factors which invariably aggravate the vasospasm. If these conservative measures fail to provide relief, sympathectomy should be considered. It again should be stressed that addictive analgesics should be avoided in these patients. The same comments may be made concerning the management of obstructive diseases such as arteriosclerosis and thromboangitis obliterans. [See Chapter 27 for the use of drugs in vasospastic disease. Ed.]

### Headache and Other Head Pains

Headache and other pains in the region of the head and neck may be due to a great number of intracranial, extracranial, systemic, and psychosomatic disorders. Mild transient headaches are rarely a cause of concern and can be adequately managed with acetylsalicylic acid. Chronic periodically recurrent headaches, on the other hand, are usually on the basis of emotional tension, anxiety, resentment and other psychologic disturbances which produce autonomic and somatic end organ discharges resulting in vascular distention and dilatation and sustained excessive contraction of skeletal muscles of the head and neck. Similar mechanisms probably play a significant role in the production of the migraine syndrome and the migraine variants. Obviously in all of these psychosomatic disorders treatment must

the pain. This should be done early before the occurrence of physical and mental defects consequent to the pain, and it is best accomplished by interruption of pain pathways by either chemical or surgical means. As previously stated, addictive analgesics should be avoided and their use limited to the control of severe acute pain for a short period of time.

### Reflex Sympathetic Dystrophies

The reflex sympathetic dystrophies, a group of seemingly unrelated disorders which appear to be similar in etiology, in clinical manifestation, and in response to therapy, are characterized by excessive, unduly prolonged pain, vasomotor disturbances, delayed functional recovery, and trophic changes. Apparently, trauma or infection stimulates and injures nerve fibers and thus produces an irritative nerve lesion which serves as a chronic focus that constantly bombards the spinal cord with an abnormal number of noxious impulses and tends to initiate and perpetuate the so-called vicious circle.

*The extremely severe burning pain and hyperalgesia of major causalgia are rarely relieved by even large doses of narcotic analgesics but are completely eliminated by interruption of the sympathetic nerves to the part.* The extremely severe burning pain and hyperalgesia characteristic of major causalgia are rarely relieved by even large doses of narcotic analgesics but are completely eliminated by interruption of the sympathetic nerves to the part. In view of the fact that without sympathetic interruption the pain persists, it is best to avoid continuous use of narcotic analgesics and to proceed with sympathetic interruption as early as possible. The same applies to postamputation pain, including pain in the phantom limb, a complicated problem which requires intensive psychotherapy and neurosurgical management. If drugs must be used, small doses of sedatives and tranquilizing agents can be prescribed.

The so-called minor reflex dystrophies which include Sudek's atrophy, minor causalgia, and the shoulder-hand syndrome, among many others, are often accompanied by dull, aching or burning pain which is persistent and may be of moderate severity. Although nonaddictive and addictive analgesics may provide relief, regional sympathetic block is preferable because it interrupts the vicious circle and thereby frequently effects a cure. Analgesics may be employed to control the pain during the interval between the nerve blocks.

### Pain of Musculoskeletal Origin

Pain caused by disorders of ligaments, joints, muscles, tendons, fascia, bones, and other mesodermal structures is usually a symptomatic manifestation of an infectious, traumatic, degenerative, or neoplastic process. Obviously, management varies according to the etiologic basis. Infectious disorders require anti-infective and/or anti-inflammatory agents. In addition, it may be necessary to employ radiation therapy and even surgical drainage. Since pain of mesodermal origin responds particularly well to acetylsalicylic acid and other nonaddictive agents, these drugs should be tried alone or in combination with small doses of narcotic analgesics. Severe acute pain may require intramuscular or intravenous administration of a narcotic analgesic, or even the infiltration of a local anesthetic agent.



Although the management of chronic pain with analgesic drugs is discussed on page 236 the intractable pain of cancer deserves special mention. The treatment of such pain revolves about two main methods of approach: removal of the cause by decreasing the size of the tumor or completely eliminating it, and the control of the pain itself with systemic analgesics, neurosurgical means, or nerve blocks. Regardless of which of these methods is to be used, it is essential to realize the great importance of *psychologic and physiologic support to these patients*. In no other disease is the patient's need for moral encouragement, sympathetic understanding, cheerfulness, reassurance, and encouragement so great. Cancer pain is often unbearable because hope, understanding, and personal interest have been withheld from the patient by the physician or nursing attendants.

In cases of incurable cancer it is well recognized that several different methods which directly influence the malignant growth can be used to control the pain. These include palliative operation, radiation therapy, castration, and the administration of sex hormones, nitrogen mustard, radioactive compounds, and other specific antitumor therapeutic agents. Hypophysectomy, or total adrenalectomy, frequently effects recession of some metastatic lesions and subsidence of the pain. The relief of pain accompanying these procedures is often dramatic and represents a great gain in time and courage. When the afore mentioned measures prove totally or partially ineffective or not feasible, it is necessary to control pain symptomatically. The principal means are general analgesics, neurosurgical operations, and analgesic blocks. The proper uses of nonaddictive and addictive analgesics, sedatives, hypnotics, and placebos in the management of chronic pain, including pain due to cancer, are discussed elsewhere in this chapter. It needs emphasis, however, that the practice of some physicians to 'snow the patient under because the end is inevitable' denotes a lack of understanding of the problem. Because it is very difficult to estimate the length of life in individual cases, such an attitude may be productive of an unnecessarily premature tolerance, and, consequently, the patient may not obtain adequate relief in the later stages even with massive doses of drugs. This method should be reserved for those patients who are so debilitated that nerve blocks or neurosurgery are contraindicated and for those who have such a short time to live that these procedures are inadvisable.

Although a detailed discussion of neurosurgical and nerve block procedures for the treatment of intractable cancer pain is outside the scope of this book, it needs to be stressed that patients with severe, chronic intractable pain should be provided the benefit of complete relief by temporary or permanent interruption of pain pathways. If the patient is still in fairly good health, peripheral neurotomy, spinothalamic tractotomy (chordotomy), or sensory rhizotomy should be carried out. In patients with very severe pain not controlled by any other means, even prefrontal lobotomy may be considered. On the other hand, in patients whose physical condition contraindicates operation, nerve blocks should be tried. When properly applied, they serve as an excellent substitute for the operation and provide greater relief than systemic analgesics. Frequently it is necessary to combine the use of nerve blocks with small doses of addictive analgesic, sedatives and other systemic drugs. Such a combination provides a greater degree of relief of pain than when systemic drugs are used alone.

be directed primarily toward eliminating the underlying psychologic disturbance with psychotherapy. In addition, sedative and tranquilizing drugs may be of great value. Acetylsalicylic acid and other nonaddictive analgesics may be employed occasionally if headache is moderately severe. Narcotic analgesics should be avoided at all costs, not only because of the chronicity of these conditions, but also because the psychologic deficiencies of these patients make them particularly vulnerable to development of habituation.

Headaches due to organic disorders require thorough investigation and the elimination of the cause. In addition to the use of nonaddictive analgesics post-traumatic headache may be relieved by injection of painful scars and the associated spastic muscle.

### Pain of Visceral Origin

Disorders of the thoracic viscera often cause pain in the chest region, which frequently requires the use of analgesic agents. Mild angina pectoris can be adequately controlled with limitation of activity and nitroglycerin drugs. Severe intractable angina pectoris may require more radical management in the form of analgesic blocks or better still sympathectomy or rhizotomy. The pain associated with acute myocardial infarction can usually be adequately controlled with narcotic analgesics. In the presence of very severe pain it is advisable to administer the drug intravenously or intramuscularly in small divided doses until the patient obtains adequate relief.

It is well appreciated by all clinicians that narcotic analgesics must be used with caution in patients with acute abdomen so as not to obscure diagnosis. On the other hand, once the diagnosis has been made, pending more definitive treatment, it is essential that the patient be provided relief of pain. The severe often excruciating pain of acute pancreatitis, biliary colic, and renal colic deserves special mention. The combination of intravenously administered narcotic analgesics with spasmolytic agents is usually effective in providing complete and prompt relief of pain.

Chronic painful conditions such as chronic pancreatitis, irritable colon syndrome, so-called idiopathic nephralgia, and postcholecystectomy syndrome require careful management. Because of the chronicity of these conditions, it is essential to avoid the narcotic analgesics.

### Pain of Malignancy

This brief discussion on the management of cancer pain has been deferred until the last in order to emphasize its great importance. Although cancer may not be painful at its onset, in many instances it eventually gives rise to pain that becomes progressively severe, finally developing into relentless suffering that causes physiologic as well as psychologic deterioration. Notwithstanding the hopeless prognosis of such cases, the pain problem deserves an intelligent appraisal and a systematic plan for relief, which will conserve the patient's physical, mental, and moral resources and his social usefulness as long as possible. The deplorable attitude of defeatism and therapeutic inactivity found in some quarters must be abandoned and replaced by courageous aggressiveness tempered by sane judgment.

salts or esters of salicylic acid and salicylate esters of organic acids, exemplified by sodium salicylate, methyl salicylate, salicylsalicylic acid, acetylsalicylic acid (aspirin), salicylamide (Salicin, Salrin, Liquiprin), and phenetsal (Salophen), respectively. The para aminophenols of interest are acetanilid (Antifebrin), acetophenetidin (phenacetin) acetaminophen (Apamide, Tempa), the pyrazolons with analgesic activity include antipyrine (phenazone), aminopyrine (Pyramidon), phenylbutazone (Butazolidin), and dipyrone (Novaldin).

The widespread use of these agents during the past century attests to their effectiveness in relieving mild pain. Today acetylsalicylic acid is used more frequently for the relief of mild pain than all other drugs combined. Certainly there is no other field in which commercial drug exploitation is so extensive as in the manufacture and unrestricted "over the counter" sale of this group of drugs. Although they are much less potent analgesics than the opiates and opioids, they possess the significant advantages in that they do not produce tolerance or addiction.

**Clinical Applications**—The chief application of these drugs is for the control of mild pain and discomfort arising from integumental structures, such as cephalalgias, arthralgias, neuralgias, and myalgias. Some of these drugs are also effective in the treatment of rheumatic disorders. Administered alone they are ineffective in controlling moderate or severe pain or in managing pain arising from smooth muscle spasm such as occurs in visceral disorders. The nature of the limited and selective action is not understood.

Acetylsalicylic acid (aspirin) and sodium salicylate are the best nonaddictive analgesic agents to use because they not only are effective but are less toxic than the para aminophenols.

Recently acetylsalicylic acid and salicylsalicylic acid have been combined in tablet form to provide prompt and longer lasting effect. This combination is said to be especially useful as a nighttime analgesic for mild chronic pain, such as occurs in arthritis. Acetophenetidin is the best substitute to use in patients who are allergic to the salicylates or for some other reason cannot tolerate them. It is considerably less toxic than its congener, acetanilid. The pyrazolons are inherent with risk of such severe toxic reactions as to make their use unjustified.

**Pharmacologic Considerations**—Since the pharmacologic details of the antiarthritic drugs are considered in Chapter 32, only those effects which are pertinent to the present discussion will be mentioned here. Because these effects of the various drugs in this group are similar, they will be dealt with together.

**MECHANISM OF ANALGESIA**—The exact mechanism by which these drugs alleviate pain is not known, but it is thought that they exert a selective depressant action on the pain perception apparatus in the central nervous system, probably at thalamic levels. Laboratory studies and clinical observations indicate that they raise the pain perception threshold but have no effect upon the reaction phase of pain. That the site of action may not be cortical is further suggested by the fact that analgesic doses of these drugs cause no mental disturbance or changes in mood or in modalities of sensations other than pain. Although some individuals claim to experience a mild sedative and hypnotic effect, this is certainly not the rule and may be either a placebo effect or may be the result of relief from pain in an individual who is fatigued and has lost sleep consequent to the pain.

## ANALGESICS

The most commonly employed method in managing pain involves the systemic administration of analgesics. Analgesics, by definition, include the drugs which through their action on the nervous system reduce or abolish suffering from pain without producing unconsciousness. This may be brought about in several ways: (1) by interfering with conduction of noxious impulses or abnormal motor responses by direct action on the peripheral nerves, (2) by interfering with conduction of noxious impulses in the neuraxis, (3) by changing the attitude or mood of the patient to pain, by promoting freedom from anxiety, mild euphoria, or feeling of well being or by inducing apathy to the painful experience, (4) by producing sedative and soporific effects, (5) by producing a combination of two or more of these effects.

Close analysis reveals that analgesics comprise several heterogeneous groups of drugs which act on various parts of the physiopsychologic system concerned with pain. These include (1) those which have their effect on the central nervous system, as, for example, the opiates and (2) those which exert a local action on the pain conduction system at the site of injection, as exemplified by the local anesthetics. Since it is not customary to include the local anesthetics when considering analgesics, these are discussed separately in Chapter 13.

**Selection of the Analgesic.**—In selecting the type of analgesic to be used, the quality and intensity of pain are the most important considerations. Mild pain can be adequately controlled with nonaddictive analgesics. Opiates and "opioids" should be postponed until the weaker drugs prove ineffective. Notwithstanding laboratory evidence that no combinations of drugs have greater pain threshold raising effect than their most effective component alone, clinically the value of combinations of drugs to provide a summated or potentiated therapeutic effect has been appreciated for many years. The exact mechanisms for potentiation are not clear. It is frequently valuable to administer a combination of drugs which produce the same result by entirely different mechanisms. This is particularly important in treating pain which is often a complex response to a number of physiologic and psychologic derangements.

**Dosage.**—It may be generally stated that with this group of drugs it is especially important to adhere to the old maxim in medicine that one should always seek and use the minimal *effective* dose. This requires good clinical judgment, especially when dealing with pain, the most subjective of all symptoms. From what has been said concerning variation in reaction to pain it is apparent that there will be considerable differences in requirements between individuals and in the same individual at different times. This is especially important when administering drugs, exemplified by the opiates, which have their predominant effect on the reaction phase of pain. Since pain is an antagonist to the depressant and other undesirable effects of drugs, the more closely the dose meets the requirements, the lower the frequencies and severity of such reactions.

### Nonaddictive Analgesics

The drugs comprising this group include the salicylates, para aminophenols and pyrazolons. Derivatives of salicylic acid of value in pain control consist of

vertigo, weakness, and anginal pain. Severe cases exhibit vascular collapse and respiratory depression. Chronic poisoning, which occasionally follows regular continuous ingestion, is more common and more difficult to diagnose.

**Pyrazolons** Toxicity of pyrazolons resembles that of para aminophenols except that cyanosis and methemoglobinemia are not characteristic, the group also may produce agranulocytosis. Sensitivity to aminopyrine is often manifested by herpetic eruptions around the lips and by angioneurotic edema, whereas antipyrine causes dermatitis medicamentosa. Because of the serious nature of these undesirable effects these drugs should not be used as analgesics.

Phenylbutazone (Butazolidin), which is also a pyrazolon, is an effective analgesic in acute arthritis, bursitis, gout, and other acute musculoskeletal disorders. Because of toxicity from prolonged use it is not indicated in patients with such chronic disorders as osteoarthritis, osteoporosis, and other chronic arthritides. More than a third of the patients experience undesirable effects such as edema, gastrointestinal distress, rash, and vertigo. Instances of severe toxic reaction consisting of agranulocytosis, thrombocytopenia, hypertension, hepatitis, and leukemia have been reported.

[Dipyrone (Methampyrone, Narone, Novaldin) is another of the series and it may be assumed with the same toxic and therapeutic potentials. Ed.]

### Design for the Use of Nonaddictive Analgesics

The most significant recent observation concerning these drugs is that they are as effective in doses of 0.6 Gm. as in much larger doses. Larger doses prolong the analgesic action but do not afford any greater relief. Therefore, sustained relief of pain obtained with a small dose repeated at frequent intervals is better.

The optimal analgesic dose of acetylsalicylic acid (aspirin) when used alone is 0.3 to 0.6 Gm., and this may be repeated every 2 to 3 hours for several doses. Because it is sparingly soluble in water, has many chemical incompatibilities, is unstable in watery solutions, and has a nauseating taste, it is best to take it in the solid dry tablet form. Sodium bicarbonate hastens the absorption of aspirin and neutralizes increased amounts of hydrochloric acid produced as a result of local stimulation by the aspirin. Therefore, in patients who already have gastric distress, it may be advisable to use sodium bicarbonate or enteric coated tablets of aspirin.

Acetophenetidin is also administered in doses of 0.3 to 0.6 Gm. The optimal dose of acetanilid is 0.2 Gm., and that of antipyrine (phenazone) and aminopyrine (Pyramidon) 0.3 to 0.6 Gm. If these doses are ineffective, larger amounts do not give any more relief. Medication with any of these drugs over a period of days is not advisable unless there are intermittent periods during which analgesic drugs from other chemical classes are substituted.

### Rational Basis for New Nonaddictive Drugs

There is a serious need for a more potent nonaddictive systemic analgesic drug. Such a drug should produce specific interruption somewhere in the pain perception apparatus in the same fashion that muscle relaxants interrupt skeletal

**OTHER EFFECTS**—In addition to their analgesic effects these drugs lower body temperature by action on the central nervous system, probably by raising the "thermostat" of the heat regulating center of the hypothalamus to a higher level. Heat production is not inhibited, but heat dissipation is increased. This effect is not seen in individuals with normal temperature, but only in febrile patients.

The salicylates increase urinary excretion of uric acid. In doses in the range used in the treatment of rheumatic fever they frequently produce a primary hyperventilation and changes in the pH and electrolyte pattern of the blood. They also may produce epigastric distress, nausea, vomiting, and even gastric ulceration with consequent hemorrhage. In analgesic doses these drugs have little or no effect on the other bodily functions.

**ABSORPTION AND EXCRETION**—The salicylates, para aminophenols, and pyrazolons used to control pain are readily and chiefly absorbed from the upper intestinal tract. Absorption also occurs from the stomach (particularly if the pH is low) and through any mucous membranes. These drugs are rapidly hydrolyzed in the plasma and their metabolites excreted, or they are excreted as conjugation products of sulfuric or glycuronic acid.

#### TOXIC REACTIONS—

*The Salicylates* Salicylate poisoning is a particularly serious problem in children especially those under 2 years of age, because of the profound physiologic alteration it produces, which may even lead to death. It either results from accidental ingestion of large amounts of the drug by the child, or is due to misguided therapeutic efforts of the parents, often upon the advice of the physician. In very large doses the salicylates produce mild toxic symptoms collectively known as salicylism which consists of headache, dizziness, tinnitus, impaired hearing, dimness of vision, mental confusion, sweating, thirst, nausea, vomiting, diarrhea, and increased respiratory and pulse rates. With toxic doses these progress to dyspnea, restlessness, incoherent speech, excitement, mania, hallucinations, and delirium. Recovery usually is prompt if the drug is withdrawn. Poisoning with excessive doses may progress to stupor, coma, and death due to cardiovascular collapse and respiratory failure. This is discussed in Chapter 41.

Painless bleeding from the gastrointestinal tract may occur following the prolonged use of aspirin. This is particularly apt to occur in patients with peptic ulcers during the winter seasons when upper respiratory infections are treated with aspirin. Idiosyncrasy to salicylates is not rare and is usually manifested by skin rashes and anaphylactoid reaction. Sensitivity to these drugs occurs more frequently in patients with asthma and allergy.

[There is no sound evidence that Calurin (calcium acetylsalicylate urate) has any advantages over aspirin. Ed.]

*Para aminophenols* Toxic reactions to acetanilid, acetophenetidin and the others are not uncommon because these drugs are found in many "headache powders" which are sold without a prescription and, therefore, are subject to misuse. The toxicity usually comes from the ingestion of large amounts over a long period of time. Overdosage results in acute poisoning, characterized by formation of methemoglobin and sulfhemoglobin, which cause the skin, mucous membranes, and fingernails to develop a cyanotic color. Symptoms encountered are dyspnea,

## ADDICTIVE (NARCOTIC) ANALGESICS

This section deals with the pharmacology, indications, complications, and clinical use of potent systemic pain relieving drugs which have as one of their inherent characteristics the potential for inducing addiction. Although it has long been the custom to refer to these as *narcotics* there is a trend to use the more specific term "addictive analgesics." In the discussion that follows these two terms will be used interchangeably.

Only those addictive analgesics that have been proved effective by extensive clinical trial will be discussed. These comprise three major classes: (1) the opiates, which are natural alkaloids of opium and include Pantopon, morphine, and codeine, (2) the synthetic opiate derivatives which include dihydromorphinone (Dilaudid), heroin (diacetylmorphine), hydroxydihydromorphinone (Numorphan) and methyldihydromorphinone (metopon), and (3) a heterogeneous group of synthetic compounds which, though dissimilar in chemical structure, have actions which are similar to the opiates. The last group was formerly collectively known as 'synthetic opiate like compounds'. Recently the simpler term 'opioids' has been adopted in lieu of the afore mentioned unwieldy phrase. These include meperidine (Demerol), methadone (Dolophine), alphaprodine (Nisentil), and levorphan (Levo Dromoran). In addition brief mention will be made of some promising newer synthetic analgesics which have been given limited clinical trial.

### Clinical Applications

Opium has been employed for the relief of pain since ancient times, and throughout the ages it has been the most widely employed drug for this purpose. Records of its use can be found in the Babylonian clay tablets, in the Ebers Papyrus, and in the writings of the Greeks, Romans, and almost every great historian and poet. This is a long story that is heroic in terms of alleviation of human suffering and pain. Almost three centuries ago Sydenham wrote, "Among the remedies which has pleased Almighty God to give to man to relieve his suffering, none is so universal and so efficacious as opium." Osler frequently referred to morphine as 'God's own medicine'. Today these statements applied to the entire group of narcotics would find endorsement by most clinicians because properly administered they are of great benefit to the patient.

**Field of Usefulness**—The addictive analgesics are capable of relieving or modifying any type of pain, except extremely severe, lancinating pains of trigeminal neuralgia, tabes dorsalis, and of certain other lesions of the central nervous system. They are of particular value to control acute, transient pain consequent to accidental or surgical trauma, burns, visceral disease, and musculoskeletal disorders. Coronary occlusion, acute pancreatitis, and biliary or renal colic are often accompanied by severe pain which requires administration of potent addictive analgesics.

Acute vascular occlusion is an outstanding indication for narcotics, regardless of the site of the lesion, whether in the peripheral or central vessels. Here the narcotic can be given in a relatively small dose and can be repeated as often as necessary. Severe pains associated with vascular occlusion are usually relieved by narcotics rather than antagonistic drugs. Severe pains associated with vascular occlusion are usually relieved by narcotics rather than antagonistic drugs.

muscle function or ganglionic blocking agents affect autonomic nervous system functions. Such a drug might produce its block in the peripheral relay by depressing nerve function or it might interfere with synaptic transmission within the neuraxis.

In order to be proved practical, such a drug should permit control of the degree of interruption as obtains with muscle relaxants, with maximal therapeutic dose it should provide complete interruption of pain perception. Moreover, it should provide controllability of duration of block. Obviously one of the most important qualities would be lack of undesirable side effects.

A drug producing interruption of pain perception specifically could be employed in patients with pain that had a relatively small affective component. It could also be used in the same manner that the nonaddictive analgesics presently available are used, in combination with a barbiturate or other hypnotic in patients who had a marked emotional factor.

**Dextro Propoxyphene (Darvon)**—A new synthetic analgesic, dextro propoxyphene, shows promise of fulfilling some of the aforementioned requisites for nonaddictive drugs. A number of studies indicate that this agent has the same analgesic potency as codeine without addictive liabilities and with significantly less incidence of side effects.

**PHARMACOLOGIC CONSIDERATIONS**—Dextro propoxyphene has a chemical structure which is different from that of all other analgesics, although resembling methadone, and is a bitter white crystalline material which is readily soluble in water.

The analgesic potency of dextro propoxyphene appears to be the same as codeine. The number of aforementioned clinical trials have shown that propoxyphene given in 30 to 60 mg doses provided analgesia which was similar in all respects to the same doses of codeine. These studies, which were carried out in patients with chronic diseases accompanied by mild to moderate pain, showed both drugs produced measurable relief of pain for 6 hours or more. Darvon produced prompt analgesia following oral administration.

Unlike other analgesic agents, propoxyphene has no antidiarrheal, antitussive, or antipyretic effects. Prolonged administration of propoxyphene in patients with chronic pain failed to produce any adverse effects on liver or kidney function, blood elements, or on the gastrointestinal tract. Moreover, no loss of analgesic activity which would indicate development of tolerance and no euphoria were observed, and, when the drug was discontinued, none of the patients developed symptoms suggesting physical dependence. The addicting liability of dextro propoxyphene has also been extensively studied in patients who were addicts or former addicts, and the evidence indicates that the drug has little or none. On the basis of these findings the drug has been classified as a nonaddictive analgesic agent and does not come under the preview of the Federal narcotic law.

**ABSORPTION AND EXCRETION**—The drug is absorbed readily after oral as well as parenteral administration and is apparently detoxified in the liver and eliminated by the kidney.

[Ethoheptazine (Zactane), a meperidine congener, is another new analgesic which is sold in combination with aspirin under the trade name of Zactirin, about which too little is known to make a definitive statement at this time. Ed.]



*Effect on Pain Perception* The second most important action of morphine and other analgesics is their interference with conduction of pain, thus raising the threshold for pain perception. The focus of such action is unquestionably within the neuraxis, most probably in the diencephalon (thalamus) and in the cerebrum. There is some evidence which suggests that morphine may depress afterdischarge in the closed internuncial chains between frontal lobes and diencephalon, and in this manner interferes with reverberating activity essential for the pain experience. Clinical evidence that morphine has a significant impeding action on the conduction of nervous impulses that give rise to the pain is available from studies on the use of these agents as supplements to general anesthesia. These studies indicate that the administration of morphine, Demerol or other analgesics before or during the administration of anesthesia significantly reduces the amount of anesthetic necessary to produce surgical anesthesia. Since the patient is of course unconscious, this action cannot be on the reaction phase, therefore the conclusion that the drug interferes with conduction of the noxious impulses is not unreasonable. This phase of the analgesic action of the morphine and other narcotics operates most efficiently when the drug is given before the painful stimulus is applied.

**PARAMETERS OF ANALGESIC ACTION**—The analgesic action of morphine is highly selective, and frequently pain may be relieved with small therapeutic doses without obtundation of other modalities of sensation and with little lethargy, alteration of mentation, or respiratory depression. Even when large doses are properly administered to relieve severe pain, most of the physiologic and psychologic effects are of a mild degree, because pain and the consequent increased irritability antagonize these effects. Moreover, there is a mutual antagonism between pain and the analgesic action of the opiates. Pain perception threshold raising action of these drugs as well as other observable effects, can be reduced or completely neutralized by pain if the pain precedes or occurs early (during the first 90 minutes) in the course of the action of the opiates. Moreover, a continuous stimulus has a greater neutralizing effect on the threshold raising action of these drugs when the pain occurs just before the administration of the drug or soon after it is given. On the other hand, when a painful stimulus is applied after critical period of 90 minutes, which is the peak of pain perception threshold raising action, the perception of pain is much less acute.

#### OTHER CENTRAL NERVOUS SYSTEM EFFECTS —

*Respiration* Morphine depresses the respiratory center directly, the degree of depression being proportional to the dose. This effect is discernible with small doses insufficient to produce sleep or disturb consciousness. There is first a decrease in rate with a compensatory increase in the tidal exchange, but the latter is gradually diminished so that eventually, with large doses there is a decrease in respiratory minute volume.

*Emesis* The vomiting center is stimulated by morphine and its congeners so that about 10 minutes after injection the subject may begin to experience nausea. Due to the psychologic effects, however, the vomiting is not associated with the usual unpleasant emotional reactions.

*Other Effects* Morphine decreases olfactory and auditory acuity, cutaneous perception, and the sense of muscular tone. Morphine also depresses the cough

ciency may indicate the use of opiates, after the salicylates and related analgesics do not prove sufficiently efficacious

In neoplastic and other chronic, hopelessly incurable disease, pain is a major problem of management because of its progressive nature and prolonged duration. The management of pain in these patients requires considerable thought and planning because of the problem of tolerance.

In order to use addictive analgesics properly the practitioner needs to be equipped with a thorough knowledge not only of the analgesic actions but of all the other effects of these drugs. For this reason and because of the important role these drugs play in the relief of pain, they will be discussed in considerable detail.

### Pharmacologic Aspects of Opiates

The opiates and other addictive analgesics have effects on every organ of the body, but only those pharmacologic actions which are pertinent to the present discussion will be presented here. Since morphine is the classic drug for the relief of severe pain and is the standard agent with which all other analgesics are compared, its pharmacologic action will be discussed in detail. Subsequently these facts will be used to compare the effects of the other addictive drugs.

#### Morphine —

**CENTRAL NERVOUS SYSTEM** —Morphine and other opiates exert their most important action on the central nervous system, particularly on the cerebrum and medulla. The cerebral effects are characterized by a change in mood and attitude and by disturbance in mentation. These are seen with the usual therapeutic doses (8 to 10 mg). Within a few minutes after morphine is administered, the individual experiences a generalized muscular relaxation followed by a change of mood and attitude characterized by euphoria or a feeling of well being. Any preoccupation, worries, fears, inhibitions, and doubts which exist in the individual's mind decrease and soon disappear, and he becomes free of anxiety, content and loquacious.

**ANALGESIC ACTION** —The relief of pain by morphine is the outstanding effect of the drug and, from a clinical standpoint, its most important action and one which is exerted wholly within the central nervous system. It is the general consensus that opiates relieve pain by (1) decreasing or inhibiting the perception of pain, (2) altering the psychologic reaction associated with such perception, and (3) inducing lethargy or sleep.

**Effect on Mood** I have no doubt and there is general agreement that the most important effect of these drugs is on the reaction phase of the pain experience. *The aforementioned cerebral effects, especially the change in mood and attitude,* usually alter the psychic reaction to pain so markedly that the individual is no longer disturbed by it. The pain is perceived, but it no longer brings forth the usual responses such as anxiety, fear, panic, withdrawal, and flight. Consequently the patient is capable of tolerating pain because it is freed of its implications. These effects are similar to those of surgical prefrontal lobotomy and have in fact been referred to as a form of pharmacologic lobotomy. The obvious conclusion is that the change in the spectrum of the psychic reaction to pain is not only an important part of the analgesic action of morphine and other narcotics, but the primary and essential part of it.

with consequent marked hypotension, anoxic hypoxia, hypercarbia, tachycardia decrease in myocardial efficiency, and inverted T waves. Movement of the morphinized patient from the supine to the sitting or semierect position may be followed by vascular collapse. This is especially likely to occur in elderly patients and is probably on the basis of the generalized vasodilatation, which can be compensated while the patient is supine but cannot be overcome in the erect position.

**BRONCHIAL TREE**—The bronchial musculature is stimulated resulting in a slight contraction but this effect is rarely if ever apparent from the use of therapeutic doses in normal man. In the asthmatic patient, however, it may precipitate an attack.

**ABSORPTION, FATE, AND EXCRETION**—Morphine and the other opium alkaloids are readily absorbed from the gastrointestinal tract and subcutaneous and intra muscular tissues, but not through the intact skin. Following administration by these routes, there is a significant variation in the rate of absorption resulting in a difference in the time when the effects of the drugs manifest themselves. This is particularly true following subcutaneous injection because of the variability of the cutaneous and subcutaneous circulation. Under normal conditions following subcutaneous injection of morphine, about 60 per cent is absorbed from the site of injection during the first 30 minutes.

Ninety per cent of the morphine is destroyed in the body tissues, particularly in the liver, and the rest is excreted unaltered by way of the urine and the feces. Following absorption, most of the drug in some altered form is stored in the liver and skeletal muscles. Detoxification proceeds slowly, and although the narcotic effects following a single dose are usually over in 4 to 6 hours, only 50 per cent of the amount is detoxified in the first 24 hours, and it is not until about 36 hours after injection that 90 per cent is destroyed. About 10 per cent of the morphine is excreted in the urine and in the feces. The end products resulting from its detoxification are eliminated by the kidneys.

**DOSAGE**—The optimal analgesic dose of morphine will vary considerably depending on the age, weight, and physical status of the patient, the intensity of his pain, the reflex irritability of his nervous system, and the presence of existing diseases which increases reflex irritability. However, excepting extremes in ages, the intensity of pain is the most important factor in determining the amount of morphine required for adequate relief. Since this subject will be discussed in detail in a subsequent section, nothing more will be said here except to emphasize that routinization of the indication and dose of morphine or any other analgesic is hazardous therapeutically and is to be deplored.

Experimental and clinical studies have shown that the optimal dose of morphine in the average 70 Kg (150 pound) adult varies from 8 to 15 mg. In laboratory investigations it has been noted that in the adult the threshold for pain perception was increased by morphine as follows: 32 per cent with 5 mg, 47 per cent with 8 mg, 60 per cent with 10 mg, and 71 per cent with 15 mg. Beyond the 15 mg dose, increments produced increasingly smaller increments in the intensity of analgesia. The maximum analgesic effect was reached in 90 minutes and duration of analgesia was 4 to 7 hours. Since these studies were carried out with experimental pain they do not indicate the effect of morphine on the re-

reflex, probably through central effects. The well known phenomenon of pupillary constriction of morphine is also a central effect. Therapeutic doses of this drug have little or no effect on the electroencephalogram but may cause an increase in intracranial pressure. Morphine usually enhances two neuronal (stretch) reflexes, but depresses multineuronal (nociceptor) reflexes.

**GASTROINTESTINAL TRACT**—Morphine, like all other phenanthrene derivatives of opium, tends to cause contraction of all smooth muscles, with the notable exception of those of the blood vessels. This is in contrast to the benzylisoquinoline derivatives (papaverine) which cause relaxation of smooth muscle. Morphine, therefore, causes an increase in tone of the gastrointestinal tract, particularly its sphincters. This results in decreased motility and a consequent increase (up to 12 hours) in the emptying time of the stomach and a decrease in secretions of the gastrointestinal tract. The resulting delay in the passage of the contents allows water to be more completely absorbed, which further delays its advance. This, coupled with the increase in tone of the anal sphincter and the decrease in the (central) perception of the normal sensory stimuli of the defecation reflex, causes constipation, which may be severe after large doses of opiates. In passing it should be pointed out that the delay in gastric emptying time following the administration of morphine will greatly delay the absorption of other drugs subsequently administered.

**BILIARY TRACT**—Morphine causes a similar increase in the tone of the smooth muscle of the biliary tract which with large doses progresses to spasm, particularly of the lower end of the common bile duct. Consequently there is increase of the intrabiliary pressure up to as much as 10 to 15 times the normal value. It is obvious, therefore, that the pain relief afforded by morphine in biliary colic is a central effect. Sometimes the administration of morphine aggravates the biliary muscle spasm so greatly that it may not be relieved by large doses of either atropine or papaverine, but requires the administration of an antispasmodic. The function of the liver, as determined by the dye test, is decreased for 6 hours following administration of morphine.

**GENITOURINARY TRACT**—Morphine increases the tone, rate, and amplitude of contraction of the intact human ureter and detrusor muscles of the urinary bladder, whereas papaverine decreases them. Although when given alone atropine has little effect on the ureter, it can eliminate the morphine-induced ureteral spasm. It should be emphasized, however, that notwithstanding this pharmacologic action, morphine very frequently proves efficacious in relieving ureteral colic. Obviously this relief is the result of its central action. Morphine has antidiuretic effects. In summary, then, the effects of morphine on the urinary tract are decreased urinary output, increased urinary urgency, and increased difficulty in micturition. The normal contraction of the uterus during labor is not significantly affected by analgesic doses of morphine, but the intervals between contractions may be increased.

**CARDIOVASCULAR EFFECTS**—Morphine and its congeners produce negligible effects on the heart and blood vessels, except for mild peripheral vasodilatation, which in the supine position has little effect. Changes which may occur following their administration are due to lessened muscular activity, sleep, decreased metabolism, and respiratory depression. Rapid intravenous administration of full therapeutic doses (10 mg) may result in severe respiratory and myocardial depression.

codeine which in the past have been underrated. Moreover, it is apparent that codeine in optimal doses is definitely inferior to morphine.

Clinically it is a well appreciated fact that 10 mg of morphine is more efficient in relieving severe pain than 64 mg of codeine. The difference is probably due to the lesser effects of codeine than morphine on the perception and the reaction phase of pain. The psychologic effects such as modification of mood elimination of preoccupation and worries, and production of feeling of well being (factors which are the primary targets of the analgesic action of narcotics) are not as prominent with codeine as they are with morphine.

**DOSAGE**—The dose of codeine for controlling mild to severe pain varies from 15 to 64 mg. Since doses greater than 64 mg merely prolong analgesia but fail to produce a commensurate increase in degree of relief, there is no advantage in using larger amounts, except in the presence of tolerance. Therefore it is better to give optimal doses at more frequent intervals.

**ROUTE OF ADMINISTRATION**—It should be emphasized that the maximum effect of codeine is obtained by parenteral administration. Therefore, it is wise to use it orally only for mild pain. In order to achieve maximum analgesic effects in the presence of severe pain it should be administered subcutaneously in doses 30 to 64 mg, depending on the size, age, and physical status of the patient and the intensity of his pain. In controlling severe pain in circumstances in which morphine is not available, codeine in 64 mg doses may be injected intravenously, but slowly.

**Dihydrocodeine (Paracodin)**—Dihydrocodeine is an analogue of codeine which has been used extensively in Europe and Central and South America for the past 45 years but apparently has escaped the attention of the American physicians. In recent years Beecher and his associates have studied this drug in post operative patients with sustained wound pain and they noted that 30 mg of dihydrocodeine produced analgesia which was almost equal both in degree and duration to that produced by 10 mg of morphine. Concerning side effects they found that dihydrocodeine produced considerably less depression on respiration and less nausea and euphoria. Indeed in their studies it was shown that 30 mg of dihydrocodeine produced no more side effects than a placebo. This is in contrast to equianalgesic (60 mg) doses of the parent compound codeine which produced significant side effects. Keats and his associates found 60 mg of dihydrocodeine to be the analgesic equivalent of 10 mg of morphine. However with this dose respiration was depressed almost as much as following 10 mg of morphine. It was also found that 90 mg of dihydrocodeine produced no greater analgesia than did 60 mg. Moreover, the analgesia with this large dose did not exceed the analgesia of 10 mg of morphine. Ruch and Ruch studied this drug in obstetrical patients and found 30 mg of dihydrocodeine to be the analgesic equivalent of 75 mg of meperidine. They noted that dihydrocodeine produced significantly less respiratory depression of the infant and of the mother than did other analgesics.

**DOSAGE**—It appears that dihydrocodeine is an effective analgesic for moderate pain. The dosage range of dihydrocodeine in adults is 30 to 60 mg. The drug is effective orally and parenterally although the subcutaneous intramuscular routes produce more prompt and more effective analgesia.

action phase of pain consequent to disease, which as previously mentioned is the primary target of morphine and other addictive analgesics

Clinical investigation in patients with pathologic pain have shown that 8 to 10 mg of morphine administered subcutaneously will afford relief from moderate postoperative pain to over 90 per cent of patients. In the presence of severe pain 10 mg of morphine provided relief to 65 to 70 per cent of patients, and 15 mg to approximately 80 per cent for periods of 6 to 8 hours. Administration of 10 mg of morphine by the oral route produced relief in 40 per cent of the patients as compared to 30 per cent with placebo. This demonstrates the ineffectiveness of morphine when administered by mouth probably due to slow absorption.

The best approach to the problem is to try what is considered the optimal dose and if this proves ineffective to give a larger amount after the proper interval of time. A crude yardstick for subcutaneous doses is as follows: 0.8 mg per 15 pounds body weight for mild to moderate pain; 1 mg per 15 pounds body weight for very severe pain. If the pain is extremely severe it is advisable to administer the drug intramuscularly or better still to administer 0.8 mg per 15 pounds body weight intravenously over a period of 3 to 5 minutes. Because of its ineffectiveness when given orally morphine should always be given parenterally.

**Codeine**—Codeine is second only to morphine as a drug of choice to relieve pain. It is frequently employed to relieve mild to moderate pain that cannot be controlled with a nonaddictive analgesic but is not sufficiently intense to warrant the use of a potent narcotic. As previously mentioned codeine is often combined with nonaddictive analgesics and hypnotics.

**PHARMACOLOGY**—Pharmacologically codeine resembles morphine except that its effects are milder. In optimal doses it produces less sedation, respiratory depression and gastrointestinal, urinary and pupillary effects than morphine. Nausea, emesis, constipation and diarrhea are seen less frequently and tolerance develops slower than with morphine. Although codeine is an addicting drug its addiction potential is less than any of the other opiates. It is these advantages of codeine which indicate its use before more potent and more addictive drugs are employed in managing patients with chronic pain.

**COMPARISON OF CODEINE WITH MORPHINE**—Even when employed in the maximum dose codeine is not as effective in relieving severe pain as 10 mg of morphine. Thus it was found that 64 mg of codeine increased the threshold of experimentally induced pain approximately 50 per cent above normal as compared to 60 per cent with 10 mg of morphine. Moreover the duration of this action was shorter with codeine. In controlled clinical studies made in postoperative patients with steady pain it has been found that 60 mg of codeine administered by mouth produced relief in 40 per cent of trials as compared to 33 per cent relief with placebo. However when the same amount of the drug was given subcutaneously it provided relief to 60 per cent of the patients as compared to 71 per cent with 10 mg of morphine. It was found that increasing the dose from 30 mg to 120 mg resulted in a real increase in analgesic potency although beyond 60 mg the principal advantage was in duration of effect. However, it was noted that troublesome side effects with doses of 60 to 120 mg of codeine were as frequent as with 10 mg of morphine. These results emphasize the potency and toxicity of

The usual clinical dose is 3 mg in an average adult. Since the drug is marketed only in 3 mg oral capsules, it is difficult to administer smaller doses. However, because this drug is usually reserved for patients with severe intractable pain due to neoplastic disease, this preparation is appropriate. With development of tolerance it will be necessary to give 6 mg or a larger amount to control severe pain. Despite the early optimism concerning its place as a specific narcotic for cancer patients, metopon has been found to offer no significant advantages over the standard drug.

**Heroin**—*Heroin diacetylmorphine*, is usually prepared as the hydrochloride salt. It is one of the most potent analgesics of the morphine derivatives. In equidoses it is 5 to 8 times as potent, but also 5 to 8 times as depressant as morphine. It is therefore employed in one fifth to one eighth the dose of morphine. With doses of 1 to 2 mg administered subcutaneously, it brings about relief of pain more quickly than the other opiates but its duration of action is much shorter than that of morphine. Heroin causes a most intense euphoria, which often supplants the marked subjective depression. Moreover, unpleasant side effects such as nausea, vomiting, and constipation, seen with other opiates, are not as common with heroin. As will be seen subsequently, these properties of heroin—its ability to produce the most potent euphoric agent and the absence of side effects—are responsible for the serious nature of addiction to this drug. For these reasons, its importation, manufacture, and sale in the United States are prohibited by law.

### Pharmacology of the Opioids

**Meperidine (Demerol)**—Demerol, synthesized in Germany in 1939, was the first practical synthetic, morphinelike analgesic and as such was the first of the opioids. The promise of an effective substitute for morphine caused Demerol to immediately gain widespread popularity and to be submitted to extensive clinical investigation. Introduced under the trade name of Demerol in America, the drug is also known as isonipicaine, in Britain as pethidine, and has the official name of meperidine.

#### COMPARISON OF MEPERIDINE AND MORPHINE —

**Relative Effectiveness** Early investigations seemed to indicate that Demerol had an analgesic potency greater than that of codeine and slightly less than that of morphine. In one investigation it was found that 75 to 100 mg of Demerol given parenterally every 3 to 4 hours was capable of completely controlling postoperative pain in 91.5 per cent of the patients and afforded moderate relief in an additional 5.2 per cent. In another well controlled study it was noted that 50 mg of Demerol produced relief in the same per cent of trials as did 10 mg of morphine, whereas 100 mg provided relief a significantly greater number of times.

**Effects on Central Nervous System** Demerol produces cerebral effects similar to morphine but of a lesser degree. When a full therapeutic dose is administered to a patient with pain or anxiety, the ensuing analgesia may result in euphoria and finally sleep. However, in patients without pain these effects are less. Indeed, dysphoria may result. Though it is generally accepted that Demerol causes less respiratory depression than morphine, available quantitative data, clinical observations, and reported cases of serious depression following its use negate claims of

**Pantopon**—Pantopon, also known as omnopon and pantopium, is a mixture of the purified opium alkaloids in the same proportions which occur naturally, thus it is a purified opium devoid of inert material which contains close to 50 per cent morphine by weight. As might be expected, its analgesic potency is not greater than that produced by optimal doses of morphine despite other claims made for this drug. In experimentally induced pain 20 mg of Pantopon produced the same effects as 8 mg of morphine. Moreover, claims made for Pantopon that it produces fewer side effects than morphine and provides in addition to the analgesic action of morphine the antispasmodic action of papaverine are not substantiated clinically. This is as might be expected because its papaverine content is too small. Pantopon is available for oral use and for parenteral injection.

**Dihydromorphinone**—Dihydromorphinone, commonly known as Dilaudid, the first biosynthetic derivative of morphine, is one of the most potent of the opiates on a weight basis. Clinically 2 mg of this drug produces analgesia which is slightly more intense than that following administration of 10 mg of morphine. However, its analgesic action is definitely briefer, it does not cause quite as much euphoria, and is markedly less sedative. The latter quality may be employed to advantage in patients in whom it is desired to provide relief of pain without causing sleep.

The other pharmacologic effects of Dilaudid are similar to those of morphine except that such side effects as nausea, vomiting and constipation are less severe and frequent. In equianalgesic doses, respiratory depression is slightly less with Dilaudid than with morphine. Dilaudid is effective by the oral and rectal routes. Since tolerance and addiction occur with Dilaudid, it has no advantage over morphine in this respect. Indeed, the greater frequency with which dihydromorphinone must be given for chronic pain increases the possibility of addiction and tolerance.

[Hydroxydihydromorphinone (oxymorphone, Numorphan) is the latest morphine congener to be added to the list. Too little is yet known, and there has been too little general experience with it to justify a conclusion that it has any real advantages over morphine. Ed.]

**Metopon**—Metopon, another synthetic opiate derivative, is the methyl analogue of Dilaudid and has some of the characteristics of the latter. Metopon has many of the pharmacologic properties of morphine with the following differences: (1) it is more rapid acting and more potent than morphine on a weight basis, (2) it is effective orally, (3) following subcutaneous injection, it produces more rapid analgesia, (4) addiction and tolerance develop more slowly than with morphine and there is relatively rapid resolution of the abstinence syndrome following withdrawal of the drug.

The early claims that equianalgesic doses of metopon produce less frequent and milder side effects has not been substantiated clinically. Recent, well controlled clinical studies have shown that respiratory depression, nausea, vomiting, drowsiness, sleep, and other undesirable actions occurred as frequently (and occasionally more frequently) with 3 mg of metopon as with 10 mg of morphine. In experimentally induced pain 6 mg raised the pain perception threshold nearly 100 per cent. Clinical studies have shown that 6 mg produced relief in 100 per cent of the doses, while 3 mg was as effective as 10 mg of morphine.



the analgesic action of Demerol lasts approximately 3 to 4 hours, which is somewhat shorter than that of morphine

**Alphaprodine**—Alphaprodine (Nisentil) is a close congener of Demerol. It is a rapid, short acting, potent analgesic with significant sedative effects

In subjects with experimentally induced pain, the pain perception threshold is said to be increased 100 per cent with maximal therapeutic doses. Administration of 60 mg subcutaneously during the first stage of labor when pain is severe results in complete relief in 80 to 92 per cent of the trials. Clinical studies of postoperative patients have shown that 40 mg of Nisentil is the equivalent analgesic dose of 10 mg morphine. Following subcutaneous administration maximal effect occurs in 8 to 15 minutes and lasts 1½ to 2 hours. Intravenous injection produces maximum analgesia within 5 minutes and relief lasts less than 1 hour.

**UNTOWARD EFFECTS**—Untoward effects are similar to those described for morphine and Demerol. Nisentil produces greater respiratory depression than equianalgesic doses of Demerol. It is an addictive drug.

**DOSAGE**—The dose for the relief of moderate pain is 0.25 mg per pound of body weight and of severe pain about 0.4 mg per pound of body weight. These doses, which are approximately 40 mg and 60 mg, respectively, for an average adult, may be repeated every two hours if necessary. The drug is effective orally and parenterally. Because of its rapid action the subcutaneous route is adequate for most patients who require parenteral injection. Intravenous injections increase the hazard of respiratory depression and should be performed slowly and only in urgent situations.

**Anileridine (Leridine)**—Anileridine is another relatively new analgesic drug which is an analogue of meperidine (Demerol). During the past several years it has been investigated extensively as an analgesic agent in the management of various types of pain including postoperative pain, labor pain and also as a supplement to general anesthesia.

**PHARMACOLOGIC PROPERTIES**—The analgesic potency of anileridine has been studied by various investigators including Keats and his associates who found 40 mg of anileridine to be the analgesic equivalent of 100 mg of meperidine, while 50 mg of anileridine exceeded 100 mg of meperidine in analgesic potency. Similar results have been reported by Driggs and his associates who found that 25 mg of anileridine injected intramuscularly produced the same degree of pain relief as did 10 mg morphine. From their results it was indicated that following intramuscular injection the equianalgesic dosage ratios appeared to be morphine 1 and anileridine 2 to 2.5 and with meperidine 3.5 to 5. The duration of relief was approximately the same with anileridine and meperidine but considerably longer with morphine.

These and other clinical studies indicate that anileridine is a potent analgesic agent which is adequate for the relief of moderate to severe pain.

**UNTOWARD EFFECTS**—The aforementioned well designed clinical studies revealed that anileridine in doses of 40 mg depressed respiration as much as 100 mg of meperidine but this depression was of significantly shorter duration than that following Demerol. Thus Keats and co-workers found that while 40 mg of anileridine depressed respiration as much as did 100 mg of meperidine after 3

the original investigators that Demerol is devoid of such hazard. Respiratory depression of the newborn infant is occasionally seen following analgesic doses of Demerol given to the mother less than 45 to 90 minutes prior to delivery. Moreover, in infants and young children, in the aged, and in patients with expanding intracranial lesions, it may cause significant respiratory depression.

Other central nervous system effects of Demerol include no significant alteration of the pupil, no depression of the cough reflex, and less hypnotic effect than morphine. It causes less nausea and vomiting than morphine. However, overdose of Demerol is frequently accompanied by excitement, uncoordinated jerky movements, and other manifestations of central nervous system stimulation.

**Gastrointestinal Effects** In contrast to morphine, Demerol relaxes smooth muscle except that in the duodenum, the biliary tract (especially the sphincter of Oddi), and the jejunum. The intensity of the spasmogenic effect in the upper gastrointestinal tract is greater than that produced with codeine, but considerably less than that of morphine. Constipation and alteration of bowel habits are less frequent with Demerol than with morphine. It should be noted that typical attacks of biliary colic may be precipitated with Demerol, but these can be regularly (although briefly) relieved by the inhalation of amyl nitrite. Demerol, like morphine, produces relief of biliary colic by its central effects. The spasmolytic effects on the bronchial tree and ureters are less than originally thought. The drug does not significantly alter the activity of the normally contracting uterus but appears to increase the tone, frequency and intensity of contractions in the uterus made hyperactive by oxytocics.

**Other Effects** Like morphine, Demerol causes vasodilatation and, if the patient assumes the upright position, hypotension, tachycardia, vertigo, and even syncope. The frequency of vertigo limits the use of this drug in the ambulant patient. Other untoward side effects include profuse sweating, dryness of the mouth, and flushing of the face.

**Addiction Danger** Habituation and addiction to Demerol are a serious menace, although they develop more slowly than with morphine. Therefore the same cautions and restrictions should be observed as with morphine.

**DOSAGE**—The dose of Demerol is approximately 10 times that of morphine. An approximate dose scale is 0.75 mg per pound of body weight, not to exceed 150 mg. Very frequently 50 mg is sufficient to relieve mild to moderate pain particularly in older patients, and most adults can be afforded relief with 100 mg. The maximum dose of 150 mg should be reserved for vigorous patients with severe pain. If this dose is ineffective, a smaller dose (50 mg) is given intravenously or another drug is tried.

Demerol can be administered orally, but the results are less satisfactory than following intramuscular injection. Although it is considered irritating to the skin, the subcutaneous route can be employed to advantage when only a few doses are to be given. In urgent situations the drug may be administered intravenously, but must be injected slowly, or severe untoward reactions particularly dizziness, restlessness, flushing, tremors, and even convulsions and syncope may occur. In a few instances the writer has seen cardiovascular collapse following a rapid dose of 50 mg in elderly patients. Following subcutaneous and intramuscular injection,

orphine to patients who have received large doses of narcotics for analgesia during the first stage of labor reduces markedly neonatal respiratory depression. The uterine tone, progress of labor, and postpartum course are unaffected by nalorphine. Severe respiratory depression or apnea of newborn infants consequent to narcotic analgesia of the mother is effectively overcome by nalorphine. This antagonist also prevents or relieves morphine-induced biliary spasm and elevation of cerebrospinal fluid pressure.

It should be emphasized that nalorphine is *not effective in preventing or abolishing respiratory depression and other depressant effects of barbiturates, general anesthetics, nonnarcotic agents, or pathologic states*. Indeed, it may even aggravate the depression in such instances.

In subjects actively addicted to morphine or other narcotic drugs, nalorphine produces effects indistinguishable from the acute morphine abstinence syndrome. The symptoms reach their peak in 30 to 45 minutes, and last 2 to 3 hours. These properties make this drug very useful in the diagnosis of addiction. Obviously it cannot be used in the treatment of addiction. Nalorphine has been known to induce the abstinence syndrome in persons who have received as little as 15 mg of morphine 4 to 5 times daily for only a few days.

**Mode of Action.** The mechanism of action is not definitely known, but it is thought that it acts as a competitor with the narcotics. According to this theory, the narcotics have an affinity for receptor and effector cells in the neuraxis. The narcotic antagonist displaces the narcotic analgesic from the receptors.

**CLINICAL USE AND DOSAGE.**—Nalorphine has proved most useful in the treatment of acute narcotic intoxication. In such cases, intravenous administration of 5 to 10 mg often produces dramatic effects: the respiration and circulation return toward normal within 3 to 4 minutes. If the increase in pulmonary ventilation and other beneficial effects are not sufficient in 10 to 15 minutes, the dose is repeated. Total dose should not exceed 40 mg. This provides a good margin of safety, since doses of 10 to 15 mg are usually effective in the average case. In newborn infants, the dose is 0.2 to 0.4 mg diluted in 2 to 3 ml of normal saline injected into the umbilical vein. In older children, the dose is 0.1 mg per kilogram of body weight.

Recently premixed solutions of nalorphine and one of the narcotic analgesics have been combined in various ratios to effect analgesia without respiratory depression. The published results have not all been favorable. In one study, a combination containing nalorphine and morphine in the ratio of 1:2 produced analgesia and side effects similar to those produced by morphine alone. Under other circumstances, the mixture resulted in more profound respiratory depression and sedation than morphine alone. Obviously, until critical ratios have been definitely established, such combinations cannot be recommended for general use.

**Levallorphan (Lorfan).**—Levallorphan, more recently synthesized than nalorphine, has the same structural relationship to levorphan (Levo Dromoran) as nalorphine has to morphine.

**COMPARISON OF LEVALLORPHAN AND NALORPHINE.**—The pharmacology of levallorphan resembles that of nalorphine. On a weight basis, it is approximately 4 to 5 times as potent as nalorphine.

hours respiration had returned to control levels following anileridine, whereas respiration remained depressed following meperidine. Dripps and co workers found itching, nausea, vomiting, and euphoria following the administration of anileridine as with other narcotics.

Studies on human volunteers and animals indicate that anileridine, unlike meperidine, does not cause liberation of histamine, a fact of significant clinical importance. Development of tolerance to anileridine is said to be less and more gradual than to morphine. Although the addiction potentiality of anileridine has not been determined in detail, it has been shown that the drug is addictive.

**DOSAGE**—Anileridine is available in 25 mg tablets for oral administration and as sterile solutions containing 25 mg per milliliter for parenteral use. The recommended oral dose in adults is 25 mg, repeated every 4 to 6 hours if necessary, in treating mild to moderate pain and 35 to 75 mg for severe pain. However, in cases of severe pain it is preferable to inject the drug subcutaneously or intramuscularly in doses of 25 to 50 mg. As in the case of morphine, intravenous administration of the drug may be employed for a more prompt and more marked effect. However, it should be stressed that small doses should be employed and the injection be carried out very slowly lest the patient develop marked respiratory depression, which may progress to apnea and/or marked hypotension.

[Ethioheptazine (Zactane) is a feeble and apparently nonaddictive congener of meperidine. It is available in a mixture with aspirin. Ed.]

**Methadone (Dolophine)**—Methadone is a comparatively new synthetic compound with pronounced analgesic properties produced by German chemists during World War II. Methadone is a heptanone derivative which is also known as Dolophine, Adanon, and amidone.

**COMPARISON OF METHADONE AND MORPHINE**—Methadone exerts many pharmacologic actions which are strikingly similar to morphine, particularly analgesia.

**Effectiveness** It is a slightly more potent analgesic than morphine. In experimentally induced pain 10 mg of methadone raised the pain perception threshold 100 per cent. Several clinical investigators report moderate to complete relief of pain in over 85 to 90 per cent of patients. As a rule, pain is relieved without significant sedation. Like morphine, the focus of the analgesic action of methadone is in the central nervous system.

**Addictive Characteristics** Methadone produces only mild euphoria in non-addicted patients when used for the relief of pain. On the other hand, in addicts and postaddicts a large dose of this drug produces euphoria which is as intense as that produced by morphine and other potent opiates and persists longer. Moreover, in these patients methadone prevents or completely alleviates the morphine abstinence syndrome. Therefore it can be employed in the therapy of opiate addiction. Tolerance to methadone develops more slowly than to morphine. Upon abrupt withdrawal of methadone the abstinence syndrome develops more slowly, is less intense and more prolonged than the abstinence syndrome of morphine.

**Other Effects** Maximal analgesic doses of methadone depress respiration and the cough reflex, increase intestinal tone and the amplitude of contractions, and produce smooth muscle spasm and miosis, almost but not quite to the same degree

following its intravenous administration have been reported. Urticaria, skin rash and contact dermatitis may occur.

Abnormal responses to the analgesic effects have also been reported in sensitive individuals. Codeine may cause severe epigastric pain, and hyperalgesia may occur in hypersensitive individuals following the disappearance of the analgesic effects.

Infants and aged and debilitated patients are more susceptible to depressant effects of narcotics, and the dose should therefore be reduced. Care must be taken in administering morphine for a prolonged period of time to pregnant women for the drug passes the placental barrier and enters the tissues of the fetus. Indeed, the newborn infant may show withdrawal symptoms if it has been repeatedly exposed to morphine in utero.

In adults, existing pathologic states which may or may not be causing the pain for which analgesics are being given may cause abnormal responses to the narcotic. The administration of small therapeutic doses of a narcotic to patients with myxedema may be followed by a severe depression, whereas hyperthyroidism increases the tolerance to the drugs. Patients with increased intracranial pressure may show marked depression following the administration of usual doses of morphine or another narcotic analgesic, whereas patients with psychoses or fever may become excited. The use of morphine in patients with hypertrophied prostate or ureteral stricture may precipitate acute urinary retention. Deaths have been reported following the administration of morphine to patients with bronchial asthma.

A change in position from the horizontal to the vertical after administration of morphine may be followed by cardiovascular collapse. This complication is probably due to a generalized vasodilatation and consequent depression of homeostatic reflex mechanisms and uncompensated drop in blood pressure. It is particularly important when morphine is administered to ambulatory patients who have serious cardiovascular disease.

**OVERDOSAGE**—Acute narcotic poisoning occurs following inadvertent clinical overdosage or as a result of a suicidal attempt. The amount of morphine necessary to cause acute poisoning varies with the individual's tolerance. The susceptibility of infants, of the aged, and of adults with certain diseases has been mentioned. A normal adult with severe pain (which is an antagonist to opiates) can tolerate up to a 60 mg. dose, whereas, if pain is not present, such a dose will prove toxic. Of course, the addict can tolerate 20 to 200 times the therapeutic dose. In normal adults a dose of 120 mg. of morphine is usually followed by serious symptoms; with larger doses the prognosis becomes progressively less hopeful, and with 240 mg. death occurs as a result of the marked respiratory depression and consequent anoxia.

Occasionally a delayed type of narcotic poisoning occurs in patients with impaired cutaneous circulation resulting from shock, neurogenic hypotension, or exposure to cold. Subcutaneous and even intramuscular injections of morphine in such circumstances may not be absorbed and thus may fail to give adequate relief of pain. The unwary physician may repeat the administration of the drug one or more times in an effort to relieve the pain, but because of the impaired absorption the drug is ineffective until, as a result of therapy for the shock, the improvement

**PHARMACOLOGIC EFFECTS**—When given in the absence of narcotics levallorphan produces slight analgesia and respiratory depression and other narcotic effects. However, when given after, together, with or before narcotics, it corrects or prevents respiratory depression and other undesirable effects.

Several clinical investigations in which levallorphan was combined with various narcotics to produce analgesia with minimal respiratory depression should be mentioned. Preliminary studies in postoperative or chronic pain indicate that a ratio of 10 parts levorphan to 1 part levallorphan provides good analgesia and adequate respiration. Administration of 0.03 mg per kilogram of levallorphan combined with either 0.66 mg per kilogram of alphaprodine (Nisentil) or 2 mg per kilogram of meperidine (Demerol) effectively prevents respiratory depression and still produces analgesia.

**CLINICAL USES AND DOSAGE**—The indications for levallorphan are the same as those for nalorphine. The initial adult dose is 0.5 to 1.0 mg administered intravenously. Several small increments are preferred to large single doses. In infants and children the dose can be calculated on the basis of 0.02 mg per kilogram of body weight.

### Complications of Narcotic Therapy

It is apparent from the preceding discussion on the pharmacology of narcotic analgesics that inherent in their use are certain undesirable side effects which evidently cannot be divorced from analgesia. With proper use of these drugs these somewhat expected effects are of a minimal degree and therefore, are of little concern. Occasionally, however, the undesirable effects are of such serious and malefic nature as to endanger the patient's life. These complications may occur as a result of overdose or prolonged administration. Overdose may be absolute or relative and is followed by acute toxic effects, whereas prolonged use of narcotics results in addiction.

#### Acute Toxicity—

**ETIOLOGY**—Acute toxic reactions may result from (1) attempt at self extinction, (2) gross error in dosage, (3) abnormal response to usual therapeutic dose, (4) delay in absorption of repeated doses, or (5) sudden disappearance of severe pain soon after the administration of large therapeutic doses.

**UNTOWARD REACTIONS TO THERAPEUTIC DOSES**—Sensitive reactions and other abnormal responses occasionally occur following administration of optimal therapeutic doses to patients who apparently have sensitivity or idiosyncrasy to narcotics. These abnormal responses are manifested by extremely severe and persistent nausea, vomiting, constipation, and central nervous system depression requiring active therapy. Some individuals, especially women, are excited by morphine and some of the other opiates, particularly codeine and heroin. In some unusual cases there is stimulation of the cerebrum resulting in tremors, rarely delirium, more rarely convulsions, and sometimes insomnia as a late sequel. Marked excitement is not infrequently observed after excessive doses of codeine. Heroin may cause central excitation and is taken by the heroin addict for its euphoric stimulation.

Allergic phenomena rarely, if ever, follow administration of narcotics. Wheals following subcutaneous injection of codeine and marked anaphylactoid reaction

methoxamine (Vasovyl), 3 to 5 mg intravenously and 10 mg intramuscularly, or phenylephrine (Neo Synephrine), 1 mg intravenously and 5 mg intramuscularly, is preferable because these drugs do not accelerate the heart. Of course, if there is shock, plasma or plasma expanders are administered.

**Other Measures** Additional measures consist of maintenance of proper fluid and electrolyte balance, maintenance of normal temperature, frequent change in the patient's posture to obviate pulmonary complications, repeated catheterization to avoid distention of the bladder, and symptomatic therapy of itching, nausea, vomiting, and confusion during the recovery period. Usually the narcotic antagonist decreases the severe gastrointestinal symptoms, but, if these persist, they may be relieved by administering an antiemetic drug such as Marezine, Dramamine, or Thorazine. Usually doses of 50 mg intramuscularly repeated every 3 to 4 hours are effective.

**Narcotic Addiction**—Prolonged consumption of morphine and other narcotic analgesics is inherent in the most serious complications of this method—addiction. Addiction may be defined as the habitual and compulsive misuse of a drug in a manner productive of results which are harmful to the user, to society, or to both. This condition is characterized by three principal phenomena: tolerance, habituation, and physiologic-dependence. Wikler adds a fourth to these: the tendency to relapse to the use of the drug after repeated "cures." Although a detailed discussion of this problem is outside the scope of this chapter, the problem is of such importance as to warrant the following summary, which will serve as a basis for the discussion concerning the design for clinical use of addictive analgesics.

**Tolerance**—Tolerance may be defined as the progressive diminution in the intensity of the effects to the same dose of drug in question during prolonged repeated use. In patients medically addicted to narcotics given for control of chronic pain, the development of tolerance is usually first manifested by a gradual increase in the amount of drug needed to provide the same degree of relief. Initially the patient may obtain sufficient analgesia with 10 mg of morphine, but, with repeated use of the drug at regular intervals, a progressively larger dose is required to control the pain. This phenomenon may progress to such a point that the individual tolerates 20 to 200 times the ordinary therapeutic dose of the narcotic.

For some unknown reason, tolerance does not occur to all manifestations of

other hand tolerance is developed to the euphoric effects, respiratory depression, lethargy and stupefaction and these fail to appear after continued use of the drug unless the dose is increased. There seems to be no apparent limit to the tolerance of the euphoric or psychic effects. Although the addict develops tolerance to the analgesic action of morphine, fortunately this tapers off when 30 to 45 mg are reached. Thus, the morphine addict with pain will experience relief of the pain with relatively small doses of the drug which will not produce psychic effects.

The time necessary to develop such tolerance varies with each drug and from individual to individual. However, 2 weeks of continued use of the drug is the average time necessary to develop some tolerance to the depressant effects. The

in the circulation leads to the sudden absorption of the morphine from the various sites and results in morphine poisoning

Another not infrequent cause of narcotic depression is administration of large doses for severe pain of a type which may suddenly lessen in severity or even disappear spontaneously. For example, the excruciating pain of renal or biliary colic or coronary occlusion may disappear coincidentally following the administration of morphine which has justifiably been given in maximum doses. As a consequence acute morphine poisoning develops

**Symptoms** Acute narcotic poisoning is manifested by central nervous system depression. In mild cases the patient is asleep or stuporous, but in severe cases this progresses to coma which may be profound. The respiratory rate may be 2 to 4 per minute, and as a result of the asphyxia a mottled cyanosis soon appears. The pupils are symmetrical and pinpoint but, if anoxia supervenes, they may dilate markedly. The blood pressure is at first maintained and may be even increased above normal due to hypercarbia but it soon begins to fall gradually because of deleterious effects of anoxia on the capillaries, with a consequent increase in their permeability and loss of blood proteins. This eventually will lead to irreversible shock if treatment is not instituted.

The triad of coma, pinpoint and symmetrical pupils, and marked respiratory depression strongly suggests a diagnosis of acute morphine poisoning.

**TREATMENT**—Treatment consists of use of narcotic antagonists and supportive measures to the respiration and circulation.

**Ventilation** The first and most important step is to provide adequate ventilation for the patient so that the tissues are properly respired. This is best accomplished by introducing an endotracheal tube and connecting it with an appliance which contains a source of oxygen and means for absorption of carbon dioxide. Inasmuch as the main drive to respiration in patients with severe narcotic depression is the hypoxic stimulation of the carotid chemoreceptors, high tensions of the inhaled oxygen will probably cause apnea. Then it will be necessary to ventilate the patient manually or by means of a mechanical ventilator.

**Narcotic Antagonists** As soon as this initial step is accomplished, the patient is given a narcotic antagonist. The initial dose is 5 to 10 mg of nalorphine (Nalline) or 0.5 to 1.0 mg of levallorphan (Lorfan) given intravenously. If the increase in pulmonary ventilation is not adequate in 10 to 15 minutes, the dose is repeated. Since a relative overdose of the antagonist (i.e., a dose larger than necessary to reverse the effects of the narcotic) will aggravate the depression, an attempt should be made to titrate by using small increments rather than to hazard overdosage. This is particularly important if the dose of the narcotic is unknown. Amounts of 10 to 20 mg of nalorphine or equiaffective amounts of levallorphan are usually sufficient to dramatically restore normal respiratory and circulatory function. It is essential, however, that the patient is observed for at least 24 hours.

**Circulation** In severe toxicity the cardiovascular system is usually depressed and requires supportive measures. In the early phases when hypotension is due to vasodilatation, vasopressors should be given. If the hypotension is accompanied by a slow pulse, ephedrine, 25 mg intravenously or 50 mg intramuscularly, will effect a sustained rise in pressure and increase in pulse. If the pulse is rapid



losis and loses weight. At the end of the fifth to the seventh day these signs and symptoms subside and the patient begins to eat, drink, and sleep and rapidly regains his composure and weight.

**THERAPY OF NARCOTIC ADDICTION**—With the exception of patients with painful fatal illness, the occurrence of narcotic addiction caused by treatment for illness is evidence of therapeutic failure.

**Diagnosis** Diagnosis of addiction in patients is simple if the physician keeps in mind the comments made in connection with tolerance. The presence of constricted pupils and scars or needle marks in the skin should arouse suspicion. An absolute diagnosis can be facilitated by administrations of small doses (2.5 mg.) of nalorphine or (0.5 mg.) levallorphan.

**Management** The management of narcotic addiction is a highly specialized problem requiring a well integrated program that includes expert medical psychiatric and nursing care and cannot be discussed here.

## DESIGN FOR USE OF ADDICTIVE ANALGESICS FOR RELIEF OF PAIN

**Principles**—The primary purpose of the preceding detailed discussion concerning the effects and complications of narcotic analgesics was to emphasize the serious nature of their clinical use. The exigencies of a busy clinical practice are often conducive to their improper use, which not infrequently results in complications. In order to minimize this risk it is necessary for the physician to consider carefully many of the details previously discussed.

At the risk of belaboring points already made, it should be stressed that the cause of pain must be ascertained and, if possible, eliminated rather than masked by drugs. On the other hand, analgesics may be useful in giving relief while attention is directed toward determining and treating the fundamental etiologic basis of pain. Moreover, the physician should not use addictive analgesics when other medicaments will accomplish the same end. As previously stated, non-narcotic analgesics alone or in combination with sedatives and hypnotics are frequently effective in relieving mild to moderate pain, especially that from integumental structures. When these no longer prove adequate, they may be combined with codeine, dihydrocodeine, or with small doses of Demerol. It should be stressed that the use of narcotics should be postponed until they are specifically needed. This is not to say that narcotics should be avoided, but they should be reserved specifically for control of moderate to severe pain in patients in whom other drugs or methods have failed or are contraindicated.

Assuming that addictive analgesics are indicated their proper prescription requires acceptance of certain premises. The relief from pain with this or any other method is always obtained at a price exacted from the patient in the form of psychologic and physiologic deviations or depletions. Although with proper application the price may be relatively small there is no addictive drug which is devoid of undesirable effects. Indeed one of the most notable profits derived from recent clinical studies of addictive analgesics is the belated realization that in equivalent analgesic doses they all produce remarkably similar undesirable effects.

It is the primary mission of the physician to select the drug of choice and use

larger the dose and the more frequent and regular the administrations, the quicker tolerance develops. The importance of prescribing the smallest dose which will provide adequate relief from pain is obvious. Cross tolerance exists between the various alkaloids, and a person tolerant to morphine is also tolerant to dihydromorphinone (Dilaudid), heroin metopon, and codeine. When medication is discontinued, tolerance usually disappears within a few days to several weeks, depending on the duration and degree of tolerance. After this interval small doses will again produce analgesia and depressant effects, but, if the continued use of the drug is resumed, tolerance develops more rapidly than it did initially.

**HABITUATION**—Habituation refers to the psychologic and emotional dependence on the drug. The drug provides a mental "crutch," without which the addict is anxious, unhappy, depressed, and irritable. The situation arises primarily because the patient has realized that the drug provides relief from anxiety, tension and the need for psychologic adaptive behavior. Psychologic dependence requires a certain readiness and there are several predisposing factors which make it one of the leading hazards in prescribing addictive drugs. These include pre-existing alcoholism, psychoneurotic tendencies, extreme degrees of anxiety overdependence, and previous psychotic episodes.

**PHARMACOLOGIC ADDICTION**—Pharmacologic dependence refers to a phenomenon which is closely related to tolerance and signifies the basic physiologic need for the narcotic the abrupt withdrawal of which is followed by an "abstinence syndrome."

**Abstinence Syndrome** The abstinence syndrome is characterized by development of the psychosomatic and autonomic complex of signs and symptoms clearly manifesting physiologic dependence on the drug. These signs and symptoms appear within 4 to 12 hours after the last dose of the opiate is omitted and they progress in degree so that within 48 hours they are severe, reach their peak in 72 or 96 hours and thereafter regress so that at the end of the fifth to the seventh day they usually cease.

The first signs are yawning, lacrimation, rhinorrhea, sneezing, perspiration, anorexia and tremors—all of which are usually mild. These are soon followed by restlessness, irritability, mental depression, muscular weakness, dilated pupils, and increased respiratory rate. At this point the addict strongly indicates the desire for the drug. All of these manifestations progress to an exaggerated degree. The weakness and depression become pronounced as do the nausea, vomiting and diarrhea. He usually experiences bouts of chills alternating with flushing. Severe muscle tremors, twitching, rigidity, headache, diplopia, delirium and occasionally mania also develop. Not infrequently severe myalgia of the abdomen, chest, back, and extremities, simulating visceral disease, occurs.

At the end of the first 8 hours or thereabouts, the addict falls into a deep sleep which may last from 8 to 12 hours, but from which he awakens more irritable, restless, and miserable than before. The syndrome may appear several times before the regression and final subsidence of the signs and symptoms take place. During the 4 or 5 days in which the signs and symptoms are very severe, the patient becomes dehydrated as a result of the vomiting, diarrhea, and sweating coupled with the failure to take fluids and food. As a consequence he develops acidosis or alkali-

prescribing the analgesic drug and assuming without follow up that the patient had relief of pain because this was the amount (and type) of medication advocated for this condition is to be deplored. Moreover, care must be exercised in avoiding labeling the patient as psychoneurotic or hypersensitive because the prescribed dose is not adequate. If proper evaluation indicates that the type and dose of the analgesic afforded adequate relief the same dose should be given if pain returns with the previous intensity. Otherwise the dose is altered accordingly.

#### Optimal Mode of Administration —

**ORAL** —The oral route is the most convenient to all concerned and the least uncomfortable to the patient. It is therefore, indicated in managing chronic pain. However, it has the disadvantage of variation in the rate and degree of absorption; consequently the degree of analgesia is not strictly predictable.

**SUBCUTANEOUS** —The subcutaneous route is most commonly employed to administer narcotics for the relief of pain. The action of the drug is more uniform and of longer duration than by any other route, the 'peak action' is not as high as it is following intramuscular or intravenous administration and, therefore the unpleasant side effects are not as marked. However, as previously stated this route should be avoided in patients with impaired cutaneous circulation that may result from shock, neurogenic hypotension or exposure to cold.

**INTRAMUSCULAR** —The intramuscular route is employed when the oral or subcutaneous routes are contraindicated or when quicker action is desired. It has the advantage over intravenous administration in that the action of the drug is more uniform of longer duration and the peak effect is slightly less and therefore the unpleasant side effects are of a lesser degree.

**INTRAVENOUS** —On the other hand, intravenous injections of narcotic analgesics afford a means of giving effective pain relief almost immediately, although for a shorter period of time. Following intravenous administration, morphine gives relief of pain within 3 to 5 minutes, has a peak action in 10 to 30 minutes and lasts only 1 to 2 hours. In addition any idiosyncrasy or abnormal sensitivity to the drug will be immediately manifested allowing the curtailment of the injection or if the total dose had already been given the physician knows of the abnormal effects immediately.

The intravenous method should be reserved (1) for extreme emergencies such as severe coronary occlusion or injury accompanied by excruciating pain (2) for very severe almost intolerable pain associated with conditions which in themselves are not emergencies such as occurs with renal or biliary colic and (3) to obtain a short peak action for the management of severe pain of very short duration like that associated with painful manipulation or instrumentation. Examples of the latter indication are the pain associated with the insertion of a cystoscope in a patient with urethral stricture, administration of the first enema to sensitive patients who have had a recent hemorrhoidectomy the changing of dressings in patients with severe burns and manipulation or reduction of a dislocation or fracture.

The dosage of the various narcotics for intravenous injection is approximately two thirds to three fourths that for subcutaneous injection. In order to avoid such unpleasant side effects as nausea, vomiting, vertigo, tinnitus, generalized

it in such a manner as to cause the least degree of disturbance of bodily function. How effectively he discharges this grave responsibility depends primarily upon his knowledge, judgment, skill, experience, interest, and patience. It is mandatory that he adhere strictly to the fundamental principles of good therapeutics, namely, (1) to give a specific drug for a specific indication, (2) to administer the drug in optimal doses, i.e., the smallest amount which will cause the desired effects, (3) to administer it by the optimal route. These entail individualization of type and amount of drug and the route of administration for the particular patient and the particular pain. From almost every standpoint the management of chronic, intractable pain must be considered quite differently from the control of acute pain. However, in either case it is important to give due consideration to the optimal dose and route of administration.

**The Optimal Dose**—The optimal dose of a drug may be defined as that minimal dose that provides the desired therapeutic effects. The importance of determining the optimal dose of narcotic in managing pain, whether it be acute or chronic, is obvious. In the treatment of acute pain there is a premium on rapid and effective relief and there is little opportunity for leisurely trial-and-error prescription. Moreover, since drugs produce unpleasant and at times dangerous side effects, the flexibilities in dosage are not as great as is permissible with many other drugs, such as penicillin, for example. In managing chronic pain the use of minimal effective dose reduces the risk of addiction.

**INFLUENCE OF PAIN INTENSITY**—The optimal dose of each drug for the "average" patient has been mentioned in the discussion on pharmacology. In determining the dose for a specific situation it is necessary to consider the age, weight, and physical status of the patient, the reflex irritability of his nervous system, the intensity of the pain, and the presence of coexisting disease. However, except in extremes of age, the *intensity of pain is the most important factor determining the amount of analgesic required for relief*. Since we possess no means of accurately assessing the severity, quality, and duration of clinical pain, the careful history and observation of the patient and the patient's description of the symptoms remain the most important guides in pain management.

**OTHER FACTORS INFLUENCING DOSAGE**—In addition to estimating the intensity of pain, other factors must be considered. Fever, like pain, increases the nervous reflex irritability and the metabolism of the individual, which in turn affects the intensity of pain. Coexisting disease such as hyperthyroidism also causes increase in metabolism, and, therefore, a greater amount of analgesic has to be given to these patients for the relief of coexisting pain. On the other hand, the dose must be decreased in patients with hypothyroidism, in those who are debilitated, and in the aged and infants.

**EVALUATING THE EFFECTS OF A DOSE**—It bears re-emphasis that the analgesic action of morphine and its congeners is so selective that pain can be relieved in most cases with 10 mg or less of morphine or the therapeutic equivalent of other drugs. All too often, larger amounts than necessary are prescribed, and consequently undesirable side effects occur, particularly respiratory depression.

Following determination and administration of the initial dose, its efficacy should be carefully assessed by the same methods. The widespread practice of

drug intravenously. In this way the physician not only provides much needed relief promptly but is better able to judge the effects and the optimal dose for subsequent administrations. For very urgent situations intravenous injections of alpha prodine (Nisentil) will provide more prompt relief than any other analgesic. In adequate relief 15 to 20 minutes after intravenous administration is an indication for an additional dose. In the presence of very severe pain it may be necessary to administer several therapeutic doses at intervals of 15 to 20 minutes. Under such circumstances the total dose of narcotic administered may be far greater than usually required but properly given it will not cause depression because the severe pain antagonizes the depressant effects of these drugs. An uncommon grievous error is to deprive patients of the relief they may obtain from analgesics by administering them in routine fashion.

**VISCERAL PAIN**—The above comments also apply to the control of severe pain associated with visceral disease. Patients with excruciating pain of acute pancreatitis, perforated peptic ulcer, severe renal or biliary colic, mesenteric thrombosis, or coronary occlusion may require up to 45 mg of morphine administered intravenously in 10 mg doses at intervals of 15 to 20 minutes. In patients with renal colic it is important to be prepared to treat acute narcotic depression (page 229) because the pain may suddenly disappear should the calculus be passed.

In patients with severe pain who are not adequately relieved with narcotics temporary interruption of the pain pathways with nerve blocking technique is indicated.

**Chronic Pain**—The management of severe, intractable, chronic pain is a most difficult problem, often taxing the therapeutic skill of the physician to the utmost. This is especially true in pain of undetermined origin, in which case there may be a tendency for the busy practitioner to take the easy way out and resort to addictive analgesics for a prolonged period. Without doubt this can sometimes be one of the most serious, if not disastrous, errors in clinical medicine. The physician may be entrapped into committing such an error by humane though ill considered decision to keep the patient from suffering. Administration of narcotics in patients with chronic pain is a frustrating short lived type of kindness such mistaken humanitarianism inevitably is nothing but a great disservice to the patient. This is so because, with continued use of the addictive analgesics tolerance to the analgesic action develops and eventually an impasse is reached in which the patient's daily narcotic requirements are high, yet the alleviation of pain is inadequate. In addition to being medically unsatisfactory this situation is fraught with the possibility of social and economic disaster for the addicted patient and his family.

It is obvious that narcotic therapy is not the answer to the management of patients with chronic pain. This is especially true of patients suffering from trigeminal neuralgia, glossopharyngeal neuralgia, causalgia, or other reflex dystrophy, chronic visceral pain, 'idiopathic' neuralgia, severe pains due to chronic arthritis, headaches, angina pectoris, and other severely painful disorders that otherwise do not constitute an immediate threat to the patient's life. These patients deserve an intelligent appraisal and a systematic plan for relief which will conserve their physical, mental and moral resources. Every other method of relieving pain should be exhausted before the patient is hopelessly abandoned to a narcotic regimen. These measures include psychotherapy, sedatives and nonnarcotic analgesics,

prunus, and respiratory depression, the drug should be administered *slowly* and with caution. It is best to dilute the analgesic drug to a total volume of 5 to 10 ml and take 3 to 5 minutes for the administration. Following the injection of the first milliliter, the patient should be observed and questioned for unpleasant symptoms. The physician should be careful to avoid suggesting them by making neutral inquiries.

**Treatment of Acute Pain**—Proper control of severe pain consequent to surgical or accidental trauma or disease with narcotics requires discretion and clinical judgment garnered from experience. It should be re-emphasized that injury, whatever the cause or degree, is not necessarily followed by severe pain. It is obviously essential to avoid routinization of narcotic therapy. If any analgesic is indicated the optimal dose should be administered at irregular intervals and *not by the clock*. Since dependence may result from as few as 1 or 2 injections of a narcotic if the injections are given to a person with special psychologic problems, these drugs should be discontinued as soon as severe pain subsides, and nonnarcotic analgesics should be substituted. *Special caution should be exercised in administering drugs to alcoholics, to patients who manifest extreme degrees of anxiety and overdependent attitudes toward the physician, to those with history of multiple operations, to individuals whose complaints are markedly out of proportion to the physical findings, and to patients with previous psychotic episodes.*

**POSTOPERATIVE PAIN**—Postoperative pain requires careful evaluation of the patient if proper use of narcotics is to be made because severe pain does not necessarily follow operations. Approximately one fourth to one third of unselected patients in general surgical wards experience no significant postoperative pain. The incidence of pain varies according to the patient, the site of operation, type of incision, etc. Operations involving superficial parts of the body, extremities, head and neck are followed by much less pain than intra-abdominal or intrathoracic procedures. Most patients who experience postoperative pain can be relieved with 10 mg of morphine or equivalent analgesic doses of other drugs administered subcutaneously. If this dose proves inadequate, a similar dose is administered intramuscularly in 2 to 3 hours. If this still proves ineffective, it is best to change to another drug.

The intensity of postoperative pain usually diminishes progressively so that at the end of 48 hours it does not require narcotics. This, together with the fact that duration of analgesic effects of narcotic drug varies among different individuals emphasize the importance of prescribing the drug in lower succeeding doses and only for relief of pain. Since many of these patients experience discomfort related to anxiety, sleeplessness, apprehension, and nausea, the intramuscular injection of pentobarbital, 100 mg per 70 kg, is a very useful adjunct to a narcotic for routine postoperative use. Good nursing care will further enhance the effectiveness of analgesics. The most important point to be made concerning postoperative pain is to avoid routine administration of narcotics at regular intervals.

injury when their general condition may preclude adequate absorption of narcotics from under the skin. In such cases it may be advisable to administer the analgesic

out divulging the amounts in each syringe. This is done to avoid bias on her part. One or two doses of placebo may also be included to ascertain the degree of placebo reaction. The nurse is requested to observe and record accurately the results after each injection. The smallest dose that provides comfort with minimal side effects is selected as the optimal dose. Obviously this prolonged search for the optimal drug and optimal dose cannot be used in acute pain.

In order to delay addiction and tolerance the narcotics should be given at irregular intervals. It should be stressed that the patient should be given sufficient amounts of the drug and at intervals to obviate periods of severe pain. One of the practices that makes psychologic dependence develop more quickly is failure to use enough of the drug to achieve the desired effects. This situation can be avoided by assuring the adequacy of the dose and by giving the drug promptly on the appearance of pain and not waiting until the patient writhes with pain.

The fear of pain and other affective reactions to pain may be modified by the use of drugs other than analgesics such as barbiturates, Thorazine and amphetamine.

## RATIONAL BASIS FOR NEW NARCOTIC ANALGESICS FOR THE RELIEF OF PAIN

Since 1803 when Sertuner discovered and isolated morphine from opium many clinicians have accepted and appreciated its virtues without much concern about the available laboratory and clinical evidence which indicates that it is and other opiates have potentialities for harm. However these disadvantages have been recognized by some clinicians, pharmacologists and chemists a fact reflected in their zeal and ceaseless effort to produce a better analgesic resulting in the synthesis of hundreds of narcotics. Serious consideration of what has been said in previous pages promptly indicates the need for better analgesics. The ideal analgesic would have the following characteristics:

- 1 It would produce satisfactory analgesia in at least 90 per cent of parenteral administrations and in 60 per cent of the oral trials.
- 2 Its side effects would be minimal particularly upon respiration, circulation and cerebration. Administration to ambulatory patients would not be followed by untoward reactions.
- 3 Since severe pain is in frequent association with spasm of smooth muscle it would have spasmolytic as well as analgesic action. It would not be spasmogenic.
- 4 Prolonged usage would not lead to tolerance, habituation or addiction.
- 5 Usefulness in patients regardless of the age or disease is desirable.
- 6 It would be administrable by any route without irritation.
- 7 It would be effective orally.
- 8 Its physical properties would allow ease of preparation, sterilization and storage without deterioration.

## NONANALGESIC DRUGS IN THE RELIEF OF PAIN

**Hypnotics and Sedatives**—Sedation may be of great value in reducing tension and thereby decreasing pain in some patients. Since pain interferes with sleep many patients derive great benefit from drug induced rest and sleep. The most

physical and roentgen therapy, analgesic blocks, and neurosurgical operations. When this is done, there is some reasonable expectation that the patient may have actual freedom from pain as well as from the discomfort of pain.

Since pain is both a sensory and an emotional experience, successful management needs to be directed simultaneously toward its several aspects. At the same time, adjustments in the patient's life setting should be an intrinsic part of the therapeutic plan. Provision for increase or decrease of physical activity, rest periods, combined with self administered physical therapy, simplification or increase of responsibility at work or at home, and exhaustive inquiry into the environment as a possible source of difficulty should be considered as part of the therapeutic plan for patients with chronic pain.

By far the most important factor in the proper management of chronic pain is the performance of the physician. If the physician views pain traditionally, merely as a symptom of physical disease, instead of considering the whole person, and further disregards the emotional changes that arise with pain, proper management is impossible. Such a physician finds it necessary to administer narcotics frequently and, because he offers nothing else, tends to encourage the use of these drugs and make them essential to his patients. On the other hand, the attentive physician, who offers his patients sympathetic understanding, kindness, cheerfulness, steady psychological support and realistic perspective, provides similar results without resorting to frequent use of addictive drugs. He prescribes such drugs only as a specific part of the relationship between physician and patient and not as a substitute for that relationship.

Patients with chronic pain who develop addiction as a consequence of prolonged narcotic therapy require equally competent management. Notwithstanding the widely held belief that medically addicted patients should not be withdrawn from narcotics as long as the underlying painful illness remains, a serious attempt should be made to manage the pain in some other way and gradually discontinue the narcotics. All of the above comments, of course, *do not apply* to patients with fatal illnesses, in whom the question of addiction is of little concern. In patients with severe pain due to inoperable or recurrent carcinoma, the major concern of the physician is to provide relief, not restoration to useful life.

**DETERMINING THE BEST DRUG**—In patients in whom, either due to the nature of the disease or other circumstances, it is necessary to control severe chronic pain with narcotics, the design for their use requires certain considerations. Although morphine is the time honored drug, there are those for whom this drug fails. For every patient who must be on a narcotic regimen in the face of intractable pain there is some opiate or opioid which is superior to any of the others. Its supremacy depends upon complex qualities besides analgesia, and the final criterion in any case is which of the drugs best satisfies the patient. His reaction to the drug represents a composite of analgesia, pleasant modification of mood, freedom from undesirable side effects and hang over, and many other things. It is essential, therefore, to plan a systematic search for the most suitable drug. This is best accomplished by the rotation system of administering a different drug every 24 hours and then having the patient decide which is the most effective.

**DETERMINING OPTIMAL DOSAGE**—To do this, several different doses of the drugs are prepared in syringes which are coded and then given to the nurse with-



**PHENOTHIAZINE DERIVATIVES**—Chlorpromazine (Thorazine) and, more recently, promethazine (Phenergan) and promazine (Sparine) have been found to enhance the relief of moderate to severe pain due to a variety of disorders. These drugs significantly potentiate the analgesic action of narcotics so that less of the latter drug needs to be employed. The sedative and tranquilizing effect of Thorazine and, to a lesser degree, of Phenergan and Sparine eliminates the patient's anxiety and tension, causing him to view his pain with detachment, an action referred to as "pharmacologic frontal lobotomy."

For the relief of pain the phenothiazine compounds are usually employed in conjunction with narcotics, sedatives, or analgesics. Oral or intramuscular administration of 10 to 25 mg of Thorazine 3 times daily permits the reduction of narcotic doses to one half to two thirds those usually employed.

Thorazine should not be used in patients who have received very large or unknown quantities of barbiturates, narcotics, or alcohol. Because it potentiates hypotension produced by spinal or extradural anesthesia, it should not be used in conjunction with nerve blocks that produce extensive vasomotor paralysis. The sedative and hypotensive effects limit the use of the phenothiazine compounds in ambulatory patients. The physician should be on the alert for signs of jaundice, a complication which occasionally occurs following the administration of chlorpromazine.

**OTHER DRUGS**—What has just been said regarding the combinations of analgesics with other agents can be applied to a heterogeneous group of drugs, which are frequently employed clinically in the management of pain.

**Amphetamine** Benzedrine and other amphetamine compounds have been shown to enhance the analgesic effect of morphine and of nonnarcotic analgesics such as acetylsalicylic acid. Moreover the amphetamine compound improves the mood and gives a feeling of well being, which in itself is important in the management of pain, particularly in chronic diseases. The average dose of the amphetamine compound for such purposes is 2.5 to 5 mg.

**Scopolamine** Because of its sedative and tranquilizing effects, scopolamine is frequently employed in combination with a narcotic agent in the management of pain, especially in patients who are restless and agitated. The optimal dose in such cases is 0.3 mg.

**Miscellaneous Sedatives** Chloral hydrate and other sedatives may be employed for the same purposes. Thus 0.5 to 1.0 Gm of chloral hydrate with therapeutic doses of salicylates may be given 2 or 3 times daily to patients who have mild or moderate pain associated with anxiety, fear, and apprehension.

**PLACEBOS**—Discussion of the use of placebos for the relief of pain belongs in this section because its effects are often very similar to those of sedatives and hypnotics. Many careful clinical studies could be cited to emphasize the effectiveness of placebos in painful disorders and other subjective responses but one will suffice. Beecher and his associates noted that fully one third of patients with severe, steady, postoperative wound pain were effectively relieved with saline or lactose placebos. In a discussion on this subject, Beecher presents a summary of 15 publications containing many data substantiating the effectiveness of the placebos. They are so potent that no physician can afford to ignore them.

common drugs used for this purpose are the barbiturates, chloral hydrate, and the recently introduced phenothiazine compounds, Thorazine and Phenergan, and even alcohol. In direct contradistinction to the analgesics, these have little, if any, effect upon pain perception but are used primarily because of their salutary modification of reaction or mood. They will be considered briefly here and only in connection with their use in the relief of pain.

**BARBITURATES**—Standard teachings have long suggested that in small hypnotic doses barbiturates are of little or no value in the management of pain. In fact, these drugs have been considered contraindicated in the presence of pain because they produce restlessness and delirium. These concepts probably developed as a result of laboratory studies which demonstrated that barbiturates fail to inhibit the perception of experimentally induced pain. However, recent clinical studies on existing 'pathologic' pain have demonstrated the efficacy of hypnotic doses (100 mg.) of pentobarbital (Nembutal) and secobarbital (Seconal) in relieving mild to moderate pain.

The mechanism of their action is undoubtedly on the reaction phase of pain. Barbiturates, like the opiates, alter the psychic modification of pain. In this manner, concern, anxiety, fear and significance are detached from pain. In some patients in whom the psychic component of pain contributes greatly to the pain experience, the barbiturates alone may be sufficient to relieve the discomfort. This is especially true in 'hypersensitive' or 'psychoneurotic' patients. In some patients, discomfort is due to a combination of pain and apprehension and therefore a small dose of barbiturates should be employed as a supplement to a small dose of narcotics to achieve maximal benefit.

Short acting barbiturates have the advantage of rapid effect and elimination, while the long-acting drugs may be used to establish a more or less sustained condition of hypnotic effect. Restlessness in children who are having pain can frequently be controlled by small doses of 30 to 60 mg. of phenobarbital.

**ALCOHOL**.—Imbibition of wine and other alcoholic beverages to relieve pain and produce euphoria dates back for centuries. Alcohol in 5 to 10 per cent solution administered intravenously produces relief of mild to moderate pain through its euphoric effects by modifying the reaction to pain and, to a lesser extent, by raising the pain perception threshold. By its cerebral effects, it also allays apprehension and eliminates fear and anxiety. Thus it is conducive to mental and physical relaxation without producing depression of respiration or the other undesirable side effects inherent in narcotic therapy. However, it is necessary to administer it under very close supervision. Rate of flow needs to be carefully regulated, for otherwise the patient may become inebriated and consequently restless, overactive, and difficult to manage. There is something to be said for oral administration of this agent.

The intravenous administration of dilute (5 to 10 per cent) ethyl alcohol may be employed in the management of mild to moderate pain. It is especially useful in geriatric patients in whom it is desirable to avoid the respiratory depression inherent in narcotic analgesics. It may be combined with nonaddictive or addictive analgesics. This method has been advocated for alleviation of the severe pain of angina pectoris and in cancer patients who otherwise require large doses of narcotics.

**NITRITES**—Nitrites relieve pain by relaxing smooth muscle through a direct (peripheral) action independent of innervation and without impairing the ability to contract on normal stimulation. Their most prominent action is on blood vessels of the coronary arteries.

**XANTHINES**—Theobromine and theophylline and their salts and derivatives exert some relaxant effect on the smooth muscle of the tracheobronchial passages.

**HISTAMINE**—The use of histamine in the management of pain is based upon the fact that it is a powerful vasodilator, being the most effective dilator of cerebral vessels. It has been found effective in histaminic cephalalgia and some cases of neuralgia. Following injection into a peripheral artery, it produces maximal vasodilation.

**Ergotamine**—Ergotamine (Gynergen) has been employed in the management of migraine headache with some success. It is believed that ergotamine interrupts the mechanism of migraine by constricting overdistended arteries. The oral or sublingual dose is 4 to 5 mg initially and 1 to 2 mg every 1 to 2 hours until 10 mg have been taken. The initial intramuscular or subcutaneous dose is 0.25 to 0.5 mg, which may be repeated in 1 to 2 hours if the headache is not relieved, but no more than 1 mg should be administered in 24 hours. In order to minimize side effects, which include nausea and vomiting, muscular weakness, leg pains, numbness, and paresthesia, it is important to employ the smallest amount effective for relief. Moreover, in order to obtain prompt relief, it is necessary to give the drug during the prodromal stage.

**Vasodilators**—These are discussed in Chapters 24 and 27.

**Intravenous Procaine**—Intravenous administration of procaine and other local anesthetics for management of pain has passed the phase of enthusiasm and at the present time is not widely used. These drugs probably exert their effects on the central and peripheral nervous systems. This method may be tried in patients with intractable postherpetic neuralgia, pain of tabes dorsalis, and reflex dystrophies. It is essential to repeat the infusion every 3 to 15 days for a prolonged period of time.

**Cobra Venom**—Cobra venom has been advocated for many years in treating chronic pain. A number of reports have been published with claims that this drug is effective in selective patients with certain types of pain. It has been suggested that this drug interferes with pain perception in the cerebrum although some believe that it has peripheral action. Despite the claims of most writers, this agent has proved ineffective in the hands of the writer and his associates. Because of equivocal results most clinicians have discarded its use.

## REGIONAL ANALGESIC BLOCK

Regional analgesic block is a very effective method of producing a physiologic, reversible interruption of pain pathways. In the management of patients with

*Mode of Action* The mechanism by which placebos relieve pain is not definitely known but probably involves the effects of suggestion on the reaction phase of pain. In the previously cited study it was noted that the effectiveness of placebo was far greater when anxiety, apprehension, and mental stress associated with the pain were greater than when they were less. There is also much objective evidence to support the thesis that the action of placebos is not limited to psychologic responses but also effects physiologic changes.

*Use* Placebo is useful in the therapy of pain and other symptoms which have a predominant reaction phase. It may also be used in dealing with neurotic patients and as an investigative tool to evaluate analgesics. Of course, the effectiveness of the placebo depends a great deal on the physician, who unavoidably exerts a placebo effect merely by having been consulted professionally. His personality, his actions, and his very attitude (including both conscious and subconscious elements) will greatly influence the direction and the magnitude of this psychotherapeutic effect. If fundamental therapy is impossible or only partially effective, he may find it advantageous to supplement this personal placebo effect by the administration of placebo medication.

There are two absolute requisites for success in the use of placebos: the first is that the patient must believe he is being given a drug intended for the use of the relief of pain, and the second is that the nurse or attendant who administers the drug shares that belief. A very effective way of prescribing a placebo is to include it in a series of doses of analgesics. Provision of the nursing staff with already prepared solutions eliminates the natural prejudice against placebo which is rampant among those who do not appreciate the effectiveness of this therapeutic tool.

## ANALGESIA BY REVERSAL OF PAIN MECHANISM

There are a large number of drugs which relieve pain by acting directly on tissues or by mechanisms independent of the central nervous system. They include the antispasmodics, sympatholytic drugs, the spasmolytic drugs, and others. Although these drugs do not fall within the scope of this chapter, their effectiveness in relieving some very severe forms of pain requires that they be briefly mentioned here. They are of course considered in detail in appropriate chapters.

**Skeletal Muscle Relaxants**—The recent widespread use of curare and other skeletal muscle relaxants in anesthesiology has naturally led to their use for the relief of pain consequent to muscle spasm such as seen in posttraumatic conditions, arthritis, poliomyelitis, tetanus, spastic states, and many other diseases. The basis for their clinical use is their ability to produce selective paresis of the skeletal muscles by blocking motor impulses at the myoneural junction. These drugs are discussed in Chapter 18.

### Smooth Muscle Relaxants—

**ANTICHOLINERGIC DRUGS**—Atropine and other anticholinergic drugs relieve spasm and excess motor activity of the smooth muscles and glands innervated by postganglionic cholinergic nerves. These drugs are widely employed in disorders involving the gastrointestinal and urinary tracts. Suitable doses diminish spasm and the associated pain and discomfort without interfering seriously with digestive processes.

## THE CHOICE OF AN ANESTHETIC

*Joseph F. Artuso, Jr., M.D.*

### THE CHOICE OF A GENERAL ANESTHETIC

#### INTRODUCTION

The general anesthetics used for the relief of pain during surgical operations are a little more than 100 years old. They have stood the test of time well for some of the original agents are still in use.

The primary purpose of general anesthesia is to render an individual unaware of the stimuli of environment, to provide freedom from pain, muscular relaxation and lack of memory for the experience. It must be stressed that more important than the anesthetic is the choice of the administrator of the anesthetic. The indications and the pharmacologic considerations of the drugs discussed in this chapter are indeed important bits of information. However the physiologic upset to the patient that these anesthetic agents produce when well administered is minute in comparison with the physiologic upheavals that develop when the same agents are given by those who do not know how to deal with changes in ventilation and circulation that occur during surgical manipulation in the anesthetic state.

#### CLINICAL APPLICATIONS AND PHARMACOLOGIC CONSIDERATIONS

**Surgical Anesthesia** Total unawareness of environment without the appreciation of pain or other sensory perception and without the memory of the experience—This degree of central nervous system depression is the most common form of pain relief in surgery today and is usually called the state of surgical anesthesia. However this degree of central nervous system depression with its concomitant depression of ventilation and circulation is detrimental to the patient's homeostatic defense mechanisms. It is gradually being replaced in many surgical centers by levels of minimal depression which are less injurious to circulation and ventilation.

The 100 per cent potent anesthetic drugs are the ones best suited for this type of pharmacologic effect, ether, chloroform and cyclopropane being the most effective. However because of the serious depression to cardiac function and peripheral circulation which occurs simultaneously with respiratory depression, chloroform is the least desirable of the three. Cyclopropane also produces this degree of central nervous system depression but, because it has little or no direct effect at the

SELECTED REFERENCES

- Alexander, F. A. D. Control of Pain, in Hale, D. E. Anesthesiology, Philadelphia, 1954,
- Depression, Anesthesiology 16 674, 1955
- Dripps, R. D., Millar, R. A., and Kneale, D. H. A Comparison of Anileridine, Morphine, & Obst 105 322, 1957
- , and Jones, R. E. A Study of the Combina  
ites for the Prevention of Respiratory Depres-  
13 332, 1955
- Analgetics, Springfield, Ill, 1955, Charles C  
Thomas
- Gruber, C. M. Codeine Phosphate, Propoxyphene Hydrochloride and Placebo, J A M A 164 956, 1957
- Hardy, J. D., Wolff, H. G., and Goodell, H. Pain Sensations and Reactions, Baltimore, 1952, Williams & Wilkins Company
- Haugen, F. P. Current Concepts of the Pain Process, J Chron Dis 4 4, 1956
- Isbell, H., and Fraser, H. F. Addiction to Analgetics and Barbiturates Pharmacol Rev 2 362, 1950
- J A M A New and Unofficial Drugs 116 1481, 1958
- Keats, A. S. Postoperative Pain Research and Treatment, J Chron Dis 4 72, 1956
- Keats, A. S., and Beecher, H. K. Pain Relief With Hypnotic Doses of Barbiturates and a Hypothesis, J Pharmacol & Exper Therap 100 1 1950
- Keats, A. S., Telford, J., and Kurosu, Y. Studies of Two New Potent Analgetics, Anileridine 112 306, 1954
- Las effectiveness of Codeine and Meperidine 112 306, 1954
- La of Morphine, J A M A 156 230,
- Livingston, W. K. Pain Mechanisms New York, 1944, The Macmillan Co
- Mauter, D. W., and Vogel, V. H. Narcotics and Narcotic Addiction, Springfield, Ill, 1954, Charles C Thomas
- Ripley, H. S. Psychologic Basis of Pain, in Bonica, J. J. The Management of Pain, Philadelphia, 1953 Lea & Febiger
- Starzl, T. E., Taylor, C. W., and Magoun, H. W. Collateral Afferent Excitation of Reticular

**Secondary Anesthesia** Total unawareness of environment, primarily used to produce a pharmacologic effect of the drug other than its effect on the central nervous system—This degree of central nervous system depression is provided as a result of inducing another pharmacologic effect with an agent which simultaneously produces general anesthesia. For example, ether is administered to patients during a drug resistant asthmatic episode because it produces bronchial dilatation when given in doses which also depress the nervous system. Such a dose will abort the attack of drug resistant asthma but will carry with it the same dangers as any other general anesthetic. The risk is thought to be justified in view of the threats inherent in uncontrolled asthma. At present ether is the best agent available for this pharmacologic effect. The great threat to the patient during a convulsive episode apart from physical injury is the secondary effect of hypoxia and hypercapnia. The respiratory musculature is contracted along with the other somatic muscles during a generalized convulsion whereas the pharmacologic effect sought of the anesthetic is relaxation of respiratory muscles. In relaxing the muscle spasm by central depression the anesthetic agent allows the muscles of respiration to function and to provide respiratory gas exchange. The great danger however is depression of the respiratory center by the anesthetic used to control the convulsion. In this situation one must be prepared to treat apnea then the recurrence of the convulsion then apnea again etc. until the cycle is broken. The danger of respiratory depression can be adequately met with suitable apparatus to provide artificial ventilation. The thiobarbiturates and the ethers are used successfully to control convulsions. Here I think the agent of choice is the intravenous barbiturate.

## THE SEVERAL DRUGS

### Surgical Anesthesia

The potent or 100 per cent anesthetic agents are the ideal drugs to produce this level of depression. However all except chloroform are explosive or flammable Volatile Vapors—

**CHLOROFORM**—Chloroform one of the most potent anesthetics in use today has a small margin of safety in that cardiac overdose occurs almost simultaneously with respiratory overdose. Resuscitation from this agent may be extremely difficult because both systems are paralyzed. Chloroform also sensitizes the heart to epinephrine arrhythmias hence one must not use epinephrine or norepinephrine with chloroform. Liver damage with central necrosis of the liver lobule is well described following chloroform administration. However, this degree of liver damage is probably caused in part by hypoxia associated with inadequate ventilation during administration.

**ETHER**—Ether is ideal for this degree of depression. It has a wide margin of safety in that the anesthetic dose is approximately half that producing respiratory arrest. When respiration does stop because of a high concentration of ether in the brain circulation is still maintained for a period of time, so that resuscitation is usually successful. The cardiac output during ether anesthesia is maintained primarily by ether's stimulation of adrenal medullary secretion and the liberation of sympathetic vasopressors by the cardiac sympathetic nerve endings. If however

neuromuscular junction more profound central nervous system depression is required to provide large muscle relaxation with it than with ether. Ether (ethyl ether) is still by far the best agent available today for this degree of anesthesia. It is potent, has good peripheral blocking action at the neuromuscular junction, and is readily controllable.

**Analgesia.** Awareness of environment with sensory perception, but without the appreciation of pain and without the memory of the experience.—This degree of central nervous system depression is comparable to the first stage of anesthesia of Guedel's classification and is sometimes called the state of analgesia. Central nervous system depression of this degree can be tolerated by patients in the extremes of age: those with cardiovascular disease, the debilitated, those with depleted blood volume from acute hemorrhage or contracted blood volume secondary to a chronic debilitating disease. Where minimal central nervous system depression is maintained throughout a surgical procedure in such patients, both the respiratory and circulatory systems withstand the stress without signs of decompensation so that they may be safely carried through extensive procedures.

It was this level of anesthesia that was once thought to be dangerous to the patient, permitting deleterious effects on the central nervous system by noxious stimuli. The great fear of entering a delirium phase made the administrators of the anesthetic agents apprehensive of using this level of anesthesia for any but operations on the surfaces of the body and of extremely short duration, but if one induces analgesia in retrograde fashion with ether so that the surgical stage is entered once in its lightest degree, the delirium phase does not develop, no matter how frequently the transition is made from a light level of depression to a deeper level of depression. The only danger inherent in this level of anesthesia, in which the patient can respond to questioning, is the possibility of remembering the experience. If there is some memory of the experience, an extremely rare occurrence, it is, however, recalled as an extremely pleasant experience and not one that was unpleasant or painful.

The best available agents today for this type of depression, I feel, are ether, nitrous oxide, and ethylene, in that order, with or without the simultaneous use of a muscle relaxant.

**Amnesia.** Awareness of environment, with pain relief provided by another agent with no memory of the experience.—This degree of central nervous system depression provides strong sedation during an operation performed under some form of regional anesthesia. During long regional procedures the patient may become restless and fatigued and frequently may interpret pressure and traction as pain. The anxiety and the misinterpretation of a stimulus as a painful one makes an excellent regional block inadequate.

A hypnotic drug will induce a state in which the individual is partially or completely aware of environment but during which anxiety, restlessness, and incorrect interpretation of the stimulus no longer exist and the operating conditions are better both for the surgeon and for the patient. The pharmacologic effect is one of relaxation and freedom from worry. It complements well performed regional anesthesia. There is little or no danger; the principle of light anesthesia obtains, so that the organism is not depressed by the anesthetic.



weak anesthetic agent, as mentioned before apply to nitrous oxide in even greater degree. To produce even the lightest level of surgical anesthesia requires 80 to 90 per cent of this gas. The danger from hypoxia is indeed great.

#### Nonvolatile Agents —

**THIOBARBITURATES** —The drug most commonly used is thiopental sodium (Pentothal Sodium). Although other thiobarbiturates have recently been introduced methitural (Neraval), thiamylal (Surital) they have little or no advantage over thiopental sodium. These agents have little or no analgesic potency, and induction of a state of surgical anesthesia requires a large amount of the agent. When they are used alone to induce this depth of depression, severe respiratory and circulatory depressions ensue. Since the thiobarbiturates are fat soluble and are readily absorbed by the fat depots when large doses are used to induce anesthesia there is considerable fat storage. The drug is released from fat maintaining the barbiturate blood level and prolonging anesthesia after its administration has been discontinued.

Because of the profound effects on both circulation and ventilation and the fat storage, it is not wise to use these agents for this degree of depression.

**TRIBROMOETHANOL (Avertin)** —This is another agent without analgesic potency. It produces greater respiratory and circulatory depression at this level of anesthetic depression than the thiobarbiturates. It is of no value for surgical anesthesia.

**HYDROXYDIONE (Viadril)** —This steroid without hormonal properties has not presented any special advantages.

#### Analgesia

##### Volatile Vapors —

**CHLOROFORM** —This extremely potent agent has really had no clinical trial for this form of anesthesia. One could speculate, however, that because of its intense analgesic properties chloroform might be the ideal agent. This drug, therefore, should be given a clinical trial for this degree of anesthesia.

**ETHER** —Ether is established as the best agent for this degree of anesthesia. There is both intense analgesia and amnesia with little or no disturbance to the cardiovascular or respiratory system.

**HALOTHANE** —While this agent may be an excellent one for analgesia there is however insufficient trial at this level of nervous system depression.

**VINYL ETHER** —Because of rapid action and rapid recovery vinyl ether is difficult to control during this level of anesthesia. Because of possible hepatotoxic effects it is not wise to use it for prolonged operations.

**ETHYL CHLORIDE** —For the same reasons as for vinyl ether, ethyl chloride is not a suitable agent with which to maintain a patient at this level of anesthesia.

##### Gases —

**CYCLOPROPANE** —Because of the rapid recovery with this agent it is difficult to maintain a steady level of analgesia but high flow nonbreathing techniques may approach a constant analgesic state with this agent.

**NITROUS OXIDE** —If this weak analgesic is given together with an apneic dose of a muscle relaxant a state can be developed which approximates the analgesic state. It must be borne in mind however, that the total effect may be related to

there is adrenal insufficiency, ether may be a serious depressant to cardiac output from the very beginning of its administration

**HALOTHANE (FLUOTHANE)**—Halothane is an extremely potent agent, more potent than chloroform. Cardiovascular depression is so severe during this degree of anesthesia when Fluothane is used as a sole agent that it should not be used for this level of central nervous system depression

**VINYL ETHER**—Vinyl ether (Vinethene) is a potent agent with a rapid onset there is rapid recovery from its effects and it is of use for this degree of depression only for procedures lasting less than 30 minutes. Used for a long period this agent has toxic effects on the liver which may become permanent. It is important to note that during the early administration of this agent convulsive movements may be seen. These are not asphyxial convulsions such as those that may be seen during diethyl ether administration but are manifestations of central irritative phenomena produced by the drug itself. They are benign and do not have the importance of the convulsions related to asphyxia during ether administration

**ETHYL CHLORIDE**—Ethyl chloride is a potent drug which produces rapid onset of anesthesia and is followed by rapid recovery. It is used primarily as an inducing agent. Its one drawback is its primary depressing effect on the heart, an action similar to that of chloroform. The patient should always be well atropinized before the administration of this agent

**TRICHLOROETHYLENE**—Although a potent agent trichloroethylene is an extremely poor one for this degree of anesthesia. At this stage of depression primary effects on the respiratory mechanism may result in tachypnea and inadequate gas exchange. Cardiac irregularities may also develop. It should never be used in closed system anesthesia associated with alkaline carbon dioxide absorbing agents because under these circumstances it breaks down into the toxic dichloroethylene

**Gases**—All available gases are explosive and inflammable except nitrous oxide which supports combustion

**CYCLOPROPANE**—Cyclopropane a potent agent is an ideal drug for this level of anesthetic depression. With it however one must be continually on guard against respiratory depression and respiratory acidosis. Through its vagal action cyclopropane depresses the sinoauricular node so that simultaneously administered epinephrine may excite foci in the ventricle which may then dominate the cardiac rhythm. Because of its potency there is usually present in the rebreathing mixture during closed system anesthesia oxygen in concentrations of at least 80 per cent. Thus it is the best gas for this level of anesthesia.

of  
trator increases the concentration of this agent, oxygen in the inspired mixture is sacrificed and the patient's central nervous system suffers from all the deleterious effects of hypoxia. Thus the great danger from this anesthetic agent, where used for this purpose, lies in its lack of potency

**NITROUS OXIDE**—Nitrous oxide is a weak inorganic gas, and because of its lack of potency it is an extremely poor one with which to produce surgical anesthesia. Nitrous oxide is a weaker anesthetic agent than ethylene. All the dangers of a

HALOTHANE may be of value in reducing blood pressure during surgical procedures

TRICHLOROETHYLENE is of no value

VINYL ETHER can be used to control convulsions for the same reasons as ether

ETHYL CHLORIDE is of the same value as vinyl ether

Gases —

CYCLOPROPANE is not suitable

ETHYLENE is not suitable

NITROUS OXIDE is not suitable

Nonvolatile Agents —

THIOBARBITURATES are of importance in controlling convulsions, but one must be aware of the danger of apnea following cessation of the convulsion

AVERTIN is effective in controlling convulsions but severe respiratory and circulatory depression limit its value

## A DESIGN FOR THE USE OF DRUGS FOR GENERAL ANESTHESIA

**Surgical Anesthesia** —The drugs used for this degree of depression are primarily the 100 per cent potent anesthetic agents. Concomitantly they depress the central nervous system and the circulatory and respiratory systems. In order to obtain the optimum anesthesia at this level one must carefully monitor the character of ventilation and its rate, the blood pressure, pulse quality, and heart rate and rhythm. The care of each patient must be individualized. When depressed to this degree there will be effects on both circulation and respiration in many, and if these are allowed to persist for even a brief period, death may ensue.

Before the introduction of the skeletal muscle relaxants, this degree of depression was necessary for abdominal surgery. However, because of the physiologic derangement produced by the concentration of anesthetic agent it was precarious to operate on extremely old patients and to permit this degree of depression to continue for long periods. A modern concept is that surgical anesthesia should be induced to the lightest degree compatible with the surgical needs. Peripheral muscle relaxation should not be produced by central action of these drugs and associated central nervous system depression but rather by the skeletal muscle relaxants.

**Analgesia** —This degree of anesthesia appears to be the least disturbing physiologically. It is a level of depression in which increasing numbers of anesthetics are being conducted for surgical procedures. Analgesia can be accomplished with low concentrations of potent agents or high concentrations of weak anesthetic agents. In either event at least 20 per cent of oxygen or more must be present in the inspired mixture at all times. In those operations requiring muscular relaxation peripheral muscle relaxants should be given simultaneously with the anesthetic agent. In procedures not requiring muscle relaxation, there is of course no such problem.

Ether administered until the patient enters a level of depression in which he is unaware of environment and does not react to stimuli and then returned to awareness of environment, provides this light degree of depression satisfactorily.

inability to move and amnesia for the experience. Because of its weak analgesic potency and the possibility of breakthrough of painful afferent stimuli, this level of depression may be deleterious to the organism.

**ETHYLENE** —Everything said previously for nitrous oxide applies to this agent.  
**Nonvolatile Agents —**

**THIOBARBITURATES** —As sole agents these are not valuable at this level of anesthesia. They possess no analgesic properties and although a state of unawareness and amnesia can be produced the patient responds actively to all stimuli as well as to pain.

**TRIBROMOETHANOL (AVERTIN)** —Tribromoethanol is of no value at this level of depression because of lack of analgesic potency.

## Amnesia

**Volatile Vapors —**

**CHLOROFORM** is of no value

**ETHER** is of no value

**HALOTHANE** is of no value

**TRICHLOROETHYLENE** is of no value

**VINYL ETHER** is of no value

**ETHYL CHLORIDE** is of no value

**Gases —**

**CYCLOPROPANE** is not suitable

**ETHYLENE** is not suitable

**NITROUS OXIDE** is not suitable

**Nonvolatile Agents —**

**THIOBARBITURATES** —These drugs are ideal for this type of psychic sedation. To prevent appreciable fat storage of the drug one only has to see that the total dose of the drug is not large.

**TRIBROMOETHANOL** —Avertin has ideal properties for this type of sedation. However, it is too depressing to both circulation and respiration and, if used, would have to be given before the regional anesthetic.

**NARCOTIC ANALGESICS** —These agents are only fairly effective for this type of depression. They do not produce real sedation. Although they will produce a type of euphoria in a large percentage of patients, dysphoria is common enough to make them undesirable.

## Secondary Anesthesia

The choice of the anesthetic agent used for this purpose depends entirely on the primary pharmacologic effect required of the anesthetic.

**Volatile Vapors —**

**CHLOROFORM** is of little or no value

**ETHER** is ideal for patients in status asthmaticus for its bronchodilating effect. The level of anesthesia must be relatively deep and of at least 30 minutes' duration. Convulsions of a variety of types are controlled by the primary effect of ether to relax the respiratory muscles and to allow ventilation to become adequate.

## THE CHOICE OF A LOCAL ANESTHETIC

### INTRODUCTION

With the introduction of the hypodermic syringe in 1853 by Alexander Wood and the demonstration of the anesthetic action of cocaine by Koller in 1884, adequate tools were available for the first time for the development of local anesthesia. Halsted in 1884 and Corning in 1885 demonstrated the clinical value of cocaine for local anesthesia by the injection of this substance in various parts of the course of nerve trunks. Since then many local anesthetics have been synthesized, largely in an attempt to reduce toxicity. A discussion of the local anesthetic agents that follows will confine itself to those agents which are most widely used today.

### CLINICAL APPLICATIONS

The action of these drugs is to interrupt pain impulses in a specific region of the body. Depending upon the clinical need, a nerve can be blocked in any portion of its course from its exit from the cord to its termination.

**Local Infiltration**—Nerve endings in the skin and subcutaneous tissues are blocked by direct infiltration of the tissue itself. With spread of the anesthetic agent throughout the tissue the nerve terminals are affected. This type of nerve blocking which is commonly known as *local anesthesia*, is used principally for surgical procedures involving a small superficial area in the healthy adult patient. In the patient who is considered a poor risk for other forms of pain relief it is also used for nerve block of deeper structures by direct infiltration.

The dangers of this type of nerve block are primarily those of too much drug in too short a period of time, with high blood level and systemic effects. Since this type of application of the drug usually requires fairly large volumes, it is important that the operator use the lowest concentration of the drug which blocks sensory perception. A careful record of the amount of anesthetic agent should be made. Since anesthesia is usually determined by the patient's response to pain one can inadvertently give enough anesthetic to produce toxic symptoms.

Although most of the available local anesthetics can be used for local infiltration anesthesia, procaine (Novocain) is the most widely used. Certainly it is one of the least toxic and best understood of the available agents. Lidocaine (Xylocaine) has enjoyed some recent popularity but has slightly higher toxicity than procaine.

**Field Block**—Field block setting up walls of anesthesia around an area, rather than direct infiltration, has lost a great deal of its previous vogue. It requires somewhat more precise knowledge of the nerves entering the area than does local infiltration, but, if done well, it provides good anesthesia within the walls of the block.

The therapeutic indications are the same as for local infiltration anesthesia in surface lesions. Since the field block itself usually infiltrates deeper structures, one must be extremely careful of inadvertent intravenous injection which can produce sudden toxicity. There is less danger, however, of giving too much anesthetic, because the field block is usually performed with a smaller total dose of drug than in local infiltration.

It also can be accomplished with nitrous oxide and oxygen at concentrations of at least 60 per cent nitrous oxide and not exceeding 80 per cent nitrous oxide, with the simultaneous use of a muscle relaxant and hyperventilation

**Amnesia**—This extremely light level of depression, often called sedation is ideally provided by the barbiturates. The thiobarbiturate, thiopental, is the best agent available today. Effects can be maintained with thiopental by adjusting the concentration so as to induce the state without excitation and without untoward side effects. The patient must be watched continuously to maintain the optimum therapeutic effect of blocking environmental stimuli and preventing anxiety. The continuous drip is preferred.

**Secondary Anesthesia**—The place for the use of an anesthetic agent for this purpose depends entirely on the primary pharmacologic objective. This problem will be considered in detail in appropriate other chapters.

## RATIONAL BASIS FOR NEW DRUGS FOR GENERAL ANESTHESIA

**Surgical Anesthesia**—The drugs available for this purpose at present seem to satisfy the need on a pharmacologic basis. However most of them are explosive and flammable; a nonflammable nonexplosive drug of this potency is needed. They would be ideal if onset and recovery were rapid. If the new drugs used did not induce cardiac arrhythmias in the presence of epinephrine, they would have still another advantage over some now in use.

It is my opinion, however, that this degree of central nervous system depression is no longer needed or desirable for most operations.

**Analgesia**—At the present writing it appears that all one needs is to produce amnesia for the experience and analgesia for the painful stimuli arriving by afferent pathways. Total unawareness of environment and muscular relaxation produced by central depression are no longer necessary; the state of analgesia may often provide the ideal anesthetic effect for both patient and surgeon.

It is for this state of central nervous system depression, however, that I feel there is the greatest room for improvement in new drugs. The target is a nonflammable nonexplosive drug sufficiently potent to induce amnesia and analgesia in concentrations of approximately 40 per cent of agent and 60 per cent oxygen. Thus there would be 3 times ambient oxygen in the inspired mixture at all times. Both assisted and controlled ventilation could be carried out vigorously at will without fear of drug overdose to the central nervous system, the circulation, or respiration. Muscle relaxation would be provided by a peripheral muscle relaxant.

**Amnesia**—Although the barbiturates are the ideal sedatives available today and the thiobarbiturates the most effective for anesthesia, the latter have the drawback of fat storage so that their effects may not be eliminated for fairly long periods of time. A drug is needed whose metabolism is more rapid than the now available thiobarbiturates and with little or no fat solubility, so that drug action will be terminated rapidly.

**Secondary Anesthesia**—Where the therapeutic objective is not anesthesia, drugs whose pharmacologic effects are not associated with concomitant deep anesthesia would be desirable.

The local anesthetics used in this fashion behave according to the principles of movement in a closed fluid system. The use of a heavy solution termed a hyperbaric solution, or a light or hypobaric solution can, by the positioning of the patient on the operating table, result in different areas of anesthesia. While the anesthetic agent penetrates the nerve roots it also affects the cord, but penetrates only its most superficial layers.

The smaller unmyelinated fibers are anesthetized first and the large myelinated ones later, so that blockade occurs first with sympathetic, then with the sensory and finally with the motor fibers. Recovery takes place in the reverse order.

The great danger in this technique is the inadvertent injection of novocaine substances other than the conventional local anesthetics, such as, for example, the contents of a mislabeled ampule or an anesthetic solution that has been contaminated during wet sterilization. Trauma during the introduction of the needle is another danger, destruction of an end artery to a segment of the cord may result in permanent disability. Because this technique always produces sympathetic block in association with sensory and motor block spinal anesthesia in the upper thoracic region is often associated with sharp falls in blood pressure. These must be guarded against and treated by the judicious use of vasopressors. An extremely high level of anesthesia may affect the medulla, so that immediate resuscitative measures are necessary to control the total spinal block. Spinal analgesia should never be performed in patients with a history of central nervous system disease or disease of the vertebral column.

In situations in which the anesthesiologist feels that general anesthesia is contraindicated due to pre-existing disease and provided it can be induced satisfactorily without paralyzing vital function it is a technique that is safe and should be encouraged.

The local anesthetic agents to be preferred for this block are procaine (tetracaine) (Pontocaine) or butethamine (Monocaine).

**Topical Block**—This type of block is accomplished by applying the anesthetic agent to mucous membrane surfaces and in that way blocking the final nerve terminals in the mucosa. The oral cavity, the pharynx, larynx and tracheobronchial tree provide surfaces for this type of nerve block. It is often used to block sensation and to interrupt reflex activity during bronchoscopy and other manipulation of the respiratory tract.

The great danger is associated with overdosage, often due to too rapid absorption of the anesthetic. To circumvent this danger one must use a fine spray of low concentration of solution, and critical attention to total volume used at any one time. In our hands *Xylocaine* (lidocaine) appears to be the best topical anesthetic, with Pontocaine, cocaine, and others nearly as satisfactory. Procaine is of little value because there is virtually no absorption from mucosal surfaces.

## GENERAL PHARMACOLOGIC CONSIDERATIONS

**Anesthetic Effect**—These agents interfere with nerve transmission and although there are many theories the exact mechanism of action is unknown. Intimate knowledge of the actual changes in the cell itself will be necessary before the

**Peripheral Nerve Block.**—This technique, commonly called regional anesthesia, places the local anesthetic agent in direct contact with the nerve. The therapeutic applications of this type of block are many. The nerve can be blocked at any portion of its peripheral distribution to induce an area of anesthesia from the site of block throughout the entire peripheral distribution of the nerve. Frequently several nerves must be blocked to produce anesthesia of a part.

Peripheral nerve block has value as a diagnostic or therapeutic aid in pain problems in most areas of the body. Local anesthetics can also be used to block nerves of the autonomic system. Thus peripheral nerve block can be used to dilate peripheral vessels which are constricted due to a sympathetic influence.

Nerve blocks of this type require relatively small amounts of anesthesia and are relatively free of the danger of overdosage. Greater danger is involved where the nerve to be blocked lies very close to blood vessels which can be entered or to closed cavities which can be inadvertently pierced. The anesthetic agent should not be put into the nerve itself but rather around the nerve. Intraneural injection invites neuroma formation.

All of the available local anesthetic drugs can be used in this type of nerve block.

**Paravertebral Nerve Block**—This blocks the entire distribution of the nerve after it leaves the intervertebral foramina. The therapeutic applications of this block are primarily the same as for blocks in the peripheral portion of the nerve, and the same general dangers are presented. However, since the block is performed in such close proximity to the subarachnoid space, large vessels and, in the thoracic region, the pleural space, the dangers are proportionately greater and the technique should be carried out only by skilled operators.

**Epidural or Caudal Block**—Epidural block is usually the choice of an anesthesiologist who particularly likes the technique, but it also may be used to prevent the sharp drops in blood pressure that may develop after subarachnoid block. It has been used recently to control postoperative pain.

It is a rather difficult technique, one usually mastered only by the anesthesiologist. It requires a large volume of solution, which increases the possibility of toxic reaction. There is also the danger of inadvertent puncture of the subarachnoid space resulting in a massive spinal block.

Caudal block is in essence an epidural block in the caudal region. It has great application in pain relief for the obstetrical patient as well as for operations in the area of the rectum or genitalia.

All of the available local anesthetic agents have been used in epidural block, and choice is a matter of one's personal preference and the desired duration of the block.

**Subarachnoid Block (Spinal Analgesia)**—Subarachnoid block, commonly called spinal anesthesia but more correctly spinal analgesia, requires that the anesthetic agent be deposited within the subarachnoid space so that the anesthetic mixes with spinal fluid. The anesthetic can be placed in this area in a single injection in which the total calculated dose is injected at that time, or, by the introduction of a malleable needle or spinal catheter, the drug may be introduced intermittently over long periods of time.



The most intelligent way to treat this type of reaction if it is severe, is by direct cardiac massage. The indications are that ventricular fibrillation is the primary cause of the circulatory collapse, and the only way to restore normal cardiac mechanism in this situation is by direct massage or defibrillation and shock therapy. In minor cardiovascular reactions, in which moderate hypotension and bradycardia are the manifestations of the reaction, intravenous administration of vasopressor drugs such as Neo Synephrine, in doses of 1 mg, may be used to restore circulatory dynamics to normal.

One can prevent these reactions or reduce their incidence by using the lowest concentration of drug suitable for the desired effect with slow meticulous injection and frequent aspiration. The testing of these patients for sensitivity is of little value since even the serious reactions can occur from the small doses and concentrations used in the testing material.

## THE SEVERAL DRUGS

### The Alcohols

The alcohol group of local anesthetics are little used today. They are liquids which are partially soluble in water. Phenol, cresol, menthol and benzyl alcohol comprise but a few belonging to the group. By far the most commonly used are benzyl alcohol and phenol. Benzyl alcohol, a representative of this group of local anesthetics, is an aromatic alcohol. It is of extremely low potency. Its greatest uses are topical application and in combination with procaine for prolongation of the action of the latter.

### The Esters

**The Benzoic Acid Esters**—Cocaine and piperocaine (Metycaine) are representative of this group of compounds which are simple aromatic acids in linkage with amino alcohol.

**COCAINE**—Cocaine, a colorless white powder with 3 times the potency of procaine decomposes on boiling. Today it is used primarily as a topical anesthetic in 4 to 10 per cent solutions. Cocaine has vasoconstrictor properties; however, there is no difference in the intensity of vasoconstrictor action of 4 per cent and 10 per cent solutions since drug levels in the blood are the same after the application of equal amounts of each to areas of similar size. It is a frequent offender in producing the central nervous system type of reaction. Cardiovascular collapse is also seen. It can produce addiction. It is probably the most widely used topical anesthetic today.

**PIPEROCAINE**—Piperocaine (Metycaine) is slightly more toxic than procaine. It is thermostable and may be boiled. It is used primarily for infiltration and nerve block anesthesia.

### The Para-Aminobenzoic Acid Esters—

**LOW SOLUBILITY**—Penzocaine (ethyl aminobenzoate, Anesthesin) is suitable only for topical anesthesia. It is frequently added to other solutions to prolong the effect. It is of low potency and toxicity and is stable in an aqueous or oily solution.

### HIGH SOLUBILITY—

**Procaine** Procaine is used primarily for infiltration and nerve block anes-

**Intensity of Effect**—The intensity of the anesthesia produced depends on the molecular structure of the anesthetic agent and the size of the nerve fiber in the area of application of the drug. The small unmyelinated fibers of the autonomic system and the small unmyelinated sensory fibers are the most susceptible because, unimpeded by myelin sheathes or dural coverings, the anesthetic agent can more readily penetrate fibers of this size. The larger sensory fibers are next affected, while the large myelinated motor fibers are affected last. It is possible to block nerve fibers differentially by adjusting the anesthetic concentration so that the block is limited to fibers of particular size.

**Duration of Action**—The duration of a local anesthetic blockade depends upon many of the factors that are inherent in the intensity of action: the drug itself, the fiber size, and the area blocked, but most especially the concentration of anesthetic agent used in the area. Blockade of large motor fibers is of short duration, while blockade of small unmyelinated sympathetic fibers is of relatively long duration.

One way to prolong infiltration, peripheral nerve block, or spinal anesthesia is to inject a vasoconstrictor with the anesthetic. Since the latter slows the rate of absorption of the anesthetic, its effects are prolonged. Vasoconstrictors are of especial value along these lines in highly vascular areas. However, vasoconstrictors are not effective in retarding absorption from mucous membranes.

**Toxic Reactions**—The toxic effects of anesthetic agents are intimately related to the concentration of the anesthetic agent in the blood stream. Common causes of high blood concentration are rapid absorption, concentrated solutions, and large volume of low concentration. Inadvertent injection of anesthetic agents into blood vessels and highly vascular areas also produces the systemic toxic reactions. High local concentrations of these anesthetic drugs not only increase the probability of systemic toxicity but also may produce localized nerve damage or necrosis of surrounding tissues.

The systemic toxic reactions are usually of two distinct varieties, a central irritative phenomenon followed by depression, the other by cardiovascular collapse.

**CENTRAL REACTION**—The central reaction is usually associated with high concentrations of anesthetic in the circulation. It is marked by irritability, talkativeness, and apprehension and may be followed by gross tonic and clonic convulsions and then depression followed by death. In other instances there may not be an excitation phase, only depression. One should be wary of the patient who suddenly becomes extremely sleepy following injection of a local anesthetic, because he may shortly become comatose.

The most effective regimen of treatment for the excitation type of reaction is to stop the injection of the anesthetic agent immediately and to use a rapid acting barbiturate, such as thiopental, intravenously, to control the convulsions. Because the barbiturate itself may also induce apnea, one must be prepared for artificial ventilation as well as treatment of a repetition of central irritation.

**CIRCULATORY COLLAPSE**—The primary circulatory reaction is most difficult to treat, and accounts for most of the deaths due to local anesthesia. It may be seen during injection of minute amounts of anesthetic agent; suddenly the patient collapses, and usually before any resuscitative measures can be applied the patient is dead.

TETRACAINE (PONTOCAINE) is of no value

BUTETHAMINE (MONOCAINE) is useful in 0.5, 1, and 2 per cent solutions. In 0.5 per cent solution the maximum dosage is 200 ml; in 1 per cent solution the maximum dosage is 100 ml; in 2 per cent solution the maximum dosage is 50 ml.

LIDOCAINE (XYLOCAINE) is useful in 1 per cent solution with a total dosage of 50 ml. It has excellent spreading power.

#### Field Block —

BENZYL ALCOHOL is of no value

COCAINE is of no value

PIPEROCAINE is useful in 1 per cent solution with a maximum total volume of 75 to 100 ml.

ETHYL AMINOBENZOATE is of no value

PROCAINE is extremely useful in 0.5, 1, and 2 per cent solutions. In 0.5 per cent solution the maximum dosage is 200 ml; in 1 per cent solution the maximum dosage is 100 ml; in 2 per cent solution the maximum dosage is 50 ml. It is extremely effective and has a duration of 1 hour.

CHLOROPROCAINE (NESACAINE) is useful in 1 to 2 per cent solutions.

TETRACAINE is of no value

BUTETHAMINE is useful in 0.5, 1, and 2 per cent solutions. In 0.5 per cent solution the maximum dosage is 200 ml; in 1 per cent solution the maximum dosage is 100 ml; in 2 per cent solution the maximum dosage is 50 ml.

LIDOCAINE is useful in 1 per cent solution with a total dosage of 50 ml. It has excellent spreading power.

#### Peripheral Nerve Block —

BENZYL ALCOHOL is of no value

COCAINE is of no value

PIPEROCAINE is useful in 1.5 per cent solution with a maximum dosage of 50 ml.

ETHYL AMINOBENZOATE is of no value

PROCAINE is extremely useful in 2 per cent solution with a maximum total dosage of 50 ml. Duration of action is 1 hour. The usual dose is 2 to 5 ml at each nerve site.

TETRACAINE is slightly useful in 0.1 per cent solution with a total maximum dosage of 75 ml.

BUTETHAMINE is useful in 1 per cent solution with a dose of 5 ml at each nerve site.

LIDOCAINE is useful in 2 per cent solution with a maximum volume of 30 ml. It has excellent spreading power. Caution must be used in nerve block in the cervical region to prevent the spread of the anesthetic agent and involvement of the recurrent laryngeal nerve, resulting in vocal cord paralysis.

#### Paravertebral Block —

BENZYL ALCOHOL is of no value

COCAINE is of no value

PIPEROCAINE is useful in 1.5 per cent solution with a maximum dosage of 50 ml.

ETHYL AMINOBENZOATE is of no value

PROCAINE is extremely useful in 2 per cent solution with a maximum total

thetia and is of little value as a topical anesthetic. It is an anesthetic of low toxicity. Today it is the most widely used infiltration anesthetic. It is a stable compound and may be boiled or autoclaved.

**Chloroprocaine (Nesacaine)** Chloroprocaine is used primarily for infiltration and nerve block anesthesia but is also used for epidural and caudal block. Its toxicity is about the same as procaine.

**Tetracaine** Pontocaine (tetracaine, amethocaine) is an agent of high potency and high toxicity, 10 times that of procaine. It is used principally for infiltration and nerve block anesthesia but it is also an effective topical anesthetic. Its duration of action is about twice that of procaine. It may be boiled or autoclaved.

**Butethamine** Monocaine (butethamine) is used for infiltration and nerve block anesthesia. It is slightly more potent than procaine. It is stable and may be boiled or autoclaved. It is little different from procaine in toxicity or use, but with perhaps some slight increase in duration.

### Miscellaneous Local Anesthetics

#### Quinoline Derivatives —

**DIBUCAINE** —The one anesthetic agent of value in this group of compounds is dibucaine (Nupercaine). It is the most potent and the most toxic of the local anesthetic agents in common use today. It is 15 times as potent and toxic as procaine. Duration of action is approximately 3 times that of procaine. It is a stable compound which may be boiled or autoclaved. It is used primarily for infiltration and regional block anesthesia and as a topical anesthetic. Having lost a great deal of its vogue in spinal anesthesia, it is used now primarily with glucose for anesthesia of the perineal region.

#### The Amino Acryl Amides —

**LIDOCAINE** —Lidocaine (Xylocaine) is the most recently introduced popular local anesthetic. It is used primarily for infiltration nerve block anesthesia (other than the intrathecal route), and for topical anesthesia. It has a high spreading factor so that it spreads over a fairly wide area following injection in tissue. Its potency and toxicity are slightly greater than procaine. It is a stable compound which can be boiled or autoclaved.

### THE RELATIVE MERITS AND USES OF SOME LOCAL ANESTHETICS

#### Local Infiltration —

**BENZYL ALCOHOL** is of no value.

**COCAINE** is of no value.

**PIPEROCAINE (METYCAINE)** is useful in 1 per cent solution with a maximum total volume of 75 to 100 ml.

**ETHYL AMINOBENZOATE** is of no value.

**PROCAINE (NOVOCAIN)** is extremely useful in 0.5, 1, and 2 per cent solutions. In 0.5 per cent solution the maximum dosage is 200 ml, in 1 per cent solution the maximum dosage is 100 ml, in 2 per cent solution the maximum dosage is 50 ml. It is extremely effective and has a duration of 1 hour.

**CHLOROPROCAINE (NESACAINE)** is useful in 1 to 2 per cent solutions.

COCAINE is used in a 2 to 10 per cent solution and provides excellent topical anesthesia with rapid onset and duration of action of about 1 hour. The total application for topical use should be limited to 1 to 2 ml of a finely nebulized solution.

PIPEROCAINE is useful in 3 per cent solution, but it is rarely used and is not as effective as lidocaine, Pontocaine, and cocaine.

ETHYL AMINO BENZOATE is useful primarily as a 5 per cent ointment, it produces surface anesthesia for as long as it remains in contact with the area.

PROCAINE is of no value.

TETRACAINE is of value in 2 per cent solution with a total dosage confined to 1 ml. Systemic toxic reactions are common. It should be finely nebulized.

BUTETHAMINE is of no value.

LIDOCAINE is excellent used in 2 per cent solution. It has a rapid onset and a duration of 1 to 1½ hours. It has a good spreading factor. It should be finely nebulized.

## RATIONAL BASIS FOR NEW LOCAL ANESTHETICS

The drugs available at present for infiltration, nerve block, and spinal anesthesia of short duration satisfy the needs of the therapeutic situation. The search should continue, nevertheless, for local anesthetics of lower toxicity than procaine. In the topical anesthetics there is considerable need for decreased toxicity.

The greatest need is for a local anesthetic with effects of long duration—days, weeks, months. The available compounds and mixtures of compounds that are recommended for local anesthesia of long duration also have extremely high local toxicity. Neurolysis with slough and necrosis of the surrounding tissues occurs. If the anesthetic agent is placed in the vicinity of the spinal cord, and such an effect develops, partial or complete transection of the cord, with permanent paralysis, may follow. An agent with low tissue and general toxicity as well as prolonged effect would solve the problems of the control of chronic pain, from whatever etiology, which, at the present time we can relieve only by agents which destroy the nerve tissue.

## SELECTED REFERENCES

### General Anesthetics

- Artusio, J. "A Quantitative Study of Diethyl Ether (Flaxedil) and a Series of Tri Methyl Anesthetized Man, Ann. New York  
 Artusio, J. "Detailed Description of the First Stage of  
 Artusio, J. F., Jr. "Ether Analgesia During Major Surgery, J. A. M. A. 157: 33, 1955  
 Beecher, H. F., Francis, L., and Anfinson, C. B. "Metabolic Effects of Anesthesia in Man  
 I. Acid Base Balance During Ether Anesthesia, J. Pharmacol. & Exper. Therap. 98  
 38, 1950  
 Brewster, W. R., Jr., Isaacs, J. P., and Waino-Anderson, T. "Depressant Effect of Ether on  
 Myocardium of the Dog and Its Modification by Reflex Release of Epinephrine and Nor-  
 epinephrine, Am. J. Physiol. 175: 399, 1953  
 Bunker, J. P., Beecher, H. K., Brizzo, B. D., Brewster, W. R., and Barnes, B. A. "Metabolic  
 Effects of Anesthesia. II. A Comparison of Acid Base Equilibrium in Man and in  
 Dogs During Ether and During Cyclopropane Anesthesia, J. Pharmacol. & Exper.  
 Therap. 102: 62, 1951

dosage of 50 ml Duration of action is 1 hour The usual dose is 2 to 5 ml at each nerve site

CHLOROPROCAINE (NESACAINE) is useful in 1 to 2 per cent solutions

TETRACAINE is slightly useful in 0.1 per cent solution with a total dosage of 75 ml

BUTETHAMINE is useful in 1 per cent solution with a dose of 5 ml at each nerve site

LIDOCAINE is useful in 2 per cent solution with a maximum volume of 30 ml It has excellent spreading power Caution must be used in nerve block in the cervical region to prevent the spread of the anesthetic agent and involvement of the recurrent laryngeal nerve resulting in vocal cord paralysis

Epidural or Caudal Block —

BENZYL ALCOHOL is of no value

COCAINE is of no value

PIPEROCAINE is useful in 1 per cent solution with a maximum dose of 75 ml

ETHYL AMINO BENZOATE is of no value

PROCAINE is useful in 2 per cent solution with a maximum total dosage of 50 ml

CHLOROPROCAINE (NESACAINE) is useful in 3 per cent solutions

TETRACAINE is slightly useful in 0.1 per cent solution with a maximum dose of 75 ml

BUTETHAMINE is slightly useful in 1 per cent solution with a total dosage limited to 75 ml

LIDOCAINE is very useful in 1.5 per cent solution with a dosage of 30 ml Extreme care must be used not to exceed the recommended total dosage

Subarachnoid Block —

BENZYL ALCOHOL is of no value

COCAINE is of no value

PIPEROCAINE is useful in 5 per cent solution, for low spinal, 50 mg, and for high spinal, 100 mg maximum dosage

ETHYL AMINO BENZOATE is of no value

PROCAINE is extremely useful in 50 to 200 mg maximum total dosage depending upon the level of anesthesia For low spinal, 50 to 100 mg, and for high spinal, 150 to 200 mg Duration of action is 1 hour

CHLOROPROCAINE (NESACAINE) cannot be recommended for use in this category at this time because of insufficient data

TETRACAINE is useful in total dosage of 5 to 20 mg It is usually given in hyperbaric solution weighted with glucose one half anesthetic agent and one half 10 per cent glucose It is advisable to limit total dosage to 14 mg, for low spinal 5 mg, and for high spinal 12 mg It is slower in onset than procaine and duration of action is 2 to 3 hours

BUTETHAMINE is useful It is similar to procaine Maximum total dosage for low spinal, 50 mg, and for high spinal 100 to 125 mg

LIDOCAINE is of no value

Topical Block —

BENZYL ALCOHOL is used in 4 per cent solution but lidocaine, Pontocaine and cocaine are more useful and more effective

## THE CHOICE OF SEDATIVES AND TRANQUILIZERS IN GENERAL MEDICAL PRACTICE

*Dale G. Friend, M.D., and*

*James T. Hamlin, III, M.D*

---

### INTRODUCTION

The concept of bringing about a calm or more tranquil mental state without any considerable degree of sedation is of recent origin although certain drugs which do this have been used in medicine for several centuries.

The antihistamine promethazine (Phenergan) was early noticed to possess the ability to calm excited emotional states. Although it produced some sedation, it did not behave like a sedative, since, when it was given in toxic amounts, it did not increase sedation but rather, if the dose was large enough, caused convulsions. It was also observed that diphenhydramine (Benadryl) possessed somewhat similar sedating properties. Many careful observers noted that these antihistamines seemed to exert their action more at the hypothalamic rather than at the cortical level. It was also apparent that cortical activity was unimpaired although relaxation and calming of emotional tension was obtained.

As a result of these observations a definite attempt was made to find more effective agents with similar properties. The antihistamines, sedatives, and many other agents were carefully explored. It is interesting to note that, in spite of the intense search, only one natural product exhibiting this type of action has been found. This was *Rauwolfia serpentina*, a drug which had been in use as a tranquilizer for centuries in India.

Analogues of promethazine were prepared and the phenothiazine series soon supplied most of the more effective tranquilizing drugs. The search for more active antihistamines led to the discovery of the diphenylmethanes, a less potent class of agents than the phenothiazines. Mephenesin, a weak irregular acting agent, supplied the stimulus that led to the preparation of the more effective propane and butanediol compounds. The barbiturates and other sedatives, especially those exhibiting weak sedative properties, and the more potent sedatives, given in small doses, also have been added to the list of agents useful as tranquilizers. Several chemically unrelated agents exhibiting tranquilizing action have been found recently and added to the list. As a result of all this activity there are now nearly

- Burnett, C H, Bloomberg, E L, Sholtz, G, Compton, D W, and Beecher, H K. A Comparison of the Effects of Ether and Cyclopropane Anesthesia on Renal Function of Man, *J Pharmacol & Exper Therap* 96 380, 1949
- Fairlie, C W, Barass, T P, French, A B, Jones, C M, and Beecher, H K. Metabolic Effects of Anesthesia in Man. IV. A Comparison of the Effects of Certain Anesthetic Agents on the Normal Liver, *New England J Med* 244 615, 1951
- French, A B, Barass, T P, Fairlie, C S, Bengle, A L, Jr, Jones, C M, Linton, R R, and Beecher, H K. Metabolic Effects of Anesthesia in Man. V. A Comparison of the Effects of Ether and Cyclopropane Anesthesia on the Abnormal Liver, *Ann Surg* 135 145, 1952
- Habif, D J, Papper, E M, Fitzpatrick, H F, Lawrence, P, Smythe, C M, and Bradley, S E. The Renal and Hepatic Blood Flow Glomerular Filtration Rate and Urinary Output of Electrolytes During Cyclopropane, Ether and Thiopental Anesthesia Operations and the Immediate Post-operative Period. *Surgery* 10 241, 1951
- Hershey, S G, Zwiefach, B W, and Rovenstone, E A. Effects of Depth of Anesthesia on Behavior of Peripheral Vascular Bed. *Anesthesiology* 14 245, 1953

### Local Anesthetics

- Arrowood, J G, and Sarnoff, S J. Differential Spinal Blocks, *Anesthesiology* 9 614 1948
- Campbell, D, and Adrian, J. Absorption of Local Anesthetic Drugs, *J A M A* 193 873, 1958
- Geddes, I C. Studies With Local Anesthetics, *Brit J Anaesth* 27 609, 1955
- Hirshfelder, A D, and Bieter, R N. Local Anesthetics, *Physiol Rev* 12 190, 1932
- Lloyd, J B. The Chemical Structure and Nomenclature of Local Anesthetics, *Brit J Anaesth* 27 286, 1955
- Steinhaus, J E. Local Anesthetic Toxicity, *Anesthesiology* 18 275, 1957
- Vandam, L D, and Dripps, R D. Long Term Follow up of Patients Who Received 10 098 Spinal Anesthetics, *J A M A* 161 586, 1956



Table 13

Drug	Usual Individual Dose	Usual Total Daily Dose
<i>Rauwolfia</i>		
Crude drug (Raudixin)	50-100 mg	100-200 mg
Purified extract (Rauwiloid)	2-4 mg	2-4 mg
Reserpine	0.1-0.25 mg	0.25-2 mg
Deserpidine (Harmonyl)	0.1-0.25 mg	1-3 mg
Rescinnamine (Moderil)	0.25 mg	0.25-0.5 mg
Syrosingopine (Singoserp)	1 mg	1-3 mg
<i>Phenothiazines</i>		
Chlorpromazine (Thorazine)	10, 25, 50, 100, 200 mg	100-300 mg
Fluphenazine (Permitil)	0.25-5 mg	0.75-30 mg
Mepazine (Pacatal)	25, 50, 100 mg	100-400 mg
Methoxypromazine (Tentone)	10-50 mg	30-1500 mg
Perphenazine (Trilafon)	2, 4, 8, 16 mg	6-64 mg
Pipamazine (Mornidine)	5-10 mg	15-30 mg
Prochlorperazine (Compazine)	5-10 mg	20-40 mg
Promazine (Sparine)	10, 25, 50, 100, 200 mg	100-400 mg
Promethazine (Phenergan)	12.5-25 mg	25-50 mg
Thiopropazine (Vontil)	0.5-1 mg	2-8 mg
Thioridazine (Mellaril)	10-100 mg	50-800 mg
Thiopropazate (Dartal)	5-10 mg	15-30 mg
Trifluoperazine (Stelazine)	2, 5, 10 mg	6-20 mg
Triflupromazine (Vesprin)	20-100 mg	75-300 mg
Trimeprazine (Temaril)	2.5-5 mg	10-30 mg
<i>Propanediols and Butanediols</i>		
Carisoprodol (Soma)	0.35-1 Gm	1 Gm
Meprobamate (Equanil, Miltown)	0.2-0.4 Gm	0.8-1.6 Gm
Phenaglycodol (Ultran)	0.2-0.3 Gm	0.6-0.9 Gm
<i>Diphenylmethanes</i>		
Azacyclonol (Frenquel)	20-100 mg	60-300 mg
Benactyzine (Suavitil, Phobex)	1 mg	4-16 mg
Capitodamine (Suvren)	50-100 mg	300-400 mg
Hydroxyzine (Atarax, Vistaril)	10, 25, 100 mg	75-400 mg
<i>Sedative Hypnotics</i>		
Butabarbital (Butisol)	15-30 mg	60-120 mg
Ethchlorvynol (Placidyl)	100-200 mg	200-600 mg
Glutethimide (Doriden)	0.25 Gm	0.75-1 Gm
Mephobarbital (Mebaral)	30-100 mg	90-400 mg
Methypylon (Noludar)	50-100 mg	50-400 mg
Phenobarbital	15-30 mg	60-120 mg
<i>Others</i>		
Ectylurea (Nostyn)	150-600 mg	0.6-2.4 Gm
Oxanamide (Quactin)	400 mg	0.4-1.6 Gm
Phenyltoloxamine (Bristamine, Histonex)	50 mg	150-200 mg
Chlormezanone (Trancopal)	100 mg	100-300 mg

some residuals of its action may be present several days after the drug has been discontinued. In view of its slow onset of action many prefer to give larger oral doses initially and reduce the dose once the desired effect is established. In situations such as hypertensive encephalopathic crises or extreme excitement and agitation, the drug may be given intramuscularly in doses of 2.5 to 5 mg every 8 hours until the desired effect is secured. Because of its mode of action and elimination it is not necessary to give slow release forms of medication.

**EFFECTS**—The effect of reserpine on the human organism is to bring about a peaceful, tranquil state where the individual develops much less emotional response to situations about him. Much of the emotional content, although recognized is

three dozen drugs recommended and being used as tranquilizers. These agents are second only to the antibiotics as the most commonly prescribed drugs, one out of three prescriptions is for tranquilizers and they continue to increase in popularity.

Although the term tranquilizer is in widespread use and seems to have general acceptance for this class of agents it is not entirely satisfactory. Various other terms such as ataractic drugs and phrenotrophic depressants have been recommended but these have not received widespread acceptance. Until there is better understanding of the mechanism of action and more selective criteria as to activity and function of these drugs the general term tranquilizer is useful as a descriptive term.

It is indeed surprising to see how quickly this group of drugs has developed into the second most commonly used medicine in the brief span of approximately 6 years. Unquestionably they are supplying an essential need in therapy. Since this is the case it is important that agents for use in this category be selected and used wisely. In order to do this it is necessary to understand the pharmacology of each class and to be aware of the untoward effects inherent in their use or produced as a result of improper administration or selection. Table 13 lists by groups most of the available agents and gives the recommended dose.

## PHARMACOLOGY, TOXICOLOGY, AND CLINICAL USE

In order to discuss these basic actions of the tranquilizers it is necessary to separate them into different categories. Members of the same group of agents behave in much the same general manner differing mainly in dose, degree of selectivity of action, and undesirable and toxic effects.

**Rauwolfia Materials**—This group consisting of *rauwolfia* and its derivatives has supplied some of the most potent, desirable and versatile of the tranquilizers. In addition to the crude drug there is the semipurified alkaloid, the purified alkaloid reserpine and three derivatives of reserpine, deserpidine (Harmony), rescinnamine (Modiril) and syrosingopine (Singoserp). Since reserpine, the purified crystalline derivative of *Rauwolfia serpentina* is for the most part representative of the action of the entire group it will be discussed in detail. Where there are significant exceptions these will be indicated.

**MODE OF ACTION** Reserpine has been shown to release bound 5 hydroxytryptamine from tissues and it in turn is metabolized to 5 hydroxyindole acetic acid and excreted in the urine. It is thought by some that much, if not all of the action of reserpine is brought about by its altering the 5 hydroxytryptamine content in the brain by releasing it in excess amounts or by lowering its total content in the brain perhaps by interfering with binding sites or by inhibition of ATP coupled serotonin transport system. This is an attractive theory and there are many things to support it but some observations such as reserpine's effect on brain norepinephrine and the action of other drugs which give similar effects but which do not alter the brain's 5 hydroxytryptamine content cannot be explained by it. Obviously the whole story has not been unraveled as yet.

**Absorption** Reserpine is readily absorbed but is a slow acting drug when given orally. It may take several hours or if the dose is small a few days to build up its maximum effect. Once in the body its effect is very slowly reversed and

There are many medical uses of reserpine and its derivatives. It is excellent in controlling agitated, tense, anxious, psychoneurotic behavior. Frequently it calms agitation created by drug withdrawal. The excitement, agitation and delirium of alcohol withdrawal is rendered less acute by reserpine. Its chief use is in the management of the hypertensive patient. The reduction in blood pressure, bradycardia, and the relaxed mental state created by the rauwolfia drugs makes them without doubt the most versatile and useful agents for this situation. It stimulates appetite and has been used successfully in the treatment of malnutrition. Because of the nasal stuffiness, appetite stimulation, bowel overactivity, and tendency to produce mental depression, it is not as desirable an agent in the treatment of mild psychoneurotic behavior, tension states, anxiety, and agitation as other members of the tranquilizer series. The phenothiazines or small doses of the sedatives, such as phenobarbital, are sometimes preferable in such cases.

**Phenothiazine Derivatives**—There are at present 15 drugs in use in this series and new ones are added to it continually. They vary from the comparatively weak promethazine and mepazine to the highly potent chlorpromazine (Thorazine), methoxypropazine (Tentone), prochlorperazine (Compazine), thiopropazate (Dartal), perphenazine (Trilafon), trifluorpromazine (Vesprin), trimeprazine (Temaril), and trifluoperazine (Stelazine). They are all derivatives of phenothiazine, and most have similar actions. They all cause sedation in varying degrees. Although most have some antihistaminic effect, this is of little significance except for promethazine, which is a potent antihistamine. They exert some action against the catechol amines, epinephrine and norepinephrine, since they reduce the pressor effect of these substances. Although these agents produce a similar central nervous system response to that seen with reserpine, they do not affect the brain content of 5 hydroxytryptamine.

**ACTION AND EFFECTS**—The phenothiazines exert so many actions in the organism that at present it is impossible to postulate any basic concept of their action. They potentiate and prolong the action of sedatives, narcotics, and anesthetic drugs. They exert a potent antiemetic effect by virtue of a selective action on the chemoreceptor cells of the central emetic trigger mechanism and to a much lesser extent on the emetic center itself, and the central heat regulating mechanism is interfered with, leading to a breakdown in the control of heat loss and conservation. Trimeprazine exerts a pronounced antipruritic effect. Chlorpromazine exerts an antiarrhythmic action on the heart in certain circumstances, and orthostatic hypotension is observed after the administration of chlorpromazine and closely related drugs.

All the phenothiazines are capable of producing an obstructive jaundice, which is usually readily reversible when the drug is discontinued. Approximately 2 per cent of patients given chlorpromazine will develop jaundice. Jaundice has occurred with prochlorperazine, but the incidence is so low that it is not a problem. Agranulocytosis is reported in about 1 in 10,000 or more patients given chlorpromazine, but as yet none has been observed with the newer highly potent agents. However, agranulocytosis must always be considered, and it is the most serious complication of the use of the phenothiazines. Higher doses of chlorpromazine produce central nervous system changes characteristic of parkinsonism. The more potent perphenazine and prochlorperazine also exhibit considerable extrapyramidal

not felt so intensely and does not elicit the usual response. For example, fighting fish no longer fight, hostile, aggressive, or frightened monkeys are no longer a problem but can be handled with ease and behave as though without fear or irritation. Rats taught conditioned reflexes lose their conditioned response and revert to the original less desirable degree of responsiveness.

Although patients receiving reserpine sleep better, relax better, and can go to sleep more readily, they do not exhibit much in the way of sedation. They can perform normally and are easily aroused even though they have been given huge doses of the drug. It increases gastrointestinal motility and the secretion of stomach hydrochloric acid, slows the heart rate, and lowers the blood pressure. There is also dilatation of small blood vessels, some muosis is created, and there is interference with temperature regulation. Recently the reserpine molecule has been altered to give a new derivative, syrosingopine (Singoserp), which has been reported to be more selective in that it has lost much of the tranquilizing action while retaining most of the hypotensive effect. It is distinctly less potent, however, than reserpine, deserpidine and rescinnamine.

It is important that the physician be familiar with the untoward effects exerted by the rauwolfia group of agents. Unquestionably reserpine is capable of causing serious toxic effects. In many reported cases it has not been the fault of the drug. Frequently it is used unwisely, given in improper dosage, or administered without proper supervision.

Dosage will be considered first. In the medical use of reserpine it is usually not necessary to give more than 0.1 to 0.25 mg daily and there is generally very little to be gained in giving doses of more than 1 mg. When the dose is over 0.5 mg daily, the danger of increased gastric secretion of hydrochloric acid, gastrointestinal ulcer, hemorrhage, or cramps with diarrhea is greatly increased. Great care should be taken in giving this drug to patients having a history of gastrointestinal ulceration or overactive bowels. Patients developing gastrointestinal distress should have the dose kept as low as possible and be put on a bland diet, antacids, and antispasmodics. If the distress is not promptly controlled reserpine should be discontinued.

Likewise mental depression is far more common with the larger doses. Reserpine should be avoided in patients with a history of or in frank mental depression and it should be stopped at the first sign of mental depression. Larger doses produce parkinsonism and in some patients, interference with skilled movements may appear even on smaller doses. This can lead to the clumsy use of hands, stumbling and other evidences of impairment of skilled coordinated movement.

Since reserpine increases appetite and patients frequently gain weight, this must be guarded against in those individuals where weight gain would be undesirable. Some patients develop severe nasal obstruction, sinusitis and epistaxis. The epistaxis may be severe and prolonged, and almost invariably requires packing of the nose for its control. In rare instances it has caused fluid retention, congestive failure and gynecomastia in males and lactation in females. Finally, patients receiving reserpine should have the drug withdrawn for at least a week prior to general anesthesia since serious collapse has been observed when patients receiving the drug are given a general anesthesia.

active behavior in children. They have been useful in obtaining weight reduction in tense, agitated compulsive eating, obese patients in whom their calming of emotional tension has permitted an effective dietary program to be carried out. They often afford relief in the menopausal syndrome, especially where there are anxiety, agitation and much emotional stress. Patients with severe gastrointestinal distress, gas, nausea, vomiting, bowel cramps and anorexia are frequently aided by their tranquilizing action.

Recently a great deal of interest has been focused on phenothiazines containing an alkyl thio substitution on the phenothiazine ring in the number 2 position. Thioridazine (Mellaril) is a methyl thio preparation of mepazine. It is a useful, although not highly potent, tranquilizer and does exert some antiemetic action. It is unique in that it does not produce extrapyramidal activity which is so commonly seen with prochlorperazine and perphenazine. This is a definite advantage in itself, but data obtained so far also indicate that it has much less toxicity than that seen in chlorpromazine. The success of this compound has stimulated work in this field and already several thio substituted phenothiazines are under study.

The success achieved in increasing potency by substituting a trifluoromethyl group in position 2 on the phenothiazine ring of chlorpromazine in place of the chlorine radical resulting in trifluorpromazine (Vesprin) will stimulate investigators to prepare other trifluoromethyl substituted preparations. Trifluoro substitution of the methyl group for chlorine in the number 2 position of the ring of prochlorperazine enhances the potency considerably as has been shown with trifluoperazine (Stelazine). Undoubtedly other preparations such as trifluoromethyl substituted thiopropazate (Dartal) and perphenazine (Trilafon) will soon be investigated. It will also be most exciting when a trifluoromethyl thio substituted perazine and perphenazine are made available. It could be that such preparations would not only greatly enhance activity but also would result in compounds much less toxic, not only regarding blood and liver injury, but also free of extrapyramidal effects. Certainly there is much yet to be done in the exciting field of phenothiazine synthesis and study.

At the present time the potent prochlorperazine and perphenazine are gaining in popularity over chlorpromazine. This is because they are even more potent than chlorpromazine and do not have its toxicity. Trifluoperazine must be used carefully to get the desired effects but it has been proved to be effective when others have failed in severely psychotic patients. For medical conditions most prefer to use prochlorperazine (Compazine), perphenazine (Trilafon) or thiopropazate (Dartal).

**Meprobamate and Phenaglycodol**—This group consists of meprobamate (Equanil, Miltown) and phenaglycodol (Ultran), meprobamate being the most effective and most widely employed. These agents are tranquilizers which were discovered in the search for a drug better than mephenesin. They exert a depressant effect on polysynaptic pathways similar to that observed for mephenesin. Although meprobamate and to a much less extent phenaglycodol, exerts a calming, tranquilizing effect, these drugs differ from reserpine and the phenothiazines in that they do not block conditioned reflex activity in the rat, potentiate strychnine or increase the threshold for electrical or chemical convulsive action. Seda-

activity, and an alarming reaction consisting of facial, jaw tongue, and neck muscle spasms has been observed after relatively small doses.

The appetite is increased and obesity can readily develop. Skin rashes are not uncommon and sensitivity to light occurs occasionally. Some patients receiving chlorpromazine develop hypotensive episodes which at times are serious. The more potent drugs of the series are much less prone to cause vascular collapse.

The use of the phenothiazines in medicine is extensive. They are excellent agents in suppressing agitation, excitement and psychoneurotic anxiety, tension and fear. The potent ones of the series are the most satisfactory tranquilizing agents available.

Most of the phenothiazines exert an antiemetic effect. Prochlorperazine and perphenazine exert a most potent antiemetic action and are used successfully in suppressing nausea and vomiting from uremia, cancer radiation sickness and pregnancy, after operations and from the use of narcotics and other drugs which cause local gastrointestinal irritation or activate the emetic chemoreceptor area. A new phenothiazine, thioperazine (Vomil), closely related chemically to prochlorperazine and perphenazine but differing from them by the addition of a dimethylsulfonate in the 2 position on the phenothiazine ring, has in our hands proved to be the most effective of any antiemetic now available. In a dose of 0.5 to 1 mg every 6 hours it exerts a highly effective antiemetic action without producing sedation or much tranquilizing action.

Chlorpromazine, promazine, prochlorperazine and perphenazine have all been used successfully in facilitating drug withdrawal in patients addicted to alcohol, barbiturates or narcotic drugs. They markedly reduce the agitation, discomfort, emotional tensions and gastrointestinal disturbance. These agents have been most useful in controlling the emotional stress, agitation and gastrointestinal disturbances attendant on alcohol withdrawal in severe alcoholics. In these patients the phenothiazines are far superior to reserpine since they suppress much of the nausea and vomiting which so frequently complicate chronic alcoholism.

The central tranquilizing action of the potent phenothiazines exerts a beneficial effect on the itching, agitation and distress accompanying severe dermatitis. Frequently they are successful in bringing a neurodermatitis under complete control. The most effective agent of the phenothiazines in controlling pruritus is trimeprazine (Temril). This agent is a potent antipruritic which does not exert much tranquilizing action.

The phenothiazines are useful in controlling hiccups and have shown remarkable action in relieving the distress of porphyria. They occasionally are useful in controlling cardiac arrhythmia and are useful in calming the agitation and anxiety from pulmonary edema and severe asthmatic bronchitis.

The weaker phenothiazines, promazine and also chlorpromazine have been used to potentiate the effect of narcotic drugs and as adjuvants in inducing and maintaining a more smooth general anesthesia. The antiemetic action is also helpful in controlling the nausea and vomiting so frequently seen with general anesthesia.

There are many less common uses for the phenothiazines. Chlorpromazine, promazine and the more potent prochlorperazine have all been used successfully in relieving agitation in aged and senile patients as well as aberrant, agitated over-

Azacyclonol has been found useful in controlling psychotic states, particularly schizophrenic behavior. Hallucinations and delirium have responded to it in some patients. Abnormal psychologic behavior, delirium, hallucinations and disorientation, such as is seen in toxic infectious states and following drug therapy and fever are occasionally controlled by azacyclonol. It does appear to be limited however in its value, since it frequently fails when a better effect might be expected. Because of its erratic behavior it is difficult to assign this drug a definite role in therapy. Some reports deny that it is of any value in disoriented states.

Captodiamine, like the other agents of this series, is an antihistamine derivative. It was developed from the diphenhydramine series. Although it prolongs the action of pentobarbital, it does not produce much sedation and hypnosis does not result even following large doses. It exerts a mild relaxing action on the gastrointestinal tract and has been found useful in treating tense, anxious patients with gastrointestinal symptoms such as occur with an irritable colon. Many claims have been made for this drug, but as yet enough well controlled studies have not been carried out to support these claims.

Benactyzine and hydroxyzine are still controversial drugs. Some studies report them to be no better than placebos, while others find them highly useful. Certainly there is a great deal of confusion as yet as to their real role in therapy. In our hands neither has been proved satisfactory as a tranquilizing agent. At least one controlled study on benactyzine has shown it to be no better than a placebo. Benactyzine may have some use as an antiphobic acting drug in the treatment of fear and anxiety but further studies must be conducted before this use can be considered as established.

Probably the best that can be claimed for benactyzine and hydroxyzine is that they are weak tranquilizers with erratic action which seem to exert a good effect in some patients and fail miserably in others. The placebo effect unquestionably is highly significant in the use of these agents and the wise physician will stop them or substitute less expensive drugs such as phenobarbital or butabarbital in small doses from time to time to be certain that there is a real need.

**Sedatives**—This group consists of sedatives used for their calming, mild sedating effect. Unquestionably mild sedation produces relaxation both mentally and physically. Emotional tension is reduced and tense muscle states are relaxed by many sedative drugs. For several decades phenobarbital has been a favorite for this purpose. It has been a most useful agent in relaxing the tense, anxious, apprehensive individual. Frequently it is the drug of choice in the limited stressful situation.

Of all the barbiturates, phenobarbital exerts the most pronounced cortical depressant effect, and it may be this feature that has made it so popular. It is however, a true sedative, and, if the dose is pushed, sedation and finally hypnosis result. Tolerance develops fairly readily so that much of its action is lost in 2 or 3 weeks unless the dose is increased. As with other barbiturates addiction can occur if the dose is sufficiently high, usually 0.4 to 0.6 Gm daily, and is maintained for a period of 3 or 4 months. Phenobarbital in the aged, senile and arteriosclerotic patient frequently causes confusion and disorientation and, as a consequence, does not calm but causes agitation and excitement. Generally its use in

patient becomes drowsy and even ataxic. However, even in large doses neither gives the sedation and hypnosis seen with the barbiturates. Their action on inter-neuronal circuits, depressing multineuronal reflexes without significantly affecting reflex activity of monosynaptic transmission, probably enables them to reduce exaggerated reflex activity and thus reduce muscle tension, anxiety, and overreactivity to emotional tensions. Meprobamate has been more thoroughly studied. It is readily absorbed. Blood levels are found in 30 minutes with peak levels at 2 hours. It is widely distributed in the body, with the lungs, the kidney, and the liver having the highest levels. Its major metabolite is the inactive hydroxymeprobamate. It is metabolized by the liver, most of it being conjugated with glucuronic acid and approximately 20 per cent being slowly excreted unchanged in the urine.

Meprobamate produces a dermatitis in approximately 2 per cent of patients. Purpura and aplastic anemia have been observed. Tolerance and then addiction develop when large doses of meprobamate are given. This can be a serious problem in patients who have been given large doses for long periods of time, since definite withdrawal effects appear and these are often confused with the agitation, excitement, and hyperactivity for which the drug was given in the beginning.

Meprobamate and to a lesser extent phenaglycodol are useful agents in the treatment of the anxious, tense, psychoneurotic patient who has no psychosis. Some relief of muscle spasm and its attendant pain syndrome is afforded by these agents. This relief, however, is not great and may be mainly a result of the sedation and relief from anxiety and emotional tension rather than a specific action. Phenaglycodol has recently been reported to be of some value as an anticonvulsant, but certainly it is not as potent as the usual anticonvulsant agents.

Both meprobamate and phenaglycodol in spite of the widespread use of the former, are still somewhat controversial. Many observers consider meprobamate not much better than a weak barbiturate like drug, and some consider both meprobamate and phenaglycodol no better than placebos. Undoubtedly neither is as useful or as effective as the more potent phenothiazines or reserpine. These two agents are expensive and frequently do not accomplish much more than phenobarbital given in small doses which, of course, is of much less cost to the patient. Since the placebo effect may be considerable in this type of medication, it is absolutely necessary for the physician to stop the use of these drugs at frequent intervals to determine if there is still any need for them or to try a less expensive agent and see if it will do as well.

[Carisoprodol (Soma), a meprobamate congener (isopropyl meprobamate), has not been examined extensively enough to establish its value as a tranquilizer. Ed.]

**Diphenylmethane Derivatives**—This category consists of the derivatives of diphenylmethane: azacyclonol (Frenquel), benactyzine (Phobex, Suavitil), captodiamine (Suvren), and hydroxyzine (Atarax, Vistaril). These agents are weak, somewhat erratic in behavior, and have not gained widespread use. They resemble the antihistamines chemically and produce sedation. They will potentiate barbiturate action, block conditioned reflex activity, and can calm excited animal behavior. They seem to raise the emotional threshold for external influences and reduce excessive reaction to stress. There has been very little critical study of these compounds.



much is known about its metabolism. It has been reported to behave like a short acting barbiturate. A central depressant action is exerted and is claimed to be useful in reducing irritable behavior and in calming anxiety tension states. There is as yet insufficient data to assign this agent a definite role in therapy. The early reports are promising, but limited experience with it on the part of the authors has not shown it to be in any way outstanding. Much more must be known about its pharmacology and action in patients before a reasonable evaluation can be given.

Phenyltoloxamine, an antihistamine derivative, is a most recently studied agent. It produces sedative and moderate hypnotic effects with drowsiness and a slowing of psychomotor and mental performance resulting. Relaxation follows the sedation and muscle tension is reduced. It appears to have a cortical site of action. One study indicates it to be superior to phenobarbital as a daytime sedative. There has been no autonomic disbalance observed from its use, and side effects have been minimal. It may have value as a sedative type tranquilizer, but much more data must be accumulated before it can be recommended as a useful agent.

## SELECTED REFERENCES

- Bein, H. J. The Pharmacology of Rauwolfia. *Pharmacol Rev* 8: 435, 1956.
- Berger, F. M., Campbell, G. L., Hendley, C. D., Ludwig, B. J., and Lynes, T. E. The Action of Tranquilizers on Brain Potentials and Serotonin. *Ann New York Acad Sc* 66: 686, 1957.
- Council on Pharmacy and Chemistry. Blood Dyscrasias Associated With Chlorpromazine Therapy. *J A M A* 160: 287, 1956.
- Cummins, J. F., and Friend, D. G. Use of Chlorpromazine in Chronic Alcoholics. *Am J M Sc* 227: 561, 1954.
- DiMascio, A., Klerman, G. L., Rinkel, M., Greenblatt, M., and Brown, J. Psychophysiologic Study of the Sedative and Anxiolytic Effects of Chlorpromazine (Thorazine) in the Treatment of Intractable Anxiety. *Am J Psychiatry* 115: 301, 1958.
- Friedgood, C. E. The Use of Chlorpromazine in the Treatment of Intractable Anxiety. *Am J Psychiatry* 115: 301, 1958.
- Friend, D. G. The Use of Chlorpromazine in the Treatment of Intractable Anxiety. *Am J Psychiatry* 115: 301, 1958.
- Friend, E. The Use of Chlorpromazine in the Treatment of Intractable Anxiety. *Am J Psychiatry* 115: 301, 1958.
- Hochman, A. The Use of Chlorpromazine in the Treatment of Intractable Anxiety. *Am J Psychiatry* 115: 301, 1958.
- Hollister, L. E. Complications From the Use of Tranquilizing Drugs. *New England J Med* 257: 170, 1957.
- Kinross Wright, J. Newer Phenothiazine Drugs in Treatment of Nervous Disorders. *J A M A* 170: 1283, 1959.
- Korst, D. R. Agranulocytosis Caused by Phenothiazine Derivatives. *J A M A* 170: 2076, 1959.
- Lear, E., Pallin, I. M., Chiron, A. E., Rousseau, L., and Aochi, O. Comparative Studies of Tranquilizers Used in Anesthesia. *J A M A* 166: 1438, 1958.
- Mechanic, R. G., and Meyers, L. Chlorpromazine type Cholangitis. *New England J Med* 259: 778, 1958.
- Melby, J. C., Street, J. P., and Watson, G. J. Chlorpromazine in Treatment of Porphyria. *J A M A* 162: 174, 1956.
- Meyer, L. M., Heave, W. L., and Bertischer, R. W. Aplastic Anemia After Meprobamate. *New England J Med* 256: 1232, 1957.
- Mohr, R. C., and Mead, B. T. Meprobamate Addiction. *New England J Med* 259: 865, 1958.
- O'Hara, J. The Use of Chlorpromazine in the Treatment of Intractable Anxiety. *Am J Psychiatry* 115: 301, 1958.
- Perera, C. The Use of Chlorpromazine in the Treatment of Intractable Anxiety. *Am J Psychiatry* 115: 301, 1958.
- Werner, C. The Use of Chlorpromazine in the Treatment of Intractable Anxiety. *Am J Psychiatry* 115: 301, 1958.
- West, W. The Use of Chlorpromazine in the Treatment of Intractable Anxiety. *Am J Psychiatry* 115: 301, 1958.

the aged should be avoided. Its cortical depressant action usually produces an unfavorable action in patients with Parkinson's disease, the tremor and agitation increase and if the dose is sufficient or if the patient is very susceptible to its action, it may seriously incapacitate the individual. An occasional patient develops a generalized skin rash and rarely a macrocytic anemia appears after long continued administration.

On the whole, however, phenobarbital is exceedingly well tolerated, and, except for its tendency to create too much sedation in many patients, it is a highly satisfactory drug in the treatment of the agitated, anxious, overactive patient who cannot sleep and is being subjected to a temporary emotional strain. It is by far cheaper than any of the other nonsedative agents and is often more effective.

Butabarbital (Butisol) in doses comparable to phenobarbital has also been used with success in treating the agitated, tense individual. It is thought by some to be less prone than phenobarbital to produce undesired sedation in the doses employed. It, like phenobarbital, is cheap and frequently affords the right degree of relaxation. It is an excellent alternate for phenobarbital and some feel it is even a better drug.

Mephobarbital (Mebaral) has also been recommended for its mild calming action with a minimum of sedation. Experience with it as a sedative tranquilizer is not sufficient as yet to ascertain its true status. It is doubtful, however, if it will be used extensively since it lacks the unique properties found useful in the more potent agents.

Other sedatives which have been recommended as sedative type tranquilizers are glutethimide (Doriden), methypylon (Noludar), and ethchlorvynol (Placidyl). Unquestionably these sedatives in small doses are useful in quieting the agitated, tense patient. They are all central nervous system depressants and effective sedatives. Their use as tranquilizers is not extensive, and certainly more experience with them is needed before they can be assigned a definite role. Glutethimide produces a skin rash in a fair number of patients and addiction to it has been reported. Methypylon and ethchlorvynol are capable of causing anorexia, nausea, mental confusion, ataxia, and hangover.

**Miscellaneous Agents**—This category consists of ectylurea (Nostyn), oxanamide (Quiactin) and phenyltoloxamine (Historex). These agents have only recently been introduced as tranquilizers and as yet have gained no widespread recognition or use. Ectylurea exerts a mild sedating effect and has been reported as useful in mild anxiety and tension. Because of its low toxicity and mild action it has been used with success in diminishing restlessness, irritability, and tension in children. It is of little or no value in the seriously agitated, overactive, excited, tense patient. Ectylurea has a low degree of toxicity. Large doses are tolerated well with only a sedative-hypnotic effect resulting. It is rapidly absorbed and metabolized with nearly two-thirds of the ingested dose appearing as urea in the urine within twelve hours. One case of cholangiolitic hepatitis with jaundice from ectylurea in a dose of 300 m., 3 times a day, has been reported. Its role as a tranquilizer is not well established and as yet its use is not extensive.

Oxanamide, a new agent, is as yet a comparatively little used tranquilizer. Chemically it differs considerably from any of the other agents and as yet not

against a great deal of anxiety during psychotherapeutic procedures. The patients maintained better emotional equilibrium, and the psychotherapy could be concentrated on their problems. Often very anxious patients need a great deal of reassurance or other ego supportive measures, and much of the psychotherapy has to be devoted to this particular task. In patients who were under drugs this function was performed by the medication, particularly so in patients who were psychotic or suffering from a neurotic disturbance which produced a great deal of anxiety and tension.

### Clinical Applications

**Manic-Depressive Psychoses**—Thorazine is very effective in controlling manic states, elation, and overactivity. Some prefer giving Thorazine by injection to a patient in an acute manic excitement, others give it orally. By injection it is possible to cut through excitement quickly, with oral treatment it takes somewhat longer. Thorazine is equally effective in acute and chronic states, both respond favorably. The psychomotor excitement in these patients is the most outstanding symptom influenced by Thorazine.

However, the same cannot be said about the manic depressive depressed patient. Depressions in general, with the exception of some of the agitated depressions, do not respond well to Thorazine. In some cases it is not only ineffectual but it can also aggravate the existing depression. This is especially true in patients suffering from a "retarded" depression. It is less effective in tense or agitated depressions. Sometimes the tension or agitation present in these patients is not clearly recognized. In doubtful cases these patients should be treated under close supervision.

In manic depressive states, rauwolfia is not used extensively. This is due to the fact that rauwolfia acts more slowly than Thorazine and, therefore, is not used to a very large extent to influence conditions considered to be acute. Rauwolfia is ineffective in patients suffering from depression. Furthermore, there is a considerable danger that rauwolfia may aggravate the existing depression and as will be pointed out later, sometimes may precipitate depressions.

In manic states different compounds such as Thorazine, Compazine, Sparine, etc., can be used. In patients who are quite excited Compazine can be given in dosages of 10 to 20 mg (2 to 4 ml intramuscularly). The injection should be given deeply into the upper outer quadrant of the buttock. In acutely disturbed patients the initial dosage may be repeated every 2 to 4 hours. If Sparine is used, it can be given intravenously in dosages of 100 to 200 mg. When the patient has calmed down maintenance dosage can then be instituted by the oral route. Thorazine also can be used in manic patients and can be given intramuscularly or orally. The initial dosage with Thorazine should be 50 mg, 3 times daily, and then brought up fairly rapidly to a level which controls the manic excitement effectively. In some patients several hundred milligrams will have to be used to control the excitement. I find it best to build up dosages in these patients rather rapidly, increasing it day by day until the manic state is controlled, not waiting several days before maximum dosage is reached. After the manic state is controlled, I maintain the patient on that dosage for about 2 weeks and then gradually with

## THE CHOICE OF SEDATIVES AND TRANQUILIZERS FOR PSYCHIATRIC DISORDERS

*Paul H. Hoch, M.D.*

---

### TRANQUILIZERS

In the discussion which follows, chlorpromazine (Thorazine) and the rauwolfia preparations, the best known and most tested of the so-called tranquilizing agents, will be considered in the main. While there are quite a number of other compounds in use not enough experience with them has been collated and only in the case of those which have been tested extensively is there sufficient knowledge to be able to formulate substantial conclusions. Opinion about the extent of their efficacy remains controversial, even in the case of Thorazine and the rauwolfia compounds, although they have been used extensively in practically every form of mental and emotional disorder in the last few years.

It is important to emphasize that these drugs do not cure definite mental disorders such as schizophrenia or manic depressive psychosis, they influence symptoms to a varying degree. Their effectiveness cuts through diagnostic lines in excitement or manic excitement states in the framework of manic-depressive psychosis, schizophrenia, and cerebral arteriosclerosis. These are all influenced equally well. The same is true about tension and anxiety states in the different neurotic groupings.

### Relationship of the Tranquilizing Drugs to Psychotherapy

The relationship of the tranquilizing drugs to psychotherapy is a very important and intricate subject still under investigation. Some patients find that because the drug completely controls their anxieties and tensions they do not need psychotherapy. How many patients have the ability to work out their conflicts if under the drug alone has not been established. Many of the patients who feel very much better under the influence of the drug still require psychotherapy in addition to the medication because they have problems and conflicts which are not solved by taking the drug alone. In my experience psychotherapy with patients who responded well to the tranquilizing drugs was much more comfortable and profitable than with those who did not receive the drug. These patients were cushioned

Depending on symptoms, in some cases hospitalization is to be preferred and in others it may be omitted. Depressed, suicidal schizophrenic patients or acting out aggressive patients are treated by preference, in a hospital. It is most important that psychotic patients treated on the outside with tranquilizing drugs be carefully supervised. With proper supervision a considerable number of acute schizophrenic patients can be treated in family settings, clinic settings, or in a day hospital setting. If appropriate supervision cannot be provided or if the patient does not accept it, hospitalization is essential if these drugs are to be used safely.

It also can be stated that if a patient is admitted to a hospital he can be treated more rapidly and effectively today than formerly. The hospital phase of the treatment is shorter than by older methods and, after improvement has been observed, he can be transferred to an ambulatory status. I feel that, at present, the greatest gain made in the treatment of schizophrenia with the tranquilizing drugs is the shortening of the treatment time. It is most important also that the shorter stay of the patient in the hospital prevents the schizophrenic patient from deteriorating and permits his reintegration into the community faster and better than in the case of those who formerly spent a longer time in the hospital.

**CHRONIC SCHIZOPHRENIA**—Second, the tranquilizing drugs are widely used in chronic schizophrenic patients. A large number of chronic patients were treated in the different state hospitals to determine what could be accomplished with tranquilizers. In the beginning there was a great deal of enthusiasm, some believing that the great majority of hospitalized chronic schizophrenic patients would respond and that they could be discharged. This is not quite the case. Many chronic schizophrenic patients show a change in their behavior and can be considered improved. However, even though their management in the hospital is far simpler, many of them do not improve to such an extent that they can leave the hospital. To a large extent this also depends on the kind of environment to which they return. If the environment is supportive they are in a far more favorable position than if the environment is nonsupportive or if they have to be released into a strange environment. Many chronic schizophrenic patients, even though they show improvement with the tranquilizing drugs, need an understanding environment or they are not able to function.

How many chronic schizophrenics can be released from the hospital is still not known. Statistics vary depending upon the severity of the type of schizophrenia treated and on the supervision which can be provided after release. I feel that about 15 per cent of the chronic patients can be released provided the community environment is such that they receive some support for their functioning. Many of these patients have to be kept for long periods—sometimes indefinitely—on tranquilizing drugs. This maintenance treatment is an important part of the therapy in the treatment of a chronic schizophrenic patient.

Third, tranquilizing drugs are used in chronic schizophrenic patients who do not improve to such an extent that they can be released from the hospital. Some aggressive, destructive, and deteriorated patients benefit from the drug through alteration of their behavior patterns permitting better functioning especially in relation to others, even though many of them do not improve to such an extent that they can be released. The basic rule applies here in the same way in which it does in shock therapy. The duration of the sickness is an important

draw the drug continuing however with the minimum effective maintenance dose. If on withdrawing the drug the patient's symptoms return the dose of the drug is elevated until the symptoms are controlled.

The question arises whether a patient suffering from manic depressive psychosis, manic type, should receive maintenance treatment between attacks. Most psychiatrists today maintain the patient on the drug for a while after the manic attack has subsided and later withdraw the drug. We do not know whether, in patients who have the tendency toward repeated manic attacks, continuous administration of the tranquilizing drugs will prevent the recurrence of attacks for conclusive investigations have not been made on this issue.

Many use Thorazine in conjunction with electroshock treatment to break through the manic excitement. It has been claimed by some that in conjunction with electroshock treatment Thorazine reduces the number and intensity of the use of Thorazine in combination with electroshock therapy is not without danger, shock treatments required. On the other hand there are some who feel that the and therefore the use of this combination should be weighed carefully.

**Involuntional Psychoses**—In the involuntional psychoses which show either a depressed picture or a paranoid one Thorazine can be used if the patient shows tension and agitation in connection with the depression. Agitated tense depressions are quite common in the involuntional age group and they respond to Thorazine even though it may take somewhat longer to influence the psychosis than with electroshock therapy. In some patients, however, Thorazine controls only the psychomotor excitement and agitation and does not influence the depression. These patients must have electroshock treatment again. The paranoid form of involuntional psychosis responds to Thorazine quite well provided the treatment is applied for a sufficient length of time.

**Schizophrenia**—The use of the tranquilizing drugs for treatment is especially important in cases of schizophrenia. This disorder constitutes the bulk of the mental hospital population and can be considered the largest and one of the most important psychiatric diagnostic entities. The tranquilizing drugs are used in three ways in schizophrenic disorders.

**ACUTE SCHIZOPHRENIA**—First these drugs are used in the treatment of acute schizophrenics if they are not too disturbed to remain in the community setting. It is hoped that in these patients the use of the tranquilizers can provide enough symptomatic relief to eliminate the need for hospitalization. We have no reliable statistics on the extent to which these drugs are able to accomplish this purpose. Clinical opinions are contradictory. Some feel that the use of the tranquilizing drugs does not prevent the ultimate hospitalization of these patients. On the other hand there are those who feel that a considerable number of schizophrenics can be treated in a clinic setting if they receive these drugs under proper supervision.

At present generalizations are not permissible. In each evaluation of symptomatology, social setting and other factors will determine how far a schizophrenic patient can be carried with the help of tranquilizing drugs on an ambulatory basis and when hospitalization is necessary. Tranquilizing drugs do not influence massive schizophrenic symptomatology immediately, unless they are given by injection or orally in such large doses that side effects may appear. Such therapy can be safely conducted only in a hospital.

phrenic patients respond better to one type of tranquilizing drug than to another, and, therefore, some experimentation with the various drugs is warranted

In my experience very few of these patients improved to such an extent that the tranquilizing drugs could be completely withdrawn. The majority have to take the drug for an indefinite period. Until a point of stabilization is achieved, these patients also need psychotherapy. They are especially prone to get into difficulties if they are not followed closely and given enough psychotherapeutic help for their problems. As yet we do not have reliable statistics indicating how many pseudo-neurotics respond well to these drugs. There are some who do not benefit from them. On the other hand, I have seen some who for the first time are able to function in relative comfort without being constantly ridden by anxiety and other neurotic manifestations.

**Psychoneuroses**—The use of the tranquilizing drugs in the psychoneuroses is far less well established than in the psychoses, although today a very large number of neurotic patients are prescribed these drugs by their physicians. Therefore, it is very important to assess their value in such patients.

It has to be emphasized that evaluation in this group of patients is far less reliable than in the psychotic individuals, for there are many pitfalls in evaluating therapeutic results in neurotic patients. In addition these drugs were first used and studied in mental hospitals so that the basic information on their efficacy and dangers applies to the psychoses specifically and, without the support of careful investigation should not be taken to apply to the neuroses. The neurotic functioning of a mildly disturbed person can be influenced in so many ways that only the most carefully conducted investigation can provide reliable information on causal connections. It is also customary to give some form of psychotherapy to these patients even if it is no more than reassurance. It is then difficult to separate the response to the drug from the response to psychotherapy. It also has to be emphasized that many neurotic patients respond to a given drug just as long as publicity and mass suggestion convince them that they are being treated with a very potent new therapeutic agent. When the suggestive influence wanes the therapeutic efficacy of the drug wanes with it.

The tranquilizing drugs are used in all kinds of neurotic disorders. In our experience it is difficult to foretell how a patient will respond. We have patients with very similar symptoms who give dissimilar responses. In some the symptoms are reduced or even eliminated, in others the symptoms are not influenced and sometimes even aggravated, and in still others even new symptoms appear. A general statement, therefore, that any or even many neurotic patients will benefit from the use of these drugs is unwarranted.

The discussions in the literature on the efficacy of these drugs in neurotic individuals are somewhat contradictory. Some believe that if patients are given the drug for a few weeks or months the neurotic manifestations disappear. This has not been my experience. It is true there are some patients who after being treated for a few months do not need any further treatment and function well. However, other patients have to take the drug for a prolonged period or a relapse will occur. There is no reliable information about the outcome of many of the neurotic disorders in patients who have been taking the tranquilizing drugs for several years.

factor. Chronic schizophrenics of 10 years duration have less chance of recovering and functioning normally than schizophrenics who have been sick for only one year, but it has to be emphasized that there are exceptions, especially in some types of schizophrenia in which deteriorative processes do not occur commonly or occur only relatively late in its course.

The great value of the tranquilizing drugs rests not alone on their efficacy in individual patients but also on the fact that it is possible to transform the atmosphere of the disturbed services into one which is much the same as that of the wards where quiet cooperative patients are housed. Where formerly many patients on the disturbed wards were isolated in special rooms, this is much less frequently necessary. Prior to the use of these drugs the disturbed wards were bare of furnishings, curtains, table clothes and eating utensils. Today the patients on these wards are quiet, composed and engaged in various activities. The furnishings and organization scarcely differ from those of wards formerly used for quiet well behaved patients.

**EFFECTS OF TRANQUILIZERS IN SCHIZOPHRENIC PATIENTS**—The tranquilizing drugs directly affect the mental symptomatology of schizophrenic patients. It has not been worked out in detail but in general the emotional symptoms respond best to the tranquilizing drugs. Anxiety, aggression, overactive behavior, delusions and hallucinations are symptoms which can be controlled quite effectively by the tranquilizers. The drugs have less influence on intellectual disorganization and on schizophrenic thinking.

The different subgroups in schizophrenia have somewhat different reactions to the tranquilizing drugs. The paranoid and catatonic forms of schizophrenia respond best. The hebephrenic and simple forms of schizophrenia often show improvement but in many chronic cases the improvement does not go so far as to allow the patient to adjust to the community. These, however, are general observations and there are many exceptions to the rule. The best policy is to treat the patient for a period of time to see what can be accomplished rather than to reject the patient for treatment because of clinical preconceptions.

The basic rule of practically all treatment in schizophrenia also applies to treatment with tranquilizing drugs. It is more complicated to treat and to achieve results with chronic patients than with acute patients. Disorganization of thought and behavior if detached from emotional components, are less influenced.

The response to tranquilizers of schizophrenics with mixed symptomatology who show manic depressive features is sometimes difficult to judge. The manic or excited phase is usually well controlled. A depression in a schizophrenic is sometimes controlled, but at other times the depressive effect is not influenced as much by the tranquilizing drug as are other symptoms. In the pseudoneurotic form of schizophrenia the tranquilizing drugs are important, because in many of them the constant state of anxiety shown by these patients is controlled. In turn, many of the neurotic manifestations are controlled.

There are pseudoneurotic schizophrenics, however, who either do not respond to the tranquilizing drugs or even become worse. They therefore, have to be carefully supervised in the first phase of their treatment. There are also patients who often complain about side effects which may or may not be present, but preoccupy the patient's attention. It has to be emphasized that some pseudoneurotic schizo-



blood pressure, sleep, appetite, and thermal regulation, showing influence on vegetative regulative centers. Studies in animals pointing to a special influence of these drugs on the midbrain and brain stem are supported by the clinical observation that the tranquilizing drugs do not interfere to any great extent with cortical function intelligence memory, and orientation. Clinical investigations indicate that the tranquilizing drugs are also selective sedatives especially affecting anxiety and tension.

**Toxic States**—The tranquilizing drugs are also used in toxic states in which the patient is delirious. Delirium due to alcohol drugs, or infection often responds rapidly to Thorazine. The confusion and the hallucinatory manifestations subside rather quickly under the influence of the drug. Thorazine can be used in all acute confusional states to advantage, especially if the patient shows hyperactivity and agitation. Here the tranquilizing drugs are superior to the usual sedatives, because consciousness is not influenced and the drugs themselves do not produce secondary manifestations so common after barbiturates in this type of patient.

The tranquilizing drugs Thorazine and rauwolfia, also have side effects which have to be taken into consideration, because they can complicate treatment and make it necessary to withdraw the drug or to apply special therapeutic measures. Fortunately the side effects are usually not very serious. Nevertheless, it is very important to pay attention to them. The side effects of these drugs can be divided into two kinds, physical and psychic.

**CHLORPROMAZINE**—One of the most important side effects of Thorazine is jaundice. This has been reported by different authors in from 1 to 5 per cent of their cases. Jaundice may occur in any type of patient regardless of dosage. It is occasionally seen after a week or two of Thorazine, but it is more common in patients who have received the drug for months. Some patients develop jaundice slowly, in other patients the jaundice comes on rather suddenly in connection with fever and grippelike symptoms.

If the patient should develop abdominal symptoms the possibility of side effects due to Thorazine should be excluded because the clinical picture sometimes simulates that of an extrahepatic obstruction.

Toxicity studies with Thorazine on animals have not shown any impairment of the liver parenchyma. Similar observations were made on human beings. The pathologic examination of biopsy specimens showed a stasis of bile in the intra-lobular canaliculi with lymphocytic infiltration. Today jaundice is considered to be caused by the lymphocytic infiltration. Occasionally eosinophils are also present.

Liver function tests in a series of patients who had been given Thorazine were usually within normal limits. It has to be noted that many tests for bile in the urine may react chemically with Thorazine, giving false positive results. If the patient develops jaundice, Thorazine should be withdrawn. The jaundice usually subsides in about 2 weeks but there are cases where the jaundice lasted much longer. In a number of patients the dose can be reduced and the drug given again without causing a recurrence of jaundice. In others, however each time Thorazine is given jaundice develops.

Special treatment for jaundice is not often necessary. Some treat the patient with a high protein high calorie diet, some give the patient ACTH or cortisone,

Many advocate the use of chlorpromazine in a number of psychosomatic conditions. An intensive study of these disorders still has to be made, although Delay and Deniker have found chlorpromazine very useful and Winkelman is of the same opinion.

**Senile and Arteriosclerotic States**—*Tranquilizing drugs are also used in senile and arteriosclerotic states in which they have had beneficial effects on agitation, anxiety reactions, delusions, hallucinations, and disorderly behavior.* Many of these patients who are belligerent, defensive, and difficult to handle become cooperative and tractable. It is important to emphasize that these drugs sedate the patient without producing a clouding of mental processes so often observed with sedatives. Actually some confused and memory-impaired patients in this group function better. Most likely this is because some emotional interference is removed. It must be stated that the tranquilizing drugs have no influence on true dementia and thus intellectual deterioration is not influenced by these compounds.

### The Mode of Action of the Tranquilizing Drugs

The mode of action of the tranquilizing drugs is not clear. Many observations have been made in the last few years on their action, but no one knows precisely how they influence emotional symptomatology. Actually it is very difficult to classify these drugs because they do more than sedate. For instance, chlorpromazine is quite effective in relieving acute confusional states in the organic psychoses. Confusion is not explained clinically by overactivity alone; other functions are involved. Sedatives like barbiturates and bromides have no influence on a confusional state. Therefore the tranquilizing drugs, in addition to sedating, must have other influences on the central nervous system. If we study the action of the tranquilizing drugs, they do not seem to sedate every psychic function uniformly. Some functions are reduced in intensity and other functions are even intensified. The drugs influence certain symptoms of the psychosis, especially those which are due to overreaction. That the tranquilizing drugs also suppress symptoms but do not affect the basic structure of the psychosis is brought out by the fact that the majority of patients have to take the drug for a long period of time, even indefinitely, to be free of their symptoms.

A number of hypotheses have been put forward to explain the site of action of the tranquilizing drugs. At present all the available experimental and clinical observations do not permit a definitive opinion on where they produce their pharmacologic effects. Neurophysiologic observations in animals implicate the midbrain and the reticular substance, but details of mode of action are still controversial. The biochemical investigations are especially concerned with the relationship of the tranquilizing drugs to adrenergic mechanisms and, more lately, serotonin mechanisms in the central nervous system. None of these studies have satisfactorily explained their efficacy.

The clinical observations with the tranquilizing drugs indicate that the midbrain is implicated. This does not exclude action on other parts of the central nervous system. Large doses of chlorpromazine or reserpine often produce parkinsonism, a clear indication of the involvement of the subcortical gray matter. In addition the tranquilizing drugs, in varying degree, affect vegetative regulation.

ness Some patients complain of being depressed and not being able to function, others that they feel they are being driven, that they are restless, and that they are not able to keep still Occasionally, instead of relieving them, Thorazine reinforces the existing psychic symptoms In general, these complications are not serious, and when the amount of the given drug is reduced or the drug is withdrawn, the symptoms disappear Some anxious patients are upset by the experience These complications can be handled much more easily when the patient is seen periodically and receives some psychotherapy in addition to the drug than when the patient receives the drug alone

**RAUWOLFIA**—Rauwolfia preparations, especially reserpine, which has been studied extensively, are also followed by complications Nasal stuffiness, tremulousness, and mild gastrointestinal disturbances are quite common Some patients complain about fatigue, drowsiness, and increased salivation, some develop edema of the face or the feet These complaints usually disappear after the treatment continues for 2 or 3 weeks In some patients convulsions have been seen, usually only 1 or 2 seizures About 5 per cent of the patients who receive large doses of rauwolfia develop typical parkinsonism which usually disappears on reduction of dosage Nevertheless, a number of therapists continue giving the medication, when they feel the patient's mental condition warrants it, even though the patient develops parkinsonism This requires expert judgment, usually discontinuance of the drug is preferable

In some patients overdosage of reserpine may cause a typical toxic psychosis characterized by loss of appetite, confusion and other manifestations of organic psychoses This disappears when the drug is reduced One of the most common complications with rauwolfia preparations is the precipitation of depression This occurs most commonly in hypertensive individuals of middle age We observed such depressions by reserpine not only in patients receiving larger doses but also in those who received comparatively small doses over a prolonged period Occasionally Thorazine also is able to precipitate a depression or aggravate an already existing one In most instances the depression disappears when the drug is withdrawn In some patients the depression remains so profound that electroshock has to be used to eliminate it

Attention should be drawn to the important fact that in those patients who are depressed the tranquilizing drugs do not prevent suicidal behavior Therefore, if depressive features are present in the clinical picture, this should be taken into special consideration

### **Meprobamate**

Meprobamate (Miltown, Equanil) is related to mephensetin, which has been widely used in a variety of conditions in which muscle spasm is a factor Miltown has been advocated and used for anxiety and tension states, including in insomnia and various psychosomatic conditions for muscle spasm in rheumatic and related disorders and for epilepsy (petit mal)

My experience with this compound is that it is ineffective in patients suffering from an acute organic psychosis and for patients suffering from an acute schizophrenic break who have massive symptoms such as delusions and hallucinations Generally speaking, the other tranquilizing drugs such as chlorpromazine

which is felt to shorten the duration of the jaundice. I withdraw the drug and allow the patient to recover spontaneously and give special medication only if the jaundice is prolonged.

Much more serious than the jaundice is the influence of Thorazine on the hematopoietic apparatus. Leukopenia is fairly common in patients who receive Thorazine, at times agranulocytosis develops; this has led to several deaths. In patients who complain of sore throat or other signs of infection, agranulocytosis should be considered. If the blood count indicates its presence, the drug should be immediately discontinued and antibiotic treatment instituted. While the presence of a mild leukopenia is not an indication for discontinuance of the drug, serious leukopenia demands it.

Another complication of Thorazine is postural hypotension. This occurs more often after the injection of Thorazine than after oral administration. Patients who try to lie down or get up suddenly experience dizziness or faintness. These patients should be carefully observed. The hypotensive effect of Thorazine may sometimes be counteracted with norepinephrine, but epinephrine should not be used because Thorazine may reverse its action. For some patients it is sufficient to remain in a recumbent position for about a half hour, after which the symptoms usually disappear. If the hypotensive effect of the drug is prolonged or very intense, it may progress into a shocklike condition; these patients should be put to bed and procedures to elevate blood pressure applied.

✓ In patients suffering from conditions in which a fall in blood pressure may have serious consequences, Thorazine should be used with caution; it should not be injected because the action of the drug develops more quickly and with more intensity than when given orally.

Thorazine also produces dermatologic reactions. These are fairly common but usually mild. The patient may complain of an urticarial rash which disappears when the drug is withdrawn. Sometimes it disappears even though the drug is continued. Thorazine induces photosensitivity, and patients using it should be advised not to expose themselves to intense sunlight. If large doses of Thorazine are given for a long period, some patients develop a typical parkinsonian syndrome. This disappears when the drug is withdrawn.

Engorgement of the breast with lactation has been reported in patients who received large doses of Thorazine. This condition disappeared when the drug was withdrawn.

Thorazine prolongs and intensifies the action of many central nervous system depressants such as barbiturates, alcohol, and narcotics. This fact should be taken into consideration if the patient receives barbiturates or narcotics in combination with Thorazine or if he takes alcohol. In our experience this potentiation is not marked when small doses are used, but it increases with larger doses. To prevent accidents, patients who receive tranquilizing drugs should be told that they should not take other medication or alcohol without the physician's knowledge.

I would like to call attention to the fact that Thorazine can also produce psychic complications. These are more common in nonpsychotic patients than in psychotic ones, and they usually occur in the initial phase of the treatment. Some patients complain about feelings of depersonalization or that they feel strange, peculiar, and out of contact. At times they complain of marked lethargy and weak

should receive the amount of medication which adequately controls his symptoms. It is obvious that the use of low dosage has certain advantages, especially in an ambulatory setting. It should be stated, however, that in some patients who do not respond to small doses, gratifying results will be obtained when larger doses of the same drug are used, even though this necessitates hospitalization for a time.

With psychotic patients I usually begin with 25 mg of chlorpromazine, 3 times a day. If the patient is disturbed, larger doses are given. Dosage is then increased either daily or every 2 or 3 days until symptoms are controlled. Some need 1,000 or 1,500 mg of chlorpromazine daily and some even larger doses—up to 4,000 mg. It is not clear how far one can or should go and where the point of no return lies. I feel that if a patient does not respond to 1,200 to 1,500 mg of chlorpromazine over a reasonable period, much larger doses will not accomplish a great deal. There are exceptions to this stand, but again I would like to stress that dosage is a highly individualized matter and the good therapist will experiment with dosage. The same applies to rauwolfia.

**Duration of Treatment**—How long the treatment should continue must also be individualized. I feel that a patient should be treated for at least 4 months with adequate dosage before it is decided that he is not responsive to a drug. Then it is advisable to change to another tranquilizer. Some patients, for a reason not yet known, respond to one tranquilizing drug and not to another, but there are patients who are refractory to all the tranquilizing drugs which are in use today.

After having treated the patient for 3 to 4 months, it is my custom to reduce dosage to a maintenance level. In some patients the adjustment of maintenance dosage involves quite a bit of experimentation.

Some patients show an adaptation to the drug, complaining that some symptoms are returning. This is an indication to raise dosage until the patient is again symptom free. I have observed a large number of patients in whom adaptation developed; they functioned quite well, however, after dosage was elevated. But the reverse can also occur and, in some patients needing a fair amount of the drug, dosage can be successfully cut down to a comparatively small amount. In some patients the drug can be discontinued after a few months. In many patients, however, the tranquilizing drugs have to be given for a long time and, in some, indefinitely. Periodic attempts should be made to reduce or eliminate the use of the drugs, otherwise the patient will continue to take the drug even when it is not needed.

True addiction to the tranquilizing drugs seemingly does not develop in the same sense as addiction to morphine. Habituation, however, may occur.

## SEDATIVES

This section also deals with sedation applying to psychiatric conditions. Most of the sedatives which were formerly used were hypnotics applied in smaller dosages than those which induce sleep. After the introduction of tranquilizing drugs, the use of these diminished considerably.

**Bromide**—Bromide was one of the most common sedatives of the last century. It depresses central nervous system function, and in dosages necessary for sedation it has a cortical action. In smaller doses, bromide causes mental calmness, in

and the rauwolfia preparations are far more effective than meprobamate in psychotic patients, and even psychotic patients with mild symptoms have reported that they feel more relaxed after these than after meprobamate.

Meprobamate is used more effectively in neurotic than in psychotic patients. The reaction of neurotic patients to this drug is unpredictable, however. There are some patients who feel more relaxed and show less anxiety, while other patients with very similar symptomatology do not. We have no clue, physiologic or psychologic, why one patient responds to meprobamate whereas another with the same symptoms does not.

There are side effects from meprobamate. Drowsiness is reported with some frequency. Some patients develop an allergic reaction in the form of urticaria or an erythematous rash which is either localized or general. In some severe reactions there was a hemorrhagic type of rash, fainting spells, and bronchial spasms. In such patients the use of the drug should be discontinued and antihistamines and cortical steroids given.

### Choice of a Tranquilizer

The selection of the tranquilizer for the treatment of different psychiatric conditions is not based on clear cut indications, but mainly on the preference of the clinician. In a psychotic patient with an acute condition such as excitement, manic attack, or where a considerable amount of psychomotor activity is present, chlorpromazine is preferable to rauwolfia because of its quicker action.

Some patients respond better to one drug than to another, but there are no definite clinical guides, at the present time on how to determine this in advance of trial. I feel that generally chlorpromazine is more effective orally than reserpine. Patients taking reserpine usually need injections for a while before they can be switched to oral administration. On the other hand, it must be taken into consideration that chlorpromazine has more frequent complications than rauwolfia. In the patient who has liver involvement rauwolfia is preferable to chlorpromazine.

I feel that chlorpromazine is the drug which is most effective and has the widest range of applicability. The rauwolfia preparations are second. Azacyclonal (Frenquel), meprobamate (Miltown, Equanil), and pipradrol (Meratran) are far less effective in psychotic patients. There have not been enough observations in different hospitals and clinics with prochlorperazine (Compazine) and promazine (Sparine) and the other newer phenothiazine preparations to have fully assessed them in relation to Thorazine. My tentative opinion is that they are not as effective as Thorazine in prolonged treatment of psychotic patients but that they have a definite place in the therapeutic armamentarium for the milder emotional disorders and psychoses.

### Regimen for Use of Tranquilizers

**Dosage.**—The dosage of the tranquilizing drugs is a highly individual affair. For instance, some patients regardless of their diagnosis and symptomatology, will respond to 50 mg. of chlorpromazine daily while others with similar symptomatology will need 1,500 mg. Some patients respond to 1 mg. of reserpine while others need 18 to 20 mg. Dosage must be tailored to the patient's condition. In addition some clinicians prefer low dosage and others high dosage. I feel the patient

should receive the amount of medication which adequately controls his symptoms. It is obvious that the use of low dosage has certain advantages, especially in an ambulatory setting. It should be stated, however, that in some patients who do not respond to small doses, gratifying results will be obtained when larger doses of the same drug are used, even though this necessitates hospitalization for a time.

With psychotic patients I usually begin with 25 mg of chlorpromazine, 3 times a day. If the patient is disturbed, larger doses are given. Dosage is then increased either daily or every 2 or 3 days until symptoms are controlled. Some need 1,000 or 1,500 mg of chlorpromazine daily and some even larger doses—up to 4,000 mg. It is not clear how far one can or should go and where the point of no return lies. I feel that if a patient does not respond to 1,200 to 1,500 mg of chlorpromazine over a reasonable period, much larger doses will not accomplish a great deal. There are exceptions to this stand, but again I would like to stress that dosage is a highly individualized matter and the good therapist will experiment with dosage. The same applies to rauwolfia.

**Duration of Treatment**—How long the treatment should continue must also be individualized. I feel that a patient should be treated for at least 4 months with adequate dosage before it is decided that he is not responsive to a drug. Then it is advisable to change to another tranquilizer. Some patients for a reason not yet known, respond to one tranquilizing drug and not to another, but there are patients who are refractory to all the tranquilizing drugs which are in use today.

After having treated the patient for 3 to 4 months, it is my custom to reduce dosage to a maintenance level. In some patients the adjustment of maintenance dosage involves quite a bit of experimentation.

Some patients show an adaptation to the drug, complaining that some symptoms are returning. This is an indication to raise dosage until the patient is again symptom free. I have observed a large number of patients in whom adaptation developed; they functioned quite well, however, after dosage was elevated. But the reverse can also occur and, in some patients needing a fair amount of the drug, dosage can be successfully cut down to a comparatively small amount. In some patients the drug can be discontinued after a few months. In many patients, however, the tranquilizing drugs have to be given for a long time and, in some, indefinitely. Periodic attempts should be made to reduce or eliminate the use of the drugs, otherwise the patient will continue to take the drug even when it is not needed.

True addiction to the tranquilizing drugs seemingly does not develop in the same sense as addiction to morphine. Habituation, however, may occur.

## SEDATIVES

*This section also deals with sedation applying to psychiatric conditions.* Most of the sedatives which were formerly used were hypnotics applied in smaller dosages than those which induce sleep. After the introduction of tranquilizing drugs, the use of these diminished considerably.

**Bromide**—Bromide was one of the most common sedatives of the last century. It depresses central nervous system function, and in dosages necessary for sedation it has a cortical action. In smaller doses, bromide causes mental calmness, in

higher doses it produces sleep. Bromide is an effective sedative, but, unfortunately in large amounts or if used for a long period of time it can produce lassitude and disturbance of intellectual processes with dullness and faulty memory. The disadvantage of bromide medication is that some patients adapt themselves to the drug so that larger and larger doses are used to obtain sedation. As a consequence, chronic bromide intoxication is not rare. Bromide is not prescribed often in psychiatric practice today and even prior to the introduction of the so-called tranquilizing drugs had been almost completely replaced as a sedative by the barbiturates.

**Barbiturates**—For sedative purposes it is customary to use barbiturates in lower dosage than that for sleep induction. A large array of barbiturates is on the market of which I would like to mention only a few. As hypnotics the barbiturates are divided into long acting, intermediate acting, short acting, and ultra short acting drugs, depending upon how quickly they are able to induce sleep and how long they maintain their hypnotic effect. For sedative purposes long acting or short acting barbiturates or a mixture of both can be used, depending upon how long one wishes to maintain sedation. Barbital and phenobarbital are used in psychiatric practice for a long acting sedation; amobarbital and butabarbital for intermediate duration; pentobarbital (Nembutal) and secobarbital (Seconal) are the common short acting barbiturates.

Barbiturates reduce tension and anxiety and therefore are able to influence some of the clinical manifestations of neurotic and mildly psychotic states. In sedative doses they do not control massive states of anxiety or excitement or influence severe emotional states occurring in the framework of a psychosis or neurosis.

At present the tranquilizing drugs are far superior to the barbiturates in controlling severe emotional states and therefore the use of barbiturates in such conditions has diminished considerably. Many patients still receive barbiturates to control some of their neurotic manifestations. Here too, however, they are being replaced increasingly by tranquilizing drugs. In psychiatric cases the replacement is due mainly to the fact that habituation to barbiturates is not uncommon in neurotic and sometimes psychotic patients. Habituation to the tranquilizing drugs is observed in some, but in general the habituation hazard seems not to be high.

Further investigations will have to be made to establish the role of the barbiturates in the treatment of neuroses, especially those of the anxiety and tension states in relationship to the tranquilizing drugs. Most likely the present trend to treat such patients with tranquilizing drugs will continue, especially in cases in which the drug has to be given over a long period. Formerly chloral hydrate, paraldehyde, and scopolamine were occasionally used in psychiatric practice to induce sleep and to sedate excited patients. They are still used to induce sleep, for chloral hydrate and paraldehyde are both effective hypnotics, but they have not been used as extensively since the introduction of the tranquilizing drugs. The unpleasant odor of paraldehyde and taste of chloral hydrate have always limited their use as sedatives. Patients who may take these drugs to induce sleep will not take them in smaller quantities more frequently for sedative purposes.

The prolonged use of barbiturates or other sedatives in patients with psychiatric disorders should be avoided. It is especially bad practice to prescribe these



drugs without knowing in detail the patient's psychiatric condition and to use the medication purely to help the patient symptomatically. Sedatives are very important in the treatment of psychiatric patients, but they should be used only after the patient's psychiatric condition is properly assessed. In many instances the patient suffering from a psychiatric disorder may need psychotherapy in addition to sedation in order to elucidate and influence the causes of the condition.

## SELECTED REFERENCES

- Borras, Joseph C. Meprobamate in Psychiatric Disorders, *M Clin North America*, 2, 1957
- Bower, W. H. Chlorpromazine in Psychiatric Illness, *New England J Med* 251: 689, 1954
- Cohen, I. M. Effects of Chlorpromazine in Psychiatric Disorders, *Am J M Sc* 299: 355, 1955
- Delay, J., and Deniker, P. Thirty eight Cases of Psychoses Under Prolonged and Continuous Treatment, *Compt rend du Congrès des Med Aliénistes et Neurologistes, Luxembourg*, July 21-27, 1952, pp 7-18
- Idem. Use in Psychiatric Therapy of a Phenothiazine With Selective Central Action, *Ann Med Psychol* 110: 112, 1952
- Elkes, J., and Elkes, C. Effect of Chlorpromazine on the Behavior of Chronically Overactive Psychotic Patients, *Brit M J* 2: 560, 1954
- Goldman, D. Treatment of Psychotic States With Chlorpromazine, *J A M A* 157: 1274, 1955
- Harris, R. Clinical Use of Reserpine (Serpasil) in Geriatrics, *Ann New York Acad Sc* 59: 95, 1954
- Hoch, P. H., Malit. . . . . Clinical Research . . . . .
- Hoch, P. H. New orders, Bu . . . . . (Dis
- Hollister, Leo E. . . . . Med
- Hollister, Leo E. Allergy to Chlorpromazine Manifested by Jaundice, *Am J Med* 23: 870, 1957
- Kinross Wright, V. Chlorpromazine Treatment of Mental Disorders, *Am J Psychiat* 111: 907, 1955
- Lehmann, H. E. Selective Inhibition of Affective Drive by Pharmacologic Means, *Am J Psychiat* 110: 805, 1954
- Miner, R. W., editor. Reserpine in the Treatment of Neuropsychiatric, Neurological and Related Clinical Problems, *Ann New York Acad Sc* 61. (Art 1) 1: 280, 1955
- Moyer, J. H., Kinross Wright, V., and Rinney, R. M. Chlorpromazine as a Therapeutic . . . . .
- Moyer, . . . . . it Evaluation 1957
- Noce, R. . . . . Management
- Plummer . . . . . erpine, Ann
- New York Acad Sc 59: 5, 1954
- Rea, E. L., Shea, J. and Fozekas, J. F. Hypotensive Action of Chlorpromazine, *J A M A* 156: 13, 1954
- Selling, L. S. Clinical Study of a New Tranquilizing Drug, *J A M A* 157: 1594, 1955
- Shaw, C. C., and Felts, P. W. Treacherous Tranquilizers, *Am J Med Sc* 237: 141, 1959
- Wallis, R. Potentiation of Hypnotics and Analgesics, *New York J Med* 55: 243, 1955
- Wilkins, R. W. Clinical Usage of Rauwolfia, *Ann New York Acad Sc* 59: 36, 1954
- Winkelmann, N. W., Jr. Chlorpromazine in the Treatment of Neuropsychiatric Disorders, *J A M A* 155: 18, 1954
- Wortis, J. Review of Psychiatric Progress, 1953, Physiological Treatment, *Am J Psychiat* 110: 507, 1954

higher doses it produces sleep. Bromide is an effective sedative, but, unfortunately, in large amounts or if used for a long period of time, it can produce lassitude and a disturbance of intellectual processes with dullness and faulty memory. The disadvantage of bromide medication is that some patients adapt themselves to the drug so that larger and larger doses are used to obtain sedation. As a consequence, chronic bromide intoxication is not rare. Bromide is not prescribed often in psychiatric practice today and even prior to the introduction of the so called tranquilizing drugs had been almost completely replaced as a sedative by the barbiturates.

**Barbiturates**—For sedative purposes it is customary to use barbiturates in lower dosage than that for sleep induction. A large array of barbiturates is on the market, of which I would like to mention only a few. As hypnotics the barbiturates are divided into long acting, intermediate acting, short acting, and ultra short acting drugs, depending upon how quickly they are able to induce sleep and how long they maintain their hypnotic effect. For sedative purposes long acting or short acting barbiturates or a mixture of both can be used depending upon how long one wishes to maintain sedation. Barbital and phenobarbital are used in psychiatric practice for a long acting sedation; amobarbital and butabarbital for intermediate duration; pentobarbital (Nembutal) and secobarbital (Seconal) are the common short acting barbiturates.

Barbiturates reduce tension and anxiety and therefore, are able to influence some of the clinical manifestations of neurotic and mildly psychotic states. In sedative doses they do not control massive states of anxiety or excitement or influence severe emotional states occurring in the framework of a psychosis or neurosis.

At present, the tranquilizing drugs are far superior to the barbiturates in controlling severe emotional states, and therefore, the use of barbiturates in such conditions has diminished considerably. Many patients still receive barbiturates to control some of their neurotic manifestations. Here too, however, they are being replaced increasingly by tranquilizing drugs. In psychiatric cases the replacement is due mainly to the fact that habituation to barbiturates is not uncommon in neurotic and, sometimes, psychotic patients. Habituation to the tranquilizing drugs is observed in some but in general the habituation hazard seems not to be high.

Further investigations will have to be made to establish the role of the barbiturates in the treatment of neuroses especially those of the anxiety and tension states in relationship to the tranquilizing drugs. Most likely the present trend to treat such patients with tranquilizing drugs will continue especially in cases in which the drug has to be given over a long period. Formerly chloral hydrate, paraldehyde and scopolamine were occasionally used in psychiatric practice to induce sleep and to sedate excited patients. They are still used to induce sleep, for chloral hydrate and paraldehyde are both effective hypnotics, but they have not been used as extensively since the introduction of the tranquilizing drugs. The unpleasant odor of paraldehyde and taste of chloral hydrate have always limited their use as sedatives. Patients who may take these drugs to induce sleep will not take them in smaller quantities more frequently for sedative purposes.

The prolonged use of barbiturates or other sedatives in patients with psychiatric disorders should be avoided. It is especially bad practice to prescribe these

siderations involved. The older literature refers to the dangers of treating cardiac patients with hypnotics (especially chloral) this erroneous concept is no longer held by most physicians.

**Addiction**—It has been unequivocally demonstrated that barbiturates can produce physical dependence. Without question these drugs can also lead to habituation. They qualify as truly addicting drugs. Although complete information on this point is not yet available regarding recently introduced agents it is probably safest to assume until proved otherwise, that newer hypnotic drugs can also lead to such addiction. On the other hand it must be emphasized that *under usual conditions of hypnotic usage, the problem of drug addiction is almost non-existent with either barbiturates or nonbarbiturates*.

**Suicidal Attempts**—Attempted suicide with barbiturates is a common occurrence. Attempted suicide with most of the newer sleeping medications has also been reported. In the case of some of these compounds death has occurred. Since it is difficult to conceive of a compound with definite hypnotic potency which can not cause death if taken in sufficient quantities it would seem only a question of time before all of the newer hypnotics have fallen into this same unfortunate category.

**Tolerance**—The development of tolerance to routine nightly doses of hypnotics, frequently discussed, has not been demonstrated conclusively. Tolerance to phenobarbital has been studied in epileptics and has definitely been shown to occur. In barbiturate addicts however, there seems to be a definite ceiling to this tolerance and its magnitude is by no means as great as that seen with drugs such as morphine.

**Cost**—The older medications such as chloral hydrate and the barbiturates are a good deal cheaper than the newer drugs.

## THE SEVERAL DRUGS USED AS HYPNOTICS

**Chloral Hydrate**—One of the oldest drugs available for the purpose of inducing sleep is chloral hydrate. It is an effective hypnotic for this purpose and its availability in capsules in recent years has increased its popularity. Trichloroethanol, the active metabolite of chloral hydrate, is also an effective hypnotic but it is as yet not available for commercial sale in either liquid or capsule form.

**Paraldehyde**—Paraldehyde is an old and effective agent for producing sleep but has drawbacks in regard to taste and odor. It is no longer employed to any great extent except in the management of alcoholics.

**Barbiturates**—The barbiturates are the most frequently prescribed hypnotics and comprise (with chloral hydrate) the most useful medications now on the market. In my experience one can get satisfactory results in most patients from either of the two most popular barbiturates (pentobarbital sodium and secobarbital sodium) when these drugs are given in doses of 0.1 or 0.2 Gm. The alleged differences in onset of action and duration of effect between these drugs have not obtained in the clinical trials conducted by us. Phenobarbital has appeared somewhat less effective and predictable than pentobarbital or secobarbital when given in similar dosage.

## THE CHOICE OF A HYPNOTIC

*Louis Lasagna, M.D.*

---

### INTRODUCTION

Adult man spends approximately one-third of his life in sleep. Whether such behavior is optimal or necessary could be debated, the fact remains that most people consider adequate sleep to be important. Experimental studies on healthy young males and casual observation on other populations indicate that sleep deprivation is compatible with essentially normal performance for long periods of time, and that such loss of sleep does not create a cumulative "sleep debt" which must eventually be paid. Nevertheless, people who usually sleep well often look and feel below par on the day after a restless night. In addition, a significant percentage of the population appears to be awake for variable periods of time on most nights, many of these individuals are bothered by their insomnia by their "tiredness" in the morning, or by both. It must be remembered, however, that some people who be awake for variable periods at night are not bothered by this and neither need nor want sleeping pills.

### CLINICAL CONSIDERATIONS

The physician is off to a good start in managing his patient's insomnia if he first ascertains certain basic pertinent facts. These data can be classified into four major categories: nature of the sleep disorder, character of the patient's daily activities, past experience with sleeping medications, and general attitude toward medications.

**Nature of the Sleep Disorder**—Some patients have difficulty only in falling asleep and, once asleep, need no additional pharmacologic help. Other patients have no trouble in falling asleep, but wake up one or more times during the night. Still other patients (and in my experience, the majority of insomniacs) have trouble in falling asleep *and* in staying asleep, and for such individuals the optimal drug is one

or most of  
such as "I

but in some patients pain is the primary cause of disturbed sleep. This latter group may require treatment with appropriate analgesics and will not be considered in this chapter.

*"average" dose does not work properly* Unless the patient rebels at the suggestion, some experimentation with dosage as recommended above is strongly advised. If an unsatisfactory performance does not result after these maneuvers, the newer drugs may be tried. My current order of preference of the new drugs is Naludar, 0.2 to 0.4 Gm, Dordon 0.5 to 1 Gm, Valmid or Placidyl, 1 Gm. Because of the tremendous background of experience with chloral hydrate and barbiturates and since these standard, cheaper drugs work so well in most patients, I believe the chief value of the newer agents to be their occasional usefulness in case of failure with the older and better known drugs.

## RATIONAL BASIS FOR NEW DRUGS FOR INSOMNIA

It would be highly desirable to have a uniformly effective hypnotic drug which did not produce hang over, tolerance, addiction, rashes, paradoxical excitation, or other bad effects. It seems unlikely that such a perfect somnifacient will be devised. In regard to hang over, for example, it is difficult to imagine that any drug capable of combating successfully the intermittent wakefulness which some patients experience throughout the night will 'turn itself off' immediately upon the patient's awakening in the morning. If patients demand a sustained hypnotic effect for 8 hours some will in all likelihood have to pay a price for this. Furthermore, certain people will probably always abuse drugs, including sedatives. Such pessimistic considerations apply to most of the other respects in which the present drugs are deficient. None of the new nonbarbiturate hypnotics represent significant advances along these lines. The pharmaceutical industry continues to search for better drugs however, and perhaps some progress will be made. It should be stressed, on the other hand, that at present therapeutic difficulties are relatively minor in the great majority of patients, who can be adequately handled by intelligent use of the drugs currently available.

## SELECTED REFERENCES

- Lasagna, L. A Comparison of Hypnotic Agents. *J Pharmacol & Exper Therap* 111:9 1954
- Lasagna, L. A Study of Hypnotic Drugs in Patients With Chronic Diseases. *J Chron Dis* 3:122 1956
- Lasagna, L. Across the Counter Hypnotics: Boon, Hazard, or Fraud? *J Chron Dis* 4:55<sup>9</sup> 1956
- Lasagna, L. The Newer Hypnotics, *M Clin North America* 35:9 1957
- Owens, A. H. Jr, Marshall, E. K., Jr, Broun, G. O., Jr, Zubrod, C. G., and Lasagna, L. A Comparative Evaluation of the Hypnotic Potency of Chloral Hydrate and Tri-chloroethanol. *Bull Johns Hopkins Hosp* 96:71 1955
- Sessions, J. T., Jr, Minkel, H. P., Bullard, J. G., and Ingelfinger, F. J. The Effect of Barbiturates in Patients With Liver Disease. *J Clin Invest* 33:1116 1954

**Methyprylon**—Noludar (methyprylon) is an effective compound which resembles pentobarbital or secobarbital in its effects. The dose required for effective use (0.2 or 0.4 Gm) is about double that for pentobarbital and secobarbital.

**Glutethimide**—Doriden (glutethimide) is somewhat similar to Noludar chemically. Its effects resemble those of the barbiturates, but it must usually be given in doses of 0.5 or 1 Gm.

**Meprobamate**—Meproamate (Miltown, Equanil) in doses of 0.4 or 0.8 Gm is satisfactory for some patients in inducing and maintaining sleep.

**Methylparafynol**—Dormison (methylparafynol) is an unsaturated alcohol of rather weak potency. Its usefulness in any but the mildest types of insomnia is extremely limited.

**Ethchlorvynol**—Placidyl (ethchlorvynol) is a drug resembling Dormison in chemical structure, but appears more potent than Dormison. It must be given in doses of 0.5 or (more often in my experience) 1 Gm for effective activity in patients with insomnia.

**Ethinamate**—Valmid (ethinamate) in my experience has to be given in 1 Gm doses in order to achieve therapeutic effectiveness in the majority of patients.

**Antihistaminics**—There are many across the counter hypnotics available on the market, most of which contain one or another antihistaminic. The most common of these antihistaminics is metapyrilene, which is relatively ineffective as a hypnotic in the recommended doses. Other antihistaminic agents such as Benadryl are capable of inducing drowsiness in some patients but they are not often prescribed in adults specifically for this purpose and are not as predictable or effective as the best barbiturates.

**"Tranquilizers"**—Most of the new potent "tranquilizing" agents are sedatives, but they are not usually employed as hypnotics. Their use as tranquilizers is discussed in another chapter.

## HOW TO USE HYPNOTICS

If a patient has difficulty only in falling asleep, a recommended practice is to prescribe chloral hydrate in a dose of 1 Gm. If, for some reason the patient objects to chloral hydrate, secobarbital or pentobarbital, 0.1 Gm, can be used. If the patient's only difficulty is awakening during the night, one can employ several therapeutic maneuvers. One can prescribe chloral hydrate to be taken if the patient awakens in the middle of the night or very early in the morning. An alternative is to prescribe secobarbital or pentobarbital in doses of 0.1 Gm at bedtime to prevent waking during the night. If the patient has difficulty both in going to sleep and in staying asleep, one should also prescribe secobarbital or pentobarbital in dose of 0.1 Gm.

In each of the instances mentioned above, the dose of medication should be doubled if the patient does not achieve enough hypnotic effect, or halved if the patient has too much residual effect. Occasionally the dose may even be tripled, but this is not recommended for most patients. (With higher doses the problems of tolerance, physical dependence, and residual sedation become serious considerations.) *It is important not to switch from one drug to another merely because the*

Table 14 Comparison of Results From Various Methods of Treatment for Epilepsy\*

	No. of Patients	Grade of Improvement (Per Cent)					Severe Toxic, or Fatal Reaction to Treatment
		4 (Secure Free)	3	2	1	0	
<b>Ambulatory Treatments</b>							
No specific treatment							
Trousseau	150	13	-	-	-	-	-
Herpin	58	50	-	-	-	-	-
Bromides							
Turner	366	24	-	28	-	-	-
Pollock	85	72	-	-	-	-	-
Arriff	144	73	-	-	-	-	-
<b>Ketogenic diet</b>							
Wilkins	30	27	-	-	-	-	-
Keith	190	35	-	18.4	-	46.3	-
Peterman	1234	-	80	-	-	20	-
Phenobarbital							
Lennox	766	-	65	-	-	-	-
Arriff	484	90	-	-	-	-	-
Ives	1114	27	19	-	-	-	-
<b>Diphenylhydantoin</b>							
Putnam and Merritt	118	58	27	5	-	10	-
Yahr and others	504	15	-	9	-	-	-
Boller	5204	23	-	24	-	15	-
Ives	924	20	28	-	-	22	-
<b>Phenanthion</b>							
Kozol	1154	-	60	-	-	40	-
Lennox	304	30	20	-	-	-	-
Loscalzo	674	32	50	-	-	18	-
Ives	414	10	29	-	-	22	-
<b>Glutamic Acid†</b>							
Price and others	84	12	38	25	-	25	-
Zimmerman and others	74	70	15	15	-	-	-
<b>Trimethadione†</b>							
Lennox	1454	33	30	21	0	16	-
Ives	444	7	29	-	-	32	-
<b>Phenacemide</b>							
Tyler and King	1,5624	37	-	31	-	32	21
Davidson and Lennox	1784	3	19	24	-	-	15

## THE CHOICE OF AN ANTICONVULSANT\*

*Tracy Jackson Putnam, M.D.*

---

### INTRODUCTION

The incidence of epilepsy is closely comparable to the incidence of diabetes, each affecting approximately one million people on this continent. At present, epilepsy probably entails more total disability and economic loss than diabetes, but it attracts far less study and intelligent understanding from the majority of doctors, and research in the field is poorly endowed. A revolution has occurred in treatment of both diseases in diabetes beginning about 35 years ago, in epilepsy about 20 years ago. But whereas every practitioner has some knowledge of the fundamental principles of treatment of diabetes and attains a high proportion of relief of symptoms in the great majority of cases, even specialists in neurology are usually fatalistic about epilepsy and tend to stick to the exclusive use of one or two drugs rather than analyzing the individual patient's needs. As a result, there is an enormous difference in the proportion of patients maintained seizure free from clinic to clinic—as low as 20, as high as 77—so that it seems likely that a widespread use of methods now available might return about half a million epileptics to employability and restoration of full citizenship.

### CLINICAL APPLICATIONS

Until about 1936, it was by no means clear that epilepsy was a disorder to be treated primarily by drugs. At that time the two prevailing schools of thought held that it was a form of conversion hysteria best treated by psychotherapy, and that it was the result of scars of the brain, theoretically best treated surgically. Largely as a result of the work of Lennox and of Gibbs, it then became clear that there was uniformly a demonstrable electrical disturbance in the cortex during an attack, more or less specific for the attack, often detectable in some degree in the interseizure period. Further, it became clear that drugs and physiologic alterations, for example, in the acid base equilibrium might have a profound effect both on the dysrhythmia and on the seizures.

---

\*The expenses of the investigation upon which this chapter is founded were borne in part by the Tracy J. Putnam Foundation and the Foundation for Research, Inc.



About the same time, also in my former clinic at the Boston City Hospital the first nonsedative anticonvulsant drug, diphenylhydantoin, was selected by animal experiment and tested clinically. The conception of such a drug and of its general configuration antedated this period by several years, as I have described elsewhere, but the actual accumulation of promising materials and the experiments were begun in 1936, and published the following year. The announcement was greeted with a torrent of abuse. Up to that time, the drugs used in treatment of epilepsy, chiefly bromides and phenobarbital, were discovered empirically, and textbooks of pharmacology stated flatly that epilepsy had to be treated, if at all with sedatives and that there was little choice between the barbiturates.

Once the possibility was demonstrated that there could be a nonsedative anticonvulsant the requirements of the ideal drug seemed clear. It should be effective in controlling seizures and the underlying dysrhythmia, it should be non-toxic in therapeutic doses, and long retained in the body. Even at that time it seemed likely that at least two different types of anticonvulsants should be sought: one type designed like diphenylhydantoin to control excessive rapid dysrhythmia, the other like ketosis, and later glutamic acid, to control the slow-wave dysrhythmia of petit mal, psychomotor episodes, and periodic dullness.

At present about 14 effective drugs are available, none of them ideal. Some of these are apparently harmless, fatality rates approaching 1 per cent have followed administration of others in some series. The practitioner and even the specialist is apt to find himself confused by the plethora, and reference to the literature is not particularly helpful. The majority of published reports fall into two groups: those which uphold the virtues of old methods of treatment such as the use of bromides, surgery, phenobarbital and the ketogenic diet, and those which extol the virtues of individual new drugs. In the latter instance, the investigator uses the new drug on patients who have been inadequately treated or not at all. Often the term "improvement" is used in an elastic manner, and it appears that some of the drugs recommended may control seizures only at the cost of disabling symptoms such as drowsiness and depression in the cases of bromides, phenobarbital and phenacemide (Phenurone), or at some risk of severe or fatal toxic

Table 15 *Reported Effect of Various Medications on Specific Types of Attacks*

	Proportion of Patients Relieved (in Per Cent)			
	Grand Mal	Petit Mal	Psycho-motor	Focal
Phenobarbital	27	?	20	?
Phenytoin	56	35	62	50
Phenantoïn	32-56	15	50	56
Glutamic acid	0	12	70*	0
Trimethadione	6	28	?	?
Paramethadione	9	?	9	?
Phenacemide	62*	29*	51*	?
Primidone	57	?	4	?
Metharbital	30	17	?	?
Phensuximide	0	22	20	?
Acetazolamide	50*	40	?	0
Pegamone	65	47	36	?
Prenderol	?	60*	?	?
Tetrantoïn	53	0	0	60

\*Greatly benefited

<b>Spirodon</b>						
Putnam and Jacobs	66	14	44	165	9	165
<b>Standard Treatment</b>						
Ives	212	31	-	-	-	-
Yahr and others	319	48	-	37	-	-
Putnam and Rothenberg	75	56	4	7	33	-
<b>Radical Treatments</b>						
<b>Excision of cortical scars</b>						
Penfield	59†	25	30	14	12	18
Excision of motor cortex						
Pitcher and others	41†	20	30	21	-	13
Intensive medical treatment						
Putnam and Rothenberg	25	64				4
Standard and/or intensive treatment			20	16	-	0
Putnam and Rothenberg	75	77	11	12	-	0
*Modified from Putnam, T. J., and Rothenberg, S. F. <i>J. A. M. A.</i> 152:1400, 1953. References in original article.						
†Selected patients. The basis of selection was not always clear.						
‡Effect on petit mal or psychomotor attacks.						

**J. A. M. A. 152:1400, 1953. Results of Intensive (Narcosis) and Standard Medical Treatment of Epilepsy,**

*Table 16 Structure and General Properties of Common Anticonvulsants\**  
(Refer to Fig 6 for key to structural formula)

Range of Daily Dose for Adults (Gm.)	R	R <sub>1</sub>	R <sub>2</sub>	Usual Use	Chief Toxic Symptoms
<b>Barbituric Acids</b>					
0.1-0.4	C.H.	C.H.	H	Grand mal, focal seizures	Sedative increases psychomotor activity, rashes deaths from suicide
0.1-0.4	C.H.	C.H.	C.H.	Similar to phenobarbital	Similar to phenobarbital
0.1-0.4	C.H.	C.H.	C.H.	Similar to phenobarbital	Similar to phenobarbital
0.25-1.5	C.H.	C.H.	C.H.	Recommended also for petit mal	Similar to phenobarbital rare bone marrow depression
<b>Hydantoins</b>					
Phenytoin (Diphenylhydantoin)	C.H.	C.H.	H	All types of seizures	Ataxia headache, hypertrophy of gums, hypertrichous Probably safest anticonvulsant 1 questionable fatality
Phenanthion (Ethylphenyl N-methyl hydantoin)	C.H.	C.H.	C.H.	Grand mal, focal	More sedative than phenytoin bone marrow depression frequently reported 8 fatalities
Tetratoin (2 tetralone hydantoin)	2, tetralone	H	H	Grand mal, focal	New drug, apparently low toxicity
Ethotoin (3, 4 dihydro 2 [1H] Naphthalene none)	C.H.	H	C.H.	All types of seizures	New drug Rashes, vomiting, drowsiness, agranulocytosis, 1 fatality
<b>Oxazolinediones</b>					
Trimethadione	C.H.	C.H.	C.H.	Petit mal, psychomotor	Sensitiveness to light drowsiness bone marrow depression 1 fatality reported
Paramethadione	C.H.	C.H.	C.H.	Similar	Similar
Succinimides	H	C.H.	C.H.	Petit mal psychomotor	Drowsiness
Phenacemide	H	C.H.	H	All types of seizures	Rash drowsiness ataxia
Acetylureas	H	C.H.	C.H.	Personal ty change bone marrow depression 1 ver damage 4 fatalities reported	Bone marrow depression 2 fatalities
Phenacemide	H	C.H.	H	All types of seizures	Drowsiness new drug
Acetazolamide	0.75	2 acetlam no 1 3 4 thiazole 5 sulphamide	5	All types reports of effectiveness vary widely	Anticonvulsant
Duethyl propanediol	4.0-8.0	2 2 diethyl 1 3 propanediol	5	Grand mal	Anticonvulsant
* Mod. fed from Toman J. E. P. and Taylor, J. D. Mechanism of Action and Metabolism					

reactions, such as those reported following the use of phenantoin, phenacemide, phethenylate, trimethadione, and paramethadione. A summary of results of the use of various methods of treatment is given in Table 14.

From data such as these and certain pharmacologic tests, it has become traditional to use some drugs first against certain types of seizures, others against other types, as summarized in Tables 15 and 16. As will be seen below (especially from Table 18 and the description of the rapid determination of optimum medication), these traditional usages are approximations. Actually, the optimum drug or combination for the individual patient can be found only by experimentation, preferably systematic, with that patient. For what it is worth, however, the data in Table 15 have been collected from the literature. The statistics shown are for the most part extremely crude and have not been collected in any uniform manner. The majority of papers written on this subject are impressionistic and give no quantitative data.

### GENERAL PHARMACOLOGIC CONSIDERATIONS

**Pharmacologic Requirements of Anticonvulsants.**—Soon after the introduction of diphenylhydantoin, I made a study of the requirements of anticonvulsants on the basis of those found effective among the first substances tested. The following attributes seemed clear:

- 1 The substance should have a high solubility in fats and a low solubility in water at neutrality.
- 2 It should contain one or more phenyl or related nuclei in a terminal position.
- 3 Usually if any other group is attached to this terminal nucleus, the substance becomes inactive.
- 4 Adjacent to the terminal, phenyl or similar nucleus, or separated from it by not more than 2 radicals (usually of aliphatic character) is a "reactive" group containing a double bond, usually  $O=O$ , which is not terminal. Other "reactive" groups which occurred in the first series were  $CNOH$ ,  $SO_2$ ,  $SO$ , and the benzoxazole linkage.
- 5 There may be other "reactive" groups in the molecule, but if so they are usually separated by "nonreactive"  $C$  or  $N$  groups.
- 6 Double bonds are found only in the "reactive" groups, with rare exceptions.
- 7 The presence of  $CH_2CH_2$  groups or longer similar chains attached to the "reactive" group causes the appearance of sedative and toxic effects, as would be expected on general pharmacologic principles (Richardson's law).
- 8 Linkages through an  $-O-$  atom, the presence of furyl nuclei, or of a terminal  $-NH_2$ , conferred toxic properties on the substances in which they were found.
- 9 In only one effective substance (diphenyl acetic acid) was a terminal  $-COOH$  group found.
- 10 There was only one alcohol in the series, phenyl glycol which showed the expected sedative action.
- 11 The only ring structures containing "reactive" groups found in the origi-

Table 17 Summary of the Fate of Some Anticonvulsant Drugs\*

Name	% Excreted Unchanged in Urine	Metabolite	% Excreted as Metabolite in Urine	% of Drug Unac counted for	Species
Phenytoin	10	—	—	90	man
	3	5, 5-diphenyl hydantoic acid 5, 5 diphenyl- $\alpha$ aminoacetic acid	4 23	70	dog
	14	5, 5 diphenyl hydantoic acid 5, 5 diphenyl $\alpha$ aminoacetic acid	15 10 27		
	0	—	—	100	rat
Phenantoïn	0	5 ethyl 5 phenyl hydantoin (Nirvanol)	16 20	80	dog
	0	5-ethyl 5 phenyl hydantoin (Nirvanol)	2 22	80	man
Nirvanol		5-ethyl 5 phenyl hydantoic acid	1	55	dog
	15	5-ethyl 5 phenyl- $\alpha$ amino acetic acid	30		
Phenobarbital	11 25	?	—	75 90	man dog
Metharbital	2 3	barbital	44	50	dog
Mephobarbital	0	phenobarbital	4	95	dog
Trimethadione	2 1 2	? ?	— —	98 98 99	man rat
Phenacemide	0	phenolic compounds phenylacetic acid and/or derivatives	30 40 20	60 70 80	man rat

\*Adapted from Toman, J. E. P., and Taylor, J. D. Mechanism of Action and Metabolism of Anticonvulsants, *Epilepsia* 1: 31, 1952

After a preliminary study to minimize the likelihood of overlooking a tumor or other progressive or operable lesion, the following principles should be observed:

1. Relatively well known and nontoxic drugs should be preferred to dangerous or untried ones. In respect to serious permanent toxic effects, diphenylhydantoin is probably the safest drug, with phenobarbital in close competition. Phenobarbital is often used successfully as a suicidal agent and practically always produces some sedation or depression in effective doses. Alarming or fatal reactions have been reported from the use of trimethadione (*Tridione*), paramethadione (*Paradione*), phenacemide (*Phenurone*), and phenantoïn (*Mesantoin*), the risk apparently increasing in about that order. In recent years, deaths from this cause have practically ceased to be reported from the 3 first named drugs, suggesting that the toxicity may have been due to some impurity in earlier batches, but Kozol recently reported that the toxicity of *Mesantoin* is due to the presence of 10% of *mesantoin* (counts) 15. Close laboratory control is essential when *Mesantoin* is used. Schwab

have pointed out, this materially increases the patient's economic burden.

2. Treatment should always be started with the most familiar, thoroughly

nal series were the barbituric acid and hydantoin rings (but several others since been demonstrated)

Most of these conclusions have been well sustained in the intervening years as will be seen in Fig 6 and Table 16 (both modified from Toman's valuable article, 1952)




Fig 6—Structural relationships between the major groups of anticonvulsants. Top row shows cross closed rings. Middle row shows three major groups: succinimide, barbiturate, and isocyanurate. Bottom row shows the relationships between the major groups. Right vertical row shows the relationships between the major groups. Toman J E P and Epilepsia 1 31 1952

Table 17 from the same source indicates the fate of some of the anticonvulsants in the human and animal body. This same article is an excellent review of the pharmacologic literature and references will not be repeated here.

## A DESIGN FOR THE USE OF DRUGS FOR CONTROL OF

Principles—A systematic program of trial and selection of drugs was foreshadowed in 1939, and more fully developed in

ness are predominant. Milontin, glutamic acid, trimethadione, paramethadione, Celontin, and phenacemide are preferred next, in that order. Amphetamine may be tried. Vigorous exercise should be required of the patient.

7 Patients should be instructed to report the occurrence of one or a few seizures, and the dose of the drug they are using ordinarily should then be increased, or a new agent should be added. In the long run, especially in growing children, some drug tolerance may gradually develop, and the tolerance dose should be readjusted every year or when symptoms recur.

8 The use of adjuvant therapy, such as exercise, the use of ataraxics as indicated, avoidance of strain and fatigue and deleterious activities and simple psychotherapy are almost always advisable. Extreme moderation in the use of alcohol must be required.

9 Surgical measures should be considered only when adequate standard medical treatment, as defined, and, perhaps, a trial of intensive treatment, as described briefly below, have failed. Similar medical measures usually have to be carried out after cortical extirpation and only sometimes are more effective afterward than they were before.

Approximate observance of these rules constitutes what has been termed the "standard treatment." A comparison of the results of such a procedure, in comparison with those restricted to individual drugs, and also with certain drastic treatments, namely, operative treatment of focal seizures, the ketogenic diet and the intensive or narcosis treatment, is given in Table 14.

**Rapid Determination of Optimum Medication**—The rigid application of these principles sometimes imposes an onerous task on the physician and patient. In a certain proportion of cases, this period of experimentation becomes intolerable. It is particularly likely to become so when a wage earner develops seizures which may deprive him of his job if they are not promptly controlled, or when a child's education is imperiled by convulsions. Under such circumstances, a rapid determination of optimum medication may be carried out, as described by Putnam, Rothenberg, and Bercel in 1954. Briefly, this consists in hospitalizing the patient for about 2 weeks. At the outset, all medication is withdrawn and an electroencephalogram is taken as a base line. Then each day, a large dose of one of the anticonvulsants—each day a new one—is given and an electroencephalogram is taken 2 or 3 hours later. If the patient has seizures or develops drowsiness, vertigo, confusion, or other toxic manifestations, symptomatic treatment is given. At the end of the period all of the electroencephalographic records are compared. It is usually perfectly clear which drugs are effective, which ineffective and which toxic. Table 18 shows the drugs tried, the dosages used, and the outcome.

Drugs which are ineffective or produce toxic manifestations in the test are seldom found clinically useful. An exception is phenytoin. Those which improve the electroencephalographic record are usually but not always well tolerated and effective in practice. The optimum dose for the individual must be determined after completion of the test. Further details should be read in the original article.

**Intensive or Narcosis Treatment**—In about 40 per cent of patients, no ambulatory treatment so far devised is successful. Under such circumstances, it is proper to consider one of the drastic treatments, such as the use of the ketogenic

tested and reliable drug and newer, less known drugs should be added or substituted only for clear cause. Diphenylhydantoin has displaced phenobarbital in this position for the majority of patients, regardless of type of seizure. The dose is usually 0.2 Gm daily and it is gradually increased at the rate of 0.1 Gm weekly. Diphenylhydantoin in oil should be used when gastric irritation is produced by the sodium salt. A special tablet is available for children, or the tasteless oily suspension may be mixed with food. A second choice is usually Mesantoin or phenobarbital in patients suffering from grand mal. Tridione, Paradione, or Milontin in those suffering from petit mal, but some of the newer drugs are now strong competitors.

3 The dose of each drug used should be increased gradually until symptoms of overdosage are produced then it should be reduced slightly. It is now clear that with practically all drugs of this group, individual tolerances vary widely, some patients tolerating 3 or 4 times as much as others per unit weight. Almost always, the best therapeutic dose is close to the toxic dose.

Hypertrophy of the gums, which occasionally occurs as a minor toxic effect of phenytoin therapy, can almost always be controlled by vigorous massage, preferably perhaps with hydrocortisone ointment. The administration of ascorbic acid and of antihistamines may also be tried, they are not very successful in my experience. Amphetamine in doses up to 5 mg or, better, pipradrol (Meratran) in doses up to 15 mg may be given in the morning to combat the drowsiness caused by some drugs in the series. Toxic rashes and leukopenia are sometimes controlled by the use of cortisone. Unless a drug under trial is clearly toxic or useless it should be continued until the next drug to be evaluated is being given in reasonable doses.

4 The method of increasing the dose of each drug gradually to the tolerance level, adding new ones to the regimen if the ones previously used are inadequate and gradually discarding those obviously ineffective or deleterious, should be continued until the seizures are controlled or until use of all the available drugs has been tried. About 3 months are required for thorough trial of each new drug or combination of drugs. This period of experimentation, which is often tedious and sometimes almost intolerable, may be shortened by use of the method of rapid determination of optimum medication to be described briefly below. Clearly this has some disadvantages also.

5 The use of phenobarbital and, probably also, of primidone (Mysoline) and Mesantoin usually should be avoided if spike and dome or 'psychomotor' complexes are present in the electroencephalogram or if definite, typical petit mal, dullness, or psychomotor manifestations are present. Phenobarbital, especially sometimes seems to convert typical petit mal attacks into psychomotor outbursts, suppressing also the "spike" in the electroencephalogram. The use of trimethadione, paramethadione or glutamic acid should be avoided except in cases in which some or all of these manifestations are present. Use of one of these latter drugs usually should be accompanied by a maximal tolerance dose of one of the hydantoins (diphenylhydantoin, Mesantoin, Spirodon).

6 Diphenylhydantoin, when the dosage is pushed to the tolerance level, is the drug of choice in patients in whom psychomotor phenomena or periodic dull



promazine or one of its analogs. The barbiturates and primidone should be avoided, as accidents have occurred following their use. Other anticonvulsants have not been tried. The principal problem is nursing care, and this makes the treatment extremely expensive. It is, however, often effective when other measures fail. Of 35 patients treated, 21 are seizure-free, a few others somewhat improved. The treatment was given twice in 2 cases. Further details should be read in the original article.

## RATIONAL BASIS FOR NEW DRUGS FOR EPILEPSY

No universal anticonvulsant has yet been found. Particularly urgent is the need for drugs which will control petit mal, psychomotor seizures, periodic dullness, epileptic psychoses, and dysrhythmias of the slow wave type. A small proportion of tantalizing good results have been obtained with starvation, the ketogenic diet, acidifying agents, and glutamic acid, which presumably act through similar mechanisms. Perhaps the hope that led to the development of glutamic acid, namely, that we might synthesize and render clinically useful some of the "ketone bodies" presumably produced in the course of fasting and the ketogenic diet, may yet be realized.

Aside from control of the dysrhythmia, symptomatic treatment of the epileptic is entering a new phase. This is of particular importance for the reason that with the advent of more effective forms of anticonvulsive treatment the incidence of (or disclosure of) posttherapeutic disturbed states is also increasing. Some success has been obtained with chlorpromazine and similar drugs, also with the meprobamate group. But much remains to be done.

## SELECTED REFERENCES

- Abbott, T. . . . . n) in  
 . . . . . cases  
 . . . . . lepsy  
 . . . . . [ A  
 Ives, E. 147 1332, 1951  
 Kozol, H. The Place of Mesantoin in the Treatment of Epilepsy. Efficacy vs Toxicity (Read before the American Academy of Neurology, April 25, 1957)  
 Lennox, W. G. The Petit Mal Epilepsies—Their Treatment With Tridione, J. A. M. A. 129 1069, 1945  
 Livingston, S., and Petersen, D. Primidone (Mysoline) in the Treatment of Epilepsy. Results of Treatment of 486 Patients and Review of the Literature, New England J. Med. 254 327, 1956  
 Lombroso, C. T., David . . . . . Further Evaluation of Acetazolamide . . . . . A 160 268, 1956  
 Merlis, J. K. Medical . . . . . 245, 1951  
 Merritt, H. H., and Putnam, T. J. . . . . Treatment of Convulsive Seizure . . . . . Neurol. & Psychiat. 42 1053, 1939  
 Merritt, H. H., and Putnam, T. J. Experimental Determination of Anticonvulsive Activity of Chemical Compounds, Epilepsia 3 51, 1945  
 Merritt, H. H., Putnam, T. J., and Bywater, W. G. Anticonvulsant Action of Sulfoxides and Sulfones, Arch. Neurol. & Psychiat. 54 319, 1945  
 Meszaros, A. F., and O'Reilly, P. O. Relation of Chlorpromazine to Epilepsy, Dis. Nerv. Syst. 17 159, 1956

*Table 18 Relative Effectiveness of Various Drugs as Revealed by Rapid Determinations\**

	Dose (Gm)	Number of Cases	Best	Second	Made Worse	Toxic Reacts
Phenytoin	10	47	14	7	2	0
Trimethadione	20	47	4	8	5	1
Phenanthoin	10	47	4	6	4	2
Phenobarbital	10	40	9	6	2	4
Phenacemide	7.5	33	3	0	11	3
Paramethadione	20	35	5	4	7	0
AC 268	20	27	3	1	5	0
Phethenylate	20	20	0	2	4	0
Phensuximide	3.5	19	1	1	2	0
Glutamic acid	30.0	18	0	2	0	0
Primidone	1.5	17	2	1	3	~
Tetrantoin	60	9	3	0	0	0
Celontin	30	2	0	1	1	0
Peganone	2.5	2	0	0	0	0
Chlorpromazine	0.1	1	0	0	0	0

	Number of Cases Improved	Best or Second			Best or Second Dysthythmia Types†				
		Grand Mal	Petit Mal	Psycho- motor†	1 2 C/S	3 4 C/S	5 7 C/S	Spike	Rapid
Phenytoin	21	20	2	6	1	6	9	2	2
Trimethadione	12	10	2	1	2	5	4	1	0
Phenanthoin	10	3	2	2	0	0	7	1	0
Phenobarbital	15	15	2	3	4	6	7	0	2
Phenacemide	3	3	0	1	1	0	1	0	0
Paramethadione	19	6	1	2	1	5	3	2	0
AC 268	4	0	0	1	1	0	0	0	0
Phethenylate	2	2	0	0	0	1	0	1	0
Phensuximide	2	2	1	0	0	1	0	0	1
Glutamic acid	2	2	0	2	0	1	0	0	0
Primidone	3	3	2	0	0	2	1	0	0
Tetrantoin	3	3	1	0	0	2	1	0	0
Celontin	2	1	0	1	0	1	1	0	0

\*Modified from Putnam, T. J., Rothenberg, S. F., and Bercel, N. M. Rapid Determination of Optimum Medication in Recalcitrant Cases of Epilepsy, *A M A Arch Neurol & Psychiat* 72: 169, 1954.

†When more than one type was improved, in the same case, all are listed.

diet, surgery, or the intensive or narcosis treatment. The published results of such procedures are summarized in Table 14, it should be remembered that they are applied presumably only to severe cases unrelieved by simple ambulatory treatment. Naturally, the first two are outside of the scope of this paper, but a note on the intensive treatment may properly be added here.

The intensive or narcosis treatment was first described by Putnam and Rothenberg in 1953, although something resembling it had been used sporadically by others before. It consists in giving massive doses of phenytoin—usually 4 Gm per day—for 4 days. The first doses are given by mouth, the patient then falls into a deep sleep. If he can be aroused sufficiently, the same dose can be given for the remaining days, it may also be given by suppository or intravenously. About 2,000 ml of 5 per cent glucose in saline is given by vein daily if the intake drops below 1,000 ml. The patient is fed if he is awake, but the development of a ketosis is desirable. He is given inhalations of 5 per cent CO<sub>2</sub> in oxygen for 10 minutes every hour, by mask. He should receive about 600,000 units of penicillin daily. Other sedatives may have to be given, of which the best seems to be chlor-

## THE CHOICE OF A SKELETAL MUSCLE RELAXANT

*Eduard B. Schlesinger, M.D.*

---

### INTRODUCTION

The theoretical basis for the use of muscle relaxants is attractive and sound. Muscle splinting or spasm is a common sequential response to many wear and tear syndromes of the motor apparatus. True spasticity is a major and crippling sign of central nervous system disorders. Any attempt at amelioration of these two entities by drugs with central or peripheral neuromuscular effects is physiologically well founded.

In the recent past the field has suffered from confusing clinical data. This confusion was a manifestation of the varying definitions of the underlying neuromuscular abnormalities, and a consequent lack of communication between clinical investigators. Spasticity, muscular spasm, rigidity, and involuntary movement were not strictly separated or defined. This led to unrealistic goals in comparing results in clinical experiments, and to inevitable disillusionment for many clinicians. A more widespread agreement as to the fundamental nature of the clinical states under study has been of inestimable value in adequate interpretation of drug effects.

Compounds for testing have come along in unprecedented numbers in recent years. Of topical interest is the fact that many of the so-called tranquilizers in such vogue today are related to muscle relaxants in certain critical dosage ranges. At least one conspicuously popular drug of this series (Miltown) was a serendipitic outcome of muscle relaxant investigation. Since many of these compounds are presented as muscle relaxants it is important to emphasize their status. Laboratory protocols demonstrate unequivocally that the drugs have the claimed effects in animal experiments (at certain dosage levels). Nonetheless in the human being the muscle relaxant effect either cannot be obtained at reasonable oral dosage levels or is masked completely by more pronounced effects which appear at ordinary dosage levels. These latter effects are of debatable definition but fall within the realm of soporific, sedative or anxiety buffering.

### CLINICAL CONSIDERATIONS

Presuming a preparation which is characterized by some degree of efficient muscle relaxant effect is available the present day usefulness of such a drug might be outlined as follows:

Penfield W. *Can J Neurol Sci* 13: 136 1956

1  
1

Putnam T J and Merritt H H. The Chemistry of Anticonvulsant Substances. *Arch*

*Neurol & Psychiat* 45: 505 1941

Putnam T J and Merritt H H. —

Putnam

Putnam

*Br J Arch Neurol & Psychiat*

Toman J E P and Taylor J D. Mechanism of Action and Metabolism of Anticonvulsants. *Epilepsia* 1: 31 1952

Tyler M W and King E Q. Phenacemide in the Treatment of Epilepsy. *J A M A* 147: 17 1951

Zimmerman F T, Burgemeister B B and Putnam T J. Effect of Glutamic Acid on Mental Functioning in Children and Adolescents. *Arch Neurol & Psychiat* 56: 489 1946

a far more complex entity than either muscle spasm or spasticity. Its susceptibility to drugs which primarily affect neuromuscular conduction is of an extremely low order. Therefore true muscle relaxants have no real place in the clinical therapy of Parkinson's disease. The antihistaminics, when they produce a useful effect upon tremor and rigidity, manifest their action by their atropine like properties rather than as muscle relaxants. Drugs of the tranquilizer series exert their beneficial effect when present by allaying anxiety and buffering the patient against tension creating stimuli which load performance unfavorably.

**Involuntary Movements Such as in Athetosis and Dystonia**—In so far as the individual case is characterized by a concomitant moiety of spasticity there may be a proportionate slight improvement in the patient's motor efficiency. The actual involuntary movement, however, will not be affected short of paralyzing doses. The fact that varying drugs of the tranquilizer series may favorably alter the ultimate efficiency of these patients has led to the misapprehension that their action is therefore muscle relaxant per se. The improvement in motor efficiency and performance really lies in the reduction of anxiety and its load of performance rather than in a direct effect on the underlying involuntary movement.

## THE SEVERAL MUSCLE RELAXANTS

The various muscle relaxant drugs characteristically act at different levels of the neuromuscular system.

**True Muscle Effect**—Quinine is, perhaps, the best example of drugs of this series although it has other actions. It is useful in the treatment of entities such as night cramps, restless legs and similar states of probable neurovascular implication. However it is ineffective in the treatment of muscle spasm or spasticity. The antihistaminics are equally effective in the treatment of so called night cramps.

**Myoneural Junction Effect**—Curare a quaternary ammonium salt is the classic example of a drug which achieves muscle relaxation by altering the myoneural junction. It is effective, predictable and controllable but unfortunately only by the intramuscular or intravenous route. Aqueous solutions such as used in anesthesia afford graded relaxation of predictable duration. Oil emulsions of curare are limited in their application. The intramuscular route of administration along with the need for constant surveillance of the patient makes their use onerous and hazardous except under strict hospital conditions.

**Drugs With More Central Effects**—Most of the remaining drugs in use seem to act by their blocking action on fairly complex interneuronal systems. Some in addition have complex effects at other levels making it possible to classify them with anticonvulsive, sedative or anxiety relieving drugs. Nevertheless their action as muscle relaxants is chiefly based on their effect on interneuronal systems within the spinal cord.

## CLINICAL AREAS OF USEFULNESS OF MUSCLE RELAXANTS

### Muscle spasm

The enhancement of conventional physiotherapeutic measures for the relief of muscle splinting and restoration of range of motion as in

**Relief of Muscle Spasm or Splinting.**—The entity clinically designated as muscle spasm is an integral part of many of the common wear-and-tear syndromes of everyday practice. The term is loosely used, but roughly it may be defined as a state of transient muscle contraction not amenable to voluntary control, characterized by resistance to stretch and usually associated with pain on attempted extension. Clinically the picture is well recognized. It may be a muscle response to irritation, whether inflammatory or traumatic. It may be reflex in origin and secondary to pathologic conditions, visceral or somatic, of like segmental neural connection.

Kellgren, Wolff, and others have shown that this latter type of muscle spasm may be perpetuated after cessation of the initiating stimulus and may thus present a major treatment problem. The various lesions which together make up the low-back syndrome are excellent examples of the importance of the problem of muscle spasm in treatment. The initiating trauma or etiologic agent is followed by muscle splinting as a protective measure. Pain enhances the splinting, which in turn is followed by more severe pain and further muscle spasm. The vicious cycle is self-perpetuating. Whether the intense pain is at least partly ischemic in origin is not fully understood. Dramatic relief may be afforded by any agent which tends to interrupt and break up the cycle of splinting and pain. There are many traditional measures, all of which have some rational and serve their purpose at times admirably. These include heat, traction, ethyl chloride spray, procaine or saline injections, and heavy sedation.

**Spasticity.**—Spasticity is characterized chiefly by loss of graded central control of reflex activity. Its outstanding feature is the hyperactive stretch response. The so-called adductor spasm, the scissors gait, and the contracted Achilles tendon are common manifestations of spasticity. Prolonged spasticity, without adequate range of motion, inevitably leads to contracture and fibrosis which, at their end point, can be affected only by surgical procedures and then with considerable sacrifice. The basis of logical physical therapy is to preserve range of motion to allow normal patterns of motor function and, thus, to improve efficiency and prevent contractions. Anything which will assist such therapy has a sound basis.

Muscle relaxant drugs which act by damping hyperactive stretch response can permit more effective range of motion exercises or voluntary activity. They have a theoretical place in the management of lesions of the central nervous system characterized by spasticity. However, where ataxia is a concomitant feature, the action of muscle relaxants is often paradoxical. For example, the ataxic multiple sclerosis patient uses his spasticity as a sort of long leg brace, and, when it is in any degree diminished, he may feel he has lost efficiency of gait.

**Rigidity.**—Rigidity is a much more complex mechanism than either muscular spasm or spasticity and is characterized both by the release of certain neuromuscular reflexes from central gradation and by simultaneous innervation of agonists and antagonists. It is therefore, not surprising that the effect of muscle relaxants is most inefficient and clinically disappointing.

**Parkinson's Disease.**—Rigidity along with tremor and akinesia form the triad of abnormal mechanisms upon which the crippling disability of parkinsonism is based. It is natural that, because of the apparent tightness of muscles, muscle relaxants have been used in an attempt to allay rigidity. As stated before, it is

of the mephensin series, except in unusually susceptible patients, have no, or almost no, relaxant effect when taken by mouth and can be considered chiefly analgesic. Drugs of the meprobamate series cannot be expected to afford true relaxation of either muscle spasm or spasticity in doses which have obvious ataractic effects. The one area where there may be a dramatic response is in the dystonic and athetoid groups. Short of the creation of drowsiness by their soporific effect, the drugs seem to insulate or buffer the patient's motor performance from the impact of his emotional environment. This may lead to a clinically perceptible increase in efficiency of performance, but such a change is completely unrelated to a true muscle relaxant action.

## SUMMARY

Muscle relaxants as a group have the dignity of being endowed with excellent sherringtonian principles in their application to the treatment of muscle spasm and spasticity. Unfortunately, there are no adequate preparations for oral use which can be counted upon to achieve a reliable muscle relaxant effect. It is necessary, therefore, to fall back on representatives of the series which are only useful by the intravenous and intramuscular route. This severely limits the application of drugs in everyday therapy. There seems, however, little doubt that the present awareness of the potential usefulness of such drugs will lead to the eventual synthesis of more efficient preparations.

#### SELECTED REFERENCES

- |              |   |  |                                   |
|--------------|---|--|-----------------------------------|
| Aneff        | J Pyzik S W., and Finkle J R.           | Inefficacy of Flexin Therapy for Spasticity Due to Spinal Cord Injuries,   | Illinois M J 112 169 1957         |
| Burns        | J J Yu, T I Berger, L., and Gutman A B. | Zoxazolamine Physiological Disposition Uricosuric Properties Am J Med 25 401, 1958   |                                   |
| Cohen        | T.                                      | Nephropathy Associated With the Oral Administration of Zoxazolamine (Flexin).  | M J 112 102 1957                  |
| Current      | .                                       | .  | Disease, New Eng                  |
| Domino       | .                                       | . .  | and Clinical Ef<br>nesin Type Ann |
| Domino       | .                                       | .  | ly Acting Muscle                  |
| Lewis        | T.                                      | .  | Visceromotor Re                   |
| Schlesing    | .                                       | .  | Tone, Ann New                     |
| Schlesinger  | E B, Drew, A L., and Wood B (RN)        | Clinical Studies in the Use of Myanexin Am J Med 4 365 1948  |                                   |
| Schlesinger, | E B., and Ragan C.                      | Muscle Spasm in Acute Low Back Pain and Similar Syndromes Am J Med 1 621 1946  |                                   |
| Schlesinger, | E B and Stinchfield, F E.               | The Use of Muscle Relaxants as an Aid in the Diagnosis and Therapy of Acute Low Back Disorders, J Bone & Joint Surg 33 480, 1951 |                                   |
| Weiss        | A A, D'Oronzio, G B and Ebel A.         | Evaluation of the Effect of Zoxazolamine (Flexin) on Spasticity, J Urol 78 294 1957  |                                   |
| Wolff        | H G.                                    | Some Observations on Pain, The Harvey Lectures Series XXXIX 39 95 1943 1944  |                                   |

Direct trauma to muscle

Protective splinting in the low back and cervical spine syndromes

Orthopedic deformities with reflex spasm

Acute and subacute arthritic states with secondary muscle splinting

So called myositis

The potentiation of traction effect as in acute stiff neck, low back syndrome, etc

As a therapeutic test to demonstrate the part played by nerve root compression in perpetuating muscular splinting as in herniated nucleus pulposus cervical and lumbar

#### Spasticity

To improve the efficiency of performance by reducing hypertonicity

To permit range of motion exercises and retraining

To prevent the appearance of irreversible contractures

#### Miscellaneous uses

In evaluating the reversibility of contractures

In allowing gynecologic, urologic, and dental examinations of the severely spastic patient

*In the management of crises of tetanus, athetosis and rabies*

As adjuvants to anesthesia (As this is a field for special consideration it will not be elaborated upon here)

## ROUTES OF ADMINISTRATION

To achieve predictable and reasonably effective responses available muscle relaxant drugs must be given by the intravenous or intramuscular routes

**Intravenous**—The most useful compound for intravenous use is the 2 per cent supersaturated solution of mephenesin. It is a potent pharmacologic agent with established toxic side effects. These are predictable and avoidable when the drug is used under reasonable circumstances.

**Intramuscular**—Although curare is an effective drug by the intravenous route it is not a practical agent for use in ambulatory patients or, indeed, in any patients who are not under ideal operating room conditions. Various intramuscular preparations including the emulsions with the advantage of slowed release have a real but narrowly limited usefulness. Their value lies in the treatment of muscle spasm of the acute type such as in the low back syndrome. Curare has histaminic effects which can prove dangerous to patients bordering on shock. It can be mentioned here parenthetically that curare is an excellent drug for the treatment of dysmenorrhea. Whether this is due to its effect on the spiral muscles of the uterus or to some complex pharmacologic effect unrelated to its usual pharmacologic effect I am not in a position to say.

**Oral**—The earliest preparation in wide use was mephenesin, followed by meprobamate (Equanil, Miltown), zoxazolamine (Flexin), and many others [These include carisoprodol (Soma), ethopropazine (Parsidol), methocarbamol (Robaxin), orphenadrine (Dipal), procyclidine (Kemadrin), and promoxolane (Dimethylane) among others. Ed.] Although all of these are not generically related they share the fact of minimal effectiveness by oral administration. Drugs



Several of these types of vertigo are of particular interest in connection with the use of drugs. Vertigo may occur in the aura of epilepsy or in migraine. One of the causes of vertigo due to brain stem lesions is the administration of streptomycin. Aural vertigo may be caused by wax in the external ear, blockage of the Eustachian canal and sudden changes in atmospheric pressure, acute and chronic suppurative otitis media, drugs, including quinine and salicylates, herpes zoster of the geniculate ganglion, acute nonsuppurative labyrinthitis, recurrent aural vertigo (Ménière's syndrome), and motion sickness.

## CLINICAL APPLICATIONS

**Recurrent Aural Vertigo (Ménière's Syndrome, Endolymphatic Hydrops)** — Ménière's syndrome comprises three principal symptoms: vertigo, tinnitus, and deafness. *Hydrops of the labyrinth* first was observed by Hallpike and Cairns in a dock laborer who met death accidentally during an attack of Ménière's syndrome. Their examination and those of later observers in other patients revealed a marked hydropic swelling of the utricle and the saccule with herniations into the horizontal semicircular canal.

Recurrent aural vertigo probably is of varied etiology. Characteristically there is recurrence of the attacks of severe giddiness leading to vomiting and prostration and usually associated with tinnitus and increasing deafness. The disorder runs a protracted course with a tendency to disappearance of the vertigo as the deafness increases.

Several suggestions have been made concerning the cause of the labyrinthine edema. One hypothesis is that it is the result of a chronic progressive herpetic neuritis of the vestibular labyrinth, being due to the rupture of one or more vesicles, with the release of a toxic fluid. The size and number of vesicles rupturing at one time determine the severity of the attacks. According to this hypothesis the paroxysmal nature of the disease is due to the continued formation and periodic rupture of these vesicles. However, the similar appearances in the canals of many labyrinths from those over the age of 40 who have had no symptoms of Ménière's disease, together with the absence of pathologic changes in the neurones, do not favor this ingenious hypothesis.

Another suggestion is that physical or emotional stimuli produce injury to certain cells in capillary loops which, owing to the local anoxia produced, are injured, with release of histamine. This is followed by alteration of the permeability of cell membranes of the capillary wall, transudation of fluid, and changes in distribution of electrolytes.

Some have held an allergy responsible for the attacks, ascribing to certain patients with Ménière's disease an action of histamine in dilating capillaries and in altering their permeability, thus provoking endolymphatic changes. The low incidence of any allergic symptoms, such as hay fever, rhinorrhea, asthma, eczema, or colitis in such patients, is not in favor of this etiology.

The attack of vertigo may be an indication of disturbances in water metabolism and capillary function. During attacks, increase in weight and other evidence of water retention may be observed. It has been suggested that the tissues responsible for Ménière's syndrome were sensitized or had increased avidity for sodium.

## THE CHOICE OF AN AGENT FOR DISTURBANCES IN EQUILIBRIUM

*Paul K. Smith, Ph D*

---

### INTRODUCTION

It was postulated early that, since interference with the labyrinth causes dizziness, the normal function of the labyrinth is to control equilibrium.

Impulses which aid in maintaining the body in an appropriate position in space include those from the otoliths which are concerned mainly in the orientation of the body with respect to gravity and those impulses from the semicircular canals which respond to movement and to angular momentum. Important contributory roles are played by visual impulses, impulses from the proprioceptors of the ocular muscles, and impulses from the proprioceptors of the joints and muscles of the neck which convey information relating the position of the head to that of the rest of the body, and impulses from the lower limbs and trunk. These afferent impulses are related mutually by central mechanisms, of which the cerebellum, the vestibular nuclei, the posterior longitudinal bundle, and the red nuclei probably are the most important.

Vertigo is the result of certain types of disturbance of the nervous mechanism involved in the maintenance of normal body balance. It may be defined as the consciousness of disordered orientation of the body in space. The external world may appear to move, the body itself may be felt to be moving or the positions and movements of the limbs may seem to be ill-adjusted and unsteady. Vertigo may be accompanied by forced movements of the body, such as falling, by nystagmus and sometimes diplopia, by the phenomenon of past pointing, and by such visceral disturbances as pallor, sweating, alterations in the pulse rate and blood pressure, nausea, vomiting, and diarrhea. Impulses from these lower centers reach the cerebral cortex mainly in the temporal and parietal lobes and so influence voluntary movements.

Dizziness or vertigo may result from stimulation, irritation, or disease of the sensory end organs of the afferent path, or of the central mechanisms concerned. It may be caused by psychogenic factors, cortical disturbances, impulses of ocular or of cerebellar origin, brain stem lesions, lesions of the eighth nerve, or by labyrinthine impulses.

believed that gastric distention occurs from loss of gastric tone, followed by generalized contraction of the duodenum and abdominal musculature

A precise estimate of the incidence of motion sickness in man is obviously impossible, for it will vary with the type, severity and duration of motion. The incidence of seasickness ranges from 0.8 per cent on large ocean liners to almost 100 per cent in certain combat landing operations. It is estimated that 40 per cent of any population group are susceptible to seasickness on sudden exposure to rough weather at sea. The incidence of airsickness shows a similar variation depending upon the persons tested, intensity of turbulence, type of plane, and duration of flight. No reliable data are available on the incidence of car sickness, train sickness or sickness on various other conveyances.

It is common knowledge that some individuals may be prostrated by turbulence which is completely without effect upon their neighbors. It can be stated categorically that for any specific case the susceptible person cannot be differentiated from the resistant except by exposure to the motion in question. The susceptibility of children to motion is high and it decreases steadily with age. It is not known whether this is due to anatomic or physiologic changes or to gradual adaptation to motion.

The relationship between vestibular stimulation and motion sickness is well established. Animals with eighth nerve section or with bilateral labyrinthectomy are no longer susceptible to motion. The receptors in the labyrinth consist of the cristae of the semicircular canals which respond primarily to angular acceleration and sensory epithelia or maculae of the otolith organs sensitive to linear acceleration. The failure to observe nystagmus during seasickness is evidence that the stimulation of the semicircular canals during rolling and pitching is inadequate to account for the development of seasickness. There is incontrovertible evidence that motion sickness may be produced on elevators and other devices giving only linear acceleration.

The sites have been more specifically identified as the utricular maculae since the saccule has been absolved from participation in labyrinthine static or kinetic reflexes. Simple up and down movements which could only act upon the otoliths effectively produce motion sickness. Further, in contrast to angular acceleration the magnitude of linear accelerations developed during pitching and heaving and even in rolling is many times the receptor organ threshold.

Perhaps the most convincing demonstration of the importance of utricular stimulation in producing motion sickness is the effect of head positioning. The relief obtained by a motion sick individual upon reclining constitutes the oldest and best treatment discovered for this ailment. Although various explanations have been offered to explain this relief, it now seems probable that the underlying mechanism is the shifting of the utricular maculae to less vulnerable positions.

The main pathway of impulses originating in the labyrinth proceeds by way of the eighth nerve to the vestibular nucleus then traverses the vestibular portion of the cerebellum (probably nodulus and uvula), stimulating the chemosensitive trigger zone in the medulla, and, finally, reaches the emetic center itself.

There can be little doubt that the labyrinthine stimulation is by far the most important factor in the genesis of any form of motion sickness. Other factors, including psychological ones, must be placed in decidedly subordinate categories.

The usual history is that the patient has suffered from slowly progressive deafness and tinnitus in one or both ears for months or even years and then suddenly has an attack of giddiness. In a severe case the patient is literally prostrated, vomiting develops, and there may be diarrhea. The pulse may be rapid or slow and the blood pressure raised or lowered and there may be profuse sweating. Double vision may occur and in very severe cases consciousness may be lost. On attempting to stand and walk, the patient is unsteady and staggers. The vertigo may last from half an hour to many hours and then gradually subside.

The attacks tend to occur at irregular intervals and with varying severity. The tendency is for the attacks to diminish in severity spontaneously and finally to cease, with an increase of the deafness.

**Vertigo Without Deafness**—The majority of cases of vertigo are not associated with auditory symptoms or with other signs of disease of the central nervous system. Many of these usually are classed under the heading, pseudo-Meniere's syndrome. Some cases of atypical Meniere's syndrome are really only early cases of true Meniere's syndrome before the development of the classical symptom triad.

The pathologic disturbances which are associated with most clinical conditions giving origin to pseudo-Meniere's syndrome are not known. The postural vertigo which is characteristic of this group usually corresponds to the type which is most frequent in proved disease of the posterior fossa in that a positional nystagmus occurs which changes direction with alteration of the position of the head. A central origin is therefore suggested.

Vestibular neuronitis is a condition in which patients suffer a sudden loss of vestibular function, as a rule on one side only but without any impairment of hearing. It is believed that the lesion lies somewhere in the vestibular neurones, and it may be associated with an infection, although in many cases there is no obvious causal factor. This also may be the condition known as epidemic labyrinthitis.

Vertigo may be a symptom of some toxic disorder. Its occurrence in septic patients and after the administration of certain drugs, especially streptomycin, is evidence for this assumption.

Occasionally vertigo is a symptom of hypertensive disease. Central causes include epilepsy, disseminated sclerosis, certain temporal lobe tumors, some tumors of the cerebellopontine angle or in the midline where the vestibular connections in the cerebellum are involved, and thrombosis of the posterior inferior cerebellar artery. Usually these are associated conspicuously with other clinical signs of intracranial disease.

**Motion Sickness**—Centuries before the Christian era, motion sickness was well known as evidenced by allusions in the writings of Homer and Hippocrates.

The usual symptoms of motion sickness include anorexia, drowsiness, pallor, epigastric awareness, malaise, cold sweat, nausea, vomiting, and retching. Salivation, headache, increased intestinal peristalsis, fatigue, and mental depression also may occur. The sequence, number and intensity of symptoms may vary considerably depending upon the individual and the kind and severity of motion experienced.

The once prevalent concept of pylorospasm and reversed peristalsis of stomach and esophagus largely has been abandoned. On the contrary, now it is

gery, nausea and vomiting after temporal bone surgery, acute vertigo from labyrinthine hydrops, and vertigo due to suppurative labyrinthitis. *Dimenhydrinate* (Dramamine), administered in the form of tablets or rectal suppositories has been reported to be helpful in patients after the fenestration operation.

In studies on human subjects it has been demonstrated that cyclizine (*Marezine*) uniformly depressed the labyrinth and prolonged the onset and shortened the duration of nystagmus. *Meclizine* (*Bonamine*) also prolonged the onset of nystagmus but its effect was not as great or predictable as that of cyclizine. *Promethazine* (*Phenergan*) also has been mentioned as a useful drug for the treatment of recurrent aural vertigo.

*Dimenhydrinate* was the first antihistamine to be used for the prophylaxis of seasickness and its effectiveness has been rapidly and repeatedly confirmed. The observation that *dimenhydrinate* and *diphenhydramine* were effective raised the interesting possibility that antinotion sickness efficacy might be related to antihistamine potency. This hypothesis was rapidly disproved by the demonstration that many strong antihistamines afford no protection against motion sickness. Thus no correlation appears to exist between antihistamine potency and motion sickness protection.

Antihistamines which have recently attracted considerable interest are members of the piperazine series. The hydrochlorides of cyclizine (*Marezine*) and *meclizine* (*Bonamine* postafene) have been shown to be effective against both sea and airsickness. The most striking feature of the effect of *Bonamine* has been the long duration of action. Given 24 hours prior to take off, *Bonamine* has protected soldiers and airmen against airsickness. Given once daily it will protect against seasickness. Recent work suggests that its duration of action may be even longer, since a single 50 mg dose taken before sailing afforded protection comparable to that obtained with other medications given 3 times daily for the first 2 to 3 days of the crossing.

**Vitamins**—The ever expanding areas of vitamin therapy coupled with the empiric search for methods of treatment of vertigo made it almost inevitable that vitamins be tested for effectiveness. It has even been suggested that *Menière's* syndrome is due to a deficiency of niacin or riboflavin or both.

**Nicotinic acid** in large doses sometimes is reported to be effective, perhaps by improving the blood supply. In several hundred patients treated with large doses of nicotinic acid one investigator was able to secure complete remission of the symptoms in two thirds of the patients as long as they continued on the treatment. After cessation of treatment, symptoms returned in a few days to 6 months. Goodman, in a smaller number of patients observed no particular improvement with nicotinic acid. Others have used pyridoxine, riboflavin and thiamine and reported some success.

The widespread use of pyridoxine in the therapy of nausea and vomiting in pregnancy and irradiation sickness stimulated its trial in motion sickness. Recently a report of a study appeared in which 500 seasick patients received 50 mg pyridoxine by mouth with marked improvement in a third of the patients. Attempts to confirm this observation in a controlled study of seasickness prophylaxis was unsuccessful.

gories These latter factors may aggravate an already existing illness or, in isolated instances, may even constitute the primary causes of motion sickness

## GENERAL PHARMACOLOGIC CONSIDERATIONS

**Vertigo Other Than Motion Sickness**—The existing numerous methods of treatment in vertigo, if they produce symptomatic relief, do so in spite of the lack of any basic understanding of the pathology involved Medical treatment of endolymphatic hydrops usually has been based either on the hypothesis that permeability of the capillaries of portions of the labyrinth was increased or on the hypothesis that fluid or electrolyte metabolism was disturbed

On the assumption that the labyrinthine cells have an increased affinity for sodium which results in retention of the sodium ion and the production of the hydrops of the endolymph and perilymph of the labyrinth it has been proposed to reduce the intake of sodium and ensure its maximum elimination by giving acid forming diuretics

Some workers suggest that an increased concentration of serum sodium observed in some cases of Meniere's disease indicates loss of tissue potassium, just as a high level of serum calcium accompanies loss of calcium from the tissues For this reason it has been suggested that the depleted potassium in tissues can be restored and electrolyte equilibrium re established by administration of additional potassium

On the basis of the theory that the vertigo is caused by an action of histamine in providing a vascular disorder of the small vessels of the labyrinth resulting in excessive formation of endolymph, desensitization to histamine has been proposed In those patients responding with an excessively large wheal and flare to 0.01 mg of histamine given intradermally, gradually increasing doses of histamine have been reported to provide relief of the symptoms presumably on the basis of desensitization Histamine desensitization, as a method of treatment, has generally lost favor

It has been suggested that in Meniere's syndrome there is an arteriolar spasm of end arteries in the membranous labyrinth which results in a passive dilation of the capillary venule network distal to the spasm In the distended loop there may be sludging of blood, liberation of toxic metabolites, hypoxia of vessel walls and increased capillary permeability leading to tissue edema and increased accumulation of endolymph Depending on which vessel or vessels are involved, the patient may experience primarily vertigo, hearing loss, tinnitus or a combination of these For these reasons vasodilating agents such as nicotinic acid have been used Actually it appears that nicotinic acid was recommended in treatment of endolymphatic hydrops because a large percentage of pellagrins have rotational vertigo

**Motion Sickness**—There is no ailment other than motion sickness, with the possible exception of the common cold, or hiccups for which the general populace and the medical profession alike have prescribed with greater assurance and occasional ingenuity The treatments are generally uncontrolled frequently amusing and occasionally ingenious The recommendations range from cuffs about the neck for control of cerebral blood flow to corsets for abdominal support, from gastronomic heroics to Spartan self restraint from ingestion of herbs to injections of vitamins

Attempts to correlate the ability of a drug to combat motion sickness with its

**Autonomic Drugs**—Epinephrine in doses of 0.3 to 0.6 ml. of the 1:1,000 solution given intravenously slowly has been used for the therapy of acute attacks of vertigo.

The mixture of dihydrogenated ergot alkaloids known as Hydergine has been used in the therapy of vertigo. Patients are given one of the 0.5 mg. sublingual tablets every 4 hours.

On the assumption that acute attacks of vertigo are associated with cholinergic hyperactivity, atropine has been given subcutaneously in doses of 0.5 to 0.75 mg. Relief of the symptoms is said to occur in 15 to 30 minutes.

There is evidence that several parasympatholytic drugs are effective in motion sickness. Atropine and 1 hyoscyamine in doses of 1 mg. are effective but perhaps because it produces milder side effects, hyoscine (scopolamine) is the most widely used of these drugs although continued administration may produce blurring of the vision and even more serious side effects. Hyoscine in initial doses of 0.5 to 1 mg. is effective in airsickness especially. Its use in seasickness is less desirable since the repeated doses that often are required may lead to unpleasant symptoms.

**Antiallergic Therapy**—Presumably on the assumption that the release of histamine is responsible for the local edema of the labyrinth in many patients with vertigo, therapy has been directed toward desensitizing the patient to histamine or toward blocking the effects of histamine. Often patients first are tested for histamine sensitivity by intracutaneous injection of 0.05 ml. of a 1:10,000 solution of histamine base. Positive reactors in 5 minutes develop a bleb 0.75 to 1 inch in diameter with an erythematous area 2 to 3 inches across. This reaction is still visible after 20 minutes. Attempts are then made to desensitize patients reacting to histamine by giving them 2 to 3 mg. of histamine phosphate intravenously slowly in 250 ml. isotonic sodium chloride solution. The rate usually must be maintained at 15 to 60 drops per minute to avoid headache. Food or antacids are given to protect the patient from the oversecretion of hydrochloric acid. This dose of histamine is repeated daily until relief of symptoms occurs.

Others advocate the much more gradual desensitization to histamine, beginning with 0.05 ml. of a 1:10,000 solution subcutaneously, then giving the drug on alternate days, increasing the dose each time by 50 per cent up to a dose of 0.4 ml. of a 1:1,000 solution.

The antihistaminic drugs diphenhydramine (Benadryl), cyclizine (Marezine) and meclizine (Bonamine) all in doses of 50 mg. dimenhydrinate (Dramamine) in doses of 100 mg. and promethazine (Phenergan) in doses of 12.5 mg. may be used in the therapy of vertigo. Because of its long duration of action, meclizine usually is given only once a day but the others may be given 3 times a day.

The most consistently effective therapy of all forms of motion sickness is one of several antihistaminic drugs. Cyclizine 50 mg., meclizine 50 mg., and promethazine 25 mg., are the most effective agents against all types of motion. Bonamine is preferred by some since one dose a day may be sufficient while the others may be required 3 times a day. Dimenhydrinate (Dramamine) 100 mg. and diphenhydramine (Benadryl), 50 mg. also are effective when given 3 times a day.

**Sedation**—Acute attacks of vertigo may be treated with sodium phenobarbital in 0.1 Gm. doses given parenterally or secobarbital sodium in 0.2 Gm. doses given





about its etiology, but because the candidate therapies, necessarily chosen empirically, in many cases have been evaluated carefully with proper attention to controls and comparison with known remedies

Admittedly it will be difficult to study the treatment of vertigo in this manner, but until this is done, perhaps in a cooperative study, the choice of therapy cannot be on a scientific basis

To this point the various drugs have been discussed primarily from the point of view of their effectiveness. As with any other drug, however, the practical value is not determined by its effectiveness alone. The incidence and severity of side effects are equally important factors. Under some circumstances it may be vital that the drug not impair the person's ability to perform his task.

In large doses, hyoscine and other belladonna alkaloids have undesirable side effects. The peripheral effects include decreased sweating and salivary flow, cycloplegia and cardiac acceleration. Centrally, large doses may produce disorientation, excitement, and even hallucinations, giving way to a secondary depression. Single doses of hyoscine required to produce such central changes would rarely be given except by accident.

Histamine, even in small doses, may produce serious hypotension, severe headache, bronchiolar constriction, and gastric hypersecretion.

By far the most common side effect of the antihistamines has been sedation. In fact, some of them have been shown to compare favorably with clinically employed doses of barbiturates in causing drowsiness. There is some evidence that cyclizine and meclizine exert relatively little sedative action. Apart from sedation, the most common complaints related to the use of the antihistamine series are symptoms associated with anticholinergic activity: dry mouth, blurred vision, dizziness, fatigue. Since the protection against motion sickness may depend upon the parasympatholytic activity of the compound, these side effects may be inevitable in any effective preparation.

## SELECTED REFERENCES

1. "The Pharmacology of the Vestibular System." New York, 1958. Grune & Stratton.
2. "The Pharmacology of the Vestibular System." New York, 1958. Grune & Stratton.
3. "The Pharmacology of the Vestibular System." New York, 1958. Grune & Stratton.
4. "The Pharmacology of the Vestibular System." New York, 1958. Grune & Stratton.
5. "The Pharmacology of the Vestibular System." New York, 1958. Grune & Stratton.
6. "The Pharmacology of the Vestibular System." New York, 1958. Grune & Stratton.
7. "The Pharmacology of the Vestibular System." New York, 1958. Grune & Stratton.
8. "The Pharmacology of the Vestibular System." New York, 1958. Grune & Stratton.
9. "The Pharmacology of the Vestibular System." New York, 1958. Grune & Stratton.
10. "The Pharmacology of the Vestibular System." New York, 1958. Grune & Stratton.
11. "The Pharmacology of the Vestibular System." New York, 1958. Grune & Stratton.
12. "The Pharmacology of the Vestibular System." New York, 1958. Grune & Stratton.
13. "The Pharmacology of the Vestibular System." New York, 1958. Grune & Stratton.
14. "The Pharmacology of the Vestibular System." New York, 1958. Grune & Stratton.
15. "The Pharmacology of the Vestibular System." New York, 1958. Grune & Stratton.
16. "The Pharmacology of the Vestibular System." New York, 1958. Grune & Stratton.
17. "The Pharmacology of the Vestibular System." New York, 1958. Grune & Stratton.
18. "The Pharmacology of the Vestibular System." New York, 1958. Grune & Stratton.
19. "The Pharmacology of the Vestibular System." New York, 1958. Grune & Stratton.
20. "The Pharmacology of the Vestibular System." New York, 1958. Grune & Stratton.
21. "The Pharmacology of the Vestibular System." New York, 1958. Grune & Stratton.
22. "The Pharmacology of the Vestibular System." New York, 1958. Grune & Stratton.
23. "The Pharmacology of the Vestibular System." New York, 1958. Grune & Stratton.
24. "The Pharmacology of the Vestibular System." New York, 1958. Grune & Stratton.
25. "The Pharmacology of the Vestibular System." New York, 1958. Grune & Stratton.
26. "The Pharmacology of the Vestibular System." New York, 1958. Grune & Stratton.
27. "The Pharmacology of the Vestibular System." New York, 1958. Grune & Stratton.
28. "The Pharmacology of the Vestibular System." New York, 1958. Grune & Stratton.
29. "The Pharmacology of the Vestibular System." New York, 1958. Grune & Stratton.
30. "The Pharmacology of the Vestibular System." New York, 1958. Grune & Stratton.
31. "The Pharmacology of the Vestibular System." New York, 1958. Grune & Stratton.
32. "The Pharmacology of the Vestibular System." New York, 1958. Grune & Stratton.
33. "The Pharmacology of the Vestibular System." New York, 1958. Grune & Stratton.
34. "The Pharmacology of the Vestibular System." New York, 1958. Grune & Stratton.
35. "The Pharmacology of the Vestibular System." New York, 1958. Grune & Stratton.
36. "The Pharmacology of the Vestibular System." New York, 1958. Grune & Stratton.
37. "The Pharmacology of the Vestibular System." New York, 1958. Grune & Stratton.
38. "The Pharmacology of the Vestibular System." New York, 1958. Grune & Stratton.
39. "The Pharmacology of the Vestibular System." New York, 1958. Grune & Stratton.
40. "The Pharmacology of the Vestibular System." New York, 1958. Grune & Stratton.
41. "The Pharmacology of the Vestibular System." New York, 1958. Grune & Stratton.
42. "The Pharmacology of the Vestibular System." New York, 1958. Grune & Stratton.
43. "The Pharmacology of the Vestibular System." New York, 1958. Grune & Stratton.
44. "The Pharmacology of the Vestibular System." New York, 1958. Grune & Stratton.
45. "The Pharmacology of the Vestibular System." New York, 1958. Grune & Stratton.
46. "The Pharmacology of the Vestibular System." New York, 1958. Grune & Stratton.
47. "The Pharmacology of the Vestibular System." New York, 1958. Grune & Stratton.
48. "The Pharmacology of the Vestibular System." New York, 1958. Grune & Stratton.
49. "The Pharmacology of the Vestibular System." New York, 1958. Grune & Stratton.
50. "The Pharmacology of the Vestibular System." New York, 1958. Grune & Stratton.
51. "The Pharmacology of the Vestibular System." New York, 1958. Grune & Stratton.
52. "The Pharmacology of the Vestibular System." New York, 1958. Grune & Stratton.
53. "The Pharmacology of the Vestibular System." New York, 1958. Grune & Stratton.
54. "The Pharmacology of the Vestibular System." New York, 1958. Grune & Stratton.
55. "The Pharmacology of the Vestibular System." New York, 1958. Grune & Stratton.
56. "The Pharmacology of the Vestibular System." New York, 1958. Grune & Stratton.
57. "The Pharmacology of the Vestibular System." New York, 1958. Grune & Stratton.
58. "The Pharmacology of the Vestibular System." New York, 1958. Grune & Stratton.
59. "The Pharmacology of the Vestibular System." New York, 1958. Grune & Stratton.
60. "The Pharmacology of the Vestibular System." New York, 1958. Grune & Stratton.
61. "The Pharmacology of the Vestibular System." New York, 1958. Grune & Stratton.
62. "The Pharmacology of the Vestibular System." New York, 1958. Grune & Stratton.
63. "The Pharmacology of the Vestibular System." New York, 1958. Grune & Stratton.
64. "The Pharmacology of the Vestibular System." New York, 1958. Grune & Stratton.
65. "The Pharmacology of the Vestibular System." New York, 1958. Grune & Stratton.
66. "The Pharmacology of the Vestibular System." New York, 1958. Grune & Stratton.
67. "The Pharmacology of the Vestibular System." New York, 1958. Grune & Stratton.
68. "The Pharmacology of the Vestibular System." New York, 1958. Grune & Stratton.
69. "The Pharmacology of the Vestibular System." New York, 1958. Grune & Stratton.
70. "The Pharmacology of the Vestibular System." New York, 1958. Grune & Stratton.
71. "The Pharmacology of the Vestibular System." New York, 1958. Grune & Stratton.
72. "The Pharmacology of the Vestibular System." New York, 1958. Grune & Stratton.
73. "The Pharmacology of the Vestibular System." New York, 1958. Grune & Stratton.
74. "The Pharmacology of the Vestibular System." New York, 1958. Grune & Stratton.
75. "The Pharmacology of the Vestibular System." New York, 1958. Grune & Stratton.
76. "The Pharmacology of the Vestibular System." New York, 1958. Grune & Stratton.
77. "The Pharmacology of the Vestibular System." New York, 1958. Grune & Stratton.
78. "The Pharmacology of the Vestibular System." New York, 1958. Grune & Stratton.
79. "The Pharmacology of the Vestibular System." New York, 1958. Grune & Stratton.
80. "The Pharmacology of the Vestibular System." New York, 1958. Grune & Stratton.
81. "The Pharmacology of the Vestibular System." New York, 1958. Grune & Stratton.
82. "The Pharmacology of the Vestibular System." New York, 1958. Grune & Stratton.
83. "The Pharmacology of the Vestibular System." New York, 1958. Grune & Stratton.
84. "The Pharmacology of the Vestibular System." New York, 1958. Grune & Stratton.
85. "The Pharmacology of the Vestibular System." New York, 1958. Grune & Stratton.
86. "The Pharmacology of the Vestibular System." New York, 1958. Grune & Stratton.
87. "The Pharmacology of the Vestibular System." New York, 1958. Grune & Stratton.
88. "The Pharmacology of the Vestibular System." New York, 1958. Grune & Stratton.
89. "The Pharmacology of the Vestibular System." New York, 1958. Grune & Stratton.
90. "The Pharmacology of the Vestibular System." New York, 1958. Grune & Stratton.
91. "The Pharmacology of the Vestibular System." New York, 1958. Grune & Stratton.
92. "The Pharmacology of the Vestibular System." New York, 1958. Grune & Stratton.
93. "The Pharmacology of the Vestibular System." New York, 1958. Grune & Stratton.
94. "The Pharmacology of the Vestibular System." New York, 1958. Grune & Stratton.
95. "The Pharmacology of the Vestibular System." New York, 1958. Grune & Stratton.
96. "The Pharmacology of the Vestibular System." New York, 1958. Grune & Stratton.
97. "The Pharmacology of the Vestibular System." New York, 1958. Grune & Stratton.
98. "The Pharmacology of the Vestibular System." New York, 1958. Grune & Stratton.
99. "The Pharmacology of the Vestibular System." New York, 1958. Grune & Stratton.
100. "The Pharmacology of the Vestibular System." New York, 1958. Grune & Stratton.

rectally Phenobarbital, in oral doses up to 0.2 Gm per day is the basic drug used by many to alleviate the symptoms of vertigo.

Sedative and hypnotic drugs are known to be effective in motion sickness only in so far as the patient may assume a supine position, thus reducing appreciably the stimulus to the vestibular apparatus.

**Vitamins**—Although there seems to be little evidence that the vertigo of Menière's disease is associated with a vitamin deficiency niacin, riboflavin, and thiamine have been used. Nicotinic acid (niacin) is used in doses of 0.1 Gm orally 3 times a day. There seems to be no justification for the parenteral administration of the drug as sometimes advocated unless vomiting is persistent. Riboflavin and thiamine in 5 mg doses daily have been used. Perhaps because niacin is an active vasodilator papaverine in doses of 0.3 to 1.2 Gm also has been used.

**Dehydrating Agents**—On the assumption that the local edema in the labyrinth may be relieved by systemic drugs the principal measures in use are restriction of sodium intake and administration of ammonium chloride and potassium salts. The diuretic acetazolamide (Diamox) frequently is used in doses of 0.25 Gm per day to hasten sodium excretion.

Usually a combination of two of these measures has been used. Patients are placed on a diet containing no more than 1 to 2 Gm of sodium per day and are given in addition 6 to 10 Gm of either potassium chloride or ammonium chloride per day. In some cases this treatment is continued indefinitely and in others it is used for a few days followed by a few days of rest and observation before therapy is resumed.

**Miscellaneous**—The present unsatisfactory state of the treatment of vertigo with any single drug is well exemplified by the treatment recommended by Kane and Strong. They suggest 0.8 mg of atropine sulfate or 0.6 mg of hyoscine hydrobromide subcutaneously plus 0.6 ml of 1:1000 epinephrine hydrochloride intravenously or 0.1 Gm of ephedrine sulfate orally plus 25 mg of chlorpromazine (Thorazine) intramuscularly plus 25 to 50 mg of pyridoxine hydrochloride intravenously plus 50 mg of dimenhydrinate (Dramamine) intramuscularly or subcutaneously.

## RATIONAL BASIS FOR NEW DRUGS FOR DISTURBANCES IN EQUILIBRIUM

The manner in which drugs exert their protective action in abolishing vertigo and the symptoms of motion sickness remains unknown. Until greater insight into the genesis of the disturbances is gained new therapy must be sought on a trial and error basis.

Reports on the therapy of Menière's disease and disturbances of equilibrium other than motion sickness seem to be characterized by a lack of adequate control observations. In a disease in which spontaneous remissions are frequent it has been common to associate relief of symptoms with whatever drug was given previously. This inevitably has led to confusion, uncertainty, and the perpetuation of remedies of doubtful value.

In contrast to the therapy of other diseases of equilibrium advances have been made in the treatment of motion sickness, not because so much more is known

## THE CHOICE OF AN ANTIEMETIC AGENT

*John H. Moyer, M.D., and*

*William L. Wilson, M.D.*

### INTRODUCTION

Usually, nausea and vomiting serve no useful purpose, and alleviation of these symptoms may become the primary concern of the therapist. Treatment may be quite difficult because so many factors contribute to the development of this symptom complex which is a prominent manifestation of numerous organic as well as psychiatric diseases. Obviously, it is preferable to relieve the cause when it is known and is amenable to therapy. Unfortunately, it may be impossible to determine the etiology and, when known, to eliminate it. In such instances symptomatic therapy may be indicated. Recently, numerous drugs have been developed which block emesis of various etiologies through depression of specific areas in the brain. The sites of action of different antiemetic agents differ and consequently their effectiveness, depending on the cause of the vomiting. It is the purpose of this communication to review the effective antiemetic agents and to attempt to outline their specific indications in the therapy of nausea and vomiting due to numerous causes.

### PHARMACOLOGIC CONSIDERATIONS

**The Mechanism of Vomiting**—Giannuzzi first suggested the possibility of a vomiting center nearly 100 years ago. However, it was not until 1948 that Borison and Wang first found that the area most responsive to electrical stimulation was the lateral reticular formation (Fig. 7). This area is localized in the midst of other medullary structures that participate in the vomiting act: the area controlling salivation, the spasmodic respiratory center, the inspiratory and expiratory center, the vasomotor center, the vestibular nuclei and the bulboexcitatory and inhibitory systems.

Like other brain stem structures, the vomiting center is activated by tonic excitatory and inhibitory nervous and metabolic stimuli. The center does not initiate vomiting by itself but coordinates the activities of the other neural struc-



meclizine (Bonamine) and cyclizine (Marezine), effective antiemetic agents long duration of action and minimum side effects. French investigators experimenting concurrently with the phenothiazine derivatives, chlorpromazine (Thorazine) and promethazine (Phenergan), found the former to have a powerful emetic action in animals. Additional phenothiazine derivatives such as prochlorperazine (Compazine) have since been synthesized.

The specific pharmacologic actions of antiemetic drugs are imperfectly understood and much experimental work has been directed toward finding the mode of action of these agents. There seems to be no correlation between antihistaminic and antiemetic potencies. For example, Thorazine, a relatively weak antihistaminic drug, appears to be one of the most potent agents in controlling the various forms of vomiting whereas many antihistaminic agents apparently exert no antiemetic action. A central anticholinergic or parasympatholytic action is a common property of most antiemetic agents. Even though Benadryl, Dramamine, Bonamine and Marezine seem to decrease vestibular sensitivity, their importance in this respect relative to antiemetic activity is not clearly understood.

#### The Specific Antiemetic Drugs —

**DIPHENHYDRAMINE**—Benadryl (diphenhydramine) not only possesses antiemetic activity but it is an effective antihistaminic agent as well. The pharmacologic properties are well known. About 50 per cent of the patients taking this drug experience sedation and somnolence. Otherwise, side reactions are not marked.

**DIMENHYDRINATE**—Dramamine (dimenhydrinate) is a combination of diphenhydramine and 8-chlorotheophylline. The latter contributes little if anything to its action as an antiemetic or an antihistaminic agent. Benadryl is equally as effective as Dramamine.

**MECLIZINE**—Bonamine (meclizine) is a weak synthetic antihistaminic agent but both its antihistaminic and antiemetic actions are prolonged. It has some anticholinergic properties. The incidence of side effects is very low and this agent exhibits less sedation and somnolence within therapeutic ranges than any of the effective antiemetic agents. It may effect its antiemetic properties by depressing the vomiting center in the medulla and the labyrinthine mechanisms. Bonadonax is merely a combination containing 50 mg of pyridoxine and 25 mg of Bonamine in each tablet. It is doubtful that the pyridoxine adds much to either the therapeutic effectiveness or the antiemetic potency of the Bonamine when used in this combination.

**CYCLIZINE**—Marezine (cyclizine) is a water soluble antiemetic agent which also exhibits moderately potent antihistaminic properties. It does not produce an adrenergic blockade but is mildly antihypertensive. It possesses smooth muscle antispasmodic properties and blocks the effect of vagus nerve stimulation. The duration of action of Marezine is not as long as that of Bonamine, being 6 to 8 hours. The incidence of sedation and somnolence is quite high. We have observed several patients in whom somnolence was pronounced for periods up to 36 hours.

**PROMETHAZINE**—Phenergan (promethazine) is known primarily for its antihistaminic action. It has low toxicity, and side effects other than drowsiness are rare. Phenergan has very little hypotensive effect and when given parenterally it

tures nearby to produce a patterned response. This response is activated through several different pathways. For example, the chemoreceptor trigger zone in the floor of the fourth ventricle responds only to emetic chemicals and is connected to the vomiting center through internuncial neurons. Thus, apomorphine does not stimulate the vomiting center directly, but rather indirectly via the chemoreceptor trigger zone. The vomiting center is also activated by labyrinthine reflexes and visceral reflexes (Fig. 7).




Fig. 7—Diagrammatic representation of the mode of action of emetic agents. These impulses are the result of stimulation of the chemoreceptor trigger zone. P. H. Connor, M.D., editor, W. B. Saunders Co.

Hess also demonstrated emetic responses following stimulation of the diencephalon and other forebrain structures. It would seem that unknown afferent supramedullary receptors and pathways not only initiate vomiting but probably influence the reflex excitability of the vomiting center by directing continuous volleys of impulses against it. It is quite likely that psychic influences affect vomiting in this manner.

**Antiemetic Agents.**—In 1916 diphenhydramine (Benadryl) was found to have antiemetic action. An analogue, dimenhydrinate (Dramamine), was reported to be especially effective in motion sickness. Further chemical synthesis yielded

hours after the drug is discontinued. I have also observed 2 patients who developed a peculiar spastic and painful contraction of the trapezius muscle apparently due to extrapyramidal involvement. This too was relieved within 12 hours after the drug was discontinued.

**PERIPIENAZINE** —Trilafon (perphenazine) is also a phenothiazine derivative. It is approximately 6 times as potent as chlorpromazine as an antiemetic. The incidence of side reactions is somewhat similar to that seen with prochlorperazine. Here again the most frequently seen side effect is somnolence. Other side effects noted are dryness of mouth, nervousness, tremor, and urticaria. The side effects other than somnolence are infrequent with doses of 16 mg or less per day but do start appearing in increasing frequency above this dosage. There has been no evidence of hepatic toxicity to date and there is less hypotension than observed with other phenothiazine derivatives.

It has been used in anxiety states and vomiting and has proved to be an effective agent in both areas. As an antiemetic the recommended dose is 4 mg every 6 hours by mouth or 5 mg intramuscularly for parenteral administration. Larger doses may be necessary in more severe nausea and vomiting but in those requiring 24 mg per day there may be a marked increase in side reactions, the most common being that of somnolence. Scurr and Robbie have used it for post-operative vomiting in a 5 mg parenteral dose with a two thirds reduction in post-operative vomiting as compared to controls with no medication. The only side reaction noted was that there was a slight prolongation of the reaction time in these patients.

In a fairly large number of cases of nausea and vomiting reported by Weiss and co-workers due to a variety of causes it appears that the agent may give good or excellent results in 80 to 90 per cent of the cases.

**TRIFLUOROPROMAZINE** —Vesprin (trifluorpromazine) is another recently developed phenothiazine derivative. It is quite effective as an antiemetic and rarely causes hypotension. It is approximately 5 times as potent as chlorpromazine. It is effective as a dose of 5 mg, 3 times a day, or every 6 hours. Large doses should be avoided because of rather severe extrapyramidal signs that may develop, however these are reversible when the drug is discontinued. The other side effects associated with phenothiazine derivatives appear to be less frequent with trifluorpromazine.

**Phenothiazine Derivatives (General Comments)** —At this time it is apparent that phenothiazine derivatives as a group have antiemetic activity. Most of the published reports concern chlorpromazine and compare it with non phenothiazine antiemetics. Reports are appearing in the literature concerning other phenothiazine derivatives, but to date they lack the completeness of the information available on chlorpromazine. Because of this fact most of the information discussed in this chapter refers to chlorpromazine. It is not the intention of the authors to intimate that chlorpromazine is the most effective or most desirable of the phenothiazines. From the reports that have appeared concerning the use of perphenazine, prochlorperazine, and trifluorpromazine it would appear that these agents are also quite effective antiemetics and are approximately 5 to 6 times more potent than chlorpromazine. These three derivatives also produce less adrenogenic blockage and

## PHENOTHIAZINE AGENTS

actually cause an increase in blood pressure. Like Thorazine, Phenothiazine has sedative properties and potentiates analgesics and hypnotics.

**CHLORPROMAZINE**—Thorazine (chlorpromazine) like Phenergan is a phenothiazine derivative unlike Phenergan, Thorazine has little if any autonomic activity but is highly active in its effect on the autonomic nervous system. It acts as an adrenergic blocking agent. In addition, the drug affects the vomiting reflex and produces sleep from which the patient is aroused. It is also used for the treatment of mental and emotional disorders. No doubt there are many other central nervous system effects which have not been uncovered as yet. It has a bitter taste, and when applied to the mucous membrane it acts as a local anesthetic much like cocaine. It can be administered both orally and parenterally and is apparently well absorbed following the former route of administration. It may increase the pulse rate but acute studies in the laboratory indicate that cardiac output is not affected appreciably. The electrocardiogram is altered only very slightly. Very large doses of the drug are administered. Although chlorpromazine appears to be a cerebral depressant, cerebral oxygen uptake is not reduced by doses up to 100 mg daily.

The effectiveness of Thorazine as an antiemetic agent probably depends on its competitive affinity for receptors in the chemoreceptor trigger zone. In addition intravenous administration of 6 mg per kilogram of Thorazine increases protection against the emetic action of intragastric copper sulfate. Since copper sulfate acts on the medullary vomiting center via the visceral afferents without involving the chemoreceptor trigger zone, a second site must be postulated for Thorazine's activity. The reticular vomiting center.

For the routine use of Thorazine as an antiemetic agent, a dose of 25 mg or less will minimize the incidence and severity of side effects. At lower doses the drug usually loses its effectiveness. An initial 10 mg dose is best for the ambulatory patient. If this is ineffective and side reactions are not marked, it can be increased to 25 mg given every 4 to 6 hours.

**PROCHLORPERAZINE**—Compazine (prochlorperazine), like chlorpromazine, is a phenothiazine derivative. Laboratory observations suggest that in equivalent doses it is even more potent (5 times) than chlorpromazine as an antiemetic. The stability both in the powdered form and in solution is comparable to that of chlorpromazine. It produces less adrenergic blockade and consequently less hypotension than chlorpromazine.

The dose of Compazine when used for the treatment of nausea and vomiting is 5 mg 4 times daily to start, it then should be adjusted according to patient response. It should probably not exceed 60 mg a day (15 mg per dose). Within this dosage range the only frequent side reaction is that of somnolence, which is observed in 10 to 20 per cent of the patients being treated. Jaundice and blood abnormalities have not been observed. When doses of more than 60 mg per day are employed, the incidence and severity of side effects rise sharply. These include somnolence, seen in about two thirds of the patients, and dizziness, hypotension, tachycardia and dry mouth. In one third to one half of the patients. These are all reversible.



A reversible paralysis rigans like syndrome occasionally develops in patients taking extremely high doses of Thorazine (more than 1,000 mg per 24 hours), but this reaction is rare when the drug is used as an antiemetic. Jaundice is seen in a small number of patients. According to Kelsey and his associates the majority of the patients developing jaundice during Thorazine therapy are receiving large doses for psychiatric reasons. The incidence of jaundice following Thorazine is about 1.4 per cent in institutionalized psychiatric patients—almost twice as great as that seen when Thorazine is used as an antiemetic. Although the clinical picture may simulate acute infectious hepatitis, the laboratory findings usually indicate obstructive jaundice. Agranulocytosis may be seen within 7 weeks after the institution of Thorazine. Therefore, serial white cell counts are important in warning of this complication.

[Trimethobenzamide hydrochloride (Tigan), a reputed antiemetic drug which is not a phenothiazine derivative, has been introduced too recently to be able to establish its relative usefulness with assurance. Ed.]

## CLINICAL APPLICATIONS

**Drug-Induced Emesis**—Nausea and vomiting associated with drug administration is due to increased sensitivity, drug toxicity, or overdosage. Most emetic drugs act by one of the following methods: (1) stimulation of the chemoreceptor trigger zone in the medulla which is followed by secondary stimulation of the vomiting center over the connecting neurons, (2) direct stimulation of the vomiting center, (3) gastrointestinal irritation with reflex stimulation of the vomiting center (Fig. 7). The antiemetic agents, when effective, block off one or more of these causative mechanisms.

Opiates—morphine, meperidine, methadone, and Pantopon—probably elicit vomiting by stimulating the chemoreceptor trigger zone directly. In addition they may act indirectly by increasing vestibular sensitivity, similar to the mechanism of motion sickness with secondary stimulation of the vomiting center; this response is most likely to occur in ambulatory patients. Benadryl, Dramamine, Marezine and Bonamine appear to be more effective than Thorazine in combating opiate induced nausea and vomiting. The fact that these antiemetic agents depress vestibular sensitivity may account in part for the fact that they are more effective than Thorazine in alleviating opiate induced vomiting.

Table 19 Therapeutic Response to Chlorpromazine of Nausea and Vomiting Due to Drug Administration

Etiology of Nausea and Vomiting	Number of Patients Treated	Therapeutic Response* in Per Cent		
		Excellent	Improved	Failure
Digitalis	16	75	25	—
Nitrogen mustard	40	60	35	5
Antibiotics	20	60	40	—
Aminophylline	12	67	33	—
Veratrum (protoveratrine)	30	—	33	67
Miscellaneous	9	11	78	11

\*Therapeutic response: excellent = complete arrest of nausea and vomiting; improved = vomiting arrested but nausea continued; failure = no improvement of nausea or vomiting.

subsequently less hypotension. None of them have been demonstrated to cause jaundice but pherphenazine has been implicated in a case of agranulocytosis. However, when the aforementioned side effects are less frequent than seen with chlorpromazine, the incidence of agitation, anxiety, and signs of extrapyramidal irritation appears to be more common. This has been reported with perphenazine and prochlorperazine to a limited extent. However, the incidence observed with trifluoperazine is considerably higher and occurred rather consistently on a dose of 150 mg per day (a comparable dose of chlorpromazine would be 750 mg).

When using trifluoperazine or prochlorperazine a dose of 5 mg every 6 hours by mouth appears to be quite effective in preventing vomiting. The comparable dose of perphenazine would be 4 mg every 6 hours. When vomiting is severe, it would be preferable to start with an intramuscular dose of 5 mg (any of the three preparations) and after the vomiting is controlled to change to the oral route for administration.

Further information will have to be obtained before the complete picture of side effects of these newer phenothiazine derivatives can be obtained.

[There has been insufficient experience at this time with pipimazine (Morfoline) for a proper relative evaluation. Ed.]

**SIDE EFFECTS OF ANTIEMETIC DRUGS**—Sedation, dizziness, dry mouth, weakness, fatigability, blurring of vision, incoordination, and lightheadedness as well as occasional headaches, insomnia, nervousness, constipation, and diarrhea are commonly seen during antiemetic therapy. These side effects, although usually mild, occur in 20 to 75 per cent of all patients and the severity is frequently proportional to the dosage. The incidence of side effects and the severity of these responses vary a great deal among the various antiemetic agents. Since tolerance is unpredictable, the initial dose should be given when the patient is not exposed to industrial or transportation hazards. There is no apparent relationship between the cause of vomiting and the development of side reactions. Intramuscular administration of antiemetic agents is sometimes followed by pain at the injection site, and phlebitis may occur after intravenous infusion. The side reactions associated with oral administration may also appear in intensified form after parenteral therapy.

Although bone marrow depression, hepatic dysfunction, and vascular collapse occasionally follow administration of these drugs, these reactions apparently occur most frequently after the use of Thorazine. About 12 per cent of the patients treated with Thorazine experience a significant hypotension. The maximal effect usually occurs 30 to 40 minutes after intramuscular injection and 60 to 90 minutes following oral administration. No consistent changes in cardiac output have been observed and renal hemodynamics remain essentially unchanged even though the blood pressure is reduced. The usual hypotensive reaction is mild but depressions of 30 to 40 mm Hg have been reported upon assumption of the upright position. Therefore patients receiving Thorazine parenterally should remain supine for 30 to 40 minutes after the maximal hypotensive reaction occurs. The blood pressure effect is an initial response and usually is not observed after the third or fourth dose. When tachycardia occurs the pulse rate usually increases only 10 to 20 beats per minute.

upon frequency of administration, rather than on the massive doses (300 to 600 mg per day) generally used. When it is used in this dosage range, hypotensive episodes are likely, especially following parenteral administration.

**Nausea and Vomiting Associated With Infection and Toxicosis**—Thorazine is the most effective agent for treating emesis secondary to infection in adults: hepatitis, cholecystitis, acute salpingitis, pneumonia, and urinary tract infections. The emetic mechanism of gastroenteritis probably is similar to that of drugs causing vomiting by intestinal irritation. About 90 per cent of several groups of patients with acute gastroenteritis obtained an excellent therapeutic response with Thorazine (Table 20).




Fig 8—A comparison of the antiemetic effect of chlorpromazine and secobarbital. Nausea and vomiting were arrested in 90 per cent of the patients receiving chlorpromazine.

therapeutic effectiveness (Courtesy Dr C W Daeschner from Moyer, John H. Effective Antiemetic Agents. In Conn, Howard F, editor. Efficacy of New Drugs. M Clin North America. March, 1957, Philadelphia, W B Saunders Co.)

Daeschner and associates compared Marezine, Bonamine, Thorazine, secobarbital, and placebo in children and found no appreciable difference in the therapeutic response (about 90 per cent) to Thorazine and Marezine, both of which were significantly superior to Bonamine, placebo, and sedation with secobarbital (Fig 8). The antiemetic agents (especially Marezine) were highly successful in controlling the vomiting associated with common pediatric infections and toxicosis. Drowsiness, the only common side effect, was less frequent with Bonamine and Marezine compared to that seen with Thorazine and secobarbital. Dizziness, tachycardia, and dry mouth occasionally accompanied Thorazine administration.

Nausea and vomiting provoked by the various toxicoses in adults—diabetic acidosis, leukemia, hepatic carcinoma, carcinomatosis, and brain tumor—respond

Drug (digitalis, apomorphine, etc) emesis that results from direct stimulation of the chemoreceptor trigger zone is most effectively blocked by Thorazine (Table 19), which depresses this structure. Thorazine is also the most effective antiemetic agent for treating nausea and vomiting associated with the use of drugs (aminophylline, antibiotics, etc) which produce vomiting by gastrointestinal irritation. The mechanism of the vomiting commonly seen with nitrogen mustard therapy remains obscure. Thorazine is effective for combating this reaction clinically whether given prophylactically or therapeutically.

The results of using Thorazine in treating the nausea and vomiting associated with veratrum administration in the hypertensive patient vary. As with intragastric copper sulfate, toxic doses of veratrum stimulate the nodose ganglion which propagates emetic impulses over the afferent vagus to the vomiting center without traversing the trigger zone (Fig 7). Presumably therefore, in order to be effective against this type of emesis, the antiemetic agent must depress the medullary vomiting center directly. Although Thorazine appears to exert this type of response, in my experience it has little if any beneficial effect on veratrum induced nausea and vomiting (Table 19).

When Thorazine is used for the therapy of drug induced emesis, it is usually necessary to give the first dose parenterally, following which the oral route may be used. Usually 25 mg given intramuscularly is adequate to arrest vomiting, but, if not, an additional 25 mg can be given after 1 hour if excessive sedation or hypotension has not occurred. After vomiting has been arrested, Thorazine can be given orally or rectally in a dose of 10 to 50 mg every 4 to 6 hours depending on the recurrence of nausea and vomiting and their severity. The dose requirement for a given therapeutic response, when the drug is given rectally or orally is usually about twice as large as that necessary by the intramuscular route. Thorazine should rarely be given intravenously since cardiovascular side reactions (particularly hypotension and tachycardia) are much more frequent following this route of administration than by any other route when equal doses are used.

Because of the lower incidence and severity of side effects, Bonamine, Marezine, Benadryl, and Dramamine appear to be more useful in the prevention of nausea and vomiting associated with drug administration. However, if these are ineffective, Thorazine should be tried. When used either prophylactically or therapeutically, Dramamine and Benadryl should be given in doses of 50 to 100 mg orally. When the patient is actively vomiting the drug can be given parenterally. When Bonamine or Marezine is used, 25 to 50 mg of the former, or 50 mg of the latter, is given. When employed for the prevention of nausea and vomiting associated with antibiotic administration, I prefer a preliminary trial of Bonamine (25 to 50 mg) or Dramamine (50 to 100 mg) given orally about 30 minutes before the administration of the antibiotic because of lower incidence of side effects. If these are ineffective, I would then use Thorazine.

Not only does Thorazine control the nausea and vomiting in acute and post alcoholic states but it also relieves the motor excitement and provides beneficial sedation. The antiemetic action allows these patients to tolerate oral feedings earlier so that dehydration and nutritional deficiencies can be corrected more rapidly. The effectiveness of Thorazine in the alcoholic patient seems to depend

upon frequency of administration, rather than on the massive doses (300 to 600 mg per day) generally used. When it is used in this dosage range, hypotensive episodes are likely, especially following parenteral administration.

**Nausea and Vomiting Associated With Infection and Toxicosis**—Thorazine is the most effective agent for treating emesis secondary to infection in adults: hepatitis, cholecystitis, acute salpingitis, pneumonia, and urinary tract infections. The emetic mechanism of gastroenteritis probably is similar to that of drugs causing vomiting by intestinal irritation. About 90 per cent of several groups of patients with acute gastroenteritis obtained an excellent therapeutic response with Thorazine (Table 20).




Fig 8—A comparison of the antiemetic effect of chlorpromazine and secobarbital.

emetic Agents. In Conn Howard F, editor. Efficacy of New Drugs, M Clin 1961 America, March 1957, Philadelphia W B Saunders Co.)

Daeschner and associates compared Marezine, Bonamine, Thorazine, secobarbital, and placebo in children and found no appreciable difference in the therapeutic response (about 90 per cent) to Thorazine and Marezine, both of which were significantly superior to Bonamine, placebo, and sedation with secobarbital (Fig 8). The antiemetic agents (especially Marezine) were highly successful in controlling the vomiting associated with common pediatric infections and toxicosis. Drowsiness, the only common side effect, was less frequent with Bonamine and Marezine compared to that seen with Thorazine and secobarbital. Dizziness, tachycardia, and dry mouth occasionally accompanied Thorazine administration.

Nausea and vomiting provoked by the various toxicoses in adults—diabetic acidosis, leukemia, hepatic carcinoma, carcinomatosis, and brain tumor—respond

Table 20 *Diagnosis and Clinical Response to Chlorpromazine of Nausea and Vomiting Due to Infections and Toxicoses*

Etiology of Nausea and Vomiting	Number of Patients Treated	Therapeutic Response in Per Cent		
		Excellent	Improved	Failure
Infection				
Acute gastroenteritis	26	88	4	8
Hepatitis	10	60	40	—
Cholecystitis	3	100	—	—
Acute salpingitis	2	100	—	—
Miscellaneous	4	50	50	—
Toxicosis				
Carcinomatosis	50	78	16	6
Diabetic acidosis	7	100	—	—
Uremia	18	56	33	11
Leukemia	3	100	—	—
Miscellaneous	9	67	33	—

Table 21 *Comparison of Therapeutic Response to Antiemetic Agents in Radiation Sickness*

	Number of			
<i>Dimenhydrinate (Dramamine)</i>				
Beeler et al	8 <sup>a</sup>	26	58	16
Defoe et al	100	—	46	54
Walker	22	36	50	14
	204		66*	34
<i>Chlorpromazine (Thorazine)</i>				
Moyer et al	40	70	20	10
Marks	84	81	14	5
O Connell	38	53	39	8
	162	72	2 <sup>a</sup>	6

<sup>a</sup>Per cent of patients benefited with therapy

particularly well to Thorazine, but intestinal obstruction must be ruled out before antiemetic therapy is instituted

Even though the specific cause of uremic vomiting is not known, Thorazine has simplified its management. Following an initial intramuscular dose, most uremia patients are able to take subsequent doses and nourishment orally within a few hours. The unpredictable cardiovascular reactions that sometimes follow intravenous administration of Thorazine contraindicate this route in patients with severe renal disease.

The antiemetic agents have become established in treating radiation sickness (Table 21). Dramamine (approximately 400 mg per day in divided doses) provides an excellent therapeutic response in about one third of the mild cases, but approximately as many fail to benefit. Benadryl has been reported to give excellent results in about 50 per cent of the patients, with about 10 per cent failures. The optimal oral dosage is 50 to 100 mg, 3 times a day, and 50 to 100 mg intravenously if the parenteral route is necessary. Thorazine has outstanding value in

these cases and, although the optimal dosage should be determined on an individual basis, 10 to 25 mg, 4 times daily usually suffices

**Postoperative Vomiting**—Although improved techniques in anesthesia have tended to reduce postoperative vomiting, it and the ensuing electrolyte imbalance wound disruption, and aspiration of vomitus may still cause great distress to the patient. The place of antiemetic agents in solving the problem of postoperative vomiting remains undefined. Yet, no matter what the complex etiology, the end result of postoperative vomiting is stimulation of the medullary vomiting center. Probable causes of postoperative vomiting are

- 1 Irritation of the gastrointestinal lining. Traction on the abdominal viscera may also excite the vomiting center through this afferent visceral reflex arc
- 2 Blood borne chemicals
- 3 Cerebral and psychic factors
- 4 The efferent pathways of the vestibular sense organ, which traverse the chemoreceptor trigger zone and may be important in causing postoperative vomiting. Morphine derivatives apparently lower the vestibular threshold increase the excitability of the medullary vomiting center, and make it more susceptible to subthreshold stimuli

- 5 Dehydration and acidosis which predispose to postoperative vomiting

Moore and his associates using a prophylactic intramuscular dose of 50 mg of Dramamine before surgery and following with four 50 mg doses reduced the incidence of postoperative vomiting from 23 to 13 per cent irrespective of the type of premedication anesthetic agent, method of anesthetic administration or postoperative therapy. Intravenous Dramamine also reduced the incidence and the severity of vomiting markedly but failed to alter the nausea. Prolonged drowsiness tachycardia and respiratory depression are the common side effects of Dramamine administration. Benadryl has also been reported to be a successful prophylactic for postoperative vomiting (Fig 9)

In the use of Dramamine as a *therapeutic agent* (rather than prophylactic) in postoperative vomiting the effectiveness compares favorably with that of the other antiemetic agents, but Thorazine appears to be more potent in this respect

Generally, Bonamine and Mareline have not been as successful as Dramamine and Benadryl in preventing postoperative vomiting (Fig 9), although Didier and his associates observed equal efficacy with the administration of 50 mg of Mareline

Thorazine is effective in the prevention of postoperative vomiting. Its chief indication in this respect is therapeutic in the patient in whom less potent agents (also agents with less side effects) have been ineffective in the prevention of nausea and vomiting. Thorazine potentiates the action of sedatives, analgesics, and anesthetics more than other antiemetic agents, and thus smaller quantities of these drugs are necessary. This action, in itself, partially decreases the incidence of postoperative vomiting

In one study we gave 12.5 to 25 mg of Thorazine intramuscularly to 90 patients about 45 minutes prior to induction of general anesthesia. Only one patient vomited in the postoperative period. Blood pressure depressions were frequent but

Table 20 *Diagnosis and Clinical Response to Chlorpromazine of Nausea and Vomiting Due to Infections and Toxicoses*

Etiology of Nausea and Vomiting	Number of Patients Treated	Therapeutic Response in Per Cent		
		Excellent	Improved	Failure
<b>Infection</b>				
Acute gastroenteritis	26	88	4	8
Hepatitis	10	60	40	—
Cholecystitis	3	100	—	—
Acute salpingitis	2	100	—	—
Miscellaneous	4	50	50	—
<b>Toxicosis</b>				
Carcinomatosis	50	78	16	6
Diabetic acidosis	7	100	—	—
Uremia	18	56	33	11
Leukemia	3	100	—	—
Miscellaneous	9	67	33	—

Table 21 *Comparison of Therapeutic Response to Antiemetic Agents in Radiation Sickness*

	Number of				
<b>Dimenhydrinate (Dramamine)</b>					
Beeler et al	82	26	58	16	
Defoe et al	100	—	46	—	54
Walker	22	36	50	—	14
	204		66*		34
<b>Chlorpromazine (Thorazine)</b>					
Moyer et al	40	70	20	10	
Marks	84	81	14	5	
O'Connell	38	53	39	8	
	162	72	22	6	

\*Per cent of patients benefited with therapy

particularly well to Thorazine, but intestinal obstruction must be ruled out before antiemetic therapy is instituted

Even though the specific cause of uremic vomiting is not known Thorazine has simplified its management. Following an initial intramuscular dose, most uremia patients are able to take subsequent doses and nourishment orally within a few hours. The unpredictable cardiovascular reactions that sometimes follow intravenous administration of Thorazine contraindicate this route in patients with severe renal disease.

The antiemetic agents have become established in treating radiation sickness (Table 21). Dramamine (approximately 400 mg per day in divided doses) provides an excellent therapeutic response in about one third of the mild cases, but approximately as many fail to benefit. Benadryl has been reported to give excellent results in about 50 per cent of the patients, with about 10 per cent failures. The optimal oral dosage is 50 to 100 mg, 3 times a day, and 50 to 100 mg intravenously if the parenteral route is necessary. Thorazine has outstanding value in



acidity predisposes to vascular endothelial damage. Because of the occasional hypotensive response I prefer not to use Thorazine intravenously.

The likelihood of response to antiemetic drugs should be weighed against the possibility of untoward reactions in each patient. It seems logical that Dramamine should be used as a prophylactic measure. Then should nausea and vomiting occur postoperatively, Thorazine or Marezine should be given. Of course, if potentiation of anesthesia is desirable, Thorazine is the preanesthetic agent of choice.

**Nausea and Vomiting of Pregnancy**—Although the exact etiology is unknown, endocrine, nutritional, and psychogenic factors appear to be important in inducing nausea and vomiting during the first trimester of one half to two thirds of all pregnancies. While oral antiemetic medication and other symptomatic therapy are usually the best prospects, serious cases require hospitalization and treatment with parenteral fluids and other more drastic therapeutic measures.

The results of comparable studies of the drugs commonly used in this country show that at least 20 per cent of the patients treated with Dramamine remain unimproved, and short duration of action, prominent side effects, and relative impotency make this drug comparatively unsatisfactory. Benadryl has also been

Table 23 *Nausea and Vomiting of Pregnancy: Comparison of Effectiveness of Antiemetic Agents*

Drug and Author	Dose* (mg)	No of Patients	Therapeutic Response† In Per Cent		
			Excel- lent	Good	Fa- lure
<i>Dimenhydrinate (Dramamine)</i>					
Carlner et al	50 100 tid	43	72	—	28
Cartwright	50 100 bid	106	23	46	31
Subtotal		149	37%	33%	30%
<i>Mecizine (Bonamine)</i>					
Bass	25 50 hs ‡	182	90	8	2
Lebherz and Harris	25 hs	92	82	10	6
Mulhern and Bryan	25 hs	100	64	24	12
Subtotal		374	81%	13%	6%
<i>Mecizine + Pyridoxine (Bonadoxin)§</i>					
Weinberg and Werner	1 tab bid	100	30	58	19
Tartkoff et al	1 tab hs	68	93	6	1
Groskloss et al	1 tab hs	287	91	5	4
Crawley	1 tab hs	65	82	12	6
Baker	1 2 tab hs	50	92	6	2
Betha	1 2 tab qd	46	48	41	11
Fox	1 2 tab qd	150	85	9	5
Subtotal		766	79%	16%	6%
<i>Chlorpromazine (Thorazine)</i>					
Mayer et al	25 qid	78	71	24	5
Benaron et al	10 50 tid qid	114	51	33	16
Subtotal		192	59%	30%	11%

\*Signifies oral administration qd = daily hs = at bedtime bid = twice a day tid = 3 times a day qid = 4 times a day

†Therapeutic response: excellent = complete alleviation of nausea and vomiting; good = vomiting controlled but nausea continued; poor = no improvement in nausea and vomiting

‡Supplemented with 12.5 25 mg upon awakening or at noon if necessary

§Bonadoxin contains 25 mg mecizine and 50 mg pyridoxine

||Includes patients responding in the first week of treatment

minimal excitation, and reflex responses were elicited within one hour after termination of anesthesia. Significant and alarming blood pressure reductions seem to have been overemphasized by some investigators. For example, Albert and Coakley found that patients undergoing anesthesia without the prior administration of chlorpromazine showed an equal reduction in blood pressure as compared to those patients who received chlorpromazine (Table 22).

Table 22 Blood Pressure Response to Preoperative Medication With Chlorpromazine (50 mg)\*




Fig 9  
ing (comp  
effective ag  
John H  
Drugs M

Morris and associates described only 2 failures when using 12.5 to 25 mg of Thorazine in 23 patients who vomited following spinal anesthesia. They found depressions of the systolic blood pressure greater than 20 mm Hg in 9 cases. In 7 other cases nausea and vomiting were purposely induced by brief traction on the stomach. After Thorazine was administered (12.5 to 25 mg intravenously), patients became refractory to subsequent tugs.

Intravenous use of Thorazine requires dilution of the solution because its

Table 24 Recommendations for Antiemetic Therapy

Source of Emesis	Recommended Agent	Dose (mg)*	Frequency
<b>Drug Induced</b>			
Digitalis	Thorazine	10-25	q i d
Antibiotics	Thorazine	10-25	q i d
Nitrogen mustard	Thorazine	25-50	q i d
Alcoholic states	Thorazine	50-150	q i d
Opiates	Bonamine, Mareline, or Dramamine	25-50 50 100	b i d q i d q i d
<b>Infections</b>	Thorazine	10-25	q i d
<b>Toxicoses</b>			
Diabetic acidosis	Thorazine	10-25†	q i d
Uremia	Thorazine	10-25†	q i d
Carcinomatosis	Thorazine	10-25†	q i d
Radiation sickness	Thorazine	10-25†	q i d
Other	Thorazine	10-25†	q i d
<b>Postoperative Vomiting</b>			
Prophylactic	Dramamine Benadryl Mareline	50 50-100 50	t i d q i d t i d q i d t i d
Therapeutic	Thorazine	25-50‡	t i d
<b>Pregnancy</b>	Bonamine (with or without pyridoxine)	25-50	bedtime

\*Refers to oral dose, parenteral doses are usually slightly less

†May increase dose to 50 mg if necessary to arrest vomiting

‡First dose usually administered parenterally

## SUMMARY OF THE THERAPEUTIC USE OF ANTIEMETIC AGENTS

The current concepts of the emetic mechanism have been summarized and the pertinent pharmacodynamics of the useful antiemetic agents have been reviewed briefly. An outline for their use is presented in Table 24.

Thorazine appears to be the most useful agent in drug induced vomiting and vomiting associated with various toxicoses. However, Dramamine, Bonamine, and Mareline are probably more effective in suppressing the emesis resulting from opiate administration. Parenteral administration of antiemetic agents should usually be reserved for patients who are unable to tolerate oral medication; subsequent doses may often be given orally.

The prophylactic use of Dramamine and Benadryl appears to offer more protection from postoperative vomiting than Thorazine. The frequency and severity of side reactions preclude the routine use of Thorazine, except therapeutically, for control of vomiting in the postoperative period.

In treating the nausea and vomiting of pregnancy, Bonamine (with or without pyridoxine) appears to be the most useful antiemetic agent, and at least 90 per cent of the patients improve under this medication. Again, Thorazine should be reserved for those whose pernicious vomiting does not respond to other therapy.

## NEW ANTIEMETIC AGENTS

Thioperazine (Vontil), which is a derivative of phenothiazine, is now under going clinical trial. The preliminary data available at this time would indicate that

reported to exert a protective action in this syndrome, but in our experience is no more effective than Dramamine.

Bonamine is especially effective and has the advantages of a long duration of action (up to 24 hours) and a minimum of untoward side reactions. The optimal dose, 20 to 50 mg at bedtime, can be supplemented with 25 mg on awakening or at noon. The combination of 50 mg of pyridoxine (vitamin B<sub>6</sub>) with 25 mg of Bonamine may also be useful, for pyridoxine supposedly exerts a beneficial ketolytic effect. The proportion of patients obtaining an excellent response (complete cessation of nausea and vomiting) with Bonamine, with or without pyridoxine, is greater than that with Thorazine or Dramamine. Also, there are fewer therapeutic failures when patients are treated with Bonamine than with the other drugs. Drowsiness, the only common side effect of Bonamine administration, usually decreases as therapy is continued and is usually proportional to the size of the daily dosage.

The use of Thorazine demonstrates an equally good response rate. However, the untoward effects of Thorazine—sedation, orthostatic hypotension, and dizziness—are a disadvantage, even though they diminish after a week of treatment. The relatively short duration of action also creates therapeutic problems in treating morning sickness, since the bedtime dose has usually worn off. Patients who are unable to retain the first daily oral dose must be given this dose intramuscularly or rectally or else take a 2 A.M. dose. Twenty-five milligrams (usually given 3 to 4 times daily) is the minimal consistently dependable dose, but a few patients respond to 10 mg. Thorazine gave excellent or good therapeutic results in a series of patients with hyperemesis gravidarum, in intramuscular doses of 25 to 60 mg given 2 or 3 times daily. It is in the patient with severe, persistent vomiting that Thorazine is the agent of choice.

Given intramuscularly in 25 mg doses every 4 hours, Thorazine also reduces the nausea and vomiting occasionally seen during labor and delivery. Karp and her associates found that synergistic action made it necessary to reduce the amount of analgesics and anesthetics used in delivery by about 50 per cent. Thorazine acts successfully without depressing the fetus or the mother and also reduces the psychomotor agitation and hyperactivity associated with scopolamine.

Compazine (prochlorperazine), an analogue of chlorpromazine, is currently under clinical trial as an antiemetic. It is more potent than chlorpromazine, and when used in doses of 15 mg or less 4 times a day, it shows promise for the treatment of nausea and vomiting of pregnancy. However, larger doses cannot be employed for outpatient and office practice due to the sharp increase in the incidence of side effects when this dosage range is exceeded.

It appears that a dose of 10 mg, given orally, 4 times a day, is adequate in the majority of patients. In a minority, 5 mg, 4 times a day, will apparently suffice. If 10 mg, 4 times a day, is not adequate, the dose can be increased to 15 mg with impunity. The drug should not be given intravenously for the treatment of nausea and vomiting. The parenteral route is indicated primarily for initial medication in order to arrest emesis, following which the oral route may be employed. It is best to use the least amount of any of these drugs which will produce the desired response.



it is approximately 50 times as potent as chlorpromazine and 10 times as potent as triflupromazine, perphenazine, and prochlorperazine

Early observations have indicated that drowsiness and hypotension are not observed in the therapeutic doses needed for severe vomiting. Also, whereas signs of extrapyramidal irritation have been observed in dogs, these have not been observed in humans.

When used prophylactically by mouth to prevent drug-induced nausea and vomiting, it is quite effective at 0.5 mg every 6 hours. However, on occasion a dose of 1 mg every 6 hours may be necessary. In severe vomiting it would be wise to administer at least the initial dose intramuscularly. In one instance of severe vomiting due to widespread abdominal carcinomatous and the administration of an anticarcinogenic agent, the patient received only partial relief from 1 mg intramuscularly every 6 hours but was completely relieved of vomiting and almost completely relieved of nausea on a dose of 1.5 mg every 6 hours. Even at this dose level there was no evidence of side effects.

**Evaluating New Antiemetic Agents.**—When evaluating new antiemetic agents, it is necessary to pay close attention to the associated effects on the central and autonomic nervous systems. The aim is to find agents which will specifically depress the emetic mechanism with minimal effects elsewhere. It is apparent that the more potent the antiemetic activity of any drug, the more likely that other (untoward) effects on the central nervous system will develop. These effects can be insidious and obscure to the observer but devastating to the patient, particularly is this true of depression, anxiety, and agitated depressive reactions.

#### SELECTED REFERENCES

- 21b, 1951  
Conner, P. K., McConn, R., and Moyer, J. H. An Attempt to Alleviate the Emetic Effect of Prothoverastine by the Concurrent Use of Chlorpromazine in the Treatment of

must also be an understanding of the probable basis of their effects in the obese patient

This is of course, no place to go deeply into the psychologic basis of obesity or the symbolic implications of overeating. It is sufficient to accept the uniformly stated opinion of experts that all cases of obesity not explainable on an organic or cultural basis are psychogenic, and that the psychogenic comprise over 90 per cent of the total. Beyond this, there is the important fact that, regardless of what measures are used to help the obese lose weight, unless something positive is done about the psychologic factors involved, when treatment stops, lost poundage will soon make its way back.

Stunkard states that most obese patients will not stay in treatment for their obesity, that of those who do, most will not lose weight, and of those who lose weight, most will regain it. There is his discouraging experience that of 100 patients who lost more than 20 pounds under his care, after a year, half had recouped their hard won losses, and within the second year there remained only 2 who were not plump once more. This means that after 2 years of treatment only 2 patients out of 100 showed any benefit from treatment.

More than half of obese patients on weight reducing regimens suffer some psychologic reaction, and half of these are severe emotional disturbances. Stunkard noted that the "night eating" syndrome often complicates otherwise successful treatment for obesity. This syndrome, which is a response to stress which appears in other situations as well, consists of insomnia, nocturnal pangs of hunger, and morning anorexia. No part of this is a specific pharmacologic reaction to drugs which are used to depress appetite, rather it is all part of a psychologic reaction to a regimen which deprives patients of a form of support of deep psychic and symbolic significance, overeating. This speaks volumes for the importance of the psychologic background of the condition as well as the intensity of the psychologic resistance (despite all apparent desire for weight loss) to measures which decrease food intake.

Lesses and Meyerson feel that the obese suffer from anhedonia, that is to say that, although there appears to be a compulsive drive to eat, the act of eating, no matter how excessive, provides neither satiety nor satisfaction. As a corollary, therefore, simple appetite depression would have little useful effect, for appetite per se has nothing to do with it. Although this may seem unusual, it is not really different from the plight of most alcoholics, many of whom often do not really enjoy the effects of alcohol and very much wish to stop drinking, but who, nevertheless, consume inordinate amounts of alcohol often very rapidly, and appear to take little or no pleasure in what seems to be a purely compulsive act.

Mayer has suggested a metabolic or "glucostatic" mechanism which normally controls appetite and hunger, others have suggested a hormonal mechanism which controls intestinal activity which is related to the hunger drive, and still others have suggested a center in the nervous system for its control. We should like to press our view that whatever the mechanism of the normal psychologic control of appetite may turn out to be, these are likely to have little to do with the problem of normal 'appetate' setting of a

## THE CHOICE OF AN ANOREXIANT

Walter Modell, M.D., and

George G. Reader, M.D.

---

### INTRODUCTION

For cultural and cosmetic reasons as well as for reasons of health, there has been great pressure on both our male and female population to shrink its diet as well as its waistline. In a country with so much good food so easily obtained, mass efforts in this direction have been notably unsuccessful. As a result, some easier way out has been sought, e.g., a drug which would assist by depressing the appetite, hence, the recent interest in anorectic agents, of which there are a number now on the commercial drug market and about whose actions and virtues there is little precise information.

In practice, the so called anorexigenic drugs are not used simply to depress the abnormal appetite, for even if there is marked bulimia or polyphagia, these drugs are not given unless there also is obesity. Thus the problem of the use of these drugs is inseparable from the problem of obesity and its causes, and any attempt to consider the question of their choice on a strict pharmacologic basis as primary anorexigenic drugs is unrealistic.

The designation "anorexigenic" to a particular group of drugs in common use is perhaps unfortunate because it implies a precise pharmacologic action on the central nervous system which has never been demonstrated and, as a matter of fact, direct depression of the central appetite controlling mechanism is never even examined in the clinical studies on the anorectic effects of drugs. What these reports actually attempt to examine is a therapeutic accomplishment in the obese, loss in weight without toxicity, which is, of course, also the result in which the practitioner is interested. Nevertheless, the group of drugs used in the treatment of obesity is now saddled with this inappropriate but highly suggestive term, and, as a consequence of its unsubstantiated implications, studies of the mechanisms involved have been obscured by it and, in our opinion, the treatment of obesity is all the worse for it.

### CLINICAL CONSIDERATIONS

As matters now stand, these drugs are used exclusively in the relief of obesity and, to choose from among them as well as to apply the choice effectively, there



It is interesting in this connection that, if these drugs were specific anorexiants and if their supporters really felt so, it would not be necessary, as all of them seem to find, to put patients on restricted diets. If their appetites were, in fact depressed by the drugs, what always happens when appetites are really depressed would also happen in this case, the obese patients would eat less regardless of how much was available. In these cases, the patients usually eat less only if less is available. It seems clear, therefore, that, despite their stated enthusiasm, even the staunchest supporters of the anorectic drugs are basically insecure about the anorectic effects of these drugs. We suggest an examination of a patient with loss of appetite after overdosage with digitalis for a view of the phenomenon of a truly depressed appetite.

Most of a large number of studies on the effects of the so-called anorexians in man indicate clinical effectiveness, and only a few suggest that they are of limited value or of no value at all. On the other hand, those that do recommend the use of appetite depressing drugs all seem to agree that the drugs are only a crutch and should be used only for a limited period of time. Whereas many of the studies on anorectic drugs currently available have indicated, by one means or another, that their use is associated with weight loss, most of these studies have no useful controls whatever, resting their case entirely on the fact that patients lost weight after taking the new drugs, and overlooking the common experience that a large proportion of obese persons tend to lose weight on entering any new treatment or even an association with a new physician. In other studies that use a placebo, a difference in the weight loss after the placebo *vis à vis* the drug, is taken as evidence of the effectiveness of the drug in question. In a relatively few instances, a double blind scheme is used to remove bias, and in a few of these a cross over plan is used so that each patient is used as the basis of comparison for his weight loss after the anorexiant.

Many studies have indicated that within 30 minutes of the taking of the modern anorectic drugs the subjects clearly experience a "lift," as improvement in the sense of well being, wakefulness, a tendency to increased activity. This being the case, even where the double blind technique is used to start, after 30 minutes the patients know which is medication and which is placebo, and only the physician remains blind. After 30 minutes there are, therefore, neither double blind nor placebo controls, and all the psychic impact of the knowledge that an effective drug is being taken is exerted in favor of the drug being tested. From this point of view, therefore, there have yet been no double blind studies, for a difference between the effects of the placebo and the drug in these studies may well be due to the detection of this difference by the patient and not due to the action of the drug itself.

While some designs undoubtedly make a sterner attempt than others to control the experiment, the fact remains that none of them are properly controlled to eliminate or take into account the well established influence of suggestion and the offer of a crutch to the obese patient about to embark on the trial of refraining from overeating. This is not the place for a thorough analysis of the many reasons which may invalidate the conclusion that none of these positive results after the taking of the anorectic drugs prove a specific anorectic action.

The long term results of weight loss therapy are very poor at present. What is urgently needed for the effective treatment of obesity is more understanding of the reasons why the obese continue to eat without reference to satiation. Failing this, an anorectic agent is likely to have as little effect on the overall problem of obesity as Antabuse (disulfiram) has had on the overall control of alcoholism. In the face of a compulsive desire to overeat, none of the anorexiants are effective unless food intake is controlled as well; hence it is obvious they are not very effective against this force. It is clear that in most instances of resistive obesity therefore psychotherapy of some sort seems the most logical therapy, and, as a matter of fact, the best (over 50 per cent improvement) as well as the most durable results reported have been after psychotherapy of some type and not through the use of drugs.

### PHARMACOLOGIC CONSIDERATIONS

Anorexiants have long been known. Anorexia is a common effect of drugs, e.g. digitalis even sodium chloride may induce nausea and thereby reduce the desire for food in even the most compulsive of eaters. The reputed search for an effective anorectic drug therefore is not really for a drug which depresses appetite but rather for one in which this effect is dissociated from distress and discomfort. This makes matters difficult, since even in the obese, drug action inducing nausea can be counted upon to continue to depress appetite without the development of tolerance whereas tolerance does develop after the use of the so-called anorexiants now in use.

The search for a useful anorectic agent is further complicated by the fact that an effect is sought on a singularly human trait, the tendency to overeat. The abnormal drive for food in man with its symbolic overtones and its psychologic complications may not be satiated by amounts of food which ordinarily satisfy the appetat drive, a pathologic situation not duplicated in the laboratory animal. Since the special communication necessary to indicate the pure anorectic state sought is not within the capacities of the laboratory animal (although we sometimes can distinguish nausea in the cat and dog), simple anorexia without nausea or other distress which may distract the appetite cannot be determined or explored in the laboratory animal. While it is a fact that by damaging the brain some laboratory animals have been made to overeat, this does not correspond to the situation in the obese patient who overeats with an undamaged and so far as we know a functionally normal brain.

Most of the reports of studies of the anorectic drugs on the drug market based on animal experimentation uniformly indicate decreased food intake and loss of weight. In these instances however not only is it impossible to compare the dosage used in the animals with that which may be used with safety in man but it is also impossible to compare the biologic effects induced or to say what minor distresses the animal might have suffered to induce the anorexia. Since anorexia in the animal may well mean something other than what is sought in man regardless of apparently desirable or meaningful effects in animals, only the experiment in man provides the final answer to the complex issues involved in the relief of obesity in man.

even new but, in the case of Benzedrine, is perhaps not overshadowed by other dramatic pharmacologic actions and hence is more obvious. At present in the same group of drugs there are also dextro amphetamine (Dexedrine), metamphetamine (Desoxyn and about 30 other proprietary names), phenylpropanolamine (Propadrine), phenmetrazine (Preludin), phenylbutylamine resin (Ionamin), diethylpropion (Tenuate, Tepanil) and Levonor (levo amphetamine alginate), which are promoted and used clinically as anorexiant. (Despite disclaimers in advertisements it is easy to demonstrate that all really belong to the same pharmacologic group of drugs as Benzedrine.)

As explained previously, it is by no means definite that these drugs have any primary effect on the appetite at all and there is a strong suggestion that they may assist in the reduction of weight through other and entirely different pharmacologic actions in the central nervous system. There is reason to suppose that the anorectic effect is due to an action on the higher centers rather than on any appetite control center situated lower in the central nervous system, e.g. patients who have bulimia after frontal lobotomy are not affected by these drugs.

In varying degree all the amphetamine like drugs induce central stimulant effects: wakefulness, increased mental and physical activity and in some instances excitement and agitation. Many patients clearly experience a 'lift'. Nor can these be properly termed side effects if it is the cephalotropic action that is the basis of their effect in obesity and if it is due to a sense of well being and elation that subjects under an emotional drive which makes them overeat are better able to accept dietary restrictions. There has been described as well a loss of acuity of olfactory and gustatory sensibility which may be an additional factor in the so-called appetite depression. The amphetamine like drugs are of no value for the night eating syndrome since their action to induce insomnia contraindicates their use late in the evening or before retiring.

Although there have been some deaths from these drugs in general they are not dangerous and relatively few cases of acute poisoning or serious reactions have been reported as the result of their large scale and continued use. Aside from the indirect consequence of prolonged insomnia the most serious complication is dependence. On the other hand tolerance may develop so that such effects as they may induce are likely to be relatively short lived while in order to continue the effects doses must be increased, a procedure which tends to increase disagreeable side effects especially nervousness and insomnia. The drugs therefore are not useful for prolonged therapy.

As sympathomimetic amines the effects on the cardiovascular system are important. A rise in blood pressure and the tendency to palpitations are often matters for serious consideration. Aside from the probable high incidence of such effects from Benzedrine (amphetamine), there is little to choose among the others and in them a proper fitting of drug and patient often has to be made by trial and error on an individual basis.

The history of most of the drugs listed below is remarkably similar—a wave of enthusiasm for it followed by a wave of enthusiasm for the next newcomer to the same series.

The fact that the sensations produced in the central nervous system by the modern anorectic drugs are very impressive is of importance to patients anxiously seeking a crutch to help them lose weight. That they appreciate some sensations after taking a drug proves to them that they are getting medical assistance. This crutch therefore means more to them than the mere taking of an inert placebo—in this case an *ert* placebo seems to have special ancillary pharmacodynamic actions worthy of further study.

The effect of the so called anorectic drugs on the psychic state of the obese patient has not been examined carefully in the case of the more recently introduced members and while such an action is disclaimed or by implication denied the high incidence of wakefulness and other central nervous system stimulant actions strongly suggests that such an action may be a regular if not the only important one. Should these drugs provide the sort of lift for which amphetamine has long been used it may indeed be a bulwark for the obese and provide a substitute for overeating. It may also explain the limited value of these drugs.

There are other interesting implications in one of the effects on the central nervous system which have been reported. There is clear evidence, in animals as well as in man that beyond a certain norm decreased physical activity increases appetite and vice versa increased physical activity decreases appetite. This applies to the obese person as well as to the thin person. Increased activity is the common symptom often termed a side effect of the anorexigenic drugs. It may well be therefore that in addition to the calorogenic effect of increased physical activity due to these drugs there is decreased intake as a concomitant and if this is so the anorexiants may be associated with a weight loss through a central stimulant action rather than a primary anorexic action. Stunkard has indicated that limited physical activity may be a more important feature of obesity than is generally appreciated and it may be that this is an important action of these drugs in some weight loss studies and that the primary effect on the appetite center so many prefer to ascribe to them is of little importance.

## THE SEVERAL DRUGS

### Amphetamine like Drugs

There is an erroneous but widespread impression that amphetamine sulfate (Benzedrine) was the first of a series of anorectic drugs leading to the development of the most recent analogue diethylpropion (Tenuate, Tepanil). As far back as 1889 tetrahydrobetanaphthylamine was synthesized and was soon recognized to have both sympathomimetic and cephalotropic as well as calorogenic actions. Because of toxic effects, interest was lost in "tetra," and even though some work with the drug continued into the first decade of the twentieth century, the similarity in its actions and structure to the recognized sympathomimetic amines was generally ignored.

The cephalotropic action of the amine drugs closely related to epinephrine and ephedrine was early recognized as a complication of their clinical use. Despite this, in the case of amphetamine, this action was emphasized as both a new and a unique one. It is now abundantly clear that this action is neither unique nor

flood of publications on the results of trials with a new drug. Like the reports for the others they indicate that phenmetrazine is an effective anorectic agent. Some publications indicate that soon (30 minutes) after administration many patients appreciate cephalotropic actions. This vitiates any attempts at placebo and double blind controls and strongly emphasizes the psychic factor in the apparent results from the drug. Phenmetrazine appears to have little or no important effect on the cardiovascular apparatus. Whether its apparent desirability is due to its relative impotence or because of a specific action remains to be demonstrated. Despite statements to the contrary, Preludin belongs to the amphetamine group of drugs.

**Phenylbutylamine Resin (Ionamin)**—Through exchange with electrolyte the resin releases phenylbutylamine, an amphetamine congener, in the gastrointestinal tract. All systemic effects, therefore, stem from an amphetamine like action. There is too little experience with this agent for a final evaluation of its position in the therapy of obesity.

**Diethylpropion (Tenuate, Tepanil)**—This amphetamine congener has just been put on the commercial drug market. There is insignificant evidence published thus far but no reason to hope that it is at all superior to dextro amphetamine.

**Summary**—Largely because the problems involved have not been dissected and because the probable role of the sympathomimetic amines in the treatment of obesity has not been defined, there is no clear basis for indicating which of these drugs for whatever it may contribute is the best. It is reasonable to suppose however that, since elevation in blood pressure and cardiac acceleration are not useful in any case and may sometimes be harmful, levo amphetamine sulfate and phenylpropanolamine are clearly the least desirable. The history of these agents is that notions of superiority regularly disappear with accumulating experience but as matters now stand, it may be taken that dextro amphetamine is probably the most desirable of the lot.

### Calorigenic Agents

About 25 years ago, dinitrophenol which increased metabolic rate without inducing the sensation of heat commonly complicating the use of thyroid materials had a brief period of trial. Weight was lost by many who tried it but because of the report of the development of cataracts, the use of the drug was abruptly discontinued. No drug with similar calorigenic effects is now in use.

**Thyroid and Related Materials**—It has long been recognized that increased thyroid activity causes loss of weight despite increased ingestion of food. This seems to provide an approach to the treatment of obesity which avoids the difficult problem of depressing the appetite of the obese, and, with this aim in view thyroid materials have been used in obesity. Unfortunately, unless deficiency in thyroid function is the basis for the obesity the approach ultimately fails. And it fails just as frequently, whether the old fashioned desiccated thyroid or the newest form liothyronine (Cytomel) is used. Neither is recommended nor is any intermediate between the two. In addition to their over all ineffectiveness the thyroid materials may lead to intense nervousness, insomnia, discomfort due

**Amphetamine (Amphate, Bar Dex, Benzedrine, Dietamine, Monophos, Pro-fetamine, Racephen, Rapphetamine)**—The cardiovascular effects of this drug (racemic and levo forms) are likely to be disturbing; therefore amphetamine has limited value in obesity and is rarely used today.

**Dextro Amphetamine (Dexedrine)**—This agent which is the dextrorotatory form of amphetamine differs from the racemic and levo forms in that while the cephalotropic actions are well developed the cardiovascular effects are much feebler. This relative segregation of effects makes this the more desirable where as in obesity the cephalotropic actions alone are needed. This also serves to emphasize the importance of the cephalotropic actions of these drugs in obesity.

**Levo Amphetamine Alginate (Levonor)**—The alginate of the levo amphetamine is so much feebler with respect to both cephalotropic and cardiovascular actions than amphetamine sulfate that the doses used are virtually if not entirely inert. This is due to the fact that the alginate comprises the bulk of the molecule so that a 5 mg tablet of Levonor contains only about one third as much amphetamine as a 5 mg tablet of the sulfate of amphetamine. It is the most recently introduced weight reducing product and therefore there is little clinical experience to indicate whether this reduction in potency has any advantages over that which could be obtained with a proportionate downward adjustment in dosage of the sulfate of amphetamine. It is our opinion that in the doses recommended there is little difference between this agent and a placebo.

**dl Amphetamine Resin Complex (Biphphetamine Resin)**—The complexing of dl amphetamine with resin may prolong its action. Whether it also segregates the cardiovascular from the cephalotropic action is doubtful and on this basis it would not appear to have any special pharmacodynamic advantage. Whatever action it has tends to be prolonged and therefore should it be demonstrated to have useful effects it could probably be given less frequently than dl amphetamine.

**Methamphetamine**—The only feature which distinguishes this analogue of amphetamine from amphetamine itself is the exceedingly large number of trade names under which this material is sold: namely Amphetroxyn, Apamine, Deofed, Desamine, Desovedrine, Desovo 5, Desoxyephedrine, Desoxyn, Desyphed, Detrex, Dexoval, Dextum, Dexoval, D O E, Doxyfed, Drinalfa, Efroline, Lanazine, Methamplun, Methedrine, Methoxyn, Miller Drine, Norodin, Oxyfed, Oxydess, Premodrin, Normadrine, Norodin, Semoxadrine, Stimdex, Syndrox. There is no evidence that its action differs from that of amphetamine in any way except that the action on the cardiovascular system is somewhat less intense and the action on the central nervous system is somewhat more intense.

**Phenylpropanolamine (Propadrine)**—The vasoconstrictant action of this drug tends to elevate blood pressure and thereby limits its usefulness in the treatment of obesity. While it is used in over the counter remedies for obesity such as Regimen tablets, Du Dol and B 121 the amount of phenylpropanolamine which they contain is too small to exert any pharmacologic effect at all.

**Phenmetrazine (Preludin)**—More has been written recently about this agent than any of the others in the group less because of real superiority than because of timing. The interval since introduction is just right for the appearance of a

with weight loss. It is agreed by those who recommend them that, however they are used and however they may work, they should not be taken for a prolonged period but rather as an adjuvant to a restricted diet in the early stages of the weight-losing regimen. There are others who take the view that the assistance these drugs provide may make it even more difficult for the obese to keep to the proper diet after the drug is discontinued. The best compromise between these two views is to use the drugs in effective doses for a short period (i.e., in doses which induce the cephalotropic effects which probably account for any action which they may exert indirectly on the appetite) and, having accomplished some weight loss with such a program, to discontinue the drug and continue with a maintenance diet. At the same time the basic psychologic trouble must be dealt with.

It is well to remember that the anorectic drugs in current use do not have the kind of depressant effect on the appetite which will keep the obese from overeating. It is necessary, therefore, also to prevent patients who are taking these drugs from overeating by some other mechanism, usually a rigidly enforced low calorie diet.

### WHAT IS NEEDED IN A NEW ANOREXIANT

What is needed in anorectic drugs is not another version of a drug which distracts the appetite of the obese person indirectly by means of a stimulant action on the central nervous system, but one which depresses the appetite control mechanism directly, that is to say, a truly specific pharmacologic anorexiant. Investigations of such a drug action would probably be better carried out in subjects with normal appetites than in those with the abnormal, complicated, and poorly understood appetite drives of the obese person.

What is needed is a drug which will keep the patient from eating too much when too much is available, not one which must be used in conjunction with food restriction. This, of course, is a clear indication of the inefficiency of the drugs now used for appetite control.

What is wanted is a drug which, when it does depress appetite, neither makes the obese patient ill nor deprives him of the emotional comfort which overeating provides. Unless it gives him a substitute comfort, there is certain to be a high incidence of emotional reaction to the regimen itself.

What is needed, therefore, is a therapy rather than a drug which with considerable specificity, corrects the psychic disturbance in the obese person which upsets his "appetate." As matters stand, no drug is available which provides it and, in its absence, it seems clear that, regardless of its expense and relative difficulty, for most patients the best approach to obesity is some form of psychotherapy. The best results (about 50 per cent improvement) have come with such methods. Since there are many symptoms they suffer in common it would seem that group therapy through an organization similar to Alcoholics Anonymous might provide the best hope for the obese person.

### SELECTED REFERENCES

- Brobeck, J. R. Neural Factors in Obesity, *Bull. New York Acad. Med.* 33: 762, 1957.  
 Brosin, H. W. The Psychiatric Aspects of Obesity, *J. A. M. A.* 155: 1238, 1954.

to the calorigenic effect excessive perspiration and palpitations. A recent publication apparently favoring the use of liothyronine examined only the effects of a combination with amphetamine hence it provides no support for the use of liothyronine alone.

### Central Sedation

Inasmuch as obesity often is an expression of some emotional disturbance which may be aggravated by attempts to restrict the intake of food it is not at all surprising that central sedation and tranquilization can sometimes assist in the weight loss regimen. If sedation is intense enough to dull mental acuity or induce a degree of sleepiness the appetite drive will be depressed along with other centrally controlled functional activities. There is evidence in a study by Ressler that tranquilizing doses of chlorpromazine (Thorazine) (and therefore presumably also of its congeners) may be effective in weight loss. Unfortunately the study by Ressler is uncontrolled. Sedation and tranquilization may be effective in the case of the night eating syndrome.

### Bulk Producers

Methylcellulose a nondigestible but otherwise harmless bulky material has been suggested as an appetite satiator for the treatment of obesity. This has proved to be no more effective a device for the treatment of obesity than the high residue low calorie diet itself. Apparently what the obese want to eat is genuine food the solution is not simply a matter of distending their stomachs with indigestible matter until they can eat no longer.

## THE CHOICE OF AN ANOREXIANT

The more important decision than the choice of an anorexiant is whether to use such a drug at all. All investigators even those who approve of the use of the anorectic drugs agree on the psychologic reasons for obesity in the patients for whom these drugs are designed. That being so there is clearly no cure for obesity in the drugs at the very best they provide only a temporary crutch during a brief initial period of dietary restriction. Any assistance the medication provides during this period is to be weighed against the letdown the patient suffers when his crutch is removed and he has to face the rigors of dietary restriction while suffering an abnormal appetite drive.

Under these circumstances the drug of choice is the one which causes the fewest side effects. It would appear that of all the drugs in common use all of them presently belonging to the amphetamine group dextro amphetamine (Dexedrine) seems to be the least likely to induce cardiovascular effects. On the other hand it does not seem likely that the cephalotropic actions can be divorced from any value these drugs may have in obesity.

## REGIMEN FOR THE USE OF ANOREXIANTS

There is evidence albeit not entirely convincing that the use of certain anorexiants all congeners of amphetamine (Benzedrine) is regularly associated



## THE CHOICE OF DRUGS FOR GASTROINTESTINAL DISTURBANCES

Thomas P. Almy, M.D., and

Herman Steinberg, M.D.

---

### THE CHOICE OF AN ANTISPASMODIC

#### Introduction

The term *antispasmodic* is applied to any of a large group of drugs used for the purpose of diminishing motor and secretory activity in the gastrointestinal tract and other structures supplied with excitatory cholinergic nerve fibers. These properties are found in the natural alkaloids of belladonna, one of which, atropine, is generally used as a standard of reference for the potency of all compounds both natural and synthetic. In the last 20 years a large number of compounds have been synthesized which have similar properties. As will be emphasized below, the term antispasmodic is a misnomer, and the adjective *anticholinergic* more truly defines the important action of these drugs.

#### Clinical Applications

**Duodenal Ulcer**—In this disease the rapid emptying of the stomach and the excessive and continued secretion of hydrochloric acid and pepsin are to a large degree dependent upon vagal stimulation. This is especially true of the *interdigestive* and particularly *nocturnal* activity of the stomach. For these reasons a "medical vagotomy" by an anticholinergic drug is a valuable part of the therapeutic program. As the sum of the stimuli they must oppose is much reduced at night, they are much more effective when given at bedtime than during the day and they can virtually replace all other methods of control of night secretion in most patients with acute duodenal ulcer.

In ulcer with *obstruction*, however, these drugs exaggerate gastric retention and through release of gastrin from the gastric antrum tend to aggravate hypersecretion. Thus in the presence of obstruction they are contraindicated.

Because extraneural stimulation of the stomach (as by gastrin) is not affected, peptic digestion is seldom completely halted by such a drug, and diet and antacids should still be given. As the most potent effect of an anticholinergic upon the

- Bruch H Role of the Emotions in Hunger and Appetite *Ann New York Acad Sc* 63 68 1955
- Fazekas J P, Ehrmantraut W R and Kleh J A Study of the Effectiveness of Certain Anorexiants *Ann New York Acad Sc* 63 121 1955
- Gadek F *Ann New York Acad Sc* 63 121 1955
- Grossman *Ann New York Acad Sc* 63 121 1955
- Hamburger *Ann New York Acad Sc* 63 121 1955
- Harris S G Clinically Useful Appetite Depressants *Ann New York Acad Sc* 63 121 1955
- Leake C D *Ann New York Acad Sc* 63 121 1955
- Lesses M *Ann New York Acad Sc* 63 121 1955
- Mayer J *Ann New York Acad Sc* 63 121 1955
- Modell A *Ann New York Acad Sc* 63 121 1955
- Quigley *Ann New York Acad Sc* 63 121 1955
- Ressler C Chlorpromazine Therapy in Selected Cases of Obesity *New York J Med* 57 1607 1957
- Ressler C Treatment of Obesity With Phenmetrazine Hydrochloride A New Anorexiant *J A M A* 165 135 1957
- Stunkard A J Untoward Reactions to Weight Reduction Among Certain Obese Persons *Ann New York Acad Sc* 63 4 1955
- Stunkard A J Physical Activity Emotions and Human Obesity *Psychosom. Med* 20 366 1958
- Stunkard A J and McLaren Hume, M The Results of Treatment for Obesity *A M A Arch Int Med* 103 79 1959
- Tepperman J Etiologic Factors in Obesity and Leanness *Perspectives Biol & Med* 1 293 1958
- Williams R H Daughaday W H Rogers W F Jr Asper S P Jr and Towery B T Obesity and Its Treatment With Particular Reference to the Use of Anorectic Compounds *Ann Int Med* 29 510 1948

shown to have impressive potency. Under clinical conditions the results of their use have been *less striking*, apparently because the neural stimuli they must counteract are more intense and because the effective dose in man is less exactly measured.

Disappointments in their use have resulted also from failure to recognize two types of disturbed motor and secretory function of the intestines, which require separate means of control: pure *hyperfunction* in normal rhythmic pattern and *dysrhythmia*. Hyperfunction, exemplified by *nervous diarrhea* and by *hypersecretion* and rapid emptying of the stomach associated with duodenal ulcer, can be related to excessive cholinergic stimulation, and can be at least partially controlled by *anticholinergics* in adequate dosage. *Dysrhythmia* or *spasm*, on the other hand, represents a disturbed *pattern* of function, with excessive nonpropulsive motility at one or several points. This occurs transiently as a result of neural stimulation integrated in the central nervous system (as in nausea or in "mucous colic"). It also develops and remains permanently as a result of absence or degeneration of the ganglia of the myenteric plexus, which is essential for the propagation of peristalsis (as in *cardiospasm*, *congenital pyloric stenosis* or *congenital megacolon*). In neither of these circumstances is an anticholinergic drug effective, unless it abolishes *all* motor activity. It cannot be expected, by virtue of its peripheral locus of action, to restore a normal *pattern* of function.

**Untoward Effects**—The use of effective doses of these compounds in intestinal disorders is accompanied by side effects such as dryness of the mouth and nose, flushing and dryness of the skin, cycloplegia, tachycardia, and urinary retention. These are the results of blockade of cholinergic impulses to other structures (salivary glands, ciliary muscle, heart, and bladder) and thus parallel in degree the desired effects on intestinal muscle and glands. Despite many claims to the contrary, there is *insufficient evidence* that in man any of the available drugs of this class regularly produces a satisfactory blockade of the intestine in the absence of these side effects. It therefore seems desirable to use the more minor of these toxic symptoms as indications that an effective dosage has been achieved. In patients with bladder neck obstruction these drugs are contraindicated because effective dosage invites serious disturbances of vesical function.

### The Several Anticholinergic Drugs

The important anticholinergic agents include both the natural alkaloids of belladonna and a variety of synthetic substances more or less closely related in chemical structure. All are substituted amines, while the more active belladonna alkaloids are tertiary amines, the majority of the useful synthetic agents have a quaternary structure. The more useful agents are grouped below.

**The Belladonna Alkaloids**—Two of these preparations are of lasting value.

**TINCTURE OF BELLADONNA**—One milliliter contains approximately 0.3 mg of mixed alkaloids and anticholinergic effects, lasting 3 to 4 hours, are obtained with 1.5 to 3 ml in the adult patient. This permits nice adjustment of the dose. The preparation, being a crude one, is quite inexpensive but can only be given orally. It is thus of maximum value for chronic administration to ambulatory patients.

stomach is to reduce its motility and as smooth muscle tension is at least a major factor in the causation of ulcer pain such a drug may abolish ulcer pain while peptic autodigestion continues. Presumably as a result of this, painless hemorrhage and acute perforation without premonitory distress have been reported during therapy with anticholinergics.

**Peptic Ulcer at Other Sites**—In marginal (gastrojejunal) and in esophageal ulcer the application of anticholinergics is essentially the same as in duodenal ulcer. In gastric ulcer the influence of vagal stimulation on the stomach is less important than that of the gastrin mechanism and interdigestive secretion and motility are usually low. For these theoretical reasons, anticholinergics are less clearly indicated than in duodenal ulcer and may actually increase the level of gastric secretion through promoting antral stasis as in an obstructed ulcer. Anticholinergic drugs are recommended only in those cases of gastric ulcer that have a demonstrated high level of acid secretion and rapid gastric emptying.

**Pancreatitis**—In acute pancreatitis and in those phases of acute pancreatic injury which punctuate the course of chronic pancreatitis the gland is affected in two ways by cholinergic stimuli. Direct vagal stimulation of the pancreas augments its secretion particularly of enzymes and concomitant hypersecretion and hypermotility of the stomach may lead through sustained acid stimulation of the duodenal mucosa to excessive production of secretin. As pancreatic damage develops rapidly and the patient is usually nauseated or vomiting parenteral use of an anticholinergic drug in large dosage is indicated.

**Diarrhea**—Diarrhea associated with functional bowel disorders (called adaptive colitis irritable colon or mucous colitis) is probably related to excessive cholinergic stimulation of the bowel; indeed it has been reproduced experimentally with acetylcholine and methacholine. Anticholinergic drugs are thus useful and rational adjuvants to the needed psychotherapy in these patients. Where diarrhea is associated with true inflammation of the bowel wall (e.g. ulcerative colitis, or salmonella enteritis) they are largely ineffective. Their use is not recommended in the malabsorption syndrome and in the postgastrectomy ("dumping") syndrome, where they are not helpful and absorption may be further impaired by their use.

**Spasm**—As explained further below anticholinergic agents may not be expected to relieve spasm at various sites unless given in sufficient dosage to terminate all normal motor and secretory activity in the intestine. An exception may be made of some examples of spasm associated with absent or degenerate ganglia—thus the painful incoordinated contractions of the body of the esophagus in some patients with cardiospasm can be relieved by these drugs.

### General Pharmacologic Considerations

The important mechanism of action of these drugs is metabolic competition with acetylcholine at the postganglionic nerve endings in intestinal muscle and glandular acini and to a lesser extent in the ganglia of the intestinal wall thus effecting a partial blockade of extrinsic neural stimulation. Under the usual conditions of testing of these drugs in the experimental animal utilizing isolated loops of intestine or intact anesthetized animals a great many compounds have been

dry at least part of the time. Such a round-the clock regimen, the same dose being given before each meal and at bedtime, is useful in all of the clinical applications outlined above, if oral medication is possible. In acute pancreatitis the same result is achieved by parenteral administration at 4 hour intervals.

In other situations it is wise to give a larger dose at that time of day when the drug will be most useful, or even confine the use of the drug to that time. In active duodenal ulcer the drug may not be needed during the daytime hours of frequent feedings and interval alkali but will be most useful when given at bedtime. During the night it acts to reduce interdigestive secretion in the stomach and to prolong the buffering action of the bedtime feeding by retarding gastric emptying. Also, adequate doses may not be acceptable to ambulatory patients during the day because of intolerable dryness of the mouth or especially blurring of vision whereas the occurrence of these in even greater degree during the hours of sleep may pass virtually unnoticed. In patients with functional diarrhea the most frequent and urgent bowel movements occur from 1 hour before arising to about 2 hours after breakfast. Such patients may be advised, for example, to take a large dose at 5:30 A.M. without getting out of bed, and then try to go back to sleep. During the remainder of the day no medication may be necessary.

No patient should be given an anticholinergic drug without precautions against the risks of acute glaucoma, bladder neck obstruction, and toxic psychosis. The history should be reviewed for delirious reactions to drugs, eye pain, conjunctivitis, changes in refraction and urinary frequency. The tension of the eyeballs and the size and shape of the prostate should be determined by palpation before the drug is given. Each patient should be seen a few days later in order to detect early any dangerous effects.

### Rational Basis for New Anticholinergic Drugs

The numerous anticholinergic drugs in current use have been prepared largely for the purpose of escaping the unpleasant side effects of atropine, methantheline, and other potent compounds. This has not been achieved except in minor degree yet there are many who believe that pharmacologic action is so specifically related to chemical structure that compounds can some day be prepared which act upon cholinergic nerve endings in the intestine but not in the bladder, the salivary glands and the eye. Such specificity would certainly be desirable if achievable.

The other limitation of presently available anticholinergic drugs is that in order to combat excessive secretion and motility the dose must be large enough virtually to abolish normal cyclic or rhythmic activity. Thus diarrhea is unlikely to be controlled without producing intestinal stasis, and this is probably due to the site of action of these drugs, at the periphery of the autonomic nervous system. True antispasmodic activity, in which normal cyclic activity is restored, can probably be obtained with drugs acting upon the integrating centers in the central nervous system. The only known example of such activity is that of the antiemetic drugs (see page 325) which abolish the duodenal spasm associated with nausea and permit a return to normal rhythmic motility. Study of other drugs capable of depressing cerebral visceromotor centers may uncover useful agents which more nearly satisfy the desiderata of 'antispasmodic' action.

**ATROPINE**—In tablets of 0.5 mg, the pure alkaloid can be given in doses of 0.5 to 2 mg orally or subcutaneously to produce varying intensities of anticholinergic effects lasting 3 to 6 hours. The dose is less easily adjusted than with tincture of belladonna and hence atropine is not as useful in the management of milder, chronic gastrointestinal syndromes, such as irritable colon where toleration of side effects must be considered. In patients with more severe and acute illness (e.g. penetrating duodenal ulcer, or pancreatitis) the severity of side effects is less important, and the more prompt and dependable action of the pure alkaloid particularly when injected hypodermically makes it more desirable.

None of the other preparations of belladonna or its alkaloids find widespread use as systemic anticholinergics.

**The Synthetic Anticholinergic Drugs**—These compounds mostly quaternary amines have appeared in large numbers in recent years. Most of them combine the postganglionic anticholinergic activity of atropine with some degree of ganglionic blockade. The vast majority have well demonstrated potency in experimental animals. A number of them have been shown by objective testing in man to inhibit motility and secretions of stomach and intestine more strongly than atropine when given in doses producing comparable dryness of the mouth, blurring of vision and other side effects. For this reason they are preferable to atropine for most gastrointestinal indications in spite of considerably greater cost. There are considerable differences in the amount and quality of clinical experience and physiologic study in man on which are based the recommended doses of the various drugs. These are the main factors on which from the literally enormous list of anticholinergic drugs available the following selections are given in the order of preference.

**METHANTHELIN**—Doses of 50 to 100 mg of methantheline (Banthine) give moderate to full effects lasting 3 to 6 hours. It is also available for parenteral use the recommended dose being 15 to 25 mg intramuscularly, for effects lasting 2 to 4 hours.

**PROPANTHELIN**—Doses of 30 to 45 mg orally of propantheline (Pro-Banthine) give effects comparable to 50 to 150 mg of methantheline. It is also available for parenteral use the recommended dosage is 10 to 20 mg.

**TRIDIMETHID**—The dosage of tridimethide (Pathilon) is from 25 to 50 mg given orally. A parenteral dosage form is also available.

### A Design for the Use of Anticholinergic Drugs

If these drugs are to be used not as placebos but for their specific pharmacodynamic effects they must be used in doses sufficient to dry the mouth or produce other minor toxic effects. There is no other way of being sure that an adequate dose has been given. Because the adequate dose varies with the current intensity of cholinergic stimuli it may be expected to vary from time to time.

For these reasons it is desirable to begin continuous therapy with such drugs by using a moderate dose (e.g., tincture of belladonna 20 drops or methantheline 50 mg) and to increase the dose stepwise each time the drug is given until minor toxic effects are noted. If these are intolerable the dosage level may be set slightly lower but thereafter frequent changes may be required to keep the mouth

physical coating may play a role in their total protective effects against acid it would seem best to judge these compounds on the more readily measurable basis of buffering or neutralizing capacity

With the more absorbable compounds, the true alkalis, antacid effects are usually achieved at the price of some degree of alkalosis and expansion of the extracellular fluid compartment. The alkalosis is due not only to the absorption of cation (usually sodium) from the antacid but also in some instances to the loss of chloride through vomiting. Symptoms include anorexia, nausea, irritability, ocular headache, muscular aches and tetany. In chronic alkalosis with persistently alkaline urine the solubility of calcium and phosphorus is reduced and phosphatic renal calculi may form. In other patients renal function is impaired, calcium excretion is depressed and hypercalcemia develops with attendant manifestations of hypertension, pruritus, band keratopathy, conjunctival crystals, and calcinosis elsewhere (the Burnett syndrome). In more acute alkalosis for which vomiting and antacid use are jointly responsible, paralytic ileus and mental disturbances are common. Especially when hypokalemia is associated, serious and sometimes fatal disturbances of electrical conduction may occur in the heart. Because of these dangers and because the true alkalis provide only very transient buffering of the gastric juice, their use in the management of peptic ulcer and allied disorders is not recommended.

By comparison the dangers inherent in the use of poorly absorbable antacids are quite minor. Some of the magnesium compounds (especially  $MgO$ ) may yield enough absorbable magnesium ion to accumulate in the extracellular fluid and cause cerebral depression. This is rarely significant unless renal function is markedly impaired. Magnesium salts are, of course, laxative agents, while calcium and aluminum salts often cause an obstinate constipation. These difficulties can usually be overcome by simultaneous use of compounds of both groups. Aluminum hydroxide binds phosphate in the intestine in large amounts but depletion of total body phosphorus is easily avoided by feeding 750 mg or more of dietary phosphorus per day—an amount readily exceeded in the usual diets for patients with ulcer.

### The Several Antacids

**Freely Absorbable Antacids**—Of the freely absorbable antacids, the only substance in common use is sodium bicarbonate. For the occasional relief of simple indigestion the powder may be taken in doses of 1 Gm ( $\frac{1}{2}$  tsp) in half a glass of water. Most proprietary preparations for the relief of nonspecific gastric distress add nothing to sodium bicarbonate except color, flavor, and expense. The combinations of sodium bicarbonate with magnesium oxide and with bismuth subcarbonate or calcium carbonate (Sippy powders or tablets) are still widely used in the treatment of peptic ulcer but because of their short duration of action and the attendant dangers of alkalosis they are not recommended.

**Poorly Absorbable Antacids**—The poorly absorbable antacids may be classified as follows:

#### INORGANIC SALTS WITH CONSTIPATING ACTION—

**Aluminum Salts** The most satisfactory and most widely used is aluminum hy-

## THE CHOICE OF AN ANTACID

### Introduction

Several kinds of therapeutic agents are widely used for reducing or neutralizing the acidity of gastric juice. This is quite important in the treatment of peptic ulcer, gastritis, hiatus hernia, and pancreatitis, but of little value in other conditions. Their rational use depends upon an understanding of the pattern of secretion of hydrochloric acid in these conditions, and the role of acid in their pathogenesis.

### Clinical Applications

In *peptic ulcer*, *gastritis*, and *peptic esophagitis*, antacids are used for the specific purpose of inactivating pepsin. This is accomplished by buffering the gastric contents to a pH of 4.0 or higher. Actual neutralization is unnecessary, and further it is undesirable, because at pH 7.0 or over the stomach empties more rapidly, sweeps the antacid out of the stomach, and terminates its useful effect. The buffering of acid should be almost continuously effective over days, weeks, or months, and to this end the agent used should be active as long as possible after a single dose, should be palatable and convenient to take, should be free even of inconvenient side effects, and should be relatively inexpensive. For these needs the compounds of aluminum and magnesium are best suited.

In *acute pancreatitis* the buffering of the free acid of the gastric contents serves to diminish the secretion of the pancreas, by reducing the acid stimulus to the secretion mechanism.

The relief of *ordinary indigestion* or epigastric fullness is a trivial but very common application of antacids. This sensation, apparently due to distention of the stomach by swallowed air in the presence of delayed gastric emptying, is well relieved by sodium bicarbonate and other mild alkalis. Their action is apparently twofold—distention of the stomach is first increased by evolution of carbon dioxide, then abruptly decreased by eructation of gas, and alkalinizing the gastric contents hastens its evacuation into the duodenum. As only the occasional relief of this symptom, without removal of the underlying cause, can be sanctioned, the use of absorbable alkali is permissible.

### General Pharmacologic Considerations

None of these agents interferes with the production of hydrochloric acid, they act only to combine with it, or otherwise modify its effects, after it is formed. The usual mechanism of action is chemical neutralization, which has been amply demonstrated both *in vivo* and *in vitro*. For many of the nonabsorbable compounds, *in vitro* studies indicate a strong capacity to adsorb hydrochloric acid, but the evidence that this is important *in vivo* is scant. Likewise, many of these agents in colloidal suspension form a tenacious coating, physically very much like mucin, over the surface of a beaker or of the mucosa of the resting stomach. In the presence of copious acid secretion, however, the material flocculates and this physical protection is apparently lost. Without denying the possibility that adsorption and



that the patient be fed hourly when awake and given antacid (e.g., 8 to 12 ml of a mixture of aluminum hydroxide and magnesium hydroxide) one half hour after each feeding. During the first few nights of treatment, the patient should be awakened every 2, 3, or 4 hours for a small feeding (120 ml) of milk and cream alternating with a dose of antacid. After this, especially if an anticholinergic drug is given at bedtime (page 356), nocturnal feeding or medication should be given only when awake. After 2 to 7 days of freedom from pain and active bleeding the patient should be advanced to the "6 feeding" regimen described below.

In most patients with gastric ulcer, hiatus hernia with or without peptic esophagitis, and pancreatitis, the stomach does not empty so rapidly and its nocturnal secretion is not as large as in duodenal ulcer. This permits the immediate adoption of the 6 feeding regimen, in which a well balanced diet is fed in 3 regular meals plus snacks at midmorning, midafternoon, and 1 hour before bedtime. Fifteen to twenty milliliters of an antacid mixture is given 60 to 90 minutes after each feeding. The timing of the several feedings and doses of antacid is of prime importance. In the hospital, whether or not a shortage of nurses exists, the patient himself should help prepare, follow, and record a time schedule, under nursing supervision. While at home and at work, responsibility for the schedule may be shared by members of the family and office associates or an interval timer may be used.

*It should be emphasized that this regimen is designed mainly to control peptic autodigestion and to permit existing ulceration or inflammation to heal. That which is most impressive to the patient—the control of pain—is actually incidental and he will usually require strong persuasion to follow this routine for the several additional months after the disappearance of pain which are apparently required for maximum benefit. In most cases of duodenal ulcer, for example, which seem not to have been benefited by this regimen, it has been used for only brief periods and antacids have been given only for the relief of ulcer pain.*

In most cases the full regimen ought to be continued for 2 to 3 months after the control of all relevant symptoms and signs. This requires careful inquiry into the daily habits of the patient. A taxi driver, for example, is more likely to take antacids regularly if they are in tablet form than if they must be poured from a bottle. In tapering off the therapeutic routine, those doses of antacid given 1 to 1½ hours after the 3 regular meals should be omitted first, then the late morning and late afternoon doses, and finally the bedtime dose. Only after 6 months of complete control of symptoms are the interval feedings omitted.

Many patients cease to take their antacid because of constipation. Though this is not often a problem with the recommended mixtures of aluminum and magnesium, it is wise not to let any patient become constipated. Milk of magnesia (30 to 45 ml) should be added to the bedtime dose of antacid at the outset of treatment and continued each night until it is clear from the results achieved that neither this nor any smaller dose is needed.

### Rational Basis for New Antacids

The poorly absorbable antacid mixtures now available are nearly free of undesirable systemic effects such as alkalosis. They have little constipating effect, interfere

dioxide gel, which is available in liquid or tablet form. It has good neutralizing power, some coating and adsorptive activity, and relatively prolonged action. The aluminum ion has been shown to inhibit pepsin independently of any changes in pH. Aluminum phosphate, basic aluminum carbonate, and dihydroxy aluminum aminoacetate offer no special advantages as gastric antacids.

**Calcium Salts** Precipitated calcium carbonate provides neutralizing power almost as great as that of aluminum hydroxide and is much less expensive. Yet because of its disagreeable, chalky taste, and because of less clear evidence of adsorptive or coating actions, it is not to be recommended as highly. Other calcium salts are impractical.

**INORGANIC SALTS WITH LAXATIVE ACTION**—These are all salts of magnesium and two are of value.

**Magnesium Salts** Magnesium hydroxide has extremely high neutralizing power and prolonged action in the stomach. Magnesium trisilicate has considerably less potency for chemical neutralization but more value as an adsorbent and for its coating properties.

#### ORGANIC MATERIALS —

**Anion Exchange Resins** The anion exchange resins are efficient adsorbents but weak antacids. They cannot produce alkalosis or constipation but they are bulky to use, gritty and somewhat unpleasant to taste, and relatively expensive. For these reasons they are little used and are not recommended.

**Gastric Mucin** Gastric mucin, a partially purified alcoholic precipitate prepared from hog stomach, also eliminates the disadvantages of alkalosis, constipation or diarrhea which characterize the inorganic antacids. But because of low neutralizing potency, considerable bulk, and disagreeable odor and taste, it is not recommended.

**Choice of Antacids**—For all routine purposes of continued antacid medication, the salts of aluminum and magnesium are recommended. Despite a proper disdain for mixtures of drugs, we suggest it is better to give the constipating and laxative agents together, to free the patient from having to plan their alternate use. In order of preference (1) aluminum hydroxide with magnesium hydroxide, (2) aluminum hydroxide with magnesium trisilicate.

All are available in liquid form (dose, 8 to 30 ml) or as 0.5 Gm tablets (dose, 2 to 8). All tablets should be chewed and thoroughly mixed with saliva before swallowing, with or without small sips of water, to permit prompt and thorough mixing with the gastric contents.

#### A Design for the Use of Antacids

Even with the best of the antacids, the duration of action of a single oral dose is disappointingly short. To approach the goal of continuous buffering of gastric acid, they must be administered frequently. As dietary protein is also a valuable buffer, the antacid should be taken between the feedings, when the stomach is likely to have emptied itself of food.

This is the basis for the well established routines of multiple feedings and interval antacids in the treatment of peptic ulcer. In acute and unobstructed denal or marginal ulcer, the extremely rapid emptying of the stomach re-

serves rather to distort and hinder the re establishment of normal habits of defecation

When such chronic use of cathartics is abruptly suspended, 'withdrawal symptoms appear—bloating, anorexia, headache, giddiness fatigue, and mental depression. It is not clear to what extent these are reactions to stress and to what extent they are reflex responses of the irritable intestine to its unevacuated contents. In any case, they are relieved promptly by a tap water enema. This is known to cleanse only the distal colon, and thus of all the available artificial aids to elimination it most nearly approximates, in its results, a normal bowel movement.

Given control of the distressing symptoms, the lasting relief of cathartic addiction depends upon re establishment of the normal reflexes of defecation. At the segmental level, mass peristalsis is reinforced by large breakfasts, by ingestion of large amounts of fluid, and by administration of nonabsorbable hydrophilic colloids, such as synthetic hemicelluloses and those of psyllium seed and agar. These agents increase the bulk and water content of formed stools and render them easier to pass in the absence of abundant mucus. At the suprasegmental level, strong conditioning of the defecation reflex is favored by a regular time for breakfast and the toilet visit, a ritualistic program of administration of the colloid material and other measures.

**Bedridden Patients**—It has been pointed out how interruptions in the normal habits of living lead to transient constipation. Any illness severe enough to confine the patient to bed or to his home may have this result. In most acute illnesses there is reduction in intestinal motility (seen in extreme form in the distention which accompanies pneumonia or heart failure), and a lowered food intake with reduced gastrocolic reflexes. The bedpan, aside from its indignity and unfamiliarity obliges the patient to assume a very unfavorable position for defecation. The constipation which usually results unhappily complicates the patient's distress, is associated with anorexia and depression, and may lead to fecal impaction. Efforts to relieve it by straining at stool may result in protrusion of hemorrhoids worsening of a hiatal hernia, bleeding from esophageal varices, pulmonary embolism or myocardial infarction. Thus its efficient management is highly important.

Early in the course of such constipation, digital examination of the rectum usually reveals large quantities of soft stool. One may infer from this that the main trouble does not lie in reduced intestinal and colonic motility and that only the evacuation of the rectum need be artificially aided. For this the optimum management is an enema at 1 to 2 day intervals. When this is not feasible because of shortage of personnel or for other reasons one should use the mildest cathartic which produces the desired results. In order of preference, this should be an anthracene derivative, milk of magnesia, or a hydrophilic colloid.

Such cathartic administration during a period of acute illness is often the starting point for prolonged habituation to their use. The physician should take the responsibility of weaning the patient from cathartics during his convalescence.

**Anal Lesions**—In the presence of hemorrhoids, anal ulcers, or other inflamed lesions about the anus, constipation results at least in part from locally induced

only to a slight degree with normal digestion and absorption, and are reasonably palatable and inexpensive. Compounds of even greater neutralizing potency are needed, so that more adequate dosage can be given with a reasonable bulk. The most valuable improvement, however, would be in a preparation which by and of itself would remain longer in the stomach and would thus reduce or eliminate the need for frequent feedings, as in current regimens.

The inherent limitation of antacids is that they act only upon acid already produced, and their dosage is variably adequate, depending upon the level of acid production. Current research into the enzymatic mechanisms of the parietal cell, and especially the nearly complete arrest of acid secretion by large parenteral doses of a carbonic anhydrase inhibitor, indicates the future possibility of practical drugs for the control of acid production.

## THE CHOICE OF A CATHARTIC

### Introduction

Drugs have been used since time immemorial for the purpose of promoting defecation. Such agents are widely self-administered by lay persons. Whatever the psychological basis there is a durable attitude spanning many centuries and many cultures that associates excrement with evil and its elimination with the expiation of guilt. The practical result is that most people in our society still regard even transitory constipation as something to be directly and promptly treated with a cathartic. In the past the medical profession has abetted these tendencies by the empiric and nonspecific use of purgation in the treatment of systemic disease (even of the common cold) and has been slow to disown the theory of intestinal autointoxication. As a consequence, more patients now consult the physician because of the untoward effects of chronic use of cathartics than for any condition that can be relieved by them.

Much of the following discussion, therefore, concerns the temporary use of some cathartic agents as a means of weaning the patient from cathartic addiction. The remainder deals with the relatively limited conditions under which a cathartic should be prescribed *de novo*. In any of these situations in which the physician administers a cathartic he is obligated to have just as when he gives a narcotic agent some plan as to how the need for the drug can and will be terminated.

### Clinical Applications

**Cathartic Addiction**—The most common cause of chronic constipation, as a presenting complaint in office or clinic practice, is the habitual use of cathartics. This arises in most instances because the patient has an unduly rigid concept of the need for regular elimination which leads him to resort to laxatives for quite transient constipation. His use of increasingly potent drugs in the attempt to restore regular and predictable bowel movements leads to persistent overstimulation and irritability of the intestines. While the average spontaneous bowel movement empties only the rectum, sigmoid and perhaps the descending colon, that produced by a cathartic may include part or all of the fluid content of the proximal colon and even of the lower ileum. As a result the self-administration of cathartics, undertaken to ensure regularity of bowel movements, rarely accomplishes this and

tion is being corrected. In some of the milder cases of Hirschsprung's disease the extra stimulation afforded by them to the dilated, normally innervated proximal segment of the colon may assist it to force stool past the narrowed distal segment. The use of urecholine or methacholine and of enemas of physiologic saline is however, more widely practiced. In all of these situations the milder agents such as milk of magnesia or cascara sagrada should be used, and more drastic cathartics will not be justified by their results.

### General Pharmacologic Considerations

**Basis of Action of Cathartics**—The general level of intestinal propulsive activity is the product of the irritability of the bowel and the stimulus provided by its luminal contents. Most cathartics act either by increasing the volume of the luminal contents or by increasing the irritability.

1 Many useful agents act by *increasing the water content* and hence the bulk, of chyme and feces. These mechanisms are

a Osmotic, as in the common saline cathartic, in milder inorganic agents such as milk of magnesia, and in a number of natural foods with cathartic properties. Thus fruits and fruit juices are laxative, at least in part because of the osmotic activity of their sugars and organic acids. The effect of such agents is most marked in the upper small intestine, where the increased volume of contents sets up peristaltic rushes and ultimately reduces the time available for dehydration of the fecal mass in the colon.

b Hydrophilic activity of certain colloids, which increase the volume of the gastric and jejunal bolus if large quantities of water are given simultaneously, and which oppose the normal dehydration of the fecal mass thus tending to increase its size.

c In comparison with these two mechanisms, it is probable that directly increasing the ingested volume of water or food roughage has only minor significance as a cathartic measure.

2 The *irritability* of the intestines can be increased by a variety of systemically acting drugs such as neostigmine, methacholine, and pituitary vasopressin which are not generally considered as cathartics and are discussed elsewhere. Many common cathartics act, however, by so irritating the intestinal mucosa that propulsive motor responses to normal or even reduced luminal contents are potentiated. The site of action of these irritants varies—with the stronger ones such as castor oil and phenolphthalein the small and large bowel are both acted upon; the milder anthracene derivatives seem to irritate only the colon.

3 Another mechanism of action, of value in some clinical situations is that of *lubrication* of the anal canal to permit the easier passage of formed stools. With agents taken orally, this is a property only of chemically inert substances such as mineral oil and the cellulose derivatives.

**THE ENEMA**—Enemas act both by increasing the fluid bulk of the colonic contents and in some instances by irritating the mucosa. Retention enemas serve to soften and lubricate the feces *easing the passage* of extremely hard stools. Thus all of the mechanisms of action of the useful cathartics are involved in the actions of enemas.

reflex spasm of the anal sphincter. Since retention of feces is followed by the necessity of passing hard fecal masses which abrade or further irritate the inflamed structures, it is important to keep the bowels moving. On the other hand, too vigorous catharsis leads to an increase in the total amount of straining at stool and to the embedding of small amounts of semiliquid feces in crypts, ulcers, and fistulous tracts. What is desired is a single, formed, well lubricated, easily passed stool each day. This is achieved, in conjunction with efforts to diminish sphincter spasm by hot sitz baths and local anesthetic agents, by the use of mineral oil or the hydrophilic colloids. While reasonable theoretical objections have been raised to the use of mineral oil on the grounds of interference with fat absorption and the possibility of setting up a granulomatous process in the inflamed tissue, in practice these do not seem significant when it is properly used. Accordingly, mineral oil is recommended as empirically superior in producing an easy bowel movement.

**Purging**—Today there remain only a relatively few indications for purging the intestines.

**PREPARATION FOR EXAMINATION**—In preparation for abdominal x rays particularly for pyelography and for barium enema, the elimination of gas shadows is desirable. For a barium enema the colon must be emptied almost perfectly of all its contents. Since saline cathartics are likely to leave behind gas and fluid residues, irritant cathartics are preferred. Empirically castor oil has proved most effective, but senna powder is often a satisfactory substitute, especially for pyelography. In preparation for sigmoidoscopy purging and enemas may be used together.

**HEPATIC COMA**—The major source of ammonia in the body is the large intestine, where bacteria produce it by acting upon products of digestion of proteins. In hepatic coma and precoma the ammonia level in the blood may be reduced not only by lowering of the protein intake and administration of broad spectrum antibiotics, but also by purging and enemas. Saturated solution of sodium sulfate is recommended, to be used each morning for 1 to 3 days.

**ELIMINATION OF POISONS**—Some poisons, especially the heavy metals such as mercury, are excreted by the lower bowel and passed in the stool. This process may be accelerated, and the damage to the intestinal mucosa apparently diminished, by purging. Again a saline cathartic such as sodium sulfate is most useful.

**IN CONJUNCTION WITH ANTHELMINTIC AGENTS**—Many of the widely used acutely acting anthelmintics, such as tetrachlorethylene, oil of chenopodium, and oleoresin of aspidium, are held to require preliminary purging of the bowel to ensure contact of worm with drug in concentrated form and further purging during or after treatment in order to prevent undue absorption of the toxic anthelmintic drug. *For these purposes sodium sulfate is recommended.*

**EXAMINATION OF STOOLS FOR PARASITES**—In the microscopic examination of the stools for amebae, other protozoa, and larvae of some worms, a fresh liquid stool is needed for maximum efficiency of examination. A rapid acting agent is required, and to avoid oily residues it must be a saline. Sodium sulfate is again the agent of choice.

**MISCELLANEOUS**—In lead poisoning, hypothyroidism, and hyperparathyroidism, laxatives may be temporarily needed while the underlying cause of constipation

catharsis may lead to persistent weakness, anorexia, and lethargy at least partly attributable to depletion of extracellular water and potassium.

**HABITUATION**—The most common untoward effect of cathartics is habituation to their use. In many patients this is the result of prolonged self administration due to complex neurotic patterns and familial misinformation. In others, as indicated previously, this hazard can be avoided when the physician assumes the same degree of responsibility for discontinuing cathartics as he does for prescribing them.

## The Several Cathartic Drugs

The most useful cathartics may be classified as follows:

**Those Increasing the Bulk (Mainly the Water Content) of the Stools—**

**OSMOTICALLY ACTIVE AGENTS, THE SALINE CATHARTICS—**

**Those With Vigorous Action, the Saline Purge** The magnesium salts (magnesium sulfate and magnesium citrate) are not recommended for repeated use because of the danger of absorption of significant quantities of magnesium ion, with consequent cerebral depression. *Sodium sulfate* is efficient, chemically nontoxic and inexpensive. A dose of 15 Gm is given, usually as the saturated (approximately 50 per cent) solution. Its only disadvantage is its bad taste, which can be overcome by substitution of *sodium phosphate* (5 to 10 Gm), or *effervescent sodium phosphate* (10 Gm).

**Those With Milder Action** The only important preparation of this class is *milk of magnesia*, an aqueous suspension of magnesium hydroxide, 15 to 45 ml gives mild laxative action.

**THE HYDROPHILIC COLLOIDS**—A wide variety of these agents are derived from agar gums (tragacanth, karraya, bissora), psyllium seeds, and other natural sources as well as synthetic cellulose derivatives. None has serious toxic effects, and their potency as laxative agents does not differ greatly from one to the other. The choice can thus be based upon considerations of palatability, convenience, expense and suitability for the ritual needs described on page 368. Accordingly, the following are recommended:

**Psyllium Hydrophilic Mucilloid With Dextrose** This material (Metamucil) is a highly purified psyllium preparation, to be taken as 1 to 2 teaspoonfuls stirred in a whole glass of water, and swallowed within 30 seconds.

**Serutan** This consists of the husks of psyllium seed (55 per cent) with dextrose and is taken in the same manner as Metamucil.

**Agents Lubricating the Stools for Easy Passage**—Here the only material of importance is *mineral oil* (liquid petrolatum). It may be light or heavy, and cheap grades, if of U.S.P. standard, are fully satisfactory. A dose of 15 to 45 ml is taken at bedtime. Flavored and emulsified preparations are more expensive and their only advantage is greater palatability. A common emulsion also contains phenolphthalein, and this should be avoided when only lubricating action is desired.

**Agents Producing Catharsis by Irritation—**

**STRONG IRRITANTS**—The most widely used agent of this type is *castor oil*, recommended as a purge in doses of 30 to 60 ml, given in the manner outlined on

An enema properly administered comes closer than any cathartic to imitating a normal bowel movement in the sense that only the rectum sigmoid and part or all of the descending colon is evacuated. If the enema fluid is to reach the sigmoid level or higher the spastic contractions of the rectosigmoid area must be prevented or overcome. For this reason enemas should be administered at or just above body temperature with the patient *lying down* in a comfortable position (not sitting on the toilet) and at a pressure not exceeding 60 cm (24 inches) of water. When an urge to defecate is experienced one may be sure the enema fluid is distending the rectum; if the tube is then clamped or the flow otherwise interrupted the sensation will soon subside as the fluid passes upward into the sigmoid. Patience with the interruption and resumptions of the procedure in this manner even several times in succession and occupying 10 to 15 minutes if necessary is a prerequisite to good results. Further details of procedure are given in the consideration of the several types of enemas in the following section.

**Therapeutic Effects**—The desired therapeutic effects of cathartics are generally either the purging of the intestinal tract or the stimulation of a normal daily bowel movement. The results depend not only upon the agent used and the dose thereof but also on the state of activity of the gut at the time it is given. Thus the speed and efficiency of action of castor oil is greatly enhanced if it is given on an empty stomach and larger doses of any laxative are required for a given result in a bedridden patient or a patient receiving other drugs such as opiates or aluminum hydroxide which have a constipating effect.

**Dangers**—The use of cathartics in any form carries with it certain risks most of which happily can be foreseen by the prudent physician.

**INFLAMMATORY DISEASE**—Inflammatory disease of the intestine and adjacent organs is often dangerously complicated by the intestinal hypermotility induced by a cathartic. The use of such an agent in acute appendicitis has undoubtedly led to perforation and peritonitis on numerous occasions and equally devastating consequences have occurred in diverticulitis regional enteritis ulcerative colitis, and other inflammatory conditions. *Abdominal pain of uncertain origin is a contra indication to the use of a cathartic.*

**INTESTINAL OBSTRUCTION**—Intestinal obstruction if present, is certainly aggravated by cathartics and may be precipitated by them de novo. With incomplete obstruction where only a narrow lumen is left by an encircling inflammatory or neoplastic process the lumen is likely to be obliterated when engorgement of the mucous membrane is provoked by the cathartic. Obstruction has also been caused chiefly in the lower esophagus when hydrophilic colloid laxatives have been taken with less than the prescribed amounts of water. *In x ray studies of patients with symptoms of obstruction the barium enema should be performed first without the customary preparation with castor oil.*

**FLUID AND ELECTROLYTE LOSS**—The fluid contents of the ileum and proximal colon are rich in  $\text{Na}^+$ ,  $\text{K}^+$ ,  $\text{Cl}^-$  and  $\text{HCO}_3^-$ . When a patient is suddenly and drastically purged dehydration hypokalemia and acidosis or alkalosis may result. While young and otherwise healthy persons may quickly recover from this insult aged individuals and those with renal disease sometimes suffer acute renal failure cerebral infarction or other unhappy consequences. The chronic use of vigorous



**RETENTION ENEMAS**—These enemas are used to soften or lubricate hard impacted fecal masses. Cottonseed oil is ordinarily used, 150 to 180 ml being slowly introduced and retained for several hours. Recently superior results have been achieved with dioctyl sodium sulfosuccinate (Colace) in 1 per cent solution, 5 ml of which is diluted in 60 to 90 ml of water for use as a retention enema. Either procedure should be followed by an evacuant enema of tap water, saline or soap suds.

### A Design for the Use of Cathartics

**Relief of Cathartic Addiction**—To accomplish this the mildest possible cathartic should be used as a temporary aid and to a large degree as a placebo in a program which also includes the re-establishment of regular visits to the toilet, a regulated diet and other ritualistic measures designed to promote defecation as a conditioned reflex. The care with which the hydrophilic colloids must be taken becomes part of this ritual. Thus one rounded teaspoonful of Metamucil or Serutan is stirred briskly into suspension in a full glass of cold water, drunk within 30 seconds then followed by another full glass of water. This procedure is followed at bedtime and again immediately on arising.

This regimen is expected to restore regular daily bowel movements only after 1 to 4 weeks and the patient is so informed. Withdrawal symptoms are relieved by a tap water or phosphate enema administered at 2 to 7 day intervals in the morning immediately after the regular toilet visit. The patient is encouraged to widen the interval between enemas as rapidly as possible and to take the enema only for the relief of severe symptoms.

After 4 to 6 weeks of such therapy, the colloid laxative can usually be discontinued. It can be used again prophylactically whenever changes in the routine of living (travel, intercurrent infection) might lead to transient constipation but it should be emphasized to the patient that he has no permanent need of this or any other cathartic agent.

It should be emphasized that the same general regimen is often successful when *all* laxatives are omitted at the start. The use of the hydrophilic colloid is recommended here mainly as a placebo.

**Bedridden Patients**—In bedridden patients the use of cathartics should be a supplement to or a reluctantly accepted alternative for, other measures which deal more rationally with their constipation.

- 1 *Encourage a regular effort* at defecation daily after breakfast.

- 2 *Banish the bedpan*. In the vast majority of bedridden patients the pan can be safely and efficiently placed in a bedside chair, or, better replaced by the commode. Whenever the patient can sit up to defecate and can use more familiar facilities constipation is less serious. Many sensitive persons find it impossible to defecate when others are in the room—hence a transfer to a single room and the temporary absence during defecation of nurses and other attendants are desirable.

- 3 *Omit constipating medication* if possible. Do not use morphine or codeine for pain if Demerol or aspirin will do. Minimize the use of constipating antacid.

page 369 Other irritants commonly used are either too strong (e.g., croton oil), or too often associated with systemic intoxication (as in the case of podophyllum or phenolphthalein)

**IRRITANT CATHARTICS OF INTERMEDIATE STRENGTH**—A useful member of this group is *compound powder of senna*, in which the laxative action of senna is combined with the demulcent and flavoring qualities of glycyrrhiza If it is to be used as a purge in preparation for abdominal x-rays, 10 Gm must be taken in the same manner as indicated for castor oil

**MILDLY IRRITANT CATHARTICS**—A useful cathartic of this type belonging to the emodin or anthracene group is *cascara sagrada fluidextract*, of which 2 to 6 ml may be taken at bedtime with expectation of a soft or semiliquid stool the following morning Its action is believed to be confined to the large intestine, but apparently the entire colon, rather than just the distal colon, is affected The only notable toxic reaction which follows its chronic use, is the symptomless development of a diffuse, blotchy, brownish black pigmentation of the entire colonic mucosa, known as *melanosis coli* This apparently has no clinical significance

Other cathartics of the anthracene group are less satisfactory—rhubarb because of secondary constipating effect, and aloin because of griping

**Enemas**—Of the many kinds of enemas, the following are recommended as most generally useful

**THE TAP WATER ENEMA**—Tap water (500 to 1,500 ml) at body temperature or slightly higher, is the most satisfactory enema fluid when irritation must be scrupulously avoided, as in diverticulitis, ulcerative colitis, or other inflammatory conditions It is contraindicated in infants with congenital megacolon, in which it is retained so long that considerable quantities of water are absorbed and the electrolytes of extracellular fluid become dangerously diluted This can be avoided by substituting physiologic saline for tap water

**THE HYPERTONIC ENEMA**—Saturated solution of sodium phosphate, 120 ml when given per rectum causes the rapid distention of the left colon as it attracts fluid osmotically into the lumen of the bowel The resulting evacuation occurs without griping, but a moderate irritation of the mucosa is produced This solution is available in disposable plastic containers at small cost and saves hours of time of nurses and attendants when substituted for tap water and soap suds enemas It is also an excellent preparation for proctoscopy It can be recommended in all patients except those with colitis or diverticulitis Of the several manufactured preparations, the only difference is in the convenience of the plastic container Recommended, in order, are Travad Enema, Glycerol, and Fleet Enema Similar advantages can apparently be obtained with a prepared enema formulation (the Sigmol enema), which contains in 120 ml Sorbitol solution, 45 Gm, and the wetting agent dioctyl potassium sulfosuccinate, 0.12 Gm This material is considered to have less irritant action upon the colonic mucosa than does sodium phosphate, and to eliminate the risk of absorption of large quantities of sodium

**SOAPSUDS ENEMA**—The procedure is the same as for tap water enema, except that white toilet soap is stirred in the water until it is moderately opalescent This is contraindicated in ulcerative colitis, diverticulitis, and other severe inflammatory disease of the colon

For all other situations in which purging is required, the use of sodium sulfate 45 to 60 ml of saturated (50 per cent) solution, is recommended. This should be given in the morning on an empty stomach and followed by 2 or more glasses of iced water, citrus fruit juice, or ginger ale. When, as in treatment of poisoning or hepatic coma, repetitive dosage is required, succeeding doses may be given as soon as the effects of the earlier dose are obtained. The volume of the stools should be measured in such cases and the calculated losses of fluid and electrolytes should be replaced.

### Rational Basis for New Cathartic Agents

The ideal cathartic, that which would most closely simulate the natural mechanism of defecation, would act on no portion of the bowel other than the distal colon. There, without irritating the colonic mucosa, it would suddenly stimulate expulsive movements confined to this area, 10 to 30 minutes after breakfast. The action of an ingested drug could be confined to the distal colon if it were completely nonabsorbable, chemically activated by contact with the digestive juices and then active on reaching a critical concentration as the feces is dehydrated. Until such a remarkable drug is made available, the nearest substitute will be an enema.

Bisacodyl (Dulcolax) is a promising laxative agent only recently released in the United States. It is said to cause evacuation by inducing reflex propulsive motility of the colon on contact with its mucosa. Evidence indicates that irritation of the mucosa is minimal to absent, and that the bowel is emptied without purging, the resulting stools being soft to formed in character. Emptying of the colon is so complete that this agent provides a very satisfactory preparation for barium enema or proctoscopy. It is effective 8 to 10 hours after oral ingestion and within an hour after insertion of a suppository. It is available as 5 mg tablets and in suppositories containing 10 mg. Recommended dosage is 15 mg orally at bedtime. If used as preparation for barium enema or proctoscopy, a suppository should be inserted 1 hour before the procedure.

## THE CHOICE OF AN ANTIDIARRHEAL AGENT

### Introduction

Antidiarrheal medications are less widely used than cathartics in the United States because diarrhea is less common a problem in temperate climates than is constipation. In addition, agents directed against diarrhea are more likely to be used under medical supervision because of the urgency of the symptom and the physiologic consequences of the severe or prolonged diarrheal state. There is nothing so disruptive of normal social and business functions as the recurrent threat of an urgent bowel movement. In general we have adequate drugs to deal with the acute diarrheal states but are sorely limited in the safe usage of drugs for the chronic diarrheas. Our limited knowledge of the basic physiologic mechanisms of diarrhea has prevented specifically directed pharmacologic therapy. We are compelled, on the one hand, to employ powerful and effective agents that have deleterious extraintestinal effects and are habit forming or on the other hand to

agents (containing calcium or aluminum) or balance these with magnesium salts. The potent anticholinergic drugs and the ganglionic blocking agents may cause obstinate constipation.

4 *Get rid of barium sulfate residues* These are very likely to become inspissated in the distal colon, especially when the barium has been given by mouth for gastrointestinal series or for outlining the left atrium. They are efficiently removed by an oil retention enema, followed by a soapsuds enema, but a saline purge or anthracene cathartic may be substituted.

5 *Give an enema*, as soon as his condition permits, to any patient who has failed to have a bowel movement in the preceding 3 days.

In the less prostrate patients, these measures should be adequate to promote fairly regular bowel movements. If, however, movements are small and hard or if none is produced for 2 days, 6 ml of fluid extract of cascara alone, or in combination with 30 ml of milk of magnesia, is given at bedtime 2 out of every 3 nights. If the bowels move on the mornings after no medication is given, the cathartic may be omitted or replaced by Serutan, Metamucil, or mineral oil given in the manner previously indicated.

In more severely ill patients, it is wise at first to minimize their effort in getting on and off the bedpan and in straining at stool, by using only enemas of tap water, of hypertonic phosphate solution, or of soapsuds every 2 or 3 days after breakfast. As they improve, it would be wise to resort at once to cascara and milk of magnesia 2 nights out of 3 without waiting to see whether they can cause their bowels to move spontaneously.

As soon as any previously bedridden patient is allowed to be up, his cathartics should gradually be eliminated and his toilet habits re-established, in the manner outlined for "cathartic addicts."

**Anal Lesions**—In the presence of painful anal lesions, the passage of a daily stool may be best aided by mineral oil. This is always given at bedtime, to avoid its mixing with food, in the amount of 30 ml. If this is insufficient, after 2 days, to be detectable on the toilet paper or as brown stained drops on the water of the toilet bowl, the dose is increased to 45 or even 60 ml. When this "leakage" is observed, the dose is reduced by 5 or 10 ml and then maintained at this level for 3 to 4 weeks after the disappearance of pain, bleeding, and other local symptoms. In this manner a maximum of lubrication is achieved without leakage, and the mineral oil is used for too short a period to incur chronic untoward effects.

**Purging**—The complete cleansing of the lower bowel called for in abdominal x rays is best accomplished with castor oil, 45 to 60 ml, given in a single dose on an empty stomach in the late afternoon preceding the day of examination. It should be well disguised by some flavoring agent such as raspberry syrup, additionally sweetened, and mixed with cold carbonated water to a total volume of over 200 ml. The purpose of all this, which is readily accomplished by the local pharmacist, is to overcome nausea and thus ensure its rapid passage through the stomach and its abrupt irritant effect upon the intestine. It may be followed after 2 hours by a light supper, and the most vigorous catharsis is likely to be over by bedtime. (The giving of castor oil at bedtime, on the other hand, practically ensures an uncomfortable night.)

helpful in reducing night diarrhea when taken in large doses at bedtime. The patient with regional enteritis, particularly terminal ileitis, may be, however, in a state of compensated, incomplete intestinal obstruction, that is, proximal intestinal hypertrophy permits flow of small bowel contents through a cicatrized lumen. Care must be taken not to produce a decompensation of this state by anticholinergic therapy. In the presence of abdominal distention, bowel sounds characteristic of incomplete obstruction or radiologic evidence of dilated loops of small bowel, this group of drugs should not be used in regional enteritis. In severe, fulminating ulcerative colitis, paralytic ileus may be precipitated by anticholinergic therapy. Such therapy is contraindicated in the patient with ulcerative colitis who is more than mildly distended or who has radiologic evidence of large bowel dilatation.

**Opiates** should not be used in this group of chronic diseases except under the following circumstances: (1) in cases of diarrhea of such severity and duration as to threaten physical exhaustion when all other measures including steroid therapy have failed; and (2) when the physician is seeing for the first time a patient who is markedly discouraged and depressed by his illness, to put an abrupt end to the diarrhea and thus gain the patient's respect and confidence as a basis for subsequent superficial psychotherapy. Under the latter circumstances it is usually wise to use steroid therapy concurrently, provided there are no contraindications. In either case the patient should be weaned gradually from opiates as soon as possible, certainly within 2 to 4 weeks.

**Malabsorption Syndrome (Sprue, Lymphoma, Whipple's Disease).**—More or less specific therapy is presently available for these disorders, and the nonspecific antidiarrheal agents are rarely if ever indicated except when the patient with lymphoma has become resistant to such therapy.

**Acute Infectious Diarrheas (Viral, Staphylococcal, Salmonella, Shigella).**—These conditions are self-limiting and of short duration. One should not hesitate to use opiates liberally under these circumstances in order to ensure patient comfort. Simultaneous replacement of fluids and electrolytes, especially in infants, must be undertaken.

**Chronic Infectious Diarrheas (Amebiasis).**—Specific therapy is indicated in amebiasis, and rarely the temporary use of opiates may be necessary until specific therapy becomes effective.

**Postvagotomy and Postgastrectomy Diarrhea.**—In view of the increased incidence of chronic salmonella infection in the postgastrectomy state, appropriate bacteriologic studies of the stool are indicated whenever diarrhea appears following resectional surgery of the stomach. In the absence of such specific etiology, the treatment of this group of diarrheas is usually limited to avoidance of (1) ice cold liquids and (2) large amounts of fruits and vegetables. Occasionally pancreatic extract in proper amounts may diminish the diarrhea of the postgastrectomy state. There is no evidence that a diet low in carbohydrate will relieve this type of diarrhea although it often will relieve other symptoms of the dumping syndrome.

**Postantibiotic Diarrheas and Pseudomembranous Enterocolitis.**—If *Staphylococcus aureus* can be cultured from the stool, appropriate antibiotic therapy can be based upon sensitivity studies of the organism. When this information is not available in patients with severe diarrhea following extensive abdominal surgery or

use more benign but much less effective medications that much too often prove inadequate for control of the diarrhea

### Clinical Applications

**Irritable Colon (Mucous Colitis, Functional Diarrhea)**—This condition may perhaps be more properly termed "irritable small intestine and colon," yet the part (if any) played by the small bowel has not been well defined. Increased peristaltic activity of the large bowel occurs with the passage of frequent stools of increased water content and usually accompanied by varying amounts of mucus. This state is often associated with nervous tension, and it may be that such tension in some susceptible patients leads to excessive neurogenic bombardment of the colon, resulting in increased peristaltic activity and increased mucus formation. The consequent decreased passage time through the water absorbing proximal colon is felt to be the basis for the liquid character of the stool. Other hypotheses, however, cannot be denied. These include the concept of a primary colonic defect in water absorption resulting in frequent "built in" enemas and the idea of dysfunction of the small bowel with secretion (or failure of absorption) of a specific irritant to the colon (perhaps a fatty acid).

*Adsorbents, mucosal astringents, and hydrophilic substances* are often used in combination as well as separately. They have the virtues of being relatively inexpensive and practically free of toxicity. However, it is doubtful whether their usefulness in the irritable colon extends beyond a placebo action. If the symptoms are mild and infrequent such placebo action may be sufficient to give the patient relief.

*Anticholinergic drugs* are uniformly effective in reducing peristaltic activity in the normal colon and may be effective in the abnormally stimulated irritable colon if properly used. The dosage must be pushed to "bearable toxicity" and untoward effects anticipated (see page 356). Together with other measures such as environmental manipulation, psychotherapy, and dietary restrictions, properly administered anticholinergic therapy often proves helpful. It has the great advantage of not being habit forming.

The *opiates* are powerful and reliable inhibitors of propulsive activity of the bowel. If used in sufficient dosage, one or the other of the opiates can almost always stop the diarrhea of the irritable colon. However, in view of their addictive properties they should be used in this chronic disease only rarely. In initiating a therapeutic regimen with a patient who has suffered from the irritable colon with diarrhea for an extended period and in whom the disease has proved incapacitating, the physician may use an opiate for a short period in order to gain the patient's confidence and establish a basis for a subsequent psychotherapeutic approach.

**Chronic Inflammatory Diseases of the Intestines (Ulcerative Colitis, Regional Enteritis)**—*Adsorbents, mucosal astringents, and hydrophilic agents* are of no use in this group of diseases.

The *anticholinergic drugs* are occasionally helpful in diminishing the diarrhea of chronic inflammatory diseases of the intestines. These drugs are particularly

**HYDROPHILICS**—These substances may occasionally impart adhesiveness to a watery stool, but do not diminish the frequency of diarrhea. The dosage of the two following products is 1 to 2 teaspoonfuls in a full glass of water, twice daily: (1) psyllium hydrophilic mucilloid with dextrose (Metamucil) and (2) Scrutan, husks of psyllium seed with dextrose.

**The Anticholinergic Drugs**—See page 354

**The Opiates**—In the patient who can take oral medication the preparations of choice are deodorized opium tincture, camphorated opium tincture (paregoric), and codeine (sulfate or phosphate). When parenteral medication is required, morphine sulfate is the drug of choice.

**DEODORIZED OPIUM TINCTURE**—This is a 10 per cent solution of powdered opium; the average adult dose of which is 0.6 to 1.5 ml, 2 to 4 times daily. It is ordinarily given as 8 to 20 drops in a small amount of liquid such as water. This medication is an effective constipating agent and has the advantage of great flexibility of dose inasmuch as it can be conveniently measured in drops.

**CAMPHORATED OPIUM TINCTURE (PAREGORIC)**—This is a 4 per cent solution of opium tincture containing a number of inactive ingredients which impart to the solution a characteristic odor and taste. The average adult dose is 4 to 8 ml given 4 to 6 times daily. This preparation has no real advantage over deodorized opium tincture.

**CODEINE**—This may be treated as pharmacologically weakened morphine. The usual adult dose is 16 to 64 mg, 2 to 4 times daily. Codeine has two distinct advantages in the treatment of the chronic diarrheal state. First, it is less addictive than opium because it does not induce the equivalent degree of euphoria. However, it is false to assume that it may never cause addiction. Second, its nondescript appearance may permit the physician to dispense the drug without informing the patient of its name or nature. This diminishes psychologic addiction to the drug.

**MORPHINE**—In doses of 8 to 20 mg by the parenteral route this drug is useful in the symptomatic treatment of exhausting, acute, diarrheal states. It should never be used in the chronic diarrheal states for fear of addiction.

### A Design for the Use of Antidiarrheal Agents

Therapy of the diarrheal state should be directed toward the etiologic agent if possible. This is readily accomplished in some of the infectious diarrheas for which we have specific antimicrobial agents. Under such circumstances, the most powerful nonspecific antidiarrheal agent available (opiates) should be employed in the acute stages before specific therapy becomes effective, provided the patient manifests enough discomfort. The self-limiting diarrheas permit the same freedom of action with the opiate group of drugs. In the care of the chronic diarrhea of unknown or poorly defined cause, however, all efforts should be made to control the diarrhea without recourse to opiates. If the patient's exhausted physical state justifies the use of opiates, the smallest dosage compatible with reasonable comfort should be employed. If at all possible, the patient should not be acquainted with the name or dose of opiate used.

In general, reliance should be placed on more physiologically oriented therapy

the use of broad spectrum antibiotics treatment should be begun at once with novobiocin 0.5 Gm 4 times daily or the combination of erythromycin 0.5 Gm 4 times daily and chloramphenicol 1 Gm 4 times daily and continued for 7 days. Any antibiotic which the patient had been receiving when the diarrhea began should of course be discontinued. The cultured milks (buttermilk, yoghurt) and the *Lactobacillus* preparations appear to be ineffective in these patients.

### General Pharmacologic Considerations

**Adsorbents, Mucosal Astringents, and Hydrophilic Agents**—These substances are said to absorb intestinal irritants physically (adsorbents) to diminish mucus secretion and transudation of fluids by precipitation of both mucus and the cell membranes of the surface epithelium and thus to provide a barrier to bowel irritants that may be present within the lumen (astringents) and to reduce the free water content of the stool by incorporating the water and producing a gelatinous mass (hydrophilics). Since none of these mechanisms is specifically directed against the postulated motor mechanism of hyperperistalsis it is not surprising that these drugs are relatively ineffective as antidiarrheal agents.

These substances are virtually free of toxicity. The amounts taken are limited by the benign dyspepsia they induce. The hydrophilic substances should be taken with large amounts of water in order to prevent esophageal obstruction.

**Anticholinergic Drugs**—See page 353.

**Opiates**—These drugs have a powerful constipating effect by virtue of their action on the smooth muscle of the colon. Opiates cause a marked increase in nonperistaltic activity and a corresponding reduction in peristaltic activity. This effect is partially antagonized by atropine. Inasmuch as all diarrheal states—whatever the diverse ultimate causes may be—are mediated through increased peristaltic activity of the colon opiates are effective in all such states.

The great deficiency of this very effective antidiarrheal group of drugs is addiction and tolerance. The threat of addiction is so great that one should hesitate to use the opium derivatives in the chronic diarrheal states except for the limited indications listed above and then for as short a period of time as possible. No such cautions are necessary in using opiates in the acute self-limiting diarrheal states. Other untoward effects of the opiates include occasional precipitation of biliary colic and acute pancreatitis as a result of induced spasm of the sphincter of Oddi. The parenteral administration of the opium derivatives to asthmatics should be given if at all only with extreme caution. The depressed state of consciousness induced by opiates has to be considered in treating the ambulatory patient.

### The Several Antidiarrheal Drugs

**The Adsorbents, Mucosal Astringents, and Hydrophilic Agents**—These are of limited value and probably exercise a therapeutic effect largely by virtue of suggestion. Choice of a particular preparation should be guided by palatability and price.

**ADSORBENTS AND ASTRINGENTS**—The dosage of the 2 listed products is 15 to 30 ml 4 times daily: (1) kaolin with pectin (Kaopectate) and (2) aluminum hydroxide.



by virtue of the general air of well being induced or by stimulation to secretion, is not known

Digestants such as hydrochloric acid, pepsin, pancreatic extracts and bile acids have no value in this condition beyond a placebo effect. However, one cannot deny that the placebo effect may be quite potent in the hands of experienced practitioners, and the use of these medications for functional dyspepsia is indicated under such circumstances

**Pancreatic Deficiency**—Large doses of a potent pancreatic extract are extremely efficient in the treatment of the steatorrhea and cretatorrhea, diarrhea, malnutrition of chronic pancreatic insufficiency, such as may be seen in chronic pancreatitis

### General Pharmacologic Considerations

**Cholinergic Drugs**—Those gastrointestinal disease states marked by hypomotility would seem to be susceptible to therapy with drugs that stimulate cholinergic receptors, inasmuch as cholinergic activity increases the functional activity of the gastrointestinal tract. However, as with anticholinergics, the cholinergic drugs available have no differential organ activity. Apart from the treatment of postoperative abdominal distention and postvagotomy gastric atony, hypoactive states of the gastrointestinal tract cannot be ameliorated without courting distressing and dangerous side effects. The latter include coronary vasoconstriction, bronchospasm and excessive sweating. This group of drugs is dangerous in the presence of asthma, chronic lung disease, and coronary artery disease.

**Digestants**—It would be reasonable to provide available digestants as substitution therapy if it could be shown that deficiency of such digestants gave rise to disease states. Of all the digestants available, the deficiency of only two—exocrine secretion of the pancreas and bile salts and acids—have been proved to give rise to significant symptoms. Achylia gastrica may give rise to pernicious anemia, but only by virtue of the absence of intrinsic factor, and not because of the deficiency of pepsin or hydrochloric acid. Pancreatic deficiency, on the other hand, gives rise to clear cut and distressing symptoms, which can be promptly corrected by adequate (page 377) amounts of commercial pancreatic extract. In some instances of chronic biliary obstruction, steatorrhea or constipation may result. It is felt that the steatorrhea is due to the absence of bile salts in the gastrointestinal lumen. In some instances of incomplete biliary obstruction constipation is said to be related to bile acid and salt deficiency. Substitution therapy is not advised, however, inasmuch as oral ingestion of bile acids would aggravate pruritis from which these patients usually suffer. Wetting agents are very effective in the treatment of this rare kind of constipation.

### The Several Stimulant and Digestant Agents

#### The Cholinergic Drugs.—

**NEOSTIGMINE (PROSTIGMIN)**—The usual parenteral (subcutaneous or intramuscular) dose in the treatment of postoperative abdominal distention is 0.25

(e.g., steroids in ulcerative colitis) on the use of placebo therapy if possible (Loperectate in mild infrequent attacks of mucous colitis), or on the anticholinergic drugs. The latter often require dosage sufficient to induce minor toxicity (as outlined on page 353). Proper respect in this case must be paid potential untoward reactions described earlier (page 354).

### Rational Basis for New Antidiarrheal Agents

A normal bowel pattern is an integrated bodily activity toward which physiologic phenomena occurring in all parts of the body contribute. The controlling center is in the central nervous system. The ideal antidiarrheal drug would have its site of action centrally at the integrating center. In the absence of such a dream drug, an agent inhibiting peristaltic activity peripherally (such as morphine) and lacking undesirable side effects (such as addiction) would seem a welcome addition to our antidiarrheal armamentarium.

## THE CHOICE OF STIMULANTS AND DIGESTANTS

### Introduction

The diagnosis of suboptimal function of the processes of digestion continues to be a favorite one among physicians. It is also a popular self diagnosis among patients. Therefore it is not surprising that the prescription of gastrointestinal stimulants and digestants, particularly the latter, constitutes a major segment of office therapy today. Unfortunately with a few notable exceptions the clinical efficacy of this group of drugs is open to much question.

### Clinical Applications

**Postoperative Distention, Including Postvagotomy Gastric Atony** —The cholinergic drugs neostigmine (Prostigmin), bethanechol (Urecholine), and methacholine (Mecholyl) are useful in postoperative abdominal distention. Neostigmine is more useful in the early postoperative period when parenteral medication is necessary. Urecholine may be given orally and is therefore used later in the postoperative course. Because of its unpleasant side effects, Mecholyl, a potent parenteral drug, is ordinarily not used unless Prostigmin proves ineffective. In the case of postvagotomy gastric atony, Urecholine appears to be the drug of choice.

**Functional Dyspepsia (Hypoactive Upper Gastrointestinal Segment)** —This condition is perhaps the most common gastrointestinal condition apart from functional constipation that the practitioner is called upon to treat. It is manifested by postprandial epigastric fullness, belching, nausea, and generalized abdominal distention. Frequently chronic constipation is present. Barium studies are negative. The diagnosis is a clinical one with no characteristic laboratory findings, although some investigators believe that the physiologic basis of the symptoms in this condition is gastroduodenal hypofunction.

The cholinergic drugs Prostigmin, Urecholine, and Mecholyl are of no use in the treatment of this condition despite the theoretical attraction. Experience has revealed that unpleasant side effects appear without the disappearance of symptoms. Alcoholic beverages are occasionally helpful in this condition, whether

Presently available digestants are almost ideal in that isolated organ replacement therapy is available (e.g., pancreatin). A more concentrated product, however, would be desirable.

## SELECTED REFERENCES

### Antispasmodics

- Bachrach, W. H., and Chapmar, J. H. *Dis* 3: 743, 1958.  
 Cummins, J. W., and Jones, C. M. Barium Tincture of Belladonna, and Placebos Man, *Gastroenterology* 23: 234, 1953.  
 Kern, F. *Drugs in the Management of Gastroenterology* 36, 1957.  
 Posey, E. Experimental and Preliminary Clinical Study Amine, Banthine, Upon the Human Colon, *Gastroenterology* 11: 344, 1948.  
 Sleisenger, W. P. Comparative Potency of Newer Antispasmodics as Determined by a Sigmoid Motility Technique, *Gastroenterology* 27: 829, 1954.

### Antacids

- Burnett, C. H., Commons, R. R., Albright, F., and Howard, J. E. Hypercalcemia Without Hypertension, *New England Journal of Medicine* 261: 1148, 1959.  
 Grace, W. J., and Jeghers, J. P. Treatment of Gastric Antacid and Antisecretory Effect Upon Gastric Secretion in Man, *Gastroenterology* 31: 1948.

### Cathartics

- Almy, T. P. Factors in the Production of Constipation, *Medical Clinics of North America* 3: 1, 1953.  
 Cornhill Conference on Therapy. The Rational Use of Cathartic Agents, New York State Journal of Medicine 47: 387, 501, 1947.  
 Dreiling, D. A., Fischl, R. A., and Fernandez, O. The Therapeutic Usefulness of Dulcolax (Bisacodyl), a New Nonpurgative Laxative, *Am. J. Digest Dis* 4: 311, 1959.  
 Ingelfinger, F. J. The Treatment of Chronic Constipation, *Ann. New York Acad. Sci.* 58: 503, 1954.  
 Poppel, M. H., and Bangappa, C. K. Bowel Preparation for Roentgenologic Procedures Using a New Evacuant, Bisacodyl, *Am. J. Roentgenol* 81: 696, 1959.

### Antidiarrheal Agents

- Adler, H. F., Atkinson, A. J., and Fry, A. C. Effect of Morphine and Dilaudid on the Ileum and of Morphine, Dilaudid and Atropine on the Colon of Man, *Arch. Int. Med.* 69: 974, 1942.  
 Emery, E. S., Jr. The Use of Absorbents in Gastrointestinal Diseases, *J. A. M. A.* 108: 202, 1937.  
 Kern, Fred, Jr., Almy, T. P., and Stolk, N. J. Effects of Certain Antispasmodic Drugs in the Intact Colon, With Special Reference to Banthine ( $\beta$ -Diethylaminoethyl Xanthene 9-carboxylate Methobromide), *Am. J. Med.* 11: 67, 1951.

### Stimulants and Digestants

- Kern, Fred, Jr., and Almy, T. P. The Effect of Acetylcholine and Methacholine Upon the Human Colon, *J. Clin. Invest.* 31: 555, 1952.  
 Schwat, R. S., and Chapman, W. B. Clinical Uses of Neostigmine, *M. Clin. North America* 31: 1238, 1947.  
 Stafford, C. F., Kugel, A. I., and Dederer, A. The Use of Urecholine in the Treatment of Postoperative Distention, *Surg. Gynec. & Obst.* 89: 570, 1949.

postoperative distention. Neostigmine is an anticholinesterase material which potentiates the effect of endogenous acetylcholine on the smooth muscle of the gut.

**BETHANECHOL (URECHOLINE)**—The usual oral dose is 10 to 30 mg, 3 or 4 times daily. The usual subcutaneous dose is 2.5 to 5.0 mg, 3 or 4 times daily. Urecholine should never be given intramuscularly or intravenously. It is the oral drug of choice in postoperative abdominal distention and both the oral and parenteral drug of choice in postvagotomy gastric atony. Urecholine acts directly on the smooth muscle cells of the gut.

**METHACHOLINE (MECHOLYL)**—The usual subcutaneous dose for abdominal distention is 5 to 20 mg. The drug is unsatisfactory for oral use because of variable destruction in the gastrointestinal tract. It is used in abdominal distention only if Prostigmin is not effective and then with a great deal of care. Mecholyl acts directly on the smooth muscle of the gut.

**UNTOWARD EFFECTS**—All cholinergic drugs may precipitate myocardial ischemia and asthmatic attacks in susceptible patients and they therefore should not be used in patients with coronary artery disease, bronchial asthma, or chronic lung disease. When used parenterally atropine should be available for immediate intravenous administration.

**Alcoholic Beverages**—These may be taken in any form 15 to 30 minutes before the heavy meal of the day in moderate amounts (equivalent of 30 to 60 ml of whiskey).

**Hydrochloric Acid, Pepsin**—These have no pharmacologic effects apart from placebo actions.

**Pancreatic Extracts**—The physiologic dose is 3 to 4 Gm with each meal. Enteric coated forms should be used to avoid gastric digestion. The large number of pills necessary is a nuisance and may be avoided by using Viokase, which assays 6 times as much proteolytic activity as triple strength pancreatin. Consequently 1 Gm of Viokase may be used 3 times daily.

**Dehydrochloric Acid (Decholin)**—This is a true hydrocholeretic agent. It is theoretically useful following plastic repairs of the extrahepatic biliary passages over foreign body tubes and in the rare condition known as sclerosing cholangitis in order to prevent the accumulation of sludge. The usual dose is 0.5 to 1 Gm 3 times daily.

### A Design for the Use of Stimulants and Digestants

The gastrointestinal stimulants should be employed to therapeutic effect unless deleterious side effects supervene. With the preparations currently available, minor side effects are to be tolerated for the therapeutic good. The contraindications for cholinergic therapy should be constantly borne in mind.

Replacement therapy with digestants should be in physiologic amounts except where merely placebo effect can be expected in which case more convenient smaller doses should be employed.

### Rational Basis for New Stimulants and Digestants

Present day stimulants have the disadvantage of generalized cholinergic activity, as opposed to differential organ activity. Side effects are thus inevitable.

- 2 Arsonic Acid Derivatives
  - a Carbarsone
  - b Bismuth glycolylarsanilate (Milibis)
  - c Balarsen
  - d Acetarsone
  - e Thiocarbarsone
- 3 Halogenated Hydroxyquinolines
  - a Chiniofon
  - b Diiodohydroxyquin (Diodoquin)
  - c Iodochlorhydroxyquin (Vioform)
- 4 4-Aminoquinolines
  - a Chloroquine
- 5 Antibiotics
  - a Tetracyclines
  - b Erythromycin
  - c Bacitracin
  - d Fumagillin
  - e Carbomycin
  - f Penicillin—streptomycin combinations
- 6 Fntamude (dichloroacethydroxy methylanilide)

The treatment of amebiasis is complicated by (1) selective tissue localization of different drugs, (2) the two forms of parasitic existence—trophozoites and cysts, and their different biologic strains, (3) the bacterial population of the intestinal tract, (4) the general condition, especially the state of nutrition, of the patient, (5) the tolerance of the patient to different drugs, (6) equivocal evaluation of many drugs, and (7) reinfection.

Since none of the drugs available satisfies the requisites of an ideal remedy, a combination of drugs is required depending on the severity of illness.

The treatment of intestinal amebiasis may be considered broadly under three headings—acute amebic dysentery, chronic amebiasis, and metastatic amebiasis.

**ACUTE AMEBIC DYSENTERY**—1 The treatment of a fulminant case of amebic dysentery may commence with the most potent amebicide, emetine. The narrow margin of safety between the therapeutic dose and the toxic dose of this drug necessitates caution in its use. The dose generally recommended is 1 mg per kilogram of body weight per day and never more than 65 mg per day for adults, 20 mg per day for children above 8 years of age, and 10 mg per day for those under 8 years. The total dose should not exceed 10 mg per kilogram of body weight per course, spread over a period of 10 days, though the drug should only be continued long enough for a clinical response which is usually evident after 5 injections. With the 5 day program electrocardiographic control is hardly necessary. We employ the intramuscular injection of emetine 65 mg daily for the first 5 days. The injections are made in the upper outer quadrant of the gluteal region, deep in the muscles and the patient apprised that the pain is usually considerable.

2 Simultaneously the patient is given another effective antiamebic preparation, such as carbarsone (containing about 30 per cent metallic arsenic), comparatively well tolerated except in arsenic sensitive individuals. It is given orally in doses of 0.25 Gm, 3 to 4 times a day, and continued for 10 days.

3 This is followed by a course of tetracycline given orally, 1.5 Gm on the first day and 1 Gm daily thereafter in divided doses for a week to 10 days or

## THE CHOICE OF DRUGS FOR INTESTINAL PARASITISM

B H Kean, M D, and

A B Choudhury, M B, D Phil

### INTRODUCTION

The choice of drugs in the treatment of parasitic diseases requires knowledge of the triumvirate formed by the parasite the host and the drugs as well as their interrelationships. Successful chemotherapy depends on a precise identification of the offending parasite, on an estimation of the intensity of infection and extent of injury to the host on the accessibility of the site of damage on a cautious assessment of the patient's general condition and on an appropriate selection of drug weighing parasitocidal efficacy against adverse effects.

Unlike antibacterial efforts radically revolutionized by the advent of antibiotics the evolution of antiparasitic measures has been slow and gradual some of the obstinate parasitic diseases continue to defy all therapeutic measures. The relatively unsatisfactory progress of this branch of chemotherapy has been due to its dependence on the empirical approach and inadequate knowledge of parasitic physiology. In recent years however information on parasitic metabolism and on host parasite relationship has reduced the indiscriminate screening of compounds and hastened the pursuit of more effective drugs. Since the publication of the first edition of this text several important additions have been made to the parasitologist's pharmacopeia.

### CLINICAL CONSIDERATIONS

**Amebiasis**—Amebiasis caused by *Endamoeba histolytica* is perhaps the most important parasitic malady afflicting mankind now that malaria can be successfully controlled. Although many antamebic agents are available, unfortunately none of them deserves to be listed as the drug of choice. The drugs currently recommended belong to the following groups

- 1 Alkaloids of *Cephaelis specacuanha*  
Emetine hydrochloride and emetine bismuth iodide

mended because of the serious nature of the disease. Emetine, 65 mg, is administered daily to an average adult by the intramuscular route for 10 days, and currently chloroquine is given orally, 1 Gm daily for the first 2 days, and 0.5 Gm daily for the next 18 days. It should be emphasized that hospitalization, frequent electrocardiograms, and close observation are necessary when emetine is used in this manner. Widening of the QRS complex and prolongation of the P-R interval warrant discontinuation of emetine. Repetition of the course or drug holiday of 2 weeks is sometimes desirable, but emetine should be given only 6 or 7 days. Therapeutic response to these drugs, however, appears early and is often of diagnostic value. All patients with metastatic amebiasis should also receive a course of treatment for intestinal amebiasis because the emetine-chloroquine combination does not deal efficiently with an intestinal infection.

*Surgical intervention in metastatic amebiasis should not be undertaken except as a last resort.*

So called diffuse amebic hepatitis, characterized by hepatomegaly, tenderness, fever, leukocytosis, and laboratory evidence of hepatic dysfunction in a patient with intestinal amebiasis, is probably nonspecific in nature and associated with ulceration of the intestinal tract, amebic or otherwise, it disappears completely following elimination of the intestinal cause.

*Giardiasis*—Of the intestinal flagellates of man, *Giardia lamblia* is most frequently considered pathogenic, although there is still dispute over its precise role. The morbid changes in the small intestine ascribed to the heavy colonization with *lamblia*, the frequent association of either a diarrheic syndrome or of one simulating biliary disease, and their ready response to treatment, provide ample justification for specific therapeutic measures.

For the last two decades, quinacrine (Atabrine) has been the drug of choice. It is given orally, 0.1 Gm, 3 times daily for 1 week, this course being repeated every 2 to 4 fortnight. Reappearance of the parasites is noted in 10 to 30 per cent of patients necessitating a third course.

Chloroquine, being less toxic especially in children, has been used in the treatment of giardiasis. But the rate of success is not high nor are results consistent. Other drugs such as Acrilanil and diiodohydroxyquin and intravenous injections of Urotropin cannot be recommended. In children the doses of quinacrine or chloroquine should be reduced but since neither drug is very toxic, the scheme may be higher than weight formulas would indicate.

*Trichomoniasis*—*Trichomonas hominis* is a much commoner parasite in the intestine of man than is generally recognized. It is frequently associated with other intestinal disorders and hence its role as the sole cause of diarrhea is often questioned. Carbarsone, 0.25 Gm, 3 times daily for 10 days, has proved effective although recurrences are not rare. Tetracycline, 1 Gm daily in divided doses for 1 week, is an alternative.

*Balantidiasis*—*Balantidium coli* is the only bona fide ciliate to parasitize man. Records of human infections are not numerous. The parasite is able to invade the mucosa of the large intestine and reach the submucosa where it causes rapid destruction of tissue. It is the cause of amebic dysentery.

unless there are troublesome gastrointestinal disorders such as nausea, vomiting and diarrhea

4 The schedule is completed with a course of diiodohydroxyquin (containing about 65 per cent iodine), another satisfactory antiamoebic drug contraindicated only in persons with gross liver damage and in those with iodine idiosyncrasy. It is used in doses of 0.65 Gm taken orally 3 times a day before meals for a period of 20 days

5 To this may be added a course of chloroquine. It is administered orally, 1 Gm daily for the first 2 days, and 0.5 Gm a day subsequently for 15 days. This last drug is considered a safeguard against any possible metastatic or extraintestinal amoebic lesion which may have escaped clinical recognition.

A cure rate of over 90 per cent can be anticipated with this regimen.

Evaluation of the success of therapy is difficult because the elimination of parasites and not the amelioration of clinical symptoms constitutes the criterion of cure. The problem is complicated by the so called "negative phase" during or shortly after specific therapy when absence of parasites in the stool does not signify cure. To have significance, examination of stool should, therefore, be done 1, 3, 6, and 12 months following completion of treatment. To avoid fallacies likely to be attendant on a single examination each re-evaluation should include three stool examinations, with at least one following the use of a saline cathartic, and should be supplemented by a proctoscopic examination. If "follow up" study reveals the presence of parasites, the whole course should be repeated.

**CHRONIC AMEBIASIS**—By chronic "asymptomatic," or nondysenteric amebiasis is meant the stage of disease in which cysts or trophozoites of *E. histolytica* are found in a routine examination of the stool of an "asymptomatic" patient. While some of these patients may be in apparent good health without specific complaints, the majority have vague intestinal discomfort or other evidences of disease of a protean nature. The potential for an acute flare up and concern for the public welfare leave little justification for complacency in the treatment of these carriers. There is, therefore, every reason to recommend treatment although emetine injections should be omitted from the regimen proposed for patients with acute amoebic dysentery. A successful program is carbarsone, 250 mg., 3 or 4 times daily for 10 days followed by Diiodoquin 0.6 Gm. 4 times daily for 14 days.

Our British colleagues prefer emetine bismuth iodide (EBI). This reddish powder is insoluble in water and is better administered in gelatin capsules than in enteric coated tablets which often pass through the intestinal tract unaltered. The proper dose is 65 mg. 3 times daily for 10 to 12 days. Children may be given 1 to 2 mg. per kilogram of body weight. If vomiting occurs, the drug may be stopped for a day or prochlorperazine dimaleate like compounds (Compazine) may be used. The symptoms of toxicity which occur when emetine hydrochloride is used by intramuscular injection are very rare when emetine bismuth iodide is used orally.

**METASTATIC AMEBIASIS**—In the treatment of metastatic amebiasis, particularly amoebic abscess of the liver, emetine has long been recognized as specific, but recently chloroquine has been found to be almost as effective. The best results are obtained when both drugs are used and such a combination is recom-



compounds is best. A number of piperazine salts, the citrate, phosphate, diphenyl acetate, etc., have been introduced by different pharmaceutical houses but they are basically similar. In the dosages recommended, piperazine produces few side effects although an occasional patient may experience nausea, vomiting, urticaria, general muscle weakness, or blurred vision. These symptoms disappear rapidly when the drug is discontinued.

An effective dosage schedule of piperazine citrate is 1 Gm daily for children up to 30 pounds in weight, 2 Gm for those weighing 30 to 50 pounds, 3 Gm for those weighing 50 to 100 pounds, and 3.5 to 4 Gm for those over 100 pounds. The dose in wafer or syrup form is given once daily for 2 consecutive days, and the program may be repeated after 1 week. No accessory purgation is required.

The simplicity, safety, and efficiency of the piperazines are eliminating the use of many compounds which were favored in the past. Santonin and oil of chenopodium are no longer considered useful. Diethylcarbamazine (Hetrazan), a substituted piperazine derivative, is not as effective as piperazine.

Hexylresorcinol, however, has good ascaricidal value but is somewhat toxic. It is administered on an empty stomach in the morning, the dose being 1 Gm for adults, 0.8 Gm for children between 6 and 10 years of age, and 0.6 Gm for those under 6 years. The capsules must be swallowed without being cracked open or chewed to avoid irritation of the buccal mucosa. A saline purge may be administered 2 hours later to facilitate removal of dead or dying worms. Food is prescribed for 4 to 5 hours to prevent gastric colic and to insure greater efficacy of the drug.

Two new bephenium but proper pyrvinium pamoate (Povan) is also being studied. Carbamazine iodide (Delvex), and the decided ascaricidal properties not available. The usefulness of

Enterobiasis—Enterobius vermicularis, popularly known as pinworm or thread worm, is most common in temperate climates. Though essentially a short lived parasite, which takes 15 to 28 days to complete its life cycle and seldom survives more than 8 weeks, the ease of reinfection accounts for the protracted course of the disease and the difficulty of effecting a cure. The negligible injury that this parasite inflicts is often exaggerated by the psychologic implication of 'having worms'. Successful treatment requires rigid enforcement of hygienic measures and simultaneous treatment of other members of the household who commonly serve as a reservoir for reinfection.

The unsubstituted piperazine salts are highly recommended for the treatment of enterobiasis. Piperazine, available in wafer or syrup form, is given once daily for 7 consecutive days according to the following schedule: for children up to 15 pounds in weight, 250 mg; 15 to 30 pounds, 500 mg; 30 to 60 pounds, 1 Gm; and for those over 60 pounds, 2 Gm. The course may be repeated after 1 week or given at regular intervals, e.g. every 3 months to keep the worm burden low in those who are reinfected. A cure rate of approximately 80 per cent may be expected with piperazine although greater efficiency has been recorded by some.

A new compound, pyrvinium, may replace piperazine as the drug of choice in the treatment of enterobiasis. Pyrvinium pamoate sold under the trade name

The best results reported thus far in the treatment of this infection have been with oxytetracycline (Terramycin), 15 to 2 Gm daily in divided doses, given for a period of 10 days. Carbarsone, 250 mg taken 4 times a day for 10 days, is also effective.

**Hookworm Infection**—Hookworm infection (*Necator americanus* and *Ancylostoma duodenale*) is one of the most prevalent helminthic diseases of man, particularly in warm climates. The worms stealthily sap the vitality of the patient long before symptoms suggest the diagnosis. If unattended the infection exacts a devastating economic and medical toll in areas where it is endemic.

Although some patients may require preliminary supportive and antianemic measures, in most the anthelmintic drugs may be used at the outset.

**(1) Tetrachloroethylene remains the drug of choice.** It is almost devoid of any toxicity provided its nonabsorption is ensured by the absence of alcohol and absorbable fat in the intestinal lumen. To guarantee its therapeutic potency, the drug should be fresh following storage in a cool, dark place. The standard procedure is to administer the drug early in the morning to a patient with a fasting stomach, following fat free liquid diet the night before. The single dose is 4 ml for an adult and 0.25 ml per year of apparent, not chronologic, age in the case of children. For the adult a saline purgative sodium sulfate (Glauber's salt) 30 Gm, is given 3 hours later in a glass of water. Recent reports suggest that better results may be obtained if the saline cathartic is omitted. Food is withheld for 4 to 6 hours following treatment.

Success of treatment should be determined upon the re examination of stool a week later, the course may be repeated if necessary. A worm removal value of approximately 90 per cent has been reported with a full therapeutic dose of tetrachloroethylene.

This drug is however unsuitable when hookworm infection and ascariasis coexist because tetrachloroethylene stimulates *Ancaris lumbricoides* to activity and grave abdominal emergencies such as intestinal obstruction or even perforation may follow migration of the parasite. To avoid this situation the treatment for hookworm infection should be preceded by one for ascariasis.

A new series of anthelmintics, the salts of bephenium including bephenium hydroxynaphthoate (Alcopara), bephenium iodide and bephenium emboate have been studied for the treatment of dog hookworm *Ancylostoma caninum* and human hookworm, especially *Necator americanus*. Although dose schedules, toxicity and efficiency of these compounds have not been evaluated fully the

3 G  
 ✓pro thought to be too dangerous—and also in those also infected with *Ancaris lumbricoides*.

**Ascariasis**—*Ancaris lumbricoides* the large intestinal roundworm is one of the most dangerous of human parasites. For its eradication one of the piperazine

blue and only slightly soluble in water, it is ordinarily not absorbed in the intestinal tract, and stools are stained blue.

Although careful clinical studies have revealed no hematopoietic, hepatic damage following the administration of therapeutic doses, acceptance of the drug by patients has been poor in our experience. Intense nausea, and some abdominal cramps with diarrhea are often reported on the first treatment and make continuation of the regimen difficult. These limitations are not important in enterobiasis and ascariasis since other drugs are available for these infections. In strongyloidiasis, which may be a serious infection, and trichuriasis, in which no other drug is adequately effective, means should be used to persuade the patient to complete the treatment.

Two methods have proved effective: (1) halve the recommended dose and treat for twice as long and (2) use antiemetics and tranquilizers such as perazine dimaleate (Compazine) the day before treatment is started and on the first 4 days.

The following is the recommended total daily dose which is divided into 4 doses and given for 10 to 14 days unless it is decided to halve the dose and administer for 20 to 28 days: children 20 to 30 pounds, 200 mg; 30 to 40 pounds, 300 mg; 40 to 50 pounds, 400 mg; 50 to 60 pounds, 500 mg; and for adults over 60 pounds, 600 mg.

Another drug somewhat effective in this condition is gentian violet administered orally in the form of enteric coated tablets. The adult dose is 10 mg 3 times a day, given with meals for a period of 16 days. The dose for children is 10 mg daily for each year of apparent age. Nausea, vomiting and colic in the abdomen at times do not permit completion of the course. Patients with a poor response with standard oral therapy may be treated with 25 ml of 1 per cent solution of the drug by transduodenal intubation.

Diethylcarbamazine (Hetrazan) has been reported to be useful in strongyloidiasis when administered orally in doses of 2 mg per kilogram of body weight daily for 20 days but this drug has not been successful in our experience.

**Trichuriasis**—Only heavy infections with *Trichurus trichiura* or whenever have been associated with symptoms of diarrhea, mild infections may be regarded as innocuous not requiring energetic treatment.

Until recently no drug could be recommended even with mild enterobiasis. Dithiazanine iodide (Delves), however, is very effective and if its toxic manifestations especially those which occur on the first or second days of its use are kept to a minimum a very high rate of cure possibly 85 to 90 per cent, may be expected. The dose schedule is identical with that described for the treatment of strongyloidiasis but should be maintained only for 5 days. The concurrent use of Compazine and other preparations is advisable in many patients (see discussion of dithiazanine under Strongyloidiasis).

In heavy infections a high retention enema with hexylresorcinol may be used. After a preliminary enema to clear the large intestine of fecal accumulation the perianal area and the buttocks are covered with a coating of petrolatum to prevent irritation. This is followed by the retention

of Povon (formerly Poquil and Vanquin) is the pamoate salt of a complex cyanine dye [6 dimethylamino-2 [2 (2,5 dimethyl 1 phenyl 3 pyrrol)vinyl] 1 methylquinolinium chloride]. It is available as a coated tablet containing 100 mg of the pyriminium base and also as a red pleasant tasting fruity suspension containing 10 mg of base per milliliter.

The drug is not absorbed from the intestinal tract. Toxic symptoms including nausea, vomiting and diarrhea are extremely rare. Patients should be warned that pyriminium colors the stools bright red and that the suspension, if spilled, will stain clothing and other materials.

Although several regimens have been tried and proved effective, pyriminium is  
 Tt  
 te

of body weight may be given and since overdosage is not dangerous, one may safely add a dose unit for any proportion of 20 or 40 pounds. For example, a 50 pound child may be given 3 teaspoonfuls (15 ml) of the suspension and a 140 pound adult may be given four 100 mg tablets.

Whether piperazine or pyriminium is used, simultaneous treatment of all members of the household is recommended. If the patient is exposed to recurrence at school, periodic treatment, e.g., every 2 or 3 months, may be necessary.

The following adjuvant measures are advised: (1) A daily shower in the morning to remove the eggs deposited in the perianal region during the night. (2) Regular application of an antipruritic ointment over the perianal area at bedtime. Mercury ointment (in petrolatum) or Perazil (chlorcycazine 1 per cent) cream serves the purpose well. (3) The use of close fitting shorts under one piece pajamas, locked by safety pins or ties at night. (4) The regular trimming of the child's nails and the scrubbing of his fingers with a brush after each visit to the toilet and the daily use of disinfectants on the toilet seats.

Gentian violet, medicinal (methylosaniline), antibiotics, tetrachloroethylene, phenothiazine, egressin, gamma benzene hexachloride, high enemas, infusions of quassia chips, and antihistaminics are not recommended.

A patient is generally considered cured when 7 consecutive perianal transparent cellophane swabs show no ova. A swab is taken each morning before bowel movement or bath, commencing one week after the end of treatment. In clinical practice, two or three negative swabs are adequate.

**Strongyloidiasis**—*Strongyloides stercoralis*, though uncommonly encountered in warm climates, has not infrequently been recorded in temperate and even in cold regions. The usual intestinal symptoms are abdominal discomfort, dyspepsia and diarrhea, alternating with constipation, tender liver, and eosinophilia.

that of any other drug. Since dithiazanine is also used for the treatment of trichuriasis and since its broad spectrum anthelmintic activity extends to pinworm and roundworm, it may be considered in some detail.

Dithiazanine is a polymethine dye, 3,3'-diethylthiadicarbocyanine iodide. Being

ning a saline purgative (30 Gm of sodium sulfate) is given. Early next morning on the empty stomach, a sedative such as phenobarbital, 60 mg, is administered orally and a duodenal tube is inserted. An hour later, 1 Gm of the quinaerine suspended in 20 ml of water is introduced through the duodenal tube and washed down with a small amount of water to prevent loss of drug in the syringe and in the tube. In case the oral administration is decided upon, 2 tablets (0.2 Gm) are given at 10 minute intervals for a total of 10 tablets (1 Gm), a little sodium bicarbonate is added each time to counteract the emetic tendency likely to attend oral medication. Two hours after the drug is administered, a saline purgative (sodium sulfate 30 Gm) is given. If a satisfactory purgation is not achieved, a sorbsuds enema should be given, after which normal diet is permitted.

For 48 to 72 hours following this therapy all stool specimens should be examined carefully for the scolex or head of the worm. The finding of the scolex indicates total expulsion of one worm but the possibility remains that more than one worm was harbored by the patient. Inability to find the scolex does not necessarily mean failure of treatment since the scolex may have been digested, lodged in the large intestine, or lost in the large bulk of worm expelled. Hence the final criterion of cure is the absence of eggs and segments in the stool for a period of 6 months following treatment. The rate of success with this technique is more than 90 per cent.

Another drug effective against tapeworm infections is oleoresin of aspidium. It may be administered through the duodenal tube as a mixture of 6 Gm of the freshly prepared oleoresin of aspidium, 30 ml of acacia, and 30 ml of a concentrated solution of sodium sulfate, no posttreatment purgative is required.

The drug may also be administered orally, 12 ml every 30 minutes for 3 doses (total 36 ml). This is followed in 2 hours by a saline purge. But a greater degree of toxicity and the difficulty in obtaining a fresh drug militate against the use of this preparation.

Recently a modification of the method prepared by De Rivas in 1932 has been designed by Rosen and Kiefer.

Before the treatment is begun the following articles should be ready at the bedside: (1) a Rehfsuss tube, (2) a 50 ml syringe, (3) a bottle of glycerin, (4) a bottle of saturated magnesium sulfate solution, (5) a thermometer (preferably centigrade), and (6) 500 ml of sterile saline solution.

The procedure for treatment is as follows: (1) Pass a Rehfsuss tube into the stomach. (2) Turn the patient on his right side and allow the tube to pass into the duodenum. (3) Check the tube by fluoroscope to be certain that the tip is well down in the second or third portion of the duodenum, beyond the ampulla of Vater. (4) When certain the tube is in position, introduce 1½ oz of magnesium sulfate solution through the tube. (5) Then introduce immediately 1½ oz of glycerin. (6) Then introduce immediately 2 oz of a mixture of equal parts of magnesium sulfate and glycerin. (7) Then introduce immediately 500 ml of the sterile saline solution which has been warmed to a temperature of 54° to 60° C or 130 to 140° F. A bucket and a bedpan should be ready in the patient's room. The bucket should contain warm water or saline solution so that if the worm is obtained it can be preserved and identified.

Of the 40 patients treated by this method 36 were considered cured, in 31 the scolex was recovered and in 5 no evidence of infection was found in 1 to 5 years.

## DRUGS FOR INTESTINAL PARASITISM

temperature, to which about 30 Gm of fine kaolin may be added to the colonic cramps. This may be repeated one week later.

**Trichinosis**—Although infection with *Trichinella spiralis* generally is causing only a "digestive upset" followed by muscular pain, it may be responsible for serious and occasionally fatal disease. The diagnosis of trichinosis, unfortunately, is difficult to establish before larvae have reached the muscles in great numbers.

With timely suspicion of the disease during its early intestinal phase attention may be made to dislodge the adult worms before they are sheltered deeply in the intestinal mucosa and before larvae are produced. Repeated administration of sodium sulfate may eliminate some of the adults so that the number of larvae available for systemic invasion is minimal. Encouraging response has been reported recently with the use of piperazine citrate in a dosage of 2 to 3 Gm. daily for one week, removing many of the adults from the intestinal tract. Since the drug is not toxic, its use is urged, although our own results have been disappointing.

Specific therapeutic agents employed against trichinosis during the stage of systemic invasion have failed. To alleviate the patient's distress, palliative measures such as bed rest, analgesics, sedatives, adequate fluids, balanced diet, saline cathartics, etc. are the essentials of treatment. Steroids such as ACTH, cortisone, and similar preparations are believed to suppress the cellular inflammatory reaction in affected muscles and to depress the eosinophilia. They are extremely useful for symptomatic relief and may be valuable in severe infections. Although the statistical evidence currently available does not provide support for the view that steroids alter the course of the disease, the drugs do afford the clinician the opportunity to offer his patient considerable relief—especially in serious situations.

**Tapeworm Infection**—Of the cestodes or tapeworms inhabiting the intestinal tract of man four deserve consideration: *Taenia saginata* (beef tapeworm), *Taenia solium* (pork tapeworm), *Diphyllobothrium latum* (fish tapeworm), and *Hymenolepis nana* (dwarf tapeworm). They have been held responsible for varying grades of vague gastrointestinal and nervous disturbances and for systemic disorders of bizarre nature attributed to the mechanical irritation, toxic products of the worms, and their ability to deprive the host of the nutritional requirements. The larvae of *T. solium*, however, are certainly dangerous since the parasite may lodge in any organ of the body, forming the stage known as *Cysticercus cellulosae*.

For the treatment of these worms, quinacrine (Atabrine) is considered best because of its high degree of efficacy and relatively low toxicity. Being a gastric irritant, the drug may cause nausea and vomiting when administered orally. Direct instillation by means of transduodenal intubation ensures a greater concentration of the drug at the required site and obviates the risk of vomiting. It should be emphasized that in *T. solium* infections reverse peristaltic waves, resulting from gastric irritation, may facilitate the transport of the eggs high in the duodenum, thus adding to the danger of cysticercosis which, unfortunately, is not amenable to any drug therapy; hence intubation should always be used in this infection.

The success of treatment depends a great deal on the careful attention to the preparation of the patient. The day before treatment the patient has a light breakfast and a liquid dinner, and only sips of water are allowed after.

2 Gm may be given in divided doses for 3 to 5 days. Nausea, vomiting, insomnia, and reddish brown discoloration of the palms and soles may necessitate reduction in the dose.

**Other Trematode Infections**—Intestinal trematodiasis occasionally results from infection with intestinal flukes, viz, *Fasciolopsis buski* (fasciolopsiasis), *Heterophyes heterophyes* (heterophyiasis), *Metagonimus yokogawai* (metagonimiasis), *Gastrocoides hominis* (gastrodiscoidiasis), *Watsonius watsoni* (watsoniasis), and the liver flukes, viz, *Fasciola hepatica* (fascioliasis), *Clonorchis sinensis* (clonorchiasis), *Opisthorchis felineus* (opisthorchiasis).

Varying grades of gastrointestinal disturbances with or without other systemic disorders are produced by these parasites, and therapeutic efforts are justified even if they are inefficient.

For the treatment of infection by intestinal flukes the drugs found useful are tetrachloroethylene and hexylresorcinol. Emetine is considered effective in the treatment of the liver fluke infection, fascioliasis, and is employed in the same manner as for the treatment of amebiasis. Success has been reported in the treatment of the liver fluke infections clonorchiasis and opisthorchiasis with gentian violet medicinal 60 mg orally, 3 times daily with meals for 30 days. Another drug reputedly effective for this purpose is chloroquine administered orally, 0.5 Gm daily for 4 weeks. Our own experience with antitrematode measures has been depressing.

## RATIONAL BASIS FOR DRUG THERAPY OF INTESTINAL PARASITISMS

The rapid introduction of therapeutic agents for the treatment of intestinal parasitism, the multiplicity of preparations which are pharmacologically similar but have been altered somewhat to permit proprietary labeling, and the differing evaluations placed on the efficacy of important drugs by experts in the field have caused considerable confusion to the clinician.

For example, in the treatment of intestinal amebiasis there are those who insist on the use of emetine whereas others consider the drug unnecessary or dangerous. The halogenated quinolines such as diiodohydroxyquin are thought to be very effective by some and almost useless by others. In annual succession, bacitracin, Aureomycin, Terramycin, and fumagillin were described as the drug of choice until the percentages of reported cures dropped rapidly.

The merits of an ideal drug for the treatment of intestinal parasitism can be conveniently listed as follows: (1) maximum efficacy, (2) minimum toxicity, (3) good margin of safety between the therapeutic and the toxic doses, (4) broad spectrum of activity, (5) suitability for children and the critically ill, (6) ease of administration in an agreeable form, (7) short duration of treatment, (8) low cost, and (9) easy availability.

One may anticipate the appearance within the next few years of many different drugs, some with entirely new pharmacologic principles, for the elimination of parasites, e.g., folic acid antagonists such as Daraprim for the prevention of malaria. Cautious evaluation of claims must be made and enthusiasm withheld until several reports from reliable investigators in various parts of the world are





## THE CHOICE OF DRUGS FOR DISEASES OF THE HEART

*Walter Modell, M D*

---

### THE CHOICE OF A DIGITALIS MATERIAL

#### INTRODUCTION

The problem of the choice of a digitalis material is as old as its use in medicine. In 1785, Withering debated whether foxglove or squill was the better for dropsy. He chose the former because of greater consistency in effectiveness, with less nausea and vomiting. While there is universal agreement that Withering's contribution to medicine was a great one, there is no such agreement that he made the proper choice of a digitalis material. Doubt along these lines has increased with the introduction of still more digitalis materials.

If anything Nature has been overgenerous with digitalis materials, they are to be found in the skin of toads and in weeds in back yards, they are found in plants indigenous to all corners of the earth. It is certainly something for which to be grateful that chemists have not yet learned how to synthesize members of this group of drugs to further complicate the problem of their choice. The use of digitalis has geographic features. The American market has a large armamentarium of its own; foreign usage differs depending often on the availability of natural sources of digitalis materials.

#### CLINICAL APPLICATIONS

The differences between the digitalis materials are quantitative, qualitatively they are all similar, the basis of a choice lies in the way the differences in parameters of action make one or another better suited for a specific clinical need. The discussion of the actions of digitalis which follows may be applied to all members of this large group.

**Heart Failure**—There is a clinical impression that digitalis is not equally effective in all cases of heart failure. However, it can be stated categorically that unless there is a specific contraindication, e.g., digitalis intoxication or ventricular tachycardia, digitalis is invariably indicated in heart failure.

#### SELECTED REFERENCES

- Anderson, H. H., Bastick, W. L., and Johnstone, H. C. Amebiasis, Pathology, Diagnosis and Chemotherapy, Springfield, Ill., 1953, Charles C. Thomas.
- Belding, D. L. Basic Clinical Parasitology, New York, 1958, Appleton Century Crofts, Inc.
- Brown, H. K., Chan, K. F., and Hussey, K. L. Treatment of Enterobiasis and Ascariasis.
- Forkner, C. E. Amebiasis, Practitioners' Conference Volume 5, New York, 1957, Appleton-Century Crofts, Inc.
- Forkner, C. E. Parasitic Infection, Enterobiasis, Practitioners' Conference Vol. 5.
- Frye, W. E. Amebiasis, Manson, C. B., Jr. and Anderson, R. W., Tropical Medicine and Hygiene, 6: 1-10, 1957.
- Goodwin, L. G., Jayewardene, L. G., and Standen, O. D. Clinical Trials With Bephenium Hydroxynaphthoate Against Hookworm in Ceylon, Brit. M. J. 1: 1572, 1958.
- Kranz, B. H. The Treatment of the Commoner Parasitic Diseases, M. Clin. North America 37: 903, 1953.
- Manson, Bahr, P. Amebiasis and Amoebic Dysentery, Brit. J. Clin. Pract. 11: 709, 1957.
- Monto, A. S. The Liver in Ulcerative Disease of the Intestinal Tract: Functional and Anatomic Changes, Ann. Int. Med. 50: 1385, 1959.
- Rodrigue, J. Amebiasis, Manson, C. B., Jr. and Anderson, R. W., Tropical Medicine and Hygiene, 6: 1-10, 1957.
- Rogers, I. Amebiasis, Manson, C. B., Jr. and Anderson, R. W., Tropical Medicine and Hygiene, 6: 1-10, 1957.
- Rosen, S. Amebiasis, Manson, C. B., Jr. and Anderson, R. W., Tropical Medicine and Hygiene, 6: 1-10, 1957.
- Sodeman, J. A. M. A. 148: 285, 1952.
- Swartzwelder, J. C., Frye, W. W., Muhleisen, J. P., Miller, J. H., Lampert, R., Chararria, A. P., Abadie, S. H., Anthony, S. O., and Sappenfield, R. W. Dithiazanine, an Effective Broad Spectrum Anthelmintic, J. A. M. A. 165: 2063, 1957.
- Tropical Diseases Bulletin, Bureau of Hygiene and Tropical Diseases, London. (This publication provides a "running" summary of all new advances in the field.)

**HEART FAILURE AND AURICULAR FIBRILLATION**—The combination of heart failure with auricular fibrillation provides the cardiodynamic setting for which digitalis seems to be best suited. Digitalis is so much more dependable in this situation than in other forms of heart failure that it strongly suggests that here, in addition to increasing the force of ventricular contraction, the direct action of digitalis to slow the ventricular rate adds to its usefulness. However, the superior results may be due to the fact that digitalis can be used with greater ease and safety than in other types of heart failure, and a satisfactory degree of digitalization, therefore, is more consistently obtained, for the consistent slowing of the ventricular rate by digitalis provides an end point of drug action found in no other clinical condition, the ventricular rate can be used as a sensitive guide to dosage.

The choice of a digitalis preparation depends largely on urgency. If rapid action is needed, a parenteral preparation should be chosen, if there is time, digitalis toxin is the drug of choice.

**HEART FAILURE WITH RAPID NORMAL SINUS RHYTHM**—The action of digitalis to slow the heart rate is indirect in this situation and depends entirely on whether the digitalis improves myocardial function sufficiently to bring about reflex slowing. In so far as digitalis is indicated in all cases of heart failure, it is indicated here, the particular material depends on the urgency.

**AURICULAR TACHYCARDIA**—As explained elsewhere (page 409), digitalis is useful in the relief of auricular tachycardia. In this situation, maneuvers which intensify vagal tone (eyeball pressure, carotid sinus pressure, emesis) may slow the tachycardia temporarily or bring it to an end. When these fail, digitalis may be used to increase the sensitivity of the sinus node to the vagal tone. After the effect of digitalis has developed, the maneuvers once ineffective, may terminate a sinus tachycardia. The situation calls for a rapid acting digitalis material. The parenteral route is probably also preferable.

**AURICULAR FLUTTER**—The uses and choice of a digitalis material in auricular flutter are considered in detail on page 409.

**AURICULAR FIBRILLATION**—The uses and the choice of a digitalis material in auricular fibrillation are considered on page 409.

**HEART BLOCK**—The uses and the choice of a digitalis material in heart block are considered on page 411.

**OTHER CARDIAC ARRHYTHMIAS**—Digitalis exerts no pharmacologic action which can be counted upon per se to restore a normal sinus rhythm in the case of cardiac arrhythmia arising from an ectopic focus. Its special action in auricular flutter is described elsewhere (page 409) and involves the induction of auricular fibrillation, while its action in auricular fibrillation is to preserve the arrhythmia while slowing the ventricular rate. It is probably dangerous in ventricular tachycardia and fibrillation.

There are instances, however, in which, following the administration of digitalis, arrhythmias disappear and normal rhythm returns. In such instances it must be assumed that the arrhythmia was secondary to the relative hypoxia or cardiac distention of the heart failure and that, with the relief of the heart failure, the cause of the arrhythmia was removed. This result of digitalization is not regularly seen and cannot be counted upon. On the other hand, since digitalis is indi-

**LEFT HEART FAILURE**—Left heart failure is characterized by increased fluid in the pulmonary bed. At times it is seen as frank edema, with râles, acute pulmonary edema, paroxysmal nocturnal dyspnea, etc. At other times, râles cannot be heard nor can fluid be demonstrated by clinical examination. In the latter, the only evidence for excess fluid in the pulmonary bed is the presence of dyspnea on effort and orthopnea. These symptoms are accepted by some, but not all, as the earlier manifestations of left heart failure caused by the transudation of fluid into the intercellular spaces, small in amount, but sufficient to interfere with respiratory function. Subsequent development of frank pulmonary edema in these patients tends to substantiate the concept. It is also conceivable that even without transudation of fluid, but merely on the basis of poor circulation through the pulmonary bed, symptoms of defective respiratory exchange may develop.

Although the left heart failure syndrome is the result of deficiency in cardiac action and although digitalis is indicated, the effects of digitalis alone are not impressive and do not satisfy the clinical needs of most patients.

The basis of this form of cardiac failure may be speculated upon, for it may explain why digitalis cannot help much. Left heart failure is commonly seen as a consequence of hypertension and rheumatic heart disease with a tight mitral valve. The difficulty in these situations, in the early stages at least, is not so much that the cardiac muscle is feeble as that a normal or nearly normal myocardium cannot cope with the mechanical barrier to the flow of blood—the tight mitral valve in one case and the constricted arteriolar bed in the other. Further increase in the force of contraction by digitalis cannot be expected to diminish appreciably the transudation of fluid due to the attempt to force fluid at a high pressure through a constricted passage.

In the acute attack of left heart failure, e.g., that seen after an acute myocardial infarction, digitalis may perhaps be expected to accomplish more. Here the need is urgent. In this instance, a rapid acting preparation administered parenterally is usually required.

**RIGHT HEART FAILURE**—While our understanding of the mechanism of right heart failure is more confused than that of left heart failure, there is greater agreement that the digitalis materials are useful. Peripheral edema in the extremities and even the abdomen may disappear after a diuresis induced by the effects of digitalis.

Since right sided heart failure per se, even with massive edema, does not threaten life, urgent measures are not usually necessary. Edema of the extremities can be removed more gradually because, unlike edema in the pulmonary bed, it does not impinge on vital function. Where accumulation of ascitic fluid causes distress, the quickest and surest method of relief is paracentesis.

In my hands, the results with digitoxin have been satisfactory in right sided heart failure for digitalization as well as maintenance. With few exceptions, I find it the drug of choice for digitalization and maintenance. The relatively low cost of the preparation is another consideration. On the other hand, when a parenteral preparation is necessary to obtain results quickly, other digitalis materials are more desirable.

due to a shift from supraventricular to idioventricular pacemaker. In other situations, prolongation of the conduction time, partial block, or complete auriculoventricular dissociation is undesirable.

**MYOCARDIAL AUTOMATICITY**—Digitalis increases myocardial automaticity, inducing premature ventricular contractions, coupling, ventricular tachycardia and ventricular fibrillation as well as auricular disturbances. These are toxic actions. This action of digitalis may, however, be used to increase the idioventricular rate in heart block.

**VOMITING**—Vomiting is a toxic effect which results from both local and systemic actions of digitalis. These are discussed below.

**OTHER CENTRAL NERVOUS SYSTEM EFFECTS**—In the rat, convulsions are seen consistently after squill, but also after other preparations. Convulsions are not seen in man but central stimulation has been reported. The action of digitalis on vision is a central nervous system effect. This sign is a substantial warning that further digitalization may be dangerous.

**DIURETIC ACTION**—From time to time, the question of a direct action of digitalis on the kidneys to cause diuresis is brought up. There is old evidence that this does occur in animals. It is more often observed when a very rapid acting digitalis material such as acetyl strophanthidin is used. The action is inconsistent and always brief. Therefore, while there is evidence of a diuretic effect of digitalis exerted through a direct action on the kidney, there is no evidence that this is a clinically significant digitalis action. As a matter of fact, it is probably of no practical importance at all.

**Parameters of Action**—Digitalis materials all share the actions just described. Their major differences lie in the parameters of these actions, and it is on the basis of these differences that one or another is the more desirable in a particular situation.

**POTENCY**—Digitalis materials vary greatly in potency. Ouabain the most potent of pure glycosides in common use has a cat unit value of 0.1 mg. Digitoxin, which is one of the less potent of the commonly used purified glycosides has a cat unit value of 0.4 mg. The partially purified materials and the crude mixtures are far less potent. Thus an average specimen of the leaf of *Digitalis purpurea* has about one thousandth the potency of digitoxin.

The significance of these differences in potency is less impressive than their magnitude seems to suggest. Provided the appropriate dose is administered and absorption is taken into account, the same therapeutic effects can be produced despite the differences in absolute potency. This is why the concept of the human unit of digitalis, which involves absorption in the human gastrointestinal tract, is so useful, it reduces all the digitalis glycosides to a common biologic denominator.

**TOXICITY**—This may be separately considered as local action in the gastrointestinal tract due to the physical and chemical nature of the drug and as systemic actions representing the effects of the drugs after they have entered the circulation. Hypersensitivity to digitalis materials occurs so rarely that no statement can be made about their relative potential or danger in this regard.

**Local Irritant Action**—Local irritant actions in the gastrointestinal tract are usually considered to be minor toxic symptoms and not a threat to the patient.

cated in virtually all cases of cardiac failure, this indirect effect is likely to be obtained in every instance in which the full benefits of digitalis are obtained through its proper use in the treatment of heart failure

**CARDIAC PAIN**—Digitalis does not relieve cardiac pain. When it appears to do so, it may be presumed (as in the case of the arrhythmias) to be secondary to the relief of heart failure

**WEAKNESS AND FATIGUE**—Digitalis has no direct effect on weakness and fatigue in heart disease. Where its use is followed by improvement in these symptoms, it must be assumed that the symptoms were manifestations of heart failure which was relieved by digitalis

## PHARMACOLOGIC BASIS OF THERAPY

The pharmacodynamic actions of all digitalis materials are qualitatively the same; they differ only in the parameters of action

**Pharmacodynamic Actions**—Digitalis has a number of actions. The following have the more important clinical implications: (1) intensification of vagal influence on the heart; (2) increase of force of contraction of the ventricle; (3) depression of conduction; (4) stimulation of myocardial automaticity; (5) stimulation of the vomiting center; (6) other central nervous system effects; (7) diuretic action

**VAGAL INFLUENCE ON THE HEART**—Digitalis slows the heart through intensification of vagal influence on the sinus pacemaker. Although there are other views, this action may be presumed to be due to a lowering of the threshold of the sinus node to vagal tone. It does not significantly slow a normal cardiac mechanism in man and has practical use only in the relief of auricular tachycardia. This slowing action can sometimes be demonstrated in the normal dog with rapid acting digitalis materials such as acetyl strophanthidin

Slowing is usually the result of other digitalis actions. When digitalis relieves heart failure, this reduces the stimulus to cardiac acceleration and reflexly results in slowing of the sinus pacemaker. In auricular fibrillation slowing may also be due to direct depression of A-V conduction. This applies only to the ventricular rate; digitalis accelerates the auricular rate in auricular fibrillation

**FORCE OF CONTRACTION**—There is substantial evidence that digitalis increases the force of contraction of the ventricle, but this action cannot be demonstrated on normal muscle. In the laboratory the isolated strip of cardiac muscle must first be fatigued; at this point, digitalis markedly increases the strength of the contraction. The same is true in man. Digitalis has no perceptible effects on cardiovascular function of the normal heart. On the other hand, there may be profound improvement in myocardial function in heart failure. It is important clinically that digitalis cannot be expected to improve myocardial function unless it is deficient. On the other hand, in cases of congestive failure in which digitalis does exert this action, the improvement in cardiodynamics produces a secondary effect on the kidney, resulting in the classic diuresis after digitalis

**DEPRESSION OF CONDUCTION**—This action is therapeutic or toxic, depending largely on the situation in which it develops. It is the basis of an important therapeutic effect in the treatment of auricular fibrillation. In the Adams Stokes syndrome, digitalis may be used to fix heart block, thus to prevent syncopal attacks

**ABSORPTION**—There are the widest possible variations in the degree of absorption of the various glycosides

**Gastrointestinal** Ouabain is not absorbed from the gastrointestinal tract. Digoxin is practically completely absorbed from the intestinal tract. It may be fairly stated that there is no other pure glycoside now available which is completely absorbed. The other glycosides lie between these extremes. Acetyldigoxin is probably only 60 per cent absorbed. Digoxin is about half absorbed, while some, like eduland, are probably only 10 to 20 per cent absorbed.

**Rectal** Almost always this route is used only when the oral is not feasible. No precise measurements have been made of the relative extent of absorption by this route. It has been assumed to approximate the oral in speed as well as extent.

**Intramuscular** This route of administration is convenient and avoids the dangers inherent in the intravenous route. While it seems unquestionable that digitalis materials are absorbed after intramuscular injection, there is little precise information on the relative speed of development of action after this route of administration. It is generally assumed that absorption is more or less complete.

It has been found that, after intramuscular injection, Lanoxin (digoxin) effects do not develop any more rapidly than after oral administration. Much the same is true of digitoxin. As matters stand, therefore, there seems to be no evidence of an advantage in time in the intramuscular administration of digitalis materials. This route, however, is available when oral or rectal or intravenous administration is not feasible.

**Intravenous** The intravenous route of administration of digitalis materials may well be considered here, because, though there are no problems of absorption into the blood stream, even by this route, there are issues of importance related to delay in the development of effects. As might be expected, by this route of administration effects develop more rapidly than by any other. It is noteworthy, however, that this difference is not invariably great enough to be of practical importance. In the case of digitoxin, for example, even after intravenous injection, there is a delay of about 6 to 8 hours before effects are fully developed, while the period for full development of effects after oral administration is not much longer, about 8 to 10 hours. The difference between rates of development of action after the two routes of administration is more distinctive in the case of Lanoxin (digoxin). In the case of some, such as acetyl strophanthidin and thevetin, effects come on almost instantaneously after intravenous injection. These two, however, are not well absorbed from the gastrointestinal tract. Effects from ouabain develop fully within about 90 minutes after intravenous injection—much the same as for Lanoxin.

The reason for latency after intravenous injection is not established, it is probable that it has to do either with some process of biotransformation which alters the drug to the form which actually induces the typical digitalis actions or to some process of cellular absorption. In any event, it is the period of latency which makes the digitalis more useful than another in the circumstance which indicates the administration of a digitalis material by the intravenous route.

The dangers incident to the intravenous injection of digitalis materials are not fundamentally different from those which complicate the administration of any other drug when the intravenous route is chosen. The rapidly acting digitalis materials

On the other hand the emesis may interfere with the regimen of medication, while the exertions incident to vomiting may be dangerous. Vomiting due to a local action usually develops within half an hour after the oral administration of relatively large doses. It may be due to impurities in the preparation although the purified glycosides also can induce a local emetic action.

The relatively pure glycosides simply because they contain less extraneous material are less likely to irritate the gastrointestinal tract, to induce nausea or vomiting than the same glycosides in cruder form. Thus 12 mg of digitoxin is less likely to induce vomiting than an equivalent biologic dose of the pulverized leaf of *D. digitalis purpurea* (12 Gm). This difference in irritant action is more likely to result in symptoms when large doses are used for digitalization than when small doses are used for maintenance.

While there are differences in the local emetic action of the purified glycosides these have not been precisely evaluated but are probably not significant.

**Systemic Actions** In so far as all digitalis glycosides have the same pharmacologic actions on the heart and the central nervous system their systemic toxic actions are the same. In each instance the development of systemic nausea or vomiting, xanthopsia or cardiac arrhythmias represent about the same relationship to the development of therapeutic effects. That is to say, the therapeutic ratio is about the same for all the glycosides. Contrary statements will be found in the literature but here careful analysis will reveal either that the doses compared were not biologically equal or that the ratio was developed on the basis of local effects. It is my opinion that there is no satisfactory evidence that any one digitalis glycoside has a greater biologic tendency to induce cardiac arrhythmias or vomiting than the others.

It is important that the action of digitalis on the vomiting center, which is so significant a warning may disappear with continued digitalization. This may be why serious poisoning is encountered more often in the patient taking digitalis daily than after the fairly rapidly induced initial digitalization.

The importance of serum and intracellular potassium in the development of cardiac arrhythmias is increasingly attracting attention. The evidence is definite that disturbances in rhythm due to digitalis are enhanced by reduction in intracellular potassium. This is not specific for any one glycoside but applies equally to all. It is not a factor in the choice of digitalis materials. On the other hand the indiscriminate treatment of all disturbances of cardiac rhythm in patients receiving digitalis with potassium has met with utter failure.

The recent report of Gubner and Kallman that based on the reciprocal relationship between blood calcium levels and digitalis toxicity systemic digitalis intoxication may be treated by chelation of blood calcium is both interesting and encouraging and is now supported by the experience of others.

**Therapeutic Ratio** Although others differ some vehemently, it is my opinion that there are no significant differences in the therapeutic ratios of the purified glycosides. There are practical differences between mixtures and impure materials. These are largely proportionate to the amount of impurity which is administered with the glycoside. These differences become relatively insignificant, however when the drug is given in small single doses for maintenance.



**INITIAL DIGITALIZATION**—The average digitalizing dose has been the subject of acrimonious dispute. In actual fact the term has many meanings because in different hands different therapeutic end points are used.

I think the concept of Gold that 1.2 mg of digitoxin is the average single full digitalizing dose would benefit by some explanation. Gold's data were obtained from patients with auricular fibrillation. These patients were used because they are the most sensitive objective clinical indicators of digitalis action. In the strictest sense, therefore, the principle of dosage which he has set refers specifically to patients with auricular fibrillation, although there is every reason to suppose that they apply to the use of digitalis in heart failure in general.

Gold's dose was determined as the largest single dose which could be used with a negligible incidence of nausea. Only 3 per cent suffered nausea or vomiting and no patient in his large series had any disturbance of cardiac rhythm after a single dose of 1.2 mg of digitoxin. When the dose was raised to 1.5 mg untoward effects rose to about 15 per cent, and with a 1.8 mg dose to about 33 per cent.

It is my feeling that it is the use of the word *full* which stands in the way of the understanding and acceptance of Gold's dosage. The 1.2 mg dose of digitoxin is by no means a full dose for most patients. The dose of 1.2 mg is really a safe starting dose; many patients require more, a very few should get less. In this sense it applies to all the situations in which digitoxin may be used.

There would have been less confusion and perhaps more precision if the dose had been called a safe single initial digitalizing dose. It is well to remember in this connection that 1.2 mg of digitoxin represents only 3 cat units. This is biologically equivalent to 0.3 mg of ouabain. Few are fearful of injecting 0.5 mg of ouabain intravenously. Security in this dosage of ouabain lies in the fact that it has been accepted that the full dose of ouabain is 1 mg. Yet the physician who gives 5 cat units of ouabain intravenously without hesitation is reluctant to give 3 cat units of digitoxin by mouth. I can explain this inconsistency only by the fact that the latter has been called a full dose, and we all hesitate to use a full dose at one time in fear that it may be excessive for sensitive patients.

In any event the initial digitalizing dose should be the one which will provide as much digitalis effect in one dose as is possible without hazard. In the case of digitoxin this happens to be 1.2 mg. Dosage with other materials varies with their absolute potency. The logical basis for the choice of a material for digitalization is largely dependent on the urgency of the situation.

**Cumulation Method of Digitalization** The amount of digitalis excreted is a relatively fixed percentage of the amount in the body so that when daily doses are given digitalis effects tend to cumulate and eventually full digitalization is achieved. It is therefore possible to digitalize by the daily administration of a small dose.

It requires considerable trial before satisfactory adjustment of the daily dose is made. It should be mentioned that the more rapidly eliminated the digitalis material the more difficulty there is in digitalization by this method. Here it is that digitoxin is by all odds the drug of preference. It should be stated however that since digitalis leaf provides its effects principally through its digitoxin content it also has these advantages and that given in the relatively smaller doses required

provide a decided convenience in producing their effects within a period of time in which it is practical to keep the patient under constant careful supervision. They are also fortunate as a group of drugs in having correspondingly rapid elimination characteristics so that in the event of overdigitalization this effect is more rapidly taken care of by time alone.

**DEVELOPMENT OF EFFECTS**—There are great differences in the rate of the development of the effects of the digitalis materials. There are, on the one hand, glycosidal materials like thevetin and acetyl strophanthidin which produce almost instantaneous effects so that even before the intravenous injection is completed the effects are seen and within 15 minutes are fully developed. At the other extreme is digitoxin which requires perhaps 3 hours for perceptible effects and 6 to 8 hours for full development after an intravenous dose. Between these extremes lie digoxin and ouabain which require about 30 minutes for the appearance of significant effects and close to an hour and a half for full effects after the intravenous injection of a dose. These statements relate to intravenous injections only. When they are given by the oral route, the time required for absorption slows the development of effects while incomplete absorption reduces the peak of effects thereby tending to reduce the difference in the rate of development of full effects of different glycosides, e.g., digitoxin and digoxin.

**ELIMINATION**—Elimination of digitalis materials can be measured only in terms of biologic effects; it is a highly individualized characteristic. Thus virtually all the effects of a single dose of acetyl strophanthidin disappear within an hour or so after an injection while the effects of an equal biologic dose of digitoxin may persist for as long as 2 weeks. Between these two extremes are drugs like Lanoxin (digoxin) and ouabain, the greater part of their effects are eliminated within 24 hours. It is of practical importance that while oral administration tends to reduce the difference in the rate of development of effects of different glycosides it has relatively little influence on the difference in the relative rates of the dissipation of effects.

**CURVE OF ACTION**—From the foregoing it is clear that the curve of action of digitalis materials tends to be symmetrical, those which develop their actions with great speed are speedily eliminated and those which develop their actions slowly are slowly eliminated. Obviously this affects the choice of the best drug for rapid digitalization and the best for maintenance.

**Dosage**—The principles of dosage laid down by Withering still obtain: "Let it be continued until it either acts on the kidneys, the stomach, the pulse, or  
se effects."

Whether . . . of digitalis depends on the use for which it is intended, the nature of the effect sought and the amount found to be necessary to produce it. Dosage depends on the specific pharmacologic aim: in auricular flutter it is the development of auricular fibrillation; in heart block it is an increase in idioventricular rate; in sinus tachycardia it is intensification of vagal tone; in auricular fibrillation it is slowing of the ventricular rate; and in heart failure with a normal sinus rhythm it is increase in force of ventricular contraction.

**INITIAL DIGITALIZATION**—The "average digitalizing dose" has been the subject of acrimonious dispute. In actual fact, the term has many meanings because in different hands different therapeutic end points are used.

I think the concept of Gold that 1.2 mg of digitoxin is the "average single full digitalizing dose" would benefit by some explanation. Gold's data were obtained from patients with auricular fibrillation. These patients were used because they are the most sensitive objective clinical indicators of digitalis action. In the strictest sense, therefore, the principle of dosage which he has set refers specifically to patients with auricular fibrillation, although there is every reason to suppose that they apply to the use of digitalis in heart failure in general.

Gold's dose was determined as the largest single dose which could be used with a negligible incidence of nausea. Only 3 per cent suffered nausea or vomiting and no patient in his large series had any disturbance of cardiac rhythm after a single dose of 1.2 mg of digitoxin. When the dose was raised to 1.5 mg untoward effects rose to about 15 per cent, and, with a 1.8 mg dose, to about 33 per cent.

It is my feeling that it is the use of the word 'full' which stands in the way of the understanding and acceptance of Gold's dosage. The 1.2 mg dose of digitoxin is by no means a 'full' dose for most patients. The dose of 1.2 mg is really a safe starting dose, many patients require more, a very few should get less. In this sense it applies to all the situations in which digitoxin may be used.

There would have been less confusion and perhaps more precision if the dose had been called a "safe single initial digitalizing dose." It is well to remember in this connection that 1.2 mg of digitoxin represents only 3 cat units. This is biologically equivalent to 0.3 mg of ouabain. Few are fearful of injecting 0.5 mg of ouabain intravenously. Security in this dosage of ouabain lies in the fact that it has been accepted that the 'full' dose of ouabain is 1 mg. Yet the physician who gives 5 cat units of ouabain intravenously without hesitation is reluctant to give 3 cat units of digitoxin by mouth. I can explain this inconsistency only by the fact that the latter has been called a "full" dose, and we all hesitate to use a 'full' dose at one time in fear that it may be excessive for sensitive patients.

In any event, the initial digitalizing dose should be the one which will provide as much digitalis effect in one dose as is possible without hazard. In the case of digitoxin this happens to be 1.2 mg. Dosage with other materials varies with their absolute potency. The logical basis for the choice of a material for digitalization is largely dependent on the urgency of the situation.

**Cumulation Method of Digitalization** The amount of digitalis excreted is a relatively fixed percentage of the amount in the body so that, when daily doses are given, digitalis effects tend to cumulate and eventually full digitalization is achieved. It is therefore possible to digitalize by the daily administration of a small dose.

It requires considerable trial before satisfactory adjustment of the daily dose is made. It should be mentioned that the more rapidly eliminated the digitalis material, the more difficulty there is in digitalization by this method. Here it is that digitoxin is by all odds the drug of preference. It should be stated, however, that since digitalis leaf provides its effects principally through its digitoxin content, it also has these advantages and that given in the relatively smaller doses required

## FACTORS FOR HEART DISEASE

by this method of digitalization the incidence of locally induced nausea likely to be higher than with digitoxin. The physician is warned here possible by this method of administration to cumulate to toxic levels when the amount excreted daily equals the daily dose, there is no further elimination and the biologic effect is stabilized. This dose then becomes the maintenance dose.

**MAINTENANCE**—Maintenance implies even and sustained digitalis. Often this means the regimen for the remainder of the patient's life. Satisfactory maintenance is therefore a major therapeutic accomplishment. Unfortunately there is no universal maintenance dose for any digitalis material. If effects are to be maintained the rate of administration must equal the rate of elimination. This requires a manipulation of dosage which takes into account maintenance dose must therefore be adjusted in such a way that the biologic effect is sustained. It is not surprising therefore that often maintenance of the range of individual variation of the elimination as well as the absorption of the digitalis material is more troublesome than the usual digitalization. The latter can often be accomplished in a day or so, the former may take weeks.

The maintenance dose also varies with digitalis materials depending on elimination as well as potency. Thus in the case of acetyl strophanthidin which is almost completely eliminated in an hour or so doses close to the initial digitalizing dose have to be given every few hours while in the case of digitoxin from one sixth to one twelfth of the initial dose may be all that is necessary. Between these extremes lies digitoxin about one-third of the initial dose being required to maintain effect. In the case of the relatively rapidly eliminated drugs the effect is not maintained on a completely even keel however but tends toward crests and troughs during the course of the day. Because of this it has been suggested recently that these materials are better administered 3 times a day whereas a level effect may be obtained with a single dose of digitoxin. For these reasons once the dose is established the slowly eliminated digitoxin is the drug of choice for maintenance.

**TOLERANCE**—Pharmacologic tolerance of the heart muscle to digitalis does not develop. Patients who once did well on digitalis often do not continue to respond as well after the long continued use of the same dose but here progression of the heart disease is usually the cause. In some of these cases, increase in the dose of digitalis may be helpful but if the patient was well digitalized initially increase in dosage is rarely helpful and may cause trouble.

**DIGITALIS TOLERANCE TEST**—A test utilizing the principle of biologic titration has been introduced to determine whether a patient will react adversely to a relatively large dose of digitalis such as would be used for rapid digitalization. This is an important problem at all times, but it is especially so when it is not known whether a patient has had digitalis recently or when there is the question of how much of previously administered digitalis has not yet been eliminated. In the test the rapid acting glycosidal material acetyl strophanthidin is given. The effect on the electrocardiogram is observed. Intolerance to digitalis is indicated by the development of electrocardiographic evidence of toxicity. The defense of the method lies in the rapid elimination of digitoxin. If toxic effects develop they may be expected to disappear.

therefore, without disaster. This has not always proved to be the case, and in two series totaling about 40 patients there were two fatalities as a result of the test. I, for one, could never defend so hazardous a test for use in a problem which can usually be solved with care and patience.

A more recent test depending on the reciprocal relationship between blood calcium levels and the electrocardiographic effects of digitalis is discussed on page 798. Here injections of calcium gluconate sufficient to elevate blood calcium levels are used to establish the presence or absence of digitalis action. Toxic effects may be overcome by the intravenous injection of chelating agents to reduce blood calcium levels.

**Summary**—Much pointless argument has developed about the choice of digitalis materials while differences between members of other pharmacologic groups have not engendered as much heat.

There are some 60 barbiturate drugs available, yet only the manufacturers seem to have strong personal feelings about their choice. It is recognized that the therapeutic ratios of all the members of the barbiturates are about the same and no supportable argument can be presented for superiority on that basis. The only meaningful differences lie in the parameters of their action: some are more slow to develop their actions than others; some more quick to eliminate theirs than others. These differences make one a useful anesthetic, another a good sedative or hypnotic.

The analogy of barbiturates with the digitalis materials suggests the basis for choice. The rapid acting digitalis materials are clearly more desirable for parenteral use in urgent situations than the slow acting ones. On the other hand the slowly eliminated ones are clearly preferable for maintenance of effects. Where there is danger of overdigitalization the more rapidly eliminated digitalis materials provide a greater degree of safety in rapid dissipation of possible excessive effects.

The cruder preparations have only the advantage of cost. This differential has been considerably reduced by improvements in manufacturing processes so that the small difference in cost may now be defensible in terms of convenience and decrease in local irritant action. But it should be remembered that there is no digitalis action on the heart which cannot be developed just as well with the crude preparation as with the same glycoside with the impurities removed.

## THE SEVERAL DRUGS

**Crude Digitalis Materials**—Only tablets made of the pulverized and hydroalcoholic extracts of the leaf (i.e., tinctures) of *Digitalis purpurea* are still in use in this country. The chief if not the only glycoside in these preparations which is absorbed from the gastrointestinal tract is digitoxin. They might well be considered merely crude preparations of digitoxin. The use of these crude preparations is declining.

**Purified Digitalis Glycosides**—These are represented by relatively pure crystalline and amorphous glycosides and mixtures of glycosides. The materials now in use are extracted from *Digitalis purpurea*, *Digitalis lanata*, *Strophanthus gratus*, *Strophanthus kombé*, and squill.

**OUBAIN**—For many years ouabain was the standard against which all digitalis

by this method of digitalization, the incidence of locally induced nausea is not likely to be higher than with digitoxin. The physician is warned here that it is possible by this method of administration to cumulate to toxic levels. However, when the amount excreted daily equals the daily dose, there is no further cumulation and the biologic effect is stabilized. This dose then becomes the maintenance dose.

**MAINTENANCE**—Maintenance implies even and sustained digitalis action. Often this means the regimen for the remainder of the patient's life. Satisfactory maintenance is therefore a major therapeutic accomplishment. Unfortunately, there is no universal maintenance dose for any digitalis material. If effects are to be maintained the rate of administration must equal the rate of elimination. The maintenance dose must therefore be adjusted in such a way that the biologic effect is sustained. This requires a manipulation of dosage which takes into account the range of individual variation of the elimination as well as the absorption of the digitalis material. It is not surprising, therefore, that often maintenance requires more attention and is more troublesome than the initial digitalization. The latter can often be accomplished in a day or so, the former may take weeks.

The maintenance dose also varies with digitalis materials, depending on elimination as well as potency. Thus in the case of acetyl strophanthidin which is almost completely eliminated in an hour or so, doses close to the initial digitalizing dose have to be given every few hours, while in the case of digitoxin from one sixth to one twelfth of the initial dose may be all that is necessary. Between these extremes lies digoxin about one third of the initial dose being required to maintain effect. In the case of the relatively rapidly eliminated drugs the effect is not maintained on a completely even keel, however, but tends toward crests and troughs during the course of the day. Because of this, it has been suggested recently that these materials are better administered 3 times a day, whereas a level effect may be obtained with a single dose of digitoxin. For these reasons, once the dose is established the slowly eliminated digitoxin is the drug of choice for maintenance.

**TOLERANCE**—Pharmacologic tolerance of the heart muscle to digitalis does not develop. Patients who once did well on digitalis often do not continue to respond as well after the long continued use of the same dose, but here progression of the heart disease is usually the cause. In some of these cases, increase in the dose of digitalis may be helpful, but if the patient was well digitalized initially increase in dosage is rarely helpful and may cause trouble.

**DIGITALIS TOLERANCE TEST**—A test utilizing the principle of biologic titration has been introduced to determine whether a patient will react adversely to a relatively large dose of digitalis such as would be used for rapid digitalization. This is an important problem at all times, but it is especially so when it is not known whether a patient has had digitalis recently or when there is the question of how

icated by the development of electrocardiographic evidence of toxicity.

The defense of the method lies in the rapid elimination of acetyl strophanthidin. If toxic effects develop, they may be expected to disappear promptly and,

**Digoxin** The similarity in the spelling of digoxin and digitoxin has led to some confusion. The recently introduced proprietary name, Lanoxin, therefore has an advantage.

Lanoxin has a curve of action which may be somewhat slower but which approximates that of ouabain. Compared with ouabain, it has the drawbacks of its slightly slower curve of action. Used orally for maintenance, effects tend to be uneven with wide variations in intensity during and between the doses.

It is not soluble in water. Recently, however, a new satisfactory parenteral preparation has been made available.

Intramuscular injection of Lanoxin provides no advantage in speed of action over the oral administration. Lanoxin is poorly absorbed from the intestinal tract, about 50 per cent of the amount administered is absorbed. This must be taken into account in dosage regimens.

**Acetyldigitoxin** This glycosidal material resembles Lanoxin more than digitoxin in its curve of action. About two-thirds of the dose administered by mouth is absorbed. It is somewhat more slowly eliminated than digoxin. This is no longer a new glycoside, special merits have not yet been demonstrated. Its present position is that of just another digitalis material with a moderately rapid curve of action and incomplete absorption.

**Digilanid** This is a mixture of the lanatoside glycosides in *Digitalis lanata*, lanatoside A, lanatoside B, and lanatoside C. The curve of action of this preparation closely simulates that of digoxin. It is very poorly absorbed, from 10 to 20 per cent of the oral doses being absorbed from the gastrointestinal tract.

**Lanatoside C** This glycoside (Cedilanid) resembles Lanoxin closely in curve of action and therefore provides no advantage over it. Only about 10 per cent of an oral dose is absorbed.

**Deslanonide** This (Cedilanid D) is still another *lanata* glycoside which has a curve of action similar to Lanoxin. It is a very recent introduction, and if it has any advantages over Lanoxin, they have not yet been established. From the information already at hand concerning its actions, there seems to be no reason to suppose that it should have unique virtues. It is available only as a parenteral preparation.

**Squill**—Squill was used in medicine as a diuretic even before Withering introduced digitalis. Although still used in this country, squill preparations have given way to digitalis preparations, perhaps largely because its parameters of action do not offer any unique advantage.

**Scillaren** This is a mixture of scillaren A and scillaren B. Its curve of action resembles that of digoxin. It may be administered by mouth but it is poorly absorbed from the gastrointestinal tract.

**Scillaren B** This is a purified glycoside for intravenous injection. The material is made up in a strongly alcoholic solution and further dilution is the safer procedure. No advantage over any of the other glycosides with an intermediary speed of action has been established.

**Urginin** This is a mixture of two squill glycosides, urginin A and urginin B. There are no published reports that this is digitalis material with special virtues and as a result it is very little used today.

materials were measured. It is the most potent of all digitalis glycosides. 0.1 mg is equivalent to 1 cat unit. 0.5 to 1 mg is a full digitalizing dose.

It is not absorbed at all from the gastrointestinal tract and is used intravenously. Its curve of action is relatively rapid, significant effects appearing within 30 minutes of intravenous injection and being fully developed within about 90 minutes. Within 24 hours most of the effects disappear.

It is relatively soluble and, of the commonly used parenteral materials, it is the only one of which a full digitalizing dose can be dissolved in a small amount of water or saline.

As matters stand, it is usually the digitalis material of choice where rapid effects by intravenous injection are desired.

**STROPHANTHIN**—This usually refers to *Strophanthus kombe*. *Strophanthus gratus* being the source of ouabain. Its curve of action is virtually identical with ouabain. Since it is a somewhat variable mixture of glycosides, its potency is equally variable. As a result and also perhaps because there is no need for more ouabain-like materials, it is little used.

**ACETYL STROPHANTHIDIN**—This is one of the most rapidly acting digitalis glycosides. It is given intravenously. Effects begin almost instantaneously and within 15 minutes are fully developed. They disappear equally rapidly. This fleeting type of action is suited for emergencies, after which it is followed by a more persistent glycoside. It is also used for arrhythmias, in which, once the effect is developed, persistence is not required. Diuretic and slowing actions have been demonstrated, but these are not of practical value. It has been used in a hazardous test to determine digitalis tolerance. Unfortunately, it is not available on the commercial drug market.

**THEVETIN**—This glycoside has a curve of action and uses virtually identical with acetyl strophanthidin. It is not available on the commercial drug market.

#### DIGITALIS PURPUREA GLYCOSIDES—

**Digitoxin**. This glycoside develops its effects more slowly than any other and is excreted more slowly. Given orally its advantages lie in its complete absorption from the gastrointestinal tract, lack of gastrointestinal distress, and the fact that once the maintenance dose is adjusted, effects may be maintained for years without difficulty.

The parenteral preparations are not so outstanding. The time required for effects to develop when they are urgently needed and for them to disappear when they are excessive constitutes its major disadvantage. It is also highly insoluble and intravenous preparations may contain large amounts of alcohol. Unless well diluted, these solutions may be irritant. More recently intravenous preparations have been made available which are more satisfactory from the physical point of view. An intramuscular preparation is also available, but its curve of action is not superior to that after oral administration.

**Gitalin**. This is an amorphous glycoside of the digitalis leaf which is poorly absorbed from the intestinal tract but is otherwise satisfactory and is favored by some experts. There has recently been a strong effort to revive its use.

**DIGITALIS LANATA GLYCOSIDES**—Digitoxin may also be obtained from *Digitalis lanata*, but it is no different from the digitoxin obtained from *Digitalis purpurea*.



Since the digitalis materials are qualitatively the same and their therapeutic ratios are identical, the basis for their choice lies in the nature of local irritant action in the gastrointestinal tract (if they are given orally) and in their parameters of action

So far as local irritant action is concerned, the problem is minimal with the pure material. In general, it is more important in digitalization than in maintenance

For urgent situations, where only fleeting effects are desired, and where there is danger of overdigitalization, the materials with the more rapid curves of action are clearly the more desirable. For such purposes there is the almost instantaneous effect of acetyl strophanthidin and the intermediary curve of ouabain and a large number of *lanata* and squill glycosides. A relatively prolonged curve of action is best suited for the maintenance of even effects. Here digitoxin (or even digitalis leaf) is the drug of choice

The dose of a digitalis material depends upon which of the several digitalis effects is sought: on cardiac contraction in heart failure, on conduction in auricular fibrillation, on auricular rhythmicity in auricular flutter, on ventricular automaticity in heart block, on vagal tone in sinus tachycardia

## RATIONAL BASIS FOR NEW DIGITALIS MATERIALS

On the basis of our present knowledge of an extremely large number of natural digitalis materials, it seems unlikely that exploration of the remaining digitalis glycosides will uncover quantitatively superior or qualitatively more desirable pharmacologic actions. Should such differences be developed a reassessment of the digitalis glycosides would be necessary

Differences in therapeutic ratio seem improbable because cardiotoxicity, the greatest danger from digitalis by overdosage, is an extension of the therapeutic action on the heart and, therefore, seems inseparable from it. It must be admitted however that a drug with such a segregation of action would have a clear advantage over those now available. Digitalis materials are far more likely to have differences in parameters of action

Local irritant actions seem to have been reduced to the null point by the purification of glycosides. Systemic emesis is a useful sign of impending toxicity and a glycoside without this might be more dangerous

Perhaps the most useful addition to what we already have would be an intramuscular preparation with a significantly more rapid curve of action than that of oral preparations or an oral preparation with a truly rapidly developing curve of action. These would provide a much needed practical intermediate between intravenous and oral administration as it now stands

## THE CHOICE OF DRUGS FOR CARDIAC ARRHYTHMIAS

### INTRODUCTION

Despite effective drugs for their relief, cardiac arrhythmias remain among the less successfully treated complaints. The choice of the drug is not so common a cause of failure as the choice of dosage. Another reason for failure in the treat

**CONVALLARIA**—This digitalis material is barely absorbed from the gastrointestinal tract and since no attribute of its action by any other route has been demonstrated to be superior, it is not in common use

**Choice of a Digitalis Material**—Two digitalis glycosides stand out

Ouabain is the rapid acting material of choice. It is a standard material with which there is great experience. No material now available commercially has a more rapid curve of action. It cannot be used orally. But this disadvantage is more apparent than real since if digitalis action is urgently needed, the oral route is not the route of choice. From this standpoint glycosides like Lanoxin with curves of action similar to, or slower than ouabain have little to offer.

Digitoxin is the drug of choice among the slow acting digitalis materials. Once developed level maintenance is more likely with it than with any other digitalis material. It is the drug par excellence for oral use being completely absorbed. The parenteral preparation appears useful only when the oral route is not feasible.

The extremely rapidly acting materials acetyl strophanthidin and thevetin, are not commercially available. The others have less clearly defined spheres of special usefulness.

**Sympathomimetic Amines**—The inotropic effect of epinephrine and related drugs to increase the contractile force of the myocardium which can be easily demonstrated in the isolated cat papillary muscle has been suggested as an added attraction of these drugs, especially norepinephrine (Levophed), methoxamine (Vasovyl) and mephentermine (Wyamine), when they are used for their effects on blood pressure in patients with shock and congestive heart failure. What such a hope fails to take into account is the fact that while digitalis increases the force of cardiac contraction in the case of *failing* heart the congeners of epinephrine stimulate the force of contraction of the *normal* myocardium. There is in fact, no substantial clinical evidence that the inotropic action of this series of drugs on the myocardium is of any value in the relief or prevention of congestive heart failure.

**Methamocetol** Unless further investigation proves that this member of the sympathomimetic amine series is an exception to the rule all that has been said above applies to methamocetol (Aranthol).

## DESIGN FOR THE USE OF DIGITALIS MATERIALS

I was impressed on reading through Withering's monograph on *The Foxglove* that he reported a higher order of success in the treatment of dropsy with his crude preparations than is usually obtained at the hands of most clinicians working 170 years later with better standardized and more highly purified materials. Withering also reported a much higher incidence of toxic effects—about 15 per cent of his 163 cases. It may have been even higher since many of his reports are fragmentary. I suggest that there is a connection between the high order of success and the high incidence of reactions. Withering pushed the drug until satisfactory effects or untoward effects developed. He followed his adage—'let it be continued until it either acts on the kidneys the stomach, the pulse or the bowel'. In 170 years no better way has been devised to squeeze the most out of digitalis.

are often triggered by anxieties and by sudden as well as continued efforts. The patient is protected from them in the hospital, but when he is sent home he is no longer so well guarded. The anxieties of family life, the understandable attempts to be less of a burden at home, the question of earning a living, the stress of the job—any one or any combination of these may be enough to trigger an attack. A disturbance in cardiac mechanism may therefore require more intensive therapy for prevention than for relief. In my own experience, satisfactory results with prophylactic therapy usually have been obtained only when dosages at least as large as those used in treatment were applied, or where practical arrangements could be made to alter home and work situations.

### Disorders of Rhythm—

**DISORDERS OF CARDIAC RHYTHM OF UNDETERMINED NATURE**—Cardiac arrhythmias which do not cause symptoms usually can wait for precise identification. The urgency of a disorder in rhythm is determined by clinical considerations, the general condition of the patient, observations on cardiovascular and respiratory function and the basic cardiac disease. Cardiac arrhythmias which develop during acute or healing phases of infarction are far more likely to have serious implications than those which develop in less consequential heart disease. Arrhythmias developing during anesthesia often disappear afterward and in the case of a normal heart usually require no treatment.

The most serious danger in the treatment of unidentified arrhythmias is the abolition of idioventricular rhythmicity in the patient with heart block. Such a drug action can only be followed by cardiac standstill. Since this possibility must be considered in every case of undiagnosed arrhythmia, the therapeutic aim at this stage must be to slow the rhythm, not to abolish it.

With this admonition in mind, quinidine or Pronestyl may be used in undiagnosed cardiac arrhythmias. The precautions outlined below for the treatment of ventricular tachycardia should be followed. The choice between the two depends largely on the mode of administration. Pronestyl is preferred for parenteral administration.

**SUPRAVENTRICULAR RHYTHMS**—Supraventricular rhythms are usually less urgent than idioventricular rhythms and, while auricular flutter and fibrillation are often serious matters, even these generally permit time for thoughtful consideration. Many supraventricular rhythms, particularly the paroxysmal types, require no treatment beyond that demanded by the physical discomforts of the patient.

**Sinus Arrhythmia** Sinus arrhythmia is a physiologic response and in itself is never an indication for treatment.

**Premature Contractions** Premature auricular contractions never threaten cardiac function and are of little prognostic import. When they impinge upon the patient's consciousness, it may be impossible to distract him from them, and in such a situation, treatment may be necessary.

Effective prevention of premature contractions through the continued use of cardiac depressants such as Pronestyl or quinidine requires large doses. Often this implies more trouble than the disturbance warrants. Quinidine is usually the preferred drug. Digitalis is effective only when cardiac failure is the cause of the

ment of cardiac arrhythmias is the belief that prophylaxis is simpler than treatment.

The useful drugs are few and their choice is fairly obvious; a more difficult decision is the choice between treatment and no treatment. The decision to treat is important not only because it may become an involved procedure, but also because it directs the patient's attention to his heartbeat and makes success imperative where it may be a matter of no importance from the point of view of cardiodynamics. Cardiac arrhythmias often do not require treatment. Rapid or irregular heart action is not dangerous to the normal heart and does not invariably interfere with cardiodynamics. Tachycardias are a threat to the diseased heart in proportion to the extent of myocardial disease, the ventricular rate, and whether the ventricular contraction is well enough organized to expel its contents efficiently. The cause of the disturbance is often a greater threat to the patient than the disturbance itself.

Until recently relatively few drugs—mainly digitalis and quinidine, were used for disturbances in cardiac rhythm. More recently Pronestyl achieved a firm position. In the last year or two, however, a large number of reports on less well understood therapies have been examined. Among these mephentermine is most prominent, but other sympathomimetic amines, chloroquine, and several tranquilizers have also attracted attention. At this time the evidence in favor of the last two is not convincing, whereas interest in the former is firm at the moment.

## CLINICAL CONSIDERATIONS

The obvious procedure in the treatment of cardiac arrhythmias is to discover the cause and to eliminate it. In so far as some disturbances in cardiac rhythm have such definitive causes as hyperthyroidism or intoxication, there is a realistic basis for an etiologic approach. On the other hand, there are cardiac arrhythmias which cannot be treated etiologically because the cause is unknown; where it is known, there is no specific treatment, or heroic measures must be applied before the information necessary for etiologic treatment can be obtained. With the importance of etiologic relief well in mind, this discussion will consider methods of alleviating cardiac arrhythmias by agents which affect the rhythmic mechanism directly, not its cause.

Precise definition of the disturbance in rhythm is most useful in decisions on drugs and dosage schedules. Unfortunately, this is not always possible. There are, however, instances in which, because precise electrocardiographic diagnosis cannot be made or cannot be made soon enough, therapy must be instituted without its help.

**Prophylaxis Versus Treatment**—Prevention has obvious advantages over treatment. When there is a history of repeated paroxysms of premature ventricular contractions which may be interpreted as precursors of ventricular tachycardia, nothing is more to be desired than effective prophylaxis.

Patients with cardiac arrhythmias may respond promptly and easily to treatment in the hospital, and therefore it is disturbing to the physician that, when they are returned to their homes, prophylactic regimens of reduced dosage are often unsuccessful. The difficulties which attend the implementation of prophylaxis arise from the fallacy that prophylaxis is simpler than treatment. Arrhythmias

rhythm in about 60 per cent of cases with auricular fibrillation. In the majority, however, the auricular fibrillation soon returns. In thyrotoxicosis or other indications causing auricular fibrillation, the normal rhythm tends to persist after restoration, while in cases of auricular fibrillation due to rheumatic and arteriosclerotic heart disease and especially those with cardiac failure, the results are likely to be short lived.

Digitalis can almost always be counted upon to slow the ventricular rate in auricular fibrillation, this is perhaps the most dependable of all its therapeutic effects. It may decrease the ventricular rate through improvement of myocardial function, diminishing the reflex stimulation to acceleration, but even when it fails to improve myocardial function, continued use of digitalis slows the heart by its other action—direct depression of auriculoventricular conduction. Excessive digitalis dosage produces exceedingly slow ventricular rates and coupling.

Statements that strophanthidin may be used to restore a normal sinus rhythm by a direct action must be questioned. There is no pharmacologic basis for such a direct action of any digitalis material on the auricle and, in addition, in the studies reported, it is likely that the successful cases had paroxysmal auricular fibrillation and that the resumption of a normal rhythm was spontaneous and not the result of the action of the digitalis material.

In the use of quinidine and Pronestyl in auricular fibrillation, the ventricular rate increases as the effects develop. In the series of changes, the auricular rate may briefly change to a flutter before the normal rhythm appears. The greatest danger in restoring a normal rhythm lies in discharging emboli from previously stagnant auricular appendages at the moment of the shift from auricular fibrillation to a normal rhythm. This is not a danger inherent in quinidine or Pronestyl but rather one which is inherent in auricular fibrillation and which exists when a drug or circumstance causes a previously inactive auricular appendage to contract. The cause, therefore, lies in the success in restoring a normal sinus rhythm in a patient with auricular fibrillation. Any blame for such an accident lies not with the drug but with the decision to restore a normal rhythm.

Digitalis is the drug of choice in all cases with long standing auricular fibrillation, auricular fibrillation with congestive heart failure or advanced heart disease. Quinidine is the preferred drug when there is little danger of embolization from heart disease, and small likelihood of recurrence of the auricular fibrillation.

#### IDIOVENTRICULAR RHYTHMS —

*Auriculoventricular Dissociation.* Failure of the ventricle to respond to auricular impulses does not in itself embarrass cardiac function. Cardiac function can proceed satisfactorily without auricular contractions or synchronism between auricle and ventricle, viz., the lack of circulatory embarrassment in many cases of heart block and in cases of slow auricular fibrillation.

Auriculoventricular dissociation is not an indication for therapy, nor will its restoration be certain to provide the answer when there is cardiodynamic embarrassment. The more important determinants of treatment are the nature of the basic heart disease, the nature of the idioventricular rhythm, and the development of a compensatory response of the abnormal cardiac mechanism.

disturbance Since digitalis is always indicated for heart failure, it is automatically used in the cases with premature auricular contractions in which it may be useful

When the premature contractions are associated with anxiety states, sedation may be effective

*Sinus Tachycardia* Sinus tachycardia is the most common form of rapid heart action Often it is an entirely normal physiologic response to cortical impulses, fever, and noncardiac disease as well as disease of the heart and congestive failure The most consistent relief comes from the removal of the cause Quinidine and Pronestyl are rarely effective in sinus tachycardia, to be effective, doses larger than those most physicians would be willing to give are usually necessary Where the sinus tachycardia is a physiologic response to a disease, it is unlikely that these agents will be effective in any dosage

*Auricular Tachycardia* When adequate dosage is employed, quinidine is more useful in auricular tachycardia than in sinus tachycardia The difference in the relative utility probably lies in the fact that in auricular tachycardia an abnormal focus is the pacemaker

Vagal stimulation through eyeball or carotid sinus pressure can be successful, but it frequently fails Here the action of digitalis to sensitize the sinus node to vagal impulses is effective though rarely used After a relatively large dose of a digitalis material, preferably a relatively rapid acting one such as acetyl strophanthidin or ouabain, eyeball or carotid sinus pressure may slow the rapid rate where previously it failed This maneuver is often a more practical approach to the problem than the use of quinidine or Pronestyl Emetics may also be used to induce intense vagal stimulation

*Nodal Tachycardia* Although the clinical features of the treatment of nodal tachycardia are similar to those of auricular tachycardia, the former is more resistant to quinidine and Pronestyl Digitalis is of no value

*Auricular Flutter* Auricular flutter is commonly paroxysmal, often it is replaced by auricular fibrillation

The action of digitalis in auricular flutter is unique It is given in doses which change the flutter to a fibrillation at which point it is discontinued and its effects are permitted to dissipate In approximately half of the cases, as digitalis effects wear off a normal rhythm appears, in the other half, the flutter reappears or the fibrillation persists Digitalis is not useful for prophylaxis, therefore Since rapidity in development and dissipation of effects are desired for treatment, a rapid acting material such as ouabain, is the drug of choice

Quinidine and Pronestyl may also be used here, much as in auricular fibrillation The former is more generally chosen

*Auricular Fibrillation* Digitalis, quinidine and Pronestyl are used in auricular fibrillation, but the pharmacologic aims are different quinidine and Pronestyl are used to abolish the fibrillation and to restore a normal rhythm, while digitalis is used only after it has been decided to accept the cardiac arrhythmia and to treat by slowing the ventricular rate

Quinidine is more firmly established than Pronestyl in this condition, although the indications are that there is little to choose between them The experience with quinidine is considerably greater and indicates that it will restore a normal

at a rate of 40 per minute does not mean that there is seriously reduced cardiac output for as the ventricular rate decreases the stroke volume tends to increase. There is of course, a critical rate below which increased stroke output cannot make up for decreased cardiac rate and when the cardiac rate falls below it cardiac output becomes inadequate.

The dramatic episodes of the Adams Stokes syndrome in which brief periods of unconsciousness and sometimes even convulsions develop always merit attention. It is common to explain these episodes as periods of ventricular asystole due to a latency between the lapse of supraventricular control and the appearance of the idioventricular pacemaker. There is also evidence that this period of latency is related to the rate at which the ventricle has been previously driven by the auricle—the faster the supraventricular rhythm, the longer the period of latency. In many cases of intermittent heart block, the auricular rhythm is not excessive and therefore, there is not likely to be a prolonged period of ventricular asystole. In such cases Adams Stokes episodes may not develop at all and if they do they are likely to be both brief and of moderate intensity.

It is less commonly recognized that Adams Stokes episodes develop during periods of exceedingly slow idioventricular rates, sometimes 20 or less and during brief paroxysms of ventricular tachycardia and of ventricular fibrillation. The pulse of the unconscious patient with heart block does not give the information necessary to distinguish between the latter two. Often the stethoscope is equally uninformative. There is no blood pressure in asystole and there is virtually none in ventricular fibrillation. On the other hand it is well to remember that in ventricular tachycardia the exceedingly rapid ventricular rate reduces the amplitude of the pulse so that although mean blood pressure may be substantial it is not detectable by the usual method, which depends on a distinction between systolic and diastolic pressures.

Isuprel is perhaps the most effective of the agents used in heart block to increase the rhythmicity of the heart. Other sympathomimetic amines are less effective and some may be dangerous.

**Ventricular Asystole.** Ventricular standstill can hardly be called an arrhythmia. Therapy must be directed to the ventricle. Isuprel is the drug of choice. Intra-cardiac injection is the only effective route of administration of drugs. The needle puncture itself may provide useful stimulation of the myocardium. In attacks which develop in the hospital, the application of the external electrical cardiac pacemaker may be effective. Vigorous direct manual cardiac massage may be useful. Recently sodium lactate has been suggested but further trial with this agent is necessary.

**INTOXICATIONS.**—Arrhythmias due to intoxication comprise a special etiologic category. Except for ventricular fibrillation even exceedingly rapid disturbances in rhythm are not so urgent as when they are the result of heart disease.

Cardiac arrhythmias induced by intoxication vary considerably depending on circumstances, the intoxicant and the presence of heart disease. If the intoxicant is removed or treated specifically the arrhythmia will usually disappear. When it does not it generally responds favorably to drug therapy. Where life is not threatened by the disturbance in rhythm there is ample time for waiting for the

*Premature Ventricular Contractions* Premature contractions of the ventricle do not require therapy per se. In some instances however, premature ventricular contraction beats may be precursors of the far more serious ventricular tachycardia, and where such a possibility exists their presence poses the problem of prophylactic therapy. The decision has to be made on clinical grounds and if it is believed that there is such a danger the use of drugs is indicated. Quinidine and Pronestyl are effective here while digitalis is not. In patients with cardiac failure digitalis should be used unless there is clear and certain evidence that the premature contractions are an evidence of digitalis intoxication.

*Ventricular Tachycardia* Ventricular tachycardia is one of the urgent cardiac arrhythmias and demands attention the moment it is suspected or even anticipated. Serious heart disease is almost invariably the basis of the disturbance and here the rapid rate may be too much for the diseased myocardium.

Grave dangers are inherent in both the existence and the abolition of the rhythm. The possibility of heart block is of critical importance for it determines whether the abolition of the rhythm will be followed by a normal sinus rhythm or cardiac standstill. Often the electrocardiographic picture is so bizarre that this critical question cannot be answered. As long as the possibility exists the therapeutic aim must be to slow the ventricular rate and not to obliterate the ectopic rhythm. Here decrease in rate from 200 to 150 is a significant therapeutic accomplishment and the therapist should be satisfied with it until he learns more. When the cardiac rate falls P waves representing sinus activity may appear in the electrocardiogram. If the electrocardiogram indicates that the auricular rate exceeds the idioventricular rate it is clear that there is heart block and it would be fatal to abolish the ventricle. If the reverse is the case it is safe to proceed with the quinidine or Pronestyl but even so increase in dosage should be gradual.

As with auricular fibrillation, the danger of catastrophe is inherent in the disturbance and not in the drug. Any substitute for quinidine or Pronestyl which abolishes a ventricular tachycardia is equally capable of leaving the heart without a pacemaker. Since the rhythm has to be treated a careful but firm attitude is requisite. Both quinidine and Pronestyl are effective. While there is a trend toward the latter its only established advantage is with parenteral administration. Digitalis is generally considered to be contraindicated although this injunction may not necessarily be absolute.

*Ventricular Fibrillation* Ventricular fibrillation is almost always an agonal disturbance which provides very little time for therapy. Daring measures are therefore indicated. Unless the rhythm develops in a hospital, electrical defibrillation is out of the question. Elsewhere, intravenous injection of Pronestyl by vein or even into the heart is the only possible approach.

*Heart Block* Heart block is considered under idioventricular rhythms because therapeutic problems which develop in this condition usually relate to some form of idioventricular difficulty.

As previously stated auriculoventricular dissociation per se does not embarrass cardiac function. Thus 3:1 and 2:1 block and complete auriculoventricular dissociation are not indications for therapy unless there is clinical evidence that the slow ventricular rate is a source of trouble. The fact that the heart is beating



treated with quinidine or Pronestyl. While it is a fact that ventricular premature contractions and even ventricular tachycardia due to digitalis can be suppressed by these agents, the justification for their use in these instances is by no means clear. On the one hand, ventricular premature contractions are unimportant as anything but a warning to stop the digitalis, and, on the other hand, the suppression of ventricular tachycardia due to digitalis with quinidine may be more hazardous than the ventricular tachycardia itself. More often than not, during the course of digitalis intoxication leading to ventricular tachycardia, heart block develops. In these cases, successful suppression by quinidine or Pronestyl leads to asystole. It is probable that most of the cases of ventricular tachycardia successfully treated with Pronestyl or quinidine were not due to the digitalis the patients were taking but to the heart disease for which they were receiving the digitalis.

A method of treating digitalis intoxication with the use of chelating agents to lower blood plasma calcium levels is of considerable interest and may prove to be the most valuable tool we have for this type of poisoning. The literature should be watched for developments along this line, but it can already be said that some early reports make this appear to be the most promising therapy for digitalis intoxication thus far.

## PHARMACOLOGIC BASIS OF THE THERAPY OF DISTURBANCES OF CARDIAC RHYTHM

Disturbances in the cardiac mechanism may be treated either by slowing the rate or substituting a preferable mechanism. This may be accomplished by (1) central sedation, (2) intensification of vagal tone, (3) depression of cardiac automaticity, (4) stimulation of cardiac automaticity, (5) depression of conduction and (6) stimulation of conduction.

**Central Sedation**—Central sedation must be distinguished from any hope to "sedate" cardiac muscle. Since a large proportion of cardiac arrhythmias are both paroxysmal and nonthreatening and since many are triggered and sustained by anxieties, sedation may remove the excitant or make tolerable the period of waiting while the disturbance subsides spontaneously. Sometimes only sleep is necessary. Often the patient permitted to sleep it off is more fortunate than the one subjected to a strenuous therapeutic routine to obliterate the arrhythmia pharmacologically. There is further support to the use of a sedative in the form of the barbiturate in animal experiments which indicate direct antiarrhythmic properties in pentobarbital sodium. Good clinical judgment is necessary to decide whether the arrhythmia is likely to be so innocuous that the sedative approach is justified.

Any of the common sedatives is satisfactory, but a rapid acting drug like pentobarbital seems preferable to a slow acting one such as phenobarbital. Sufficient sedative should be used, in general, doses closer to the hypnotic are more likely to be effective than the common sedative dose.

**Intensification of Vagal Tone**—Vagal stimulation is an old and well established approach for the treatment of supraventricular disturbances. There are several time honored physical maneuvers. Eyeball pressure is sometimes effective but few are able to press strongly enough on the eyes to accomplish anything. Carotid sinus pressure has to be applied precisely and therefore is not routinely

effects of etiologic treatment and, should this fail to provide relief, for well considered symptomatic therapy

*Thyrotoxicosis* Auricular fibrillation and flutter, usually paroxysmal, are seen in thyrotoxicosis, but sometimes the auricular fibrillation persists. When the disturbances in rhythm persist or recur frequently, especially when associated with thyrotoxic heart disease, treatment is clearly necessary. If the thyroid disease is adequately treated, quinidine is usually effective and the result is permanent.

*Anesthesia* Cardiac arrhythmias occurring during anesthesia tend to excite both surgeons and anesthetists. Ventricular as well as auricular arrhythmias may develop. The therapeutic situation is comparable to that in thyrotoxicosis: in the absence of heart disease, the arrhythmias are rarely threatening and tend to disappear spontaneously, rarely persisting after the anesthetic has been eliminated. Unfortunately, it is rarely practical to stop the anesthesia in order to relieve the arrhythmia—although it is sometimes feasible to change the anesthetic—and treatment may become necessary. Here, parenteral therapy is indicated and, on this basis, Pronestyl is the drug of choice.

*Digitalis* Arrhythmias are frequently reported as a result of digitalis overdosage. Overdigitalization may cause ventricular premature contractions, ventricular tachycardia, ventricular fibrillation, heart block coupling, and occasionally, auricular fibrillation. It is my opinion that these are less common than reported and that spontaneous cessation is too often taken to indicate that removal of digitalis or use of potassium abolished the disturbance in rhythm and, hence, to prove a digitalis arrhythmia. There is no evidence that one digitalis material is more likely than any other to induce cardiac arrhythmias; it is always a matter of relative dosage.

Most of the digitalis materials in common use are excreted relatively slowly—some, like digitoxin, very slowly indeed. The prospect of waiting through 24 to 48 hours of intoxication for significant amounts of drug to be eliminated without any treatment tests the sturdiest therapist. While waiting, it is well to remember that digitalis is given only to patients with heart disease and in this group the incidence of spontaneous arrhythmias is far greater than in the normal population. The diagnosis of a digitalis arrhythmia should be made cautiously, for it implies removing the digitalis or at least reducing the intensity of a digitalis effect which the patient may need.

Low levels of blood potassium increase the sensitivity of the heart to digitalis, and arrhythmias which develop on this basis can be abolished with potassium. Clinical evidence that potassium will help in all cases of digitalis intoxication is not substantial, however. Few of the reported successes are supported by laboratory data. The latter are sometimes especially difficult to prove because intracellular potassium deficits are not always reflected in the blood plasma. Since potassium itself may be dangerous, especially when given intravenously, it must be given carefully. It is my opinion that more often than otherwise the disappearance of cardiac arrhythmias after potassium is due to time rather than kalium. In any event, I do not believe that digitalis intoxication warrants the use of potassium unless the disturbance in rhythm threatens cardiac function or hypokalemia is established.

Statements are to be found in the literature that digitalis arrhythmias may be

Epinephrine and Isuprel will accelerate the sinus node which, if it becomes more rapid than the ectopic focus, may then become the pacemaker. Unfortunately, the duration of such an action is not likely to be longer than the short lived action of the drugs themselves. Occasionally, however, the abnormal focus may not reappear when drug effects disappear. Should persistent sinus stimulation be the only way to maintain the sinus as pacemaker, this may be even more undesirable than the arrhythmia itself, since the rate at which sinus control can be maintained is greater than that of the arrhythmia. It is of interest that close examination of some of the case records of cardiac arrhythmias abolished by mephentermine indicates that this is precisely what has happened. The relative infrequency of a simple sinus bradycardia as a source of cardiac embarrassment accounts for the fact that sinus stimulation per se is not often required or even desirable. On the other hand excessive sinus acceleration may be distinctly undesirable in heart disease.

More frequently, stimulation of cardiac automaticity is used to accelerate the ventricular pacemaker in heart block. The site of action of epinephrine and Isuprel in the ventricle is not clear, but both produce the desired effect. In the Adams Stokes syndrome due to ventricular asystole or fibrillation, Isuprel prevents or terminates the episode. Epinephrine induces other effects which may be undesirable. Chief among these is ventricular fibrillation. There is some dispute whether this does not also apply to Isuprel but most cardiologists seem to think that there is a reduced liability of inducing ventricular fibrillation. Isuprel also has no pressor action. For these reasons and also because it can be given sublingually, Isuprel is the drug of choice. It has virtually replaced all other sympathomimetic amines in the Adams Stokes syndrome.

The use of digitalis to stimulate cardiac automaticity requires explanation, largely because its possibilities are rarely explored. It may provide an answer in instances in which Isuprel is not successful and other sympathomimetic amines are undesirable. The action of digitalis on the myocardial tissues is to increase rhythmicity. In the presence of an idioventricular bradycardia its effect is to accelerate the ventricular pacemaker or to increase the heart rate through the development of extra ventricular contractions. The dose of digitalis necessary to produce such an effect is in the range of the minor toxic dose, but done carefully it can be achieved without distress. The use of digitalis when the Adams Stokes episodes are due to ventricular fibrillation or tachycardia is another matter. Here the contraindication is definite. Before using digitalis for the Adams Stokes syndrome, it is important to establish precisely the basis of the syncope episode.

Quinidine and Pronestyl are dangerous in heart block. Barium chloride has long been considered too toxic. The usefulness of sodium bicarbonate has yet to be fully explored.

**Stimulation of Conduction**—Stimulation of conduction may be useful in complete or functional heart block. In marked bradycardia stimulation of conduction may reduce a state of 3:1 to 2:1 block—50 per cent acceleration of ventricular rate. While there is no clear evidence for it this is presumed to be one of the actions of the sympathomimetic amines useful in heart block. Epinephrine

successful In some instances, holding the breath as long as possible will induce enough vagal tone to slow an auricular tachycardia The results tend to be short lived, but little is lost by trying In this connection it is interesting to note that Demerol (meperidine) has a vagolytic action its use for pain during a cardiac arrhythmia may therefore be followed by acceleration rather than by any beneficial slowing action as is sometimes seen after morphine

More recently pressor agents such as phenylephrine (Neo-Synephrine) and mephentermine (Wyamine) have been used to bring about slowing through intense stimulation of the depressor reflex This device has serious intrinsic hazards and therefore has not been widely practiced

**EMESIS**—When emesis is associated with sufficient vagal tone, it is sometimes effective in supraventricular disturbances Emesis is essential to the development of sufficient vagal tone, the use of small doses of emetics will fail On the other hand, apomorphine vomiting may be so intense as to be dangerous to a patient with heart disease Consequently, syrup of ipecac is the emetic more commonly used for this purpose It might be added that this disagreeable, although often effective, approach to the therapy of some cardiac arrhythmias is little used today

**DIGITALIS**—Digitalis exerts a useful effect by lowering the threshold of excitability of the sinus node to vagal stimulation The results are the same as increasing vagal tone It has already been mentioned in the section on sinus tachycardia that where eyeball pressure or emesis fail, digitalization, by sensitizing the sinus node to vagal tone may lead to success when the maneuver is repeated The digitalis material of choice in this instance is a rapidly acting form since speed of onset rather than persistence of action is needed

**CHOLINERGIC DRUGS**—Vagomimetic drugs, like Mecholyl, have been used in the treatment of supraventricular tachycardias Although their effect is perhaps the most consistent of any which intensify vagal tone, the stimulation of the parasympathetic nervous system is diffuse and, consequently, is associated with widespread disagreeable symptoms Distress closely simulating anginal attacks has been described Patients with a history of allergic reaction are bad subjects, attacks of bronchial asthma may be precipitated These considerations have led to the virtual abandonment of cholinergic drugs in cardiac arrhythmias

**Depression of Cardiac Automaticity**—Unfortunately, there is no drug with such highly developed specificity of action that it depresses only specific sites of cardiac automaticity Quinidine and Pronestyl are general cardiac depressants, depressing not only automaticity, but also conductivity and cardiac muscle function They do not improve cardiac dynamics by any direct action It is axiomatic, therefore that unless suppression of the arrhythmia is really necessary, these drugs are not really beneficial and may even be harmful Quinidine and Pronestyl may be useful in cases in which they depress an abnormal focus of excitement in doses which do not significantly depress other cardiac functions when the rhythm they suppress is a source of embarrassment and when the pacemaker they permit to control the heart is a superior substitute

**Stimulation of Cardiac Automaticity**—Stimulation of cardiac automaticity provides two types of therapeutic action in cardiac arrhythmias stimulation of the normal pacemaker and stimulation of an abnormal pacemaker

**VENTRICULAR ARRHYTHMIAS**—In general, digitalis materials are contraindicated in idioventricular rhythms other than the special instance of heart block discussed above. More recently the possibility of their use in ventricular arrhythmias has been reopened but the question is not yet settled.

**HEART BLOCK**—When digitalis is used deliberately to produce persistent block longer acting digitalis materials such as digitoxin are indicated for maintenance. When digitalis is used to increase myocardial rhythmicity in heart block, continuous action is also desired. Digitoxin is therefore, the drug of choice.

**Quinidine**—Quinidine is a universal cardiac depressant. The safe use of such an agent lies in the possibility that it can depress an undesirable focus of cardiac activity or make it slower so as to permit another more desirable focus to become the cardiac pacemaker. Unlike digitalis, it does not improve myocardial function. Relatively large doses are required for a high order of success. When small doses are used to avoid the possibility of toxicity, therapeutic failure is common. An effective regimen must be carefully followed to control the extent of myocardial depression. The electrocardiogram is invaluable for this purpose.

There is a tendency for cardiac arrhythmias to reappear after the apparent successful use of quinidine.

In defense of quinidine, it may be said that it is effective against all types of arrhythmias and, therefore, may be used when a precise identification cannot be made. Second, when it is used in treating arrhythmias due to some form of intoxication or to a cause which can be eliminated, the results are likely to persist after the drug is removed. Finally, as discussed above, some of the accidents following the use of quinidine are inherent in the cardiac rhythm and not in the drug and would occur were other drugs successfully used to abolish the abnormality.

When quinidine is used in heart block, there is the possibility of disaster, for suppression of the abnormal pacemaker may result in cardiac standstill. The use of quinidine to produce gradual ventricular slowing while following the effects with the electrocardiograph is the best insurance.

Quinidine is slowly absorbed and approximately 2 to 3 hours elapse after an oral dose before full effects develop. To maintain effects dosage is administered every 3 or 4 hours or if longer intervals are desired the doses must be larger. The proper dosage schedule must be explored in each case for so called average doses tend to be too small. The dose which produces a therapeutic effect without toxic action is the proper one. Dosage regimens are altered either by increasing or decreasing dosage intervals or by altering individual doses depending on which is more convenient. When relatively large doses or short intervals between them are used these should not be adjusted until an electrocardiogram insures against excessive depressant actions on the myocardium.

Quinine is feeble in its cardiac action than quinidine and cannot be substituted for it when any appreciable effect is desired.

**PREPARATIONS**—There is no difference between the salts of quinidine when oral dosage is contemplated. Intravenous use of soluble quinidine salts is not considered acceptable. This view requires reconsideration since the accidents reported about 25 years ago on which the injunction is based were probably due to im-

can be used for this purpose, but the longer-acting sympathomimetic amines are preferable. Isuprel is the drug of choice.

**Depression of Conduction**—Depression of conduction is a pharmacologic aim in auricular fibrillation because the supraventricular discharges are both rapid and of varying intensity and it is undesirable to have the ventricle respond to all of the impulses. Depression of auriculoventricular conduction provides a filterlike action, preventing the feebler impulses from reaching the ventricle. As depression is intensified, the ventricular rate is slowed, while the ventricular contractions stimulated only by the stronger supraventricular impulses are both stronger and of more nearly equal intensity. Digitalis is the only drug that produces such an effect. Unfortunately, this action does not produce the same effects when digitalis is used in a normal cardiac mechanism or in sinus tachycardia. Here, progressively larger doses of digitalis produce first partial and then complete block.

By perpetuating the state of complete heart block in patients with Adams-Stokes episodes, digitalis may prevent recurrences of attacks of syncope which develop only during the transition from supra- to idioventricular pacemakers in intermittent heart block.

In all of these instances maintained drug action is desired. Digitoxin is, therefore, the drug of choice.

## THE SEVERAL DRUGS

**Digitalis Materials**—The reader is referred to page 402 for discussions of the several digitalis materials. No general statement concerning their choice can be made because in each case it depends on the particular disturbance in rhythm for which treatment is contemplated. The choice of digitalis materials is considered here, therefore, only in relation to their use in cardiac arrhythmias and especially in relation to their speed of action.

**CARDIAC FAILURE**—Cardiac failure may induce tachycardia and disturbances of the rhythmic mechanism (1) through accelerator mechanisms, mainly mediated through the sympathetic nervous system, (2) through physical distention due to abnormal chamber pressure, and (3) through hypoxia. To the extent that digitalis alleviates failure in these cases it may provide relief for arrhythmia as well. Digitalis is indicated in heart failure, and, therefore, this capacity of digitalis to restore a normal mechanism is usually explored as a consequence of the treatment of the heart failure.

**VAGAL TONE**—The use of digitalis to increase vagal tone in treating supraventricular arrhythmias is discussed on page 415. The more rapidly acting materials are more desirable, but acetyl strophanthidin, the most rapidly acting, is not easily obtained, and therefore ouabain, which is slower, is usually the best choice.

**AURICULAR FLUTTER**—The more rapidly acting digitalis materials such as ouabain should be chosen for the treatment of auricular flutter.

**AURICULAR FIBRILLATION**—In treating persistent auricular fibrillation, a long-continued effect is wanted. Long-acting digitalis materials such as digitoxin are most fitting, although a more rapidly acting material may be used to produce the first effects when there is need for prompt action.

There seems to be no danger in its use in the Adams Stokes syndrome of episodes of ventricular fibrillation or tachycardia, whereas this is a real hazard when some of the other sympathomimetic amines especially epinephrine, are used

**Ephedrine and Other Sympathomimetic Amines**—Ephedrine and other sympathomimetic amines which are effective orally have been largely replaced by suprel in the treatment of heart block. Mephentermine (Wyamune), methoxamine (Vasoxyl) and phenylephrine (Neo-Synephrine) have been reported on favorably but there is still considerable question regarding their general utility as well as their safe use in supraventricular and idioventricular tachycardias

**Potassium**—Laboratory evidence indicates that digitalis induced cardiac arrhythmias are sometimes associated with a decrease in blood potassium levels and that the administration of potassium, parenterally or orally, may suppress or prevent such arrhythmias. It has been assumed that this applies to similar situations in man and clinical reports support this assumption. The suggestion has also been made that parenteral use of potassium may be followed by alleviation of cardiac arrhythmias not associated with the use of digitalis and that the incidence of assistance in these cases approximates the incidence of assistance in patients given digitalis. This has not been corroborated and in general the indiscriminate use of potassium has not been successful. The present position of potassium in therapy of cardiac arrhythmias—whether due to digitalis or not—is not clear although it appears that there are instances in which it is useful

The best routine for its use is not established. Since intravenous injection of potassium is attended by some risk its indications should be determined before that route is used. It might be well to give the drug orally until its need is established and the risk of intravenous administration justified

**Atropine and Other Vagolytic Agents**—Atropine accelerates the sinus rate and in this way may accelerate a slow sinus and assist it in taking control of the heart. This action of atropine and other vagolytic agents is more persistent than that of any of the sympathomimetic agents and would seem to be advantageous. However, when doses which effectively block vagal tone in the heart are used diffuse effects on salivation and vision, often persisting even longer than the cardiac effects, make the drugs undesirable. Reports of their use in preventing attacks of tachycardia in the Wolff Parkinson White syndrome are suspect as is also the prophylactic action against ventricular tachycardia in acute myocardial infarction

**Sodium Lactate**—Recently evidence has been presented that since lactate appears to increase the rhythmicity of both the sinus node and the ventricle molar sodium lactate may be used in the treatment of patients with slow heart rates Adams Stokes syndrome, and episodes of cardiac arrest. Although the initial reports are encouraging and in addition the agent itself seems unlikely to cause any adverse reactions since the precise indications and probable situations of effectiveness have not yet been established it seems appropriate at this time to advise not using the drug in preference to one that is better established but to watch carefully developments in the literature

**Chelating Agents**—Because of the reciprocal relationship between the intensity of the digitalis effect and the blood calcium level lowering of the blood calcium

ing that Pronestyl can be used intravenously with greater safety than quinidine. Test doses of quinidine are not likely to reveal any information which would make subsequent use of the drug safer.

Intramuscular preparations of quinidine are available, but they are not absorbed more rapidly than from the gastrointestinal tract and, therefore, should be considered only for patients who cannot take the drug orally.

There is a suggestion in the recent literature that quinidine gluconate induces longer lasting effects than those induced by the sulfate. There is also the report in question indicates that the prolonged effects described are due to the use of a so-called long acting form of tablet. There is also the recent Report to the Council on Drugs of the American Medical Association stating that such extended action preparations are too irregular to be relied upon in critical situations. This admonition may apply with more force to some situations with arrhythmia than others.

**Procaine Amide**—There is little evidence to support a contention that Pronestyl (procaine amide) is safer or more effective than quinidine. Early experiences with Pronestyl dealt largely with patients who developed arrhythmia as a result of anesthesia rather than from heart disease. The results were excellent and the accidents few. The drug was used against a background of experience and, in these hands the initial intravenous experience was a good one. What the results would have been in less experienced hands or in patients whose arrhythmias developed primarily as a consequence of serious heart disease can only be conjectured. With widespread use in patients with serious heart disease, accidents have certainly been reported after Pronestyl.

Pronestyl continues to be used intravenously because the accidents occurring after its use have been more carefully analyzed than those occurring after the intravenous use of quinidine. Current usage, however, defends the former and condemns the latter, and until the issue is clarified—especially since there is no decided advantage in quinidine—Pronestyl will be the drug of choice for intravenous use. The intramuscular preparation of Pronestyl has a clear advantage over the intramuscular preparation of quinidine because effects develop more rapidly. Orally, there is probably no basis for a choice.

All dangers inherent in the treatment of cardiac arrhythmias which apply to quinidine apply equally to Pronestyl.

**Epinephrine**—Epinephrine has been employed principally in treating heart block. Its use to accelerate a slow or normal sinus in order to replace an aberrant pacemaker with a normal one has limitations because of its brief action and the danger of ventricular fibrillation. In all instances of cardiac arrhythmias, it has been largely displaced by Isuprel.

**Isoproterenol**—Isoproterenol (Isuprel) stimulates automaticity in specialized cardiac tissue and perhaps also in the muscle mass itself. The precise localization of all its effects have not been charted, but the influence on rate together with an absence of pressor action make it the drug of choice in heart block. It may enhance conduction. Since it can be taken sublingually and produces lasting effects, it has supplanted other sympathomimetic drugs for this purpose.



There seems to be no danger in its use in the Adams Stokes syndrome of episodes of ventricular fibrillation or tachycardia, whereas this is a real hazard when some of the other sympathomimetic amines especially epinephrine, are used

**Ephedrine and Other Sympathomimetic Amines**—Ephedrine and other sympathomimetic amines which are effective orally have been largely replaced by Isuprel in the treatment of heart block. Mephentermine (Wyamine), methoxamine (Vasovyl) and phenylephrine (Neo-Synephrine) have been reported on favorably but there is still considerable question regarding their general utility as well as their safe use in supraventricular and idioventricular tachycardias

**Potassium**—Laboratory evidence indicates that digitalis induced cardiac arrhythmias are sometimes associated with a decrease in blood potassium levels and that the administration of potassium, parenterally or orally may suppress or prevent such arrhythmias. It has been assumed that this applies to similar situations in man and clinical reports support this assumption. The suggestion has also been made that parenteral use of potassium may be followed by alleviation of cardiac arrhythmias not associated with the use of digitalis and that the incidence of assistance in these cases approximates the incidence of assistance in patients given digitalis. This has not been corroborated and, in general the indiscriminate use of potassium has not been successful. The present position of potassium in therapy of cardiac arrhythmias—whether due to digitalis or not—is not clear although it appears that there are instances in which it is useful

The best routine for its use is not established. Since intravenous injection

**Atropine and Other Vagolytic Agents**—Atropine accelerates the sinus rate and in this way may accelerate a slow sinus and assist it in taking control of the heart. This action of atropine and other vagolytic agents is more persistent than that of any of the sympathomimetic agents and would seem to be advantageous. However, when doses which effectively block vagal tone in the heart are used diffuse effects on salivation and vision, often persisting even longer than the cardiac effects make the drugs undesirable. Reports of their use in preventing attacks of tachycardia in the Wolff Parkinson White syndrome are suspect as is also the prophylactic action against ventricular tachycardia in acute myocardial infarction

**Sodium Lactate**—Recently evidence has been presented that since lactate appears to increase the rhythmicity of both the sinus node and the ventricle molar sodium lactate may be used in the treatment of patients with slow heart rates Adams Stokes syndrome, and episodes of cardiac arrest. Although the initial reports are encouraging and in addition the agent itself seems unlikely to cause any adverse reactions since the precise indications and probable situations of effectiveness have not yet been established it seems appropriate at this time to advise not using the drug in preference to one that is better established but to watch carefully developments in the literature

**Chelating Agents**—Because of the reciprocal relationship between the intensity of the digitalis effect and the blood calcium level lowering of the blood calcium

through the action of a chelating agent will reduce the toxic effects of digitalis. In attempting to treat digitalis intoxication in this way it is well to remember, however, that in this case the chelating agent is not the calcium edathamil, which will not chelate calcium, but the sodium salt, which will. Large doses of the latter, of course will lower blood calcium sufficiently to induce hypocalcemic tetany and even death and, used over a long period of time in small doses, will cause demineralization of the bones.

**Others**—Recently, and this may be taken as evidence of the current wide search for antiarrhythmic agents superior to those in common use and described above, reports of antiarrhythmic properties of a wide variety of unrelated drugs have appeared in the literature. It has been shown in our laboratory that pentobarbital has this property, by others that this is true of chloroquine and other antimalarial agents, hydroxyzine, reserpine, and other ataractics, etc. Clinical trials with these drugs along these lines have not been carried out sufficiently, however, for any substantial opinion of their practical value in the treatment of cardiac arrhythmias.

**Barium Chloride**—Barium chloride is too toxic to use.

**Aconite**—Aconite is an archaic drug.

## A DESIGN FOR THE USE OF DRUGS IN CARDIAC ARRHYTHMIAS

The indications for treatment of cardiac arrhythmias are variable. There are arrhythmias (1) which are not a threat to cardiac function or which are likely to cease spontaneously before they threaten function, (2) which are not a threat to function but which impinge on consciousness sufficiently to require therapy, (3) which embarrass cardiac function but which do not urgently require treatment, and (4) which constitute an immediate threat to life and require prompt and even heroic attention. Depending upon the category into which the arrhythmia falls the symptom can be left untreated, the patient can be given well-considered, well-planned, and carefully tested treatment, the patient must be promptly subjected to treatment most likely to ameliorate the situation in the shortest time. The cause of the arrhythmia and identification of its nature play important roles in determining the best design of treatment. Other features such as the existence of heart disease, its nature and severity, the presence of heart failure, preceding or as a result of the arrhythmia, the patient's general condition, the presence of non-cardiac diseases and the state of shock, all modify the course to be taken and the choice of drugs.

Effectiveness and safety in treating cardiac arrhythmias also rest on the knowledge of when to treat as well as how to treat. The danger of embolization in auricular fibrillation is inherent in the initial decision to restore a normal rhythm. An inconsequential ectopic rhythm replaced by ventricular fibrillation may result in disaster, while the replacement of a sinus bradycardia by a sinus tachycardia may aggravate matters for the patient.

A large number of cardiac arrhythmias are short-lived and inconsequential while at the same time they are difficult to suppress. The best therapy is to have the patient accept these arrhythmias. He may be assisted by nonspecific sedative or hypnotic therapy. Often, the patients sleep off their palpitations.

There seems to be no danger in its use in the Adams Stokes syndrome of episodes of ventricular fibrillation or tachycardia, whereas this is a real hazard when some of the other sympathomimetic amines, especially epinephrine are used

**Ephedrine and Other Sympathomimetic Amines**—Ephedrine and other sympathomimetic amines which are effective orally have been largely replaced by Isuprel in the treatment of heart block. Mephentermine (Wyamine), methoxamine (Vasoxyl) and phenylephrine (Neo Synephrine) have been reported on favorably but there is still considerable question regarding their general utility as well as their safe use in super- and idioventricular tachycardias

**Potassium**—Laboratory evidence indicates that digitalis induced cardiac arrhythmias are sometimes associated with a decrease in blood potassium levels and that the administration of potassium parenterally or orally, may suppress or prevent such arrhythmias. It has been assumed that this applies to similar situations in man and clinical reports support this assumption. The suggestion has also been made that parenteral use of potassium may be followed by alleviation of cardiac arrhythmias not associated with the use of digitalis and that the incidence of assistance in these cases approximates the incidence of assistance in patients given digitalis. This has not been corroborated and in general the indiscriminate use of potassium has not been successful. The present position of potassium in therapy of cardiac arrhythmias—whether due to digitalis or not—is not clear although it appears that there are instances in which it is useful.

The best routine for its use is not established. Since intravenous injection of potassium is attended by some risk its indications should be determined before that route is used. It might be well to give the drug orally until its need is established and the risk of intravenous administration justified.

**Atropine and Other Vagolytic Agents**—Atropine accelerates the sinus rate and in this way may accelerate a slow sinus and assist it in taking control of the heart. This action of atropine and other vagolytic agents is more persistent than that of any of the sympathomimetic agents and would seem to be advantageous. However when doses which effectively block vagal tone in the heart are used diffuse effects on salivation and vision, often persisting even longer than the cardiac effects make the drugs undesirable. Reports of their use in preventing attacks of tachycardia in the Wolff Parkinson White syndrome are suspect as is also the prophylactic action against ventricular tachycardia in acute myocardial infarction.

**Sodium Lactate**—Recently evidence has been presented that since lactate appears to increase the rhythmicity of both the sinus node and the ventricle molar sodium lactate may be used in the treatment of patients with slow heart rates, Adams Stokes syndrome, and episodes of cardiac arrest. Although the initial reports are encouraging and in addition the agent itself seems unlikely to cause any adverse reactions since the precise indications and probable situations of effectiveness have not yet been established, it seems appropriate at this time to advise not using the drug in preference to one that is better established but to watch carefully developments in the literature.

**Chelating Agents**—Because of the reciprocal relationship between the intensity of the digitalis effect and the blood calcium level lowering of the blood calcium

through the action of a chelating agent will reduce the toxic effects of digitalis. In attempting to treat digitalis intoxication in this way it is well to remember, however, that in this case the chelating agent is not the *calcium* edathamil, which will not chelate calcium, but the *sodium* salt which will. Large doses of the latter, of course, will lower blood calcium sufficiently to induce hypocalcemic tetany and even death and used over a long period of time in small doses, will cause demineralization of the bones.

**Others**—Recently, and this may be taken as evidence of the current wide search for antiarrhythmic agents superior to those in common use and described above, reports of antiarrhythmic properties of a wide variety of unrelated drugs have appeared in the literature. It has been shown in our laboratory that pentobarbital has this property, by others that this is true of chloroquine and other antimalarial agents, hydroxyzine, reserpine, and other ataractics, etc. Clinical trials with these drugs along these lines have not been carried out sufficiently, however, for any substantial opinion of their practical value in the treatment of cardiac arrhythmias.

**Barium Chloride**—Barium chloride is too toxic to use.

**Aconite**—Aconite is an archaic drug.

## A DESIGN FOR THE USE OF DRUGS IN CARDIAC ARRHYTHMIAS

The indications for treatment of cardiac arrhythmias are variable. There are arrhythmias (1) which are not a threat to cardiac function or which are likely to cease spontaneously before they threaten function, (2) which are not a threat to function but which impinge on consciousness sufficiently to require therapy, (3) which embarrass cardiac function but which do not urgently require treatment, and (4) which constitute an immediate threat to life and require prompt and even heroic attention. Depending upon the category into which the arrhythmia falls the symptom can be left untreated, the patient can be given well considered, well planned, and carefully tested treatment, the patient must be promptly subjected to treatment most likely to ameliorate the situation in the shortest time. The cause of the arrhythmia and identification of its nature play important roles in determining the best design of treatment. Other features such as the existence of heart disease, its nature and severity, the presence of heart failure, preceding or as a result of the arrhythmia, the patient's general condition, the presence of non-cardiac diseases and the state of shock, all modify the course to be taken and the choice of drugs.

Effectiveness and safety in treating cardiac arrhythmias also rest on the knowledge of when to treat as well as how to treat. The danger of embolization in auricular fibrillation is inherent in the initial decision to restore a normal rhythm. An inconsequential ectopic rhythm replaced by ventricular fibrillation may result in disaster, while the replacement of a sinus bradycardia by a sinus tachycardia may aggravate matters for the patient.

A large number of cardiac arrhythmias are short lived and inconsequential, while at the same time they are difficult to suppress. The best therapy is to have the patient accept these arrhythmias. He may be assisted by nonspecific sedative or hypnotic therapy. Often, the patients sleep off their palpitations.

In many cases, external causes such as intoxications can be found. Sometimes but less often than patients believe, excessive use of coffee or tobacco causes arrhythmias. In any event, all external causes should be eliminated. Often, however, these include anxiety charged situations, family difficulties, and problems and irritants in work which, even when identified are difficult to remove.

For paroxysmal arrhythmias, preventive therapy is more desirable than treatment of the attack. The setting in which attacks develop may be an important factor. Treatment at home is often more difficult than treatment in the hospital. Success will be more frequent when this difference is accepted and when equal, if not larger, dosage of drugs are used in the prophylaxis of attacks than in treating them. Because this is so, prophylactic therapy is warranted only when the attacks are severe.

Where treatment is indicated, the decision has to be made whether to obliterate the abnormal rhythm or to slow the rate since the former requires not only removal of the ectopic focus but provisions for a new and effective pacemaker. If there is permanent heart block, it is clear that an idioventricular rhythm cannot be replaced by a normal rhythm.

It is safer to use quinidine and Pronestyl to depress than to obliterate ectopic foci. It is good practice in all cases, especially since the decrease of a rapid rate is in itself a therapeutically significant accomplishment. Although ventricular tachycardia is a serious arrhythmia, the ventricle responds with an organized contraction to the ectopic focus, slowing is therefore useful. Only in the completely disorganized and ineffectual fibrillation of the ventricle is the termination of the rhythm and its replacement by another mechanism for ventricular stimulation an absolute necessity. Here is the indication for heroic measures.

**Dosage**—There are no absolute dosages in the treatment of cardiac arrhythmias. The amount of drug necessary varies widely with the disturbance of rhythm and the heart disease present. Biologic effects must be the guides to dosage and dosage regimens. In the more serious situations in which relatively large doses of depressant drugs such as quinidine or Pronestyl are used, it is wise to follow with the electrocardiogram to determine whether or not serious myocardial depression is developing.

## RATIONAL BASIS OF NEW DRUGS FOR THE RELIEF OF CARDIAC ARRHYTHMIAS

The existing need is for drugs with highly selective depressant actions on cardiac function. Quinidine and Pronestyl are effective in all cardiac arrhythmias and may be used therefore in cases where there is no precise diagnosis, but their universal action limits utility. Drugs with a selective action on pacemaker tissue, conducting tissue, and auricular or ventricular muscle are much to be desired.

As matters stand, such a drug is not available. Statements that a new drug has such actions must be examined carefully. When Pronestyl was introduced it was stated that it was superior to quinidine in its ventricular effects but inferior in auricular effects. Further experience showed this claim to be unsubstantial and also that the greater safety claimed for Pronestyl was equally meretricious.

through the action of a chelating agent will reduce the toxic effects of digitalis. In attempting to treat digitalis intoxication in this way it is well to remember however, that in this case the chelating agent is not the *calcium* edathamil, which will not chelate calcium but the *sodium* salt which will. Large doses of the latter, of course will lower blood calcium sufficiently to induce hypocalcemic tetany and even death and used over a long period of time in small doses, will cause demineralization of the bones.

**Others**—Recently, and this may be taken as evidence of the current wide search for antiarrhythmic agents superior to those in common use and described above, reports of antiarrhythmic properties of a wide variety of unrelated drugs have appeared in the literature. It has been shown in our laboratory that pentobarbital has this property, by others that this is true of chloroquine and other antimalarial agents, hydroxyzine, reserpine, and other ataractics, etc. Clinical trials with these drugs along these lines have not been carried out sufficiently, however for any substantial opinion of their practical value in the treatment of cardiac arrhythmias.

**Barium Chloride**—Barium chloride is too toxic to use.

**Aconite**—Aconite is an archaic drug.

## A DESIGN FOR THE USE OF DRUGS IN CARDIAC ARRHYTHMIAS

The indications for treatment of cardiac arrhythmias are variable. There are arrhythmias (1) which are not a threat to cardiac function or which are likely to cease spontaneously before they threaten function, (2) which are not a threat to function but which impinge on consciousness sufficiently to require therapy, (3) which embarrass cardiac function but which do not urgently require treatment, and (4) which constitute an immediate threat to life and require prompt and even heroic attention. Depending upon the category into which the arrhythmia falls the symptom can be left untreated, the patient can be given well considered, well planned and carefully tested treatment, the patient must be promptly subjected to treatment most likely to ameliorate the situation in the shortest time. The cause of the arrhythmia and identification of its nature play important roles in determining the best design of treatment. Other features such as the existence of heart disease, its nature and severity, the presence of heart failure, preceding or as a result of the arrhythmia, the patient's general condition, the presence of non-cardiac diseases and the state of shock all modify the course to be taken and the choice of drugs.

Effectiveness and safety in treating cardiac arrhythmias also rest on the knowledge of when to treat as well as how to treat. The danger of embolization in auricular fibrillation is inherent in the initial decision to restore a normal rhythm. An inconsequential ectopic rhythm replaced by ventricular fibrillation may result in disaster, while the replacement of a sinus bradycardia by a sinus tachycardia may aggravate matters for the patient.

A large number of cardiac arrhythmias are short lived and inconsequential while at the same time they are difficult to suppress. The best therapy is to have the patient accept these arrhythmias. He may be assisted by nonspecific sedative or hypnotic therapy. Often, the patients sleep off their palpitations.

## CLINICAL APPLICATIONS

**Coronary Occlusion**—The pain of the myocardial infarction is characteristically severe, resistant to the coronary dilators, and difficult to relieve even with morphine

When coronary dilators alleviate severe precordial pain, this militates against a diagnosis of coronary infarction. Occasionally, however, the pain is relieved in cases in which electrocardiograms and post mortem examination prove the existence of infarction. In such instances, it may be assumed that the dilator action was central to the completely occluded portion of the coronary artery, perhaps in constricted segments of the coronary arteries adjacent to the occlusion which on dilatation permitted the flow of blood to some hypoxic areas of myocardium. This assumption provides the only rational basis for the continued use of coronary dilators in myocardial infarction to improve circulation to areas adjacent to the infarction to promote the healing and subsequent revascularization of the infarcted area. It was for this purpose that aminophylline and others of the xanthine series were recommended in the treatment of coronary infarction. The evidence for this kind of therapy was analyzed by Gold and his associates some years ago both in animals, in which the influence of the drugs on the size of the infarct was examined and in man, in whom the effects on the coronary pain were evaluated. In each case aminophylline was found wanting. Since then, the use of drugs for this purpose has been virtually abandoned.

In summary, it might be stated that in the therapy of the myocardial infarction the presently available coronary dilators provide little for the relief of its pain while there is no good evidence that they assist in the growth of new blood vessels to the infarcted area of the heart or in any other way accelerate healing. Their only utility lies in the dilatation of vessels in spasm as a reaction to occlusion.

**Anginal Syndrome**—For purposes of exploring the physiologic and pharmacologic basis for the use of agents to relieve the pain, this syndrome may be divided into six categories: (1) hypoxia of the myocardium due to coronary artery spasm; (2) hypoxia due to coronary insufficiency; (3) hypoxia due to low diastolic pressure; (4) hypoxia due to other cardiodynamic disturbances; (5) hypoxia due to respiratory disturbances; and (6) hypoxia due to extracardiac disturbances.

**CORONARY ARTERY SPASM**—Regardless of the merits of the arguments presented concerning the mechanism of pain and its relief in the anginal syndrome the fact remains that the nitrites are pre eminent in the relief of its pain.

In this situation proper dosage with nitrite rarely fails to provide relief. As a matter of fact so consistent is this action of the nitrites that it is used for diagnostic purposes: failure of the nitrites to relieve the pain casts doubt on the diagnosis of spasm of the coronary arteries.

Drugs such as khellin and xanthines, are not effective in relief of acute pain. They will be considered in more detail below but it is clear even in the reports of the most enthusiastic they are neither as potent nor as consistent in providing relief as are the nitrites.

The use of coronary artery dilators for the prevention of anginal attacks is another matter. Here there is considerable dispute regarding the value of any of them, even the nitrites. In many patients, the incidence of attacks of anginal pain

The drugs presently available may be given orally therefore, no particular advantages are manifest in a new drug unless its oral action is more quickly developed. The dangers of intravenous therapy with quinidine require reassessment before still another quinidine like drug is credited with being safer by that route.

## CHOICE OF A CORONARY ARTERY DILATOR

### INTRODUCTION

The coronary artery dilators are so named because of presumptions that the mechanism of the pain of the anginal syndrome is insufficient coronary blood flow and that agents which relieve the pain must, therefore, dilate the coronary arteries to accomplish this.

The first presumption is that this pain is the consequence of hypoxia of the actively beating myocardium. In support of this contention is the fact that similar pain develops in its severest form in the unquestioned hypoxia of myocardial infarction. Further support is found in a model. If the blood supply to the arm is cut off with a blood pressure cuff and the hand contracted regularly, unendurable pain develops. The pain disappears as soon as the circulation to the arm is restored. This corresponds to anginal pain induced by cardiac contractions during hypoxia and relief of the pain by the nitrites, which are accepted as coronary artery dilators.

The second presumption that drugs which relieve this pain do so by relieving constriction of the coronary artery is based on the observation that the nitrites induce relaxation of all smooth muscle including that of the arterial system. The inference that there is specialized coronary dilatation is based on the observation that anginal pain may be relieved by nitrites without producing generalized hypotension and since anginal pain is presumed to be due to coronary spasm, anything which relieves the pain must do so by relieving the spasm.

This then, is an example of circular reasoning in which the proof of specific coronary artery dilatation by nitrites rests on the presumption that the pain is due to constriction of the coronary arteries, while the weight of the latter presumption rests on the fact that the pain is relieved by nitrites. While both presumptions are very likely true neither is proved for there are no direct observations of a spasm of a coronary artery during an anginal attack or its relaxation by a nitrite. Electrocardiographic changes do not provide more definite proof. Direct observations on coronary flow before and during anginal pain and before and after its relief by nitrites are now in progress and should provide a proper conclusion for this semantic concern over the reputed mechanism of anginal pain. Nevertheless it is a generally accepted and useful hypothesis and it is also probably a fact that anginal pain is due to a state of hypoxia in an area of actively contracting cardiac muscle resulting from spasm of a branch of the coronary arteries and that the spasm and the pain it causes are relieved by drugs which relatively specifically relieve the spasm of the coronary arteries. It is to be emphasized that this specificity of action is essential in any drug used for coronary spasm for obvious reasons: diffuse arterial dilatation is highly undesirable.



through the use of diuretics is discussed in the appropriate section (page 87). In so far as it represents hypoxia due to transudation of fluid into the pulmonary bed on assuming the recumbent position, this can be relieved and prevented by the judicious use of diuretics and digitalis or more simply, if not medicinally, by propping the patient up in bed. Vasodilating drugs are of little value in this pain.

**NONCARDIAC DISEASES**—There is a variety of extracardiac diseases—particularly anemias and hypothyroidism—in which there may be relative myocardial hypoxia. The combination with a degree of coronary sclerosis is even more likely to result in anginal pain. Since here there is no spasm of the coronary artery, the coronary dilators cannot be expected to be useful, in fact they might make matters worse. On the other hand, relief of the extracardiac cause may provide excellent relief of the pain.

## PHARMACOLOGIC BASIS OF THERAPY

**Pharmacodynamic Actions**—The pharmacologic action needed for myocardial hypoxia is increase of coronary blood flow. This may be accomplished by an increase in blood pressure as a result of increased cardiac output or an increase in the caliber of the coronary arteries.

Increase in cardiac output increases the work of the heart. While such an action might be applicable to anginal pain due to noncardiac conditions, in heart disease this action is not desirable.

Increased coronary flow through specific dilatation of the coronary artery is theoretically ideal. Such an effect does not increase the work of the heart. It restores the myocardium to a more nearly normal state of nutrition and perhaps reduces the insult to it.

The drugs which effectively dilate the coronary arteries are relatively non-specific. The nitrites, which may be used as the example of the effective coronary dilator, relax all smooth muscle. This diffuse action results in relaxation of smooth muscle of bile ducts, gastrointestinal tract, bronchial tree, ureters, and arterioles. In general, the arterioles are more sensitive to this action than the remaining structures with smooth muscle, so that depression in blood pressure usually develops before any important action on smooth muscle in other systems. This relative selectivity confines the utility of the nitrites to the vascular system.

The selectivity of areas of arterial dilatation is another matter. Evidence for a highly specific action on the coronary arteries is not conclusive. Though there are experiments in which direct measurements indicate both dilatation and increase in blood flow in the coronary arteries following nitrites and other vasodilating agents, there is no evidence that dilatation does not also occur elsewhere.

Only in the patient with anginal syndrome is there a pharmacologic effect after the nitrites without diffuse action resulting in hypotension. It may be that the drugs useful in this condition exert a specific effect only in the presence of abnormal arterial sensitivity and that this special state is spasm of the coronary artery and therefore, that such small doses can be used for the relief of spasm that they do not induce a systemic effect. If this is so, it casts considerable doubt on the utility of the same drugs for improving coronary circulation when there is no spasm.

## DRUGS FOR HEART DISEASE

relates to anxiety and extraneous forces. In so far as these tend to produce attacks, placebo and sedative, rest and relaxation, and even reassurance all tend to prevent them. Since all or most of these are concomitants of the doctor's treatment with nitrite or with any other so-called coronary dilator, there is great difficulty in determining their action in preventing anginal attacks. As matters stand the picture is utterly confused and the usefulness of drugs for this purpose requires careful re-evaluation.

**CORONARY INSUFFICIENCY**—In coronary insufficiency, myocardial hypoxia is presumed to be due to narrowed lumina of coronary arteries which, though able to conduct sufficient blood for basal requirements, are functionally insufficient when the heart muscle requires more. Pain produced by this mechanism is not due to coronary spasm. Coronary artery dilators now available have little effect on selective vessels, they are effective dilators of soft and reactive arteries. Inasmuch as coronary insufficiency is fundamentally due to arteriosclerotic changes, the drugs now available can be expected to improve coronary circulation very little. As might be anticipated, experience proves that the pain of coronary insufficiency is not relieved by nitrites or other coronary artery dilators. Removal of calcifications from coronary arteries by chelation has been tried, but unfortunately for most of us the results have been uniformly negative.

**LOW DIASTOLIC BLOOD PRESSURE**—There may be typical anginal pain in aortic valvular insufficiency. Here myocardial hypoxia is the result of very low diastolic blood pressure which fails to force enough blood through the coronary arteries for myocardial needs. In this situation, there already is physiologic vasodilatation, viz., the bottomless blood pressure and the capillary pulsations seen in the nail beds. Coronary artery dilation would, therefore, not be useful. This is the usual clinical finding, and in patients in whom it is otherwise it is necessary to reconsider the nature of the circulatory defect causing the pain.

**MISCELLANEOUS CARDIAC DISTURBANCES**—Typical anginal pain also occurs in pericarditis, myocarditis, cardiac arrhythmias, and cardiac failure. In the inflammatory conditions, the radiation of pain may be classic for angina, but since there is no defect in coronary circulation, neither nitrites nor other dilators provide relief. In cardiac arrhythmias, in so far as circulatory deficiency may cause myocardial hypoxia, relief of the rhythmic disturbance may relieve the anginal pain. Similarly, when congestive heart failure provides less blood or less oxygen to the myocardium than is needed, there may be pain which is relieved when cardiac failure is relieved (page 393). Anginal pain increases in incidence as these cardiac difficulties combined with a degree of coronary artery sclerosis together induce enough myocardial hypoxia to cause pain where each alone was insufficient.

**RESPIRATORY DISTURBANCES**—Respiratory insufficiency, uncomplicated by coronary disease, is not commonly associated with typical anginal pain, but, if it is associated with coronary sclerosis there may be anginal pain. In this situation, poor oxygenation of blood and reduction in the lumina of the coronary arteries combine to produce myocardial hypoxia.

Anginal pain sometimes develops in these patients only when they assume the upright position, the *angina decubitus*. This form of pain may be presumed to be an expression of left sided heart failure and, as such, its genesis is

extremely rapid curve of action. The other nitrite drugs have appreciably longer curves of action but in all other respects they appear pharmacologically similar. They may profitably be considered as a group.

**ACTIONS**—It has long been assumed that the action of these drugs is related to the liberation of the nitrite ion. More recently, however, this conception has been questioned and it has been suggested that it is the organic nitrate *per se* which actually does the job.

The action on the coronary arteries is to relax smooth muscle. This applies to all smooth muscle: arterial, intestinal, biliary, ureteral, and bronchial. Action on the coronary arteries is supported by studies in which nitrites have been shown to prevent the typical electrocardiographic effects of the exercise tolerance test in patients with coronary sclerosis.

A selective action on the coronary arteries without producing systemic hypotension may be explained by the presumption that the arterial smooth muscle in spasm is relatively sensitive to the action of the nitrite. While nitrites may relieve anginal pain without other symptoms in the normal person the first perceptible nitrite action usually is severe headache or other evidence of diffuse action. When the coronary arteries are physically occluded by a thrombus the nitrites do not relieve the pain. On the other hand these drugs do not relieve the pain of intermittent claudication but here the presence of relatively advanced arterio-sclerosis may be the interfering factor.

**TOLERANCE**—The regularity with which tolerance is developed to the nitrites is outstanding. This is important in both medicine and industry.

In industry tolerance is a valuable attribute of the nitrites: its development makes possible continued work with nitrites. New workers develop severe headaches but the headaches disappear within a few days. This tolerance is short-lived however and if the worker fails to be exposed during a brief illness or a long week-end his tolerance is likely to vanish. To avoid this loss, workers carry some nitrite with them when they leave their work. Men often put nitroglycerin in their hat bands. The material is volatile and the small amounts of the nitrite in the atmosphere is sufficient to keep them from losing their tolerance.

In medicine the same feature of the nitrites stands in the way of prophylaxis. If the nitrites are given too frequently during the day or if a long acting compound is used which liberates nitrite slowly into the blood stream the likelihood of tolerance is great. However its brief duration means that if a patient develops tolerance through excessive use, a few days of abstinence is sufficient to restore the former efficacy of the drug.

**DANGERS**—Hypotension caused by diffuse nitrite action is usually caused by administration to unsuitable patients or by inappropriate dosage.

Methemoglobinemia is a relatively rare occurrence in the nitrite industry. It rarely if ever occurs in medicine after therapeutic doses even when taken very frequently. It commonly develops after massive single doses taken accidentally e.g., the ingestion of the contents of a bottle of pills by an infant.

There is the possibility of increase in intraocular pressure due to dilatation of intraocular vessels which may constitute a danger in incipient glaucoma. This does not develop after doses only large enough to dilate the coronary artery in

## DRUGS FOR HEART DISEASE

The rate of onset of action of the coronary dilators is an important element in their choice. In general the curves of action follow a symmetrical pattern. Those drugs whose actions develop rapidly exert effects equally briefly and, conversely, those whose actions come on slowly exert the action for a relatively longer period of time.

For the relief of an attack of coronary pain, the most rapidly acting drug is the most desirable. Most attacks of anginal pain subside promptly on resting. When a drug with considerable latency is used, rest may relieve the pain before the pharmacologic effect of the drug develops. Only when the speed of action approximates that of amyl nitrite is there no question of a cause and effect relationship between drug and relief of pain. From this point of view, none of the drugs available are superior or equal to amyl nitrite and nitroglycerin.

Once the pain disappears no further drug action is necessary. Were it otherwise pain would return soon after its relief. Thus, long acting coronary artery dilators begin to act after the pain is relieved spontaneously and continue to exert their effects long after the need has disappeared.

Interest in persistent action stems from a real need for a drug for preventing attacks. Several problems are posed by this prophylactic goal if the drugs now available are to be used. In addition the nitrites the most useful of the dilators of the coronary artery have a well developed propensity for the induction of tolerance with continued use.

Another approach is to provide a continued concentration of vasodilator drug which will not influence blood pressure but will dilate the artery in spasm promptly, hence relieving pain virtually before it develops. For this purpose a host of so called slow acting or delayed absorption nitrites have been introduced. There is no evidence that it is possible to provide, on a continuing basis the delicate balance between diffuse effect and prophylactic effect on which such a program is postulated.

The literature abounds in contradictory statements regarding this possibility. Some suggest that we do have effective agents for the continued prophylaxis of anginal pain others are certain of their negative results. Many of the studies are obviously poor and do not provide substantial answers to this important problem.

**Dangers Inherent in Coronary Artery Dilators**—The chief danger inherent in the drugs now in use lies in the fact that none is a specific coronary dilator. Those which are useful apparently depend on the existence of the special circumstance of spasm. The danger is that the therapeutic action will extend to other vascular beds and induce generalized hypotension. Beyond this, the dangers of toxicity are due to the properties of particular drugs.

**Tolerance**—This is an especially pertinent problem, for a high order of tolerance does develop to nitrites. This is an important factor in limiting the prophylactic value of nitrites.

## IF SEVERAL DRUGS

**The Nitrites**—The nitrites comprise a list of drugs of which amyl nitrite and nitroglycerin are the best known and the most used. They are distinguished by an

the patient as in the case of the nitrite taken by inhalation. Nitroglycerin is therefore considerably safer for the patient to use in the physician's absence.

The effects of nitroglycerin take a bit longer to develop and last a bit longer than those of amyl nitrite. It has usefulness as a prophylactic agent in special circumstances. Patients who know they are to be exposed to an emotion charged situation may be effectively primed with a tablet 15 minutes before the exposure. On the other hand, used regularly through the day to prevent attacks, it is usually ineffective.

There are patients who regularly take 30 or more tablets daily, apparently with undiminished effectiveness. In these patients there are the unsettled questions whether they take so many because there is tolerance and the relief is psychologic and whether the agent of relief is the rest they invariably take with the tablet.

Sustained release capsules and tablets are now available. Every argument against the utility of nitroglycerin for continuous prophylaxis applies here. In addition there is the fact that nitroglycerin is destroyed in the liver so that administration by mouth with absorption into the portal circulation is ineffective. For this reason therefore orally administered nitroglycerin is useless. Yet this is the means by which the so called sustained release form of nitroglycerin is used. Recent studies have indicated that it is without clinical value. To what extent this applies to other orally administered organic nitrates has not been established.

#### LONG ACTING NITRITES —

*Sodium Nitrite* Although it is almost never used in angina sodium nitrite is mentioned because it represents the first form of the drug used clinically. Since it continues to be used in medicine and industry, its typical nitrite action on blood vessels is still important.

*Organic Nitrates* This comprises a large group of nitrates which exert relatively prolonged nitrite actions. Nitroglycerin is really one of the organic nitrates but its rapid curve of action is exceptional. The typical curve of action has long been attributed to the rate of liberation of nitrite, the rate of development of action and its duration relating directly to the rate at which this biotransformation occurs. Recently the question has been raised whether this occurs at all and whether it is not that each drug acts in its original state. The merits of each case are not argued here for regardless of which turns out to be the fact, it is important that the fundamental pharmacodynamic action is the same as that of amyl nitrite in all instances. The curves of action of the members of the group differ little.

Since they all have relatively slow curves of action as a group their use as prophylactic agents is their most attractive therapeutic potential and it is for this purpose that their manufacturers promote them.

Each of these agents is used hopefully when introduced but with decreasing enthusiasm as the attempt to achieve prophylaxis proves elusive.

The drugs belonging to this series and now in use follow: erythrityl tetranitrate (Erythrol Tetranitrate), inositol hexanitrate (Tolanate), mannitol hexanitrate (Maxitate Nitranitol), pentaerythritol tetranitrate (Angicap Nitrotalans Peritrate), triethanolamine trinitrate (aminotrate Metamine). The fact that these drugs are now commonly sold in mixtures which contain ataractics or barbiturates

spasm, hence it is exceedingly rare as a complication of the treatment of the anginal syndrome

Headache, sometimes exceedingly severe, may complicate the use of nitrites. This symptom is unnecessary, for in most instances the headache results from excessive doses. If headache follows the use of even the smallest common doses, say 0.3 mg. of nitroglycerin, before the drug is discarded as useless, still smaller doses should be tried. In some cases, doses half that size have been effective.

Nitrite syncope is an unpredictable complication and has been reported from as little as 0.25 mg., although it is usually the result of appreciably larger doses. It is believed to be due to dilatation of the capillary bed. It is aggravated by the orthostatic position and often can be overcome by placing the patient in a horizontal position. Statements in the literature indicate that this complication is not rare but this has not been my experience. This discrepancy may possibly be attributed to the fact that I always use the smallest effective doses.

**RAPID ACTING NITRITES**—Rapid acting nitrites take effect within a fraction of a minute after application.

**Amyl Nitrite** Amyl nitrite is a volatile material which produces its effects more promptly than any other nitrite. It is administered by inhalation. Its use is conspicuous and dramatic. Its administration is punctuated by the explosive noise of the vial breaking and its pervasive, unpleasant odor. Everyone about is soon aware of it, some even suffering headache. It is usually limited to instances where speed is the prime consideration.

It is dispensed in sealed vials covered with fabric which soaks up the liquid and contains the glass fragments of the broken vial. The vials contain far less amyl nitrite than is required for a single dose, it should be withdrawn therefore as soon as satisfactory effect develops. Dosage is difficult to control and, as a precaution, the patient should be lying down or at least sitting when the drug is administered.

**Octyl Nitrite** Octyl nitrite (Ocnitrite) is another rapid acting agent administered by inhalation. Dosage is controlled by the patient, and serious overdosage is possible. Although its odor is not as unpleasant as amyl nitrite, it has no other advantages over the latter. It is relatively expensive and is not widely used.

**Nitroglycerin** The official name for nitroglycerin, glyceryl trinitrate, has apparently been chosen with little regard for the resistance of the medical profession to new names, especially to one longer than the traditional name. There is no hope that the profession will call it glyceryl trinitrate as there is for acetylsalicylic acid rather than aspirin. The term nitroglycerin will be used therefore.

The pharmacologic effects of nitroglycerin develop almost instantaneously after lingual application. Oral administration is ineffective for reasons to be discussed later.

Since the dose is minute, the tablets are small and a large number may be tried inconspicuously. Although there are advantages in administering the drug without the cooperation of the patient, whereas even the unconscious patient may be made to breathe amyl nitrite.

Since the dosage form is fixed, it is controlled by the physician.

the patient as in the case of the nitrite taken by inhalation. Nitroglycerin is therefore considerably safer for the patient to use in the physician's absence.

The effects of nitroglycerin take a bit longer to develop and last a bit longer than those of amyl nitrite. It has usefulness as a prophylactic agent in special circumstances. Patients who know they are to be exposed to an emotion charged situation may be effectively primed with a tablet 15 minutes before the exposure. On the other hand, used regularly through the day to prevent attacks, it is usually ineffective.

There are patients who regularly take 30 or more tablets daily, apparently with undiminished effectiveness. In these patients, there are the unsettled questions whether they take so many because there is tolerance and the relief is psychologic and whether the agent of relief is the rest they invariably take with the tablet.

Sustained release capsules and tablets are now available. Every argument against the utility of nitroglycerin for continuous prophylaxis applies here. In addition, there is the fact that nitroglycerin is destroyed in the liver so that administration by mouth with absorption into the portal circulation is ineffective. For this reason, therefore, orally administered nitroglycerin is useless. Yet this is the means by which the so called sustained release form of nitroglycerin is used. Recent studies have indicated that it is without clinical value. To what extent this applies to other orally administered organic nitrates has not been established.

#### LONG ACTING NITRITES —

**Sodium Nitrite** Although it is almost never used in angina, sodium nitrite is mentioned because it represents the first form of the drug used clinically. Since it continues to be used in medicine and industry, its typical nitrite action on blood vessels is still important.

**Organic Nitrates** This comprises a large group of nitrates which exert relatively prolonged nitrite actions. Nitroglycerin is really one of the organic nitrates but its rapid curve of action is exceptional. The typical curve of action has long been attributed to the rate of liberation of nitrite, the rate of development of action and its duration relating directly to the rate at which this biotransformation occurs. Recently, the question has been raised whether this occurs at all and whether it is not that each drug acts in its original state. The merits of each case are not argued here for regardless of which turns out to be the fact, it is important that the fundamental pharmacodynamic action is the same as that of amyl nitrite in all instances. The curves of action of the members of the group differ little.

Since they all have relatively slow curves of action as a group, their use as prophylactic agents is their most attractive therapeutic potential and it is for this purpose that their manufacturers promote them.

Each of these agents is used hopefully when introduced but with decreasing enthusiasm as the attempt to achieve prophylaxis proves elusive.

The drugs belonging to this series and now in use follow: erythrityl tetranitrate (Erythrol Tetranitrate), monitol hexanitrate (Tolamate), mannitol hexanitrate (Maxitate Nitranitol), pentaerythritol tetranitrate (Angicap Nitrotafans Peritrate), triethanolamine trinitrate (aminotrate Metam ne). The fact that these drugs are now commonly sold in mixtures which contain ataractics or barbiturates

## DRUGS FOR HEART DISEASE

as well as the fact that patients using them are also regularly instilled with nitroglycerin with them just in case, shows the uncertain confidence of the medical profession in the prophylactic utility of the nitrites.

**SUMMARY**—The nitrites are pre eminently useful in the relief of attack of anginal pain. Here the rapid acting members far outstrip the slower acting members. The choice for this purpose depends on the requirements. The choice for this purpose depends on the requirements. On the other hand, where seconds or fractions of minutes count, the choice is superior.

The history of failures with so called long acting nitrites is an unbroken record. From our understanding of the action of these drugs, such a quality is not to be expected. Since they could have no other useful attribute, no so called long acting nitrite is the drug of choice in the anginal syndrome.

**Monamine Oxidase Inhibitors**—A rather large group of agents belonging to this series, iproniazid (Marsilid), isocarboxazid (Marplan),  $\beta$  phenyl isopropylhydrazine (Catron), phenelzine dihydrogen sulfate (Nardil) and mianserin (Miamid) have rather suddenly burst into the scene all within the last 3 months. On the one hand it has been said of them by some that they afford the best prophylactic treatment yet available for anginal pain, whereas on the other hand serious hepatitis and hypotensive reactions have developed as a consequence of the use of Marsilid, the first of these to appear. Others have suggested that the dangers attending their use are far greater than those indicated by these toxic reactions alone.

Nothing is known of the way in which these drugs relieve patients with angina although it is clear enough that many of them obtain substantial prophylactic benefits. A recent communication indicates clearly what had been in doubt before that the fact that these are monamine oxidase inhibitors is merely a coincidence and has nothing at all to do with the mode of their action in anginal patients. One action which seems to be important has been established—the action on mood. These are all 'psychic energizers' (see Chapter 10) and provide a 'lift' which in all probability elevates the threshold of disagreeable sensations (the pain of angina is characteristically associated with a sense of anxiety) arising as the result of deficient coronary circulation. The hypotensive action of these drugs is far less likely to be an important element because (1) they are useless as continuous therapeutic agents in hypertension and (2) the hypotensive action is a diffuse systemic one, and, should it develop to any significant degree, it would no doubt produce the same sort of collapse which marked the undesirable side reactions noted in the early use of Marsilid. Some have claimed that grave danger exists in their use in anginal pain through the depressed awareness of, or concern with the painful warnings which develop in insufficiency of coronary circulation. With these forebodings in mind it is only fair to repeat that the experience with some of these drugs makes it clear that they may provide prophylactic relief which is far superior to that provided by the nitrites. On the other hand, until more is known about the end results of the use of these drugs in coronary disease, an extended period of time, it would be well to view them with some caution.



and to use them only when acceptable relief cannot be provided by the nitrites. However, should it be proved that they are safer than the more cautious physicians seem to think, they will also probably be the most effective prophylactic medication for angina.

**Visammin (Khellin)**—Visammin dilates blood vessels and has been shown to increase the flow of blood through the coronary arteries in the intact anesthetized animal. In this action it is not so potent as nitroglycerin. It has been reported, however, that it prevents the development of characteristic electrocardiographic changes which may develop during the exercise tolerance test in patients with coronary sclerosis, but it has not been demonstrated that khellin can dilate the sclerotic coronary artery. No pharmacologic advantages over nitrite action have been demonstrated.

At present, the clinical utility of khellin as a prophylactic is in dispute. On the one hand, there are a number of clinical studies in which the regular use of this drug has been reported to provide complete relief in slightly more than half the patients with anginal syndrome and improvement in another third. These observations, along with others on the effect of electrocardiograms in the exercise tolerance test and evidence that patients using khellin require less nitroglycerin than others, form the basis of the case for khellin. On the other hand, in the study by Greiner and others, patients with angina were not able to distinguish between khellin and a placebo. The drug is little used and as a matter of fact, is not even available in most pharmacies.

**Xanthines**—The xanthine drugs—caffeine, theobromine, and especially aminophylline—have been extensively used over the years for angina. Evidence of coronary artery dilatation rests on the demonstration in an isolated preparation that their use is followed by increased coronary flow and that in animals with ligated coronary arteries their use results in better healing of the infarcted area. The former action is explained better by increased cardiac output than by coronary dilatation per se. The latter contention was refuted by studies in which the size of infarcted areas in treated and untreated cats after coronary ligation was carefully measured under controlled conditions. In addition, studies of the influence of xanthines on anginal pain in which the results were compared with those of placebo failed to reveal any difference between them.

Although xanthines continue to be used in this condition, the amount prescribed is steadily decreasing. A new member, choline theophyllinate, has been ushered into clinical use on the basis of poorly controlled studies which others have failed to corroborate. It is not recommended here.

**SUMMARY**—The present state of the xanthines in the relief of anginal pain is that as a group they provide little for the relief or prevention of an attack and that there is little in their known pharmacologic action on which to base such a hope.

**Thioureas**—The thioureas, e.g., propylthiouracil, have been used in the treatment of anginal syndrome. While there have been reports of successes, many have had indifferent results. It has been stated that the only indications for these drugs in patients with the anginal syndrome are for those with hyperthyroidism and as a test to determine whether euthyroid patients with the anginal syndrome will

as well as the fact that patients using them are also regularly instructed to carry nitroglycerin with them, 'just in case,' shows the uncertain confidence their proponents really have for their prophylactic utility.

**SUMMARY**—The nitrites are pre eminently useful in the relief of the acute attack of anginal pain. Here the rapid acting members far outstrip the others in satisfying the requirements. The choice for this purpose depends on the convenience and ease of controlling dosage and application. Usually, nitroglycerin is the choice. On the other hand, where seconds or fractions of minutes are important, amyl nitrite is superior.

The history of failures with so called long acting nitrites is an unbroken one. From our understanding of the action of these drugs, such a quality is not within the province of nitrite action and should be sought in some other type of drug. Since they could have no other useful attribute, no so-called long acting nitrite is the drug of choice in the anginal syndrome.

**Monamine Oxidase Inhibitors**—A rather large group of agents belonging to this series, iproniazid (Marsilid), isocarboxazid (Marplan),  $\beta$  phenyl isopropylhydrazine (Catron), phenelzine dihydrogen sulfate (Nardil), and nialmide (Niamid) have rather suddenly burst into the scene, all within the last 3 months to a year. On the one hand it has been said of them by some that they afford the best prophylactic treatment yet available for anginal pain, whereas, on the other hand serious hepatitis and hypotensive reactions have developed as a consequence of the use of Marsilid, the first of these to appear. Others have suggested that the dangers attending their use are far greater than those indicated by these toxic reactions alone.

Nothing is known of the way in which these drugs relieve patients with angina although it is clear enough that many of them obtain substantial prophylactic benefits. A recent communication indicates clearly what had been in doubt before, that the fact that these are monamine oxidase inhibitors is merely a coincidence and has nothing at all to do with the mode of their action in anginal patients. One action which seems to be important has been established—the action on mood. These are all 'psychic energizers' (see Chapter 10) and provide a 'lift' which, in all probability, elevates the threshold of awareness to disagreeable sensations (the pain of angina is characteristically associated with a sense of anxiety) arising as the result of deficient coronary circulation. The hypotensive action of these drugs is far less likely to be an important element because (1) they are useless as continued therapeutic agents in hypertension and (2) the hypotensive action is a diffuse systemic one, and, should it develop to any significant degree, it would no doubt produce the same sort of collapse which marked the undesirable side reactions noted in the early use of Marsilid. Some have claimed that grave danger exists in their use in anginal pain through the depressed awareness of, or concern with the painful warning which develops in insufficiency of coronary circulation.

With these forebodings in mind it is only fair to repeat that the experience with some of these drugs makes it clear that they may provide prophylactic relief which is far superior to that provided by the nitrites. On the other hand, until more is known about the end results of the use of these drugs in coronary disease for an extended period of time, it would be well to view them with circumspection.

sime salt of edathamil used in lead poisoning and that unless this one is carefully watched, it provides a hazard of hypocalcemic convulsions and death as well as of serious demineralization of the bones. The results of this therapy, thus far reported, are discouraging.

## DESIGN FOR THE USE OF CORONARY ARTERY DILATORS

There are two important aspects of the therapy of anginal pain—its relief and its prevention.

There is the possibility that the myocardium suffers cumulative insults from the repeated episodes of hypoxia. It is realistic, therefore, to attempt to alleviate each attack as promptly as possible and not to wait until it develops into a severe one which the patient treats when he can no longer tolerate the pain.

The choice of the drug depends on the speed of relief desired. Amyl nitrite is the quickest but is unpleasant in other respects, and since dosage is not limited it is more dangerous in the hands of the patient than fixed forms. Nitroglycerin is only slightly slower but far more convenient. It is safer than amyl nitrite since dosage is fixed. It is usually the coronary dilator of choice.

Relief with nitrite is an all or none proposition. Therefore, the smallest dose which will relieve the pain is the proper dose. Larger doses will provide no further relief but may induce undesirable side effects. The best approach to dosage, therefore, is to start with the smallest possible therapeutic dose and work upward. Such a procedure is feasible only when treating a patient with a history of repeated attacks. For the single attack seen by the physician for the first time, amyl nitrite may be used until the pain is relieved.

Prevention is quite another matter. The nitrites are ineffective, and because of fundamental pharmacologic properties which are common to all thus far examined, it seems unlikely that any new nitrite will be any better.

It should not be overlooked, however, that by the preliminary use of a nitrite it is possible to prevent a particular attack of angina when it seems likely to develop. This prophylactic use of nitrites is not possible unfortunately, on a maintenance basis.

Other drugs reputed to be effective coronary artery dilators are either ineffective or require re-evaluation. Until such evidence is available the only drugs which can be counted upon to dilate coronary arteries and relieve anginal pain are the nitrites.

## RATIONAL BASIS FOR NEW DRUGS

Many drugs are effective in angina—what is clearly desirable and not so clearly available is a drug which prevents the attacks. The persistent failure of nitrites to provide prophylaxis, presumably because of the development of tolerance, suggests that the search for still another nitrite is likely to be fruitless. A drug of another pharmacologic group should be sought, one against which tolerance does not develop. Since the useful action in the anginal syndrome is relief of coronary artery spasm by doses which do not dilate other vessels, it is a drug which has this particularized type of action and not another diffuse vasodilator which is needed.

benefit by thyroidectomy They will not, therefore, be further considered here

**Papaverine**—Papaverine is a time honored arterial dilator but its record is unimpressive The consensus is that papaverine is not a useful drug in anginal syndrome

**Dioxyline**—Dioxyline (Paveril) is similar to papaverine not only in structure but in its pharmacologic and therapeutic actions as well It is not surprising therefore, that it is as ineffective as papaverine in relieving the anginal syndrome

**Heparin and Bishydroxycoumarin**—Recent studies have failed to confirm earlier suggestions that heparin and Dicumarol (bishydroxycoumarin) are of value in the prophylactic treatment of angina

**Alcohol**—It is commonly observed that alcohol in the form of spirit is of value in relieving anginal pain Although complaints of pain may decrease, there is no evidence that this improvement develops through dilatation of the coronary arteries It is a common practice to permit or even recommend alcoholic drinks for patients with angina pectoris Any beneficial action which may develop is probably due to the sedative action which reduces anxiety and makes patients less likely to expose themselves to the particularized stimuli which precipitate attacks

**Vitamin E**—The tocopherols have evoked considerable acrimonious dispute There is not a vestige of evidence adduced by way of well controlled study that they have any pharmacologic action which directly or indirectly might be useful for the anginal syndrome

**Androgens and Estrogens**—Clinical reports on the utility of androgens and estrogens in the anginal syndrome have conflicted There is no basis in laboratory experiment or theoretic knowledge for effective use of either of these agents in anginal pain Support in evidence of their utility has been poorly controlled Their use is fast waning

**Nicotinic Acid**—The well known flush which appears after nicotinic acid is used is due to dilatation of the cutaneous capillary bed There is no evidence that this effect is exerted in more deeply placed arterioles certainly no evidence clinical or otherwise supports the suggestion that nicotinic acid dilates coronary arteries

On the other hand the obvious effect of nicotinic acid is impressive to the patient and this may constitute strong suggestive therapy

**Tissue Extracts**—From time to time tissue extracts which exert a histamine like action are introduced as specific coronary artery dilators They invariably prove useless but their introduction continues The most fantastic of these are derived from cardiac muscle an obvious attempt at an irrational connection between the muscle used for making the extract and the site of its intended action

**Calcium Chelators**—Edathamil sodium (EDTA), a material which makes in soluble forms of calcium soluble and hastens their excretion has been used to dissolve kidney stones and abnormal calcium deposits in tissues and in dirty milk cans More recently it has been suggested that this action might be useful in the treatment of sclerosed coronary arteries Since these arteries do not react to nitrites such an effect would here be a valuable one

Until the utility of this procedure is established by carefully controlled experiment it must be considered to be an untested procedure Should one wish to apply this measure he should be aware of the fact that this is not precisely the

- Gold H and Corday E Vasopressor Therapy in the Cardiac Arrhythmias New England J Med 260 1151 1959
- Kayden H J Brode B B and Steele J M Procaine Amide—A Review Circulation 15 118 1957
- MacMurray F G Stokes Adams Disease New England J Med 256 643 1957
- Silverman L M and Fichter H F Molar Sodium Lactate Compared With Electrical Therapy in the Treatment of Cardiac Arrhythmias
- Thom W Iso
- Zoll I External Electrical Currents on the Heart Circulation 14 745 1956

### Coronary Vasodilators

- Anrep G V Kenway M R and Barsoun G S The Coronary Vasodilator Action of Nitroglycerin Am Heart J 37 531 1949
- Brachfeld N Bozer J and Gorlin R Action of Nitroglycerin on the Coronary Circulation in Normal and in Mild Cardiac Subjects Circulation 19 697 1959
- Chevalier H and Simon J The Management of Angina Pectoris Am Heart J 58 120 1959
- Cold H Kuntz N T and Otto H Xanthines in the Treatment of Cardiac Pain JAMA 108 2173 1937
- Coodman L S and Gilman A The Pharmacological Basis of Therapeutics ed 2 New York 1955 The Macmillan Co p 730
- Gorlin R Brachfeld N MacLeod C and Bopp P Effect of Nitroglycerin on the Coronary Circulation in Patients With Coronary Artery Disease or Increased Left Ventricular Workload Circulation 19 685 1959
- Greiner T
- Heffell L Sol Chen
- Heffner L L Fredman B Reeves T J Eddleman E E Jr and Harrison T R Symposium on the Pharmacology of Nitroglycerin Med Clin 31/1
- Melville J
- Rosenman R
- Shohkes G W Iproniazide in Angina Pectoris—A Double Blind Study Circulation 20 17 1959
- Traks E Hackel D B and Sancetta S M Effects of a New Coronary Vasodilator on the General and Coronary Hemodynamics and Myocardial Metabolism of Man Ann Int Med 51 31 1959
- Wegra R Pharmacology of the Coronary Circulation Pharmacol Rev 3 197 1951

When new drugs are presented for evaluation the tendency of anginal pain to subside spontaneously upon resting and of sedative drugs to reduce their incidence must be taken into account.

## SELECTED REFERENCES

### Digitalis Materials

- Bryfogle J W, Santoli T, Saltzman H A and Bellet S. Therapeutic and Toxic Indexes of Digitalis. *New England J Med* 256: 767, 1957.
- Cohen M D. Digitalis Poisoning and Its Treatment. *New England J Med* 246: 225, 254, 1952.
- Cornell Conferences on Therapy. Selection of Digitalis Preparations and Their Proper Administration. *Am J Med* 13: 883, 1953.
- Ganz H F. Intramuscular Administration of Digitalis. *Am J Med* 93: 349, 1957.
- Gold, H. Intramuscular Administration of Digitalis. *Am J Med* 132: 547, 1946.
- Gubner J. Intramuscular Administration of Digitalis by Chelation of Serum Calcium. *Am J Med* 132: 547, 1946.
- Krantz J. Digitalis Glycosides in Medical Practice. *Postgraduate Med* 24: 724, 1958.
- Lown B and Levine S A. Current Concepts in Digitalis Therapy. *New England J Med* 250: 771, 1954.
- Lown B and Levine S A. Current Concepts in Digitalis Therapy. Boston, 1954. Little Brown and Company.
- Lown B, Wyatt N F, Crocker A T, Goodale W T and Levine S A. Interrelationship of Digitalis and Potassium in Atrial Tachycardia With Block. *Am Heart J* 45: 589, 1953.
- Marrott H J L. Digitalis. *Am J Med* 40: 870, 1946.
- McGee R R and Modell W Pearl. Digitalis and the Treatment of Advanced Heart Failure. *Fed Proc* 6: 338, 1947.
- Nalbandian, R M, Gordon S, Campbell R and Kaufman J. A New Quantitative Digitalis Tolerance Test Based Upon the Synergism of Calcium and Digitalis. *Am J Med Sc* 233: 503, 1957.

### Cardiac Arrhythmias

- Beckwith J R, Ibarra J A and Wood J E Jr. The Problem of Established Atrial Fibrillation. *Am J Med Sc* 231: 519, 1956.
- Bellet S, Wasserman F and Brody J I. Fibrillation. *Am J Med* 19: 918, 1955.
- Bettenger J. Cardiac Arrhythmias. *Am J Med* 19: 918, 1955.
- Brown C. Cardiac Arrhythmias. *Am J Med* 19: 918, 1955.
- Burill Z L. Chloroquine and Hydroxychloroquine in the Treatment of Cardiac Arrhythmias. *New England J Med* 258: 798, 1958.
- Catell McKeen and Gold Harry. Relation of Rhythm to Force of Contraction of Mammary Cardiac Muscle. *Am J Physiol* 182: 307, 1955.
- Cohen B M. Digitalis Poisoning and Its Treatment. *New England J Med* 246: 225, 254, 1952.
- Cohen B D, Spritz N, Lubash G D and Rubin A L. Use of a Calcium Chelating Agent (NaEDTA) in Cardiac Arrhythmias. *Circulation* 19: 918, 1959.
- Connolly D C. Arrhythmias Associated With Digitalis Therapy. *Postgrad Med* 25: 509, 1959.
- Cornell Conferences on Therapy. Management of Disorders of Cardiac Rhythm. *Am J Med* 5: 110, 1948.
- Duncan C R, Stevenson I and Rpley H S. Life Situations, Emotions and Paroxysmal Atrial Tachycardia. *Psychosom Med* 12: 23, 1950.
- Emswiler C D. Treatment of Cardiac Arrhythmias. *A M A Arch Int Med* 95: 123, 1955.
- Entwistle George. The Cardiac Arrhythmias. *M Clin North America* 39: 1367, 1955.
- Gold H. Quinidine in Disorders of the Heart. New York, 1950. Paul B Hoeber Inc.

chiefly rauwolfia alkaloids and salt restriction. The condition may be suspected in patients above the age of 55 years with a high systolic pressure and a diastolic pressure below 100 to 110 mm Hg or, at an earlier age, when some other condition which predisposes to early arteriosclerosis such as diabetes prevails.

Contrary to frequently expressed opinions, this type of hypertension tends to be labile, perhaps because the loss of arterial elasticity prevents the normal modulation of arterial pressure with changes in peripheral tonus and cardiac output. Therefore, it is not uncommon to see extremely high pressures followed by relatively normal pressures a few hours or days later. The condition denotes extensive arteriosclerosis and is probably associated with many of the accompanying vascular accidents such as cerebral lesions, coronary accidents, aneurysmal dilatations and thrombosis of the large arteries to the extremities. These complications, due largely to arteriosclerotic vascular disease, are often the cause of death of patients with arteriosclerotic hypertension. Since the elevation of the blood pressure is secondary to the arteriosclerosis rather than its cause, there is usually little to be accomplished by blood pressure reduction or control in these individuals.

**Mild and Extremely Labile Hypertension**—This is defined on the basis of wide random fluctuations in the blood pressure. This condition is usually not associated with signs of vascular disease and is customarily considered an early form of hypertension. Treatment is therefore generally of the more temperate variety. In each case frequent recordings of blood pressure are necessary to arrive at an appropriate diagnosis and to establish intelligent treatment. No evidence is available to show that any of the antihypertensive drugs reduce lability of blood pressure but they may by lowering the basal value, reduce the maximum blood pressure reached at peak levels. This may be of practical value in preventing attacks of left ventricular failure or severe hypertensive headaches due to acute rises in blood pressure. It is possible but not proved, that the reduction of frequent surges of hypertension will delay the onset of more serious complications of the disease.

**Established Hypertension Without Complications**—This is the form of the disease which offers the greatest difficulty in the selection of drugs for treatment. On the one hand, many patients live the normal life span without injury to target organs while in others this stage is merely a brief prelude to a fatal termination. If one were able to determine the prognosis, one might decide whether mild or vigorous treatment is the more desirable.

It is the general experience that particular prognostic features are ominous and when present, should guide the therapist to more vigorous treatment even when the disease appears to be benign. Among these are (1) youth, (2) high diastolic pressure, (3) male sex, and (4) the Negro race.

In addition to these general considerations, prognosis is dependent on the progressive elevation of blood pressure or on changes in heart, brain, or kidneys. For this reason, a careful record of blood pressure readings as well as of target organ disease should be kept in every case. Complications which tend to indicate a serious prognosis follow in approximate order of severity: (1) progressing renal failure, (2) the development of hemorrhages or fresh exudates in the retina, (3) cardiac failure as evidenced by history, or cardiac enlargement, (4) cerebrovas-

## THE CHOICE OF DRUGS IN THE TREATMENT OF HYPERTENSION

Sibley W. Hoobler, M D

---

### INTRODUCTION

The choice of drugs in the treatment of hypertension is not easy. In the first place, it is not sufficient to make a diagnosis of hypertension; one must take the stage of the illness and its prognosis into account before selecting drugs. In the second place, the drugs used in this disease are not uniformly effective or free from unpleasant side effects. Consequently, one must weigh the therapeutic benefits to be achieved against the side effects produced by these agents. In the third place, hypertension is a chronic disease in which no drug is curative, and all treatment must be considered as suppressive; thus, any agent used for hypertension must be considered in terms of a lifetime procedure. This means that more than usual care must be taken in selecting the agent to be used and in measuring its effects on the blood pressure. In the fourth place, the mechanisms of hypertension are so poorly understood that the effectiveness of treatment is evaluated largely by evidence of a reduction in blood pressure, a criterion which is not easy to establish in a disease notable for spontaneous fluctuations.

### CLINICAL APPLICATIONS

Table 25 presents the various categories of hypertensive disease. The general type of treatment recommended for each condition depends on the prognosis.

**"Curable" Forms of Hypertension**—Certain forms of hypertension may be cured by surgery. This text does not cover such aspects of hypertensive disease, but the reader should always consider the possibility of *unilateral renal lesions*, *Cushing's disease*, *primary aldosteronism*, and *coarctation of the aorta*. Although an *adrenal medullary tumor* is an exceptional cause of hypertension, it is often wise also to exclude this possibility by appropriate pharmacologic testing.

**Arteriosclerotic Hypertension**—This represents a category in which inelasticity of the aorta and large vessels gives rise to a higher than normal systolic pressure during ventricular systole. There is no increase in the resistance of the arterioles and consequently the diastolic pressure remains near normal limits. This condition is generally benign and, therefore, treatment should be of a mild variety involving



**Low Fat Diets** These have also been recommended but, in addition to doubt concerning their efficacy in preventing vascular atherosclerosis, they have no specific value in treating the blood pressure per se

**Weight Reduction** Such a program has its place in relieving cardiac work, but it is doubtful that, apart from the apparent improvement which comes from measuring the blood pressure on a thinner arm, there is actual reduction in blood pressure

**VASODILATORS**—The *nitrites* and *nitrites*, *theobromine derivatives*, and *nicotinic acid* have been largely replaced by more potent agents. The *nitrites* may have specific use in the treatment of angina pectoris accompanying hypertension but are not useful in the treating of the blood pressure per se. The *thiocyanates* have been demonstrated to produce a slight reduction in blood pressure only in the milder forms of hypertension

**RAUWOLFIA**—Rauwolfia in crude and purified forms lowers the blood pressure moderately but continuously in about 50 per cent of cases of mild and moderately severe hypertension. Since it is usual for the blood pressure to fall spontaneously as the patient and physician develop a degree of rapport, it is important to distinguish this from the specific effects of rauwolfia. Since treatment is expensive it is distinctly worth while to establish whether the drug is producing the blood pressure reduction. Consequently, a control period of blood pressure readings with nonspecific treatment is useful. If this is not practical, it is advisable to have readings of both blood pressure and pulse rate at least every 2 weeks during drug therapy. The patient is given 0.25 mg. of reserpine or its equivalent 3 to 4 times daily for at least 2 months and the dosage increased if side effects permit and the pulse rate does not slow. At the end of 8 to 10 weeks, blood pressure reduction should reach a maximum. If it seems significant when compared with the starting blood pressures the total daily dose may be reduced to 0.25 mg. daily and the patient advised to continue with the drug indefinitely. If the patient, who has been treated with rauwolfia by another physician, experiences a rise in blood pressure and pulse rate after 3 to 4 weeks of treatment withdrawal, the indications are that the drug has been helpful and should be reinstituted.

Among the more important side effects of rauwolfia are a tendency to gain weight, occasional formation of edema, and the development of nasal stuffiness (often prevented by combining the drug with an antihistaminic). Serious mental depression may occur at any time. This should be watched for and both the patient and a relative warned of the possibility. Frequently, it makes its appearance as an apathetic or agitated reaction but sometimes as an excessive reaction to a normally depressing experience. It is important to remember that the effects of rauwolfia wear off slowly and that it may be several weeks before recovery from the depression is complete. If this complication is constantly watched for no serious risk is entailed, but this is nevertheless the major danger of therapy with this agent.

**PARENTERAL RESERPINE**—This is a useful method to treat emergencies in which prompt blood pressure reduction is needed (subarachnoid hemorrhage, impending hypertensive encephalopathy, convulsive encephalopathy of renal disease or toxemia of pregnancy, or acute anxiety states accompanied by severe hyper

# DRUGS IN TREATMENT OF HYPERTENSION

Table 25 Classification of Hypertension in Terms of Therapeutic Needs  
4 Secondary Forms of Hypertension

Type	Definition	Diagnostic Sign or Procedure	Frequent Clinical Findings	Prognosis Without Treatment	Treatment Objective	Treatment Technique
Curable	Unilateral renal	Intravenous pyelogram	None	Serious	Normal BP	Nephrectomy
	Cushing's disease	Hydroxy and ketosteroid excretion	None	Serious	Normal BP	Adrenalectomy
	Hyperaldosteronism	Low serum potassium	Hyperglycemia characteristic of obesity etc	Serious	Normal BP	Adrenalectomy
	Coarctation	Lower BP in legs than arms	Weakness polyuria	Moderately serious	Normal BP	Resection of coarctation
Arteriosclerotic	Age over 55 or diabetic diastolic BP 110 mm Hg or less	Histamine or Regu line test*	Young persons systolic murmur	Serious	Normal BP	Adrenalectomy
		None	Vasomotor attacks	Serious	Moderate BP reduction	
Toxemia of pregnancy	High BP and albuminuria with overt or increase in last trimester	Clinical diagnosis	Arteriosclerotic complications	Moderately serious depends on locus of atherosclerosis		Rauwolfia chlorothiazide SBA† rarely advised in cerebral insufficiency anticoagulants if BP kept <200 mm systolic
			Edema excess weight gain	Variable	(1) Many hypertensive women without complications can carry pregnancy safely under close supervision (2) Terminate pregnancy after three weeks of uncontrolled toxemia	(1) Prophylactic or therapeutic (a) Extreme salt restriction (200 mg Na d et), chlorothiazide and rauwolfia (2) Veratrum if necessary in addition to keep BP below 160 mm systolic
Acute nephritis	Hematuria, albuminuria edema	Clinical diagnosis	Edema retinopathy heart failure anorexia BP labile	Variable	BP control only as necessary to prevent or relieve encephalopathy	(1) Magnesium sulfate IM (especially in children) (2) Rauwolfia parenterally (3) Veratrum or SBA if necessary

\*See Chapter 42 on Diagnostic Tests  
†SBA—sympathetic blocking agents

When these are ineffective, sympathectomy may be advised in cases of

Table 26 Comparative Action and Uses of Various Ganglionic Blocking Agents\*

Generic Name	Dosage and Duration	GI Absorption	Renal Excretion	Characteristic Side Effects†	Preferred Clinical Indications	Remarks
(a) Tetra ethyl ammonium Cl	IV 200-300 mg not advisable for continuous infusion, lasts 20-30 min <i>Oral</i> Ineffective	-----	Complete	Paresthesias, brief BP rise precedes fall	(a) Provocative test for pheochromocytoma when BP normal (b) Differential diagnosis of headaches due to high BP	(1) Increased effect in elderly and azotemias use smaller dose
(b) Trimethaphan camphor sulfonate	<i>Parenteral</i> † 4-20 mg IV per min by infusion lasts 5-20 min <i>Oral</i> Ineffective	None	Partial	Flushing, hyperpnea, nausea with overdose	(a) For rapid, precise BP control in emergency (b) Used in hypotensive anesthesia	(2) Has mild direct vasodilator as well as ganglion blocking action, this drug by infusion requires constant supervision
(c) Hexamethonium	<i>Parenteral</i> † IV 1-50 mg for rapid effects on BP, 2-5-25 mg subcutaneously every 4 hr, lasts 2-4 hr	-----	Complete	-----	(a) Parenterally, for initial control of BP in hypertensive emergencies	(3) Chronic oral use has been replaced by longer acting drugs
(d) Pentolinum	<i>Parenteral</i> † 0.5-10 mg IV as in (c), 1-15 mg subcutaneously every 6 hr, lasts 4-6 hr <i>Oral</i> 25-150 mg 3-4 times daily, lasts 5-7 hr	-----	Complete	-----	(a) Parenterally, for longer action in control of BP	(4) Dosage after toleration may have to be increased

## DRUGS IN TREATMENT OF HYPERTENSION

44

tension) A single dose of 25 to 50 mg may be given intramuscularly and repeated every 4 to 6 hours for several days. Maximal vascular effects appear in 30 to 60 minutes along with sedation, flushing, and other characteristic side effects. The blood pressure falls at least to the usual level for the patient and often may reach near-normal values. Shock, postural hypotension, ileus and urinary retention which may accompany emergency treatment with ganglionic blocking agents, are not caused by reserpine. It is particularly useful for treatment in the home where continuous supervision of blood pressure to avoid excessive hypotension is not feasible. The safety of this treatment is attested by its wide use in mental hospitals in much larger doses than recommended here. Such larger doses rarely produce greater blood pressure reductions than the 5 mg dose.

**CHLOROTHALIDZIDE**—This drug is the treatment of choice for mild hypertension and as an adjuvant to other regimens. See more extensive discussion on page 453.

### Potent Treatment Regimens—

**HYDRALAZINE**—Apresoline (hydralazine) is recommended as a hypertensive drug which dilates vessels generally. It also increases cardiac output and has a general excitatory effect on the circulation. However, hydralazine alone rarely lowers the blood pressure significantly for more than a short period.

Its use is attended by many side effects, some of them most distressing to the patient, among which are severe generalized headache, palpitation, tachycardia, edema, nausea, vomiting, chills, and fever. Early in treatment, joint pain and an influenza-like syndrome suggesting serum sickness sometimes develop. A more serious late manifestation of hydralazine treatment, occurring after 6 months or more of therapy, is a lupus erythematosus-like syndrome with arthritis, fever, malaise, leukopenia. In most cases, the syndrome subsides on discontinuing treatment. Cortisone may, however, be necessary. This syndrome is partially but not entirely related to dosage. It is uncommon when the total daily dose of Apresoline is below 200 mg.

Many experienced physicians use the drug in combination with reserpine or in combination with ganglionic blocking agents, which, while minimizing some of the hydralazine side effects, add others. It is my opinion that the drug rarely offers sufficient promise to justify its general use. On the other hand, it is the experience of some of the more enthusiastic supporters of this treatment that over a period of several months there is a gradual reduction in the requirement for the more potent ganglionic blocking agents, if hydralazine is combined with them in the treatment program. This claim, however, requires substantiation, but if it were established it would indicate an important quality of this agent. The contraindications for hydralazine include angina pectoris and peptic ulcer, which may be aggravated by the cardioexcitatory and the stimulant effect on gastric secretion.

**VERATRUM ALKALOIDS**—These agents unquestionably lower the blood pressure and are quite safe, but they also cause nausea and vomiting. When used intravenously or parenterally for short periods, blood pressure reduction can be achieved without emetic side effects, but in long-term oral use there is such a narrow margin between these effects that blood pressure reduction is often limited.

the cost of suffering nausea or vomiting 2 or 3 times a week. These are not the drugs of choice for the management of hypertension.

For many years, veratrum has been used parenterally in the treatment of toxemia of pregnancy. This is probably an effective sphere of usefulness, for the parenteral administration of the drug may lower the blood pressure quickly and sustain the effect for the short period before delivery.

• The side effects of veratrum treatment include paresthesias in the throat and perioral region, nausea, and anorexia. In addition, at the peak of drug action there may be vomiting and extreme hypotension.

The effects on heart rate and rhythm are dramatic. There is, first of all, a pronounced bradycardia, sometimes followed by varying degrees of heart block and of idioventricular rhythms. Despite the ingestion of massive doses, however, very few serious effects have been reported. Bradycardia and rhythm disturbances may be promptly stopped by the intravenous administration of 1 mg of atropine sulfate. This should always be at hand when the drug is given by the parenteral route. Since at least some of the blood pressure reducing effect is due to a decrease in cardiac output, the increase in rate and the rise in output following atropine usually raise the blood pressure somewhat. If the rise is insufficient, it may be increased with such pressor agents as Neo-Synephrine and norepinephrine.

#### Heroic Treatment Regimens: Sympathetic Blockade.—

**CAROTIDIC BLOCKING AGENTS**—These agents lower the blood pressure in the great majority of hypertensive individuals. It appears that they do so by reducing cardiac output rather than by a major decrease in total peripheral resistance. Their effectiveness in lowering blood pressure is the chief argument in favor of their use when vigorous treatment is necessary. Full advantage should be taken of the postural fall in blood pressure and the patient should be treated until the standing systolic blood pressure becomes as low as tolerable. If this can be kept in the range of 110 to 150 systolic,\* it is not likely that the effects of high blood pressure on the vessels will be serious, and further progression of the disease will be prevented. At the same time, syncopal effects will be avoided if the pressure is kept above the level of 110 mm Hg.

Since such fine control is rarely possible without strict monitoring of the blood pressure, patients on this program are advised to record their own blood pressure on a chart and bring it with them to the doctor's office for review. In opposition to the generally accepted feeling that the patient should not know much about his blood pressure, I have found that this program actually breeds confidence on the part of the patient that the disease is really under as good control as is possible. It is only the exceptional person who becomes a "blood pressure neurotic" on this program, whereas the uncertainty of not knowing the blood pressure or of trying to guess the blood pressure from symptoms or from the physician's attitude has indeed caused much anxiety.

\*Systolic blood pressure falls more than diastolic and is easier to determine, while the relationship of systolic to diastolic and recumbent to standing blood pressure cannot be materially altered by changing the dosage of the drug. For the purpose of simplifying control programs, therefore, the systolic blood pressure reading is stressed as the more likely to indicate impending syncope.

(e) Chlorzoxime	Parenteral † 0.5-10 mg I.V. as 0.5-1.0 mg subcutaneously 2-3 times daily lasts 5-7 hr	Complete	Mydriasis prominent	(a) For long acting parenteral effect especially in cases with renal function
	<i>Oral</i> 25-150 mg 2-3 times daily lasts 6-8 hr	Complete	Mydriasis prominent	(b) Second choice when mecamylamine causes undesirable side effects
(f) Mecamylamine	<i>Parenteral †</i> 2.5-10 mg I.V. or 1 mg rarely used because onset of action delayed 30 min or more lasts 7-10 hr	Partial greater excretion when urine is acid		(5) Mydriasis often affects ability to work, treat with low pilocarpine eye drops, tinted glasses and refractive correction (6) Complete oral absorption on slow onset and duration of action less retention in renal failure less tolerance and fewer side effects make it drug of choice
	<i>Oral</i> 2.5-30 mg 2-3 times daily lasts 8-12 hr or more	Complete	Coarse tremor, nystagmus with renal insufficiency or cerebral artery occlusion occurs occasionally	(7) If control ineffective trimethoprim or chlorzoxime is next choice
(g) Trimethoprim methanesulfate	<i>Oral</i> 50-100 mg 3-4 times daily	Partial	Mydriasis	(8) Very parasympathetic blocking effects

\*Symptomatic blockage of drugs not tabulated here described in text

†In total trial dose should always be small to exclude hypotension

‡Other than those of general autonomic blockade as described in text

Patent should also receive chlorzoxime 500 mg twice daily

less effective than *mecamylamine* causes more mydriasis and exhibits greater variation in day-to-day absorption

Other side effects can be only partially relieved. *Pilocarpine* eye drops sometimes improve the visual symptoms, but when the treatment has been stabilized refraction and the prescription of new glasses may be the only measure of value to those seriously disabled by this complication. Dizziness relieved by recumbency is usually a sign of excessive action of the drug or that the blood pressure is being lowered beyond the patient's vascular tolerance. In this situation, the dosage is reduced. For impotence, temporary cessation of the drug may be effective. Although prolonged withdrawal of these agents may result in serious hypertension, cessation for 2 to 3 days will not be as serious as some of the complications which might follow the continued use of these drugs in the face of serious side effects. Blood pressure should be followed with particular care when the drugs are stopped since this will demonstrate the advent of a potentially dangerous hypertensive rebound.

**Parenteral Use** The parenteral use of ganglionic blocking agents may be indicated (1) in acute hypertensive crises and (2) in the more precise control of blood pressure in patients with impending renal failure in which reduction must not be excessive for fear of aggravating azotemia. Since most ganglionic blocking agents may be given intravenously or subcutaneously with similar but more dependable effects than by the oral route, this form of treatment is often the desirable one.

For the hypertensive emergency not responsive to reserpine other parenteral treatment is necessary. Intravenous infusion of trimethaphan (*Arfonad*) at the rate of 4 to 20 mg per minute with constant supervision of blood pressure will bring about a prompt fall that is reversible. The rate of infusion can be used to control the degree of blood pressure reduction. If symptoms do not improve, the restoration of hypertensive levels is rapid on discontinuing treatment.

Another method for treating the emergency case involves the intravenous administration of hexamethonium to the patient in the sitting position at the rate of 1 mg per minute until a blood pressure reduction halfway to normal levels is achieved or until 50 to 75 mg of the agent has been given. It is extremely important that the blood pressure be checked every minute during this treatment and that overdosage be avoided.

If more gradual blood pressure reduction is desired it may be sufficient to give hexamethonium subcutaneously every half hour, beginning with a dose of 2.5 mg (to exclude the extremely sensitive case). The dose is then increased to 5, 10 and 20 mg at successive half hour intervals until the blood pressure has reached a point halfway between its previous level and normal. Comparable parenteral doses of pentolinium (*Ansolysen*) or chlorisondamine (*Ecolid*) are 1, 2, 4 and 8 mg. Maintenance doses of these agents every 4 to 6 hours will sustain the blood pressure reduction for the first several days of inpatient treatment until the patient can be placed on an oral regimen.

**SELECTIVE SYMPATHETIC BLOCKADE**—*Bretylium tosylate* (*Darenthin*) is representative of a new class of sympathetic blocking agents which are said to prevent release of norepinephrine at sympathetic nerve endings without producing postural tachycardia and parasympathetic or ganglionic blockade. They do not inhibit the





vented with potassium chloride or fruit juice supplements, and by spacing the doses at 12-hour intervals. After reduction in fluid volume, a self-limiting mechanism is yet not understood, prevents further fluid depletion. Ingestion of moderate amounts of sodium chloride (2 to 4 Gm) duly does not overcome these effects although a greater intake will result in salt repletion and cancellation of the physiologic effect of chlorothiazide. Cessation of treatment may result in an abrupt rise of blood pressure. discontinuance of this medication therefore demands careful supervision.

A quite regular effect is observed when chlorothiazide is used in conjunction with sympathetic blocking agents. It may reduce the requirement for these drugs by 50 per cent in most patients. It also potentiates the effects of sympathectomy, so that patients who have previously responded poorly to surgery now exhibit significantly reduced blood pressure levels. The sensitizing effects of chlorothiazide are similar to those described when a mercurial diuretic is given to a hypertensive patient who is receiving a ganglionic blocking agent.

In view of this fact, patients are now given ganglionic blocking agents only after 3 days of chlorothiazide therapy. If blockade has been established, blood pressure may fall a few hours after adding chlorothiazide. In such cases therefore the level is carefully watched and the dosage of the ganglionic blocking agent is promptly reduced when necessary. The effect is retained with maintenance dosage (0.5 Gm twice daily).

Potentiating effects of this drug in combination with other antihypertensive agents, hydralazine, reserpine, and veratrum, have also been reported. It has not yet been established, however, whether the blood pressure reduction reported for such combinations is additive or synergistic. Until more information is available, there appear to be no reasons why such combinations should not be tried.

For the present, my preference is to use chlorothiazide with or without reserpine in mild to severe hypertension without complications, after sympathectomy and whenever there is an indication for the use of sympathetic blocking agents. If the drug is to be effective in a particular patient, careful observations of blood pressure will establish this fact within a few days or a week. prolonged therapeutic trial or precise dosage adjustment are not necessary. In an occasional refractory case a temporary increase in daily dosage to 2 to 3 Gm may produce the desired response, but it has been established that prolonged administration of doses in excess of 1 Gm daily is unnecessary.

There are no reports of serious toxic effects due to chlorothiazide. Potassium depletion and aggravation of azotemia seem the most likely dangers. Therefore potassium should be given orally, whereas in patients with severe azotemia the drug is given carefully. In hypertensive patients with cardiac disability, the drug would appear to be potentially of great value, but if digitalis is being taken potassium depletion should be avoided. The effect of the drug on the cerebral complications of hypertension has not been determined, but severe hypotension and delirium should not be induced in patients liable to cerebrovascular thrombosis.

The dangers of cumulative toxic effects have not yet been established. Chlorothiazide seems safe and there are no present, clear contraindications or special warnings other than that the physician should carefully and conscientiously follow

effects of epinephrine and its congeners on the peripheral vessels and thus may be differentiated from dibenamine like compounds

Clinical experience with these drugs is at present very limited, and it is difficult at this time to predict their usefulness. Over a period of several months Boura and collaborators have reported no evidence of toxicity. A brief experience indicated that orthostatic normotension can be produced in most hypertensive subjects by doses of 200 to 600 mg 3 times daily with meals that overdosage or increased responsiveness may lead to postural hypotension with symptoms of lightheadedness, syncope or weakness and that as with ganglionic blocking agents, recumbent hypertension is little affected by doses sufficient to reduce standing blood pressure readings to normal. However the disabling effects of parasympathetic blockade are absent. It is probable that improved derivatives will soon become available. One long acting compound guanethidine has been described which unfortunately causes diarrhea in some patients. As might be expected the effect of these adrenergic blocking agents is potentiated by chlorothiazide which should therefore be prescribed concomitantly.

**DRUGS OF CHOICE.**—For reasons outlined in Table 26 of all the ganglionic blocking agents my preference is for mecamylamine (Inversine). Its regular and dependable absorption from the gastrointestinal tract makes oral administration feasible and safe. After good bowel activity has been secured this agent is given in dosage of 2.5 mg, 2 to 3 times daily increasing by increments of 2.5 mg every day while in the hospital or every third day on an outpatient basis until the blood pressure is at a desired level or the side effects of parasympathetic blockade become intolerable. It is estimated that with great care in supervision there will be satisfactory blood pressure reduction without intolerable side effects in approximately 80 per cent of patients on this regimen. The selective sympathetic blocking agent bretylum may after more experience be proved superior to mecamylamine.

**Chlorothiazide.**—The introduction of the orally effective diuretic and saluretic drug chlorothiazide (Diuril) has provided a new tool for the management of hypertension. This agent related to sulfanilamide appears to inhibit the renal absorption of water, sodium chloride, and to a lesser extent potassium by mechanisms which resemble both those involved in the diuretic actions of acetamide (Diamox) and the mercurial diuretics. In an extensive experience with this drug exhibit weight loss with some degree of asthenia. Rare toxic effects include skin reactions, thrombocytopenia and jaundice. When the drug is used at a moderate antihypertensive effect has been observed in from one fourth to half of cases with milder forms of the disease when salt is avoided. When the hypertension is associated with occult or manifest edema particularly in patients on the nonedematous subject a loss of 2 to 4 pounds can be expected when administered twice daily for 1 to 3 days. This is due to reduction in plasma and extracellular fluid. The effect on the blood pressure corresponds to expected in patients with essential hypertension subjected to a 200 mg sodium fluid depletion produced by the chlorothiazide may be maintained with twice daily. Serum potassium levels may decline but this can be pre-

out his life using home, not office blood pressure, as a measure of adequate control. Regression of vascular lesions must be a further measure of effectiveness.

Reduction in blood pressure taken at home must be continuously demonstrated\*. Such a reduction must exceed 20 to 40 mm pressure from the untreated level. The systolic standing blood pressure at all times should remain below 180 to 190 and should preferably be below 150. If these stipulations are not met it is doubtful that chronic suppressive treatment will be worth while.

It should be stressed that management of hypertension is chronic and long continued and the patient should never remain for long periods away from the physician's observation since this may result in interim rises in blood pressure of considerable degree unknown to the patient and, therefore, untreated by the physician. There is a common but fallacious hope among hypertensive patients that once a blood pressure reduction apparently has been secured by a particular regimen the treatment plan never needs revision. Nothing could be farther from the truth. The disastrous experience of occasionally discharging a patient on a simple treatment program only to find him some years later with severe hypertension and hypertensive encephalopathy has convinced me that once the hypertensive patient requires treatment he also requires frequent re-examination at least at 3 to 6 month intervals throughout the remainder of his life.

## RATIONAL BASIS FOR NEW DRUGS FOR THE TREATMENT OF HYPERTENSION

The criteria of an ideal antihypertensive agent may be summarized as (1) complete oral absorption, (2) persistent effects (3) action at the site of the deranged vascular mechanism by relaxing arteriolar constriction and (4) no tendency to tolerance. It is apparent that no drug presently available fulfills the criteria of a successful to say nothing of this ideal antihypertensive agent and that increasing the potency of agents with the pharmacologic properties of those presently available will not lead to it.

While the rauwolfia alkaloids satisfy some of the criteria there is no evidence that they act directly on the constricted arterioles. Furthermore, they are not sufficiently potent to be effective in cases of great severity. The evidence that reserpine acts by depleting serotonin and that an antagonist to serotonin is no more effective than reserpine in lowering blood pressure indicates that more potent reserpine-like agents will probably not have greater effectiveness.

With the possible exception of mecamylamine, patients develop tolerance to the ganglionic blocking agents. These drugs do not have the desired site of action. Although it is still controversial most authors agree that cardiac output is reduced by them. Blood pressure reduction based on this mechanism is not desirable. It would appear that the effectiveness of ganglionic blockers has reached its peak with mecamylamine which is completely absorbed and has persistent action with side effects that are frequently tolerable.

\*Occasionally it is well to advise a therapeutic vacation during which the blood pressure is followed. This will demonstrate to patient and physician whether there is any value to the treatment and at the same time dangerous rebound will be prevented if the drug is immediately resumed should blood pressure rise excessively.

current reports of medical experience with this interesting and effective diuretic agent

A number of chlorothiazide derivatives (e.g., hydrochlorothiazide, flumethiazide) have been recommended in preference to the parent drug usually on the basis of lesser kahuresis. The differences are not of great clinical significance. Skin reactions and thrombocytopenia from chlorothiazide may sometimes be avoided by changing to these newer derivatives. [There is no reason, however, to believe that similar reactions cannot also develop as the result of the use of these newer derivatives of chlorothiazide. Ed.]

## A DESIGN FOR THE USE OF DRUGS IN THE TREATMENT OF HYPERTENSION

My general philosophy of the treatment of hypertension involves the use of three established agents in the management of various forms of hypertension—chlorothiazide, rauwolfia alkaloids, and mecamlamine.

**The First Choice**—In patients in whom relief is not urgent, chlorothiazide 0.5 Gm. twice daily, is first used for a period of 2 to 3 months. If blood pressure can clearly be shown to be reduced by this treatment to levels below about 180/110, the author does not proceed to more complicated treatment programs. If the response is inadequate, reserpine 0.25 mg. 3 times daily for 2 months, may be given followed by a maintenance dose of 0.25 mg. per day.

**The Second Choice**—Should this program fail to affect the blood pressure, there is little evidence that its continued use is helpful. A decision must then be made whether or not the patient belongs in the category of hypertensive disease which justifies more vigorous treatment with ganglionic blocking agents in addition to chlorothiazide. In this decision the age of the patient, the sex and race, the evidences of progression of the disease, particularly as found in the search for the vascular complications mentioned in Table 25, are weighed to determine whether more vigorous treatment is desirable. If it is decided to use a ganglionic blocking agent, the patient is instructed in self determination of the blood pressure,\* a suitable 2 to 4-week base line of standing morning and early evening blood pressures is recorded, chlorothiazide and cathartics are given routinely, and mecamlamine is started in increasing doses until there is satisfactory blood pressure reduction or until despite a daily laxative, distention or obstipation is intolerable.

If treatment is attended by too many side effects but is still necessary, the following steps are considered: (1) addition of reserpine or hydralazine to the program in an effort to permit reduction of dosage and side effects of ganglionic blocking agents; (2) conversion to trimethidinium or bretylium tosylate; (3) sympathectomy, and (4) if the latter is unsuccessful, reversion to chlorothiazide, reserpine and ganglionic blocking therapy, since after sympathectomy patients tend to exhibit increased sensitivity to such a program. Three guiding principles are followed. The prognosis of the disease must justify the introduction of the side effects of the treatment. The patient must expect continued supervision through

\*Sphygmomanometers designed for this purpose are available from the Proper Manufacturing Company.

## THE CHOICE OF VASOCONSTRICTOR DRUGS FOR HYPOTENSION AND SHOCK

*John H. Moyer, M.D., and*

*Leuis C. Mills, M.D.*

### INTRODUCTION

The primary purpose for the systemic administration of vasoconstrictor drugs is to increase arterial blood pressure. It is quite obvious that the most effective method for treating severe hypotension, whether or not it is associated with other clinical manifestations of shock, is to correct the underlying disease responsible for the reduction in blood pressure. However, it is not always possible to correct the cause of the hypotension immediately. Under these circumstances it may be lifesaving to maintain the blood pressure artificially for variable periods of time so that an adequate supply of blood may continue to flow through the brain and other vital vascular beds.

There are a number of patients in shock, particularly those with medical complications, who do not respond to the administration of fluids or blood transfusions. Indeed, fluids may sometimes be contraindicated. Even when the shock is due to hemorrhage and other surgical causes, vasopressor agents may prove to be valuable as a temporary expedient either to maintain blood pressure until blood can be replaced or as a supplemental measure in those patients who do not obtain a prompt and adequate response to blood and fluid administration.

### PHARMACOLOGIC CONSIDERATIONS

**General Considerations**—Vasopressor agents should restore systemic blood pressure quickly and should direct circulating blood to the more vital vascular beds which are critical for life, it is of primary importance that the circulation be maintained through the brain, the heart, the liver, and the kidneys. In maintaining the circulation it is essential that this not be brought about by stimulating the heart and increasing cardiac output only, else cardiac complications may follow. For example, epinephrine is useless in man when used as a vasopressor agent since the primary effect is on the myocardium, increasing cardiac output, and at the same time having very little constrictive effect on the peripheral vessels unless ex-

The ideal drug should relieve the excessive vasoconstriction at the arteriole rather than reduce blood pressure, even in part, by decreasing cardiac output. From this standpoint, hydralazine and the nitrites exert a desirable effect. Unfortunately, hydralazine does not act in all cases, and when it does, it produces many undesirable side effects. Furthermore, there appears to be a stimulation of cardiac output which is clearly undesirable.

The nitrites and other direct-acting vasodilators unfortunately act on smooth muscle of veins as well as of the arterioles and it is probable that a decrease in cardiac output also plays a role in their action. This is deduced from the fact that postural hypotension frequently develops following their use, suggesting that the effect on venous tone and reduced cardiac output are factors in the blood pressure reduction. Furthermore, tolerance develops rapidly.

One would imagine that a sympathetic blocking agent which does not have parasympatholytic properties would be of greater value since at least the distressing side effects of parasympathetic blockade would be avoided. Dibenamine-like compounds which, like phentolamine, do not block the cardiac sympathetic innervation have side effects of postural hypotension and tachycardia which are most undesirable. Bretylium tosylate, a recently introduced agent, avoids these objections, but in doses tolerated by the ambulatory patient has little effect on recumbent hypertension. [Not available on the commercial drug market. Ed.]

The ideal drug would dilate arterioles without other effects on the autonomic nervous system or on cardiac output. This agent would have to have the unusual properties of reducing arteriolar smooth muscle tone without seriously affecting venomotor tone.

## SELECTED REFERENCES

- Boura, A. L., Green, A. F., McCoubry, A., Laurence, D. R., Moulton, R., and Rosenheim, M. L. Darenthun Hypotensive Agent of New Type, *Lancet* 2: 17, 1959.
- Chapman, C. B., and Gibbons, T. B. Diet and Hypertension. A Review, *Medicine* 29: 29, 1950.
- Dontas, A. S., and Hoobler, S. W. Drug Treatment of Hypertension, *Pharmacol. Rev.* 5: 135, 1953.
- Activity
- Hyper
- k, 1959,
- Moyer, J. D. *Hypertension*, 1959.
- Page, I.
- Paton, J.
- Pickering, G. W. High Blood Pressure, New York, 1955, Grune & Stratton.
- Schroeder, H. A. Hypertensive Diseases: Causes and Control, Philadelphia, 1953, Lea & Febiger.
- 9 383 540 703 712, 839 1954
- Charles C. Thomas, Publisher
- ial Reference to Chlorothiazide,

*Table 27 Cerebral Hemodynamic Effect of Blood Pressure Elevation to Hypertensive Levels in Normal Subjects\**

	Metaraminol		Norepinephrine	
	Control	Drug	Control	Drug
Mean Blood Pressure (mm Hg)	88	128	94	124
Cerebral Blood Flow (ml/100 Gm./min.)	58	53	57	50
Cerebral Oxygen Uptake (ml/100 Gm./min.)	3.4	3.2	3.7	3.5
Cerebrovascular Resistance (MBP/CBF)	1.6	2.4	1.7	2.6

\*Average values in 11 patients

MBP = Mean blood pressure

CBF = Cerebral blood flow

is primarily that of peripheral vasoconstriction with minimal direct cardiac effect (Fig. 10). Consequently, the primary response to an infusion of norepinephrine is a rise in diastolic blood pressure with an associated and secondary rise in systolic pressure (Figs. 10 and 11).

Throughout the literature, pharmacodynamic studies have been done on normal subjects, and deductions thus have been drawn as to the probable action of these drugs in various disease states. This has been particularly true of drugs which affect the cardiovascular and the autonomic nervous systems. It has become increasingly obvious that such deductions are frequently inaccurate. For example, when vasoconstrictor drugs are given to normotensive subjects and the blood pressure increased to hypertensive levels, blood flow through such vital areas as the brain and the kidneys is reduced. Contrariwise, when the blood pressure is raised from shock levels to normotensive levels, blood flow, which was previously depressed in these areas, increases toward normal. Similar discrepancies have been noted when electrocardiographic observations have been made during the administration of vasopressor agents to the normotensive subject (made hypertensive by the drug) as compared to the patient who was previously hypotensive and who was then made normotensive (rather than hypertensive) by the drug.

**Cerebral Hemodynamic Effects**—When the blood pressure is increased from normotensive to hypertensive levels, cerebral blood flow is reduced slightly (Table 27) because of the vasoconstrictive effect of the drugs on the cerebral vessels. Moreover, in the presence of hypotension due to shock or to ganglionic blockade (Table 28) the cerebral arterial pressure is inadequate to maintain blood flow through the brain and as a result, the cerebral blood flow is reduced also. The brain partly compensates for the reduced cerebral blood flow by extracting more oxygen from that blood which is circulating through it. However, when the mean cerebral arterial blood pressure is reduced below 55 mm Hg, cerebral blood flow may be reduced to a point at which the increased extraction of oxygen may not be adequate. As a result, cerebral oxygen uptake is reduced and hypoxia results. Apparently, there is very little difference in this cerebral hemodynamic response whether the hypotension is produced by hemorrhage or hypotensive drugs such as ganglionic blocking agents (Table 28). The degree of blood pressure reduction is the important feature since the cerebral blood flow during hypotension is en-

cessive doses are used (Fig 11). Thus, when a continuous infusion is given, systolic blood pressure rises (due to the increase in resistance) whereas the diastolic blood pressure falls. By contrast, the action of




Fig 10—Site of action of vasoconstrictor agents. Not all are equally responsive to the sympathomimetic agents. It is not a predominant constrictive effect in less vital vascular beds but a constrictive effect in such vital areas as the brain, heart, liver, and




Fig 11 The blood pressure response to norepinephrine. The systolic pressure rises after both but after epinephrine a result of an overall reduction in peripheral resistance and Millis L C. Norepinephrine Effect in Normal Unresponsive to Other Measures Am J Med 15:93





Table 29 Observations on Cerebral Oxygen Metabolism and Cerebral Hemodynamic Response to Blood Pressure Fluctuation With Vasopressor Agents Following Initial Hypotension Due to Ganglionic Blockade or Shock\*

Patient	Ganglionic Blocking Agent	Vasopressor Agent	Mean Blood Pressure (mm Hg)			Cerebral Blood Flow			Cerebrovascular Resistance			Cerebral O <sub>2</sub> Consumption		
			C	D	V	C	D	V	C	D	V	C	D	V
Patients Who Were Hypotensive Due to Ganglionic Blockade														
1	Arfonad	Nor epinephrine	96	52	120	40	25	36	24	21	33	26	20	24
2†	Arfonad	Nor-epinephrine	96	75	105	58	38	51	17	20	21	28	29	32
3	Arfonad	Nor-epinephrine	110	58	110	48	35	38	23	17	29	25	27	29
4	Arfonad	Nor-epinephrine	94	44	110	41	25	35	23	18	31	29	26	26
5	Hexamethonium	Aramine	108	61	120	52	44	56	21	14	21	41	37	38
6	Hexamethonium	Aramine	98	68	118	49	36	64	20	19	18	26	22	29
7	Hexamethonium	Aramine	104	61	105	75	36	65	14	17	16	41	33	40
8	Hexamethonium	Nor epinephrine	100	80	140	69	58	65	15	14	22	30	26	34
9	Hexamethonium	Nor epinephrine	96	54	118	56	40	50	17	14	24	28	31	25
10	Hexamethonium	Nor epinephrine	100	53	95	54	34	42	19	16	23	36	29	30
11‡	Pend omide	Nor epinephrine	111	66	110	49	51	53	23	12	21	29	32	30
Mean			101	61	114	54	38	50	20	17	24	31	28	31
Patients Who Were Hypotensive Due to Shock														
ETIOLOGY			S	V	S	S	V	S	V	S	V	S	V	V
12	Hemorrhage	Nor epinephrine	52	94	42	42	56	12	17	20	34			
13	Cardiogenic	Nor epinephrine	48	100	38	38	48	13	21	23	30			
14	Septicemia	Nor epinephrine	40	95	32	32	40	13	24	18	24			
*From Moyer, J H, and Morris, G Cerebral Hemodynamics During Controlled Hypotension Induced by the Continuous Infusion of Ganglionic Blocking Agents (Hexamethonium Pendiomide, and Arfonad) J Clin Invest 33 1081, 1954														
†When blood pressure increased from 105 to 145, the cerebral blood flow decreased to 38														
‡When blood pressure increased from 110 to 155, the cerebral blood flow decreased to 49														
G = Control observations D = observations after blood pressure reduction with ganglionic blocking agent V = observations after blood pressure elevation with vasopressor agent S = observations while in shock														

\*From Moyer, J. H., and Morris, G. Cerebral Hemodynamics During Controlled Hypotension Induced by the Continuous Infusion of Ganglionic Blocking Agents (Hexamethonium, Pentium de, and Arfonad). J. Clin. Invest. 33: 1081, 1954

†When blood pressure increased from 105 to 145, the cerebral blood flow decreased to 38

‡When blood pressure increased from 110 to 155, the cerebral blood flow decreased to 49

G = Control observations D = observations after blood pressure reduction with ganglionic blocking agent V = observations after blood pressure elevation with vasopressor agent S = observations while in shock

Table 28 Cerebral Hemodynamic Effect of Blood Pressure Reduction\*

Cause of Blood Pressure Reduction Function Study	Hexa methonium		Tri methaphan		Shock			
					Hemorrhagic		Cardiogenic	
	Con trol	Drug	Con trol	Drug	Re covery†	Shock	Re covery†	Shock
Mean Blood Pressure (mm Hg)	99	69	99	57	105	59	112	58
Cerebral Blood Flow (ml/100 Gm/min)	57	42	52	36	54	32	49	36
Cerebral Oxygen Uptake (ml/100 Gm/min)	32	29	31	28	30	21	31	24
Cerebrovascular Resistance (MBP/CF)	18	15	20	17	20	16	23	16

\*Average values for 6 or more patients

†One to two weeks after recovery

tirely dependent on the cerebral arterial blood pressure and the inherent cerebrovascular vasoregulatory mechanisms (Fig. 12). The degree of cerebral vasoconstriction is unrelated to sympathetic nervous system activity in man.

When the blood pressure is raised from hypotensive toward normotensive levels cerebral blood flow (which was reduced because of the hypotension) increases significantly and it may return entirely to normal (Table 29 and Fig. 13). Table 29 summarizes some observations that we have made on cerebral hemodynamics before and after the administration of vasopressor agents to patients who were hypotensive either from hemorrhage or following the administration of ganglionic blocking agents. It is quite obvious that when the cerebral blood flow was depressed due to hypotension this was followed by a significant increase in

## CONTROL



CEREBRAL BLOOD FLOW  
DEPENDENT ON CAROTID  
BLOOD PRESSURE AND  
INHERENT VASO REGULATORY  
MECHANISM IN BRAIN

## INCREASED CARDIAC OUTPUT



PERIPHERAL BLOOD FLOW  
DEPENDENT ON CARDIAC  
OUTPUT AND SYMPATHETIC  
NERVOUS SYSTEM VASO  
REGULATION

response has been observed with norepinephrine, metaraminol (Aramine), and phenylephrine (Neo Synephrine). We have not had occasion to study the response to other vasopressor agents when administered to patients in shock. The increase in glomerular filtration rate can be observed clinically by observing the increase in urine output. Generally, when the urine output is adequate, the blood pressure is adequate to maintain renal blood flow as well as blood flow through the other vital areas.

Table 30 Renal Hemodynamic Response to a Continuous Infusion of Various Vasopressor Agents in Normal Human Subjects

Drug	Mean Arterial Blood Pressure (Mm Hg)			Glomerular Filtration Rate (Ml/Min)			Renal Blood Flow (Ml/Min)			Renal Vascular Resistance (MBP/RBF)		
			Per Cent of Control			Per Cent of Control			Per Cent of Control			Per Cent of Control
	Control	Drug	Control	Drug	Control	Drug	Control	Drug	Control	Drug	Control	Drug
Methoxamine	90	122	136	115	75	63	1129	668	59	0.082	0.445	615
Norepinephrine	97	132	130	108	102	94	1143	705	63	0.091	0.195	224
Metaraminol	86	125	147	99	109	109	1134	1038	94	0.082	0.128	162





Fig 14—A comparison of the renal vasoconstriction produced by various vasopressor agents in the normal dog

In patients who have suffered severe hemorrhage and are markedly hypovolemic, renal function will not improve to the same extent that it will in the patient who is hypotensive but normovolemic, as, for example, in the patient who is hypotensive and oliguric following a hypotensive drug. It has also been shown experimentally in dogs that are in severe shock due to hemorrhage that administration of norepinephrine results in no improvement in renal blood flow and may

cerebral blood flow when the patient was again made normotensive, although frequently it did not return entirely to normal

In patients with severe hypertensive vascular disease, the degree of reduction in cerebral blood flow due to hypotension is even more marked at equivalent levels (hypotensive) of absolute blood pressure than it is in patients who were previously normotensive. Consequently, when shock is being treated in patients who previously had severe hypertensive vascular disease, it is necessary to increase the arterial blood pressure to mildly hypertensive levels if the cerebral blood flow is to be returned to normal



**Renal Hemodynamic Responses**—In some respects the renal hemodynamic responses to vasopressor agents are quite similar to those observed in the brain. When a vasopressor agent is administered to a normotensive dog (Fig 14) or to a normotensive human subject (Table 30), renal blood flow decreases. There is considerable variation in this response among the different vasopressor agents. Methoxamine (Vasoxyl) has the most marked renal vasoconstrictive effect (Fig 14 and Table 30) when administered to the normal subject.

By comparison with the normal subject, when vasopressor agents are administered to patients whose renal function is depressed due to hypotension, glomerular filtration rate and renal blood flow increase. This occurs whether the hypotension be due to drug administration, hemorrhage, or shock from other causes. A similar

Figs 17A and 17B summarize the responses of two patients who were in shock but in whom the blood volume was normal. Patient J. M. (Fig 17A) had severe hypokalemia (2.2 mEq per liter) associated with leukemia. Glomerular filtration rate and renal blood flow increased to approximately two thirds of the normal value when the blood pressure was increased with norepinephrine. Subsequently the cause of the hypotension was determined and potassium was administered to this patient, following which renal function returned entirely to normal. Nonetheless the vasopressor agent had proved lifesaving by preventing cerebral ischemia and irreversible damage to the brain and other vital tissues while laboratory procedures were being carried out in order to establish the correct diagnosis, which fortunately was amenable to specific therapy.




Fig 15B—A response similar to that shown in Fig 15A was observed when metaraminol was administered to a similar patient (From Moyer, J. H., Morris, G., and Beazley, H. Renal Hemodynamic Response to Vasopressor Agents in the Treatment of Shock, *Circulation* 12:96-107, 1955; reprinted by permission.)

Patient D. L. (Fig 17B) was oliguric due to hypotension resulting from a myocardial infarction. When the hypotension was corrected, glomerular filtration rate and renal blood flow increased. When the norepinephrine was temporarily discontinued, renal function decreased. Subsequently, the condition of the patient improved so that norepinephrine was no longer required to maintain the blood pressure, and renal function remained stabilized.

Even in the presence of renal damage, when function is further impaired by hypotension, vasopressor agents may improve renal function. Patient L. H. (Figs

actually decrease it. Likewise, the normovolemic patient who is in shock and has deteriorated, thus requiring large doses of vasopressor agents to maintain blood pressure, will not obtain a response comparable to the patient who is less ill. This is particularly true in patients who are in the terminal stages of cardiogenic shock or hypotension from an overwhelming infection.

Given (Fig. 15A) were in hemorrhagic shock, produced a rather dramatic increase in glomerular




Fig. 15A—Renal hemodynamic response to blood replacement therapy in a patient who was in shock due to blood loss. Renal filtration rate and renal blood flow increased progressively as the blood pressure was returned to normotensive levels. (H. J. H. Renal Hemodynamic Response to Blood Replacement Therapy, 1955, reprinted by permission.)

filtration rate and renal blood flow. Although these determinations were not accurate during the period of maximum hypotension (due to the low urine output), it is obvious that there was a progressive rise in renal function as the blood pressure was returned to normotensive levels. Oddly enough, renal function during the infusion of norepinephrine was approximately the same as it was following blood replacement therapy.

Fig. 16 compares the renal hemodynamic response to norepinephrine and metaraminol in the same patient. If any difference does exist, metaraminol produces a slightly greater improvement in renal function than norepinephrine at equivalent blood pressure levels.

is observed. When the vagus is blocked with atropine, the vagal response is entirely lost and tachycardia follows (Figs 20A and 20B). This reflex vagal response to hypertension resulting from vasopressor administration also tends to produce arrhythmias. Therefore it is essential that the blood pressure not be increased to hypertensive levels, particularly in the presence of myocardial disease, otherwise




Fig.  
20. Block due  
to Beazley H  
Circulation

mem  
and  
lock

disastrous results may follow. Also, it is probably not wise to administer cholinergic blocking agents such as atropine during vasopressor administration since the vagal restraining effect on blood pressure is then lost and the blood pressure may become quite labile and difficult to regulate. Likewise the tachycardia may become quite severe.

When the blood pressure is raised from hypotensive levels to normotensive

18A and 18B) had severe renal damage following intravaginal administration of Lysol in an attempt at self-induced abortion. She became oliguric but not anuric. On the third hospital day she developed shock and became nearly anuric, at which time the initial renal function tests were done. Following the administration of norepinephrine, renal function, including the excretion rates of water and electrolytes, increased to the preshock levels. Although these values cannot be considered as absolute, due to the limitations of the techniques under these circumstances, they do give some estimate of qualitative directional changes indicating some improvement in renal function.




Fig 16—Comparison of the renal hemodynamic response to metaraminol and norepinephrine in the same patient. As the blood pressure was returned to normal, glomerular filtration rate and renal blood flow increased. There was very little difference in response to the two drugs. (From Moyer, J. H., and Beazley, H. L. Effectiveness of Aramine in the Treatment of Shock, *Am Heart J* 50: 136, 1955.)

When blood pressure reduction is excessive following the administration of hypotensive agents, patients may become anuric due to inadequate glomerular perfusion pressure. Under these circumstances, vasopressor agents produce an immediate return of glomerular filtration rate and urine volume toward normal (Figs 19A and 19B).

#### Cardiac Effects of Vasopressor Agents —

**ARRHYTHMIAS**—When the blood pressure is raised from normotensive to hypertensive levels with vasopressor agents, bradycardia due to reflex vagal effects



**PERIPHERAL RESISTANCE**—Calculated peripheral resistance usually increases but this is not always the case. When the blood pressure is returned to normal with vasopressor agents, cardiac output increases. The administration of norepinephrine is associated with an increase in peripheral resistance. Thus, vasopressor agents are capable of increasing vasoconstriction over and above that which has resulted from increased sympathetic nervous system activity resulting from hemorrhage. It should be noted, however, that in hemorrhagic shock cardiac output increases considerably more after blood transfusions than it does during the administration of vasopressor agents.




Fig 18A—Patient (L. H.) in shock with primary renal damage due to Lysol. Glomerular filtration rate and renal blood flow were markedly depressed. As the vasopressor agent was administered both glomerular filtration rate and renal blood flow increased. The increase in renal blood flow may well have prevented the development of irreversible renal damage in this instance. (From Moyer J. H., Morris C., and Beazley, H. Renal Hemodynamic Response to Vasopressor Agents in the Treatment of Shock, *Circulation* 12: 96, 10, 1955, reprinted by permission.)

**EFFECTS ON PULMONARY CIRCULATION**—Vasopressor agents also constrict the pulmonary vessels, resulting in a marked increase in pulmonary artery pressure. This could be a reflection of increased venous return and inadequate pulmonary outflow associated with the bradycardia, rather than a direct effect of the drug on the pulmonary circulation and the

ones, reflex arrhythmias rarely, if ever, occur. When the cardiovascular system of patients has deteriorated and it becomes necessary to administer excessive doses of norepinephrine, toxicity may occur and arrhythmias may be produced. Such reactions are occasionally observed in patients with overwhelming infections and following massive myocardial infarctions.

**CARDIAC OUTPUT**—When the blood pressure is raised from normotensive to hypertensive levels, norepinephrine produces little, if any, increase in cardiac output. Metaraminol likewise does not alter cardiac output. When atropine is given during the administration of norepinephrine or metaraminol, there is frequently a sharp increase in cardiac output and in pulse rate. This does not necessarily mean that the vasopressor agent affects the heart directly, more likely it produces venous and capillary constriction which causes an increased venous return. These effects followed by the vagal release due to the atropine, result in an increase in pulse rate and in cardiac output.




Fig 17B—Renal hemodynamic response to norepinephrine in a patient with normovolemic shock of moderate severity due to a myocardial infarction (Patient D I) (From Moyer J H, Morris G, and Beazley H. Renal Hemodynamic Response to Vasoconstrictor Agents in the Treatment of Shock. *Circulation* 12:96-107, 1955 reprinted by permission.)

Probably one of the major factors responsible for improved peripheral circulation following the increase in blood pressure from shock levels to normotensive ones during the administration of vasopressor agents is the increased venous return which is followed by an increase in cardiac output. This response can occur without a direct effect of the drugs on the heart although some of the agents may have a direct cardiac stimulant effect. Following hemorrhage or cardiogenic shock, cardiac output is depressed.




Fig 194—Renal response to blood pressure elevation with norepinephrine in a patient who became anuric following an excessive response to hexamethonium (From Moyer, J H, and Dennis, Edward W Treatment of Hypertension Part IV Pharmacology and Therapy of Hypertensive Emergencies, South M J 49 580, 1956 )




Fig 19B—Renal response to norepinephrine in a patient who became markedly hypotensive following the administration of pentolinum (From Moyer, J H, and Dennis, Edward W Treatment of Hypertension Part IV Pharmacology and Therapy of Hypertensive Emergencies, South M J 49 580, 1956 )

subsequent increase in pulse rate the pulmonary hypertension persists suggesting a direct constrictor effect of the drug on the pulmonary vessels

## THE DRUGS OF CHOICE

Numerous vasopressor agents are available for clinical use. Generally speaking, the clinician should select a short acting drug for continuous intravenous infusion. The outstanding agent in this category is norepinephrine (levarterenol, Levophed). In addition, the therapist should select a longer acting vasopressor






Fig. 18B.—Despite a persistent depression of glomerular filtration rate in the presence

miss on )


agent which is suitable for continuous intravenous infusion as well as for intermittent intramuscular use. In this category I prefer metaraminol (Aramine) and phenylephrine (Neo Synephrine). Some therapists prefer methoxamine (Vasoxyl) because it is somewhat longer acting than phenylephrine and metaraminol. Having selected one or two of these agents, it is best to use them more or less exclusively. This allows the therapist to become familiar with the characteristics




A Lead aVf - Control  
Blood Pressure 122/81  
Heart Rate 71



B Lead aVf - Methoxamine 188 mg/Kg/min  
Blood Pressure 165/97  
Heart Rate 47



C Lead aVf - Methoxamine 188 mg/Kg/min  
(Immediately before administration of atropine)  
Blood Pressure 175/100  
Heart Rate 47



D Lead aVf - 5 minutes after atropine 1 mgm IV  
Blood Pressure 191/120  
Heart Rate 128

Fig 20B—Electrocardiographic changes during the intravenous infusion of methoxamine (From Mills, L C, and Moyer, J H. Methoxamine. Effect on Blood Pressure and Renal Hemodynamics, Am J M Sc 233 409, 1957)

## VASOCONSTRICTOR DRUGS FOR HYPOTENSION AND SHOCK

of the vasopressor agent that he employs. When the therapist employs a large variety of compounds, it is difficult to evaluate the desirable qualities as well as the undesirable ones for each drug. Occasionally a patient may become unresponsive to one of the vasopressor agents but may respond to another. When this occurs, however, the patient's general condition is rapidly deteriorating and the prognosis is usually hopeless.

The pharmacodynamics of metaraminol are almost identical with phenylephrine, although it apparently produces somewhat less renal vasoconstriction and is not quite as potent. Mephentermine (Wyamine) is of little value since it is unpredictable and not adequately potent. Methoxamine (Vasoxyl) may be as




Fig. 20A—The effect of atropine administration on blood pressure and pulse rate during the intravenous infusion of methoxamine. (From Mills L. G. and Moyer J. H. Methoxamine. Effect on Blood Pressure and Renal Hemodynamics. *Am J Med Sci* 233: 409, 1957.)

good as phenylephrine, but since it produces more pulmonary and renal vasoconstriction than do norepinephrine, phenylephrine and metaraminol, as well as some other undesirable effects when used for the treatment of shock, it should be used as an alternative drug for intermittent intravenous or intramuscular administration in those patients who do not respond to phenylephrine or metaraminol. However, methoxamine is effective in preventing a decrease in blood pressure when used prophylactically for the prevention of hypotension during spinal anesthesia and is used for this purpose it has the advantage of longer duration of action with central nervous system stimulation.

countered with extravasation of phenylephrine and metaraminol. Epinephrine is contraindicated as a vasopressor agent for the treatment of shock. Metaraminol and phenylephrine can be administered by intermittent intramuscular or subcutaneous injections, but the degree of blood pressure response following this method of administration is unpredictable. The drugs are administered by this route in emergency conditions when a continuous intravenous infusion is not possible at the moment.

**Hypotension and Shock Due to Severe Infections**—The prognosis is poor in patients who require vasopressor agents because of hypotension due to infection. This merely emphasizes that unless the etiology of the infection can be treated irrespective of the cause, the patient in shock will ultimately succumb. Therefore it is essential that the infection be treated vigorously with appropriate antibiotics and other means available for reducing toxemia. The patients should be well hydrated but not overhydrated. When the infectious process appears to be toxic and temporarily unresponsive to antibiotic therapy, steroids should be administered in the amount of 100 to 200 mg. of hydrocortisone every 8 hours.

Vasopressor agents are only temporary expedients and the patients frequently respond poorly to them since the toxic process is associated with widespread vascular damage as well as the loss of intravascular fluids. Since potency is usually an important factor, we consider norepinephrine to be the agent of choice here. However, Weil has found metaraminol (Aramine) effective under these circumstances. Ezzo found norepinephrine superior to methoxamine in the treatment of bacterial shock. Uhl reported a case of shock from meningococcemia that failed to respond to all forms of treatment including adrenocortical therapy but that responded to norepinephrine with ultimate recovery.

**Hypotension Associated With Drug Administration**—In the treatment of hypotension due to drug administration, the prognosis is usually good when the hypotension is due to vasodilatation rather than a toxic effect on the myocardium or severe arrhythmia such as ventricular fibrillation. Frequently the vasoconstrictor response is only required for short periods. A frequent use of vasopressor agents is to combat excessive hypotension associated with antihypertensive agents particularly the ganglionic blocking agents. Vasopressor agents are also useful for the treatment of hypotension associated with overdoses of barbiturates.

When the hypotension is not severe, a single intravenous injection of phenylephrine (4 to 10 mg.) or metaraminol (5 to 10 mg.) will be adequate. This can be followed by the intramuscular or subcutaneous administration of the effective dose of metaraminol or phenylephrine every 20 to 40 minutes or as frequently as necessary.

When the hypotension is more persistent, it is usually best to give a vasopressor drug by continuous intravenous infusion. Phenylephrine and metaraminol are easier to manage and less variable but may not be sufficiently potent. If not then norepinephrine should be used starting with a concentration of 4 mg. per 1,000 ml. of intravenous fluid and increasing the concentration as much as needed.

**Surgical Hypotension**—Generally speaking when shock occurs in the surgical patient it is a direct result of some complicating factor. It goes without saying that the primary objective should be to correct the complicating disturbance.

## CLINICAL USE

**Cardiogenic Shock** Vasopressor agents are useful in numerous circumstances when the blood pressure is not high enough. Probably the most frequent indication for these compounds is hypotension due to cardiac disease, i.e., cardiogenic shock. This is seen most frequently following myocardial infarctions and less frequently in association with severe heart failure and following pulmonary infarction. Results indicate that shock resulting from a cardiac origin has a poor prognosis, and a high percentage of these patients die even though the blood pressure is returned toward normal with vasopressor agents. However, almost all investigators of this problem feel that many of the patients who do survive most surely would have died had not vasopressors been used in the acute episode, and a survival rate greater than 50 per cent has been reported by some investigators. Siglin reported a case of myocardial infarction with survival following use of norepinephrine intravenously for 14 days.

**DETAILS OF REGIMEN**—Particular care should be exercised to avoid sudden and excessive increases in blood pressure in the presence of cardiovascular disease particularly in patients with myocardial infarctions. In a patient who was previously normotensive it is usually preferable to maintain the systolic blood pressure within the range of 90 to 110 mm Hg. When the blood pressure is allowed to increase to hypertensive levels untoward effects may occur. As noted above any of the vasopressor agents may produce arrhythmias when the blood pressure is allowed to increase to hypertensive levels. Ventricular fibrillation and death may follow. When the blood pressure is allowed to increase excessively in patients with heart failure and poor myocardial function acute pulmonary edema may be precipitated. This is particularly likely to result when large amounts of fluid are given concurrently.

It should also be noted that the sudden administration of 200 to 300 ml of 5 per cent glucose or normal saline may precipitate or aggravate pulmonary edema in a patient who is already in heart failure. When the patient is anuric and the administration of fluids contraindicated then vasopressor agents such as metaraminol or phenylephrine can be given intramuscularly or subcutaneously every 20 minutes to 2 hours thus avoiding the administration of fluids. Irrespective of the route of drug administration it is a good rule to maintain the blood pressure at the minimum level that will maintain the circulation so that the patient is free of clinical manifestations of shock. This assures adequate blood supply to vital tissues and at the same time keeps the cardiac work load at the minimum level necessary for life. When the patient has had severe or malignant hypertension prior to the emergency it is frequently necessary to keep the blood pressure at mildly hypertensive levels in order to ensure an adequate blood flow to the brain.

Close nursing supervision is required when intravenous infusions of vasopressor agents are being used. Intravenous infusions of norepinephrine are preferable for severe shock. However, when less potent agents are required, phenylephrine (Neo Synephrine) or metaraminol (Aramine) may be preferable, especially when prolonged administration is required. After the infusion rate has been regulated and the blood pressure stabilized with these longer acting agents, fluctuations in blood pressure are less likely to occur. In addition, cutaneous sloughs are not en-



to be as effective as methoxamine, with the latter having the longer duration of action. Complications were minimal with both drugs. It appears that both of these agents are equally effective when used to prevent hypotension from spinal anesthesia, and the drug of choice in this instance would depend on the clinician's familiarity with one or the other drug.

## THE ADMINISTRATION OF VASOPRESSOR AGENTS

**Norepinephrine**—Norepinephrine must be given by continuous intravenous infusion and the dose must be individually titrated for each patient, i.e., the rate of infusion is adjusted so as to maintain the blood pressure at low normotensive ranges (systolic pressure between 90 and 110 mm Hg). When norepinephrine is used, the concentration of this agent in the infusion solution is 4 mg per 1,000 ml of 5 per cent glucose or normal saline. When the patient is in congestive failure saline should be avoided. When the required rate of infusion becomes too great at this concentration, the concentration of norepinephrine is increased in 4 mg increments per 1,000 ml of solution until the required response is obtained. There is no limit to the concentration of norepinephrine that may be employed, concentrations as great as 48 mg per 1,000 ml of solution have been used safely. However, when increasing concentrations are required, the prognosis is usually poor and rarely do patients recover when more than 12 mg per liter of fluid is required to maintain the blood pressure. In patients with cardiogenic shock due to myocardial infarction, it is particularly important that the blood pressure not be increased above normotensive ranges, or disastrous results may follow. Therefore it is very important that constant supervision be given to the intravenous administration of vasopressor agents. Extreme caution must be used at all times in order to avoid extravasation of the infusion, else serious cutaneous sloughs will occur.

When norepinephrine is to be administered for a prolonged period of time it is necessary that an intravenous catheter be used. This is done either by exposing a vein and inserting a plastic tube into it or by using a relatively large (16 gauge) needle through which the plastic catheter is inserted into the vein. When a "cut down" is used and the vein ligated at the site of insertion of the catheter, it is necessary to insert the catheter far enough so that the tip lies in a relatively large vein where the flow of blood is quite large. If these precautions are not followed during prolonged infusion of norepinephrine, a cutaneous slough will frequently be produced. This no doubt results from back diffusion of the drug into smaller vascular channels, which is followed by intense vasoconstriction and local ischemia followed by necrosis. In my experience, it has usually been best to insert a plastic catheter through a needle into the femoral vein and up into the inferior vena cava. When a "cut down" is required, it is best to use the saphenous vein in the groin inserting the plastic catheter up into the inferior vena cava. Foot veins should be avoided whenever possible.

**Long-Acting Vasopressor Agents**—Of the longer acting vasopressor agents for continuous intravenous infusion, phenylephrine (Neo Symphephrine) and metaraminol (Aramine) seem to be the agents of choice. The longer action of metaraminol according to Weil and Spink also offers a distinct advantage over norepinephrine in that the route of administration may be changed to intermittent

However, it may become necessary to support the blood pressure until specific corrective measures can be instituted. Even when due to hemorrhage and other surgical etiologies, vasopressor agents alone or together with blood may prove to be valuable as a temporary expedient for maintaining blood pressure in those patients who do not respond promptly and adequately to blood and fluid administration.

When surgical shock has existed for prolonged periods, it may not respond to fluid replacement therapy and corrective surgery. This has been well documented experimentally in animals in which shock following blood loss became irreversible after prolonged periods of time, despite transfusion of more blood than was originally removed. Under these circumstances, further fluid administration also will be valueless and is contraindicated since it may lead to acute heart failure and pulmonary edema. Undoubtedly, a large factor in the production of the so-called "irreversible shock state" is damage to the brain and other vital organs as a result of inadequate perfusion pressure during the period of hypotension. It is inescapable that the sooner the blood pressure returns to a level adequate for perfusion of these vital organs, the more likely the patient is to recover, provided he does not die from the primary disease process which is responsible for the hypotension.

Hypotension during the postoperative period may also result from infection as a complicating factor. When this occurs, the hypotension should be treated as in any other instance of severe infection. The primary objective is to treat the infection.

**TRAUMA**—Trauma is of extreme importance in the etiology of shock. Frequently these patients will not respond to blood and fluid replacement. It then becomes necessary to support the blood pressure with vasopressor agents. Patients with trauma to the brain are particularly likely to develop shock.

**ISCHEMIA**—Ischemia during vascular surgery may be followed by severe hypotension, especially following surgery on major vessels such as the aorta and its branches. When the blood pressure is supported following release of the vascular clamps, excessive hypotension may be avoided. This is of importance since extreme blood pressure reduction for only 3 to 5 minutes may result in irreversible cerebral damage. It may become necessary to use an intra-arterial infusion of a vasopressor agent. Probably phenylephrine is the agent of choice for this purpose, in a concentration of 15 to 20 mg per 1,000 ml of solution. If this is inadequate, then norepinephrine in a concentration of 2 mg per 1,000 ml of fluid may be employed.

**SPINAL ANESTHESIA**—Vasopressor drugs have been extremely useful in preventing the blood pressure reduction which commonly results from spinal anesthesia. It has become the routine of many anesthesiologists to give one of these agents as a prophylactic measure. The longer acting vasopressor agents such as metaraminol (Aramine) and methoxamine (Vasoxyl) are more suitable for this purpose because of the longer duration of action as well as the ease of administration. A 10 mg dose of methoxamine is usually injected subcutaneously prior to induction of spinal anesthesia. The dose of metaraminol used by Poe was 3 to 5 mg. King and Dripps found that methoxamine was longer acting and that it offered other advantages over the other vasopressor agents. Poe found metaraminol

- Mills, L. C., and Moyer, J. H. Metabolism and dynamics, *Am J M Sc* 226 653, 1953
- Mills, L. C., and Moyer, J. H. Metabolism and dynamics of vasopressor agents, *Am J M Sc* 226 653, 1953
- Mills, L. C., Moyer, J. H., and Sampson, J. M. The Effect of Norepinephrine and Epinephrine on Renal Hemodynamics, *Am J M Sc* 226 653, 1953
- Moyer, J. H., and Beazley, H. Effectiveness of Aramine in the Treatment of Shock, *Am Heart J* 50 136 1955
- Moyer, J. H., Handley, C., and Huggins, R. The Effect of Adrenergic Blockade and Norepinephrine on Renal and Cardiovascular Hemodynamics Following Hemorrhage, *Circulation Res* 2 441, 1954
- Moyer, J. H., Morris, G., and Beazley, H. Renal Hemodynamic Response to Vasopressor Agents in the Treatment of Shock, *Circulation* 12 96, 1955
- Moyer, J. H., Morris, G., and Snyder, H. A Comparison of the Cerebral Hemodynamic Response to Aramine and Norepinephrine, *Am J M Sc* 229 661, 1955
- Poc, M. F. The Use of Vasopressor Agents in Shock, *Am J M Sc* 229 661, 1955
- Sampson, J. J., and Zipser, A. Norepinephrine in Shock Following Myocardial Infarction Influence Upon Survival Rate and Renal Function, *Circulation* 9 38, 1954
- Selzer, A., and Rytand, D. A. Use of Drugs in Shock Accompanying Myocardial Infarction, *J A M A* 168 763, 1958
- Siglin, I. S. Prolonged Use of Arterenol for Shock Following Myocardial Infarction With Patient Survival, *A M A Arch Int Med* 98 372, 1956
- Weil, M. H., and Spink, W. W. Clinical Studies on a Vasopressor Agent Metaraminol (Aramine) I. Observation in Normotensive Subjects, *Am J M Sc* 229 661, 1955

## VASOCONSTRICTOR DRUGS FOR HYPOTENSION AND SHOCK

tent subcutaneous or intramuscular injection (every  $\frac{1}{2}$  hour to 2 hours) circumventing some of the problems of continuous nursing care as well as the possibility of cutaneous sloughs. The initial concentration of phenylephrine metaraminol is 25 mg per liter of 5 per cent glucose or normal saline. If an adequate response is obtained without excessive fluid administration, these agents are given by intravenous infusion the duration of action is considerably shorter than when an equally effective vasopressor dose is given subcutaneously. Of the drugs available for subcutaneous or intramuscular administration, phenylephrine and metaraminol seem to be quite adequate in most instances. Clinicians prefer methoxamine (Vasovyl). The usual initial dose of phenylephrine is 4 or 5 mg given intramuscularly and if this is not adequate it can be increased in 5 mg increments repeated every 10 to 20 minutes as required to maintain blood pressure. The initial intramuscular dose of metaraminol is 3 to 5 mg. If this is inadequate the dose can be increased in 3 to 5 mg increments and repeated as frequently as every 10 to 20 minutes.

**Combinations.**—It is frequently advantageous to use a combination of phenylephrine and norepinephrine in the same infusion. This gives the therapist the potency of norepinephrine with less fluctuation in blood pressure as a result of the phenylephrine in the solution. In addition, the vasopressor effect is not lost as rapidly and an occasional patient obtains an effective vasopressor response to this combination whereas an excessive dose of norepinephrine or phenylephrine would have been required had the agents been administered alone.

## EVALUATION OF NEW VASOPRESSOR AGENTS

A vasopressor agent which is superior to those already available should increase the blood pressure promptly and should maintain or show an increase in blood flow to vital areas at the expense of less essential vascular beds such as the skin and striated muscles. In other words it should increase over all peripheral resistance but at the same time increase the blood flow through the coronary the renal the hepatic and the cerebral vessels. The drug should have minimal side effects and should maintain or increase cardiac output. It should not produce cardiac arrhythmias. The degree of vasoconstriction produced by vasopressor agents should be controlled readily tachyphylaxis and secondary vasodilation following discontinuation of the drug should not occur. The drug should be effective when administered by different routes. Especially it should not be necessary to give large volumes of fluid when the drug is administered by the intravenous route. Local tissue damage at the site of injection should not occur following any route of administration.

## SELECTED REFERENCES

1. J. A. Knight and W. B. Knight: *Bacterial Shock*. *Am. Arch. Int. Med.* 99: 701, 1957.  
 2. B. D. Dripps and R. D. Dripps: *The Use of Methoxamine for Maintenance of the Circulation During Spinal Anesthesia*. *Surg. Gynec. & Obst.* 90: 659, 1950.  
 3. W. Moyer and J. Chapman: *The Cardovascular and Renal Effects of Aramine*. *Am. Heart J.* 47: 745, 1954.

lowing sympathectomy which proved to be inadequate, and in vascular diseases involving both upper extremities where surgery, of necessity, is more extensive and apt to be ineffective

Before a vasodilator drug is employed for prolonged periods, the therapist should ascertain the inoperability of the condition. For example, if the obstruction to the circulation is a localized process, arterial homograft or arterial bypass is the therapy of choice. Contrariwise, the latter approach is of little value when the disease is a diffuse process.

The effective medical management of occlusive vascular disease is largely dependent upon factors other than vasodilator agents, which, if ignored, usually render the drugs ineffective. There are frequently one or more ancillary disease processes which result in increased disparity between blood supply and demand, i.e., congestive heart failure, anemia, diabetes, and recent arterial occlusion. The frequency with which occlusive manifestations diminish or even disappear following resolution of such ancillary factors is remarkable. The importance of these associated conditions is re-emphasized in respect to their role in the production of gangrene. Somewhat in excess of 50 per cent of extremities which are amputated are lost as a result of trauma or infection, both of which will be greatly magnified in the event the patient's condition is not optimum. A thorough orientation of the patient regarding such matters as foot care, avoidance of temperature extremes, tobacco, exercise, etc., with reassurance, is usually a simple matter and is invariably expedient and limb preserving.

**Evaluation of Results**—In estimating a patient's response to vasodilator therapy, the physician should remind himself that symptoms of occlusive arterial disease are not always stable and spontaneous improvement shortly after the onset of the complaint is frequently observed. Variations in the degree of exercise tolerance are a part of the natural history of the disease. Often the therapist must be satisfied with symptomatic relief alone, with the use of vasodilators. Similarly surgery may produce gratifying healing of ulcerations and warmth in a previously cold extremity but no change in exercise tolerance.

**Dangers**—Finally, the use of vasodilating drugs is not without risk, and such undesirable complications as activation of quiescent peptic ulcers, coronary thrombosis, myocardial infarction, and cerebral thrombosis do occur. The possibility of secondary arterial and venous thrombosis has already been mentioned. Side effects from the drugs vary and may occasionally be so numerous or so unpleasant as to prevent continued use.

## PHARMACOLOGIC CONSIDERATIONS

Vasodilator drugs act either directly on the smooth muscle of the arterioles or indirectly by depressing the number of vasoconstrictor impulses traveling over the sympathetic nervous system, i.e., by decreasing the degree of functional constriction of the arterioles. Most of the effective therapeutic agents in use today act by the latter mechanism, i.e., depressing the sympathetic nervous system. Obviously the impedance to the circulation must be due in part to vasoconstrictive nervous impulses if the drugs blocking these impulses are to be effective.

The drugs which are effective in depressing the sympathetic nervous system

## THE CHOICE OF VASODILATOR DRUGS FOR THE TREATMENT OF PERIPHERAL VASCULAR DISTURBANCES

John H. Moyer, M.D., and  
Charles H. Heider, M.D.

### INTRODUCTION

Vasodilator drugs have been advocated enthusiastically from time to time for the treatment of peripheral vascular disease. Although initial reports for any one drug have usually been favorable, subsequent reports by other investigators have been less encouraging. To date there is no single effective measure for the treatment of occlusive disease which has gained wide acceptance. The major difficulty encountered in the systemic administration of vasodilator drugs is their inability to produce selective vasodilation in specific ischemic areas without simultaneous generalized vasodilation. This may result, paradoxically in a reduction of blood flow to the area of vascular disease particularly when drugs which reduce systemic blood pressure are used in treating morphologic occlusive disease. In fact hypotension has been implicated in the occurrence of secondary arterial and venous thrombosis in such a situation. This hazard seems particularly imminent in cases of unilateral occlusive disease in which generalized vasodilation would logically result in a shunting of blood from the ischemic occluded extremity to the normal extremity thereby aggravating the ischemia.

**Uses and Limitations**—Beneficial results from vasodilator drugs are obtained most frequently in those conditions in which reduced regional blood flow is due to functional vasoconstriction resulting from increased activity of the sympathetic nervous system i.e. Raynaud's phenomenon. These agents tend to block the most active components of the sympathetic system. The vasodilator effect can also be concentrated in a specific vascular bed by the intra arterial injection of some of the adrenergic blocking agents. Occasionally this approach is useful as an adjunct to surgery i.e. to ascertain the level of a localized vascular occlusion or to predict the feasibility of sympathectomy.

In general long term treatment with vasodilator agents is undesirable. However continuous medication may become necessary in some instances. Such a program is usually resorted to in conditions involving more than two extremities, fol-

**Adrenergic Blocking Agents**—These compounds act directly on the blood vessels blocking the transmission of vasoconstrictor nervous impulses from the sympathetic nervous system to the smooth muscle in the vessel wall. The more important compounds useful for this purpose are azapetine (Ilidar), phenoxybenzamine (Dibenzyline), tolazoline (Priscoline), and phentolamine (Regitine). In addition, Hydergine and hydralazine have some adrenergic blocking properties. Recently, nylidrin (Arlidin) has been reported to produce selective vasodilatation in the skeletal muscles by direct action on the arteriole rather than by adrenergic blockade.

**TOLAZOLINE (PRISCOLINE)**—Tolazoline is a peripheral vasodilator and adrenergic blocking agent, but it has many other actions. Although the drug is a peripheral vasodilator, it may increase the pulse rate and the cardiac output similarly to a sympathomimetic agent, thus accounting for some of the cardiac side effects caused by it. It may precipitate palpitations and anginal attacks. It increases the myocardial response to epinephrine, and myocardial infarctions following the administration of tolazoline have been reported. Other side reactions consist of shivering sensations, flushing of the face and neck, and conjunctival injection. The drug has a variable effect on arterial blood pressure, sometimes increasing it and sometimes decreasing it.

**PHENTOLAMINE (REGITINE)**—Phentolamine is one of the imidazoline series similar to tolazoline. Unlike tolazoline, however, this agent is more specific in its adrenergic blocking properties and does not exert sympathomimetic effects. It blocks both circulating norepinephrine and epinephrine vasopressor effects. Its actions appear to be similar to phenoxybenzamine (Dibenzyline). When taken orally it produces nausea, vomiting, and diarrhea in a very high percentage of patients. Consequently, it is administered primarily by the parenteral route.

**AZAPETINE (ILIDAR)**—Azapetine is also an adrenergic blocking agent which blocks sympathetic vasoconstrictor impulses at the blood vessels. It has minimal effect on blood pressure although occasional patients may get a significant reduction. Nasal congestion, vertigo, drowsiness, and conjunctival injection are observed with its use.

**PHENOXYBENZAMINE (DIBENZYLIN)**—This agent has a definite hypotensive effect when given in adequate doses. Fatigue and orthostatic tachycardia may be observed. Green found azapetine and tolazoline to be superior to phenoxybenzamine as vasodilators in normal volunteers. While phenoxybenzamine was more effective in the hands than in the feet, it was, nevertheless, relatively ineffective in both. The dose must be adjusted carefully so that an excessive blood pressure reduction is not produced. Nausea, pallor, and tachycardia are symptoms produced by an excessive reduction in blood pressure.

**Drugs Acting Directly on the Smooth Muscle of the Arterioles**—There are several well known agents which act directly on the arteriole, producing vasodilatation. The most important of these are histamine, nylidrin, papaverine and nitrites.

**HISTAMINE**—This drug acts directly on the smooth muscle, producing vasodilatation. It must be given in a very dilute solution intra arterially in order to

can be divided into three groups by virtue of their site of action (1) centrally acting agents, (2) ganglionic blocking agents, and (3) adrenergic blocking agents which block sympathetic impulses at the blood vessels. Generally speaking, the adrenergic blocking agents are most useful for the treatment of peripheral circulatory diseases.

**Centrally Acting Agents**—These consist of the rauwolfia compounds, hydralazine (Apresoline), and Hydergine. In large doses the latter two also have peripheral adrenergic blocking activity. In my experience, the centrally acting drugs are of limited use, being effective only in those diseases in which the vasoconstriction is on a functional basis such as in Raynaud's disease. These compounds are of little or no benefit in vascular diseases in which there is anatomical damage to the vessels.




Fig. 21.—Diagram of the autonomic nervous system and the point of action of the various drugs which block sympathetic nervous system impulses, i.e., centrally acting agents, ganglionic blocking agents, and adrenergic blocking agents.

**Ganglionic Blocking Agents**—These compounds, e.g., hexamethonium, pentolinium, mecamylamine, and chlorisondamine, effectively block the transmission of vasoconstrictor impulses over the sympathetic nervous system, but at the same time they block impulses going over the parasympathetic nervous system, and consequently side effects are numerous. The chief untoward side effects are orthostatic hypotension, constipation, decreased salivation, and inability to focus the eyes. These side effects can be minimized by the administration of more effective than are usually preferable.



D 555 5 C 10 CE 550 196

the symptoms of the two since they are both dependent upon a sudden interruption of blood flow to an affected area. Naturally, the level of occlusion will determine the ability of collateral circulation to develop. Usually, the more rapidly the occlusion develops the greater will be the associated vasospasm. When partial occlusion exists for a sufficient time prior to complete occlusion collateral blood supply will frequently have developed and associated vasospasm is less prominent.

**EMBOLISM**—The heart is the chief source of emboli, most commonly a detached thrombus or portion of a thrombus which develops during auricular fibrillation. Myocardial infarction with mural thrombi, cardiac valvulitis in acute or subacute bacterial endocarditis and thrombosis of the wall of the heart attributable to a failing heart from any cause may give rise to emboli which detach. In addition, thrombi on the walls of the arteries carrying the systemic circulation may give rise to emboli. These develop in aneurysms on arteriosclerotic plaques and as a result of injury or inflammation. Emboli tend to lodge where the artery suddenly becomes reduced in caliber, ordinarily at points of bifurcation or compression in the arterial tree.

**THROMBOSIS**—Acute arterial thrombosis may occur in the presence of obvious peripheral vascular disease, as a result of direct trauma or contusion of the vessel wall as a sudden occlusive thrombus in a previously unrecognized aneurysm or finally as simple arterial thrombosis in which all embolic and local vascular factors are absent. Sudden arterial thrombosis occurs in about 10 per cent of cases of thromboangitis obliterans, and also occurs with hemoglobinopathies, septicemia, and chronic debilitating diseases. Obviously under such circumstances the prognosis as to life and limb is dependent upon the underlying disease processes responsible for occlusion and upon the early institution of treatment.

**TREATMENT**—The use of drugs in acute arterial occlusive disease is for temporary expediency only. If embolectomy and/or thromboendarterectomy are feasible treatment should be primarily surgical with the least possible delay. Vasodilator drugs serve two purposes in this condition—to define more clearly the level of the occlusion—to relieve the powerful reflex vasoconstriction in the collateral vessels adjacent to the area of occlusion as well as in the major pathway itself. We have found that the agents of choice for these purposes are the adrenergic blocking agents tolazoline (Priscoline) and phenotolamine (Regitine). Intra-arterial injection above the site of occlusion is preferable (see page 491).

When the acute occlusive disease is diffuse and nonoperable intra-arterial injection may be followed after 2 or 3 days with oral medication. Probably phenoxymethamine (Dibenzylamine) or azapetine (Ilidar) is preferable for this purpose. It is necessary to titrate the dose of these drugs for each patient (see page 491).

#### Raynaud's Disease and Other Vasospastic Conditions—

**RAYNAUD'S DISEASE**—Raynaud's phenomenon is an episode of constriction of the small arteries or arterioles of the extremities resulting in intermittent changes in color of the skin of the extremities such as pallor and cyanosis. Following the episode of constriction hyperemia may produce a red color. This phenomenon may occur primarily as in Raynaud's disease or it may occur in association with a number of conditions and diseases and hence is no particular indication of the status of the peripheral vascular system.

minimize systemic reactions consisting of headache tachycardia bronchospasm hypotension and sometimes shock

**PAPAVERINE**—This drug acts directly on smooth muscle to induce relaxation. It has not proved very effective.

**NITRITES**—Nitroglycerin has been reported by Burke and his associates to produce increased blood flow through the extremities. This response is reported to be associated with an increase in cardiac output. In our experience the nitrites have been unpredictable in their effect on patients with peripheral vascular disease. [Their use for dilatation of the coronary arteries is discussed in Chapter 24. Ed.]

**NYLIDRIN (ARLIDIN)**—This is an epinephrine type compound which acts directly on the arterioles, producing dilatation. It appears to be selective for the vessels of the skeletal muscle. The drug has been reported to increase peripheral blood flow and exercise tolerance in patients with peripheral vascular disease, especially in patients with intermittent claudication.

Nylidrin increases cardiac output and may on occasion precipitate angina in patients with coronary artery disease. Anxiety and palpitations have also been observed.

## CLINICAL CONDITIONS AND THE USE OF VASODILATOR DRUGS

The term peripheral vascular disease is a general term which has led to much confusion in the diagnosis of diseases of the peripheral blood and lymph vessels. As a group of individually distinct diseases their diagnosis depends upon a careful analysis of the history of the illness, an appreciation of specific findings during the general physical examination and finally the application of a rather limited number of specific diagnostic techniques. It is not the purpose of this writing to discuss the varied features of peripheral vascular disease and no attempt will be made to proceed further than a brief description of basic pathologic findings and the disturbance in physiology as it applies to therapy with vasodilator drugs. The various conditions responsible for arterial insufficiency are discussed as follows:

### Intra arterial occlusive conditions

Embolism ✓

Thrombosis ✓

### Functional vasospastic diseases

Raynaud's disease ✓

Raynaud's phenomenon in associated conditions ✓

Acrocyanosis ✓

### Morphologic occlusive disease involving the arterial wall

Arteriosclerosis obliterans ✓

Thromboangitis obliterans ✓

### Post frostbite syndrome ✓

Causalgia ✓

Venous thrombosis and thrombophlebitis ✓

Delayed wound healing ✓

**Intra arterial Occlusive Conditions**—Sudden arterial occlusion may be the result of either embolism or thrombosis. There is no functional difference between

ically to designate a degenerative arteriopathy producing insufficiency of the arterial system. The most common lesion producing occlusion of arteries is atherosclerosis with thrombus formation, although frequently a combination of atherosclerosis and medial calcification occurs in older individuals. Occasionally, extensive calcareous deposits occur in the medial coat in the absence of atheroma. The degenerative arteriopathies may be widespread, but both medial arteriosclerosis and atherosclerosis are essentially focal lesions. The degree of ischemia produced by obstruction from arteriosclerosis obliterans may be augmented by arteriolar constriction from any cause and in such instances may be lessened by arteriolar dilatation with vasodilator drugs. Sympathectomy and vasodilator drugs are indicated when the disease process is diffuse or small arteries are occluded. When the lesion is localized in a larger artery, surgery, establishing a vascular bypass of the obstructed area is the procedure of choice.

In general, arteriosclerosis obliterans is a progressive, degenerative disease and the long term prognosis for survival of the extremity affected by this disease is not good. Unfortunately, life expectancy is also reduced, for the factors which produce arteriosclerosis of the lower extremity are likely to lead to similar lesions in other parts of the body, and sooner or later coronary or cerebral atherosclerosis usually develops and, less commonly, peripheral arterial aneurysm or abdominal aortic aneurysm. There are, however, many extenuating factors which vary greatly in individual cases and the prognosis directly depends upon the stage at which proper treatment is instituted, extent of arterial occlusion, rapidity of development, presence of collateral circulation, and complicating and associated diseases of other organ systems.

**THROMBOANGITIS OBLITERANS**—Thromboangitis obliterans (Buerger's disease) is an inflammatory condition of the arteries, adjacent vein, and nerve of the extremities resulting in obliterative occlusion which is frequently segmental. The lower extremities are more commonly involved and usually more severely. In the great majority of cases the disease begins in medium sized arteries or small arteries i.e. posterior tibial, radial, ulnar, plantar, palmar, and digital. Large arteries, such as the femoral and brachial, are affected only late and only when the disease is severe and progressive. Involvement of the veins is less common than involvement of arteries. Small and medium sized veins are chiefly involved and large venous trunks are rarely affected.

The striking physiologic change in thromboangitis obliterans is the local impairment of arterial blood flow with reduction particularly in the more distal portion of the limb. Another factor which contributes to the severity of the ischemia is arteriolar spasm. Only this component of the disease is benefited by vasodilator drugs. In general the more severe and more extensive the arterial occlusive disease, the less the possibility that the arterial circulation may be improved by a vasodilating procedure.

The clinical course of the disease is episodic, characterized by exacerbations with some tendency to slow improvement between exacerbations, but the lesions are organic and produce permanent arterial occlusion. The course thus depends upon the rapidity of development and extent of arterial lesions versus the development and capacity for blood flow in anastomosing arteries. In general the

The diagnosis of Raynaud's disease should be limited to those cases exhibiting Raynaud's phenomenon and demonstrating the typical changes of the extremity in which the initiating lesion is not a morphologic change in the vessel. The cause of the attacks is considered to be either an increased local sensitivity to stimuli which normally produce vasoconstriction or a pathologic reinforcement of the reflex mechanism which responds to the stimulus. The underlying cause of this remains unknown. Greater emphasis has been placed on the bilateral symmetrical cutaneous gangrene which occurs in the absence of demonstrable organic arterial disease than on the less spectacular and less serious color changes which occur on exposure to cold or during emotional upsets. The disorder may remain rather stationary for a period of years but it tends to get progressively worse. Rarely is spontaneous improvement noted. Raynaud's phenomenon in the progressive or advanced stages of Raynaud's disease may be so severe and may appear so frequently that it is disabling. Sclerodermatous changes of considerable degrees in the skin of the involved parts may interfere considerably with normal use of the extremity, particularly of the fingers.

Raynaud's phenomenon may also be associated with a variety of contributing conditions and diseases. Among these may be mentioned (1) trauma including occupational and surgical injuries, (2) neurogenic origin including cervical rib scalenus anticus syndrome, and costoclavicular syndrome (3) intoxication by heavy

condition characterized by painless and persistent coldness and cyanosis of the distal parts of the extremities. The mechanism producing the vascular changes is not clearly understood. Trophic changes, ulceration and gangrene do not occur and examination of peripheral arteries will not reveal any evidence of occlusive arterial disease.

**SYMPATHICOTONIA**—Disorders associated with increased sympathetic activity are the most amenable to therapy. Phenoxylbenzamine, tolazoline, and azapetine given orally are all useful agents in this condition. Patients who respond to these adrenergic blocking agents will usually respond to sympathectomy, particularly if confined to one extremity. Phenoxylbenzamine (Dibenzyline) may be superior to tolazoline and azapetine. When the drugs are given parenterally, tolazoline is the drug of choice. The ganglionic blocking agents have also been reported to be effective for this condition, but we feel that these agents should only be resorted to when the adrenergic blocking agents have failed.

The centrally acting agents may be of considerable value in the therapy of the vasospastic conditions by central depression of vasoconstrictor impulses. The rauwolfia compounds and Hydergine are the only useful drugs in this class for the therapy of vasospastic states. Occasionally improvement may be dramatic. The virtue of these drugs, when effective, is the low incidence of side effects and minimal hypotensive response. The rauwolfia compound selected can be given orally whereas Hydergine must be given intramuscularly.

#### **Morphologic Arterial Occlusive Disease.—**

**ARTERIOSCLEROSIS**—Arteriosclerosis obliterans is a descriptive term used clin

found that in 25 patients with *cruralgia* who were given phenoxylbenzamine or hexamethonium 6 had permanent and complete relief even after the drug was discontinued, 13 patients experienced complete relief while taking the drug 3 obtained partial relief, and in 3 there was no relief. Phenoxylbenzamine was found to be an accurate method for predicting the anticipated response to surgical sympathectomy.

**Venous Thrombosis and Thrombophlebitis**—Vasodilator drugs are of little value, although some investigators have noted symptomatic improvement following sympathectomy.

**Delayed Wound Healing**—Phenoxylbenzamine (Dibenzylamine) is effective here if any drugs are effective. This drug acts by increasing circulation to the skin which may be of value if skin ischemia is a factor.

## THE ADMINISTRATION OF DRUGS USED FOR THE TREATMENT OF PERIPHERAL VASCULAR DISEASE

The patient with peripheral vascular disease of the extremities will frequently have vascular disease elsewhere, particularly those patients with arteriosclerosis. Therefore associated coronary sclerosis is common. The therapist should remember this when prescribing drugs since so many of them have secondary cardiac effects which could be disastrous.

Also the therapist must remember that vasodilator drugs are also hypotensive and the greatest degree of vasodilation will occur in those vessels which are most elastic and resilient. Thus, if a blood vessel is organically damaged, it is not likely to dilate significantly. It is only the collateral vessels which may be in a state of increased tone that the therapist can expect to dilate with vasodilator drugs. Systemic administration of vasodilator drugs may decrease blood flow to the surgically sympathectomized extremity for this reason.

**Centrally Acting Agents**—As indicated previously, the only indication for the use of the centrally acting vasodilator drugs is the treatment of functional vasospastic conditions. The only centrally acting drugs that seem to have any merit are the *rauwolfia* compounds. These agents depress the sympathetic nervous system centrally. One of the following *rauwolfia* materials should be given orally.

Reserpine—0.25 mg twice a day

Akeroylon—2 mg twice a day

Whole root of *Rauwolfia serpentina*—50 mg twice a day

**Ganglionic Blocking Agents**—There is little indication or basis for the use of these drugs in the therapy of peripheral vascular disease. However, when the therapist does use these drugs they can be given orally or parenterally. When the parenteral route is used, it is for short term use only, and hexamethonium given intramuscularly is the agent of choice. When given orally, the agent of choice is pentolinum.

The initial dose of hexamethonium given intramuscularly is 15 mg. This should be given every 4 to 8 hours. If the response to 15 mg is not adequate the subsequent doses should be increased in 15 mg increments to a maximum of 50 mg per dose or until excessive orthostatic reduction in blood pressure occurs.

collateral circulation about obstructed lesions in patients with thromboangitis obliterans is better than around similarly obstructed areas in patients having arteriosclerosis. Fortunately, there is a tendency toward ultimate cessation of development of arterial and venous occlusion and, if this stage may be reached without the loss of digits or legs the outlook improves. In contrast to arteriosclerosis obliterans, this disease is essentially one of young adults with good capacity for tissue healing and repair, and the majority of patients seem to be singularly free from other nonvascular diseases. The prognosis as to loss of limbs or portions thereof is difficult to estimate. The actual incidence of all varieties of amputations seems to vary from 30 to 60 per cent depending upon the duration of the disease and whether patients are supervised, restrict their activity, and persistently follow a good therapeutic regimen. Sympathectomy may prove to be very effective in some patients.

**DRUG THERAPY IN OCCLUSIVE VASCULAR DISEASE**—The chronic obliterative arterial diseases demand very careful treatment. There is no widely accepted method of management of intermittent claudication. Treatment is fraught with controversy and management is difficult at best. Therapy is generally directed toward the relief of claudication. However, although frequently disabling, claudication in itself is not the specter of the disease, but the chief danger lies rather in the decreased blood supply to the skin. Therefore, treatment should be directed not only toward the relief of claudication but also toward the prevention of gangrene. When patients do not obtain an adequate response to sympathectomy, vasodilator drugs may be used; the results are variable.

Moser and his associates have found that improvement in peripheral circulation was more marked after hexamethonium intravenously than after tolazoline intra arterially. These investigators suggest that sympathectomy is indicated in any patient obtaining a significant response to these agents. Since long term therapy is required it is essential that a regimen be established which is easy to follow. Thus only vasodilator drugs which can be self administered are indicated. Orally effective drugs are the agents of choice. Hydergine has been used but it must be given by the subcutaneous route.

Phenoxylbenzamine (Dibenzyline) has been reported to be effective and at present is the agent of choice. The degree of response will naturally depend on the extent of involvement and the amount of associated functional vasoconstriction. Patients with mild disease respond best and those with moderate disease respond erratically.

Tolazoline (Priscoline) and azapetine (Ilidar) have been reported to be effective. More recently, nylidrin (Arlidin) has been used. Since it does not act by blocking sympathetic impulses but has been reported to have direct vasodilator action particularly in the vessels of the striated muscles, it may prove to be the agent of choice.

**Post Frostbite Syndrome**—The symptoms of increased sweating, burning of feet, sticking sensation and increased susceptibility to cold are improved with tolazoline and phenoxylbenzamine but the results are not very encouraging.

**Causalgia**—Phenoxylbenzamine is the agent of choice for this syndrome and has been proved to be quite effective in alleviating symptoms. Fowler and Moser

obliterans Side effects to date consist of nervousness and palpitations The results with this drug in our hands have not been as satisfactory as those reported by others

The drug must be given orally and the dose titrated The initial dose is 6 mg given 3 times a day with meals This dose can be increased to as much as 24 mg given 3 times a day

Histamine --Histamine is given intra arterially The solution is made up by placing 2.75 mg of histamine acid phosphate in 500 ml of normal saline The solution is then administered with a mercury pump or by a syringe at the rate of about 40 to 60 drops per minute The method is cumbersome Side reactions are quite common and consist of headaches, nausea, tachycardia and occasionally hypotension when the drug is given too rapidly

## SELECTED REFERENCES

- Boyd A M Oral Dibenzylamine in Senile Obliterative Arteritis, *Lancet* 271 869 1956  
 Clark J *Rational Treatment of Vasomotor Disturbances Involving the Upper Extremities*  
*Am Surgeon* 22 420, 1956  
 Fontaine, Rene Remarks Concerning Venous Thrombosis and Its Sequelae, *Surgery* 41 6  
 1957  
 Fowler, F, and Moser M Use of Hexamethonium and Dibenzylamine in Diagnosis and Treatment of Causalgia *J A M A* 161 1051, 1956  
 Freedman  
 Green, H  
 Moser M  
 1953  
 Murphy, T, Haglin, J, and Felder, D The Effect of Generalized Vasodilatation Upon the Sympathectomized Extremity, *Surgery* 41 178 1957  
 Renner W F Medical Management of Arteriosclerosis Obliterans, *Maryland State M J* 5 731, 1957  
 Stallworth J, and Jeffords J Clinical Effects of Azapetine (Ilidar) on Peripheral Arterial Disease  
 Stein, I A  
 on I  
 Wessler S

odilator With Selective Action

15

## VASODILATOR DRUGS FOR PERIPHERAL VASCULAR DISTURBANCES

The initial dose of pentolinum given by the oral route is 20 mg given 6 to 8 hours. This should be increased at weekly intervals in increments of 20 until the desired effect is obtained or excessive orthostatic reduction in blood pressure occurs. The maintenance dose is kept just below this level. Cathartics should be used freely whenever constipation is a problem.

### Adrenergic Blocking Agents —

**INTRA ARTERIAL ADMINISTRATION** — The agents useful for intra arterial injection are tolazoline (Priscoline) and phentolamine (Regimine). The dose of tolazoline is 50 to 75 mg dissolved in 5 to 10 ml of normal saline. The dose of phentolamine is 5 to 10 mg given in 2 to 10 ml of normal saline. When these drugs are given intramuscularly, the dose of phentolamine is 5 to 10 mg and the dose of tolazoline is 50 to 150 mg.

**ORAL ADMINISTRATION** — Tolazoline (Priscoline) is usually given orally, starting with a dose of 50 mg with each meal. The dose should be progressively increased until the desired effects are obtained or undesirable side effects supervene. These consist of chest pain and coronary insufficiency in patients with coronary artery disease. Less frequently, chilliness, nausea, restlessness, increased sweating and palpitations are observed.

**Phenorybenzamine (Dibenzyline)** This drug should not be given parenterally as a therapeutic measure. When given intramuscularly it causes pain and necrosis. When given intravenously it can cause tachycardia and an excessive reduction in blood pressure for which there is no antidote. By the oral route it is relatively easy to handle but the dose must be titrated. The initial dose should be 10 mg given after meals twice a day. The dose should then be progressively increased at weekly intervals until the desired response is obtained or the side effects become intolerable. The usual dose is 60 to 100 mg per day. Boyd has suggested that the maximum dose should be 60 mg.

Untoward effects consist of weakness, lethargy, drowsiness, stuffy nose, nausea and dry mouth. Sometimes just a small reduction in the dose will greatly decrease the severity of side effects.

**Azapetine (Ildar)** Azapetine is an adrenergic blocking agent and may also be a direct vasodilator which can be given orally or intravenously. When given intravenously the dose is 1 mg per kilogram of body weight in 250 ml of normal saline. There are few if any indications for the use of this drug by this route except for tests of therapeutic efficacy or acute vasospastic states and acute arterial occlusion. When given orally the dose should be titrated starting with 25 mg given 3 times a day. The dose should be increased in 25 mg increments until relief of symptoms is obtained.

**Aridin Hydrochloride (Aridin)** This drug acts by direct vasodilation of the vessels supplying striated muscles. It has little, if any, effect on the skin circulation. It may be effective in obliterative disease of the arteries especially in patients with intermittent claudication since it increases muscle blood flow. Thus it is indicated in patients with peripheral vascular disease associated with thrombophlebitis, thromboangitis obliterans, ischemic ulcers and arteriosclerosis.



symptom can be obtained from a survey of the incidence figures for chronic bronchopulmonary disease in the United States in which cough is an invariable concomitant. The National Health Survey of 1935-1936 showed that 1,700,000 persons had chronic bronchitis and 1,150,000 had chronic sinusitis. To these must be added the 3 to 4 million people who are afflicted with bronchial asthma, bronchiectasis, and pulmonary emphysema. These data become even more impressive when it is realized that 13 per cent of the population of this country will be over 65 years of age at the end of this century, and of these 13 per cent, it is estimated that 6 per cent will be "chronic coughers" as a result of chronic lung disease.

The common occurrence of cough in the acute respiratory diseases has made cough remedies an indispensable item in the household medicine cabinet along with aspirin and bicarbonate of soda. Before considering the various pharmaceutical agents which suppress cough, a discussion of the etiologic factors and physiological mechanisms involved in coughing is desirable if adequate and efficient management is to be achieved.

The causes of cough are so numerous that they are difficult to classify. Because of its wide distribution throughout the population, cough is often taken for granted by the patient and paid scant attention by the physician.

**Etiologic Factors**—A classification based on etiologic factors includes

#### INFECTIOUS

*Viral* Common cold, influenza, atypical pneumonia, measles, psittacosis, etc.

*Bacterial* Pneumonia, diphtheria, tuberculosis, pertussis, tularemia, bubonic plague.

*Rickettsial* Q fever.

*Mycotic* Actinomycosis, blastomycosis, coccidioidomycosis, histoplasmosis, moniliasis.

*Spirochetal* Vincent's infection.

*Parasitic* Ascariasis, oxyuriasis, distomiasis.

#### IRRITATIVE

*Mechanical* Foreign bodies, retained secretions, excessive strain or improper use of voice.

*Chemical* Smoke, fumes, noxious gases.

*Thermal* Exposure to marked variations in temperature.

**ALLERGIC**—Asthma, hay fever, vasomotor rhinitis.

#### NEOPLASTIC

*Intraluminary* benign, malignant.

*Extraluminary with compression* lymphomas, Hodgkins, etc.

**VASCULAR**—Congestive heart failure, aneurysm, embolism, pericarditis.

**PSYCHOGENIC**—Tension, habit spasm or 'tic,' psychoneurosis.

The recognition of the causative factor initiating the cough reflex is of primary importance if appropriate measures, either medical or surgical, are to be instituted. Although the investigation of the cause of cough is often difficult and complex, the following pertinent inquiries are helpful in defining the nature and hence the etiology of the cough: (1) duration of the cough, (2) association with an acute

## THE CHOICE OF ANTITUSSIVE AGENTS

*Hyman A. Bickerman, M.D.*

### INTRODUCTION

In pursuing its primary function of gas exchange, the lungs normally ventilate from 600 to 1,000 cubic feet of air daily. Because of its exposed position with respect to the external environment, the lung is endowed with an elaborate protective mechanism which efficiently cleanses, humidifies, and warms the inspired air. In spite of exchanging enormous quantities of air laden with particulate matter, noxious gases and fumes, and microorganisms, the lower respiratory tract remains sterile. Any disturbance in these mechanisms for self cleansing frequently results in respiratory disease.

The factors concerned with bronchoelimination are integrated by reflex activity so that gas exchange so necessary to survival is not impeded. The hairs at the entrance to the nasal passages serve as a gross filter and provide the first line of defense. More important mechanisms which serve to protect the alveoli against inhaled foreign material and retained secretions are ciliary activity, mucus formation, phagocytosis, bronchoconstriction with peristaltoid contractions, and cough. From a clinical standpoint, cough is probably the most prominent of the mechanisms concerned with bronchoelimination. In emphasizing the protective nature of the cough reflex in this introduction to antitussive agents, it might be well to repeat the old aphorism that more people have died from an inability to cough effectively than from the act of coughing itself.

### CLINICAL CONSIDERATIONS

Since cough is a protective, physiologic reflex, it occurs in health as well as disease and is frequently the presenting symptom in a wide variety of pathologic states ranging from a mild to a serious and even fatal illness. Because of its universality and the fact that most patients do not consider cough a serious enough symptom to seek medical advice, there are no available statistics regarding the prevalence of cough. Nevertheless, some inkling of the importance of this

\*The assistance of Miss Sylvia Itkin in preparing this chapter is gratefully acknowledged.

phase, it is depressed and fixed but rises sharply in the expulsive phase. The extent of this rise appears to be related to the intensity and character of the cough. In ordinary coughing, it does not rise to its fullest height, but seems to act as a controlling mechanism determining the amount of abdominal pressure that is exerted upon the chest.

When the intensity of the stimuli evoking the cough response is increased there are several expulsive efforts for a single inspiration with closure of the glottis between each. With severe irritation, the cough becomes paroxysmal in character, and a series of short severe expulsive efforts are noted followed by a quick deep inspiratory gasp and again a series of coughs. Under the fluoroscope the diaphragm can be seen to rise sharply for a short distance with each cough as the volume of the thoracic cage contracts.

As the glottis opens, an explosive gust of air is expelled from the respiratory passageways at a high initial velocity. This velocity is the resultant of the high intrathoracic to mouth pressure gradient, and the marked contraction of the tracheobronchial lumina, which reduces the cross sectional diameters of the bronchial tree to between one third to one tenth of normal. The velocity of escaping air has been estimated to be 0.5 to 2.0 meters per second in the bronchioles and between 50 to 120 meters per second at the glottis. Under special circumstances, the initial velocity of air expelled during a vigorous cough has approximated the speed of sound.

In paroxysmal coughing provoked by severe irritation or bronchial obstruction or compression, efforts at expulsion become greater and greater accompanied by a progressive narrowing of the bronchial lumina leading to localized or diffuse bronchospasm. This type of response, far from being a protective reflex, may actually cause serious alterations in cardiopulmonary function.

**The Regulation of Cough**—Cough is a highly integrated reflex act which is partially under voluntary control. This voluntary control is more complete than that which exists with other comparable reflex mechanisms such as sneezing or vomiting. Although the cough center has been located in the medulla near the sensory portion of the vagus nerve and adjacent to the vomiting center, the central nervous system pathways for coughing have not been clearly elucidated. In fact little is known of the interactions between the cough center, the respiratory center, and other reflexes associated with respiration.

The afferent impulses which initiate the cough reflex may arise from many areas both within and outside of the respiratory tract including central stimuli which act directly on the cough center. Normally, coughing is produced by the stimulation of the sensory endings of the glossopharyngeal and vagus nerves. The major reflexogenous zones and their nerve pathways are illustrated in Table 31.

Infrequently, dyspepsia may provoke coughing by stimulating sensory fibers of the gastric branch of the vagus nerve. From the clinical point of view, perhaps the most important cause of coughing outside of the respiratory tract results from the sensitivity of the external reign bodies, and even ularly in children ie sensitivity of the re

upper respiratory infection, (3) seasonal variations, (4) daily variation in intensity, (5) dry or productive and the character of the expectoration, (6) quality of the cough and whether associated with changes in voice, wheezing, or emesis. Although the protective aspects of the cough reflex have been stressed in the opening paragraphs of this chapter, there are numerous instances in clinical medicine when the continued propagation of this reflex may be harmful. In many disease states such as pertussis pulmonary tuberculosis, chronic bronchitis, and obstructive disease of the tracheobronchial tree, the cough reflex becomes self-perpetuating and the resultant severe paroxysms of unproductive coughing cause serious debilitation of the chronically ill patient. The dry, hacking, irritative cough of some acute infections of the upper respiratory tract such as laryngitis and tracheobronchitis may in itself become a major factor in retarding recovery by causing loss of sleep, inadequate food intake, nausea, and emesis. Furthermore, there is some experimental evidence that the inspiratory rush of air which accompanies the first phase of the act of coughing may actually spread the infectious material deeper into the finer ramifications of the bronchial tree. Several authors have stressed the role played by chronic ineffectual cough in the causation of pulmonary emphysema.

While measures to ensure correct diagnosis and treatment of the underlying cause hardly need any comment the importance of vigorous symptomatic control of certain instances of coughing from a public health standpoint requires further emphasis. Droplet nuclei containing the infectious agent may be expelled for a distance of 15 to 20 feet following a cough and remain suspended for long periods thus serving as a primary factor in the airborne transmission of disease. The significance of this factor in connection with the acute respiratory diseases (ARD) alone is impressive when it is realized that there is an average of 25 "colds" for every person in the United States each year accounting for the loss of over 100 million workdays.

## GENERAL PHYSIOLOGIC AND PHARMACOLOGIC CONSIDERATIONS

Before discussing the management of cough and the pharmacologic agents which act as cough suppressants a brief review of the mechanics of coughing and regulation would be appropriate.

**The Cough Mechanism**—Three chief phases have been described during the act of coughing: (1) *inspiratory*—a sharp deep inspiration ending with closure of the glottis, (2) *compressive*—contraction of the muscles of the thorax and abdomen with the diaphragm fixed, resulting in a high but momentary increase in thoracic pressure, and (3) *expulsive*—the rapid expulsion of air at high velocity. During the first stage, there is an increase in the vertical diameter of the chest elongation and widening of the entire tracheobronchial passageway. Compression of the expiratory muscles, especially abdominal, during the short compressive stage tends to draw the sternum and ribs downward, decreasing the capacity of the thorax and thus applying pressure to the entrapped air within the lung. This pressure has been recorded as high as 80 to 160 mm Hg. The diaphragm contracts to regulate and adjust the expulsive efficiency of the cough. In the second

## PHARMACOLOGIC AGENTS EMPLOYED IN THE MANAGEMENT OF COUGH

The symptomatic management of cough is justified only when adequate investigative measures are undertaken to ascertain the etiologic factor. While this is a relatively simple procedure in acute self limited infections of the respiratory tract the causative factors involved in chronic cough often prove much more elusive. Nevertheless without this knowledge, appropriate therapy whether medical, surgical, or psychological cannot be instituted to eradicate this symptom. It is not the purpose of this chapter to discuss the many detailed therapeutic approaches to the correction of each disease entity which may cause cough, since this would entail a consideration of chemotherapeutic agents, antiallergic regimens, cardiotonic drugs and specialized surgical techniques. Since 'time is often of the essence particularly in the debilitated patient and infant, the symptomatic control of cough is clearly indicated concurrent with more definitive therapy.

Considerable disagreement and confusion has arisen over the basic classification and nomenclature of antitussive drugs first proposed by Brown in 1937 and since published in many textbooks on pharmacology. Expectorants were classified as (1) sedative—soothes acute inflammation by aiding the secretion of protective mucus, (2) stimulant—stimulates repair in chronic inflammatory processes within the respiratory tract and (3) anodyne—depresses the cough reflex by central inhibition. Within the past two decades, the synthetic organic chemist has added to the number of cough suppressants which now total well into the hundreds. This is further complicated by the fact that many cough remedies are mixtures. The possible combinations are limited only by the knowledge and imagination of the physician and the ingenuity of the pharmaceutical industry. Despite the new drugs and advances in our basic knowledge concerning the cough, 'It seems to be a field in which polypharmacy and shotgun mixtures have enjoyed immunity from attack for it makes little difference what the ingredients are or how many are included if the mixture only expressed the art of mixing palatable materials.'

In view of the increasing opposition to the term 'expectorant,' a much more sound physiologic classification has been expressed by Gold. It is well to confine the term cough remedy in a specific sense to a drug which acts to raise the threshold of the cough center in the central nervous system or acts peripherally in the respiratory tract to reduce the impulses which pass to this center, or a mixture which combines both actions."

### Centrally Acting Antitussive Agents

To a large extent, most drugs which depress the central nervous system may influence the cough center in the medulla. However, the drugs which have proved especially useful in diminishing the cough reflex by raising the central threshold for noxious stimuli consists of the narcotic antitussives and the nonnarcotic centrally acting cough suppressants.

**Narcotic Antitussives**—Until recently the phenanthrene alkaloids of opium consisting mainly of morphine and codeine, have been the most effective and commonly used cough suppressants. In fact these drugs together with narcotics synthesized from the opium alkaloids, constituted the only potent agents available

ceptor zones vary in different areas of the respiratory tract. Two types of receptors appear to be present. The mucosa of the larynx and trachea are most responsive to mechanical irritation with only a weak response elicited below the level of the main bronchi, whereas the sensitivity to chemical irritants extends throughout the tracheobronchial tree. Tolerance often develops on continued stimulation, resulting in a decrease in excitability of the cough reflex. In addition it would appear that the terminal bronchioles and alveoli contain few if any receptors since they are unresponsive to cough stimuli.

Table 31 Afferent Neurogenic Arcs Mediating the Cough Reflex

Receptor Area	Nerve Pathway
External meatus of the ear	Auricular branch of vagus (Arnold's nerve)
Pharynx	Afferent fibers of glossopharyngeal and pharyngeal branch of vagus
Larynx	Superior laryngeal branch of vagus
Trachea	Afferent fibers of pulmonary branches of the vagus
Bronchi	Afferent fibers of the phrenic nerve
Pleura	Cardiac and esophageal branches of the vagus
Diaphragm	
Pericardium	

**Respiratory Tract Fluid**—Since the cough reflex is intimately concerned with the expulsion of secretions within the respiratory tract as well as irritants the nature of the respiratory tract fluid and the alterations produced by disease states and pharmacologic agents are of considerable importance in any discussion of antitussive drugs. The glandular cells lining the respiratory tract normally secrete a tenacious lubricating fluid that serves to protect the lungs by trapping particulate matter and microorganisms. The alveoli and terminal bronchioles form a rich scanty secretion diluted by a more watery secretion from the glands of the bronchial mucosa. Normally four factors are concerned with propelling these secretions toward the glottis where it is either expectorated or swallowed. These include (1) bronchiolar constriction or peristaltoid movements (2) movement of the respiratory cycle (3) alterations in bronchial dimensions with inspiration and (4) ciliary activity which propels the secretions forward at a rate of 3 cm per minute. These secretions are composed of 5 to 6 per cent solids and 95 per cent of which is mucin. Three types of sputum have been reported by Basch, Holinger and Poncher. The first portion of sputum result of studies on patients with bronchiectasis. The first portion of sputum coughed up is a bronchial mucus plug which is highly viscous and not ordinarily affected by expectorant agents. The second type is a liquefied fraction with consistency. Liquefaction of this portion results from the secretion of fluids from bronchial glands resorption of solid constituents and bacterial and enzymatic action. The expectorant drugs act mainly on this second type of sputum by decreasing its viscosity and thus rendering it more fluid and less tenacious. The third type of sputum occurs in the most dependent portions of the respiratory tract and is coughed up. It has a high viscosity which is unaffected by drug or aerosol.

codeine with fewer side effects. Even if this be so, it is quite obvious that the common practice of prescribing multiple dose quantities would make the dispensing of morphine especially hazardous.

**CODEINE DIHYDROCODEINONE, AND PHOLCODEINE**—In general while these drugs are weaker antitussives than the morphine group, they have been widely employed as cough suppressants because of the lower incidence of adverse side reactions.

**Codeine** Codeine is approximately one quarter as depressant to respiration as morphine. Furthermore, as the dose of codeine is increased, commensurate increase in respiratory depression does not occur. In fact, large doses tend to stimulate the cerebral centers, causing excitement rather than depression. Nausea, vomiting and constipation are significantly less prominent than with morphine. Codeine in common with the other opiates, exerts a 'drying' action upon the mucosa of the respiratory tract which may be of some advantage where excessive mucus or an actual bronchorrhea is present. In disease states characterized by bronchospasm such as asthma and pulmonary emphysema the indiscriminate use of codeine may precipitate severe respiratory insufficiency resulting from the increased viscosity of the bronchial secretions and suppression of the cough reflex.

Both tolerance and addiction occur with codeine and other members of this group. While codeine addiction is thought of as being relatively infrequent among drug addicts since it produces little euphoria compared with heroin and morphine it might be well to point out that a survey published in the *United States Public Health Reports* indicates that codeine addiction is not as rare as formerly believed and occurs to a large extent among patients who have received the drug for a therapeutic purpose, principally as cough medication.

**Dihydrocodeinone** Dihydrocodeinone (Hycodan, Dicodid) is marketed as the bitartrate in oral tablets and in a syrup. Pharmacologically it is more active than codeine and as a consequence, possesses more addicting liability than codeine. In fairly extensive clinical trials, particularly in patients with chronic cough due to pulmonary tuberculosis it has been proved to be an effective antitussive agent superior in many ways to codeine because of the lower incidence of side effects. Constipation, nausea, drowsiness and vertigo were reported as being minimal with this drug as compared with codeine. Occasional nausea has been noted when Hycodan was administered on an empty stomach. At the customary dosage level of 5 to 10 mg 3 or 4 times daily, rapid and effective relief of cough is obtained, lasting as long as 4 to 5 hours following a single dose. At this dosage level, coughing was decreased in frequency but not completely suppressed. There was no difficulty in expelling mucus and retained exudate so that no significant interference with the elimination of secretions was observed. Some dryness of the pharynx and occasional 'tightness' of the chest have been noted. Despite the proved addiction liability of Hycodan, a number of clinical reports take exception by inferring that there is no evidence of tolerance, dependence, or addiction in patients treated with this drug for periods up to 32 months.

**Tussionex** (ion exchange resin complex of dihydrocodeinone) contains 5 mg of dihydrocodeinone in combination with 10 mg of phenyltoloxamine an anti-histaminic preparation in a resin complex. This has been shown to yield a uniform sustained release of antitussive agent over a period of 8 hours. In a recent clinical

It has been estimated that over 25 per cent of the total medical supply of narcotics in the United States are employed as ingredients in cough mixtures. A list of the narcotic drugs which have been used as antitussive agents and the "average" adult dose for cough suppression are shown in Table 32.

Table 32 Narcotic Drugs Which Possess Antitussive Activity

Generic Name	Trade Name	Average Adult Dose (Mg.)
Codaine		80 150
Morphine		20 30
Levomorphine		80 150
Dihydromorphinone		05 10
Hydrocodone		50 100
Propionylmorphine		100
Unifed Opium Alkaloids		20 30
Ethadone		15 20
Peridine		250 500
Vorphan		05 10
	Dilaudid	
	Hycodan	
	Dicodid, Tussone	
	Pholcodine	
	Pantopon	
	Dolophine, Adanon	
	Amidone	
	Demerol	
	Levo-Dromoran	

Heroin, diacetylmorphine, was at one time widely employed for cough suppression but has not been included in the above table since it may not be used for any purpose in the United States. As Diamorphine, it is incorporated in many cough remedies prescribed in Great Britain and the Commonwealth nations. The major therapeutic effect of most of the members of this group of drugs is relief of pain which is discussed in Chapter 12. To a greater or less degree of the drugs in the narcotic group affect respiratory activity and the reflexes associated with respiration. This is primarily one of depression as a result of direct action on the medullary centers. With respect to potency both as analgesics and sedatives, the natural and synthetic alkaloids of opium may be divided into two

**MORPHINE, DIHYDROMORPHINONE, LEVORPHAN, AND PANTOPON**—Although exerting greater cough suppression the clinical usefulness of these drugs as antitussives is limited by adverse side effects involving the respiratory tract and other smooth muscle of the tracheobronchial tree, thus predisposing to bronchoconstriction particularly in allergic and asthmatic patients. Other effects on the respiratory tract include a reduction in the glandular activity of the bronchial tree resulting in a more viscid secretion, and partial paralysis of peristaltic activity and ciliary activity. Undesirable reactions from widespread effects on the nervous system and peripheral organs result in dulling of the sensorium, headache, nausea and vomiting, anorexia, and constipation. The hazard of addiction is just as serious in the treatment of chronic cough as in therapy of pain. Except for certain special circumstances which include (1) aortic aneurysm, etc., (2) acute left ventricular failure associated with pulmonary infarct, tension pneumothorax, etc., these potent narcotic agents are in the management of cough. There are some physicians who feel that appropriately adjusted doses of morphine are more effective than



superior to codeine on a milligram per kilogram basis. In severe asthma associated with paroxysmal coughing, 50 mg of meperidine administered orally after meals and on retiring frequently diminishes the racking, spasmodic coughing and provides much needed relaxation. This will be discussed further in Chapter 29, The Ch of Antiallergic Agents. In general, respiration is not depressed at this dose level. However the author has observed marked depression of respiration in patients who exhibited drug sensitivity to meperidine. Dizziness, nausea, and occasional vomiting may be encountered in the ambulatory patient. Although meperidine has less addiction liability than morphine, tolerance and habituation can occur and hence proper precautions must be observed to prevent addiction in treatment of chronic cough. In our clinic, the use of meperidine is restricted to 3 to 5 day course of therapy.

**Nonnarcotic Antitussives**—While the narcotic agents discussed above are effective antitussive drugs, all have the disadvantage of being potentially addictive and most produce undesirable side effects when administered at optimum dose levels or for long periods. For the past decade or two, the National Research Council's Committee on Drug Addiction and Narcotics, with the help of individual investigators and the medical research divisions of several pharmaceutical firms has been seeking nonaddicting antitussive substitutes for the opium derivatives. In recent years several new types of compounds have been developed which are capable of increasing the threshold of the medullary cough center to afferent tussive impulses without the undesirable effects of the narcotics. A list of the more commonly used nonnarcotic preparations is shown in Table 33.

Although d methadone and d isomethadone have been reported as having antitussive activity comparable to codeine in dogs, these nonnarcotic congeners of methadone have not been adequately studied in man.

**DEXTROMETHORPHAN**—Dextromethorphan hydrobromide (Romilar), the dextro isomer of the methyl ether of levorphan, unlike its levorotatory congener possesses no significant analgesic properties, exhibits no depressant effect on respiration and lacks addiction liability. Extensive experimental and clinical studies with this compound have amply demonstrated its antitussive activity. By the use of experimentally induced cough in cats, it was noted that Romilar increased the central threshold for the cough reflex. The frequency of coughing was diminished but the amplitude remained unchanged. Furthermore, ciliary activity was not inhibited at dose levels below 5 mg per kilogram. In assessing antitussive activity in healthy human subjects stimulated experimentally by citric acid aerosols, significant cough suppression was noted over a 4 hour period.

Table 33 Nonnarcotic Antitussive Agents

Generic Name	Trade Name	Average Adult Dose (Mg)
Dextromethorphan hydrobromide	Romilar	10-20
Noscapine (Narcotine)	Nectadon	15-30
Carbetapentane citrate	Toelase	15-30
Caramphen ethanesulfonate	Toryn	10-20
Levo Propoxyphene		65-130
Benzonate	Tessalon	50-100
Homarylamine		15-30
D-m-hexanoate		25

study by Cass and Frederik this sustained release preparation produced effective cough suppression over a 10- to 12-hour period following a single dose. This possesses manifest advantages, particularly in suppressing distressing night cough.

**Morpholinylethylmorphine** Pholcodine (morpholinylethylmorphine) is at present undergoing limited experimental and clinical trials in this country, although its properties as an antitussive have been studied in England and France. By an experimental technique in cats, May and Widdicombe found that Pholcodine was "more active in blocking the expiratory efforts caused by an endotracheal foreign body than codeine, but less active than morphine, it differed from morphine and codeine in seldom causing respiratory depression and gave far more consistent results than codeine." Experimental studies in man in which the cough reflex was stimulated by inhaled citric acid aerosol and by the intravenous administration of lobeline demonstrated that Pholcodine has significant antitussive activity when compared with placebo and codeine controls. The degree of cough suppression for 10 mg of Pholcodine appeared to be comparable to 15 mg of codeine and persisted over a period of 4 hours. This has been confirmed in clinical trials on patients with cough due to various disease entities including chronic bronchitis, bronchiectasis, asthma, emphysema, lung cancer, and the acute respiratory infections. Toxicity studies indicate that Pholcodine is one-fifth to one-seventh as toxic as codeine at the customary clinical dosage level of 10 mg, 4 times daily. Adverse side reactions appeared to be significantly less with Pholcodine than with morphine or codeine. There was no evidence of respiratory depression. Except for occasional instances of mild sleepiness or lightheadedness, the sensorium was intact. Gastrointestinal disturbances including nausea, anorexia, and constipation were considerably less than with comparable doses of codeine. The Export Committee on Drugs Liable to Produce Addiction of the World Health Organization expressed the opinion that Pholcodine "is not more liable than codeine to produce addiction" and that it is less readily convertible than codeine to an addiction-producing drug."

**METHADONE AND MEPERIDINE**—Two synthetic analgesic drugs not derived from the opium alkaloids but which show some of the pharmacologic properties of morphine are methadone and meperidine.

**Methadone** Methadone (Dolophine, Amidone) is a potent antitussive equivalent to morphine in this regard. The oral administration of 15 to 20 mg of methadone is as effective as 15 to 30 mg of codeine in suppressing the cough reflex. However, the addiction liability of methadone far exceeds that of codeine and so to a great extent the usefulness of this drug as a cough suppressant is subject to the same drawbacks as morphine. Nevertheless, it should be pointed out that most of the other adverse side effects such as depression of respiration, nausea, dizziness, lightheadedness, drowsiness, and constipation are less than with morphine.

**Meperidine** Meperidine (Demerol) shares some of the pharmacologic activities of morphine and atropine. Although some textbooks on pharmacology state that this drug does not depress the cough reflex, there is sufficient clinical experience to indicate that it is an effective agent in ameliorating spasmodic type cough, one particularly in asthma. Furthermore, experimental assessment in cats has shown

been limited to the acute type of cough associated with upper respiratory infections in which Toclase was administered for periods of 5 days or less. Additional data including controlled experimental studies in man and clinical trials in patients with chronic cough due to various disease states are necessary for a more complete evaluation of this drug as an antitussive.

**CARAMIPHEN**—Caramiphen ethanesulfonate (Toryn) is a nonaddicting antitussive agent with minimal adverse side reactions. It is not a depressant to the central nervous system or respiration and does not cause constipation. Experimental studies in cats indicated that the antitussive effect resulted from an increase in the threshold of the cough center to afferent impulses. As with Toclase, there have been too few controlled studies to be able to establish definitely the clinical usefulness of Toryn in the management of cough. Cass and Frederik found 10 mg of Toryn to be less effective in suppressing chronic cough than 10 or 20 mg of Romilar or 15 mg of codeine.

**LEVO PROPOXYPHENE**—Levo-propoxyphene is a new nonnarcotic antitussive which has been studied over the past 2 years. Unlike the dextrorotatory preparation, it does not appear to possess any analgesic properties. Experimental studies in man with citric acid induced cough demonstrated significant cough suppression over a 4 hour period with the 65 mg dose being somewhat more active than 15 mg of codeine. Long-term clinical trials have been conducted on patients with chronic cough. At dose levels of 65 to 130 mg, moderate to excellent relief of cough was obtained in 75 per cent of the patients tested. This was comparable to the relief afforded by 5 to 10 mg of dihydrocodemone. Moreover, the incidence of side effects was significantly less than with dihydrocodemone, and chronic toxicity studies in patients receiving 250 to 300 mg daily for periods of 2 to 6 months have shown no deleterious effects. In addition, responsiveness to medication appears to be maintained with no development of tolerance.

**BENZONATATE**—Benzonatate (Tessalon) is a unique nonnarcotic cough suppressant which appears to have both a central and a peripheral action. Experimental studies in animals showed effective inhibition of the transmission of stimuli within the central nervous system. Its principal effect, however, appears to be on the stretch receptors of the lungs causing alteration in inspiratory response to cough stimuli. It has been demonstrated that decreasing the inspiratory, or first, phase of cough results in striking diminution in the intensity of cough. This will be discussed further under Peripherally Acting Antitussive Agents.

**HOMARYLAMINE**—Homarylamine (N-methylhomopiperonylamine) is a new synthetic antitussive agent. Experimental studies in man employing the citric acid stimulated cough indicated that at 20 mg dosage levels it was approximately equiactive with codeine 15 mg. Furthermore, the time response curves were similar to that of codeine with the peak cough suppression occurring 2 hours after ingestion of the drug. Increasing the dosage did not appear to result in a proportional increase in antitussive potency. The preliminary results of clinical trials in patients with chronic cough showed moderate to excellent reduction in cough over a 3 to 4 hour period in approximately 75 per cent of the patients tested. Side effects at dosage levels up to 40 mg administered at 4 hour intervals have been negligible in this preliminary series.

Comparisons with other antitussives including codeine and placebo controls yielded good dose response relationships with 10 mg of Romilar equivalent to 15 mg of codeine. In well controlled clinical studies by Cass and Frederik and others in a large series of patients with severe chronic cough of varied etiology, evaluations based on multiple observation periods attested to the antitussive effect of Romilar in which respect it ranked approximately as great as that produced by equal amounts of codeine. Long term clinical trials have shown no addiction effects and no evidence of tolerance. The incidence of adverse side effects has been remarkably low, being of the same order of magnitude as that obtained with placebo and considerably less than with codeine.

**NOSCAPINE**—Of all the alkaloids in opium, noscapine (nectadon, narcotine) (6 per cent) is second only to that of morphine (about 10 per cent). As a member of the benzylisoquinoline group the pharmacologic properties of the former are quite distinct from the phenanthrene derivatives or narcotic alkaloids. Noscapine in keeping with the other benzylisoquinoline alkaloids is not a narcotic and has no addiction liability. At dosage levels within the therapeutic range it shows little or no effect on the central nervous system. In animals toxic levels produce signs of excitation rather than depression. It exhibits no analgesic properties and tends to stimulate respiration.

Although noscapine is not a new drug and a great number of conflicting reports have appeared in the literature since 1821 concerning its pharmacologic properties, no therapeutic applications for this compound were available until recently. In 1952 Winter and Flataker demonstrated the antitussive effect of noscapine in guinea pigs and dogs exposed to inhaled irritants. They also noted that noscapine appeared to suppress allergic cough produced in sensitized guinea pigs exposed to an aerosol of specific antigen. These experimental studies were confirmed by Konzett and Rothlin in animals and by Bickerman and Barach in man. In controlled studies employing various dose levels of noscapine, codeine and placebo, an antitussive effect of noscapine appeared to be equal to that of codeine. Extensive clinical trials by a number of investigators both in this country and abroad have shown that noscapine is a potent nonaddicting cough suppressant with minimal reactions. No intolerance was observed even in doses as high as 90 mg daily for a period of 4 to 6 weeks. Constipation and other gastrointestinal reactions were not encountered and expectoration was not inhibited. Noscapine appeared particularly effective in the treatment of spasmodic cough. Because of its margin of safety it was possible to increase the dose in order to obtain a more antitussive effect for the control of severe paroxysmal coughing. Further dose response curves showed increasing cough suppression as the dose was increased which persisted for as long as 6 to 8 hours in several instances. Repetitive doses frequently elicited an additive response.

**CARBETAPENTANE** (Toclase) is a nonnarcotic antitussive which is said to inhibit the hyperactive cough reflex by selective action on the cough center. In addition to its antitussive activity, Toclase has local anesthetic properties. Experimental studies in animals indicate that side effects were minimal and that cough suppression was equal to that of codeine. Few clinical studies have been reported in this country and these have

lungs Tessalon, a congener of pontocaine, has received extensive clinical study here and abroad where it has been shown to have excellent antitussive activity with little or no toxicity. No side effects such as dizziness, constipation, gastrointestinal intolerance, or depressive effects on respiration or the central nervous system were observed after prolonged therapy. Aside from the relief of cough, the sensation of dyspnea and tightness of the chest particularly in patients with bronchitis associated with bronchial asthma was relieved. In a controlled study employing a placebo substitution technique, Tessalon was administered to patients with chronic cough accompanying bronchiectasis, bronchial asthma, and pulmonary emphysema. The author noted that approximately 70 per cent of the patients experienced moderate to excellent relief of cough. It was of interest that benefit was greatest in those patients with clinically demonstrable bronchospasm and was accompanied by a mean increase of 20 per cent in the vital capacity. A course of therapy consisted of 100 mg. of Tessalon, 3 times daily over a 2 week period. Where Tessalon appeared to be ineffective in ameliorating cough, increasing the dose did not alter the response. Adverse side effects occurred in 3 patients; one complained of nasal congestion and two noted a pruritic, macular dermatitis which promptly subsided on withdrawal of the medication. More recent studies employing experimentally induced cough indicated that Tessalon is effective in suppressing the acute cough due to pharyngeal or tracheal irritation, and compares favorably with the effect of 15 mg. of codeine.

**Expectorants**—Agents which modify the output and viscosity of the respiratory tract fluid are designated as expectorants in the pharmacologic literature. Unfortunately, the term 'expectorant' has led to considerable confusion in classification, as has been remarked upon previously. According to the dictionary, 'expectorant' is defined as "a tendency to facilitate the act of expectorating." If we accept Boyd's definition of expectorant as a drug which increases the output of respiratory tract fluid, then such terms as stimulant expectorant and sedative expectorant, still widely used in pharmaceutical classifications, are wholly misleading. Preparations which affect the respiratory tract fluid are antitussive in that (1) by decreasing the viscosity of the bronchial secretions, their elimination is facilitated so that the vicious cycle of ineffectual coughing is not perpetuated and (2) by increasing the amount of respiratory tract fluid, a soothing or demulcent action is exerted upon the mucosal lining thus relieving the dry, unproductive cough due to irritation of the respiratory airway.

Although the use of gargles, lozenges, troches, and cough drops is helpful in stimulating the flow of saliva and thus preventing the 'drying out' of the pharyngeal mucous membranes, most of the stimuli which give rise to cough originate in the lower respiratory tract, not reached by demulcent saliva. Many of the drugs which increase the respiratory tract fluid and make the sputum more fluid and less tenacious are nauseants which, reflexly, increase the secretions within the respiratory tract. This group includes the iodides, antimony and potassium tartrate, ammonium chloride, ipecac, emetine, and syrup of squill, and senega. In addition to its nauseant action, iodine is rapidly excreted by the bronchial glands and can be detected in the secretions within 15 to 25 minutes after oral or intravenous administration.

**DIMETHOXANATE**—Dimethoxanate (Cothera) is an alkyl ester of phenothiazine which appears to possess antitussive activity. It is nonnarcotic, and clinical trials have indicated that side effects are minimal. This preparation is devoid of central depressant or analgesic properties. The preliminary data suggest that 25 mg of Cothera has an antitussive potency equivalent to 15 mg of codeine. Further controlled studies are necessary to properly assess its place among the newer non-narcotic agents.

## Peripherally Acting Antitussive Agents

This class of drugs acts principally by decreasing the local irritation within the respiratory tract and thus reducing the tussal impulses which serve as the afferent arc for the cough reflex. A decrease in the impulse to cough may be effected locally by (1) the production of a mild analgesic or anesthetic action on the mucosa of the respiratory tract, (2) the reduction in the viscosity of the mucus within the respiratory passages so as to facilitate the evacuation of retained secretions, (3) the humidification of the respiratory tract, and (4) the relaxation of the smooth muscle of the bronchi in the presence of bronchospasm. Before discussing these drugs it should be made clear that with few exceptions, most of the agents in this category do not have specific local effects but tend to show considerable overlap. To a large extent our knowledge concerning the mode of action of many of these drugs is incomplete although syrups have been employed for the relief of cough for over four centuries. Whether by pharmacologic or psychologic effect chief of cough by any one of a multitude of aromatic syrups and elixirs has afforded increased comfort to the patient and hence these preparations have been the empiric remedies. While they may aid in reducing local irritation, most of these agents are employed as vehicles for the more specific antitussive drugs discussed in the preceding section.

**Demulcents**—Demulcent preparations are bland substances which act by pro-viding coating the irritated pharyngeal mucosa and possibly by exerting a mild analgesic effect locally. Most of these preparations serve as vehicles for prescrip-  
**y** Compound ether spirit and chloroform water have also been prescribed for their 'expectorant' and local analgesic properties.

**Local Anesthesia**—The inhibition of the cough reflex by the instillation of an anesthetic agent into the respiratory tract is an important feature of cer-  
tain procedures such as bronchoscopy and bronchography. However, the instilla-  
tion of anesthetics for the management of cough is impractical since it would  
be necessary to anesthetize all of the receptors by this method. Animal experi-  
ments have demonstrated that the amplitude and frequency of coughing was modi-  
fied to a large extent by the preceding inspiration. This is mediated by the Hering-  
Breuer reflex whereby the stretch receptors within the lung modify the expiratory  
act of coughing.  
In the past two years polyethylene glycol derivatives of p-butylaminobenzoic  
acid have been tested clinically for their effect on cough. These substances are  
effective with an apparent selective effect on the stretch receptors of the

**'Stimulant' Expectorants**—There are a number of substances, employed principally as vehicles in cough remedies, which have been used empirically to lessen the amount of mucus in chronic productive cough associated with chronic bronchitis, bronchiectasis and lung abscess. These have been classified in the older literature as 'stimulant expectorants' and are presumed to aid healing in the chronic stage of inflammation by producing a mild irritation. Creosote preparations consisting mainly of calcium creosote and creosote carbonate have been used to decrease the amount of sputum and render its odor less objectionable. Perhaps the best known member of this group is terpin hydrate. There are considerable differences of opinion with regard to the mechanism of action of the terpins. It is claimed that like other volatile and aromatic oils, terpin hydrate does not act reflexly upon the stomach but directly upon the secretory glands of the respiratory tract. Rather than lessening sputum formation, Boyd states that it is a true expectorant and increases the respiratory tract fluid. From the clinical point of view, the average recommended dose of elixir terpin hydrate contains only 68 mg per teaspoon (5 ml) which is considerably less than the pharmacologically effective dose of 300 mg. Its main action, therefore, is to serve as a pleasant tasting vehicle for more specific antitussives.

**GLYCERYL GUAIACOLATE**—Although the guaiacols are usually classified with the creosotes, glyceryl guaiacolate (Robitussin) deserves mention. Experimental studies by Boyd and his associates indicated that respiratory tract fluid was increased by almost 200 per cent following the administration of glyceryl guaiacolate, whereas the carbonate and sulfonate of potassium guaiacol were without effect. The oral administration of these conjugated derivatives does not result in the appearance of guaiacol in the pulmonary passages, as has been observed after ingestion of the free guaiacol or its ethereal derivatives.

While it has been my general plan to avoid discussing mixtures of drugs of which there are many hundreds in this particular field of therapy, a fairly extensive literature has accumulated with respect to Robitussin (glyceryl guaiacolate 100 mg, desoxyephedrine 1 mg in 5 ml of aromatic syrup). Studies in adults and children with cough due to a wide variety of disease states indicate that it is a highly effective antitussive with virtually no side effects. It was felt that the clinical efficacy of Robitussin was for the most part due to the marked increase in respiratory tract fluid produced by the glyceryl guaiacolate which reduced the viscosity of these secretions. It is doubtful whether a 1 mg dose of desoxyephedrine would have any significant bronchodilator effect on the smooth muscle of the tracheobronchial tree. The aromatic vehicle would be expected to have an effect similar to other demulcents on the pharyngeal mucosa.

**Humidification**—It has long been recognized that cough may be materially decreased by proper humidification of the respiratory passageways. In addition to providing a demulcent action of the mucosal surfaces, the respiratory tract fluid is increased thus lowering the viscosity of the bronchopulmonary secretions. The clinical effectiveness of the steam kettle and croup tent have been well documented particularly in the spasmodic and croupy cough of children.

Within the past two decades, new techniques employing aerosols have been developed which provide 'cold humidification'. In addition to increasing the

**Iodides**—Salts of iodine have been used for over a century in the treatment of cough and bronchial asthma. Combinations of iodides with specific bronchodilator agents are frequently employed in the management of bronchospastic states such as asthma and pulmonary emphysema. This will be discussed in Chapter 29, The Choice of Antiallergic Agents. There are two types of iodide preparations: (1) Inorganic iodides, such as saturated solution of potassium iodide or syrup of hydriodic acid, are generally employed and, although they may impart a bitter, metallic taste, this can be partially concealed by prescribing them with milk or in various demulcent syrups. An initial dose of a saturated solution of potassium iodide, 0.5 ml, 4 times daily, after meals and at bedtime, gradually increasing to 1 to 2 ml, 4 times daily provides effective 'expectorant' action. Enteric-coated tablets containing 0.5 Gm and 1 Gm of potassium iodide (Enkide) are available for patients who complain of gastric intolerance to the saturated solution. (2) Organic preparations such as Lipiodine, Triode, Organidin, and Amend's iodides, but are absorbed more slowly.

The iodides may be given for long periods since tolerance rarely develops. Nevertheless, this drug in common with the other expectorant agents should not be prescribed for longer than is necessary once the cough has become quite productive. The usefulness of the iodide preparations is limited in a large measure by the unpleasant taste and the common occurrence of minor side effects which include coryza, acneiform skin eruptions, erythema of face and chest, and painful swelling of the salivary glands. These reactions quickly subside on discontinuation of the medication. True sensitivity reactions as denoted by fever, malaise, and generalized skin eruptions have been successfully treated by corticotropin and the adrenal steroids. The presence of inactive pulmonary tuberculosis does not contraindicate the use of the iodides despite such statements in the older literature. Jobby believes that the thinning out of the secretions (by iodides) produces more sputum and floats out bacteria already present, but it does not cause reactivation or read of the disease.

**Ammonium Salts**—Although the ammonium salts—chloride, carbonate, and citrate—are probably the most commonly used "expectorants," the amounts incorporated in cough preparations are often less than the dose necessary to increase the volume of the respiratory tract fluid. Their action is transitory and it is not unlikely that some of the beneficial action ascribed to ammonium salts is in reality due to the ingestion of large amounts of water taken with these salts. (Goodman and Gilman's discussion of the nauseant compounds, ipecac is perhaps the only one which induced a considerable increase in respiratory fluid secretion. Ratner reported excellent results from syrup of ipecac in asthmatic children with inspiratory distress who were resistant to epinephrine. In tight groups cough in children, small doses of ipecac 0.5 to 2 ml are frequently of valuable help in relaxing the bronchi of thick tenacious mucus. Ipecac also appears to relax the smooth muscle of the bronchi and has been employed in our clinic chiefly in asthma which is hypersensitive to the iodides. The average "expectorant" dose in children has been 0.5 ml 4 times daily.



bronchial tree (3) It is believed to have a local bronchodilator effect on the smooth muscle of the respiratory tract In effect, carbon dioxide inhalations modify the respiratory tract fluid and aid in the elimination of retained secretions These mechanisms serve to convert tussal insufficiency into an effective cough, particularly in the debilitated patient

Treatment is carried out by administering 5 per cent carbon dioxide in combination with 95 per cent oxygen at a rate of 5 to 7 liters per minute, by means of a mask or nasal catheter Each treatment consists of 10 to 15 minutes of gas inhalation repeated 3 to 4 times daily until cough is alleviated Since this technique for managing cough involves specialized apparatus and careful supervision of the patient, its usefulness has for the most part been restricted to the hospitalized patient

In addition, there are a number of contraindications which further limit its usefulness in certain disease entities associated with cough These include (1) cough due to pleural involvement, (2) recent evidence of hemoptysis, (3) diseases associated with an elevated  $pCO_2$ , such as pulmonary emphysema, severe bronchial asthma pulmonary fibrosis, etc., (4) systemic hypertension, and (5) cough originating outside the respiratory tract such as from aneurysms, irritation of Arnold's nerve etc

Radiation—In certain specialized instances, particularly in children where cough is the result of compression on the respiratory passageway by thymic enlargement or tracheobronchial lymphadenopathy, radiation therapy over the affected areas has been reported as beneficial when all other measures have failed The promiscuous use of irradiation for other disease entities such as asthma and infections of the lung in which cough is a prominent symptom can only be condemned in the light of more specific therapeutic measures for these conditions and the well known hazards of radiation

## BASIC PRINCIPLES GOVERNING THE SELECTION AND USE OF ANTITUSSIVE AGENTS

While space does not permit detailed discussion of the best application of all the antitussive agents mentioned in the previous section certain basic principles are worth emphasizing to obtain maximum therapeutic effect with a minimum of undesirable side reactions Although pharmacists still stock a multitude of antitussive agents and mixtures many of which have been used on an empiric basis reevaluation of these drugs by controlled clinical and experimental techniques will eventually result in the discarding of many of the time honored mixtures and elixirs and permit more rational selection of the remaining pharmacologically active drugs

There is considerable justification in objecting to the current practice of ordering a fixed dose of an antitussive to be administered at stated intervals such as every 4 hours, etc Except in rare circumstances, cough is sporadic in character and, depending upon the causative factors, usually has well defined predilections time of day, degree of exertion changes in posture and that ever present scape goat 'the weather' Moreover, it is well recognized clinically that within certain limits increasing the dose results in little or no potentiation of the antitussive effect



author that the combination of an effective nonnarcotic centrally acting antitussive with a true "expectorant" would perhaps serve as a more rational approach to the management of cough




Fig. 22—Relative potency of Romilar, Nectadon (narcotine) and I propoxyphene compared with placebo and codeine, based upon the per cent decrease in cough frequency from the control level over the entire 4 hour period (from Bickerman, H A, et al. *Am J Med Sc* 234 191, 1957)

Of the peripherally acting agents with a local anesthetic effect, Tessalon deserves some comment. It may prove to be a valuable adjunct, together with bronchodilator preparations, for the intractable chronic cough frequently encountered in such bronchospastic diseases as bronchial asthma and pulmonary emphysema. It should be pointed out that if no clinical benefit is derived after one week's trial, further therapy would prove worthless.

For example, in the treatment of the majority of patients with cough, 15 mg of codeine has far fewer side effects and is almost as effective as 30 mg of codeine and dihydrocodeinone. With respect to these agents it has proved advantageous to employ smaller doses at more frequent intervals rather than a large dose frequently. In this connection the use of 10 or 15 mg of codeine for example every 2 hours has resulted in more effective control of intractable cough than doses of 30 to 60 mg every 4 to 6 hours. In keeping with the more potent narcotic agents these drugs have well defined undesirable side reactions particularly when used in the treatment of chronic cough and the development of tolerance and addiction.


Gastrointestinal intolerance, constipation, central nervous system depression, and the development of tolerance and addiction are the major drawbacks in prolonged therapy. A sustained release preparation such as Lussione's may overcome some of the drawbacks by providing effective cough suppression with minimal dosage since 2 tablets containing 5 mg each of dihydrocodeinone maintains antitussive activity over a 24 hour period.

Recently as a result of intensive investigation nonnarcotic agents have been developed which compare favorably in antitussive effectiveness with codeine. Since these agents are nontoxic and possess few if any, of the undesirable reactions characteristic of the narcotic agents it is my own opinion that in time these preparations will largely supplant the more popular narcotics employed today, except for certain special instances where analgesic and sedative euphoric effects are desired. This would be pertinent to the use of morphine in the treatment of cough associated with malignancy or the use of Demerol in the tense, anxious patient with bronchial asthma. Onset of cough suppression with these newer synthetic preparations is fairly rapid (20 to 30 minutes) with effectiveness persisting 4 to 6 hours and in the treatment of children these agents are especially suitable for prolonged use they are virtually nontoxic. While the dosage in children is usually calculated on the basis of body weight more frequent or increased dosage has not elicited any untoward effects. The relative effectiveness of some of these agents as compared with codeine and placebo are illustrated in Figs 22 and 23. These evaluations are based upon experimental studies employing citric acid red cough.

Although considerable doubt has been expressed within recent years on the value of so called 'expectorant' agents in the treatment of cough there is sufficient evidence presented by Boyd and others to indicate that agents which increase respiratory tract fluid lower the viscosity of such secretions and in addition exert a solvent effect on the bronchial mucosa. The physiologic effect, then, would be that it favors the removal of these secretions and diminishes the usual irritation from irritated areas within the respiratory tract. From the evidence presented it would appear that humidification plays an equal role in producing these effects. Indeed it is the opinion of many practitioners that the in-creased steam or cold vapor by aerosol is the most efficacious measure in the treatment of nonproductive cough. Of the agents which influence respiratory secretions only two are worth considering the iodides and glyceryl guaiacolate. In view of the confusion which already exists with respect to the multitude of mixtures dispensed as cough remedies it seems quite appropriate to



**Psychogenic Cough and "Night Cough"**—The management of two special instances of coughing which have not been previously discussed are the cough of psychogenic origin and the 'night cough'. The pharmacologic therapy of psychogenic cough has been, on the whole, disappointing. As with the psychosomatic symptoms referable to other organs, any new preparation exhibits remarkable but, alas, only temporary benefit. In the treatment of this type of patient one must display his knowledge of the art of medicine in addition to his knowledge of rational pharmacology. There are several proprietary cough remedies, such as dihydropyrene (Sedulon), which are purported to act as sedative antitussives for 'night cough'. Although there may be special merit for such preparations any effective cough suppressant combined with a suitable hypnotic may insure a restful night if administered prior to bedtime.



Comparisons of the antitussive activity of various drugs over a 4 hour period with the effect of placebos and codeine as standards of reference

**Smoker's Cough**—While an extensive literature has been devoted to the smoker's cough, this term still remains ill defined and excites almost as much controversy as the role played by cigarette smoking as a causative factor in the etiology of lung cancer. In all probability this is not a single entity but composed of varying etiologies, such as chronic bronchitis, etc., which is undoubtedly

edly aggravated by the inhalation of specific irritants, namely tobacco smoke and its accompanying combustion products. While the cessation of smoking may improve such coughing clinically, the eradication of the underlying disease process together with appropriate symptomatic measures as outlined in the preceding sections are also necessary for adequate therapy.

Since cough is a symptom complex which may arise from any one of a multitude of disease entities, treatment of the etiologic factors in itself is antitussive. In the main, this chapter has dealt with the symptomatic control of cough by various means. An "antitussive" requires the presence of such secretions. It represents perhaps the most effective method of reducing secretions. In the

presence of such secretions the ideal antitussive might well be one which, although reducing the number of ineffective coughs, permits an adequate flow rate in the remaining coughs so as to aid bronchial drainage. In the absence of secretions when cough is purely irritative or reflex in character, a decrease in the frequency of coughs as well as the intensity would be desirable. The ideal antitussive, furthermore, might effectively convert a nonproductive cough to a productive one by measures designed to increase the respiratory tract fluid and thereby reduce the paroxysmal character of such coughing.

The search for the ideal antitussive has gained new impetus during recent years through the development of experimental techniques. Prior to this, a review of the literature on the evaluation of antitussive agents disclosed that the majority of the reports were concerned with clinical appraisals in patients suffering from disease entities associated with chronic cough. Since 1938, when Ernst first described an experimental technique for eliciting cough, a total of 21 reports on this method of assessing antitussive activity have been published. Many of these experimental methods have been reviewed by Tiffeneau. Of these, only 8 papers pertain to studies on human subjects.

In keeping with the nonspecificity of this field of therapy, this discussion, of necessity, has been unduly lengthy. Perhaps more than any other symptom, the treatment of cough emphasizes the art of the practice of medicine. The rational approach to cough therapy is still in its infancy. It is only within the past decade that a small beginning has been made in wedding the experimental approach to the well controlled clinical study which will ultimately quantitate the effect of pharmacologically active agents on the many variables of the cough mechanism. Preparations assessed in this manner will not be empiric but will have well defined antitussive characteristics which can be integrated into a sound program for the management of cough.

## SELECTED REFERENCES

- Abelman, W. H., Gaensler, E. A., and Badger, T. L. Clinical Evaluation of Torsyn D-1. *Chest* 25: 532, 1954.
- Banyas, A. L. Fifteen Years' Experience With Carbon Dioxide in Management of Cough. *Dis. Chest* 13: 1, 1947.
- Barach, A. L., and Bickerman, H. A. Pulmonary Emphysema. Baltimore, 1956. The Williams & Wilkins Co., Inc.
- and Chemical Properties of Sputum from Different Parts of the Trachea.

## ANTITUSSIVE AGENTS

- Bickelmann, H. A. *Proc. Soc. Exptl. Biol. Med.* 48: 207, 1942
- Ibid
- Boyd, J. *Proc. Soc. Exptl. Biol. Med.* 48: 207, 1942
- Ibid
- Brown, J. *Proc. Soc. Exptl. Biol. Med.* 48: 207, 1942
- Cass, L. J. *Proc. Soc. Exptl. Biol. Med.* 48: 207, 1942
- Ibid Quantitative Comparison of Cough Suppressing Effects of Romilar  
sives, *J. Lab. & Clin. Med.* 48: 879, 1956
- Ibid The Clinical Evaluation of Sustained Release Antitussives, *Ann.*  
1958
- Cass, L. J., Frederik, W. S., and Andosca, J. B. Quantitative Com-  
methorphan Hydrobromide and Codeine, *Am. J. M. Sc.* 227: 291,  
Chakravarty, N. K., Matallana, A., Jensen, R., and Borison, H. L. Cen-  
tussive Drugs on Cough and Respiration, *J. Pharmacol. & Exper.*  
1956
- Denton, R. Continuous Nebulization Therapy, *Pediat. Clin. North Amer.*  
Douglass, B. E. Causes and Therapy of Cough, *M. Clin. North America.*  
Goodman, L. S., and Gilman, A. The Pharmacological Basis of Therapy,  
York, 1955, The Macmillan Company
- Green, A. F., and Ward, N. B. The Action of Analgesics and Nalorphine  
Reflex, *Brit. J. Pharmacol.* 10: 418, 1955
- Hayes, E. W. *Proc. Soc. Exptl. Biol. Med.* 48: 207, 1942
- Hobby, A. W. *Proc. Soc. Exptl. Biol. Med.* 48: 207, 1942
- Konertz, H. *Proc. Soc. Exptl. Biol. Med.* 48: 207, 1942
- May, A. T. and Widdowson, J. C. *Proc. Soc. Exptl. Biol. Med.* 48: 207, 1942
- Phillips, J. *Proc. Soc. Exptl. Biol. Med.* 48: 207, 1942
- Ratner, I. *Proc. Soc. Exptl. Biol. Med.* 48: 207, 1942
- Tiffeneau, R. La toux experimentale Methode de production Exposé a  
11: 263, 1956
- Tuft, L. and Levin, N. M. Studies of the Expectorant Action of Iodo-  
203 717 1942
- Van Dongen, K. The Effect of Narcotine, Ticarda and Romilar on the  
Movements of the Cilia in the Air Passages, *Acta physiol. et p.*  
500, 1956
- Winter, C. A. and Flataker, L. Antitussive Compounds Testing Meth-  
*Pharmacol. & Exper. Therap.* 112: 92, 1954



## THE CHOICE OF ANTIALLERGIC AGENTS

*Hylan A. Bickerman, M.D., and*

*Alvan L. Barach, M.D.*

---

### INTRODUCTION

The scope of a chapter which discusses pharmacologic agents possessing anti allergic activity should include a precise definition of "allergic" phenomena. In the past half century, since von Pirquet first coined the term "allergy" to describe the altered reaction of tissues to repeated contacts with infectious and antigenic substances, such as bacterial vaccine, tuberculin, and foreign serum, the newer concepts developed in immunology, biochemistry, and cytochemistry have extended the field of allergy into almost every pathologic process involving man. In order to maintain the integrity of the "milieu interieur," various defense mechanisms, some simple and others more elaborate, constantly guard against the impingement of a foreign or external environmental attack. Reactions of the host have been noted to such influences, principally of a protein and carbohydrate nature, but often including organic compounds such as drugs or physical agents such as heat and cold. Access through the various portals of the body have been observed, including the respiratory tract, the alimentary system, the skin and conjunctiva. Allergic responses comprise the etiologic and pathogenetic bases for a wide variety of disease states. The term "allergy" has been applied to a multitude of conditions in which the tissues or organs of one person respond to contact with some foreign material in a definitely different manner from the corresponding tissues or organs of other persons of the same species.

The allergic reaction is highly specific, it implicates a precise antigen antibody type of reaction. Most allergists use the term "hypersensitivity" interchangeably with that of "allergy" to designate reactions in which a specific antigen antibody response is involved or is considered probable. Some confusion has existed with respect to the inability to demonstrate repeated or previous contact with the exciting agent (antigen). In these instances the similarity in clinical manifestations necessitate their inclusion among the allergic disorders.

- Bickerman, H. A., Cohen, B. Subjects Stimulated by Antitussive Agent  
Ibid The Cough Response Part II Evaluation  
Boyd, Ibid  
Brown  
Cass, Ibid  
Ibid  
Ibid  
1958  
Cass, L. J., Frederik, W. S., and Andosca, J. B. Quantitative Comparison of Dextromethorphan Hydrobromide and Codeine, *Am J M Sc* 227 291, 1954  
Chakravarty, N. K., Matallana, A., Jensen, R., and Borison, H. L. Central Effects of Antitussive Drugs on Cough and Respiration, *J Pharmacol & Exper Therap* 117 127, 1956  
Denton, R.  
Douglas, B.  
Goodman, L. New York  
Green, A. F., and Haddad, J. D. The Action of Analgesics and Nalorphine on the Cough Reflex  
Hayes, E. W., Chro  
Hobby, A. W.  
Kozarek, H. 67 3  
May, V. Reflex by Pentobarbitone and  
Phillips, Cough Analysis of Etiologic 1956  
Ratner, Clin North America 31  
Tiffeneau, R. La toux experimentale Methode de production Exposé analytique, *Therapies* 11 265, 1956  
Tuft, L., and Levin, N. M. Studies of the Expectorant Action of Iodides, *Am. J M Sc* 203 717, 1942  
Van Dongen, K. The Effect of Narcotine, Ticarda and Rotular on Coughs and on the Movements of the Cilia in the Air Passages, *Acta physiol et pharmacol neerl* 4 500, 1956  
Winter, C. A., and Flataker, L. Antitussive Compounds Testing Methods and Results, *J Pharmacol & Exper Therap* 112 99, 1954

Table 34 Clinical Allergic Disorders

<b>A Involving Multiple Systems —</b>	
1	<i>Serum sickness</i> Usually occurring 7 to 12 days after administration, injected or ingested, of a foreign serum or drug
2	<i>Allergic or "anaphylactic" shock</i> Acute reactions to foreign substances to which patient has been previously sensitized, occurring within seconds or minutes
<b>B Involving the Respiratory System —</b>	
1	<i>Allergic rhinitis</i>
(a)	Seasonal rhinitis hay fever, pollinosis
(b)	Perennial rhinitis (vasomotor rhinitis)
2	<i>Bronchial asthma</i>
(a)	Extrinsic inhalants, ingestants, injectants
(b)	Infectious (so-called "intrinsic") bacterial allergens, foci of infection
<b>C Involving the Gastrointestinal System —</b>	
1	<i>Acute</i> pylorospasm, nausea, emesis, diarrhea, colicky pain
2	<i>Subacute or chronic</i> spastic constipation, mucous colitis, pruritus ani, perianal eczema
3	<i>Henoch's purpura</i>
<b>D</b>	
1	<i>Acute</i> contact dermatitis due to plants, vegetable sources, chemicals, cosmetics
2	<i>Atopic dermatosis</i>
(a)	<i>Eczematoid</i> contactants and occasionally inhalants
(b)	<i>Venenata</i> contact dermatitis due to plants, vegetable sources, chemicals, cosmetics and animal danders
(c)	<i>Medicamentosa</i> drug eruption due to individual idiosyncrasy or hypersensitivity
<b>E Involving the Blood and Vascular System —</b>	
1	<i>Agranulocytosis</i> drug and chemical hypersensitivity
2	<i>Erythroblastosis fetalis</i> passive transfer of hemolytic antibodies (Rh) from maternal circulation to fetus
3	<i>Urticaria</i>
<b>F</b>	
2	<i>Rheumatic fever</i>
3	<i>Lupus erythematosus disseminatus</i>
4	<i>Thromboangitis</i>
5	<i>Nonthrombocytopenic purpura</i>

## PHYSIOLOGIC AND PHARMACOLOGIC CONSIDERATIONS

In order to assess the value of pharmacologic agents in the management of allergic disease, a brief review of some of the current concepts on pathogenesis appears to be desirable. Both antigens and antibodies have been demonstrated by biochemical technique. It has been found that most antigens consist mainly of protein, although polysaccharides and lipids in combination with carbohydrates can produce antibodies in mammals. Landsteiner and others have shown that low molecular weight substances, such as drugs, often display antigenic activity. In these instances it has been postulated that the drug or chemical compound acts as a hapten and becomes coupled with protein which is capable of inducing antibody formation. Since it is commonly recognized that most living cells possess the ability to produce protein, it is theoretically possible for these cells to produce antibody when they come in contact with antigen and secure it. Considerable recent

## CLINICAL CONSIDERATIONS

The diseases of allergy comprise a group of heterogeneous disorders with both acute and chronic manifestations. The symptoms may vary from a mild urticaria or rhinitis to a severe anaphylactic reaction with fatal termination. It has been variously estimated that approximately 10 per cent of the population of the United States or between 16 and 17 million people, suffer from allergic disease which ranks third in prevalence among the chronic diseases in this country.

In classifying the disorders of allergy due to hypersensitivity the allergist for the most part has been guided by historical developments in the field of immunology in which the antigen antibody relationship has played a dominant role. While these concepts have been invaluable in the development of diagnostic procedures and specific management, i.e. using the suspected allergen in determining the cause as well as for treatment by hyposensitization nevertheless from the pharmacologic point of view which involves symptomatic management of these disorders the immunologic classification has generally proved cumbersome. Perhaps a simpler way to consider these disease entities especially from the viewpoint of drug therapy, is to group them anatomically with reference to a specific organ or tissue. Such a classification is illustrated in Table 34.

From the clinical viewpoint the allergic disorders involving the respiratory system are perhaps the most important representing over 50 per cent of the allergies encountered in the practice of medicine.

Although it is generally recognized that the tendency to develop sensitivities is hereditary the exact genetic mechanism remains in doubt. The particular persons to which a person predisposed by heredity will become sensitized depends on environmental exposure. It appears likely that any protein which is ingested or inhaled may cause sensitivity and the list of such active agents is constantly expanding. Emphasis is scarcely required to point out that each new drug and miracle drug developed introduces the problem of iatrogenic disease in a group of sensitized individuals.

There are a number of allergic disorders, i.e. asthma, perennial rhinitis, and in which extrinsic allergens cannot be regularly demonstrated. In some there is an associated chronic infection particularly of the paranasal sinuses and tonsils. The causal relationship to infection is only infrequently the relief of symptoms occurring after the medical or surgical eradication of infection. The occurrence of upper respiratory viral infection is associated with exacerbation of the allergic state, whereas pneumococcal infection is followed by lessening of the allergic state. There is a body of experimental evidence which suggests that bacterial sensitization is a factor in the pathogenesis of such disease states as rheumatic fever, scarlet fever, peritonsillar abscess, acute lupus erythematosus, and perhaps diseases. Hypersensitivity has generally been accepted as one aspect of response which serves to localize infection and protect the organism of widespread dissemination. More recent studies by Rich and others doubt upon the protective nature of this hyperimmune response. The form of hypersensitivity as the mechanism for the pathogenesis of the diseases mentioned above.

mental anaphylaxis and some of the clinical manifestations of allergy. However the treatment of clinical anaphylaxis requires epinephrine and its alleviation by antihistamines has been questioned.

## PHARMACOLOGIC MANAGEMENT OF ALLERGIC DISORDERS

Basic knowledge has been accumulated over the past half century in the field of allergy; however, advances in clinical management based upon this knowledge have only scratched the surface. In reviewing the material presented above we have been impressed but not a little disappointed by the apparent difficulty in applying the strides made in the laboratory to the practical care of the allergic patient. It is evident that much careful work remains for the inquiring physician.

The application of allergic principles to clinical practice is based upon (1) removal of the offending allergen when such can be demonstrated, (2) hyposensitization procedures with preparations of specific allergen and (3) symptomatic management. Before undertaking treatment, diagnostic procedures including both the type of allergic disorder and the etiologic causation must be thoroughly investigated. As with other disease syndromes, a complete history and physical examination are imperative since they often provide a clue to the offending substance or substances involved in the allergic reaction. Skin tests may confirm the history or help in bringing to the attention of the patient and physician a forgotten bit of history. Most clinicians now believe that when a discrepancy exists between the history and skin tests, the history is a more accurate diagnostic tool. The history may indicate that the patient is sensitive to a given substance despite the fact that the skin test reaction is negative.

If the allergic disorder can be traced to one or more antigen antibody reactions, the prognosis for successful control by means of elimination or hyposensitization is frequently good. Skin test reactions are usually multiple and are more frequently encountered in children than adults. Food sensitization with test allergens is discovered more readily in children. The use of elimination diets is required to determine the etiologic factor when the skin test is negative. When the cause is undetermined, major recourse must be made to the symptomatic management of the allergic manifestation.

### Environmental Control

If the allergic symptoms in the main are caused by contact with offending substances in the environment, the logical treatment is either removal of the patient from that environment or removal of the offending substance from the patient's vicinity. Ingestant offenders may be controlled by eliminating them from the patient's diet. When the offending allergen is an inhalant, there are two avenues available for control by elimination. The patient may temporarily take up residence in a pollen free area when seasonal pollinosis is implicated. Depending upon the type of inhalant responsible, another measure includes scrupulous attention to the maintenance of an atmosphere free from such substances as dusts, molds, feathers, animal danders, wools, cottons and horsehair. This is aided by mechanical devices such as air filters and room air conditioners equipped with an efficient

## ANTIALLERGIC AGENTS

evidence supports the view that the plasma cell and lymphocyte are the major source of antibody. The interaction between antigen and antibody results in certain pathophysiologic changes in various tissues and organs of the body. In the main these involve smooth muscle blood vessels glands, and collagen. The major pathologic changes which occur in these tissues are edema smooth muscle contraction, and hypersecretory activity of glands. In asthma allergic rhinitis urticaria, and angioedema the basic response is local vasodilatation and increased capillary permeability leading to tissue edema in the mucosa of the respiratory tract, skin and subcutaneous tissues. In addition spasm of the smooth muscle of the bronchial tree and the increased secretion of seromucinous material from the bronchial glands are responsible for the major pathologic changes. It is not known whether the reaction between antigen and antibody takes place in the cells upon the surface of the cells or in the blood stream.

There has been considerable speculation concerning the intermediary mechanisms whereby the union of antigen and antibody results in the tissue changes described above. Since Dale's original studies with histamine and sensitized uterine muscle strips an enormous literature has accumulated concerning the chemical nature of an intermediate substance produced by the reaction of antigen and antibody which in turn causes the various phenomena observed in allergic disease. It has been proposed that tissue alteration results from the release of such chemical substances as histamine heparin acetylcholine serotonin and possibly other chemical agents. There is in fact no simple explanation for the chemical mediation of the allergic reaction. In this respect Feldberg and Smith have advanced the theory that serotonin which is found abundantly in platelets and in the granules of tissue mast cells both of which are present in large numbers in the respiratory tract during the allergic reaction is responsible for the release of histamine from the sensitized individuals or animals by histamine and can be reproduced in non-sensitized individuals or animals by known antihistamine activity. histamine or a histamine substance has been implicated as the intermediary in allergic reactions. The exact nature of its place in allergy remains in dispute. It is beyond the scope of this chapter to review all the properties of histamine. Perhaps the most adequate summation was made by Dragstedt in 1915. The evidence for the function of histamine in certain physiological and pathological reactions varies. The assumption and illogical inference to substantially concrete and proved evidence indicating histamine as responsible for anaphylaxis first proposed resulting from the liberation of histamine from an inert bound form and injury is caused by the interaction of antigen and antibody has been extended to other types of allergic manifestations. However Croke has attempted to demonstrate an excess of histamine in the blood of attacks of allergic disease have generally failed. From the clinical evidence the strongest evidence in favor of the histamine hypothesis is the relative effectiveness of potent antihistamines.

determining the type of offending allergen by various skin testing procedures the techniques of hyposensitization are described in current textbooks of allergy.

### Symptomatic Management With Pharmacologic Agents

Although specific measures of environmental control and hyposensitization provide a rational basis for the therapy of allergic disorders, these measures do not promptly eliminate symptoms in a considerable number of patients. Expert symptomatic management is therefore sought by the use of suitable pharmacologic agents. Combined employment of specific therapy referred to above and administration of antiallergic drugs have often provided adequate control of many of the distressing symptoms of allergy. In the presence of such acute states as anaphylaxis and status asthmaticus, drug therapy alone is at times lifesaving.

The administration of suitable agents may restore to normal the pathophysiologic disorders caused by allergic disease. Because of the variations in response to the different disease entities, the claim has often been made that the antispasmodic, expectorants, antihistaminics, and sedatives commonly used have no effect on the course of the allergic process and in certain instances may be more disturbing than effectual. Because of the inconsistent results achieved, many of these patients are denied a considerable measure of relief which could be provided by properly applied drug therapy. The rationale of the use of substances in the prevention and treatment of allergic manifestations is as follows: (1) relief of vasodilatation, mucosal edema, and bronchospasm; (2) facilitation of bronchial drainage; (3) inhibition of histamine activity; (4) sedation; (5) modification of tissue reactivity by corticotropin and the corticosteroids; and (6) less well defined therapeutic objectives. Many of the drugs to be discussed provide relief by more than one mode of action. Thus, vasoconstrictors such as epinephrine are potent bronchodilators and the xanthine derivatives, in addition to relaxing smooth muscle spasm, have a pharmacologic effect on tissue edema.

**Relief of Vasodilatation, Mucosal Edema, and Bronchospasm**—Although many therapeutic agents have been effective as vasoconstrictors and bronchodilators, no single drug has proved entirely satisfactory. Adverse side reactions, lack of sustained effect, and the development of tolerance have presented major stumbling blocks. The judicious use of combinations of drugs, addition of sedative and antinausea factors, and alternate routes of administration have been helpful in overcoming some of these obstacles. From a pharmacologic standpoint, the most common drugs of this category are the sympathomimetics, anticholinergics, and the xanthine derivatives. The principal drugs, together with their newer analogues in common use today will be discussed in this section.

**ADRENERGIC OR SYMPATHOMIMETIC AGENTS**—Among the most effective drugs in the treatment of allergic manifestations resulting from vasodilatation, mucosal edema, and bronchospasm are the sympathomimetics. A list of these is illustrated in Table 35.

**Epinephrine** Since its isolation at the turn of the century, this hormone of the adrenal medulla has been the most widely used agent in the symptomatic management of the allergic state. Its action includes constriction of the blood vessels

filter. Relief of the symptoms of hay fever or asthma caused by air borne inhalants is not complete since recent investigations into the efficacy of these devices have shown that many conventional room air conditioners remove only the larger pollens from the air. A combination of cloth filter and electronic precipitator is probably the best arrangement now available, especially when used continuously. Efficiency in the removal of pollen is increased when cooling units are used in conjunction with recirculation of air since much of the pollen will deposit upon the moist condensing coils, however, this may be accompanied by excessive cooling with continuous operation. The relief from these devices depends upon the habits of the patient and the amount of time spent in such a room. A filter in the room may be of considerable value to people who cannot use other measures. Environmental control of allergic disorders caused by the inhalants does not result in cure but may give considerable relief to individuals who remain in a pollen free area for extended periods. Complete restriction to a pollen free room, even in a hospital, has generally not met with patient acceptance (Novey and associates).

### Hyposensitization

Although the exact mechanisms involved in hyposensitization remain obscure, the best evidence at present points to the formation of a circulating antibody, described by Cooke as the 'blocking antibody,' which is believed to prevent the union of antigen and its antibody. Gradually increasing doses of allergenic extracts injected at appropriate intervals produce an increased titer of the 'blocking' antibodies in the serum which then has the capacity to combine preferentially with the allergen and thus apparently prevent it from reacting with the sensitizing antibody. The basic principle in hyposensitization therapy is to increase the tolerance of the patient to the causative allergen. A review of the literature indicates that considerable variation exists in the exact degree of benefit conferred by hyposensitization. This appears to be due to the variable influence of the following factors: (1) the demonstration of a reliable positive skin test, (2) the degree of hypersensitivity, (3) the type of allergic disorder, (4) the age of the patient, (5) predisposing environmental factors such as dust humidity, and temperature, (6) chronic or intercurrent infection and (7) emotional trauma.

Although specific hyposensitization therapy is time consuming and often trying for the patient, it maintains its position as the most effective method of treatment in certain disorders such as hay fever. Similarly in seasonal asthma, where identification of the causative agent has been achieved the results have been successful in the majority of cases. On the other hand injection therapy is generally unsuccessful in cases of nonseasonal asthma in which identification of the causative allergen has not been possible. In patients in whom multiple allergies exist, hyposensitization with a single offending allergen will have little or no effect upon the symptoms of the disease. Lowell has re-emphasized the fact that the correct selection of these (allergenic extracts) is of immense importance and this step is unquestionably best undertaken by one who has had considerable experience. Indiscriminate administration of allergenic extracts leads not only to failure but also to an understandable reluctance among many critical physicians to subject their patients to this rather expensive and time consuming procedure." The details of



Parenteral epinephrine (1:1000) is the most useful drug in acute allergic emergencies such as anaphylactic shock and angioedema of the larynx, in which it may be given intravenously in doses of 0.3 to 0.4 ml for rapid effect. In the treatment of asthma, injection of more than 0.3 ml subcutaneously is rarely necessary, with larger doses caution must be observed in the presence of coronary artery disease, hypertension and hyperthyroidism. Larger doses are attended by a higher incidence of toxic reactions involving the cardiovascular and central nervous systems. Tremor, excitability, palpitation, abnormal cardiac rhythms and occasionally a shocklike state are among the side effects encountered with larger or too frequently repeated doses.

Self medication by hypodermic injections is not recommended for routine use since patients in an effort to obtain sustained relief, often overtreat themselves resulting in the rapid development of a refractory state. Tolerance to bronchopneumine is reported as developing less frequently and to a lesser degree than with epinephrine. A recent study by Blumenthal and his co-workers suggests that epinephrine fastness or refractoriness may be influenced by changes in the blood pH.

The deposition of a fine bronchodilator mist on the mucosa of the bronchi and bronchioles of the respiratory tract presents many significant advantages over the parenteral use of epinephrine. Since the topical effect predominates with relatively little activity resulting from systemic absorption, toxic effects in the therapeutic dosage range are minimal. The ease of administration and its ready availability affords the patient with bronchospastic disease a measure of security not obtainable with injection therapy. However, as with parenteral administration excessive use leads to increasing tolerance which can be overcome in some instances by the substitution of other sympathomimetic aerosols and by brief periods of withdrawal.

As little as 0.1 ml of 1:100 epinephrine, 2.25 per cent racemic epinephrine (Vaponefrin) or 2.5 per cent racemic epinephrine with 0.5 per cent atropine sulfate (Dylephrin) nebulized by 4 to 6 compressions of the hand bulb of a Vaponefrin or DeVilbiss #40 nebulizer may abort or relieve a mild bronchospastic attack within a few minutes. The relief, however, may be only temporary, and Richards and Barach have demonstrated that prolonged inhalations of dilute aerosols of epinephrine and phenylephrine (Neo-Synephrine HCl) over a period of 20 to 30 minutes 3 or 4 times daily, provided more effective bronchodilatation and bronchovasoconstriction in intractable bronchospastic states. Diglio and Munch reviewed the reports of other investigators on the long term use of pressor aerosols and conducted a study in patients with hypertension, cardiac disease, thyrotoxicosis and diabetes. They found no untoward effects following the inhalation of many times the therapeutic doses of epinephrine. Improper use of the aerosol may cause excessive dryness of the pharynx, and swallowing of the aerosol solution may cause epigastric pain.

**Isoproterenol** Substituting an isopropyl group on the nitrogen in place of the methyl group in the epinephrine formula appears to increase the bronchodilating and vasodilating effects with a lowering of the pressor effect. This compound, isoproterenol, is a valuable addition to epinephrine in the aerosol therapy of bronchial asthma. Although its acute toxicity appears to be less than epinephrine

Table 35 Adrenergic Agents Employed in Allergic Disease

Generic Name	Trade Name	Route of Administration	Usual Adult Dose
Epinephrine (levo)	Adrenalin, Suprarenin	Parenteral (1:1000) Ophthalmic (1:1000) Aerosol (1.0%)	0.2-0.3 ml
(racemic)	Vaponefrin Dylephrin*	Aerosol (2.25%)	0.2-0.5 ml
Ethvlnorepinephrine	Bronkaphrine, Butanefrine	Parenteral (1:500)	0.5 ml
Isoproterenol	Isuprel, Norisodrine	Sublingual Aerosol (0.5-1.0%)	5.0-10.0 mg 0.2-0.5 ml
	Aludrine, Aerolone Cpd., Nebu-Prel	Aerosol (0.5%)	0.2-0.5 ml
<i>Congeners</i>			
Isoprophephnamine		Oral	20 mg
$\alpha$ Protocatechyl Ale	Gaytine	Oral Aerosol (0.5-1.0%)	2.0 mg 0.2-0.5 ml
Ephedrine (levo)	Efedron, Ephetonin	Oral Nasal Solution (0.5-2.0%)	15.0-50.0 mg 0.2 ml
(racemic)	Eonephrin Racephedrine	Oral	15.0-50.0 mg 25.0 mg
<i>Congeners</i>			
Methoxyphenamine	Orthoxine	Oral	50.0-200.0 mg
Ethylephedrine	Nethamine	Oral	25.0-50.0 mg
1-Henylephrine	Neo-Synephrine	Nasal Solution (0.25-1.0%) Aerosol (1.0%) Ophthalmic (0.12%)	0.1-0.2 ml 0.5-1.0 ml 0.1 ml
Phenylpropanolamine	Propadrine	Nasal Jelly (0.66%) Nasal Solution (1.0-3.0%)	0.2 ml
Naphazoline	Privine	Nasal Solution (0.1-0.05%) Ophthalmic Solution (0.1%)	0.1 ml 0.1 ml
Tetrahydrozoline	Tyzine	Nasal Solution (0.1-0.05%)	0.1-0.2 ml

\*With atropine

and diminution of exudation of fluids in the tissue responsible for the particular allergic symptoms, and, probably more important than these properties, a potent bronchodilator effect. Experimental evidence indicates that epinephrine acts directly on the smooth muscle of bronchi and bronchioles to relieve bronchoconstriction. There are two routes of administration, parenteral and by inhalation as an aerosol. Onset of activity is rapid by either method usually within minutes, but the effects are transient for the most part, and frequent administration is therefore necessary to maintain relief of symptoms. To overcome this limitation parenteral use of epinephrine, slow release preparations, such as Ad and aqueous epinephrine suspension (Sus-Phrine) have been employed.

ephedrine therapy in the older patient with prostatism. It should be used cautiously, in small doses (15 mg) with aminophylline, in the presence of hypertension and coronary artery disease. The maximum bronchodilator effect is usually reached within one hour after ingestion and persists for a period of approximately 6 hours. Increased duration of bronchodilator activity has been obtained with a sustained release preparation containing 50 mg of ephedrine combined with an ion exchange resin (Ionephrin). In a preliminary study, clinical benefit has been maintained for approximately 6 to 8 hours following administration. The incidence of side effects does not appear to be any greater than with smaller doses of the conventional ephedrine preparation.

If ephedrine is given 3 or more times daily, its effectiveness often begins to decline after several weeks because of the development of tolerance. Increasing the dose may sustain the antispasmodic effect for a time, complete withdrawal for a period of 4 days or more frequently enables the patient to regain his former responsiveness to this drug. If the side effects of ephedrine prove troublesome, synthetic amines chemically related to ephedrine, such as Racephedrine, ethyl ephedrine (Nethamine), isoephedrine (Pseudoephedrine) and methoxyphenamine (Orthoxine), may be substituted. These preparations produce a similar but less effective bronchodilator response milligram for milligram. Except for isolated instances it is questionable whether or not they offer any real advantages over ephedrine.

The nasal solution of ephedrine is essentially a local vasoconstrictor with decongestant properties and its pharmacologic effects are similar to the vasoconstrictor agents to be discussed below.

*Phenylephrine, Phenylpropanolamine, Naphazoline, and Tetrahydrozoline*—These members of the sympathomimetic group are effective vasoconstrictors whose main usefulness in the treatment of allergy pertains to their topical decongestant action upon the mucous membranes of the upper respiratory tract and the conjunctiva. Although effective in the temporary relief of nasal congestion and ophthalmic symptoms, all of these preparations to a greater or lesser degree result in rebound vasocongestion and should not be continuously used in chronic allergic states of the upper respiratory tract. In this connection naphazoline (Privine) has been reported as perpetuating chronic rhinitis with prolonged use. Another side effect of naphazoline shared by tetrahydrozoline (Tyzine) is the occurrence of sedation particularly in infants and children. In fact excessive dosages may cause severe drowsiness accompanied by profuse sweating. Coma and shock have been reported in young children after overdosage or improper administration of a 0.1 per cent solution of Tyzine. For children under 6 years of age 1 to 3 drops of a 0.05 per cent solution has been recommended at intervals of not less than 4 to 6 hours. Since all of the agents of this group are pressor drugs it has been customary to urge caution when applied to patients with hypertension or hyperthyroidism. In addition to their use as topical vasoconstrictors phenylephrine and phenylpropanolamine have provided moderate relief of bronchospasm and edema of the bronchial mucosa when employed as aerosols in combination with epinephrine or isoproterenol.

clinical experience indicates that side reactions, principally tachycardia, are often more marked than those of epinephrine. Because of its effect of lowering blood pressure and peripheral resistance, its use may be preferred in patients with an associated hypertension, but increased excitability may outweigh these advantages. Sublingual tablets containing 10 mg of isoproterenol, and an inhalant powder are available. However, occasional depression of the T waves on the electrocardiogram has been observed following their use. Clinical effectiveness of these routes of administration has been more erratic than with aerosol inhalation, and the incidence of adverse reactions with adequate doses has been considerably higher, averaging about 30 per cent. These consisted of nervousness, tremor, dizziness, palpitation, precordial pain, nausea and vomiting.

The most effective, as well as the safest method of administration clinically appears to be by aerosol inhalation in doses of 0.1 to 0.5 ml of the 1:200 dilution. With this route of administration only a small percentage of patients experience toxic effects. Pharmacologic activity of isoproterenol develops rapidly, usually within several minutes following inhalation. Clinical experience has indicated that it may continue to exert bronchodilator activity in patients who have become refractory to epinephrine. This compound has recently stimulated intensive research for chemical analogues possessing potent bronchodilator activity with minimal adverse effects. The addition of phenylephrine, as in Nebu Prel (isoproterenol 0.4 per cent, phenylephrine, 2 per cent) ameliorates some of the adverse cardiovascular effects such as the tachycardia and hypotensive reactions.

Among newer congeners of isoproterenol undergoing clinical trial isoprophephrine and protocatechyl alcohol (Caytine) show considerable promise. In common with the parent compound these preparations are potent bronchodilators whose main advantage appears to be their effectiveness by oral administration as well as by inhalation. Onset of relief of asthma takes place approximately 30 minutes after ingestion but incidence of side effects is variable. In general, reactions appear to be less than with sublingual isoproterenol. When used as an aerosol, reactions to Caytine were rare in a large series of cases studied in our clinic. In some patients with moderate asthma the degree of relief afforded by 20 mg of isoprophephrine frequently approached that of parenteral epinephrine, and when this oral preparation was combined with a tranquilizer or a mild sedative the severity of sympathomimetic stimulation was reduced.

**Ephedrine.** Either alone or in combination with theophylline, ephedrine is the most frequently employed oral medication for the relief of allergic symptoms, especially the bronchospasm of asthmatic patients. In the usual dose of 15 to 25 mg administered 2 or 3 times daily, it generally provides effective relief of a mild attack. At this dosage level its administration also appears to have a prophylactic value. The British advocate ephedrine as the preferred antispasmodic for routine use. The dosage employed, however, is much greater than that commonly used in this country, 50 mg at the beginning to 100 mg later on in treatment. Doses as high as 200 to 300 mg were reported by Herxheimer as being well tolerated with a low incidence of side reactions. In our experience, however, doses in excess of 50 mg are accompanied by an increased incidence of side effects including palpitation, excitation, and insomnia. Acute urinary retention is a distressing complication of

orded effective relief of obstructive dyspnea in selected patients. In hay fever, perennial rhinitis and coryza, the anticholinergic drugs inhibit excessive nasal and ocular secretions, thus affording symptomatic relief. In fact, many proprietary "cold remedies" contain atropine or one of the other belladonna alkaloids. These alkaloids as well as antihistaminic agents have, to a major degree, the disadvantage of excessive drying of the mucous membrane of the laryngobronchial tree as well as the nose, on continued use. None is recommended for maintenance therapy for any reason.

**Untoward Reactions.** Adverse side effects of the anticholinergic drugs are on the whole rather unpredictable. For example, the dosage level of atropine required for effective bronchorelaxation may exceed that ordinarily considered safe, the cholinergic congeners mentioned above were accompanied by mild side effects for the most part. These included dryness of the mouth and oropharynx, occasional blurring of vision, dizziness and, in some instances, urinary retention. The anticholinergic drugs are of course contraindicated in the presence of glaucoma. Since these agents have a tendency to depress bronchial secretions, they are not suitable for continued use and should be employed with caution in patients with retained secretions who appear to have difficulty in raising thick, tenacious sputum. The treatment of asthmatic with bronchorrhea may be benefited temporarily by this drying action.

**XANTHINE DERIVATIVES.**—The effectiveness of the xanthines in the treatment of bronchial asthma is based on their ability to relax the smooth muscle of the laryngobronchial tree and reduce edema of the bronchial mucosa. The most active member of this group is theophylline and its various salts. A list of these preparations, together with some of the more common ephedrine combinations, is given in Table 37.

Since the report of Herrmann and Aynesworth in 1937, the administration of aminophylline has become recognized as a valuable procedure for the relief of intractable bronchospasm. Bronchial asthma refractory to epinephrine frequently responds favorably to theophylline and its derivatives. Acute paroxysmal dyspnea associated with cardiac failure responds to theophylline not only because of bronchodilatation, but also because of its potent diuretic action. All preparations of theophylline are to some degree irritating to the gastric mucosa, this side effect makes it difficult to administer the full therapeutic dose orally without the aid of measures designed to decrease gastric intolerance. The effective use of aminophylline in a program of asthma therapy has often been neglected in spite of the well documented evidence concerning its effective bronchodilator activity.

Patients with severe obstructive dyspnea who are refractory to the adrenergic compounds frequently obtain marked relief following the intravenous administration of 0.25 Gm aminophylline in 10 ml of diluent. This injection should be given slowly over a period of 8 minutes and may be repeated in 15 to 30 minutes.

Rapid administration has been accompanied by severe reactions and in some cases death. More prolonged bronchial relaxation in patients with severe dyspnea can be accomplished by the infusion of 200 to 500 ml of 5 per cent dextrose in distilled water containing 0.5 Gm aminophylline. The first 100 ml should be administered rapidly so as to obtain a high initial blood level and the remainder

**ANTICHOLINERGIC AGENTS**—Since one of the mechanisms postulated to mediate the smooth muscle spasm of bronchial asthma is the release of acetylcholine produced by stimulation of the parasympathetic nervous system, blockade of these bronchoconstrictor stimuli by anticholinergic agents would appear to offer a pharmacologic approach to the effective relief of this type of bronchospastic state. In theory, atropine and its congeners should be effective not only because of its bronchodilating action but also because it suppresses excessive secretions from the bronchial glands. A list of the more common members of this group is illustrated in Table 36.

Table 36 *Anticholinergic Agents Used in Allergic Disease*

Generic Name	Trade Name	Route of Administration	Usual Adult Dose
Atropine		Oral	0.4-0.6 mg
		Subcutaneous	0.4-0.6 mg
		Aerosol (0.5%)	0.2-0.5 ml
Scopolamine (Hyoscine)		Oral	0.5 mg
		Parenteral	0.5 mg
Methantheline	Banthine	Oral	50 mg
		Parenteral	50 mg
Epoxytropine tropate methylbromide	Pamine	Oral	2.5 mg
Oxyphenonium	Antrenyl	Oral	5 mg
		Aerosol (0.05%)	1 ml
		Intravenous	1 mg
Diphemanil	Prantal	Oral	100 mg
		Parenteral	35-50 mg

Among the earlier symptomatic remedies for the treatment of asthma has been the inhalation of smoke from the burning of stramonium in the form of various powders and 'asthma' cigarettes. Occasional individuals were benefited and relief when it did occur was due largely to coughing and expectoration of retained secretions. This form of therapy has been generally abandoned. Of the naturally occurring belladonna alkaloids, atropine, while it produces relaxation of the smooth muscles of bronchi and bronchioles, is a considerably less potent bronchial anti-spasmodic in the conventional dosage recommended than drugs of the adrenergic group. In general, the clinical results obtained with these anticholinergics in acute episodes of asthma have been erratic and disappointing. Their chief usefulness has been limited to combinations with drugs of the adrenergic or xanthine groups to help diminish the frequency and severity of attacks. Aerosol preparations of this type include Dylephrin and Aerolone Compound.

Clinical reports have attested to the value of several synthetic anticholinergic preparations in the treatment of bronchospasm. Methantheline (Banthine) in doses of 50 mg increases in vital capacity and produces symptomatic improvement of asthma. It has been reported with aerosols of epoxytropine tropate (Pamine) and oxyphenonium (Antrenyl). In our clinic, 35 to 50 mg of diphemanil (Prantal) intramuscularly

**Untoward Effects** The most troublesome side effect of oral aminophylline is the high incidence of gastric intolerance, nausea and vomiting often limits the administration of effective therapeutic amounts of this drug. Enteric coated aminophylline although materially reducing the incidence of these side reactions results in impaired absorption with blood levels about 10 per cent of those required for bronchodilatation. It is therefore useless. In attempting to mitigate gastrointestinal intolerance to oral aminophylline and not interfere with absorption it has been combined with various anti-nausea preparations. For example, Aminodrox contains aluminum hydroxide gel, in Cardalyn and the Dainite tablets aminophylline is combined with 160 mg of aluminum hydroxide and 30 mg of ethyl aminobenzoate. Patients are able to tolerate 300 mg of aminophylline in these combinations with relatively few side effects. These anti-nausea factors do not impair absorption since blood levels of theophylline following oral ingestion of 300 and 600 mg of Cardalyn were almost as good as those obtained after the intravenous or rectal administration of comparable doses of aminophylline.

A 20 per cent alcoholic solution of theophylline (Elixophyllin) has been studied in our clinic. With an average dose of 45 ml in the mid-afternoon and 60 ml on retiring approximately 85 per cent of 149 patients obtained moderate to excellent relief of obstructive dyspnea and wheezing. In general side reactions were mild and only 3 patients found them severe enough to warrant discontinuance of medication. Ventilatory function studies following a single dose of 60 ml of Elixophyllin equivalent to 400 mg of aminophylline showed significant increases in vital capacity and midexpiratory flow rates. The efficacy of this preparation in the relief of bronchospasm may be attributed to (1) more rapid absorption of theophylline, possibly because of its facilitation by the alcohol and of the fact that a liquid preparation is more readily available than a compressed tablet for absorption from the upper gastrointestinal tract and (2) the relaxing effect of alcohol itself in the tense anxious patient.

In an effort to augment therapeutic effectiveness by permitting higher dose levels orally, several new salts of theophylline have been made which are reported to cause less gastric irritation and a more rapid rate of absorption than aminophylline. Among the preparations available for clinical use are choline theophyllinate (Choledyl) theophylline methylglucamine, and theophylline sodium glycinate. The clinical value of these newer salts above that of aminophylline combined with anti-nausea factors has not been demonstrated satisfactorily. In fact the present coating on Choledyl although it removes the odor delays absorption.

The long term daily use of aminophylline prophylactically may in some instances result in a cumulative effect with an increase in adverse side reactions as well as the development of refractoriness. This can be prevented by a program of intermittent therapy in which ephedrine is substituted for aminophylline for periods of a week or more. A number of reports have stressed the dangers of aminophylline therapy in children. In addition to severe side reactions including acidosis, delirium, hyperpyrexia, convulsions and coma, a number of deaths have occurred in children under 4 years of age who were given rectal suppositories containing 0.25 Gm or more of aminophylline. In this connection it must be

## ANTIALLERGIC AGENTS

Table 37 Salts of Theophylline and the More Common *L*-Ephedrine Employed in Bronchial Asthma

Generic Name	Trade Name	Route of Administration
Theophylline	Elixophyllin	Oral
Aminophylline		Oral Intravenous Intramuscular Rectal
Theophylline Monoethylamine	Theamin, Glysmathane	Rectal
Choline Theophyllinate	Cholexyl	Oral
Theophylline Methylglucamine	Glucophylline	Oral Parenteral Rectal
Theophylline Sodium Glycinate	Glytheonate	Oral Rectal
	Theoglycinate	Oral Rectal
Ephedrine combinations with varying salts of Theophylline	Amasec Cholarate Daminite Luamin Nephenalin Quadrinal Tedral	Oral Oral Oral Oral Oral Oral Oral

infused over a period of 1 to 2 hours. This may be repeated 3 successive days in order to terminate a severe attack.

The rectal instillation of 0.6 Gm dissolved in 30 ml produces effective relief without the danger of serious cardiovascular reaction; this method has the advantage of offering the parenteral administration which can be performed by a member of the medical staff with a F catheter and 30 ml syringe. A disposable plastic unit is available.

The use of aminophylline has produced variable results. Thus in the spastic states probably results from variations in absorption. The administration of aminophylline is exceedingly irritating and painful which is only partially mitigated by the addition of 1 to 2 ml of 1% procaine to the injection.

For prophylactic therapy and the relief of mild to moderate bronchospasm, administration of aminophylline by mouth on a regular schedule is a valuable method of producing relaxation of the bronchial



**Untoward Effects** The most troublesome side effect of oral aminophylline is the high incidence of gastric intolerance, nausea and vomiting often limits the administration of effective therapeutic amounts of this drug. Enteric coated aminophylline, although materially reducing the incidence of these side reactions, results in impaired absorption, with blood levels about 10 per cent of those required for bronchodilatation. It is therefore useless. In attempting to mitigate gastrointestinal intolerance to oral aminophylline and not interfere with absorption, it has been combined with various antiemetic preparations. For example, Aminodrox contains aluminum hydroxide gel, in Cardalin and the Dainite tablets, aminophylline is combined with 160 mg of aluminum hydroxide and 30 mg of ethylmagnesium benzoate. Patients are able to tolerate 300 mg of aminophylline in these combinations with relatively few side effects. These antiemetic factors do not impair absorption since blood levels of theophylline following oral ingestion of 300 and 600 mg of Cardalin were almost as good as those obtained after the intravenous or rectal administration of comparable doses of aminophylline.

A 20 per cent alcoholic solution of theophylline (Elixophyllin) has been used in our clinic. With an average dose of 45 ml in the midafternoon and 45 ml on retiring approximately 85 per cent of 149 patients obtained moderate to excellent relief of obstructive dyspnea and wheezing. In general side reactions were mild and only 3 patients found them severe enough to warrant discontinuance of medication. Ventilatory function studies following a single dose of 60 ml Elixophyllin, equivalent to 400 mg of aminophylline, showed significant increases in vital capacity and minute expiratory flow rates. The efficacy of this preparation in the relief of bronchospasm may be attributed to (1) more rapid absorption of theophylline, possibly because of its facilitation by the alcohol and the fact that a liquid preparation is more readily available than a compressed tablet for absorption from the upper gastrointestinal tract and (2) the relaxing effect of alcohol itself in the tense anxious patient.

In an effort to augment therapeutic effectiveness by permitting higher doses orally, several new salts of theophylline have been made which are reported to cause less gastric irritation and a more rapid rate of absorption than aminophylline. Among the preparations available for clinical use are choline theophyllinate (Choledyl), theophylline methylglucamine, and theophylline sodium glycinate. The clinical value of these newer salts above that of aminophylline combined with antiemetic factors has not been demonstrated satisfactorily. In fact the present experience with Choledyl, although it removes the odor, delays absorption.

The long term daily use of aminophylline prophylactically may in some instances result in a cumulative effect with an increase in adverse side reactions as well as the development of refractoriness. This can be prevented by a program of intermittent therapy in which ephedrine is substituted for aminophylline for periods of a week or more. A number of reports have stressed the dangers of aminophylline therapy in children. In addition to severe side reactions including convulsions, delirium, hyperpyrexia, convulsions, and coma, a number of deaths have occurred in children under 4 years of age who were given rectal suppositories containing 0.25 Gm or more of aminophylline. In this connection it must be emphasized that the usual dose of aminophylline in children should not exceed

1 mg per pound of body weight and should not be given more often than twice in a 24 hour period. In children under 4 years of age, special precautions should be observed regarding hydration and the avoidance of acidosis.

Although descriptions of mixtures and combinations of drugs have been avoided in this chapter for the most part, it should be emphasized that many of the more popular remedies for the treatment of asthma contain ephedrine in combination with various salts of theophylline. The major usefulness of these oral preparations consist in their ability to control minor attacks of asthma and to lessen the frequency of such attacks. There are a number of reports which would indicate that the addition of ephedrine to theophylline potentiates bronchodilator activity with a corresponding increase in toxicity however. The administration of aminophylline by aerosol or powder insufflation is clinically ineffective and may intensify bronchospasm due to local irritation.

**Facilitation of Bronchial Drainage**—In addition to bronchospasm retention of bronchial secretion is frequently operative in the production and maintenance of partial bronchial obstruction. An excessive production of mucus often occurs as a result of an allergic response to inhaled allergens or unknown factors. The presence of these retained secretions provokes paroxysms of coughing and accentuates spasm of the tracheobronchial tree. Certain physiologic mechanisms for the removal of these secretions such as the ciliary action of the lining epithelium are frequently impaired. The consequences of bronchial obstruction by retained secretions are as warrant every effort both pharmacologic and mechanical to facilitate bronchial drainage. The following section deals with pharmacologic therapy as expectorants and aerosols which aid the elimination of retained secretions from the tracheobronchial passageways. Tuft and Levin describe two mechanisms of (1) secretolysis—liquefaction of the bronchial secretions, thereby making them more fluid and less viscid and (2) excretomotor—stimulation of the muscle of the bronchi to increase peristaltoid activity. Liquefaction is about by the actual secretion or excretion of secretions. The oral preparation clearing the upper bronchial passages of secretions. The oral preparation known as "expectorants" which serve to increase the respiratory tract fluid in the form of Robitussin appears to be at times a moderately effective agent in asthmatic children. The two preparations which have been used to help liquefy sputum or mucopurulent material. They have been classified as humectant, and mucolytic. This is particularly true in those cases of chronic respiratory disease. This is particularly true in those cases

of the country where colder weather means spending the major portion of day in an artificially heated room. A combination of excessive dryness and dust has accumulated about steam radiators or in hot air ducts appears at times to perpetuate symptoms of obstructive dyspnea in patients with asthma. The steam kettle was a relatively ineffective method of attempting to correct the low humidity.




Fig. 24—Adequate humidification is provided by a superheated nebulizer which delivers approximately 3.5 ml. per minute of aerosol mist thermostatically controlled to maintain a temperature of 120 to 125° F.

The inhalation of a mist produced by the nebulization of normal saline solution may be helpful. 2 to 10 ml. is nebulized by the mouth rebreathing bag technique or into a plastic face tent by means of a small pump or oxygen at a flow rate of 4 liters per minute 4 times daily. The Vaponefrin or DeVilbiss #40 nebulizer provides a small particle size mist ranging between 2 to 3 microns in mean diameter. Within the past 2 years a more efficient method has been employed in our clinic which provides for the inhalation of a saline or 10 per cent glycol aerosol heated to 120 to 125° F. This is accomplished by means of a thermostatically controlled high flow nebulizer, illustrated in Fig. 24, capable of nebulizing 3.5 ml. of solution per minute. The wide range of particle size results in deposition along the entire tracheobronchial tree. In addition, considerable water vapor occurs when the heated aerosol comes in contact with the relatively cooler mucous membranes of the respiratory tract. Clinical studies have demonstrated increased ease in the expectoration of inspissated plugs of mucus and retained secretions from the lower respiratory tract as demonstrated by microscopic studies of the recovered material. The rationale for the use of detergent or 'wetting' agents is based on their

3 mg per pound of body weight, and should not be given more often than twice in a 24 hour period. In children under 4 years of age, special precautions should be observed regarding hydration and the avoidance of acidosis.

Although descriptions of mixtures and combinations of drugs have been avoided in this chapter for the most part, it should be emphasized that many of the more popular remedies for the treatment of asthma contain ephedrine in combination with various salts of theophylline. The major usefulness of these oral preparations consist in their ability to control minor attacks of asthma and to lessen the frequency of such attacks. There are a number of reports which would indicate that the addition of ephedrine to theophylline potentiates bronchodilator activity with a corresponding increase in toxicity, however. The administration of aminophylline by aerosol or powder insufflation is clinically ineffective and may intensify bronchospasm due to local irritation.

**Facilitation of Bronchial Drainage**—In addition to bronchospasm retention of bronchial secretion is frequently operative in the production and maintenance of partial bronchial obstruction. An excessive production of mucus often occurs as a result of an allergic response to inhaled allergens, irritation of an edematous bronchial mucosa, chronic bronchial infection, or unknown factors. The presence of these retained secretions provokes paroxysms of coughing and accentuates spasm of the tracheobronchial tree. Certain physiologic mechanisms for the removal of these secretions, such as the ciliary action of the lining epithelium are frequently impaired. The consequences of bronchial obstruction by retained secretions are so serious as to warrant every effort, both pharmacologic and mechanical, to facilitate bronchial drainage. The following section deals with pharmacologic therapy, such as expectorants and aerosols which aid the elimination of retained secretions.

**EXPECTORANTS**—These drugs assist in the removal of mucus or exudate from the tracheobronchial passageways. Tuft and Levin describe two mechanisms of action: (1) secretolysis—liquefaction of the bronchial secretions, thereby making the sputum more fluid and less viscid, and (2) excretomotor—stimulation of the smooth muscle of the bronchi to increase peristaltoid activity. Liquefaction is brought about by the actual secretion or excretion of the expectorant agent into the bronchial secretions with a lowering of the viscosity so that it becomes less tenacious. The cough mechanism may be more effective after the use of expectorants in clearing the upper bronchial passages of secretions. The oral preparations known as "expectorants," which serve to increase the respiratory tract fluid and render the bronchial secretions less viscid, have been described in detail in Chapter 28, *The Choice of Antitussive Agents*. The two preparations which have proved most effective in the treatment of bronchial asthma are the iodides (inorganic salts and organic compounds), and syrup of ipecac. In addition, glyceryl guaiacolate, in the form of Robitussin, appears to be at times a moderately effective "expectorant" agent in asthmatic children.

**AEROSOL THERAPY**—Three types of aerosols have been used to help liquefy tenacious mucoid or mucopurulent material. They have been classified as humidifying, detergent, and mucolytic.

Humidification has been considered helpful in the treatment of certain patients with acute and chronic respiratory disease. This is particularly true in those sec-

ether anesthesia is occasionally lifesaving in status asthma where air flow is slightly impeded by retained secretions. The indication for this measure is far common in our experience as a result of the use of steroids, and mechanically induced cough.

**Inhibition of Histamine Activity**—The theoretical rationale for the use of histamine antagonists, or 'blocking agents,' in modifying or preventing allergic manifestations has been discussed in the previous section. Their chief action involves competition with released histamine or 'H substance' at its site of action, preventing its effect on the receptor cells. Since the demonstration by Bovet and Vassant in 1937 that certain phenolic ethers possess antihistaminic activity, literally hundreds of drugs of this group have been synthesized. To add to the confusion, a plethora of drugs introduced into clinical practice in the past decade has yielded no points of discrimination between them either in terms of effectiveness or degree of toxicity. 'Perhaps in no other class of therapeutic agents does the physician have a wider choice of preparations, but in no other group of drugs does a single drug offer less reward.'

As with many other palliative pharmacologic agents, the clinical evaluation of antihistamine therapy depends on the therapeutic benefit derived as opposed to adverse side reactions. The antihistamine of choice, therefore, would be one which is most effective with the fewest side reactions. Since this may vary for each individual, many physicians have resorted to the empiric use of a number of antihistaminic drugs for each patient in order to select the most effective one. It should be emphasized that recourse to several different drugs of this class at varying dosage levels should be made before concluding that antihistamines are ineffective in any given individual.

Since the organic structure and pharmacologic activity of the antihistamines are similar, there has been little attempt to classify these agents other than to outline individual preparations which may depart somewhat from the pattern of the group. Brown has divided the antihistamines into 3 main groups based on their toxic side reactions.

**Group I**—These are least potent and least reactive. Antistine, Neohetramine, Thephorin.

**Group II**—These are moderately potent and moderately reactive. Pyribenzamine, Chlor Trimeton, Trimeton, Diatrine, Perazil, Histadyl, Neo Antergan, Tagathen, Ambodryl and Clistin.

**Group III**—These are highly potent but also highly sedative. Benadryl, Decapryn and Phenergan.

The antihistamines have found wide usage in the symptomatic therapy of a variety of allergic states. Although varying degrees of clinical benefit are evident in conditions such as hay fever, perennial vasomotor rhinitis, urticaria, serum sickness and perhaps anaphylactic like states, these agents have been disappointing in the treatment of bronchial asthma. Best results are achieved in patients with allergic hay fever, or urticaria. In hay fever, relief is often more apparent in the edematous phase when itching, sneezing and rhinorrhea are pronounced. However, when nasal obstruction becomes more prominent, the antihistamines

ability to lower viscosity of sputum. Numerous investigators have pointed out that the local deposition of wetting agents will reduce surface tension and loosen retained mucus secretions from the mucosa by their emulsifying action. Agents such as alcohol, glycerin, and Zephiran chloride have been used by aerosol as vehicles for antibacterial or antispasmodic drugs for some time. Following the enthusiastic report by Miller and his associates on the use of a nontoxic detergent, superinone, in the aerosol preparation Alevaire, an extensive and controversial literature has accumulated. Preliminary studies with Alevaire aerosol in our clinic showed that this material was at times irritating to the respiratory tract, and other investigators have remarked on the irritant nature of Alevaire, suggesting that the alkaline pH in excess of 8.5 was responsible.

Levine reported a study on 96 patients with bronchopulmonary disease complicated by bronchospasm or bronchial obstruction, many of whom were apparently benefited by a new detergent aerosol which contains potassium iodide as a mucolytic chemical. This aerosol, Tergemist, has the following composition: 0.125 per cent of the detergent Tergitol 08 and 0.1 per cent potassium iodide in sterile water. The total daily dose ranged between 12 and 25 ml administered in four 30 minute periods of inhalation. No irritation or toxicity was noted.

However, there are no convincing well controlled studies which adequately confirm the value of these detergents. In our studies detergents did not enhance the absorption of penicillin aerosol as might have been expected if surface tension of retained secretions were lowered. The therapeutic efficacy reported may depend wholly or in part on other measures, i.e., the addition of bronchodilator and antibiotic agents administered in conjunction with these aerosols, and the obvious benefit of humidification accompanying such aerosol therapy.

Following the initial optimistic reports concerning the effectiveness of mucolytic or proteolytic enzymes such as trypsin and pancreatic desoxyribonuclease in digesting and thinning out the bronchial secretions in chronic pulmonary disease, recent studies have more clearly defined the indications for the use of enzyme therapy and stressed the hazards of such therapy. It has become evident that little or no benefit is obtained in bronchial asthma; the liquefaction of sputum with facilitation of bronchial drainage in this allergic disease is at best only temporary. Our experiences with Tryptar (crystalline trypsin) and pancreatic dornase (pancreatic desoxyribonuclease) have not been encouraging. Using the recommended dose of 125,000 units of Tryptar dissolved in 3 ml of Sorenson's buffer twice daily, irritation with pharyngitis and glossitis became apparent in a considerable number of patients by the third or fourth day of treatment, with bronchospasm precipitated by the aerosol itself. Less irritation took place after the inhalation of *pancreatic dornase*, but the degree of benefit we observed was not worth the trouble. In addition to local irritative phenomena, marked allergic reactions may occur since enzymes derived from nonhuman sources are capable of exciting antibody production in hypersensitive individuals. Considerable speculation has arisen concerning the late toxic effects of these enzymes on the epithelium of the bronchial mucosa, described by Farber as atypical metaplasia.

While it is not the purpose of this chapter to discuss physical or mechanical measures for aiding bronchial drainage, the use of bronchoscopic aspiration under

Benadryl and Phenergan, may offer a special advantage, particularly in the short term therapy of severe pruritus and "night cough" where the antihistaminic effect is augmented by much needed sedation

Table 38 Selected Antihistaminic Agents Employed in the Treatment of Allergic Diseases

Trade Name	Remarks	Usual Adult Dose
Antistine	Therapeutic action weaker than most of the other antihistamines, less irritating, 20% of patients exhibit side reactions such as nausea and drowsiness	100 mg qid (Nasal 0.5% Soln)
Benadryl	Has moderate antispasmodic action, produces high incidence of sedation	50 mg tid (Parenteral 10 mg)
Chlor Trimeton	Good therapeutic efficacy with low incidence of side effects	2-4 mg qid (Parenteral 5-20 mg)
Clistin	Potent with low incidence of side effects, exhibits weak atropine like, anticholinergic activity	4 mg tid
Decapryn	" " " " " "	12.5 mg tid
Diatrine	" " " " " "	50 mg qid
Dimetane	" " " " " "	2-4 mg tid
Histadyl	reactions Incidence of sedation low	50-100 mg tid or qid
Neo Antergan	Incidence of sedation, low	25-50 mg tid
Neohetramine	Requires larger dosages but side effects are less sedation less frequent	50-100 mg qid
Perazil	Prolonged action and low incidence of toxic effects	50 mg bid
Phenergan	Longer duration of action, usefulness in asthma limited useful for motion sickness depresses central nervous system	25 mg bid or tid
Plimasin	Pyribenzamine 25 mg and Ritalin 5 mg	1 tab tid or qid
Polaramine	The dextrorotatory salt preparation of Chlor Trimeton	2 mg tid or qid
Pyribenzamine	Citrate more palatable in liquid than the hydrochloride (in which form it also comes), sedation moderate gastrointestinal irritation common but slight	50 mg tid or qid
Pyrrolazote	Similar to Phenergan agranulocytosis has been reported after excessive dosage	25-50 mg tid
Tagathen		25 mg tid or qid
Theruhistin	Anticholinergic and antiserotonin activity effective with minimal sedation unlike the other antihistamines appears to be more effective in bronchial asthma	2-4 mg tid
Trimeton		25 mg tid

**Sedation**—Many patients with severe bronchial asthma are restless and apprehensive. Lack of sleep and inadequate nutrition initiate a vicious cycle in which labored respiration and dehydration combine to accentuate retention of secretions and bronchospasm, and thereby increase obstruction to air flow. In other allergic diseases accompanied by severe pruritus, restlessness and insomnia frequently accentuate the allergic manifestations. In the already debilitated patient this cycle of events results in serious deterioration. Although there is a manifest hazard in the use of narcotic drugs, some form of mild sedation is often desirable in the tense patient who finds it difficult to obtain adequate rest. In this connection, obviously, there is no substitute for the ministrations of a calm, confident physician, the reassuring presence of a cheerful nurse, and a relaxing environment.

provide little or no benefit and, in fact, the drying action of these drugs may increase the discomfort. These agents are rarely indicated as maintenance therapy for perennial vasomotor rhinitis. They are more effective in acute than chronic urticaria and occasionally in certain allergic dermatoses, primarily due to their antipruritic and local anesthetic effects.

Although the response of angioedema is less impressive, the duration and extent of the edematous areas may be reduced. While antihistamines are of some benefit in serum sickness and of questionable value in anaphylactoid reactions, ephedrine, as previously mentioned, remains the drug of choice for these states. Although in agreement with the general consensus that asthma is not helped by antihistamines and may in fact be aggravated, Peshkin believes that appropriate doses of these drugs are helpful in asthmatic infants who have no evidence of respiratory infection. Allergic cough in children may also be improved, but the hazards of such therapy have been discussed in Chapter 28, The Choice of Antitussive Agents. The antihistaminic agents have been employed in a number of miscellaneous allergic conditions with varying degrees of success. Prophylactically they have been used in conjunction with blood transfusions and in hypersensitization procedures. However, present opinion has veered to the view that a striking reduction in allergic reactions does not take place. In certain instances reactions are delayed which may induce a false sense of security on the part of the physician. Ophthalmic preparations may provide some relief from the pruritic symptoms of allergic conjunctivitis but are less effective than the local vasoconstrictors and steroids. No beneficial effects have been obtained in the collagen group of diseases. In common with the other symptomatic pharmacologic measures, the histamine antagonists suppress certain allergic manifestations but do not affect the underlying course of the disease.

**UNTOWARD EFFECTS**—All the drugs of the antihistamine group produce undesirable side reactions, the incidence and severity varying for each of the drugs, the dosage levels, and the individual response. The most common side effect is excessive sedation, inability to concentrate, dizziness, and disturbed coordination are related to this action. Frequently this sedative effect begins to wane after 3 or 4 days, indicating the development of tolerance. The combined use of amphetamine or an amphetamine like substance such as Ritalin may neutralize some of the sedative effect. In occasional individuals the major untoward effect is that of agitation or excitation with insomnia, tremors, nervousness, and even convulsions. Other adverse reactions include lassitude, muscular weakness, gastrointestinal disturbances, and urinary retention. Dryness of the oropharynx is common. Of more serious significance is the drying of the mucous membrane of the bronchi which at times results in intractable coughing, generally unrecognized as a consequence of antihistamines. The advantage of local application for the relief of pruritus may be outweighed by the occurrence of local sensitization to the antihistamine.

A list of some of the more common antihistamines employed in clinical practice is shown in Table 38.

Some antihistamines have been incorporated in specialized coatings or matrices in order to prolong or delay their action. The sedative effect of others, such as



upright position Since the dyspnea of intractable bronchial asthma is a constant, chronic burden to the patient, the possibility of *meperidine* addiction, when given subcutaneously, is a real hazard In view of this, it is essential that the program be restricted to a period of 4 to 5 days

Mild side effects include dizziness, loss of appetite, constipation, nausea, and occasional emesis Although no instance of serious respiratory depression has been encountered with the above program in over 300 patients in our clinic, the possible occurrence of such an untoward response must be kept in mind in a hypersensitive individual, especially if barbiturates are also administered In the event that respiratory depression should occur, nalorphine (Nalline) has been demonstrated to antagonize effectively the depressant action of meperidine The depressant effect of meperidine has also been counteracted by caffeine and amphetamine

**TRANQUILIZERS**—Clinical reports continue to appear in the literature following the recent introduction of the ataractic or tranquilizing drugs It is as yet too early to properly assess the value of these agents in allergic disease since few long term, well-controlled studies have been performed Carrier states that meprobamate and chlorpromazine have been effective in controlling tension in asthmatic patients "with little depression of the respiratory center" We have found meprobamate at times of value in patients with a hyperventilation syndrome, which is sometimes present in cases of pulmonary emphysema as well as bronchial asthma Individual reports have attested to the efficacy of parenteral chlorpromazine in doses of 25 to 50 mg Hydroxyzine (Atarax) and a new phenothiazine compound trimeprazine (Temaril), have been reported as being effective in the treatment of allergic dermatoses and urticaria In addition to being tranquilizers these preparations appear to have some antihistaminic, antiserotonin and anticholinergic like activity By allaying tension and anxiety, these tranquilizing agents aid in reducing the intensity of allergic symptoms in selected patients They have no direct effect on the allergic state and are perhaps best employed as a temporary aid in allergic management While the major side reactions are drowsiness weakness and somnolence there have been a number of reports of a more serious nature including bone marrow depression with agranulocytosis and hepatitis In our opinion the use of reserpine in allergic disease is contraindicated since allergic rhinitis and obstructive dyspnea are often aggravated In addition the superimposition of acute depression has been noted with this drug in tense anxious patients

**Modification of Tissue Reactivity With Corticotropin and the Corticosteroids**—A decade has passed since Hench and his associates first described the effects of cortisone in patients with rheumatoid arthritis Ample evidence has since accumulated demonstrating that although corticotropin and the adrenocorticosteroids result in remarkable improvement in the clinical manifestations of a wide variety of disease entities, the basic mechanisms involved are as yet unknown Early reports indicated dramatic relief of the symptoms of asthma as well as other allergic diseases such as hay fever, vasomotor rhinitis, and allergic dermatitis in over 80 per cent of the patients treated with these hormones A provocative chapter has been opened by these hormones in the therapy of allergic disease

It has now become evident that (1) they are the most effective agents available today for the symptomatic treatment of a wide variety of allergic conditions

**BARBITURATES**—In the past few decades, the barbiturates have become the most widely prescribed agents for insomnia. Small doses (8 to 30 mg) of these drugs are often incorporated with ephedrine theophylline combinations in order to counteract the excitatory side effects of these bronchodilators. In high dosage or with too frequent administration, particularly in the fatigued dyspneic patient, the barbiturates, like morphine, may depress respiration.

**CHLORAL HYDRATE**—Because of a low incidence of side effects and rarity of allergic reaction in asthmatic patients, chloral hydrate is the drug of choice for mild sedation. It may be given in doses of 0.5 to 1 Gm orally or by rectum at 8 to 12 hour intervals without fear of respiratory depression.

**ETHER**—In special instances where heavier sedation or bronchodilatation is desired in an effort to terminate intractable bronchospasm, 60 to 90 ml of ether dissolved in an equal amount of olive oil has been administered rectally as a retention enema. This normally produces restful sleep with good relaxation for a period of 2 to 4 hours. Certain precautions must be observed in the use of rectal ether: (1) constant surveillance during sleep by a nurse and (2) maintenance of a patent airway by positioning the patient on his side with the head of the bed flat.

**MORPHINE**—There is universal agreement that morphine is contraindicated in asthma, and there have been several documented instances of death due to obstructive asphyxia or irreversible respiratory acidosis. The deleterious effects of morphine include (1) central respiratory depression, (2) augmentation of bronchospasm due to cholinergic activity, (3) inhibition of glandular secretion of the bronchial mucosa, (4) diminution of striated muscle tone including the diaphragm and intercostal muscles, and (5) suppression of the cough reflex. However, with the use of codeine in the range of 15 to 30 mg repeated at 4 to 6 hour intervals, we have encountered only minor side effects such as cough suppression and a "dry mg" action on the bronchial secretions.

**MEPERIDINE**—Prior to the introduction of the corticosteroids, meperidine (Demerol) was frequently employed in selected patients with severe intractable bronchial asthma who had become refractory to other forms of bronchodilator therapy. Its use in proper dosage and under close supervision is still warranted to obtain bronchial relaxation in special instances. Pharmacologically, meperidine is anticholinergic and possesses spasmolytic action on bronchial smooth muscle. The development of progressive lack of response to bronchodilator drugs in severe bronchial asthma presents a serious problem when definite contraindications to the use of steroids also exist. One of the simpler methods of restoring sensitiveness to bronchodilator agents in these refractory patients is accomplished by a program of bed rest and the administration of meperidine for a period of 3 to 5 days. This program consists of the intramuscular administration of meperidine 50 mg every 6 to 8 hours for a period of 4 days. Bronchodilator drugs such as ephedrine, aminophylline, and epinephrine are generally discontinued during this period with the aim of restoring responsiveness to them.

Although less effective, oral meperidine, 50 mg, may at times be substituted for intramuscular administration, but the patient must be cautioned to rest in bed for 2 hours after each dose since vertigo and nausea are more apt to occur in the

**CORTICOTROPIN**—Except for the special instances when a more rapid effect is desirable, as in status asthma, *longer lasting preparations* such as the gel or zinc salts of ACTH are more commonly employed. The usual course in our clinic with the highly purified gel preparation consisted of an *initial dose of 80 mg* given once daily until relief becomes clinically apparent, usually by the second or third day, then gradual reduction in stepwise fashion to 60 mg daily for 2 days, then 40 mg. The average duration of a course has ranged between 6 to 12 days. Although it is claimed that the zinc preparation produces a smoother and more prolonged ACTH effect, a recent report of the Committee on Drugs of the American Academy of Allergy states that corticotropin zinc and Acthar Gel are of approximately equal therapeutic effectiveness. Increased duration of action of the zinc preparation could not be uniformly demonstrated but was considerably easier to administer than the gel. For intravenous use, 20 mg of crystalline corticotropin is dissolved in 1,000 ml of 5 per cent dextrose in distilled water with 40 mEq of potassium chloride added. This is administered slowly over an 8 to 10 hour period for the first day or two then the longer acting preparations are substituted intramuscularly. Since the intensity of adrenal cortical stimulation is a direct function of the maintenance of a high level of circulating ACTH, the effects of 20 mg of corticotropin administered in a slow infusion are comparable to 100 to 150 mg of ACTH given by the intramuscular route. However for the treatment of allergic disease the corticotropins offer few, if any advantages over the steroids. There are two disadvantages, (1) commercially available corticotropin contains foreign protein, and hypersensitive reactions have been reported and (2) it must be given by injection. The major usefulness of ACTH is in the prevention of adrenal insufficiency by stimulating endogenous steroid production at the termination of a course of corticosteroid therapy.

**ADRENOCORTICOSTEROIDS**—Because of less interference with electrolyte balance (sodium retention and potassium excretion) and greater activity, prednisone and prednisolone have to a large extent, replaced the use of oral cortisone and hydrocortisone in the treatment of allergic disease. On a milligram for milligram basis the dosage requirement for prednisone is only one third to one fifth that of the older steroids. We have been unable to detect any significant differences in either dosage requirement, therapeutic effectiveness or toxic manifestations, between prednisone and prednisolone. The major principles which govern proper dosage are the administration of a sufficient amount of steroid over a long enough period of time to suppress the allergic symptoms, and then establishment of the smallest dose of steroid empirically, which will maintain benefit when supplemented by other symptomatic agents.

In severe intractable bronchial asthma the average course in the adult patient is initiated by 60 to 80 mg daily in 4 divided doses after meals and on retiring for the first day or two, followed by a decrease of 10 to 20 mg each 2 or 3 days thereafter depending upon the response of the patient. Each dose of the steroid is routinely administered with milk followed by aluminum hydroxide or calcium carbonate 1 to 2 hours later. At the end of 7 to 10 days, an approximate maintenance dose of 5 to 20 mg daily is instituted which frequently requires temporary revision based on the clinical state of the patient. Increased dosage is generally

(2) the underlying allergic process in all probability is not altered, (3) the pharmacologic activity inevitably results in undesirable side effects, and (4) the more hazardous adverse reactions have given rise to a number of iatrogenic diseases complicating the allergic process. While allergic or inflammatory edema appears to be markedly reduced clinically, *in vitro* studies on sensitized trachea, challenged with histamine or egg albumin showed that contraction was not inhibited by the corticosteroids and is in accord with the observation that these steroids do not prevent experimental anaphylactic shock in animals or interfere with antigen-antibody reactions. The physiologic and pharmacologic activity of corticotropin and the adrenocorticosteroids has been extensively studied and the accumulated literature continues to expand rapidly. For a better understanding of the clinical role these hormones play in the management of allergic disease and for basic pharmacologic review, the reader is referred to the comprehensive reports by Thorn, Ingle, Kinsell and others.

The preparations available at the present time are illustrated in Table 39.

*Table 39 Corticotropin and Corticosteroids Employed in Allergic Disease*

Generic Name	Type of Preparation	Route of Administration
Corticotropin (ACTH)	Crystalline	Intravenous, intramuscular
	Gel	Intramuscular
	Aqueous zinc	Intramuscular
Cortisone	Tablet	Oral
Dexamethasone	Tablet	Oral
Fludrocortisone	Ointment, lotion	Topical
Fluorometholone	Cream	Topical
Hydrocortisone	Tablet	Oral
	Suspension	Intra articular, intramuscular, aerosol
	Aqueous solution	Intravenous, ophthalmic, nasal spray
	Ointment	Topical
Methylprednisolone	Tablet	Oral
Prednisolone	Tablet	Oral
	Aqueous solution	Intravenous, parenteral ophthalmic nasal spray aerosol
	Ointment	Topical
Prednisone	Tablet	Oral
Triamcinolone	Tablet	Oral

The ingenuity of the organic chemist, stimulated by the more widespread use of these preparations in clinical medicine, will no doubt create newer analogues in which therapeutic efficiency (ratio of activity to side reactions) will be enhanced.

Clinical management with these agents must be individualized for each patient since they are nonspecific and the optimum dosage is usually a matter of trial and error based on the clinical acumen of the physician. In general, the amounts required are related more to the severity of the disease process than to body weight or age. The clinical responses of the patient may be highly variable, requiring frequent changes in schedule to establish the maximal therapeutic benefit with minimal adverse reactions; hence patients on steroid therapy should be under close medical supervision. It hardly needs to be emphasized that these agents should be employed only after every effort has been made to establish an etiologic diagnosis and to carry out a well conceived program of allergic pharmacologic and physiologic management.

although more extensive clinical trials are necessary before the value of this route of administration can be assessed

Triamcinolone (Aristocort) is a potent corticosteroid with an antiallergic activity slightly greater than that of prednisone. In the maintenance therapy of patients previously on prednisone, approximately 20 per cent less was necessary to maintain remission when triamcinolone was substituted. In contrast to their experience with prednisone, many of these patients reported a decrease in appetite, and a tendency to weight loss. This weight loss may be due in part to appetite suppression, variations in water balance since it enhances sodium and potassium excretion and increased protein catabolism. In a number of patients on long term maintenance, a peculiar syndrome consisting of headache, weakness, dizziness, and somnolence has been noted. In general this drug produces most of the side effects observed with the other steroids.

Methylprednisolone (Medrol) is also highly effective in the treatment of allergic manifestations. Feinberg and his associates have recently reported that the dose in asthma was comparable to or somewhat smaller than that of prednisone. Like triamcinolone, "methylprednisolone did not show the tendency to cause weight gain as experienced with prednisolone. Part of this was due undoubtedly to the lesser appetite stimulating properties of methylprednisolone." While it has been reported that a more favorable therapeutic ratio of potency to side effects exists with this steroid, adverse reactions in our series have been comparable to those of prednisone.

Dexamethasone (Decadion, Deronil) is a new synthetic corticosteroid with an antiallergic potency reported to be 4 to 6 times as great as prednisone and 25 times that of hydrocortisone on a weight basis. Preliminary studies indicate that at conventional dosage levels this preparation, like prednisone, does not cause excessive salt or water retention or potassium depletion. In our studies it has been appetite stimulating. It is as yet too early to estimate the incidence of side effects peculiar to steroid therapy until additional experience has accumulated on long-term administration.

Fludrocortisone (fluorohydrocortisone) applied to the skin in the form of lotions and ointments has been effective in controlling the manifestations of allergic dermatoses including atopic eczema, contact dermatitis, and neurodermatitis. In this respect it is approximately 10 times as effective as hydrocortisone.

Corticotropin and the corticosteroids are generally not effective for acute anaphylactic type reactions which occur within a few minutes in highly sensitive individuals. Here, as already mentioned, epinephrine, subcutaneous or intravenous, is the drug of choice. With delayed reactions accompanied by severe bronchospasm or angioedema, maximal benefit may be obtained with simultaneous administration of intravenous corticosteroid and epinephrine.

[There has not been sufficient experience with fluorometholone (Oxylone) for substantial evaluation. Ed.]

**Untoward Effects** The hazardous nature of the side effects encountered with these hormones makes close cooperation between the patient and his physician imperative. Since the clinical effectiveness of these hormones requires dosages in ex-

required at times of increased stress such as infection, accidents, surgery, and emotional crises. During surgery, for example, it may be necessary to provide an infusion containing 100 mg of hydrocortisone or 50 mg of prednisolone 21 phosphate (Hydeltrasol) which could be repeated 2 or 3 times daily for a period of 2 to 3 days.

The duration of a course of steroid therapy must be as highly individualized as the dosage schedule. Short intensive courses of prednisone have been found exceedingly useful in tiding the seriously ill patient over an acute episode of bronchospasm or severe serum sickness which is refractory to other forms of therapy. In fact, these hormones are the drugs of choice where severe status asthma has been initiated either by an infection or as the result of exposure to increased concentrations of inhalant allergens such as dust or pollens because they will usually control the situation with no necessity for prolonged therapy once the emergency is past.

Patients with chronic intractable asthma and the bronchospastic type of pulmonary emphysema unresponsive to conventional forms of treatment must be considered for prolonged maintenance therapy. Burrage and his co-workers believe that there is no definite contraindication to steroids and that patients with known duodenal ulcer, osteoporosis or old tuberculosis may have to assume a calculated risk if failure to control asthma is an even greater risk to life. Furthermore, maintenance therapy has enabled many of these patients to return to partial or full activity. Marked improvement in morale accompanies their "escape" from social and economic invalidism. It is desirable that even these patients be regularly "weaned" from the steroids since changes in the allergic state and occasional spontaneous remissions occur during the course of their illness. During the tapering off process it may be desirable to administer 60 mg of corticotropin gel daily for one week.

There is suggestive clinical evidence that a state of relative adrenal insufficiency may persist for long intervals following withdrawal of hormone therapy. This has been illustrated by shocklike states induced by stress such as surgery. The reinstitution of steroid therapy before contemplating surgery and maintenance for an adequate period usually ranging between 4 to 7 days has been employed prophylactically in these instances.

Topical preparations consisting of aqueous solutions or suspensions of hydrocortisone and prednisolone have been used as ophthalmic drops or nasal sprays for the treatment of allergic conjunctivitis and vasomotor rhinitis. These steroid preparations are frequently combined with vasoconstrictors, antibiotics, and antihistamines. Such mixtures have become increasingly popular although few data are available concerning the relative effectiveness of the steroid in these combinations. A number of recent reports discuss the use of aerosolized steroids in the treatment of bronchial asthma and the insufflation of powder preparations for both seasonal rhinitis and asthma. In general, a daily dose of 15 mg of hydrocortisone appeared to be beneficial in hay fever when applied intranasally. Approximately 75 mg of prednisolone daily in divided doses as an aerosol had the equivalent therapeutic effect of 40 mg of hydrocortisone orally. No side effects were reported. The usefulness of these steroid aerosols may be in prolonged maintenance therapy.

element of bacterial infection is considered to be a primary factor. Twelve of the 84 cases reported were demonstrated to have hypogammaglobulinemia prior to treatment. From the data thus far accumulated it would appear that the optimum dose is in excess of 0.3 ml per kilogram of body weight administered intramuscularly every 2 to 4 weeks. Except for instances in which infection and hypogammaglobulinemia play a role its use at the present time would appear to be unwarranted. A longer period of observation is required before any conclusions can be drawn as to the effectiveness of such therapy in asthma uncomplicated by hypogammaglobulinemia.

**Less Well Defined Therapeutic Objectives**—Both nitrogen mustard and artificial fever therapy produced by the intravenous administration of typhoid vaccine or Piromen (polysaccharides derived from *Pseudomonas aeruginosa*) have induced remissions in states of intractable bronchospasm refractory to the conventional bronchodilator agents. The mechanism of action has been attributed to a stimulation of endogenous adrenocorticosteroid secretion. Prednisone has largely supplanted these procedures in the seriously ill refractory patient. Kirk's typhoid vaccine is still occasionally employed in our clinic in selected patients who have shown excellent clinical remissions following a course of fever therapy. The usual course consists of 3 intravenous injections of this vaccine administered every other day or at weekly intervals. The first dose contains 2.5 to 5 million organisms (0.025 to 0.05 ml), and, depending upon the febrile response this dose is doubled with each succeeding injection. Knight prefers subcutaneous or intramuscular Piromen; however, we have not been unimpressed with the efficacy of these routes of administration.

The mode of action of Fowler's solution (potassium arsenite) is obscure, but various observers over a period of many years have noted beneficial effects of small doses in patients with intractable bronchospasm. A dose of 0.2 ml administered 3 times daily for a period of 7 days is followed by 0.1 ml, 3 times daily for an additional 7 days. The hazards of arsenical therapy, particularly by the Gay method have been emphasized by Hansen Pruss and Carryer who caution against the dangers of heavy metal toxicity.

Calcium salts are well known agents for the relief of allergic manifestation but their efficacy has never been clearly established. Since many of the symptoms of allergy are based on pathophysiologic changes involving capillary permeability a number of investigators have questioned the possibility of a calcium deficiency mediating these changes. Epstein and Sevag found that the potassium content of the bronchial secretions in patients with asthma was significantly higher than in patients with chronic pulmonary disease of nonallergic origin. They postulated that the potassium loss was due to injury and increased permeability of the cell membrane and that this was corrected by the administration of 3 Gm daily of calcium and potassium glutamate (Capomate). There is no evidence that the salts of calcium affect the mechanisms of allergy and additional well controlled clinical trials are necessary before any conclusions can be drawn as to their clinical benefit.

Although they are not pharmacologic agents a complete discussion of the management of allergic disease requires brief mention of psycho- and climato-

a 'Cushingoid' state usually is present. The incidence of these reactions appears to bear a direct relationship to the quantity of steroid administered and the duration of therapy. Mild side effects such as rounding or 'mooning' of the facies, abnormal fat distribution about the pelvis, abdomen, and shoulder girdle, hirsutism, acne, and facial rubor are usual but of only moderate concern. Of the more serious side reactions, salt and water retention with potassium depletion encountered with the older steroids has been largely eliminated with the introduction of prednisone.

A list of other serious side reactions which have been encountered include (1) alteration in mental state ranging from irritability to frank psychoses, (2) masking or acceleration of infection which accounts at times for the lack of response to steroid therapy, (3) reactivation of pulmonary tuberculosis, (4) gastrointestinal disturbances ranging from dyspepsia and flatulence to serious and even fatal gastrointestinal hemorrhage or perforation of a peptic ulcer, (5) osteoporosis resulting in pathologic fractures, (6) thromboembolic phenomena, (7) aggravation of pre-existing hypertension or diabetes and (8), more infrequently, impotence.

None of these adverse reactions constitute absolute contraindications to steroid therapy, and ancillary measures are often available to either prevent or lessen the hazards of their occurrence. For example, milk, antacids, and occasionally anticholinergic agents aid in ameliorating the gastrointestinal reactions. Androgen or estrogen therapy combined with calcium and a high protein intake may serve to mitigate the catabolic and osteoporotic effects of these hormones. The administration of 3 Gm of potassium daily is often effective in counteracting excessive potassium depletion. The use of appropriate antibiotics and concurrent therapy with antituberculous agents should be promptly instituted when these complications are suspected. In this respect adequate screening procedures for detecting such infections, as well as diabetes, must be included in the routine management.

In addition, the physician must be aware of the possibility of a 'withdrawal syndrome,' consisting of headache, nausea, vomiting, restlessness and muscle or joint pains, following the cessation of long-term therapy. Because of the spontaneous diurnal variation in adrenal cortical secretory activity, Di Ramondo and Forsham point out: 'When going through the weaning off' process after a high dose suppressive course of corticoids or corticotropin one would do well once down to low dosage, to administer it all in one dose at 8 A.M. so as to allow the anterior pituitary corticotropin secretion to return gradually while supporting the patient with corticoid when receiving a minimal endogenous supply.'

It should be stressed that the aim in long term maintenance therapy should be the relief of severe bronchospasm by the combined employment of bronchodilator drugs, aerosols, and potassium iodide as well as the steroid, and not simply the steroid alone. The use of conventional antiallergic measures should be continued in order to decrease the dosage of the steroid hormone to a minimum. In this regard the persistence of minor symptoms while on low dosage is preferable to the maintenance of complete suppression of allergic manifestations by high, potentially dangerous levels of hormone.

**GAMMA GLOBULIN**—Modification of tissue, or host, reactivity involving the use of gamma globulin is under study in selected cases of asthma in which the



appointing There is no proof that the effector cell is protected by any of the drugs presently available Future research may delineate the common denominator involved in the allergic reaction With identification of this factor the accomplishment of complete pharmacologic control through specific blocking or barrier action may ultimately take place

Modification of tissue reactivity by the corticosteroids provides symptomatic relief in selected cases of severe self-limited or resistant allergic disease This is accomplished, however, at the price of adverse side reactions which accompany the use of these hormones Of equal importance to the search for newer and safer analogues of the corticosteroids is the employment of these hormones as investigative tools in allergy research

In summary, a list of the more common allergic diseases and the pharmacologic agents employed in their control is presented

**Anaphylactoid Reactions** Epinephrine—drug of choice Supplementary therapy occasionally with intravenous steroid or intravenous antihistamine Aminophylline intravenously for intense bronchospasm

**Serum Sickness** Sympathomimetics For severe reactions brief course of steroids or corticotropin

**Allergic Rhinitis** See "Allergic Rhinitis" and "Environmental Control" Temporary use of sympathomimetics for symptomatic improvement Perennial rhinitis identified Oral ephedrine

**Bronchial Asthma** Hyposensitization and environmental control if due to pollinosis Sympathomimetics and theophylline salts—drugs of choice for non-asthmatic bronchitis

**Asthmatic Bronchitis** Sympathomimetics and theophylline salts—drugs of choice for non-asthmatic bronchitis Measures listed Measures to promote bronchial drainage Avoidance of food allergen Antihistamines, epinephrine, sympathomimetics, and topical vasoconstrictors

**Atopic Dermatitis** Environmental control including discontinuance of responsible drug, food, or contactant Oral ephedrine Dermatologic preparations including topical steroids if severe Brief course of antihistamines if pruritus is severe

**Urticaria** Similar to allergic dermatitis, antihistamines are effective in the acute form

**Angioedema** Similar to allergic dermatitis, antihistamines are effective in the acute form Concurrent use with intravenous corticosteroids Effective in controlling symptoms Antiasthmatic regimen in previous chapters for bronchospasm

A half century has passed since allergy was first recognized as a distinct clinical entity During this time basic knowledge concerning the mechanisms of the allergic process have been applied only sporadically to therapy Most of the drugs employed in the treatment of allergic disease today leave much to be desired In seeking a rational basis for newer agents the ideal characteristics to be considered are (1) a universal preparation affecting all allergic manifestations by neutralizing the allergen, (2) a preparation affecting the effector tissue and the humoral agents which

therapy Much has been written about the psychodynamics of the allergic personality, and it is apparent to the practicing physician that the acute allergic attack is often accompanied by emotional disturbances Support for the emotional factors in triggering and maintaining allergic symptoms is partially supported by evidence presented by Tuft, who showed that 80 per cent of children with severe asthma had marked relief when separated from their home environment This study was controlled to exclude the effects of changes in climate or removal from specific allergen exposure In our experience hyperventilation of nervous origin results at times in serious aggravation of asthma with increased trapping of air and broncholarynospasm

The benefits of temporary residence in a pollen free area for the treatment of hay fever and pollen asthma have already been discussed Aside from this short term environmental control, the advantages of climatotherapy involving permanent relocation continue to appear in the literature It is the opinion of most authorities, and of the authors, that such therapy involving numerous hardships with socioeconomic derangements and the frequent breaking up of the family unit, is not warranted in view of the equivocal benefit derived In this connection, Gottlieb suggests that this form of therapy more often than not, may be a measure of desperation

## DISCUSSION AND SUMMARY

The very nature of the allergic process involving as it does almost every cell and tissue of the body, makes any discussion of pharmacologic therapy necessarily cumbersome and involved Specific therapy limited at the present time to hypsensitization and environmental control has many serious drawbacks Even in those instances where the offending allergen has been positively identified, these forms of therapy may be impractical For example, certain manifestations of allergic disease occur rapidly and are fulminating, requiring immediate correction not possible with the specific measures mentioned above In other instances eco

in the environment or treatment with injections of suitably selected allergenic extracts "

Unfortunately, it has not been possible to identify the specific allergen in a majority of patients suffering from allergic disease In many of these individuals, multiple factors are operative in the causation of symptoms For this entire group as well as those afforded incomplete relief with hyposensitization, symptomatic therapy constitutes the only avenue of control Antihistaminics and corticosteroids, while contributing much to the pharmacologic treatment of allergic states, are simply additions to symptomatic therapy and have not provided any solution to a quest for a universal, specific antiallergic drug In this regard, the idea of "barrier therapy" possesses considerable merit However, most of the drugs which serve as a barrier between the cells and those substances such as histamine, acetylcholine, and serotonin, believed to mediate the allergic response, have been dis-

- Segal, M. S., Dulfano, M. J., and Herschfus, J. A. Aerosol Therapy, Dis  
 f Ragweed Pollen From  
 196  
 196, New York J Med  
 37, 1429, 1957
- Segal, M. S., Dulfano, M. J., and Herschfus, J. A. Advances in the Physiology and Treat  
 1960, 1960, 1960
- Sherman, S.  
 Sherwood, S.
- Thorn, G.
- Tuft, L., 203-717, 1942.

are responsible for the allergic response, (2) decreased incidence of toxicity, which at the present time seriously limits the more effective agents in use today, and (3) sustained, effective action with absence of tolerance. Intensification of research in this field initiated within the past 5 years holds much promise for the future.

# SELECTED REFERENCES

- Arbesman, C. A. Newer Drugs for Relief of Allergic Diseases, *New York J Med* 56: 3678, 1956.
- Barach, A. L. Rectal Instillation of Aminophylline in Intractable Asthma, *J A M A* 128: 589, 1945.
- Barach, A. L. Remissions in Bronchial Asthma and Hypertrophic Pulmonary Emphysema, *J A M A* 147: 730, 1951.
- Barach, A. L., and Bickerman, H. A. Pulmonary Emphysema, Baltimore, 1956, The Williams & Wilkins Co.
- Barach, A. L., Bickerman, H. A., and Beck, G. J. Clinical and Physiological Studies on the Use of Metacortandracin in Respiratory Disease. I. Bronchial Asthma, *Dis Chest* 28: 515, 1955.
- Bickerman, H. A., Beck, G. J., Itkin, S., and Drimmer, F. Evaluation of Oral Bronchodilator Agents in Patients With Bronchial Asthma and Pulmonary Emphysema, *Ann Allergy* 11: 301, 1953.
- Black, R. L., Yielding, L. K., and Bunim, J. J. Observation on New Synthetic Antirheumatic Steroids and Critical Evaluation of Prednisone Therapy in Rheumatoid Arthritis, *J Chron Dis* 5: 751, 1957.
- Blumenthal, J. S., Brown, E. B., and Campbell, G. S. Molar Sodium Lactate in Acute Anaphylactic Shock: A Study of 10 Patients, *Ann Allergy* 14: 506, 1956.
- Burrage, W. S., Greene, J. E., Burgin, L. B., Itkin, I. H., Novey, H. S., Engler, J., and Irwin, J. W. Medical Progress: Allergy, *New England J Med* 255: 79, 128, 1956.
- Garryer, Cooke, F. Digilio, Therapy of the J Med
- Dr. Raim
- Dragstedt
- Farber, S.
- Feinberg,
- Irwin, J.
- Kabat, E.
- Kinsell, J.
- Knight,

**Hypercholesterolemia**—Treatment of hypercholesterolemia with estrogen is still in the experimental stage. Large doses have been used 0.25 to 1 mg of ethinyl estradiol a day corresponding to 2,500 to 10,000 rat units. With women it is quite possible to give estrogens over a long period provided progesterone is given 4 days out of each month. Men will become feminized with this dosage of estrogen, and for that reason the treatment is seldom acceptable to them.

The evidence thus far available does not justify recommending estrogen as a regular preventive of atherosclerosis even in women, but it may be tried in familial hypercholesterolemia. There has been no adverse effect on women who have been treated as long as a year and a half in the small group thus far studied.

Several studies have now been reported indicating that nicotinic acid is effective in lowering elevated blood cholesterol to normal levels. Three to 6 Gm a day is required by mouth. There is almost invariably an uncomfortable flush after each dose the first 3 days, but this usually disappears by the end of a week. Pruritus occasionally occurred too during the first few days of treatment. No serious toxic effects have thus far been encountered. Further study will have to be done to determine whether the lowering of the blood cholesterol level reduces atheroma formation or reverses atherosclerosis.

**Hyperlipemia**—Increase of neutral fat in the blood or hyperlipemia, is a different kind of disorder of blood fat and is affected by agents other than those that tend to reduce the blood cholesterol level. Some untreated diabetics develop gross hyperlipemia so that the blood may contain 6 to 8 Gm or more of neutral fat per 100 ml. Small doses of insulin may clear the blood of this excess fat within a few hours.

**HEPARIN**—After eating a fatty meal everyone tends to have a transient physiologic hyperlipemia, the disappearance of which cannot be speeded up with insulin. Heparin acts rapidly to clear the blood of neutral fat within a few minutes after an injection of heparin the plasma is perfectly clear. The mechanism of this action has been studied extensively but is not yet thoroughly understood.

**Familial Hyperlipemia**—There is also a condition known as familial hyperlipemia in which patients have a hereditary defect in the ability to eliminate fat from the blood. At each meal the fat ingested accumulates until very large quantities of neutral fat are present and the plasma has the appearance of cream. Neither insulin nor heparin will assist in clearing the blood of fat in this instance, but spacing of fat ingestion over several days will control the condition.

**Diet and Atherosclerosis**—Aside from its effect on the blood cholesterol a diet low in calories seems to protect people from serious atherosclerosis as evidenced by coronary artery disease. Such diets usually have a relatively small proportion of fat and this has focused attention on the question of whether the type of fat makes a difference. Evidence is now beginning to appear relating the type of fat in the diet to atherosclerosis. The highly saturated fats like butter fat and lard appear to be more deleterious in this regard than the unsaturated fats like corn oil, peanut oil, and fish oils. A carefully controlled study of Ahrens suggests that corn oil in the diet in place of butter fat will actually cause blood cholesterol to be decreased by raising its rate of excretion. There are no specific therapeutic implications as yet except that people in middle life may be well advised to eat a diet low in calories and fat.

## THE CHOICE OF DRUGS IN CERTAIN DISORDERS OF METABOLISM

*George G. Reader, M.D.*

---

### INTRODUCTION

A group of pharmacologically active agents that owe their use to their ability to alter body metabolism in some highly selective way may well be considered together. These include the lipotropic agents which are of use in lowering blood lipids, antipyretic drugs, drugs which alter the metabolism of alcohol to make it intolerable to the body, and insulin and other drugs that alter carbohydrate metabolism.

### LIPOTROPIC AGENTS AND ATHEROSCLEROSIS

Elevation of levels of blood lipids and particularly of cholesterol, which occurs in a variety of conditions such as myxedema, untreated diabetes, nephrosis, and familial hypercholesterolemia and in many otherwise normal American men and woman is thought to increase the tendency toward formation of atheromas, thus leading to severe atherosclerosis, arterial thrombosis, and occlusion. The effect is most evident in patients with extremely high levels of serum cholesterol, above 400 mg per 100 ml, a high proportion of whom develop severe atherosclerosis.

**Thyroid Hormone**—Various agents may be effective in altering blood cholesterol. Thyroid is known to lower the blood cholesterol, and the use of preparations containing thyroxine will regularly diminish the concentration of cholesterol in the blood. This is most evident in myxedema but is seen in normal people as well if enough thyroid hormone is given.

**Estrogens and Androgens**—Other hormones that affect blood cholesterol are estrogens and androgens, the former tending to reduce the levels, and the latter to raise them. Not only is the absolute level of serum cholesterol modified, but the cholesterol phospholipid ratio is altered as well, toward normal with estrogen and away from normal with androgen. In myxedema, for instance, estrogen will reduce the cholesterol level even when thyroid is omitted and when the basal metabolic rate still remains low. Treatment by estrogen in patients with familial hypercholesterolemia and xanthomatosis affects lipid relationships favorably and, in some, results in return to normal concentration and distribution of cholesterol and phospholipids.

effective Disulfiram is absorbed fairly rapidly from the alimentary tract but is much more soluble in fat than in aqueous solutions. It may be that the fat depots take up most of the drug for some period before sufficient amounts can accumulate in the circulation to produce the characteristic effect.

Once the patient has taken his morning dose of either disulfiram or CCC he knows that he cannot drink for at least 3 or 4 days. This provides him with a breathing spell wherein effective psychotherapy may be started. If he does ingest alcohol the patient will soon note flushing of the face followed by nausea and vomiting and in severe reactions by hypotension to shock levels. Calcium carbimide is considered to be preferable for long term treatment because it has fewer disagreeable side effects of its own. Disulfiram may tend to cause acneiform eruptions lassitude fatigue sexual impotence, headache, and dizziness all of which are said not to develop after calcium carbimide.

## INSULIN, ORAL ANTIDIABETIC DRUGS, AND DIABETES

Diabetes mellitus is a disease characterized by a defect in carbohydrate metabolism so that blood glucose is not utilized by the tissues. There is a drop in blood sugar levels with the administration of insulin and for treatment of the diabetic patient a variety of insulins have been prepared.

**Regular Insulin**—Regular insulin is an aqueous solution of the active hormone of the pancreas which affects the metabolism of glucose. Presumably the glucose concentration of the blood ordinarily determines how much hormone the pancreas puts out into the circulation. In the diabetic patient, however, when the insulin must be administered parenterally, regular insulin has a prompt effect on the blood sugar but is rapidly metabolized so that frequent doses must be given in order to keep the blood sugar at normal levels. Regular insulin still finds considerable use in treatment of diabetic acidosis and for the patient who is suffering an intercurrent infection or having an operation but for ordinary use some means of delaying absorption by modification of the insulin is usually employed.

### Long Acting Insulins—

**PROTAMINE ZINC INSULIN**—Protamine zinc insulin (PZI) is insulin which is combined with zinc and with protamine derived from the sperm of fish. It forms a complex with an isoelectric point at pH 7.2 and is only slowly absorbed from body fluids so that an amount injected will often be active in depressing blood sugar for 48 to 72 hours.

**GLOBIN ZINC INSULIN**—Globin zinc insulin is a complex of insulin with zinc and the globin from beef hemoglobin which has a shorter duration of action than protamine zinc insulin but longer than regular—16 to 24 hours.

**ISOPHANE INSULIN**—Isophane insulin is also known as NPH insulin. It is a controlled preparation of protamine zinc insulin which has a duration of action of 28 to 30 hours.

**LENTE INSULINS**—The newest insulin preparations are the lente insulins developed by Hallas Moeller. They are regular insulins modified by combination with zinc. A suspension of amorphous insulin and zinc particles, called semilente

vised to avoid a large amount of fat in their diets particularly dairy products, and should attempt to substitute corn or peanut oil for animal fats when possible

[A large scale long term study of the effect of the so-called low cholesterol diet on already existing atherosclerosis is now under way Ed.]

**Ineffective Agents**—Choline and methionine have been known to restore liver tissue to normal when it has been infiltrated with fat but there is no evidence that either of these two drugs affects blood lipid levels or atherosclerosis Similarly sitosterol which is the plant analogue of animal cholesterol has had no demonstrated effect on patients with abnormal blood lipids when administered over a long period of time nor has it shown any tendency to lessen atherosclerosis These agents alone together or mixed with vitamins are of no value and should not be recommended for treatment or prevention of atherosclerosis

## ANTIPYRETIC AGENTS AND FEVER

Fever is a physiologic response to a foreign protein and probably represents a manifestation of an important defense mechanism Unless it becomes so high as to raise the question of damage to protoplasm it is probably best ignored and may even be considered beneficial At dangerous elevations physical means of reducing body temperature are more satisfactory than pharmaceutical methods but occasionally a patient can be made to feel more comfortable by administration of antipyretics

The two that are most satisfactory are the salicylates and acetophenetidin Both act on the heat regulating mechanism of the central nervous system to cause a greater dissipation of body heat through cutaneous vasodilatation

The antipyretic dose of salicylates and of acetophenetidin is from 0.3 to 1 Gm orally every 3 to 4 hours

## ANTI-ALCOHOLIC DRUGS AND ALCOHOLISM

Alcoholism is a complicated disease of personality maladaptation whereby the patient seeks to nullify the painful aspects of his environment through ingestion of large amounts of alcohol One approach to treatment is to administer a drug to the patient that causes alcohol to produce marked toxic symptoms This serves to prevent the ingestion of alcohol and conditions the patient against it If the personality disorder is not too firmly fixed and alternative forms of adjustment exist for the patient he may be induced to give up alcohol and will continue to get along without it after weaning Usually the anti-alcoholic drugs are at best adjuvants to psychotherapy for the alcoholic patient

**Disulfiram and Citrated Calcium Carbimide**—Two drugs are available disulfiram (Antabuse) and citrated calcium carbimide (Temozol CCC) Both act in much the same way to inactivate one or more enzymes which are required to oxidize acetaldehyde The sensitizing drugs not only cause an accumulation of acetaldehyde after alcohol ingestion but may also alter the vascular reaction to acetaldehyde

With citrated calcium carbimide all subjects have been sensitized with a single dose of 50 to 100 mg whereas with disulfiram a single dose may or may not be



Chlorpropamide (Diabinese) is more potent than tolbutamide, partly because it is more slowly excreted. It may be given in doses of 500 mg or less daily. Geriatric patients may be more sensitive to the hypoglycemic effects and should be started on no more than 250 mg daily. As much as 1 Gm may be required by younger patients, but doses higher than this should be avoided. Serious drug reactions have been reported with toxic effects on the liver in a few cases, and the drug should be used with caution.

The hypoglycemic effect of the biguanides such as phenformin (DBI) results from decreased glucose output by the liver and increased glucose uptake by the muscles. Insufficient clinical studies have been carried out with this group of drugs to know what place they may have in the future management of diabetes. They frequently cause nausea and vomiting, which will probably limit their usefulness.

## SELECTED REFERENCES

- Achor, R. W. P., Berge, K. G., Barker, N. W., and McKenzie, B. F. Treatment of Hypercholesterolemia With Nicotinic Acid, *Circulation* 17: 497, 1958.
- Ahrens, E. H., Jr., Blankenhorn, D. H., and Tsaltas, T. T. Effect on Human Serum Lipids of Substituting Plant for Animal Fat in Diet, *Proc. Soc. Exper. Biol. & Med.* 86: 872, 1954.
- Barr, D. P. Some Chemical Factors in the Pathogenesis of Atherosclerosis, *Circulation* 8: 641, 1953.
- Beaser, S. B. Diabetes Mellitus. *New England J. Med.* 259: 525, 1958.
- Done, A. L. *Proc. Soc. Exper. Biol. & Med.* 93: 774, 1959.
- Ferguson, G. A New Drug for Alcoholism, *J. A. M. A.* 169: 1468, 1959.
- Gilder, R. C. Effect of Hormones on the Metabolism of Carbohydrates, *J. A. M. A.* 169: 1468, 1959.
- Goldner, B. M. A. Arch. Int. Med. 92: 830, 1958.
- Haunz, E. A. Clinical Evaluation of Lente Insulin in 109 Diabetic Patients, *J. A. M. A.* 159: 1611, 1955.
- Jost, F. Blood Dyscrasias Associated With Tolbutamide Therapy, *J. A. M. A.* 169: 1468, 1959.
- Krall, L. P., and Bradley, R. F. Clinical Evaluation of Formamidineyliminourea, a New Biguanide Oral Blood Sugar Lowering Compound. Comparison With Other Hypoglycemic Agents, *Ann. Int. Med.* 50: 586, 1959.
- Martensen, Larsen, O. Five Years Experience With Disulfiram in the Treatment of Alcoholics. *Quart. J. Stud. Alcohol.* 14: 406, 1953.
- Keyes, A. The Diet and the Development of Coronary Heart Disease, *J. Chron. Dis.* 4: 364, 1956.
- Keys, A., and Buzina, R. Blood Coagulability Effects of Meals and Differences Between Populations, *Circulation* 14: 479, 1956.
- Stadie, W. C. Current Views on the Mechanisms of Insulin Action, *Am. J. Med.* 19: 257, 1955.
- Symposium. Insulin and the Oral Hypoglycemic Agents. Part II, Metabolism 8: 469, 1959.
- Unger, R. H., and Davidson, J. W. Current Status of Aryl Sulfonylureas in Treatment of Diabetes Mellitus, *J. A. M. A.* 162: 447, 1956.

of large particle size is called ultralente and has a duration of action of over 30 hours. A third preparation is a suspension of insulin crystals of small particle size (lente) which has a duration of action of approximately 24 hours.

The lente insulin now on the market is a mixture of minute particles of crystalline zinc insulin and amorphous zinc insulin in proportions of about 70 and 30 per cent, and is relatively insoluble at the pH of the blood. Because no foreign protein other than insulin itself is included, the danger of allergic reactions is less. Lente insulin can be substituted for isophane insulin on a unit for unit basis, but usually slightly less is required for satisfactory control.

**Choice of an Insulin Preparation**—In the treatment of the diabetic patient insulin is preferable to any of the oral hypoglycemic agents in the patient who develops his diabetes in childhood or early adult life. The type of insulin to be used depends upon the clinical situation. Regular insulin is best when the patient is first being regulated, in the presence of infection or acidosis, or immediately before and after surgery. It may be given intravenously when absorption might be delayed from a subcutaneous site in severe acidosis or shock.

One of the longer acting insulins should eventually be chosen for those diabetic patients who require insulin at all because of the ease of management with one injection per day. Lente insulin would appear to be satisfactory as far as uniformity of response over 24 hours from one dose is concerned, but its advantages over NPH are slight. Actually NPH and globin insulins are entirely adequate, and it is possible to learn to use any one of the long acting insulins with complete satisfaction. Some physicians prefer to tailor the dose of long acting insulin to their patient's needs by mixing PZI and regular insulin to get the exact amount of prolongation of action required. The excess of zinc in the PZI acts to prolong the action of the regular insulin mixed with it.

**Oral Antidiabetic Drugs**—There are presently three agents available that may be given by mouth to produce a hypoglycemic effect. These are the sulfonylureas (tolbutamide [Orinase] and chlorpropamide [Diabinese]) and the biguanide (phenformin [DBI]). Analogues of DBI, the amyl and isoamyl biguanides, are not available on the commercial drug market at this time.

The sulfonylureas supposedly cause increased insulin activity, possibly by a direct stimulation of insulin production in the islet cells. Their best use is in older diabetic patients in whom it has been shown that tolbutamide, according to most authorities, is a safe substitute for insulin. They are dangerous in brittle diabetic patients and in young diabetic patients because ketosis may occur despite adequate dosage. Some physicians have claimed better control of brittle diabetes with a combination of sulfonylurea and insulin, but this work must be further evaluated.

The recommended dosage of tolbutamide (Orinase) is 1 Gm daily. A few patients respond only to higher dosage, sometimes as much as 3 Gm a day. Patients should continue to test their urine carefully for glucose and ketones, and the dosage should be altered accordingly or insulin therapy substituted. [Blood dyscrasias have been noted. With the increasing use of tolbutamide, the literature should be followed for further reports on toxicity of this drug as well as of the other oral hypoglycemic agents. Ed.]

## THE PITUITARY GLAND

The pituitary gland, the governing agent of the endocrine system, is concerned with the secretion of a large number of hormones. The pituitary hormones are protein in nature and may be classified into two categories based upon their specific effect—a direct one upon metabolic processes of the body (growth hormone or vasopressin) and an indirect one which induces its effects through an intermediary organ e.g., the gonadotropic hormone, which in the absence of the gonads is without demonstrable activity.

The pituitary gland is divided into two principal portions, the anterior lobe and the posterior lobe. Between the two lobes is the intermediate lobe, the function of which is problematical inasmuch as no specific hormones, with the possible exception of the melanophoric hormone, have been established as being secreted by the intermediate lobe. The anterior lobe produces a number of different specific hormones which have been more or less characterized as separate entities in recent years.

The four types of cells in the pituitary gland are chromophobes, acidophils, basophils and amphophils. The chromophobes presumably have no endocrine secretion and as stem cells give rise to the chromophils. The specific hormones which have been extracted from the anterior lobe are the adrenocorticotrophic hormone (ACTH), the thyrotrophic hormone (TSH), the gametogenic hormone, which is also referred to as the follicle stimulating hormone (FSH), the luteinizing hormone or interstitial cell stimulating hormone (ICSH), the luteotropic or lactogenic hormone and the growth hormone, also referred to as the somatotrophic hormone.

The posterior lobe of the pituitary gland is responsible for two hormones only—the vasopressor substances and oxytocic hormone. The vasopressor hormone also possesses antidiuretic hormonal activity. There is some disagreement whether the posterior lobe actually produces these hormones or whether they are secreted into the posterior lobe from more or less specific hypothalamic areas. The precise chemical structure of the posterior lobe hormones have been identified and synthesized. This has yet to be accomplished for the hormones secreted by the anterior lobe.

### Anterior Pituitary Hormones

**Growth Hormone**—The growth or somatotrophic hormone presumably arises from the acidophilic cells. The therapeutic use of growth hormone in the past has not been very effective in inducing adequate growth in stunted or dwarfed children. The growth hormone preparations on the market at present cannot be considered as being therapeutically active and are of little value. More recently, with the availability of human growth hormone and that produced from the glands of the Rhesus monkey, there is evidence to indicate that such preparations may well be effective clinically. Preliminary data indicate that growth may be induced in children who are undersized. Unfortunately, this material is available for only limited use. Recent evidence has indicated that partial digestion with proteolytic enzymes of the growth hormone extracts prepared from the glands of animals may so alter the preparation that physiologic effects may be noted in human beings.

## THE CHOICE OF DRUGS IN ENDOCRINE DYSFUNCTION

*Herbert S. Kuppman, M.D.*

---

### INTRODUCTION

With the advent of thyroxin and adrenaline, the first hormones of the endocrine system to be crystallized, endocrinology raised its head during its infancy. Further developments led to the ultimate condemnation of the prevalent empirical therapy with the crude glandular extracts then available. Particularly in the last two decades, there has been a flood of newer crystalline hormonal preparations which have been available to the physician for the treatment of different endocrinopathies and allied conditions. In addition, their use, not only for therapy but for diagnostic purposes, has led to greater diagnostic acumen and eventual therapeutic application.

The hormone preparations which are available to date may be divided into the steroidal and the nonsteroidal substances. The steroidal hormones are classified on the basis of their chemical structure. The lipid-soluble substances or steroidal hormones are produced by the glands of internal secretion derived from the mesoderm. The nonsteroidal hormones are secreted by those endocrine glands which have their origin in the ectoderm.

Hormones have been used for several different specific purposes. They, of course, are available to supplement or replace the function of any specific gland. They are also used for pharmacologic effects which have no relationship at all to any endocrine deficiency disease (e.g., corticoids in pemphigus and rheumatoid arthritis). Hormones are used to inhibit the function of certain endocrine glands (e.g., thyroid hormone to inhibit the thyroid-stimulating, or thyrotropic, hormone (TSH) of the pituitary gland and thereby to help in the treatment of exophthalmos). They are also employed to induce a more nearly normal physiologic state in certain instances where there may be no precisely determined deficiency, but where the endocrine preparation is used for its specific pharmacologic activity and not as a replacement substance (e.g., corticoids in refractory edema and insulin in anorexia). In this chapter the disease entities and hormones of each specific endocrine organ will be considered separately.

administration of parenteral ACTH in such persons does not represent a propitious form of therapy

The use of ACTH is paramount in delineating between primary or secondary adrenal insufficiency. The administration of 40 units of ACTH gel should result in an appreciable increase in 17-hydroxysteroids in the blood within 3 to 4 hours after the intramuscularly administered injection. In the event that there is no increase in 17 hydroxysteroids in the blood one can assume that the patient has adrenal glands incapable of functioning either because of complete suppression by exogenous corticoids or because of destruction by some pathologic process. The management of patients with either primary or secondary adrenocortical insufficiency however would still be the same and would entail the use of oral corticoids. Hence, the ACTH procedure is important, purely from the academic point of view, in differentiating between primary and secondary hypoadrenocorticism.

Diagnostically ACTH has been employed to determine the presence or absence of hypofunction or hyperfunction of the adrenal gland, as well as to differentiate between hyperplasia and neoplasia in certain hyperadrenal corticoid states. The use of ACTH in determining the extent of increased adrenocortical activity is particularly applicable to patients with Cushing's syndrome, for in these persons enhanced responsiveness of the adrenal cortex may be observed. While the absolute value of excretion of the steroids from the adrenal cortex may be relatively small, the marked increase in activity induced after ACTH is administered is of the utmost importance in determining the presence or absence of Cushing's syndrome. Once a diagnosis is made the treatment of this disease is surgery. Hence it is imperative that the provocative test with ACTH assume an important place in the diagnostic armamentarium of the physician called upon to differentiate between Cushing's syndrome and allied clinical entities.

The procedure entails the administration of either 40 units of ACTH gel intramuscularly or 25 units of ACTH intravenously as an aqueous solution. The 17-hydroxysteroids in the blood are determined before ACTH administration and 3 to 4 hours after the intramuscular injection, or immediately after an 8 hour infusion with the ACTH solution. Urinary 17 hydroxysteroids and 17 ketosteroids are determined for 24 hours before the ACTH administration as well as for 24 hours after the intramuscular injection of ACTH, or at 8 hour intervals if ACTH is given intravenously. The 8 hour periods of urine collection are set up as follows: The 8 hours before ACTH infusion, the 8 hours during the infusion, and the 8 hours after the infusion has been completed.

In a patient with Cushing's syndrome the blood 17-hydroxysteroid level will exceed 50 gammas per 100 ml and the urinary 17 hydroxysteroid excretion will exceed 50 to 60 mg per 24 hours after the injection of ACTH. Patients receiving the infusion will have a comparable rise in urine and blood levels.

In patients in whom an elevated urinary 17 hydroxysteroid level is already present and in whom the blood 17 hydroxysteroids are also markedly elevated but in whom no changes occur after ACTH injection, the possible diagnosis of adrenal neoplasm must be considered. However, one must be cognizant of the fact that more and more patients with adrenal neoplasm are being recognized who still show

There are certain undesirable side effects that growth hormone may induce which would ordinarily limit the widespread use of this preparation, the principal one being the creation of a diabetic like state in some patients receiving therapeutically effective doses. Obviously, in a potentially diabetic patient this may be disastrous. In addition the animal preparations have the ever present possibility of inducing antihormone production.

**Thyrotropic Hormone (TSH)** —In recent years the thyrotropic hormone has been made available for diagnostic purposes. It plays no part in therapy inasmuch as the treatment of thyroid insufficiency secondary to pituitary hypofunction is readily managed by the administration of any one of the many oral thyroid preparations available. However, TSH has an important place in the physician's diagnostic armamentarium in differentiating between primary and secondary hypothyroidism. The patient with primary hypothyroidism will show no response to a test dose of 5 IU of TSH administered each day for 3 days. On the other hand hypothyroidism secondary to pituitary failure would result in a more nearly normal thyroid state under the influence of the TSH administered as previously stated. Diagnostically it is conceivable that TSH administration may differentiate anaplastic thyroid disease from nonanaplastic thyroid disease. Theoretically a carcinoma of the thyroid gland will not respond to TSH. Hence, this preparation may be useful in differentiating anaplasia from hyperplasia in patients with thyroid nodules.

**Adrenocorticotrophic Hormone (ACTH)** —Adrenocorticotrophic hormone found a useful place in therapeutics with the demonstration of the action of corticoids upon certain collagen diseases. The diagnostic use of ACTH is also of importance. While its principal effect is achieved by stimulating the adrenal cortex to greater secretion, ACTH may also have a primary effect upon raising blood lipid and cholesterol levels in the absence of the adrenal gland.

Therapeutically ACTH may be used to supplement or replace the corticoids in the different collagen diseases. It may also be used therapeutically to enhance the activity of the patient's adrenal gland. The importance of ACTH in clinical medicine is due in part to its enhancing adrenocortical activity in patients in whom suppression of endogenous ACTH secretion has occurred as a result of corticoid therapy. The use of ACTH in these persons may at times be important in maintaining the function of the adrenal cortex which otherwise would have been completely suppressed indeed to the point of adrenal atrophy as a result of exogenous corticoids. The combined use of ACTH and corticoids is a rational form of therapy in those diseases in which endogenous corticoid elaboration may be more helpful than the use of cortisone alone. It has been suggested that ACTH is more effective in the management of certain hematologic diseases as well as in conditions of stress. Therapeutically ACTH may be employed in the treatment of severe allergic manifestations associated with dermatitis venenata, in which enhancing the function of the adrenal gland of the patient may at times result in a better therapeutic response than that obtained by the use of cortisone alone. ACTH therapy has no place in the treatment of patients with secondary adrenal insufficiency due to pituitary insufficiency. Inasmuch as oral therapy with corticoids will more than amply supplement the needs of the patient, the chronic

age Failure for this development to occur by the age of 14 or 15 years must be considered evidence of delayed puberty Consequently, the physician's clinical judgment must be tempered by the patient's appearance and the age of the patient in determining whether therapy is indicated

In addition, the 17-ketosteroid assay is a valuable laboratory test in determining the existence of hypogonadism Normally in boys up to the ages of 8 or 9 the maximum 17 ketosteroid excretion is 1 mg per 24 hours per year of life Values which are considerably below this must be considered as evidence of depression and, if present, together with the clinical manifestations of hypogonadism would indicate the need for active therapy

Another important criterion listed above is the psychosomatic need of the patient There is nothing so cruel as the *ridicule of the friends who may be aware of a young patient's affliction* In order to prevent damage to the psyche of these hypogonadal boys and to prevent feelings of inferiority associated with abnormal behavior patterns of overcompensation, it is of the utmost importance that therapy be instituted The beneficial effects are not only observed in a change in the *overt behavior of the boys*, but also by *normal external genital development* when the child matures sexually

The doses of chorionic gonadotropin employed for the treatment of hypogonadism have been arbitrarily set 1,000 IU, 3 times a week for 3 weeks, followed by 1,000 IU twice a week for 3 weeks in children above the age of 10 years Children under 10 received one half this dose in the same manner

**CRYPTORCHIDISM**—Cryptorchidism, or failure of the testes to descend bilaterally or unilaterally, may or may not be associated with hypogonadism Therapy for undescended testicles is not predicated upon the presence of hypogonadism but upon the need to bring the testes down from the abdomen into the scrotum Irreparable damage to spermatogenesis may take place if the testes reside in the abdomen Hence, *treatment of cryptorchidism should be initiated as soon as a diagnosis is made, after the age of 5 years* Therapy consists of the administration of chorionic gonadotropin in doses comparable to those listed above for hypogonadism If descent of the testes fails to occur, the patient must then be considered a candidate for orchiopexy, inasmuch as irreparable damage, resulting in sterility in the bilateral cases, may occur if the testis is left in the abdomen The sooner the testis is brought down into the scrotum the less likely the possibility of damage

**OLIGOSPERMIA**—The use of chorionic gonadotropin at the present time for the treatment of adult males with oligospermia is of little value and must be considered experimental This is based upon the present knowledge of the factors controlling spermatogenesis While there is a need for androgenic substances to maintain spermatogenesis the primary effect of human chorionic gonadotropin is to stimulate androgenic production by interstitial cell hyperplasia Spermatogenesis requires follicle stimulating hormone activity *Very little or none is present in human chorionic gonadotropins*

**HCG IN THE FEMALE**—The use of chorionic gonadotropin in the female has little or no therapeutic value As a matter of fact, its use in the female in whom

an increased response to ACTH. This may at first appear paradoxical. It is difficult to explain in the light of our present knowledge in that an adrenal neoplasm is thought to be independent of pituitary control. Since it is now clear that ACTH may stimulate adrenal neoplasms, the concept that an adrenal neoplasm lives unto itself needs revision.

**Gonadotropic Hormone**—Although there are several types available for use clinically, the gonadotropic substances which are used most widely in medicine are those prepared from the urine of the pregnant human female and those obtained from the serum of the pregnant mare. The other pituitary gonadotropins have not been used much in recent years because they may induce antihormone production.

**Human chorionic gonadotropin (A.P.L.)** is primarily luteotropic and luteinizing in effect in the female and interstitial cell stimulating in the male. In other words, this hormone is important in maintaining the function of the corpora lutea in the female, thereby enhancing the secretion and production of progesterone, and in enhancing testosterone and estrogen production from the Leydig cells in the male. However, the clinical use of chorionic gonadotropin should be primarily confined to the male. There is little or no evidence that this hormone is therapeutically important or significant in the female.

Therapy with human chorionic gonadotropin (HCG) in the male may at times be accompanied by the development of gynecomastia. It is wise, therefore, before HCG is administered to discuss this possibility with prospective patients or parents so that the appearance of mastodynia or mazoplasia is not regarded as an unexpected catastrophe. The Leydig cells, apparently having a biphasic potential, will secrete estrogens as well as testosterone or the increased amount of testosterone may be degraded partly into estrogen. Whatever the mechanism may be, sufficient estrogen-like substances may be formed to induce significant gynecomastia. The gynecomastia developing during chorionic gonadotropin therapy is seen primarily in the prepubertal or pubertal boy and is akin to the spontaneous gynecomastia noted during puberty, occurring as a result of endogenous testicular stimulation. Gynecomastia seen with HCG therapy is an undesirable, albeit physiologic, expression of testicular stimulation. It will, as in most cases of pubertal gynecomastia, subside without residual effects. There is no specific hormonal therapy at the present time capable of preventing exogenously induced gynecomastia or of nullifying endogenous gynecomastia.

**MALE HYPOGONADISM**—The use of chorionic gonadotropin in the male is confined to hypogonadism for both therapeutic and diagnostic purposes. In addition, it may also be used as a therapeutic test in patients with cryptorchidism in an attempt to induce descent of the testes. The hypogonadal male is characterized by a lack of response to chorionic gonadotropin in the hypogonadal male is warranted. (1) clinical evidence of hypogonadism: (a) delayed development of the phallus and the testes or the retardation of the development of the secondary sex characteristics; (b) the finding of an abnormally low 17-ketosteroid excretion; and (c) the patient's own concern and apprehension about his small genitalia. The clinical manifestations of hypogonadism are obvious in the male. Normally, one expects the male to go through puberty at 11 to 14 years of



## Anterior Pituitary Disturbances

The pituitary conditions which require some type of hormonal therapy follow

**Acromegaly**—Patients with this condition have enlargement of the pituitary gland due in part to an eosinophilic adenoma. The hypertrophy and hyperplasia of the eosinophilic elements may be of such a degree that by the process of compression and pressure alone various other components of the pituitary gland may be destroyed and there may be erosion of the bony components of the sella turcica. Therapy for acromegaly is dependent in part on the extent of the condition. If the patient shows acromegalic features and has neither significant enlargement of the sella turcica nor visual field constriction one may temporize and utilize the methylated steroids as a means of preventing further pituitary enlargement. This is particularly applicable to the male in whom methyltestosterone and/or methandroliol may be used with some effectiveness in slowing down the process.

The patient should be watched carefully. No further therapy besides the oral steroid preparation is indicated unless encroachment of the visual field is noted. In such patients and in those in whom considerable enlargement of the sella turcica has also resulted in erosion of the clinoid processes radiation therapy is indicated. Radiation therapy does not provide the solution to treatment inasmuch as during the process of radiation postradiation swelling of the elements receiving the therapy may occur resulting in increased limitation of the visual field.

It is important for the clinician and radiologist to work closely with the ophthalmologist with visual field examinations being made repeatedly during the process of administering 4 000 to 5 000 roentgens. If the visual field is diminished during this treatment by one third of that prior to therapy hypophysectomy should be performed. The surgical removal of the pituitary gland of course dooms the patient to persistent hypopituitarism. On the other hand some female patients who have had a course of radiation therapy have had regular menstrual periods recur a decade or more after the radiation therapy was discontinued. These patients as well as others reported in the literature provide a reason for sparing the scalpel and using less strenuous techniques especially in patients desiring to retain reproductive function.

Acromegalic patients in whom pituitary destruction has occurred as a result of pressure necrosis and/or radiation should be treated precisely the same way as the panhypopituitary patient. There has been evidence of some damage to the brain in patients receiving inappropriate radiation therapy. With the modern approach to radiation techniques such sequelae are less prone to occur.

**Craniopharyngioma**—This pituitary abnormality usually occurs in the younger age group and may be associated with a marked expansion of the sella turcica or the region above the sella turcica so that blindness may result from the pressure on the optic chiasma. Radiation in these patients may be of no avail. They may require surgical removal of the cyst and the neoplastic process. Obviously such patients will then suffer from panhypopituitarism and require replacement therapy.

**Chromophobic Tumor**—Although there are four types of pituitary cells it has been said that the chromophobic cells are the parent or stem cells which give

fertility is desired may result in the formation of anti A and B factors in the body because of the presence of blood grouping factors in the combined urine extract obtained from many pregnant women. As a result HCG may produce a hematologic picture comparable to that seen in RH negative mothers in whom an anti RH titer has developed during pregnancy. This possibility in an infertile patient desiring cyesis might adversely affect her conception even if infertility is successfully treated.

**GNADAL FAILURE IN THE FEMALE**—The chorionic gonadotropic hormone prepared from the serum of pregnant mares (PMS Equinev) is primarily FSH (follicle stimulating hormone) in activity although it does have some degree of luteinizing hormone activity. This preparation has been used in both men and women. Its use in females because of its powerful follicle stimulating properties may result in the formation of cystic ovaries. The use of pregnant mares serum (PMS) in the female should be relegated to diagnostic procedures alone. Injections of 500 IU of PMS 3 times a week for 3 weeks in a female with evidence of ovarian failure may be employed as a diagnostic test to determine the functional capacity of the ovaries. If the ovaries are capable of responding the FSH activity of the equine gonadotropin would be effective in inducing an increased estrogen output from the ovaries. Evidence of the increased estrogenic production by the ovary would be manifested by maturation of the vaginal smear, increased breast tenderness, swelling and the occurrence of menses after the PMS is discontinued. This technique has been used to determine whether the ovaries of patients with primary or secondary amenorrhea are irrevocably inactive or capable of response.

semiferous tubules of the testes. Patients with oligospermia and a low FSH production from their own pituitary glands may be helped therapeutically by the administration of PMS in doses of 500 IU 3 times a week for 5 to 7 weeks. Prolonged administration of PMS may have the inherent danger of production of antigonadotropic hormone since the gonadotropic extract is prepared from sources other than the human being. This must be an ever present potential contraindication to the chronic use of PMS. Before its use, particularly when there is a history of sensitivity to horse protein, the patient should either be skin tested or be checked by topical application of the extract on the conjunctiva. If a significant reaction occurs, the preparation should not be employed in such a patient. The use of a highly purified preparation now available (Equinev) has not induced any untoward reaction in the past 5 to 6 years in my experience.

**PANHYPOPITUITARISM**—The use of pituitary hormones in clinical syndromes such as panhypopituitarism is limited by the fact that the preparations must be administered parenterally and all of them except ACTH are prone to induce antihormone formation. The inconvenience of administration and the nullification of activity by antihormone formation makes it necessary to resort to end organ replacement therapy using those hormones of the target glands which are normally responsible for maintaining the homeostasis of the body.

## Anterior Pituitary Disturbances

The pituitary conditions which require some type of hormonal therapy follow

**Acromegaly**—Patients with this condition have enlargement of the pituitary gland due, in part, to an eosinophilic adenoma. The hypertrophy and hyperplasia of the eosinophilic elements may be of such a degree that, by the process of compression and pressure alone, various other components of the pituitary gland may be destroyed and there may be erosion of the bony components of the sella turcica. Therapy for acromegaly is dependent, in part, on the extent of the condition. If the patient shows acromegalic features and has neither significant enlargement of the sella turcica nor visual field constriction one may temporize and utilize the methylated steroids as a means of preventing further pituitary enlargement. This is particularly applicable to the male, in whom methyltestosterone and/or methandroliol may be used with some effectiveness in slowing down the process.

The patient should be watched carefully. No further therapy besides the oral steroid preparation is indicated unless encroachment of the visual field is noted. In such patients and in those in whom considerable enlargement of the sella turcica has also resulted in erosion of the clinoid processes radiation therapy is indicated. Radiation therapy does not provide the solution to treatment, inasmuch as during the process of radiation, postradiation swelling of the elements receiving the therapy may occur resulting in increased limitation of the visual field.

It is important for the clinician and radiologist to work closely with the ophthalmologist with visual field examinations being made repeatedly during the process of administering 4,000 to 5,000 roentgens. If the visual field is diminished during this treatment by one third of that prior to therapy, hypophysectomy should be performed. The surgical removal of the pituitary gland, of course, dooms the patient to persistent hypopituitarism. On the other hand some female patients who have had a course of radiation therapy, have had regular menstrual periods recur a decade or more after the radiation therapy was discontinued. These patients as well as others reported in the literature, provide a reason for sparing the scalpel and using less strenuous techniques, especially in patients desiring to retain reproductive function.

Acromegalic patients in whom pituitary destruction has occurred as a result of pressure necrosis and/or radiation, should be treated precisely the same way as the panhypopituitary patient. There has been evidence of some damage to the brain in patients receiving inappropriate radiation therapy. With the modern approach to radiation techniques, such sequelae are less prone to occur.

**Craniopharyngioma**—This pituitary abnormality usually occurs in the younger age group and may be associated with a marked expansion of the sella turcica or the region above the sella turcica, so that blindness may result from the pressure on the optic chiasma. Radiation in these patients may be of no avail. They may require surgical removal of the cyst and the neoplastic process. Obviously, such patients will then suffer from panhypopituitarism and require replacement therapy.

**Chromophobic Tumor**—Although there are four types of pituitary cells, it has been said that the chromophobic cells are the parent or stem cells which give

## DRUGS IN ENDOCRINE DYSFUNCTION

rise to the basophilic, eosinophilic, or amphophilic cells. Chromophobic adenomas occur in patients in all decades of life, but patients with these tumors do not respond as well to radiation therapy as does the acromegalic patient. As in patient with craniopharyngioma, surgical intervention may be the procedure of choice with the resulting panhypopituitarism being treated as described on page 5.

**Sheehan's Syndrome**—This syndrome is one of panhypopituitarism arising as a result of pituitary thromboses or ischemia usually occurring following postpartum hemorrhage or excessive blood loss. Such a patient is a female looking somewhat older than her stated age, with absence of pubic and axillary hair without cachexia, so that her breast development remains moderately normal. The skin is wrinkled and gives the face a wizened appearance. All the laboratory examinations indicate low or absent thyroid, adrenal, and gonadal function, as well as absence of pituitary activity. Therapy in such patients requires complete replacement treatment with thyroid, adrenal, and gonadal therapy. Adrenal therapy usually includes only glucocorticoids for their effects upon carbohydrate metabolism and combating stress. The sodium retaining steroids usually are not required but are employed only in those patients with the systolic blood pressure below 100 mm Hg.

**Chiari-Frommel Syndrome**—This syndrome may be a variant of Sheehan's syndrome. However, persons with this syndrome do not show the wizened appearance characteristic of Sheehan's syndrome, but exhibit the amenorrhea associated with acromegalic like facies and persistent lactation. The prognosis with respect to fertility as in those with Sheehan's syndrome is hopeless. However, with gonadal-replacement therapy alone these patients do splendidly.

A characteristic of this syndrome is galactorrhea, which is usually not very responsive to suppressive doses of the sex steroids. It will however diminish in sufficient degree to make the patient more comfortable and less troubled with soiled lingerie. The use of the 19 norsteroids with estrogen will diminish the galactorrhea and at the same time induce menstrual periods at periodic intervals for as long as the patient is on steroid therapy. Spontaneous resumption of periods cannot be expected. However when therapy is discontinued after a year or two of persistent treatment the galactorrhea may return, but it will be markedly less than that initially.

The acromegalic like facies, the enlargement of the sella turcica, together with partial encroachment of the visual field in some patients makes the diagnosis of the Chiari-Frommel syndrome a complex one and tends to point to multiglandular defects. However, galactorrhea is not uncommon in persons with acromegaly not giving a history of previous cystitis. In addition, persistent galactorrhea has been noted post partum and also following surgical procedures such as hysterectomy, oophorectomy, and cholecystectomy. The stress of surgical procedures upon pituitary release of lactogenic hormone is no doubt a factor in these latter cases. Lactation in such individuals may be suppressed by the use of the 19 norsteroids discussed on page 564.

**Pituitary Dwarfism**—Patients with pituitary dwarfism show a defect in growth, but are without evidence of any other endocrinopathy. It is presumed

## Anterior Pituitary Disturbances

The pituitary conditions which require some type of hormonal therapy follow

**Acromegaly**—Patients with this condition have enlargement of the pituitary gland due, in part, to an eosinophilic adenoma. The hypertrophy and hyperplasia of the eosinophilic elements may be of such a degree that, by the process of compression and pressure alone various other components of the pituitary gland may be destroyed and there may be erosion of the bony components of the sella turcica. Therapy for acromegaly is dependent, in part, on the extent of the condition. If the patient shows acromegalic features and has neither significant enlargement of the sella turcica nor visual field constriction, one may temporize and utilize the methylated steroids as a means of preventing further pituitary enlargement. This is particularly applicable to the male, in whom methyltestosterone and/or methandroliol may be used with some effectiveness in slowing down the process.

The patient should be watched carefully. No further therapy besides the oral steroid preparation is indicated unless encroachment of the visual field is noted. In such patients and in those in whom considerable enlargement of the sella turcica has also resulted in erosion of the clinoid processes, radiation therapy is indicated. Radiation therapy does not provide the solution to treatment, inasmuch as during the process of radiation, postradiation swelling of the elements receiving the therapy may occur, resulting in increased limitation of the visual field.

It is important for the clinician and radiologist to work closely with the ophthalmologist with visual field examinations being made repeatedly during the process of administering 4,000 to 5,000 roentgens. If the visual field is diminished during this treatment by one third of that prior to therapy, hypophysectomy should be performed. The surgical removal of the pituitary gland, of course, dooms the patient to persistent hypopituitarism. On the other hand some female patients, who have had a course of radiation therapy, have had regular menstrual periods recur a decade or more after the radiation therapy was discontinued. These patients, as well as others reported in the literature, provide a reason for sparing the scalpel and using less strenuous techniques, especially in patients desiring to retain reproductive function.

Acromegalic patients in whom pituitary destruction has occurred as a result of pressure necrosis and/or radiation, should be treated precisely the same way as the panhypopituitary patient. There has been evidence of some damage to the brain in patients receiving inappropriate radiation therapy. With the modern approach to radiation techniques such sequelae are less prone to occur.

**Craniopharyngioma**—This pituitary abnormality usually occurs in the younger age group and may be associated with a marked expansion of the sella turcica or the region above the sella turcica, so that blindness may result from the pressure on the optic chiasma. Radiation in these patients may be of no avail. They may require surgical removal of the cyst and the neoplastic process. Obviously, such

replacement therapy  
pituitary cells, it  
cells which give

nse to the basophilic, eosinophilic, or amphophilic cells. Chromophobic adenomas occur in patients in all decades of life, but patients with these tumors do not respond as well to radiation therapy as does the acromegalic patient. As in the patient with craniopharyngioma, surgical intervention may be the procedure of choice with the resulting panhypopituitarism being treated as described on page 561.

**Sheehan's Syndrome**—This syndrome is one of panhypopituitarism arising as a result of pituitary thromboses or ischemia usually occurring following postpartum hemorrhage or excessive blood loss. Such a patient is a female looking somewhat older than her stated age, with absence of pubic and axillary hair without cachexia so that her breast development remains moderately normal. The skin is wrinkled and gives the face a wizened appearance. All the laboratory examinations indicate low or absent thyroid, adrenal, and gonadal function as well as absence of pituitary activity. Therapy in such patients requires complete replacement treatment with thyroid, adrenal, and gonadal therapy. Adrenal therapy usually includes only glucocorticoids for their effects upon carbohydrate metabolism and combating stress. The sodium retaining steroids usually are not required but are employed only in those patients with the systolic blood pressure below 100 mm Hg.

**Chiari-Frommel Syndrome**—This syndrome may be a variant of Sheehan's syndrome. However, persons with this syndrome do not show the wizened appearance characteristic of Sheehan's syndrome but exhibit the amenorrhea associated with acromegalic like facies and persistent lactation. The prognosis with respect to fertility as in those with Sheehan's syndrome, is hopeless. However, with gonadal replacement therapy alone these patients do splendidly.

A characteristic of this syndrome is galactorrhea, which is usually not very responsive to suppressive doses of the sex steroids. It will however, diminish in sufficient degree to make the patient more comfortable and less troubled with soiled lingerie. The use of the 19 norsteroids with estrogen will diminish the galactorrhea and at the same time induce menstrual periods at periodic intervals for as long as the patient is on steroid therapy. Spontaneous resumption of periods cannot be expected. However, when therapy is discontinued after a year or two of persistent treatment the galactorrhea may return, but it will be markedly less than that initially.

The acromegalic like facies, the enlargement of the sella turcica, together with partial encroachment of the visual field in some patients makes the diagnosis of the Chiari-Frommel syndrome a complex one and tends to point to multiglandular defects. However, galactorrhea is not uncommon in persons with acromegaly not giving a history of previous crisis. In addition, persistent galactorrhea has been noted post partum and also following surgical procedures such as hysterectomy, oophorectomy, and cholecystectomy. The stress of surgical procedures upon pituitary release of lactogenic hormone is no doubt a factor in these latter cases. Lactation in such individuals may be suppressed by the use of the 19 norsteroids discussed on page 564.

**Pituitary Dwarfism**—Patients with pituitary dwarfism show a defect in growth, but are without evidence of any other endocrinopathy. It is presumed

that these persons may have a selective insufficiency of the eosinophilic cells similar to that seen in certain dwarfed strains of mice

Specific therapy requires the administration of pituitary growth hormone, preferably that from either human beings or monkeys. The use of such a preparation would not be conducive to the formation of antihormone and consequently would not result in decreasing effectiveness as therapy is continued. The prognosis with respect to reproduction and other activities is good. If growth can be achieved with growth hormone, a comparatively normal physiologic reproductive state would be assured.

Of course the panhypopituitary dwarf could never be expected to achieve normal functions and would, of necessity, have to be maintained upon complete replacement therapy similar to that advocated for patients with panhypopituitarism in the adult stage.

**Gigantism**—Gigantism is as distressing as dwarfism to the person affected. The prevention of gigantism, however, can be relatively simple if early diagnosis is made. In contrast to the poor prognosis with respect to increasing height in patients with pituitary dwarfism some assurance of effectiveness of therapy can be given the parents of the excessively tall child. The use of steroid hormones to close the epiphyses of probable giants is the procedure of choice. Both estrogen and testosterone can be readily employed in either sex with a predominance of estrogen being used in the female and testosterone in the male. The question arises whether such steroid hormone therapy would have an adverse effect upon the future reproductive potential. Fortunately there is a physiologic analogy between the effect of excessive sex steroids secreted early in life upon genital function and patients with congenital adrenogenital syndrome. The latter, as will be discussed later, are subjected to unusually large amounts of sex steroids from their prenatal period on. Nevertheless at any stage in life—at the age of 10, 20 or 30 years—when placed upon appropriate corticoid therapy, these patients begin to function normally as far as reproductive activity is concerned. These data indicate that prolonged and excessive sex steroid effects early in life do not have a deleterious effect upon later gonadal function.

**TREATMENT**—The following therapeutic approach to gigantism in the female is advised: oral administration of 25 mg of conjugated equine estrogens or 0.1 mg of ethinyl estradiol twice daily for a continuous period of 6 to 12 months at 4 to 5 week intervals; a weekly course of therapy with norethynodrel (Enovid) or norethindrone (Norlutin), 10 mg 3 times a day, or 25 mg 3 times a day of medroxyprogesterone acetate (Provera).

The purpose of these 19 norsteroids is to induce secretory changes in the endometrium so that the resulting catamenia will prevent endometrial hyperplasia. The progestational therapy achieves a medical curettage, preventing excessive uterine stimulation and inducing menstrual bleeding according to plan. Without such therapy cystic glandular hyperplasia of the endometrium may result, eventually causing excessive and abnormal uterine bleeding.

If oral therapy is difficult, the patient may then be given 10 mg of estradiol cyclopentylpropionate (Depo Estradiol) or 20 mg of estradiol valerate (Delestrogen) at 10 day intervals, together with the oral 19 norsteroid therapy as recom-

rise to the basophilic, eosinophilic or amphophilic cells. Chromophobic adenomas occur in patients in all decades of life but patients with these tumors do not respond as well to radiation therapy as does the acromegalic patient. As in the patient with craniopharyngioma surgical intervention may be the procedure of choice with the resulting panhypopituitarism being treated as described on page 561.

**Sheehan's Syndrome**—This syndrome is one of panhypopituitarism arising as a result of pituitary thromboses or ischemia usually occurring following postpartum hemorrhage or excessive blood loss. Such a patient is a female looking somewhat older than her stated age with absence of pubic and axillary hair without cachexia so that her breast development remains moderately normal. The skin is wrinkled and gives the face a wizened appearance. All the laboratory examinations indicate low or absent thyroid, adrenal and gonadal function as well as absence of pituitary activity. Therapy in such patients requires complete replacement treatment with thyroid, adrenal and gonadal therapy. Adrenal therapy usually includes only glucocorticoids for their effects upon carbohydrate metabolism and combating stress. The sodium retaining steroids usually are not required but are employed only in those patients with the systolic blood pressure below 100 mm Hg.

**Chiari Frommel Syndrome**—This syndrome may be a variant of Sheehan's syndrome. However persons with this syndrome do not show the wizened appearance characteristic of Sheehan's syndrome but exhibit the amenorrhea associated with acromegalic like facies and persistent lactation. The prognosis with respect to fertility as in those with Sheehan's syndrome is hopeless. However with gonadal replacement therapy alone these patients do splendidly.

A characteristic of this syndrome is galactorrhea which is usually not very responsive to suppressive doses of the sex steroids. It will however diminish in sufficient degree to make the patient more comfortable and less troubled with soiled lingerie. The use of the 19 norsteroids with estrogen will diminish the galactorrhea and at the same time induce menstrual periods at periodic intervals for as long as the patient is on steroid therapy. Spontaneous resumption of periods cannot be expected. However when therapy is discontinued after a year or two of persistent treatment the galactorrhea may return but it will be markedly less than that initially.

The acromegalic like facies, the enlargement of the sella turcica together with partial encroachment of the visual field in some patients makes the diagnosis of the Chiari Frommel syndrome a complex one and tends to point to multiglandular defects. However galactorrhea is not uncommon in persons with acromegaly not giving a history of previous cyesis. In addition persistent galactorrhea has been noted post partum and also following surgical procedures such as hysterectomy, oophorectomy and cholecystectomy. The stress of surgical procedures upon pituitary release of lactogenic hormone is no doubt a factor in these latter cases. Lactation in such individuals may be suppressed by the use of the 19 norsteroids discussed on page 564.

**Pituitary Dwarfism**—Patients with pituitary dwarfism show a defect in growth but are without evidence of any other endocrinopathy. It is presumed





mended previously. To potentiate the effect of estrogen upon the epiphyses, 10 mg of methyltestosterone twice daily may be added to the above regimen and continued for as long a time as is necessary unless acne intervenes. The epiphyses of these patients should be studied at 4-month intervals, and, if closure is imminent, further steroid therapy can be discontinued.

Treatment in the male with gigantism also requires the use of estrogen because estrogen is by far the most effective agent in accelerating premature closure of the epiphyses. The parenteral therapy of choice is as follows: 10 mg of estradiol cyclopentylpropionate or 20 mg of estradiol valerate intramuscularly every 2 to 3 weeks, plus 100 mg of testosterone cyclopentylpropionate (Depo-Testosterone) at the same intervals. The patient will develop some evidence of gynecomastia and breast tenderness which will usually disappear at the cessation of therapy and may even become less evident while the steroid therapy is being continued. When epiphyseal closure is obvious such therapy may be discontinued. It is gratifying to be able to arrest excessive growth so easily, thereby changing a potentially grotesque person into a normal one.

Prior to the initiation of any steroid hormone therapy for the purpose of inducing epiphyseal closure it is important of course to examine the sella turcica and make sure that there is no evidence of pituitary tumor. In cases of suspicious enlargement of the sella turcica or if the patient complains of loss of visual acuity visual field studies should also be examined. If they are abnormal appropriate therapy should be initiated as outlined for treatment of acromegaly.

### Posterior Pituitary Hormone Defects

**Diabetes Insipidus**—The primary disease concerned with disturbances of posterior pituitary hormone is diabetes insipidus. Either as a result of a neurogenic lesion in the area of the hypothalamus above the posterior lobe of the pituitary gland or of disease in the posterior lobe itself, inadequate amounts of antidiuretic hormone are elaborated. The absence of this hormone may be of such a degree that the patient may excrete tremendous amounts of urine, thereby requiring excessive ingestion of water to prevent serious dehydration.

Therapy for such patients involves the use of posterior pituitary hormone. This may be administered in a number of different ways. The topical use of a powder by nasal insufflation may give very effective control in those who do not develop nasal sensitivity to the powder. It is usual to advise the patient to insufflate the material into his nose every time he urinates. In so doing the more he urinates the more powder he takes, resulting in eventual control of urinary frequency thereby requiring less frequent insufflation of the powder. This has been an excellent device for controlling urination in most patients with diabetes insipidus. Because of its self regulatory features overdosage with posterior pituitary powder is most unlikely. If the powder cannot be tolerated, the patient may take the posterior pituitary hormone by injection in the form of Pitressin Tannate in oil. The usual dose required is 5 units (1 ml) intramuscularly every 2 to 3 days. Occasionally some patients require more and some less frequent administration. The use of the aqueous preparations has no place in the therapy of diabetes

**Sodium Levothyroxine (Synthroid)** Sodium levothyroxine is a crystalline preparation chemically pure, which has the advantages of being reproducible in preparation and manufacture and not dependent on biological assays for standardization. It does not deteriorate with age and maintains its effectiveness on the shelf when exposed to a normal degree of moisture.

**Liothyronine (Cytamel)** This crystalline compound presumably is the pure thyroid hormone in the form utilized at the tissue level l triiodothyronine. It has the reproducibility of sodium levothyroxine and none of the disadvantages of the crude biological products. It is not affected by storage or aging. It theoretically is the drug of choice in those patients with the hypometabolic syndrome.

**General Considerations** The thyroid preparations listed above can be characterized with respect to their duration of effect, dissipation of activity, and comparative activity. Thyroid extract, thyroglobulin, and sodium levothyroxine take 2 to 3 weeks to achieve their full effect and consequently require 2 to 3 weeks to be completely dissipated. It is unwise therefore to alter the dose of thyroid any more frequently than every 2 to 3 weeks with these preparations since cumulative effects with subsequent toxicity may develop. It is also obvious that a dose of thyroid taken before sleep will not disturb the patient's sleep that night but may do so 2 to 3 weeks later. In contrast, l triiodothyronine achieves its full effect within 2 to 3 days and is as rapidly dissipated. The comparable dose relationship between these thyroid preparations is listed in Table 40.

Table 40 Comparative Activity of Different Thyroid Preparations

Product	Average Maintenance Dose in Mg
Thyroid Extract	100
Thyroglobulin	100
Na levothyroxine	0.3 (300γ)
Liothyronine	0.1 (100γ)

**dl Triiodothyronine (Tnon**  
(liothyronine) inasmuch as its more evanescent, and the response less predictable. Its action is as desirable as the levo form. While theoretically the dl form of a chemically pure preparation is one half as active as the levo form, the dl form would contain only a fraction of the levo form if the levo form is the active preparation and the dl form is not readily changed into its levo configuration.

While the actions of the above preparations, particularly the first three, take 2 to 3 weeks to develop their full effects, it should be noted that their effect upon kidney function is more prompt and rapid. The peculiar effect of thyroid in increasing renal blood flow and glomerular filtration will be promptly noted in the responsive patient by a diuresis that may occur shortly after the thyroid material has been ingested, often in 24 hours. It is, of course, unnecessary to administer any of the above thyroid preparations in divided daily dosage. A single dose may be taken at any time of the day.

Thyroid preparations will achieve their most dramatic and important effect in patients with congenital cretinism. It is important that the diagnosis be made

thyroid function. There are also other supportive laboratory data, substantiating the clinical evidence of decreased thyroid function, viz., an elevated cholesterol, a flat glucose tolerance curve, and a low BMR. Dryness of the skin, loss of cephalic hair, intolerance to cold, constipation, muscle pains and aches, and a slow rebound of the patella reflex are the usual classical signs anticipated in decreased thyroid function.

The laboratory evaluation of thyroid disease achieves its greatest usefulness in hypothyroidism. We feel that no single parameter should be relied upon to establish the diagnosis. Cholesterol values may be a valuable index of thyroid function when the procedure is done well and studied with respect to response to therapy. The glucose tolerance test is a valuable adjunct in diagnosing aberrations of thyroid function. This is based in part upon the property of thyroid hormone to increase phosphorylization. Consequently, carbohydrate absorption from the intestinal tract may be normal, depressed, or accelerated, depending upon whether the patient is euthyroid, hypothyroid or hyperthyroid. When the tests listed above are evaluated in conjunction with the basal metabolism test, radioactive iodine studies, and protein bound iodine test, a complete picture of the thyroid status and diagnosis of hypothyroidism, hyperthyroidism, hypometabolism, or euthyroidism can be established.

**THERAPEUTIC AGENTS**—The therapeutic approach to the treatment of hypothyroidism is of course the use of specific hormonal products. There are four such compounds on the market at the present time.

**Thyroid Extract** This compound is the original preparation made available for clinical use and is standardized purely on the basis that the extract has an appropriate percentage of iodine, namely 0.2 per cent. There are no other specific criteria that must be met. Consequently an unusual degree of variability may be noted in a patient's response to thyroid extracts made in different commercial houses. Thyroid extract obtained from the gland of a cow killed in Texas, while having the same iodine content per gram as that from a cow killed in Chicago would not necessarily have the same physiologic activity. It must be emphasized that the physiologic activity of any one preparation is not dependent solely upon its iodine content. The activity of the extract is affected by the nutritional state and the endocrine status of the animal from which the gland has been obtained, and the stress to which the animal is exposed prior to slaughtering. In addition, the longer the preparation stays on the pharmacist's shelf the more likelihood there is that there will be a diminution of activity. This loss is markedly accelerated in the material stored in moist areas.

**Thyroglobulin** This preparation represents some attempt of purification and is prepared so that 1 mg. is equal in activity to 1 mg. of USP thyroid extract. In addition the iodine content of thyroglobulin is precisely the same as that of thyroid extract, namely, 0.2 per cent. Thyroglobulin however is a more precise preparation than USP thyroid in that the preparation is biologically assayed in thyroidectomized animals. This provides a double set of standards and removes the variability noted with USP thyroid itself. However while all lots are biologically comparable when freshly prepared, they also deteriorate with age and upon exposure to moisture.

Once the diagnosis is made, the therapeutic approach, of course, is surgical removal of the parathyroid glands, which may be adenomatous in character. Unfortunately, many times it is difficult to locate the adenoma and, despite the diagnosis, surgical evidence of the disease may be lacking. In these patients it is important to limit the intake of calcium. The use of sodium phytate, in doses of 8 Gm per day, may be effective in diminishing the absorption of calcium from the intestinal tract. This, of course, may be of value in patients in whom surgical demonstration of the disease was not possible. After the removal of the parathyroid adenoma, the patient may go into a temporary phase of hypoparathyroidism. Here the intravenous use of calcium gluconate may prevent tetany or arrest it. The material may be administered intravenously, slowly and with caution in doses of 0.5 Gm. Obviously, a patient also receiving digitalis should receive calcium salts very cautiously to avoid serious cardiac arrhythmias.

## THE ADRENAL GLANDS

Therapy directed toward abnormalities of adrenal function is principally concerned with disease of the cortex. While the medulla is an integral part of the adrenal gland, there is little in the way of medical therapy that may be utilized in a disturbance of function of the medulla.

### Adrenal Medulla

The only abnormality of medullary function which can be recognized and corrected is that of hyperactivity seen in patients with a pheochromocytoma. In such patients therapy is primarily surgery; however, medical means must usually be employed to establish the correct diagnosis. The drugs most commonly used in the diagnostic procedures are those which induce a provocative response in normotensive phases or lysis of blood pressure during the periods of active overactivity. The provocative drugs which have been most effective are histamine and methacholine. Their mechanism of action is primarily to induce a sympathomimetic overplay, either directly by stimulation of the medullary tissue or extra-adrenal chromaffin tissue, or indirectly by visceral vasodilatation whereby the reduction in blood pressure so induced acts as a stimulus for secretion of epinephrine from the adrenal medullary or chromaffin tissue. In the presence of a pheochromocytoma, an exaggerated increase in blood pressure will occur. In patients in whom hypertension is present, lysis of the blood pressure may be achieved by the use of phentolamine (Regitine) or benzodioxane. Phentolamine is the drug of choice inasmuch as it may be administered either intramuscularly, intravenously, or subcutaneously in doses of 5 mg to induce lysis of the blood pressure in most patients with an active phase of pheochromocytoma. When hypertension of sufficient magnitude is induced with the provocative drugs, lysis of the blood pressure may be accomplished with these drugs, thereby offering substantiation of the diagnosis.

Chemical tests for  
may eventually replace  
tests for                      of

of increased catecholamine excretion in the urine  
c procedures previously described. Biological  
like substances in the urine, utilizing special

early In addition to the laboratory criteria, a study of the bone age may be of utmost importance in establishing the diagnosis of cretinism or severe hypothyroidism. The presence of fine lanugo-like hair growth is also an important pathognomonic sign of hypothyroidism in infants or children. It is in these patients that one can achieve a splendid effect, provided the thyroid dose is pushed to tolerance.

The best criterion for determining tolerance to thyroid is the effect on the child's pulse while asleep. It is as important a criterion for determining maximum tolerance of dosage as we have. The normal pulse of a sleeping child below the age of 1 year may range between 90 and 100. That of a child above 1 year of age may range from 90 down, depending upon the age of the child. A parent who takes the pulse accurately serves his physician well in helping him determine the dose best suited for the patient. An important rule of thumb in thyroid therapy is that the markedly hypothyroid patient is much more sensitive to thyroid drugs than is the euthyroid or hyperthyroid individual. One should note that initial thyroid medication may change the long-standing cretin from a jocular, chirpy, happy person to one who is morose, belligerent and difficult to handle. These personality changes must be considered in the decision of whether to institute therapy in the long-standing cretin, since therapy at that time will have little effect on the mental retardation or ravages of the primary disease.

**Hyperthyroidism**—The treatment of hyperthyroidism has encompassed three major forms of diverse therapeutic approaches—surgery, radioactive iodine, and antithyroid therapy. In a chapter on the use of drugs in different disease entities it is, of course, important that the medical management of a syndrome be emphasized. In general the medical control of hyperthyroidism has been relegated to the background because of the rapidity of results achieved with surgical treatment and the convenience of radioactive iodine therapy. There is no question that in the elderly thyrotoxic cardiac patient the use of radioactive iodine (RAI) is the most propitious form of therapy. Similarly the surgical removal of a toxic gland, so enlarged that pressure upon the esophagus and adjacent structure leads to discomfort as well as to an unaesthetic appearance, is no doubt the procedure of choice.

The use of RAI in patients below the age of 30 or 35 years should be questioned because of the potential neoplastic effects in the thyroid glands of these patients, particularly 2 to 3 decades after the RAI has been administered. Similarly, the increasing incidence of nodularity in the thyroid gland of children who have received RAI for hyperthyroidism in the past makes such a procedure seem undesirable. The surgical management of the thyrotoxic gland in a patient showing no evidence of nodularity and in whom the gland is not grotesquely enlarged appears to be unwarranted in view of the anticipated good results in cooperative patients following appropriate medical management in the manner described below.

**TREATMENT**—The medical management of hyperthyroidism is the procedure of choice in patients with exophthalmos who also have a marked phobia against any surgical procedure. The use of the antithyroid drugs in these persons must be for an extended period of time, with adequate safeguards set up to prevent untoward toxic effects or undesirable side effects of consequence. Propylthiouracil

Once the diagnosis is made, the therapeutic approach, of course, is surgical removal of the parathyroid glands, which may be adenomatous in character. Unfortunately, many times it is difficult to locate the adenoma and, despite the diagnosis, surgical evidence of the disease may be lacking. In these patients it is important to limit the intake of calcium. The use of sodium phytate, in doses of 8 Gm per day, may be effective in diminishing the absorption of calcium from the intestinal tract. This, of course, may be of value in patients in whom surgical demonstration of the disease was not possible. After the removal of the parathyroid adenoma, the patient may go into a temporary phase of hypoparathyroidism. Here the intravenous use of calcium gluconate may prevent tetany or arrest it. The material may be administered intravenously, slowly and with caution in doses of 0.5 Gm. Obviously, a patient also receiving digitalis should receive calcium salts very cautiously to avoid serious cardiac arrhythmias.

## THE ADRENAL GLANDS

Therapy directed toward abnormalities of adrenal function is principally concerned with disease of the cortex. While the medulla is an integral part of the adrenal gland, there is little in the way of medical therapy that may be utilized in a disturbance of function of the medulla.

### Adrenal Medulla

The only abnormality of medullary function which can be recognized and corrected is that of hyperactivity seen in patients with a pheochromocytoma. In such patients therapy is primarily surgery; however, medical means must usually be employed to establish the correct diagnosis. The drugs most commonly used in the diagnostic procedures are those which induce a provocative response in normotensive phases or lysis of blood pressure during the periods of active overactivity. The provocative drugs which have been most effective are histamine and methacholine. Their mechanism of action is primarily to induce a sympathomimetic overplay, either directly by stimulation of the medullary tissue or extra-adrenal chromaffin tissue, or indirectly by visceral vasodilatation whereby the reduction in blood pressure so induced acts as a stimulus for secretion of epinephrine from the adrenal medullary or chromaffin tissue. In the presence of a pheochromocytoma, an exaggerated increase in blood pressure will occur. In patients in whom hypertension is present, lysis of the blood pressure may be achieved by the use of phentolamine (Regitine) or benzodioxane. Phentolamine is the drug of choice inasmuch as it may be administered either intramuscularly, intravenously, or subcutaneously in doses of 5 mg to induce lysis of the blood pressure in most patients with an active phase of pheochromocytoma. When hypertension of sufficient magnitude is induced with the provocative drugs, lysis of the blood pressure may be accomplished with these drugs thereby offering substantiation of the diagnosis.

Chemical tests for detection of increased catecholamine excretion in the urine may eventually replace the diagnostic procedures previously described. Biological tests for detection of norepinephrine like substances in the urine, utilizing special

artery sections obtained from the rabbit dorsal aorta, have been described. Significant *in vitro* contraction of the aorta strip will occur with the addition of norepinephrine or urine from a patient with a pheochromocytoma. When diagnosis is definitely established by provocative tests, lytic drugs, chemical isolation, or biologic procedures, surgical ablation of the tumor is necessary. In this procedure the use of phentolamine may be helpful in preventing serious or fatal hypertensive crisis which may occur during the manipulation of the tumor.

### Adrenal Cortex

The adrenal cortex, having a multiplicity of functions, may produce a multiplicity of diseases. In understanding the therapeutic approach to diseases of the adrenal cortex one must comprehend the interrelationship between the pituitary gland and the adrenal glands. The adrenal cortex is not entirely controlled by pituitary ACTH. The adrenocorticotrophic hormone stimulates primarily the two innermost zone layers of the adrenal cortex, namely, the zona fasciculata and the zona reticularis. The zona glomerulosa, the third and outermost zone layer of the adrenal cortex, is not under pituitary ACTH control. The steroid produced by the zona glomerulosa is aldosterone.

**Aldosterone**—Aldosterone is primarily concerned with the control of water and electrolyte metabolism; its secretion being influenced by electrolytes and the degree of hydration which it itself controls, either directly or indirectly via the diencephalon. The stimulus for aldosterone secretion is low sodium, high potassium level, or dehydration. Aldosterone secretion is inhibited by high sodium, low potassium, or overhydration. The clinical use of aldosterone is limited not only by its cost and relative unavailability, but also by the fact that it must be administered intramuscularly. Inasmuch as other synthetic steroids are much more effective orally in inducing sodium retention, they are the drugs of choice in the treatment of the electrolyte disturbance associated with adrenal insufficiency or Addison's disease.

**Other Cortical Hormones**—Of the two innermost zone layers of the adrenal cortex the zona fasciculata, the middle zone layer, is concerned with the formation and elaboration of hydrocortisone. Hydrocortisone under the stimulus of ACTH from the pituitary gland is formed from cholesterol taken up by the zona fasciculata from the blood stream. Cholesterol is converted in stepwise progression to pregnenolone, progesterone, 17-hydroxyprogesterone, Compound S, and finally to hydrocortisone. This is an orderly process with the end products, Compound S and hydrocortisone, being formed by the process of hydroxylation at C 21 and C 11 so that 17-hydroxyprogesterone is converted to hydrocortisone. The control of adrenal stimulation by ACTH rests in hydrocortisone itself. When the hydrocortisone level reaches a critical point, further ACTH secretion is inhibited or prevented. Consequently excessive stimulation of the adrenal cortex by ACTH is controlled as long as adequate production of hydrocortisone is assured. ACTH also stimulates the zona reticularis to produce the sex steroids, of which the 17-keto steroid precursors are the principal ones. The sex steroids are three in number, namely, androgens (17 ketosteroid precursors), estrogens, and progestogens. The



androgens and the estrogens have an ever-present potential sex steroid effect when they are present in excessive amounts

**Hypoadrenocorticism**—Decreased function of the adrenal cortex may be due to primary disease of the adrenal gland itself, or it may be secondary to pituitary ACTH insufficiency. The clinical manifestations of Addison's disease are classical and need no emphasis at this time. It is important to note, however, that the asthenia and fatigue these patients show are perhaps the most important clinical manifestations of adrenal insufficiency. In addition to the classical clinical features the diagnosis of adrenal insufficiency also rests upon a finding of low levels of 17 ketosteroids and 17 hydroxysteroids in the urine and a low level of 17 hydroxysteroids in the blood. One can differentiate between primary and secondary hypoadrenocorticism by the administration of ACTH, 40 units of the gel will have no effect in increasing the 17 hydroxysteroids in the blood or urine or the urinary 17-ketosteroids in patients with primary adrenal disease. Secondary adrenal insufficiency is characterized by an increased excretion of 17 ketosteroids in the urine and 17-hydroxysteroids both in the urine and blood after the administration of ACTH. Another important clinical difference is the presence or absence of pigmentation. Pigmentation is invariably noted in patients with primary adrenal disease and rarely, if ever, in patients with secondary adrenal insufficiency. The inability of patients to excrete water under a water load is another classical finding in Addison's disease which can be readily established in the physician's office by a water-tolerance test.

Therapy of Addison's disease is no longer the problem of magnitude it had been in the past. Before the days of corticosteroids, excessive salt intake was the only measure for the treatment of adrenal insufficiency. In contrast to the ineffectiveness of sodium alone with the advent of crude adrenocortical extracts, patients with adrenal crises could be saved by large doses. Unfortunately, these extracts were prohibitively expensive and required frequent daily administration to achieve a therapeutic effect. A decided advancement in therapy was made when desoxycorticosterone acetate (DCA) was made available. This steroid decreased the difficulties of frequent administration and provided adequate control for most patients with Addison's disease except during a crisis or when the patient was exposed to a stress situation.

DCA is available as an oil solution containing 5 mg per milliliter, as a 2 mg Linguet and as a pellet for intramuscular or subcutaneous implantation. Although convenient, the use of the Linguet was not predictable. The use of the oil solution required injections daily or every 2 days, but assured the patient of adequate control. Pellet implantation would last approximately 4 to 6 months and was a very convenient form of therapy, as the pellets could be implanted in the office and were well tolerated. The site of implantation may be in either the inguinal or subscapular areas. The dose to be implanted is dependent upon the intramuscular daily maintenance dose of DCA in oil. Usually one uses one 75 mg pellet for each 0.25 mg of DCA required per day.

The preparations listed above however, must now be considered as being largely of historical interest since the following two modes of therapy have been

artery sections obtained from the rabbit dorsal aorta have been described. Significant *in vitro* contraction of the aorta strip will occur with the addition of norepinephrine or urine from a patient with a pheochromocytoma. When diagnosis is definitely established by provocative tests, lytic drugs, chemical isolation or biologic procedures, surgical ablation of the tumor is necessary. In this procedure the use of phentolamine may be helpful in preventing serious or fatal hypertensive crisis which may occur during the manipulation of the tumor.

### Adrenal Cortex

The adrenal cortex, having a multiplicity of functions, may produce a multiplicity of diseases. In understanding the therapeutic approach to diseases of the adrenal cortex, one must comprehend the interrelationship between the pituitary gland and the adrenal glands. The adrenal cortex is not entirely controlled by pituitary ACTH. The adrenocorticotrophic hormone stimulates primarily the two innermost zone layers of the adrenal cortex, namely, the zona fasciculata and the zona reticularis. The zona glomerulosa, the third and outermost zone layer of the adrenal cortex, is not under pituitary ACTH control. The steroid produced by the zona glomerulosa is aldosterone.

**Aldosterone**—Aldosterone is primarily concerned with the control of water and electrolyte metabolism, its secretion being influenced by electrolytes and the degree of hydration which it itself controls, either directly or indirectly via the diencephalon. The stimulus for aldosterone secretion is low sodium, high potassium level or dehydration. Aldosterone secretion is inhibited by high sodium, low potassium or overhydration. The clinical use of aldosterone is limited not only by its cost and relative unavailability, but also by the fact that it must be administered intramuscularly. Inasmuch as other synthetic steroids are much more effective orally in inducing sodium retention, they are the drugs of choice in the treatment of the electrolyte disturbance associated with adrenal insufficiency or Addison's disease.

**Other Cortical Hormones**.—Of the two innermost zone layers of the adrenal cortex, the zona fasciculata, the middle zone layer, is concerned with the formation and elaboration of hydrocortisone. Hydrocortisone, under the stimulus of ACTH from the pituitary gland, is formed from cholesterol taken up by the zona fasciculata from the blood stream. Cholesterol is converted in stepwise progression to pregnenolone, progesterone, 17-hydroxyprogesterone, Compound S, and finally to hydrocortisone. This is an orderly process with the end products, Compound S and hydrocortisone, being formed by the process of hydroxylation at C 21 and C 11, so that 17-hydroxyprogesterone is converted to hydrocortisone. The control of adrenal stimulation by ACTH rests in hydrocortisone itself. When the hydrocortisone level reaches a critical point, further ACTH secretion is inhibited or prevented. Consequently, excessive stimulation of the adrenal cortex by ACTH is controlled as long as adequate production of hydrocortisone is assured. ACTH also stimulates the zona reticularis to produce the sex steroids of which the 17-ketosteroid precursors are the principal ones. The sex steroids are three in number, namely, androgens (17-ketosteroid precursors), estrogens and progestogens. The

**CUSHING'S SYNDROME** The diagnosis of Cushing's syndrome may be made upon the classical clinical findings which need no further description here. In most instances however confirmation by laboratory data such as decreased glucose tolerance, occasionally insulin resistance, normal or low 17 ketosteroids, elevated 17 hydroxysteroids in the urine and blood, and marked increase in blood and urinary 17 hydroxysteroids after a provocative ACTH test is required. In the intravenous or intramuscular provocative ACTH test urine and blood are collected before and after the injection of ACTH as previously described. Blood and urinary 17 hydroxysteroid values above 50 gammas per 100 ml or 50 mg per 24 hours respectively, after ACTH administration are indicative of Cushing's syndrome.

In such patients bilateral total adrenalectomy is the procedure of choice. The preoperative management of these patients requires the use of cortisone the day before surgery and the day of surgery in doses of 50 to 100 mg intramuscularly. During the surgical procedure the patient receives 100 mg of hydrocortisone intravenously. Following surgery cortisone is administered in the range of 50 mg 3 or 4 times daily for 3 days followed by gradual reduction of the dose so that at the end of a week the patient can be maintained orally on 25 to 30 mg of hydrocortisone per day. If at any time the patient shows significant adrenal insufficiency intravenous administration of hydrocortisone hemisuccinate is the drug of choice during the phase of acute insufficiency, followed by repetition of the initial doses of cortisone used postoperatively. It is imperative to note that in the treatment of any patient with large doses of corticoids plus sodium marked potassium depletion may occur. This may result in loss of tissue potassium sufficient to induce some signs of cardiac irregularities. Potassium supplementation with orange juice and 10 to 20 ml of K<sub>2</sub>CO<sub>3</sub> per day would prevent untoward reactions due to the hypokalemia.

The management of patients after adrenalectomy is precisely the same as that in patients with hypoadrenocorticism. In such patients who have hypertension which is sustained after the adrenalectomy there is little need for the sodium retaining corticoids which are used only when significant hypotension develops. Pigmentation may appear shortly after adrenalectomy but can usually be ameliorated by the administration of the glucocorticoids. The sodium retaining corticoids in doses adequate for the control of electrolyte metabolism are less effective in preventing or inhibiting pigmentation. The adrenalectomized patient is markedly sensitive to hypotensive drugs so that while reserpine may be very effective in reducing blood pressure elevation maintained after adrenalectomy caution is advised with the use of any antihypertensive agent in the adrenalectomized patients.

**HYPERADRENOCORTICISM WITH ADRENOGENITALISM**—Hyperadrenocorticism concerned with the adrenogenital syndrome is an entirely different clinical entity from that of Cushing's syndrome. Females with the adrenogenital syndrome are usually masculinized while in males the external genitalia except for the testes are unusually well developed. This syndrome has been ascribed to a metabolic disturbance in the zona fasciculata whereby hydroxylation is interfered with. The process of hydroxylation is essential to complete the stepwise progression of steroid synthesis in the orderly progression from cholesterol to hydrocortisone.

and to be decidedly more convenient and acceptable to both the patient and the physician. Addison's disease may now be controlled parenterally by the use of the long acting desoxycorticosterone triphenylacetate (DCTPA). This preparation is an aqueous suspension containing 25 mg per milliliter. The usual dose is 1.5 ml (75 mg) every 4 to 5 weeks. All patients with Addison's disease can be satisfactorily managed orally with 10 mg of hydrocortisone twice to three times a day or 0.1 mg of 9 alpha fluorohydrocortisone per day. The fludrocortisone (9-alpha fluorohydrocortisone, Florinef) is used only in those patients in whom hypotension is present. Hydrocortisone is employed to prevent hypoglycemia and to permit the patient to go through stress situations without untoward effects. Other glucocorticoids may be substituted in equivalent doses in most patients with comparable therapeutic efficacy.

It is important to emphasize that the patient with Addison's disease is unusually sensitive to the sodium retaining qualities of any corticoid. There are, however, four cardinal signs of overdosage of fludrocortisone which would give the physician an index to the fact that excessive doses of the salt-retaining steroid are being administered. The patient will show the following changes with such overdosage: (1) elevation of blood pressure, (2) excessive increase in weight, (3) increase in heart size, and (4) dependent edema. When these signs of excessive sodium retention are noted the administration of 9 alpha fluorohydrocortisone should be stopped. All the symptoms usually subside within 3 to 4 days.

It is rare for a patient to need more than 0.1 to 0.15 mg of fludrocortisone per day. The patient may or may not use supplementary salt intake, depending upon his desire. As a rule, adequate use of salt in the preparation of food will supply the patient with a normal amount of sodium. Occasionally overdosage with fludrocortisone will also produce muscle weakness which can be attributed to excessive potassium loss. Usually this can be treated very effectively and simply by the ingestion of potassium in the form of orange juice rather than in the form of oral medication. If additional amounts of potassium are still required, this may be managed without gastrointestinal irritation by the use of a liquid, palatable combination known as Kaon.

**Hyperadrenocorticism.**—Because of the multiple nature and activity of the adrenal cortex, hyperfunction may produce several different disease entities. Increased activity of the adrenal cortex resulting in Cushing's syndrome may be attributed in part to overactivity of the zona fasciculata, resulting in increased hydrocortisone production. While formerly believed to be due primarily to basophilic changes in the pituitary gland, in the light of our present knowledge Cushing's syndrome can be attributed in its entirety to overproduction of hydrocortisone. The rationale for adrenal rather than pituitary origin follows: (1) The disease can be induced with cortisone. (2) Basophilic changes in the pituitary and are in all probability due to retrograded changes. Cortisone will induce pituitary basophilism. In addition Crooke's cells noted in some cases of pituitary basophilism no doubt represent a cell with degenerative hyaline changes. (3) Many patients in whom adrenalectomy has been performed for the classical Cushing's syndrome have failed to show morphologic evidence of increased activity in the adrenal gland, yet dramatic clinical cure was achieved despite this.

change in 17 ketosteroids during any of the 8 hour periods. If there is hyperplasia, significant depression of 17 ketosteroids will occur during the infusion. The ovary must also be considered as a site of the neoplasm because adrenal rest tumors of the ovary may simulate the adrenogenital syndrome. Obviously, when the diagnosis of neoplasia is made, the therapy consists of removal of the neoplasm either from the adrenal cortex or the ovary.

## THE GONADS

### Female\*

The treatment of gonadal dysfunction in the female usually revolves around the management of menstrual abnormalities, the use of hormones in the climacteric, and related conditions. The menarche normally occurs between the ages of 10 and 14 years. Occurrence of the menarche before the age of 10 years may be considered as precocious and after the age of 14 years as delayed. The development of the female is usually progressive, the thelarche is followed by the pubarche and then by the menarche.

**Sexual Precocity**—Precocious sexual maturity in the female child warrants attention. It is imperative that possible organic pathologic causes be ruled out before a diagnosis of constitutional sexual precocity is made. If this diagnosis is made, it is important that precautionary measures be taken to prevent pregnancy. These children readily succumb to the advances of sexual deviates because of their inadequate intellectual development. The growth problem in these children is also important. While in the early stages of their syndrome their height far exceeds the stature of those in their age group, the over-all height of these patients is considerably less than that of the average adult. The reason for this is that the steroid hormones cause growth by stimulating the epiphyseal centers, but at the same time, unlike the growth hormone, cause premature epiphyseal closure.

These patients should be given gonadotropic hormone prepared from the pituitary glands of animals. One may employ hog, sheep, or beef pituitary gonadotropic extracts in doses of 25 rat units 3 times a week. Therapy must be continued for as long a time as endogenous gonadotropic inhibition is desired. While this treatment may sound paradoxical, it is effective in inducing antihormone formation. As a result, the antigonadotropic hormone will inhibit the endogenous secretion of gonadotropic hormone by the patient's pituitary gland, thereby producing temporary cessation of gonadal function, and epiphyseal closure will be delayed.

**Amenorrhea and Delayed Menstruation**—Delay in onset of menstruation and primary or secondary amenorrhea may be effectively treated, provided that a correct diagnosis is made. It is necessary to rule out disorders of the thyroid or the adrenal glands before attempting to identify which component of the pituitary-ovarian uterine axis is responsible for failure of menstruation.

In patients with amenorrhea due to supratentorial or hypothalamic factors, monthly administration of progestational steroids, either as progesterone, 100 mg in

\*[Many of these problems are also discussed in Chapter 36. Ed.]

When hydroxylation is incomplete, inadequate amounts of Compound S and hydrocortisone are produced. As a result, inhibition of pituitary ACTH by hydrocortisone does not take place so that increased ACTH elaboration occurs. Inasmuch as ACTH also stimulates the zona reticularis to produce the 17 ketosteroid precursors, a marked increase in 17 ketosteroid excretion is usually noted. 17-Hydroxyprogesterone, the steroid which is not completely converted to Compound S, is excreted as pregnanetriol. Since elevated levels of 17-hydroxyprogesterone occur in this syndrome, elevated pregnanetriol excretion takes place.

The therapy of this syndrome in cases of hyperplasia demands the appropriate use of corticoids. The following corticoids may be employed with their comparative doses administered 3 times a day: cortisone, 12.5 mg; hydrocortisone, 10 mg; prednisone or prednisolone, 2.5 mg; methylprednisolone (Medrol), 2 mg; triamcinolone (Aristocort, Kenacort), 2 to 3 mg; and dexamethasone (Decadron, Deronil, Gammacorten), 0.375 mg. When these doses are used there is no need to restrict the dietary intake of salt or to add potassium. No special dietary restrictions are necessary in the management of the patient. The effectiveness of therapy is judged by the level of 17-ketosteroids and/or pregnanetriol excretion. In the postpubertal adrenogenital syndrome medication may be stopped, and if elevation of the 17 ketosteroids and pregnanetriol does not occur, there is little need to reinstitute it. The patient with congenital adrenocortical hyperplasia, however, must be maintained on corticoids indefinitely. When pregnancy occurs in patients with adrenocortical hyperplasia, the need to continue corticoid therapy is questionable because the placenta apparently takes over corticoid function and activity effectively.

**ADRENOGENITAL SYNDROME IN THE NEWBORN INFANT**—The newborn infant with the adrenogenital syndrome may occasionally have a salt-losing syndrome. It was first believed that this might be due, in part, to a specific steroid producing excretion of sodium. However, in the light of our recent knowledge, infants with the salt losing syndrome no doubt have a complete blockage of hydroxylation which prevents the formation of hydrocortisone. However, aldosterone is present at normal levels. In the absence of hydrocortisone, aldosterone cannot maintain its sodium-sparing effect. The addition of corticoids promptly corrects this abnormality of electrolyte metabolism and permits endogenous aldosterone to effect a sodium-sparing effect. Doses of corticoids to be used in these infants are essentially the same as those suggested previously. Guides to therapy may also be based upon urinary 17-ketosteroid and pregnanetriol levels.

If there is no depression of elevated 17-ketosteroids and pregnanetriol with oral corticoid therapy, one must suspect neoplasia of the adrenal cortex or ovary. Normally, individuals with the clinical characteristics of the adrenogenital syndrome and neoplasia of either the adrenal cortex or ovary will not have increased pregnanetriol excretion. The diagnosis of neoplasia may be confirmed by the intravenous administration of 100 mg of hydrocortisone hemisuccinate or 25 mg of either prednisolone hemisuccinate or 6 methyl prednisolone hemisuccinate. Urine specimens are collected for 8-hour periods before, during, and after the infusion. The infusion of the corticoid is allowed to run for 8 hours using the appropriate dose of the selected steroid. If the patient has a neoplasm, there will be no significant

pituitary gland or as a consequence of an inability of the ovary to discharge the ovum because of a thickened capsule. A differential diagnosis, as well as a therapeutic induction of ovulation, may be attempted by the intravenous use of 20 mg of conjugated equine estrogens. Before this procedure is used one must rule out abnormalities of the thyroid and adrenal glands by the methods discussed on page 566. The patient must also show an adequate proliferative phase as manifested by the occurrence of a menstrual period following the oral or intramuscular administration of progestational steroids. If ovulation fails to follow the injection of conjugated equine estrogens, the injection should be repeated for 2 successive menstrual cycles 14 or more days after a spontaneous or progesterone induced period. If the patient fails to ovulate after all three injections, the likelihood of a thickened tunica of the ovary must be considered as being responsible for blocking ovulation.

In these patients a wedge resection of the ovary may confer fertility and regular menstrual periods upon the patient. The rationale for the use of intravenous estrogen is based upon our knowledge of the interrelationship existing between the pituitary and the ovary. In the sequential secretion of the gonadotropic hormones, estrogen has a dual effect—inhibition of FSH hormone activity and stimulation of release of luteinizing hormone. The latter effect may occur either by direct action on the pituitary gland or by indirect action by way of the hypothalamus, probably on the area between the paraventricular and supraoptic nuclei. When ovulation is so induced and pregnancy is desired, the patient should be instructed to have intercourse as frequently as possible after the intravenous injection of conjugated equine estrogens.

**Uterine Bleeding**—While amenorrhea may be a difficult problem to manage, the control of excessive uterine bleeding by appropriate hormonal therapy is also important. Excessive bleeding occurring either from the time of the menarche or up to the age of 25 is most commonly associated with anovulatory cycles. Excessive uterine bleeding occurring at the time of the climacteric must be investigated to rule out neoplastic disease prior to institution of hormonal therapy. As in the younger age group, despite the neoplastic propensities in the older woman, the common cause of the bleeding is also anovulatory cycles. Treatment of active bleeding consists of the parenteral use of 25 mg per day each of testosterone propionate and progesterone in oil intramuscularly for 5 days. The testosterone is used for hemostasis, presumably by its myotropic effect; the progesterone changes the endometrium into a secretory phase so that 'a medical curettage' will be achieved 4 to 5 days after the last injection. *Bleeding will usually stop after the first or second combined injection and will occur again with the medical curettage.* This therapy has been efficacious in controlling abnormal uterine bleeding of the anovulatory type and makes it unnecessary to do a dilatation and curettage in young unmarried women, thus sparing them both the physical and psychologic trauma of an unnecessary surgical procedure.

The patients who have received the combined testosterone and progesterone injections during the active phase of bleeding thereafter receive only 100 mg of progesterone in oil intramuscularly, or one of the oral progestational steroids in the doses previously recommended for 1 week starting 4 weeks after the first combined injection used during the active phase of bleeding. At this time there is no

## DRUGS IN ENDOCRINE DYSFUNCTION

oil (50 mg per milliliter) intramuscularly, or oral progestational agents, norethynodrel (Enovid) or norethindrone (Norlutin), 10 mg of either twice for 7 days, or 25 mg 3 times daily of 6 methyl prednisolone (Provera) for 7 days, will usually induce a menstrual period within 2 weeks. Ethisterone, in doses of 3 mg 3 times a day for 7 days, or progesterone in suppository form, 50 mg daily for 7 days, may also induce the same response. The use of progestational therapy for 2 to 3 successive months will usually be effective in inducing regular menstrual periods. There is a long-acting progestational steroid known as hydroxyprogesterone caproate (Delalutin) which will induce a secretory effect in doses of 250 mg administered intramuscularly in oil. This preparation may not be substituted for progesterone in oil when a rapid or prompt effect is desired.

After a diagnosis of ovarian failure has been made by appropriate techniques, cyclic menstruation should be induced in younger women to maintain adequate development of the secondary sexual characteristics or to induce such development of either parenteral or oral estrogens—parenterally in the form of estradiol cyclopentylpropionate (Depo-Estradiol) or estradiol valerate (Delestrogen), 10 mg of either every 2 weeks, or orally in the form of conjugated estrogens, equine, 1.25 mg (Vallestril), 6 mg, dienestrol 0.5 mg, and stilbestrol, 0.1 mg, all being administered twice daily, or any other appropriate estrogen in comparable doses for three weeks.

These preparations are followed by the progestational agent of choice. One should note in the treatment of patients with primary amenorrhea that therapy may be simplified by the estrogen medication being taken continuously, while the progestational steroid is administered at monthly or 5-week intervals. It is important to emphasize here that while aqueous progesterone suspensions are on the market, their use is associated with pain and marked induration at the site of injection. Progesterone as an aqueous suspension is the most irritating steroid available. Such compounds have no place in the armamentarium of the physician because of the marked tissue reaction and pain they induce.

The treatment of secondary amenorrhea may require only the use of progestational steroids. Secondary amenorrhea may be due, in part, to a failure of ovulation to take place. In such persons, because of persistent or constant secretion of estrogen, there is insufficient change in estrogen level to induce menstrual bleeding. Provided there is an adequate proliferative phase, administration of progesterone by parenteral or oral route will induce a menstrual period. The doses of progesterone used intramuscularly or orally are the same as those stated previously. This type of therapy may lead to spontaneous regular menstrual periods. However, if the patient has blockage of ovulation at the ovarian level, such progestational therapy could be purely palliative and would have to be administered at regular intervals every 4 to 6 weeks to prevent excessive building up of the endometrium. Progesterone therapy would induce periodic desquamation of the endometrium so that excessive bleeding would not occur.

Ovulatory failure in patients with menstrual irregularities or with infertility problems may be due either to failure of release of luteinizing hormone-



ing all the symptoms of the climacteric deserves appropriate treatment. The most effective is the use of estrogens alone or in combination with androgens, particularly when vasomotor symptoms are severe and predominant. The following doses of estrogens have proved to be appropriate in controlling the menopausal syndrome without adverse effects: conjugated equine estrogens, 1.25 mg per day, ethinyl estradiol, 0.05 mg per day, chlorotrianisene (Tace), 12 mg per day, dienestrol 0.5 mg per day, methallenestrol (Vallestril), 3 mg per day, and stilbestrol, 0.1 mg per day.

Androgen therapy may be effective in enhancing the response to estrogens, and in so doing permits the physician to use less estrogen if undesirable side effects such as breast tenderness, uterine bleeding, etc., develop. It is important to emphasize that the androgens will not nullify or neutralize the undesirable side effects of estrogens but, by permitting less steroid to be used, the therapeutic efficacy is maintained with fewer or less intense side effects. Half the dose of estrogens recommended above may be used if 5 mg of methyltestosterone is added to the daily regime. Androgens alone will usually not be as effective as the estrogens alone. As a rule 10 mg of methyltestosterone per day is the lowest nonarthenomimetic dose that can be employed with any therapeutic efficacy. Osteoporosis of the menopause will be more effectively ameliorated with estrogens and androgens than with estrogens alone.

**Frigidity**—The use of hormones in correcting deficiency of libido has not been utilized to its fullest extent. Although psychiatrists may deny the role of hormones in libido in the female, there is little doubt that androgens enhance libido in women who have once experienced it. The mechanism of action is perhaps based upon the clitoral stimulation achieved by androgens. Doses of 10 mg of methyltestosterone per day, 100 mg of testosterone cyclopentylpropionate (Depo-Testosterone) or 200 mg of testosterone enanthate (Delatestryl) every 4 weeks will enhance libido in women who have once known libido but now find intercourse a laborious duty. Women who have always been frigid cannot be expected to be helped by hormonal therapy; they do require psychiatric treatment. In contrast to the beneficial effect that androgens have upon libido, progesterone tends to diminish it. Progesterone suppositories in 25 to 50 mg per day will decrease the libidinous drive.

**Postpartum Breast Engorgement**—The treatment of postpartum breast engorgement with hormonal agents has ranged from a wide variety of oral steroids to an equal number of parenteral steroids. The most effective form of therapy includes the parenteral use of 5 mg of estradiol cyclopentylpropionate (Depo-Estradiol) plus 100 mg of testosterone cyclopentylpropionate (Depo-Testosterone) in a single intramuscular injection. An alternate preparation is 10 mg of estradiol valerate plus 300 mg of testosterone enanthate intramuscularly. These represent simple and efficacious treatments without adverse sequelae for postpartum breast engorgement. Obviously the neurogenic stimulation of suckling must be held in abeyance; fluid restriction as well as breast binders help in diminishing pain, engorgement, and discomfort at this time. Norethindrone (Norlutin) and norethynodrel (Enovid), in doses of 10 mg 3 times a day for 5 to 7 days, provide an oral means for controlling postpartum lactation. These compounds may also be used

need for androgens since the patient is not actively bleeding. The same progesterone regimen is repeated for 2 more 4 week intervals. This will usually result in a high percentage of good results. If the patient fails to respond, the possibility of intrauterine disease or excessive bleeding from secretory endometrium must be considered. In the former, surgical intervention is necessary. In the latter, an intravenous injection of conjugated equine estrogens, 20 mg, is effective in decreasing or stopping the flow. This is due in part to the fact that the estrogens enhance the production of prothrombin precursors, thereby facilitating prompt hemostasis.

**Dysmenorrhea**—The treatment of dysmenorrhea has been an enigma and has resulted in the recommendation of a great variety of procedures for its alleviation. Since primary intractable dysmenorrhea has been found to be associated with ovulatory changes in the endometrium, inhibition of ovulation with steroids or synthetic estrogens has resulted in good results with relief of pain. Doses of 1 mg of stilbestrol, 125 mg of conjugated equine estrogens, or 0.05 mg of ethinyl estradiol (Estinyl) administered twice a day from the eighth to the twentieth day of a 28 day menstrual cycle, will inhibit ovulation in most cases and thereby relieve pain. However, subsequent cycles require larger doses of the estrogen to prevent ovulation from 'breaking through'. An alternative method of inhibiting ovulation may be accomplished by the use of the 19 norsteroids (norethindrone or norethynodrel) administering either compound 10 mg twice a day for 10 days, starting 5 days before the anticipated time of ovulation, i.e., on the ninth day of a 28 day cycle. Unlike the estrogens, there is no break through of ovulation with continued cyclic therapy with the 19 norsteroids. This procedure is obviously unphysiologic and is contraindicated in patients with an infertility problem. Pre-ovulatory administration of methyltestosterone, 10 mg 3 times a day, or methandriol (methylandrostenediol), 25 mg twice daily for 8 days starting 4 days before the anticipated day of ovulation, will control dysmenorrhea without inhibiting ovulation. Aqueous extracts of corpus luteum administered orally have been ineffective in controlling dysmenorrhea. Parenteral extracts have been effective but are prohibitively expensive.

**Premenstrual Molimen**—The common premenstrual complaint of many women is that of premenstrual molimen, characterized by nervousness, irritability, breast tenderness, abdominal bloating and weight gain. Indeed many women show personality changes at this time to such a degree that some penal authorities claim that most of the crimes committed by women take place during this premenstrual state. Beyond the use of the usual diuretics, if the patient has dysmenorrhea the preovulatory administration of methyltestosterone or methandriol will be exceedingly effective in combating the premenstrual molimen. If the patient does not have dysmenorrhea the use of 10 mg of ethisterone, twice daily for 7 days premenstrually will control most premenstrual symptoms. If mastodynia is the primary complaint, the use of methandriol in doses of 30 to 50 mg per day for 7 to 10 days premenstrually will be followed by remarkable improvement.

**Climacteric**—Many women approaching the menopause or climacteric may be sufficiently uncomfortable or incapacitated to require therapy. The treatment of the climacteric may include the use of sedatives, ataractic drugs, estrogens androgens, or estrogens and androgens combined. The menopausal patient exhibit-

gence when there is a change of pasture. Fortunately, there are several diagnostic procedures that may be performed to uncover any possible endocrine deficiency accounting for diminished libido. In these males low 17 ketosteroid and/or elevated gonadotropic (FSH) excretion specifically identify the endocrine nature of the loss of libido and offer promise of improvement with therapy. These patients usually respond well to the same doses of androgens recommended previously for hypogonadism. The difference is that in long term management, the steroid may be gradually diminished in amount as soon as an adequate therapeutic response is achieved and maintained. Therapy may be continued for as long a period of time as necessary, provided that adequate rechecking of the patient is made at frequent enough intervals to detect excessive prostatic hypertrophy. In addition patients with hypercholesteremia obviously should have repeated determinations of blood cholesterol to rule out any possible adverse effect which the exogenous androgens might have.

One cannot anticipate a satisfactory response of enhanced libido following hormonal therapy in males with normal 17 ketosteroid and FSH excretion.

**Climacteric.**—A discussion of the male climacteric should follow a discussion of libido inasmuch as one of the primary complaints in these patients, in addition to the other symptoms of the climacteric, is the loss of libido and/or potentia. This syndrome includes vasomotor symptoms, irrationality, irritability, an inability to concentrate associated with a loss of judgment, depression, and a loss of ability to get along with people and occasionally suicidal tendencies. If these patients also have a high FSH excretion and a low 17 ketosteroid excretion, they invariably respond with a considerable degree of improvement to the androgenic regimens advised previously.

**Gynecomastia.**—Another problem of major concern in the male is gynecomastia. This condition may occur spontaneously at the time of puberty or may follow the use of certain cyclopentenophenanthrene steroid preparations such as estrogens, adrenocortical hormones, methyltestosterone, and cardiac glycosides. It may also be seen in elderly patients or in those with hepatic cirrhosis due to alcoholism, and occasionally it follows traumatic injury to the breast. Gynecomastia may be due to enhanced endogenous production of estrogens from the testes or to an estrogen secreting neoplasm of the adrenal or testes.

By and large there is no specific hormonal therapy for idiopathic gynecomastia or that appearing spontaneously in the pubescent male. In the majority of these patients it subsides spontaneously. When it does not, therapy with norethandrolone 10 mg twice or three times a day may be of some help. If there is no response after 6 to 8 weeks of this therapy, mastoplasty is the procedure of choice.

The use of methyltestosterone is contraindicated in any patient with gynecomastia since it may increase breast size. Parenteral androgens are without effect and may also stimulate breast growth in cases in which exogenous androgens may be converted to estrogens. Where an etiologic agent may be indicted, whether endogenous or exogenous, the removal of the cause will usually result in total or marked reduction of the gynecomastia. It may never completely disappear in some cases and if this is cosmetically undesirable, a mastoplastic procedure would then be the one of choice.

in doses of 10 mg twice daily for 15 to 20 days in controlling galactorrhea seen during the menstrual cycle or following pelvic or abdominal surgery

### Male

Endocrine problems of the male, while not as diverse or as complex as those in the female do not often respond to specific therapy as dramatically as in the female

**Hypogonadism**—Hypogonadism in the adolescent male has been described and will not be repeated here Hypogonadism in the adult male, when associated with testicular failure, responds dramatically to the administration of the newer longer acting androgenic preparations now available Primary testicular failure may occur following bilateral herniorrhaphy as well as surgical procedures for orchopexy It may also be seen as a result of congenital disease of the testes, as Klinefelter's syndrome or in primary eunuchoidism In both the acquired and congenital forms of testicular failure the urinary gonadotropic excretion is invariably elevated above the upper limits of normal The prognosis for spontaneous restoration of testicular function with respect to androgenic activity, when absent or for fertility is practically hopeless

In the adult male the use of testosterone cyclopentylpropionate (Testosterone), testosterone enanthate (Delatestryl), or testosterone phenylacetate (Perandren Phenylacetate), in doses of 200 mg, 400 mg and 200 mg, respectively every 2 to 3 weeks induces an excellent response as far as development of male sex characteristics and restoration of potency is concerned Adrenocortical therapy with primary testicular failure should also receive the same type of treatment Ordinarily, androgens should not be used in the prepubertal or adolescent male unless irreversible testicular failure is evident

The crucial diagnostic test delineating primary from secondary testicular failure is the finding of elevated FSH excretion in the former The treatment of the adult male with secondary testicular failure due to hypopituitarism is by treatment with chorionic gonadotropin hormone therapy Since this is impractical because of the necessity of frequent injections, except in the preadolescent male, the therapy previously recommended is also that of choice

Oral therapy with fluoxymesterone (Halotestin Ultadren) in doses of 10 mg per day is also effective in maintaining a normal androgenic state An advantage of fluoxymesterone over methyltestosterone is that it does not cause jaundice is presumably less hepatotoxic Comparable doses of methyltestosterone are 50 mg per day Use of testosterone (never the propionic ester) in the form of implantation will give prolonged and smooth therapy Usually nine to ten implants placed in either the right or left inguinal or subscapular areas will give a less painful and is not affected by activity However, the skin in the inguinal region is thicker than that in the inguinal region and is somewhat more difficult to puncture with the trocar The effect lasts about 6 months

**Loss of Libido**—While many men complain of loss of libido, this is a consequence of endocrine deficiency Psychosomatic problems in the male are of even greater importance than in the female The vernacular is that a man who lacks libido with his

## CONCLUSIONS

A brief resume of modern concepts of endocrine therapy has been presented. The use of the methods described will, in most cases, provide the physician with some degree of diagnostic acumen and therapeutic success in the treatment of the common endocrinopathies. As time goes on, no doubt, many of these concepts of therapy will be altered. One must never lose sight of the fact that, while much of the new will replace the old, many of the new hormonal materials provide no real advantage to anyone but the manufacturers. Their great number should not discourage the physician, but should make him wary and cautious in the selection of an appropriate therapeutic agent. The physician should confine himself to prescribing those selected new compounds which he himself or other competent investigators have evaluated.

## SELECTED REFERENCES

- Albright, F., Forbes, A. D., and Henneman, P. H. Pseudo pseudohypoparathyroidism. *Tr*  
 ailer, J. . . . . 1952  
 Greiner, . . . . . 57  
 Kern, R. . . . . 2 517,  
 1957  
 Upperman, H. S., and Epstein, J. A. Endocrine Therapy of Sterility. *Am Pract & Digest*  
 Treat 9 547, 1958  
 Upperman, H. S., and Studdiford, W. T. Endocrine Therapy in Gynecic Disorders. *Post*  
*grad Med* 14 410, 1953  
 Upperman, H. S., Wetchler, B. B., and Blatt, M. H. G. Contemporary Therapy of the  
 and Migeon A. J. Further  
 Hyperplasia With Cortisone, J  
 1955, W. B. Saunders Co

**Infertility**—Occasionally the infertile male with oligospermia will present himself for therapy. By and large the therapy of this problem is doomed to failure. However in patients with low FSH excretion and low 17 ketosteroid excretion a course of therapy with pregnant mare's serum (Equine PMS) consisting of 500 IU 3 times a week for 6 weeks plus biweekly injections of 150 mg of testosterone cyclopentylpropionate (Depo Testosterone) or comparable doses of another long acting androgen will usually significantly increase spermatogenesis and sperm count. Unfortunately because of antihormone production this gonadotropic hormone cannot be administered for longer than 6 weeks. The androgen however may be continued at 2 to 3 week intervals for as long a period of time as spermatogenesis is maintained at an increased level. These doses of androgens will not suppress pituitary gonadotropic function. Since androgens maintain spermatogenesis in the hypophysectomized animal they may also have a spermatogenic effect in the human being. In addition the fact that FSH alone will not maintain or initiate spermatogenesis but requires either ICSH hormone or concomitant androgens points in favor of the use of such doses of androgens in the oligospermic male. Methyltestosterone in doses of 25 mg twice a day may be substituted and may also be effective not only in oligospermia but also in increasing motility and diminishing the extent of necrospermia.

### *Anabolic Steroids*

Anabolic steroids in patients with anorexia nervosa or those with protein depletion associated with debilitating disease have proved to be of some benefit. Androgens alone or together with estrogens are certainly excellent protein anabolic steroids. However because of the undesirable side effects due to the androgens themselves their use is limited in patients in whom arrhenomimetic effects would be undesirable. Several steroids have been recommended because of their potential effect upon protein anabolism without significant androgenicity. Whether or not a steroid has selective anabolic activity without androgenicity is still a question. There are several preparations on the market which tend to show less androgenicity than does testosterone despite the fact that they are potent anabolic agents. These include norethandrolone (Nilevar) and methandriol (Stenediol) both of which may be administered orally and a recent parenteral preparation known as nandrolone phenpropionate (Durabolin). The dose of 10 mg 2 or 3 times a day of the oral anabolic agent has been proved to be of value in producing a positive protein balance. Norethandrolone because of its progestational activity, may also be administered to females in whom progestational effects are lacking and in whom there may also exist a negative protein balance. An adequate progestational effect can be achieved with 10 mg of norethandrolone 3 times a day for 7 days. This effect is usually accompanied by some weight gain in patients who previously had a negative protein balance. Nandrolone phenpropionate which is structurally norethandrolone plus an ester is said to be effective in producing a positive protein balance. The compound 2 or 3 times a week may also be used to counteract the effects of androgens. They may also be employed in the treatment of patients with senile osteoporosis.

acid The latter preparations possess essentially similar pharmacologic actions and no attempt will be made to differentiate them The anti inflammatory effect is related to the liberation of the salicylate ions although the therapeutic potency of acetylsalicylic acid is considerably greater than that of sodium salicylate Their use is generally advisable orally, and parenteral administration is indicated infrequently and in unusual situations only Analgesia is probably the most sought for therapeutic action of salicylates in the several arthritides Other uses of salicylates, such as for simple headache, nonspecific aches and pains and unidentified viral or bacterial infections of the upper respiratory tract are discussed in other sections of this volume

There are three common rheumatic disorders in which salicylates are of great value These are osteoarthritis rheumatoid arthritis and acute rheumatic fever in order of clinical incidence The therapeutic value is in the reverse order The etiology of osteoarthritis has not been revealed but it is believed to be associated with abnormal or possibly normal wear and tear of joint structures i.e., a direct effect of degenerative aging processes rather than the consequences of a specific causative agent Rheumatoid arthritis and acute rheumatic fever, on the other hand, are unanticipated developments in afflicted individuals, and although the etiology of the respective maladies is inadequately defined there are several observations in the literature that suggest etiologic mechanisms Rheumatoid arthritis manifests itself clinically by disseminated articular symptoms, but the disease basically is believed to be a reaction of connective tissue to one or more inciting agents The connective tissue widely distributed throughout the body undergoes change as a consequence of the inciting agent principally in articular, periarticular, and vascular structures Acute rheumatic fever is believed to be an immunologic reaction of cardiac structures and to a lesser degree, of periarticular structures to a hemolytic streptococcal infection

**PHENYLBUTAZONE**—Phenylbutazone (Butazolidin), a congener of aminopyrine and antipyrine has been introduced only recently into clinical medicine The analgesic action is similar to the salicylates in the management of rheumatoid arthritis the uricosuric action is inferior to probenecid Currently this preparation finds its greatest value in the treatment of the acute attack of gouty arthritis although there are a few reports of its employment daily as a prophylactic in the intercritical period The incidence of toxicity is responsible for its limited use in patients with rheumatoid arthritis and the need for caution in the daily use of this compound in patients with gout

**Colchicine**—Colchicine is specific for the alleviation of distress in acute gouty arthritis It has no recognized clinical effect upon other types of acute or chronic joint disease Colchicine is of great value also in the prophylactic management in the intercritical period of the patient moderately or severely afflicted with gouty arthritis Although the precise steps in the intermediary metabolism of uric acid have not been determined most of the experimental evidence suggests that gout is caused by an increased production of uric acid The pathogenesis of the acute articular episode is essentially unknown

**Probenecid (Benemid)**—This compound was the result of a systematic investigation of a number of selected substances endowed with uricosuric properties

## THE CHOICE OF AN ANTIARTHRITIC AGENT<sup>\*</sup>

*John H. Talbott, M.D.*

---

### INTRODUCTION

This chapter embraces a discussion of the oldest specific pharmacologic agents used in the treatment of arthritic disorders as well as a discussion of selected drugs most recently available. Herbs, barks, and other botanicals were the source of the antiquated or traditional preparations, the organic chemical laboratory is the source of the contemporary compounds. Infusions containing salicin and methyl salicylate, recovered from willow bark, were known to the ancients as antipyretic nostrums. The descendants of these impure preparations, acetylsalicylic acid and sodium salicylate, continue to occupy an enviable position in current clinical practice because of their anti-inflammatory properties. The use of colchicum, the predecessor of colchicine and the only specific antiarthritic agent in the pharmacopeia, may be traced to the earliest medical records of Egypt, possibly Greece and India also. The Ebers Papyrus, the oldest comprehensive medical text, which was prepared in approximately 1500 B.C., is reported to contain a reference to colchicum, an ingredient of several of the species of autumn crocus or meadow saffron. Colchicine has not lost its enviable position as an antigout drug. The antiarthritic agents prepared most recently include the adrenal steroids, probenecid, and phenylbutazone. For most therapeutic purposes, the adrenal steroids and adrenocorticotropin (ACTH) may be considered to be interchangeable. The cinchophens and the aminophenols occupy an intermediary position chronologically and a secondary position therapeutically.

### CLINICAL APPLICATIONS

#### Salicylates and Pyrazolons —

**SALICYLATES**—Since salicylic acid is too irritating for internal use, the discussion of this group of agents will be confined to sodium salicylate and acetylsalicylic

---

<sup>\*</sup>Investigations on gout were supported in part by a Grant in Aid from the National Institutes of Health, Public Health Service, Bethesda, Md.



mend ACTH in the selected case of acute gouty arthritis that does not respond to other antigout preparations. I agree in each circumstance. It is the consensus that a bout of acute rheumatic fever should be treated for several weeks with adrenal steroids or ACTH. Finally, almost every physician that is confronted with the management of the unusual collagen disorders, i.e., systemic lupus erythematosus, acute dermatomyositis, systemic scleroderma and polyarteritis, will have no hesitation in recommending one of the steroids for continuous use so long as acute or subacute manifestations of the disease are detected.

**Gold Salts**—Preparations of gold have been used by rheumatologists in the treatment of acute rheumatoid arthritis for more than two decades. Historically, gold was recommended in the mistaken belief that rheumatoid arthritis was caused by the tubercle bacillus and gold was indicated in tuberculosis. The premise was faulty but the clinical results were noteworthy. The mechanism of the action of gold in rheumatoid arthritis is not known. Probably it is a mild poison that insults the affected tissues and, for reasons not revealed, alleviation of articular distress follows. Toxicity, mild or ominous, is the principal contraindication to its use initially or continually. The following gold compounds are available: gold sodium thiosulfate, gold sodium thiomalate (Myochrysine), or aurothioglucose (Solganal). The choice of the compound appears to be a personal matter with the physician, although certain advantages support gold sodium thiomalate (Myochrysine) as the preferred agent.

**Drugs of Doubtful Utility**—It is obvious that the specific items discussed above in no way represent the long list of antiarthritic preparations available currently for clinical use. Included in this category are vitamin D, sulfonamide preparations and antibiotics, bee venom, antireticulocytotoxic serum, post partum plasma, para amino benzoic acid, and vaccine, as well as combinations of reliable preparations with substances of doubtful value. It is my belief that only those preparations discussed in detail under the appropriate headings merit clinical use, also that combinations of substances of proved value are less desirable than individual preparations.

## GENERAL PHARMACOLOGIC CONSIDERATIONS

### The Salicylates and the Pyrazolons—

**SALICYLATES**—Salicylates are endowed with an analgesic, an anti-inflammatory, and an antipyretic action. Whether the site of action may be identified in rheumatoid arthritis as the cells affected, or whether it is mediated through the central nervous system, has not been determined. Surely the antipyretic action of salicylates resides in the hypothalamus and lowers the body temperature in fever through vasodilatation and dissipation of heat. There may be some hemodilution and reduction in viscosity of the circulating blood. Several other presumed effects of salicylates have been studied but are believed to play a minor role only in the treatment of rheumatic disorders. Other actions not considered pertinent to joint disease include an increase in depth and rate of respiration, depletion of liver glycogen, increase in uric acid excretion in the urine, alteration of the acid base balance in the blood, and local gastrointestinal irritation. In or near the toxic

Caronamide was the first of the group to be identified with uricosuria. Probenecid is the most powerful uricosuric agent in current clinical use, also it is the least toxic of any of the substances that alter the exchange of uric acid by the kidney. Probenecid finds its greatest value in the prophylaxis of chronic gouty arthritis. The penicillin inhibitory action should be noted also. This action is not pertinent to a discussion of rheumatic disorders. Probenecid is not an anti-inflammatory agent.

**Sulfinpyrazone**—Sulfinpyrazone (Anturan), a sulfoxide analogue of phenylbutazone, is a potent uricosuric agent which has been under clinical trial for more than 2 years. In short term experiments, the uricosuric and hypouricemic action is from 3 to 5 times as great as probenecid. The half life of action is shorter than that of probenecid, and the drug must be administered in several divided doses each day. Preliminary studies reveal that this drug is no more toxic than probenecid. However, extensive clinical trial is necessary before discounting the possibility of serious toxic effects upon hematopoiesis such as has been reported with the parent compound phenylbutazone.

**The Adrenal Steroids and ACTH**—Compound E (cortisone) and adrenocorticotropin (ACTH) were made available for clinical trial at approximately the same time in 1948. Attention was focused primarily upon their use in rheumatoid arthritis and acute rheumatic fever and to a lesser extent in gouty arthritis and osteoarthritis. It is believed that one of the principal indications for ACTH in the arthritic field at the present time is in the treatment of the acute bout of rheumatic fever. Compound E was used extensively in the management of rheumatoid arthritis, irrespective of the severity, with encouraging results originally, but has been largely replaced by more powerful anti-inflammatory agents.

Compound F (hydrocortisone) was the next adrenal steroid to be widely used. It has replaced, in large part, Compound E. In 1954, prednisone and prednisolone were found to be endowed with superior anti-inflammatory properties and fewer undesirable effects upon electrolyte metabolism. The next steroid that held promise was triamcinolone (Aristocort). This drug was somewhat more effective in some patients with rheumatoid arthritis but was especially so in psoriatic arthritis as well as in psoriasis uncomplicated by joint disease. The untoward effects are similar to those of the other steroids save for an anabolic effect which appears as an alarming symptom in a limited few patients.

The most recent steroid that has been released to the medical profession is dexamethasone (Decadron, Deronil). This has been reported to be from 6 to 8 times as potent as prednisone and 5 times as potent as triamcinolone in the treatment of rheumatoid arthritis. The sodium retaining property of this compound is negligible. The ulcerogenic action is similar. Clinical trial with this drug has been too short to determine the side effects which develop usually upon prolonged medication. [Recent reports indicate a potent and disturbing osteolytic action. Ed.]

There is no agreement among rheumatologists regarding indication and contraindication for the employment of the adrenal steroids in the treatment of rheumatoid arthritis. I believe that their use is extremely limited in this condition. A number of physicians recommend the intra-articular use of Compound F following the aspiration of fluid for hyarthrosis of a large joint. A similar number recom-

The development of probenecid as a uricosuric agent followed the observation by Wolfson and associates that caronamide inhibits the conjugation of glycine and benzoic acid and thereby alters urate exchange. The conjugation involves coenzyme A and adenine triphosphate. Probenecid competes effectively with benzoate in the activation reaction but has no effect upon the subsequent transfer to glycine. This interferes with the transport by forming a complex with coenzyme A that is only slightly dissociable. Probenecid is endowed with no anti-inflammatory action. It is rapidly and effectively absorbed from the gastrointestinal tract and is carried in the blood stream partially bound to plasma proteins. The unbound portion gains access to the glomerular filtrate but is largely resorbed by renal tubules. The blocking action of probenecid may be apparent within a few hours after beginning ingestion. In addition to the above described findings it results eventually in a decrease in the metabolic pool and an increase in the turnover rate of uric acid. It is interesting that the uricosuric action of probenecid may be nullified totally or partially by the simultaneous administration of salicylates.

The incidence of toxicity is low, but there are three items that may be recounted. In doses as large as 2 Gm per day there may be some gastrointestinal irritation. This may be prevented by ingestion of probenecid with meals or reduction of the daily intake. There have been a few instances reported of a skin rash. In our experience, this has not been a contraindication to prolonged therapy. One severe anaphylactic reaction has been reported in the literature. The incidence of renal stones at one time was thought to be increased as a result of the uricosuric action of probenecid. Subsequent experience has not borne out this assumption.

**Sulfinpyrazone (Anturan)**—The pharmacologic action of this preparation is similar to probenecid. Gastrointestinal distress has been observed as a side effect which appears to be common to all oral uricosuric agents. The most serious problem however is the tendency to form uric acid gravel or uric acid stones. Obviously the greater the uricosuria the greater the tendency to the formation of uric acid stones. A high fluid intake is urged for all patients receiving a uricosuric drug. Alkalinizing agents have been recommended on theoretical grounds to minimize this tendency. In my experience the addition of alkalies has not reduced the incidence of uric acid stones in patients with gout either on or off a uricosuric drug.

**The Adrenal Steroids and ACTH**—A comprehensive discussion of the many pharmacologic effects of ACTH and the adrenal steroids is beyond the scope of this chapter. The use of these compounds in the treatment of arthritis embraces several of the recognized actions of the steroids and probably excludes the correction of a deficiency of circulating hormones. In other words the adrenal steroids do not replace any demonstrable hormone deficiency in any of the arthritic states under discussion.

Although most of the evidence suggests that the adrenal glands appear normal histologically in patients with rheumatoid arthritis there are selected observations which suggest a functional depression of the adrenals when this malady is active. The need for excessive amounts of adrenal steroids, in comparison to quantities required in recognized adrenal deficiency states implies that there may be an altered adrenal function. That this may reflect a markedly increased demand by inflamed tissue for steroids or excessive catabolism is purely speculative.

range, tinnitus, nausea and vomiting develop from central stimulation, followed by profound central nervous system depression. Hypoprothrombinemia may lead to purpura or, in isolated instances, to severe hemorrhage.

Salicylates are readily absorbed from the gastrointestinal tract and are carried in the blood bound to plasma proteins. The ultrafiltrable portion readily enters the red cell as well as the joint fluid. It also crosses the placental membrane. A fraction of the material is conjugated with glycine to form salicyluric acid, an analogue of hippuric acid, in which compound it is excreted unchanged. A small portion is converted to gentisic acid. Salicyluric acid is of no value in the treatment of arthritis, and gentisic acid is of such limited value that it may be ignored in favor of salicylates if such a preparation is desired.

The pharmacologic action of salicylates in acute rheumatic fever has not been clearly defined. There are at least two phases in the pathogenesis in which salicylates conceivably could be operating. Acute rheumatic fever usually follows a hemolytic streptococcal infection, generally in the nasopharynx. The next stage is accompanied by disseminated focal inflammatory lesions, sometimes recognized as Aschoff bodies, in the cardiovascular system, in the central nervous system, in the joints, and in the serous membranes. Later, substances elaborated by the streptococci are conjugated in the tissues to form an antigenic complex. The analgesic and antipyretic action of salicylates most likely is operating in minimizing the insult of the streptococcal infection. There may also be a steroidlike effect through the pituitary-adrenal axis which inhibits connective tissue changes in the several affected sites just noted. Although evidence is not conclusive there are some observations which suggest that salicylates decrease hypersensitivity reactions and immunologic tissue responses.

**PHENYLBUTAZONE**—Phenylbutazone was used originally in Europe in combination with aminopyrine but it soon became apparent that the pure preparation was endowed with valuable pharmacologic properties. Phenylbutazone is primarily an antipyretic and analgesic preparation and has a uricosuric action similar to aminopyrine to which it is closely related and to the salicylates. The first two properties are the principal reasons for recommending it in the treatment of acute gouty arthritis since any uricosuric action is unimportant in the acute phase.

**Colchicine**—Colchicine remains an enigma in revealing its pharmacologic action. It does not alter the concentration of uric acid in the serum or excretion of uric acid in the urine in gouty patients.

**Probenecid**—The pharmacologic action of probenecid is clearly defined. This drug exerts no effect upon the intermediary metabolism of uric acid nor does it alter the exchange of other electrolytes by the kidneys. Probenecid causes an alteration in the exchange of urates by the renal tubules, it decreases the reabsorption of urate in glomerular filtrate and concomitantly leads to an increased excretion of uric acid in the urine. A decrease in the concentration of uric acid in the serum follows. This preparation is of great value as a prophylactic agent for use in the intercritical period of gouty arthritis. It does not alter the duration or severity of the acute gouty episode, nor is there any contraindication to continuing the ingestion of probenecid during the acute attack in patients who are prescribed this drug daily during the intercritical period.

deficiency may lead to general muscle weakness. The clinical impact of the recently available steroids upon carbohydrate metabolism is negligible. The development of Cushing's syndrome is probably the most important contraindication to continued ingestion. A gain in weight, an increase in blood pressure, a tendency to an elevated blood sugar, loss of tissue proteins, osteoporosis, coronary disease, peptic ulceration, an alteration in metabolism of fat, a decrease in protein bound iodine of the blood, gonadal dysfunction, and a moon face constitute an alarming array of findings, sometimes critical but usually not so. The masking of infection, such as lobar pneumonia, acute appendicitis or pulmonary tuberculosis, hemorrhage from a peptic ulcer, central nervous system imbalance, compression fractures of vertebral bodies and congestive heart failure are other possible serious manifestations of toxicity. The corticosteroids are the usual offenders because they are the preparations customarily employed for long term maintenance. If full therapeutic quantities of ACTH are administered for similar periods of time, similar toxic manifestations may develop.

**Gold**—Gold preparations are recommended in *rheumatoid arthritis* in selected cases only. They are administered by intramuscular injection in either an aqueous or an oily suspension. Gold is absorbed slowly from the site of injection and is distributed in the soft tissues throughout the body. As much as 80 per cent may be fixed in the tissues, with the kidney, liver, and spleen absorbing a proportionately larger share.

**DANGERS**—The toxic effects of gold may be critical, frequently they are the determining factor which interrupts a full course of treatment. The incidence of severe toxic reactions has been reported to be as high as 30 per cent. A few fatalities have been reported. Albuminuria has been observed in a number of patients receiving gold. Occasionally, hematuria or even nephrosis has developed. Skin manifestations vary from a mild pruritus to severe exfoliative dermatitis. Agranulocytosis, thrombocytopenia, or aplastic anemia reflect an insult to the hematopoietic system. Stomatitis, gastritis, colitis, and possibly hepatitis reflect damage to the gastrointestinal tract. Severe reactions to gold may be counteracted by the administration of dimercaprol (BAL).

## A DESIGN FOR THE USE OF THE ANTIARTHRITIC DRUGS

### Rheumatoid Arthritis and Osteoarthritis—

**SALICYLATES**—The salicylates are believed to be the drug of choice initially in the management of patients with *rheumatoid arthritis* and *osteoarthritis*. The benefit is purely symptomatic and little claim has been made for any alteration basically of the articular changes which develop. Symptoms may wax and wane, sometimes depending upon activity and use, at other times, without any recognized cause. Either sodium salicylate or acetylsalicylic acid in amounts of 0.6 to 0.9 Gm., 3 to 5 times daily should constitute a full therapeutic regimen. This should be maintained so long as articular symptoms are severe. The quantity should be reduced depending upon relief of complaints or evidence of toxicity. Other measures, particularly in rheumatoid arthritis are equally valuable. These include rest of acutely inflamed joints, physiotherapy, attention to nutrition and

It is presumed that adrenocorticotrophic hormone promotes the elaboration of adrenal hormones, and the ultimate effect upon the target cells is similar. The articular structures, the adrenal cortex, and the anterior pituitary comprise the system under consideration. There are two principal groups of steroids of physiologic significance elaborated by the adrenals, i.e., the mineraloids and the corticoids. Each may have some overlapping effect with the other. Desoxycorticosterone acetate has been used for the treatment of the electrolyte disturbance in adrenal insufficiency. It has no significant clinical effect in the connective tissue diseases.

**PHARMACOLOGIC FEATURES**—There are several pharmacologic features of the cortisones. They increase gluconeogenesis at the expense of tissue proteins. The inhibitory effect upon protein anabolism is brought about in the muscle by interference with carbohydrate oxidation which provides the energy for protein synthesis. An exaggerated effect upon carbohydrate metabolism has led in some instances to the development of diabetes mellitus. This is a reversible process and, with the newer steroids, is unimportant clinically. Although Compound E helps promote fatty acid oxidation, the gluconeogenic effect is antiketogenic. The uricosuric action of the steroids and ACTH is unimportant in rheumatoid arthritis as well as in gouty arthritis. Steroids inhibit adrenocortical activity and thyroid function. The antianabolic or catabolic function is apparent in osteoporosis, delayed wound healing, and depression of formation of peritoneal adhesions. The action upon the central nervous system depends upon the state of the adrenals. Therapeutic quantities of Compound E have led to marked euphoria in a few patients with rheumatoid arthritis. Another small number have become overt psychotics. Each of the steroids employed clinically is absorbed rapidly in the gastrointestinal tract.

**ACTIONS IN RHEUMATISM**—The mechanism of action of the steroids in rheumatoid arthritis and acute rheumatic fever is unknown. The anti-inflammatory effect is obvious clinically but it has not been determined whether the mechanism is one of interference with the antigen-antibody mechanism, correction of an alteration of enzyme activity, interference with cellular permeability, or some other mechanism as yet unknown. Steroids are not specific for any one disease or any group of disorders except for replacement of gross endocrine deficiency. They depress the hypersensitivity or inflammatory processes generally. Their ability to inhibit growth of pathogenic organisms or counteract bacterial toxins is nil. On the contrary, any demonstrable action in infectious diseases is one of stimulating bacterial growth. The response of clinical symptoms in rheumatoid arthritis is temporary, and as soon as steroids are withheld, articular symptoms return, at times in what appears to be a greater intensity. In spite of presumably adequate therapeutic amounts, the pathologic changes of rheumatoid arthritis may progress unremittingly.

**UNTOWARD EFFECTS**—The untoward effects of corticoids vary from those of minor clinical significance to sufficient severity to warrant immediate cessation of administration. The sodium retaining action of Compound E may lead to fluid retention and to a gain in body weight. Compound F is weaker in this property, prednisone and prednisolone are weaker still. Each of the preparations promotes the excretion of potassium in the urine as sodium is retained. Critical potassium

tinuing the preparation. Since a gain in weight may be expected, patients should be placed upon a restricted caloric intake once the optimum level of body weight is reached. Large doses of the corticosteroids may lead to nitrogen depletion and negative potassium balance, hence, diets high in protein with supplementary potassium salt should be considered. These recommendations usually are not necessary if less than 10 mg of prednisone is taken daily. There appears to be no interference with growth and development when steroids are administered to young or adolescent children. The intake of sodium chloride need not be curtailed unless there is formation of edema. Osteoporosis may be a contraindication to prolonged steroid therapy in the older individual. There is no effective means known to prevent this complication. Gastric irritation and the development of a peptic ulcer are sufficient to warrant the addition of antacids with each dose of steroids as well as the administration of the steroids with meals. The relative adrenal insufficiency may compromise the patient's ability to deal with acute stressful situations such as a severe infection, a surgical procedure, or psychic trauma. It may be necessary to administer large amounts of adrenal steroids, 25 to 50 mg of prednisone or 100 to 200 mg of Compound F intravenously to avoid serious consequences.

The intra articular administration of steroids has a limited place in the treatment of rheumatoid arthritis, osteoarthritis, and gouty arthritis. The acetate of Compound F has been used in doses ranging from 25 to 100 mg. Usually, acutely affected large joints are selected but some rheumatologists have no hesitation in injecting smaller quantities in some of the smaller joints of the body such as the interphalangeals or the metacarpals. Any excess synovial fluid should be aspirated before instillation of the steroid. The injection may be repeated one or more times, at weekly intervals.

**GOLD**—Following salicylates and steroids in order of significance, in the treatment of rheumatoid arthritis is gold. A number of physicians who are responsible for a large group of patients afflicted with this type of joint disease recommend gold. Manifestations of toxicity are the determining factor in continuing use of this preparation. Physicians should be thoroughly familiar with such potentialities before prescribing a course of gold. Examination of the patient at regular intervals while under treatment should be the responsibility of the physician and should not be delegated to a nurse or an assistant who may give the parenteral preparation. The blood should be examined at regular intervals with particular reference to the white blood cells, the red blood cells, and the concentration of platelets. The urine should be studied for the presence of albumin and casts. A rash may be the signal for cessation of therapy in some patients, but not in all. The skin complications may be controlled by the adrenal steroids. If toxic reactions develop to a critical degree, dimercaprol (BAL) should be administered. Gold is administered in from 10 to 20 mg doses biweekly until from 200 to 300 mg have been given. This constitutes one course. There is no contraindication to the combined use of gold and steroids nor is there any particular advantage except as noted above.

**PHENYLBUTAZONE**.—Phenylbutazone (Butazolidin) enjoys a limited position in the treatment of rheumatoid arthritis. Not more than 200 or 300 mg should be taken daily in divided doses for continuous medication. Larger quantities may be taken daily in divided doses for short courses. The antiarthritic effect may be

general hygiene, prevention and correction of deformities, and physiatrie measures. It is believed that most rheumatologists would recommend a course of therapy embodying these general features in rheumatoid arthritis before considering other pharmacologic agents notably gold, adrenal steroids or phenylbutazone.

**ADRENAL STEROIDS**—The adrenal steroids occupied a prominent position in the treatment of rheumatoid arthritis a few years ago. Enthusiasm for their use has fluctuated, probably because the ideal steroid preparation has not yet been discovered. Compound F (hydrocortisone) represented an improved product over Compound E. Prednisone and prednisolone have been proved to be superior in many respects to Compound F. Triamcinolone holds promise for being a yet superior product. Until this hope is confirmed or dashed, prednisone and prednisolone probably are the adrenal steroids of choice in the treatment of rheumatoid arthritis, if steroids are selected. These may be administered orally in contrast to ACTH which must be given parenterally. Steroids should be most effective in the acute inflammatory stage of the disease. It is folly to expect restoration of severely distorted structural changes.

*Use of Adrenal Steroids* If adrenal steroids are selected, quantities should be kept at the irreducible minimum to achieve the submaximal antiarthritic effect rather than attempt to ameliorate the entire gamut of articular symptoms. The disadvantages of such a regimen are obvious. The patient becomes dependent upon large quantities of steroids and the opportunities for serious toxic effects are many. It may be desirable to begin therapy with doses as large as 20 or 30 mg of prednisone, but maintenance doses should be kept at levels between 5 and 15 mg and not higher. The maintenance dose of dexamethasone is in the range of 2 mg a day. Maintenance requirements must be judged by the clinical response rather than by any restoration of laboratory abnormalities. Doses should be regulated so that the total amount recommended daily will be consumed in three or four divided amounts.

*Dangers* The longer that patients receive adrenal steroids, the greater the likelihood that they will become addicted and the greater the problem of withdrawal. Any reduction in dosage should be gradual. A sudden decrease may produce alarming symptoms. If the patient has been on steroids for a number of months, withdrawal should be accomplished over a period of several weeks. Atrophy of the adrenals following ingestion of corticoids or hypertrophy following parenteral administration of adrenocorticotropin are potential hazards in long term therapy with either preparation. Although it has not been an invariable rule to alternate preparations at infrequent intervals, this is desirable theoretically. Since the adrenal steroids constitute the principal group of substances in this category for long term maintenance therapy, such a course should be interrupted every 3 or 4 months with a few days of adrenocorticotropin, 20 to 40 units daily. I am aware of no general disadvantages to this practice and, in a minority of patients on long term steroid therapy, I recommend it.

*Contraindications* Contraindications to steroids include a past history or symptoms suggesting current activity of a peptic ulcer, active tuberculosis, psychoneurosis, severe diabetes mellitus, malignant hypertension, and generalized osteoporosis. Many of the undesirable effects of steroid therapy are reversible and regress after discon-



stances in our experience, the afflicted are maintained on steroids indefinitely so long as acute or subacute symptoms persist.

Just as in acute rheumatic fever, and without any better supporting data I recommend a course of ACTH in full therapeutic amounts daily for 2 or 3 weeks. From 40 to 80 mg ACTH gel is prescribed daily for this period of time. A change is then made to prednisone usually from 15 to 30 mg daily for several weeks. Thereafter the dosage is reduced gradually until a level is reached consistent with partial or complete alleviation of symptoms and avoidance of untoward or toxic effects. The use of antimalarials, sometimes recommended in the treatment of systemic lupus, will not be discussed here. It is my practice to rely upon the steroids in the treatment of these unusual connective tissue diseases.

### Gout and Gouty Arthritis —

**COLCHICINE AND PROBENECID**—Colchicine and probenecid are the two favored drugs in the treatment of gout and gouty arthritis in this clinic. Colchicine has stood the test of time as an effective arthritic agent during acute articular symptoms. Ingestion of this drug should begin at the earliest possible indication of acute symptoms. A delay of even a few hours may impair the effectiveness in relief from articular distress. A good rule to follow is to recommend 1 mg of colchicine every 2 hours until from 4 to 6 such doses have been ingested or until the onset of gastrointestinal distress, i.e. nausea, vomiting or diarrhea. A gastric sedative such as tincture of camphorated opium 5 ml, is prescribed to counteract this distress. The dose is to be repeated every 2 hours so long as symptoms persist. The administration of colchicine intravenously in the management of the acute attack of gout may be desirable in selected instances. This route should be used to complement but not to supplement the oral use. Patients with an irritable gastrointestinal tract who tolerate oral colchicine poorly or patients undergoing surgery are candidates for this mode of administration. From 3 to 5 mg may be administered over a period of 6 hours in divided doses (1 to 2 mg) for the full therapeutic effect. In the intercritical period after the acute symptoms have been brought under control a combination of colchicine and probenecid has been proved to be highly efficacious.

In patients severely afflicted with chronic tophaceous gout, from 1 to 2 Gm of probenecid and 1 mg of colchicine in divided doses are taken daily. Gouty patients mildly afflicted may take on an average of 1 Gm of probenecid and 1 mg of colchicine daily. Patients mildly afflicted may take minimum quantities of colchicine (0.5 mg) and probenecid (0.5 Gm) daily or at less frequent intervals. Patients who suffer one or more attacks of acute gouty arthritis per year should be on colchicine and probenecid at regular intervals. If these prophylactic agents are taken regularly there need be no modification in diet beyond the elimination of high purine substances such as liver, kidney, and sweetbreads. A high fluid intake is necessary to aid in the elimination of the additional quantity of uric acid in the urine. A reasonable intake of alcoholic beverages is permitted.

**PHENYLBUTAZONE**—Phenylbutazone has been recommended in the treatment of the attack of acute gouty arthritis. It has the advantage over colchicine in that gastrointestinal distress is avoided. In doses ranging from 600 to 800 mg daily for 2 or 3 days the articular response may be similar to that of a full regimen of

inferior to that achieved by submaximal amounts of salicylates. The salicylates are preferred to phenylbutazone in most instances.

#### Acute Rheumatic Fever —

**SALICYLATES** — Acute rheumatic fever responds to the salicylates and to the adrenal steroids. Both preparations are believed to be more specific for this malady than for rheumatoid arthritis although statistical proof in support of this assumption is lacking. For several decades there was considerable difference of opinion as to whether or not salicylates were quasi-specific or nonspecific in their effect upon the acute inflammatory condition. Currently it is believed that salicylates are sufficiently specific that they occupy a prominent place in the treatment of this malady. Subtoxic doses of salicylates should be prescribed and the daily level of intake maintained at the toleration point for a number of weeks. It is suggested that 0.15 Gm of salicylate per kilogram of body weight be given. This quantity should achieve a plasma level greater than 30 mg per 100 ml. Although full therapeutic amounts of salicylates are effective in reducing inflammation, there is inconclusive evidence as to their value in the prevention of cardiac lesions. Irrespective of this deficiency, as soon as a diagnosis of acute rheumatic fever has been made or even suspected, rigorous salicylate therapy, as just described or steroid therapy, as noted below, should begin at once.

**CORTICOTROPIN** — I prefer to use corticotropin initially in the management of acute rheumatic fever. Amounts varying from 60 to 80 mg of ACTH gel are administered daily for a few days. The quantity is decreased to the 20 to 30 mg range at the end of 2 weeks. Thereafter a switch is made to an oral steroid preparation, preferably prednisone, 15 to 30 mg daily, and continued for an additional 2 or 3 weeks. Maintenance doses of 5 to 10 mg of prednisone or 2 mg of dexamethasone daily are continued thereafter until all evidence of the acute process has been in abeyance for several weeks. A long term follow up study will be required before evidence is produced regarding the incidence of endocardial or myocardial lesions months or years after the acute insult, as a result of salicylate or steroid medication. Although the joint involvement in acute rheumatic fever does not lead to permanent damage of these structures, bed rest, adequate nutrition, and other measures should be insisted upon for general reasons.

The erythrocyte sedimentation rate is a helpful guide in determining effectiveness of therapy and activity or subsidence of the underlying process. Other non-specific tests such as the C reactive protein, the white blood cell count, and the electrocardiogram may be used also as measuring sticks. If cardiac failure develops, this should be treated with digitalis or other appropriate preparations, meanwhile continuing steroid ingestion. It is particularly important under such circumstances *to restrict the salt intake, if this is ineffective, a diuretic should be administered*.

#### Unusual Connective Tissue Disorders —

**ADRENAL STEROIDS** — Next in clinical significance to acute rheumatic fever, in the use of steroids, are the unusual collagen disorders, systemic lupus erythematosus, acute dermatomyositis, systemic scleroderma, and polyarteritis. No one of these maladies is cured by steroids. Some patients afflicted are benefited little or not at all. I believe, however, that each patient suffering from one of these several morbid processes should receive a long clinical trial with steroids. In most

that this (Compound E) may not be the beginning of the end (in the treatment) but only the end of the beginning" Literally, an endless number of congeners of the basic substance Compound E have been synthesized in the laboratory and tested for their anti inflammatory effect A much smaller number has been subjected to clinical trial The goal is an effective anti inflammatory agent that will reverse the disturbances of connective tissue, meanwhile remaining free of the undesirable effects which include alteration of electrolyte metabolism, formation of peptic ulcer aggravation of coronary vessel disease, central nervous system stimulation and osteoporosis The clinical use of triamcinolone has produced impressive anti inflammatory effects out of proportion to the incidence of undesirable side action At the present time, screening of steroids in this related field appears the most promising approach

The problem in acute rheumatic fever is a dual one Prevention of the immunochemical ravages of hemolytic streptococcal infections embodies the prompt and effective use of antimicrobial agents Potent antimicrobials are now available but must be employed at the earliest possible moment If these pathogens are permitted to elaborate toxins, tissue responses begin in a percentage of patients At this stage of the pathogenesis of acute rheumatic fever, salicylates and adrenal steroids appear to be effective Whether or not they are corrective in restoring the defense mechanism in the tissues and thereby preventing the development of cardiac changes has not been established This information can be collected in human beings only after a long term follow up of patients with well developed or occult acute rheumatic fever It is hoped that as more effective agents are devised for the treatment of rheumatoid arthritis these same agents will be equally effective in preventing or correcting the tissue responses in acute rheumatic fever

The specific management of the diffuse collagen disorders is less satisfactory than the management of either rheumatoid arthritis or acute rheumatic fever The problem therefore, is a more critical one The etiology and pathogenesis of each of the diffuse disorders are unknown Certain similarities suggest that an agent effective in the early stages of rheumatoid arthritis would also be of value in the early stages of the unusual disorders Hence, the development of better corticoids should make available more effective agents in the treatment of the early stages of the less common maladies The antimalarials have been employed in the treatment of systemic lupus with varying results My experience with these agents in the treatment of systemic lupus is limited In deference to my more optimistic colleagues however further study of antimalarials surely is justified It may be that outside of the malarial areas in the United States this class of drugs may have greater clinical application in the treatment of the collagen disorders than in the treatment of endemic malaria

The currently satisfactory management of patients with gout has removed some of the critical need for the development of newer and improved antigout agents Colchicine and phenylbutazone are effective in the management of the acute articular bout while probenecid is an effective uricosuric agent in the long term management in the intercritical period The advantages of a more potent uricosuric agent are limited This would consist primarily in a smaller dose per day Undoubtedly such a drug or drugs will be available in the not too distant future

colchicine If phenylbutazone is discontinued after such a period of time, the undesirable effects, agranulocytosis fluid retention, and skin rash need not be a problem I use phenylbutazone for acute gouty arthritis only if colchicine is contraindicated or if a full course of colchicine has been administered and for some reason has not produced satisfactory relief of articular symptoms Phenylbutazone is not recommended by me during the intercritical period

**OTHER URICOSURIC DRUGS UNDER CLINICAL STUDY**—Anturan (sulfapyrazone) because it is a more potent uricosuric agent than probenecid has been the focus of considerable interest by rheumatologists Except for its increased potency milligram for milligram it has no recognized advantages over the more widely used and better known probenecid The potential hazard from an effect upon hemato poiesis warrants caution in the use of this drug at the present time There is yet one other uricosuric agent not mentioned previously in this chapter This is zoxazolamine (Flexin [2 amino-5 chlorobenzoxazole]) This drug was designed as a muscle relaxant and has an unanticipated action an effect upon the exchange of uric acid in the renal tubules The half life of action is less than 6 hours Its effectiveness milligram for milligram is similar to or slightly greater than that of Anturan The drug is still under clinical trial and is not recommended for use generally at this time

**SALICYLATES**—The anti inflammatory property of the salicylates in the management of acute gout is less satisfactory than that of colchicine Since they negate the uricosuric action of probenecid they have no role to play as a prophylactic agent if probenecid is prescribed regularly There has been a renewal of interest in the use of large amounts of salicylates daily as prophylaxis However I believe that colchicine and probenecid should be the foundation stones in the treatment of gouty arthritis

## RATIONAL BASIS FOR NEW DRUGS FOR THE RHEUMATIC DISEASES

It is believed that any therapeutic agent of value in osteoarthritis must be applied as a preventive agent rather than a corrective one Since osteoarthritis is considered to be one manifestation of the aging process that appears prematurely in some individuals preventive therapy must begin in the early decades of life The precise mode of action of the preventive agent would be purely speculative Because cartilage bone and synovial tissue participate in the production of osteoarthritis maintenance of normal structure of soft tissues as well as bony tissues would be sought Possibly a deficiency of enzymes or adrenal steroids might be responsible Any approach to the problem seems rather fruitless at the present time and basic investigations must be pursued before any rational approach to the development of therapeutic agents would be justified

Considerably more progress has been made in our understanding of the pathogenesis and treatment of rheumatoid arthritis even though clinical results continue to be discouraging in a number of patients The status as expressed by Hench when Compound E was first made available in 1948 is still valid He paraphrased Winston Churchill's famous quotation and stated We certainly realize ourselves

that this (Compound E) may not be the beginning of the end (in the treatment) but only the end of the beginning" Literally, an endless number of congeners of the basic substance Compound E have been synthesized in the laboratory and tested for their anti inflammatory effect A much smaller number has been subjected to clinical trial The goal is an effective anti inflammatory agent that will reverse the disturbances of connective tissue, meanwhile remaining free of the undesirable effects which include alteration of electrolyte metabolism, formation of peptic ulcer, aggravation of coronary vessel disease, central nervous system stimulation and osteoporosis The clinical use of triamcinolone has produced impressive anti inflammatory effects out of proportion to the incidence of undesirable side action At the present time, screening of steroids in this related field appears the most promising approach

The problem in acute rheumatic fever is a dual one Prevention of the immunochemical ravages of hemolytic streptococcal infections embodies the prompt and effective use of antimicrobial agents Potent antimicrobials are now available but must be employed at the earliest possible moment If these pathogens are permitted to elaborate toxins, tissue responses begin in a percentage of patients At this stage of the pathogenesis of acute rheumatic fever, salicylates and adrenal steroids appear to be effective Whether or not they are corrective in restoring the defense mechanism in the tissues and thereby preventing the development of cardiac changes has not been established This information can be collected in human beings only after a long term follow up of patients with well developed or occult acute rheumatic fever It is hoped that as more effective agents are devised for the treatment of rheumatoid arthritis, these same agents will be equally effective in preventing or correcting the tissue responses in acute rheumatic fever

The specific management of the diffuse collagen disorders is less satisfactory than the management of either rheumatoid arthritis or acute rheumatic fever The problem therefore, is a more critical one The etiology and pathogenesis of each of the diffuse disorders are unknown Certain similarities suggest that an agent effective in the early stages of rheumatoid arthritis would also be of value in the early stages of the unusual disorders Hence, the development of better corticoids should make available more effective agents in the treatment of the early stages of the less common maladies The antimalarials have been employed in the treatment of systemic lupus with varying results My experience with these agents in the treatment of systemic lupus is limited In deference to my more optimistic colleagues however, further study of antimalarials surely is justified It may be that outside of the malarial areas in the United States this class of drugs may have greater clinical application in the treatment of the collagen disorders than in the treatment of endemic malaria

The currently satisfactory management of patients with gout has removed some of the critical need for the development of newer and improved antigout agents Colchicine and phenylbutazone are effective in the management of the acute articular bout while probenecid is an effective uricosuric agent in the long term management in the intercritical period The advantages of a more potent uricosuric agent are limited This would consist primarily in a smaller dose per day Undoubtedly such a drug or drugs will be available in the not too distant future

but will require long-term clinical trial before the physician is assured that the drug is endowed with as low an incidence of toxicity as is probenecid

It is important in the prophylactic management during the intercritical period for patients with gout to achieve maximum uricosuria. A decrease in the metabolic pool and a decrease in the concentration of uric acid in the serum should lead eventually to withdrawal of the urate deposits in bone and soft tissues. Such a state would represent a normal situation and the patient would theoretically be immune to acute attacks of gout. Yet another approach to the problem would be the correction of the underlying pathogenic mechanism. If this is a disturbance of the intermediary metabolism of uric acid, an inhibitor of xanthine oxidase might be effective. Such a preparation was available for clinical trial a few years ago and found to be ineffective in so far as could be determined in altering the concentration of uric acid in the serum or the excretion of this substance in the urine.

### SELECTED REFERENCES

- Bishop, C., Rand, R., and Talbott, J. H. The Effect of Benemid (p-[di-n-propylsulfamyl] benzoic acid) on Uric Acid Metabolism in One Normal and One Gouty Subject, *J Clin Invest* 30: 889, 1951.
- Bishop, C., and Talbott, J. H. Uric Acid: Its Role in Biological Processes and the Influence Upon It of Physiological, Pathological and Pharmacological Agents, *Pharmacol Rev* 5: 231, 1953.
- Committee of the American Rheumatism Association. Primer on the Rheumatic Diseases, *J A M A* 152: 323-405, 552, 1953.
- Engleman, E. P., Krupp, M. A., Forsham, P., Griffin, A. C., Johnson, H., Green, T., and Goldfen, A. Studies on the Effect of Phenylbutazone in the Treatment of Gout, *Am J Med* 15: 414, 1953.
- Fischel, E. E., Frank, C. W., and Ragan, C. Observations on Treatment of Rheumatic Fever With Salicylate, ACTH and Cortisone: Appraisal of Signs of Systemic and Local Inflammatory Reaction During Treatment: the Rebound Period and Chronic Acute Phase, *Am J Med* 13: 744, 1952.
- Hollander, J. L. Intra-articular Hydrocortisone in the Treatment of Arthritis, *Ann Int Med* 39: 735, 1953.
- Kersley, C. B., M. J. L. and Laffer, M. B. Gold, Sodium and Its Function in Rheumatoid Arthritis, *Br J Rheumatol* 1: 13, 1953.
- Lowman, J. W. The Treatment of Gout With Rheumatoid Arthritis, *Br J Rheumatol* 1: 13, 1953.
- Lukens, F. M. The Value of Sodium Salicylate in Treatment, *Quart J Med* 24: 351, 1953.
- Marson, R. The Value of Sodium Salicylate in Treatment, *Quart J Med* 24: 351, 1953.
- Smith, G. E., and Wilson, G. M. Treatment of Gout, *A M A Arch Int Med* 97: 783, 1956.
- Talbott, J. H. The Effect of Benemid (p-[di-n-propylsulfamyl] benzoic acid) on Uric Acid Metabolism in One Normal and One Gouty Subject, *J Clin Invest* 30: 889, 1951.
- Talbott, J. H. The Effect of Benemid (p-[di-n-propylsulfamyl] benzoic acid) on Uric Acid Metabolism in One Normal and One Gouty Subject, *J Clin Invest* 30: 889, 1951.
- Wolfson, J. The Effect of Benemid (p-[di-n-propylsulfamyl] benzoic acid) on Uric Acid Metabolism in One Normal and One Gouty Subject, *J Clin Invest* 30: 889, 1951.
- Yu, T. F., Burns, J. J., and Gutman, Alexander, B. Results of a Clinical Trial of G 28315, a Sulfonamide Analog of Phenylbutazone, as a Uricosuric Agent in Gouty Subjects, *Arth & Rheum* 1: 532, 1958.

## THE CHOICE OF DRUGS FOR CANCER AND ALLIED DISEASES†

*David A. Karnofsky, M D*

---

### INTRODUCTION

In the past twenty years, and particularly since 1946, there has been an extraordinary search in progress for drugs effective in controlling the growth or accomplishing the destruction of neoplastic cells wherever they occur in the body. The list of substances that have been proposed for clinical use is long and it is increasing in length. It is difficult and time consuming to establish the therapeutic efficacy of a palliative drug in cancer, and new drugs are being introduced for general clinical use before a scientific amenity—clear proof of distinctive or unique activity—has been observed. Thus, the real progress that has been made in chemotherapy of cancer is sometimes overshadowed, confused, or distorted by immoderate or premature claims or actual misrepresentations of the benefits achieved by new forms of treatment. A proper therapeutic appraisal of the value of the available drugs must be based on convincing clinical evidence. An acceptable chemotherapeutic agent should have definite and specific indications and should not be employed merely as part of a general barrage against the many presently insoluble therapeutic problems in patients with disseminated or advanced neoplastic disease.

### GENERAL CONSIDERATIONS

There are no drugs effective against all forms or all stages of cancer. Several basic considerations are important in determining the indications for a chemotherapeutic agent and in selecting the proper drug for a specific type of cancer and at a particular stage of the disease.

Many different types of cancer occur, these vary as to site of origin, histologic appearance, retention of functional properties from their tissue of origin, rate of growth, and pattern of metastases. Even in patients with the same type of cancer, the disease, in each individual, runs a distinctive course. Also, a specific form of cancer may show a wide range of responsiveness to established chemo-

†This paper is based on work which has been supported in part by Grant C1889 from the National Cancer Institute of the National Institutes of Health of the United States Public Health Service and by grants from the American Cancer Society and the Lasker Foundation.

but will require long-term clinical trial before the physician is assured that the drug is endowed with as low an incidence of toxicity as is probenecid.

It is important in the prophylactic management during the intercritical period for patients with gout to achieve maximum uricosuria. A decrease in the metabolic pool and a decrease in the concentration of uric acid in the serum should lead eventually to withdrawal of the urate deposits in bone and soft tissues. Such a state would represent a normal situation and the patient would theoretically be immune to acute attacks of gout. Yet another approach to the problem would be the correction of the underlying pathogenic mechanism. If this is a disturbance of the intermediary metabolism of uric acid, an inhibitor of xanthine oxidase might be effective. Such a preparation was available for clinical trial a few years ago and found to be ineffective in so far as could be determined in altering the concentration of uric acid in the serum or the excretion of this substance in the urine.

#### SELECTED REFERENCES

- Bishop, C., Rand, R., and Talbott, J. H. The Effect of Benemid (p [di n propylsulfamyl] abolism in One Normal and One Gouty Subject, J  
E  
Its Role in Biological Processes and the Influence  
ological and Pharmacological Agents, Pharmacol  
Committee of the American Rheumatism Association Primer on the Rheumatic Diseases,  
J A M A 152 323, 405 552, 1953  
Engleman, E. P., Krupp, M. A. Forsham P., Griffin, A. C., Johnson H., Green T. and  
Goldfen, A. Studies on the Effect of Phenylbutazone in the Treatment of Gout  
Am J Med 15 414, 1953  
Fuschel, E. E., Frank, C. W., and Ragan C. Observations on Treatment of Rheumatic Fever  
With Salicylate, ACTH and Cortisone Appraisal of Signs of Systemic and Local  
Inflammatory Reaction During Treatment, the Rebound Period and Chronic Ac  
tivity, Medicine 31 331, 1952  
Freyberg, R. H., and Stevenson, C. R. Management of the Patient With Rheumatoid Ar  
thritis, M Clin North America 37 1235, 1953  
Gutman, A. B., and Yu, T. F. Current Principles of Management of Gout, Am J Med  
13 744, 1952  
Hart  
Helen  
1949  
Hollander, J. L. Intra articular Hydrocortisone in the Treatment of Arthritis, Ann Int  
Med 39 735, 1953  
Kersley, G. D. Mandel, I. and Telford, M. R. Gold Sodium and Liver Function in Rheu  
Lowman, the Patient With Rheumatoid  
Lukens, F. The Blakiston Co  
Marson, nce to the Value of Sodium  
Smith, G. A Arch Int Med 97 783  
1956  
Talbott, J. H., Bishop, C., Norcross B. M. and Lockie, I. M. The Clinical and Metabolic  
n Physicians 64 372, 1951  
Talbott, J. Grune & Stratton, Inc  
Wolfson Transport and Excretion of Uric  
Effect of Carbonamide (Abst 1,  
Yu, T. F., Burns, J. J., and Gutman, Alexander, B. Results of a Clinical Trial of G 28315,  
a Sulfoxide Analog of Phenylbutazone, as a Uricosuric Agent in Gouty Subjects  
Arth & Rheum 1 532, 1958



patient is acutely ill with fever, bleeding manifestations, infection, or rapid progression of the disease

A folic acid antagonist may be started as soon as the diagnosis is established if the patient is in good condition it is given alone. Treatment may have to be continued for 4 to 6 weeks with an antifolic in order to produce a satisfactory hematologic response, in patients in poor condition it is safer to try to alleviate the acute problem with the adrenal steroids while the trial of a folic acid antagonist is started. The folic acid antagonists induce complete hematologic remissions in about 35 per cent of children, and in another 15 to 20 per cent the clinical situation is markedly improved, although the blood picture is not entirely restored to normal. Remissions may continue for 3 to 6 months or longer, when the patient relapses he may respond again to a course of folic acid antagonist therapy if a satisfactory response has occurred.

The purine analogue mercaptopurine (Purinethol) may be used initially in the same manner as the folic acid antagonists, as well as in patients who have become resistant to the folic acid antagonists. Mercaptopurine produces hematologic remissions in 50 to 70 per cent of leukemic children, which usually last for an average of 3 to 4 months, but once resistance appears the patient does not ordinarily respond to a second course of treatment. The glutamine antagonist, azaserine (serylal), while it does not exert a primary effect on the disease, may enhance the action of mercaptopurine to produce more prolonged, and a higher percentage of, complete hematologic remissions.

Using the folic acid antagonists and mercaptopurine, with or without azaserine, to induce sustained remissions, with short courses of the adrenal steroids for acute situations, about 70 per cent of leukemic children can be maintained in good general health during the major portion of their illness. Survival has been prolonged in 50 per cent of the children to 1 year or longer as compared to an average survival time of 4 months prior to the time when these agents became available. During the final relapse the child is refractory to all known forms of treatment and death usually occurs from infection or bleeding.

#### Drugs of Choice —

**ADRENAL STEROIDS** —Prednisone is the adrenal steroid of choice. Treatment is usually begun with large doses—25 to 50 mg daily divided into 4 to 6 doses daily. Within 1 to 2 weeks, if a favorable response is evident from the patient's clinical condition and his peripheral blood and bone marrow pictures, the dose may be decreased, and, finally, discontinued in 7 to 10 days. Large doses are given initially because a child unresponsive to a lower dose, may go into a prompt hematologic remission at a higher one. Nevertheless, if the leukocyte count is markedly elevated, or the child has bulky lymph nodes and a greatly enlarged liver and spleen these large doses must be given cautiously, since in responsive cases rapid dissolution of the neoplastic cells may result in severe hyperuricemia and renal injury. The leukocyte count and renal function should be followed carefully, and the prednisone dosage temporarily interrupted when a rapid fall in the leukocyte count occurs. In patients in the resistant terminal stage, doses of 100 mg of prednisone may be given with partial alleviation of fever and bleeding tendencies, although a hematologic remission is no longer expected.

therapeutic agents, suggesting numerous differences in the metabolism of the cancer cells or the host. In this complicated situation, established drugs are not uniformly or predictably effective despite careful case selection under well defined conditions. A useful drug, however, should exhibit a consistent range of therapeutic activity in specific situations, with improvement lasting for an appreciable period of time.

Since the available drugs are feeble as therapeutic agents in most cases, there are honest differences of opinion as to when a drug should be given and for what purpose. Some prefer treating patients with disseminated cancer early, in the hope of delaying the disease, whereas others wait to start chemotherapy until the patient has symptoms and measurably progressive disease. Late in the disease, some physicians pursue an aggressive therapeutic policy, even when there is little hope of obtaining a satisfactory response, whereas others decry these efforts as improper. One looks forward to the day when these differing views are rendered irrelevant by more effective agents. Nevertheless, we believe that the patient with advanced cancer deserves active treatment, and the honest physician who attempts thus to provide solace to the patient and family in desperate situations exemplifies the highest purposes of medicine.

The chemotherapeutic agents in cancer are given in many instances, to the maximum tolerated dose in an attempt to elicit a therapeutic response. Severe and sometimes prolonged host toxicity may occur with some drugs, and their pharmacology must be clearly understood for their safe and yet adequate administration.

While this report is concerned with drugs, it must not be forgotten that x ray therapy is the single most important method available for the palliation of advanced cancer, and it must be considered also in most situations where the use of chemotherapeutic agents is entertained. In many instances local irradiation will prove to be the treatment of choice and in other cases it will be given in association with chemotherapy.

With these general comments, we can turn to the specific drugs useful in each type of cancer. A few of the appropriate features of each form of neoplastic disease as it relates to chemotherapy will be reviewed, and then the drugs of choice will be presented in detail.

## CLINICAL CONSIDERATIONS

### Acute Leukemia

Acute leukemia in children, young adults, and adults has different ranges of responsiveness to the available chemotherapeutic agents, and different sequences of drug administration are indicated. Each age group will be discussed.

**Children**—The folic acid antagonists, the purine analogues, and the adrenal steroids are effective in producing temporary remissions of the disease. When the leukemic process becomes resistant to one drug, and relapse occurs despite continuing therapy, it may still respond to another type of antileukemia therapy. Adrenal steroids are promptly effective in about 70 per cent of the patients, but remissions are usually brief, and even if the treatment is maintained, relapse often occurs within 2 to 4 weeks. Adrenal steroids are thus used for a brief period when the

patient is acutely ill with fever, bleeding manifestations, infection, or rapid progression of the disease

A folic acid antagonist may be started as soon as the diagnosis is established, if the patient is in good condition it is given alone. Treatment may have to be continued for 4 to 6 weeks with an antifolic in order to produce a satisfactory hematologic response, in patients in poor condition it is safer to try to alleviate the acute problem with the adrenal steroids while the trial of a folic acid antagonist is started. The folic acid antagonists induce complete hematologic remissions in about 35 per cent of children, and in another 15 to 20 per cent the clinical situation is markedly improved, although the blood picture is not entirely restored to normal. Remissions may continue for 3 to 6 months or longer, when the patient relapses he may respond again to a course of folic acid antagonist therapy if a satisfactory response has occurred.

The purine analogue mercaptopurine (Purinethol) may be used initially in the same manner as the folic acid antagonists, as well as in patients who have become resistant to the folic acid antagonists. Mercaptopurine produces hematologic remissions in 50 to 70 per cent of leukemic children, which usually last for an average of 3 to 4 months, but once resistance appears the patient does not ordinarily respond to a second course of treatment. The glutamine antagonist, azaserine (serynl), while it does not exert a primary effect on the disease, may enhance the action of mercaptopurine to produce more prolonged, and a higher percentage of, complete hematologic remissions.

Using the folic acid antagonists and mercaptopurine, with or without azaserine, to induce sustained remissions, with short courses of the adrenal steroids for acute situations, about 70 per cent of leukemic children can be maintained in good general health during the major portion of their illness. Survival has been prolonged in 50 per cent of the children to 1 year or longer as compared to an average survival time of 4 months prior to the time when these agents became available. During the final relapse the child is refractory to all known forms of treatment and death usually occurs from infection or bleeding.

#### Drugs of Choice —

**ADRENAL STEROIDS** — Prednisone is the adrenal steroid of choice. Treatment is usually begun with large doses—25 to 50 mg daily divided into 4 to 6 doses daily. Within 1 to 2 weeks, if a favorable response is evident from the patient's clinical condition and his peripheral blood and bone marrow pictures, the dose may be decreased, and finally, discontinued in 7 to 10 days. Large doses are given initially because a child, unresponsive to a lower dose, may go into a prompt hematologic remission at a higher one. Nevertheless, if the leukocyte count is markedly elevated, or the child has bulky lymph nodes and a greatly enlarged liver and spleen, these large doses must be given cautiously, since in responsive cases rapid dissolution of the neoplastic cells may result in severe hyperuricemia and renal injury. The leukocyte count and renal function should be followed carefully, and the prednisone dosage temporarily interrupted when a rapid fall in the leukocyte count occurs. In patients in the resistant terminal stage, doses of 100 mg of prednisone may be given, with partial alleviation of fever and bleeding tendencies although a hematologic remission is no longer expected.

Despite persistent adrenal steroid therapy, resistance ultimately develops. Sustained treatment with the adrenal steroids usually produces only brief remissions, and children treated with hormones alone have shown no important prolongation of survival time. For this reason, prednisone is usually reserved for acute clinical situations.

The consequences of large doses of the adrenal cortical hormones are well known. Children develop moon faces, a voracious appetite and obesity, and hypertension with occasional coma. Fluid retention has not been an important problem with prednisone, and it is of interest that steroid induced diabetes mellitus is rarely seen in children. With short treatment periods these complications need not be severe, they occur in the late stages of the disease when prolonged adrenal steroid therapy at very high doses is used in the hope of prolonging life. While adrenal steroids increase susceptibility to infection, when the leukemic patient is in relapse and infection is present, dosage is usually increased because of the stressful situation and in the hope of improving hematopoiesis. Generally supplemental potassium or testosterone has not been necessary with prednisone therapy.

The mechanism of action of the adrenal steroids on leukemic cells, or the nature of cellular resistance has not been determined. Adrenal steroids are lympholytic and cells of acute leukemia may possibly retain some of the responsiveness of normal lymphocytes. These hormones inhibit the growth of some mesenchymal cells, and the leukemic cells may be biochemically related to these. In responsive cases the action of the adrenal steroids on the leukemic marrow is very specific. The abnormal cells disappear promptly, thereby decompressing the marrow and permitting, even in the presence of the hormone, the rapid regeneration of normal bone marrow elements. By contrast, the antimetabolites, in therapeutic doses ordinarily cause depletion of all elements of the leukemic marrow following which the normal hematopoietic elements gradually reappear to produce a hematologic remission. Thus, the antimetabolites are bone marrow depressants in the range of the therapeutic dose whereas the adrenal steroids do not depress the normal bone marrow. In further contrast the polyfunctional alkylating agents and x rays which destroy lymphocytes and leukemic cells and depress the normal bone marrow, do not produce hematologic remissions in acute leukemia.

*Related Adrenal Steroids of Clinical Value* There is no evidence for any qualitative differences in the therapeutic activity of prednisone and other adrenal steroids or ACTH in acute leukemia.

Cortisone was initially used in the treatment of leukemia, at doses of 100 to 150 mg in divided doses daily. Because of the frequent tendency to salt and fluid retention it has been largely supplanted by prednisone. Hydrocortisone is the intravenous preparation of choice. In patients unable to take the adrenal steroids by mouth, or in whom rapid treatment is essential, hydrocortisone succinate (Solu-Cortef), 100 to 200 mg, may be given daily by direct injection as an infusion by dissolving it in 5 per cent glucose in water.

Triamcinolone has no apparent advantage over prednisone in acute leukemia.

There is rarely any indication for the use of ACTH. However in patients who are bleeding severely prompt improvement has been obtained by the continuous infusion of ACTH. This is presumably due to its rapid action in stimu-

lating high levels of adrenal steroid production by the adrenal, rather than to the production of adrenal steroids with high antileukemic activity. In children, 25 mg of ACTH has been dissolved in 5 per cent glucose and given by continuous infusion over a 24 hour period. Intramuscular injections are avoided in acute leukemia in relapse because of the severe bleeding tendency.

**FOLIC ACID ANTAGONISTS**—Amethopterin (Methotrexate) is the folic acid antagonist of choice. The usual daily dose in children is 2.5 mg. In most instances this dose is given daily for 7 to 10 days, if there is no evidence of fall in leukocyte count or oral toxicity the dose may be increased to 3.75 mg for another week or 10 days and then in the absence of toxicity, to 5 mg per day. Ordinarily, within 2 to 3 weeks amethopterin will produce changes in the peripheral blood picture and bone marrow with definite evidence of oral toxicity. If renal function is impaired the toxicity of amethopterin may be markedly enhanced due to its delayed excretion, and a lower initial dose is given.

It is essential in acute leukemias to give an adequate trial of amethopterin. It may be necessary to produce toxic manifestations on several separate occasions or to maintain the patient on the edge of toxicity for several weeks before a satisfactory hematologic remission occurs. When a complete hematologic remission occurs as determined by examination of the bone marrow and the absence of clinical signs of the disease, amethopterin therapy is usually discontinued until signs of relapse appear. Early relapse is usually detected first in the bone marrow, and frequent bone marrow aspirations are therefore essential for proper management. When relapse begins amethopterin is restarted, and second and third remissions in the responsive cases are frequent occurrences.

If a complete hematologic remission does not occur, amethopterin may be continued at near toxic levels as long as the patient remains in satisfactory clinical condition. Clinical improvement in some cases may be maintained for months on amethopterin without a complete bone marrow remission. If the patient's condition continues to deteriorate after an adequate trial of amethopterin, resistance is clearly present and the drug is discontinued. Some clinics have continued amethopterin at maintenance dosage during periods of remission, but our preference has been intermittent therapy. In patients with leukemic involvement of the meninges which is not responding well to systemic therapy, amethopterin has been given intrathecally. The usual dose is 0.3 to 0.5 mg per kilogram of body weight, and, because of its slow absorption from the spinal fluid, it may produce severe systemic toxicity.

Appreciation of the toxic manifestations of amethopterin is essential to adequate therapy, since toxicity is frequently induced in order to obtain a good response. There are no immediate reactions to the ingestion of amethopterin. The earliest and most easily recognized signs of toxicity are oral ulcerations. These may occur on the lips, the buccal mucosa, tongue, or palate. These lesions may be confused with herpes simplex or the oral complications of leukemia. If amethopterin is continued, these ulcerations usually progress and diarrhea may then appear, due to ulcerations of the lower digestive tract. This may be very severe, and intestinal hemorrhage, particularly in leukemic patients, is a formidable possibility.

Despite persistent adrenal steroid therapy, resistance ultimately develops. Sustained treatment with the adrenal steroids usually produces only brief remissions, and children treated with hormones alone have shown no important prolongation of survival time. For this reason, prednisone is usually reserved for acute clinical situations.

The consequences of large doses of the adrenal cortical hormones are well known. Children develop moon facies, a voracious appetite and obesity, and hypertension with occasional coma. Fluid retention has not been an important problem with prednisone, and it is of interest that steroid induced diabetes mellitus is rarely seen in children. With short treatment periods these complications need not be severe, they occur in the late stages of the disease when prolonged adrenal steroid therapy at very high doses is used in the hope of prolonging life. While adrenal steroids increase susceptibility to infection, when the leukemic patient is in relapse and infection is present, dosage is usually increased because of the stressful situation and in the hope of improving hematopoiesis. Generally, supplemental potassium or testosterone has not been necessary with prednisone therapy.

The mechanism of action of the adrenal steroids on leukemic cells, or the nature of cellular resistance has not been determined. Adrenal steroids are lympholytic, and cells of acute leukemia may possibly retain some of the responsiveness of normal lymphocytes. These hormones inhibit the growth of some mesenchymal cells, and the leukemic cells may be biochemically related to these. In responsive cases the action of the adrenal steroids on the leukemic marrow is very specific. The abnormal cells disappear promptly, thereby decompressing the marrow and permitting even in the presence of the hormone, the rapid regeneration of normal bone marrow elements. By contrast, the antimetabolites, in therapeutic doses, ordinarily cause depletion of all elements of the leukemic marrow following which the normal hematopoietic elements gradually reappear to produce a hematologic remission. Thus, the antimetabolites are bone marrow depressants in the range of the therapeutic dose whereas the adrenal steroids do not depress the normal bone marrow. In further contrast the polyfunctional alkylating agents and x rays which destroy lymphocytes and leukemic cells and depress the normal bone marrow, do not produce hematologic remissions in acute leukemia.

*Related Adrenal Steroids of Clinical Value* There is no evidence for any qualitative differences in the therapeutic activity of prednisone and other adrenal steroids or ACTH in acute leukemia.

Cortisone was initially used in the treatment of leukemia at doses of 100 to 150 mg in divided doses daily. Because of the frequent tendency to salt and fluid retention it has been largely supplanted by prednisone. Hydrocortisone is the intravenous preparation of choice. In patients unable to take the adrenal steroids by mouth, or in whom rapid treatment is essential, hydrocortisone succinate (Solu-Cortef) 100 to 200 mg, may be given daily by direct injection as an infusion by dissolving it in 5 per cent glucose in water.

Triamcinolone has no apparent advantage over prednisone in acute leukemia. There is rarely any indication for the use of ACTH. However in patients who are bleeding severely prompt improvement has been obtained by the continuous infusion of ACTH. This is presumably due to its rapid action in stimu-

Other drugs with antifolic activity have been tried clinically. Two major types are the diaminodichlorophenyl pyrimidines, which are related to the antimalarial drug, pyrimethamine (Daraprim), and the dihydrotriazines. While these drugs may have some intrinsic therapeutic effect on acute leukemia they are not effective in amethopterin resistant patients, and they are more difficult to use.

**PURINE ANALOGUES**—Mercaptopurine (Purinethol) is the purine analogue of choice. The usual daily dose is 2.5 mg per kilogram of body weight (a dose of 25 to 75 mg per day). It may be taken as a single dose at any time during the day. There are no immediate toxic manifestations, but, after prolonged use, nausea or abdominal discomfort may develop. These may be corrected by lowering the dose or using another purine analogue.

The initial dose of 2.5 mg per kilogram is well tolerated and can usually be continued for long periods. Hematologic remissions may occur without any important symptoms of host toxicity. As with amethopterin, adequate dosage is essential. This often requires the production of severe leukopenia and bone marrow hypoplasia due to the elimination of the leukemic elements, then normal hematopoiesis may begin while Purinethol is continued. In some cases, however, persistent leukopenia and bone marrow aplasia may be due to the toxic action of the drug, and brief interruption in treatment will permit the recovery of the normal constituents of the bone marrow. Resistance develops fairly rapidly to Purinethol and if treatment is interrupted relapse is fairly prompt. Purinethol is given, therefore at maintenance doses, usually at the level of 1.5 to 2.5 mg per kilogram daily, and the drug is discontinued when definite hematological signs of relapse occur. Increasing the dose has rarely been useful. The average remissions on Purinethol last 3 to 4 months.

The principal toxicity produced by Purinethol is a decrease in the formed elements of the blood and aplasia of the bone marrow. This occurs regularly at excessive doses and can lead to death. During treatment the peripheral blood picture should be examined at frequent intervals and the dose diminished if an unexpected fall in the leukocyte or platelet counts occurs. Bone marrow recovery after discontinuation of Purinethol is usually prompt. Occasional patients develop skin eruptions, apparently a sensitivity reaction, Purinethol has been observed to be pyrogenic in rare instances.

Purinethol is adequately absorbed by mouth and is excreted in the urine in part as mercaptopurine and 6 thiouric acid. It presumably acts by interfering with the incorporation of purines into nucleic acid thus inhibiting cellular proliferation. While the leukemic process develops a fairly prompt and marked resistance to Purinethol, these resistant cells may still be responsive to amethopterin.

**Related Compounds** 6 Thioguanine, 6 chloropurine, and 6 methylmercaptopurine are probably as effective as mercaptopurine in acute leukemia. The dose of 6 thioguanine and 6 methylmercaptopurine (2.5 mg per kilogram of body weight per day) is the same as mercaptopurine, whereas the 6 chloropurine dose is about 10 times more (20 to 30 mg per kilogram each day).

These drugs are tolerated as well as Purinethol and occasionally a patient who is nauseated on Purinethol will take one of the other purine analogues without difficulty. Occasional patients on 6 chloropurine have developed evidence of liver

Another major action of amethopterin is bone marrow depression, and even in normal individuals it can cause fatal aplasia. This is usually seen in the peripheral blood as a decrease in granulocytes, followed by thrombocytopenia and reticulocytopenia and bleeding manifestations. Anemia results from bleeding and interruption in red cell formation. The bone marrow is hypoplastic but contains megaloblasts. If the drug is discontinued and the patient sustained with blood transfusions bone marrow recovery may begin in 5 to 7 days. In favorable situations amethopterin may selectively destroy the leukemic cells with relatively little injury to normal hematopoiesis. Nevertheless it may be necessary to produce definite marrow hypoplasia by persistent therapy, and the normal blood forming elements will then regenerate preferentially. In patients with elevated leukocyte counts, amethopterin may cause a rapid fall of the white cell count to low levels, in these situations the drug should be started cautiously.

Other less frequent undesirable effects of amethopterin consist of increased pigmentation, alopecia and diminished resistance to infection. In children on prolonged amethopterin therapy cirrhotic changes in the liver have been observed, apparently related to a chronic nutritional deficiency state.

The toxic and therapeutic effects of amethopterin may be prevented by the simultaneous administration of the citrovorum factor (Leucovorin), a tetrahydro formyl derivative of folic acid. Folic acid is without protective value against amethopterin. Once overt toxic effects have appeared they cannot be corrected by Leucovorin.

Amethopterin interferes with the functions of folic acid, a vitamin which is essential for the proliferation of many normal tissues including the blood forming organs and the lining of the intestinal tract. Amethopterin prevents the conversion of folic acid to citrovorum factor and also interferes directly with its action. The citrovorum factor is necessary for the transfer of single carbon fragments in the *de novo* synthesis of purines, purines are essential components of nucleic acid which are replicated during cellular proliferation and of coenzymes vital to the energetics of the cell. It is presumably the block in purine synthesis which prevents the formation of leukemic cells. Ultimately the leukemic process becomes resistant to these agents; this is attributed to the appearance of mutant leukemic cells with altered metabolic pathways.

*Related Compounds.* A host of other 4 amino analogues of folic acid have been used clinically in the hope of finding one more effective against leukemia.

Aminopterin was the first 4 amino analogue of folic acid to be used clinically. It is approximately 5 times as active by weight as amethopterin and the usual daily dose in children is therefore 0.25 to 0.5 mg by mouth. While Aminopterin is as effective as amethopterin in our experience amethopterin is more convenient to use. Other changes in the 4 amino folic acid molecule have produced less toxic derivatives but this has not enhanced the therapeutic ratio of the drug and there is no evidence for the existence of a more specific antileukemic analogue of folic acid. Furthermore cross resistance develops to these analogues so a leukemia patient resistant to amethopterin is also resistant to Aminopterin.

Aminopterin is water soluble and can be given intramuscularly or intravenously, although there is rarely any indication for its parenteral use.



mercaptopurine is the drug of choice. About 30 per cent of the patients who survive longer than 3 weeks after the beginning of mercaptopurine therapy will obtain hematologic and clinical improvement which usually lasts for 2 to 4 months and sometimes longer. This agent should be started as soon as possible, at a dose of 2.5 mg per kilogram of body weight per day, and continued as long as there is any evidence of improvement or sustained clinical remission.

Ordinarily less than 5 per cent of young adults treated with amethopterin develop hematologic improvement. However, patients who have responded to mercaptopurine and then become resistant may occasionally show striking hematologic and clinical remissions on amethopterin. This suggests that in some cases mercaptopurine resistant cells have acquired an increased sensitivity to amethopterin. A vigorous trial of amethopterin is indicated in these situations using an initial dose of 50 mg per day and raising or lowering the dose on the basis of the hematologic findings and evidence of oral toxicity.

**Older Adults**—Over the age of 40 there is a marked decrease in the response of leukemic patients to the drugs effective in childhood leukemia. Prednisone rarely produces any improvement in hematopoiesis, although in acute situations doses of 100 mg per day may diminish fever and bleeding manifestations. In our experience a dose of 100 mg per day for 2 to 3 weeks is an adequate trial since larger doses, up to 1,000 mg per day, have not produced additional benefit. The large doses of prednisone used in these patients may produce hyperglycemia and occasionally diabetic coma and fluid retention.

The drug of choice is mercaptopurine, which induces hematologic remission in about 20 to 30 per cent of patients for 2 to 4 months or longer. The usual dose is 2.5 mg per kilogram of body weight per day, continued to the point of producing maximum

regeneration of normal bone marrow. 6 Chloropurine, which was investigated after mercaptopurine, appeared to give a slightly higher remission rate. This was apparently due to the more aggressive use of 6 chloropurine, because later, when mercaptopurine was given to produce equivalent degrees of marrow depression, the response rate from the two drugs was similar. While amethopterin alone does not have any important therapeutic activity in adult leukemia, it has induced an appreciable number of partial and complete remissions in patients who responded and then developed resistance to mercaptopurine.

**MISCELLANEOUS COMPOUNDS**—The polyfunctional alkylating agents, colchicine, urethan and Fowler's solution have no consistent therapeutic action on acute leukemia.

### Chronic Myelocytic Leukemia

This disease runs a much more prolonged course than acute leukemia, and there is little evidence that life is conspicuously prolonged by treatment. The average survival time is 3 to 4 years from clinical onset, and by proper treatment the patient may be maintained in relatively good health during the major portion of the course of the disease. During the early stages of chronic myelocytic leukemia patients are extremely responsive to many different forms of treatment, and the treat

damage While this may be coincidental and attributable to a serum hepatitis from the numerous blood transfusions these patients receive, the possible hepato-toxic effect of 6 chloropurine should be kept in mind Leukemic cells in mice and man have developed cross resistance to these agents, indicating the similarity in their mechanism of action A number of other purine analogues have been examined clinically thus far, including 8 azaguanine, 2,6 diaminopurine, 6 methylpurine, purine and aminonucleoside, without consistent evidence of therapeutic activity in acute leukemia

**GLUTAMINE ANTAGONISTS**—The drug of choice in acute leukemia is azaserine (seryl), 25 mg A dose of 10 mg per kilogram may be tolerated for several days, but when combined with mercaptopurine the toxicity of azaserine is enhanced When used in combination therapy, mercaptopurine is given at the usual dose of 2.5 mg per kilogram, and azaserine at 1.25 to 2.5 mg per kilogram

When given alone, azaserine has had little effect on acute leukemia, it is being used in combination with mercaptopurine since the combination appears to prolong the hematologic remissions produced by mercaptopurine When resistance develops to mercaptopurine, however, the addition of azaserine is of negligible value

The principal toxic effect of azaserine is the development of a red and sore tongue and in some cases, oral ulcers Continuous treatment may also cause diarrhea, in a few cases the leukocyte and platelet counts are reduced All manifestations of toxicity subside within 3 to 5 days after the drug is stopped

Azaserine is a potent inhibitor of purine synthesis, presumably by interfering with the incorporation of nitrogen into the 3 position of the purine skeleton a step dependent on the presence of glutamine While it inhibits tumor growth in laboratory animals, and interferes with purine synthesis in vivo and in vitro azaserine has had minimal effects on the proliferation of leukemic cells

**Related Compounds** 6 Dioxo 5 oxo 1 norleucine (DON) is closely related to azaserine structurally and is 40 to 50 times as active by weight It has shown no remarkable activity in acute leukemia and comparative studies on the combination of azaserine mercaptopurine and DON mercaptopurine are incomplete The usual dose of DON is 0.1 to 0.2 mg per kilogram (5 to 10 mg) daily by mouth Its toxic manifestations are similar to azaserine, but mercaptopurine does not seem to aggravate the oral toxicity caused by DON thus DON can be used in nearly full doses in combination with mercaptopurine

**Young Adults**—The treatment of acute leukemia in young adults is similar to that in children, but the available drugs are less consistently effective In acute problems, prednisone is the drug of choice The initial dose is 100 mg daily by mouth, usually in divided doses (4 to 6 times daily), and this dose is decreased as soon as signs of a hematologic response appear The hematologic response in young adults is usually slower than in children, and 3 to 4 weeks of treatment may be necessary before maximum improvement occurs In some cases a smaller dose is effective for maintenance purposes and the patient is continued on this for several weeks while antimetabolite therapy is established Prednisone will produce some evidence of improvement in about 50 per cent of the patients

In patients responding to prednisone, or initially in patients in good condition,

**BUSULFAN**—Busulfan (Myleran) is the drug of choice in chronic myelocytic leukemia. The usual dose is 6 to 10 mg per day, and at the beginning the patient is followed at weekly intervals. The dose may be raised or lowered, depending on the white cell count, until a gradual but adequate response has been obtained. In early cases it is often worth while to stop Myleran to determine the length of the remission without treatment. Prolonged remissions would lead to intermittent courses of busulfan, brief remissions would indicate maintenance therapy. In chronic myelocytic leukemia the leukocyte count is a good guide to treatment since in contrast to other conditions, the leukocyte count stops falling within a few days after treatment is stopped.

In responsive patients busulfan can maintain the patient in good clinical remission for 2 years or longer. As the disease progresses, however, it becomes more resistant to treatment, and the leukocyte count may rise and the spleen continue to enlarge despite increasing doses of busulfan. It then becomes apparent that normal hematopoiesis is being suppressed by doses that are no longer controlling the disease. In other instances, the patient abruptly goes into an acute blastic phase, and busulfan should be discontinued.

**TEM**—Other polyfunctional alkylating agents may be used in place of busulfan. TEM (triethylene melamine) may be given orally or intravenously. The dose ranges from 2.5 to 5 mg, and it is taken with plain water before breakfast on an empty stomach. Some clinics administer each dose with 2 Gm of sodium bicarbonate to prevent the inactivation of TEM by the gastric acidity, I do not believe this practice is essential. About 50 per cent of patients tolerate this dose without difficulty, whereas the remainder may develop a brief period of nausea and occasional vomiting. The initial dose is 2.5 mg daily for 4 days, and then further dosage is determined on the basis of weekly blood counts. If there is a prompt fall in the leukocyte count, treatment is interrupted, but if it remains high, doses of 5 mg weekly may be necessary. While the therapeutic effects of TEM parallel those of Myleran, the latter is easier to use and better tolerated.

The routine intravenous dose of TEM is 0.04 mg per kilogram (2 to 3 mg) for 3 to 4 days. It is available in vials containing 5 mg, the drug is dissolved in saline, and the appropriate dose then is injected into the tubing of a running intravenous infusion of physiologic saline. Intravenous TEM is the drug of choice when it is desirable to produce a prompt fall in the leukocyte count. It should be noted again, however, that the rapid dissolution of leukemic cells may cause hyperuricemia and renal injury.

Nitrogen mustard ( $\text{HN}_2$ , Mustargen), Thio TEPA (triethylene thiophosphoramide, TSPA) and a number of other related compounds have been used, but they offer no advantages over busulfan or TEM in chronic myelocytic leukemia.

**Purine Analogues**—The agent of choice is mercaptopurine (Purinethol). At an initial dose of 2.5 mg per kilogram by mouth this drug produces excellent control of the disease in responsive patients. Maintenance therapy is usually indicated since the leukemic process usually exacerbates promptly when mercaptopurine is stopped. The starting dose of 2.5 mg per kilogram may not be tolerated indefinitely and the blood count should be taken at weekly intervals until a satisfactory maintenance dose is established. Mercaptopurine is particularly indicated in pa-

ment of choice will depend on the patient's clinical situation and the physician's facilities and experience. It is important to select a therapeutic agent which will cause the least interference with the patient's normal activities, and to avoid a regimen which tends to produce invalidism. One of the most satisfactory methods of treatment is splenic irradiation, a single course can produce remissions of 6 months or longer in responsive cases. There are a number of drugs which are useful also.

**Polyfunctional Alkylating Agents**—These are a number of different agents which have two or more reactive alkylating groups, each alkyl group capable of being introduced in place of an active hydrogen into many organic and inorganic molecules. While these agents react with a great number of components of biologic systems they appear to have a special affinity for nucleic acids. Desoxyribonucleic acid appears to be the particularly vulnerable component of the cell as far as continued cellular proliferation is concerned.

The polyfunctional alkylating agents presumably act by interfering with the formation of new cells in both normal and neoplastic tissues. In the normal animal these agents are specifically injurious to the blood-forming organs and the intestinal lining which are composed of cells which divide frequently. The polyfunctional alkylating agents also cause involution of lymphatic tissue. In man, also, these agents produce bone marrow depression with leucopenia, thrombocytopenia and bleeding manifestations and anemia.

At toxic doses these effects usually appear 2 to 3 weeks after a course of treatment and if the patient survives, the peripheral blood picture returns to normal within 2 to 3 weeks. When recovery is complete, another course of treatment can be given if indicated without appreciable cumulative bone marrow toxicity. In patients with unpaired marrow function due to disease however, therapeutic doses may cause prolonged bone marrow depression.

These agents may be given as intermittent courses, or by continuous administration. Intermittent therapy is usually safer, since the blood picture has recovered before a second course is given. Continuous therapy requires precise and regular dosage control with frequent blood studies particularly if it is necessary to increase the dose in resistant patients in the hope of producing a more satisfactory response. Poorly controlled maintenance therapy may result in cumulative and severe bone marrow damage, since the evidences of bone marrow depression may continue to evolve for 2 to 3 weeks after the drug is stopped. The polyfunctional alkylating agents often are given to the point where appreciable bone marrow depression is produced in order to obtain a therapeutic response, and dosage must be adjusted to the drug used, the type of neoplasm, and the stage of the disease.

Although the polyfunctional alkylating agents have similar cytotoxic actions they differ in their acute pharmacologic effects. Nitrogen mustard, for example, produces nausea and vomiting by central action shortly after administration, whereas the ethylamines rarely do so. Some are readily tolerated by mouth, whereas others cause nausea and vomiting.

The efficiency of absorption by the oral route varies among these drugs and from patient to patient, and more rapid treatment and precise dosage control can be achieved by administering the drugs intravenously, when possible. These are considerations in the selection of these agents for clinical use.

cause a prompt fall in the leukocyte count and regression of enlarged nodes, if this occurs, further treatment is withheld for several weeks. If there is no definite hematologic response to this trial dose, on the following week 2.5 mg on 2 successive days may be given. In some cases it may take 20 to 40 mg over a 2 month period to produce a satisfactory response. In some cases a complete hematologic remission may occur, in that all signs of the disease disappear for many months and sometimes years.

A complete remission is not an essential objective of TEM therapy, however, since often a vigorous attempt to lower the leukocyte count to normal levels may cause severe bone marrow depression. Once clinical improvement has occurred the regular TEM administration is discontinued, and single doses of 2.5 to 5 mg are given at intervals thereafter if the leukocyte count begins to rise or lymph nodes enlarge. After prolonged TEM therapy, a responsive patient may begin to develop a fall in hemoglobin level and platelet count, while the lymphocyte count remains elevated. TEM should be discontinued in these resistant patients, and other forms of treatment employed.

In hospitalized patients TEM may be started intravenously at a dose of 0.02 mg per kilogram (1 mg in the 50 kilogram individual) and further dosage determined by periodic blood counts.

**Chlorambucil**—Chlorambucil (Leukeran) is a polyfunctional alkylating agent as acceptable as TEM in chronic lymphocytic leukemia. It is usually well tolerated, although occasional patients may complain of nausea and vomiting. The initial daily dose is 0.05 to 0.1 mg per kilogram daily (2 to 6 mg). This is given each day, and dosage is regulated by weekly blood counts. If the leukocyte count falls the drug is temporarily discontinued but if it is unchanged after three weeks the dosage may be increased. When the desired clinical response is obtained, chlorambucil should be stopped and restarted when signs of renewed activity of the disease appear.

The other polyfunctional alkylating agents have no special role in chronic lymphocytic leukemia.

**Adrenal Steroids**—These drugs are extremely useful in selected situations in chronic lymphatic leukemia. In patients who are refractory to TEM and have a lowered hemoglobin level with thrombocytopenia and bleeding prednisone, 50 mg per day, may cause a prompt rise in hemoglobin and platelet count and a decrease in the size of enlarged nodes, liver, and spleen. The leukocyte count may rise abruptly when treatment is started, a not undesirable sign and then fall gradually on continued treatment. If a favorable result occurs, the prednisone dose is reduced in 2 to 3 weeks. Patients have been maintained for long periods on doses as small as 10 mg per day.

Once a patient has responded, it is advisable to continue maintenance doses of prednisone indefinitely. Distressing complications of continuous high doses of prednisone may be acute or resistant infections and steroid induced diabetes. During periods of infection an increased dose of prednisone is often indicated and when diabetes occurs the dose may be lowered.

In another complication of chronic lymphocytic leukemia, acquired hemolytic anemia, prednisone begun at 25 mg per day usually causes prompt hematologic

## DRUGS FOR CANCER AND ALLIED DISEASES

tents who have become refractory to the alkylating agents and radiation, may produce a separate period of improvement. Patients in the terminal stage of the disease should receive an adequate trial of Purimethol.

6 Chloropurine and 6 thioguanine are effective, but have no therapeutic advantage over mercaptopurine.

**Miscellaneous Compounds**—Other agents which have been used in chronic myelocytic leukemia but offer no particular advantages are given here.

**AMETHOPTERIN**—At near toxic doses amethopterin will reduce the leukocyte count but it rebounds promptly as soon as the drug is stopped.

**POWELL'S SOLUTION**—A 1 per cent solution of potassium arsenite is sometimes used as a mild suppressive in early cases of chronic myelocytic leukemia, but its activity is weak compared to other agents. The dosage sequence is 3 drops, 3 times daily and this is increased at the rate of 1 drop per dose per day until a maximum total of 20 drops 3 times daily is reached unless evidences of toxicity appear or a marked fall in the leukocyte count intervenes. The dose is then reduced to a maintenance level.

**URETHAN** While urethan produces excellent results in some cases, its use may be associated with nausea and vomiting, drowsiness and occasionally hepatitis, and it offers no special therapeutic advantages over the available drugs.

**COLCHICINE ANALOGUES**—The most prominent colchicine analogue used in chronic myelocytic leukemia is demecolcin. The daily dose is 5 to 10 mg by mouth. While this dose is well tolerated and produces a fall in the leukocyte count and clinical improvement demecolcin does not appear to be effective in patients resistant to other forms of treatment.

**ADRENAL STEROIDS**—Prednisone is of little value in chronic myelocytic leukemia and in some instances it seems to aggravate the disease. In the terminal acute stage 100 mg of prednisone daily may reduce bleeding manifestations although it has not produced any important hematologic remissions.

**RADIOACTIVE PHOSPHORUS**—Radioactive phosphorus ( $P^{32}$ ) will produce satisfactory remissions in the responsive stage of chronic myelocytic leukemia. It does not appear to offer any advantage over Myleran or x-ray and technically its use is more complicated.

### Chronic Lymphocytic Leukemia

This disease frequently runs a prolonged and relatively benign course. Treatment should be conservative since premature or excessive therapy may result in serious complications more disabling than the disease itself. In the early and relatively asymptomatic stages of the disease treatment is not indicated. If localized enlargement of the spleen, liver or lymph nodes causes difficulties, small doses of rays to these areas may be the most satisfactory procedure. In active symptomatic disease several drugs are of definite value.

**TFM**—The initial drug of choice is TFM (triethylenemelamine). Chronic lymphatic leukemia may be extremely sensitive to the polyfunctional alkylating rays (both the excessive lymphocytes and the normal blood forming cells). Therefore it must be given cautiously. The initial single oral dose is 2 g.

cause a prompt fall in the leukocyte count and regression of enlarged nodes if this occurs further treatment is withheld for several weeks. If there is no definite hematologic response to this trial dose, on the following week 2.5 mg on 2 successive days may be given. In some cases it may take 20 to 40 mg over a 2 month period to produce a satisfactory response. In some cases a complete hematologic remission may occur, in that all signs of the disease disappear for many months and sometimes years.

A complete remission is not an essential objective of TEM therapy, however, since often a vigorous attempt to lower the leukocyte count to normal levels may cause severe bone marrow depression. Once clinical improvement has occurred, the regular TEM administration is discontinued, and single doses of 2.5 to 5 mg are given at intervals thereafter if the leukocyte count begins to rise or lymph nodes enlarge. After prolonged TEM therapy, a responsive patient may begin to develop a fall in hemoglobin level and platelet count, while the lymphocyte count remains elevated. TEM should be discontinued in these resistant patients, and other forms of treatment employed.

In hospitalized patients TEM may be started intravenously at a dose of 0.02 mg per kilogram (1 mg in the 50 kilogram individual) and further dosage determined by periodic blood counts.

**Chlorambucil**—Chlorambucil (Leukeran) is a polyfunctional alkylating agent as acceptable as TEM in chronic lymphocytic leukemia. It is usually well tolerated, although occasional patients may complain of nausea and vomiting. The initial daily dose is 0.05 to 0.1 mg per kilogram daily (2 to 6 mg). This is given each day and dosage is regulated by weekly blood counts. If the leukocyte count falls the drug is temporarily discontinued, but if it is unchanged after three weeks the dosage may be increased. When the desired clinical response is obtained, chlorambucil should be stopped and restarted when signs of renewed activity of the disease appear.

The other polyfunctional alkylating agents have no special role in chronic lymphocytic leukemia.

**Adrenal Steroids**—These drugs are extremely useful in selected situations in chronic lymphatic leukemia. In patients who are refractory to TEM and have a lowered hemoglobin level with thrombocytopenia and bleeding, prednisone, 50 mg per day, may cause a prompt rise in hemoglobin and platelet count and a decrease in the size of enlarged nodes, liver, and spleen. The leukocyte count may rise abruptly when treatment is started, a not undesirable sign, and then fall gradually on continued treatment. If a favorable result occurs the prednisone dose is reduced in 2 to 3 weeks. Patients have been maintained for long periods on doses as small as 10 mg per day.

Once a patient has responded it is advisable to continue maintenance doses of prednisone indefinitely. Distressing complications of continuous high doses of prednisone may be acute or resistant infections and steroid induced diabetes. During periods of infection an increased dose of prednisone is often indicated and when diabetes occurs the dose may be lowered.

In another complication of chronic lymphocytic leukemia, acquired hemolytic anemia, prednisone begun at 25 mg per day usually causes prompt hematologic

improvement. The dose is then reduced to maintenance levels and continued indefinitely. The other adrenal steroids offer no advantage over prednisone.

**Miscellaneous Compounds**—Amethopterin, mercaptopurine, and azaserine are of no value. Colchicine, urethan, and Fowler's solution exhibit irregular and uncertain effects and there is no indication for their use. While radioactive phosphorus is an effective agent it is less convenient to use than the chemicals available.

### Monocytic Leukemia

This is a particularly difficult form of leukemia to manage, and it usually runs an acute course. Mercaptopurine appears to be the agent of choice and it should be given an adequate trial. Patients responding and then relapsing on mercaptopurine merit a trial of amethopterin. In the more chronic varieties of monocytic leukemia busulfan may produce considerable symptomatic improvement. The adrenal steroids are of no specific value.

### Hodgkin's Disease

Hodgkin's disease presents a variety of clinical pictures, from the localized and slowly progressive to the generalized and symptomatic forms. The appropriate treatment will depend on the stage and extent of the disease, the rate of progression, and the response to previous therapy. X-ray therapy is the most important method of treatment at all stages of the disease, and it should not be neglected. Chemotherapeutic agents are useful in the disseminated form of the disease with systemic symptoms. Fever, itching, anorexia, and weakness may be rapidly alleviated sometimes within 24 to 48 hours after treatment. With intermittent therapy, improvement usually lasts for 6 to 10 weeks, and then another course can be given. By proper maintenance therapy, with brief interruptions, these periods of symptomatic relapse may be prevented. While the available drugs do not produce a general and substantial increase in survival time, they are important in prolonging comfortable and useful life.

**Polyfunctional Alkylating Agents**—Nitrogen mustard (Mustargen), TEM and chlorambucil have their individual advantages in treatment.

**NITROGEN MUSTARD**—This is the drug of choice in hospitalized patients, in whom prompt treatment is indicated. The drug is dissolved in 10 ml of saline to make a 1 mg per milliliter solution, and the appropriate dose is injected into the tubing of a running intravenous infusion of physiologic saline. The usual dose is 0.4 mg per kilogram given in a single dose, or divided into 2 to 4 single daily doses. This dose is well tolerated when no evidence of bone marrow depression is present but in advanced cases with unpaired marrow function, or in patients who have already received repeated courses of a polyfunctional alkylating agent, it is safer to give a smaller initial dose of 0.2 mg per kilogram. If the therapeutic response is inadequate, further dosage may be given within 1 to 2 weeks if a satisfactory blood picture is maintained. In some cases by cautious but persistent treatment to the point of a moderate leukopenia and thrombocytopenia a satisfactory temporary therapeutic response may be achieved.



Nitrogen mustard may induce thrombophlebitis in the injected vein, particularly if venous pressure is high. Extravasation results in a painful area of induration, which may sometimes slough. Nausea and some degree of vomiting is a common consequence of each intravenous dose of nitrogen mustard. It may occur  $\frac{1}{2}$  hour to 8 hours after the injection and subsides in a few hours. Nausea and vomiting may be alleviated by giving nitrogen mustard late in the afternoon and sedating the patient for the night. One routine procedure is to administer sodium phenobarbital, 100 mg intramuscularly, shortly after treatment, and to repeat the dose once if vomiting persists, with Thorazine, 25 mg intramuscularly, given in 4 hours if necessary.

The advantages of nitrogen mustard are that the dosage is well established and the therapeutic effectiveness of a polyfunctional alkylating agent in a specific patient can be promptly assessed. Furthermore, the optimal therapeutic dose of nitrogen mustard can be more precisely controlled when an alkylating agent is used in combination with x ray therapy.

**TEM**—This drug, as an alternative polyfunctional alkylating agent, can be given orally or intravenously. The oral dose ranges from 5 to 10 mg in divided doses during the first week, and the average tolerated dose during the first month of treatment is 20 to 40 mg. TEM can cause severe bone marrow depression, and it must be used with care. If an adequate response occurs, the patient may be maintained by intermittent doses at 2- to 4 week intervals, or TEM may be restarted when signs of relapse appear. The intravenous dose of TEM is 0.04 mg per kilogram daily for 3 doses; this is as effective as nitrogen mustard and TEM is less likely to produce nausea and vomiting.

**CHLORAMBUCIL**—Chlorambucil is given orally and is well tolerated. In contrast to the intermittent dosage used with TEM, chlorambucil is given daily at an initial dose of 0.1 to 0.2 mg per kilogram (6 to 12 mg). The blood count is followed at weekly intervals, and if it is not depressed and the therapeutic response is inadequate, the dose may be increased to 0.3 or 0.4 mg per kilogram. Bone marrow depression is the principal hazard from persistent therapy, and we prefer continuing the drug until a satisfactory clinical response occurs or a worrisome fall in the leukocyte and platelet count begins; the drug is then stopped, and restarted, in the former case when signs of relapse occur.

The other polyfunctional alkylating agents appear to offer no advantage over nitrogen mustard, TEM, and chlorambucil.

**Adrenal Steroids**—Prednisone is rarely of specific value in Hodgkin's disease. It is usually effective, of course, in acquired hemolytic anemia which sometimes complicates Hodgkin's disease. Doses of 10 to 25 mg per day may be sufficient to control the process. In the advanced stages of the disease, prednisone may be useful as a supportive agent, in reducing fever and in improving the patient's appetite and outlook. When pancytopenia is present, possibly as a consequence of an enlarged spleen, prednisone 50 mg per day may improve the blood picture. If a response occurs, the dose should be reduced to the lowest level which still maintains the therapeutic response. Prednisone should not be used early in the disease, its use is not often rewarding, and prolonged therapy at high doses may introduce its own complications.

improvement. The dose is then reduced to maintenance levels and continued indefinitely. The other adrenal steroids offer no advantage over prednisone.

**Miscellaneous Compounds**—Amethopterin, mercaptopurine, and azaserine are of no value. Colchicine urethan and Fowler's solution exhibit irregular and uncertain effects and there is no indication for their use. While radioactive phosphorus is an effective agent it is less convenient to use than the chemicals available.

### Monocytic Leukemia

This is a particularly difficult form of leukemia to manage, and it usually runs an acute course. Mercaptopurine appears to be the agent of choice and it should be given an adequate trial. Patients responding and then relapsing on mercaptopurine merit a trial of amethopterin. In the more chronic varieties of monocytic leukemia busulfan may produce considerable symptomatic improvement. The adrenal steroids are of no specific value.

### Hodgkin's Disease

Hodgkin's disease presents a variety of clinical pictures, from the localized and slowly progressive to the generalized and symptomatic forms. The appropriate treatment will depend on the stage and extent of the disease, the rate of progression and the response to previous therapy. X-ray therapy is the most important method of treatment at all stages of the disease, and it should not be neglected. Chemotherapeutic agents are useful in the disseminated form of the disease with systemic symptoms. Fever, itching, anorexia and weakness may be rapidly alleviated sometimes within 24 to 48 hours after treatment. With intermittent therapy improvement usually lasts for 6 to 10 weeks, and then another course can be given. By proper maintenance therapy, with brief interruptions, these periods of symptomatic relapse may be prevented. While the available drugs do not produce a general and substantial increase in survival time, they are important in prolonging comfortable and useful life.

**Polyfunctional Alkylating Agents**—Nitrogen mustard (Mustargen), TEM and chlorambucil have their individual advantages in treatment.

**NITROGEN MUSTARD**—This is the drug of choice in hospitalized patients, in whom prompt treatment is indicated. The drug is dissolved in 10 ml of saline to make a 1 mg per milliliter solution and the appropriate dose is injected into the tubing of a running intravenous infusion of physiologic saline. The usual dose is 0.4 mg per kilogram given in a single dose or divided into 2 to 4 single daily doses. This dose is well tolerated when no evidence of bone marrow depression is present but in advanced cases with impaired marrow function, or in patients who have already received repeated courses of a polyfunctional alkylating agent it is safer to give a smaller initial dose of 0.2 mg per kilogram. If the therapeutic response is inadequate, further dosage may be given within 1 to 2 weeks if a satisfactory blood picture is maintained. In some cases by cautious but persistent treatment to the point of a moderate leukopenia and thrombocytopenia a satisfactory temporary therapeutic response may be achieved.

The mechanism of action of urethan is not known, it is rapidly metabolized, and it has been suggested that it acts as an antimetabolite. An adequate trial of urethan is indicated in patients with disseminated multiple myeloma, with bone marrow involvement, hyperglobulinemia, and anemia. It may take 2 or more months before a favorable response occurs, and treatment should be persistent and continuous if the patient's condition does not continue to deteriorate. About 15 to 35 per cent of patients with multiple myeloma obtain significant hematologic improvement on urethan.

**Adrenal Steroids**—Prednisone may produce prompt relief of pain, a fall in serum protein, and general improvement in about 30 per cent of patients. The usual dose is 50 to 100 mg per day, and if a satisfactory response occurs the dose is decreased. Prednisone is generally used in patients with conspicuous symptomatology. If prednisone is begun simultaneously with urethan, and if immediate improvement occurs due to the prednisone, the dosage should be reduced so that the continuing effects of urethan can be evaluated.

**Miscellaneous Drugs**—Stilbamidine has produced no consistent response in multiple myeloma. The polyfunctional alkylating agents are generally without value. They have been combined with urethan in some cases, but the additional benefit from this combination has not been demonstrated. Radioactive iodine and radioactive phosphorus have also been used with inconsistent results.

#### Carcinoma of the Breast

Drugs have no place in the management of resectable cancer of the breast. In recurrent or metastatic breast cancer alterations in the hormonal balance of the patient may cause temporary regression of the cancer for periods of 6 to 12 months or longer. The present trend in treatment is to alter hormone balance by the removal of endocrine glands—the ovaries, the adrenals, and the pituitary. In postmenopausal patients with breast cancer, oophorectomy or adequate radiation therapy gives a higher percentage of objective regression of disease than androgen therapy, and patients who respond to ovariectomy can expect, when relapse occurs, a period of further improvement from adrenalectomy, hypophysectomy, or removal of androgens. A treatment program must be designed for each patient, and therapeutic measures applied in a planned sequence so that their effectiveness can be evaluated and the indications for the next therapeutic step established. The following drugs are used in recurrent and advanced breast cancer.

**Androgenic Hormones**—These are given principally to patients who are premenopausal or less than 10 years postmenopausal. The drug produces objective improvement in approximately 20 per cent of patients for periods of 4 to 10 months or longer. An adequate therapeutic trial should be continued for 2 months or longer if the patient is not deteriorating. If objective improvement occurs, androgens are continued, and when relapse occurs under treatment, the drug is stopped. Sometimes a patient who responds and then becomes refractory to androgen therapy will have another period of remission when the drug is stopped.

Androgens apparently act on breast cancer by antagonizing estrogens and by inhibiting the function of the pituitary. In the presence of an unfavorable hor-

**Miscellaneous Agents**—Amethopterin and mercaptopurine have not proved useful in Hodgkin's disease. Butazolidin, colchicine, and azaserine sometimes alleviate fever briefly, but they are not often effective. Actinomycins C and D may reduce enlarged nodes and fever, but these antibiotics are unusually toxic (nausea, vomiting, oral lesions, enteritis, alopecia, dermatitis, and some evidence of bone marrow depression), and they appear to have no therapeutic advantages over the polyfunctional alkylating agents.

### Lymphosarcoma

Lymphosarcoma, while it is closely allied to Hodgkin's disease and in many cases parallels its clinical course, shows even more extreme variations of clinical behavior in individual cases and in its response to therapy. X-ray therapy is the major and most universally effective form of treatment. Nitrogen mustard, TEM, and chlorambucil are occasionally useful. They should be started cautiously since in some cases lymphosarcoma may be as sensitive to these agents as the occasional patients with chronic lymphatic leukemia. These agents are administered according to the same principles discussed for Hodgkin's disease, but generally they have not proved as effective. Prednisone may prove very beneficial in some cases of lymphosarcoma, as it is in chronic lymphatic leukemia, and it merits an earlier and more persistent trial than is indicated in Hodgkin's disease. This is particularly recommended in patients with fever and hematologic disturbances no longer suitable for treatment with x-rays or nitrogen mustard. The initial dose is 50 mg per day, and it is lowered in responsive cases to maintenance levels; in some cases a dose of 10 mg daily may sustain a satisfactory remission.

Lymphosarcoma in children may respond to the agents used in childhood leukemia, and in the generalized stage of the disease, with or without bone marrow involvement, adequate trials of mercaptopurine, amethopterin, and prednisone are indicated.

### Multiple Myeloma

Multiple myeloma is not highly responsive to available chemotherapeutic agents. Local disease which produces pain, usually due to bone involvement, is best treated by local radiation. Urethan is the drug of choice. Urethan may be made up in a 10 per cent solution in distilled water for intravenous use. For oral use we prefer the 25 per cent solution of urethan, since there is some question about the efficiency with which urethan is liberated from enteric coated capsules in the gastrointestinal tract. The usual dose is 2 to 4 Gm (2 to 4 teaspoonfuls) daily. It is taken before meals. Dosage should be carefully regulated by repeated blood counts since the most important toxic effect of continuous therapy is bone marrow depression. In many cases it is desirable to produce a significant leukopenia in order to achieve the maximum possibility of a hematologic remission.

About 50 per cent of patients complain of nausea and vomiting or drowsiness, and the dose of urethan should be reduced, and various stratagems tried to make the urethan tolerable. In rare cases, severe hepatic injury has been associated with urethan administration.

**Adrenal Steroids**—Adrenal steroids will occasionally be effective in advanced breast cancer. This may be used in large doses (prednisone, 100 mg per day), which may cause brief objective regressions of disease, even in patients not responding to alterations in sex hormone balance, and as a supportive measure (15 mg per day). In hypercalcemia due to metastatic disease, prednisone frequently reduces the serum and urinary calcium levels. Prednisone may promptly alleviate the neurologic manifestations of cerebral metastases from breast cancer.

**Polyfunctional Alkylating Agents**—Ordinarily these agents are of little value in breast cancer. In advanced cases, however, a course of nitrogen mustard may alleviate dyspnea due to pulmonary metastases and neurological signs due to cerebral metastases. I prefer to use nitrogen mustard, 0.4 mg per kilogram, because the response, if it occurs, will be prompt. Nitrogen mustard is also given intrapleurally for recurrent pleural effusions.

**DON**—This drug does not have an established role in the management of breast cancer. DON has corrected hypercalcemia due to osseous metastases in over 50 per cent of the treated patients. The usual dose of DON is 0.1 to 0.2 mg per kilogram daily by mouth, and it can be given parenterally at the same dosage. Treatment may be started at larger doses in acute situations. Subsequent dosage is regulated by the appearance of redness of the tongue and oral ulcerations, the earliest manifestations of toxicity. DON is also used in combination with mercaptopurine; the latter is usually given at a dose of 1.5 mg per kilogram daily.

**Maintenance Therapy Following Removal of the Adrenals or Hypophysis**—Following complete adrenalectomy, the patient is usually maintained on oral cortisone, 37.5 to 50 mg per day, divided into 3 doses, and fludrocortisone, 0.1 mg per day. The latter is used in preference to desoxycorticosterone (DOCA). During periods of stress, the dose of cortisone must be increased. After hypophysectomy the patient is usually maintained on oral cortisone, 37.5 mg per day, and desiccated thyroid, 120 mg per day. Diabetes insipidus is sometimes a complication of hypophysectomy. Pitressin tannate in oil given by intramuscular injection (2 to 5 units every 2 to 5 days), or posterior pituitary powder, 3 to 4 snuffs per day, usually provides adequate control.

Quantitative aspects of replacement therapy are necessarily determined separately for each patient.

## Prostate Cancer

The treatment of choice in nonresectable carcinoma of the prostate is combined castration and estrogen administration. This procedure seems to provide better control of the disease and extend the survival time longer than either procedure alone. Castration or estrogen therapy alone can produce satisfactory remissions; however, the response to castration occurs more quickly, usually within 48 hours as compared to 10 days to 3 weeks. Patients who have become refractory to estrogens may show a second period of improvement after castration. Castration relapses do not respond as well to estrogen therapy. Hormonal control measures produce benefit in 70 to 80 per cent of the patients treated and objective regression of local

monal environment, some tumors dependent for their maximal growth on estrogenic stimulation will temporarily regress

The consequences of large doses of androgens in women are well known. They include signs of masculinization—deepening of the voice, hirsutism and acne—increased libido, perineal itching, and fluid retention. In patients with some degree of cardiac impairment fluid retention may precipitate heart failure. These patients should be placed on a low salt diet and receive periodic injections of a mercurial diuretic. Occasionally in patients with osseous disease, androgen therapy may exacerbate the disease and produce an acute episode of hypercalcemia. This possibility should be held in mind during the initiation of androgen therapy.

**TESTOSTERONE**—Testosterone propionate is the drug of choice. It is available for intramuscular injection and the recommended dose is 100 mg, 3 times weekly.

Two androgenic compounds are effective orally. 17 methyl testosterone (methyl testosterone) is effective by mouth and the daily dose equivalent to the parenteral testosterone propionate schedule is 200 mg daily given in divided doses. The drug is more expensive than testosterone propionate and it is not always certain that the patient is taking the full dose regularly. Fluoxymestrone (Halotestin) appears to be as effective as parenteral testosterone propionate at a dose of 20 mg per day.

**OTHER ANDROGENS**—There are other androgenic steroids available including long acting suspensions for intramuscular injection. There is no satisfactory clinical evidence that at comparable therapeutic doses one androgen is less virilizing or more effective against breast cancer than the others. Depot androgens may be dangerous because the release of the drug is continuous and uncontrollable and androgens may sometimes exacerbate the disease.

**Estrogenic Hormones**—These are used principally in patients 10 years or more postmenopausal. They produce objective improvement in approximately 30 per cent of patients for periods of 6 to 12 months or longer. An adequate trial should continue for at least 2 months if the disease is not progressing, and in responsive patients the drug is continued until relapse occurs.

Estrogens apparently act on breast cancer by inhibiting the pituitary gland. Thus there are instances where a brief exacerbation of the disease is induced at the onset of estrogen therapy (direct tumor stimulation) to be followed by tumor regression (pituitary inhibition). In hypophysectomized patients known to have estrogen dependent tumors, estrogen administration has not stimulated tumor growth.

Excessive estrogen activity in women causes fluid retention, enlargement of the breasts and uterine bleeding, which usually appears when the drug is stopped. When uterine bleeding occurs during estrogen therapy, it may cease when the dose is increased. In males estrogens produce enlarged tender breasts and diminished libido.

**Diethylstilbestrol** is the drug of choice. The usual dose is 15 mg per day (5 mg 3 times daily). Stilbestrol may occasionally cause nausea and vomiting. An alternative preparation is ethinyl estradiol, which is more active than stilbestrol by weight. The usual dose is 3 mg daily (1 mg, 3 times daily). Estradiol benzoate is available for intramuscular administration, the dose is 5 mg, 3 times weekly.

localized radiotherapy. One important indication for a chemotherapeutic agent is the superior vena cava syndrome (consisting of swelling of the neck face and arms, elevated venous pressure in the arms and dyspnea). This may be relieved promptly in 80 to 90 per cent of the cases by nitrogen mustard. In this situation it is advisable to try to prolong the response by local irradiation of the tumor.

**Polyfunctional Alkylating Agents**—Nitrogen mustard (Mustargen) is the treatment of choice. The usual dose, given intravenously, is 0.4 mg per kilogram and in patients who have a blood picture within normal limits I prefer giving it as a single injection. These patients usually tolerate larger doses of nitrogen mustard and if the expected response has not occurred a second dose can be given in 2 to 3 weeks if the blood count is not depressed. The usual duration of improvement is 4 to 6 weeks.

Nitrogen mustard is preferred to the other alkylating agents because an adequate dose can be given and the maximum response is obtained promptly. My experiences with the oral alkylating agents have not been satisfactory, since treatment is given over a prolonged period and it is more difficult to administer the maximum tolerated dose safely.

**Adrenal Steroids**—Cortisone is used as a supportive agent in advanced lung cancer. Adrenal metastases occur frequently in lung cancer although a true adrenocortical deficiency state is difficult to demonstrate. Cortisone 50 mg per day divided into 2 doses, may cause symptomatic improvement, but there is no evidence of any direct effect on the disease.

### Carcinoma of the Ovary

In advanced ovarian cancer, with large pelvic masses, ascites or intestinal obstruction the polyfunctional alkylating agents may sometimes provide considerable temporary relief. Approximately 30 per cent of the patients have obtained objective evidences of tumor regression and clinical benefit, averaging 2 to 4 months and sometimes longer.

TEM (triethylene melamine) is the drug of choice. Generally, the hospitalized patient is given a complete course of treatment intravenously, 0.04 mg per kilogram in 3 daily doses. If a favorable response occurs, the patient is maintained on oral TEM, at doses of 2.5 to 20 mg per month. Long continued therapy can lead to bone marrow depression, and the administration of TEM should be controlled carefully.

Nitrogen mustard is probably equally satisfactory for intravenous therapy and the patient also can be maintained on chlorambucil (Leukeran), 0.1 to 0.2 mg per kilogram by mouth. The other alkylating agents have no advantage over TEM, nitrogen mustard and chlorambucil in ovarian cancer.

In advanced cases prednisone, 15 to 25 mg per day, may be of supportive value although it does not appear to influence the disease directly.

### Carcinoma of the Thyroid

Carcinoma of the thyroid is generally treated first by surgery. Of those with unresectable or metastatic cancer, 10 to 20 per cent have tumors which can be

disease and metastases in a substantial number of cases. They unquestionably prolong survival time.

Diethylstilbestrol is the drug of choice. The usual dose is 10 mg, 1 to 3 times daily. Although these small doses are adequate to produce a response, larger doses have been used. If stilbestrol is not well tolerated, ethinyl estradiol is an effective alternative. The dose is 0.1 mg, 1 to 3 times daily. Treatment is continued during the period of improvement. There are other estrogenic substances available which are effective in prostatic cancer, but they offer no advantages over diethyl stilbestrol.

Prednisone may occasionally produce brief periods of improvement in patients refractory to the estrogenic hormones. The usual dose is 50 to 100 mg each day in divided doses.

Adrenalectomy and hypophysectomy have proved far more useful in breast cancer, although occasional patients with prostatic cancer have responded. In general these operative measures are not recommended.

### Choriocarcinoma

Metastatic choriocarcinoma in the female is a rare type of cancer. It is composed of cells of fetal origin and thus its cells, immunologically, are not entirely identical with its maternal host. It has proved responsive to chemotherapeutic agents.

**Folic Acid Antagonists**—The treatment and drug of choice is amethopterin (Methotrexate). One suggested schedule of treatment is 25 mg of amethopterin by mouth daily for 5 days. This dosage schedule is repeated at intervals, after signs of toxicity from the previous course have cleared, until evidence of the disease has disappeared. This dose has reduced the titer of chorionic hormone in the urine and caused remarkable clinical improvement. In 27 patients 5 apparently had complete remissions and 7 partial remissions in that the only remaining evidence of disease is an elevated chorionic hormone titer. Some of these patients may be free of cancer. It is not certain that this large and possibly hazardous dose schedule is essential; it is possible that similar results can be obtained by the use of more conventional therapy, i.e., 5 mg of amethopterin as an initial daily dose continued and increased at intervals until signs of oral or hematologic toxicity occur.

**Polyfunctional Alkylating Agents**—Nitrogen mustard (0.4 mg per kilogram) has produced prolonged improvement, and one apparently cured patient has been reported. Possibly the combination of nitrogen mustard and amethopterin may prove more effective.

In males amethopterin, nitrogen mustard, and DON have produced no important or consistent effect in choriocarcinoma.

### Carcinoma of the Lung

In nonresectable, apparently localized carcinoma of the lung, and for circumscribed metastases, radiotherapy offers the best chance for prolonged control of the disease. In patients with extensive pulmonary disease, with widespread metastases, chemotherapeutic agents may provide brief periods of relief, with reduction in cough, sputum, pain, and weakness. They are often given in conjunction with



ivative of nitrogen mustard (Melfhalan, Sarcolysin) is reputed to produce improvement in seminomas, as have Thio-TEPA in melanoma and E39 (an ethylenimine derivative) in gastric cancer. It is very probable that all these agents have the same mechanism of action, and the responses reported in individual patients from a particular derivative could have been produced by adequate doses of any one of the active polyfunctional alkylating agents.

**Adrenal Steroids**—Cortisone, prednisone, and related steroids are occasionally of supportive value in patients with advanced cancer, but they do not produce any specific effects on the disease. *Their general use is not recommended.*

**Actinomycin D**—This agent has produced regression of pulmonary metastases from Wilms's tumors in children, the consistency of this response has not been established. The usual dose is 0.015 mg per kilogram (0.3 mg in the 20 kilogram child) daily for 4 to 5 days, and treatment may be repeated when the signs of toxicity clear.

### Regional Chemotherapy

Polyfunctional alkylating agents have been given by intra arterial and by intrapleural injection in order to produce a more drastic effect on local disease. While many derivatives have been tried, nitrogen mustard is the drug of choice. Experience has led us to use intra arterial injection only in the pelvic area. A wide-bore needle is introduced into the femoral artery and a polyethylene catheter threaded through it up to the desired level of the aorta. A single dose of 0.4 mg per kilogram of nitrogen mustard is injected slowly into the tubing, and the catheter is then withdrawn. The pelvic organs undoubtedly receive, through their arterial supply, a higher concentration of nitrogen mustard, but this route of administration nevertheless also produces systemic effects similar to those following intravenous injection. The procedure has produced temporary improvement in carcinoma of the cervix and ovary and in lymphosarcoma in the pelvic region. Tumor regression has occurred, uremia due to ureteral compression has been relieved, ascites cleared and leg edema and pelvic pain diminished.

In recurrent pleural effusions due to cancer, nitrogen mustard has produced prolonged control in about 25 per cent of the patients treated, the most consistent responses have occurred in effusions due to breast and lung cancer. After rapid recurrence of a pleural effusion has been demonstrated, the usual procedure is to withdraw the fluid almost completely and to inject 0.4 mg per kilogram of nitrogen mustard in 20 ml of saline into the residual fluid. The patient then breathes deeply and sits up and lies down several times to distribute the drug. In some patients this dose is readily absorbed from the pleural space and induces the usual systemic effects of nitrogen mustard. A similar technique is used for the intra peritoneal injection of nitrogen mustard in patients with recurrent ascites.

**Radioactive Gold ( $\text{Au}^{198}$ )**—Radioactive gold is now widely used in recurrent pleural effusion and ascites. In the case of pleural effusion, it does not appear to be more effective than nitrogen mustard. The usual intraperitoneal dose is 80 to 120 millicuries, injected after the major portion of the ascitic fluid has been withdrawn.

shown to concentrate iodine, as indicated by uptake studies with tracer doses of radioactive iodine. In these patients the ability of the cancer to concentrate iodine can be enhanced by removing or destroying the normal thyroid (by surgery or radioactive iodine) and then pretreating the patient with an antithyroid drug.

Methimazole (Tapazole) is the drug of choice. The usual dose is 15 mg, 4 times daily (60 mg per day), for 1 to 2 months. Tapazole is then stopped for 2 days and a tracer dose of radioactive iodine is given to determine whether there is sufficient uptake to warrant a therapeutic dose. The dose of radioactive iodine, calculated from the uptake of the tracer dose, is in the range of 50 to 500 millicuries, and is given orally. About 50 per cent of the patients selected for treatment obtain clinical benefit, due to destructive effects of radiation from the radioactive iodine on the neoplastic cells.

At present,  $I^{131}$  (8 day half-life, beta and gamma emitter) is preferred, but in selected situations the use of  $I^{132}$  and  $I^{133}$  has been suggested. These latter isotopes are difficult to obtain, and their therapeutic advantages over  $I^{131}$  have not been demonstrated.

The administration of desiccated thyroid (0.2 to 0.3 Gm per day), thyroxine (0.4 mg per day), or triiodothyronine (100 to 200 mcg per day) by mouth has been reported to produce clinical benefit in occasional patients with extensive metastatic cancer, one of these preparations may be tried in patients resistant to other forms of treatment.

### Neuroblastoma

Metastatic neuroblastoma may undergo spontaneous regression in 5 to 10 per cent of all cases. Vigorous treatment with x-rays, nitrogen mustard, adrenal steroids, and antimetabolites may inhibit the progression of the disease, and in some cases the patient may survive long enough to obtain a spontaneous regression. In this condition, vigorous, persistent, and hopeful therapy is indicated.

### Miscellaneous Types of Cancer

In general, chemotherapeutic agents have not been effective in most forms of cancer, including carcinomas of the esophagus, stomach, pancreas, urinary bladder, rectum, large bowel, cervix, in brain and bone tumors, and in melanomas. This cannot be a categorical statement, since in rare instances these tumors have been found to show a transient response to a chemotherapeutic agent. These reports can be explained by an unusual metabolic pattern of the tumor rendering it responsive to a drug, by a temporary spontaneous regression, or by the natural history of the disease. While these isolated responses are of interest, we are primarily concerned here with drugs which exhibit a consistent effect on certain forms of cancer. Agents that have been associated with rare improvement in miscellaneous types of cancer include the following:

**Polyfunctional Alkylating Agents**—In rapidly progressive and anaplastic carcinomas, nitrogen mustard has caused measurable regressions in carcinomas of the stomach, uterus, and kidney, in Wilms's tumor, and in neuroblastomas and seminomas. It has relieved fever in osteogenic sarcoma. The phenylalanine de-

definite toxicity in the host in order to elicit a therapeutic response. These drugs have a narrow spectrum of action in that they only affect a few of the many different forms of cancer. They are not curative, and only in acute leukemia in children and in carcinoma of the prostate can chemotherapy be said to have definitely prolonged survival time. The available drugs cause only temporary improvement at best, and the neoplastic cells ultimately develop resistance and continue to proliferate despite further treatment.

It would be desirable to have less toxic and more specific agents with a wider spectrum of therapeutic activity. The problem of cellular resistance will have to be overcome. Exploration of analogues of the available types of compounds has not been rewarding, and very likely the major advances will be in discovering new classes of drugs.

[Experience with cyclophosphamide (Cytosan) is too limited for evaluation. Ed.]

### SELECTED REFERENCES

- Ackerman, L. V., and Del Regato, J. A. Cancer Diagnosis, Treatment and Prognosis, St Louis, 1954, The C. V. Mosby Co.
- Burchenal, J. H. Current Status of Clinical Chemotherapy. Current Research in Cancer. Committee on Cancer Chemotherapy of the American Cancer Society, February 1956.
- Burchenal, J. H., Tan, C. T. C., Leone, L. A., and Rhoads, C. P. Clinical Evaluation of a New Antimetabolite, 6-Mercaptopurine, in the Treatment of Leukemia and Allied Diseases, Blood 8: 965, 1953.
- Burchenal, J. H., Murphy, M. L., and Tan, C. T. C. Treatment of Acute Leukemia, Pediatrics 18: 643, 1956.
- Conference on the Therapeutic and Biological Effects of Alkylating Agents, Ann. New York Acad. Sci. 107: 1-100, 1962.
- Creech, R. O. Carcinoma by Isolation.
- Curren, J. W., and Rhoads, C. P. Clinical Chemotherapy of Cancer.
- Farber, S. Leukemias: Advances in Cancer Research 4: 112, 1956.
- Hertz, R., Bergenstal, D. M., Lipsett, M. B., Price, E. G., and Hilbish, T. F. Chemotherapy of Choriocarcinoma and Related Trophoblastic Tumors in Women, J. A. M. A. 168: 845, 1958.
- Karnofsky, D. A. Chemotherapy of Neoplastic Disease. New England J. Med. 239: 226, 1968.
- Sykes, M. R., and Kunkel, L. J. in the Management of Far 133, 1955.

### Drugs and Procedures of Recent Interest

**Fluorinated Pyrimidines**—The fluorinated pyrimidines including 5 fluorouracil (FU) and 5 fluorodeoxyuridine (FUDR) are under intensive clinical investigation. These compounds must be given in near toxic doses in order to produce clinical benefit and temporary regressions have been observed in large bowel and breast cancers and in primary hepatomas. The consistency and duration of improvement produced by these drugs are not well defined and this class of drug is still in the experimental category. The drugs cannot be recommended yet for general use.

**Isolation Perfusion Technique**—The blood supply to certain tumor bearing areas has been isolated and the area perfused for short periods with high concentrations of chemotherapeutic agents without producing serious systemic intoxication. Phenylalanine mustard and nitrogen mustard as well as other agents have been used. The indications and the benefits to be expected from this procedure have not been established.

**Intra arterial Infusion**—Another technique recently described consists of the continuous intra arterial infusion of a drug to the tumor bearing area with the systemic administration of a suitable antidote to prevent systemic toxicity. The drugs thus far used are amethopterin intra arterially and citrovorum factor intramuscularly to counteract the effects of amethopterin on the bone marrow and intestinal tract. Regressions have been observed in carcinomas in the head and neck region but the general applicability of this method has not yet been determined.

### UNPROVED FORMS OF TREATMENT

The patient with advanced cancer is often desperate and seeks any possible help. To take advantage of his plight many drugs or systems of treatment are being promoted and flagrantly publicized as effective or curative in advanced cancer. These unproved methods irrespective of their source are being examined as they appear by trained investigators for any possible effect against cancer. Anything of value will certainly be immediately confirmed and the information made available to the medical profession. Meanwhile, the use by a physician of a secret mysterious irrational or shady method of treatment is obviously unjustified. By recommending or sanctioning the use of these agents one adds to the reputation and income of the cancer quack. The physician is cautioned to investigate carefully any claims concerning new drugs for the treatment of cancer and to insist on acceptable scientific evidence to support the claims. Usually the more flamboyant the claim the scantier the scientific evidence.

### FUTURE OF CHEMOTHERAPY IN CANCER

No drugs available for the treatment of cancer are entirely satisfactory. It is a tribute to the clinical investigators in the cancer chemotherapy field that these drugs have been examined very thoroughly and their virtues and failings clearly described. The available drugs are not specific for cancer, and are injurious to some of the normal tissues of the host. In many cases it is necessary to produce

definite toxicity in the host in order to elicit a therapeutic response. These drugs have a narrow spectrum of action in that they only affect a few of the many different forms of cancer. They are not curative, and only in acute leukemia in children and in carcinoma of the prostate can chemotherapy be said to have definitely prolonged survival time. The available drugs cause only temporary improvement at best, and the neoplastic cells ultimately develop resistance and continue to proliferate despite further treatment.

It would be desirable to have less toxic and more specific agents with a wider spectrum of therapeutic activity. The problem of cellular resistance will have to be overcome. Exploration of analogues of the available types of compounds has not been rewarding, and very likely the major advances will be in discovering new classes of drugs.

[Experience with cyclophosphamide (Cytovan) is too limited for evaluation Ed.]

## SELECTED REFERENCES

- Ackerman, L. V., and Del Regato, J. A. *Cancer Diagnosis, Treatment and Prognosis*, St Louis 1954, The C. V. Mosby Co.
- Burchenal, J. H. *Current Status of Clinical Chemotherapy*. *Current Research in Cancer* 1956.
- Burchenal, J. H., and C. T. C. Leone, L. A. Rhoads, C. P. *Clinical in the Treatment of Leu*
- Burchenal, J. H. *t of Acute Leukemia*, *Pedi*
- Conference on Comparative Clinical and Biological Effects of Alkylating Agents, *Ann New York Acad Sc* 68: 657, 1958.
- Creech, O., Jr., Ryan, R. F., and Krementz, E. T. *Treatment of Melanoma by Isolation Perfusion Technique*, *J A M A* 169: 339, 1959.
- Curreri, A. R., Ansfield, F. J., McIver, F. A., Waisman, H. A., and Heidelberger, C. *Clinical Studies With 5-Fluorouracil*, *Cancer Res* 18: 478, 1958.
- Farber, S., Toch, R., Sears, E. M., and Pinkel, D. *Advances in Chemotherapy of Cancer in Man*, *Advances in Cancer Research* 4: 171, 1956.
- Galton, D. A. G. *The Use of Myleran and Similar Agents in Chronic Leukemias*, *Advances in Cancer Research* 4: 73-112, 1956.
- Hertz, R., Bergenstal, D. M., Lipsett, M. B., Price, E. G., and Hilbish, T. F. *Chemotherapy of Choriocarcinoma and Related Trophoblastic Tumors in Women*, *J A M A* 168: 845, 1958.
- Karnofsky, D. A. *Chemotherapy of Neoplastic Disease*, *New England J Med* 259: 226-260, 1958.
- Karnofsky, D. A. *the Treatment of Leu*
- Karnofsky, D. A. *American Cancer So*
- Karnofsky, D. A. *Service, Philadelphia*
- Karnofsky, D. A. *te Combinat on Cancer*
- Karnofsky, D. A. *amascular Citrovorum*
- Karnofsky, D. A. *Triethylene Melamine*
- Karnofsky, D. A. *Gynec & Obst* 101

## THE CHOICE OF DRUGS FOR HEMATOLOGIC DISORDERS

*William McFarland, M.D., and*

*William Dameshek, M.D*

---

### INTRODUCTION

As one approaches hematologic disorders from a therapeutic standpoint, it is interesting to observe that treatment in this particular branch of medicine antedates the days of Hippocrates when iron was recognized as a beneficial medicament. Also, as a result of years of curiosity and investigation regarding the blood and its abnormalities an unusual number of specific therapeutic agents is available. This fact exacts correct diagnosis in order that specific therapy may be instituted.

Since our purpose in this chapter is to discuss our preference for various therapeutic agents, as well as to present a design for their use, we wish to remind the reader of several points. First, the various clinical syndromes will be mentioned with little or no reference to the signs, symptoms, or diagnostic essentials. Second, in many cases we will not be presenting *total care* for the patient with the hematologic disorder under discussion. Third, certain conditions for which there is no known therapeutic agent may be mentioned only briefly or omitted entirely.

It should be pointed out also that the various myelodepressants, antimetabolites, and alkylating agents used in the therapy of leukemias and lymphomas are discussed in Chapter 33.

### CLINICAL APPLICATIONS

For the sake of brevity, the various clinical syndromes encountered in hematologic practice and included in this chapter may be classified in three main groups: (1) cytopenic disorders, including anemias, leukopenias (particularly granulocytopenia), and thrombocytopenias, (2) myeloproliferative disorders, including polycythemia vera, granulocytic leukemia, thrombocythemia, and myeloid metaplasia, and (3) hemorrhagic disorders.

#### **Cytopenic Disorders—**

**ANEMIAS.** From the practical standpoint, clinically and therapeutically, we may think of the anemias as the result of defects in (1) the diet or the gastrointestinal tract, (2) the bone marrow, or (3) the blood.

definite toxicity in the host in order to elicit a therapeutic response. These drugs have a narrow spectrum of action in that they only affect a few of the many different forms of cancer. They are not curative, and only in acute leukemia in children and in carcinoma of the prostate can chemotherapy be said to have definitely prolonged survival time. The available drugs cause only temporary improvement at best, and the neoplastic cells ultimately develop resistance and continue to proliferate despite further treatment.

It would be desirable to have less toxic and more specific agents with a wider spectrum of therapeutic activity. The problem of cellular resistance will have to be overcome. Exploration of analogues of the available types of compounds has not been rewarding, and very likely the major advances will be in discovering new classes of drugs.

[Experience with cyclophosphamide (Cytosan) is too limited for evaluation  
Ed.]

## SELECTED REFERENCES

- Ackerman, L. V., and Del Regato, J. A. Cancer Diagnosis, Treatment and Prognosis, St Louis, 1954, The C. V. Mosby Co.
- Burchenal, J. H. Current Status of Clinical Chemotherapy. Current Research in Cancer Committee on Cancer Chemotherapy of the National Cancer Institute, February, 1956.
- Burchenal, J. H., Tan, C. T. C., Leone, L. A., and Rhoads, C. P. Clinical Use of Mercaptopurine, in the Treatment of Leukemia. J. Clin. Oncol. 1: 53, 1953.
- Burchenal, J. H. Treatment of Acute Leukemia, Pediatrics, 1954.
- Conference on Comparative Clinical and Biological Effects of Alkylating Agents, Ann. New York Acad. Sci. 68: 657, 1958.
- Creech, O., Jr., Ryan, R. F., and Kremenetz, E. T. Treatment of Melanoma by Isolation Perfusion Technique, J. A. M. A. 169: 339, 1959.
- Current, J. H. Cancer Chemotherapy, J. Clin. Oncol. 1: 1, 1953.
- Farber, S. Cancer Chemotherapy, J. Clin. Oncol. 1: 1, 1953.
- Galton, I. Advances in Cancer Research, J. Clin. Oncol. 1: 1, 1953.
- Hertz, R., Bergental, D. M., Lipsett, M. B., Price, E. G., and Hilbish, T. F. Chemotherapy of Choriocarcinoma and Related Trophoblastic Tumors in Women, J. A. M. A. 168: 845, 1958.
- Karnofsky, D. A. Chemotherapy of Neoplastic Disease, New England J. Med. 239: 226, 260, 299, 1948.
- Karnofsky, D. A. Chemical Agents Used in the Treatment of Inoperable and Far Advanced Neoplastic Disease, Monographs in Med., Series 1, pp. 582-636, 1952.
- Karnofsky, D. A., Myers, W. P. L., and Phillips, R. Treatment of the Inoperable Pulmonary Cancer, Primary and Metastatic, Am. J. Surg. 89: 526, 1955.
- Karnofsky, D. A., and Rawson, R. W., editors. Symposium on the Medical Aspects of Cancer, J. Clin. Oncol. 1: 1, 1953.
- Antagonists in the Treatment of Leukemia, sponsored by American Cancer Society, U. S. Public Health Service, Philadelphia, 1954.

## THE CHOICE OF DRUGS FOR HEMATOLOGIC DISORDERS

*William McFarland, M D , and*

*William Dameshek, M D*

### INTRODUCTION

As one approaches hematologic disorders from a therapeutic standpoint, it is interesting to observe that treatment in this particular branch of medicine antedates the days of Hippocrates when iron was recognized as a beneficial medicament. Also, as a result of years of curiosity and investigation regarding the blood and its abnormalities an unusual number of specific therapeutic agents is available. The fact exacts correct diagnosis in order that specific therapy may be instituted.

Since our purpose in this chapter is to discuss our preference for various therapeutic agents, as well as to present a design for their use, we wish to remind the reader of several points. First the various clinical syndromes will be mentioned with little or no reference to the signs, symptoms, or diagnostic essentials. Second, in many cases we will not be presenting *total care* for the patient with the hematologic disorder under discussion. Third, certain conditions for which there is no known therapeutic agent may be mentioned only briefly or omitted entirely.

It should be pointed out also that the various myelodepressants, antimetabolites and alkylating agents used in the therapy of leukemias and lymphomas are discussed in Chapter 33.

### CLINICAL APPLICATIONS

For the sake of brevity, the various clinical syndromes encountered in hematologic practice and included in this chapter may be classified in three main groups: (1) cytopenic disorders, including anemias, leukopenias (particularly granulocytopenia), and thrombocytopenias; (2) myeloproliferative disorders, including polycythemia vera, granulocytic leukemia, thrombocythemia, and myeloid metaplasia; and (3) hemorrhagic disorders.

#### Cytopenic Disorders —

**ANEMIAS** — From the practical standpoint, clinically and therapeutically we may think of the anemias as the result of defects in (1) the diet or the gastrointestinal tract, (2) the bone marrow, or (3) the blood.



**Deficiency Anemias** Accordingly, the first group includes the deficiency anemias, whether the deficiency is primarily dietary or the result of defective absorption from the gastrointestinal tract or the result of increased requirement. This group includes anemias resulting from deficiencies of iron, vitamin B<sub>12</sub> (Addisonian pernicious anemia postgastrectomy fish tapeworm infestation), other members of the vitamin B group (pellagra anemia due to pyridoxine deficiency), and folic acid (macrocytic anemias of sprue, steatorrhea, celiac disease, pregnancy, surgical procedures or abnormalities of the gastrointestinal tract). Treatment of this group requires administration of the specific deficient factor with some overlapping in the case of folic acid and vitamin B<sub>12</sub>, viz., most macrocytic anemias of pregnancy respond to folic acid, whereas a few may require B<sub>12</sub>.

**Marrow Defects** The second group of anemias is due to a failure on the part of the marrow to produce cells normally. This group is characterized by cytopenias in the peripheral blood but the marrow may vary from a picture of hypercellularity to one of aplasia. The bone marrow failure may be idiopathic in which case the anemia is termed refractory or aplastic anemia or the bone marrow failure may be secondary to known toxic or inhibiting agents such as propylthiouracil, benzene, heavy metals, chloramphenicol, phenylbutazone, nitrogen mustard and other chemical substances, < radiation, uremia, infection, hypothyroidism and hypersplenism. Also included in this group are the myelophthytic anemias in which the marrow apparently fails because of the presence in the marrow space of abnormal cells, viz., metastatic neoplasm, multiple myeloma, leukemia, Gaucher cells, lymphomas and myelofibrosis. There are no specific drugs for therapy of this group of anemias except where hormonal factors are lacking as in hypothyroidism. We use corticosteroids and blood transfusions in the idiopathic bone marrow failures with occasionally gratifying results. The secondary group may respond to removal of the offending toxic agent if present or to treatment of the underlying infection, uremia or leukemia.

**Blood Loss** The third group of anemias results from excessive blood loss through either hemorrhage or hemolysis. If due to acute hemorrhage, blood transfusions are required. If due to chronic hemorrhage, a nutritious diet and iron may be the only requirements in addition to treatment of the underlying cause.

**Hemolytic Anemias** Hemolytic anemias are classified as congenital or acquired. The congenital group includes congenital spherocytosis, thalassemia, sickle cell disease and other hemoglobinopathies. There is no specific drug therapy of this group of anemias. Blood transfusions are utilized as seldom as possible because of the danger of hepatitis and eventual hemochromatosis and the individual must live within the bounds of his established level of anemia.

The acquired hemolytic anemias are immune or nonimmune, depending upon whether or not an immune mechanism can be established. The immune varieties include autoimmune hemolytic anemia, erythroblastosis fetalis, transfusion reactions and paroxysmal cold hemoglobinuria. The most important of these from the standpoint of drug therapy is autoimmune hemolytic anemia which may be idiopathic or may occur in association with a primary disease such as chronic lymphocytic leukemia, lymphosarcoma or disseminated lupus erythematosus. Corticosteroid therapy has proved quite beneficial in this disease.

## THE CHOICE OF DRUGS FOR HEMATOLOGIC DISORDERS

*William McFarland, M D, and*

*William Dameshek, M D*

---

### INTRODUCTION

As one approaches hematologic disorders from a therapeutic standpoint, it is interesting to observe that treatment in this particular branch of medicine antedates the days of Hippocrates when iron was recognized as a beneficial medicament. Also, as a result of years of curiosity and investigation regarding the blood and its abnormalities an unusual number of specific therapeutic agents is available. It is a fact exacts correct diagnosis in order that specific therapy may be instituted.

Since our purpose in this chapter is to discuss our preference for various therapeutic agents as well as to present a design for their use, we wish to remind the reader of several points. First the various clinical syndromes will be mentioned with little or no reference to the signs, symptoms, or diagnostic essentials. Second, in many cases we will not be presenting *total care* for the patient with the hematologic disorder under discussion. Third certain conditions for which there is no known therapeutic agent may be mentioned only briefly or omitted entirely.

It should be pointed out also that the various myelodepressants, antimetabolites, and alkylating agents used in the therapy of leukemias and lymphomas are discussed in Chapter 33.

### CLINICAL APPLICATIONS

For the sake of brevity, the various clinical syndromes encountered in hematologic practice and included in this chapter may be classified in three main groups: (1) cytopenic disorders including anemias, leukopenias (particularly granulocytopenia), and thrombocytopenias; (2) myeloproliferative disorders, including polycythemia vera, granulocytic leukemia, thrombocythemia, and myeloid metaplasia; and (3) hemorrhagic disorders.

#### Cytopenic Disorders —

**ANEMIAS** —From the practical standpoint clinically and therapeutically, we may think of the anemias as the result of defects in (1) the diet or the gastrointestinal tract, (2) the bone marrow, or (3) the blood.

Myeloid metaplasia may occur *sui generis* or in association with polycythemia vera, leukemias, lymphomas, metastatic malignancies, and others. At present, there is no satisfactory drug therapy for this condition, although we occasionally use one of the alkylating agents in small doses. In general, therapy is limited to blood transfusions, and when a hemolytic component is evident, splenectomy may be performed, with a resultant reduction in transfusion requirements. Fortunately, the disease is rather chronic unless secondary to a malignant lesion, and affected individuals may often lead normal lives for years without any form of therapy.

**Hemorrhagic Disorders**—A complete classification of the hemorrhagic disorders is beyond the scope of this discussion. Briefly, however, hemorrhagic disorders can be considered primarily as (1) vascular, (2) platelet, (3) coagulation defects, and (4) those due to the development of a fibrinolytic defect. There is frequently much overlapping, and a single defect is only rarely the cause of the entire disturbance.

**VASCULAR DEFECT**—Of the many hemorrhagic disorders on the basis of vascular defect, most of them are benign, require no therapy, and therefore will not be discussed here. The use of flavone derivatives, including rutin, in this group has been generally unsatisfactory. The hemorrhagic tendency in scurvy is ordinarily due to increased vascular permeability and responds readily to the administration of vitamin C. The more important anaphylactoid purpura (Henoch-Schönlein purpura) and so-called "vascular pseudohemophilia" may respond to corticosteroid therapy, and treatment of these cases will be presented.

**PLATELET DEFECT**—Platelet deficiencies have been discussed above as cytopenic disorders.

**COAGULATION DEFECT**—Hemorrhagic disorders due to coagulation defects may be considered according to whether the defect is primarily in Stage I, II, or III of the coagulation mechanism. Stage I deals with the thromboplastin complex and deficiencies in this group may include platelets (*vide supra*), antihemophilic globulin (hemophilia), plasma thromboplastin component (PTC deficiency or Christmas disease), and plasma thromboplastin antecedent (PTA deficiency). Stage II is concerned with thrombin complex, and the recognized factors of this group are prothrombin, proaccelerin (Factor V or labile factor) and proconvertin (Factor VII or stable factor). Deficiencies in this group may be congenital but more commonly result from liver disease, vitamin K deficiency secondary to biliary obstruction or antibiotic sterilization of intestinal flora, or from anticoagulant therapy with the coumarins.

**FIBRIN DEFECT**—Stage III of the coagulation mechanism is concerned with the conversion of fibrinogen to fibrin, and deficiencies in this stage may be congenital or acquired. The mechanism of the acquired deficiency is not distinct. It may be fibrinolytic as in certain cases of leukemia, carcinoma, and operative procedures on the prostate, lung, uterus, pancreas, and possibly other organs. Or, the mechanism may be one of defibrinogenation, as in hemorrhagic disorders associated with abruptio placentae, retention of dead fetus, and amniotic fluid embolization. Admittedly, the separation of these cases according to whether the mechanism is mainly one of fibrinolysis or defibrinogenation is arbitrary, as both mechanisms may be operative in any one case. Both require rapid replacement of

The nonimmune acquired hemolytic anemias include those due to various chemical, bacterial, and protozoal agents and others occurring in association with malignancies. Treatment of this group obviously requires removal of the offending toxic agent or treatment of the primary disease. In addition there are the rare disturbances of paroxysmal nocturnal hemoglobinuria and thrombohemolytic thrombocytopenic purpura both of which are difficult to classify.

#### LEUKOPENIAS —

**Agranulocytosis** Agranulocytosis may occur in an acute form (agranulocytic angina) or in a chronic or recurrent form. The etiology of the acute form is usually the development of an unusual degree of hypersensitivity to a drug or chemical which when removed may permit recovery of the marrow and restoration of the granulocytes to normal. However the etiology of the chronic or recurrent forms is more obscure and includes immune mechanisms, hypersplenism, and bone marrow failure from unknown causes. In addition to removing toxic substances when present and the administration of antibiotics, corticosteroids may occasionally be used. The exact value of the steroids is difficult to assess because controls are never available but it is possible that they exert a favorable effect through inhibition of immune mechanisms.

**THROMBOCYTOPENIAS** —A platelet deficiency may be quantitative or qualitative, the former being the most common and therefore most important. Thrombocytopenia may be idiopathic in which case megakaryocytes are present in the marrow in normal or increased numbers. Secondary or megakaryocytic thrombocytopenia results from bone marrow failure from any cause and in this case marrow megakaryocytes are decreased or absent. Corticosteroids are helpful and occasionally curative in idiopathic thrombocytopenic purpura and cases failing to respond to steroids may respond to splenectomy. Secondary thrombocytopenias obviously require therapy of the primary disease. Therapy of thrombotic thrombocytopenic purpura appears to be completely ineffectual.

**Myeloproliferative Disorders** —Under this heading we include polycythemia vera, granulocytic leukemia, erythroleukemia, thrombocythemia, and myeloid metaplasia. Since the leukemias are discussed in Chapter 33 we shall be concerned here with polycythemia, thrombocythemia, and myeloid metaplasia.

The principal danger in polycythemia vera is the increased tendency to arterial and venous thromboses resulting from the increased viscosity of the blood and the abnormally high platelet count. The increased blood volume and viscosity are directly related to the increased red cell mass and treatment therefore consists of reducing this mass by phlebotomies with or without the administration of a myelo-depressant such as  $P^{32}$ . This agent depresses marrow activity in general thereby limiting production of all elements including platelets. In addition anticoagulants are sometimes useful temporarily until the threat of thromboses is controlled. An iron deficient diet is occasionally helpful in limiting red cell production and decreasing the frequency of  $P^{32}$  administration.

The rare case in which thrombocythemia is the outstanding abnormality is fraught with the danger of thromboses and paradoxically hemorrhages. Therapy in these cases consists of the administration of  $P^{32}$  and temporary anticoagulant therapy until the  $P^{32}$  has effectively reduced platelet production toward normal levels.

min B<sub>12</sub>. The corticosteroids are grouped together since it is difficult to prove a selective hematologic action of any one hormone. However, we have the distinct impression that prednisone is more beneficial and can be effective with fewer side effects than the others, therefore, we use it almost exclusively at present. That this policy may not continue to be justified is evidenced by the increasing reports in the literature of recalcitrant, nonhematologic conditions which failed to respond to one steroid hormone but which did respond when another was substituted. This has also been our experience on rare occasions.

Several of the antihemorrhagic agents listed above could also be listed as "Specifics," but it seems more convenient to think of them in connection with hemorrhagic disorders.

Perhaps the two most important ancillary agents used in hematology are anti-coagulants and antibiotics. Their use will not be discussed in this chapter as they are discussed thoroughly elsewhere (Chapters 8 and 35), and the same fundamentals apply to their use in hematologic disorders as in other fields of medicine. Of course, ancillary agents should also include all agents used in symptomatic therapy, such as sedatives, salicylates and others, but they are merely mentioned in the interest of completeness.

## GENERAL PHARMACOLOGIC CONSIDERATIONS

**Iron**—Through rather recent advances in the understanding of iron metabolism it is known that a 70 Kg man has approximately 4 to 5 Gm of iron in his body, of which 60 to 70 per cent is in hemoglobin, and most of the remainder in available iron stores. Iron metabolism is virtually a closed system in which, under normal conditions, only about 1 to 2 mg of iron is absorbed and excreted daily. Dietary iron occurs mainly as ferric hydroxide and loose chelates from which ferric iron is made available in the presence of an acid medium, as in the stomach. This is then converted to the ferrous form by the action of reducing substances such as vitamin C and it is this ferrous form that is absorbed through the gastrointestinal mucosa of the stomach and small bowel. Accordingly, therapeutic iron is administered in the ferrous form, and the amount absorbed approximates 10 per cent of the iron available in the gastrointestinal tract. In the presence of iron deficiency and certain other anemias, this figure is higher and supposedly accounts for the tendency for hemochromatosis to develop in patients with refractory or hemolytic anemias given iron over many years.

Iron in accidental overdosage in children has resulted in vomiting, lethargy, coma, and death. In the usual therapeutic doses, it may cause abdominal cramps with diarrhea or constipation. Given intravenously, there may be reactions consisting of flushing, chest and back pain, hypotension, tachycardia, and syncope. Fortunately this route of administration has been indicated rarely, if at all, since the advent of an effective iron dextran preparation which is remarkably free of serious side effects when given intramuscularly.

**Vitamin B<sub>12</sub> and Other Vitamins**—Vitamin B<sub>12</sub>, or cyanocobalamin, is a dark red, crystalline compound of highly complex chemical structure which is obtained commercially from cultures of several species of *Streptomyces*. It occurs naturally

fibrinogen by the use of blood or plasma with the addition of concentrated preparations of fibrinogen. When a fibrinolysin can be demonstrated, corticosteroids are helpful.

**THERAPY**—Therapy of hemorrhagic disorders due to coagulation defects requires replacement of the deficient factor, and the manner of replacement can be simple and all-inclusive or more complex, depending upon the urgency of the situation and whether or not specific therapeutic products are available. In other words, any bleeding disorder due to coagulation defects can be treated by the administration of fresh whole blood if there is anemia, or plasma—either fresh, fresh frozen, or lyophilized—in the absence of anemia. In fact, in any case in which hemorrhage has been severe, fresh whole blood or plasma should be combined with replacement of the specific deficient factor, because with hemorrhage a loss of other factors normally present occurs, thereby creating multiple deficiencies.

## THE SEVERAL DRUGS

According to the clinical indications enumerated above, the several therapeutic agents used in hematologic disorders may be outlined as shown in Table 41.

It is obvious that a number of therapeutic agents have been omitted from this outline. For instance, we have omitted other metals such as copper, cobalt, manganese, and molybdenum, which appear to have no sound application in therapy of anemia. Liver extract is not listed as such since its activity is proportional to its content of vitamin B<sub>12</sub> and will be included in the discussion of the use of vita-

*Table 41 The Several Therapeutic Agents Used in Hematologic Disorders*

Groups	Agent	Clinical Applications
Specifics <sup>1</sup>	Iron	Iron deficiency anemia
	B <sub>12</sub> and liver extract	Pernicious anemia Anemia following gastrectomy Certain macrocytic anemias not responsive to folic acid
	Folic acid	Macrocytic anemias of sprue, steatorrhea, celiac disease, pregnancy, surgical or developmental anomalies of the gastrointestinal tract, fish tapeworm infestation
Nonspecifics <sup>1</sup>	Other vitamins (B group, C)	Pellagra, scurvy, pyridoxine deficiency
	Corticosteroids (prednisone, ACTH, cortisone)	Aplastic anemia Hemolytic anemia Idiopathic thrombocytopenic purpura Vascular purpura Fibrinolysis <sup>2</sup>
	Myelotoxic agents	Polycythemia vera Thrombocythemia
Antihemorrhagic agents	P <sub>32</sub> , Myleran, etc (excluded are other myelotoxic agents discussed in Chapter 33)	
	Platelets	Thrombocytopenia
	Antihemophilic globulin	Hemophilia
Ancillary agents	Serum	PTC deficiency
	Vitamin K	Prothrombin deficiency
	Fibrinogen	Fibrinogen deficiency
Ancillary agents	Blood or plasma	Any hemorrhagic disorder
	Anticoagulants	Polycythemia thrombocythemia
	Antibiotics	Agranulocytosis, bone marrow failure, leukemia

hydrate complex (Astrifer) can be accepted. Ed.]

**OTHER METALS**—At this point, it should be stated that we find no indication for the administration of other metals such as copper, manganese, cobalt, or molybdenum in the therapy of anemia. It is true that cobalt in the form of cobaltous chloride is capable of eliciting a mild erythropoietic response which may be helpful occasionally in the anemia of uremia or chronic infections. But the erythropoietic response appears unphysiologic in that it continues only so long as the cobalt is administered and side effects of gastrointestinal and thyroid disturbances occurring with cobalt administration seem to militate against its use.

**Vitamin B<sub>12</sub> in Pernicious Anemia**—With the firm establishment in recent years of vitamin B<sub>12</sub> as the active antianemia principle in liver extract, there appears to be very little indication for the latter as a therapeutic agent. This conclusion seems justified in spite of the many "liver injections" that patients continue to receive. However, liver extract may be used as a source of vitamin B<sub>12</sub> in place of more concentrated preparations, since liver extract is now assayed according to its content of the vitamin. Another use according to scattered reports, may be in certain rare types of chronic anemia which are said to respond only to crude liver injections. However, in general, liver preparations have nothing to recommend their use over the readily available vitamin B<sub>12</sub> preparations.

**INITIAL THERAPY**—The initial therapy of a "fresh" case of pernicious anemia or one in relapse is quite flexible within certain bounds. As little as 1 mcg intramuscularly daily can produce complete remission in certain cases. However, this represents minimum therapy where one is usually interested in replacing depleted B<sub>12</sub> stores. The other extreme is represented by the demonstration that, as 80 mcg per dose is exceeded, proportionally larger quantities are excreted in the urine. Therefore, we adopt a middle road and may administer 30 to 100 mcg vitamin B<sub>12</sub> intramuscularly daily for 5 to 7 days, then every other day for the second week and at progressively longer intervals thereafter. Finally, the patient is maintained on approximately 2 mcg daily, which we usually give in a single monthly intramuscular injection of 60 mcg.

**MAINTENANCE**—The exact maintenance dosage and interval of administration varies with each case according to tendency to relapse, particularly neurological relapse. Patients should be tested for vibratory sense and tendon reflexes at the time of each visit. When neurological involvement is apparent, supermaximum doses of vitamin B<sub>12</sub> are justified for initial and maintenance therapy.

**Oral Therapy**—Recently there have been many investigations into the feasibility of maintaining the patient with pernicious anemia on oral therapy. This consists of daily administration of tablets or capsules containing vitamin B<sub>12</sub> in conjunction with stomach extract, thereby supplying 'intrinsic factor' and permitting absorption of the vitamin. This method of maintenance therapy has proved satisfactory and is no doubt preferred by many patients. However, at present, B<sub>12</sub> given by injection appears more dependable and it is cheaper. Furthermore, it requires that the patient be observed from time to time. Patients maintained on pills alone often forget to return to their physician. It may prove advantageous in certain cases to provide optimum therapy or to prolong the interval between injections by combining both the oral and injectable forms of therapy.

in meats, eggs, cheese, milk, and other foods, and is synthesized by intestinal bacteria. It is readily absorbed from the gastrointestinal tract in the presence of "intrinsic factor," is found in plasma in combination with  $\alpha$  globulins mainly, and is stored for the most part in the liver. The exact mechanism through which vitamin  $B_{12}$  functions as an antianemia principle is uncertain. However, it is known to be concerned in the formation of nucleic acids and is closely related in its action to the action of folic acid. There are no known acute or chronic toxic reactions to the administration of vitamin  $B_{12}$  even in large doses parenterally.

Other members of the B vitamins including pyridoxine, riboflavin, and nicotinic acid, undoubtedly function in hematopoiesis, but they are relatively unimportant from a therapeutic standpoint and therefore will be omitted from this discussion. Vitamin C appears to be interrelated in the functions of vitamin  $B_{12}$  and folic acid without having a specific action of its own in hematopoiesis.

**Folic Acid**—Folic acid or pteroylglutamic acid is a yellow crystalline compound whose chemical structure consists of a pteridyl group, p-aminobenzoic acid and glutamic acid. A number of conjugate forms are known, and the formyl derivative, so called citrovorum factor or folinic acid, is worthy of mention. These substances are widely distributed in nature and maximally concentrated in certain foods such as liver, yeast, and green leafy vegetables. They are also synthesized by intestinal bacteria so that minimal daily requirements are difficult to determine. Absorption from the gastrointestinal tract is efficient except in cases with severe malabsorptive defects. As indicated previously, folic acid plays a role with vitamin  $B_{12}$  in the synthesis of nucleic acids. But the two cannot be substituted interchangeably, as evidenced by the fact that folic acid may produce a hematologic remission in pernicious anemia while the neurologic lesions progress.

**Radio-Phosphate**—Radioactive phosphorus ( $P^{32}$ ) inhibits bone marrow activity by its emission of beta rays, which have a maximum penetration in tissues of about 0.7 cm. This isotope has a physical half-life of 14.3 days, but since it is metabolized and excreted as any stable phosphorus atom, it has an estimated biologic half-life in man of 8 days. Phosphorus is incorporated in the nucleoproteins of growing cells, which accounts for the localization and effectiveness of the radioactive isomer in proliferating tissue such as marrow or neoplasms. Overdosage may cause severe bone marrow despression or fatal aplasia.

**Vitamin K**—Vitamin K exists in a number of forms, all of which contain a naphthoquinone group. It occurs naturally as vitamin  $K_1$  in plants and vitamin  $K_2$  in animals. However, the dietary source is relatively unimportant as the vitamin is synthesized by intestinal bacteria and, being fat soluble, is readily absorbed in the presence of bile salts. The vitamin is essential for the synthesis of normal amounts of prothrombin by the liver, although the details of this process are unknown. Obviously, prothrombin production may be impaired through hepatic dysfunction or through deficient supply of vitamin K secondary to obstructive biliary disease, absorptive defects, or disruption of bacterial synthesis as a result of antibiotic therapy. There is evidence that excessive administration of vitamin K in man may cause prolongation of the prothrombin time, particularly in the presence of hepatic dysfunction. Also, hyperbilirubinemia has been noted in premature infants following excessively high doses of vitamin K.



Table 43 Summary of Therapy of Hypoplastic Anemia or Bone Marrow Failure

<b>First Step</b>	
1 Transfusions	Whole, fresh blood in an effort to maintain approximately 8 Gm of hemoglobin Fresh whole blood " " " " " " " " " "
2 Corticosteroids	" " " " " " " " " "
3 Antibiotics	thorough trial Tetracycline, 1 Gm daily, or other antibiotic as indicated if infection imminent due to low granulocyte level
<b>Second Step</b>	
1 Splenectomy	To be considered as a final measure and more likely to be effective when there is evidence of hematopoiesis in the marrow
2 Thymectomy	In rare cases in which a thymus tumor is detected

**Corticosteroids in Hypoplastic Anemia or Bone Marrow Failure**—The use of corticosteroids in this group of diseases is a moot point since, as pointed out previously, the exact effect of steroids on the bone marrow is unknown. Our feeling is that these cases should be treated thoroughly, including the use of corticosteroids, because remissions do occur. Fresh blood, collected in plastic bags or siliconized glassware, should be administered as necessary to maintain the hemoglobin at an approximate level of 8 to 9 Gm. There is no necessity for pushing blood values higher as patients become "conditioned" to these relatively low values of hemoglobin and, furthermore, too many transfusions may have a suppressive effect on erythropoiesis. Antibiotics may be administered in the presence of extremely low granulocyte counts as a prophylactic measure. For this purpose, one of the broad-spectrum antibiotics such as tetracycline in doses of 1 Gm daily orally is satisfactory.

In our experience, corticosteroids seem beneficial and appear to have produced remissions in rare cases. In any event, they tend to reduce the bleeding tendency, possibly through a nonspecific effect on vascular integrity. In cases where there may be an element of hemolysis, corticosteroid therapy is pre eminent. In short, we give corticosteroids a thorough trial in any case of hypoplastic anemia, beginning with large doses of prednisone (100 mg daily) for 7 to 10 days and then gradually reducing the dosage, depending on any obvious effect on the blood count until a relatively safe maintenance dosage is attained (5 to 20 mg prednisone). If prednisone therapy appears ineffectual after a thorough trial, we may try large doses of ACTH or cortisone on the basis that one corticosteroid may be effective where another is not. As a final measure, splenectomy may be advisable since it has proved beneficial in a few cases particularly those with some evidence of hematopoiesis in the marrow. The possibility of transplanting normal marrow is now under investigation (Table 43).

**Corticosteroids in Autoimmune Hemolytic Anemia**—The corticosteroids and prednisone in particular, have proved in our hands very valuable in the management of autoimmune hemolytic anemia of either the "idiopathic" or the "symptomatic" type. In this disease, our program of therapy involves four distinct phases (1) initial treatment with high doses of corticosteroids until a remission has been ob-

Although the main applications of vitamin B<sub>12</sub> are in pernicious anemia and postgastrectomy anemia, in which the source of intrinsic factor may have been removed, there are a number of cases of macrocytic anemia which etiologically would be classified as responsive to folic acid and yet do not respond to folic acid. In these cases, after a thorough trial of folic acid, B<sub>12</sub> should be administered and may induce a remission (Table 42)

*Table 42 Summary of Therapy of Pernicious Anemia*

Initial and relapse therapy	First week	Vitamin B <sub>12</sub> 30 to 100 mcg I M daily—dosage depending on individual case
	Second week	Vitamin B <sub>12</sub> 30 to 100 mcg I M every 2 days
	Third to sixth week	Vitamin B <sub>12</sub> 30 to 100 mcg I M weekly
Maintenance therapy		Vitamin B <sub>12</sub> 60 to 100 mcg I M monthly—dosage and interval depending on individual case

**Folic Acid in Macrocytic Anemias**—The exact interrelationship between vitamin B<sub>12</sub> and folic acid in hematopoiesis is unknown. Either will cause a hematologic remission in pernicious anemia, but if folic acid is the sole therapeutic agent in this disease, the neurologic manifestations may progress in spite of the improved blood picture. For this reason, folic acid is contraindicated as the primary or sole therapeutic agent in pernicious anemia.

In spite of the fact that the exact metabolic roles of vitamin B<sub>12</sub> and folic acid remain an enigma by the use of newer diagnostic methods utilizing vitamin B<sub>12</sub> serum levels, radioactive cobalt labeled vitamin B<sub>12</sub> uptake studies and various tolerance tests designed to demonstrate absorption defects, it is possible to delineate the specific deficiency in most cases of macrocytic anemia. In general, however, given a case of macrocytic anemia, which according to the clinical picture is not pernicious anemia or intrinsic factor deficiency as a result of gastrectomy, the first therapeutic agent of choice is folic acid. Examples of such macrocytic anemias have already been enumerated and include sprue, steatorrhea, celiac disease, macrocytic anemia of pregnancy, and surgical or developmental anomalies of the gastrointestinal tract, and fish tapeworm infestation. In these conditions, folic acid may be administered initially in doses from 10 to 100 mg orally daily with subsequent maintenance doses of 5 to 10 mg daily.

In some of these conditions, particularly the malabsorption group, hematologic remission may not be complete, but clinical improvement may be sufficient to warrant continuation of therapy with folic acid. Where there is no response to folic acid and where facilities for detailed absorptive studies are not available, vitamin B<sub>12</sub> may be administered parenterally, with response in some cases.

**CITROVORUM FACTOR**—Citrovorum factor appears to have the same action as folic acid, although there are reports of cases of macrocytic anemia which failed to respond to folic acid but which responded when citrovorum factor was administered. However, citrovorum factor is specific in combating the toxic effects of antifolic compounds such as Aminopterin, in which instance folic acid may be ineffective. Citrovorum factor may be administered intramuscularly in doses of 3 to 6 mg, once or twice daily.

with a broad spectrum agent such as tetracycline 1 Gm orally daily or other antibiotics as indicated by sensitivity studies if specific organisms can be cultured. In most cases, infection can be controlled and granulocytes reappear in the bone marrow and peripheral blood without other forms of therapy.

However, there are cases in which the course is more protracted, and in these one may administer corticosteroids on the basis that they may suppress antibody formation and may even have a myelostimulatory effect. Suffice it to say that, in our own series of cases, we have rarely resorted to steroid therapy, and in these it is impossible to assess the role of the steroid.

**Corticosteroids in Idiopathic Thrombocytopenic Purpura**—In 1916, Kaznelson demonstrated that splenectomy was an effective therapeutic procedure in idiopathic thrombocytopenic purpura since, postoperatively, there is a fairly consistent rise in platelet levels. Thereafter for years, splenectomy remained the treatment of choice, and the operation was frequently an emergency procedure, often attended by a high mortality rate.

Then, about 1950, two measures of great importance were added to the therapeutic regimen of idiopathic thrombocytopenic purpura. It was found that ACTH or cortisone could effectively control the hemorrhagic state prior to splenectomy, thereby rendering the patient a better operative risk. Also, by collecting blood in plastic bags or siliconized glassware, it became possible to raise the patient's platelet count significantly by transfusing fresh blood containing viable platelets. But as more splenectomies were done and patients were followed for longer periods, it became apparent that there was a high relapse rate in spite of months or even years of remission.

Originally, the action of ACTH and cortisone in controlling the hemorrhagic diathesis was felt to be a nonspecific effect on vascular continuity since increased platelet counts were not prominent. However, the corticosteroid role was reinvestigated due to the frequent relapses following splenectomy, and it became apparent that most cases respond to corticosteroid therapy with a rise in platelets, possibly as a result of suppression of antibodies. This response has been so consistent, particularly with prednisone in our laboratory, that we feel corticosteroids have largely replaced splenectomy in the therapy of idiopathic thrombocytopenic purpura. In a recent review of 17 consecutive cases of this disorder treated by us, only 6 cases failed to respond to prednisone alone, and 4 of these failures subsequently responded to splenectomy and prednisone.

We customarily classify cases of idiopathic thrombocytopenic purpura as acute or chronic, depending on the history, although admittedly this division is sometimes possible only in retrospect. Our initial daily dose of prednisone may vary from 50 to 250 mg, depending on the condition of the patient and the urgency of the situation. On this dosage, hemorrhagic manifestations usually cease, and in most cases the platelet count begins to rise within 14 days. The platelet count is usually normal in 8 to 30 days, acute cases tending to respond faster than chronic ones. As the platelet count rises toward normal, the dose of prednisone is reduced, with an aim toward maintaining a normal or slightly subnormal platelet count with the patient on less than 10 mg prednisone daily. In some cases, particularly acute ones, it is possible to discontinue prednisone entirely. A return to a com-

TABLE 4. SUMMARY

Initial Therapy	1. Prednisone	
	2. Vincristine	3. Cyclophosphamide
Maintenance Therapy	1. Cyclophosphamide	
	2. Vincristine	3. Prednisone
Therapy of Relapse	1. Cyclophosphamide	
	2. Vincristine	3. Prednisone

timed 2 reduction in the dose of prednisone to 10 mg per day is the minimum is obtained 13 reduction in the dose of prednisone to 5 mg per day is the minimum is obtained 14 reduction in the dose of prednisone to 2 mg per day is the minimum is obtained 15 final approach is to reduce the prednisone dose to 1 mg per day on doses of steroid which are not able to maintain the patient in remission must be maintained.

In autoimmune hemolytic anemia the use of prednisone is the mainstay of therapy. We know from experience that the dose of prednisone must be high enough and therefore it is better to start with a high dose and then reduce it. We now use prednisone doses of 40 to 60 mg per day in the initial phase of therapy. 100 mg per day. Beginning remission is obtained by a reduction in prednisone to a maintenance of the red cell count to a level of 3.0 million per cubic millimeter and an improvement in the clinical picture. Following the initial hemolytic response the dose of prednisone is gradually reduced to the lowest level which will sustain satisfactory hemoglobin and erythrocyte values. Important feature is indicated by a slight fall in the red cell count or hemoglobin level with a rising reticulocyte count. The dose is then may remain constant over the next few months. Relapses of hemolytic disease are often. Cases which relapse after therapy to corticosteroid therapy or which relapse after therapy of corticosteroids the produce toxic side effects are then considered for splenectomy. Relapses following splenectomy are uncommon but when they occur they are managed similarly with steroids.

The over all picture of results with corticosteroids or corticosteroids plus splenectomy indicates a complete remission rate of approximately 50 per cent. In this regard several points should be realized. Individualization in the management of each patient is the key note of therapy. Although we present remission rates in a discussion such as this patients vary widely in their responsiveness. Once an autoimmune mechanism develops it is usually of perpetuating and may persist permanently or may relapse after years of remission. Therefore management varies greatly from one case to another (Table 4).

Antibiotics in Agranulocytosis—There is increasing evidence that agranulocytosis is an immune disorder resulting from an abnormal hypersensitivity reaction of granulocytes and that if an offending drug or other toxic substance can be detected and removed the granulocytes will recover spontaneously. This was seldom possible before the era of antibiotics the patient usually died of overwhelming infection as a result of granulocytopenia. At present however we use the therapy

By vascular pseudohemophilia we refer to the *hemorrhagic disorder in which prolonged bleeding time is the only demonstrable abnormality*. Therefore, we include cases in which thrombasthenia is detectable (von Willebrand's disease) as well as those in which an unknown vascular defect is responsible for symptoms. Either of these appears to respond favorably to corticosteroid therapy as outlined above for anaphylactoid purpura, and here again we use the corticosteroids for a brief period when symptoms are present. The manner in which corticosteroids are beneficial in these cases is unknown. There seems to be a specific action in restoring vascular integrity as is evident in thrombocytopenic purpura where hemorrhagic manifestations may cease as a result of corticosteroid therapy long before there is evidence of a rise in platelets.

**Therapy in Polycythemia Vera**—There are two main methods of controlling the high blood levels of polycythemia vera: (1) removal of the excess blood by repeated venesections, and (2) reduction of the activity of the bone marrow by use of myelodepressant agents such as  $P^{32}$  or Myleran, and perhaps by institution of iron deficient diet.

**VENESECTION**—Venesection alone had been the mainstay of therapy in polycythemia for many years. However, with the advent of radioisotopes and the demonstration that  $P^{32}$  is concentrated in the marrow with destruction of its cellular elements, this substance became the preferred method of therapy by many workers.

**RADIO PHOSPHATE**— $P^{32}$  may be administered orally in water or intravenously,

if the red cell count and, particularly, the platelet count remain at dangerously high levels.

**Combinations With Venesection** In most cases, venesections are combined with  $P^{32}$  therapy. That is a new case or one in relapse is given the estimated dose of  $P^{32}$  and at the same time venesections are started daily or every other day. The first few attempts at venesection are usually difficult because of the increased viscosity, therefore, one must be satisfied with small amounts of blood and repeat the procedure daily or every other day, gradually increasing the quantity withdrawn at each operation until the hematocrit is finally below 50 per cent or the hemoglobin below 14 Gm. The hematocrit and platelet levels in 2 to 3 months are then used as criteria of the effectiveness of the previously administered  $P^{32}$ .

**Dangers** There is no doubt that the use of  $P^{32}$  in polycythemia vera has been very effective in producing remissions and rendering these patients symptom free for intervals of 1 to 2 years in some cases. However, we would be remiss were we not to mention that at present there are statistics to suggest that there is a higher incidence of leukemia as a terminal development in patients with polycythemia vera treated with  $P^{32}$ , than in those previously treated with venesections alone. The subject is far from settled at this time because of the lack of controlled series. Suffice it to say that because of the incidence of leukemia in  $P^{32}$  treated cases we are again treating most of our cases with venesections.

*Table 45 Summary of Therapy of Idiopathic Thrombocytopenic Purpura*

<i>Initial Therapy</i>	
1	Prednisone 50 to 250 mg daily until platelet count begins to rise
2	Transfusions of fresh, whole blood collected in plastic bags or siliconized bottles for platelet effect, the number depending on the degree of hemorrhage
<i>Maintenance Therapy</i>	
1	-
2	-
<i>Therapy of Relapse</i>	
1	Same as remission therapy
2	Splenectomy if doses of prednisone required to maintain a remission are toxic or too high to be compatible with prolonged therapy

pletely normal level of platelets is not essential, since the patient can get along well on approximately one half normal platelet count without evidence of bleeding tendency.

However, in some cases the platelet count may fall to pretreatment levels when the prednisone is reduced or discontinued. When this happens, the high dosage of prednisone is reinstituted, usually with the same beneficial effect as the first course. Then again we attempt to reduce the prednisone without a relapse in the platelet count. In other words, we try to render the patient symptom free with normal or subnormal platelet levels on a daily prednisone dose of less than 10 mg. Where this is impossible, we resort to splenectomy, but only after a thorough trial of prednisone. We have come to regard "medical therapy" the treatment of choice in idiopathic thrombocytopenic purpura, resorting to splenectomy only as a last measure (Table 45).

**Corticosteroids in Vascular Purpuras.**—As mentioned previously, the majority of purpuras which occur on the basis of a vascular defect are benign and do not require therapy. The two most important from the standpoint of frequency of occurrence and morbidity are anaphylactoid or Henoch Schönlein purpura and so called "vascular pseudohemophilia."

Henoch Schönlein purpura may be acute or chronically recurrent with generalized involvement of the skin, joints, gastrointestinal tract, and kidneys due to a widespread vasculitis affecting small blood vessels. Some cases are mild and of short duration, requiring little more than salicylates and sedation for relief of symptoms. In the more severe and particularly in recurrent attacks, we administer corticosteroids with prompt relief of symptoms in most cases. Our rationale for the use of corticosteroids is that anaphylactoid purpura appears to be an autoimmune disease involving small blood vessels throughout the entire body. Therefore, corticosteroids would be expected to exert a beneficial effect, as in most allergic disorders. We ordinarily administer corticosteroids for 1 to 2 weeks during the acute attack. We may start with 50 mg of prednisone daily for 2 to 3 days and then rapidly reduce the dose over the next few days, depending on the progress of the patient. Proportionally smaller doses are used for children. We do not use corticosteroids prophylactically except in rare cases where there are frequent recurrences at short intervals. In this case we may maintain the patient on 5 to 10 mg prednisone daily.

Table 47 Summary of Therapy of Hemophilia

Hemorrhagic Phase	1	Fresh whole blood or fresh frozen plasma continuously until hemorrhage stops
	2	If open wound, debridement followed by pressure dressings of thromboplastin or thrombin
	3	After hemorrhage ceases continue to administer fresh whole blood or fresh frozen plasma approximately 20 ml per kilogram every 4 to 8 hours for several days or more
Nonhemorrhagic Phase	1	Education of patient and family
Prophylactic Therapy	2	Orthopedic measures to limit deformities from hemarthroses
	1	" " " " " " " "
	2	" " " " " " " "
on the operation and progress		

**PROPHYLACTIC AHG ADMINISTRATION**—AHG may be administered prophylactically in instances where dental extractions are mandatory. In such cases we prefer to hospitalize the patient and give 250 to 500 ml plasma just prior to operation with continuous plasma infusion during the operation. Postoperatively plasma is administered every 4 to 8 hours in amounts of approximately 2 ml per kilogram for several days, depending on the patient's progress.

Prophylactic AHG may also be necessary in preparation for abdominal surgery, particularly appendectomy. However, hemophiliacs are notoriously poor surgical risks, and therapy should always lean toward conservatism. Indeed, most "surgical abdomens" in hemophiliacs represent occult bleeding, and the mortality rate is compounded by surgery (Table 47).

**Vitamin K in Prothrombin Deficiency**—Prothrombin deficiencies may be congenital or acquired. Fortunately, the congenital varieties are quite rare and, since they do not respond to the administration of vitamin K, they must be treated during hemorrhagic episodes by the administration of whole blood or plasma.

**ACQUIRED HYPOPROTHROMBINEMIA**—Acquired hypoprothrombinemia may occur neonatally as so called hemorrhagic disease of the newborn or as the result of biliary disease, malabsorption, antibiotic sterilization of the bowel, or anticoagulant therapy. In any of these situations, vitamin K may be administered orally or parenterally, depending upon details of the particular case and urgency of the situation. However, in general we administer vitamin K parenterally, using either menadione or vitamin K<sub>1</sub>. The former, given in a dose of 2 mg subcutaneously, will usually result in greater than 20 per cent improvement in the prothrombin time (Quick) in 12 hours in the presence of normal liver function. And this method of therapy appears to be satisfactory for most cases of hypoprothrombinemia except those resulting from anticoagulant therapy. In these, as perhaps in all hypoprothrombinemias responding to vitamin K therapy, vitamin K<sub>1</sub> appears to be of greater efficacy in restoring prothrombin than the synthetic preparations. Vitamin K<sub>1</sub> may be administered orally in doses of 5 to 20 mg daily or intravenously in 5 per cent glucose solution in doses of 5 to 50 mg or more daily. The amount of vitamin K<sub>1</sub> required varies with each case, and it must be administered until the prothrombin

[illegible]

The most important measures during this phase are education of the patient toward prevention of trauma and institution of any necessary orthopedic procedures in an attempt to prevent deformities from hemarthroses.



normal ones. A step in this direction has already been made by introduction of the alkylating agents, and research continues in an effort to make their action more selective. Also, knowledge of an etiologic agent such as a virus in neoplastic growths may lead to the development of prophylactic methods. Any or all of these may be future therapeutic possibilities as a result of further insight into normal and abnormal marrow physiology.

## SELECTED REFERENCES

- Dameshek W, and Komninos, Z D The Present Status of Treatment of Hemolytic Anemia With ACTH and Cortisone, Blood 11 648, 1956
- Dameshek, W, Rubio, F, Jr, Mahoney J P, Reeves, W H, and Burgin, L The Treatment of Idiopathic Thrombocytopenic Purpura With Prednisone, J A M A 166 1805, 1958
- Franklin, M, Rohse, W G, de la Huerga, J, and Kemp, C R Chelate Iron Therapy, J A M A 166 1685, 1958
- Fruhman, G J, and Gordon, A S Quantitative Effects of Corticosterone on Rat Bone Marrow, Proc Soc Exp Biol Med 88 120, 1955
- Granick  
Hechter,  
Quittner,  
1951  
L. H. ...  
F.  
S.  
Stratton Inc  
Stoerk, H C Cortisone in Relation to Lymphoid Tissue and Immunity In Fifth Annual Report on Stress 1955-56, by H Selye and G Heuser, New York, MD Publications, Inc  
Sturgeon, P Iron Metabolism—a Review With Special Consideration of Iron Requirements During Normal Infancy Pediatrics 18 267, 1956  
Wintrobe M M Clinical Hematology, ed 45, Philadelphia, 1956, Lea & Febiger

is restored to the desired level. When restoration of normal prothrombin activity represents an emergency, whole blood or plasma should be utilized as a source of available prothrombin in addition to the administration of vitamin K.

**Fibrinogen in Hypofibrinogenemia**—Hypofibrinogenemia or afibrinogenemia may occur as congenital deficiencies, in which cases there are not usually serious hemorrhagic manifestations. This is fortunate because efforts to raise the fibrinogen level by administration of fibrinogen are successful only temporarily, the administered fibrinogen disappearing in 3 to 4 days.

More commonly, hypofibrinogen occurs as a complication of obstetrical conditions, including abruptio placentae, long standing intrauterine fetal death, and amniotic fluid embolization. It has also occurred as a complication of prostatic, lung, pancreatic, and uterine surgery, as well as in certain malignancies. In some cases, the hypofibrinogenemia is the result of a fibrinolytic mechanism. In any case, recognition of hypofibrinogenemia depends mainly on a clinical awareness on the part of physicians engaged in the fields where the condition most commonly occurs.

Fortunately, a simple test (Fibrindex) which demonstrates failure of the patient's plasma to form a normal clot on addition to thrombin is readily available and serves as a rough index of fibrinogen level. Where suitable laboratory facilities are available, however, actual fibrinogen determinations can be made.

Once the diagnosis of hypofibrinogenemia has been established therapy becomes an emergency since these patients rapidly develop circulatory collapse. Whole blood either fresh or stored or plasma is administered as soon as possible and serves as a source of fibrinogen as well as replacement of blood volume. In addition concentrated fibrinogen is administered intravenously, usually 2 to 10 Gm in divided dosage depending on progress of the patient. After cessation of hemorrhage, approximate fibrinogen levels may be determined at intervals for several days to be certain that adequate fibrinogen is maintained.

## RATIONAL BASIS FOR NEW DRUGS IN HEMATOLOGY

A number of *specific* therapeutic agents presently available in hematology are on a sound physiologic basis, i.e., each agent supplies the missing factor and its use is curative. Examples of such agents are iron in iron deficiency anemia, B<sub>12</sub> in pernicious anemia, folic acid in most macrocytic anemias, vitamin K in most hypoprothrombinemias, and fibrinogen in hypofibrinogenemia. Obviously anyone's hope for the future would be that factors as specific and physiologic as these could be discovered for such serious diseases as leukemia, lymphoma, aplastic anemia, idiopathic thrombocytopenic purpura, and others.

We can hope for factors capable of controlling bone marrow production as a thermostat controls a furnace. These would include factors capable of stimulating or suppressing normal growth, differentiation, maturation, and exfoliation of marrow cells. These factors may even be specific for a cell line like the erythropoietic factor which is already being investigated widely. Then if abnormal growth and maturation are found to be uninfluenced by normal control mechanisms, one would desire agents capable of destroying the abnormal cells preferentially and sparing

nosis and proper treatment warrant the use of the drugs. Then therapy with drugs is based on a reasonable understanding of how they produce their effect, how the degree of effect can be controlled so that untoward effects are avoided successfully as possible.

Fortunately the physician need not be conversant with the many details which are now involved in the present day concept of the mechanisms concerned in coagulation of blood. No other field of physiology is more rampant with terminology which is sometimes confusing even to those persons who are actively conducting research in this field. This confusion in terminology results from the complexity and the only partially evaluated, multiple details of the clotting mechanism. For general purposes, the formation and resolution of the clot result from the following sequence of reactions:

- 1 Formation of thromboplastin
- 2 Conversion of prothrombin to thrombin by thromboplastin
- 3 Conversion of fibrinogen to fibrin by thrombin
- 4 Resolution of fibrin by fibrinolysin

Although tissue thromboplastin is liberated whenever the integrity of the tissue cells is disrupted, this form of thromboplastin is usually involved in the clotting of blood only when the tissue is grossly traumatized. However, it may be that clotting in the intact vasculature is initiated by this form of thromboplastin resulting from a minor amount of tissue injury or pathology, for it is well recognized that blood does not spontaneously clot in the normal intact vasculature.

In order for the rapid formation of thromboplastin to take place, the blood must contain a normal complement of platelets, antihemophilic globulin, and plasma thromboplastin component. Although the source of blood thromboplastin is not clearly established, it is believed to be derived either from the platelets or the antihemophilic globulin. When thromboplastin becomes available it will react with prothrombin resulting in the formation of thrombin. However, rapid formation of thrombin involves at least two additional protein factors which are normally present in plasma. These factors are known as convertin and accelerin. Convertin is involved in the initiation of the conversion of prothrombin to thrombin and accelerin accelerates the rate of this reaction. Calcium ions also take part in the reaction, but clinically, calcium ions are not a limiting factor. In the presence of thrombin, fibrinogen is rapidly converted to fibrin. Fibrin is the matrix of the clot. Normal blood also contains the precursor (profibrinolysin) of an enzyme (fibrinolysin) which is capable of resolving the fibrin of a clot. All therapeutic agents which influence the coagulation or resolution of blood produce their effect through influencing one or more of the reactions mentioned above.

## THE ANTICOAGULANTS

Anticoagulant therapy represents an attempt to prevent enlargement of an existing thrombus and the occurrence of additional new thrombi in the vascular bed. Anticoagulant therapy is used for this purpose in the treatment of the clinical conditions which follow:

# THE CHOICE OF DRUGS AFFECTING THE COAGULATION OF BLOOD

T A Loomis, Ph D, M D

## INTRODUCTION

Drugs which influence the coagulation of blood may be divided into four main groups on the basis of their clinical usefulness. The first group is the anticoagulants and includes those agents which are given for the purpose of preventing the clotting of blood in the intact vasculature of the patient. The second group consists of the coagulant agents which may be given for the purpose of correcting certain hemorrhagic tendencies but which are not intended to produce actual clot formation. The third group consists of the coagulant agents which are intended to arrest bleeding or promote coagulation of blood by the actual production of a clot at the site of their application. The fourth group consists of those lytic agents which are given for the purpose of enhancing resolution of a blood clot. This chapter will consider these four groups of drugs in the order presented above. In the instances in which a single drug may be useful in more than one category, reference will be made to its additional uses in the discussion of each category.

Any preference for the recommendation of a particular agent when several similarly used agents are available is based on the following considerations. The first consideration will be the nearness to which the drug approaches all of the criteria which are considered as being ideal for the hypothetically perfect drug. The second consideration will be the degree to which the drug has proved itself by the test of time and use in the hands of many investigators. The last consideration is rather intangible one as it is concerned with the individual physician's preference which has resulted from personal experience in using the drugs. Unfortunately personal experience is not usually scientifically controlled and therefore is not subject to experimental evaluation. However, such personal experience frequently emphasizes merits and drawbacks associated with the use of particular drugs.

Therapy with any drug which influences the coagulation of blood is based on proper accurate diagnosis and a sound understanding of the fundamental concepts of the mechanism involved in the coagulation of blood and resolution of blood clots. Many of the drugs which are considered in this chapter are potentially useful agents. A patient should not be subjected to such agents unless the diag-

and the more slowly acting, synthetic coumarin and coumarin like compounds. The closest approach to ideal anticoagulant therapy is accomplished through the combined use of heparin and Dicumarol or an agent like it. Recent evidence indicates that the coumarin like compound which most closely approaches the prerequisite of the ideal agent is warfarin sodium, but this compound is the newest of the coumarin like compounds and has not yet had the test of time and use in the hands of numerous investigators. Where there is no necessity for rapid initiation of anticoagulant therapy, Dicumarol or warfarin is the drug of choice.

**Heparin**—Heparin is a mucosin polysaccharide which is normally present in blood and which some investigators believe is the naturally occurring agent which maintains normal fluidity of the blood. The presently available forms of heparin are completely nontoxic except for their anticoagulant action. Its advantages are that its anticoagulant action on the blood is immediate, its effect can be determined by the relatively simple Lee White clotting time test at the bedside, a single intravenous dose produces a predictable uniform response, it does not produce cumulative toxic effects on repeated administration, and its duration of action is sufficiently short so that if bleeding occurs treatment of overdose usually involves only discontinuance of the drug.

The greatest disadvantage in heparin therapy is that the drug must be administered by the parenteral route. The intravenous route is the route of choice because subcutaneous or intramuscular preparations are prone to produce either pain at the injection site or hematoma formation on repeated administration and in unpredictable degree of effect on the coagulation of the blood in different patients. Another disadvantage of heparin is its extremely short duration of action. The short duration of action (2 to 6 hours depending on the dose) following intravenous administration of heparin results in a nonstable degree of effect. However, stable uniform intensity of effect on the clotting time can be obtained by continuous intravenous infusion of heparin. Continued medication with heparin is costly not only because of the initial high cost of the drug but also because of the necessity for hospitalization during medication arising from the need for repeated injections at 4 to 6 hour intervals.

Heparin has four effects on the blood clotting mechanism. First, it has an antithromboplastin action which is mediated through a plasma cofactor, that is, heparin reacts with a plasma cofactor, resulting in the formation of a substance which inactivates thromboplastin. Second, heparin has an antithrombin action which is also mediated through a normal plasma factor, that is, it is believed that heparin either reacts with a plasma cofactor or activates the precursor of an antithrombin which results in the formation of a substance which inactivates thrombin. Third, heparin decreases the adhesiveness of the platelets. Although the role of the platelets in the clotting mechanism is not clearly defined, it is believed by some investigators that initiation of the clotting process is associated with the fusion and agglutination of the platelets. Last, heparin has been shown in animal experiments to promote the resolution of a newly formed clot. However, heparin does not dissolve the fibrin of a well established blood clot.

**DOSAGE**—Adequate heparin induced anticoagulant therapy is present when the clotting time is elevated from 2 to 3 times normal value as measured by the

- 1 Pulmonary embolism due to an intravascular clot
- 2 Coronary occlusion with myocardial infarction
- 3 Venous or arterial thrombosis
- 4 Postoperatively and post partum in all patients who have a previous history of embolic disease, and following all major vascular surgery
- 5 Rheumatic heart disease with auricular fibrillation
- 6 Excessive traumatic injury, gangrene, or frostbite of the extremities

Although the currently available evidence is inconclusive, apparently favorable results can be expected by the use of anticoagulant therapy in chronic obliterative vascular disease and in congenital heart failure (for the prevention of thrombosis)

Although there is only meager evidence to indicate that the anticoagulant drugs are capable of hastening resolution of preformed clots, these drugs should be administered to prevent extension of the initial clot. Unless the initial thrombus is of such magnitude as to occlude the blood supply to a vital structure or area, adequate anticoagulant therapy will prevent extension of the clot and the occurrence of additional thromboembolic sequelae.

The nature of the diseases which indicate the use of the anticoagulant drugs frequently necessitates the prolonged use of these agents. Adequate prolonged therapy can be achieved only when the physician has available adequate facilities for determining certain coagulation tests. Excessive drug effect may lead to hemorrhagic complications, and inadequate dosage will not achieve protection for the patient from the thromboembolic complications for which he is being given the drugs. Therefore, it is necessary for the physician to acquaint himself with the laboratory tests which are used to evaluate the degree of anticoagulant effect and also for him to impress upon the patient the importance of adhering to the suggested dosage regimen.

**The Ideal Anticoagulant**—The theoretically ideal anticoagulant agent should have all of the following features. It should have a reasonably high therapeutic index, and the therapeutic dose should be uniform between individuals and not produce an effect of such magnitude so that excessive therapeutic effect (toxic effect) will occur in any single patient. The therapeutic dose should produce a predictable response on the coagulation mechanism which can be measured by a simple laboratory test. It should be effective when administered by either the oral or parenteral route. It should have a rapid onset of action for use in medical emergencies and a sufficiently prolonged duration of action so that continuous medication can be accomplished with little inconvenience to the patient. Its effect on coagulation should cease within a reasonable period of time following discontinuance of the medication or be rapidly reversed by the use of a suitable nontoxic antagonistic agent. It should not produce cumulative or toxic side effects on repeated administration. Adequate therapy with the agent should be economically reasonable and its therapeutic value must be clinically established.

No single anticoagulant is available at the present time which fulfills all of the previously described ideal conditions. The two types of drugs which are used as anticoagulants are represented by the rapidly acting, naturally occurring heparin



**Lee White method** Two types of dosage schedules are suggested. Heparin may be administered intravenously in a dose of 50 mg every 4 hours or in a dose of 100 mg every 6 hours depending upon the results of a whole blood clotting time test performed at the bedside just prior to each additional dose. If the clotting time is less than 2 times normal, the next dose is increased by one third to one half. If the clotting time is more than  $2\frac{1}{2}$  times normal the next dose is reduced by one third to one half. If the clotting time is between 2 and  $2\frac{1}{2}$  times normal the regular dose is repeated.

**UNTOWARD EFFECTS**—It is interesting that temporary elevation of the clotting time to as much as 10 times the normal value will not result in spontaneous bleeding if the vasculature is grossly intact. Prolonged heparinization for several days may lead to bleeding from mucous membranes. In the presence of active bleeding heparin is contraindicated as it will intensify the bleeding. All of the known pharmacologic effects of heparin can be specifically neutralized by administration of protamine sulfate, toluidine blue or hexadimethrine bromide (Polybiene). These compounds react with the electronegative radicals of heparin thereby abolishing its effect. Protamine sulfate is prone to produce severe hypotension and toluidine blue produces varying amounts of methemoglobinemia which may result in hypoxia. Hexadimethrine bromide is the heparin antagonist of choice because it is notably free of toxic effects. Hexadimethrine 1 to 2 mg as a solution of 1 mg per milliliter in isotonic saline when administered slowly intravenously will neutralize the effect of 1 mg (100 units) of heparin. In excessive dosage hexadimethrine has been shown to produce an anticoagulant effect in animals. It is indicated as a heparin antagonist when emergency surgery is necessary on heparinized patients. It is commonly used following extracorporeal circulation in open heart surgery for heparin neutralization. The effect of all heparin antagonists is determined by the Lee White clotting time test.

Only about one fifth the injected dose of heparin is excreted in the urine; therefore the presence of kidney disease does not contraindicate the temporary use of this drug. No specific information is available concerning the prolonged use of heparin in the presence of kidney disease. Liver disease unless accompanied by hypoprothrombinemia likewise does not contraindicate the use of this drug with adequate laboratory control.

**DEXTRAN**—Several synthetic heparin like drugs have been developed in the laboratory. Of these only dextran sulfate is currently in use. Dextran sulfate is not currently available in the United States but has been used extensively in England where it was developed. Its anticoagulant properties are identical with those of heparin. Prolonged use of dextran sulfate may lead to the development of alopecia, a side effect which has occurred with other synthetic heparin like anticoagulants and has precluded their use in this country.

**Coumarin and Coumarin like Drugs**—Following the discovery of Dicumarol seven additional compounds have become available which have a mechanism of action similar to that of Dicumarol. All these compounds are of either the coumarin or the indandione type of structure. They are all used for the same purposes and differ from each other mainly in their dose and onset and duration of action. The advantages possessed by this group of agents are that they are readily



tinued when the prothrombin clotting time has been properly prolonged. This type of combined therapy is recommended in all cases of pulmonary embolism because of the imminent danger of additional emboli and infarctions. However, such combined therapy should be considered in all patients who have a previous history of repeated thromboembolic episodes and in whom the clinical findings indicate the presence of a major thrombus. In the absence of active bleeding, there is no hazard in the use of initial heparin therapy in any patient who is waiting for the onset of drug action from the administration of a hypoprothrombin inducing agent. Combined therapy gives the patient the advantage of immediate and prolonged anticoagulant effect with minimal discomfort and maximal economy.

**Regimen of Combined Treatment** The following schedule is recommended for routine use of combined heparin and coumarin or indandione drug therapy.

- 1 Heparin (50 to 75 mg every 4 hours) is given intravenously for the first 24 to 48 hours to bring the prothrombin time to 2 to 3 times normal. The daily dose is then determined in the following manner:
  - a. The daily dose is recommended. If the prothrombin time is less than 10 per cent of normal, the drug is omitted for that day. The daily dose may be administered in divided doses and given with food if the patient develops gastrointestinal complaints following medication. The general trend in the prothrombin level as determined day by day will usually enable the physician to predict the need for alteration of the dosage. Hyporeactors as well as hyperreactors should always be anticipated in any group of patients.
  - b. Only after a stable dosage requirement is established may the laboratory prothrombin determinations be performed at less than daily intervals. Urinalysis for the presence of hematuria should also be done at regular intervals for a minimum of 7 days. If there is no evidence of thromboembolic episode or with vascular insufficiency, it is desirable to continue anticoagulant therapy on a long term basis.

## RATIONAL BASIS FOR NEW ANTICOAGULANTS

The excellent cooperative types of clinical studies which have established the rational for the use of the anticoagulant drugs have also stimulated researchers to attempt development of better anticoagulants. As far as the hypoprothrombinemic agents are concerned, this trend has resulted in a longer list of available drugs as each year goes by. However, these new drugs are essentially of similar chemical

**CONTRAINDICATIONS**—The presence of liver disease contraindicates the use of the drugs which produce hypoprothrombinemia. Aged and debilitated patients generally require a significantly lower dose than is required by average, well developed persons. The compounds are excreted both as such and in the form of unidentified breakdown products. Therefore the presence of markedly impaired kidney function contraindicates the use of the drugs. The availability of adequate reliable laboratory facilities is a necessity and in their absence the drugs should not be used. Surgery should not be performed on patients receiving these drugs until the prothrombin time has been restored to near normal by the use of vitamin K<sub>1</sub>. Any pre existing defect in blood coagulability, such as disorders which manifest purpura, contraindicates the use of anticoagulant drugs. Evidence of the loss of vascular integrity in the gastrointestinal tract which may be the consequence of the presence of ulcerative lesions also contraindicates the use of these drugs.

**HYPOPROTHROMBIN-INDUCING DRUGS**—The eight hypoprothrombin inducing drugs which are in common use are bishydroxycoumarin (Dicumarol), cyclocoumarol (Cumopyran), ethyl biscoumacetate (Tromexan Ethyl Acetate), warfarin sodium (Coumadin Sodium Prothromadin) acenocoumarol (Sintrom), phenindione (phenylindandione, Danilone Hedulin Indon) diphenadione (Dipaxin), and anisundione (Miradon). All of these drugs are administered orally except warfarin sodium which may also be given intravenously. The onset of therapeutic action following a single dose varies with the particular drug used and may be from 12 to 36 hours minimum with warfarin sodium, ethyl biscoumacetate or phenindione, to 72 hours maximum with bishydroxycoumarin. The duration of action following discontinuance of the drugs also varies with the different drugs and may be from a minimum of one day with phenindione and ethyl biscoumacetate to 15 to 20 days with diphenadione and cyclocoumarol.

**The Anticoagulant of Choice** Of the several hypoprothrombinemia-producing drugs which are available for clinical use the agent which most nearly approaches the requirements of the ideal anticoagulant is warfarin sodium. However, since it is one of the newer of the anticoagulants, it has not undergone the test of time or use in the hands of numerous investigators. A principal desirable feature of warfarin sodium is that with proper laboratory control a stable effect on prothrombin clotting time can be readily achieved. Clinical results to date indicate that there is minimum variation between patients in dose requirements. The incidence of hemorrhage resulting from excessive anticoagulant effect following the use of warfarin sodium is no greater than for the other drugs of this group. The onset of action is relatively rapid, being as short as 12 hours following intravenous administration, but at least 24 hours following oral medication. Heparin may be used in conjunction with warfarin sodium if immediate anticoagulant therapy is desired and may be discontinued after 3 or 4 doses. Vitamin K<sub>1</sub> readily elevates excessive hypoprothrombinemia induced by warfarin sodium to safe levels in 6 to 12 hours.

**COMBINED HYPOPROTHROMBIN INDUCTION AND HEPARIN THERAPY** Adequate clinical anticoagulant therapy can be obtained with any one of the hypoprothrombinemic agents. When rapid initiation of anticoagulant action is necessary, heparin may be given along with the hypoprothrombin inducing agent and then discon-

is biologically standardized in hemophilic human beings. A hemophilic patient who has lost an excessive amount of blood by hemorrhage must be administered whole blood so that the multiple complications of excessive blood loss are prevented. In the absence of hemorrhage or hemorrhagic signs, the prolonged prophylactic use of the antihemophilic globulin is of a questionable purpose.

**Vitamin K Deficiency**—A deficiency of vitamin K may result in hemorrhagic disease. It may be due rarely to dietary insufficiency but more commonly to the failure of intestinal flora to synthesize the vitamin (during antibiotic therapy). In sprue and celiac disease absorption of the vitamin from the bowel is impaired and in biliary obstruction the lack of bile in the intestine results in failure of absorption even in the presence of adequate quantities of the vitamin. Finally, the vitamin may fail to be utilized in the presence of severe liver disease or in anti-coagulant therapy with the coumarin like agents. The lack of vitamin K results in a hypoprothrombinemia and, also possibly a hypoconvertinemia which, if sufficiently severe, will result in spontaneous bleeding from mucous membranes.

**VITAMIN K**—The two synthetic, water soluble vitamin K preparations which are available for clinical use are menadiol sodium diphosphate and menadione sodium bisulfite. They may be administered intravenously every 6 hours in a dose of about 75 mg, and in the presence of adequate liver function elevation of the prothrombin clotting time to safe levels may be expected in 12 to 18 hours. Vitamin K<sub>1</sub>, as phytonadione is also available for clinical use. It is synthesized and is identical with the naturally occurring vitamin. It is not water soluble but is available as an emulsion for intramuscular or intravenous use. The hypoprothrombinemias which are not due to the presence of severe liver damage will respond to vitamin K<sub>1</sub> usually within 6 hours following the intravenous dose of 50 to 100 mg.

**Vitamin K Preparation of Choice** In the presence of impending or actual hemorrhage resulting from lack of vitamin K, the drug of choice is phytonadione because of its more rapid action. However, in the presence of vitamin K deficiency states, the water soluble forms are completely adequate. Since the liver is the site of synthesis of prothrombin and probably certain other factors involved in the clotting mechanism the administration of the vitamin in the presence of severe liver disease may not result in the restoration of the deficient prothrombin.

No toxic effects have been described as a result of the properly controlled therapy with either vitamin K or vitamin K<sub>1</sub>. Therapy with these agents should be instituted only in the presence of a prolonged prothrombin clotting time and should be evaluated by repeated prothrombin time determinations. There is no rationale for administration of vitamin K in the presence of normal prothrombin values.

**CARBAZOGHROME (ADRENOSEM)**—Following experimental evidence indicating that adrenochrome shortens the bleeding time in normal animals, the use of a soluble and stable adrenochrome derivative, *Adrenosem*, has been advocated for the treatment of conditions where oozing of blood from inaccessible vascular beds is present. Animal experiments indicate that parenterally administered *Adrenosem* will protect certain vascular beds (the hamster cheek pouch) from hemorrhage produced by topically applied snake venom. Such experiments indicate that *Adrenosem* increases capillary resistance to such vascular injury.

*Table 48 Suggested Dosage Schedule for Anticoagulant Drugs*

Acenocoumarol	30 (1st day) 20 (2nd day)	2 8
Phenindione	200 300	50 100
Diphenadione	20 30	5 15
Anisindione	300 (1st day) 200 (2nd day) 100 (3rd day)	75 100

structure and biologic and toxicologic action. Any further development of such drugs would be significant only if the possibility of hemorrhage from excessive dosage was considerably less than that of the existing members of this group of drugs. Attempts to develop substitutes for heparin which possess heparin like activity have so far been discouraging, and so there is no list of such drugs. However a heparin substitute provided it had no greater toxicity than that shown by heparin and particularly if it were orally effective would be a highly desirable therapeutic tool.

The final answer as to whether the practicing physician should transfer from a drug with which he has had experience to one of the newer drugs rests on the appearance in the literature of well controlled, extensive clinical studies which conclusively demonstrate that the new drug possesses more of the attributes of the ideal anticoagulant."

## COAGULATION-PROMOTING AGENTS

Certain hemorrhagic disorders have been shown to be the result of deficiency of one or more factors involved in the coagulation of blood, for which specific drug therapy other than whole blood transfusion, is available. Among these diseases are the following: true hemophilia, hyperheparinemia, hypoprothrombinemia resulting from liver damage or vitamin K deficiency. Drug therapy of these disorders is not intended to produce active clotting in the vasculature but rather is intended to correct the deficiency and thereby restore the normal body defense against spontaneous hemorrhage.

**Hemophilia**—Hemophilia is a sex linked hereditary disease characterized by a deficiency of circulating antihemophilic globulin. Excessive hemorrhage may result from only minor lacerations of the vascular bed and generally requires whole blood transfusion to replace the loss of blood. It is interesting that small amounts of whole blood will partially restore the clotting power of hemophilic blood, but even multiple transfusions do not completely restore the clotting power to normal. The antihemophilic globulin is available as the globulin fraction obtained from pooled human plasma by the low salt, alcohol fractionation method of Cohn. It

clot promoting agent may be washed away before it can produce its effect. When thrombin is applied topically to denuded areas in the presence of blood, it is inactivated by antithrombin in the blood and adsorbed to the fibrin so there is little danger of systemic absorption resulting in intravascular thrombosis. Thrombin should never be injected intravenously as it will lead to widespread intravascular thrombosis and death within a few minutes.

**Russell Viper Venom and Trypsin**—Many proteolytic enzymes have multiple effects on blood coagulation and resolution of clots. Certain of these enzymes particularly that of the Russell viper venom (Stypven) and the enzyme trypsin are available for clinical use. Minute quantities of these enzymes when added to blood *in vitro* are capable of substituting for thromboplastin and thereby promote the conversion of prothrombin to thrombin with the subsequent formation of a clot. In contrast to this high concentrations of the enzymes have the reverse effect of inhibiting clot formation and also degrade fibrinogen. The clinical value of these agents in hemorrhagic disease is not as yet established. Clinically it appears that the topical use of the enzyme from the Russell viper venom offers no clot promoting benefits that could not be achieved more rationally by the use of topical thrombin.

**Sclerosing Agents**—The vascular sclerosing agents act indirectly as clot producing agents. The treatment of varicosities involves the use of the sclerosing agents. These agents are strong irritants to the intimal lining of the blood vessel. They produce sufficient irritation and breakdown of the intimal surface at the site of their injection so that clot formation is initiated. These agents are most effective in the treatment of small varicosities remaining after surgery involving vein stripping or ligation.

Two types of sclerosing agents are in common use. The first and most widely used preparation is sodium morrhuate. It is prepared from fish liver oils. A rare patient will show a minor skin hypersensitivity to the preparation. It is injected as a 10 per cent solution and the dose will vary from 0.1 ml for a small varicosity to 1 ml for a large varicosity. Application of a pressure bandage immediately following the injection will facilitate adherence of the walls of the collapsed vein by the fibrin of the intravascular clot and thus ensure permanent obliteration of the vessel. The second preparation is sodium psyllate, which is prepared from the oil of psyllium seed. The preparation is used in the same manner as that described for sodium morrhuate. It should be used in all patients who show sensitivity to sodium morrhuate.

## FIBRINOLYTIC AGENTS

A blood clot which has been formed in the vascular bed may undergo either resolution with no subsequent sequelae or organization with the subsequent formation of fibrous tissue. When resolution occurs spontaneously, it is believed to be the result of the action of the lytic enzyme (fibrinolysin). This enzyme exists in inactive form as profibrinolysin in blood. It is slowly activated by cell fragments

is an enzyme which is produced and secreted by certain strains of beta hemolytic streptococci. The

**OTHERS**—Certain agents influence the normal ability of the capillaries to prevent the passive transfer of red blood cells through their walls. Thus increased capillary permeability to red cells may result from vitamin C deficiency. The use of ascorbic acid as a specific therapeutic agent in this disorder is classical. However, certain cases of increased capillary permeability to red cells may not be controlled by the administration of vitamin C alone. The flavone glycosides are known to influence favorably certain cases of increased capillary permeability. The preparation in use is rutin. It is usually administered orally in conjunction with ascorbic acid. The exact mechanism of action of rutin on the capillary wall is not understood. Several naturally occurring bioflavonoids are currently under clinical investigation as anti-inflammatory and antihemorrhagic agents and show promise of a higher order of activity than that produced by rutin.

The use of estrogenic substances in the management of uterine bleeding has been popular for many years. Recent investigations have led to the use of these compounds in the management of epistaxis, postoperative hemorrhage, and in urinary tract and gastrointestinal bleeding. Although well controlled clinical studies are not available, evidence obtained on dogs has established that intravenous estrogen produces a prompt (within 1 hour) increase in circulating prothrombin and accelerator globulin and a decrease in antithrombin activities of the blood. Theoretically these changes tend to enhance coagulability of the blood, thereby providing a rationale for the current, popular, short term use of estrogens in spontaneous hemorrhage. Epistaxis or hemorrhage following adenoidectomy may be treated with a single dose of intravenous conjugated estrogens (20 mg).

## COAGULATION PROMOTING AGENTS WHICH RESULT IN CLOT FORMATION

There is no substitute for the pressure of the surgeon's gloved finger and the hemostat for the prevention of gross bleeding from an exposed, severed blood vessel. However, certain drugs are of great value to allay the continuous oozing of blood from denuded areas that become so troublesome to the physician and terrifying to the patient. The agents to be described here are generally indicated only in those situations where mechanical hemostasis has not been or cannot be achieved either because of lack of accessibility or extensiveness of the bleeding area. The combined use of pressure and an agent to promote clot formation is frequently advantageous.

**Thrombin**—Bovine thrombin is available in lyophilized form for topical use to initiate clot formation. In the presence of blood as a source of fibrinogen, the application of thrombin will result in the almost immediate formation of a clot. When a pad of fibrin (fibrin foam) or an absorbable gelatin sponge (Gelfoam) or oxidized cellulose (Oxycel) is saturated with a solution of thrombin and the pad is placed over a denuded area which is oozing blood, the pad acts as a preformed network to trap the blood. The presence of thrombin immediately forms a clot which effectively seals off the bleeding area with a coating of normal blood clot. Thrombin may also be instilled as a solution into the stomach to hasten the formation of a firm clot over a peptic ulcer which is oozing blood. However, in the presence of an active flow of blood, this procedure may fail to be effective since the

clot promoting agent may be washed away before it can produce its effect. When thrombin is applied topically to denuded areas in the presence of blood, it is inactivated by antithrombin in the blood and adsorbed to the fibrin, so there is little danger of systemic absorption resulting in intravascular thrombosis. Thrombin should never be injected intravenously as it will lead to widespread intravascular thrombosis and death within a few minutes.

**Russell Viper Venom and Trypsin**—Many proteolytic enzymes have multiple effects on blood coagulation and resolution of clots. Certain of these enzymes, particularly that of the Russell viper venom (Stypven) and the enzyme trypsin, are available for clinical use. Minute quantities of these enzymes when added to blood *in vitro* are capable of substituting for thromboplastin and thereby promote the conversion of prothrombin to thrombin with the subsequent formation of a clot. In contrast to this, high concentrations of the enzymes have the reverse effect of inhibiting clot formation and also degrade fibrinogen. The clinical value of these agents in hemorrhagic disease is not as yet established. Clinically it appears that the topical use of the enzyme from the Russell viper venom offers no clot promoting benefits that could not be achieved more rationally by the use of topical thrombin.

**Sclerosing Agents**—The vascular sclerosing agents act indirectly as clot producing agents. The treatment of varicosities involves the use of the sclerosing agents. These agents are strong irritants to the intimal lining of the blood vessel. They produce sufficient irritation and breakdown of the intimal surface at the site of their injection so that clot formation is initiated. These agents are most effective in the treatment of small varicosities remaining after surgery involving vein stripping or ligation.

Two types of sclerosing agents are in common use. The first and most widely used preparation is sodium morrhuate. It is prepared from fish liver oils. A rare patient will show a minor skin hypersensitivity to the preparation. It is injected as a 10 per cent solution and the dose will vary from 0.1 ml for a small varicosity to 1 ml for a large varicosity. Application of a pressure bandage immediately following the injection will facilitate adherence of the walls of the collapsed vein by the fibrin of the intravascular clot and thus ensure permanent obliteration of the vessel. The second preparation is sodium psyllate which is prepared from the oil of psyllium seed. The preparation is used in the same manner as that described for sodium morrhuate. It should be used in all patients who show sensitivity to sodium morrhuate.

## FIBRINOLYTIC AGENTS

A blood clot which has been formed in the vascular bed may undergo either resolution with no subsequent sequelae or organization with the subsequent formation of fibrous tissue. When resolution occurs spontaneously, it is believed to be the result of the action of the lytic enzyme (fibrinolysin). This enzyme exists in inactive form as profibrinolysin in blood. It is slowly activated by cell fragments and rapidly activated by streptokinase.

**Streptokinase**—Streptokinase is an enzyme which is produced and secreted into the nutrient medium by certain strains of beta hemolytic streptococci. The

commercial preparation of streptokinase is extracted from such nutrient media along with an additional mixture of enzymes which are collectively called streptodornase. These enzymes are capable of degrading many complex proteins into nucleotides and smaller protein fragments. Streptodornase is of value clinically since it will depolymerize desoxyribonucleoprotein which is the principal component of thick purulent exudates. Both streptokinase and streptodornase are standardized on the basis of units of activity. Freshly prepared solutions of the lyophilized enzymes are effective in promoting the liquefaction of fibrin and exudates. They are therefore used as a means of enzymatically debriding surface wounds. Streptokinase has also been used to promote lysis of fibrin in the pleural space.

The combination of streptokinase and streptodornase is used topically as a freshly prepared solution in phosphate buffer of pH 7.5. Depending on the amount of coagulum present a solution containing from 1,000 to 200,000 units of streptokinase with 250 to 50,000 units of streptodornase is applied once daily as a wet soak for a 4 to 6 hour period. The preparation may be used in conjunction with antibiotic agents. This preparation has recently been recommended for systemic intramuscular use to stimulate dissolution of fibrin and promote penetration of concomitantly administered antibiotics.

Parenteral use of these enzymes leads to the development of antienzymes, a rare allergic reaction of pyrogenic nature and mild tenderness at the injected site when administered intramuscularly. Streptokinase should not be given to patients known to have blood clotting defects.

**Trypsin**—Trypsin readily liquefies fibrin and will degrade hemoglobin. Well formed fibrous tissue is not influenced by the enzyme. Because of the fibrinolytic action of trypsin it is used as a means of enzymatic debridement of surface wounds. For maximum activity it must be used in a buffer medium having a pH of 7. This is obtained by dissolving the pure crystalline trypsin (200 to 500 mg.) in a phosphate buffer. The solution is topically applied as a wet soak and is changed every 2 to 3 hours until satisfactory debridement is achieved. Fresh blood contains a trypsin inhibitor (antiprotease) which effectively limits the activity of the enzyme.

## SELECTED REFERENCES

- Alexander, B. Coagulation, Hemorrhage, and Thrombosis. *New England J. Med.* 252: 437-484, 1956, 1955.
- Barrone, A. M. *Varicose Veins and Venous Thrombosis*. New York, 1948. Intern.
- Marple, H. *Thrombosis and Hemorrhage*. New York, 1948. Intern.
- Nichol, J. *Thrombosis and Hemorrhage*. New York, 1948. Intern.
- Owren, H. *Thrombosis and Hemorrhage*. New York, 1948. Intern.
- Tocant, F. *Thrombosis and Hemorrhage*. New York, 1948. Intern.
- Wenckert, A., and Nilsson, I. M. Thromboplastin and Russell Viper Venom, *Scandinav. J. Clin. & Lab. Invest.* 7: Supp. 15, 6, 1955.
- Wright, I. S. *Pathogenesis and Treatment of Thrombosis*, New York, 1957, Grune & Stratton, Inc.



## THE CHOICE OF DRUGS IN OBSTETRICS AND GYNECOLOGY

*M. Eduard Davis, M.D., and*

*Nicholas W. Fugo, Ph.D., M.D.*

---

### INTRODUCTION

The practice of obstetrics and gynecology employs the same therapeutic armamentarium utilized in the other recognized specialties of the medical arts.

**Obstetrics**—In obstetrics, however, a unique situation exists, for in the administration of a drug one must consider not only its effect on the mother but also its possible reaction on the developing conceptus. This is important for several reasons. Although all therapeutic agents are not capable of transmission across the placental membranes, the vast majority of drugs do affect the fetus in one way or another.

The inability of a drug to pass into the fetal circulation is desirable so that effective and therapeutic levels may be attained in the maternal organism without the danger of toxic levels in the fetus. This may be true of such agents as the barbiturates which normally are detoxified by the liver. However, the inability of a drug to be transported across the placental barrier does not assure complete protection to the unborn child. Drugs which induce uterine contractility may alter the uterine blood supply and interfere with placental circulation to such an extent as to produce anoxia in the fetus with serious damage or even fetal death. This is true of such drugs as pituitary extracts or ergot derivatives.

Furthermore, the physiologic changes of pregnancy may induce an altered response to some therapeutic agents. An example of this phenomenon is the greatly increased tolerance of the pregnant female to the oral administration of large doses of the synthetic estrogen, diethylstilbestrol. Care must also be taken in prescribing drugs to lactating mothers since some agents are secreted in the milk and may cause toxic effects in the newborn infant.

The recent advances in the medical sciences have made it possible for many women with chronic diseases to reach the reproductive age and to bear children. This is especially true of females who develop diabetes mellitus in childhood and in women with Addison's disease. These advances have altered our concepts of the reproductive process and have added new problems in the care of these chronically ill patients and their offspring.

commercial preparation of streptokinase is extracted from such nutrient media along with an additional mixture of enzymes which are collectively called streptodornase. These enzymes are capable of degrading many complex proteins into nucleotides and smaller protein fragments. Streptodornase is of value clinically since it will depolymerize desoxyribonucleoprotein which is the principal component of thick purulent exudates. Both streptokinase and streptodornase are standardized on the basis of units of activity. Freshly prepared solutions of the lyophilized enzymes are effective in promoting the liquefaction of fibrin and exudates. They are therefore used as a means of enzymatically debriding surface wounds. Streptokinase has also been used to promote lysis of fibrin in the pleural space.

The combination of streptokinase and streptodornase is used topically as a freshly prepared solution in phosphate buffer of pH 7.5. Depending on the amount of coagulum present, a solution containing from 1,000 to 200,000 units of streptokinase with 250 to 50,000 units of streptodornase is applied once daily as a wet soak for a 4 to 6-hour period. The preparation may be used in conjunction with antibiotic agents. This preparation has recently been recommended for systemic intramuscular use to stimulate dissolution of fibrin and promote penetration of concomitantly administered antibiotics.

Parenteral use of these enzymes leads to the development of antienzymes, a rare allergic reaction of pyrogenic nature and mild tenderness at the injected site when administered intramuscularly. Streptokinase should not be given to patients known to have blood clotting defects.

**Trypsin**—Trypsin readily liquefies fibrin and will degrade hemoglobin. Well formed fibrous tissue is not influenced by the enzyme. Because of the fibrinolytic action of trypsin it is used as a means of enzymatic debridement of surface wounds. For maximum activity it must be used in a buffer medium having a pH of 7. This is obtained by dissolving the pure crystalline trypsin (200 to 500 mg) in a phosphate buffer. The solution is topically applied as a wet soak and is changed every 2 to 3 hours until satisfactory debridement is achieved. Fresh blood contains a trypsin inhibitor (antiprotease) which effectively limits the activity of the enzyme.

## SELECTED REFERENCES

- Alexander, B. Coagulation, Hemorrhage, and Thrombosis, *New England J Med* 252: 432, 484-526, 1955.  
 Barrone, A. M. Varicose Veins and Venous Thrombosis of the Lower Extremity, Chicago, 1916.  
 Tocantins, L. M. The Coagulation of Blood, Methods of Study, New York, 1955, Grune & Stratton, Inc.  
 Wenckert, A., and Nilsson, I. M. Thromboplastin and Russell Viper Venom, *Scandinav J Clin & Lab Invest* 7 Supp 15, 6, 1955.  
 Wright, I. S. Pathogenesis and Treatment of Thrombosis, New York, 1952, Grune & Stratton, Inc.

necessary to prescribe calcium and phosphorus if the patient consumes sufficient milk and milk products. In the event that these foods cannot be tolerated, it is necessary to supplement diet with these minerals. It is customary to provide additional amounts of vitamins A and D throughout pregnancy even when the dietary intake is otherwise considered adequate.

### Specific Difficulties —

**MORNING SICKNESS** — In about half of all pregnant women the early weeks of the pregnancy are associated with 'morning sickness,' nausea with or without vomiting or a distaste for many foods. This disorder is probably the result of the altered metabolic processes of gestation. If it is neglected, this complication may result in serious electrolyte and fluid imbalances which will necessitate hospitalization. Morning sickness usually disappears by the end of the first trimester, and if properly treated it will remain a minor discomfort.

The management consists of reassurance, fresh air and moderate exercise, and dietary regulation. The patient is advised to eat small amounts of dry food at frequent intervals, to avoid greasy foodstuffs, and to alternate dry feedings and liquids. The odors of cooking should be eliminated, and the desire for unusual foods may be encouraged. Emotional factors do play an important role in morning sickness.

Drugs are of some benefit if used judiciously. There are a number of antiemetic agents available today which are effective in many cases. These are discussed in Chapter 20.

One of the most practical agents from the viewpoint of simplicity and cost is a mixture of phenobarbital either in 15 or 30 mg doses, with 7.5 mg of belladonna. This mixture when administered 2 or 3 times a day is a satisfactory adjunct to wet and dry feedings.

If these simple measures are inadequate and the patient is unable to tolerate any food if she becomes dehydrated and exhibits symptoms of electrolyte imbalance she should be hospitalized immediately and parenteral solutions administered. Blood electrolyte levels should be determined and deficiencies corrected. The patient should be heavily sedated with Amytal Sodium 0.2 Gm intramuscularly at 3 or 4 hour intervals. In most cases this therapeutic regimen is sufficient to correct the disorder. The patient should not be allowed visitors or phone calls. The room should be kept darkened and all outside stimuli should be avoided. It may be necessary to institute tube feeding in severe cases. Rarely is it necessary to interrupt the pregnancy to cure the patient.

**CYSTITIS AND PYELITIS** — Cystitis occurs predominantly in the puerperium rather than in the antenatal period. If it occurs before delivery it often consists of mild irritation of the trigone. On the other hand, when it occurs post partum, due to the trauma of delivery, it is a much more serious complication. Not only is there edema but in some cases extravasations of blood. This may be sufficient to cause obstruction of the urethra and acute retention. These conditions frequently lead to a true cystitis. If the bladder has become overdistended and the patient does not void spontaneously, after a maximum of 3 catheterizations at intervals of 6 to 8 hours, it is wise to insert an indwelling catheter for a period of approximately 72 hours to ensure rest to the bladder and its complete emptying.

Even the lifesaving procedure of blood transfusion to a young girl may in later life be hazardous to her reproductive performance. The administration of unsuitable blood may induce Rh antibodies in a young woman who marries an Rh positive husband. She may deliver erythroblastotic infants, some of whom may be stillborn or fail to survive in spite of modern therapy in the form of exchange transfusions.

Other physiologic changes in the pregnant woman must be considered when using drug therapy. The emptying time of the stomach is increased, allowing administered drugs to remain in the stomach for a longer time. This slows the development of the action of orally administered drugs. Weight gain, water retention, the elevation of the basal metabolic rate, altered kidney function, the retention of nitrogen, as well as other alterations in metabolic patterns in pregnancy, influence the selection and utilization of therapeutic agents.

Gynecology—The problems in gynecology, on the other hand, are essentially the same as those encountered in the fields of surgery. Pre and postoperative care present no problems unique to gynecology. Most therapeutic agents utilized are in the nature of anesthetics, sedatives, replacement fluids, and hormones. The proximity of the ureters, bladder, and rectum to the pelvic organs concerns the skills rather than special therapeutic agents.

## NORMAL PREGNANCY

Principles—In no specialty of medicine is the concept of preventive medicine more important than in the care of the pregnant woman. Prenatal care has a dual role of assisting the patient to meet the demands of pregnancy and of anticipating and preventing possible complications. The first visit to the physician should include a careful history of previous gestations and systemic diseases as well as a complete physical examination. The physical evaluation should include blood and urine examinations and routine chest x-ray. Inoculation against poliomyelitis is recommended for the incidence of this infection is higher in pregnant women than in the general population. A history of rheumatic or congenital heart disease should be carefully evaluated, since heart disease is becoming one of the important causes of maternal death. The patient is usually advised to return at 3-week intervals during the first 7 months of gestation, at 2 week intervals during the eighth month, and weekly during the last month of pregnancy.

The present philosophy of maternity care is that it is a physiologic process and that it need not be enmeshed in obsolete taboos, fears, and fancies. To this end the education of mothers and fathers concerning the reproductive process is of paramount importance. An intelligent discussion with a patient concerning some new complaint may be more rewarding than the administration of the latest tranquilizer. Too often in the care of pregnant women, drugs take the place of intelligent medical guidance.

Nutrition is of the utmost importance in pregnancy. An adequate diet to meet the physiologic demands of the mother and the growth needs of the baby will decrease the likelihood of maternal complications and increase the chance of a healthy baby. Diet instruction is an essential part of prenatal care. It is rarely

**CONSTIPATION** One of the most common complaints of pregnant women is constipation. This is not serious, but it is troublesome and should be corrected. Furthermore, it tends to increase the incidence of hemorrhoids. Cathartics should be avoided during pregnancy although in the past the hazards of mild purgatives to the pregnancy have probably been overemphasized.

Frequently, small doses of mineral oil or preparations containing agar and oil will promote ease in evacuation, with little or no harm. There is a theoretic objection to their use in that some fat soluble vitamins are taken up by these compounds. More recently, surface active (wetting) agents which soften the stool for easy passage have been developed. These work well in the ambulatory patient. Dioctyl sodium sulfosuccinate in doses of 100 mg. once or twice daily with an adequate intake of water will alleviate most cases of constipation encountered in pregnancy provided there is no organic disease. The use of a glycerin suppository on awakening in the morning may prevent excessive straining.

**Bisacodyl** Recently there has appeared a promising new synthetic compound Bisacodyl which is colorless, tasteless and practically insoluble in water and alkaline solutions. Its action is dependent on contact with the colonic mucosa. It can be administered orally or by rectal suppository. Its action is to induce normal peristalsis throughout the colon and it has little or no effect on the small intestine. It is an effective laxative in all types of constipation. It may be used in preparation for operations or post partum. The suppositories may be used to replace enemas. It is available in two forms: (1) enteric coated tablets swallowed whole in dosage of one to two 5 mg. tablets or (2) 10 mg. suppositories. The suppositories are effective in 15 to 60 minutes. The compound apparently has little or no toxicity for it is not absorbed.

**HEMORRHOIDS**—In the later months of pregnancy hemorrhoids are frequently a disturbing complication. These are best treated by bed rest and various types of rectal suppositories of which there are many on the market. In recommending suppositories for this condition it is wise to avoid those containing local and topical anesthetics usually but not always easily identified by the "caine" suffix in their names. Many of these are sensitizing agents and always present the danger of allergic reactions. We have had satisfactory results with suppositories containing a mixture of opium and belladonna. If the hemorrhoid has been recently thrombosed, great relief can be provided by the evacuation of the clot. The pain of hemorrhoids associated with edema can be relieved by ice packs to the rectum.

**LEG CRAMPS**—In recent years much has been written regarding the therapy of leg cramps commonly encountered in the last trimester of pregnancy. It is thought by some that this symptom develops as the result of an imbalance of the calcium and phosphate ions. This condition is extremely painful and difficult to avoid. The elimination of foods high in phosphate content may be of some value. General measures such as the avoidance of chilling and the application of heat are helpful in some cases.

**HEARTBURN**—The delay in the emptying time of the stomach in the latter months of pregnancy may cause heartburn in patients. This can be treated by the use of aluminum hydroxide. Sodium bicarbonate is also helpful.

This also prevents overdistention and residual urine in the bladder. The patient should take large amounts of fluids and it is wise to use sulfisoxazole in 0.5 Gm doses 4 times a day prophylactically.

**PYELOURETERITIS**—There is about a 2 per cent incidence of pyeloureteritis during pregnancy. The process usually is bilateral but when unilateral it is more often right sided. It is usually acute. The patient complains of costovertebral angle tenderness, burning on urination, frequency, and not infrequently she develops a rise in temperature. Diagnosis is easily and quickly made by a microscopic examination of a catheterized urine specimen. This will contain clumps of red and white cells and frequently bacteria. Once the diagnosis is established it is wise to culture the urine and to determine antibiotic sensitivity.

Most urinary tract infections will respond to sulfisoxazole in dosage of 1 Gm 4 times a day. If the patient cannot tolerate the oral administration the drug may be given intravenously diluted 2 Gm to 1000 ml of 5 per cent dextrose in water. While this drug is of low toxicity the usual precautions should be observed as with other sulfonamides. The patient should be given large amounts of fluids. Persistence or recurrence of symptoms and the presence of bacteria in the urinary cultures demonstrate resistance to this therapeutic agent. Oxytetracycline is a valuable agent in such cases because of its truly broad spectrum of activity. The usual dosage is 250 mg 4 times a day.

**ANEMIA OF PREGNANCY**—The determination of hematocrit and hemoglobin values during pregnancy is an important part of prenatal care. It should be repeated at 3 month intervals and it is desirable that the last determination be made within 4 weeks of the expected date of confinement. The physiologic anemia which normally develops about the end of the second trimester of pregnancy as a result of blood dilution may be sufficiently marked to warrant therapy. The normal hematocrit range for pregnant women is between 35 and 45 per cent. The lowest value will be obtained at approximately 30 to 32 weeks gestation. If the hematocrit value drops below 32 per cent therapy is indicated. Most anemias of pregnancy are due to iron deficiency which is easily remedied by the oral administration of iron. One of the most satisfactory preparations for this purpose contains ferrous sulfate with molybdenum oxide. The usual dose is 1 to 2 tablets 3 times daily.

There are occasional patients who do not do well on oral iron therapy. This may be due to gastrointestinal upsets or the patient may be lax in taking the medication, or circumstances may require more rapid accumulation of iron stores than is possible by the oral route. Under these conditions intramuscular administration of iron may have excellent results. The compound of choice is a solution of iron dextran complex which provides 50 mg of ferrous iron per milliliter of solution. The response obtained is reported as equal to intravenous injections. The average dose is 500 mg of elemental iron per week. If the anemia is not markedly improved in a reasonable period of time a complete blood study is indicated to determine the nature of the anemia. If the patient has difficulty with ferrous sulfate frequently preparations of ferrous gluconate or ferrous glycinate can be better tolerated. Rarely is it necessary to treat iron deficiency anemia with blood transfusion.

Many physicians prefer the local infiltration of the perineum with anesthetic agents or pudendal block because of the simplicity and safety of these procedures. However, these methods do not provide adequate pain relief for many patients.

In our clinic the anesthetic of choice is saddle block. The agent employed is hyperbaric Nupercaine solution in 2.5 mg dosage. The anesthetic is not administered until the patient is in the second stage of labor and can be delivered immediately if necessary. The subject is placed in the sitting position with the back arched outward and head down. A 22 gauge spinal needle is introduced at the level of L 3 or 4. The Nupercaine is injected over a 3 second interval only during a period free of uterine contractions. The needle is left in place for exactly 10 seconds after the initiation of the injection. The needle is withdrawn and the patient is told to straighten her back. The subject remains in the sitting position for exactly 20 seconds longer, she is then placed flat with the head elevated by means of a pillow. A period of 5 to 10 minutes is allowed to elapse to stabilize the anesthetic level. The fetal heart tones and blood pressure are checked at frequent intervals. Rarely hypotension occurs and this is easily corrected by placing the patient in the lithotomy position. If this rigid routine is followed the height of the level of anesthesia is limited to the level of the umbilicus. The perineum is well anesthetized to permit major operative procedures. Exploration of the birth canal and uterus can be performed with little or no discomfort to the patient.

In our experience with normal cephalic deliveries this is the anesthetic of choice. We have successfully performed over 22,000 saddle block anesthetics with no known sequelae of a serious nature. An occasional patient complains of post-anesthetic headache which may last two or three days. These are best treated by having the patient lie flat in bed.

Saddle block anesthesia is not recommended for deliveries where marked uterine relaxation is necessary for the successful delivery of breech, multiple pregnancy or abnormal presentations. These procedures usually necessitate inhalation anesthetics and deep surgical relaxation. The safest agent under these conditions is open drop ether. When this anesthetic agent is used premedication is necessary. If the patient has taken food in the period immediately prior to the delivery it may be wise to empty the stomach by gavage or induced vomiting since nausea is a common concomitant and aspiration an important hazard. Furthermore the peril of postpartum hemorrhage from an atonic uterus must be considered. Fetal anoxia can also occur and must be dealt with by means of tracheal catheterization and oxygen administration.

### Oxytocic Drugs —

**GENERAL CONSIDERATIONS** —The human uterus is capable of responding to many stimuli. Nervous, chemical and even mechanical agents can produce marked reactions, many of which are poorly understood physiologically. While the myometrium is richly supplied with autonomic nerves, the response of the uterus is apparently dependent on the titer of estrogens and progesterone.

Normal uterine motility is dependent upon the presence of calcium and estrogens. The addition of stimulating drugs may alter these patterns or produce marked contraction of the entire organ. Under normal conditions, in the presence

compounds should be avoided since these are absorbed and if retained favor the development of edema

**PTYALISM**—Rarely is a pregnant patient bothered by excessive ptyalism. This condition is not serious but it is uncomfortable, these patients may be seen walking around holding a receptacle into which to expectorate. Many remedies have been suggested, none of which correct the condition. The simplest and probably most effective is tincture of belladonna. Dosage can start with 1 or 2 drops in a half glass of water 2 or 3 times per day. This amount can be increased, but it should not exceed 10 drops per dose. Frequently the side effects of the belladonna are more disturbing than the ptyalism so that the patient stops the medication of her own accord and says no more about her troubles.

**Analgesia During Labor**—Drugs for the relief of the discomfort of labor are legion. Hardly a month goes by without claims for an ideal substance which will convert labor into a pleasant experience without hazard to mother or baby. The large number of amnesic, analgesic and anesthetic drugs available to the practitioner bears mute but substantial evidence that the answer to our age old problem is not to be found in drugs alone.

**GENERAL CONSIDERATIONS**—The present pattern of maternity care is designed to remove all fears concerning this fundamental physiologic function to prepare the individual by lectures, discussions and exercises to look forward to the most important episode in her life and to allow her to participate in this wonderful emotional experience to the limit of her capabilities. Obviously such an enlightened approach toward labor places little stress on pain relief and great emphasis on education. It is hoped that the old goal of removing every vestige of discomfort and blotting out all memory of life's greatest experience has passed.

Patients should be told that labor contractions will become uncomfortable as active labor progresses, that we have a number of drugs available which will relieve such discomfort and that they can be administered with safety to mother and baby. This will decrease the need for sedative and pain relieving drugs early in the course of the labor, which occasionally may interfere with its normal progress. Furthermore, it will prevent apprehension on the part of the patient that she may not be given pain relief.

**Dangers** All pain relieving drugs in labor exercise a double threat, to the mother and to her baby. They may interfere with uterine activity, prolonging labor and thus occasionally predisposing to difficult operative procedures. They interfere with the establishment of normal respiration by the newborn at birth, necessitating measures for resuscitation and for combating anoxia. The choice of the drug, the amount administered and the period in labor when it is given, all influence its undesirable sequelae. General anesthetic agents likewise tend to increase the incidence of respiratory difficulties in the newborn.

**OPIMUM DERIVATIVES AND SYNTHETIC SUBSTITUTES**—The opium derivatives such as morphine and codeine and their synthetic substitutes, methadone and meperidine, are widely used in obstetrics. The main function of these drugs is the alleviation of pain associated with uterine contractions of labor. In using a drug for this purpose the ideal agent would be one that would have marked analgesic activity with little or no depressant action on fetal respiration or inhibiting action



At times, because of the injudicious or untimely administration of the drug in a uterus overdistended because of twins or polyhydramnios, or deep surgical anesthesia, the myometrium will fail to respond to the oxytocic drug. If the uterus is found to be flaccid, a second dose of ergonovine may be administered intravenously. It is our practice to repeat the oxytocic drug only once. When the bleeding persists, it is essential that other factors responsible for postpartum hemorrhage be determined. The uterus and birth canal must be carefully explored. Retained placental fragments must be removed. There must be no trauma to the uterus or cervix. The birth canal must be free of lacerations. If, after all these possibilities are eliminated, hemorrhage still persists, a uterine pack may be inserted. If the patient bleeds through the pack, hysterectomy should be performed. Fortunately this is an extremely rare complication, but one should always be aware of the possibility.

It is mandatory in the care of pregnancy and labor complications associated with excessive bleeding to start an intravenous drip of saline or 5 per cent dextrose solution and to use blood in ample amounts when necessary. These should always be available.

**PITUITARY MATERIALS**—Extracts of the posterior lobe of the pituitary have three types of activity: vasopressor, antidiuretic, and oxytocic. There are two principles, however, one of which, in the human, exerts oxytocic as well as vasopressor and antidiuretic actions and the other of which is entirely oxytocic. Both are inactive orally and must be given parenterally.

The response of the human myometrium to posterior pituitary extracts is extremely variable, depending on many factors, hormonal titers for example. In general, large doses may produce uterine tetany which may last for as long as 15 minutes, followed by gradually increasing clonic contractions, while smaller doses produce only clonic contractions.

**Posterior Pituitary Extract** The major use of posterior pituitary extracts in obstetrics is in the prevention of postabortal or postpartum uterine atony. It is more effective in postabortal states than is ergonovine but less effective than the latter drug post partum. It can be given subcutaneously or intramuscularly quite safely in doses up to 10 units. It must be used in much smaller doses, however, when given intravenously. If given without due respect for its unpredictability of action, this procedure is fraught with danger, it may produce uterine rupture or fetal death due to anoxia.

**Pitocin** Pituitary induction of labor should never be attempted without competent personnel in constant attendance. The preferred method is the dilution of 10 units of Pitocin in 1,000 ml of 5 per cent dextrose in water. It should be given intravenously extremely slowly because of its greater safety and controllability. It should always be started in extremely small doses and increased cautiously.

Pitocin drips should never be used during labor if there is any evidence of fetal distress. Care should be taken that no cephalopelvic disproportion or abnormal presentation exists. Because of the danger of uterine rupture, labor must never be induced with Pitocin if the patient has had cesarean section in a previous pregnancy. Because of increased scar tissue in the uterus it is also contraindicated in patients of high parity (5 or more) or in those over 35 years of age. If the pa-

of estrogens the uterus has normal rhythmic contractions which are initiated in the fundus in the region of the fallopian tubes and course down the corpus toward the cervix. The normal progress of labor depends on the rhythmicity of the uterine contractions as well as their increasing frequency, duration, and intensity. It is believed that normal uterine motility and progress in labor are influenced by the metabolism of the steroid hormones which control the reproductive function. There is evidence that the responsiveness of the uterus can be greatly enhanced by the administration of ionized calcium salts.

The oxytocic drugs are those that promote uterine contractions. They are most often used in the management of the placental stage of labor and in the postpartum period. These drugs are derivatives of ergot, posterior pituitary extracts, or synthetic preparations. In recent years the posterior pituitary extracts have gained renewed popularity for the induction of labor. The dangers of their use will be discussed later.

**ERGOT ALKALOIDS**—Ergot is a fungus (*Claviceps purpurea*) which grows on rye and certain other grains. Ergot contains a great number of pharmacologically active substances. The ergot alkaloids occur in pairs which are optical isomers, the levo forms are active, having oxytocic properties while the dextro forms are inactive. The most active of these is ergonovine, a derivative of lysergic acid.

**Ergonovine** Ergonovine is the hydroxyisopropylamide of lysergic acid. The maleate, the only salt that is water soluble, is used. In therapeutic doses (0.2 to 0.4 mg.) it induces tonic uterine contractions on which are superimposed clonic contractions. These are the result of direct muscle stimulation. Side effects are rare after therapeutic doses. Elevation of blood pressure may be encountered rarely and is more likely if spinal anesthesia is used. Vasoconstriction, sufficient to cause gangrene, may occur but ergonovine is much less toxic in this regard than the other ergot alkaloids and for all practical purposes there is no danger of gangrene when the drug is used as an oxytocic.

In our institution ergonovine maleate is used routinely in the management of the third stage of labor. Immediately after the anterior shoulder of the infant is delivered under the symphysis, 1 ml. of solution containing 0.2 mg. of the drug is injected intravenously. Approximately 30 seconds is allowed to elapse, after which the delivery is completed slowly and deliberately. In many cases the remainder of the infant will be delivered by the contraction of the uterus induced by the ergonovine. The completion of the birth of the infant is followed by the expulsion of the placenta by Crede's maneuver with a minimal amount of blood loss in most instances. Infrequently, and especially if the delivery of the infant is rapid, the placenta may be trapped in the lowermost portion of the corpus and lower segment. If this occurs, it is a simple maneuver to slip the hand into the cervix like a shoehorn and, with moderate traction on the cord, ease the completely separated placenta out of the birth canal.

On rare occasions, the placenta fails to separate completely spontaneously. If uterine bleeding occurs under these circumstances we do not hesitate to invade the uterus removing the adherent placenta manually with sterile precautions. In most cases complete removal of the placenta will allow the uterus to contract and terminate the bleeding.

**EPINEPHRINE**—It has been suggested that epinephrine is an effective agent for the relaxation of contraction rings during labor, but clinical experience does not bear this out. There is also the danger that when this drug is given by intramuscular injection in doses adequate to relieve contraction rings or tetany, a prolonged period of uterine atony with hemorrhage may follow.

In clinical practice, when local anesthesia is employed epinephrine is frequently added to the anesthetic agent for purposes of prolonging its effect. The concentration of epinephrine is 1:200,000, and 50 ml of the anesthetic is administered. The patient receives a dose of 0.25 mg of epinephrine. In many cases this is sufficient to interfere with the mechanism of labor and may cause prolongation of the second stage and possibly uterine atony and hemorrhage.

**NOREPINEPHRINE**—Norepinephrine has become popular for the support of blood pressure due to surgical or anesthetic shock. This substance, unlike epinephrine, induces an increase in uterine contractility and in this event it is possible that the increased uterine contractions, in the presence of depressed blood pressures, will further embarrass the fetus. With this possibility in mind norepinephrine if used at all should be used with great caution in the gravid woman.

**RELAXIN**—In recent years relaxin (Releasin) the water soluble ovarian extract first described by Hisaw as the hormone responsible for the relaxation of pubic ligaments in the pocket gopher and guinea pig has been further purified and its use in women during pregnancy has been advocated.

The claims made for this substance are rather broad. It is stated that relaxin can halt premature labor and facilitate it at term when labor is prolonged or difficult because of cervical dystocia. There have appeared innumerable reports on this subject. In our hands and in personal communication with Caldeyro-Barcia the substance is without therapeutic effect in altering the course of labor. Only time and much carefully conducted clinical research can determine the value of this agent.

## TOXEMIAS OF PREGNANCY

The toxemias of pregnancy are still major complications of human reproduction and are responsible for considerable maternal and perinatal mortality. The hazards to mother and baby have been reduced appreciably in recent years largely as a result of the prevention of the convulsive stage, eclampsia, by intelligent prenatal care and improvement in obstetric practice. The cause of pre-eclampsia is unknown and thus there are no specific therapeutic agents for its prevention or cure.

Toxemias of pregnancy are classified into two groups. Pre-eclampsia and eclampsia have their origin in pregnancy and are true pregnancy toxemias. Hypertensive renal disease exists prior to the onset of pregnancy and is aggravated by the metabolic alterations of gestation. The incidence of toxemia is 6 or 7 per cent distributed equally between the two groups.

**Pre-eclampsia and Eclampsia**—Pre-eclampsia and eclampsia are complications of the last 16 weeks of pregnancy. They occur most commonly in the young primigravida although they may complicate any gestation and at any age. Although the etiology is definitely unknown present thinking suggests that they may

tient has an extremely irritable uterus or is already in labor Pitocin induction must be used with great caution if at all

*Pitocin induction is not likely to be successful unless the state of the cervix is favorable for the onset of labor* A favorable or ripe cervix is soft the cervical canal is completely effaced and its thickness is no more than 1 cm These conditions apply to primiparas and multiparas except that cervical dilation of at least 2 cm should be present in the multipara before induction is attempted Effacement of the cervix is not a prerequisite in the multipara as in the primigravida Rupture of the membranes will increase the chances of success with Pitocin drip However the rupture of the membranes should not be attempted in the presence of an unfavorable cervix unless abdominal delivery is contemplated within 24 hours In many instances unsuccessful Pitocin inductions will be followed by evidence of fetal distress This may be indicated at the time of delivery by meconium stained amniotic fluid

*Synthetic Oxytocic Drugs* The cost and the unpredictable supply from Spain and Russia of ergot as a source for ergonovine have spurred organic chemists to study the ergot alkaloids with the hope of developing synthetic preparations In recent years the elucidation of the chemical structure of lysergic acid has led to intensive investigation of methods for synthesizing this basic unit of the ergot alkaloids

One of the new oxytocic drugs is methylergonovine tartrate a partially synthesized derivative of lysergic acid which is closely related to ergonovine and is quite similar to it in its action Clinical observations have indicated that the intensity and duration of its oxytocic activity are similar to those of ergonovine Its action and uses also closely approximate those of ergonovine its therapeutic use and dosage are the same

Largely through the work of du Vigneud and his associates it was possible to isolate pure oxytocin from the posterior pituitary gland and to determine its precise structure Synthesis followed rapidly on the heels of this information As a matter of fact this was the first time a polypeptide hormone was synthesized It is both chemically and physiologically identical with the naturally occurring oxytocin In our clinic we have used a synthetic posterior pituitary oxytocic hormone with excellent results In every respect it compares favorably with the naturally occurring hormone

**Uterine Relaxants**—There are only two indications for inhibiting uterine contractions the premature onset of labor at a time when the baby has not reached a safe period of viability and rarely for the relief of a contraction ring of the uterus in abnormal labors Until recently there were no drugs developed expressly for these purposes

**SYSTEMIC SEDATION**—Everyone familiar with the physiology of labor is aware that myometrial activity is impaired by most sedative and general anesthetic agents such as opium derivatives (in large doses) ether and chloroform In average dosage barbiturates have less effect Ether is perhaps the best agent in safe dosage and is probably the most effective means of relaxing constriction rings during labor or in a postpartum uterus strongly contracted by an oxytocic drug There is however, always the danger of serious hemorrhage during the period of relaxation

Sufficient oral fluid intake is desirable to maintain the urinary output at about 2,000 ml daily. In the presence of cardiac decompensation, the daily fluid intake should be restricted to 500 ml and the patient digitalized. The hypertension is treated by bed rest. Sedation should be avoided because of the possibility of masking the signs and symptoms which would indicate the progression of the disease. There is no specific treatment for proteinuria. Quantitative determinations should be made every 24 hours. Catheterized specimens are preferred. Urinary protein excretions of 1 to 3 Gm is serious, and if the amount exceeds 3 Gm daily it is of ominous import. The patient with mild pre eclampsia can be treated for periods of 7 to 14 days until the state of the cervix warrants induction of labor. Cesarean section should be considered if eclampsia is imminent. The imminence of eclampsia is indicated by the following signs and symptoms: a progressive rise in the blood pressure or a systolic blood pressure which is maintained at a level of 170 or more, proteinuria which is in excess of 3 Gm for 24 hours, a weight gain which is in excess of 100 Gm daily or any sudden increase in weight, the occurrence of headache, nausea, vomiting, blurring of vision, scotomata, oliguria, the occurrence of hematuria or jaundice, a persistent pulse rate of 120 or more, the appearance of pulmonary edema, cyanosis, or indications of increasing hemoconcentration.

Convulsions and coma herald the onset of eclampsia. The therapeutic regimen should be directed toward the control of the convulsions, the maintenance of kidney function and the stabilization of the patient so that delivery can be carried out.

Eclamptic seizures can be controlled by the use of sedatives such as 6 to 12 ml of 50 per cent magnesium sulfate intramuscularly, 0.25 Gm of Amytal Sodium intravenously every 3 to 6 hours, 3 Gm of chloral hydrate by rectum every 6 to 12 hours with the addition of morphine sulfate if necessary. The anuric or oliguric patient presents a difficult problem, for more patients are killed by the overuse of fluids than by neglect. Hypertonic glucose solutions (20 to 50 per cent) in limited quantities should be given. Dextran or human albumen may be of value. Termination of the pregnancy should be accomplished as quickly and as atraumatically as possible.

The patient with hypertensive disease may constitute an obstetric emergency at the time of her first prenatal visit. Consequently, she should be evaluated at this time. If the urea clearance is 50 per cent or more of normal, the Addis count is not markedly abnormal, the 24 hour urinary protein excretion is less than 0.5 Gm, and if there are no significant fundoscopic findings and no evidence of cardiac disease, the patient should be advised that the pregnancy may be continued if she is willing to accept the slight but definite risk which its continuation entails. Blood pressure, body weight and 24 hour urinary proteins should be determined at each visit. If there is an increase in hypertension and proteinuria or if edema or dyspnea develops, hospitalization for study is mandatory. Once the decision to continue the pregnancy has been made, every effort is directed to prolong the gestation to at least 32 weeks. However, a sudden increase in proteinuria of 1 Gm or more in 24 hours, sustained increases of 30 mm Hg in systolic blood pressure or 15 mm Hg in the diastolic blood pressure, the progression of retinal pathology, or evidence of renal impairment makes termination of the pregnancy mandatory for both mother and fetus.

be related to alterations in the normal steroid metabolism of pregnancy. Timely termination of the pregnancy results with few exceptions in complete reversal of the process. Residual damage and recurrence of the toxemia in subsequent pregnancies are rare. These patients evidence a marked disturbance in their water and electrolyte metabolism. An excess weight gain occurring in the second trimester of pregnancy is the first manifestation of these abnormalities. As the disease progresses hypertension, proteinuria, and edema appear. Eclampsia, which has a 7 per cent maternal mortality and a 40 per cent fetal mortality, is the major complication of pre eclampsia.

**Hypertensive Vascular and Renal Diseases**—These diseases in women who become pregnant comprise the second group of toxemias. These complications usually manifest themselves in the first trimester of pregnancy. The pregnancy may induce an exacerbation of the underlying chronic disease. The basic abnormality persists after delivery. Marked alterations of water and electrolyte metabolism are unusual in this group. Late abortion, intrauterine fetal death, severe abruptio placentae occurring in the last trimester of pregnancy and the delivery of premature infants who are markedly underweight for their gestational age are characteristic occurrences.

**Treatment**—The definitive treatment of the toxemias of pregnancy is the termination of the gestation at the most opportune time. All other therapeutic measures are palliative. Such nonspecific therapy is employed in the mild or moderate forms of the disease with the hope of retarding the abnormal process until delivery of a surviving infant can be reasonably expected. A secondary objective of this palliative therapy is to prolong the gestation to the point where delivery through the birth canal can be accomplished. The status of the patient with any type of toxemia can deteriorate rapidly. Consequently frequent observation and repeated evaluation are of utmost importance in the general management.

Although pre eclampsia cannot be prevented, eclampsia is preventable in the vast majority of instances provided the patient seeks prenatal care early and follows the advice of her physician. Once severe pre eclampsia develops, eclampsia is imminent. Hence every patient with moderate pre eclampsia is a potential obstetric emergency and should be hospitalized for evaluation. Hospitalization is indicated if one or more of the following signs or symptoms is present: a blood pressure of 150/100 mm Hg or more, pretibial or more extensive edema, 24 hour quantitative urinary protein excretion of 1 Gm or more, headache, visual symptoms, nausea, vomiting and gastric distress or oliguria.

When these patients are hospitalized the edema is treated by a low sodium low potassium low chloride diet. This regime should not be continued beyond 14 days for prolonged use may lead to serious electrolyte imbalance. A diuretic drug may be administered to speed the restoration of a normal fluid and electrolyte balance.

Chlorothiazide is most useful and effective in increasing sodium excretion and combating fluid retention in pregnancy. It is safe for both mother and fetus and can be administered at any time in the pregnancy under careful supervision. In addition to its diuretic effect, chlorothiazide is also effective in reducing hypertension in some cases.

the threatened loss of a much wanted baby. If it is demonstrated that the pregnancy is still viable the pregnancy hormone progesterone, can be administered in moderately large doses. It is entirely possible that this key steroid will compensate for the inadequate production of hormones by a poorly developed corpus luteum or by a normal corpus luteum that does not receive enough stimulation by the chorion of a faulty developing conceptus. Temporary supplementation of this vital steroid may likewise bridge the gap during the transition from corpus luteum to chorionic hormonal support of the pregnancy.

At the first prenatal examination the patient should be instructed to inform her physician if any vaginal bleeding occurs. In early pregnancy the causes of the bleeding and its significance are not easy to determine. In most instances it is good management to entertain a diagnosis of threatened abortion and treat accordingly.

The patient should be put to bed and advised to avoid coitus and catharsis. She should save for the doctor's inspection the perineal pads, as well as clots and bits of tissue she may pass. A barbiturate or some mild sedative may be indicated in some individuals to allay apprehension. If the bleeding diminishes or disappears she can be allowed to resume her normal activities in 48 or 72 hours. The prognosis for a pregnancy under these circumstances is good.

If she continues to bleed actively or there is a brownish discharge for longer than a week the prognosis of the pregnancy deteriorates. The appearance of lower abdominal cramps brought on by uterine contractions may foreshadow the progress of the threatened phase into an inevitable abortion. The management of the patient need not change greatly. After several days rest in bed she may be up and about with some restriction of her activities. Unless the patient develops excessive vaginal bleeding or the process culminates in an incomplete abortion there is no need to terminate the gestation. Only continued observation and vaginal examination at intervals will reveal what has happened to the pregnancy. Failure of the uterus to grow and a decrease in its size is positive evidence of the death of the conceptus. A pregnancy test may provide confirmatory evidence.

Abortion is said to be habitual in the woman who has had three consecutively. In such a patient an exhaustive study should be made to determine any abnormal factors which may contribute to the abortions. Hysterosalpingography is of great value in determining abnormalities of the uterus. Some may lend themselves to correction. A basal metabolic rate determination may also give valuable information. It has been our experience that while hypothyroidism may not exist in the patient hypometabolism may contribute to repeated miscarriages. Many patients who have histories of abortions and in whom basal metabolic rates are within the normal range ( $-10$  to  $-20$ ) benefit from small doses of thyroid extract (30 to 120 mg). This therapy is usually continued to the viability of the fetus.

**PROGESTERONE**—Perhaps the most logical therapy for abortion is the use of progesterone. Progesterone deficiency plays an important role in very early pregnancy when abortion may result from inadequate development of the endometrium or from imperfectly developed decidua. Later, at about 10 to 12 weeks the transfer of the progesterone secreting function from the corpus luteum to the placenta may be faulty resulting in hormonal deficiency and disturbing normal pregnancy growth and development. Previously primarily because of its high cost proges-

The termination of the pregnancy can be initiated by the simple rupture of the membranes, provided that the cervical findings suggest that delivery can be anticipated in 24 hours. If labor and delivery do not ensue, cesarean section can be performed.

Hypertension can be managed by the deep intramuscular injections of 12 ml of 50 per cent magnesium sulfate. This is followed by the additional administration of 6 ml every 4 to 6 hours for a maximum amount of approximately 40 ml in 24 hours.

The antihypertension drugs have proved to be merely palliative agents. It has been the general experience that, although the blood pressure can usually be controlled by these drugs, the underlying disease process is unaltered. If visual or cerebral symptoms are present, or if oliguria occurs, a 20 per cent glucose solution in amounts of 1,000 ml is administered in a 40 minute period and repeated every 8 hours if necessary.

## ABORTION

It has been estimated that about 10 per cent of early pregnancies terminate in spontaneous abortion. The incidence increases with age, parity, long periods of infertility, and socioeconomic factors. The reduction of fetal loss from abortion is an important medical problem.

**Causes**—Abortions occur because of (1) defective germ plasma, (2) environmental abnormalities sufficiently great to interfere with the normal implantation and development of the conceptus, and (3) inadequate hormonal support. In the studies on the etiology of abortion it has not always been possible to uncover all of the factors which may have contributed to the early interruption of a pregnancy. Often the factors are interrelated. The woman who has a poorly developed endometrium resulting in environmental failure probably also suffers from inadequate hormonal support. The interference with the development of the conceptus may result in an insufficient amount of gonadotropic hormone elaborated by the chorionic cells necessary to maintain a healthy corpus luteum.

Defective germ plasma, the most important cause of early pregnancy failures, accounts for more than half the spontaneous abortions. Hertig and Livingstone have reported that in 489 of 1,000 aborted conceptuses ovular lesions were present. It is possible that many abnormal conceptuses are the result of environmental factors which knowledge of the physiology of reproduction could prevent.

It has been argued by some that no therapy is indicated for patients who threaten to abort. They reason that ovular defects are present in more than 50 per cent of these patients and, obviously, no one wishes to prolong such pregnancies. Furthermore in a good many women who threaten to abort the process is inevitable because the damage to the conceptus is sufficiently great to preclude fetal survival. Such a defeatist attitude is not consonant with modern dynamic medicine. Intelligent therapy can salvage many pregnancies that threaten to abort.

**Treatment**—There is no specific drug therapy for threatened abortion. Small doses of phenobarbital may be prescribed for the emotional upset engendered by



it, and the acquired discomfort increases in severity. Endometriosis is a common cause. In others ovarian neoplasms, adenomyosis of the uterus, inflammatory disease and submucous myomas may be found on examination.

**Therapy**—The patient who develops painful menstruation should have a careful pelvic examination to establish the cause of the discomfort. In some women the extent of the pathology may warrant the removal of the uterus. In others only an examination under anesthesia or a diagnostic curettage may be sufficiently revealing. Drugs for the relief of the discomfort during menstruation are indicated as temporary expedients but should rarely be continued indefinitely.

**HORMONES**—Steroid hormones, estrogens, progestins, and androgens have been used in the treatment of dysmenorrhea. The rationale in their use is the suppression of ovulation during the cycle in which they are administered, thereby preventing discomfort.

The young woman with primary dysmenorrhea should take 5 mg of diethyl stilbestrol orally each day beginning on the last day of menstruation and continuing for 20 days. The subsequent period may be somewhat delayed but it is likely to be painless. This regimen may be repeated for 3 or 4 months or even longer, and omitted for a month or two. If the dysmenorrhea recurs and is sufficiently severe to interfere with the patient's normal activities, it can be resumed. No undesirable sequelae have been reported following such therapy. The cessation of treatment is followed by normal ovulatory cycles. Eventually the young woman may marry and become pregnant. Following the birth of her baby the dysmenorrhea is not likely to return.

Similar therapy can be used in the management of secondary amenorrhea induced by endometriosis. Long continued estrogen medication to a patient in this condition may keep the disease quiescent, thereby postponing surgical treatment indefinitely.

Androgens have also been used to suppress ovulation. However, the amounts that need be administered each month may be so large as to induce signs of virilization such as acne, hair growth in the masculine pattern, enlargement of the clitoris, and even voice changes. Their use in dysmenorrhea and endometriosis has no advantage over estrogens and hence they are rarely used today for this condition.

## MENSTRUAL DISTURBANCES\*

**General Considerations**—The onset of puberty is heralded by the appearance of menstruation. The average age of this occurrence is 12½ years. However, as a result of some neoplasm or endocrinologic derangement, precocious menstruation may occur at a much earlier age or the onset of menses may be delayed until the late teens. During the first year or two following the initial episode of bleeding the periods may recur at grossly irregular intervals. Maturity and ovulation bring with them a regular menstrual pattern.

Irregularities of the menstrual function can occur at any time in life. Physiologic amenorrhea occurs in pregnancy and with the menopause. Menses may

\*[This is also considered in Chapter 31. Ed.]

terone was administered in small doses (5 to 25 mg per day) without outstanding success

Since the development of synthetic progesterone, especially long acting progesterone (17-alpha hydroxyprogesterone 17 u caproate), better results have been obtained. A single injection of 125 to 250 mg produces effects lasting as long as 2 weeks. It is administered intramuscularly in doses of 250 mg once or twice a week. In the patient who has had repeated abortions treatment should be begun immediately after the missed menstrual period. In patients who have experienced early abortions, it should be continued until 2 weeks after the third missed menstrual period, while in patients who have had late abortions it should be continued to fetal viability. Although this therapy is not a panacea for the problem of habitual abortion, it is a logical approach.

There has been some discussion as to whether large doses of progesterone or its derivatives given during pregnancy will influence the development of the genital system of the fetus. Follow up studies from this clinic and elsewhere have not revealed any aberrations in the development of the reproductive systems of infants whose mothers were treated with progestins during gestation.

**DIET**—An adequate high protein diet supplemented with essential vitamins, particularly A and D, is important in providing optimum metabolism in pregnancy.

**REASSURANCE**—Emotional support to the patient who is extremely fearful because of a poor obstetrical history has not been sufficiently emphasized in the past.

## DYSMENORRHEA\*

**Primary Dysmenorrhea**—Primary dysmenorrhea usually begins several years after the onset of the menses with the initiation of ovulation. It may be characterized by emotional tension together with cramplike pains in the lower abdomen which may be due to uterine contractions. Pelvic examination reveals normal reproductive organs. Normal ovarian function is present, for this type of dysmenorrhea is associated with ovulatory periods. Suppression of ovulation by estrogens or progesterone may reduce or completely eradicate the menstrual discomfort.

Medical treatment should be directed toward psychic and emotional factors which may predispose to the painful periods. Young women should be encouraged to participate in exercises of all kinds. Many lead sedentary lives. Good dietary habits, with weight reduction in the young woman who is overweight, should be encouraged. Psychotherapy is an extremely valuable adjunct in management and properly used may obviate the need of drugs or hormones. There are many combinations of drugs on the market, all of which will give satisfactory results in some cases and fail completely in others. These consist mainly of combinations of sedatives, analgesics, and antispasmodics.

**Secondary Dysmenorrhea**—Secondary dysmenorrhea is usually the result of pelvic pathology. Characteristically the young woman has been free from discomfort for a number of years after the establishment of the menses. She then develops pain of varying degrees associated with the onset of bleeding or preceding

\*[Some of these problems are also discussed in detail in Chapter 31. Ed.]

doctrinal cycle. The withdrawal of progesterone would lead to endometrial bleeding in 1 day or two. However, no additional advantages accrue to the patient by the addition of progesterone.

**Secondary Amenorrhea**—The cessation of menstrual periods after they have been established is not an uncommon occurrence. This may be the result of physiologic changes such as pregnancy and the menopause. It can be induced by ovarian failure of varying degrees. In some, psychic or emotional factors bring about a limited period of amenorrhea probably as a result of hypothalamic influence on the pituitary gland. A major change in the environment may stop the menses for a short period. The marked loss in weight such as occurred in young women incarcerated in the infamous concentration camps resulted in long periods of amenorrhea. It may be brought about by ovarian and adrenal tumors that produce steroid hormones, such as the granulosa neoplasms.

**TREATMENT**—The treatment of secondary amenorrhea depends on its cause. The correction of nutritional faults is of prime importance. In both overweight and underweight patients, measures to bring the weight to normal are often followed by the return of menstrual periods. If the basal metabolic rate is below normal the patient may benefit from moderate doses of thyroid extract. Reassurance that menstrual irregularities are rarely of serious import or affect well being may be useful.

Excessive and prolonged episodes of uterine bleeding interspersed with periods of amenorrhea may be a part of the clinical picture of functional uterine bleeding. Mild or moderate degrees of ovarian failure may be evident in the lack of ovulation or its sporadic occurrence. A diagnostic curettage may be indicated not only because the endometrial studies will rule out more serious pathology than hyperplasia but also because it will stop the uterine bleeding temporarily. Occasionally it is followed by the recurrence of regular periods.

**Hormones** Steroid hormone administration is not often indicated in secondary amenorrhea. However, if the condition does not improve as a result of the measures that have been instituted and the amenorrhea has lasted for as long as a year, estrogens and progesterone may be tried. Where sufficient estrogen is given to maintain the normal vaginal mucosa as demonstrated by inspection and cytologic studies and where the reproductive organs appear normal progesterone can also be administered. The intramuscular administration of 125 mg of a long acting progesterone twice a week for several weeks should result in uterine bleeding. This treatment may be repeated a week or 10 days after the bleeding episode.

In these patients there is sufficient estrogen provided by growing follicles to maintain the reproductive organs while progesterone induces progestational changes and on its withdrawal bleeding ensues. At the end of 5 or 6 months this regimen can be interrupted to see if natural menses return.

If the level of endogenous estrogens has declined so that atrophic changes in the reproductive organs develop, the administration of exogenous estrogen is indicated. Usually 1 mg of diethylstilbestrol orally, or its equivalent in other estrogenic drugs will result in the recovery of the reproductive organs in a period of several months, following which the daily dose can be reduced to 0.5 mg. This simple substitution therapy does not influence ovarian function so that it has to

never appear in some young women (primary amenorrhea) Adolescence may be complicated by long episodes of bleeding necessitating therapy Rarely, ovarian tumors with endocrine function, such as the granulosa neoplasms may reinitiate menstrual like episodes of bleeding long after the climacteric Short and long periods of amenorrhea may appear during the active reproductive years of many women (secondary amenorrhea)

Menstruation is an expression of the failure of conception Its character and regularity are influenced primarily by the steroid hormones which control the reproductive function However, physical well being, the state of body nutrition emotional factors, systemic disease, and local pathology, all play important roles The most important part of the management of menstrual irregularities is a painstaking study of each case to determine the cause of the menstrual disorder

**Primary Amenorrhea**—The failure to establish menstrual periods may be due to the absence of the uterus or complete obstruction to the escape of menstrual blood because of an imperforate hymen The absence of menses may be endocrine in origin The anterior lobe of the pituitary may not produce gonadotropic hormones to stimulate the ovaries, the ovaries may fail to respond to pituitary stimulation or the adrenals may be at fault

No therapy is indicated until the cause of the amenorrhea is established The patient should be subjected to a complete physical examination which should include the visualization of the sella turcica and an x ray study of the urologic tract In the absence of organic causes the endocrinologic investigation should include quantitative urinary assays for gonadotropins and ketosteroids the evaluation of thyroid function and the determination of the genetic sex of the individuals These studies will establish the cause of the primary amenorrhea

**TREATMENT**—The treatment of primary amenorrhea ovarian or pituitary in origin, is hormonal substitution In most instances the administration of estrogens induces rapid development of the undifferentiated secondary sex characters the infantile reproductive organs grow to normal adult proportions, and the epiphyses of the long bones close, bringing to a halt continued skeletal growth We administer 1 mg. of diethylstilbestrol daily This medication can be continued without interruption indefinitely

These young women may continue to harbor a feeling of inadequacy until it is demonstrated that they can have menstrual periods This is brought about by the withdrawal of estrogens and a breakdown of the endometrium and may last for periods of 3 to 7 days This can be readily accomplished by administering the drug for intervals of 3 or 4 weeks A week or 10 days after the cessation of the medication vaginal bleeding will occur Following the cessation of bleeding the administration of diethylstilbestrol can be resumed Once it has been demonstrated to the patient that she can menstruate if she wishes, she is no longer interested in this useless phenomenon It must be kept in mind that the ovaries are not stimulated by estrogens and that reproduction is impossible It is hoped that it may be possible some day to stimulate such ovaries physiologically, perhaps by pituitary gonadotropic preparations and thereby establish normal ovarian function

A need to substitute for progesterone lack has not been demonstrated One can administer estrogens and progesterone, thereby simulating the normal en-

Preparation for the "changing years" should begin long before the onset of the climacteric. Mothers should be made to realize that *theirs* will be a changing role in their family circles. They should be encouraged to develop new interests in the home, in the social group to which they belong, in the church, or in the community. An intelligently occupied woman is less likely to develop emotional problems and is better able to cope with bodily readjustments brought on by the climacteric. Such enlightened orientation of the patient may be the most important therapeutic tool at the disposal of the physician.

**HORMONES**—Estrogens provide specific therapy for the ovarian failure that brings on the menopause. The dosage will vary with the estrogen and the mode of administration. When estrogens were first introduced they were ineffective when administered orally. However, today there are numerous estrogenic preparations that are effective orally, and the need for parenteral administration should arise rarely.

The natural climacteric in most women is likely to have a rather slow onset over a period of several years. In most patients the administration of estrogen can be postponed until menses have ceased. It is well to begin with 0.5 mg of diethylstilbestrol every other day and continue this dosage until the menses have ceased. The dose can then be increased to 0.5 mg every day. In a few women this amount may have to be further increased to 1 mg daily for some months in order to control the symptoms completely, following which it should be reduced to 0.5 mg daily. We have found that it is best to administer estrogens at bedtime.

In a few the onset of therapy with estrogens will cause nausea for a week or 10 days, following which this troublesome symptom disappears. It is well to inform the patient that this may occur but that it is of no significance. If it persists the hormone can be taken during the day. The rare individual may continue to have some transient nausea. Natural and synthetic estrogens behave in the same way. The cause for this transient nausea is not known.

**TREATMENT OF SURGICAL MENOPAUSE**—The induction of the menopause by the surgical removal of the ovaries or their destruction by irradiation will precipitate the symptoms of the climacteric within a week or 10 days. Experience has taught us that complete substitution of ovarian function in a young woman can be attained by the administration of 1 mg of diethylstilbestrol daily. Obviously the woman in the active reproductive years who has lost her ovaries should be placed on 1 mg of diethylstilbestrol orally, or its equivalent in other estrogens within the first week following her operation. This dosage will suppress all menopausal symptoms indefinitely. The dose can be cut in half at the end of 6 months and again at the end of a year or two. It is important to maintain younger women on a daily dose of 0.5 mg for a longer period than women at or beyond the menopausal age.

**DURATION OF TREATMENT**—One should remember that estrogens only suppress the menopause. The sudden cessation of therapy will be followed by the recurrence of hot flashes in a week or two. It is important, therefore, that when it is desirable to discontinue medication it should be accomplished by a slow reduction in the amount of the drug administered rather than its sudden withdrawal.

be continued until ovarian function recovers or, failing that, indefinitely

**Irradiation** Radiation therapy to the ovaries and the pituitary has been advocated from time to time. There is little doubt that some good results have been achieved, but in view of the present increasing concern over the deleterious effects of all radiation such therapy is not warranted for any menstrual disturbance not due to neoplastic disease

## THE MENOPAUSE\*

**General Considerations**—The onset of the climacteric is a normal physiologic episode in the lives of most women. However, in the minority it may be associated with troublesome symptoms which may tax the physician's armamentarium. The slow extinction of ovarian function influences other glands of internal secretion as well as the metabolism of the entire body. The necessary readjustments that must be made may be tolerated extremely well by the majority of women but they will cause violent emotional upsets in a few.

The period of the menopause frequently coincides with major family and social changes in the lives of many women. As the years of the climacteric approach the responsibilities of homemaking become less demanding or completely disappear. The children reach maturity and go forth to build their own lives. The role of homemaker becomes less exciting and often actual drudgery. The family income improves and the husband's business affairs consume more and more of his hours. The wife finds that she has more and more time which she occupies by uninteresting and even boring routines. She becomes cognizant of many aches and pains real or imaginary.

The symptoms and the management of the menopause must be evaluated against the foregoing background. Every complaint of a patient from 30 to 60 years old for which the physician has not uncovered an organic cause has been labeled menopausal and often treated as such. This approach carries a considerable hazard, for it may overlook serious disease in its incipency, on the one hand or promote emotional disturbances to the point where they are difficult or impossible to treat, on the other hand. There is only one symptom that is pathognomonic of the climacteric, the hot flashes. They are vasomotor in origin and are the result of a marked decline in estrogens or their sudden withdrawal. Undoubtedly other symptoms occur because of the major hormonal and metabolic changes induced by the lack of estrogens but these are more subtle and more difficult to diagnose.

**Treatment**.—The treatment of the patient who consults a physician because of the change of life must be more comprehensive than the administration of a daily pill if it is to be intelligent treatment. The patient should have a complete physical examination to eliminate any organic disease. She should have a cytologic study of the cervical and vaginal secretions to uncover cancer sufficiently early to be cured. She should be instructed to return for periodic medical examinations. Exercise and dietary limitations may be necessary so that she may retain or regain her ideal weight.

\*[This is also considered in Chapter 31. Ed.]

night at bedtime Treatment over a 2 to 4 week period will cure all but the most resistant cases Gentian violet, 1 per cent in glycerin is effective in many cases The vaginal canal is dried with cotton pledgets and then wiped out with the gentian violet solution A tampon lightly saturated with gentian violet may be placed in the vagina and removed in several hours This can be repeated at weekly intervals Nystatin, an antibiotic, in the form of vaginal tablets which can be inserted by an applicator, appears to be an effective agent against moniliasis A tablet can be placed in the vagina each night for a week or 10 days and then every second and third night for 3 or 4 weeks This antibiotic does not disturb the normal bacterial flora

**Vaginal Trichomoniasis**—This lower genital tract infection is much more difficult to eradicate than is the monilia infection Although many women harbor this protozoan a favorable environment is necessary to produce an acute infection in the vaginal tract with intense burning itching and a profuse purulent discharge The entire lower genital tract is reddened and an abundant bubbly discharge is present The mobile protozoan is easily seen in an unstained hanging drop

There is no specific therapy for this infection Many forms of medication have been recommended, with good results However, in some patients any form of treatment will eradicate the inflammation and in others no therapy is effective It is fairly easy to cure the patient in the acute stage but very difficult if a chronic state exists Recurrences are frequent

An important principle in treatment is to restore the normal biologic environment in the lower genital tract Alpha lactose tablets are inserted in the vagina each night in order to restore the normal pH of the vaginal secretions This medication has been made available in various forms After using these tablets for 4 or 5 nights the patient should douche with vinegar Therapy should be continued for at least 2 months It is important to eradicate foci of infection in the cervix and occasionally in the urethra particularly in the patient who has had a recurrence

In our clinic we have used the following empiric treatment very satisfactorily for many years Negatan, a proprietary drug is a formaldehyde derivative The entire surface of the vagina and portio of the cervix is scrubbed with this preparation and the excess carefully removed Its action is to produce superficial desquamation of the vaginal and portio epithelium The vaginal lumen is then filled with half strength Lassar's paste A tampon is inserted as the speculum is removed to keep the paste from escaping The patient is told to remove the tampon the next day The patient is treated once a week for 5 or 6 weeks and after each of the following three menstrual periods The latter precaution is to diminish the likelihood of recurrences which seem to follow menstruation

Trichomoniasis is difficult to eradicate during pregnancy and the use of alpha lactose tablets will help to control the troublesome itching and discharge

**Gonorrheal Vaginitis**—Most of the strains of gonococci encountered are susceptible to one of several antibiotics penicillin streptomycin chlortetracycline oxytetracycline, and carbomycin When any of these substances are given over a 4 day period in adequate dosage the infection will be eradicated Local therapy is avoided but the patient should be followed at weekly intervals for urethral

How long should women remain on minimal amounts of estrogens? This question has not yet been answered. There are more and more data which support the long-continued administration of estrogens, perhaps into senility. Many advantages accrue from small amounts of this hormone. Marked atrophy of the vaginal mucosa and postmenopausal vaginitis are prevented. Osteoporosis may be delayed or fail to develop. Estrogens serve as a tonic to aging tissues because of their influence on the vascular system, and cardiovascular degenerative changes may be delayed or prevented.

**DANGERS**—The numerous beneficial effects of the therapeutic use of the estrogens are always clouded by the fear that the treatment may induce neoplasia. This is not surprising, for these hormones are the most potent growth promoting factors known. However, there are no data which definitely implicate estrogens in the development of cancer. If there were such a danger, the widespread use of these hormones in small and large amounts for many years should have incriminated them more seriously as carcinogenic agents by this time. Emge, a student of this problem for a great many years, has stated that estrogens are not carcinogenic and that at the worst, they may improve the soil for neoplasia in those who are genetically susceptible to neoplastic growth. Intelligent treatment with estrogens is probably far less hazardous than treatment with many apparently innocuous drugs that are far less useful.

The highly desirable therapeutic benefits of estrogens in the management of the climacteric are not without some hazard. They may induce uterine bleeding when the administration of the drug is stopped the dose excessive the amount varied, or even on continued administration. Some women are particularly sensitive to estrogens and in them these substances may induce bleeding even when given in small amounts. Estrogenic bleeding is of no importance in itself, for it will cease with the withdrawal of the hormone. However, bleeding during the climacteric or following its establishment is always a suspicious sign of cancer of the uterus and this serious condition which can be cured in its incipency, must not go unrecognized. Every woman who exhibits vaginal bleeding on estrogenic medication and in whom the bleeding does not stop promptly on discontinuing the hormone should have a careful pelvic examination including a curettage.

## LOWER GENITAL TRACT INFECTIONS

During the reproductive years most irritations of the vagina are due to one of two organisms. *Trichomonas vaginalis*, a protozoan parasite, or *Candida albicans*, a fungus.

**Moniliasis**—Of these two infections moniliasis (candidiasis) is the most easily eliminated. This condition is characterized by itching or burning, a profuse irritating discharge cheesy in character. Diagnosis should be confirmed by the presence of mycelia in a hanging drop preparation. In the patient who is not pregnant one should always suspect diabetes mellitus and examine a urine specimen for reducing substance. This organism is present in about 25 per cent of pregnant women. There are several agents for the treatment of moniliasis. There is available a vaginal gel containing as its active ingredient ricinoleic acid which is very effective. This material is placed deep into the vagina by means of an applicator tube each



night at bedtime. Treatment over a 2 to 4 week period will cure all but the most resistant cases. Gentian violet, 1 per cent in glycerin, is effective in many cases. The vaginal canal is dried with cotton pledgets and then wiped out with the gentian violet solution. A tampon lightly saturated with gentian violet may be placed in the vagina and removed in several hours. This can be repeated at weekly intervals. Nystatin, an antibiotic, in the form of vaginal tablets which can be inserted by an applicator, appears to be an effective agent against moniliasis. A tablet can be placed in the vagina each night for a week or 10 days, and then every second and third night for 3 or 4 weeks. This antibiotic does not disturb the normal bacterial flora.

**Vaginal Trichomoniasis**—This lower genital tract infection is much more difficult to eradicate than is the monilia infection. Although many women harbor this protozoan, a favorable environment is necessary to produce an acute infection in the vaginal tract with intense burning, itching, and a profuse purulent discharge. The entire lower genital tract is reddened and an abundant bubbly discharge is present. The mobile protozoan is easily seen in an unstained hanging drop.

There is no specific therapy for this infection. Many forms of medication have been recommended, with good results. However, in some patients any form of treatment will eradicate the inflammation and in others no therapy is effective. It is fairly easy to cure the patient in the acute stage but very difficult if a chronic state exists. Recurrences are frequent.

An important principle in treatment is to restore the normal biologic environment in the lower genital tract. Alpha lactose tablets are inserted in the vagina each night in order to restore the normal pH of the vaginal secretions. This medication has been made available in various forms. After using these tablets for 4 or 5 nights the patient should douche with vinegar. Therapy should be continued for at least 2 months. It is important to eradicate foci of infection in the cervix and occasionally in the urethra, particularly in the patient who has had a recurrence.

In our clinic we have used the following empiric treatment very satisfactorily for many years. Negatan, a proprietary drug, is a formaldehyde derivative. The entire surface of the vagina and portio of the cervix is scrubbed with this preparation and the excess carefully removed. Its action is to produce superficial desquamation of the vaginal and portio epithelium. The vaginal lumen is then filled with half strength Lassar's paste. A tampon is inserted as the speculum is removed to keep the paste from escaping. The patient is told to remove the tampon the next day. The patient is treated once a week for 5 or 6 weeks and after each of the following three menstrual periods. The latter precaution is to diminish the likelihood of recurrences which seem to follow menstruation.

Trichomoniasis is difficult to eradicate during pregnancy and the use of alpha lactose tablets will help to control the troublesome itching and discharge.

**Gonorrheal Vaginitis**—Most of the strains of gonococci encountered are susceptible to one of several antibiotics: penicillin, streptomycin, chlortetracycline, oxytetracycline, and carbomycin. When any of these substances are given over a 4 day period in adequate dosage the infection will be eradicated. Local therapy is avoided but the patient should be followed at weekly intervals for urethral

smears and cultures. In immature females the most common cause of vaginitis is the gonococcus. The thin mucosa of the vagina at this age makes the individual especially susceptible to this disease.

**Condylomata Acuminata**—These are benign papillomas which occur on the vulva and vagina but rarely on the cervix. They are believed to have a viral etiology. Frequently they are associated with other vaginal infections such as trichomoniasis.

The treatment consists of instituting proper vaginal hygiene. The local lesions are treated effectively with 25 per cent podophyllin salve. The ointment is applied only to the condylomas and left in place for  $\frac{1}{2}$  to 1 hour. The medication should then be carefully removed with soap and water. Reapplication can be carried out at weekly intervals if necessary. In rare cases where the growth is excessively large surgery may be indicated.

**Postmenopausal or Senile Vaginitis**—The atrophy of the external genitalia and the mucosa of the vagina predispose to trauma. Trauma invites infection. The patient experiences burning or smarting and a serosanguineous discharge. On examination the mucosa appears smooth and glistening and reddened and superficial petechiae are visible. In some instances it is the burning and smarting at urination that brings the patient to the physician.

The treatment is to administer small amounts of estrogens for a period of 6 to 8 weeks. The atrophic mucosa rapidly is restored to the normal state and the superimposed infection disappears. In women who develop a lower genital tract infection due to trichomoniasis, estrogens are the most important part of the treatment in the postmenopausal period.

## CHILD SPACING

Child spacing may be desirable because of medical or socioeconomic reasons. The physician may wish to instruct the patient concerning the means of preventing pregnancy best suited for the individual's needs.

Roman Catholic women who cannot use chemical or mechanical measures to prevent conception may be instructed in the physiologic approach to this problem. The normal cyclical changes in the reproductive organs provide for periods of fertility and infertility. Abstinence from coitus during the fertile periods decreases the likelihood of pregnancy. The basal body temperature is a fairly accurate mirror of these changes. The patient can prepare a daily temperature curve by taking her temperature orally immediately upon awakening each morning and recording it promptly. The typical temperature graph will highlight the fertile period. Suitable graph paper, basal thermometers for easy reading and instructions are available.

Contraceptives include occlusive devices such as diaphragms or condoms, spermicidal jellies, creams, capsules and suppositories. Spermicidal preparations act as chemical agents. Diaphragms serve solely as mechanical obstructions to the migration of spermatozoa upward into the fallopian tubes. They likewise provide receptacles for the spermicidal agents. Diaphragms should never be used alone. The patient who objects to spermicidal agents for personal reasons can use the condom successfully.

Spermicidal preparations consist of jellies or creams which provide partial obstruction and in addition contain nontoxic chemical agents which immobilize sperm at relatively low concentrations. The viscosity of these preparations should be high enough to prevent leakage but at the same time allow spreading over the cervix and vaginal mucosa.

Many compounds have been utilized for this purpose. Some of these include 0.33 per cent acetic acid, ricinoleic acid and its derivatives, and many others. These agents should not contain greasy substances such as lanolin or petrolatum which tend to cause deterioration of occlusive devices made of rubber.

The usual dosage of the creams or jellies is approximately 5 ml. Capsules or suppositories are placed in the vagina about 15 minutes before coitus to allow sufficient time for them to melt, spread, and release their active ingredients. Regardless of the measure employed, douches should not be taken within 8 hours following intercourse.

**Oral Contraceptives**—Oral medication which has been rather effective as contraceptive agents has recently been introduced. These compounds are the 19 nor steroids, derived from 19 nortestosterone, which is a potent oral progestin. The action of these compounds is to inhibit ovulation in both experimental animals and the human female.

One of these compounds, norethindrel, was selected for trial as a contraceptive agent in Puerto Rico. Women were given 10 mg of the drug from the fifth to twenty-fourth days of the menstrual cycle. Withdrawal bleeding occurred within 4 days of cessation of treatment in most cases. In 1,279 cycles in which the medication was taken according to directions, not a single pregnancy occurred.

Fourteen women who discontinued medication after 1 to 17 cycles became pregnant within 3 months, suggesting that this drug does not impair subsequent fertility. These compounds are important in that they demonstrate that control of conception can be achieved with oral medication even though the particular compounds used may not be the ultimate answer.

## SELECTED REFERENCES

- Davis M Edward. *Natural Child Spacing*. Garden City N Y, 1954. Hanover House.
- Davis, M Edward, Adair, Fred L., and Pearl, Sarah. Present Status of Oxytocics in Obstetrics, *J A M A* 107 261, 1936.
- Dieckmann Wm J. *Toxemias of Pregnancy*, ed 2. St Louis 1952. The C V Mosby Company.
- Dieckmann, William J, Harrod, John P, and Monardo Alfred. The Treatment of Preeclamptic Edema With Acetazolamide (Diamox), *Am J Obst & Gynec* 73 789 1957.
- Eastman Nicholson J. *Williams Obstetrics* ed 11, New York, 1956, Appleton Century Crofts Inc.
- Ernig, Ludwig A. Estrogen Imbalance and Uterine Cancer. *West J Surg* 58 490 1950.
- Fugo, Nicholas W, and Dieckmann William J. A Comparison of Oxytocic Drugs in the Management of Labor, *Am J Obst & Gynec* 76 141, 1958.
- Charles G Thomas. *Threatened and Incomplete Abortion*. Springfield Ill 1954.
- Jones G Segar. The Management of Endocrine Disorders of Menstruation and Fertility. Springfield Ill 1954, Charles C Thomas.
- Pincus G, Rock J, and Garcia C R. Effects of Certain 19 Nor Steroids Upon Reproductive Processes, *Ann New York Acad Sc* 71 479 1958.

smears and cultures. In immature females the most common cause of vaginitis is the gonococcus. The thin mucosa of the vagina at this age makes the individual especially susceptible to this disease.

**Condylomata Acuminata**—These are benign papillomas which occur on the vulva and vagina but rarely on the cervix. They are believed to have a viral etiology. Frequently they are associated with other vaginal infections such as trichomoniasis.

The treatment consists of instituting proper vaginal hygiene. The local lesions are treated effectively with 25 per cent podophyllin salve. The ointment is applied only to the condylomas and left in place for  $\frac{1}{2}$  to 1 hour. The medication should then be carefully removed with soap and water. Reapplication can be carried out at weekly intervals if necessary. In rare cases where the growth is excessively large, surgery may be indicated.

**Postmenopausal or Senile Vaginitis**—The atrophy of the external genitalia and the mucosa of the vagina predispose to trauma. Trauma invites infection. The patient experiences burning or smarting and a serosanguineous discharge. On examination the mucosa appears smooth and glistening and reddened, and superficial petechiae are visible. In some instances it is the burning and smarting at urination that brings the patient to the physician.

The treatment is to administer small amounts of estrogens for a period of 6 to 8 weeks. The atrophic mucosa rapidly is restored to the normal state and the superimposed infection disappears. In women who develop a lower genital tract infection due to trichomoniasis, estrogens are the most important part of the treatment in the postmenopausal period.

## CHILD SPACING

Child spacing may be desirable because of medical or socioeconomic reasons. The physician may wish to instruct the patient concerning the means of preventing pregnancy best suited for the individual's needs.

Roman Catholic women, who cannot use chemical or mechanical measures to prevent conception, may be instructed in the physiologic approach to this problem. The normal cyclical changes in the reproductive organs provide for periods of fertility and infertility. Abstinence from coitus during the fertile periods decreases the likelihood of pregnancy. The basal body temperature is a fairly accurate mirror of these changes. The patient can prepare a daily temperature curve by taking her temperature orally immediately upon awakening each morning and recording it promptly. The typical temperature graph will highlight the fertile period. Suitable graph paper, basal thermometers for easy reading, and instructions are available.

Contraceptives include occlusive devices such as diaphragms or condoms, spermicidal jellies, creams, capsules, and suppositories. Spermicidal preparations act as chemical agents. Diaphragms serve solely as mechanical obstructions to the migration of spermatozoa upward into the fallopian tubes. They likewise provide receptacles for the spermicidal agents. Diaphragms should never be used alone. The patient who objects to spermicidal agents for personal reasons can use the condom successfully.

**TOXICITY**—Toxicity of cholinergic drugs is manifested by severe gastrointestinal cramping, profuse sweating generalized or localized paresthesia, shock, bladder pain, salivation and diarrhea. The antidote is atropine. The intravenous use of 5 per cent glucose in normal saline may sometimes be necessary.

**CONTRAINDICATIONS**—The cholinergic drugs are contraindicated in (1) patients with myasthenia gravis who are receiving neostigmine, (2) progressive muscular atrophy or bulbar palsy, (3) mechanical intestinal or urinary obstruction, and (4) severe cardiac disease. Asthma also makes their use hazardous.

#### Use of Cholinergic Drugs in Nonobstructive Urinary Retention—

**POSTOPERATIVE URINARY RETENTION OR POSTTRAUMATIC URINARY RETENTION WITHOUT OBVIOUS SPINAL CORD INVOLVEMENT AND WITHOUT VESICAL OVERFLOW INCONTINENCE**—Pilocarpine, 6 to 8 mg, 4 times a day by mouth, may be tried first. If pilocarpine fails, Urecholine 10 to 20 mg, 4 times a day, is the next choice. If urinary retention persists there should be a cystoscopic examination to eliminate the possibility of either prostatic or urethral obstruction. If no obstruction is found, a retention catheter should be used while cholinergic drugs are continued. After 4 days the catheter should be removed but the medication continued for an additional 10 days.

**POSTOPERATIVE OR POSTTRAUMATIC URINARY RETENTION WITH OVERFLOW INCONTINENCE**—In this situation the insertion of a retention catheter for 5 days or until the patient is ambulatory for 48 hours is indicated. The purpose of the retention catheter is to place the bladder at complete rest and thus augment detrusor compensation by enforced inactivity. Pilocarpine 6 to 8 mg 4 times a day by mouth is continued through the catheter period and maintained for 10 days after removal of the catheter. If spontaneous urination following removal of the catheter does not occur cystoscopic evaluation is indicated.

**URINARY RETENTION OF PSYCHIC ORIGIN**—In the absence of mechanical bladder neck obstruction as proved by cystoscopy, and with a full bladder treatment consists of intravenous injection of 1 ml of 1 per cent pilocarpine (10 mg). The unpleasant side effects of the pilocarpine as well as the cholinergic action stimulate a distinct desire to urinate normally. This therapeutic regimen is never to be used in the presence of cardiac disease.

## ANTICHOLINERGIC DRUGS

On pages 354 to 356 Almy and Steinberg have described the properties of the anticholinergic drugs as applied to the gastrointestinal tract. The factors involved in the urinary tract are essentially identical.

**A Design for the Use of Anticholinergic Drugs in Urology**—In urology the most useful place for these drugs is in the control of a variable degree of vesical spasm which may be occasioned by either pressure (retention catheter or tumor) or irritation (infection tissue congestion).

The bladder neck spasm which is not infrequently associated with a retention catheter may be greatly benefited by the use of tincture hyoscyamus 20 to 30 drops 4 times a day or with methantheline (Banthine), 50 mg 4 times a day. In particularly severe instances of vesical spasm the intramuscular use of methantheline, 25 mg every 4 to 6 hours may give relief.

## THE CHOICE OF DRUGS FOR UROLOGIC DISORDERS

*Robert Lich, Jr, M D, M S (Path)*

---

Drugs are used in urologic disorders to combat pain, urosepsis, smooth muscle spasm, to depress or stimulate nerve sensitivity of the urinary tract, and to relieve urinary tract irritation. Hormones are also useful in the control of inoperable prostatic cancer, to assist in the problem of infertility, and on occasion to resolve the problem of cryptorchism.

The anti-infective drugs and agents have made possible unbelievable strides in the treatment of infections while the antispasmodics have had little success. If capable of producing smooth muscle paralysis, the latter would interrupt urinary tract function, which would extend rather than correct the patient's plight. The antispasmodic must of necessity be limited to serve as an adjunct to specific therapy by hastening subjective relief.

In urology symptoms often are the result of the ceaseless rhythmic smooth muscle contractures of hollow viscera which cause distress, the severity is a mirror image of the violence of the irritant. It is axiomatic that, except in uncomplicated urologic infection, until the calculus is removed, the obstruction is overcome, or the tumor is removed, medication can serve only as a temporary adjunct.

### CHOLINERGIC DRUGS

**Introduction**—The cholinergic drugs are used in urology to stimulate smooth muscle activity of the bladder and, on occasion, of a neurogenically mildly disturbed ureter. The cholinergic drugs have their greatest applicability in functional vesical dysfunction and bladder atony resulting from prolonged and recently relieved mechanical urinary tract obstruction. Vesical atony may be due to (1) postoperative or posttraumatic urinary retention, (2) postprostatectomy bladder atony, or (3) psychic urinary retention.

#### **Pharmacologic Considerations**—

**MODE OF ACTION**—Most of the cholinergic drugs now available act as parasympathetic nervous system stimulants by inhibition of cholinesterase, although pilocarpine acts by a different mechanism, stimulating directly. Since the parasympathetic nervous system stimulates detrusor and ureteral activity, at least in part, cholinergic drugs may be expected to reproduce this action.

**General Pharmacologic Considerations**—Sodium bicarbonate is the alkali most commonly used in urology. However, the acetates, citrates and lactates may also be used since they are converted to carbonates. Their effects are those of the chlorides before absorption and those of the carbonates subsequently. Oxidation is virtually complete so that less than 5 per cent of the acetate, lactate, or citrate is excreted in the urine unchanged.

The acetate and citrate of potassium may be used to increase alkalinity of the urine and possess the attribute of not neutralizing the gastric juice or disturbing digestion.

Sodium lactate, in  $\frac{1}{6}$  molar concentrations, may be administered intravenously with safety. Subcutaneous extravasation will not cause a slough as it may with sodium bicarbonate. The lactate solution is also more easily sterilized than the bicarbonate solution. Citrates cannot be administered intravenously because they interfere with blood clotting. They may also affect the heart adversely by depleting the calcium content of the blood through the formation of an undissociable calcium salt.

**SODIUM CITRATE**—Sodium citrate is the drug of choice when protracted periods of alkalization are necessary as is the situation in the prevention of uric acid and cystine stones. These substances remain in solution in an alkaline urine. The patient must maintain the urine alkaline at all times. This must be frequently checked with Nitrazine paper. It is essential that a low calcium diet (no milk or milk products, butter excepted) is followed since the alkaline urine may precipitate calcium and the patient formerly troubled with uric acid or cystine stones may find himself confronted with calcium phosphate urolithiasis.

**SODIUM LACTATE**—The  $\frac{1}{6}$  molar solution administered intravenously is useful in combating the acidosis of uremia or diabetes mellitus. It has the advantage of being nontoxic to tissues and possessing a safety factor of wide latitude. Sodium bicarbonate on the other hand is toxic to tissues and possesses a markedly small factor of safety so that the patient can easily go from severe acidosis to an equally dangerous alkalemia.

Sodium lactate should not be used in severe hepatic disease because its value rests on the action of the liver to alter and make it available as carbonate for the correction of the acidosis.

## ANTI INFECTIVE DRUGS

The anti infective drugs have played an important role in urologic therapy. Since the introduction of sulfanilamide, the list of chemotherapeutic and antibiotic agents has grown. This is most fortunate for many of the earlier members have lost their effectiveness. Penicillin is a striking example. 95 per cent of the strains of *Staphylococcus aureus* were sensitive to penicillin when it was introduced but, within a decade the percentage of sensitivity dropped to less than 10 per cent. The drug of choice depends on the specific infection as well as the clinical setting. Precise diagnosis is therefore, essential to good relief and permanent cure.

In the short time that chemotherapeutic and antibiotic agents have been available, there have been three phases of therapy: first, the narrow spectrum era (e.g., penicillin, streptomycin, sulfonamides), second, the broad spectrum era (e.g.,

The troublesome urinary frequency often found in women, particularly elderly women, without evidence of urinary tract disease is often materially benefited by the use of methantheline, 50 mg, or propantheline, 15 to 30 mg every 4 to 6 hours. In this situation the concomitant use of a sedative is materially effective.

## URINARY ACIDIFIERS

**Introduction**—Acidification of the urine in urologic disorders has two uses as an adjunct to certain types of urinary antiseptics and as a preventive for urolithiasis in specific instances.

**Clinical Application and Pharmacologic Considerations**—

**ANTISEPSIS**—Urine acidification is sometimes essential to urinary antiseptics.

**Methenamine** Even today, methenamine has applications in the treatment of urinary infections. The value of this drug is a function of the urinary pH, and its optimum antibacterial action depends upon a urine pH of 5 or less.

**Mandelic Acid** Mandelic acid effectiveness depends upon an adequate urine concentration of the drug as well as urinary pH of 5 or less.

**Penicillin** The potency of penicillin in urinary tract infections is enhanced by acidity of the urine.

**PREVENTION OF STONES**—Urine acidification may be useful for the prevention of urinary stones.

**Sodium Acid Phosphate** Sodium acid phosphate is the drug of choice in patients forming calcium containing calculi. This drug possesses moderate acidifying properties and reduces urinary calcium excretion, since it depresses serum calcium levels. There is some increase in the urinary phosphorus excretion, but this is in the soluble sodium acid phosphate form. Sodium acid phosphate will not produce acidosis or bone demineralization. It is used in doses of about 0.6 Gm, 4 times a day. It should be noted that since it must be absorbed in the upper intestinal tract, the enteric coated tablet is valueless. Contraindications exist in urea splitting infections since the salt results in more phosphate in the urine in the insoluble magnesium ammonium phosphate form and increases its already excessive deposition.

**Ammonium Chloride** Ammonium chloride is a much more effective acidifier than sodium acid phosphate. It is useful as an acidifying agent in conjunction with chemotherapy of the urinary tract, i.e., mandelic acid, or penicillin. However, ammonium chloride must not be administered over a protracted period since there are certain inherent dangers, i.e., bone demineralization, increase of renal excretion of calcium phosphate, and the production of acidosis. The dosage is of the order of 0.6 Gm 4 times a day. More may be given if the urine pH is not sufficiently depressed.

## URINARY ALKALINIZERS

**Introduction**—In urologic problems, drugs affecting alkalinization serve a fourfold purpose: (1) to reduce the irritating quality of the urine during periods of bladder inflammation, (2) to prevent precipitation and calculus formation of particular substances, (3) to increase the effectiveness of certain drugs, and (4) to combat acidoses associated with renal failure.



isms including pathogens resistant to other chemotherapeutic and antibiotic agents. The precise mechanism of its action is unknown. In the case of urinary tract infections it possesses all the attributes of the antibiotics without their ill effects: minimal overgrowth, blood dyscrasia, staphylococcus enteritis, or crystalluria. Antibacterial concentrations of the drug appear in the urine 30 minutes after ingestion.

While it is not common, sensitization does occur. The symptoms include urticaria, rash, and fever. The drug should be taken with food to prevent the common side effect of nausea. Dosage is 100 mg, 4 times a day.

**METHENAMINE MANDELATE**—Methenamine mandelate (Mandelamine) is a chemical combination of methenamine and mandelic acid. Mandelic acid is ineffective unless the urinary pH is less than 5.5, and although the methenamine assists in lowering the urinary pH, it may be necessary to supplement with ammonium chloride to obtain the desired urinary acidity. Drug fastness rarely develops, permitting its use over prolonged periods of time without loss of its effectiveness.

Its use is contraindicated in renal failure, since the necessary acidity might cause serious acidosis, and is also ill advised in the presence of urea splitting organisms, e.g. *Proteus vulgaris*, which may augment calcium precipitation and calculus formation.

Dosage is 4 to 6 Gm per day until the urine is sterile; following this the patient may be maintained on half the initial dose.

#### Antibiotics—

**PENICILLIN**—Penicillin is most effective against gram positive organisms and thus has only limited value in genitourinary infections.

The procaine salt of crystalline penicillin G in an aqueous suspension is the most commonly used form. Penicillin V is stable in an acid medium and consistent rapid therapeutic blood levels are attained after oral administration. Penicillin is usually given in doses of 200 000 to 300 000 daily. In unusually severe infections the dosage may be increased to 1 or 2 million units daily. Penicillin V may be given in doses of 600 000 to 1 200 000 units daily.

**STREPTOMYCIN**—Streptomycin is a narrow spectrum antibiotic which attacks gram negative organisms and the tubercle bacillus. Due to its limited scope of action it has been largely replaced by broad spectrum antibiotics in the treatment of infections due to gram negative organisms.

**DIHYDROSTREPTOMYCIN**—Dihydrostreptomycin is used in conjunction with streptomycin in the protracted treatment of tuberculosis because of reduced neurotoxicity.

The dosage regimen in tuberculosis is about 1 Gm daily for 1 week and 1 Gm twice weekly for at least a year. This must be supported by isoniazid 100 mg 3 times a day and paraaminosalicylic acid 12 Gm daily during the year of streptomycin therapy.

**CYCLOSERINE (SEROMYCIN)**—This potentially markedly neurotoxic drug is useful in streptomycin resistant cases of tuberculosis and is produced by a strain of *Streptomyces orchidaceus*.

Because of its serious neurotoxic properties cycloserine must always be accom-

tetracyclines), and now the era of combination therapy. The present approach is based not only on the possibility of synergism, but even more important, it represents an attempt to forestall the formation of resistant bacterial strains: it is by no means 'shotgun' treatment.

The development of sensitivity tests *in vitro* have proved to be a useful adjunct for specific anti-infective medication. However, it must be realized that although sensitivity tests are valuable, they are not infallible. The therapeutic action and bacterial activity *in vitro* does not always reflect the *in vivo* potentialities of the therapy, and clinical judgment still has first place in the treatment of urosepsis.

#### Chemotherapeutic Agents —

**SULFONAMIDES** —The greatest danger with sulfonamides is precipitation of acetylated sulfonamide in the renal tubule with renal failure. This hazard may be minimized by using sulfonamides with little tendency to acetylation and fluid intake which will induce a urine output of at least 2 liters in 24 hours. Alkalinization of the urine greatly increases sulfonamide solubility and enhances its therapeutic effect as well.

The sulfonamides are effective principally against gram-negative organisms which are prevalent in urinary tract infections: *re. Escherichia coli*, *Aerobacter aerogenes* and to a lesser extent *Proteus vulgaris* and *Pseudomonas aeruginosa*.

The most common toxic effects are nausea, vomiting, urticaria, rash, fever and hematuria. Leukopenia or agranulocytosis occur rarely but should be considered during prolonged therapy or even intermittent usage.

**Sulfisoxazole** (Gantrisin) (sulfisoxazole) does not have a pyrimidine ring as do most sulfonamides in common use and is so soluble at normal urine pH that alkali and large amounts of fluid are not required. The usual dosage regimen is 2 Gm followed by 1 Gm every 4 hours. Recently, this drug has been made available as its N<sup>1</sup> acetyl derivative (Gantrisin Acetyl) which is insoluble and tasteless and useful therefore as a pediatric preparation.

**Sulfisomidine** (Elkosin) (sulfisomidine) has a high solubility and low risk factor. The usual dosage is 1 Gm followed by 0.5 Gm every 4 to 6 hours.

**Sulfamethoxypyridazine** (Sulfamethoxypyridazine) (Kynex, Midicel) is a sulfonamide which is excreted extremely slowly in the urine, permitting low dosage at widely spaced intervals. Its slow elimination results in low concentration in urine and prevents crystalluria, but it is nonetheless effective in urinary tract infections. Dosage is 2 Gm initially and 0.5 Gm daily thereafter.

**Sulfadimethoxine** (Madinon) (sulfadimethoxine) is a low dosage sulfonamide possessing high solubility and excreted as a highly soluble glucuronide. Dosage is 1 Gm initially and 0.5 Gm daily in adults.

**Sulfaethylthiadiazole** (Sul Spansion) (sulfaethylthiadiazole) is a single sulfonamide suspended in a liquid to provide a sustained release of the drug. This drug not only has the lowest degree of acetylation of the common sulfonamides but the acetyl derivative is more soluble than the nonacetylated form. Dosage is 2 tablespoons initially, followed by 1 tablespoonful every 12 hours (each tablespoonful contains 2 Gm of the drug).

**NITROPURANTOIN (FURADANTIN)** —This drug possesses a wide range of antibacterial activity which includes both the gram-negative and gram-positive organ-

**CHLORAMPHENICOL (CHLOROMYCETIN)**—This is a chemically pure, crystal line broad spectrum antibiotic elaborated by *Streptomyces venezuelae*. Cross resistance to the tetracyclines does not usually extend to chloramphenicol. Dosage is 1 to 2 Gm, divided into 4 doses per day.

**NOVOBIOGIN (ALBAMYCIN, CATHIOMYCIN)**—This is a broad spectrum antibiotic that is useful in urinary tract infections resistant to other antibiotics. It is recommended in *Proteus* infections. Side reactions are infrequent but do occur in the form of urticaria, maculopapular dermatitis, fever, and leukopenia. These reactions subside rapidly upon discontinuation of the antibiotic.

Dosage is 1 Gm followed by 250 mg every 6 hours or 500 mg every 12 hours until systemic symptoms are absent for 48 hours.

**NYSTATIN (MYCOSTATIN)**—This antibiotic, derived from cultures of *Streptomyces noursei*, is the only one available which suppresses the growth of yeasts fungi, and *Candida albicans* (monilia). It is well tolerated and virtually free from side effects.

Dosage is 500,000 to 1,000,000 units 3 times a day and twice as much for systemic moniliasis or severe yeast infections of the urinary tract.

**POLYMYXIN, NEOMYCIN, AND BACITRACIN**—The therapeutic spectra of these antibiotics follow. Polymyxin, all gram negative bacilli but *Proteus vulgaris*; neomycin, in small doses, gram negative organisms and only larger doses gram positive organisms; bacitracin, gram positive cocci. All present the danger of nephrotoxic effects: albuminuria, casts, and reduced specific gravity of the urine. These findings alone do not, however, constitute an indication for drug interruption, since changes tend to reverse after cessation of therapy. On the other hand, oliguria (daily output of less than 500 ml with normal fluid consumption) or progressive azotemia demands immediate discontinuation, otherwise permanent or even fatal lower nephron damage may follow. Azotemia without oliguria can occur, and this too demands cessation of the medication. These antibiotics should not be used in the face of pre-existing intrinsic renal disease.

Dosage regimens for these drugs follow: Polymyxin 2 to 5 mg per kilogram per 24 hours; neomycin 10 mg per kilogram per 24 hours; bacitracin 1,000 units per kilogram per 24 hours.

**A Design for the Use of Drugs in Urosepsis**—It must be realized that in spite of modern chemotherapy and antibiotics, therapeutic failures may occur and in such instances the patient must have the advantage of a complete urologic and bacteriologic survey. Furthermore, the medication must be continued well beyond the period of symptomatology to prevent recurrence. Evidence of cure of a urinary tract infection demands that a microscopically or culturally normal urine be obtained on three consecutive weekly examinations after medication has been discontinued. The ever rising incidence of serious or even fatal pyelonephritis is attributable to the inadequately treated cystitis of years gone by.

If the urine containing pus is acid and gram negative bacilli are observed, one can assume the presence of a simple *Escherichia coli* urinary tract infection. The sulfonamides and Mandelamine are the drugs of choice since they do not induce resistance to the infecting organism. In the event of a sulfonamide allergy, Mandelamine or one of the tetracyclines may be used.

panied by pyridoxine hydrochloride which prevents the neurotoxic manifestations of severe vertigo, mental disturbance, and convulsions

Dosages of 2 Gm daily with 300 mg of pyridoxine hydrochloride are necessary, particularly in seriously ill patients. The effective blood level of cycloserine must be maintained at 25 to 30 mcg per milliliter

**ERYTHROMYCIN PROPIONYL (ILOSONE)**—This propionyl ester of erythromycin is effective against most gram positive organism and *Neisseria* and is specifically indicated in staphylococcal infections

The bacterial balance of the intestine is undisturbed after oral administration and therefore staphylococcus enteritis, moniliasis, and avitaminosis do not occur. Propionyl erythromycin permits much higher effective blood levels with similar dosages than with the erythromycin base

Dosage is 250 mg every 6 hours and in severe infections may be increased to 500 mg every 6 hours

**VANCOMYCIN (VANCOCIN)**—This intravenous bactericidal antibiotic is effective against severe staphylococcal and streptococcal infections that are resistant to other antibiotics. It does not exhibit any cross reaction with any other known antibiotics or chemotherapeutic agent

This antibiotic should be reserved for desperately ill patients. In excessive serum levels it has induced deafness, and in borderline renal disease the presence of casts, albuminuria, and azotemia has been reported

The dosage is 500 mg diluted in 100 to 200 ml of 5 per cent glucose in water or saline and given intravenously over a 30 minute period every 6 hours. During the first 10 days 2 Gm is given daily and thereafter 1 Gm daily. In children the maximum dosage is 20 mg per pound of body weight

**KANAMYCIN SULFATE (KANTREX)**—This bactericidal antibiotic is derived from *Streptomyces kanamyceticus*. It is effective against *Staphylococcus aureus* and *albus*, *Escherichia coli*, *Aerobacter aerogenes*, *Bacillus proteus* and *Neisseria*

The possible toxic manifestations are (1) renal irritation, seldom seen in children but in adults particularly those with impaired renal function, azotemia may occur with the production of casts, red cells, and albuminuria (these signs of toxicity usually subside upon discontinuation of the drug), (2) eighth nerve dysfunction, in individuals past 50 years of age, manifested by auditory impairment, and (3) skin eruptions occurring infrequently

The dosage is 1 to 2 Gm in 24 hours given intramuscularly in 2 to 4 equally divided doses. In children the intramuscular dose is 15 to 30 mg per kilogram in 2 to 4 equally divided doses per 24 hours

**TETRACYCLINES**—Recently, tetracycline itself has been added to the original tetracyclines, Aureomycin and Terramycin. We now also have tetracycline with sodium metaphosphate and tetracycline phosphate complex. The advantages claimed for newer members of the broad spectrum group are more rapid and more complete absorption, absorption higher in the intestinal tract, greatly increased blood levels, and increased urine concentration. Cross tolerance is likely to prevail in the case of the tetracyclines, since all exert their antibacterial action through the same mechanism

**CHLORAMPHENICOL (CHLOROMYCETIN)**—This is a chemically pure, crystal line broad spectrum antibiotic elaborated by *Streptomyces venezuelae*. Cross resistance to the tetracyclines does not usually extend to chloramphenicol. Dosage is 1 to 2 Gm. divided into 4 doses per day.

**NOVOBIOGIN (ALBAMYCIN, CATHOMYCIN)**—This is a broad spectrum antibiotic that is useful in urinary tract infections resistant to other antibiotics. It is recommended in *Proteus* infections. Side reactions are infrequent but do occur in the form of urticaria, maculopapular dermatitis, fever, and leukopenia. These reactions subside rapidly upon discontinuation of the antibiotic.

Dosage is 1 Gm. followed by 250 mg. every 6 hours or 500 mg. every 12 hours until systemic symptoms are absent for 48 hours.

**NYSTATIN (MYCOSTATIN)**—This antibiotic, derived from cultures of *Streptomyces noursei*, is the only one available which suppresses the growth of yeasts fungi, and *Candida albicans* (monilia). It is well tolerated and virtually free from side effects.

Dosage is 500,000 to 1,000,000 units 3 times a day and twice as much for systemic moniliasis or severe yeast infections of the urinary tract.

**POLYMYXIN, NEOMYCIN, AND BACITRACIN**—The therapeutic spectra of these antibiotics follow. Polymyxin, all gram negative bacilli but *Proteus vulgaris*, neomycin in small doses, gram negative organisms, and only larger doses, gram positive organisms. bacitracin, gram positive cocci. All present the danger of nephrotoxic effects: albuminuria, casts and reduced specific gravity of the urine. These findings alone do not, however, constitute an indication for drug interruption, since changes tend to reverse after cessation of therapy. On the other hand, oliguria (daily output of less than 500 ml. with normal fluid consumption) or progressive azotemia demands immediate discontinuation, otherwise permanent or even fatal lower nephron damage may follow. Azotemia without oliguria can occur, and this too demands cessation of the medication. These antibiotics should not be used in the face of pre-existing intrinsic renal disease.

Dosage regimens for these drugs follow: Polymyxin, 2 to 5 mg. per kilogram per 24 hours; neomycin, 10 mg. per kilogram per 24 hours; bacitracin, 1,000 units per kilogram per 24 hours.

**A Design for the Use of Drugs in Urosepsis**—It must be realized that in spite of modern chemotherapy and antibiotics therapeutic failures may occur and in such instances the patient must have the advantage of a complete urologic and bacteriologic survey. Furthermore, the medication must be continued well beyond the period of symptomatology to prevent recurrence. Evidence of cure of a urinary tract infection demands that a microscopically or culturally normal urine be obtained on three consecutive weekly examinations after medication has been discontinued. The ever rising incidence of serious or even fatal pyelonephritis is attributable to the inadequately treated cystitis of years gone by.

If the urine containing pus is acid and gram negative bacilli are observed one can assume the presence of a simple *Escherichia coli* urinary tract infection. The sulfonamides and Mandelamine are the drugs of choice since they do not induce resistance to the infecting organism. In the event of a sulfonamide allergy Mandelamine or one of the tetracyclines may be used.

Should the infection not respond, it may be that it is caused by *Aerobacter aerogenes*, provided the urinary reaction is unchanged. The tetracyclines, if not used previously or Furadantin may be used. Usually the tetracyclines demonstrate cross resistance. If so, an entirely different drug group should be used when changing medication. In the event of continued failure and if no urologic complication has been demonstrated chloramphenicol (Chloromycetin), 100 mg, plus propionyl erythromycin (Ilosone), 125 mg, given 4 times a day, are most effective.

If pyuria is found in an alkaline urine, the probability of *Proteus vulgaris* infection is most likely. In this instance novobiocin (Albamycin, Cathomycin, or Albapenicillin) is usually effective. However this organism usually suggests the presence of a urinary tract complication (i.e., calculus, residual urine, foreign body, etc.). Unless an immediate response is evident, a complete urologic survey is mandatory.

Other preparations effective in *Proteus* infections include chloramphenicol plus sulfonamide Furadantin, and streptomycin.

Another increasingly common bacterial infection is that caused by *Pseudomonas aeruginosa*. Although this organism is resistant to therapy, it usually responds to one or more of the following: streptomycin in combination with Terramycin or Chloromycetin or a sulfonamide, Furadantin in combination with Chloromycetin, or polymyxin. Furadantin with Chloromycetin is thought to be more effective than when used alone. Polymyxin is a toxic drug and should be reserved for serious infections resistant to other therapies.

If cocci including enterococci are found in the urine after it has been thoroughly acidified penicillin is useful or Ilosone with or without sulfonamides may be used regardless of previous acidification of the urine.

**SUMMARY**—As a group, chemotherapeutic agents are more useful than antibiotics in treating urosepsis, since bacterial resistance is less likely to develop and their antibacterial spectrum is broader. Combinations of antibiotics, and antibiotics together with chemotherapeutic agents, offer additional protection against therapeutic failure due to bacterial mutation and unrecognized secondary invaders.

## ANALGESICS FOR GENITOURINARY PAIN

**Introduction**—The narcotics are virtually the only analgesics useful in urologic disorders associated with pain due to smooth muscle spasm, i.e., urolithiasis, infection, tumor penetration, etc.

### The Several Drugs—

**MORPHINE**—Morphine is the most useful drug in the treatment of urinary tract colic. Dosage must be adequate, in a healthy robust male with ureteral colic this is 30 mg followed by 15 mg every 3 or 4 hours.

There is the danger of respiratory failure. However, since pain causes respiratory stimulation as long as it persists, pain is an effective antidote.

**DEMEROL**—Demerol (meperidine) is a less effective analgesic than morphine, but it has less tendency to induce smooth muscle spasm. Dosage is of the order of 100 or 150 mg intramuscularly, repeated every 3 hours in 100 mg doses. In the doses above, the danger of respiratory depression is less than with morphine.

## RATIONAL BASIS FOR NEW CHEMOTHERAPEUTIC AND ANTIBIOTIC DRUGS

The production of new chemotherapeutic and antibiotic agents will continue and valuable products will evolve. However, as in the past, not all additions will be useful or even desirable. The factors to be considered in evaluating a new product are (1) effective bacterial spectrum, (2) effective antibacterial blood level, and (3) toxicity.

It is important to realize that the actual blood level of any drug or antibiotic is not necessarily indicative of its effectiveness, since charts showing blood levels are often most useful in sales promotion. Factors of toxicity must be carefully evaluated and investigated, since the manufacturer is careful to point out the hazards but not infrequently these factors have not attained their full evaluation when the product is released.

Drug or antibiotic combinations have certain advantages, but the combined product may be designed to catch the physician's eye rather than his judgment. Generally the physician can prescribe his own combination which will be much more effective in the particular situation considered.

In short as the new antibiotic and chemical agents are released, it is the physician's responsibility to consider each on its merits and proved capabilities rather than to adopt a spectacular graph which may reflect only an enthusiastic conclusion based upon studies under the most optimal conditions.

## SELECTED REFERENCES

### Cholinergic Drugs

- Henderson, V. E., and Roepke, M. H. The Role of Acetylcholine in Bladder Contractile Mechanisms and in Parasympathetic Ganglia, *J. Pharmacol. & Exper. Therap.* 51: 97, 1934.
- Scott, M. Retention of Urine of Neurogenic Origin. Relief by Subcutaneous Injection of Pilocarpine Hydrochloride, *J. Urol.* 47: 582, 1947.

### Alkalinizers

- Finland, M., Murray, R., Harris, H. W., Kullam, L., and Meads, M. Development of Streptomycin Resistance During Treatment, *I. A. M. A.* 132: 16, 1946.
- Lich, R., Jr. Kidneys: Fluids and Electrolytes. *J. Kentucky M. A.* 53: 219, 1955.

### Acidifiers

- Keefer, C. S. Evaluation of Antibiotic Therapy, *Postgrad. Med.* 9: 101, 1951.
- Lich, R., Jr. Some Basic Therapeutic Concepts in Uroepsis, *M. Times* 85: 22, 1957.
- Lich, R., Jr. Some Practical Considerations Concerning Fluid and Electrolyte Therapy, *South. M. J.* 43: 542, 1950.
- Prien, E. L. Pathogenesis and Medical Management of Urolithiasis. *Bull. New England Med. Center* 13: 102, 1951.
- Yeaw, R. C. The Effect of pH on the Growth of Bacteria in the Urine. *J. Urol.* 44: 689, 1941.

Should the infection not respond, it may be that it is caused by *Aerobacter aerogenes*, provided the urinary reaction is unchanged. The tetracyclines, if not used previously, or Furadantin may be used. Usually the tetracyclines demonstrate cross resistance. If so, an entirely different drug group should be used when changing medication. In the event of continued failure and if no urologic complication has been demonstrated, chloramphenicol (Chloromycetin), 100 mg, plus propionyl erythromycin (Ilosone), 125 mg, given 4 times a day, are most effective.

If pyuria is found in an alkaline urine, the probability of *Proteus vulgaris* infection is most likely. In this instance novobiocin (Albamycin, Cathomycin, or Albapenicillin) is usually effective. However, this organism usually suggests the presence of a urinary tract complication (i.e., calculus, residual urine, foreign body, etc.). Unless an immediate response is evident, a complete urologic survey is mandatory.

Other preparations effective in *Proteus* infections include chloramphenicol plus sulfonamide, Furadantin and streptomycin.

Another increasingly common bacterial infection is that caused by *Pseudomonas aeruginosa*. Although this organism is resistant to therapy, it usually responds to one or more of the following: streptomycin in combination with Terramycin or Chloromycetin or a sulfonamide; Furadantin in combination with Chloromycetin, or polymyxin. Furadantin with Chloromycetin is thought to be more effective than when used alone. Polymyxin is a toxic drug and should be reserved for serious infections resistant to other therapies.

If cocci including enterococci are found in the urine after it has been thoroughly acidified, penicillin is useful or Ilosone with or without sulfonamides may be used regardless of previous acidification of the urine.

**SUMMARY**—As a group, chemotherapeutic agents are more useful than antibiotics in treating urosepsis, since bacterial resistance is less likely to develop and their antibacterial spectrum is broader. Combinations of antibiotics and antibiotics together with chemotherapeutic agents, offer additional protection against therapeutic failure due to bacterial mutation and unrecognized secondary invaders.

## ANALGESICS FOR GENITOURINARY PAIN

**Introduction**—The narcotics are virtually the only analgesics useful in urologic disorders associated with pain due to smooth muscle spasm, i.e., urolithiasis, infection, tumor penetration, etc.

### The Several Drugs—

**MORPHINE**—Morphine is the most useful drug in the treatment of urinary tract colic. Dosage must be adequate in a healthy robust male with ureteral colic; this is 30 mg followed by 15 mg every 3 or 4 hours.

There is the danger of respiratory failure. However, since pain causes respiratory stimulation as long as it persists, pain is an effective antidote.

**DEMEROL**—Demerol (meperidine) is a less effective analgesic than morphine, but it has less tendency to induce smooth muscle spasm. Dosage is of the order of 100 or 150 mg intramuscularly, repeated every 3 hours in 100 mg doses. In the doses above, the danger of respiratory depression is less than with morphine.



Phemerol and mercurials have been recommended for use as bactericidal terostatic agents. However, sterility will not be maintained unless the sealed

Boric acid retards the growth of fungi but does not kill pathogenic. Many of the wetting agents such as Zephiran do not inhibit the growth of organisms; some of the agents are incompatible with many of the alkaloids. The combination of polymyxin B and Zephiran possesses a broad spectrum rapidly bactericidal.

**STABILITY OF SOLUTIONS**—The stability has been thought to be related to hydrogen ion capacity. Some activity may have to be sacrificed to maintain stability.

**CHOICE OF VEHICLE**—In order to facilitate the passage of medication through the cornea, hydrophilic compounds should be administered in aqueous vehicles and lipid soluble compounds in aqueous solution.

**ointment Vehicles**—The most popular ointment vehicle is a petrolatum base containing 25 per cent hydrous wool fat or lanolin. Ointments are used because they remain in contact with tissue longer than do aqueous preparations.

**METHODS OF APPLICATION OF OINTMENTS AND SOLUTIONS**—The tip of the squeezed for application should not touch the diseased surface, especially the cul de sac. Ointment may be applied to the lid margin with a sterile cotton applicator. Most ointments applied to the lids will not induce damage to the conjunctiva.

Drops for the conjunctiva are usually instilled in the lower cul de sac. The drug may also be applied by having the patient look down while the upper lid is everted. The dropper or the tip of a plastic bottle should never touch the eye. The dropper or bottle should not be used for several patients without sterilization. Since the annoyance may be considerable, gelatin discs or wafers (lamellae) for instillation into the cul de sac are no longer in widespread use.

Drugs may be applied directly to the conjunctiva, lids or corneal surface by dipping a bit of cotton wrapped tightly on a metal or wooden applicator that has been dipped into the agent. The excess of the drug is allowed to flow off prior to ocular application. While it is a safe procedure, application directly to the cornea is rarely practiced.

**METHODS TO ENHANCE INTRAOCULAR PENETRATION OF LOCALLY APPLIED DRUGS**—*Subconjunctival injections* are usually made in eyes previously anesthetized locally. The injection may however induce subconjunctival hemorrhage. *Cotton packs* are performed by placing some wisps of cotton in the cul de sac of the anesthetized eye and soaking these cotton fibers with the selected solution. The cotton pack must not rub on the lower or upper poles of the cornea, since corneal abrasion might lead to corneal ulcer. *Corneal baths* by means of various cups are not widely employed.

*Heat* may be applied to the eye in dry form by means of an infrared lamp. Moist heat may be applied with hot compresses generally as hot as can be endured on the back of the hand and placed on the closed lids. They should be removed and changed every second hour for at least twenty minutes every second hour.

## THE CHOICE OF DRUGS FOR OPHTHALMIC USE

*Irving H. Leopold, M.D.*

### ADMINISTRATION METHODS FOR OCULAR PHARMACOLOGIC AGENTS

All the routes of administration are employed in ophthalmology: oral, topical, intradermal, subcutaneous, intramuscular, intravenous, and inhalation. Most common, however, is local administration in the form of drops, ointment, cotton packs, corneal baths, and subconjunctival injections. Iontophoresis or electrophoresis is sometimes used to increase the penetration of some drugs. Drugs may also be injected directly into the anterior or vitreous chamber, or retrobulbarly.

**Local Ophthalmic Preparations**—The ideal ophthalmic solution should be free of microorganisms, easily sterilized, nonirritating, physiologically active, stable, of low toxicity and surface tension, of high wetting power, compatible with other agents, and inexpensive.

The hydrogen ion concentration of a solution necessary to maintain its best physiologic activity and stability, to reduce irritability, and to facilitate corneal penetration may be controlled and maintained by buffering. Tears have a high buffering capacity. A very satisfactory buffer is a mixture of anhydrous dry sodium phosphate.

**DETERGENTS AS OPHTHALMIC VEHICLES**—The penetration of most agents through the cornea can be facilitated by lowering of surface tension or by wetting agents. While it has been pointed out that detergents such as aerosol and Duponol have some toxic features, Phemerol and benzalkonium (Zephiran) have excellent wetting power, low toxicity, and also have bacteriostatic and bactericidal properties. Despite some drawbacks benzalkonium has received widest use. It has been suggested that all ophthalmic solutions should be isotonic with tears. Most solutions are hypertonic, but, owing to the protection of the tears and conjunctival fluid, do not produce irritation or damage unless repeatedly instilled or used in large amounts.

Solutions can be sterilized by mechanical filtration, heat, and the use of chemicals. Boric acid, chlorbutanol, derivatives of benzoic acid, benzalkonium chloride,

### The Several Miotics —

**PHYSOSTIGMINE (ESPRINF)** — This drug should be dispensed in a small well enclosed container which has been protected from light and stored in a cool place. Instillations of ointment will blur visual acuity and therefore are usually reserved for use at retiring. Solutions of physostigmine salicylate are irritating to most eyes and decomposition further increases the irritation. Boric acid added to the solution will reduce the tendency to decomposition. Preparations in an oily base are less irritating. Solutions of physostigmine are used as a miotic and are instilled frequently enough to control intraocular pressure. A strong eserine solution may have to be employed to counteract the effect of cycloplegics such as homatropine or atropine.

**PILOCARPINE** — Pilocarpine solutions are stable in air and do not deteriorate on standing. Whereas the miosis of eserine might persist for 2 days, that of pilocarpine usually persists for less than 1 day, but pilocarpine is generally less irritating and is the best tolerated of all the miotics to date.

**NEOSTIGMINE (PROSTIGMIN)** — Neostigmine is an anticholinesterase agent which unites with this enzyme in reversible fashion. The bromide is soluble in water and alcohol and stable in solution. It is often used alternately with Mecholyl chloride.

**METHACHOLINE (MECHOLYL)** — Methacholine solutions lose potency on standing. A solution of 10 or 20 per cent concentration should be renewed every 2 or 3 weeks; it should be refrigerated.

**CARBACHOL (CARCHOLIN, DORYL)** — Carbachol is more stable than Mecholyl. Because it is poorly absorbed through the cornea, it must be used with a wetting agent or in an anhydrous vehicle such as petrolatum. It can be used to replace pilocarpine when sensitivity makes that desirable.

**BETHANECHOL (URFCHOLINE)** — Bethanechol is probably as effective as carbachol, both should be used with caution in asthmatic patients. Urecholine may be used in 1 or 2 per cent concentration with a wetting agent.

**ISOFLUROPHATE (DFP, FLOROPRYL)** — This drug is a powerful miotic with more prolonged effect than either physostigmine or Prostigmin. It is used in 0.01 to 0.1 per cent concentration. It must be made up in an anhydrous vehicle. In strong solution it may produce a precipitous rise in intraocular pressure, particularly in eyes with narrow angles.

**MINTACOL (BAYER 600)** — Mintacol lowers intraocular pressure in concentrations from 1:5,000 to 1:10,000. It is water soluble but less potent than DFP.

**PHOSPHOLINE IODIDE (ECHOTHIOPHATE, 217-MI)** — This drug in concentrations as dilute as 0.2 per cent aqueous solution is stable at room temperature for at least 1 month. It possesses all the disadvantages of other strong miotics but is extremely effective in the control of chronic wide angle glaucoma, aphakic glaucoma and congenital glaucoma.

**ADRENERGIC BLOCKING AGENTS** — These agents induce mild miosis by relaxation of the dilator of the pupil.

Dibenamine is administered intravenously, the pupil becomes small, the conjunctival blood vessels dilate, and in normal human eyes there may be a slight fall in intraocular pressure. Administered by slow drip in saline, it is effective in acute

## DRUGS FOR OPHTHALMIC USE

Most cold can also act as an analgesic since it induces vasoconstriction. sage may sometimes be employed to facilitate filtration after a glaucoma

## THE SEVERAL DRUGS

### Miotics

**Clinical Applications of Miotics**—Miotics are primarily used in the treatment of glaucoma but have recently been applied in accommodative esotropia or convergent strabismus. They prevent the iris from moving into the surgical incision intraocular surgery. The anticholinesterase variety of miotics is used for the treatment of pediculosis of the lashes.

**Disadvantages of Miotics**—Miotics may produce ciliary spasm, brow ache, headache, false myopia and undesirable rises in intraocular pressure. Most miotics have action of only short duration. Patients may become hypersensitive to the agent and many eyes develop resistance. Miotics may be absorbed systemically after instillation in the eye and may produce undesirable parasympathomimetic stimulation. Asthma due to bronchial constriction may result.

**Mode of Action of Miotics**—Decreased resistance to outflow due to miotics can occur either by an increase in the diameter of each channel. Through their dilating or by a slight increase in the diameter of each channel. Through their dilating effect on the small intraocular vessels, miotics may reduce the intraocular osmotic pressure of the aqueous humor, i.e. vasodilation tends to lower the intraocular osmotic pressure with the consequent diminished tendency to draw fluid from the blood stream.

Table 49 Drugs Acting on Parasympathetic System (Parasympathomimetics)

Drugs acting on effector cells so as to mimic action of acetylcholine or the so-called neurotransmitters	Inhibitors of the enzyme cholinesterase which normally hydrolyzes the neurohumoral transmitting agent acetylcholine (the action of the locally produced acetylcholine is therefore markedly prolonged)
Pilocarpine	Phyostigmine ( eserine )
Carbachol (Doryl)	Neostigmine (Prostigmin)
Furthrethonium (Farmethide)	Isoflurophate (Floropryl)
Methacholine (Mechoyl Cl)	Mintacol (Bayer 600)
	Phospholine iodide (217 MI)
	Echothiophate
	Demecarium Br (BC 48) (Humorsol)

Despite different pharmacologic activities and sites of action the influence of miotics on intraocular pressure appears to be similar. Some miotics work much better when a wetting agent is added to the vehicle, e.g. carbachol (Doryl). Isoflurophate (Floropryl) is stable only in an anhydrous solvent. Echothiophate (phospholine iodide) is practically as potent but stable in water solution for several weeks at room temperature. Mintacol (Bayer 600) is also more stable in solution than is isoflurophate. It is advisable for the physician to have several miotics since each can serve different purposes and switching may sometimes be necessary when hypersensitivity reactions occur.

employed in aphakic glaucoma if the weaker or the less congestive ones fail; uveitis the stronger miotics are usually avoided.

**STRABISMUS**—In accommodative strabismus, central innervation of the ciliary muscle is reduced by stimulating the ciliary muscle by local administration, and the associated convergence mechanism is not called into play in a strong fashion. The long acting miotics such as dilute preparations of DFH and echothiophate are utilized.

### Mydriatics and Cycloplegics

**Purpose of Mydriasis**—Mydriasis allows adequate examination of the fundus. Usually the weaker mydriatic agents are employed. These are also used to dilate the pupil, to reduce the incidence of posterior synechia formation in uveitis, as a provocative test in eyes with narrow angles to determine whether dilatation of the pupil will lead to closure of the angle and a rise in intraocular pressure.

The stronger mydriatics, which also act on the ciliary body and put the ciliary muscle at rest, are known as *cycloplegics*. They are employed so that refractive errors can be measured accurately and to bring about rest of the pupil in the dilated position and of the ciliary body in iritis, cyclitis, and diffuse uveitis. The stronger cycloplegics are not used for examination of the fundus as their action lasts too long.

Table 50 Classification of Autonomic Drugs Used in Ophthalmology—Cont

Drugs acting as sympathomimetic agents	Drugs producing varying degrees of parasympathetic paralysis
Amphetamine (Benzedrine)	Atropine
Cocaine	Homatropine
Epinephrine	Eucatropine (Euphthalmine)
Ephedrine	Scopolamine
Hydroxyamphetamine (Paredrine)	Hyoscyamine
Naphazoline (Privine)	Dibutylamine (Dibutyl)
Phenylephrine (Neo-Synephrine)	Methantheline (Banthine)
Procaine	Oxyphenonium (Antrenyl)
	Atropine methylnitrate (Eumydrin)
	Cyclopentolate (Cyclogyl)
	Lachesine (E 3)
	Ganglionic blocking agents
	Tetraethylammonium chloride (TEA, Etamon)
	Pentamethonium
	Hexamethonium
	Pentolinium (Ansolysin)

**The Several Mydriatics**—Atropine, in 1 to 3 per cent concentrations, produces the maximum of pupillary dilatation in approximately 2 hours. It is a very potent cycloplegic and mydriatic of long lasting action. It should be avoided in patients with narrow angles. The action of hyoscyamine is the same as that of atropine. Scopolamine is most commonly employed in a strength of 0.25 per cent. Homatropine has its maximum effect on the pupil and ciliary muscle within 1 to 2 hours; its action persists for approximately 24 hours. Lachesine (E 3) is well tolerated and produces satisfactory mydriasis in 30 minutes. Its cycloplegic effect is variable.

glaucoma Some cases of narrow angle glaucoma respond by a fall in intraocular pressure The drug should not be used in patients with cardiovascular disorders Tolazoline (Priscoline) causes a slight rise in intraocular pressure when injected subconjunctivally With parenteral administration no significant influence on intraocular pressure has been observed It has more effect on glaucomatous than on normal eyes it has been suggested for a provocative test for early glaucoma when administered subconjunctivally

#### Clinical Applications —

**ACUTE GLAUCOMA**—Acute glaucoma is both a medical and a surgical problem Medical treatment aims at opening the angle of the anterior chamber At attempts to lower intraocular pressure by medical means should be made for at least 12 hours before performing emergency surgery During the attack the comfort of the patient may require the administration of morphine hypertonic solutions and also dibenamine applied intravenously as well as carbonic anhydrase inhibitors The effect of oral administration will be less rapid During the acute rise in intraocular pressure not associated with congestion the weaker miotics should be employed When the eye is congested or the pressure is high combinations such as 2 per cent pilocarpine and 0.25 to 0.5 per cent physostigmine can be used Anticholinesterase agents other than eserine and physostigmine should be avoided in acute or angle closure glaucoma It should be remembered that the use of large amounts and concentrated solutions of miotics may be followed by such systemic symptoms as nausea diarrhea muscular twitching and urinary urgency During the acute phases miotics must also be instilled into the unaffected eye as it may be subject to an attack of angle closure glaucoma

#### CHRONIC SIMPLE GLAUCOMA —

**Criteria of Control and Selection of Miotic** The treatment is largely medical as long as the intraocular pressure is controlled and there is no evidence of visual deterioration as indicated by changes in the visual fields If the pressure tends to rise on the high side of normal and there is no change in the visual fields the patient is usually carried on medical therapy

**Administration** The frequency and concentration required for instillation depends on the severity of the glaucoma Usually the miotic is instilled on awakening in the morning at noon evening and on retiring If the pressure is controlled demonstrated by checking the visual fields the patient may continue on this regimen indefinitely It is important that the pressure be checked at different times during the day as well as at regular intervals throughout the year The mainstay of therapy for chronic glaucoma is pilocarpine The newer miotics are to be employed as adjuvants to replace pilocarpine if necessary or in combination with it DFP and phospholine iodide (echothiophate) are the most potent available and have prolonged action but should not be used in eyes with narrow angles lest they cause a rise in intraocular pressure

**SELECTION OF MIOTIC IN SECONDARY GLAUCOMAS**—Miotics are particularly useful in aphakic glaucoma and in the late stages of glaucoma secondary to quiet inflammation and may be helpful in the glaucoma associated with hemorrhage in the anterior chamber or that due to exfoliation of the lens capsule or pigmentary deposition in the angle The stronger miotics such as DFP and phospholine may be

4 times a day is warranted. *Neo Synephrine* can also be applied as a pack in the cul de sac. Atropine can be instilled into the pack at the same time. These agents can be administered subconjunctivally to break synechia or to obtain wider dilatation of the pupil. Sympathomimetic agents administered in this fashion may bring about cardiovascular effects, apprehension, tension and even hypertension.

### Analgesics and Anesthetics

Analgesics and anesthetics are used *pre* and *postoperatively*. Morphine, morphine derivatives and substitutes are frequently used, but codeine is commonly used for the relief of postoperative pain. Acetylsalicylic acid is frequently employed for relief of mild pain, often in combination with codeine.

**Local Anesthetics**—Cocaine was employed in local ocular anesthesia for many years. At present tetracaine (*Pontocaine*) is the most widely used local anesthetic. The 2 per cent solution may be employed for the removal of corneal sutures or for the removal of a foreign body from the cornea. Very little conjunctival irritation follows instillation into the cul de sac and it does not appear to influence the intraocular pressure or accommodation.

*Benoxinate (Dorsacaine)*, in a 0.4 per cent solution produces rapid anesthesia with minimal irritation by local instillation. It is short acting and is satisfactory for the removal of foreign bodies and if repeatedly instilled for corneal surgery.

Butacaine (*Butyn*) has a rapid onset of action and long duration. It does not affect the pupil when locally applied into the cul de sac and is less damaging to the cornea than is cocaine. The high degree of hypersensitivity it produces limits its usefulness. Dibucaine (*Nupercaine*) is a potent but very toxic local anesthetic. Piperocaine (*Metycaine*) is used as a 2 per cent solution or 4 per cent ophthalmic ointment. Phenacaine (*holocaine*), as a 1 per cent solution is slightly irritating, smarts when instilled but produces very little hypersensitivity. Proparacaine (*Ophthaine*) is rapid in action, does not damage the corneal epithelium and seems to be less irritating than most of the other agents.

**RETROBULBAR ANESTHESIA**—The drug used most for retrobulbar block in ophthalmology is procaine in 2 to 4 per cent solution. Lidocaine (*Xylocaine*) may be a trifle more potent than procaine but is also more toxic than procaine. The addition of a vasoconstrictor prolongs their activity.

More rapid anesthesia is induced by the additional use of hyaluronidase. Following hyaluronidase and procaine infiltration behind the globe, the intraocular pressure as well as the retro orbital pressure is reduced considerably. This is believed to reduce loss of vitreous in cataract extraction.

For local anesthetic purposes drugs such as tetracaine (*Pontocaine*) and phenacaine (*holocaine*) may be used interchangeably. For infiltrating anesthesia procaine is still the drug of choice although lidocaine may be substituted if necessary.

### Hypotensive Ocular Drugs

**Treatment of Glaucoma**—Treatment really began with the use of eserine and pilocarpine, the mainstays of medical antiglaucoma therapy. In addition to miotics which are applied locally to the globe, there are agents which lower intraocular

**Untoward Effects**—A number of these agents have undesirable features and all of the cycloplegics may produce flushing of the face and may induce fever. Patients develop hypersensitivity to local instillation of these agents. One of the disadvantages of refraction with a cycloplegic is that the patient is inconvenienced during its effect. Cyclogyl has been popular in recent years since its cycloplegic effect wears off rather quickly.

**Miotic agents** can be instilled to overcome the cycloplegic or to neutralize precisely. Instillations of drugs (With strong mydriatics one must employ a strong miotic agent such as physostigmine or scopolamine) and DFP are used to correct the effect of a cycloplegic. (Cycloplegics are used to correct the effect of a mydriatic.)

years since its cycloplegic effect wears off rather quickly. With strong mydriatics one must employ a stronger miotic or mydriatic effect (echothiophate) and DFP are used to counteract strong cycloplegics such as atropine or scopolamine. Instillations have to be made repeatedly, it is difficult to neutralize precisely the effect of one drug with the other.

**CLINICAL VALUE OF SYMPATHOMIMETIC AGENTS.**—Most of the sympathomimetic agents are employed to dilate the pupil or to blanch the conjunctival vessels and some of them will lower intraocular pressure in glaucoma. Neosynephrine is frequently used in the treatment of glaucoma. Neosynephrine should not be used in eyes with narrow angles. Neosynephrine is frequently used in the treatment of glaucoma. Neosynephrine should not be used in eyes with narrow angles. Neosynephrine is frequently used in the treatment of glaucoma.

CLINICAL VALUE OF SYMPATHOMIMETIC AGENTS.—Most of the sympathomimetic agents are employed to dilate the pupil or to blanch the conjunctival vessels, and some of them will lower intraocular pressure in glaucomatous eyes. They should not be used in eyes with narrow angles. Neo Symphehrine in 10 per cent concentration is frequently used in the treatment of wide angle glaucoma and in glaucoma secondary to uveitis to dilate the pupil, which helps to put the eye at rest, prevents synechia and also tends to lower intraocular pressure. These agents can be used in combination with cycloplegics to bring about greater dilatation of the pupil to help break synechia and to prevent the pupil from being closed by inflammatory membranes. Cycloplegics as well as mydriatics may provoke a rise in intraocular pressure in eyes with narrow angles. The physician should check anterior chamber pressure and also if possible determine the state of the angle of the eye before using the weaker mydriatics for examination of the fundus. Otherwise, it is safer to use the weaker mydriatics prior to the instillation of these agents. Particularly of the angle closure variety. Design for the Use of Mydriatic Agents.—Some eyes are ready for refractive changes by instillation of mydriatics. Some eyes are not ready for refractive changes by instillation of mydriatics. Some eyes are not ready for refractive changes by instillation of mydriatics. Some eyes are not ready for refractive changes by instillation of mydriatics.

**Design for the Use of Mydriatic Agents**—When Cyclogyl is used, the patient is ready for refraction within 45 to 50 minutes. Its action can be come by instillation of 1 per cent pilocarpine. The effect of the drug wears out spontaneously within 12 to 18 hours. Following instillation of homatropine, instillation can be done after 1 hour. However, its cycloplegic and mydriatic persists longer than that of 5 per cent Cyclogyl. Otherwise, it is safe or dilatation of a pupil in an eye with uveitis, atropine should be instilled times a day. If necessary, the addition of 10 per cent Neo Symphephrine 3 or



or in temporary lowering of intraocular pressure so that miotics can become more effective

**SUMMARY**—The carbonic anhydrase inhibitors have proved to be of definite value in the therapy of glaucoma. Patients with chronic glaucoma have been maintained over a 3 year period with their use along with that of miotics. On the other hand in angle closure types of glaucoma the prolonged use of Diamox may allow peripheral synechia to develop so that more serious intraocular surgery will be needed when the pressure is no longer controlled.

The carbonic anhydrase inhibitors also have side effects: weakness, central nervous system disturbances, drowsiness, numbness, loss of appetite, diarrhea, tingling in the fingers, toes, and around the lips and nose, renal calculi and colic, skin eruptions, blood dyscrasias, and perhaps even liver damage.

The problem of the control of intraocular pressure may be approached locally and/or systemically. More attention is now paid to combined medication. Obstruction to the aqueous outflow, the basic defect in glaucoma as a rule, can be relieved medically by the use of miotics in chronic simple or wide angle glaucoma and with surgery in uncomplicated angle closure types, i.e. miotics and iridectomy.

### Anti inflammatory Agents

Agents which retard inflammation in the eyes include those which oppose infection as well as those with specific anti inflammatory activity, e.g. steroids and analgesics.

There are a number of ocular inflammations for which the etiology cannot be determined. This is particularly true of uveitis. Here nonspecific measures such as the use of foreign protein, steroids, antihistamines, and alicylates must be employed. For some corneal diseases for which the etiology cannot be established or when the etiology is due to a virus for which there is no specific agent, therapy with cauterants has been tried.

Antibiotics administered systemically do not all penetrate into the eye equally well. Chloramphenicol penetrates better than most of them. Isoniazid also penetrates readily. The sulfonamides differ in their ability to penetrate. There are variations in the penetration of locally applied drugs depending on the water solubility, the vehicle, the state of the corneal epithelium, the tonicity of the solution, and whether or not a wetting agent is included.

**Steroids**—Steroid therapy has definite value in a wide variety of ocular conditions. They control inflammation and exudation produced by allergies, trauma, and bacteria until other forces overcome the inflammation. Administration is local as well as systemic, only ACTH is restricted to systemic administration.

Undesirable side effects occur with all the steroids. Fortunately most eye conditions can be treated locally and do not require prolonged systemic use, although a few of them, such as sympathetic ophthalmia and chronic uveitis, may. Dosage must be adequate and carefully graded. Careful observation of all patients is essential. Virus diseases of the cornea such as herpes simplex keratitis may progress during steroid therapy though the patient is comfortable.

**Other Anti inflammatory Agents**—Acetylsalicylic acid as well as the salts of salicylic acid are used by mouth as antipyretics and analgesics in a variety of

pressure when administered systemically. They include those which lower systemic blood pressure, those which affect the central nervous system, carbonic anhydrase inhibitors such as Diamox, hypertonic solutions, adrenergic blocking agents such as dibenamine, hormones such as pituitrin, enzymes such as hyaluronidase, and curariform agents.

Adrenergic blocking agents and ganglionic blocking agents, such as hexa methonium, are thought to decrease the rate of formation of intraocular fluids. Chlorpromazine may reduce intraocular pressure by reducing the inflow of intraocular fluid. General anesthetics, for example, ether, have no specific effect on intraocular pressure, but thiopental and other central nervous system depressants, frequently employed as preoperative medication, may induce a marked drop in intraocular pressure in eyes with chronic simple glaucoma. Local anesthetics such as 2 per cent procaine hydrochloride and 1 per cent lidocaine hydrochloride cause a decrease in intraocular pressure of at least 5 mm Hg in most instances after retrobulbar injection.

**HORMONES**—An increase in intraocular pressure during menstruation and lowering of intraocular pressure with progesterone in glaucoma have been reported. These effects are of short duration. In patients in whom glaucoma may be secondary to an intraocular inflammation the pressures may be lowered as a result of the quieting of the inflammatory process by ACTH. Pituitrin injected subconjunctivally has been shown to lower intraocular pressure.

**ENZYMES**—The injection of hyaluronidase was found by Barany to cause a decrease of approximately 50 per cent in the resistance to outflow in excised animal eyes. However, the addition of hyaluronidase to the aqueous humor *in vivo* or the injection of hyaluronidase outside the eye has not been observed to lower intraocular pressure.

**CURARIFORM AGENTS**—These agents may lower intraocular pressure by diminishing the tone of the extraocular muscles.

**DIURETICS**—In glaucoma, irrespective of its cause, there is usually an accompanying local decompensation and water logging. It was found that a number of diuretics reduce intraocular pressure. Salyrgan with theophylline produces a very slight drop in intraocular pressure, a reduction in resistance to outflow, and a slight reduction of inflow. Peak effects are seen 24 hours after administration.

**CARBONIC ANHYDRASE INHIBITORS**—Inhibitors such as Diamox and dichlorphenamide (Daranide) produce a drop in intraocular pressure. Patients who were formerly controlled on 250 mg of Diamox 4 times a day were controlled on 100 mg of Daranide (dichlorphenamide) 4 times a day, or 200 mg 3 times a day. Cardrase (ethoxzolamide) and Neptazane (methazolamide) are other effective carbonic anhydrase inhibitors. [No significant difference among the four has been established. Ed.]

**CENTRAL NERVOUS SYSTEM DEPRESSANTS**—Because of the profound influence of emotion on intraocular pressure, there is interest in the tranquilizing agents in glaucoma. Chlorpromazine (Thorazine) and reserpine, among others, have been shown to lower intraocular pressure but there is no great practical value to most of them. Perhaps their chief value lies in pre- and postoperative care of patients.

Table 51 Prophylaxis of Intraocular Infection\*

Agent	Dosage	Time of Administration	
		Preoperative	Postoperative
Chloramphenicol	Initial 3 Gm orally Maintenance 1 Gm every 6 hr	3 hr	48 hr
Penicillin† Streptomycin	Initial 1,000,000 units—IM or IV 2 Gm IM or IV Maintenance 1,000,000 units every 8 hr 1 Gm every 8 hr	1 hr 1 hr	48 hr 48 hr
Tetracycline	Initial 3 Gm orally Maintenance 1 Gm every 6 hr	3 hr (or earlier)	48 hr
Gantrisin or sulfonamide combinations	Initial 2 Gm orally Maintenance 1 Gm every 4 hr		48 hr
Erythromycin or bacitracin or novobiocin + polymyxin B	Subconjunctival at time of surgery 2.5-5 mg/0.5 ml 10,000 units/0.5 ml 15,000 units/0.5 ml 50,000 units/0.5 ml		

\*From Leopold, I H. Recent Advances in Ocular Therapy, New York J Med 56:2807, 1956.

†Benemid 2 Gm orally with initial dose of penicillin ½ Gm every 6 hours for maintenance.

## INFECTIONS OF THE LIDS, CONJUNCTIVA, CORNEA, AND LACRIMAL APPARATUS

**Marginal Blepharitis.**—Inflammations of the lid margin may be due to infections, allergy or degenerative diseases. Cases of seborrheic origin may respond to local applications directed against seborrhea, anointing the lid margins carefully with Selsun or various antifungal dyes such as brilliant green, or mechanical cleansing followed by the application of a bland ointment. Staphylococcal blepharitis may respond to sulfonamide preparations or to various ointment bases containing gram positive effective antibiotics. Cases of allergic origin will respond to steroid applications. A number of conditions will not respond to local therapy with chemotherapeutic agents, these include localized lupus erythematosus, xeroderma pigmentosum, and others.

**Conjunctivitis.**—This requires specific diagnosis and therapy. Solutions should be instilled every hour or two during the day and ointments applied for the night. Any discharge should be irrigated from the eye with an innocuous collyrium prior to instillation.

**Corneal Infections.**—Corneal inflammations usually require large doses of antibiotics systemically as well as locally. Subconjunctival injection and iontophoresis are satisfactory local methods of obtaining adequate concentration.

## DRUGS FOR OPHTHALMIC USE

ocular conditions and sometimes rectally in infants. Phenylbutazone (Butazolidin) administered orally is used primarily as an antipyretic and analgesic, but it is also used to help in rheumatoid conditions and in such ocular diseases as uveitis. The initial intramuscular dose of 25 mg a week is gradually increased until a total of 1 000 mg has been given.

**ORGANIC GOLD COMPOUNDS**—Aurothioglucose may be employed in uveitis particularly in those forms related to rheumatoid arthritis. It appears to have some value in nondisseminated lupus erythematosus. The initial intramuscular dose of 25 mg a week is gradually increased until a total of 1 000 mg has been given. Gold sodium thiosulfate is given by intravenous injections starting with a dose of 5 mg and is cautiously increased. Gold therapy may cause severe reactions toward reactions and opinion is divided as to whether the risk is worth taking.

**ORGANIC MERCURY COMPOUNDS**—Merbromin (Mercurochrome) is a non-irritating moderately active antibacterial agent. It is incompatible with acid salts heavy metals hydrogen peroxide and most alkaloids and local anesthetics. The aqueous alcohol acetone solution called merbromin surgical solution is more rapid in action than the aqueous solution. The drug penetrates significantly only into dying or dead tissue. Solutions of nitromersol (Metaphen) should be prepared as needed as they tend to precipitate upon standing. It is a local antibacterial agent is relatively nonirritating and is employed particularly in ophthalmology for disinfection of the skin. Thimerosal (Merthiolate) is usually used in a 0.1 per cent solution and as such it is a relatively nontoxic skin disinfectant. Like other mercurial antiseptics it cannot be relied upon to produce complete sterilization. Spores are particularly resistant.

Ammoniated mercury is prepared in ophthalmic ointment and is used on the eyelids as an antiseptic. It is employed for crab louse infestation of the lashes and eyelid margins for impetigo psoriasis and ringworm. Yellow mercuric oxide ointment is rarely used in ophthalmology since in effective doses it is extremely irritating to the eye. Mercury bichloride is applied as an antibacterial ointment in the form of a mercury bichloride ophthalmic ointment mixed with water and white petrolatum.

**ZINC COMPOUNDS**—Zinc sulfate may be employed as an eyewash for the treatment of conjunctivitis caused by *Morax-Axenfeld bacillus*. It may also be applied to the skin of the lids as a 4 per cent solution for treatment of acne vulgaris, lupus erythematosus and impetigo. Zinc oxide is usually employed around the lids in eczema impetigo ringworm pruritus and psoriasis. Zinc is chiefly used for its astringent and antiseptic properties.

**BORIC ACID**—Boric acid solution is used chiefly as an irrigant and for application to the cul de sac and cornea. A 2.2 per cent solution is thought to be isotonic with tear fluid. Serious poisoning can result from oral ingestion of as little as 5 Gm.

**IODINE**—Strong iodine solutions are used for the cauterization of corneal ulcers particularly those due to herpes simplex. No excess iodine should touch the adjacent cornea. This is followed by instillation of 4 per cent cocaine solution after which the eye is flushed to remove any excess iodine.

Isoniazid may be used effectively locally on external tuberculous infection of the eye but it is predominantly employed systemically along with streptomycin.

Nitrofurazone (Furacin) is used in 1:500 solution or ointment for the treatment of mixed infection of the lids and conjunctiva. For preoperative preparation of the skin and for irrigation of the eye, benzalkonium is an all purpose local antibacterial agent with a detergent, keratolytic and emulsifying action. In concentrations of 1:2000 or stronger, it may produce reparable corneal infiltrations and irritation which clear when the drug is stopped.

### The Use of Steroids

**Cortisone**—Cortisone is now used for acute inflammatory processes in the posterior segment and for anterior ocular inflammations which do not respond to local therapy. For ophthalmic patients oral administration is satisfactory. The usual dose is 300 mg the first day in divided doses, 200 mg the second day and 100 mg thereafter. Therapy in reduced dosage should be continued until all danger has subsided. When the drug is cut down gradually, the physician must be on guard against recurrences. For topical therapy suspensions and ointments of cortisone may be employed. The following routine is suggested. Cortisone acetate suspension in drops of 0.5 per cent or 2.5 per cent should be used every hour and ointment of 1.5 per cent should be applied at night because it may produce blurring. If this fails, subconjunctival injection of 0.5 ml of a 2.5 per cent suspension of cortisone acetate every 3 days should be used. If this fails oral and parenteral therapy may be tried.

**Hydrocortisone**—Oral administration is started at 100 mg a day in divided dosage and is reduced with clinical response. Hydrocortisone may also be given intravenously.

**Corticotropin (ACTH)**—ACTH is without effect locally nor can it be given by mouth. It may be administered intramuscularly. Initial dosage varies from 80 to 100 mg per day divided into 4 doses given at 6 hour intervals. These intervals should be continued and doses reduced or increased according to response. Long acting preparations may be given at 12 hour intervals. For intravenous therapy 25 mg a day of ACTH may be dissolved in glucose in water and given as an intravenous drip over a period of 8 hours once daily. This method seems to be from 8 to 12 times as effective as the intramuscular route. After the ocular tissues have responded one may switch to intramuscular ACTH. Some cases which fail to respond to cortisone hydrocortisone and to other steroids may respond to ACTH.

**Prednisone and Prednisolone**—These may be given orally in doses of 30 to 40 mg daily until therapeutic response (2 weeks maximum) followed by the minimal amount required to maintain the remission. Intramuscular prednisone acetate 25 mg per ml is not often indicated in ocular disease suspensions are used at 0.5 to 2.5 per cent.

**Others**—Methylprednisolone (Medrol), triamcinolone (Aristocort) and dexamethasone (Decadron, Deronil), are now also available for systemic administration. They are effective at a lower dosage schedule than is required for prednisone or prednisolone.

# DRUGS FOR OPHTHALMIC USE

Table 52 Therapy of Intraocular Infection\*

Agent	Method of Therapy	Antibiotic	Dosage	Frequency
Penicillin-streptomycin combination†	Subconjunctival injection	Penicillin + Streptomycin	1,000,000 units/1 ml of 1 1,000 Adrenalin or water 100,000 µg/1 ml of 1 1,000 Adrenalin or water	Inject 0.5 ml for 2 d
			(If overwhelming infection) 5 000 units/0.05 ml	Once
	Intravitreal injection	Penicillin + Streptomycin	1,000 units/0.5 ml followed by subconjunctival injection as above	
			(Also give same drugs systemically)	
	Systemic therapy	Penicillin‡ Streptomycin	1,000,000 units—initially I V 1,000,000 units I M 1 Gm—initially—I V 1 Gm I M	Every 6 Every 8
Chloramphenicol‡	Systemic	Chloramphenicol	3 Gm stat 1 Gm	Every 6
Tetracycline	Systemic	Tetracycline	3 Gm stat 1 Gm	Every 6
Other antibiotics	Subconjunctival injection	Polymyxin B + Erythromycin or Novobiocin or Bacitracin	50,000 units/0.5 ml H <sub>2</sub> O with 1 1,000 Adrenalin 2 5.5 mg/0.5 ml H <sub>2</sub> O 15,000 units/0.5 ml H <sub>2</sub> O 10,000 units/0.5 ml H <sub>2</sub> O	
	Systemic	Gantrisin + any of above subconjunctival injections	2 Gm stat 1 Gm	Every 4

\*From Leopold I H Recent Advances in Ocular Therapy, New York J Med 2808, 1956

†Therapy to be instituted if prophylactic chloramphenicol therapy has been unsuccessful

‡To be used if prophylactic penicillin and streptomycin therapy have been unsuccessful

§Benemid 2 Gm orally with initial dose of penicillin, ½ Gm every 6 hours for tenance

**Lacrimal Infections**—Inflammations of the lacrimal gland are rare even mumps the lacrimal gland may not be affected For tuberculosis and sy treatment is the same as for these diseases in other parts of the body In infections involving the canthus with Streptothrix, removal of concretions mechanically usually suffices

Infections of the lacrimal sac can be cleared temporarily with antibiotic chemotherapeutic agents Unless the obstruction, which usually occurs below lacrimal sac, is removed the infection will recur Antibiotics may be administered systemically or may be injected into the sac Injection into the sac, if attempted is extremely painful and should be avoided if possible Once the obstruction is overcome, the obstruction may be removed by surgical procedures Tables 51 and 52 for concentrations used in subconjunctival administration

dermatitis of the lids, allergic blepharitis, insect bites, and in the prophylactic therapy of virus keratitis

Antazoline (Antistine) is not as irritating as many other locally applied antihistaminics. Diphenhydramine (Benadryl) produces considerable sedation. Promethazine (Phenergan) produces effective sedation and is also used for its antiemetic action.

When systemically administered antihistaminics may produce blurred vision, weakness of accommodation and corneal edema.

### The Use of Antibiotics

With the advent of antibiotics and chemotherapeutic agents there has been a great reduction in visual loss due to infection. For successful antibiotic therapy it is essential that the organism causing the infection be identified, that it be sensitive to the antibiotic chosen, and that an effective concentration of the chosen agent reaches the site of infection. If an infection fails to respond within 48 or at the most 72 hours a switch to other medication is indicated. Sensitization to penicillin following local instillation may prevent the use of penicillin for a more serious systemic infection at a later date. Ophthalmologists therefore tend to use such antibiotics as bacitracin, neomycin, polymyxin and gramicidin which are not likely to be used systemically. They may be administered locally in the form of solutions with or without a detergent. The penetration of antibiotics into the eye may be enhanced by iontophoresis, subconjunctival injection, retrobulbar injection and injection directly into the chambers of the eye.

If antibiotic therapy fails, considerable destruction of normal tissue may have taken place and visual loss may continue. Corneal abscesses may become sterile under treatment but, because of the tissue destruction associated with the infectious process the cornea may perforate.

**Prophylaxis and Therapy of Intraocular Infections.**—In the potentially infected wound, e.g., penetrating foreign body injury it is advisable to treat the eye as though it were infected. A broad spectrum antibiotic or a combination of antibiotics should be used. In intraocular surgery some ophthalmologists are reluctant to use prophylactic anti-infective drugs. Here the ophthalmologist must weigh the advantages to the patient against the risks involved. No one questions the use of chemotherapeutic agents in the patently infected case. The major problem is the use of antibiotics in clean and contaminated cases.

Wounds inflicted on the eye with the keratome or knife and scissors may be contaminated. In spite of all precautions, infection is reported in approximately 0.5 per cent of most large series of intraocular surgical cases. With the exception of the hemolytic streptococcus the causal organisms are frequently resistant to the commonly employed antibiotics. The fact that antibiotics are inefficient in the presence of dead tissues makes it unlikely that routine chemoprophylaxis will further reduce this low incidence of postoperative infections in clean surgical cases.

The combination of penicillin and streptomycin provides a broad antibacterial spectrum which in adequate concentration should be bactericidal against many organisms that are secondary invaders in the eye. Chloramphenicol may be used

Ointments may cause visual blurring and are preferred for night use. Subconjunctivally 0.5 ml. of a 2.5 per cent suspension of prednisone or prednisolone acetate may be injected under Tenon's capsule for severe diseases of the anterior segment. Prednisolone phosphate may be used in 0.5 to 2.5 per cent solution for drops or for subconjunctival injection. Fludrocortisone, methylprednisolone, triamcinolone, and dexamethasone are available for topical use.

Topical therapy makes for high local concentrations without systemic effects. The drugs absorbed into the anterior segment are of benefit in *iritis*, aphakic toxic reactions, and in other conditions of the anterior uveal tract. They are of no value for inflammation of the posterior segment.

**Clinical Applications**—The steroids are useful in the following conditions:

Seborrheic blepharitis, marginal blepharitis due to contact dermatitis and drug reactions.

Conjunctivitis due to staphylococcal toxin sensitivity, phlyctenular conjunctivitis, allergic blepharoconjunctivitis, chemical and thermal burns.

Inflammation of the cornea and sclera: marginal ulcer of cornea, interstitial keratitis (syphilitic or nonspecific), superficial punctate keratitis, atopic keratoconjunctivitis, keratitis disciformis with close observation for recurrence of dendritic ulceration, recurrent corneal erosions, scleritis, episcleritis.

Inflammation of the uveal tract (nongranulomatous and granulomatous): *iritis*, *iridocyclitis* or *chorioretinitis* (acute or chronic).

Miscellaneous conditions: herpes zoster ophthalmicus, neovascularization of conjunctiva and cornea, pseudotumor of the orbit, glaucomatocyclitic crisis, glaucoma secondary to uveitis, postoperative corneal edema following keratoplasty.

**Untoward Effects in the Eye**—Except for the possibility of combinations with acetylsalicylic acid and vitamin C which may allow smaller doses of steroids to bring about the desired effect, combinations of steroids with other drugs should be avoided. General contraindications and the careful observation required in the use of adrenocorticosteroids are familiar to all physicians.

Local use of steroids may delay the absorption of blood from the anterior chamber and also of cortical material after extracapsular extraction of the lens or traumatic injury of the lens. The prolonged use of a combination of steroids with antibiotics may contribute to an increased number of fungous infections in the cornea.

Local use of steroids may be followed by complications such as the onset or advance of herpetic keratitis. Make certain that there is no herpes keratitis and *watch the patient closely so that this can be detected as soon as it develops*. If, in addition, the physician is alert to the possibility of a fungus keratitis developing in an already diseased eye, it may be safe to try these agents in red eyes before an etiologic diagnosis is made.

### The Use of Antihistamines

**Clinical Use**—Antihistamines are most effective in allergic conjunctivitis, urticaria of the lids, and reactions to drugs. They may also be helpful in contact



## THE CHOICE OF DRUGS FOR OTOLARYNGOLOGIC DISORDERS

William H. Saunders, M D.

### THE CHOICE OF ANTIBIOTICS

In otolaryngology most failures with antibiotics and chemotherapeutic agents are due to the fact that the following criteria are not followed (1) The micro-organism must be sensitive to the drug, (2) the drug must be given in effective dosage, (3) the infected area must have a good blood supply, and (4) there must be adequate drainage of pus.

The systemic use of these drugs is usually more effective than topical administration. Topical application also tends to sensitize the patient to the drug. When the infecting organism has been identified, the choice of antibiotic or chemotherapeutic agent is usually the same as in any other infection. The reader is therefore referred to Chapters 7, 8, and 9 on the choice of antimicrobial agents. Only the basic problems of their application to otolaryngologic infections will be considered here.

### THE SEVERAL OTOLARYNGOLOGIC DISEASES

#### Diseases of the Ear

**External Otitis**—The chief symptom of acute external otitis is pain and that of chronic external otitis is itching. In the normal ear canal only *Staphylococcus albus* and diphtheroids are present, neither is pathogenic. In external otitis (acute or chronic) the streptococcal, *Staphylococcus aureus*, proteus, and pyocyanus organisms predominate. Often the infection is mixed. Most of these infections can be controlled by a combination of bacitracin, neomycin, and polymyxin B. Albamycin (novobiocin) is the only common systemic antibiotic that now seems to be effective against most of the strains of staphylococci.

**ACUTE EXTERNAL OTITIS**—Unfortunately, even though *in vitro* tests are used to determine the best drug, for several reasons not all patients recover with local treatment. First, failure to clean the ear canal carefully before applying medication leaves masses of soggy debris of macerated epithelium in which bacteria continue to grow. Second, the ear canal may be so swollen that the medication (used as



**Complications of Acute and Chronic Otitis Media.**—Although such complications as meningitis, brain abscess, epidural abscess, and labyrinthitis are rare, they still occur. When they do, heroic antibiotic therapy is essential. Massive doses of penicillin are used in meningitis. Chloromycetin and sulfadiazine are also given if indicated.

**ACUTE MASTOIDITIS**—Acute mastoiditis results from acute otitis media. If myringotomy is done for acute otitis media and if the proper antibiotic is given long enough and in sufficient dosage, acute mastoiditis rarely develops. In the now rare case of acute mastoiditis, antibiotics administered in high dosage and for a prolonged period (several weeks) usually cures. A few still require simple mastoidectomy to remove granulation tissue and diseased bone.

**CHRONIC OTITIS MEDIA AND CHRONIC MASTOIDITIS**—In chronic otitis media or chronic mastoiditis (usually the two co exist) the problem often consists of one part low grade infection and two parts obstruction. The normal mastoid is a honeycomb of air cells and normal drainage is obstructed. The bone infection, granulation tissue, and cholesteatoma require surgical removal. Systemically and topically administered antibiotics are of little use.

### Diseases of the Nose and Paranasal Sinuses

The nose and paranasal sinuses have cilia that beat constantly and as a result topical medications are carried away with the mucous blanket. Therefore, topical anti infective medication is not very effective in the nose or paranasal sinuses.

**Acute Sinusitis**—Obstruction that makes for poor drainage is common in sinusitis and as a result, antibiotics are less effective than was originally hoped. The treatment of uncomplicated acute sinusitis is almost always medical; no hard and fast rule can be given, however. Manipulative or surgical procedures are contraindicated because they tend to spread infection or even cause osteomyelitis. Patients with fever and pain may require antibiotics, others may not.

**Acute Rhinitis**—Acute rhinitis is almost always due to the common cold, a viral disease. Here antibiotics are not effective.

**Chronic Sinusitis**—As in chronic mastoiditis, so in chronic sinusitis antibiotics are ineffective. Multiple small abscesses form in the mucosa of the sinuses and mucocoeles or polyps obstruct drainage. Some patients with a subacute form of sinusitis respond well to irrigations of normal saline. Treatment of chronic sinusitis is surgical.

**Other Acute Nasal Conditions**—Septal abscess and acute bacterial rhinitis respond well to antibiotic therapy.

### Diseases of the Pharynx

The blood supply is good and usually there is no obstruction to drainage. All that is needed is the correct drug given long enough in adequate dosage.

**Acute Tonsillitis**—This condition responds readily to most of the broad spectrum antibiotics. Repeated infections may, however, also indicate a tonsillectomy. Peritonsillar abscess (quinsy) is another indication for tonsillectomy.

**Adenoiditis and Nasopharyngitis**—The adenoid often causes disease of the ear and nasal obstruction. When these are produced by an adenoid which is not

## DRUGS FOR OTOLARINGOLOGIC DISORDERS

drops) cannot get far enough along the canal. A third reason for failure is spread of infection to neighboring tissues. Lymphadenopathy and periauricular edema indicate that topical medication will not do and that systemic antibiotics are needed. In most patients with a severe acute external otitis it is always necessary to use antibiotics or sulfonamide drugs systemically in addition to local medication. In some patients, particularly those without fever or great pain, it is not always necessary or even advisable to use topical antibiotics in the ear canal. Occasionally however a wick saturated with Burow's solution, half strength, works well as a sole therapeutic agent.

**CHRONIC EXTERNAL OTITIS**—In chronic external otitis without acute exacerbation the chief symptom is itching and the patient greatly enjoys having his ear cleaned. It is extremely important to remove every bit of debris from the ear canal and surface of the eardrum. Depending upon the condition of the epithelium ointments or ear drops should be used. On scaly dry epithelium, ointments work better. Liquid preparations are better for oozing macerated epithelium. When infection is present the proper antibiotic should be used in an ointment. When infection is minimal a mild exfoliating and antipruritic ointment such as that below is satisfactory.

		Gm or ml
R	Phenol	10
	Salicylic Acid	10
	Precipitated Sulfur	10
	Petrolatum	10
S	Use once daily for 1 or 2 weeks or even indefinitely to control itching and scaling	300

Patients often do not apply ointments properly. Usually they use a commercially prepared cotton applicator that is too thick for the ear canal. They should make their own applicators with a tuft on the end by winding cotton about a toothpick.

For the wet type of chronic external otitis ear drops of half strength Burow's solution should be used first. When the skin has become dry an ointment should be used.

**Otitis Media**—Acute otitis media is caused by an infection passing up the eustachian tube. Often it is more important to reestablish the function of the tube than to treat with antibiotics. In children and in some adults hyperplastic adenoid tissue is the most common cause of obstruction and adenoidectomy is the best treatment. When there is an abscess in the middle ear pus must be released and myringotomy may be more important than drugs. Hearing is spared by releasing pus.

Topically applied antibiotics are of little or no use in acute otitis media if the eardrum is not ruptured. The drops cannot reach the middle ear whereas if the eardrum is perforated the draining pus keeps the drops out. Systemically administered antibiotics or sulfonamides are indicated in most instances. A culture of the pus is often not possible because the pus is behind an intact eardrum. If pus is obtained through myringotomy it is still necessary to begin treatment before the infecting organism is identified. Penicillin, erythromycin, and sulfonamides are good drugs to use at this time.

**Cresatin**—Used as drops or on a cotton wick, Cresatin is a good fungicide. Care must be taken, however, not to cause additional irritation. The drug may also cause some burning in patients with acute external otitis. Treatment is usually continued several days or a week.

**Nystatin (Mycostatin)**—This drug is effective in ear drops and ointments.

### **Drugs Used in the Oral Cavity**

The treatment of monilial and other fungous growths of the oral cavity is an old problem to the otolaryngologist. Two per cent aqueous gentian violet applied topically helps many but not all patients. Nystatin, 2 or 3 tablets (500,000 units each), 3 times daily, helps more. Many cases of stomatitis are produced by antibiotics (particularly as lozenges) which deplete the normal bacterial flora of the mouth and permit overgrowth of yeasts.

## **NOSE AND THROAT SPRAYS AND PAINTS**

In the days before antibiotics, infections of the pharynx were commonly treated with sprays or paints. The physician, pressed to do something for his uncomfortable patient, applied medications directly to the inflamed pharynx. None of the drugs he used was curative. Nevertheless, some of these medications did provide symptomatic relief and even now, many patients still ask to have their throats painted. Still useful because of its great symptomatic benefit, and also probably of some curative value, is a stream of hot water directed at the posterior pharyngeal wall. A quart of hot unmedicated water is used in an enema or douche can two feet above the patient's head. Water runs in, strikes the tonsillar area or posterior pharyngeal wall and runs out into a basin. Gargling is much less effective.

## **CORTICOSTEROIDS**

The corticosteroids are probably of less value in otolaryngology than in most other medical specialties, but there are several otolaryngologic conditions in which these drugs are useful and sometimes essential.

**External Otitis**—Sometimes good results in acute external otitis are obtained with an ointment containing hydrocortisone. Edema and inflammation are reduced and in some instances pain is relieved faster than would be expected otherwise. Fortunately, no local or systemic reactions result from the use of hydrocortisone.

When used in chronic external otitis hydrocortisone may seem to give a good result at first but often the relief is short lived and the itching returns. Preparations containing 1 to 2.5 per cent hydrocortisone in hydrophilic ointment are available with and without antibiotics.

**Acute Allergic Rhinitis**—Although not the drug of choice in the treatment of the average patient with acute allergic rhinitis corticosteroids administered systemically sometimes control symptoms controlled by usual methods. The topical intranasal use of hydrocortisone was originally expected to provide great relief in hay fever but these high hopes did not materialize.

## DRUGS FOR OTOLARYNGOLOGIC DISORDERS

infected but is hyperplastic, adenoidectomy is the only treatment adenoid becomes infected, systemic antibiotic therapy is indicated

### Diseases of the Oral Cavity

The usual throat lozenge, with its relatively low concentration of does no good, but it may do harm by permitting overgrowth with yeast moniliasis develops

### Diseases of the Larynx and Trachea

**Inflammatory Laryngitis**—Most patients have acute laryngitis as part upper respiratory infection. However, laryngitis may be the only abnormality

**VOICE REST**—Patients with inflammation of the larynx get well faster if rest the larynx. Complete voice rest implies that the patient neither speaks whispers, partial voice rest, that he may whisper softly when necessary

**STEAM INHALATION**—Inhalation of water vapor (steam from a teakettle) does much to relieve cough and to restore moisture to a larynx which may be dry and feel scratchy. The water need not be medicated. Failure to obtain relief by the use of steam may be due to the use of a small steamer in a large room. If a room steamer is to be effective, droplets of water should form on the walls

**ANTITUSSIVES**—The patient with laryngitis does better if he can be kept from coughing. The best cough suppressive is codeine, which should be given every 2 hours

**SMOKING**—Although smoking is absolutely contraindicated many patients who complain bitterly about laryngitis refuse to give it up even for a short time

**THROAT SPRAY**—In the era before antibiotics physicians anxious to do something for their patients often prescribed various topical medications for relief of laryngitis. None did much good. Laryngitis is not only a superficial mucosal inflammation but also a submucosal one. There is some justification for antibiotic sprays or aerosol preparations but in general when used at all these should be used only as adjuncts to systemic antibiotic therapy

## SULFONAMIDES

The sulfonamides may be destined for a comeback as more and more organisms develop resistance to the antibiotics. The new sulfonamides can be given at long intervals and hence are most convenient. In addition they are cheaper than antibiotics

## FUNGICIDAL DRUGS

### Drugs Used in the Ear

In temperate climates, fungous infections of the external auditory canal are common. Most external otitis is due to bacteria but occasionally both acute and chronic external otitis are caused by fungi. Treatment with fungicidal drugs is usually successful if the ear canal is carefully cleansed of accumulated cerumen and keratinized epithelium.

drug is used as is necessary. Only a hand spray, not a pressure spray, should be used to obtain topical anesthesia in the throat. Since only the drug which adheres to the mucosa is effective, the patient should expectorate the excess material. In the nose a spray can be used, or the anesthetic can be applied on a cotton pledget, excess anesthetic solution should not drip into the throat.

**Cocaine**—Cocaine is still the best and most effective topical anesthetic. There has been a great deal written about accidents associated with this drug, but when examined carefully such reports are often found to be misleading. Used correctly, cocaine solution, 5 to 10 per cent, is safe for mucous membranes of the nose and throat.

**Tetracaine (Pontocaine)**—Pontocaine is as potent a topical anesthetic as cocaine and at least as toxic.

**Lidocaine (Xylocaine)**—Much modern bronchoscopy is done under topical Xylocaine anesthesia. The drug is relatively less toxic than cocaine and Pontocaine, but it is also weaker. Xylocaine viscous is useful in patients with ulcerated painful lesions in the mouth, pharynx, or esophagus, in which a moderately potent topical anesthetic is needed.

**Dyclonine (Dyclone)**—Dyclone is another good topical anesthetic for oral lesions. It can be used in a mouthwash and expectorated or, better, applied to cotton and left in place. The drug may also be swallowed in amounts up to one ounce to provide anesthesia of the esophagus preliminary to esophagoscopy.

**Topical Anesthesia of the Eardrum**—There is no good topical anesthetic for the eardrum because the external layer of the eardrum is squamous epithelium derived from skin. Unlike mucous membranes which can be anesthetized with topical anesthetics the unbroken skin and its derivatives are resistant to them. Hence no solution of cocaine, tetracaine (Pontocaine), dibucaine (Nupercaine), or any other topical anesthetic is effective on the eardrum. However, if there is a perforation of the eardrum or if its surface epithelium is abraded or infected the common topical anesthetics induce their effects.

Bonain's solution is an old preparation which induces good anesthesia of the eardrum. It consists of equal parts of phenol, methol and cocaine alkaloid. The constituents are crystals, but when mixed they form a thick brownish liquid. When the solution is applied to the drumhead with a small piece of cotton and left in place 5 or 10 minutes, satisfactory anesthesia develops, but care must be taken because ischemia with permanent damage to the eardrum can also ensue.

**Topical Anesthesia of the Nose and Paranasal Sinuses**—In the nose topical anesthesia is often produced by use of "cocaine mud," made by mixing 0.3 Gm of cocaine flakes with aqueous Adrenalin solution (1:1,000). The thick syrup produced is taken up on cotton tipped wire applicators which are inserted into the nose. Usually one applicator is placed near the sphenopalatine ganglion and the other near the anterior ethmoidal nerve. As in all situations requiring local anesthesia, it is very important to wait long enough for the drug to act.

**Topical Anesthesia of the Larynx**—For topical anesthesia of the larynx cocaine or tetracaine (Pontocaine) is ordinarily used. For lighter anesthesia lidocaine (Xylocaine) is satisfactory. Two methods may be used. The first is to apply 5 or 10 per cent cocaine solution or 1 or 2 per cent Pontocaine solution on

**Status Asthmaticus.**—Corticosteroids may be the only drugs which are effective their intravenous administration can be lifesaving

**Angioneurotic Edema.**—Edema due to allergic reactions may threaten the patient's life if laryngeal tissues swell sufficiently. Intravenous injections of corticosteroids or their local infiltration may be lifesaving

**Bell's Palsy.**—There have been favorable reports regarding the corticosteroids in Bell's palsy. By reducing inflammatory reaction corticosteroids are said to restore function sooner than would otherwise occur

**Caustic Burns of Esophagus.**—By utilizing that action of corticosteroids which delays fibroblastic proliferation, caustic burns of the esophagus are permitted to epithelize before scar tissue contracture develops. Esophageal dilatation is also required

**Erythema Multiforme.**—Erythema multiforme, really a dermatologic condition, is frequently detected first by the otolaryngologist because of oral manifestations. Treatment with corticosteroids usually produces amazingly rapid relief but remissions often occur after treatment is discontinued

**Midline Lethal Granuloma.**—This unusual and commonly fatal disease usually responds well initially to corticosteroids. The destruction of the midline facial structures stops and tissues heal. Sometime thereafter the disease usually progresses and then often fails to respond to even higher doses than were successful at first

## ANALGESICS

There is little which is new or different about analgesics in otolaryngology that does not apply to other specialties. Aspirin affords relief for most pains. For more severe pain, e.g., in acute external otitis or acute tonsillitis, 30 mg. of codeine may be needed. Rarely is an injection of morphine or meperidine (Demerol) required. It should be noted that 50 mg. of Demerol given by mouth is generally less effective than 30 mg. of codeine. Combinations of tranquilizers and mild analgesics have worked well in some patients

Local analgesia for the throat and oral cavity is obtained by lidocaine (Xylocaine viscous) or by dyclonine (Dyclone). Formerly patients with severe laryngeal pain, e.g., those with tuberculous laryngitis, were given sips of cocaine solution before mealtime but the less toxic local anesthetics are now used

## ANESTHETICS

### General Anesthetics

General anesthesia for otolaryngologic patients presents problems not encountered in anesthesia in other fields. The airway must be maintained with special care because often there is blood in the pharynx during the operation. The endotracheal tube is therefore important. Deep anesthesia is generally not required since complete muscular relaxation is not essential

### Topical Anesthetics

Topical anesthetics are of greater importance in otolaryngology than in most specialties. Correct use of any potent topical anesthetic means that only as much



is cleared by antibiotics. In recurrent cases, adenoidectomy is necessary for permanent relief.

## DRUGS FOR TINNITUS

Ringing in the ear is a very common complaint which is very difficult to treat. When the condition is caused by impacted cerumen in the external ear or serous otitis media (both infrequent causes), the tinnitus stops when the plug is removed or the eustachian tube is opened. In most instances, however, tinnitus is due to disease of the inner ear or of the central connections, and treatment is difficult, if not completely ineffective. Vasodilators such as nicotinic acid and intravenous histamine may be tried but these measures seldom, if ever, relieve the head noise. The patient needs strong reassurance that he is not becoming deaf or that he has not had a stroke, although both of these conditions may, indeed, be associated with tinnitus.

## MÉNIERE'S DISEASE (ENDOLYMPHATIC HYDROPS)

This important otologic disease is discussed in Chapter 19.

## POSTOPERATIVE MEDICATION

The only special point about postoperative medication in otolaryngologic patients is that the cough reflex must not be too deeply depressed. It is better for the patient to have some discomfort than to be narcotized so deeply that he is endangered because he cannot cough at all. Codeine, 30 mg, which depresses cough also usually controls pain on the first postoperative day. On the day of operation, however, most otolaryngologic patients may need morphine or Demerol for their pain as well as cough.

## VASOCONSTRICTORS AND DECONGESTANTS

Vasoconstrictors are used in otolaryngology to stop bleeding and to open the nasal airway.

**Epinephrine (Adrenalin)**—This very potent agent is widely and well used for nosebleed and in bleeding from the postoperative tonsillar or adenoid fossa. Such bleeding usually responds well to packing with a tampon soaked in aqueous Adrenalin solution, 1:1000. Larger vessels should, of course, be ligated.

**Ephedrine**—Ephedrine (3 per cent), applied to cotton tampons or used as a nasal spray, is a good vasoconstrictor for office use. As a nosedrop, the ½ per cent concentration is generally preferred. Ephedrine may produce undesirable central stimulation. The drug is not effective for more than 30 to 60 minutes.

**Phenylephrine (Neo-Synephrine)**—In ¼ and ½ per cent strength this is the most commonly used nosedrop. The action on nasal cilia is not deleterious and the drops are well tolerated but the duration of the action is brief.

**Naphazoline (Privine)**—Although Privine is one of the longest acting and effective vasoconstrictors, it unfortunately is followed by strong rebound reactions so that many patients who used these nosedrops for a week or longer may become

an applicator for about 3 minutes in each pyriform recess. The second method is to spray the larynx 2 or 3 times, at intervals of 2 or 3 minutes, with the cocaine or Pontocaine solution. The direct application is more certain.

The trachea is anesthetized by instillation of one of the topical anesthetics. When the patient coughs, the solution is distributed over the mucosa. This technique often gives adequate anesthesia for bronchoscopy, but sometimes, once the bronchoscope reaches the carina, additional anesthesia is needed. Here a spray bottle with a very long cannula or a cotton tipped bronchial applicator may be used.

## DRUGS FOR NOSEBLEED

In nosebleed, conditions that are rarely the cause of nosebleeds require as much emphasis as those that are common causes. Physicians who are not adept at intranasal packing and cautery often attribute nosebleeds to a disturbance in the blood clotting mechanism. Depression of vitamin K, vitamin C blood levels, prothrombin content of blood, bleeding time, or clotting time are not, however, commonly associated with epistaxis. When epistaxis is due to systemic causes such as scurvy, leukemia, or a change in the blood prothrombin content, the patient bleeds from other mucous membranes into the skin and the viscera as well. Drug hemostasis in nosebleeds is often dangerous because it may lead the physician to rely upon medical treatment for a surgical condition.

**Epinephrine (Adrenalin)**—Adrenalin, aqueous 1:1,000, is of great value in treatment of the usual nosebleed from the anterior part of the nasal septum. Applied on cotton and pressed hard against the bleeding point, it produces local vasoconstriction in a few minutes and the bleeding usually stops. The nose can then be examined and the bleeding vessel cauterized. There are no significant systemic reactions from Adrenalin applied topically in the nose; the drug is safe to use even in older patients.

**Morphine**—In doses adequate to produce relaxation and mild euphoria, morphine is a valuable drug for patients with severe nosebleed. It is not to be used when bleeding can be readily controlled with simple cautery, but only for the patient who needs a postnasal pack or hospitalization.

**Chemical Cautery**—Silver nitrate fused on the end of wooden applicators is an excellent agent for cautery of a bleeding vessel. It may be used without topical anesthesia in many patients. Another effective chemical cauterant is trichloroacetic acid.

## DRUGS FOR DEAFNESS

Except occasionally in Meniere's disease, nerve deafness is not helped by drugs. Many instances of conductive deafness are surgical matters and do not require, or respond to, medical treatment. However, otitis media is a common cause of conductive deafness which does not respond to antibiotics. When cerumen has occluded the ear canal, instillation of hydrogen peroxide or any oily drops will soften it so that it can be washed out more easily. Hearing should improve.

**Serous Otitis Media**—In serous otitis media due to obstruction of the eustachian tube by infected adenoid tissue, hearing is restored when adenoiditis

## THE CHOICE OF DERMATOLOGIC DRUGS

*Marion B. Sulzberger, M.D.*

---

### INTRODUCTION

The problems and procedures of the dermatologist are often unique and may appear to be quite heterodox to those who have no knowledge of the specialty. Prescriptions, directions, rules, methods and equipment designed for and admirably suited to other branches of medicine often do not fit the specialty of dermatology. Conversely, some of the most useful dermatologic therapeutic measures are of little interest and less use in other fields. The following are among the reasons which account for the unusual position of dermatologic therapy.

1 The skin is unique in that its reactions in health and disease are the measurable resultants not only of the action of substances and influences coming from within but are, to the very highest degree, the products of all the ever changing forceful impacts coming from the outer world.

2 The skin is unique in that it presents a microcosmos of almost all the problems of medicine and of surgery. Almost every known diagnostic and therapeutic approach, every pharmaceutical agent, and every physical or surgical procedure has not only its place but often its special modification in the management of the skin and its diseases.

3 In addition, the skin is unique in that the management of its diseases demands special procedures which are almost, if not entirely, the sole province of dermatology. Among these are the special diagnostic techniques for demonstrating fungi, burrows and mites and for testing the skin's reaction to allergens, light, heat, cold, stroking and other stimuli, or the special therapeutic procedures for superficial radiation, for the excision or the freezing, fulguration, desiccation, or cauterization of benign or cancerous skin tumors and other lesions, for flattening scars, for bleaching or darkening pigment, for removal of hairs, and, to close a list which could be expanded almost ad infinitum, the special procedures and the special pharmacology for the repeated topical, localized, and direct application of medicaments to the skin lesions themselves.

It is this last listed highly specialized form of dermatologic procedure which will constitute a good part of the present chapter. Just as the causal factors of

virtually addicted. The nose closes completely from the rhinitis medicamentosa, and only Pristine can reopen the passages.

**Propylhexedrine (Benzedrex) Inhaler**—This popular device does a good job of vasoconstriction and decongestion. If the patient does not receive too much psychic stimulation, there appears to be no contraindication to its use.

**Cocaine**.—A 2 per cent solution of cocaine is an excellent nasal vasoconstrictor for office use. The mild anesthesia produced is often useful when minor intranasal manipulations are necessary.

**Comment**.—In general, nosedrops are useful for symptomatic relief of acute nasal obstruction, but they should not be used for prolonged periods. In patients with chronic nasal obstruction, there almost always is better medical or surgical relief available. Nosedrops probably do little to improve drainage in acute sinusitis. Only nosedrops, once very popular, have fallen into disrepute because of the rare case of lipid pneumonia.

## SELECTED REFERENCES

- Cullen, S. C., and Santos, C. C. Analgesia for Postoperative Pain Without Respiratory Depression, *Anesthesiology* 16: 674, 1955.
- Flynn, Thomas F. The Uses and Abuses of the Adrenocortical Steroids in Otolaryngology, *A. M. A. Arch. Otolaryng.* 64: 203, 1957.
- Heinberg, C. J. Practice, A. . . . . in Otolaryngologic . . . . .
- Saunders, W. H. . . . .
- Saunders, W. H. . . . . diagnosis, *Ann. Int. Med.* 47: . . . . .
- Saunders, W. H., Sue, Ted, and Sroufe, S. A. The Microflora and the Treatment of External Otitis and Otitis Media, *Postgrad. Med.* 25: 176, 1959.

rather unorthodox, fashions in particular dermatoses (e.g., sulfapyridine and sulfones in dermatitis herpetiformis, antimalarials in chronic discoid lupus erythematosus, hormones and antibiotics in acne vulgaris, and steroids in eczematous eruptions)

2 Certain agents are classed merely as bleaches, antipruritics, antipsoriatics, antieczematous agents, or keratolytic agents. These classifications are not "unscientific" or vague but indicate that dermatologic local therapy has scientifically demonstrated such agents to be the most effective in the mentioned dermatologic state or disease, just as internal medicine has demonstrated acetylsalicylic acid to be effective against certain fevers or headaches, or digitalis preparations against certain anomalies of cardiac function. However, since many drugs have a variety of dermatologic effects and several different indications in dermatology, they will perforce be listed repeatedly and under the heading of each of their particular fields of usefulness. This necessitates considerable duplication and repetition, but such duplication is considered necessary for the sake of simplicity and clarity, being distinctly preferable to the many cross references which would be required were each drug mentioned in one place only. For in that case the physician attempting to find the drugs of choice for treating a given dermatosis would constantly be turning the pages in order to find them and would nowhere find them conveniently assembled in one section.

3 The many prescription mixtures given in detail are essential in dermatologic topical therapy and are logically and scientifically compounded of selected ingredients, each having its special purpose and function. To write simply, "Use 6 per cent ammoniated mercury as a bleach" or "1 per cent chrysarobin as an antipsoriatic" would make things much easier for the author but would serve no useful purpose for the practitioner unless accompanied by the precise formulation of the vehicles, adjuvants, etc., with which the drug of choice must be prescribed. In short, in dermatology it is the *complete prescriptions which are matters of choice*, not merely the active drugs themselves.

In many instances there are available complete modern dermatologic prescriptions which are supplied as "ethical products" by reliable manufacturers of pharmaceuticals. Often these "proprietarys" have greater stability, uniformity, and "elegance" and may even cost less to the patient than the equivalent dispensed on prescription by a local pharmacy. In such instances, I have not hesitated to give the trade names of the proprietary mixtures.

According to the best figures available today, about 1 patient in every 7 comes to the general physician because of a complaint in the field of dermatology. Fortunately, however, about 90 per cent of these legions of sufferers are affected by some dermatosis falling within one of the 10 or 12 commonest categories of skin diseases. It is within these most common categories of skin diseases that the practitioner will find his field of particular usefulness, and it is for the general run of cases in these common categories that the drugs of choice in this chapter have been assembled and discussed. In the present arbitrary selection of cutaneous entities and measures for their treatment, more diagnoses have been omitted than mentioned, and more dermatologic remedies are left out than included. However,

dermatoses are commonly of both internal and external origin, so also skin diseases must generally be treated both from within and from without. Soporifics, sedatives, and tranquilizers, "antibiotics" and other anti-infective agents, anesthetics, antiallergic and anti-inflammatory agents, vitamins and diets, hormonal preparations, and all the measures and medicaments of medicine in general must be constantly and properly used in dermatologic therapy. Sometimes the usual medical and systemic measures are used in the usual fashions, not infrequently they must be modified and adjusted to fit the peculiarities of the specific problems of the skin disease. Despite the ever-growing importance of the systemic medical approaches, the fortunate circumstance that potent and effective medicaments can be applied directly and repeatedly to the skin lesion itself still remains one of the mainstays of dermatology. This advantage, coupled with the fact that objective critical and comparative observations with the unaided naked senses can be used to evaluate the effects of each such application, has led to the development of unusually effective and scientifically controllable forms of therapy. For example, dermatology is unique in that two or more similarly affected symmetrically situated skin sites can be treated simultaneously with different topical medicaments, and the results compared by both clinical and laboratory procedures, hourly, daily, weekly, or at any other chosen intervals. This is known as the method of "simultaneous symmetrical paired comparison."

In view of these advantages, it is not astounding that through many decades of careful use and controlled evaluation of the effects of topical medication, dermatologists have often discovered and adopted fundamental rules of therapy some time before they were apparent to practitioners in other branches of therapeutics.

Thus preparations containing combinations and mixtures of medicaments with similar or additive effects have long been used and are still among the standard and most efficient of topical agents. For dermatologists long recognized that they could combine, for example, phenol and menthol (as antipruritics), or resorcin and sulfur, or mercurials and salicylic acid (as keratolytics), etc., and thus achieve a summation and sometimes even a potentiation of therapeutic effectiveness without an accompanying augmentation of undesirable irritations, toxic effects, or allergic sensitizations. Then, again, since external therapy makes the most exigent demands upon the physical and other properties of the topical preparations and vehicles, these properties—their staining, sting, or stench, their viscosity, thickness, stickiness, melting point, stability of emulsion, etc.—are matters of major consequence. In order to achieve the optimum in all these respects it is often necessary to select carefully and to compound and mix together in a single prescription a variety of different powders, greases, oils, emulsifiers, wetting agents, coloring agents, etc.

This rather long preamble is intended mainly to make the following matters clearer to those who consult this chapter.

1 While practically all drugs have their indications in dermatologic therapy, the present chapter will be devoted almost entirely to those for topical application. Since systemic medicaments are fully covered in other chapters of this text, these will be discussed here only when they are to be used in specialized, sometimes

rather unorthodox, fashions in particular dermatoses (e.g., sulfapyridine and sulfones in dermatitis herpetiformis, antimalarials in chronic discoid lupus erythematosus, hormones and antibiotics in acne vulgaris, and steroids in eczematous eruptions)

2 Certain agents are classed merely as bleaches, antipruritics, antipsoriatics, antieczematous agents, or keratolytic agents. These classifications are not 'unscientific' or vague but indicate that dermatologic local therapy has scientifically demonstrated such agents to be the most effective in the mentioned dermatologic state or disease, just as internal medicine has demonstrated acetylsalicylic acid to be effective against certain fevers or headaches, or digitalis preparations against certain anomalies of cardiac function. However, since many drugs have a variety of dermatologic effects and several different indications in dermatology, they will perforce be listed repeatedly and under the heading of each of their particular fields of usefulness. This necessitates considerable duplication and repetition, but such duplication is considered necessary for the sake of simplicity and clarity, being distinctly preferable to the many cross references which would be required were each drug mentioned in one place only. For in that case the physician attempting to find the drugs of choice for treating a given dermatosis would constantly be turning the pages in order to find them and would nowhere find them conveniently assembled in one section.

3 The many prescription mixtures given in detail are essential in dermatologic topical therapy and are logically and scientifically compounded of selected ingredients, each having its special purpose and function. To write simply, "Use 6 per cent ammoniated mercury as a bleach" or "1 per cent chrysarobin as an antipsoriatic" would make things much easier for the author but would serve no useful purpose for the practitioner unless accompanied by the precise formulation of the vehicles, adjuvants, etc., with which the drug of choice must be prescribed. In short, in dermatology it is the *complete prescriptions which are matters of choice* not merely the active drugs themselves.

In many instances there are available complete modern dermatologic prescriptions which are supplied as "ethical products" by reliable manufacturers of pharmaceuticals. Often these 'proprietarys' have greater stability, uniformity, and "elegance" and may even cost less to the patient than the equivalent dispensed on prescription by a local pharmacy. In such instances, I have not hesitated to give the trade names of the proprietary mixtures.

According to the best figures available today, about 1 patient in every 7 comes to the general physician because of a complaint in the field of dermatology. Fortunately, however, about 90 per cent of these legions of sufferers are affected by some dermatosis falling within one of the 10 or 12 commonest categories of skin diseases. It is within these most common categories of skin diseases that the practitioner will find his field of particular usefulness, and it is for the general run of cases in these common categories that the *drugs of choice* in this chapter have been assembled and discussed. In the present arbitrary selection of cutaneous entities and measures for their treatment, more diagnoses have been omitted than mentioned, and more dermatologic remedies are left out than included. However,

it is hoped that in this chapter will be found most of the simple medicaments which can be tried first in most of the common and more readily diagnosable dermatoses \*

### ANTIACNE AGENTS (Agents Used in Acne Vulgaris, Acne Rosacea, and Other Acneiform Eruptions)

**Resorcinol and Sulfur**—Resorcinol—as a reducing agent—keratolytic and antiseptic is used in 2 to 6 per cent in shake lotions, creams, and pastes Sulfur precipitate—as a reducing agent—keratolytic and antiseptic is used in 3 to 10 per cent in shake lotions, creams, and pastes Resorcinol and sulfur precipitate are usually combined in order to summate their therapeutic effects without summation of irritancy

#### REPRESENTATIVE PRESCRIPTIONS —

	<i>Gm or ml unless otherwise indicated†</i>
<b>R</b>	
Resorcinol	20 to 60
Sulfur precipitate	30 to 60
Zinc oxide	
Talc aa	200 to 250
Glycerin	100
Water	
Alcohol aa	400
<b>S</b>	Antiacne shake lotion apply at night and wash off in morning
[May be made skin-colored (cuti color) and used by women during the day by the addition of bentonite and oxides of iron (Almay Neutra color) 20 to 40, and the substitution of pre- pared calamine for the zinc oxide]	
<b>R</b>	
Resorcinol	06 to 18
Sulfur precipitate	09 to 30
Rose water ointment ad	300
<b>S</b>	Antiacne cream apply at night and wash off in morning
<b>R</b>	
Resorcinol	06 to 18
Sulfur precipitate	09 to 30
Paste of zinc oxide ad	300
<b>S</b>	Antiacne paste apply at night wash off in morning

The concentrations of resorcinol and precipitated sulfur must be adjusted and readjusted to bring about slight but not uncomfortable or unsightly dryness and scaliness of the skin In the shake lotion of the first prescription the quantities and ratios of the other ingredients must be varied to achieve the desired shade thickness etc

\*In closing this introduction I wish to express my gratitude to Drs Frances Pascher, Rudolf L. Baer, Alfred Pelzig, and H. H. Sawicky and to Miss Claire E. Isenstein and to Mr. P. H. Baer for their helpful suggestions and criticisms.

Der . . . . .  
Med . . . . .



rather unorthodox, fashions in particular dermatoses (e.g., sulfapyridine and sulfones in dermatitis herpetiformis, antimalarials in chronic discoid lupus erythematosus, hormones and antibiotics in acne vulgaris and steroids in eczematous eruptions)

2 Certain agents are classed merely as bleaches, antipruritics, antipsoriatics, antieczematous agents or keratolytic agents. These classifications are not unscientific' or vague but indicate that dermatologic local therapy has scientifically demonstrated such agents to be the most effective in the mentioned dermatologic state or disease just as internal medicine has demonstrated acetylsalicylic acid to be effective against certain fevers or headaches, or digitalis preparations against certain anomalies of cardiac function. However, since many drugs have a variety of dermatologic effects and several different indications in dermatology, they will perforce be listed repeatedly and under the heading of each of their particular fields of usefulness. This necessitates considerable duplication and repetition but such duplication is considered necessary for the sake of simplicity and clarity, being distinctly preferable to the many cross references which would be required were each drug mentioned in one place only. For in that case the physician attempting to find the drugs of choice for treating a given dermatosis would constantly be turning the pages in order to find them and would nowhere find them conveniently assembled in one section.

3 The many prescription mixtures given in detail are essential in dermatologic topical therapy and are logically and scientifically compounded of selected ingredients, each having its special purpose and function. To write simply, 'Use 6 per cent ammoniated mercury as a bleach' or '1 per cent chrysarobin as an antipsoriatic' would make things much easier for the author but would serve no useful purpose for the practitioner unless accompanied by the precise formulation of the vehicles, adjuvants, etc., with which the drug of choice must be prescribed. In short in dermatology it is the complete prescriptions which are matters of choice not merely the active drugs themselves.

In many instances there are available complete modern dermatologic prescriptions which are supplied as ethical products by reliable manufacturers of pharmaceuticals. Often these proprietaries have greater stability, uniformity, and elegance' and may even cost less to the patient than the equivalent dispensed on prescription by a local pharmacy. In such instances, I have not hesitated to give the trade names of the proprietary mixtures.

According to the best figures available today about 1 patient in every 7 comes to the general physician because of a complaint in the field of dermatology. Fortunately however about 90 per cent of these legions of sufferers are affected by some dermatosis falling within one of the 10 or 12 commonest categories of skin diseases. It is within these most common categories of skin diseases that the practitioner will find his field of particular usefulness and it is for the general run of cases in these common categories that the drugs of choice in this chapter have been assembled and discussed. In the present arbitrary selection of cutaneous entities and measures for their treatment more diagnoses have been omitted than mentioned and more dermatologic remedies are left out than included. However,

## DERMATOLOGIC DRUGS

it is hoped that in this chapter will be found most of the :  
can be tried first in most of the common and more readily

### ANTIACNE AGENTS (Agents Used in Acne Vulgaris, Acneiform Eruptions)

Resorcinol and Sulfur—Resorcinol—as a reducing  
antiseptic is used in 2 to 6 per cent in shake lotions, or  
precipitate—as a reducing agent—keratolytic and antiseptic  
cent in shake lotions, creams, and pastes. Resorcinol :  
usually combined in order to summate their therapeutic :  
of irritancy

#### REPRESENTATIVE PRESCRIPTIONS —

	<i>Gm</i> <i>unless</i> <i>indicated</i>
<b>R</b>	
Resorcinol	2 0
Sulfur precipitate	3 0
Zinc oxide	
Talc aa	20 0
Glycerin	31
Water	
Alcohol aa	41
<b>S</b> Antiacne shake lotion apply at night and wash off in morning	
[May be made skin-colored (cuti-color)]	
<b>R</b>	
Resorcinol	0 6
Sulfur precipitate	0 9
Rose water ointment ad	31
<b>S</b> Antiacne cream apply at night and wash off in morning	
<b>R</b>	
Resorcinol	0 6
Sulfur precipitate	0 9
Paste of zinc oxide ad	3
<b>S</b> Antiacne paste apply at night wash off in morning	

- R  
Sulfurated lime solution (Vlemineckx' solution)  
Lime 16.3  
Sublimed sulfur 25.0  
Water sufficient to  
boil down to 100.0  
*Must be freshly prepared*
- S 1 tablespoonful (16 ml) to 1 pint of hot water to make approximately 1:32 dilution applied as hot wet compresses  $\frac{1}{2}$  hour several times daily in cystic and pustular acne  
(Action and Uses: Keratolytic, anti-inflammatory, antibacterial)

It is often advantageous to prescribe Vlem-Dome Powder Packets to assure a fresh and active preparation

- R  
Vlem Dome Powder Packets
- S 1 powder to each quart (weak), or pint (strong), of hot water (as hot as the skin will tolerate). Apply with cloths as wet compresses for 15 to 30 minutes 2 to 4 times daily. Use a glass or porcelain, not a metal container. Remove all jewelry, silver, etc., from person and room where solution is prepared and used, and avoid getting solution into eyes

### Quinolol —

- R  
Compound Quinolol Ointment  
Oxyquinolin sulfate  
Oil of white thyme  
Eucalyptol aa 0.5  
Petrolatum ad 100.0  
[The benzoyl peroxide has been omitted because of danger of explosion while compounding]

This ointment is very useful as a nightly application in many cases of acne vulgaris. It is best started in dilute form by prescribing 1 part of Compound Quinolol Ointment to 2 parts of petrolatum, then, if tolerated, equal parts of the quinolor ointment and petrolatum, and finally the undiluted Compound Quinolol Ointment.

**Estrogenic Therapy.**—In otherwise entirely healthy young women (carefully examined especially as to their mammary and genital state before and regularly during period of administration) mild estrogenic therapy may be useful. It may generally be instituted with safety after the age of 16 or 17 to prevent exacerbations of acne vulgaris.

If tolerated, effective, and without contraindications, this treatment can be continued during the entire "acne age" (usually into the early twenties).

**Antibiotics.**—Oral administration of antibiotics, e.g., tetracycline, oleandomycin, etc., in doses of 250 mg., at the beginning 4 times daily and gradually reducing to once daily or less, is often effective and well tolerated. Antibiotic treatment should be accompanied by regular examinations of the patient, including periodic complete blood counts, routine urinalyses, etc. Provided no adverse effects appear, the administration of antibiotics can be continued if necessary during the entire "acne age" and in the minimum dosage required to suppress the acne eruptions ("morbidistatic" doses).

## DERMATOLOGIC DRUGS

it is hoped that in this chapter will be found most of the simple medicaments which can be tried first in most of the common and more readily diagnosable dermatoses.

### ANTIACNE AGENTS (Agents Used in Acne Vulgaris, Acne Rosacea, and Acneiform Eruptions)

**Resorcinol and Sulfur**—Resorcinol—as a reducing agent—keratolytic and antiseptic is used in 2 to 6 per cent in shake lotions, creams, and pastes precipitate—as a reducing agent—keratolytic and antiseptic is used in 3 to 10 per cent in shake lotions, creams, and pastes. Resorcinol and sulfur precipitate are usually combined in order to summate their therapeutic effects without summation of irritancy.

#### REPRESENTATIVE PRESCRIPTIONS —

R	Gm or ml unless otherwise indicated†
Resorcinol	
Sulfur precipitate	
Zinc oxide	20 to 60
Talc aa	30 to 60
Glycerin	
Water	200 to 250
Alcohol aa	100
S Antiacne shake lotion apply at night and wash off in morning	400
(May be made skin-colored (cutis color), and used by women during the day, by the addition of bentonite and oxides of iron (Almay Neutra color) 20 to 40, and the substitution of pre- pared calamine for the zinc oxide.)	
R	
Resorcinol	
Sulfur precipitate	
Rose water ointment ad	06 to 18
S Antiacne cream apply at night and wash off in morning	09 to 30 300
R	
Resorcinol	
Sulfur precipitate	
Paste of zinc oxide ad	06 to 18
S Antiacne paste apply at night wash off in morning	09 to 30 300

The concentrations of resorcinol and precipitated sulfur must be adjusted and readjusted to bring about slight but not uncomfortable or unsightly dryness and scaliness of the skin. In the shake lotion of the first prescription the quantities and ratios of the other ingredients must be varied to achieve the desired shade thick-  
ness, etc.

\*In closing this introduction I wish to express my gratitude to Drs. Frances Pascher, Rudolf L. Baer, Alfred Pelzig and H. H. Sawicky and to Miss Claire E. Isenstein and to Mr. Paul Hoeber for the help I received from the invaluable data in the second edition of *Dermatologic Formulary of the New York Skin and Cancer Unit* (Paul B. Hoeber, Inc., Medical Book Department of Harper and Brothers, New York, 1937).

†Throughout this section the numerals in the prescriptions are in parentheses unless specified otherwise.

R	
Ammoniated mercury	18
Zinc oxide	
Bismuth subnitrate aa	60
Lanolin	
Petrolatum 33	ad 300
S	Apply to hyperpigmented skin areas by gentle massage before retiring and leave on overnight
R	
Benoquin ointment	
	75
	300
S	reas by
	ave on
	overnight
[If tolerated, the half strength and finally the full strength Benoquin ointment may then be prescribed]	

Both of these bleaches are strong sensitizers and thus the potential causes of allergic contact type dermatitis. The mercurials are also capable of producing systemic poisoning and should not be applied to large areas or for long periods of time without regular medical supervision.

Of course, the protection of hyperpigmented skin areas from exposure to sun light will in many cases cause some diminution of the amount of pigment and disfigurement. Change of habits, the use of covering clothing, of sun screening preparations, and of all the other measures for reducing the skin's exposure to light are therefore of some slight value in managing certain patients suffering from hyperpigmentations. (See section on 'Sun Screens,' page 771.)

## AGENTS USED IN BULLOUS DERMATOSES

The most important representatives of the bullous dermatoses are pemphigus, dermatitis herpetiformis, and erythema multiforme bullosum. While these may present large bullae, there are numerous variants and stages in which frank clinical bullae are absent. Clinical diagnosis is therefore often a specialized task, and in many cases special adjuvant laboratory and other methods may be required.

**Pemphigus**—Modern therapeutic advances have transformed pemphigus from a practically invariably fatal disease into one in which early adequate management can prolong the lives in most cases and perhaps ultimately save the lives in many. Modern treatment consists essentially in the administration of corticosteroids and/or ACTH, in whatever doses necessary to bring about control of the eruption, together with all modern measures to prevent, reduce, or counteract the undesirable effects of prolonged high dosage of these hormones (low salt diets, antibiotics, antacids, antidiabetic measures, tranquilizers, psychiatric approaches, surgical interventions, potassium supplements, anabolic agents, and others).

Opinion is still divided as to whether it is advantageous to combine or alternate ACTH injections with the oral corticosteroid therapy. In my considerable clinical material of ambulatory patients, I have found that corticosteroid therapy alone was usually as effective and safe as the combination with ACTH.

**Miscellaneous Measures**—In addition to, and sometimes as important as, any of the foregoing are the regular scrubbings with soap and hot water, the dietary prohibitions, the selection of proper clothing, and the elimination of external acneogenic irritants and internal acneogenic drugs (e.g., iodides, bromides). More important still, no otherwise refractory case which is severe or tends to scarring should ever be deprived of the benefits of x-radiation, which, when all else fails, is often effective and is absolutely safe when given by experts such as qualified dermatologists. (Of course, the gonads must be properly shielded.)

**Scarring**—One of the relatively common and most serious sequelae of acne is the scarring, which can occur principally on the face, back, and chest. This often produces permanent physical and psychic handicaps. The best modern technique for improving the appearance of patients with severe acne scarring of the face is the dermatosurgical method of "plastic planing" or "dermabrasion" as employed by dermatologists in carefully selected cases. This, like all other minor surgical and physical procedures in acne and other dermatoses, falls outside the scope of a book on drugs.

**CHEMOSURGERY**—In certain cases, however, a degree of improvement of facial acne scarring can be obtained by the use of peeling drugs according to the older dermatologic techniques. ('Chemosurgery' is an appropriate term introduced by F. Mohs, which is applicable to all such chemical means for removing tissue.) Examples of chemosurgery for acne scarring include the application of liquid phenol or trichloroacetic acid or of resorcinol containing pastes or of solid carbon dioxide ("dry ice") in various forms (including its mixture with acetone sufficient to make a "sherbetlike" consistency).

All of these peeling measures are quite safe when the necessary caution is used and specific precautions are observed. They can be fairly effective when applied and reapplied by experienced specialists in proper fashion at correct intervals and in carefully selected appropriate cases only. It is doubtful, however, whether the nondermatologist will generally wish to devote the time and study necessary to ensure the safety and usefulness of these or any other chemosurgical 'keratolytic' methods.

## BLEACHES

The bleaching of *hair* is best accomplished by the usual cosmetic procedures using peroxides, especially solution of peroxide of hydrogen followed by alkalinizing agents such as ammonia water. Many effective commercial preparations are available and quite safe when properly applied. The bleaching of *hyperpigmented skin areas* is quite another matter, and there are as yet no really effective and completely safe drugs for this purpose.

Unless the hyperpigmentation is directly attributable to endocrinologic, dietary, or other sources (e.g., ovarian, adrenal, or pituitary disease, hyperpigmentation of pregnancy, of pellagra, etc.) no causal, internal or surgical therapy is possible and the external application of topical bleaching agents is the sole approach.

The preparations of choice are of two kinds—mercurials or hydroquinones—especially, ammoniated mercury or the monobenzoylester of hydroquinone. Representative prescriptions follow.

**Dermatitis Herpetiformis**—Unfortunately this polymorphous and usually extremely itching and burning dermatosis can present itself in many guises and forms which are, even for the expert, difficult to diagnose clinically. According to the form, stage, signs and symptoms the treatment includes the topical and systemic antipruritic and anti-inflammatory measures outlined in the sections on Anti-eczematous Agents and on Antipruritics. However, the most important aspect of the therapy of dermatitis herpetiformis is the proper use and choice of the morbidistatic systemic medicaments. The drug of choice is

- R Sulfapyridine tablets 0.5  
 S In divided doses after meals 4 to 8 or more tablets daily as required to achieve and maintain control of the eruption. Reduce dose to minimum required to maintain morbidistasis.

All the necessary measures to prevent or reduce the possible ill effects of this medication should be carried out (e.g., 10 Gm. of bicarbonate of soda with each gram of sulfapyridine, regular examinations of the blood and urine, and others).

Other sulfonamides, alone or in combination, can be tried when sulfapyridine cannot be tolerated. While they may be better tolerated, they are usually inferior to sulfapyridine in effectiveness in dermatitis herpetiformis. The sulfones as well as corticosteroids have a place in some cases which do not respond to or cannot tolerate sulfapyridine.

- R Sulfoxone sodium tablets 0.33  
 S 1 tablet 2 to 3 times daily. Reduce to lowest morbidistatic dose. [Blood studies before and regularly during treatment].
- R Promacetin tablets 0.5  
 S Daily dose of 30 to 40 Gm. in divided doses. Reduce to maintenance dose or less as soon as possible. Precautions as with preceding prescription.
- R Hydrocortisone tablets 20 mg  
 S 4 to 10 tablets daily as required.

As of today it appears that in this disease, as in so many other dermatoses triamcinolone may be the most effective of the available steroids. It is given in the ratio of about 3 to 4 mg. of triamcinolone as equivalent to 20 mg. of hydrocortisone.

The oldest classic remedy is arsenic in various forms. This is now little used because of the risks of early toxicity and late sequelae. A usual form of prescription follows.

- R Potassium arsenite solution 10.0  
 (Fowler's solution)  
 Peppermint water q.s. ad 30.0  
 S 1 drop after each meal in  $\frac{1}{2}$  glass of water. Increase the after meal dose by 1 drop each day until 30 to 40 drops are being taken 3 times daily. Then reduce the after meal dose by 1 drop daily.

This course of arsenical can be repeated several times if necessary.

Heroic measures and heroic doses are completely justified in cases of pemphigus, as it is obviously better to have the patient alive with a gastroduodenal ulcer, a transitory psychosis, diabetes, or a pathologic bone fracture (all of which can today be treated with hope of success), than to have the patient die of pemphigus. In general, the initial dose of oral steroid must be a very large one in order to gain control of the severe case. This large initial dose can usually be reduced gradually and a maintenance dose of much smaller size reached and continued. In most patients finally under satisfactory control on lower doses, there will occur sporadic short periods when the relatively low maintenance dose must be temporarily but materially increased in order to combat situations of stress or "escapes" and "break-throughs" of the disease due to various ascertainable or unascertainable causes. In some cases the final maintenance dose is very small, and in some the pemphigus seems to "burn itself out" and the patient requires no continuation of therapy. In other words *the dread and classic example of fatal disease, pemphigus, is not generally fatal, provided the patient can be kept alive long enough to allow nature's curative forces to master the disease.* Representative drugs and dosage schedules follow.

break through of the dermatosis appears, and then raise the dose to the minimum which

According to specific indications instead of hydrocortisone, oral cortisone acetate or oral prednisone, prednisolone, triamcinolone, Medrol, or dexamethasone may be substituted in the biologically equivalent doses. That is, 25 mg of cortisone acetate or 5 mg of prednisone or prednisolone or 4 mg of triamcinolone or Medrol can be given in the place of each 20 mg of hydrocortisone. The delta steroids will be *especially indicated* in cases *where salt and water retention* are the imminent dangers and be *especially contraindicated* where *gastrointestinal hyperfunction and ulceration* are the paramount hazards.

In place of oral corticosteroids (or alternating with them), ACTH may be used as follows:

**R** Repository corticotropin injection  
**S** 20 to 100 mg once to twice daily  
(gradually reducing dosage as de-  
scribed above for hydrocortisone)

When the dermatosis proves refractory to the procedures mentioned or when the situation is extremely grave or death seems imminent, the administration of necessary doses of corticotropin solution (ACTH) should be given in 500 ml glucose solution by slow intravenous drip.

Intravenous Medrol (Solu Medrol) and depot Medrol intramuscularly are newly introduced forms of corticosteroid administration which show promise



This preparation is highly irritating and like all the other caustics listed should never be applied except by physicians well acquainted with the technique, the risks and the essential precautions

## ANTIECZEMATOUS AGENTS

These include the following agents used in eczematous and eczematoid dermatoses e.g. allergic eczematous contact dermatitis, simple inflammatory dermatitis from chemical or physical causes atopic eczema or atopic dermatitis in infants ( 'infantile eczema' ), children adolescents, or adults, nummular eczema, circumscribed lichenified dermatoses (such as circumscribed lichen simplex, circumscribed neurodermatitis) and eczematized eruptions in general

Since most eczematous and eczematoid eruptions itch, and many itch very severely the antipruritic measures given on page 757 are indicated in this group also. Moreover in the large number of cases in this category which are due to chemical or physical agents and allergens the discovery and reduction or elimination of exposure to the causal agents are obviously the most fundamental therapy. Dermatologic radiation (grenz ray, superficial x ray, thorium  $\lambda$ ) is also often one of the very best modes of treatment. For reasons such as these, the etiological diagnosis and proper therapy of the persistent cases of 'eczema' often become matters requiring specialistic skills and equipment. However, local external treatment coupled with systemic sedation tranquilization antihistaminic administrations and as a final resort systemic corticosteroid therapy are still among the most potent weapons. These measures are often adequate, especially in self limited eczematous conditions (e.g. plant dermatitis and atopic dermatitis in infants children and adolescents).

Selection of correct local external treatment depends not so much upon the cause as upon the site, the extent and the stage of the eruption (e.g. acute and angry or subacute or torpid, thickened and lichenified). Finally, the drug of choice depends upon which agents the physician finds by systematic trial to be most effective and best tolerated by the individual and site.

**Acute and Angry, Bright Red, Swollen, Blistering, Oozing or Weeping Eruptions**—Wet applications should be applied as open wet compresses immersions or soaks. To be most effective these require great skill and patience and *special nursing techniques*. The dressings must never be allowed to become warm or to dry out. Usually the applications are made in periods of  $\frac{1}{2}$  to 1 hour and repeated 4 to 6 or more times daily.

### *Approximately Physiologic Saline Solution*

- R Sodium chloride 0.5%
- In distilled water 100
- S Keep in basin at room temperature and apply by means of sopping wet smooth cloths. Keep changing continuously never allowing cloths to dry out or become worn.
- R Fresh milk
- S As for above prescription  
(An excellent O/W emulsion almost always available in an emergency)

**Erythema Multiforme Bullosum.**—In the bullous form of erythema multiforme, the treatment is similar to that outlined for pemphigus. In milder cases, local treatment, antihistaminics, calcium preparations, sedatives, and antipruritics will usually suffice.

The search for possible causes is here essential, as many cases are due to drugs, e.g., salicylates, iodides, bromides, barbiturates, antibiotics, and innumerable other common and unusual medicaments, or to other allergens, or to foci of infection, such as streptococcal, tuberculous, or viral infections of systems or organs other than the skin.

The local treatment is analogous to that specified under eczematous dermatitis (page 736).

Calcium is best administered in the following forms:

- |   |   |     |
|---|---|-----|
| R | Calcium gluconate solution 10%  | 100 |
| S | For intravenous use Inject contents of one ampule slowly 1 to 2 times daily |     |
| R | Calcium gluconate tablets   | 10  |
| S | 1 tablet 3 times daily before meals   |     |

Salicylates in the usual forms are also sometimes useful.

### CAUTERIZING AGENTS (Caustics)

These are used to destroy warts, condylomata, keratoses, xanthelasma and certain forms of moles when carefully selected and diagnosed as safe by experienced specialists. They can also be used to produce peeling (a specialistic procedure).

- |   |   |
|---|---|
| R | Monochloroacetic acid solution<br>(to prepare—add a few drops of distilled water to 1 Gm. of monochloroacetic acid crystals)  |
| R | Trichloroacetic acid solution<br>(to prepare—as above)  |
| S | Apply with sharply pointed applicator stick sur-<br>rounded by wisp of cotton. Application must<br>be strictly confined to area or lesion to be de-<br>stroyed.                               |
| R | Liquefied phenol (i.e., 95%)  |
| S | Apply with applicator stick and cotton to area<br>to be peeled or removed. Beware of phenol<br>poisoning by absorption and by inhalation!<br>[Selected cases! small areas! good ventilation!] |

Podophyllin or, better, podophyllum resin can be used to cauterize and destroy the lesions of hypertrophic lichen planus and torpid cornified circumscribed neurodermatitis (lichen simplex circumscriptus) but is most valuable in treating condylomata acuminata of the genital areas.

- |   |  |     |
|---|--|-----|
| R | Podophyllum resin                                | 10% |
|   | in compound tincture of benzoin                  |     |
| S | Apply to lesions but keep away from normal skin! |     |

Resorcinol 2% to 3%  
(as "reducing," drying, antiseptic and desquamating agent)

in

Zinc oxide 15%  
Talcum aa  
Glycerin 10%  
Dilute alcohol (50%)

q s

[Medicaments listed above can be added to this base as indicated for the specified effects, either alone or in combination]

- S Medicated shake lotion Shake bottle well and paint on affected areas two, three, or more times daily with a large flat paint or varnish brush

R

(Combinations of menthol, phenol, solution of coal tar, resorcin, and benzocain can be added as specified in above prescription)

Zinc oxide  
Talcum  
Lanolin (anhydrous) aa 15%  
Olive oil (or sesame, cotton seed, etc., oils) 50%  
Tween 80 (polysorbate) 3%  
Solution of aluminum acetate 3%  
Water q s

- S Medicated emulsion—paint on 2, 3, or more times daily with flat, wide paint or varnish brush

R

(Combinations of menthol, phenol, solution of coal tar, resorcin, and benzocain can be added as specified in above prescription)

Triethanolamine 3%  
Lubriderm (unscented) q s

- S As for above prescription

**Subacute to Chronic, Torpid, Thickened Lichenified Eczemas and Eczematoid Conditions**—When the eruptions are widespread, the baths, shake lotions, and emulsions specified above are often the most practical means of getting effective therapy repeatedly and efficiently to all areas

Tars, and especially coal tar preparations, have long been sovereign remedies in chronic eczemas and lichenified dermatoses. The "unrefined" crude coal tar is generally more effective than the decolorized and "refined" products. Among drawbacks are its odor and staining properties and its tendencies to produce folliculitis on hairy areas and photosensitization dermatitis in some cases. The folliculitis can sometimes be avoided by combining the coal tar with antiseptics such as ammoniated mercury or quinolines or antibiotics

R

Crude coal tar 2% to 10%  
{ Ammoniated mercury 3% }  
or { Vioform 3% }  
Zinc oxide ointment ad 300  
One of the medicaments in brackets can be included to reduce tendency to pyoderma

- S Apply to affected areas 2 or more times daily

- R Solution of aluminum acetate 5% to 10% in water (Burow's solution modified) (Freshly prepared)
- S As for above prescription

Convenient proprietary forms are

- R Domeboro Powder  
or  
Domeboro Tabs  
or  
Buro-Sol Powder  
One tablet or one package of powder to a pint or quart of water is the usual range of proper concentrations

Where the lesions are inclined to be purulent and infected ('impetiginized') or where greater drying is required (as in fungous infections and intertrigo), the following are indicated

- R Potassium permanganate tablets 0.3
- S 1 tablet to 2 quarts (or 2 liters) of water (Approx 1:6000 solution for wet compresses or foot and hand soaks)
- or
- For baths (estimated 50 gallons or 400 liters to tubful of water)
- S 20 to 30 tablets to the tubful of water (Roughly 1:60000 to 1:40000 solution)
- (N.B. Be sure to dissolve thoroughly before adding to bath preferably in a milk bottle or other container. Contact of the skin with undissolved particles can cause severe burns!)
- R Cornstarch (hydrolyzed)  
e.g. Linet starch (unscented) (1 pound to tubful of water)
- S Starch bath for soothing and softening
- R Oatmeal bath  
Aveeno
- S Oatmeal bath for soothing and softening  
1 package to tubful of water
- (See warnings regarding slipperiness of tub on page 746)

[Medicated baths e.g. with tars as listed under section on Antipsoriatics on page 760 may prove useful also in generalized eczematous processes]

In generalized or widespread cases, where wet compressing is not feasible and in subacute to chronic eczematous dermatoses the following shake lotions and emulsions find their indications

- R Menthol  $\frac{1}{4}\%$  to  $\frac{3}{4}\%$   
Phenol  $\frac{1}{4}\%$  to  $\frac{1}{2}\%$   
(combined antipruritics)
- and/or
- S Solution of coal tar 5% to 20%  
(as "reducing, antieczematous, and antipruritic agent")
- and/or

Product	Concentration of Corticosteroid	Other Active Ingredients	Vehicle	Quantities and Containers
<b>Group I—Hydrocortisone Only</b>				
Cort Dome Creme	0.25, 0.5, 1, and 2%	None	Acid Mantle Creme	1/4, 1, 4, and 16 oz jars
Cort Dome Lotion	0.5, 1, and 2%	None	Acid Mantle Lotion	1/2, 1, and 4 oz plastic squeeze bottles
Cortef Acetate Ointment	1 and 2.5%	None	Ointment	5 and 20 Gm tubes
Cortufan Cream 1%	1%	None	Water washable cream	10 Gm tube
Cort spray	0.5%	None	Liquid	15 ml squeeze spray bottle
Cortril Acetate Topical Ointment	1 and 2.5%	None	Ointment	5 and 15 Gm tubes
Hydrocortisone Acetate Ointment	1 and 2.5%	None	Ointment	5 and 20 Gm tubes
Hycortole Cream	1 and 2.5%	None	Cream	5 and 15 Gm tubes
Hycortole Lotion	1%	None	Lotion	15 ml bottle
Hycortole Ointment	1 and 2.5%	None	Ointment	5 and 15 Gm tubes
Hydrocortone Acetate Topical Ointment	1 and 2.5%	None	Zinc stearate, polyethylene glycol, propylene glycol water ointment	5, 15, and 30 Gm tubes
Hydrocortone Topical Lotion	0.5, 1, and 2.5%	None	Lotion	15 ml plastic bottle
Topicort Ointment	1 and 2.5%	None	Ointment	5 and 20 Gm tubes
Topicort Spray	0.5%	None	Lotion	15 ml aerosol spray
<b>Group II—Hydrocortisone Plus Other Active Agents</b>				
Acne Cort Dome Creme	0.25%	4% sulfur 1% thiois (4, 6 d chlorophenol), 3% resorcinol monoacetate	Acid Mantle Creme	1 oz tube
Acne Cort Dome Lotion	0.25%	4% sulfur 1% thiois (4, 6 d chlorophenol), 3% resorcinol monoacetate	Acid Mantle Lotion	1 oz plastic squeeze bottle
Achrocort	1%	3% tetracycline hydrochloride	Water-washable cream	5 Gm tube

- R Crude coal tar 10% to 20%  
 Tween 20 0.5%  
 Ointment of zinc oxide ad 300  
 S Water washable crude coal tar ointment, apply

tion)

A great variety of modified tar preparations is commercially available and may present advantages where ordinary coal tar cannot be used, e.g., Tarbonis Cream and Kolpix

- R Solution of coal tar 100  
 S Tar solution—paint on affected areas one or more times daily  
 [N.B. In torpid, very thickened, circumscribed, lichenified areas the coal tar solution can be painted on the thickened sites, covered immediately with adhesive tape (e.g., Elastoplast), left in place for 2, 3, or more days and then removed and freshly applied. This procedure can be repeated as often as required.]  
 R Vioform ointment  
 or  
 Vioform cream  
 or  
 Sterosan ointment  
 or  
 Sterosan cream  
 S Apply to affected parts 2 or more times daily and bandage on as required

The above preparations are particularly useful in secondarily impetiginized or otherwise infected "eczemas" and especially in "eczemas" of certain sites such as the hands and feet (e.g., "housewives eczemas," "dishpan hands," dysidrotic eczemas, "pustular bacterids," recalcitrant vesiculopustular and scaly eruptions of the hands and feet, and otitis externa). The ointments are generally less drying and better tolerated where lubrication is desired. Combinations of these quinoline derivatives as well as of coal tar with hydrocortisone, are among the most effective and modern of local remedies and have a wide range of usefulness in a great variety of eczematous and eczematoid eruptions (see prescriptions given on page 745).

For Both Acute and Chronic Forms and for Special Sites—Topical steroids have been proved to be perhaps the most versatile and effective of external remedies developed for dermatologic therapy. One of the newest of these compounds triamcinolone acetomide (Kenalog or Aristocort acetomide), has in our hands shown superior effectiveness in most cases of inflammatory dermatoses responsive to any form of topical steroid therapy.

There have been no reported systemic ill effects from any of the topical steroids except fludrocortisone (occasional sodium chloride and water retention). In our hands topical steroid preparations have been proved entirely safe or widespread applications in the management of even the most extensive and long lasting dermatoses. Moreover, there have been no reported instances of local

Table 53—Cont'd

Product	Concentration of Corticosteroid	Other Active Ingredients	Vehicle	Quantities and Containers
Hydroderm Ointment	1 and 2.5%	0.35% neomycin base, 1,000 units zinc bacitracin per gram	Emollient base	5 and 15 Gm tubes
Hydro-Tar	0.5 and 1%	5.83% liquor carbonis detergens	Cream	15 Gm tube
Neo Cort Dome Creme	0.5 and 1%	0.5% neomycin sulfate	Modified Acid Mantle Creme	1/2, 1, and 4 oz tubes
Neo-Cort Dome Lotion	0.5 and 1%	0.5% neomycin sulfate	Acid Mantle Lotion	1/2, 1, and 4 oz plastic squeeze bottles
Neo Cortef Cream	1 and 2.5%	0.5% neomycin sulfate	Cream	5 Gm tube
Neo Cortef Lotion 1%	1%	0.5% neomycin	Lotion	15 and 30 ml plastic bottles
Neo Cortef Ointment	0.5, 1, and 2.5%	0.5% neomycin sulfate	Ointment	5 and 20 Gm tubes
Neopolicyn HC Ointment	1%	Neomycin sulfate 3 mg, bacitracin 400 units, polymyxin B sulfate 8,000 units per gram	Neomycin Tartrazine Ointment	5 Gm tube
Neo Resulin F	0.5%	1.5% resorcinol monoacetate, 20% sulfur, 0.5% neomycin sulfate	Cream	15 Gm tube
Neo-Tarcortin Ointment	0.5%	0.35% neomycin sulfate, 5.0% coal tar extract (Tarbonis)	Hydrophobic vanishing cream	7 Gm and 1 oz tubes
Pantho F Cream	0.2 and 1%	2% pantothenylol	Water miscible cream	0.2% in 5, 15, and 20 Gm and 2 oz tubes and 1 lb jar; 1% in 5 and 20 Gm tubes
Resulin F Cream	0.5%	1.5% resorcinol monoacetate, 2% sulfur	Cream	15 Gm tube
Selsunef Ointment	0.5%	0.5% selenium disulfide	Soft petrolatum	5 Gm tube
Sterosan Hydrocortisone Ointment and Cream	1%	3% 5, 7-dichloro 8 hydroxy-quinaldine	Ointment or cream	5 Gm tube
Supertah 5	1%	Supertah (a concentrate of crude coal tar) equivalent to 5% crude coal tar	Washable base	1/2 oz jar

Achromycin Ointment 3%	2%	3% tetracycline hydrochloride	Ointment	5 Gm tube
Bicrimycin with Hydrocortisone 1%	1%	0.5% neomycin, 500 units bacitracin per gram	Ointment	1/4 oz tube
Bur Cort	0.25, 0.5, and 1%	None	Burrow's emulsion	1/2, 1, and 2 oz plastic bottles
Calder-cort	1%	3% calcium undecylenate 0.5% neomycin sulfate	Water washable ointment	7 Gm tube
Cort Acne Lotion	0.25%	8.5% n sulfanilyacetamide, 2% resorcinol, 3% colloidal sulfur	Flesh colored greaseless lotion	1 oz bottle
Cort Tar Quin Creme	0.5 and 1%	2% solution of coal tar U.S.P., 1% diiodohydroxyquinoline U.S.P.	Acid Mantle Creme	1/4, 1 and 4 oz tubes
Cort Tar Quin Lotion	0.5 and 1%	2% solution of coal tar U.S.P., 1% diiodohydroxyquinoline U.S.P.	Lotion	15, 30, and 120 ml plastic bottles
Cortisporin Ointment	1%	5,000 units polymyxin B sulfate, 400 units bacitracin, 5 mg neomycin per gram	Petrolatum	1/4 oz tube
Cort Quin Creme	0.5 and 1%	1% diiodohydroxyquinoline	Cream	15 and 30 Gm tubes
Cortomycin	1 and 2.5%	0.5% neomycin sulfate	Ointment	15 and 20 Gm tubes
Epiderm ap Creme	0.5%	2% salicylic acid, 1% iodochlorhydroxyquin, 1/4% menthol	Cream	15 and 20 Gm tubes
F A Cort Creme	0.5 and 1%	56,000 IU estrone per ounce 100,000 U.S.P. units Vitamin A per ounce	Acid Mantle Creme	15 Gm tube
Hist A Cort E	0.5 and 1%	100,000 units synthetic vitamin A and 56,000 IU estrone per ounce, 2% pyrilamine maleate	Acid Mantle Creme	1/4 and 1 oz tubes
Hydrobalm Topical Cream	0.5%	3% benzocaine, 0.05% hexylated metacresol	Water washable fleshstone calamine cream	5, 15, and 30 Gm tubes
Hydrobalm Topical Lotion	0.5%	3% benzocaine, 0.05% hexylated metacresol	Water washable fleshstone calamine lotion	15 and 30 ml plastic bottles

(Table 53 continued on pages 742-744)



Table 53—Cont d

Product	Concentration of Corticosteroid	Other Active Ingredients	Vehicle	Quantities and Containers
<b>Group IV—Fludrocortisone</b>				
Allorone Acetate Lotion	0.1 and 0.25%	None	Lotion	15 ml plastic bottle
Allorone Acetate Ointment	0.1 and 0.25%	None	Emollient base	5 and 15 Gm tubes
F Cortef Ointment	0.1 and 0.2%	None	Ointment	5 Gm tube
Florinef Lotion	0.05, 1, and 0.2%	None	Lotion	15 ml plastic squeeze bottle
Florinef Ointment	0.1 and 0.2%	None	Plastibase	5 and 20 Gm tubes
Florinef S Cream	0.1%	0.25% neomycin, 0.025% gramicidin	Cream	5 Gm tube
Florinef S Lotion	0.05 and 0.1%	0.25% neomycin, 0.025% gramicidin	Lotion	15 ml plastic squeeze bottle
Florinef S Ointment	0.1%	0.25% neomycin, 0.025% gramicidin	Plastibase	5 and 20 Gm tubes
Myconef Ointment	0.1%	0.25% neomycin, 0.025% gramicidin, 100 000 units nystatin per gram	Plastibase	15 Gm tube
<b>Group V—Hydrocortisone Ethamate Hydrochloride)</b>				
Magnacort Topical Ointment	0.5%	None	Ointment	1/8 and 1/2 oz tubes
Neo Magnacort Topical Ointment	0.5%	0.5% neomycin sulfate	Ointment	1/8 and 1/2 oz tubes
Aristocort Aceton de Cream	0.1%	None	Cream	5 and 15 Gm tubes
Kenalog Cream	0.1%	None	Cream	5 and 15 Gm tubes
Kenalog Ointment	0.1%	None	Ointment	5 and 15 Gm tubes
Kenalog Lotion	0.1%	None	Lotion	15 ml plastic squeeze bottle

\*Based on Table 1 in Sulzberger, M. B., Witten, V. H., and Kopf, A. W. The Topical and Systemic Use of Corticosteroids in the Treatment of Skin Disease, Postgrad Med 24: 379, 1958.

†N.B. The number of topical preparations containing corticosteroids alone or in combination has continued to multiply at such a rate that it appears inexpedient to attempt to tabulate all the new items and combinations, which add few if any therapeutic advantages over those listed in this table which is complete to 1959. However, it should be mentioned that two new groups of compounds have been added to the available topical corticosteroid preparations: fluorometholone (Oxylone Cream and Neo Oxylone Ointment) and dexamethasone (Neo Decadron Cream).

		5% coal tar extract		Hydrophilic vanishing cream		7 Gm. and 1 oz tubes	
Tarcorin Ointment	0.5%						
Tarcorin Lotion	0.5%				Lotion	15 ml. plastic squeeze bottle	
Terra Cortril Ointment	1%				Ointment	5 and 15 Gm tubes	
Vioform Hydrocortisone Cream	1%				Cream	5 and 20 Gm tubes	
Vioform Hydrocortisone Lotion	1%				Water washable lotion	15 ml. plastic squeeze bottle	
Zetone Cream	0.25%				Vanishing cream base	1 oz. jar	
Zetone Lotion	0.25%				Flesh colored greaseless lotion	30 ml. bottle	
<i>Group III.—Prednisolone and Prednisolone 21 Phosphate</i>							
Hydeltrasol Topical Lotion	0.5% prednisolone				Lotion	15 ml. plastic squeeze bottle	
Hydeltrasol Lotion	0.5% prednisolone 21 phosphate (as sodium salt)				Lotion	15 ml. plastic squeeze bottle	
Hydeltrasol Ointment	0.5% prednisolone 21 phosphate (as sodium salt)				Ointment	5 Gm tube	
Metu Derm Aerosol	0.3% prednisolone (a 3 second spray delivers approximately 0.5 mg prednisolone)				Liquid	150 Gm. aerosol spray can	
Metu Derm Cream	0.5% prednisolone				Water washable cream	10 and 25 Gm tubes	
Metu Derm Ointment with Neomycin	0.5% prednisolone				White petrolatum	10 and 25 Gm tubes	
Neo Delta Cortef Lotion	0.5% prednisolone				Lotion	15 ml. bottle	
Neo Delta Cortef Ointment Topical	0.5% prednisolone				Ointment	5 and 20 Gm tubes	
Neo-Hydeltrasol Lotion	0.5% prednisolone 21 phosphate (as sodium salt)				Lotion	15 ml. plastic squeeze bottle	
Neo-Hydeltrasol Ointment	0.5% prednisolone 21 phosphate (as sodium salt)				Ointment	5 Gm tube	

(Table 53 continued on page 744)

## EMOLLIENTS AND DEMULCENTS

This class of medicaments is used to make the skin surface supple and less dry or scaly. They do this by confining and preventing evaporation of the sensible and insensible perspiration and/or by supplying water (humectant action), colloids, oils, and greases to the horny layer and by softening and/or removing excess scales.

- R Rose water ointment
- S Apply as often as required and especially after each washing or bathing
- R Acid Mantle Creme
- S As for first prescription
- R Liquid mineral oil
- S As for first prescription
- R Lanolin or Borofax
- S As for first prescription
- R White petrolatum
- S As for first prescription
- R Nivea oil  
(Emulsion of cholesterol derivatives of lanolin)
- S As for first prescription
- R Lubriderm (unscented)  
(Emulsion of cholesterol derivatives)
- S As for first prescription
- R Acid Mantle Lotion
- S As for first prescription.
- R Aveeno for the bath
- S
- some protection ]
- R Linist starch (unscented)  
(Hydrolyzed cornstarch)
- S 1 pound to tubful of lukewarm water  
[Caution As for preceding prescription]
- R Glycerin and rose water lotion  
'Lotio glycerini'
- Glycerin
- Rose water   āā
- S As for first prescription  
[Especially useful for dry or chapped hands—probably because of humectant action of the proportions of glycerin and water]

irritation or allergic sensitization. This remarkable efficacy and clinical record of safety, plus the lack of sting, stench, or stain, have made this drug one of choice as an antieczematous agent in practically all stages of "eczema," as an antipruritic and as a general anti-inflammatory topical remedy. Despite their present high cost to the patient, hydrocortisone or other topical steroids, alone or in combination with other topical agents, often prove themselves more economical than older remedies by virtue of the speedy relief afforded, sometimes by relatively small quantities. However, topical steroids should not generally be relied upon *alone*, for they should never be regarded as specific or curative agents but rather as *morbidity-static* ones. Topical steroids, just like systemic ACTH or corticosteroid therapy, should be depended upon only to give relief while nature, either alone or together with the remedies prescribed by the physician, strives to effect the cure.

- R Hydrocortisone free alcohol 1% to 2½%  
 Petrolatum ad 150  
 or  
 Hydrocortisone 1% to 2½%  
 Hydrophilic ointment ad 150  
 S Apply by gentle massage two or more times daily  
 R Hydrocortisone lotions 1% to 2½%  
 S Apply to affected parts 2 or more times daily

[Proprietary lotions containing 1 to 2½ per cent hydrocortisone as the free alcohol or acetate are available as proprietaries manufactured by many reliable pharmaceutical houses (See Table 53)]

Especially in widespread dermatoses, these lotions are sometimes more economical and effective than the ointments or creams, as they can be more rapidly applied and evenly spread in a thin film over large skin areas.

**COMBINATIONS OF TOPICAL HYDROCORTISONE WITH CRUDE COAL TAR AND DERIVATIVES**—These are among the best antieczematous agents available. They are marketed under a variety of names (See Table 53).

The following are particularly effective for eczematous or eczematoid eruptions in special areas, e.g., hands, feet, anogenital regions, external ear and external ear canal, eyelids, labial and perioral areas, and for infected "eczemas" in general.

- R Combinations of hydrocortisone with quinolines  
 (See Table 53), e.g.,  
 Vioform ointment with  
 1% to 2½% hydrocortisone free alcohol  
 or  
 Vioform cream with  
 1% hydrocortisone

- R . . . . .

- R Kenalog cream or Kenalog ointment or lotion

R	Dihydroxyanthranol (Anthralin) ointments 0.1, 0.25, 0.5, and 1.0%	
S	Apply by gentle massage with finger covered by rubber finger cot, 1 to 3 times daily [Start with weaker concentrations and increase as required]	
R	<i>Modified Whitfield's Ointment</i>	
	Salicylic acid	0.9
	Benzoic acid	1.8
	Petrolatum	
	Lanolin aa ad	30.0
S	Rub into affected areas 2 or more times daily	
R	<i>Tincture of Benzoic and Salicylic Acid</i>	
	Salicylic acid	3.6
	Benzoic acid	7.2
	Alcohol ad	120.0
S	Paint on affected areas 1 to 3 times daily and powder over with talcum or antimycotic powder [See following prescriptions]	
R	Resorcinol	3.0 to 6.0
	Calamine lotion ad	100.0
S	Paint on affected areas once to twice daily until desquamation occurs. Then soothe with plain calamine lotion. Repeat if and as necessary.	
R	Salicylic acid	0.9 to 1.5
	Sulfur precipitate	1.5 to 3.0
	Ointment of zinc oxide	30.0
S	Apply to affected areas once to twice daily	

For prevention of recurrences and in managing mild cases of dermatophytosis of the feet and intertriginous areas, the application of preparations containing fatty acids (e.g., propionic, undecylenic, and caprylic acid) is often useful. Many proprietary preparations are available under various names. Among those having quite general acceptance are Desenex powder, ointment, and tincture, Sopronol powder, ointment, and tincture, new Salundek ointment.

An important feature of management is the prevention of skin damage by friction, sogginess, maceration, heat, and humidity, as these furnish the conditions for the rapid multiplication and developing pathogenicity of the fungi. For this reason, the skin of intertriginous areas (beneath breasts, folds of the pendulous abdomen, intergluteal, inguinal and perivulvar folds, between toes, at the labial commissures, etc.) should be kept dry and 'aerated' by every possible means such as, for example, soft cloths or lamb's wool wisps separating the toes aerated, perforated shoes, sandals, loose absorbent clothing, scrupulous gentle drying after bathing, and the daily application of one of the fatty acid containing powders to the areas prone to fungous infection. It can be predicted that topical therapy and depilation by x rays will be almost entirely superfluous when the griseofulvin safety and efficacy have been established in the treatment of the common fungous infections of the hair and nails. The following descriptions of pre-griseofulvin approaches will then be of historical rather than practical value. When griseofulvin is given orally in doses of from 250 to 1,000 mg daily (the lower dose for smaller children), fungous infections of scalps will generally yield in a few weeks. This

Since scaliness and dryness are often the result of either clinically observable or 'subclinical' inflammation, most of the milder measures recommended for eczematous dermatitis (page 738) will be found useful as emollients and demulcents in many cases of 'dry skin'. Moreover, 'dry skin' is frequently a symptom of systemic changes which should be correctly treated when possible, e.g., hormonal (thyroid) disturbances, nutritional defects, senescence, and hereditary anomalies.

### ANTIFUNGAL AGENTS (Agents Used in Superficial Fungous Infections by Dermatophytes and *Candida* [Monilias])

Dermatology deals mainly with the fungous infections of the glabrous skin, hair, and nails by the dermatotropic fungi known as dermatophytes and by *Candida albicans*. This section is confined to the presentation of the drugs of choice in these particular infections which are today generally called dermatophytosis and candidiasis or moniliasis.

**Infections of the Glabrous Skin by Dermatophytes**—A new oral antibiotic, griseofulvin (Fulvicin, Grisfulvin), is now showing remarkable promise in the treatment of all forms of dermatophytic infections of the skin, hair, and nails. Following the report of Gentles' studies on guinea pigs and according to the now numerous published clinical reports the administration by mouth of 1 to 2 Gm per day is generally well tolerated and usually leads to clinical clearing of most of the skin lesions in a few weeks. If this *Penicillium* derivative lives up to only a part of its early spectacular promise it will represent a drug of choice for microsporon infections including those of children's scalps and all trichophyton infections including athlete's foot, etc. There are also reports of its efficacy in certain deep mycoses notably those due to *Nocardia brasiliensis* (Latapi and co workers).

However, there are still many unknowns concerning this antifungal antibiotic including its long term toxicity, its allergenic potentials, the recurrence rate and reinfection rate after treatment, whether or not or when it is advantageous to combine the administration of internal antibiotics with the older external remedies, etc.

For these reasons among others, the old established forms of treatment are at this moment still indispensable and are here described.

The main old established therapeutic mechanism in dealing with these is the peeling off or other removal of the horny layer, soggy macerated skin surface, or horny structures which harbor the massive colonies of the causal fungi, combined with a surface fungicidal or fungistatic effect which prevents the spread of the colonies and invasion of new areas. The following are among the most useful preparations for these purposes.

- |   |                                   |         |
|---|-----------------------------------|---------|
| B | Dilute tincture of iodine         |         |
|   | Tincture of iodine                | 1 part  |
|   | Alcohol                           | 6 parts |
| S | Dab on affected areas twice daily |         |
|   | Powder over with talcum           |         |
| B | Ammoniated mercury ointment       |         |
| S | Apply to affected areas by gentle |         |
|   | massage 2 to 3 times daily        |         |

- R** Dihydroxyanthranol (Anthralin)  
ointments 0.1, 0.25, 0.5, and 1.0%
- S** Apply by gentle massage with finger covered by rubber finger cot 1 to 3 times daily [Start with weaker concentrations and increase as required]
- Modified Whitfield's Ointment*
- R**
- |                |      |
|----------------|------|
| Salicylic acid | 0.9  |
| Benzoic acid   | 1.8  |
| Petrolatum     |      |
| Lanolin aa     | ad   |
|                | 30.0 |
- S** Rub into affected areas 2 or more times daily
- Tincture of Benzoic and Salicylic Acid*
- R**
- |                |       |
|----------------|-------|
| Salicylic acid | 3.6   |
| Benzoic acid   | 7.2   |
| Alcohol        | ad    |
|                | 120.0 |
- S** Paint on affected areas 1 to 3 times daily and powder over with talcum or antimycotic powder [See following prescriptions]
- R**
- |                 |            |
|-----------------|------------|
| Resorcinol      | 3.0 to 6.0 |
| Calamine lotion | ad         |
|                 | 100.0      |
- S** Paint on affected areas once to twice daily until desquamation occurs. Then soothe with plain calamine lotion. Repeat if and as necessary.
- R**
- |                        |            |
|------------------------|------------|
| Salicylic acid         | 0.9 to 1.5 |
| Sulfur precipitate     | 1.5 to 3.0 |
| Ointment of zinc oxide | 30.0       |
- S** Apply to affected areas once to twice daily

For prevention of recurrences and in managing mild cases of dermatophytosis of the feet and intertriginous areas, the application of preparations containing fatty acids (e.g., propionic, undecylenic and caprylic acid) is often useful. Many proprietary preparations are available under various names. Among those having quite general acceptance are Desenex powder, ointment, and tincture; Sopronol powder, ointment, and tincture; new Salundek ointment.

An important feature of management is the prevention of skin damage by friction, sogginess, maceration, heat, and humidity, as these furnish the conditions for the rapid multiplication and developing pathogenicity of the fungi. For this reason, the skin of intertriginous areas (beneath breasts, folds of the pendulous abdomen, intergluteal, inguinal and perivulvar folds, between toes at the labial commissures, etc.) should be kept dry and 'aerated' by every possible means such as, for example, soft cloths or lamb's wool wisps separating the toes, aerated, perforated shoes, sandals, loose absorbent clothing, scrupulous gentle drying after bathing, and the daily application of one of the fatty acid containing powders to the areas prone to fungous infection. It can be predicted that topical therapy and depilation by x rays will be almost entirely superfluous when the griseofulvin safety and efficacy have been established in the treatment of the common fungous infections of the hair and nails. The following descriptions of pre-griseofulvin approaches will then be of historical rather than practical value. When griseofulvin is given orally in doses of from 250 to 1,000 mg daily (the lower dose for smaller children), fungous infections of scalps will generally yield in a few weeks. Thus

holds true for favus and *Trichophyton tonsurans* infections as well as for those due to other trichophytons and microsporons. Fungous infections of the nails generally yield more slowly and it can take several months before the affected nails are replaced by normal structures. Unfortunately *Candida albicans* infections resist griseofulvin therapy and may indeed be made worse by it. The duration of cure and the incidence of recurrence and/or reinfection are not yet known.

**External Treatment of Fungous Infections of the Hairy Scalp**—This section will deal only with the common mycotic infections of the hairy scalp in children as caused in our geographic region by the two most frequently encountered species of *Microsporum* fungi namely *M. audouinii* and *M. lanosum*. In order to treat these safely and correctly it is imperative that the precise species of the infecting fungus be established by examination and culture from the hairs. If the microorganism is *M. audouinii* and the child is well below the age of puberty only x ray epilation by established dermatologic procedures will prove a safe and regularly effective external method.

If on the other hand the infecting organism is a *M. lanosum* or other zoophilic fungus caught from a cat or dog or other animal and is not the very refractory anthropophilic *M. audouinii* careful repeated daily external applications and vigorous shampooing will often lead to a cure. Preparations such as those listed above under fungous infections of the glabrous skin and especially the tincture of iodine and the mercurial ointment applied alternately or Salundek used assiduously, are among the drugs of choice. Very often the local applications and shampooing must be carried out to the point of slightly increased local irritation in order for the desired result to be achieved. It is probable that just as in the case of the cure of fungous infections of the glabrous skin the main therapeutic effect is achieved through ridding the tissues of the masses of growing fungi by means of the actual removal of the infected hairs and other horny material itself together with the simultaneous prevention of the spread of the infection to new structures and areas by the surface presence of antifungal drugs.

Whether oral griseofulvin or external therapy is used to prevent recurrences and to be sure of permanent cure the freedom of the scalp from infected hairs must be assured by regular routine examinations under the dark ultraviolet or Wood's light and when necessary by microscopic and cultural examination of suspected hairs.

**External Treatment of Fungous Infections of the Nails**—Generally mild fungous infections of the nails which are causing no marked disfigurement and no cutaneous disease are best left untreated. This applies especially to toenails for the infection is so very common and generally innocuous that it is best to let sleeping dogs lie.

When nails are to be treated by topical measures the first principle of removing the horny material which contains the masses of fungous colonies still applies (see page 747). This can be done by dermatosurgical measures which range from complete surgical avulsion of the affected nails (a method usually necessary when the infecting fungus is a *Trichophyton purpureum*) to daily scraping off of the infected surface material with the edge of a glass slide, with an abrasive stone or with a dental burr. Whatever the method of removal, one of the antifungal



medicaments listed above in the section on treatment of the glabrous skin should be applied regularly before and after the removal of the infected masses of keratin and, if possible, bandaged on at night

The not uncommon accompanying paronychias must be treated by systemic measures, hot soaks, and topical medicaments designed to allay the inflammation and combat the pyogenic as well as the fungal pathogens. For these purposes the following prescriptions are useful

- R Vioform and hydrocortisone cream
- R Sterosan and hydrocortisone cream
- R Mycostatin ointment
- R Neosporin ointment

**Monilial Infections**—As stated, griseofulvin appears to be entirely ineffective against monilial infections. This is particularly unfortunate because among the most common fungous infections of the skin and nails are those caused by *Candida albicans*—formerly known as *Monilia albicans*. It is often difficult to establish the causal significance of this fungus even when present, as it is among the common nonpathogenic skin saprophytes and may grow exuberantly whenever the skin is damaged by other causes and is kept moist, macerated, and warm. Therefore, moniliasis is most likely to occur in the large skin folds in the intergluteal and anal genital areas at the angles of the mouth (perleche) and around the fingernails (paronychia) and in "wet workers." It is also likely to occur in obese persons and in those with diabetes.

In addition to the antifungal measures described in the section on Dermatophytes, the following prescriptions are of antimonal value

- R *Gentian Violet Solution*

Methylrosaniline chloride	0.6
Alcohol	6.0
Distilled water q.s. ad	60.0
- S Paint on affected areas 2 to 3 times daily and powder over with antifungal powder (see previous section)
- [NB Stains can be removed from skin with aromatic spirits of ammonia, and from clothing by washing with sodium carbonate, soap and water]
- R Mycostatin ointment or powder
- S Apply to affected areas 2 to 3 times daily

Often the control or elimination of contributory and predisposing factors takes on even more importance than direct antifungal therapy. These include the control of diabetes, obesity, hyperhidrosis, macerating occupational and other exposures, reduction of the occlusive and frictional effects of clothing and footwear, and oral hygiene and dental correction of malocclusion.

At present it is of utmost importance to recall that overgrowth of monilias and resultant moniliasis is today not infrequently the consequence of destruction

holds true for favus and *Trichophyton tonsurans* infections as well as for those due to other trichophytons and microsporons. Fungous infections of the nails generally yield more slowly, and it can take several months before the affected nails are replaced by normal structures. Unfortunately *Candida albicans* infections resist griseofulvin therapy and may indeed be made worse by it. The duration of 'cure' and the incidence of recurrence and/or reinfection are not yet known.

**External Treatment of Fungous Infections of the Hairy Scalp**—This section will deal only with the common mycotic infections of the hairy scalp in children as caused in our geographic region by the two most frequently encountered species of *Microsporum* fungi, namely, *M. audouinii* and *M. lanosum*. In order to treat these safely and correctly it is imperative that the precise species of the infecting fungus be established by examination and culture from the hairs. If the microorganism is *M. audouinii* and the child is well below the age of puberty, only x ray epilation by established dermatologic procedures will prove a safe and regularly effective external method.

If, on the other hand the infecting organism is a *M. lanosum* or other "zoophilic" fungus caught from a cat or dog or other animal and is not the very refractory anthropophilic *M. audouinii*, careful repeated daily external applications and vigorous shampooing will often lead to a cure. Preparations such as those listed above under fungous infections of the glabrous skin, and especially the tincture of iodine and the mercurial ointment applied alternately, or Salundek used assiduously, are among the drugs of choice. Very often the local applications and shampooing must be carried out to the point of slightly increased local irritation in order for the desired result to be achieved. It is probable that just as in the case of the cure of fungous infections of the glabrous skin the main therapeutic effect is achieved through ridding the tissues of the masses of growing fungi by means of the actual removal of the infected hairs and other horny material itself, together with the simultaneous prevention of the spread of the infection to new structures and areas by the surface presence of antifungal drugs.

Whether oral griseofulvin or external therapy is used to prevent recurrences and to be sure of permanent cure the freedom of the scalp from infected hairs must be assured by regular routine examinations under the 'dark ultraviolet' or Woods light and when necessary by microscopic and cultural examination of suspected hairs.

**External Treatment of Fungous Infections of the Nails**—Generally mild fungous infections of the nails which are causing no marked disfigurement and no cutaneous disease are best left untreated. This applies especially to toenails for the infection is so very common and generally innocuous that it is best to let sleeping dogs lie.

When nails are to be treated by topical measures the first principle of removing the horny material which contains the masses of fungous colonies still applies (see page 747). This can be done by dermatosurgical measures which range from complete surgical avulsion of the affected nails (a method usually necessary when the infecting fungus is a *Trichophyton purpureum*) to daily scraping off of the infected surface material with the edge of a glass slide, with an abrasive stone, or with a dental burr. Whatever the method of removal, one of the antifungal

- R Salicylic acid 5% to 15%  
 Petrolatum ad 30 0
- S Apply once or several times daily to areas to be peeled
- R Salicylic acid plaster 40%  
 (on moleskin adhesive)
- S Cut to fit area to be peeled, apply and leave in place 24 to 72 hours. Remove, clean away macerated horny material, and reapply plaster as often as required
- R Benzoic and salicylic acid ointment  
 (modified Whitfield's ointment)
- S Apply one or more times daily until desired peeling sets in—then apply soothing remedies  
 [Especially useful in fungous infections of the feet, etc.]
- R Resorcinol 3% to 6%  
 Zinc oxide  
 Talc aa 15 0  
 Glycerin 10 0  
 Water  
 Alcohol aa 40 0
- S Apply one or more times daily until desired peeling sets in. Then soothe  
 [Especially useful in superficial fungous infections of the groins and other intertriginous areas]
- R Salicylic acid collodion
- S Apply to corn or callus as required until peeling sets in  
 [Especially useful in treating corns]
- R Salicylic acid 10 0  
 Diachylon ointment ad 100 0
- Lead Oleate Plaster*
- R Lead monoxide 1000 0  
 Olive oil 1000 0  
 Lard 1000 0  
 Water qs
- Diachylon Ointment*
- R Lead oleate plaster 50 0  
 Lavender oil 1 0  
 White petrolatum 49 0
- S Rub into hyperkeratotic thickened skin areas with a soft nailbrush or toothbrush one or more times daily  
 [Especially useful in hyperkeratotic lesions of palms and soles. Do not rub into large denuded areas as lead poisoning may result]

N B See also the topical remedies given for acne (page 729), and for superficial fungous infections (page 747), since these too act mostly by virtue of their keratolytic effects

**AGENTS USED IN INFESTATIONS (Antiscabietic and Antilouse Drugs)**

R	Gamma benzene hexachloride ointment	600
S	'	'

For Pediculus:—Apply directly to all the in-

R	Crotamiton cream (Eurax)	200 to 600 Gm
S	As above	

B	Benzyl benzoate chlorophenothane lotion (Topocide a mixture of DDT benzyl benzoate, and benzocaine)	120
---	--	-----

S Apply evenly to entire body from neck down after taking a warm soap-and water bath and drying thoroughly. Massage in carefully to predisposed areas such as wrists between fingers around nipples on axillary folds. Do not get into eyes. Leave on for 24 hours then take a warm soapy bath again and change to all clean freshly washed bedclothes under clothes and if possible dry cleaned outer garments. Have all members of family and other contacting persons examined by doctor and treated if necessary.

Lice and nits of the eyelash area are best treated with ophthalmic yellow oxide of mercury ointment.

## KRATOLYTICS

Keratolytics are used to remove excess horny material or keratin—as in treating calluses, corns, scabies, hyperkeratotic and superficial fungous infections, hyperkeratotic plugs in acne, etc. Since these agents act not by lysis or dissolving of keratin but by producing desquamation, only time-honored custom justifies retention of the designation "keratolytics" rather than that of "desquamating agents" or "peeling agents" for this class of drugs.

lupus erythematosus like skin changes, exfoliative dermatitis, ophthalmic disorders and blood dyscrasias) Regular complete examinations, including dermatologic inspections blood counts, and examinations for disturbances of visual accommodation, are essential while patients are taking the above drugs

In addition to the systemic medication, all measures to protect the skin against great or prolonged exposures to sunlight and artificial ultraviolet rays are indicated For, while not all cases of discoid lupus erythematosus are manifestly harmed by exposures to light, spread of the eruption, exacerbation and transformation into subacute or acute disseminated forms are not altogether unusual following exposures to sun or ultraviolet rays

The chemical and physical sun screening preparations are therefore among the drugs to be used in lupus erythematosus (See section on "Sun Screens," page 771)

**Acute Disseminated (Systemic) Lupus Erythematosus**—The treatment of acute disseminated lupus erythematosus is in many ways similar to that of pemphigus, at least in so far as the use of morbidistatic doses of corticosteroids and/or ACTH is concerned (See section on Bullous Dermatoses page 732)

In addition, the administration of the antimalarials, somewhat as used in chronic discoid lupus erythematosus, is today believed by many authorities to be of value Other authorities believe these antimalarials to be dangerous and strictly contraindicated in acute systemic lupus erythematosus It is my impression that the ill effects observed by some who used the antimalarials may be based on mechanisms similar to those of the Herxheimer reaction in syphilis, and that these may be avoided or reduced by starting with very small doses of antimalarials and by the concomitant steroid therapy

I usually give the antimalarials simultaneously with the corticosteroids, but often (and especially at the beginning) in much smaller doses than those employed in chronic discoid lupus erythematosus

A most important feature in prolonging the lives of patients with acute disseminated lupus erythematosus is the forestalling and/or treatment of such dire manifestations and complications as pleurisy and other pulmonary disease, pericarditis and other cardiopathy, and especially renal disease and renal failure by the indicated anti-infectious dietary, and supportive measures

**Subacute Disseminated Lupus Erythematosus**—The nosology of this form places it between the chronic discoid form of lupus erythematosus and the acute disseminated form Treatment is essentially along the lines of both these forms with special emphasis on avoiding or combating stresses which can lead to the transition into the acute disseminated form Prominent among these stresses are various intercurrent infections exposure to cold heat, and particularly light All measures to protect against these must be scrupulously and persistently carried through (See section on "Sun Screens" page 771)

### ANTIPERSPIRANTS (Agents Used in Hyperhidrosis)

Hyperhidrosis or excessive sweating and faulty delivery and composition of the sweat are contributory factors which can be of great importance in such dermatoses as fungous infections (*dermatophytosis moniliasis* of the skin), eczema

## DERMATOLOGIC DRUGS

### AGENTS USED IN LICHEN PLANUS

There are no drugs which are regularly effective in lichen planus. In the past arsenic and bismuth have been considered as the measures. Corticosteroids and recently especially triamcinolone therapy, remain the measures most frequently employed.

Antipruritic measures (page 757) are often required. In eczematous dermatitis (page 738) are also indicated. In the early stage, and site of the lesions (e.g., thickened, hyperkeratotic plaques) intralesional injections of hydrocortisone or other effective corticosteroids are often beneficial.

### AGENTS USED IN LUPUS ERYTHEMATOSUS

At least three clearly recognizable forms of disease are designated as lupus erythematosus in their designations: (1) chronic discoid lupus erythematosus, (2) acute disseminated lupus erythematosus (also today some call it *lupus erythematosus*), and (3) subacute disseminated lupus erythematosus.

It is probable that these three designations apply to different degrees of the same syndrome, and there are undeniable evidences of transition from one form to another.

However, the therapy of the different forms differs and is not at all similar. Discoid lupus erythematosus generally is an essentially cosmetic condition, acute disseminated lupus erythematosus is fatal unless kept under constant adequate morbidistatic treatment. Subacute disseminated lupus erythematosus is a very serious disease, acute form. The differential diagnosis rests on clinical observation upon the presence or absence of the "LE factor" and the detection of the "LE phenomenon" in the blood.

**Chronic Discoid Lupus Erythematosus.**—The older drug has been almost entirely replaced by the antimalarial quinine. In rare refractory cases will the specialist still be forced to resort to gold, bismuth, and other drugs which were routine until recently. The following are representative of the present drugs of choice.

R	Quinacrine hydrochloride tablets	1
S	1 to 2 tablets daily	
R	Chloroquine phosphate tablets	2
S	1 tablet daily for first few days. If tolerated, increase dose to 2 or 3 tablets daily. Continue as tolerated and for some time after skin has become inactive.	
	Tingon	
R	Atabrine (quinacrine) HCl	25 m

Among the drugs to be used symptomatically and systemically in controlling hyperhidrosis of the palms and soles in particular, but of other body areas as well are the potent anticholinergic drugs like Banthine or Pro Banthine

When anticholinergics are given, the side effects such as blurring of vision difficulty of urination, and dryness of the mouth are the limiting factors, and very often the dose which will control the hyperhidrosis is the same as that which begins to produce such side effects

Ephedrine atropine, ergotamine tartrate, and barbiturates are among the older drugs which are sometimes useful in controlling nervous and emotional hyperhidrosis, in particular, and some other forms as well. Combinations of these are common

Here again the limiting factors are the side effects of dryness of the mouth dilatation of the pupil, etc., which are produced by doses usually very close to those necessary to bring about a reduction of sweating

One of the best specialistic procedures for managing certain forms of localized hyperhidrosis is a course of properly administered and safely dosed x-radiations. This is not only the domain of the experienced specialist but also outside the scope of this book on drugs

## PIGMENT PROMOTING AGENTS

Too little pigment in certain skin areas can be fully as disfiguring as too much pigment. Loss of pigment, as in vitiligo or leukoderma probably brings a greater number of patients to the doctor than does excessive pigmentation

The internal or systemic or other cause can be discovered in only a small proportion of cases e.g., in syphilitic or psoriatic leukodermas in loss of pigment due to dietary and vitamin B deficiencies, to hormonal disturbances, in achromia parasitaria due to fungi, or in pigment loss caused by exposures to external agents such as rubber articles and medicaments containing hydroquinones, etc. Therefore in most cases of vitiligo and other disfiguring loss of pigment, the treatment cannot be causal but remains symptomatic. As of today, the treatment of skin areas with too little pigment is quite as inadequate and unsatisfactory as the treatment of hyperpigmentation. (See section on Bleaches page 731)

However, the oral administration of 8-methoxypsoralen (methoxsalen, Orsoralen) combined with exposure to natural sunlight or, when sunlight is not available to ultraviolet lamps, will bring about repigmentation in a certain proportion of the properly treated cases. Cosmetically fairly satisfactory repigmentation in about 1 case in 7 is the figure obtained by us in the series of patients treated at the Skin and Cancer Unit of New York University Hospital

The repigmentation obtained is not necessarily lasting. It may remain only a few weeks, but sometimes lasts up to several years without requiring retreatment. Not only does the larger number of cases fail to respond, but even in responsive cases some areas are likely to remain refractory. Particularly the hands and the genitalia are notorious for their lack of pigmentary response, but any skin areas can prove to be unyielding

tous and eczematoid eruptions dyshidrosis of hands and feet intertrigos, prickly heat, etc. The control of hyperhidrosis is therefore an important medical matter as well as being of generally recognized esthetic and cosmetic importance in our society

Almost all of the purchasable antiperspirants are effective in moderate degrees of axillary sweating and are relatively safe—as attested by their daily use by tens of millions of persons. They are almost all based upon their content of aluminum salts including aluminum chloride and aluminum chlorhydroxide as the simplest representatives

On occasion, however the preparations containing these salts produce allergic contact dermatitis or primary irritant dermatitis and can contribute or actually cause abscesses of the large sweat glands and apocrine glands especially of the axillae. In such cases they either cannot be used at all or can be used only sparingly. No very effective substitute for the aluminum salts has yet been found. However, considerable control of the axillary odors can be achieved by using preparations containing antibiotics such as neomycin even without the antiperspirant aluminum salt. Moreover the soaps containing good skin surface germicides such as Lifebuoy soap Dial soap and others are effective in controlling axillary odors for many hours and sometimes even days after their thorough use

A representative prescription of an antihidrotic lotion is the following

R	Aluminum chloride	24 0
	Dilute alcohol to make	100 0
S	Dab on with absorbent cotton as needed in cases of excessive sweating of palms soles or armpits	

In hyperhidrosis of the feet the following powder has been found useful by our group

R	<i>Medicated Foot Powder</i>	
	Salicylic acid powder	2 0
	Boric acid powder	6 0
	Zinc stearate	3 0
	Exsiccated alum	1 0
	Starch	10 0
S	Purified talc to make	100 0
	Dust on 2 to 4 times daily as required	

Foot baths with a 10 per cent solution of formaldehyde solution (37 per cent formalin) are also helpful in cases of excessive sweating of the feet. Even painting with the full strength formaldehyde solution (Formalin) may be used by the physician who has the necessary experience and judgment to apply material when indicated.

When using formaldehyde in any form one must bear in mind the very high incidence of contact type allergic dermatitis which the drug produces and is common for cases of hypersensitivity which are sometimes extreme in degree. Of course, in all forms of hyperhidrosis the underlying causes must be sought and eliminated where found. Many cases are based upon nervous mechanisms and anal and psychic effects and the experienced skin specialist has learned how to distinguish between typical cases of these forms and others of different causation.



causes, a great number of cases of generalized and localized itching remain unclarified as to causation. The following medicaments are those of choice in the treatment of such 'idiopathic' pruritus. They are also to be applied in pruritus of ascertainable etiology during the search for causes and while the reduction of causal mechanisms is being carried out and until causally directed measures bring complete relief.

**Topical Antipruritics**—Often the medicaments listed under Antieczematous Agents (page 736) and simple Emollients and Demulcents (page 746) are also very effective and useful antipruritics (e.g. preparations containing tars medicated baths). Moreover, physical agents, such as applications of very hot or very cold water ethyl chloride spray, slapping etc., will often act as temporary antipruritics. In addition for purely antipruritic effect are the following

- R
- |   |                             |
|---|-----------------------------|
| Menthol   | 1/8% to 1%                  |
| and Phenol  | 1/8% to 1%                  |
| in Tinctures  | (e.g., dilute alcohol, 50%) |
| or Lotions (e.g., calamine lotion)                    |                             |
| or Cold creams (e.g., rose water ointment)            |                             |
| or Water washable creams (e.g., hydrophilic ointment) |                             |
- or
- Antipruritic Powder*
- I.
- |                  |       |
|------------------|-------|
| Powdered camphor | 4.5%  |
| Menthol          | 0.5%  |
| Zinc oxide       | 40.0  |
| Talcum           | 45.0  |
| Benzonite q.s.   | 100.0 |
- S Dust on freely 3 or more times daily
- [N.B. Particularly useful in itching intertrigo moniliasis, etc.]

Local anesthetics as well as topical antihistaminics while often effective carry with them considerable risks because of their strong tendencies to sensitize and to produce (sometimes very severe) allergic dermatitis.

Of all topical antipruritics topical *hydrocortisone* and derivatives are probably the safest and most generally effective, especially in thin skinned areas (eyelids ear canals scrotum genitalia in general, perianal region, etc.)

Special types of pruritus and itching of particular sites often require special forms of local medication. For example itching of the legs as found in association with the varicose or stasis complex is often best relieved by elastic stockings or Ace bandages or with some form of Unna's Zinc Gelatin Boot.

One simple way to apply a zinc gelatin boot is to use a ready made form such as Dome Paste Bandage.

**Systemic Antipruritics**—In addition to the elimination or medical or surgical treatment of all possible systemic causes of pruritus all the antihistaminic drugs (page 516) sedatives and tranquilizers (page 262) and soporifics (page 287) will have their indicated place in the relief of itching their selection must be made according to the type periodicity time and site of the itching and the particular requirements and responses of the individual case.

Moreover, systemic administration of ACTH or of adrenocortical steroids have their distinct sphere of usefulness in managing acute self limited and severe cases

- R Methoxsalen capsules or tablets 10 mg  
 S In children under 6, 1 tablet daily, in children over 6 and in adults, 2 tablets daily, followed in about 2 hours by exposure to sunlight or artificial ultraviolet in daily increments of gradually ascending amounts. The light should be so dosed as to produce a slight erythema of depigmented spots.

This form of treatment appears to be relatively safe. Although it is tedious and time-consuming and difficult to carry out and is, as stated, ineffective in many cases and many areas, it is nevertheless the best available today. Methoxsalen by the oral route is the drug of first choice, having almost entirely superseded the older more dangerous and less effective methods such as painting with liquefied phenol or the topical application of methoxsalen tinctures or solutions followed by exposures to light.

Very recently, *dermabrasion* of vitiligo sites has been reported to be successful, but this *dermatosurgical* procedure falls outside the scope of this book on drugs.

### AGENTS USED IN PITYRIASIS ROSEA

This is usually a self-limited eruption. Mild peeling measures such as the milder keratolytic lotions, oils, and creams (see section on Keratolytics, page 751) and mild peeling with generalized ultraviolet light can be used to hasten the involution. A useful prescription is

- R  
 Menthol 0.25  
 Resorcinol 3.0  
 Calamine lotion ad 100.0

There is usually pruritus varying from mild to very severe. Its management relies on the measures detailed in the section on Antipruritics.

Bathing and scrubbing with soap and particularly with one of the soaps containing surface active germicides (page 764) will be found useful in some cases. In others, bathing and soaping prove irritating and bathing must be reduced and emollients or demulcents added to the bath water (page 746).

### ANTIPRURITICS (Agents Against Itching)

As stated in the discussion of antieczematous agents (see page 736) the causes of itching are manifold. They may be external or internal or both. In itching also it is obvious that the most effective therapy will be that which includes the discovery and reduction or elimination of the causal factors. Therefore, in every case of protracted itching such internal causes as hepatic disease, blood dyscrasias, diabetes, gout, intestinal infestations, drug sensitivities, endocrine disturbances, dietary and metabolic and psychic influences, and others must be sought for and appropriately treated when present. Moreover, causal external factors, such as allergic and other reactions to contact agents (including insects, plants, clothing, topical medicaments, cosmetics, cleansers and occupational and household exposures), the varicose or stasis complex of the lower legs, the prurigenic skin infections and infestations, and itching dermatoses, must be looked for and controlled when discovered. However, even after the most expert and painstaking attempts to find and remove

causes, a great number of cases of generalized and localized itching remain unclarified as to causation. The following medicaments are those of choice in the treatment of such "idiopathic" pruritus. They are also to be applied in pruritus of ascertainable etiology during the search for causes and while the reduction of causal mechanisms is being carried out, and until causally directed measures bring complete relief.

**Topical Antipruritics**—Often the medicaments listed under Antieczematous Agents (page 736) and simple Emollients and Demulcents (page 746) are also very effective and useful antipruritics (e.g., preparations containing tars, medicated baths). Moreover, physical agents, such as applications of very hot or very cold water, ethyl chloride spray, slapping, etc., will often act as temporary antipruritics. In addition, for purely antipruritic effect are the following

<b>R</b>	
Menthol	1/8% to 1%
and Phenol	1/8% to 1%
<i>in Tinctures</i> (e.g., dilute alcohol, 50%),	
<i>or Lotions</i> (e.g., calamine lotion),	
<i>or Cold creams</i> (e.g., rose water ointment),	
<i>or Water washable creams</i> (e.g., hydrophilic ointment)	
or	
<i>Antipruritic Powder</i>	
<b>R</b>	
Powdered camphor	4.5%
Menthol	0.5%
Zinc oxide	40.0
Talcum	45.0
Benzonite q.s.	100.0
<b>S</b>	Dust on freely 3 or more times daily
[N.B. Particularly useful in itching intertrigo, moniliasis, etc.]	

Local anesthetics, as well as topical antihistaminics, while often effective, carry with them considerable risks because of their strong tendencies to sensitize and to produce (sometimes very severe) allergic dermatitis.

Of all topical antipruritics, topical *hydrocortisone* and derivatives are probably the safest and most generally effective, especially in thin skinned areas (eyelids, ear canals, scrotum, genitalia in general, perianal region, etc.).

Special types of pruritus, and itching of particular sites often require special forms of local medication. For example, itching of the legs as found in association with the varicose or stasis complex is often best relieved by elastic stockings, or Ace bandages, or with some form of Unna's Zinc Gelatin Boot.

One simple way to apply a zinc gelatin boot is to use a ready made form, such as Dome Paste Bandage.

**Systemic Antipruritics**—In addition to the elimination or medical or surgical treatment of all possible systemic causes of pruritus, all the antihistaminic drugs (page 516), sedatives and tranquilizers (page 262), and soporifics (page 287) will have their indicated place in the relief of itching, their selection must be made according to the type, periodicity, time, and site of the itching and the particular requirements and responses of the individual case.

Moreover, *systemic* administration of ACTH or of adrenocortical steroids have their distinct sphere of usefulness in managing acute self limited and severe cases,

as well as chronic very severe cases of itching, provided all other measures have failed. Of course in administering these hormones all the necessary preliminary and concomitant examinations must be carried out and all the necessary caution and precautions observed.

Many specialized and selected dermatologic physical procedures are also among the sovereign remedies for localized and generalized pruritus, e.g., x-ray, grenz-ray, thorium X, CO<sub>2</sub> slush, localized peeling with caustics (page 735) and keratolytics (page 751).

Many systemic measures have been used in the attempt to allay pruritus. None has been entirely satisfactory.

Sedatives and soporifics while they may allay pruritus for a short time are not effective as a rule for the following reasons: (1) because they very often produce sufficient drowsiness and sleepiness to make their employment dangerous or impossible during daytime working hours and (2) because while they may produce sleepiness and some disturbances of consciousness very often the scratch reflex will continue and patients will tear at their skin even more than if they were able to use conscious control to prevent scratching. Thus one finds some patients scratching violently even in their sleep.

While the antihistaminics in general have some antipruritic effect they are not universally useful to allay itching. However by trial and error one will often find that in one patient or another a particular antihistaminic will be valuable in allaying pruritus. Therefore each antihistaminic must be given a trial in each individual before one can say that none of this group of compounds will be of any use in a particular case. Obviously where the pruritus is based upon an allergic mechanism as in certain cases of urticaria the antihistaminics may be useful in allaying the reaction of allergy itself.

Although the so-called tranquilizers as a group are not very valuable in reducing the itch sensation itself there are individuals who will react very well to one or another member of the so-called tranquilizer or ataractic group.

Although these drugs as a group will not be discussed here since they have been included elsewhere in the text there is one that may deserve particular mention as a systemic antipruritic. This is a phenothiazine derivative called trimepazine (Temaril).

When originally tried out by our group the material was supplied in 5 mg, 10 mg and 25 mg tablets. These larger doses were sometimes effective in allaying pruritus but they were also often highly soporific and frequently left hangovers in the morning. The dosage was then gradually reduced and at present Temaril is marketed in 2.5 mg units. One, two, three or even four of these taken at night before retiring will be helpful in reducing the itching in a fair proportion of patients. However in some patients even the smallest dose produces too much sleepiness and in many the drug cannot be taken during the day whereas in others even the larger doses are not effective in allaying the pruritus. While this phenothiazine is sometimes a useful adjuvant in the systemic management of itching it is by no means the ideal drug and is not universally effective as was originally hoped. Moreover there has been at least one well documented instance of a blood dyscrasia following its use.

Other systemic measures for reducing itching include autohemotherapy, injections of calcium salts, and others

Of course, the best means of treating pruritus is to combat the basic pathologic mechanism which was the producing factor, e.g., the elimination of contact and ingested or inhaled allergens, external irritants, intestinal parasites, insects, dyes, and causal allergenic drugs, and the management of diabetes, gout, liver disease, and blood dyscrasias

### ANTIPSORIATICS (Agents Used in Psoriasis)

**General Remarks**—Psoriasis is a skin disease of entirely unknown cause, of very poorly understood pathogenic mechanism, and of very high incidence. It has been estimated by some observers that, if one searches for and includes the very mildest cases, from 10 to 25 per cent of the adult white population of the United States may be affected at one time or another. The disease can remain confined to one or a few scarcely noticeable small areas of slight scaling or it can be wide spread or generalized and be completely incapacitating and refractory to all treatment. The association with joint changes is much higher than can be accounted for by fortuitous coincidence. In most patients and particularly in early mild forms, longer or shorter remissions of the skin eruption can be brought about by proper management. In some fortunate patients the disease disappears after treatment or occasionally even without treatment, and the remission lasts for months, years, or even for the duration of the patient's life.

The systemic treatment of psoriasis is largely unsatisfactory. However, when the patient is *completely incapacitated or in dire distress*, Aminopterin by mouth or triamcinolone may be valuable after all else has failed. According to a schedule of Rees B. Rees, Aminopterin is given by mouth in doses of 0.5 mg daily for 6 consecutive days, interrupted for 1 week, and resumed for 6 consecutive days. Of course, the usual regular checkups for hematologic changes, oral lesions etc., must be rigorously carried.

In addition to deliberate change of environment and climate (especially to dry, warm, even temperatured places), *local external measures* are the only regularly effective ones in psoriasis. Among the best of these are such specialistic procedures as x rays, grenz rays, thorium X, various combinations of tar baths, tar applications, and ultraviolet light exposures.

Severe or widespread cases and chronic forms are usually nearly unmanageable except where there are specially trained personnel and specially equipped hospital facilities available for their care. In many countries outside of the United States, such installations are available for the care of psoriatics, and many patients whose psoriasis remains refractory under haphazard and ambulatory treatment will respond to the proper applications carried out in special hospital areas skillfully, precisely, and patiently by devoted and experienced dermatologic nursing personnel.

In the absence of the special dermatologic personnel and facilities in hospitals, the local medicaments listed below are often valuable in treating ambulatory patients with ordinary and not too widespread or inveterate psoriasis. However here too, success is largely dependent upon the way in which the external medica-

as well as chronic very severe cases of itching, provided all other measures have failed. Of course in administering these hormones all the necessary preliminary and concomitant examinations must be carried out and all the necessary caution and precautions observed.

Many specialized and selected dermatologic physical procedures are also among the sovereign remedies for localized and generalized pruritus e.g. x-ray grenz ray, thorium X CO<sub>2</sub> slush, localized peeling with caustics (page 735) and keratolytics (page 751).

Many systemic measures have been used in the attempt to allay pruritus. None has been entirely satisfactory.

Sedatives and soporifics while they may allay pruritus for a short time are not effective as a rule for the following reasons: (1) because they very often produce sufficient drowsiness and sleepiness to make their employment dangerous or impossible during daytime working hours and (2) because while they may produce sleepiness and some disturbances of consciousness very often the scratch reflex will continue and patients will tear at their skin even more than if they were able to use conscious control to prevent scratching. Thus one finds some patients scratching violently even in their sleep.

While the antihistaminics in general have some antipruritic effect they are not universally useful to allay itching. However by trial and error one will often find that in one patient or another a particular antihistaminic will be valuable in allaying pruritus. Therefore each antihistaminic must be given a trial in each individual before one can say that none of this group of compounds will be of any use in a particular case. Obviously where the pruritus is based upon an allergic mechanism as in certain cases of urticaria the antihistaminics may be useful in allaying the reaction of allergy itself.

Although the so-called tranquilizers as a group are not very valuable in reducing the itch sensation itself there are individuals who will react very well to one or another member of the so called tranquilizer or anesthetic group.

Although these drugs as a group will not be discussed here since they have been included elsewhere in the text there is one that may deserve particular mention as a systemic antipruritic. This is a phenothiazine derivative called trimoprazine (Temaril).

When originally tried out by our group the material was supplied in 5 mg, 10 mg and 25 mg tablets. These larger doses were sometimes effective in allaying pruritus but they were also often highly soporific and frequently left lying overs in the morning. The dosage was then gradually reduced and at present Temaril is marketed in 2.5 mg units. One, two, three or even four of these taken at night before retiring will be helpful in reducing the itching in a fair proportion of patients. However in some patients even the smallest dose produces too much sleepiness and in many the drug cannot be taken during the day whereas in others even the larger doses are not effective in allaying the pruritus. While this phenothiazine is sometimes a useful adjuvant in the systemic management of itching it is by no means the ideal drug and is not universally effective as was originally hoped. Moreover there has been at least one well documented instance of a blood dyscrasia following its use.

Other systemic measures for reducing itching include autohemotherapy, injections of calcium salts, and others

Of course, the best means of treating pruritus is to combat the basic pathologic mechanism which was the producing factor, e.g., the elimination of contact and ingested or inhaled allergens, external irritants, intestinal parasites, insects, dyes, and causal allergenic drugs, and the management of diabetes, gout, liver disease and blood dyscrasias

### ANTIPSORIATICS (Agents Used in Psoriasis)

**General Remarks**—Psoriasis is a skin disease of entirely unknown cause of very poorly understood pathogenic mechanism, and of very high incidence. It has been estimated by some observers that, if one searches for and includes the very mildest cases, from 10 to 25 per cent of the adult white population of the United States may be affected at one time or another. The disease can remain confined to one or a few scarcely noticeable small areas of slight scaling or it can be wide spread or generalized and be completely incapacitating and refractory to all treatment. The association with joint changes is much higher than can be accounted for by fortuitous coincidence. In most patients and particularly in early mild forms, longer or shorter remissions of the skin eruption can be brought about by proper management. In some fortunate patients the disease disappears after treatment or occasionally even without treatment, and the remission lasts for months years, or even for the duration of the patient's life.

The systemic treatment of psoriasis is largely unsatisfactory. However, when the patient is *completely incapacitated or in dire distress*, Aminopterin by mouth or triamcinolone may be valuable after all else has failed. According to a schedule of Rees B. Rees, Aminopterin is given by mouth in doses of 0.5 mg daily for 6 consecutive days, interrupted for 1 week, and resumed for 6 consecutive days. Of course, the usual regular checkups for hematologic changes, oral lesions, etc. must be rigorously carried.

In addition to deliberate change of environment and climate (especially to dry, warm, even temperatured places), *local external measures* are the only regularly effective ones in psoriasis. Among the best of these are such specialistic procedures as x rays, grenz rays, thorium X, various combinations of tar baths, tar applications, and ultraviolet light exposures.

Severe or widespread cases and chronic forms are usually nearly unmanageable except where there are specially trained personnel and specially equipped hospital facilities available for their care. In many countries outside of the United States, such installations are available for the care of psoriatics, and many patients whose psoriasis remains refractory under haphazard and ambulatory treatment will respond to the proper applications carried out in special hospital areas skillfully, precisely, and patiently by devoted and experienced dermatologic nursing personnel.

In the absence of the special dermatologic personnel and facilities in hospitals the local medicaments listed below are often valuable in treating ambulatory patients with ordinary and not too widespread or inveterate psoriasis. However here too, success is largely dependent upon the way in which the external medica

tion is used, applied, and removed. In many instances the medicaments are counterirritants and their therapeutic effects are very close to their irritant effects upon normal skin. Thus it often occurs that the psoriatic patches do not begin to yield until there is some visible irritation of the normal skin around the patches which are being treated. Usually the visible psoriatic lesions themselves and a narrow band of clinically apparently normal skin around them do not become irritated by concentrations and medicaments which irritate the rest of the patient's skin.

**General Directions**—In torpid thickened lesions scrub off the scales with a soft brush or turkish washcloth while in a warm bath and before each application of medication. Rub the local medication in thoroughly by gentle massage, either with the finger (rubber finger cot) or with a toothbrush or with a piece of pumice stone of suitable size, shape and abrasiveness.

When the skin around the lesions begins to become reddened, eczematized, swollen, or otherwise irritated, and in cases that are spreading or irritable or itchy or show signs of aggravation stop all the antipsoriatic remedies proper, and apply nothing but soothing medication as outlined under Antieczematous Agents (page 736) and Emollients and Demulcents (page 746). In soothing the skin which has been irritated by active antipsoriatic drugs the hydrocortisone-containing preparations are of outstanding value. The antipsoriatic remedies can be started cautiously (perhaps in higher dilutions than before) after the skin irritation has subsided, but not until then.

#### FOR THE SCALP—

To remove scales

- |   |   |          |
|---|---|----------|
| R | Salicylic acid  | 2% to 3% |
|   | in  |          |
|   | Olive oil   |          |
|   | or  |          |
|   | Mineral oil q.s.  |          |
| S | Apply 2, 3 or more times weekly to entire scalp, leave on overnight and wash out in morning |          |
- 
- |   |                              |    |
|---|------------------------------|----|
| R | Salicylic acid               | 3% |
|   | Triethanolamine              | 3% |
|   | Lubriderm (unscented) q.s.   |    |
| S | As in preceding prescription |    |
- 
- |   |   |
|---|---|
| R | P & S Liquid                                      |
|   | (Less than 2% phenol in sodium chloride solution) |
| S | Shake well and apply to all scaly areas nightly   |

Helpful in removing scales, ointments, creams, etc., in psoriasis of scalp are the tar-containing shampoos, e.g.

- |   |   |
|---|---|
| R | Almay tar shampoo   |
|   | Zetar shampoo   |
|   | Facker's tar shampoo, etc.  |
|   | [Fostex Cream shampoo can also be used, but not in combination with mercurials] |



In addition, one of the following scalp oils and ointments should be applied nightly or as often as required and feasible:

R

Salicylic acid	3%
Ammoniated mercury	3% to 6%
Solution of coal tar	3% to 20%

**S**

quired

(Beware of hypersensitivity, especially to mercurials. Do not combine with sulfur containing applications.)

R

Salicylic acid	2%
Ammoniated mercury	3% to 6%
Solution of coal tar	6% to 10%
or	
Oil of cade	6% to 10%
Hydrophilic ointment	
or	
Hydrophilic petrolatum q.s.	
(or proprietary emulsion base or	
water washable base)	

**S**

As for above prescription.

R

Pyrogallie acid (pyrogallol)	3%
Salicylic acid	3%
in	
Hydrophilic petrolatum	q s

**S**

Rub thoroughly into thickened scaly affected areas at night with a toothbrush or finger covered by finger cot

(Beware of irritations to eyes, do not get on face, remove from fingers after each application, do not use on light colored blond, gray, or white hair—will cause discoloration)

For superficial psoriasis of face, trunk, or extremities, the mercurial and tar preparations recommended for seborrheic dermatitis (page 766) may be the drugs of first choice. When these fail or when the psoriatic plaques are thicker and inveterate, one of the following is chosen for trial:

R

Chrysarobin            0.25% to 5% or even 10%  
Petrolatum            q s  
(Must be freshly prepared)

3

Rub thoroughly into affected areas 2 or more times daily. Stop when skin around lesions becomes inflamed.

(Do not use on face. Beware of irritation of eyes, discoloration of hair, clothing bedding, etc.)

**R**

Chrysarobin	1% to 5%
Chloroform	q s

5

Chloroform q s  
Chrysarobin tincture—apply to affected areas  
2 or more times daily, observing same precau-  
tions as for preceding prescription and in addi-  
tion beware of excessive inhalation!

tion is used, applied, and removed. In many instances the medicaments are counterirritants and their therapeutic effects are very close to their irritant effects upon normal skin. Thus it often occurs that the psoriatic patches do not begin to yield until there is some visible irritation of the normal skin around the patches which are being treated. Usually the visible psoriatic lesions themselves and a narrow band of clinically apparently normal skin around them do not become irritated by concentrations and medicaments which irritate the rest of the patient's skin.

**General Directions**—In torpid thickened lesions, scrub off the scales with a soft brush or turkish washcloth while in a warm bath and before each application of medication. Rub the local medication in thoroughly by gentle massage, either with the finger (rubber finger cot) or with a toothbrush, or with a piece of pumice stone of suitable size, shape and abrasiveness.

When the skin around the lesions begins to become reddened, eczematized, swollen, or otherwise irritated, and in cases that are spreading or irritable or itchy, or show signs of aggravation, stop all the antipsoriatic remedies proper, and apply nothing but soothing medication as outlined under Antieczematous Agents (page 736) and Emollients and Demulcents (page 746). In soothing the skin which has been irritated by active antipsoriatic drugs, the hydrocortisone containing preparations are of outstanding value. The antipsoriatic remedies can be started cautiously (perhaps in higher dilutions than before) after the skin irritation has subsided, but not until then.

FOR THE SCALP —

### To remove scales

R Salicylic acid 2% to 3%  
in  
Olive oil  
or  
Mineral oil qs

S Apply 2, 3, or more times weekly to entire  
scalp leave on overnight and wash out in morn  
ing

R	Salicylic acid	3%
	Triethanolamine	3%
	Lubriderm (unscented) qs	
S	As in preceding prescription	

**P & S Liquid**  
(Less than 2% phenol in sodium chloride solution)

Helpful in removing scales, ointments, creams, etc., in psoriasis of scalp are the tar containing shampoos, e.g.

Almay tar shampoo  
Zetar shampoo  
Packer's tar shampoo, etc.

[Fostex Cream shampoo can also be used, but not in combination with mercurials]

R

Cignolin (Anthralin, in Eng land, 'Dithranol')	0.4%
Salicylic acid	2.0%
Zinc oxide	25.0%
Starch	25.0%
Petrolatum q s ad	30.0 Gm

As stated at the outset, the local treatment of psoriasis can be highly satisfactory even in ambulatory patients, but the chances of success are incalculably greater where the adequate special personnel and institutional facilities are available and the patient can be intensively treated and closely observed.

## AGENTS USED IN PYODERMAS

Pyoderma is the inclusive term applied to skin infections by pyogenic microorganisms, principally staphylococci and/or streptococci. Their management depends mainly on the sites and depth of the infection, its distribution, and its course (acute or chronic).

In general, the acute superficial pyodermas (e.g., impetigo, folliculitis) can be treated by external measures. The deeper pyodermas (e.g., furuncles, carbuncles, ecthyma, cellulitis), particularly when chronic, usually require systemic therapy plus the external medicaments.

Infections of the skin can still be adequately controlled by older medicaments. The slow rate of absorption makes it possible to use as local external applications on skin infections many old established antibacterial agents which are much too toxic for systemic administration to combat infections of internal sites. *These older remedies also have the great advantages of not contributing to the emergence of antibiotic resistant strains of staphylococci and other cocci and not producing hypersensitivity to useful antibiotics in the patients.* Thus, the tremendous superiority of systemically administered sulfonamides and antibiotics over older systemic remedies for internal infections is not quite as marked in relation to the pyogenic infections of the skin.

Among the older drugs of choice for superficial pyodermas are

R

Compound Quinolol Ointment  
(full strength or diluted equal parts with petrolatum) (See page 730)

R

Vioform ointment

R

Vioform cream

R

Sterosan ointment

R

Sterosan cream

R

Ammoniated mercury ointment 30.0

R

Sulfur precipitate	10 to 30
Salicylic acid	0.6 to 1.0
Ointment of zinc oxide ad	30.0

- R D hydroxyanthranol (Anthralin) ointments  
 0.1% 0.25% 0.5% or 1.0%  
 Petrolatum q.s. 60.0  
 S Begin with weaker concentrations. If tolerated  
 work upward as required. Precautions as with  
 chrysarobin ointments

For widespread or generalized eruptions mercurial oils (see above) or Riaseol are often the most practical and satisfactory local measures. Tar containing baths are also of some use.

A long time favorite and often the best treatment despite the difficult and time consuming nature of the procedure is the combination of applications of tar and daily exposures to ultraviolet light e.g. as follows

- 1 Soak in tar bath in evening before retiring brushing off scales while in tub

Examples

- R Coal tar solution 20.0  
 Polysorbate 80 5.0  
 Alcohol q.s. 100.0  
 S 4 tablespoonfuls to tub of water  
 or

- R Almay Tar Bath  
 S As above  
 or

- R Zetar emulsion  
 S 2 tablespoonfuls to the bath

- 2 Apply tar in one of the following forms to each of the lesions

- R Soluton of coal tar  
 or

- R Tar ointment  
 or

- R Crude coal tar 2% to 3%  
 Polysorbate 80 2% to 3%  
 in  
 Ointment of zinc oxide q.s.

- 3 Expose all the affected parts and the intervening skin to ultraviolet light \* giving doses which are just below or just at the erythema producing level and continuing at this level by gradually raising the exposure time and/or decreasing the distance of source to skin in pace with the increasing skin tolerance
- 4 Repeat this treatment daily for as long as required unless the psoriasis spreads or the skin becomes irritated or other prohibitive ill effects appear

A modification of the above is the treatment with Cignolin paste as carried out for example in the antipsoriatic installation in Leeds England. In this the application of the following paste confined precisely and absolutely to the visible psoriatic lesions and covered by bandages takes the place of the nightly tar applications

\*Burdick Hanovia Mercury Vapor Arc or Westinghouse or General Electric RS bulb

In the deeper pyodermas and even in the superficial persistent ones, systemic administration of penicillin and of other antibiotics is frequently indicated. Penicillin can be given by injection, either in the aqueous or repository vehicles, or it can be administered by mouth. For the newer oral penicillin preparations with forms for quicker absorption see page 141. Other antibiotics are given by mouth or by systemic injection as well.

While giving the antibiotics for the protracted periods sometimes required to finally master a chronic or chronic recurrent pyoderma, vitamin B complex should be administered concomitantly.

In all pyodermas, and particularly in persistent or chronic recurrent ones, the first order of business is to search for, rule out, or treat underlying predisposing factors, including especially diabetes, blood dyscrasias, gout, dietary deficiencies, skin infestations, internal foci of infection, and pruritus from various causes.

## AGENTS USED IN SARCOIDOSIS

The treatment consists of all general medical measures directed against the multiform manifestations in the affected organs and sites. Systemic treatment includes prolonged administration of corticosteroids, but in smaller doses than in pemphigus or acute/disseminated lupus erythematosus. (See sections on Bullous Dermatoses and Lupus Erythematosus, pages 732 and 753.)

## ANTISEBORRHEICS

Among the main groups of standard topical remedies for seborrhea and seborrheic dermatitis are those containing mercury and those containing sulfur. These are likely to be incompatible and should not be used together. In each case the best tolerated and most effective should be chosen (as determined by the individual's response, allergic hypersensitivity, etc.). The sulfur and the mercurial remedies are each generally employed in combination with other keratolytics, tars, etc.

Shampooing regularly is an essential of management of the scalp.

### Shampoos

- R Med cinal soft soap liniment  
     or  
     shampoo containing hexachlorophene—e.g.,  
     Dial shampoo, pflisoflex, Gamphen  
     or  
     tar shampoos—e.g., Almay tar, Zetar, etc.  
 S Shampoo thoroughly one or more times weekly  
   [When sulfur combinations are being prescribed  
   locally, Fostex Cream shampoo can be used.  
   (This can be used also for washing face and  
   other areas affected by seborrheic dermatitis.)]

### Sulfur-Containing Regimen for Scalp

- |   |                      |            |
|---|----------------------|------------|
| R | Sulfur precipitate   | 10 to 30   |
|   | Salicylic acid       | 0.6 to 1.5 |
|   | Solution of coal tar | 1.5 to 3.0 |
|   | Hydrophilic ointment | ad 30      |

R		
	Resorcin	30 to 50
	Sulfur precipitate	30 to 100
	Zinc oxide	
	Talcum	
	Glycerin $\mathfrak{ss}$	150
	Water	
	Alcohol $\mathfrak{ss}$ ad	1000

One of the above ointments or creams or the lotion is selected according to the patient's sensitivities and previous responses and is applied to affected and surrounding areas 2 or more times daily by gentle massage or painted on with a flat brush [NB The mercury ointment should not be used over large areas or for prolonged periods unless the patient is under regular observation by the physician. The main dangers are absorption and systemic toxicity—especially renal irritations—and particularly allergic sensitization and contact dermatitis.]

Among the newer remedies are the mixed antibiotic-containing ointments, e g

R	R	R
Neosporin ointment	Bacitracin ointment	Terramycin ointment
Polysporin ointment	Aureomycin ointment	Achromycin ointment

These have the advantage of lack of irritancy, relatively low sensitizing potential and low systemic toxicity, with a very wide antibacterial spectrum.

The affected and surrounding areas should be washed with antiseptic-containing soaps or detergents. Among these are the following:

Mercurial soaps—e g, Neko soap  
or  
Soaps containing hexachlorophene—e g, Dial soap, pflisoHex,  
or  
Soaps containing tetramethyl thiuram disulfide (TMTD)—e g, Lifebuoy soap

Cleanliness of person (e g, hands and fingernails) and cleanliness of clothing, bed linens, towels (regular washing with soap and hot water and regular cleansing of outer garments by dry cleaning or cleaning fluids) are essential to prevent reinfection, spread and continuation of the disease.

In addition, daily "antiseptic" baths should be prescribed in all widespread or long-lasting pyodermas, e g, with potassium permanganate

R  
S

Among the drugs of choice for deeper pyodermas are the above topical remedies plus continued hot, wet compresses with mild antiseptic solutions such as Burow's solution, e g

R	R
Domeboro Powder	Domeboro Tabs

These are especially useful in bringing abscesses, carbuncles, and furuncles to ripen, to "point," to open, and to drain.

## Mercury-Containing Regimen for Scalp

R	Ammoniated mercury	10 to 45
	Salicylic acid	0.6 to 1.5
	Hydrophilic ointment ad	30.0
S	Apply to scalp by thorough massage, leave on overnight and remove by any nonsulfur containing shampoo	

## Mercury-Containing Regimen for Face and Trunk

R	Ammoniated mercury	18
	Bismuth subnitrate	18
	Zinc oxide	18
	Talcum	18
	Lanolin	
	Petrolatum ad	30.0
S	Test for 48 hours by applying several times to a small area of normal skin (about the size of a 50-cent piece). If no untoward reaction ensues, apply to affected areas of face, trunk, etc., two or more times daily	

## Newer Preparations

Newer forms of management include the following and are particularly useful when the standard approaches with sulfur or mercury are not tolerated or prove ineffective

R	Vioform cream	
S	Apply to affected parts 2 or more times daily	
R	Vioform cream with hydrocortisone	
	or	
	Sterosan cream with hydrocortisone	
S	Apply to affected parts 2 or more times daily	

## Combinations of hydrocortisone and antibiotics—e.g.

R	Neo-Cortef ointment	1% to 2½%
	or	
	Terra Cortril ointment etc	
S	Apply to affected areas 2 or more times daily	

## Combinations of tar and hydrocortisone—e.g.

R	Solution of coal tar	12
	Hydrocortisone free alcohol	0.1
	Hydrophilic ointment ad	20.0

Tar containing properties, as well as those with added hydrocortisone and/or quinolines, can often be advantageous despite their usually substantially higher cost—e.g.

R	TarCortin cream	
	or	
R	Cor Tar Quin	

In addition to the listed topical agents, highly irritated forms of seborrheic dermatitis will often require preliminary treatment with the soothing applications

- S Apply to scalp by thorough massage leave on overnight and shampoo out with Fostex or other recommended shampoo  
[Pragmatar is a very useful combination of sulfur, salicylic acid, and tar, which can be used in place of above prescription]

R

Selenium sulfide (Selsun) suspension

- S Apply once or twice weekly for first two weeks, then less often as required  
First wash hair and scalp with the usual shampoo and rinse out Work 1 to 2 teaspoonfuls into scalp until a lather is obtained Rinse out and repeat process Allow Selsun to remain in contact with scalp for at least 5 minutes Rinse out thoroughly  
[Beware of toxicity! Should not be used by young children If hair begins to fall excessively or becomes increasingly oily, this preparation must be discontinued and replaced by others

or

R

Sebizon

- S Apply to scalp by thorough rubbing in at bed time Brush hair 2 to 3 minutes and allow medication to remain in overnight Repeat for 8 to 10 successive nights If scalp and hair are oily or greasy application should be preceded by a nonirritating shampoo  
[In contrast to preceding prescription, this is not likely to cause increased oiliness can be used by young children contains no sulfides and can therefore be used in combination with mercurials as well as sulfur]

or

R

Sebulex 120

- S Massage a liberal amount into the wet hair and scalp for 2 to 5 minutes Rinse and repeat Rinse thoroughly Shampoo in this manner as often as required to keep scalp clean and comfortable

## Sulfur-Containing Regimen for Face and Trunk

R

Pragmatar	
(Cety alcohol coal tar distillate)	40
Sulfur precipitate	30
Salicylic acid	30
O/W Emulsion base ad	100 0

- S Apply to affected areas two or more times daily

R

Resorcinol	10 to 50
Sulfur precipitate	30 to 100
Solution of coal tar	30 to 100
Zinc oxide	
Talc	200 to 250
Glycerin	100
Water	
Alcohol	400

- S Lotion paint on affected areas 2 or more times daily



R

## Antibiotic lozenges

(Each troche contains zinc bacitracin 300 U, neomycin sulfate, 5 mg, polymyxin B sulfate, 2,000 U)

S

Place one lozenge in mouth after meals and hold until completely dissolved Average dose is 3 or 4 lozenges a day

[Useful in recurrent aphthous stomatitis, bullous eruptions of the mouth, e.g., oral pemphigus, ectodermosis erosiva pluriorificialis]

R

## Nuporals

(Dibucaine hydrochloride, 10 mg in an inert base)

S

Permit 1 lozenge to dissolve slowly in the mouth before eating or drinking, do not exceed 8 lozenges in 24 hours

[Useful as local anesthetic for painful mouth lesions as in oral pemphigus and painful forms of stomatitis]

R

## Neomycin solution

Neomycin	0.5%
Distilled water	ad 250 mg
	50.0

(Must be freshly prepared Keep refrigerated  
Wide spectrum antibiotic)

S

Apply with cotton swab or camel's hair brush 3 or 4 times a day

[Useful in aphthous stomatitis acute herpetic stomatitis Stevens Johnson syndrome, oral pemphigus, Vincent's infection]

R

## Antiseptic solution mouthwash

Boric acid	2.5
Thymol	0.05
Chlorothymol	0.05
Menthol	0.05
Eucalyptol	0.01
Methyl salicylate	0.2
Thyme oil	30.0
Alcohol	30.0
Distilled water	ad 100.0

S

Add 2 teaspoonfuls to ½ glassful of warm water Swish through mouth after meals May also be used as a gargle

[Antiseptic, soothing Useful in poor oral hygiene, fetor, bismuth stomatitis, nonspecific forms of stomatitis]

Silver nitrate, as toughened silver nitrate sticks or as 10 per cent aqueous solution can be applied to torpid denuded or ulcerated areas once to twice daily. This should be done only by the physician and only over short periods because of the risk of producing argyria in susceptible individuals.

Of course, specific forms of stomatitis, vulvitis, and vaginitis must be treated by specific measures—e.g., syphilitic (systemic penicillin), moribund (gentian violet or borax solutions, Mysteclin, etc.), gonorrheal (sulfonamides, antibiotics, etc.) vitamin deficiency (appropriate diets and vitamin administrations, etc.)

of the antieczematous agents used in acute eczematous dermatitis (page 798) Highly impetiginized forms will often require the milder remedies used as anti-infective agents in impetigos and other pyodermas Moreover, dietary restrictions (low fats and carbohydrates) vitamin adjuvants (especially high doses of thiamine, riboflavin, pyridoxine and B<sub>12</sub>) are considered valuable by many dermatologists

Change of environment exposure to sunlight correction of hormonal and psychic maladjustments may be of some benefit in certain cases

What is more certain is the fact that in chronic and refractory cases, radiation therapy, including the safe small doses of superficial x rays (gonads shielded in persons below 40') and the effective doses of grenz rays, both as used by qualified dermatologists, are among the most valuable as well as cleanest and safest of measures

Seborrheic dermatitis is a chronic recurrent disease which may require constant management While many cases can be satisfactorily controlled by the above measures, others become refractory and fail to yield, while still others are forerunners of psoriasis

## AGENTS USED IN SOAP SENSITIVITY

In some cases of hand eczemas, atopic dermatitis, infantile eczema, generalized dermatitis, generally irritable and/or dry and senile skins alkali hypersensitivity, and other conditions oatmeal colloids (Aveeno) and hydrolyzed cornstarch (Lanit, unscented) can be useful to "soften" bath and wash water (See section on Emollients and Demulcents, page 746)

Soap substitutes e g

Lowila  
pHIsoderm  
pHIsolix (contains 3% hexachlorophene)  
Aveeno  
Soyaloid

or

Superfatted soaps and low pH soaps e g

Basis soap  
Oilatum soap  
Dove soap

It may also be helpful after each washing to oil the skin with such oils as Nivea oil or Lubriderm

## AGENTS USED IN STOMATITIS

Many skin diseases are associated with lesions of the mouth and other orificial mucous membranes Differential diagnoses of skin diseases and their management therefore require expertness in recognizing and treating various kinds of oral, vulvovaginal, and anal lesions Similarly, recognition and management of lesions of the mucous membranes often require expertness in dermatologic diagnosis and therapy

In the management of different forms of stomatitis the prescriptions which follow are among the useful ones

applying a galvanic electrical current or an electrocoagulating current. This can be done only by skilled, trained, and conscientious persons.

For the *temporary* removal of hair the many proprietary and cosmetic preparations are based upon their content of sulfides of various kinds and especially today on the thioglycollates. These are usually effective and safe for the temporary removal of hair from the axillae, legs, and other portions of the body.

## ANTIURTICARIAL AGENTS (Agents Used in Urticaria and Urticarial Eruptions)

This section includes acute urticaria, chronic urticaria, and eruptions with pronounced urticarial components such as certain forms of angioneurotic edema, multiform erythemas, drug eruptions, and polymorphous light eruptions. (See also section on 'Sun Screens,' page 771.) The first and most fundamental step is the search for causal agents and their reduction or elimination. In many cases of acute urticaria the causes can be found, but in only a sadly small minority of chronic cases of urticaria or angioneurotic edema will even the most expert and painstaking search discover the causes. In all urticarial eruptions the drug treatment consists of palliative measures to be given while the search for causes is going on and as long as the disease continues. Acute urticaria and acute multiform erythemas run their course in a matter of days to a few weeks. Chronic and recurrent urticaria sometimes lasts for years and can endure for life. The essential drugs of choice are

1 Antihistaminics usually given in doses sufficient to suppress the manifestations. For this purpose the forms with prolonged and/or delayed action are often the most efficacious. (See page 516.)

2 Corticosteroids and/or ACTH given in morbidstatic doses, as in pemphigus (see section on Bullous Dermatoses page 732), and lupus erythematosus (see page 753), but in much smaller doses than used initially in these two diseases e.g., daily 50 to 150 mg of cortisone acetate or biologically equivalent dose of other corticosteroid. The corticosteroids and/or ACTH are to be used only when the situation is serious and has failed to yield to antihistaminics and other remedies. It is my observation that some cases respond to ACTH and not to corticosteroids and vice versa some to antihistaminics and not to the hormones, and vice versa. I know of no satisfactory explanation for these individual peculiarities in response.

The remainder of the drug treatment of urticarias and urticarial eruptions includes

1 Sedatives of the usual types. Here one must be particularly on the alert not to give barbiturates, bromides, salicylates, or other drugs to which the patient is hypersensitive and which may be prolonging the eruption or *actually causing it!*

2 Tranquilizers. Recently Atarax has been reported effective as a morbidstatic agent in a high percentage of cases of *chronic* urticaria.

3 Antipruritics (page 757). Among the older remedies useful on occasion and in emergencies are

R

Epinephrine hydrochloride solution  
0.3 to 1.0 ml. by subcutaneous inject on  
(Especially indicated in laryngeal edema!)

1 1 000

S

## SUN PROTECTIVE MEASURES ("Sun Screens")

These are used in cases of photosensitivity, albinism, polymorphous light eruptions, Darier's disease, and in all forms of lupus erythematosus in order to avoid severe sunburn, to promote tanning, to reduce hyperpigmentation, and to protect against chronic actinic damage, keratoses, skin cancer formation, etc. They include physical protection such as all possible avoidance of exposure, exposure only during the early or late hours of the day, shading hats, clothing, heavy covering, and 'make-up'

The topical drugs of choice include the following para-aminobenzoic acid, menthyl anthranilate, tannic acid, and others

There are numerous 'ethical' proprietaries and over the counter preparations and cosmetics containing these ingredients. Examples are Skolex and Almay Sun Protection Lotion

A simple useful prescription is the following

R		
	Para aminobenzoic acid	45
	Hydrophilic ointment ad	300
S	Apply before exposure to sunlight	

[N.B. This preparation is difficult to compound as the para aminobenzoic acid crystals must be very finely powdered and carefully triturated in the ointment. Moreover this and other preparations containing para-aminobenzoic acid and derivatives are occasionally elicitors of allergic contact dermatitis.]

Systemically, in papular, urticarial, and polymorphous light eruptions, chloroquine phosphate tablets (Aralen tablets), 250 mg, 1 to 3 times daily, will often prevent the eruption if taken 1 to 2 hours before exposure to the sunlight

R	
	A* Fil Cream (contains menthyl anthranilate)
R	
	Neo A* Fil Cream (contains Digallol trioleate)

8-Methoxypsoralen (Oxsoresalen, methoxsalen), taken by mouth in doses of 20 mg daily for adults, will in many persons increase the skin's sensitivity to sunlight. However, included in this increased sensitivity is an augmented stimulus to formation of a thicker stratum lucidum and an increase in melanin formation, both of which filter out substantial quantities of the irritating, erythema producing wave lengths of the solar spectrum. Therefore, slowly increasing, carefully graded daily exposures to sunlight while taking methoxsalen by mouth,  $\frac{1}{2}$  to 2 hours before the exposures, will in selected subjects lead to protection against sunburn and some degree of increased sun tanning. Nevertheless, the fact that this secondary protection results from a primary increased sensitivity indicates the limitations of the method and the need for delicate adjustment of the early exposures to avoid excessive sunburn.

## AGENTS USED FOR THE REMOVAL OF SUPERFLUOUS HAIR (HYPERTRICHOSIS)

There is no safe and effective way of removing hair *permanently* except by destroying the hair root and bottom of the hair follicle by inserting a needle and

## THE CHOICE OF DRUGS FOR THE TREATMENT OF POISONING

Alan K. Done, M D

---

### INTRODUCTION

Poisoning is a common medical problem which every physician and hospital should be prepared to handle. The majority of acute poisonings are either accidental or suicidal, and the emergent circumstances surrounding their occurrence frequently result in confusion and a feeling of helplessness on the part of the one who is in the best position to render lifesaving service to the patient—the physician who is first contacted. All too frequently the basic principles of good medical care are forgotten and conservatism is abandoned in favor of ill considered or unnecessarily heroic measures. Attempts to identify the poison and to find a specific antidote are often made at the expense of vital supportive measures. Few poisons have specific antidotes and the most effective antidote available is of little value to the patient who is not respiring adequately, has circulatory collapse, or is drowning in his own vomitus. Moreover, the administration of an antidote tends often to produce a false sense of security. Especially might this be true of the administration by lay persons of the so-called 'universal antidote,' which actually is of little value in most instances of poisoning.

The approach to the management of poisonings need differ but little from the approach to other medical problems. Every effort should be made to identify the poison but indicated symptomatic treatment should not be withheld in the meantime, just as digitalis would not be withheld pending an etiologic diagnosis in the patient with acute congestive heart failure. In many instances of poisoning, as in other medical situations, it is both possible and advisable to institute intelligent symptomatic treatment on the basis of a presumptive *clinical* diagnosis. Specific antidotes, when available, should be considered as adjuncts to a general therapeutic program, much as antibiotics would be looked upon in the treatment of an infection.

Occasional poisonings e.g., cyanide, represent urgent emergencies wherein specific measures must be instituted promptly if a fatal outcome is to be avoided. In circumstances such as these it is helpful to have ready access to information regarding the use of antidotes and sources of more detailed discussions than would

- R Epinephrine in oil injection 1 500  
 S 0.2 to 1.0 ml deep intramuscularly (buttocks) every 8  
 to 16 hours as required

## SELECTED REFERENCES

- Latapi, F., Lavalley, P., Novales, J., and Ortiz, Y., Griseofulvin en Micosis Cutaneas  
 V. Mosby Company  
 Chicago, 1954, The  
 it of University Hos  
 York, 1957, Hoeber  
 Harper  
 Polano, M. K. Skin Therapeutics, New York, 1952, Elsevier Publishing Co  
 Sulzberger, Marion B. The Pharmacopoeia and the Physician The Treatment of Infantile  
 Eczema, J. A. M. A 112 38, 1939  
 Sulzberger, Marion B., and Baer, Rudolph L. Treatment of Pyodermas (Common Pus  
 Forming Infections of the Skin) 1950 Year Book of Dermatology and Syphilology,  
 Chicago, 1951, The Year Book Publishers, Inc.  
 Sulzberger, Marion  
 ment ed  
 Sulzberger, Marion  
 1953 54  
 Publishers, Inc.  
 cortisone for  
 dermatologic  
 ologic My  
 Moniliasis  
 Year Book  
 Publishers, Inc., p. 5  
 Welsh / American Lecture Series, Springfield, Ill.,  
 Witten, the Treatment of Skin Diseases, Ann. New  
 Witten, Acne Vulgaris and Seborrhea Capitis, Pediat  
 Witten, Acne Vulgaris, in Current Therapy, edited by  
 Saunders Co

# THE CHOICE OF DRUGS FOR THE TREATMENT OF POISONING

Alan K. Done, M D

---

## INTRODUCTION

Poisoning is a common medical problem which every physician and hospital should be prepared to handle. The majority of acute poisonings are either accidental or suicidal and the emergent circumstances surrounding their occurrence frequently result in confusion and a feeling of helplessness on the part of the one who is in the best position to render lifesaving service to the patient—the physician who is first contacted. All too frequently the basic principles of good medical care are forgotten and conservatism is abandoned in favor of ill considered or unnecessarily heroic measures. Attempts to identify the poison and to find a specific antidote are often made at the expense of vital supportive measures. Few poisons have specific antidotes and the most effective antidote available is of little value to the patient who is not respiring adequately, has circulatory collapse, or is drowning in his own vomitus. Moreover, the administration of an antidote tends often to produce a false sense of security. Especially might this be true of the administration by lay persons of the so-called 'universal antidote' which actually is of little value in most instances of poisoning.

The approach to the management of poisonings need differ but little from the approach to other medical problems. Every effort should be made to identify the poison, but indicated symptomatic treatment should not be withheld in the meantime, just as digitalis would not be withheld pending an etiologic diagnosis in the patient with acute congestive heart failure. In many instances of poisoning as in other medical situations it is both possible and advisable to institute intelligent symptomatic treatment on the basis of a presumptive clinical diagnosis. Specific antidotes when available should be considered as adjuncts to a general therapeutic program much as antibiotics would be looked upon in the treatment of an infection.

Occasional poisonings e.g. cyanide, represent urgent emergencies wherein specific measures must be instituted promptly if a fatal outcome is to be avoided. In circumstances such as these it is helpful to have ready access to information regarding the use of antidotes and sources of more detailed discussions than would

be feasible here. For this reason poisons for which antidotes are available are listed alphabetically in the section entitled Specific Measures on pages 785, and particularly useful articles on individual types of poisoning are included in the references at the end of the chapter.

## DIAGNOSIS

In most instances of acute poisoning a history of the accidental or suicidal ingestion of a toxic substance is readily available. At times, however, such information may not be given spontaneously. It may be intentionally withheld in cases of suicidal or criminal poisoning. A patient may not realize that he has been exposed to a potentially toxic substance, and such a history may be forthcoming only after specifically oriented questioning. Furthermore, in the case of chronic poisoning exposure may have occurred at some time in the past. Children frequently come to the physician with sudden unexplained illnesses which are later found to be due to the accidental ingestion of a toxic substance.

Without a history of exposure the diagnosis of poisoning is not likely to be made unless there is a high index of suspicion. *The possibility of poisoning should be suspected in any patient with an obscure illness*, particularly when sudden illness strikes a person who was previously well. Poisoning should always be considered in the differential diagnosis of unexplained cyanosis, cardiovascular collapse, sudden loss of consciousness, convulsions or vomiting. There is scarcely a disease which cannot be mimicked by some type of poisoning, especially of the chronic variety. The most painstaking inquiry will often fail to uncover a source of poisoning exposure unless questions are directed toward specific possibilities. For example, a history that a child habitually chews on painted window sills and furniture is not likely to be provided spontaneously by the parents or to be uncovered in the course of a routine history. On the other hand such information would likely be obtained by the physician who considered the possibility of lead poisoning in a child with papilledema, convulsions and increased protein content in the spinal fluid. Relatively simple chemical tests are available for the identification of certain poisons but definite clues as to likely possibilities must be afforded the chemist if his results are to be available sufficiently early to be of value in the immediate management of the patient.

The following have been found to be valuable aids in the accurate diagnosis of the type of poisoning:

**Obtaining the Container**—The poison container and any remaining poison should always be obtained. This is important for several reasons: (1) it may be of medicolegal importance should a suspicion of criminal poisoning arise; (2) the errors which are frequently made by lay persons in reading and interpreting chemical nomenclature will be avoided; (3) if the contents are not specified on the label, such information usually can be obtained through a telephone call or telegram to the manufacturer, or from the brand name of the product (see following paragraph); (4) in the case of a prescription the druggist can identify the material from the prescription number; (5) it may be possible to identify the material by its appearance or physical or chemical properties; (6) many manufacturers pro-



vide reliable information relative to treatment of poisoning on the labels of their potentially toxic products, and (7) knowing the amount of material remaining and the amount originally present in the container, it is possible to determine the maximum amount which could have been taken.

The text by Gleason Gosselin and Hodge lists over 15 000 trade names of products, identifies their constituents, and provides expert information regarding treatment. The *Pesticide Handbook* by Frear lists the constituents of a large number of pesticides. Rodman enumerates the toxic constituents of different types (categories) of household products. Wood's article is a valuable reference to the toxic components in plants and the book edited by Buckley and Forges is an excellent treatise on venoms.

**Searching of the Poisoning Locale**—When acute poisoning is suspected, it is often possible to identify the responsible material by conducting a search of the home or other areas in which exposure may have occurred. Having a parent return to the home to look carefully about will usually uncover telltale evidence, such as an open bottle and a few spilled tablets. In this regard it is important to question older siblings who may have administered medicines or other substances to a very young child. The garage, yard, and even the homes, garages, and yards of neighbors should not be neglected if a search of the house does not provide the answer. The search is usually facilitated by having some knowledge, based upon clinical impression, of what types of materials are likely to have caused the poisoning in question. When suicidal poisoning is suspected, the responsible agent may be identified from discarded containers or wrappers found in wastebaskets or garbage cans. Police departments generally are expert and extremely cooperative in uncovering such evidence.

It is advisable at times to extend the search for possible sources of poisoning exposure to the patient's place of employment or other activities outside the home. For example, a number of warehouse workers who suddenly developed unexplained illness were found to have been poisoned with parathion which was leaking from its shipping container.

**Clinical Diagnosis**—Many poisonings manifest more or less typical clinical syndromes which if not absolutely diagnostic, at least make it possible to limit and pursue further the likely diagnostic possibilities and to institute intelligent supportive and expectant management. For example, hyperpnea, stupor, and vomiting suggest salicylate intoxication; signs of intense parasympathetic stimulation (salivation, lacrimation, sweating, excessive bronchial and salivary secretions, constriction of pupils, etc.) in association with weakness and muscle fasciculations suggest organic phosphate insecticide poisoning; hyperpyrexia associated with marked dryness of the skin and fixed, dilated pupils suggest poisoning with a belladonna alkaloid. Table 54 enumerates clinical signs which may be of value in the differential diagnosis of virtually any sign or symptom; only those which are felt to be valuable are included.

The appearance or odor of the vomitus or material obtained by gastric lavage may provide additional diagnostic clues. Luminescence of the vomitus or urine

be feasible here. For this reason poisons for which antidotes are available are listed alphabetically in the section entitled Specific Measures on pages 785 and particularly useful articles on individual types of poisoning are included in the references at the end of the chapter.

## DIAGNOSIS

In most instances of acute poisoning a history of the accidental or suicidal ingestion of a toxic substance is readily available. At times however such information may not be given spontaneously. It may be intentionally withheld in cases of suicidal or criminal poisoning. A patient may not realize that he has been exposed to a potentially toxic substance and such a history may be forthcoming only after specifically oriented questioning. Furthermore in the case of chronic poisoning exposure may have occurred at some time in the past. Children frequently come to the physician with sudden unexplained illnesses which are later found to be due to the accidental ingestion of a toxic substance.

Without a history of exposure the diagnosis of poisoning is not likely to be made unless there is a high index of suspicion. *The possibility of poisoning should be suspected in any patient with an obscure illness* particularly when sudden illness strikes a person who was previously well. Poisoning should always be considered in the differential diagnosis of unexplained cyanosis, cardiovascular collapse, sudden loss of consciousness, convulsions, or vomiting. There is scarcely a disease which cannot be mimicked by some type of poisoning, especially of the chronic variety. The most painstaking inquiry will often fail to uncover a source of poisoning exposure unless questions are directed toward specific possibilities. For example a history that a child habitually chews on painted window sills and furniture is not likely to be provided spontaneously by the parents or to be uncovered in the course of a routine history. On the other hand such information would likely be obtained by the physician who considered the possibility of lead poisoning in a child with papilledema, convulsions, and increased protein content in the spinal fluid. Relatively simple chemical tests are available for the identification of certain poisons but definite clues as to likely possibilities must be afforded the chemist if his results are to be available sufficiently early to be of value in the immediate management of the patient.

The following have been found to be valuable aids in the accurate diagnosis of the type of poisoning.

**Obtaining the Container**—The poison container and any remaining poison should always be obtained. This is important for several reasons: (1) it may be of medicolegal importance should a suspicion of criminal poisoning arise; (2) the errors which are frequently made by lay persons in reading and interpreting chemical nomenclature will be avoided; (3) if the contents are not specified on the label such information usually can be obtained through a telephone call or telegram to the manufacturer or from the brand name of the product (see following paragraph); (4) in the case of a prescription the druggist can identify the material from the prescription number; (5) it may be possible to identify the material by its appearance or physical or chemical properties; (6) many manufacturers pro-

Table 54 Clinical Signs in the Differential Diagnosis of Some Common Poisonings

	Vomiting, diarrhea or abdominal pain	Hematemesis and bloody diarrhea	Coma*	Convulsions	Dilated pupils*	Constricted pupils	Respiratory depression	Cyanosis*	Shock	Albuminuria	O t h e r s
Arsenic (acute) (chronic)	F	C	F	O	O				C	F	Garlic odor to breath stupor, delirium, muscle spasm Weakness, coryza symptoms, skin rashes, liver damage, peripheral neuritis muscle paralysis, and atrophy
Atropine and belladonna alkaloids			O		C			F	O		Hyperpyrexia, dry skin and mucous membranes confusion, mania
Barbiturates			C		O	F	C	O	F		Depressed superficial and deep reflexes
Carbon monoxide			C	F	O		C		O		Cherry red color to skin and mucous membranes, headache, confusion, intolerant of exertion
Chlorinated hydrocarbons (DDT, chlordane, lindane, etc)	O		F	C							Tremors, confusion
Cyanide			C	F	F		O <sub>2</sub>	C	F		Odor of bitter almonds on breath or vomitus
Fluoride	C	C		O					C	F	Tetany if death delayed
Fluoroacetate	F		C	F					F		Pulsus alternans, ectopic beats
Iron salts	C	C							C		
Lead (acute) (chronic)	C	F	F	F	F				C	F	Muscular weakness, pain cramps Papilledema, confusion, increased spinal fluid pressure and protein anemia, lead lines in long bones (x ray)
Mercury	C	C							F	C	After 1-3 days glossitis, gingivitis, dysentery, renal damage and failure

suggests phosphorus poisoning. An intensely pungent, finely granular black powder suggests calcium cyanide, and the diagnosis of cyanide poisoning is further suggested by an odor of bitter almonds to the breath or vomitus. A garlicklike odor to the breath or vomitus suggests that phosphorus, arsenic, or garlic was ingested. Finally, recognizable pills or undissolved capsules may be found.

**Laboratory Diagnosis**—A number of factors sharply limit the clinical value of toxicologic analyses in cases of acute poisoning. Techniques for the identification of many intoxicants are available only in specialized laboratories. Exceptions are barbiturates and salicylates which can be determined in many clinical laboratories. Even when the analyses are readily available, their value is limited by the fact that they are often time consuming and a general toxicologic survey is impossible with the amount of material which could be obtained from a living patient. Thus it is essential that careful consideration be given to a differential diagnosis based on clinical signs and the history of possible exposures before specimens are submitted for examination.

A simple test which can be performed in any laboratory or physician's office permits the rapid identification of *salicylate* in urine. A urine specimen should be boiled briefly in order to volatilize acetoacetic acid, which may give a false positive reaction. The addition of a few drops of a 10 per cent ferric chloride solution results in the formation of a blue to violet color in the presence of salicylates. The test is of no quantitative value, however, since a strongly positive test may be found in association with relative low blood levels of salicylate. (This test cannot be used to identify aspirin in gastric contents since the color complex is formed only with free salicylic acid.) A very simple and highly reliable test applicable to any hospital or clinical laboratory has been devised for measuring salicylate concentrations in blood. Because of the frequency with which unknown quantities of salicylates are ingested accidentally by children or with suicidal intent by adults, ready access to salicylate measurements in the blood is extremely valuable. The test can be used as an aid in deciding before illness is apparent whether or not hospitalization is advisable for observation or additional treatment.

The presence of *methemoglobinemia*, which may be caused by nitrites, chlorates, aniline, acetanilid, and bromates, is suggested when blood obtained from the patient is found to be chocolate brown in color and does not become bright red on exposure to air. The presence of the abnormal hemoglobin can be confirmed by spectroscopic examination of the blood.

## REMOVAL OF THE POISON

Perhaps the most valuable single measure in the treatment of acute poisoning is the removal of the poison from the body before it is absorbed. Obviously attempts to remove poison lose their effectiveness rapidly with the passage of time and should be made at the earliest possible moment. Occasionally, however, it is wise to delay until after institution of other forms of treatment. Cyanide exerts its effects so rapidly that death is likely to ensue unless antidotal treatment is begun immediately. In strychnine poisoning, fatal convulsions may be precipitated by attempts to empty the stomach unless barbiturate sedation is instituted beforehand.

Poisons which have been applied externally should be removed by copious washing with soap and water. It is just as important to remove certain poisons, e.g., parathion and nicotine, from the skin and mucous membranes as it is to remove them from the stomach, since cutaneous absorption is appreciable.

**Emesis**—Most poisons are in themselves emetics. If vomiting does not occur spontaneously, it can often be induced by stroking the posterior pharynx with a finger (with precautions being taken to prevent biting) or other blunt object. Emetic drugs are rarely necessary and should be used with caution. Emetics act by medullary stimulation either directly or reflexly through irritation of the gastric mucosa. With the former type, stimulation occurs first and is followed by depression. It is possible, therefore, to increase the severity of symptoms if poisoning is due to a drug which affects the central nervous system. Moreover, either type of emetic is likely to be ineffective in the patient who is poisoned with a depressant. *Emetics should never be used in a patient who is severely depressed or has ingested a caustic material such as lye.* In the severely depressed patient, aspiration of vomitus into the lungs is a grave danger. In the patient who has ingested a caustic material, vomiting is likely to result in further damage to an already eroded esophagus.

When the employment of an emetic is felt to be justified the most useful drugs are apomorphine and syrup of ipecac. Apomorphine is a more certain emetic and can be given parenterally to the patient who will not cooperate by taking an oral preparation. The recommended subcutaneous dose is 1 mg for a small child or 6 mg for an adult. Syrup of ipecac is somewhat safer and can be given orally in doses of 1 to 4 teaspoonfuls. In the home, effective emetics may be prepared by mixing 1 teaspoonful of powdered mustard or 2 teaspoonfuls of salt in a glass of warm water.

**Gastric Lavage**—Gastric lavage if properly performed is a more certain and thorough method of removing poison from the stomach than the production of emesis alone. It is *contraindicated in caustic alkali ingestion* where perforation of the stomach or esophagus is a danger and in strychnine poisoning at least until the patient has been sedated sufficiently to prevent the precipitation of convulsions. It should be performed very cautiously, if at all in cases of the ingestion of kerosene, furniture polish or other volatile hydrocarbons, in which the consequences of pulmonary aspiration are so dangerous.

A number of steps can be taken to enhance the effectiveness of gastric lavage. The largest tube which can be passed safely should be used in order to facilitate aspiration of particulate matter and undissolved pills and to prevent frequent plugging of the tube which will delay completion of the procedure. Vomiting should be induced prior to lavage if the patient is conscious and has recently eaten or if the poison was in a slowly disintegrating form, such as enteric coated pills. Washing of the stomach after initial aspiration of its contents should be accomplished with small volumes of fluid instilled under little pressure. Instillation of more than 15 to 20 ml of fluid at a time (or less in small children), or the use of more than very gentle pressure will result in forcing of the remaining poison through the pylorus into the small intestine where it is not recoverable and can be absorbed readily.

# DRUGS FOR TREATMENT OF POISONING

Methanol	C	C	O	G	C	F	C	Severe acidosis, During recovery blindness weakness im- paired renal function
Nitrites	C	O	F	F	C	F	C	Salivation sweating mental disturbances
Nitrites chlorates acetanild	F	O	F	O	C	C	F	Methemoglobinemia chocolate color to skin mucous mem- branes and blood (blood does not turn red on shaking narrow vertigo)
Opiates	F	C	C	C	C	F	F	Depressed reflexes improvement with nalorphine or levallorphan
Phosphates organic	F	F	F	C	F			Intense parasympathetic stimulation salivation lacrimation sweating excess bronchial and salivary secretions bronchospasm hypertens on weakness muscle fascicula- tions
Phosphorus	C	C	F	F				
Salicylates	vom	F	O		C	O	O	F F Garlic odor breath and vomiting later hepatomegaly jaundice hemorthagie diathesis oliguria hematuria
Strychnine		O	C		F	F	O	Urine positive for acetone and salicylate (ferrocyanide test) Respiratory alkalosis → metabolic acidosis

\*Distinct from that associated with shock or exodus  
 In children less frequently or rarely seen in adults  
 C—Characteristic  
 F—Frequently seen  
 O—Occasionally seen  
 Subscripts 1 and 2—Sequence of occurrence (e.g. hyperpnea followed by respiratory depression)

muscularly in doses of 3 to 6 mg for adults or 0.1 mg per pound of body weight for children every 15 to 30 minutes. The above doses are continued until tendon and gag reflexes return or slight facial twitching is observed.

Pentylenetetrazol (Metrazol), amphetamine (Benzedrine) and dextro amphetamine (Dexedrine) have also been used with success in severe depression due to barbiturates and other depressants. Nalorphine or levallorphan are drugs of choice in the treatment of depression due to morphine and other narcotics (see Narcotics under Specific Measures). Bemegride (Megimide, Mikedimide) is purported to be a structural antagonist to the barbiturates. While it is true that this compound can lessen the degree of depression produced by barbiturates or glutethimide there is little evidence that its mode of action differs from or that it is in any way superior to the known analeptics.

**Convulsions**—Convulsions may occur in the course of poisoning with a wide variety of compounds and may be due to a specific excitatory effect of the intoxicant (e.g. strychnine, organic phosphate insecticides, chlorinated hydrocarbons) or secondary to such nonspecific phenomena as hypoxia, hypocalcemia, water intoxication, hypoglycemia, cerebral edema, or systemic metabolic disturbances. Measures aimed at correcting these latter factors should be undertaken and may be effective alone in terminating the convulsions. Many patients will also require anticonvulsant medications irrespective of the etiology of the convulsions. However, such medications are likely to be relatively ineffective unless the underlying disturbances are corrected.

The use of anticonvulsant drugs is discussed in Chapter 17. The situation with respect to poisoning differs somewhat from the treatment of epilepsy in that drugs which are effective as prophylaxis against convulsions may be ineffective in terminating seizures. The cautious use of a barbiturate with rapid onset and short duration of action is the anticonvulsive therapy of choice for chemically induced convulsions. If intravenous administration seems indicated, the sodium salts of thiopental (Pentothal), pentobarbital (Nembutal), or amobarbital (Amytal) are preferable to phenobarbital sodium since the delayed onset of action of the latter may be cause for overdosage. The recommended intravenous dose of amobarbital sodium is 2.5 to 4 mg per pound of body weight in children or 300 to 600 mg in adults given slowly until the convulsions cease. Intramuscular administration of a barbiturate is safer and should be used in preference to the intravenous route where possible. Phenobarbital sodium can be given intramuscularly in doses of 1.5 to 3 mg per pound of body weight in children or 100 to 200 mg in adults. Phenobarbital is preferable to other barbiturates for maintenance prophylaxis against subsequent convulsions because of its selective anticonvulsant properties. Paraldehyde is a useful adjunct in the treatment of acute central nervous excitation and may be given intramuscularly or rectally in doses of 0.3 ml per pound of body weight in children or 25 to 40 ml in adults. If convulsions are protracted and do not respond to the above measures, the induction of anesthesia with open drop ether may be advisable. For this it is wise to enlist the aid of an experienced anesthetist if possible.

**Respiratory Problems**—Narcosis, a frequent cause of respiratory insufficiency in cases of poisoning, was discussed previously under Central Nervous Depression.

Careful precautions should be taken to prevent aspiration of gastric contents or lavage fluid into the lungs. These precautions are particularly important in the patient who is severely depressed or has ingested kerosene furniture polish, or other volatile hydrocarbons. The patient should be placed in a head down position either prone or with the head turned to the side. An assistant should stand by ready to aspirate the pharynx promptly should vomiting occur. When the tube is removed it should be pinched tightly to prevent spillage of its contents into the lungs as the tip passes through the pharynx.

Gastric lavage should be continued until the fluid returns clear. Antagonists to certain poisons may be used in the lavage fluid or instilled into the stomach after gastric lavage. (See individual poisons under Specific Measures.)

## SUPPORTIVE MEASURES

Supportive measures are at least as important in the treatment of poisoning as the administration of specific antidotes. The majority of patients will recover with good supportive care alone and without it the best of antidotes will be of little value. Moreover there are few poisons for which there are specific antagonists so that the treatment of most poisonings is entirely supportive. With few exceptions the problems which arise are not at all peculiar to poisoning and the approach to management is essentially the same as in the symptomatic treatment of disease. The reader is referred to other chapters for more detailed discussions of general supportive measures. This section discusses those aspects which are particularly relevant to the treatment of acute chemical poisoning.

**Central Nervous System Depression (Narcosis)**—The use of stimulants to vital medullary centers is discussed in another section (Chapter 11).

There is a widespread tendency to overtreat patients poisoned by depressants. Most of these patients will recover if treated as though they were recovering from anesthesia. Support of the circulation, maintenance of a patent airway and the use of oxygen and artificial respiration where indicated are imperative.

The use and abuse of analeptic drugs has been a subject of much debate. Certainly there is no justification for their employment in patients with active reflexes, response to pain and adequate respirations. Whether analeptics are of value in patients who are more deeply depressed is the point of controversy. It has been suggested that better results can be obtained in the treatment of barbiturate poisoning using supportive care alone rather than in combination with analeptics even in patients who are severely depressed. It is my opinion that analeptics are rarely indicated but that they are of value if properly used in carefully selected patients. These drugs should not be permitted to supplant essential supportive care and their use should be reserved for those patients in whom recovery seems doubtful with supportive care alone. No attempt should be made to restore consciousness rather the objective should be to restore and to maintain active reflexes and adequate respiration.

Picrotoxin is probably the analeptic of choice for severe barbiturate depression. The dose and route of administration depend upon the urgency of the situation. Picrotoxin can be given as a continuous intravenous infusion in a dose of 1 mg per minute in adults or proportionately smaller doses in children or intra



Chapter 26 provides a detailed discussion of the use of vasopressor drugs. When shock is severe and presumably due to vasodilatation norepinephrine (Levophed) is probably the vasopressor of choice. It is given by continuous intravenous infusion the rate of infusion being regulated by the blood pressure response. A 4 mg vial of norepinephrine is mixed with a liter of 5 per cent glucose or normal saline. Care should be taken that extravasation does not occur, since tissue sloughs may result. With less severe degrees of shock phenylephrine (Neo-Synephrine) hydrochloride may be used intramuscularly in a dose of 0.1 mg per kilogram of body weight.

The intravenous administration of adrenocortical hormones has been found occasionally to be a valuable adjunct in the treatment of cardiovascular collapse which is refractory to the methods of treatment described previously. Hydrocortisone may be given intravenously in a dose of 2 to 4 mg per kilogram of body weight. The free alcohol preparation should be diluted in no less than 250 ml of 5 per cent glucose or physiologic saline. This preparation has the disadvantage of requiring dilution in and administration of relatively large volumes of fluid in order to achieve the high doses of hormone which are required. The succinate or phosphate esters of hydrocortisone can be administered rapidly intravenously in small volumes of fluid. The doses are approximately the same as for the free alcohol of hydrocortisone.

**Acidosis**—Metabolic acidosis may occur in the course of poisoning with methyl alcohol, phenol, polymeric phosphates, formalin and in salicylate intoxication in children. The early administration of polyionic solutions containing glucose will often retard the development of severe acidosis. If severe metabolic acidosis is present alkali therapy is indicated. Either M/6 sodium lactate or 3.75 per cent sodium bicarbonate may be used intravenously as alkalinizing solutions. The carbon dioxide of the blood can be used as a rough estimate of the amount of alkali which should be given. The amounts of lactate or bicarbonate necessary to elevate the carbon dioxide content of the blood are

*To raise CO<sub>2</sub> content*

	<i>1 mEq/L</i>	<i>1 volume per cent</i>
Sodium bicarbonate	0.058 Gm/Kg	0.076 Gm/Kg
M/6 Sodium lactate	4.2 ml/Kg	1.8 ml/Kg

Only enough alkali should be given to raise the CO<sub>2</sub> content to approximately 15 mEq per liter or 30 volumes per cent.

**Salicylate Intoxication**—Special problems arise with respect to salicylate intoxication in which a mixed acid base disturbance may occur. In children metabolic acidosis may be superimposed upon respiratory alkalosis. Under these circumstances it cannot be determined on the basis of CO<sub>2</sub> content or combining power whether acidosis or alkalosis is present since these values are reduced in either instance. Certain differentiation can be made only with determination of blood pH. If acidosis is mild the intravenous administration of a mixture of 1 part of M/6 sodium lactate, 1 part of saline and 2 parts of 5 per cent glucose in water is recommended. If the status of acid base disturbance cannot be determined but ketosis is present and more than 6 to 8 hours have elapsed following

Failure to establish and maintain an adequate airway will render all other efforts useless. This is a particularly difficult problem in the deeply narcotized patient. Bronchial and pharyngeal secretions may be copious and should be removed with suctioning. The tongue should be prevented from falling back into the pharynx and thus causing obstruction. Pulling the mandible forward, extending the neck, and placing the patient in the prone position will usually accomplish this. The use of an oropharyngeal airway and, occasionally, intratracheal intubation may be of value. However, these appliances should be removed as soon as the patient arouses sufficiently to 'fight' the airway. Tracheotomy may be necessary if more conservative measures fail or the threat of obstruction is expected to persist for more than two or three days. Poisoning associated with inhalation of irritating fumes or the aspiration into the trachea of irritating substances may result in laryngospasm and/or laryngeal edema. Tracheotomy or intratracheal intubation under such circumstances is lifesaving.

Frequent postural changes and the early prophylactic use of antibiotics are important in preventing hypostatic pneumonia in patients with prolonged coma. Artificial respiration, including, where necessary the use of a tank respirator, is imperative when respiratory movements become inadequate. Although oxygen administration is a valuable adjunct, it cannot replace artificial respiration when spontaneous respirations are ineffective in maintaining adequate gaseous exchange.

Oxygen should be used not only in the treatment of respiratory insufficiency but also under any circumstance in which tissue hypoxia occurs, such as shock, carbon monoxide or cyanide poisoning and in the presence of methemoglobinemia. In carbon monoxide poisoning, oxygen has a specific action in promoting the dissociation of carboxyhemoglobin. Oxygen should be used in poisonings associated with severe central respiratory depression, but one should be prepared to apply artificial respiration, since oxygen administration frequently results in apnea due to removal of the hypoxic stimulus to spontaneous respiration.

Pulmonary edema may respond to alcohol vapor inhalation used in conjunction with the usual measures. This can be achieved by bubbling oxygen through a 50 per cent solution of ethyl alcohol and administering the mixture by positive pressure.

**Shock**—Shock is a frequent occurrence in acute chemical poisonings and may be the result of a number of factors. It may occur because of pooling and extravasation of blood and fluids into the intestinal tract in the course of poisoning with such materials as arsenic, fluoride and phosphorus from a direct vasodepressor effect of the poison or its metabolites (as is thought to be the case in iron poisoning) as a nonspecific effect of tissue hypoxia or metabolic disturbances (poisoning with central depressants, cyanide, fluoroacetate and general protoplasmic poisons), or in association with the trauma and tissue destruction produced by corrosives. Thus the treatment of shock due to poisoning should include an attack upon underlying factors as well as replacement of fluids and the administration of vasopressor agents. Specific antidotes (if available), oxygen, and intravenous fluids should be given. Vasomotor stimulants should be used only for vasomotor collapse and not to support a failing circulation when fluids or blood transfusion is needed to replace diminished blood volume.

**Acetamid** See Methemoglobinemic poisoning

**Acetophenetidin** See Methemoglobinemic poisoning

**Acetylcholine** See Cholinergic compounds

**Acids** Magnesium oxide magnesium hydroxide (*milk of magnesia*), or aluminum hydroxide should be given by mouth at the earliest possible moment to neutralize strong acids and thus prevent or minimize damage to the esophagus and stomach. Sodium bicarbonate and magnesium carbonate effectively neutralize acids but they have the disadvantage of releasing carbon dioxide which may cause dangerous gastric distention. Demulcents such as milk aluminum hydroxide gel or olive oil should be used after neutralization of the acid.

**Alkali** Attempts should be made to neutralize caustic alkali with a weak acid such as diluted vinegar lemon juice, or orange juice at the earliest possible moment. Olive oil should be applied to affected areas and given frequently by mouth if swallowing is possible. Theory and experimental and clinical observations suggest that antiphlogistic adrenocortical hormones such as cortisone, hydrocortisone prednisolone, or prednisone may be of benefit in minimizing stricture formation. The reader is referred to other sources for discussions of the important problems of esophageal dilatation and the surgical treatment of caustic strictures of the esophagus.

**Alkaloids** Potassium permanganate reportedly destroys many alkaloidal substances including strychnine physostigmine, conine, and quinine, although there is some question as to its efficiency in this regard. It is irritating to the stomach in concentrations of greater than 1:10,000 and care must be taken to ensure that no undissolved particles are present. The solution may be used as the lavage fluid.

**Alphaprodine** See Narcotics

**Amanita toxins** (toxic mushrooms) *Amanita muscaria* produces rapid poisoning with symptoms of intense parasympathetic stimulation (muscarinic effect). Atropinization is the treatment of choice (see Cholinergic compounds). *Amanita phalloides* produces poisoning which is comparatively delayed in onset (6 to 12 hours) and is characterized by damage to cells of the liver, kidney, heart, brain, and other tissues. There is no specific treatment for this type of poisoning.

**Amphetamine** The central excitatory effects of amphetamine and related compounds may be reversed dramatically by chlorpromazine (Thorazine). The doses of chlorpromazine which are required are in the upper therapeutic range and are not in themselves depressive. This is in contrast to the use of barbiturate, which usually produces a less satisfactory response, and then only in very large doses. Moreover, with the small doses of chlorpromazine which are required, postexcitatory depression is not aggravated. The suggested dose of chlorpromazine for a 2 year old child is 15 mg intramuscularly.

**Amyl nitrite** See Methemoglobinemic poisoning

**Aniline** See Methemoglobinemic poisoning

**Antimony** See Heavy metals

**Arecoline** See Cholinergic compounds

**Arsenic** See Heavy metals

**Barium salts** Sodium sulfate forms insoluble salts with barium. The recommended dose is 2 to 3 Gm for a 2 to 3 year old child. An initial dose is given and then removed by gastric lavage. A second dose is given after completion of lavage.

**Benzedrine** See Amphetamine

**Bismuth** See Heavy metals

**Bromide** Sodium or ammonium chloride hasten the excretion of bromide. The dose and route of administration depend upon how severe and acute is the bromide intoxication. Mercurial diuretics are also of value in promoting the excretion of bromides.

**Cadmium** See Heavy metals

**Caustic soda** See Alkali

**Chlorates** See Methemoglobinemic poisoning

**Cholinergic compounds** Atropine will reverse the muscarinic effects of cholinergic drugs (e.g., acetylcholine pilocarpine methacholine), the toxic mushroom *Amanita muscaria*, and the organic phosphates. The muscarinic effects include profuse sweating, excessive secretion

the ingestion of large amounts of salicylate by a small child, the administration of a similar solution would be appropriate. With more severe degrees of acidosis, the above mentioned scheme for calculating alkali requirements on the basis of  $\text{CO}_2$  content of the blood has been proved highly satisfactory.

**Oliguria and Anuria.**—Acute renal failure may occur in the course of poisoning with a variety of compounds including mercury and other heavy metals, phosphorus, carbon tetrachloride, bromate, and hemolytic substances such as castor beans and naphthalene. In most instances renal failure is reversible, and, if the patient is able to survive, kidney function can be expected to resume in from 1 to 3 weeks. Consequently the aim of therapy is to prolong the patient's life until function returns. Avoidance of overhydration and hyperkalemia are critical problems in management during the period of oliguria or anuria. Fluid intake should be limited to replacement of measurable fluid losses (stool, urine, vomitus) plus insensible water loss. Insensible water loss is in the range of 450 to 500 ml per square meter of body surface area at usual room temperatures. Balance studies of Blumle and associates suggest that, at least in adults, a fluid intake of 330 ml per square meter of body surface area, in addition to measured losses, is closer to the true fluid requirement and may be more appropriate for patients with renal failure. Additional water loss will occur in the presence of fever, high environmental temperature or hyperventilation; under these circumstances daily weights will provide an index as to the adequacy of fluid replacement. Estimations of body surface area in children may be obtained from Table 1, page 52. Potassium should be assiduously avoided. Protein should be excluded from the diet, and sodium intake should be restricted to replacement of losses.

Oral feeding is preferable if it can be accomplished in order that caloric balance may be maintained. With resumption of kidney function, diuresis occurs and may be accompanied by dangerous losses of water and electrolytes. Careful replacement therapy is then necessary.

Since in most instances of renal failure due to poisoning recovery is reasonably certain a conservative approach initially is warranted. Hemodialysis (the use of the 'artificial kidney') has been proved to be of value in the treatment of anuria particularly in regard to the control of electrolyte concentrations. In the hands of skilled and experienced teams, hemodialysis may be lifesaving, but it is seldom indicated in acute renal failure. Peritoneal lavage has been used with success in the treatment of acute renal failure, but has largely been replaced by hemodialysis.

### SPECIFIC MEASURES (ANTIDOTES)

There are few poisons for which there are specific antidotes. The following list includes only those poisons for which chemical antidotes or relatively specific physiologic antagonists are available. The discussion of each poison is limited largely to a consideration of the use of the antidotes. The reader is referred to the section on Supportive Measures and to the Selected References for a discussion of other aspects of the treatment and the symptomatic treatment of poisoning with compounds for which there are no antidotes.

dose of 50 to 100 mg to an adult or 10 to 20 mg to a small child See Chapter 35 for a more detailed discussion of Dicumarol, warfarin, and related compounds

**Digitalis** Preliminary observations suggest that chelation of serum calcium by the sodium salt of ethylenediaminetetraacetic acid (EDTA, Versene) is effective in the treatment of digitalis intoxication and offers certain advantages over potassium therapy See Chapter 24

**Dilaudid** See Narcotics

**Dromoran** See Narcotics

**ENP** (ethyl *p* nitrophenyl thionobenzene phosphonate) An organic phosphate See Cholinergic compounds

**Ferrous sulfate** Sodium bicarbonate (a 5 per cent solution in gastric lavage) will react with ferrous sulfate to form ferrous carbonate which is less corrosive and less soluble Irritation may be relieved by milk or bismuth subcarbonate Edathamil calcium disodium (Versenate) is capable of chelating iron, and suggestive benefit from its use in the treatment of poisoning with iron salts has been reported (see Heavy metals) Dimercaprol (BAL) increases the mortality in experimental iron poisoning

**Fluoride** The toxicity of soluble fluoride salts is due in large part to the fact that fluoride is intensely irritating and forms insoluble salts with calcium, the latter effect leading to hypocalcemia The repeated administration of calcium is of value in preventing or correcting hypocalcemia and in binding the fluoride ion Gastric lavage with lime water or the installation of a 5 per cent solution of calcium chloride or large amounts of milk will impede absorption by causing the formation of insoluble calcium fluoride Hypocalcemia should be combated early by the slow intravenous injection of 2 to 10 ml of a 10 per cent solution of calcium gluconate This should be followed for sustained effect by the intramuscular injection of similar doses at 4 to 6-hour intervals, with intravenous calcium supplementation as necessary to prevent tetany

**Fluoroacetate** The toxic effects of fluoroacetate have been attributed to interference with intermediary metabolism Fluoroacetate competes with acetate for condensation with oxal acetate fluorocitrate is formed and the tricarboxylic acid cycle is blocked at that point The resulting metabolic derangement manifests itself primarily in disturbances of the central nervous system and the heart, with death resulting usually from ventricular fibrillation

In animal experiments, compounds which are capable of serving as acetate donors have been found to be effective antidotes The most effective and least toxic of the substances studied is glyceryl monoacetate (monacetin) Although therapeutic regimens have not been established in human subjects, studies in monkeys suggest that an appropriate dose would be in the range of 0.1 to 0.5 ml per kilogram intramuscularly at least hourly for several hours Careful monitoring of the cardiac status is essential sufficiently frequent injections of monacetin should be given to prevent or reverse pulsus alternans or electrical alternans on the electrocardiogram Although monacetin has not been evaluated in human subjects, its use seems justified on the basis of its relatively low toxicity and the potentially disastrous results of fluoroacetate poisoning

**Formaldehyde** Ammonium salts convert formaldehyde to methenamine, which is relatively nontoxic Dilute ammonia water (0.2 per cent) or a dilute solution of ammonium acetate can be used

**Glyceryl trinitrate** See Methemoglobinemic poisoning

**Gold** See Heavy metals

**Heavy metals** Dimercaprol (BAL) is an effective antidote against those heavy metals which form mercaptides with sulfhydryl enzymes It is most effective against arsenic, mercury, and gold and is ineffective against selenium and uranium Other metals occupy an intermediate position Dimercaprol markedly increases the excretion of cadmium but may enhance its nephrotoxicity When dimercaprol therapy is indicated it is important that it be instituted at the earliest possible moment The recommended dose is 3 to 5 mg per kilogram of body weight administered intramuscularly every 4 hours for the first 2 days, every 6 hours during the third day and every 12 hours thereafter for 10 days or until recovery is complete Within the 3 to 5 mg per kilogram range, dosage should be dic

of lacrimal, salivary, and bronchial glands, intestinal spasm, tachycardia, bronchospasm and myosis. Atropine does not effectively reverse the nicotinic effects (muscle fasciculations and weakness) or effects on the central nervous system (headache, confusion, coma, and convulsions) of these compounds, which must be treated symptomatically. It is especially important that artificial respiration be instituted when muscle weakness is sufficiently severe to result in respiratory insufficiency. The dose and route of administration of atropine depend upon the severity and urgency of the situation. In general, the more intense the symptoms of parasympathetic stimulation the greater the doses of atropine which will be required and the greater the tolerance to atropine.

In the case of poisoning with organic phosphate insecticides, atropinization must be rapidly instituted and vigorously pursued because of the grave consequences of inadequate or delayed treatment. If symptoms are severe, the initial dose of atropine probably should be no less than 2 mg in the adult and in the range of 0.5 mg in the 2- or 3-year old child. It may be advisable to give part of the initial dose intravenously in the severely involved patient. Atropine administration should be repeated every 30 to 60 minutes until the desired control is achieved or until signs of atropine overdosage appear. Fractional doses should then be given every 4 to 8 hours as necessary to maintain the therapeutic effect.

**Codeine.** See Narcotics

**Compound 1080.** See Fluoroacetate

**Cyanide.** Cyanide combines readily with iron in the ferric state and in this way reversibly inhibits certain cellular oxidizing enzymes such as cytochrome oxidase. It does not form a complex with hemoglobin, since such iron is in the ferrous state. The most effective method yet devised for the treatment of cyanide poisoning is based upon the intentional conversion of hemoglobin iron from the ferrous to the ferric state (methemoglobin) by the administration of nitrite. Methemoglobin combines effectively with cytochrome oxidase for cyanide. Sodium thiosulfate is then given to combine with the cyanide, released by the dissociation of cyanomethemoglobin to form thiocyanate, which is excretable and relatively nontoxic.

Speed is of the essence, since the course of cyanide poisoning is rapidly fatal. Treatment offers some promise of survival even after respiratory arrest has occurred; indeed, patients who were thought to be dead have recovered. Amyl nitrite should be given by inhalation for 30 seconds of every minute while a sodium nitrite solution is prepared for injection. Artificial respiration should be used if the patient is apneic. Sodium nitrite is then injected intravenously in a dose of 10 to 15 ml of a 3 per cent solution over a period of 2 to 4 minutes. A fall in blood pressure may occur during the injection of nitrite, but this usually will not progress if the rate of injection is slowed momentarily. If blood pressure does not return shortly to its previous levels the administration of intravenous fluids or a vasopressor such as ephedrine may be necessary. It is advisable to have a slow intravenous infusion operating throughout the course of treatment to provide a ready route for the administration of fluids and vasopressor agents.

After injection of sodium nitrite, sodium thiosulfate is injected intravenously through the same needle in a dose of 50 ml of a 25 per cent aqueous solution over a period of 10 minutes. If symptoms reappear, the above schedule should be repeated in half doses.

Overdosage of nitrite is suggested by deepening cyanosis (due to excessive methemoglobinemia) in the presence of improvement otherwise. Oxygen administration will usually suffice to allay symptoms of excessive methemoglobinemia. If not, blood transfusion is preferable to inducing a reversion of methemoglobinemia, as would ordinarily be done in the treatment of methemoglobinemia due to nitrite poisoning.

**Demerol (meperidine).** See Narcotics

**Demeton.** An organic phosphate. See Cholinergic compounds

**Dexedrine.** See Amphetamine

**DFP (diisopropyl fluorophosphate).** An organic phosphate. See Cholinergic compounds

**Dicumarol.** The hypoprothrombinemic effects of Dicumarol and warfarin are reversed by vitamin K. Vitamin K<sub>1</sub> or K<sub>2</sub> oxide may be given intramuscularly or intravenously in a

biturates and other nonnarcotic central nervous system depressants. Nalorphine or levallorphan are so effective and specific in this regard that the diagnosis of poisoning with a narcotic agent should be questioned in a patient who fails to respond. Hazardous narcotic withdrawal reactions may be induced by these compounds *in add cts*.

The recommended intravenous dose of nalorphine is 5 to 10 mg in adults and 1 to 2 mg in the small child. Levallorphan doses are approximately one fourth of those of nalorphine. In the newborn infant who is depressed from narcotic analgesics given to the mother during labor, levallorphan in a dose of 0.05 to 0.10 mg or nalorphine in a dose of 0.2 to 0.4 mg diluted in 2 to 3 ml of normal saline may be injected into the umbilical vein.

One half the initial dose of nalorphine or levallorphan may be given after 10 minutes if adequate spontaneous respiration does not ensue.

**Neostigmine** See Cholinergic compounds

**Nickel** See Heavy metals

**Nicotine** If ingested, universal antidote or activated charcoal should be given as a slurry in water, followed by lavage as for Alkaloids. Treatment otherwise is strictly symptomatic.

**Nisental (alphaprodine)** See Narcotics

**Nitrites** See Methemoglobinemic poisoning

**Nitrobenzene** See Methemoglobinemic poisoning

**OMPA (octamethyl pyrophosphoramide)** An organic phosphate. See Cholinergic compounds

**Oxalate** Hypocalcemia should be combated as in fluoride poisoning. See Fluoride

**Pantopon** See Narcotics

**Parathion** An organic phosphate insecticide. See Cholinergic compounds

**Phenacetin** See Methemoglobinemic poisoning

**Phenol** Olive, castor, or other vegetable oils instilled into the stomach will delay the absorption and facilitate removal of phenol.

**Phosphate organic** See Cholinergic compounds

**Phosphates polymeric** Hexametaphosphate, tripolyphosphate, and pyrophosphate have been shown to produce hypocalcemia and acidosis in rats. Personal observations indicate that profound hypocalcemia may occur as well in human subjects poisoned with these compounds. Calcium should be administered as in Fluoride poisoning.

**Phosphorus** Gastric lavage with a 0.2 per cent solution of copper sulfate impedes absorption by coating the phosphorus particles with insoluble copper phosphide. Treatment otherwise is symptomatic.

**Pilocarpine** See Cholinergic compounds

**Potash caustic** See Alkali

**Potassium bromate** See Methemoglobinemic poisoning

**Potassium chlorate** See Methemoglobinemic poisoning

**Potassium hydroxide** See Alkali

**Prussic acid** See Cyanide

**Sodium bromate** See Methemoglobinemic poisoning

**Sodium chlorate** See Methemoglobinemic poisoning

**Sodium fluoride** See Fluoride

**Sodium fluoroacetate** See Fluoroacetate

**Sodium hexametaphosphate** See Phosphates polymeric

**Sodium hydroxide** See Alkali

**Sodium nitrite** See Methemoglobinemic poisoning

**Sodium pyrophosphate** See Phosphates, polymeric

**Sodium tripolyphosphate** See Phosphates, polymeric

**Strychnine** Fatal convulsions may be precipitated by attempts to empty the stomach unless barbiturate sedation is instituted beforehand. Potassium permanganate lavage then should be employed (see Alkaloids). The 'universal antidote' can be given as a slurry to delay

tated by the severity of poisoning and the response of the patient. Undesirable side effects from dimercaprol itself are rather frequent and include nausea, vomiting, a burning sensation of the lips, mouth, throat and eyes, hypotension, muscle aches, and rarely coma and convulsions. Premedication with ephedrine is effective in preventing or minimizing many of these symptoms. Dimercaprol appears to be less effective than edathamil calcium disodium in the treatment of lead poisoning and is contraindicated in the treatment of poisoning with iron salts.

Edathamil calcium disodium (Calcium Disodium Versenate, EDTA) is an effective chelating agent for those metals (e.g., lead and iron) which can be chelated more securely than calcium. It appears to be superior to BAL in the treatment of acute or chronic lead poisoning. EDTA does not appreciably alter the mortality rate in rats poisoned with iron. However, both theory and clinical observations suggest that it deserves more extensive trial in human cases of ferrous sulfate poisoning. Only the calcium disodium salt of EDTA should be used in the treatment of poisoning with heavy metals, or dangerous hypocalcemia may result.

Edathamil calcium disodium should be administered intravenously in a concentration not exceeding 3 per cent. Two infusions a day may be given at a maximum rate per kilogram of body weight of 38 mg per hour or 73 mg per day. The course may be continued for 5 to 7 days, the maximum total dose being 550 mg per kilogram. An additional course of treatment may be given if necessary, but a rest period of 7 to 10 days between courses is recommended. Suggested indications for the second course of therapy include increased concentrations of lead in the blood (greater than 0.1 mg per 100 Gm of whole blood), increase in urinary coproporphyrin excretion (in excess of 250 mcg per 24 hr), or persistence of severe neurologic manifestations.

Heroin. See Narcotics.

HFTP. (hexaethyl tetraphosphate). An organic phosphate. See Cholinergic compounds.

Hydrocyanic acid. See Cyanide.

Iodine. A starch solution will neutralize iodine. It can be used as the lavage fluid, and the procedure should be continued until the return fluid is no longer blue. If starch is unavailable, the immediate swallowing of milk or eggs is of benefit.

Iron. See Ferrous sulfate.

Lye. See Alkali.

Malathion. An organic phosphate insecticide. See Cholinergic compounds.

Mercury. Gastric lavage with sodium formaldehyde sulfoxylate (5 per cent) causes the precipitation of mercury. If this is not available, an egg white solution can be used. See Heavy metals for specific systemic treatment.

Mecholyl. See Cholinergic compounds.

Meperidine (Demerol). See Narcotics.

Methacholine. See Cholinergic compounds.

Methadone. See Narcotics.

Methamphetamine. See Amphetamine.

Methemoglobinemic poisoning. A number of chemicals including nitrite, chlorate and bromate salts, acetophenetidin (phenacetin), acetanilid, aniline, and other nitro organic compounds are capable of oxidizing hemoglobin to methemoglobin, which is incapable of transporting oxygen. Other effects may be produced as well (e.g., the nephrotoxic effects of bromates and chlorates and the hypotensive effects of nitrites), but treatment of manifestations other than methemoglobinemia is symptomatic. If methemoglobinemia is severe, it may be reversed by methylene blue. Methylene blue can be administered intravenously or intramuscularly in a dose of 1 to 2 mg per kilogram of body weight or orally in a dose of 3 to 5 mg per kilogram. The action is much slower by the latter route.

Morphine. See Narcotics.

Mushrooms, toxic. See Amanita toxins.

Narcotics. The depressant effects of morphine and its derivatives and the synthetic narcotics are effectively and dramatically antagonized by nalorphine (Nalline) or levallorphan (Lorfan). These compounds do not antagonize the respiratory depression caused by bar-



Partial replacement of blood may be of great benefit in the treatment of poisonings which are associated with the formation of abnormal forms of hemoglobin methemoglobin (poisoning with nitrites, aniline, acetanilid, bromates, chlorates, etc.), sulfhemoglobin (poisoning with the same compounds which cause methemoglobinemia), and carboxyhemoglobin (carbon monoxide poisoning). The object is to supply normal hemoglobin capable of transporting oxygen. This often can be accomplished through simple transfusion. However, the amount of blood required may be sufficiently large so that it must be administered by the process of exchange.

## AN EMERGENCY "KIT" FOR THE TREATMENT OF POISONING

Any hospital, clinic, or individual physician likely to be called upon to provide emergency treatment in cases of poisoning should be prepared by having available at least those drugs which are important in the management of the more common types of poisoning. Dangerous delays in the institution of proper treatment can be avoided if these materials are kept together in a poisoning treatment "kit."

*Table 55 Suggested Constituents of a Kit for Treatment of Poisoning*

Acetic acid 5% (or vinegar)	Methylene blue, 1% aqueous (parenteral)
Activated charcoal	Nalorphine or levallorphan
Ammonia water, 0.2%	Norepinephrine (Levophed) (parenteral)
Amphetamine SO <sub>4</sub> (parenteral)	Olive oil
Amyl nitrite pearls*	Paraldehyde
Amytal sodium (parenteral)	Phenobarbital sodium (parenteral)
Apomorphine (parenteral)	Phenylephrine (Neo Synephrine) HCl (parenteral)
Atropine SO <sub>4</sub> (parenteral)	Picrotoxin (parenteral)
Caffeine and sodium benzoate (parenteral)	Potassium Cl (tablets and parenteral)
Calcium Cl 5% (or lime water)	" "
Calcium gluconate 10% (parenteral)	" "
Copper SO <sub>4</sub> 0.2%	" "
Dimercaprol (BAL)	" "
Dithionite†	" "
Edathamil calcium disodium (EDTA)	" "
Glycerol monoacetate (Monacetin)‡	" "
Hydrocortisone succinate or phosphate (parenteral)	Sodium thiosulfate, 25% (parenteral)*
Ipecac syrup	Starch
Magnesium hydroxide (milk of magnesia)	Universal antidote
	Vitamin K or K <sub>1</sub> oxide

\*Materials for the antidotal treatment of cyanide poisoning (amyl nitrite, sodium nitrite and sodium thiosulfate) can be obtained ready for use in a kit specifically designed for this purpose from the Eli Lilly Company and includes expert instructions concerning its use.

†Preliminary observations suggest usefulness in severe thallium poisoning. Availability suggested if thallium is a significant local hazard.

‡Experimental evidence of usefulness in fluoracetate poisoning. Availability suggested if fluoracetate is a significant local hazard.

Suggested constituents of such a kit are listed in Table 55. The list does not include intravenous fluids or general supportive drugs which are routinely available in hospitals except for those which are likely to be needed urgently. Additional supplies which should be made readily available include equipment for gastric lavage, oropharyngeal airways, a laryngoscope, intratracheal catheters and apparatus for suctioning and for the administration of oxygen.

pending gastric lavage. Treatment otherwise is symptomatic and expectant, consisting principally of barbiturate sedation and avoidance of sensory stimuli. Muscle relaxants (e.g., mephenesin) are reported to be useful adjuncts.

An organic phosphate insecticide. See Cholinergic compounds.

**Thy.** See Fluoracetate.

(tetraethyl pyrophosphate). An organic phosphate. See Cholinergic compounds.

**Thall.** Potassium chloride and activated charcoal have been shown to increase the excretion of thallium in the urine and feces, respectively. Potassium chloride can be administered in doses of 3 to 5 Gm. per day orally or by vein. The recommended dose of activated charcoal is 0.5 Gm. per kilogram of body weight twice daily for a period of at least 5 days.

**Thio.** Dimercaprol (BAL) and edathamil calcium disodium have not been proved effective. Dithizon (diphenylthiocarbazon) is capable of chelating thallium and early clinical experience has suggested that this compound may be of considerable benefit in the treatment of severe thallotoxicosis. The dose of dithizon is 10 mg. per kilogram of body weight daily by mouth or gastric tube. It is insoluble in water but may be mixed with gum and suspended in water. Further cautious trials of this drug seem warranted. See Amanita toxins.

**Throm.** A Dicumarol-like anticoagulant used both medically and as an insecticide. See Coumatel.

## ARTIFICIAL REMOVAL OF POISON FROM THE BODY

Poisons for which there are no effective antagonists may be absorbed into the body in amounts which, for practical purposes, are invariably lethal even with the best of supportive care. Methods for artificially achieving a reduction in the amount of poison in the body offer some hope for recovery under such circumstances.

These measures may also be of value when elimination of the poison fails to occur, as in renal failure in the case of poisoning with a compound which depends upon urinary excretion for removal from the body.

**Hemodialysis (The "Artificial Kidney").**—The use of hemodialysis in the treatment of renal failure has been mentioned under Oliguria and Anuria on page 786. Completely aside from its use in renal failure per se, hemodialysis has been found with some success as a means for rapidly removing large amounts of dialyzable poisons.

To date, it has been used successfully in the treatment of poisoning with urates, salicylates, bromides, thiocyanate and glutethimide. Hemodialysis cannot be expected to remove large molecule poisons which are not dialyzable, nor poisons which are irreversibly bound to tissues, cells or plasma proteins. This procedure is not without danger and should be performed only by experienced personnel. It should be reserved for highly selected instances of very severe poisoning and should be used in conjunction with careful supportive care.

**Replacement Transfusion.**—Replacement (exchange) transfusion has also been found useful in achieving a marked reduction in circulating concentrations of a number of poisons. This procedure offers certain advantages over hemodialysis: it is familiar to most physicians, does not depend upon diffusibility of the toxin, requires no specialized equipment, and does not require the exceptional experience which is necessary for the safe use of hemodialysis, especially in the young child. It has the obvious limitation that, in other than very small children, it is technically difficult and presents the hazard of transfusion reaction, since it may be necessary to obtain donor blood from several sources.

*Lead*

Chisolm, J., Jr., and Harrison, H. E. The Treatment of Acute Lead Encephalopathy in Children, *Pediatrics* 19 2, 1957

*Methemoglobinemia*

Bodansky, O. Methemoglobinemia and Methemoglobin Producing Compounds, *Pharmacol Rev* 3 144, 1951

*Narcotics*

Eckenhoff, J. E., Filder, J. E., Jr., and King, B. D. N-Allyl Normorphine in the Treatment of Morphine or Demerol Narcosis, *Am J M Sc* 223 191, 1952

*Nicotine*

Oberst, B. B., and McIntyre, R. A. Acute Nicotine Poisoning, *Pediatrics* 11 338, 1953

*Phosphates*

Gosselin, R. E., Tidball, C. S., Megrian, R., Maynard, E. A., Downs, W. L., and Hodge, H. C. Metabolic Acidosis and Hypocalcemia as Toxic Manifestations of Polymeric Phosphates, *J Pharmacol & Exper Therap* 108 117, 1953

*Phosphorus*

Diaz Rivera, R. S., Collazo, P. J., Pons, E. R., and Torregrosa, M. V. Acute Phosphorus Poisoning in Man. A Study of 56 Cases, *Medicine* 29 269, 1950

*Renal Failure*

Bluemle, L. W., Jr., Potter, H. P., and Elkinton, J. R. Changes in Body Composition in Acute Renal Failure, *J Clin Invest* 35 1094, 1956

Kolff, W. J. Acute Renal Failure. Causes and Treatment, *M Clin North America* 39 1, 1955

Swann, R. C., and Merrill, J. P. The Clinical Course of Acute Renal Failure, *Medicine* 32 215, 1953

*Salicylate*

Done, A. K. Salicylate Intoxication, *Clin Med* 3 755, 1956

Singer, R. B. The Acid Base Disturbance in Salicylate Intoxication, *Medicine* 33 1, 1954

Trinder, P. Rapid Determination of Salicylate in Biological Fluids, *Biochem J* 57 301, 1954

Winters, R. W., White, J. P., Hughes, M. C., and Ordway, N. K. Disturbances of Acid Base Equilibrium in Salicylate Intoxication, *Pediatrics* 23 260, 1959

*Thallium*

Chamberlaine, D. H., and W. D. R. T., and Panos, T. C. Thallium

Lund, A. . . . . on and the Toxicity of Thallium

## SELECTED REFERENCES

## General

- Alway R H Acute Poisoning in Childhood in Brennemann's Practice of Pediatrics  
Hagerstown 1957 W F Prior Co Inc vol 1 chap 17
- Buckley E E and Porges N editors Venoms Washington 1956 American Association  
for the Advancement of Science
- Dresbach R H Handbook of Poisons Los Altos 1955 Lange Medical Publications
- Frear D E H Pesticide Handbook (Annual Publication) State College Pa College  
Science Publishers
- McGraw-Hill Inc Technology of Commercial Products  
of Therapeutics ed 2 New  
Products J Pediat 46 171

Wood W H Poisonous Plants J Pediat 50 499 1957

## Individual Poisons and Problems

*Alkali*

- Carver G M Sealy W C Dillon M C Jr Management of Alkali Burns of the  
Esophagus J A M A 160 1447 1956
- Fennerty J J Late Treatment of Caustic Structures of the Esophagus S Clin North  
America 34 353 1954
- Ray E S and Morgan D L Cortisone Therapy of Lye Burns of the Esophagus J Pediat  
49 394 1956

*Babute*

- Nelson E On Treatment of Barbiturate Poisoning A Modified Clinical Aspect Acta med  
scandinav 139 (suppl) 1951

*Choline Compounds*

- Gordon A S and Frye C W Large Doses of Atropine Low Toxicity and Effectiveness  
in Anticholinesterase Intoxication J A M A 159 1181 1955
- Grob D and Harvey A M The Effects and Treatment of Nerve Gas Poisoning Am J  
Med 14 52 1953

*Cyanide*

- Chen K K and Rose C L Nitrite and Thiosulfate in Cyanide Poisoning J A M A  
149 113 1952

*Digitalis*

- Gubner R S and Kallman H Treatment of Digitalis Toxicity by Chelation of Serum  
Calcium Am J M Sc 234 136 195

*Fluoride*

- Peters J H Therapy of Acute Fluoride Poisoning Am J M Sc 216 278 1918

*Fluoroacetate*

- Chenoweth M B Kandel A Johnson L B and Bennett D R Factors Influencing  
Fluoroacetate Poisoning Practical Treatment With Glycerol Monoacetate J  
Pharmacol & Exper Therap 102 31 1951

*Heavy Metals*

- Braun H A Lusky L M and Calvery H O Therapy of Poisoning by Compounds  
of Mercury and Nickel J Pharmacol & Exper  
Conference Use of Calcium Ethylenediaminetetra  
ing A M A Arch Indust Hyg 7 137 1953

*Iron*

- Hoppe J O Macell G M and Tanter M L A Review of the Toxicity of Iron  
Compounds Am J M Sc 230 558 1955

*Lead*

Chisolm, J., Jr., and Harrison, H. E. The Treatment of Acute Lead Encephalopathy in Children, *Pediatrics* 19: 2, 1957

*Methemoglobinemia*

Bodansky, O. Methemoglobinemia and Methemoglobin Producing Compounds, *Pharmacol Rev* 3: 144, 1951

*Narcotics*

Eckenhoff, J. E., Elder, J. E., Jr., and King, B. D. N-Allyl Normorphine in the Treatment of Morphine or Demerol Narcosis, *Am J M Sc* 223: 191, 1952

*Nicotine*

Oberst, B. B., and McIntyre, R. A. Acute Nicotine Poisoning, *Pediatrics* 11: 338, 1953

*Phosphates*

Gosselin, R. E., Tidball, C. S., Megirian, R., Maynard, E. A., Downs, W. L., and Hodge, H. C. Metabolic Acidosis and Hypocalcemia as Toxic Manifestations of Polymeric Phosphates, *J Pharmacol & Exper Therap* 108: 117, 1953

*Phosphorus*

Diaz Rivera, R. S., Collazo, P. J., Pons, E. R., and Torregrosa, M. V. Acute Phosphorus Poisoning in Man: A Study of 56 Cases, *Medicine* 29: 269, 1950

*Renal Failure*

Bluemle, L. W., Jr., Potter, H. P., and Elkinton, J. R. Changes in Body Composition in Acute Renal Failure, *J Clin Invest* 35: 1094, 1956

Kolff, W. J. Acute Renal Failure: Causes and Treatment, *M Clin North America* 39: 1, 1955

Swann, R. C., and Merrill, J. P. The Clinical Course of Acute Renal Failure, *Medicine* 32: 215, 1953

*Salicylate*

Done, A. K. Salicylate Intoxication, *Clin Med* 3: 755, 1956

Singer, R. B. The Acid-Base Disturbance in Salicylate Intoxication, *Medicine* 33: 1, 1954

Trinder, P. Rapid Determination of Salicylate in Biological Fluids, *Biochem J* 57: 301, 1954

Winters, R. W., White, J. P., Hughes, M. C., and Ordway, N. K. Disturbances of Acid-Base Equilibrium in Salicylate Intoxication, *Pediatrics* 23: 260, 1959

*Thallium*

Chamberlain, P. H., Stavimoha, W. B., Davis, H., Antker, W. T., and Panos, T. C. Thallium Poisoning, *Pediatrics* 22: 1170, 1958

Lund, A. The Effect of Various Substances on the Excretion and the Toxicity of Thallium in the Rat, *Acta pharmacol et toxicol* 12: 260, 1956



Alarming syncope and shock have been reported as sequelae. Fatalities have resulted both from immediate reactions of anaphylactic type and from more delayed reactions apparently due to damage of viscera by the injected material. There have been similar experiences with the use of other opaque media in the conduct of angiography of the heart and blood vessels. Even the new and improved agents for visualization of organs and vessels are not without danger.

All of the radioactive substances that serve a purpose in diagnosis are used at present in very small amounts and are not known to exert deleterious effects. There is, however, increasing suspicion that any radiation of the body is potentially harmful. At present, physicians must continue to be anxious lest small amounts of radiation may injure germ plasma, the developing embryo, or increase the susceptibility of offspring to leukemia and other diseases.

These hazards must be considered separately from recognized contraindications to the diagnostic use of drugs in patients with a history of allergy, known idiosyncrasy, impairment of the function of heart, circulation, lungs, liver, or kidney, or chronic debilitating diseases.

Danger from diagnostic procedures arises not only from the use of hazardous individual tests but also from the multiplication of relatively simple measures, each of which has its own element of risk. Enthusiasm for thorough clinical study may lead to the use of 20 or 30 different diagnostic procedures, some of which are repeated on several occasions.

In the practice of modern medicine, discriminating judgment is essential in the selection not only of therapeutic agents but also of diagnostic tests. With the wealth of new drugs iatrogenic disease, always frequent, is becoming in the aggregate one of the commonest clinical conditions. Not a few of the mishaps and accidents that constitute it have their origin in the well intentioned use of diagnostic measures. It behooves all physicians to evaluate thoughtfully the need of every test and to reserve the use of measures involving the introduction of actionable drugs, or possible adverse reactions, for those situations where effective management depends upon them.

[The sections which follow consider the problems of the choice of drugs as diagnostic agents in the several specialties; therefore, only diagnostic tests using drugs are considered. Each section was written by the author of the chapter on the choice of drugs for that specialty.—Ed.]

## DIAGNOSTIC TESTS IN HEART DISEASE

WALTER MODELL, M.D.

precipitation  
coronary

tests. A special problem in cardiac therapy arises when it is important to know how much digitalis a patient has had prior to examination and circumstances surrounding the case make it impossible to determine this with precision or even to make a reasonable guess. Where the exigency of the situation demands a prompt decision, a test which would provide information regarding the state of digitalis

## THE CHOICE OF A DIAGNOSTIC AGENT

---

### INTRODUCTION

DAVID PRESWICK BARR, M D , LL D , SC D

Diagnostic methods formerly simple have become increasingly complex and frequently involve the use of drugs of which some are ostensibly innocuous while others possess pharmacologic potency or undesirable side actions. Modern practice sanctions the use of injections of a variety of organic substances for visualization of the liver, gall bladder, urinary tract, bronchi, lungs, heart, blood vessels and spinal canal. Drugs of variable nature are used in studies of blood flow, blood volume, red blood cell turnover and for diagnosis of diseases such as pernicious anemia, amyloidosis or hemochromatosis. An increasing number of radioactive substances, including iodine<sup>131</sup>, chromium<sup>51</sup> and cobalt<sup>60</sup>, are being introduced as valuable indices of organic function. These examples of drugs used in diagnosis are merely indicative. The list is not inclusive even for present usage and is constantly being extended.

Each test has its own rationale and purpose; each may be occasionally or frequently crucial to mature judgment concerning diagnosis, prognosis, or management, and each must be used courageously as clinical situations demand. It must be remembered, however, that no one of the occasionally indispensable diagnostic tests may be undertaken without risk.

The simplest as well as the most complicated possess inherent dangers. Viral or even bacterial infection may be introduced by a needle. Sudden death from anaphylactic reaction has followed the intravenous administration of such a relatively inert substance as dehydrocholic acid (Decholin) for the estimation of circulation rate. Glucose tolerance tests may be dangerous for patients with Addison's disease because of the severe hypoglycemia that often develops 1 to 4 hours after administration of the sugar. Retrograde cystoscopy with opaque organic iodine compounds may be followed by acute renal shutdown. The introduction of iodized oil for visualization of the bronchi and upper respiratory tract may produce iodism as well as local obstruction in chronic pulmonary disease.

Administration of Diodrast and similar compounds for intravenous urography, although often unaccompanied by serious symptoms, is frequently followed by flushing, nausea, vomiting, urticaria, venospasm, pain in the shoulder or phlebitis.



for blood and to indicate by the electrocardiogram the capacity of the coronary circulation to supply more oxygen via the blood, viz., the several standardized exertion tests and the anoxia test

These leave much to be desired, for, on the one hand, they do not produce positive electrocardiographic changes in all instances of coronary artery disease and on the other hand they have been known to precipitate severe anginal attacks and even prolonged attacks of coronary insufficiency. Pain is a regular complication

The more recently introduced ergonovine stress test is now being used by some. Ergonovine a sympatholytic drug produces no electrocardiographic changes in the normal patient but tends to induce S T segment and T wave changes in patients with coronary artery disease. It is by no means definite that this type of stress test is superior to the others, for it is not established that the correlation between disease and positive reactions is appreciably better, while reactions of severe and even prolonged pain also occur after ergonovine in the patient with coronary artery disease. One is constrained to speculate whether it is conceivable that any test for coronary artery disease which is based on subjecting a presumably defective coronary circulation to an abnormal stress can be free of the danger of precipitating anginal attacks since stimuli not significantly different are the ones which precipitate the attacks in normal circumstances

**Digitalis Tolerance Test**—The limitation and the dangers of the test in which the degree of digitalization is determined by the intravenous administration of acetyl strophanthidin are discussed at some length on page 401. The dangers are so substantial that it is difficult to envision any application at least in its present form as defensible

on the interrelationship between blood calcium and digitalis toxicity recently been reported. Calcium levels in the blood are raised by the administration of calcium salts. Further experience is necessary, but the fact that toxic effects can be counteracted instantly by the use of chelating agents makes this a more promising prospect than the acetyl strophanthidin test (see pages 402 and 413)

### Drug Sensitivity Tests—

**QUINIDINE**—The question of quinidine hypersensitivity recurs every time there is, as there now seems to be, a recrudescence of the use of quinidine. A preliminary test dose of 0.2 Gm has been suggested as a means of avoiding hypersensitivity reactions. While it is conceivable that they may eliminate some serious reactions, such a dose is also large enough to set off full blown reactions in hypersensitive patients. There is no good evidence that such a dose, or even a smaller one has been particularly useful in this regard while there have been disasters in patients who responded negatively to the test dose. It is probable as has been explained in Chapter 24, that many precipitous reactions are the concomitants of the therapeutic effects of the quinidine and not toxic reactions at all

**DIURETICS**—Skin tests for sensitivity to diuretics, more especially the mercurial diuretics are not useful. Most of the bad results from diuretics have been due to excessive diuresis and the electrolyte disturbances consequent to uncontrolled salt loss. Where there is time, explorations of the diuretic effects of small doses are far more likely to lead to optimal dosage than the skin test

zation would be of the utmost use. Reactions due to drug sensitivity occur in heart disease much as they do in the therapy of other systems but may seem far more pressing because of the critical status of some patients and the extremely narrow margin for error in heart disease. Drug sensitivity tests are therefore also of considerable interest in heart disease.

**Angiocardiography**—The best angiocardigrams are obtained when a large dose of a radiopaque iodide is injected rapidly into the vein. It is not surprising therefore that reactions are common. The over all death rate has been reported to be around 0.5 per cent—that is to say, 1 of every 200 patients subjected to this diagnostic procedure may be expected to die. Such an accident rate would be considered prohibitive for therapeutic procedures in many serious diseases; today even appendectomy has a lower mortality rate.

Despite this dismal statistic the risk may be justified. The angiocardigram not only makes the precise diagnosis in some cases but also may provide the surgeon, as in coarctation of the aorta, with important details for the design of the operation. However the angiocardigram is not always so vital and unfortunately sometimes not useful at all. Yet angiocardiology has been applied to cases in which the diagnosis was already established as well as to cases in which it was not conceivable that it could be useful for either surgical or diagnostic purposes. Too often neither the limitations nor the dangers of angiocardiology are appreciated by those who order it for their patients; it is not in the same class with most other roentgenographic procedures.

These considerations become all the more important because of the too often overlooked diagnostic usefulness of cardiac catheterization, often where angiocardiology is of little value and sometimes as an alternate diagnostic measure. It is surprising to many and not sufficiently well known that despite the fact that catheterization is more complicated and indeed seems far more precarious, it is in fact considerably less hazardous than angiocardiology. In a series of 6,000 cases a death rate of 0.1 per cent was reported, less than one fifth the disaster rate of angiocardiology. Thus where either will serve, cardiac catheterization is clearly the procedure of choice over angiocardiology; the latter is indicated where the former cannot help or fails to help and then only when there is a reasonable expectation that angiocardiology will supply vital diagnostic information.

**RADIOPAQUE IODIDES**—Several radiopaque iodides are presently available for angiocardiology: acetrizolate (Urokon), diatrizoate (Hypaque), diatrizoate methylglucamine (Cardiografin), iodomethamate (Neo-Iopax) and iodopyracet (Diodrast). While there is no significant difference in catastrophe rate, there appears to be an appreciable difference in the rate of minor toxic symptoms after these drugs. It is the opinion of some that the desirable highly concentrated solutions of iodine can be injected with fewer reactions in the form of Hypaque than the others and therefore better angiocardigrams can be obtained with Hypaque with a lower incidence of untoward reaction. It is to be repeated however that this difference does not apply to the death rate. Nevertheless diatrizoate (Hypaque) is presently the drug of choice.

**Ergonovine Stress Test**—Tests to determine the adequacy of the coronary circulation usually involve a scheme to increase the demands of the myocardium

Roth and Kvale, in their original description of the test, indicated that this should exceed the rise caused by the cold pressor stimulus. In my experience, any rise in blood pressure of more than 20 mm systolic and 10 mm diastolic above the control reading should be treated as a potential positive reaction. It is noteworthy that this usually occurs within 2 to 3 minutes after the injection.

If there is no transient blood pressure reduction, a second dose should be given to ensure that (1) the histamine actually enters the vein and (2) an adequate hypotensive stimulus to the adrenals is obtained. While it is possible that the stimulus for epinephrine liberation from the adrenal gland is direct and not secondary to an acute fall in blood pressure, this reduction is so common in the average patient as to cast doubt on the validity of the test if it does not occur. If the test is suspected of being falsely positive, it may be repeated at a second sitting, if falsely negative, a double dose may be given to exclude definitely the possibility of pheochromocytoma. In the event other observations have made the diagnosis strongly probable, the preliminary injection of smaller doses of histamine in order to produce presumably lesser rises in blood pressure is a wise move. As little as 0.005 mg of a test dose may produce a marked pressure rise and 0.01 mg may be given subsequently before reaching the full recommended dose. If the test with histamine is repeatedly positive or suggestive, the use of tetraethylammonium (TEA, Etamon) 200 mg intravenously, as described by LaDue, while less reliable, is nevertheless a valuable corroborative test.

**Method of Testing When the Blood Pressure Exceeds 180/110 mm Hg**—It is important to remember that many patients with pheochromocytoma may have sustained hypertension or, at least, may have hypertension at the time of the visit to the physician's office. To avoid the risk of precipitating a severe hypertensive crisis in these circumstances, it is probably wise to use an adrenolytic drug. For this purpose, phentolamine (Regitine), 5 mg intravenously, is preferred. No fixed contraindications to such testing exist although the drug may occasionally produce extreme tachycardia and consequently, may induce paroxysms of angina in patients with this disease. There is also the possibility of inducing arrhythmias, but this outcome has not been reported.

**PROCEDURE**—The patient should be placed in a quiet room and the blood pressure allowed to reach a base line. After the needle has been introduced into the vein and before injection, the blood pressure reading should be repeated to establish that the act of venipuncture has not of itself, artificially elevated the blood pressure. After a reasonably stable base line has been achieved and the patient has been appropriately reassured that no symptom except possibly palpitation will follow the test, phentolamine is given intravenously over a 45 second period. The blood pressure is then recorded at 30 second intervals for approximately 5 minutes. A blood pressure reduction exceeding 25 mm diastolic is considered a positive reaction.

**INTERPRETATION**—It has been my experience that there will be a drop in blood pressure of this magnitude in approximately 10 per cent of hypertensive patients. On subsequent testing these patients prove not to have pheochromocytoma. The test is not diagnostic because phentolamine has a weak vasodilating and ganglionic blocking activity in addition to being an adrenolytic drug. In pa-

**Circulation Time**—A variety of materials have been injected intravenously during the past 30 years to obtain data which, in one way or another, reflect circulation time. Some drugs have been used to indicate the time required to produce a detectable odor in expired air after an intravenous injection, presumed to indicate time through the lesser circulation. Some drugs have been used in much the same way to produce a detectable taste, presumed to indicate complete circulation time. Of a large number only Decholin (sodium dehydrocholate), which produces a bitter taste, continues to be used. Reactions to Decholin are by no means rare, some have been serious and a few fatal. It is my opinion that the data obtained by means of the intravenous injection of Decholin very rarely provide insights into the state of circulatory dynamics useful for diagnosis or therapy, and the use of Decholin is, therefore, rarely defensible.

Sodium succinate has been suggested as a substitute and while it is not yet established that it has any advantage over Decholin in indicating circulation time, it may be that it is superior in that reactions are less common and less severe. More experience is needed.

## THE CHOICE OF DIAGNOSTIC DRUGS FOR THE DISTINCTION BETWEEN PHEOCHROMOCYTOMA AND HYPERTENSION

SIBLEY W. HOOBLER, M.D.

Patients with transient or sustained hypertension are potentially curable if they can be shown to harbor a pheochromocytoma. The following diagnostic procedures will usually be satisfactory for making or ruling out the possibility in suspected cases.

**Patients With Blood Pressures Below 180/110 mm Hg at Time of Testing**—For those who have a history of elevated blood pressure, tachycardia, or other presumptive manifestations of pheochromocytoma, the use of histamine intravenously, as suggested by Roth and Kvale, may be effective. The following precautions should be taken for this test. (1) Patients with angina pectoris or with severe asthma should be tested with great care, if at all. (2) The patient should remain in a quiet room and a basal blood pressure reading should be obtained before introduction of the needle. He should then be cautioned not to talk, should be guarded against emotional disturbance during the procedure, and should be reassured concerning the expected side effects from histamine injection: flushing, headaches, and tachycardia. (3) The needle should be left in the vein for 2 to 3 minutes after the injection, and phentolamine (Regitine), 5 mg, should be available for administration in the event of a positive reaction.

The dose of 0.05 mg of histamine phosphate, usually diluted to 2.5 ml, is injected intravenously in approximately 15 seconds. The blood pressure is determined every 30 seconds for several minutes.

**INTERPRETATION**—The normal response is a brief depression in blood pressure followed by a prompt return to the preinjection levels. In the patient with pheochromocytoma, the same events occur except that, following the blood pressure depression, there is a rebound rise of considerable magnitude above the base line.

## THE CHOICE OF AGENTS FOR GASTROINTESTINAL DIAGNOSIS

THOMAS P. ALMY, M.D., AND HERMAN STEINBERG, M.D.

**Introduction**—In several of the diagnostic procedures used in gastrointestinal disease, the physician must introduce some chemical compound into the body as a stimulus or a test material. Where a choice of these materials is possible, it is important that a maximum of useful information be obtained with a minimum of risk to the patient. In this section, consideration will be given to those commonly used laboratory procedures in which the choice of the diagnostic agent is to some degree in the hands of the individual physician, and in which this choice affects not only the usefulness of the test but also the patient's safety or comfort. For a fuller discussion of the laboratory methods and the interpretation, reference is made to other publications.

**Gastric Analysis**—In only a few clinical situations is it important to know whether the stomach can secrete hydrochloric acid. Its absence is helpful in the diagnosis of pernicious anemia and in some circumstances offers presumptive evidence of gastric cancer, its presence contributes to the diagnosis of peptic ulcer and peptic esophagitis, which conversely can be virtually excluded by the demonstration of true achlorhydria. On the other hand, because the quantitative variation in output of acid by normal stomachs nearly covers the range of volume and of concentration encountered in disease, and because the ranges of secretory capacity of the stomach in various diseases overlap each other considerably, the quantity of acid secreted even in response to a standard stimulus is rarely of any diagnostic importance.

Accordingly, the first and often the only need is to establish the presence or absence of free hydrochloric acid in the stomach. If this is present in fasting (basal) secretion recovered by aspiration through a Levin tube, no stimulus is required. If the basal specimen is anacid, a number of stimuli may be used, which are listed here in the ascending order of potency:

- 1 *Bread and water*—a slice of bread and 200 ml of water, taken by mouth
- 2 *Alcohol*—50 ml ethyl alcohol (7 per cent) by stomach tube
- 3 *Caffeine and Sodium Benzoate*—0.5 Gm orally or subcutaneously
- 4 *Histamines*

**HISTAMINE**—Histamine, 0.3 to 0.5 mg (as base) subcutaneously, the most potent of the available stimuli, usually leads to flushing of the skin, sweating, tachycardia, hypotension, and headache. At the site of injection a burning sensation appears for a few minutes. It is contraindicated in the presence of asthma, angina pectoris, myocardial infarction, and paroxysmal hypertension or other signs of pheochromocytoma.

**BETAZOLE**—Betazole (Histalog) is a synthetic substance closely related to histamine, which is said to be slowly converted to histamine in the tissues and which in doses of 50 mg subcutaneously produces comparable stimulation of the stomach with few of the serious side effects described for histamine.

In those patients whose clinical findings indicate the probability of abundant acid secretion, as with a working diagnosis of duodenal ulcer or marginal ulcer, stimulation with caffeine or alcohol is recommended. Each specimen should be

tients in whom sympathetic vasomotor tone is prominent in maintaining blood pressure, therefore, blood pressure reduction may occur from excessive sensitivity to sympathetic blockade.

The test is useful as a screening maneuver, and, if there is a presumptive positive result, it may be repeated on another occasion or a smaller dose may be tried to attempt to indicate the sensitivity of the patient to the adrenolytic drug. If half the usual dose, given over the 45 second interval, produces a significant blood pressure reduction as defined above, the probability of pheochromocytoma is great.

False-positive responses have been reported in the presence of hypertension and azotemia and after the use of sedatives and antihypertensive agents such as rauwolfia alkaloids. It is, therefore, suggested that all pheochromocytoma testing, particularly with adrenolytic drugs, be performed before therapy is begun. In the case of a positive reaction in a patient already under treatment, the treatment should be discontinued before retesting, for 1 or 2 weeks for rauwolfia and for 1 to 2 days for barbiturates and other drugs.

**CONFIRMATORY TESTS**—Should the phentolamine response be positive, a test of lesser value is performed with one of the benzodioxanes such as piperoxan (Benodaine), as recommended by Aranow and associates. This agent is given by a carefully specified routine over a period of 2 minutes into the vein. In patients with essential hypertension, the blood pressure will rise or will show no change.

In patients with pheochromocytoma a moderate drop in diastolic blood pressure occurs, usually of lesser magnitude than with phentolamine. Should a patient have a positive response the probability of pheochromocytoma is greatly increased. It should be emphasized that the benzodioxane test also is sometimes positive in patients who have azotemia or are under the influence of sedatives.

In certain cases of severe hypertension, piperoxan may induce a rather sharp pressor rise, and its side effects may, in these cases, resemble those of epinephrine: tachycardia, excitation, and a sense of marked anxiety. In order to reduce the frequency of these effects, particularly in patients with systolic blood pressures of 250 or more, it is advisable to give the drug slowly in one arm while recording the blood pressure in the other. To avoid unpleasant side effects, if there is a sharp rise in blood pressure at the end of the first minute of the injection period the remainder of the drug is not administered and the test is recorded as negative.

It should be emphasized that occasionally patients with pheochromocytoma show false negative responses to piperoxan, whereas such a response is very exceptional with phentolamine.

**Urine Catecholamines**—Should the above mentioned tests be suggestive, or some contraindications apply, it is advisable to perform a test for catecholamines in a 24 hour urine sample collected in an acidified specimen bottle. This should be done in all suspect cases before exploratory surgery. The majority of cases of pheochromocytoma show elevated catecholamine excretion in a 24 hour urine sample, particularly when the blood pressure is elevated, but also frequently even when the blood pressure is normal during the urine collection period.

the tips of the tube, placement of one aspirating tip in the stomach and the other in the descending duodenum, continuous aspiration of both lumina, and timed specimens

If these details as well as those of the chemical analytic procedure are meticulously carried out, the procedure can have diagnostic value. This value is limited by the fact that the range of normal pancreatic output is wide and that normal values can be maintained by only a small group of functional acini properly connected with the duct system and the duodenal lumen. Thus, significantly abnormal values can be expected only when a destructive lesion of the pancreas is diffuse (as in pancreatitis), or when a lesion (such as a carcinoma) blocks both of the major ducts or, of course, when the gland has been totally removed. In patients with chemically proved steatorrhea due to pancreatic deficiency, the measured output of pancreatic juice is nearly always very low. Therefore, the finding of a normal output in response to stimulation virtually proves that the steatorrhea is due to an absorptive defect.

The stimuli commonly used include both hormonal and neurochemical agents reflecting the dual mechanism of natural stimulation of the pancreas.

**SECRETIN**—Secretin is prepared in purified form for intravenous use from extracts of intestinal mucosa. The standard dose is 1 unit per kilogram. It is a protein and as different batches vary in purity to some degree, there is a variable incidence of pyrogenic and allergic reactions. The available preparations are essentially free of cholecystokinin. The pancreatic juice obtained in this manner is of large volume, high in bicarbonate, but poor in enzymes.

**METHACHOLINE**—Methacholine (Mechoyl) is closely related chemically to acetylcholine and, on subcutaneous injection in doses of 10 to 15 mg, reproduces nearly all the effects of strong cholinergic (parasympathetic) stimulation throughout the body. The pancreatic juice thus produced is of low volume, poor in bicarbonate but rich in enzymes. As cholinergic effects on the heart and bronchi may be dangerous, it should never be given to patients with advanced heart disease, coronary artery disease, or asthma. As it stimulates the glands of the stomach and intestine as well as the pancreas, the resulting duodenal juice is not as good a reflection of pancreatic secretion as if secretin were used instead.

**BETHANECHOL**—Bethanechol (Urecholine), 10 mg subcutaneously, may be substituted for methacholine and has somewhat more prolonged effects, making the timing of the collection of specimens less critical. The contraindications to methacholine apply equally here.

Because of greater specificity for the pancreas and better defined standards for the normal response, secretin is the preferred stimulant. When it is not available, either of the cholinergic agents may be substituted if the contraindications are observed.

**Excretory Function of the Liver**—The presence of jaundice clearly indicates either an absolute or a relative insufficiency of hepatic excretory capacity. In milder dysfunction of the liver, significant impairment of excretion may be detected by "loading" tests and such a test may be the most sensitive and reliable indication of liver injury.

tested with indicator as it is withdrawn, and the procedure terminated when acid is obtained. In the small number who fail to show acid after this stimulus, Histalog or histamine may be given without interrupting the procedure. These latter agents should be used at once in those patients in whom the expected result is an achlorhydria (e.g., in pernicious anemia) because the absence of acid after other stimuli is not of certain diagnostic value. In some elderly patients with vascular disease in whom the diagnosis of pernicious anemia or gastric cancer is suggested by other findings, one is obliged in the interests of their safety to use the milder stimuli first. As achlorhydria in pernicious anemia is associated with a deficiency of intrinsic factor measurable by the uptake of  $\text{Co}^{60}$ -labeled vitamin  $\text{B}_{12}$  from the intestine (Schilling test), the latter procedure may be substituted. As the deficiencies of acid and of intrinsic factor both are permanent and unaffected by therapy, either procedure may be deferred until the patient's condition is improved by specific treatment.

While this conservatism in the use of histamine may seem excessive, the occurrence of cardiac and cerebral vascular accidents in elderly individuals and of gastrointestinal hemorrhage in persons with ulcer is frequent enough to make it seem wise.

**'TUBELESS GASTRIC ANALYSIS**—"Tubeless" gastric analysis is the name applied to recently developed techniques for the detection of gastric anacidity by analysis of the urine following the ingestion of ion exchange resins. In this procedure azuresin (Diagnex), a carbaerylic resin chemically joined to an azure A radical, is given orally. In the presence of gastric hydrochloric acid the azure A is exchanged for hydrogen ion, absorbed from the upper intestine, and promptly excreted in the urine, where its concentration is proportional to the depth of blue or green color. In the usual procedure, urine is collected both in the basal state and after gastric stimulation by caffeine and sodium benzoate given orally.

There seems no reason to doubt that in the vast majority of instances these "tubeless" methods provide reliable information as to the presence or absence of acid. They are thus preferable to intubation procedures on the basis of acceptance by the patient and saving of the time of technicians and nurses when surveys of the population for achlorhydria are undertaken. However, in the clinical situations defined above in which the presence or absence of gastric hydrochloric acid enters importantly into the diagnosis, it is better to intubate the patient and detect free acid directly in the gastric juice. If none is detected by this procedure, it may be due to improper placement of the tube tip, to admixture with bile or other alkaline juices, to variations in gastric responsiveness, or other factors. In such a situation the use of a "tubeless" method provides a valuable check on the validity of the earlier findings.

**Pancreatic Secretion**—While the presence of complete pancreatic achylia can sometimes be established by quantitative tests for trypsin in fasting duodenal juice, the more subtle grades of deficiency of external secretion of the pancreas require quantitative measurement of the output of pancreatic juice in response to a potent stimulus. There is no point in doing this *unless care is taken* to ensure quantitative collection of duodenal contents in the manner outlined by Lagerloef, Dreiling, Twiss, and others. This involves a double-lumen tube, fluoroscopic visualization of



*Iopanoic Acid (Telepaque)* The usual dose is 3 to 6 Gm the night before the examination. Telepaque gives a very dense shadow in the well functioning gall bladder. It may have the disadvantage of occasionally obscuring calculi by virtue of the dense shadow it imparts; this deficiency, however, is more than compensated for by the very excellent outline of the gall bladder dye provides.

*Iodoalphonic Acid (Priodax)* The dosage is the same as for Telepaque. It should be given the afternoon prior to the morning of the examination. The shadow produced by this organic iodide is adequate, but not quite as dense as with Telepaque (iopanoic acid).

**INTRAVENOUS CHOLANGIOGRAPHY**—When some organic iodides are introduced intravenously, the extrahepatic biliary tree may be visualized radiographically within a matter of minutes, thus providing a rapid method of revealing gross pathologic changes in the common bile duct. The caution to observe prior to the administration of an intravenous organic iodide is to test the patient and inquire carefully into the possibility of an allergic history. Side effects such as nausea and hypertension are relatively frequent.

Intravenous cholangiography is indicated under the following sets of circumstances: (1) in patients who continue to have symptoms referable to the biliary tract after cholecystectomy, (2) prior to cholecystectomy for calculous disease, to determine whether or not there has been satisfactory visualization of the gall bladder by cholecystography, and (3) if the patient vomits following the ingestion of the material.

*Iodipamide (Cholografin)* For visualization of the extrahepatic biliary ducts, excluding the gall bladder, the method of choice is the intravenous injection of iodipamide sodium (Cholografin Sodium) or iodipamide methylglucamine (Cholografin Methylglucamine). (The latter may be preferable because only half as much is injected; the doses are the same, however, since the methylglucamine solution is twice as concentrated as the other.) These materials of high iodine content permit visualization of the ducts 15 to 20 minutes after intravenous injection of 15 ml of the Cholografin Sodium and 20 ml of the Cholografin Methylglucamine. The duct demonstration is far more satisfactory than after the ingestion of 1 to 2 doses of iopanoic acid (Telepaque) and is not inferior to combined oral intravenous cholangiography.

Inasmuch as the extrahepatic ducts can be visualized only if the radiopaque material is excreted by the liver, severe liver dysfunction, as reflected by serum bilirubin levels above 5 or 6 mg per 100 ml or by Bromsulphalein retention of more than 25 or 30 per cent, usually prevents adequate visualization of the ducts.

Both preparations have given rise to transient side effects such as nausea, vomiting, and restlessness when injected in less than 10 minutes. Sensitivity reactions must be guarded against by careful questioning for a history of allergic manifestations, such as asthma, urticaria, hay fever, and iodine sensitivity. The first three are relative contraindications, the last absolute. It is recommended that an antihistaminic be routinely administered parenterally either immediately before or with the Cholografin.

These tests involve the intravenous injection of a standardized amount of bilirubin or some other substance which depends almost wholly on the liver for excretion. The rate of clearance from the plasma becomes a measure of the excretory capacity of the liver if the rate of hepatic blood flow is within normal limits. Thus the disappearance of these substances from the plasma will be delayed not only in liver disease but in cardiac failure and shock due to hemorrhage, trauma, myocardial infarction, or the postoperative state. False positive results are also obtained in some febrile illnesses and during other pyrogenic reactions. The test substances are the following:

**BILIRUBIN**—Bilirubin itself, given intravenously in alkaline solution in doses of 1 mg per kilogram, although in theory the ideal material, in its purified form is expensive and not readily available. The variation in normal values obtained is wide. Hence it is rarely used in clinical practice.

**SULFOBROMOPHTHALEIN**—Sulfobromophthalein (Bromsulphalein) is a dye which can be readily measured colorimetrically in the plasma. It is marketed in standard ampules containing 50 mg per milliliter and is injected intravenously in dosage of 5 mg per kilogram. As it is highly irritating to the tissues, it must be given fairly slowly (in approximately 1 minute) and extravasation must be avoided. Its purple color is brought out in alkaline medium and hence urine and stools or the returns from a soapsuds enema may turn purple. The skin when washed with alkaline soap may take on a reddish purple hue. The only significant systemic effect is fever which occurs rarely. It can be used in patients with jaundice and may be cleared normally if the jaundice is due to hemolysis or to defective formation of bilirubin glucuronide (constitutional hepatic dysfunction). Otherwise, its use is properly limited to patients with amictic liver disease or with gastrointestinal hemorrhage.

**ROSE BENZAL**—Rose bengal is so rapidly excreted by the liver that its level in the blood must be measured within a few minutes after injection. Unless these specimens can be timed with extreme accuracy serious errors of interpretation may result. The photosensitivity of this compound is dangerous. For these reasons it is rarely used in clinical practice.

### The Concentrating Power of the Gall Bladder Oral Cholecystography and Intravenous Cholangiography—

**ORAL CHOLECYSTOGRAPHY**—Inflammatory and calculous disease of the gall bladder impair the ability of the gall bladder mucosa to absorb and thus to concentrate substances excreted by the liver. We take advantage of this deficiency on the part of the diseased gall bladder as a diagnostic test. In the presence of adequate liver function, the normally functioning gall bladder will be well outlined by the radiopaque dye on the radiograph. The dyes presently in use for cholecystography are administered orally. The patient should be asked about iodine sensitivity. Mild diarrhea is often encountered and this may be prevented by the oral administration of paregoric with the dye. Inasmuch as a greater or lesser (depending upon the substance used) proportion of the dye is excreted by the kidney cholecystography is contraindicated in the patient with acute nephritis or uremia.

100 000 examinations. The contraindications to intravenous urography may be listed: (1) history of allergy or previous serious reaction to radiopaque iodides; (2) blood dyscrasias (particularly hemolytic types); (3) severe electrolyte disturbances (particularly acid base imbalance); (4) cardiac disease; and (5) hyperpyrexia.

**TECHNIQUE**—It is important to obtain the greatest possible density of the radiopaque material in the collecting system and to dispel adjacent abdominal shadows. The patient should not be permitted to take fluids or food for at least 12 hours before the examination. To reduce confusing bowel shadows, the patient should have a laxative not more than 14 hours prior to examination.

If this method of preparation is not possible or is inadvisable, the patient can be prepared by the administration of 1 ml of Pitressin subcutaneously followed by the intravenous injection of the contrast medium within 30 minutes. Pitressin possesses a twofold action: on the bowel to expel gas, and on water reabsorption in the renal tubule to concentrate the excreted organic iodide.

The patient should be tested for sensitivity by the intravenous injection of a small amount of the dye or by the placing of a drop in the conjunctiva, followed by a wait of 20 minutes for reaction. There is some question whether either method of testing sensitivity is entirely dependable, but it is probable that each possesses some merit. The specific method of determining sensitivity for the particular product is outlined by the manufacturer in the literature supplied with each ampule.

**EMERGENCY TREATMENT OF PATIENT REACTIONS**—Epinephrine should never be used since it may induce ventricular fibrillation. Respiratory stimulants should never be used because they may cause convulsions. If cardiac arrest occurs and chest pounding does not re-establish cardiac function, the chest should be opened within 3 minutes and cardiac massage instituted.

Oxygen (100 per cent) should be administered nasally immediately and an intravenous infusion started. Depending upon the symptoms, the following drugs should be given intravenously: (1) Seconal, 1 g; (2) Benadryl, 20 mg for allergic symptoms; (3) for shock or air hunger, if not followed by in 1 minute 4 mg of norepinephrine in 500 ml fluid should be given as an intravenous drip.

**CONTRAST MEDIA FOR EXCRETORY PYELOGRAPHY**—The following are some of the more popular contrast media used in excretory pyelography: (1) Diodrast, (2) Miokon, (3) Hypaque, (4) Renografin, and (5) Urokon.

In my opinion, Renografin produces excellent urinary tract shadow. In addition, it is followed by a minimal number of side reactions, making it particularly useful in routine excretory urography.

**Nephrography**—Nephrography, the radiologic demonstration of the renal parenchyma, is particularly satisfactory as an excellent means of determining the precise surgical procedure indicated. When pyelograms are also desired, the subsequent films are exposed at the usual intervals for such a study.

## THE CHOICE OF DIAGNOSTIC DRUGS IN GYNECOLOGY

M. EDWARD DAVIS, M.D., AND NICHOLAS W. FUGO, PH.D., M.D.

One of the most important procedures in any sterility study is hysterosalpingography. This diagnostic approach will not only determine patency of the fallopian tubes but also visualize the uterine cavity and internal cervical os. It will diagnose intrauterine tumors and abnormalities of the tubes such as salpingitis or hydrosalpinx. In addition to its value as a diagnostic procedure, hysterosalpingography has a definite therapeutic use. Not infrequently patients with long histories of infertility will conceive within 3 months after a hysterosalpingogram. The explanation for this observation is not definitely known, but it is logical to assume that some temporary obstructions are alleviated by this diagnostic aid.

Hysterosalpingography when done as part of a sterility workup should be performed during the proliferative stage of the cycle and after all evidence of vaginal bleeding has ceased. This timing is to avoid hysterosalpingography when early pregnancy exists.

Several agents are available for this purpose. Ideally this diagnostic agent has a low viscosity, is markedly radiopaque, is not irritating to tissues, and is absorbed by the peritoneum slowly, over a period of 6 to 7 days. There is no substance which fulfills all of these requirements.

One of the most satisfactory of the agents available is purified iodized ethyl ester of poppy seed oil stabilized with 1 per cent poppy seed oil. This substance has a high order of radiopacity and has low viscosity as well. It is absorbed slowly from the peritoneum; if it is confined in a hydrosalpinx, it may remain there almost indefinitely.

Another preparation which has had increasing use is a mixture of polyvinyl pyrrolidone and sodium acetate. This substance is absorbed rapidly from the fallopian tubes and the peritoneum, occasionally interfering with a positive demonstration of tubal patency. Since its rapid disappearance decreases the likelihood of irritation to tissues, hysterosalpingography can be repeated if necessary.

## THE CHOICE OF DIAGNOSTIC DRUGS FOR UROLOGIC DISORDERS

ROBERT LICH, JR., M.D., M.S. (PATH.)

**Introduction.**—Urography is the x-ray visualization of the various drainage and reservoir portions of the urinary tract. The kidneys and ureters may be visualized by either excretory or retrograde urograms. The bladder is demonstrated by cystography and the urethra by urethrography. The renal parenchyma is outlined by nephrography and the renal vascular pattern by arteriography.

The radiopaque materials used to visualize each of the sections of the urinary tract must produce shadows of adequate density and must have little toxicity as well. Nevertheless, each involves a risk and to minimize the risk, attention must be paid to every detail of procedure. The several methods of visualizing the urinary tract by roentgenography will be discussed separately.

**Excretory or Intravenous Urography.**—As benign as this procedure may seem, it must be appreciated that one fatal reaction occurs in approximately every

**TECHNIQUE**—The patient is placed in the recumbent position and the contrast medium is injected into the urethral meatus. In the male, the penis is stretched to dispel any folds which might afford a confusing urethrogram. A film is exposed during the injection of the last 5 ml. of the medium.

**CONTRAST MEDIUM**—Thixokon, a sterile thickened aqueous solution of thixovon, permits films of excellent contrast.

#### Renal Function Tests—

**PHENOLSULFONPHTHALEIN (PSP) TEST**—In the average well hydrated patient, the phenolsulfonphthalein is given intravenously. This uncomplicated test is beyond question a most valuable clinical renal function test and has the attributes of simplicity and safety. False PSP values are commonly obtained in the presence of residual bladder urine, subcutaneous or intramuscular injection of contrast medium, dehydration, or circulatory inadequacy.

**PITRESSIN URINE CONCENTRATION TEST**—This test is more rapid, but less accurate, than the Mosenthal concentration test. It is based upon the effect of pituitrin on the tubule cells of the kidney, causing a marked increase in the absorption of water, followed by a secondary diuresis. Epilepsy, angina pectoris, coronary thrombosis, severe renal failure, toxemia of pregnancy, arteriosclerosis and hypertension are contraindications.

**Rational Basis for New Diagnostic Drugs for Urology**—The primary consideration for any new diagnostic drug in urology is the absence of toxic and allergic reactions. In recent years the difficulty of obtaining adequate concentrations has been overcome. The ultimate goal is to provide a drug that can be administered orally so that the parenteral route may be avoided and thus materially simplify the radiographic delineation of the urinary tract.

The methods of determining renal function possess an important deficiency in their inability to demonstrate potential renal function. Our presently available renal function tests provide information only on function at the time of the test. It is true that renal angiography gives some information regarding renal circulation and thus indirectly, potential renal function may be suggested, but this lacks accuracy. Furthermore in order to understand the various clinical manifestations of renal pathology more clearly a simple test which would distinguish the function of the primary units of the kidney is sorely needed.

It is obvious from the foregoing that this area of urology is still in its infancy and much is to be accomplished in the future.

## THE CHOICE OF DIAGNOSTIC AGENTS IN OPHTHALMOLOGY

IRVING H. LEOPOLD, M.D.

Various drugs are used as diagnostic aids in ophthalmology. Corneal ulceration may be determined by simply looking at the eye with the proper type of light and noting an irregular reflex on the surface. This however can be aided by the instillation of a drop of sodium fluorescein. Mercurochrome or rose bengal.

Mydriatics have been used as a provocative test in angle closure glaucoma.

CONTRAINDICATIONS —The contraindications are identical with those of excretory urography. Nephrography should never be repeated within 24 hours. Inadequate veins, in which a 14 gauge needle cannot be used for injection, may prevent its use.

TECHNIQUE —The precise details are outlined by Wall and Rose.

CONTRAST MEDIA —Diodrast Concentrated Solution, Renografin, and Urokon are all used for nephrography, but I think the best results are obtained with 50 ml of 75 per cent Urokon.

Renal Arteriography or Aortography —This procedure is hazardous and should be undertaken only by the experienced operator. The contrast medium is introduced rapidly into the abdominal aorta through a needle inserted through the back of an anesthetized patient. An immediate postinjection film of the kidneys demonstrates the arterial pattern within the renal substance as well as the contour and caliber of the renal artery. This radiographic procedure reveals renal neoplasms, renal cysts, unilateral renal aplasia, renal artery aneurysm, congenital and acquired abnormalities of renal position, and renal vascular inadequacies.

CONTRAST MEDIA —Urokon and Renografin are commonly used, but I prefer Neo-Iopax (75 per cent).

Retrograde Urography —This is a means of outlining the collecting system of the kidneys and ureters by injecting the contrast medium into the kidneys through ureteral catheters introduced into the renal pelvis at the time of cystoscopy. It is important to inject sufficient dye to fill the renal pelvis and calyces adequately but, at the same time, not to overfill and produce lymphatic or vascular reflux. The ureters should be completely outlined by injecting as the ureteral catheters are withdrawn. Furthermore, in the presence of normal ureteral patency and peristalsis, the kidney and ureter should be free of the contrast medium within 10 minutes of injection.

CONTRAST MEDIA —Skiodan and Urokon are commonly used, although any of the intravenous contrast media may be used for retrograde urography, provided the concentration is not greater than 30 per cent. I prefer Skiodan (20 per cent).

Cystography —Cystography is useful for outlining the bladder and will reveal the following: (1) bladder size, (2) bladder contour, (a) displacement due to extravescical disease or tumor, (b) bladder elevation or "tear drop" deformity due to perivesical hemorrhage commonly associated with fractures of the pelvis, (3) bladder wall irregularities such as rupture of bladder, diverticula, cellulitis of the bladder, tumors of the bladder, (4) nonopaque stones of the bladder, (5) intravesical projection of the prostate, (6) ureteral reflux.

TECHNIQUE —The contrast medium is introduced, by catheter, into the bladder until the patient complains of vesical distention or until the operator is of the opinion that the amount is adequate.

CONTRAST MEDIUM —Sodium iodide (5 per cent) is the most satisfactory, but any organic iodide used in retrograde or excretory urography may be used.

Urethrography —This is a study of urethral contour and is useful to reveal the following: (1) urethral tumor, (2) stricture, (3) perforation (traumatic, inflammatory), (4) diverticula, (5) fistula, and (6) bladder neck pathology (contracture, prostatic hyperplasia).

- eenfield, Irving Sodium Succinate as a Test of Circulatory Efficiency, *Ann Int Med* 44 524, 1950
- own, B., and Crocker, A. T., and Levine, S. A Digitalis Tolerance Test, *Proc New Eng* ...
- ... A New Quantitative Digitalis ... and Digitalis, *Am J M Sc*

## Pheochromocytoma and Hypertension

- Hord, R. W., Roth, G. H., and Kvale, W. I. Evaluation of a New Adrenolytic Drug (Regitine) as a Test for Pheochromocytoma, *J A M A* 149 1628, 1952
- Kvale, W. F., Roth, G. M., Manger, W. M., and Priestley, J. T. Pheochromocytoma, *Circulation* 14 622, 1956
- Due, J. S., Murison, P. J., and Pock, G. T. The Use of Tetraethylammonium Bromide as a Diagnostic Test for Pheochromocytoma, *Ann Int Med* 29 914, 1948
- Roth, G. M., and Kvale, W. F. A Tentative Test for Pheochromocytoma, *Am J M Sc* 210 653, 1945

## Gastrointestinal Disease

- am, T. H., editor A Syllabus of Laboratory Examinations in Clinical Diagnosis, Cambridge, 1953, The Harvard University Press, pp 310-317 (gastric analysis), pp 333-335 (Bromsulphalein test)
- rsner, J. B., Levin, Erwin, Palmer, Walter L., and Ford, Harold Gastric Secretory Response to 3 Beta Aminoethyl Pyrazole in Man, *Gastroenterology* 20 138, 1952 (On Betazole)
- ttman, A., Fox, B. W., Hammerling, Erwin M., and Fox, N. I. A Single Aspiration Caffeine Gastric Analysis in Duodenal Ulcer and Control Patients, *Gastroenterology* 28 953, 1955
- eGlenahan, J. L., Evans, J. A., and Braunstein, P. W. Intravenous Cholangiography in ...
- gal, H. ... hydra by Tubeless
- gal, H. ... With an Azure A
- wiss, J. ... Philadelphia, 1955,
- Lea & Febiger, pp 430-441

## Urologic Disorders

- ntino, W., Zeitel, B. E., Jacobson, H. G., and Poppel, M. H. Intravenously Given Urographic Mediums, *J A M A* 161 606, 1956
- ch, R., Jr. A Compendium of Urology, St Louis, 1954, John S. Swift Co., Inc
- ch, R., Jr., and Lewis, P. J. The Use of the Antidiuretic Property of Pitressin in Ex ...
- ndergr ... C., and Burdick, E. D. Further ... Following Administration of ... states, *Acta radiol (Supp)* 116
- 84, 1954
- all, B., and Rose, D. K. The Clinical Intravenous Nephrogram, *J Urol* 66 305, 1951

## Ophthalmology

- aphy, E. B., Dowling, J. L., and Scott, A. Experiences With Radioactive Phosphorus in Tumor Detection, *A M A Arch Ophth* 57 485, 1957
- edore, F. H., and Feinstein, R. R. Practical Suggestions for Preparation and Maintenance of Ste ...
- omas, C. I., Krohn ...
- Localization ...
- ughn, D. A., Jr.

tency of the nasolacrimal apparatus can be determined by instillation of a drop containing saccharine or fluorescein

Uveitis that responds to the use of Daraprim rapidly and in a shorter period of time than one would anticipate for a nonspecific response might be indicative of a toxoplasmic etiology. A rapid response to tuberculostatic drugs might indicate tuberculous etiology. Keratoconjunctivitis sicca may show much staining of the conjunctiva as well as the cornea following the instillation of rose bengal or fluorescein

Sodium fluorescein is usually employed as a 2 per cent solution in distilled water. It will reveal any break in the epithelial surface of the cornea or the conjunctiva. This solution can become contaminated easily and has been the source of infections of the cornea with *Bacillus pyocyaneus* and other organisms. It has been recommended that filter paper be impregnated with fluorescein with a 2 per cent solution and autoclaved. Bits of the filter paper are then placed by sterile forceps into the cul de sac and flushed out with normal saline.

**Provocative Tests for Glaucoma**—The intraocular pressure is measured and a drop of 1 per cent Paredrine or 10 per cent Neo-Synephrine is instilled into the cul de sac. This may be repeated if wide dilatation is not obtained within 15 or 20 minutes. If there has been a rise of 8 mm Hg or more of intraocular pressure following instillation one may consider this a positive provocative test for angle closure glaucoma. After completion of the test the pupils should be constricted with 2 per cent pilocarpine nitrate or stronger miotics. The provocative dilatation test should be done only after a dark room dilatation test has failed. A negative provocative test does not insure that the patient is free of the possibility of angle closure glaucoma.

Tolazoline (Priscoline) and vasculat cause a slight rise in intraocular pressure when injected subconjunctivally. Since the rise is greater in glaucomatous than in normal eyes it provides a provocative test for early glaucoma. Other agents that may be used for provocative tests include 2 per cent cocaine and 2 per cent eucatropine.

**Radioactive Isotopes**—Radioactive  $P^{32}$  has been used as an aid in the differential diagnosis of intraocular malignancy. Five hundred microcuries of  $P^{32}$  are injected intravenously and readings are taken at 1, 24 and 48 hours later. A positive reading is one which produces a level of at least 30 per cent higher reading over the involved site as compared to a similar area in the opposite eye or an average reading of 30 per cent higher in the involved area as compared to the average of the four quadrants of the opposite eye. This test is a diagnostic aid of considerable accuracy. The results are to be evaluated along with clinical evidence, however, and judgment as to the handling of the patient should not be based solely on its results.

## SELECTED REFERENCES

### Heart Disease

- Dotter, C. T. and Steenberg, I. Angiocardiography. Baltimore, 1952. Williams & Wilkins Co.  
Gilbert, Robert and Lyons, Richard H. Clinical Evaluation of a Digitalis Tolerance Test. *Am. J. Med. Sc.* 232: 144, 1956.



**ACETYLPHENYLHYDRAZINE***Administration* Oral*Dosage form* Capsule, 100 mg**ACETYLPROMAZINE**

Not available on the commercial drug market

**ACETYSALICYLIC ACID***Synonyms* Acetulum, Acetophen, Acetylsal, Aspirin, Aspro, Salacatin, and many others  
*Trade names* Asteric (Brewer), Ecotrin (Smith, Kline & French)*Administration* Oral*Dosage form* Tablets, 0.1 and 0.3 Gm**ACETYL STROPHANTHIDIN**

Not available on the commercial drug market

**- ACETYL SULFISOXAZOLE***Trade names* Gantrisin Acetyl (Roche), Lipogantisin (Roche)*Administration* Oral*Dosage form* Solution, 100 mg per kg**ACHROMYCIN (Lederle)**

Trade name for Tetracycline

**ACHROMYCIN HCl (Lederle)**

Trade name for Tetracycline HCl

**ACHROMYCIN V (Lederle)**

Trade name for Tetracycline PO, Buffered

**ACHROSTATIN V (Lederle)**

Trade name for mixture of Tetracycline PO, Buffered and Nystatin

**ACID MANTLE CREME (Dome)**

Protective cream

**ACID MANTLE LOTION (Dome)**

Protective lotion

**ACIDOLATE (White)**

Detergent cleanser

**ACIDORIDE (Abbott)**

Trade name for Glutamic Acid HCl

**ACIDOTHYN (Flint, Eaton)**

Trade name for Glutamic Acid HCl

**ACIDULIN (Lilly)**

Trade name for Glutamic Acid HCl

**ACIJEL (Ortho)**

Trade name for Ricinoleic Acid

**ACLOR (Cole)**

Trade name for Glutamic Acid HCl

**ACON (Endo)**

Trade name for Vitamin A, Water Miscible

**ACORTO (Breon)**

Trade name for Corticotropin

**ACRIFLAVINE BASE***Administration* Topical*Dosage forms* Tablets, 32 mg, powder**ACRIFLAVINE HCl***Administration* Topical*Dosage forms* As such, tablets 30, 100 mg  
troche, 6 mg, ointment 1%**ACTAMER (Monsanto)**

Trade name for Bithionol

**ACTASE (Ortho)**

Trade name for Fibrinolysin, Human

**ACTH**

Synonym for Corticotropin

**ACTHAR (Armour)**

Trade name for Corticotropin

**ACTHAR GEL (Armour)**

Trade name for Corticotropin Gel

**ACTIDIL (Burroughs Wellcome)**

Trade name for Triprolidine HCl

**ACTROPE (United)**

Trade name for Corticotropin

**ACYLANID (Sandoz)**

Trade name for Acetyldigoxin

**ADALIN (Winthrop)**

Trade name for Carbromal

**ADANON HCl (Winthrop)**

Trade name for Methadone HCl

**ADEMOL (Squibb)**

Trade name for Flumethiazide

**ADENOSINE MONOPHOSPHATE***Trade name* My B Den (Bischoff)*Administration* Oral, intramuscular*Dosage forms* Tablet, 20 mg, ampule, 100 mg per ml**ADIPHENINE HCl***Trade name* Trasentine (Ciba)*Administration* Oral intramuscular*Dosage forms* Tablet, 75 mg, ampule, 33 mg per ml

## DRUG INDEX

---

### ABASIN (Winthrop)

Trade name for Acetylcarbromal

### ABBOCILLIN (Abbott)

Trade name for Procaine Penicillin

### ABMINTHIC (Pfizer)

Trade name for Dithiazanine I

### ACACIA

Administration Oral

Dosage forms As such mucilage, syrup

### ACENOCOUMAROL

Trade name Sintrom (Geigy)

Administration Oral

Dosage form Tablet, 4 mg

### ACETAMINOPHEN

mg per ml

### ACETANILID

Administration Oral

Dosage form Tablet, 0.2 Gm

### ACETAZOLAMIDE

Trade name Diamox (Lederle)

Administration Oral, Intravenous

Dosage forms Tablet, 0.25 Gm scored, vial, 0.5 Gm

### ACET DIA MER-SULFONAMIDES

Synonyms Sulfacetamide Sulfadiazine Sulfametazine Mixture

Trade names Cetazine (Bowman), Dorasulfas (Smith Dorsey), Terrasul (Rorer), Tri-combusul (Scherong), Trizil (Central)

Administration Oral

Dosage forms Tablets, 0.25 and 0.5 Gm, solutions of various strengths

### ACETIC ACID

Administration External and by lavage

Dosage form 36% and diluted (6%)

### ACETOMEROCTOL

Trade name Merbak (Schieffelin)

Administration Topical

Dosage form Tincture, 0.1%

### ACETOPHENETIDIN

Synonym Phenacetin

Administration Oral

Dosage form Tablets, 0.2 and 0.3 Gm

### ACETOSULFONE

Trade name Promacetin (Parke, Davis)

Administration Oral

Dosage form Tablet, 0.5 Gm

### ACETPYROGALL

Synonym Triacetyl Pyrogallol

Trade name Lenigallol (Bilhuber Knoll)

Administration Topical

Dosage form Ointment 6%

### n ACETYL-p-AMINOPHENOL

Synonym for Acetaminophen

### ACETYLBROMDIETHYLACETYL-CARBAMID

Trade name Sedamyl (Schenley)

Administration Oral

Dosage form Tablet, 0.25 Gm

### ACETYLCARBROMAL

Trade names Abasin (Winthrop), Carbased (Mallard)

Administration Oral

Dosage form Tablet, 0.3 Gm

### ACETYLDIGITOXIN

Trade name Acylamid (Sandoz)

Administration Oral

Dosage form Tablets, 0.1 and 0.2 mg

**ALMINATE (Bristol)**

Trade name for Dihydroxy Aluminum Amino acetate

**ALMORA (Durst)**

Trade name for Magnesium Gluconate

**ALOE**

Administration Oral

Dosage form Pill 0.25 Gm

**ALOIN**

Administration Oral

Dosage form Pill 15 mg

..

Trade name Caytine (Lakeside)

Administration Oral, inhalation, parenteral

Dosage forms Tablet, 2 mg solution 1%, vial 0.5 mg per ml

**ALPHAESTRADIOL TRIACETATE**

Trade name Estrate (Lakeside)

Administration Intramuscular

Dosage form Ampule 1 mg per ml

**ALPHA LACTOSE**

Administration Intravaginal

Dosage forms Powder, tablet and capsule, usually made up on prescription

**ALPHA LOBELINE HCl**

Trade names Lobelin (Buschoff), Lobeline (Sandoz)

Administration Intravenous, intramuscular

Dosage form Ampules 3 and 10 mg

**ALPHAPRODINF HCl**

Trade name Nisentil HCl (Roche)

Administration Subcutaneous, intravenous

Dosage form Ampules 40 and 60 mg per ml

**ALPHA TOCOPHEROL ACETATE**

Administration Oral, intramuscular

Dosage forms Capsules, 50 and 100 I U ampule 1 Gm bottle 5 Gm, vial, 200 mg per ml

**ALSEROXYLON**

Trade names Koglucoid (Panray), Rau Tab (National), Rautensin (Smith Dorsey), Rauwiloid (Riker)

Administration Oral

Dosage form Tablet, 2 mg

**ALTAFUR (Eaton)**

Trade name for Furaltidone

**ALTHOSE (Wyeth)**

Trade name for Methadone HCl

**AL-U CREME (Macallister)**

Trade name for Aluminum Hydroxide Gel

**ALUDRINE HCl (Lilly)**

Trade name for Isoproterenol HCl

**ALUDROX (Wyeth)**

Trade name for Magnesium and Aluminum Hydroxide Mixture

**ALUM**

Administration Topical

Dosage form Solution, 1 to 5%

**ALUMINUM ACETATE SOLUTION**

Synonym Burow's Solution

Trade name Buro-Sol (Doak), Domeboro (Dome)

Administration Topical

Dosage form Solution, 5%

**ALUMINUM CARBONATE GEL, BASIC**

Trade name Basaljel (Wyeth)

Administration Oral

Dosage form Suspension 50 mg per ml

**ALUMINUM Cl**

Administration Topical

Dosage form Solution, 25%

**ALUMINUM HYDROXIDE GEL**

Trade names Alkagel (Lantec), Al U Creme (Macallister), Creamahn (Winthrop), Vanogel (VanPelt and Brown), Amphogel (Wyeth)

Administration Oral

Dosage forms Tablet 0.5 Gm, suspensions of various concentrations

**ALUMINUM PENICILLIN**

Administration Oral

Dosage form Tablet 50,000 units

**ALUMINUM PHOSPHATE GEL**

Trade name Phosphaljel (Wyeth)

Administration Oral

Dosage form Suspension, 40 mg per ml

**ALURATE (Roche)**

Trade name for Aprobarbital

**ALZINOX (Patch)**

Trade name for Dihydroxy Aluminum Ammonioacetate

**AMASEC (Lilly)**

Each capsule contains Aminophylline, 0.13 Gm Ephedrine HCl, 25 mg, Amobarbital 25 mg

**AMBENONIUM Cl**

Trade name Mytelase Cl (Winthrop)

Administration Oral

Dosage form Tablets, 10 and 25 mg

**ADRFNAL CORTX EXTRACT**

*Trade name* Eschatin (Parke Davis)  
*Administration* Intramuscular, subcutaneous, intravenous  
*Dosage form* Ampule 50 dog units per ml

**ADRENALIN (Parke, Davis)**

*Trade name for* Epinephrine

**ADRENALIN HCl (Parke Davis)**

*Trade name for* Epinephrine HCl

**ADRENOSEM SALICYLATE (Massengill)**

*Trade name for* Carbazochrome Salicylate

**ADRESTAT (Organon)**

*Trade name for* Carbazochrome Salicylate

**ADRIN (Merck)**

*Trade name for* Epinephrine HCl

**AEROLONE COMPOUND (Lilly)**

Each 100 ml contains Cyclopentamine HCl 0.5 Gm Isoproterenol HCl 0.25 Gm Atropine SO<sub>4</sub> 0.1 Gm Procaine HCl, 0.2 Gm

**AEROSPORIN (Burroughs Wellcome)**

*Trade name for* Polymyxin B SO<sub>4</sub>

**AFAXIN (Winthrop)**

*Trade name for* Oleovitamin A

**A\* FIL (Texas Pharmacal)**

Menthyl Anthranilate and Titanium Dioxide cream and stick

**AGAR**

*Synonym* Agar Agar  
*Administration* Oral  
*Dosage form* As such

**ALBAMYCIN SODIUM (Upjohn)**

*Trade name for* Novobiocin Sodium

**ALBOLINE (McKesson & Robbins)**

*Trade name for* Petrolatum

**ALBUMIN (HUMAN) SALT POOR**

*Administration* Intravenous  
*Dosage form* Ampule, 0.25 Gm per ml

**ALBUMIN, NORMAL (HUMAN) SERUM**

*Trade name* Albumisol (Merck)  
*Administration* Intravenous  
*Dosage form* Ampules, 50 and 250 mg per ml

**ALBUMISOL (Merck)**

*Trade name for* Albumin, Normal (Human) Serum

**ALCOPARA**

*Synonym for* Bephen um Hydroxynaphthoate

**ALDARSONF (Abbott)**

*Trade name for* Phenarson Sulfosylate

**ALDINAMIDE (Lederle)**

*Trade name for* Pyrazinoic Acid Amine

**ALEVAIRE (Winthrop)**

*Trade name for* Superanone

**ALFLORONF (Merck)**

*Trade name for* Fludrocortisone Acetate

**ALIDASE (Searle)**

*Trade name for* Hyaluronidase

**ALKAGEL (Lantern)**

*Trade name for* Aluminum Hydroxide Gel

**ALKAVERVIR**

*Trade name* Veriloid (Riker)  
*Administration* Oral  
*Dosage form* Tablets, 1, 2 and 3 mg

**ALLOBARBITAL**

*Trade name* Dial (Ciba)  
*Administration* Oral  
*Dosage form* Tablets 30 and 100 mg

**ALLYLBARBITAL**

*Trade name* Sandoptal (Sandoz)  
*Administration* Oral  
*Dosage form* Tablet, 0.2 Gm

**ALMAY HYPOALLERGENIC SHAMPOO**

(Almay)  
*Nonmedicated shampoo*

**ALMAY JUNIPER TAR (Almay)**

Juniper Tar

**ALMAY LIQUID CLEANSER (Almay)**

Detergent cleanser

**ALMAY PINE (Almay)**

Pine Oil

**ALMAY SUNBURN PREVENTIVE LIQUID (Almay)**

Para aminobenzoic acid liquid

**ALMAY SUPERFATTED SOAP (Almay)**

Superfatted soap

**ALMAY TAR SHAMPOO (Almay)**

Tar shampoo

**ALMEFRIN (Meyer)**

*Trade name for* Phenylephrine HCl

**AMITRFPF (Normand)**Trade name for Amphetamine SO<sub>4</sub>**AMMIVIN (National Drug)**

Trade name for Vitamin material

**AMMONIATED MERCURY**

Synonym White precipitate

Dosage form Ointment, 1 to 5%

**AMMONIUM CO<sub>3</sub>**

Administration Oral

Dosage forms Solutions of various concentrations

**AMMONIUM CI**

Trade name Amchlor (Brewer)

Administration Oral

Dosage form Tablets, 0.3 and 0.5 Gm (enteric coated)

**AMMONIUM NO<sub>3</sub>**

Administration Oral

Dosage form Tablet, 0.2 Gm

**AMNESTROGEN (Squibb)**

Trade name for Estrogenic Substances, Conjugated

**AMNIOTIN (Squibb)**

Trade name for Estrone

**AMOBARBITAL**

Trade name Amytal (Lilly)

Administration Oral

Dosage forms Tablets, 8, 16, 50, 100 mg, elixir, 4 and 8 mg per ml

**AMOBARBITAL SODIUM**

Trade name Amytal Sodium (Lilly)

Administration Oral, intramuscular

Dosage forms Capsules, 60 and 200 mg, vials, 0.125, 0.25, 0.5, and 1.0 Gm

**AMODIAQUIN HCl**

Trade name Camoquin HCl (Parke, Davis)

Administration Oral

Dosage form Tablet, 200 mg

**AMOEBICON (C.M.C.)**

Trade name for Glycobiarsol

**AMOLANONE HCl**

Trade name Amethone HCl (Abbott)

Administration Oral, intramuscular, intra-urethral

Dosage form Capsule, 50 mg, vial 20 ml (9%) to be diluted to 500 ml (0.33%) before using

**AMPHEDRINE (VanPelt & Brown)**Trade name for Amphetamine SO<sub>4</sub>**1 AMPHETAMINE ALGINATE**

Trade name Levonor (Nordmark)

Administration Oral

Dosage form Tablet, 5 mg

**AMPHETAMINE PO<sub>4</sub>**Trade name Raphetamine PO<sub>4</sub> (Strassenburgh)

Administration Oral, intravenous

Dosage forms Vial, 10 ml containing 20 mg per ml, tablet, 5 mg

**AMPHETAMINE RFSIN COMPLEX**

Trade name Biphetamine Resin (Strassenburgh)

Administration Oral

Dosage form Capsule, 20 mg

**AMPHETAMINE SO<sub>4</sub>**Trade names Amphedrine (VanPelt & Brown), Benzedrine SO<sub>4</sub> (Smith, Kline & French), Linampheta (Lincoln)

Administration Oral, intravenous

Dosage forms Tablets, 5 mg, 10 mg, ampule, 1 ml containing 20 mg

**AMPHEX (Algro)**Trade name for Dextro Amphetamine SO<sub>4</sub>**AMPHOJEL (Wyeth)**

Trade name for Aluminum Hydroxide Gel

**AMPHOTERICIN B**

Trade name Fungizone (Squibb)

Administration Intravenous

Dosage form Ampule, 2.5 mg per ml

**AMPROTROPINE PO<sub>4</sub>**

Trade name Syntropan (Roche)

Administration Oral

Dosage form Tablets, 50 and 100 mg

**AMT (Wyeth)**

Trade name for Magnesium Trisilicate and Aluminum Hydroxide

**AMYLGESTIN (McNeil)**

Trade name for Pancreatin

**AMYL NITRITE**

Administration Inhalation

Dosage form Fabric covered ampules containing 0.3 ml

**AMYLSINE HCl (Novocol)**

Trade name for Nacaine HCl

**AMYTAL (Lilly)**

Trade name for Amobarbital

**AMYTAL SODIUM (Lilly)**

Trade name for Amobarbital Sodium

**AMBODRYL HCl (Parke, Davis)**

Trade name for Bromodiphenhydramine HCl

**AMBUTONIUM Br**

Administration Oral

Dosage form Tablet, 10 mg

**AMCHLOR (Brewer)**

Trade name for Ammonium Cl

**AMENDS SOLUTION**

Administration Oral

Dosage form Solution, contains 14 mg Iodine per ml

**AMETHOCAINE HCl**

Synonym for Tetracaine HCl

**AMETHONE HCl (Abbott)**

Trade name for Amolanone HCl

**AMETHOPTERIN**

Trade name Methotrexate (Lederle)

Administration Oral

Dosage form Tablet 2.5 mg

**d AMFETASUL (Pitman Moore)**

Trade name for Dextro Amphetamine SO

**AMIDONE HCl**

Synonym for Methadone HCl

**AMIDOPYRINE**

Synonym for Aminopyrine

**AMID SAL (Glenwood)**

Trade name for Salicylamide

**AMINITROZOLE**

Trade name Tritheton (Ortho)

Administration Oral

Dosage form Tablet, 100 mg

**AMINOACETIC ACID**

Synonym Glycine

Administration Oral

Dosage form As such

**AMINOACETIC ACID AND CALCIUM CARBONATE**

Trade name Turalac (Schenley)

Administration Oral

Dosage forms Tablet, 0.5 Gm, powder as such

**AMINOACETIC FERROUS SO. COMPLEX**

Trade name Ferronord (Nordmark)

Administration Oral

Dosage form Tablet, 40 mg ferrous iron

**AMINOCARBOFLUORENE**

Trade name Pavatrine (Searle)

Administration Oral

Dosage form Tablet, 125 mg

**AMINO METHYL-NAPHTHOL HCl**

Trade name Synkamin (Parke, Davis)

Administration Oral parenteral

Dosage forms Capsule, 4 mg, ampule, 1 mg per ml

**AMINOPENTAMIDF**

Trade name Centrine (Bristol)

Administration Oral

Dosage forms Tablet, 0.5 mg liquid, about 0.75 mg per ml

**AMINOPHYLLINE**

Synonym Theophylline with Ethylenediamine

Administration Oral, intramuscular, intravenous

Dosage forms Tablets, 0.2, 0.3 Gm capsules for intravenous injection 25 mg/ml, for intramuscular injection 5 mg per ml

**AMINOPTERIN SODIUM Tartrate**

Trade name for Sodium aminopterin tartrate

**AMINOPYRINE**

Trade name Pyramidon (Wehring)

Administration Oral

Dosage form Tablets, 0.2 Gm

**AMINOSALICYLIC ACID**

Synonym Para Aminosalicylic Acid

Trade names Pamisol (Parke, Davis), Pas (Gold Leaf), Parasal (Parke, Davis), para (Merck)

Administration Oral

Dosage forms Tablet, 0.5 Gm capsules, 0.5 Gm

**AMINOTRATE**

Trade names Metamne (Squibb), tamin (Squibb)

Administration Oral

Dosage form Tablet, 2 mg

**AMIPHENAZOLE**

Synonym for Daptazole

**AMISOMETRADINE**

Trade name Rolictoc (Schenley)

Administration Oral

Dosage form Tablet, 4 mg

**AMITHIOZONE**

Synonym Contebz (Schenley)

Administration Oral

Dosage form Tablet, 2 mg

**ANTIMONY SODIUM TARTRATE**

Not readily available on the commercial drug market

**ANTIMONY SODIUM THIOGLYCOLATE**

*Administration* Intramuscular intravenous  
*Dosage form* Ampule, 5 mg per ml

**ANTIMONY THIOGLYCOLAMIDE**

*Administration* Intramuscular intravenous  
*Dosage form* Ampule, 4 mg per ml

**ANTIPYRINE**

*Synonyms* Analgesine, Anodynine, Parodyne, Phenazone, Phenylone, Pyrazoline, and many others

*Administration* Oral  
*Dosage form* Tablets 0.2 and 0.3 Gm

**ANTISTINE (Ciba)**

Trade name for Antazoline HCl

**ANTRENYL Br**

Trade name for Oxypheonium Br

**ANTRYPOL**

Synonym for Suramin Sodium

**ANTUITRIN (Parke Davis)**

Trade name for Chorionic Gonadotropin

**ANTURAN (Geigy)**

Trade name for Sulfapyrazone

**ANZOL (Veltex)**

Trade name for Benzethonium Cl

**APAMIDE (Ames)**

Trade name for Acetaminophen

**APEXOL (Roerig)**

Trade name for Oleovitamin A

**A.P.L. (Ayerst)**

Trade name for Chorionic Gonadotropin

**APOMORPHINE HCl**

*Administration* Subcutaneous  
*Dosage form* Hypo tablet

**APRESOLINE (Ciba)**

Trade name for Hydralazine HCl

**APROBARBITAL**

*Trade name* Alurate (Roche)  
*Administration* Oral  
*Dosage form* Elixir, 75 mg per ml

**AQUADIOL (National Drug)**

Trade name for Estradiol

**AQUAPHOR (Duke)**

Hydrophilic ointment base

**AQUASOL A (U S Vitamin)**

Trade name for Vitamin A, Water Miscible

**AQUA TESTERONE (Endocrine)**

Trade name for Testosterone

**AQUATYL (Irwin, Neisler)**

Trade name for Dioctyl Sodium Sulfosuccinate

**AQUIOL (Fstro)**

Trade name for Estradiol

**ARALEN PO. (Winthrop)**

Trade name for Chloroquine PO

**ARAMINE BITARTRATE (Merck)**

Trade name for Metaraminol Bitartrate

**ARANTHOL (Bilhuber Knoll)**

Trade name for Methamocetol

**ARCOFAC (Armour)**

Trade name for Cholesterol Lowering Factor

**AR EX TAR (Ar Ex)**

Trade name for Juniper Tar

**ARFONAD (Roche)**

Trade name for Trimethaphan Camphor sulfonate

**1 ARGININE HCl**

*Trade name* R Gene (Cutter)  
*Administration* Intravenous  
*Dosage form* Solution 5%

**ARGYROL (Barnes)**

Trade name for Silver Protein, Mild

**ARISTOCORT (Lederle)**

Trade name for Tramcinolone

**ARISTOL (Merck)**

Trade name for Thymol I

**ARLIDIN HCl (Arlington)**

Trade name for Nyldrin HCl

**ARMAZIDE (Armour)**

Trade name for Isoniazid

**ARSENIC TRIOXIDE**

*Administration* Oral  
*Dosage forms* Tablet, 10 mg, solution, 1%

**ARSTHINOL**

*Trade name* Balarsen (Endo)  
*Administration* Oral  
*Dosage form* Tablet, 100 mg

**ANALIST (Anahist)**  
Trade name for Thonzylamine HCl

**ANALGESINE**  
Synonym for Antipyrine

**ANAYODIN (Bischoff)**  
Trade name for Chlorthalidone

**ANDIRA (Maney)**  
Trade name for Pectin

**ANDRODIOL (Carnrick)**  
Trade name for Methandrolo

**ANDROLIN (Lincoln)**  
Trade name for Testosterone

**ANDROLIN IN OIL (Lincoln)**  
Trade name for Testosterone Propionate

**ANDROLONE (National)**  
Trade name for Stanolone

**ANDROMETH (Central)**  
Trade name for Methyltestosterone

**ANDRONAQ (Central)**  
Trade name for Testosterone

**ANDRONATE (Central)**  
Trade name for Testosterone Propionate

**ANDRUSOL (C. D. Smith)**  
Trade name for Testosterone

**ANDRUSOL P (C. D. Smith)**  
Trade name for Testosterone Propionate

**ANECTINE Cl (Burroughs Wellcome)**  
Trade name for Succinylcholine Cl

**ANESTHESIN (Abbott)**  
Trade name for Ethyl Aminobenzoate

**ANGICAP (Pro Acet)**  
Trade name for Pentaerythritol Tetranitrate  
Sustained release capsules containing three  
10 mg doses released separately at timed  
intervals

**ANGITET (Harvey)**  
Trade name for Pentaerythritol Tetranitrate

**ANILERIDINE HCl**  
Trade name Lertine HCl (Merck)  
Administration Oral  
Dosage form Tablet 25 mg

**ANILERIDINE PO**  
Trade name Lertine PO (Merck)  
Administration Parenteral  
Dosage forms Ampules 25 mg per ml  
vial 25 mg per ml

**ANISE OIL**  
Administration Oral  
Dosage forms As such spirit

**ANISINDIONE**  
Trade name Miradon (Schering)  
Not available on the commercial drug market

**ANODYNINE**  
Synonym for Antipyrine

**ANSADOL (Rorer)**  
Trade name for Salicylaldehyde

**ANSOLYSEN (Wyeth)**  
Trade name for Pentolinum

**ANTABUSE (Ayerst)**  
Trade name for Disulfiram

**ANTAZOLINE HCl**  
Trade name Antistine (Ciba)  
Administration Oral, topical  
Dosage Tablet 100 mg solution 0.5%

**ANTEPAR CITRATE (Burroughs Wellcome)**  
Trade name for Piperazine Citrate

**ANTHALAZINE (Bowman)**  
Trade name for Piperazine Hexahydrate

**ANTHIOMALINE**  
Synonym for Lithium Antimony Triomaleate

**ANTHRALIN (Abbott)**  
Trade name for Dihydroxyanthranol

**ANTIHEMOPHILIC GLOBULIN**  
Administration Intravenous  
Dosage form Ampule 200 mg

**ANTIHEMOPHILIC PLASMA (HUMAN)**  
Administration Intravenous  
Dosage form Vial to be diluted to 50 and  
100 ml equivalent to 60 and 120 ml of  
plasma

**ANTIHIST (Lipton)**  
Trade name for Pyrilamine Maleate

**ANTIMONY POTASSIUM TARTRATE**  
Administration Intravenous  
Dosage form Ampule, 10 mg per ml



**AZOCHLORAMID** (Wallace & Tiernan)

Trade name for Chlorazodol

**AZODYNE** (Stuart)

Trade name for Phenylazo-diamino pyridine HCl

**AZULIDINE** (Pharmacia)

Trade name for Salicylazosulfapyridine

**AZURESIN**

Trade name Diagnex Blue (Squibb)

Administration Oral

Dosage form Powders in set of packets

**BACITRACIN**

Trade names Parentracin (CSC), Topitracin (CSC)

Administration Topical, intramuscular

Dosage forms Ointment, 500 units per Gm  
vial, 50,000 units suppository, 10,000 units**BAL**

Synonym for Diurecaprol

**BALARSEN** (Fndo)

Trade name for Arsthinol

**BANOCIDE**

Synonym for Diethylcarbamazine

**BANTHINE Br** (Searle)

Trade name for Methantheline Br

**BARBITAL**

Synonyms Veronal Barbitone

Administration Oral

Dosage form Tablet or capsule, 0.3 Gm

**BARBITAL SODIUM**

Trade name Medinal (Warner Chilcott)

Administration Oral, rectal

Dosage form Tablet, 320 mg

**BARBITONE**

Synonym for Barbitol

**BARIUM SO.**

Administration Oral

Dosage form As such

**BASALJEL** (Wyeth)Trade name for Aluminum Carbonate Gel,  
Basic**BASERGIN** (Sandoz)

Trade name for Ergonovine Tartrate

**BASEX** (Columbus)

Trade name for Polyamine Methylene Resin

**BASIS SOAP** (Duke)

Trade name for Superfatted soap

**BEADOX HCl** (Premo)

Trade name for Pyridoxine HCl

**BELLADONNA**

Administration Oral

Dosage form Tincture

**BELLADONNA EXTRACTS**Trade names Bellafoline (Sandoz), Vinobel  
(Merrill)**BELLAFOLINE** (Sandoz)

Trade name for Belladonna Extract

**BENIFGRIDE**

Trade names Megimide (Abbott), Midedimide (Panray)

Administration Intravenous

Dosage form Ampule, 5 mg per ml

**BENACTYZINE HCl**Trade names Phobex (Lloyd), Suavitil  
(Merck)

Administration Oral

Dosage form Tablet, 1 mg

**BENADRYL** (Parke, Davis)

Trade name for Diphenhydramine HCl

**BENASEPT** (Blue Line)

Trade name for Benzalkonium Cl

**BENEMID** (Merck)

Trade name for Probenecid

**BENODOLINE HCl** (Merck)

Trade name for Piperhexan HCl

**BENOQUIN** (Elder)

Trade name for Monobenzene

**BENOXINATE HCl**

Trade name Dorsoxaine HCl (Dorsey)

Administration Topical

Dosage form Solution, 0.4%

**BENTONITE**

Adsorbent, emulsifier, gel former

**BENTYL HCl** (Merrill)

Trade name for Dicyclomine HCl

**BENZALKONIUM Cl**Trade names Benasept (Blue Line), Roccal  
(Winthrop), Zephiran Cl (Winthrop)Dosage forms Solutions, 12.8% and 0.1%,  
tincture, 0.1%

**CARTANE HCl (Lederle)**

Trade name for Trihexyphenidyl HCl

**ARTHENOLONE (Ayerst)**

Trade name for Pregnenolone

**ARTHROPAN (Purdue Frederick)**

Trade name for Choline Salicylate

**ASCORBATE SODIUM**

Trade names Ascorbin (Lakeside), Ceno-

late (Abbott) Natrasorb (U S Vitamin)

Administration Parenteral

Dosage form Ampule, 250 mg per ml

**ASCORBIC ACID**

Synonym Vitamin C, Cevitamc Acid

**ASCORBIN (Lakeside)**

Trade name for Ascorbate Sodium

**ASPIDIUM OLEORESIN**

Administration Oral

Dosage forms Capsule or emulsion of various sizes

**ASPIRIN**

Synonym for Acetylsalicylic Acid

**ASTERIC (Brewer)**

Trade name for Acetylsalicylic Acid

**ASTEROL (Roche)**

Trade name for Diamthazole

**ASTRAFER (Astra)**

Trade name for Iron Carbohydrate Complex

**ATABRINE HCl (Winthrop)**

Trade name for Quinacrine HCl

**ATARAX (Roerig)**

Trade name for Hydroxyzine HCl

**ATOPHAN (Warner Chilcott)**

Trade name for Cinchophen

**ATRATAN (Irwin, Neisler)**

Trade name for Atropine Tannate

**ATROPINE SO.**

Administration Oral parenteral

Dosage forms Tablets and solutions in a large variety of forms and sizes

**ATROPINE TANNATE**

Trade name Atratan (Irwin, Neisler)

Administration Oral

Dosage form Tablet, 1 mg

**AU<sup>199</sup>**

Synonym for Radio-Gold Colloid

**AURCOLOID**

Synonym for Radio Gold Colloid

**AUREOMYCIN CALCIUM (Lederle)**

Trade name for Chlortetracycline Calcium

**AUREOMYCIN HCl (Lederle)**

Trade name for Chlortetracycline HCl

**AUROTHIOGLUCOSE**

Trade name Solganal (Schering)

Administration Intramuscular

Dosage form Vials, 10, 50 100 mg per ml

**AUROTHIOGLYCANIDE**

Trade name Lauron (Endo)

Administration Intramuscular

Dosage form Vials, 50 and 150 mg per ml

**AUROTHIOSULFATE SODIUM**

Synonym for Gold Sodium Thiosulfate

**AVEENO COLLOIDAL OATMEAL**

(Fougera)

Trade name for Oatmeal preparation

**AVEENO SKIN CLEANSER (Fougera)**

Detergent cleanser

**AVERTIN (Winthrop)**

Trade name for Tribromoethanol

**AVLOSULFON (Ayerst)**

Trade name for Dapsone

**AZACYCLONOL HCl**

Trade name Frenquel (Merrell)

Administration Oral

Dosage form Tablet, 20 mg

**AZAMETHONIUM Br**

Trade name Pendiomide (Ciba)

Administration Intravenous

Dosage form Ampule 50 mg per ml

Remarks Not available on drug market

**AZAPETINE PO.**

Trade name Ildar (Roche)

Administration Oral

Dosage form Tablet, 25 mg

**AZASERINE**

Synonym Scrynl

Not available on commercial drug market

**BETAXIN (Winthrop)**

Trade name for Thiamine HCl

**BETAZOLF HCl**

Trade name Histalog (Lilly)

Administration Intramuscular, subcutaneous

Dosage form Ampule, 50 mg per ml

**BFTHANECOL Cl**

Trade name Urecholine Cl (Merck)

Administration Oral, subcutaneous

Dosage forms Tablet, 5 mg, ampule, 5 mg per ml

**BEVATINE 12 (Dorsey)**

Trade name for Cyanocobalamin

**BEVIDORAL (Abbott)**Trade name for Intrinsic Factor with Vitamin B<sub>12</sub>**BEVIDOX (Abbott)**

Trade name for Cyanocobalamin

**BEXITAB (Chicago)**Trade name for Intrinsic Factor with Vitamin B<sub>12</sub>**B F I POWDER (Merck)**

Fungicide mixture used largely in Europe

**BIALLYLAMICOL HCl**

Trade name Camoform HCl (Parke, Davis)

Administration Oral

Dosage form Tablet, 250 mg

**BICHLORACETIC ACID**

Administration Topical

Dosage form As such

**BICHLORIDE OF MERCURY**

Synonym for Mercuric Cl

**BICILLIN (Wyeth)**

Trade name for Benzathine Penicillin G

**BICOL (McNeil)**

Trade name for Ox Bile Extract

**BIFACTON (Organon)**Trade name for Intrinsic Factor with Vitamin B<sub>12</sub>**BILE EXTRACTIVES**

Trade name Ketochol (Searle)

Administration Oral

Dosage form Tablet, 0.25 Gm

**BILEIN (Abbott)**

Trade name for Ox Bile Extract

**BILRON (Lilly)**

Trade name for Iron and Bile Salts

**BIO DES (Grant)**

Trade name for Diethylstilbestrol

**BIOEPIDERM (Breon)**

Trade name for Biotin

**BIOPAR (Armour)**Trade name for Intrinsic Factor with Vitamin B<sub>12</sub>**BIOPAR FORTE (Armour)**Trade name for Intrinsic Factor with Vitamin B<sub>12</sub>**BIOTIN**

Trade name Bioepiderm (Breon)

Administration Intramuscular

Dosage form Ampule, 0.25 mg per ml

**BIPHETAMINE RESIN (Strassenburgh)**

Trade name for Amphetamine Resin Complex

**BISACODYL**

Trade name Dulcolax (Geigy)

Administration Oral rectal

Dosage forms Tablets, 5 and 10 mg suppository, 10 mg

**BISHYDROXYCOUMARIN**

Trade name Dicumarol (Various manufacturers)

Administration Oral

Dosage forms Tablets, 25, 50 mg capsules 50, 100 mg

**BISMUTH OCTOXYACETATE**

Trade name Lipo B smol (Parke Davis)

Administration Intramuscular

Dosage form Ampule, 100 mg, as Bismuth per ml

**BISMUTH SUBCARBONATE**

Administration Oral

Dosage form As such tablets of various sizes

**BISMUTH SUBGALLATE**

Administration Oral

Dosage form As such, tablets of various sizes

**BISMUTH SUBNITRATE**

Administration Oral

Dosage form As such tablets of various sizes

**BISMUTH SUBSALICYLATE**

Trade name Stabisol (Squibb)

Administration Intramuscular

Dosage form Ampule about 75 mg, as Bismuth, per ml

**BENZAPAS** (Smith Dorsey)

Trade name for Calcium Benzoyl Ammonium clyate

**BENZATHINE PENICILLIN G**

Trade names Bicillin (Wyeth) Neolin (Lilly) Penmapen (Pfizer)

Administration Oral intramuscular

Dosage forms Tablets 100 000 200 000 units fluid, 60 000 units per ml ampoules 300 000 600 000 and 1 000 000 units per ml

**BENZ**

**BENZEDREX** (Smith, Kline & French)

Trade name for Propylhexedrine

**BENZEDRINE SO**, (Smith Kline & French)

Trade name for Amphetamine SO

**BENZENE HEXACHLORIDE, GAMMA**

Synonym for Gamma Benzene Hexachloride

**BENZESTROL**

Administration Oral vaginal intramuscular

Dosage forms Tablets 0.5 1.0 mg suppository 0.5 mg vaginal 5 mg per ml

**BENZETHONIUM Cl**

Trade names Anzol (Veltex) Phemerol Cl (Parke Davis)

Dosage forms Solution 0.1% 3% tincture 0.2%

**BENZOCAINE** (Merck)

Trade name for Ethyl Aminobenzoate

**BENZODIOXANE**

Synonym for Peroxan HCl

**BENZOIC ACID**

Administration Topical

Dosage forms Various concentrations and physical forms are available

**BENZOIN**

Administration Inhalation

Dosage form Compound tincture

**BENZONATATE**

Trade name Tessalon (Ciba)

Administration Oral

Dosage form Perles 100 mg

**BENZOTHIAZOLIUM I**

Synonym for D thiazanine I

**BENZPYRINIUM Br**

Trade name Stigmonene Br (Warner Chilcott)

Administration Intramuscular

Dosage form Ampule 20 mg per ml

**BENZTROPINE METHANESULFONATE**

Trade name Cogentin Methanesulfonate (Merck)

Administration Oral

Dosage form Tablet 2 mg

**BENZYL ALCOHOL**

Administration Topical

Dosage form Solutions 1 to 4%

**BENZYL BENZOATE**

Trade name Vanzoate (VanPelt & Brown)

Administration Topical

Dosage forms Emulsion 50% solution 20%

**BENZYLPHENYL CARBAMATE**

Trade name Diphenan (Burroughs Wellcome)

Administration Oral

Dosage form Tablet 0.5 Gm

**BEPHENIUM HYDROXYNAPHTHOATE**

Synonym Alcopara

Not yet available on the commercial drug market

**BERUBIGEN** (Upjohn)

Trade name for Cyanocobalamin

**BETA CONCERN** (Mertell)

Trade name for Vitamin B Complex

**BETADINE** (Carbin & Conwell)

Trade name for Povidone Iodine Complex

**BETALIN** (Lilly)

Trade name for Vitamin B Complex

**BETALIN S** (Lilly)

Trade name for Thiamine HCl

**BETALIN 12** (Lilly)

Trade name for Cyanocobalamin

**BETANAPHTHOL BENZOATE**

Administration Topical

Dosage form To be made up

**BETAPLEXIN** (Winthrop)

Trade name for Vitamin B Complex

**BETA PYRIDYL-CARBINOL**

Trade name Ronacol (Roche)

Administration Oral

Dosage forms Tablet 50 mg liquid about 12.5 mg per ml

**BURO-SOL (Doak)**

Trade name for Aluminum Acetate Solution

**BUROW'S SOLUTION**

Synonym for Aluminum Acetate Solution

**BURSOLINE (Burnham)**

Trade name for Diglycocoll Hydroiodide-Iodine

**BUSULFAN**

Trade name Myleran (Burroughs Wellcome)

Administration Oral

Dosage form Tablet, 2 mg

**BUTABARBITAL SODIUM**

Trade names Bubartal Sodium (Columbus), Butisol (McNeil)

Administration Oral

Dosage forms Capsule, 100 mg, tablets, 15, 30, 50, and 100 mg, elixir, 6.6 mg per ml

**BUTACAINE SO.**Trade name Butyn SO<sub>4</sub> (Abbott)

Administration Topical

Dosage form Solution, 2%

**BUTAMBEN PICRATE**

Trade name Butesin Picrate (Abbott)

Administration Topical

Dosage form Ointment, 1:5,000 and 1:100

**BUTANEFRINE HCl (Winthrop)**

Trade name for Ethylnorepinephrine HCl

**BUTAZOLIDIN (Geigy)**

Trade name for Phenylbutazone

**BUTESIN PICRATE (Abbott)**

Trade name for Butamben Picrate

**BUTETHAL**

Trade name Neonol (Abbott)

Administration Oral

Dosage form Tablet, 100 mg

**BUTFTHAMINE FORMATE**

Trade name Monocaine Formate (Novocol)

Administration Intrathecal

Dosage form Solution, 5%, as such

**BUTETHAMINE HCl**

Trade name Monocaine HCl (Novocol)

Administration Parenteral

Dosage forms Ampules, 1 and 1.5% with Epinephrine

**BUTISOL SODIUM (McNeil)**

Trade name for Butabarbital Sodium

**BUTYN SO<sub>4</sub> (Abbott)**Trade name for Butacaine SO<sub>4</sub>**CADE OIL**

Synonym for Juniper Tar

**CADMIUM SULFIDE SUSPENSION**

Trade name Capsebon (Pitman Moore)

Administration Topical

Dosage form Suspension, 1%

**CAFFEINE AND SODIUM BENZOATE**

Administration Subcutaneous, intramuscular, intravenous

Dosage form Ampule, 2 ml containing 0.5 Gm

**CALAMINE**

Administration Topical

Dosage forms Lotion and Ointment

**CALCIFEROL**Synonyms Viosterol, Vitamin D<sub>3</sub>

Trade names Deltalin (Lilly), Deratol (Brewer), Drisdol (Winthrop), Ertron (Whittier), Metadec (Merck), and many others

Administration Oral, parenteral

Dosage forms An endless variety

**CALCIPHOS (Bilhuber-Knoll)**

Trade name for Inositol Hexaphosphate

**CALCIUM ACETYSALICYLATE CARBAMIDE**

Trade name Calurn (Smith Dorsey)

Administration Oral

Dosage form Tablet, 0.3 Gm

**CALCIUM AMINOSALICYLATE**

Trade name Parasal Calcium (Panray)

Administration Oral

Dosage form Tablet, 0.5 Gm

**CALCIUM BENZOYL AMINOSALICYLATE**

Trade name Benzapas (Smith Dorsey)

Administration Oral

Dosage forms Tablet, 0.5 Gm, powder, 4 Gm

**CALCIUM CARBOVATE**

Administration Oral

Dosage form As such

**CALCIUM Cl**

Administration Intravenous, oral

Dosage forms Capsules, tablets, solution, 5%

**CALCIUM CO<sub>3</sub> PRECIPITATED**

Administration Oral

Dosage forms A large variety

**CALCIUM DIOCTYL SULFOSUCCINATE**

Trade name Dioxical (Lloyd)

Administration Oral

Dosage form Capsules, 50 and 240 mg

**BISMUTH TRIBROMOPHENATE**

*Trade name* Xeroform (Warner)

*Administration* Oral

*Dosage form* As such

**BISTRIUM Br (Squibb)**

*Trade name for* Hexamethonium Br

**BISTRIUM Cl (Squibb)**

*Trade name for* Hexamethonium Cl

**BI-SULFAZINE (Warren Teed)**

*Trade name for* Dia Mer Sulfonamides

**BISULFON (Veltex)**

*Trade name for* Dia Mer Sulfonamides

**BITHIONOL**

*Trade name* Actamer (Monsanto)

*Administration* Topical

*Dosage form* As such

**BITTER ORANGE OIL**

*Administration* Oral

*Dosage forms* As such, tincture

**BLOCKAIN (Breon)**

*Trade name for* Propoxycaine HCl

**BLOOD HUMAN WHOLE**

*Administration* Intravenous

*Dosage form* As such

**BLUE OINTMENT**

*Synonym for* Mercurial Ointment Mild

**BLUTENE Cl (Abbott)**

*Trade name for* Tolonium Cl

**BONADOXIN**

*Trade name for* mixture of Meclizine HCl and Pyridoxine HCl

**BONAMINE HCl (Pfizer)**

*Trade name for* Meclizine HCl

**BONINE (Pfizer)**

*New trade name for* Meclizine HCl (Bonamine)

**BORIC ACID**

*Administration* Topical

*Dosage forms* Various concentrations and physical forms are available

**BORNATE (Wyeth)**

*Trade name for* Isobornyl Thiocyanacetate

**BOROFAX (Burroughs Wellcome)**

*Trade name for* Boric Acid Cream

**BRADOSOL Br (Ciba)**

*Trade name for* Domiphen Br

**BRAIN EXTRACT SOLUTION**

*Synonym* Thromboplastin

*Administration* Topical oral subcutaneous, intravenous

*Dosage form* Vial 20 ml

**BREWER'S YEAST**

*Nonproprietary preparation of* Vitamin B Complex

**BRILLIANT GREEN**

*Administration* Topical

*Dosage forms* As prescribed

**BRISTAMIN (Bristol)**

*Trade name for* Phenyltoloxamine D hydrogen Citrate

**BROMISOVALUM**

*Trade name* Bromural (Bilhuber Knoll)

*Administration* Oral

*Dosage form* Tablet 0.3 Gm.

**BROMODIPHENHYDRAMINE HCl**

*Trade name* Ambodryl HCl (Parke, Davis)

*Administration* Oral intravenous intramuscular

*Dosage forms* Capsule 25 mg vial 5 mg per ml

**BROMSALIZOL (Hynson)**

*Trade name for* Monobromosalicyl Alcohol

**BROMSULPHALEIN (Hynson)**

*Trade name for* Sulfobromophthalein Sodium

**BROMURAL (Bilhuber Knoll)**

*Trade name for* Bromisovalum

**BRONKEPHIRINE HCl (Breon)**

*Trade name for* Ethylnorepinephrine HCl

**BROXOLIN (Breon)**

*Trade name for* Glycobarsol

**BUBARTAL SODIUM (Columbus)**

*Trade name for* Butabarbital Sodium

**BUCLIZINE HCl**

*Trade names* Sofiran (Stuart) Vibazine (Pfizer)

*Administration* Oral

*Dosage form* Tablet, 50 mg

**BUNAMIODYL**

*Trade name* Orablex (Fougera)

*Administration* Oral

*Dosage form* Capsule 0.75 Gm

**CARBACHOL**

*Synonym* Carbamylcholine Cl  
*Trade name* Doryl (Merck)  
*Administration* Subcutaneous  
*Dosage form* Ampule 0.25 mg per ml

**CARBACRYLAMINE RESIN**

*Trade name* Carbo-Resin (Lilly)  
*Administration* Oral  
*Dosage form* Powder 8 Gm

**CARBAMIDE**

*Synonym* for Urea

**CARBAMIDOPHENYL DI (CARBOXY-METHYLTHIO) ARSENITE**

*Trade name* Thiocarbarson (Lilly)  
*Administration* Oral  
*Dosage form* Capsules, 25-50 mg

**CARBAMYLCHOLINE CL**

*Synonym* for Carbachol

**CARBARSON**

*Administration* Oral, intravaginal  
*Dosage forms* Capsule, 0.25 Gm tablets  
 0.05 and 0.25 Gm suppository, 0.13 Gm

**CARBASED (Mallard)**

*Trade name* for Acetylcarbromal

**CARBAZOCHROME SALICYLATE**

*Trade names* Adrenosem Salicylate (Mas-sengill), Adrestat (Organon)  
*Administration* Oral intramuscular  
*Dosage forms* Tablets, 1 and 2.5 mg, syrup,  
 0.5 mg per ml, ampule, 5 mg per ml

**CARBETAPENTANE CITRATE**

*Trade name* Toclase (Pfizer)  
*Administration* Oral  
*Dosage form* Tablet, 25 mg

**CARBETHYL SALICYLATE**

*Trade name* Sal Ethyl Carbonate (Parke, Davis)  
*Administration* Oral  
*Dosage form* Tablet, 0.3 Gm

**CARBINAZOLF (Denver)**

*Trade name* for Imidazole

**CARBOL-FUCHSIN PAINT**

*Trade name* Carfusin (Rorer)  
*Administration* Oral  
*Dosage form* Paint, 0.3%

**CARBOLIC ACID**

*Synonym* for Phenol

**CARBOMYCIN**

*Trade name* Magnamycin (Pfizer)  
*Administration* Oral  
*Dosage form* Tablets 100-250 mg

**CARBON DIOXIDE**

*Administration* Inhalation  
*Dosage form* Metal bottles, 5 to 10% in oxygen

**CARBON TETRACHLORIDE**

*Administration* Oral  
*Dosage form* As such

**CARBO RESIN (Lilly)**

*Trade name* for Carbacrylamine Resin

**CARBOXYLIC RESIN**

*Trade names* Natrinil (National Drug), Resodex (Smith, Kline & French)  
*Administration* Oral  
*Dosage form* Powder 10 and 15 Gm

**CARBROMAL**

*Trade name* Adalin (Winthrop)  
*Administration* Oral  
*Dosage form* Tablet, 0.3 Gm

**CARBUTAMIDE**

Not available on the commercial drug market

**CARDALIN (Irwin Neisler)**

Each tablet contains Aminophylline, 0.325 Gm, Aluminum Hydroxide 0.16 Gm, Ethyl Aminobenzoate, 0.03 Gm

**CARDAMON**

*Administration* Oral  
*Dosage form* Elixir

**CARDIAZOL (Bilhuber Knoll)**

*Trade name* for Pentyletetrazol

**CARDIGIN (National Drug)**

*Trade name* of Digitoxin

**CARDILATE (Burroughs Wellcome)**

*Trade name* for Erythrityl Tetranitrate

**CARDIOGRAFIN (Squibb)**

*Trade name* for Diatrizoate Methylglucamine

**CARDIOMONE (Endo)**

*Trade name* for Heart Muscle Extract

**CARDRAS (Upjohn)**

*Trade name* for Ethoxzolamide

**CARFUSIN (Rorer)**

*Trade name* for Carbol Fuchsin Paint

**CARICIDE**

*Synonym* for Diethylcarbamazine

**CARINAMIDE**

*Synonym* for Caronamide

# **CALCIUM GLUCONATE**

*Trade name* Calglucon (Sandoz)

*Administration* Intravenous

*Dosage forms* 10 ml containing 1 Gm

# **CALCIUM GLUCONOGALACTOGLUCONATE**

*Trade name* Neo Calglucon (Sandoz)

*Administration* Intravenous intramuscular, oral

*Dosage forms* Ampules 10 and 20% tablet, effervescent 4 Gm syrup

# **CALCIUM HYDROXIDE**

*Administration* Oral

*Dosage form* Solution, 3 mg per ml

# **CALCIUM IODOSTEARATE**

*Trade name* Stearodine (Parke Davis)

*Administration* Oral

*Dosage form* Tablet 10 mg Iodine

# **CALCIUM KINATE GLUCONATE**

*Trade name* Maxukal (Breon)

*Administration* Intravenous

*Dosage form* Ampule 50 mg Ca per ml

# **CALCIUM LACTATE**

*Administration* Oral

*Dosage form* Tablets 0.3 0.6 Gm

# **CALCIUM LEUCINATE**

*Administration* Intravenous intramuscular

*Dosage form* Ampules 100 mg per ml

# **CALCIUM MANDELATE**

*Trade name* Camdelate (Abbott)

*Administration* Oral

*Dosage form* Tablet 0.5 Gm

# **CALCIUM PENICILLIN**

Available in ointments

# **CALCIUM PO**

*Administration* Oral

*Dosage form* Powder

# **CALCIUM PO, TRIBASIC**

*Administration* Oral

*Dosage forms* A variety of forms available

# **CALCIUM UNDECYLENATE**

*Trade name* Caldesene (Maltibac)

*Administration* Topical

*Dosage form* Shaker 5%

# **CALDESENE (Maltibac)**

Trade name for Calcium Undecylenate

# **CALGLUCON (Sandoz)**

Trade name for Calcium Gluconate

# **CALOMEL**

Synonym for Mild Mercurous Cl

# **CALURIN (Smith Dorsey)**

Trade name for Calcium Acetylsalicylate Carbamide

# **CAMDELATE (Abbott)**

Trade name for Calcium Mandelate

# **CAMOFORM (Parke Davis)**

Trade name for Ballylaminol HCl

# **CAMOFORM HCl (Parke Davis)**

Trade name for Ballylaminol HCl

# **CAMOQUIN HCl (Parke Davis)**

Trade name for Amodiaquin HCl

# **CAMPHOR**

*Administration* Intramuscular

*Dosage form* 10% in oil

# **CAMPOLOX (Winthrop)**

Trade name for Liver Injection Crude

# **CANTAXIN (Winthrop)**

Trade name for Ascorbic Acid

# **CANTIL (Lakeside)**

Trade name for Mepenzolate Methylbromide

# **CAPROKOL (Merck)**

Trade name for Hexylresorcinol

# **CAPRYLIC COMPOUND**

*Trade name* Naprylate (Strassenburgh)

*Administration* Topical

*Dosage forms* Ointment 15% suppository 0.45 Gm

# **CAPSEBOX (Pitman Moore)**

Trade name for Cadmium Sulfide Suspension

# **CAPSICUM**

*Administration* Oral

*Dosage forms* As such tincture

# **CAPTODIAMINE HCl**

*Trade name* Suvren (Ayerst)

*Administration* Oral

*Dosage forms* Tablets 50 and 100 mg

# **CARAMIPHEN ETHANEDISULFONATE**

*Trade name* Toryn (Smith Kline & French)

*Administration* Oral

*Dosage forms* Tablet 10 mg syrup 2 mg per ml

# **CARAMIPHEN HCl**

*Trade name* Panparnit (Geigy)

*Administration* Oral

*Dosage form* Tablets 12.5 and 50 mg



**CHINIOFON***Synonym* Yatren*Trade names* Anayodin (Bischoff), Quinoxyl (Burroughs Wellcome)*Administration* Oral*Dosage form* Tablets, 120, 250 mg**CHINOSOL (Jewell)***Trade name for* Oxyquinoline SO<sub>2</sub>**CHLORAL HYDRATE***Trade names* Lorinal (Arnar-Stone), Noctec (Squibb), Somnos (Merck)*Administration* Oral*Dosage forms* Solutions of various strengths, capsules, 0.25 and 0.5 Gm**CHLORAMBUCIL***Trade name* Leukeran (Burroughs Wellcome)*Administration* Oral*Dosage form* Tablet, 2 mg**CHLORAMINE-T***Trade name* Chlorazene (Frost)*Dosage form* As such tablet, 0.3 Gm**CHLORAMPHENICOL***Trade name* Chloromycetin (Parke, Davis)*Administration* Oral, intramuscular, topical*Dosage forms* Capsules, 50, 100, 250 mg, vial, 10 Gm for dilution, variety of topical forms**CHLORAMPHENICOL SUCCINATE***Trade name* Chloromycetin Succinate (Parke, Davis)*Administration* Parenteral*Dosage form* Vial, equivalent of 1 Gm Chloramphenicol in 10 ml**CHLORAZANIL***Trade name* Daquin (Riker)

Not available on the commercial drug market

**CHLORAZENE (Frost)***Trade name for* Chloramine T**CHLORBUTANOL***Trade names* Chlorotone (Parke, Davis), Clortran (Wampole)*Administration* Oral, inhalation*Dosage form* Capsule, 0.3 Gm, inhalant**CHLORCYCLIZINE HCl***Trade names* Di-Paralene HCl (Abbott), Perazil (Burroughs Wellcome)*Administration* Oral*Dosage form* Tablets, 25, 50 mg**CHLORESIUM (Rystan)***Trade name for* Chlorophyll**CHLORTONE (Parke, Davis)***Trade name for* Chlorbutanol**CHLORIODIZED OIL***Trade name* Iodochlorol (Searle)*Administration* Direct application*Dosage form* Bottle, as such**CHLORISONDAMINE Cl***Trade name* Ecolid Cl (Ciba)*Administration* Oral*Dosage form* Tablets, 25 and 50 mg**CHLORMFRODRIN***Trade name* Neohydrin (Lakeside)*Administration* Oral*Dosage form* Tablet, 18.3 mg**CHLORMEZANONE***Trade name* Trancopal (Winthrop)*Administration* Oral*Dosage form* Capsule, 100 mg**CHLOROAZODIN***Trade name* Azochloramid (Wallace & Tiernan)*Administration* Topical*Dosage forms* Ointment, 1, 1,000, tablet, 0.55 Gm, solutions, 1:125 and 1:500 in Triacetin**CHLOROFORM***Administration* Inhalation*Dosage form* Bottles, as such**CHLOROFORM WATER***Administration* Oral*Dosage form* As such**CHLOROGUANIDE HCl***Synonym* Proguanil HCl*Trade names* Guanatol HCl (Lilly), Paladrine HCl (Ayerst)*Administration* Oral*Dosage form* Tablets, 100, 300 mg**CHLOROMYCETIN (Parke, Davis)***Trade name for* Chloramphenicol**CHLOROMYCETIN SUCCINATE (Parke, Davis)***Trade name for* Chloramphenicol Succinate**CHLOROPHENOETHANE***Synonym* DDT*Administration* Topical*Dosage forms* In a variety of mixtures with other agents**CHLOROPHYLL***Trade name* Chloresium (Rystan) and others*Administration* Topical*Dosage forms* Ointment and solution, 0.2 to 0.5%

**CARISOPRODOL**

*Trade names* Relax (Schering) Soma (Wallerace)

*Administration* Oral

*Dosage form* Tablet 350 mg

**CARNACTON (Cavendish)**

*Trade name for* Diaphragm Muscle Extract

*Administration* Oral and parenteral

**CAROID (Am Terment)**

*Trade name for* Papaya Enzyme

**CARONAMIDE**

*Trade name* Statcin (Merck)

*Administration* Oral

*Dosage form* Tablet 0.5 Gm

**CAROTENE**

*Synonym* Provitamin A

*Administration* Oral

*Dosage form* Solutions 5 000 7 500 U per ml

**CARYOLYSINE HCl (Merck)**

*Trade name for* Mechlorethamine HCl

**CASCARA SAGRADA**

*Trade names* Peristaltin (Ciba) Peristim (Mead Johnson)

*Administration* Oral

*Dosage forms* Extract fluid extract aromatic fluid extract

**CASTOR OIL**

*Administration* Oral

*Dosage forms* As such emulsions capsules

**CATHOMYCIN SODIUM (Merck)**

*Trade name for* Novobiocin Sodium

**CATRON (Lakeside)**

*Trade name for*  $\beta$  Phenylisopropyl Hydrazine

**CAYTINF (Lakeside)**

*Trade name for* Alpha (alpha methyl 3,4-methylenedioxyphenethylamino) methyl pyrocatechyl Alcohol HCl

**CCC**

*Synonym for* Citrated Calcium Carbimide

**CEBIONE (Merck)**

*Trade name for* Ascorbic Acid

**CEDILANID (Sandoz)**

*Trade name for* Lanatoside C

**CEDILANID D (Sandoz)**

*Trade name for* Deslanoside

**CEEPRYN Cl (Merrell)**

*Trade name for* Cetyl Pyridinium Cl

**CELLOTHYL (Warner Chilcott)**

*Trade name for* Methylcellulose

**CELLULOSE OXIDIZED**

*Trade names* Hemo Pak (Johnson & Johnson) Oxycel (Parke Davis)

*Administration* Topical

*Forms* Cotton gauze and cones of various sizes

**CELONTIN (Parke Davis)**

*Trade name for* Methsuximide

**CENOLATE (Abbott)**

*Trade name for* Ascorbate Sodium

**CENTRINE (Bristol)**

*Trade name for* Aminopentamide

**CEROCILLIN POTASSIUM (Upjohn)**

*Trade name for* Potassium Penicillin O

**CERVILAXIN (National)**

*Trade name for* Relaxin

**CETAZINE (Bowman)**

*Trade name for* Acet Diamer Sulfonamides

**CETYL PYRIDINIUM Cl**

*Trade name* Ceepryn Cl (Merrell)

*Dosage forms* Solutions and tinctures 1 200 1 500 1 1000 suppositories 1 1000

**CEVALIN (Lilly)**

*Trade name for* Ascorbic Acid

**CEVEK (Walker)**

*Trade name for* Ascorbic Acid

**CEVITAMIC ACID**

*Synonym for* Ascorbic Acid

**CHALK**

*Administration* Oral

*Dosage form* As such but usually in mixtures

**CHARCOAL**

*Administration* Oral

*Dosage form* Tablets as such

**CHARCOAL ACTIVATED**

*Administration* Oral

*Dosage form* Powder

**CHELATE CALCIUM DISODIUM**

*Synonym for* Edatham Calcium Disodium

**CHIL IRON (Kinney)**

*Trade name for* Ferrocholate

**CHENOPODIUM OIL**

*Administration* Oral

*Dosage form* Capsules 0.3 and 0.6 ml

**CHOLINF SALICYLATE**

*Trade name* Arthropan (Purdue Frederick)  
*Administration* Oral  
*Dosage form* Flavored solution, 0.9 Gm per 5 ml

**CHOLINE THEOPHYLLINATE**

Synonym for Oxytriphylline

**CHOLOGRAFIN METHYLGLUCAMINE (Squibb)**

Trade name for Iodipamide Methylglucamine

**CHOLOGRAFIN SODIUM (Squibb)**

Trade name for Iodipamide Sodium

**CHONDODENDRON TONENTOSUM**

*Trade name* Intocostrin (Squibb)  
*Administration* Intramuscular, intravenous  
*Dosage form* Vial, 20 units per ml

**CHORIOGONIN (Lakeside)**

Trade name for Chorionic Gonadotropin

**CHORIONIC GONADOTROPIN**

*Synonym* Growth hormone, Somatotropin  
*Trade names* Antuitrin (Parke, Davis), A.P.L. (Ayerst), Choriogonin (Lakeside), Entromone (Endo), Follutein (Squibb), Gestasol (National), Korotrin (Winthrop), Pregnyl (Organon), Riogon (Breon)  
*Administration* Intramuscular  
*Dosage forms* Vials, 500, 1,000 I.U. per ml

**CHOTHYN DIHYDROGEN CITRATE (Flint, Eaton)**

Trade name for Choline Dihydrogen Citrate

**CHROMIUM ANHYDRIDE**

*Administration* Topical  
*Dosage form* Solution, 20%

**CHRYSAROBIN**

*Administration* Topical  
*Dosage form* Ointment, 5%

**CHYMAR (Armour)**

Trade name for Chymotrypsin

**CHYMOTRYPSIN**

*Trade names* Chymar (Armour), Cytolav (Armour), Enzeon (Breon)  
*Administration* Oral, intramuscular  
*Dosage forms* Capsule, 7 mg, vial, 500 U per ml

**CIGNOLIN**

Synonym for Dihydroxyanthranol

**CILLORAL PENICILLIN (Bristol)**

Trade name for Potassium Penicillin G

**CINAPHYL (Ascher)**

Trade name for Theophylline Sodium Glycinate

**CINCHOPHEN**

*Trade name* Atophan (Warner Chilcott)  
*Administration* Oral  
*Dosage form* Tablets, 0.3 and 0.5 Gm

**CINCHOPHEN HYDRIODIDE**

*Trade name* OxyI-Iodide (Lilly)  
*Administration* Oral  
*Dosage form* Tablet, 0.3 Gm

**CINNAMON OIL**

*Administration* Oral  
*Dosage form* As such

**CITRATED CALCIUM CARBIMIDE**

*Synonym* CCC  
*Trade name* Temposil (Lederle)  
 Not available on the commercial drug market

**CITROVORUM FACTOR**

*Synonym* Folinic Acid  
*Trade name* Leucovorin (Lederle)  
*Administration* Intramuscular  
*Dosage form* Ampule, 3 mg per ml

**CLARIN (Leeming)**

Trade name for Heparin Potassium

**CLINOCAINE HCl**

*Trade name* Naucaine (Taylor)  
*Administration* Oral  
*Dosage forms* Tablet, 120 mg, solution, 100 mg per ml

**CLISTIN MALEATE (McNeil)**

Trade name for Paracarbinoxamine Maleate

**CLOPANE HCl (Lilly)**

Trade name for Cyclopentamine HCl

**CLORTRAN (Wampole)**

Trade name for Chlorbutanol

**CLYSTROL (Clyserol)**

Trade name for Sodium PO<sub>4</sub> enema

**CLYSMATHANE (Fleet)**

Trade name for Theophylline Monoethanolamine enema

**COAL TAR**

*Trade names* Too numerous to list  
*Administration* Topical  
*Dosage forms* Various, 1 to 5%

**COBRA VTOM PREPARATION**

*Trade names* Cobroxin (Hynson), Nyloxin (Hynson)  
*Administration* Intramuscular  
*Dosage form* Ampules, several strengths

### CHLOROPROCAINE HCl

*Trade name* Nesacaine HCl (Maltbie)

*Administration* Parenteral

*Dosage form* Ampules 1, 2 and 3 cc

### CHLOROPROCAINE PENICILLIN O

*Trade name* Depo Cler O Cillin Chloroprocaine (Upjohn)

*Administration* Intramuscular

*Dosage form* Ampule 300 000 units per ml

### CHLOROQUINE PO

*Trade name* Aralen PO (Winthrop)

*Administration* Oral

*Dosage form* Tablet 0.25 Gm

### CHLOROTHEN CITRATE

*Trade name* Tagathen (Lederle)

*Administration* Oral

*Dosage form* Tablet 75 mg

### CHLOROTHIAZIDE

*Trade name* Diuril (Merck)

*Administration* Oral

*Dosage form* Tablet 0.25 and 0.5 Gm

### CHLOROTHIAZIDE SODIUM

*Trade name* Duрил Sodium (Merck)

*Administration* Intravenous

*Dosage form* Vial 0.5 Gm

### CHLOROTHYMOL

*Administration* Topical

*Dosage form* Solution 0.05%

### CHLOROTRIANISENE

*Trade name* Tace (Merrell)

*Administration* Oral

*Dosage form* Capsule containing 12 mg in oil

### CHLORPACTIN (Guardian)

*Trade name* for Monochlorosene

### CHLORPHENIRAMINE MALEATE

*Trade names* Chlor Trimeton Maleate (Schering) Teldrin (Smith Kline & French)

*Administration* Oral intramuscular subcutaneous

*Dosage forms* Tablets 4, 8 and 12 mg solution 10 to 100 mg per ml

### CHLORPHENOXAMINE HCl

*Trade name* Phenoxene (Pitman Moore)

*Administration* Oral

*Dosage form* Tablet 50 mg

### CHLORPROMAZINE HCl

*Trade name* Thorazine (Smith Kline & French)

*Administration* Oral intravenous intramuscular rectal

*Dosage forms* Tablets 10, 25, 50, 100 and 200 mg vial 25 mg per ml suppository 25 and 100 mg

### CHLORPROPAMIDE

*Trade name* Diabinese (Pfizer)

*Administration* Oral

*Dosage form* Tablets 100 and 250 mg

### CHLORQUINALDOL

*Trade name* Sterosan (Geigy)

*Administration* Oral

*Dosage forms* Cream ointment 3%

### CHLORTETRACYCLINE CALCIUM

*Trade name* Aureomycin Calcium (Lederle)

*Administration* Oral

*Dosage form* Syrup about 30 mg per ml

### CHLORTETRACYCLINE HCl

*Trade name* Aureomycin HCl (Lederle)

*Administration* Oral parenteral topical

*Dosage forms* Capsules 50, 100, 250 mg and a variety of other forms

### CHLOR TRIMETON MALEATE (Schering)

*Trade name* for Chlorpheniramine Maleate

### CHLORYLEN (Schering)

*Trade name* for Trichloroethylene

### CHLORZOXAZONE

*Trade name* Paraflex (McNell)

*Administration* Oral

*Dosage form* Tablet 250 mg

### CHOLANDH (Maltbie)

*Trade name* for Dehydrocholic Acid

### CHOLARACE (Nepera)

Mixture of Ephedrine, Pentobarbital and Theophylline

### CHOLEDYL (Nepera)

*Trade name* for Oxytriphylle

### CHOLESTEROL LOWERING FACTOR

*Trade names* Sass (Abbott) Arcofac (Armour)

*Administration* Oral

*Dosage form* As such

### CHOLINE Cl

*Administration* Oral

*Dosage form* Solution 0.5 Gm per teaspoonful

### CHOLINE DIHYDROGEN CITRATE

*Trade name* Chothyn Dihydrogen Citrate (Fint Eaton)

*Administration* Oral

*Dosage forms* Tablets 0.5, 0.65 Gm capsules 0.75, 0.5 Gm

### CHOLINE GLUCONATE

*Administration* Oral

*Dosage form* Solution 50%

**CORPUS LUTFUM**

*Trade name* Lutein (Hynson), Progesterone (Carnick)

*Administration* Intramuscular

*Dosage form* Ampule, extractive of 0.45 Gm per ml

**CORTAR QUIN (Dome)**

*Trade name* for preparation containing Hydrocortisone 0.5% and 1.0%, Duodohydroxyquin, 1% Liquor Carbonis Detergens, 2% in Acid Mantle vehicle

**CORTATE (Schering)**

*Trade name* for Desoxycorticosterone Acetate

**CORT DOME (Dome)**

*Trade name* for Hydrocortisone

**CORTFF (Upjohn)**

*Trade name* for Hydrocortisone

**CORTEF ACETATE (Upjohn)**

*Trade name* for Hydrocortisone Acetate

**CORTICOTROPIN**

*Synonym* ACTH

*Trade names* Acthar (Armour), Actrope (United), Cortrophin (Organon), Depo-ACTH (Upjohn), Solacthyl (Squibb)

*Administration* Intravenous intramuscular

*Dosage forms* Vials 10, 15, 25, 40 units per ml gel, 20, 40, 80, 100 units per ml

**CORTICOTROPIN ZINC HYDROXIDE**

*Trade name* Cortrophin Zinc (Organon)

*Administration* Intramuscular

*Dosage form* Vial, 40 units per ml

**CORTINAQ (Central)**

*Trade name* for Desoxycorticosterone Acetate

**CORTISONE ACETATE**

*Synonym* Compound E

*Trade names* Cortogen Acetate (Schering), Cortone Acetate (Merck), Cortivite

(United) Isopto Cortisone (Alcon Labs)

*Administration* Oral intramuscular, topical

*Dosage forms* Tablets 5, 25 mg, vial, 50 mg per ml ointments 0.5, 1.5, 2.5%

**CORTIVITE (United)**

*Trade name* for Cortisone Acetate

**CORTOGEN ACETATE (Schering)**

*Trade name* for Cortisone Acetate

**CORTONF ACETATE (Merck)**

*Trade name* for Cortisone Acetate

**CORTRIL (Pfizer)**

*Trade name* for Hydrocortisone

**CORTRIL ACETATE (Pfizer)**

*Trade name* for Hydrocortisone Acetate

**CORTROPHIN (Organon)**

*Trade name* for Corticotropin

**CORTROPHIN ZINC (Organon)**

*Trade name* for Corticotropin Zinc Hydroxide

**COSA (Pfizer)**

*Trade name* for Glucosamine

**CORTARNIN F CI**

*Trade name* Stypticin (Merck)

*Administration* Topical, oral

*Dosage form* Solution, 30% as such

**COTHERA (Ayerst)**

*Trade name* for Dimethoxyanate HCl

**COTINAZIN (Pfizer)**

*Trade name* for Isontazid

**COTOPHEROL (Endo)**

*Trade name* for Tocopherols Mixed

**COUMADIN SODIUM (Endo)**

*Trade name* for Warfarin Sodium

**COVICONE (Abbott)**

*Trade name* for Silicone protective cream

**CREAMALIN (Winthrop)**

*Trade name* for Aluminum Hydroxide Gel

**CREMODIAZINE (Merck)**

*Trade name* for Sulfadiazine

**CREOLIN PEARSON (Merck)**

*Trade name* for Cresol

**CRESATIN (Merck)**

*Trade name* for Metacresylacetate

**CRESOL**

*Trade names* Creolin Pearson (Merck), Cresylone (Parke, Davis), Phenolor (Squibb)

*Administration* Topical

*Dosage forms* Various concentrations are available

**CRESYLONE (Parke Davis)**

*Trade name* for Cresol

**CROTAMITON**

*Trade name* Eurax (Geigy)

*Administration* Topical

*Dosage forms* Cream, 10%, lotion 10%

**COBROXIN (Hynson)**

Trade name for Cobra Venom Preparation

**COCAINE**

*Administration* Topical

*Dosage form* Solutions 1 to 4%

**COD LIVER OIL**

*Administration* Oral

*Dosage forms* As such emulsion 50%

**CODEINE ALKALOID**

*Administration* Oral

*Dosage forms* Varied

**CODEINE PO**

*Administration* Parenteral

*Dosage forms* Hypo tablets 15 30 and 60 mg

**CODEINE SO**

*Administration* Oral

*Dosage forms* Varied

**CO DELTRA (Merck)**

Trade name for Prednisone

**COGENTIN METHANESULFONATE (Merck)**

Trade name for Benztropine Methanesulfonate

**COHISTINE (Pitman Moore)**

Trade name for Methapyrilene HCl

**CO HYDELTRA (Merck)**

Trade name for Prednisolone

**COLACE (Mead Johnson)**

Trade name for Dioctyl Sodium Sulfosuccinate

**COLCHICINE**

*Trade name* Colchin (Parke Davis)

*Administration* Oral intravenous

*Dosage forms* Tablets 0.65 mg ampules 0.5 1.0 mg

**COLCHIN (Parke Davis)**

Trade name for Colchicine

**COLLOIDAL GOLD**

*Trade name* Rexaurum (Kahlenberg)

*Administration* Oral intravenous intramuscular

*Dosage form* Solution 1 mg per ml

**COLOCYNTH**

*Administration* Oral

*Dosage form* As such

**COLOGEL (Lilly)**

Trade name for Methylcellulose

**COLPROSTERONE (Ayerst)**

Trade name for Progesterone

**COMBISTREP (Pfizer)**

Trade name for Streptoduoquin

**COMPAZINE (Smith Kline & French)**

Trade name for Prochlorperazine Dimaleate

**COM PEN (C.S.C.)**

Trade name for Procaine Penicillin G

**COMPENAMINE (C.S.C.)**

Trade name for 1 Ephedamine Penicillin G

**COMPOCILLIN (Abbott)**

Trade name for Hydrabamine Penicillin G

**COMPOCILLIN V (Abbott)**

Trade name for Phenoxymethyl Hydrabamine Penicillin

**COMPOCILLIN VK (Abbott)**

Trade name for Potassium Phenoxymethyl Penicillin

**COMPOUND E**

Synonym for Cortisone Acetate

**COMPOUND ETHER SPIRIT**

*Administration* Oral

*Dosage form* As such

**COMPOUND F**

Synonym for Hydrocortisone

**CONESTRON (Wyeth)**

Trade name for Estrogenic Substances Conjugated

**CONGO RED**

*Administration* Intravenous

*Dosage form* Ampule 10 mg per ml

**CONTEBEN**

Synonym for Amithozone

**COPARAFFINATE**

*Trade name* Iso Par (Medical Chem.)

*Administration* Topical

*Dosage form* Ointment 20%

**COPPER COMPOUND**

*Trade name* Cuprex (Merck)

*Administration* Topical

*Dosage form* Solution

**COPSAMINE (Durst)**

Trade name for Pyrrolamine Maleate

**CORAMINE (Ciba)**

Trade name for Nikethamide

**CYCLOPENTOLATE HCl***Trade name* Cyclogyl HCl (Schieffelin)*Administration* Topical*Dosage form* Solutions 0.5 and 1.0%**CYCLOPROPANE***Synonym* Trimethylene*Administration* Inhalation*Dosage form* Cylinders**CYCLOSERINE***Trade name* Seromycin (Eli Lilly)*Administration* Oral*Dosage form* Tablet 250 mg**CYCLOSPASMIOL (Ives Cameron)***Trade name for* Cyclocladate**CYCRIMIN HCl***Trade name* Pagitan HCl (Eli Lilly)*Administration* Oral*Dosage form* Tablets 125 and 250 mg**CYTLLIN (Lilly)***Trade name for* Sitosterols**CYTOLAV (Armour)***Trade name for* Chymotrypsin**CYTOMEL (Smith Kline & French)***Trade name for* Sodium Liothyronine**DACTIL (Lakeside)***Trade name for* Piperidolate HCl**DADFX (Central)***Trade name for* Dextro Amphetamine SO**DAINITE (Irwin Neisler)**

Each day tablet contains Sodium Pentobarbital 16 mg Aminophylline 0.2 Gm Ephedrine HCl 16 mg Ethyl Aminobenzoate 16 mg Aluminum Hydroxide 0.16 Gm Each night tablet contains Phenobarbital 25 mg Sodium Pentobarbital 32 mg Aminophylline, 0.25 Gm Ethyl Aminobenzoate 16 mg Aluminum Hydroxide 0.16 Gm

**DALYDE (Hynson)***Trade name for* D-bromocetylaldehyde**DANILONF (Schieffelin)***Trade name for* Phenindone**DANTHRON***Synonym for* Dihydroxyanthraquinone**DAPSONE***Trade name* Avlosulfon (Ayerst)*Administration* Oral*Dosage form* Tablet**DAPTAZOL***Synonym* Amphenazofe

Not available on the commercial drug market

**DAQVIN (Riker)***Trade name for* Chlorazepate**DARA SUN SCRFEN (Dara)***Isobutyl Para aminobenzoate cream***DARANIDF (Merck)***Trade name for* Dichlorophenamide**DARAPRIM (Burroughs Wellcome)***Trade name for* Pyrimethamine**DARBD (Smith Kline & French)***Trade name for* Isopropamide I**DARICON (Pfizer)***Trade name for* Oxyphencyclimine HCl**DARROW'S SOLUTION (MODIFIED)**

*Synonyms* Potassium and Sodium Chloride with Sodium Lactate Solution Potassium Saline

*Trade name* Ionosol PSL Electrolyte Solution (Abbott)*Administration* Intravenous subcutaneous*Dosage form* Bottles as such**DARSTINE Br (Merck)***Trade name for* Mepiperphenidol Br**DARTAL HCl (Searle)***Trade name for* Thioproparate HCl**DARVON (Lilly)***Trade name for* Dextro Propoxyphene HCl**DASTROL (Tyron)***Trade name for* Mephenesin**DBI (US Vitamin)***Trade name for* Phenformin**DDT***Synonym for* Chlorophenothane**DEANER (Riker)***Trade name for* Deanol Acetaminobenzoate**DEANOL ACETAMIDOBENZOATE***Trade name* Deaner (Riker)*Administration* Oral*Dosage form* Tablet 25 mg**DECADRON (Merck)***Trade name for* Dexamethasone**DECAMETHONIUM Br***Trade name* Syncurine (Burroughs Wellcome)*Administration* Intravenous*Dosage form* Ampule 1 mg per ml

# CRYPTENAMINE

*Trade name* Unistensen (Irwin Neisler)  
*Administration* Intramuscular  
*Dosage form* Vial, 2 mg per ml

# CRYPTENAMINE TANNATE

*Trade name* Unistensen Tannate (Irwin Neisler)  
*Administration* Oral  
*Dosage form* Tablet, 2 mg

# CRYSTAMIN (Armour)

*Trade name for* Cyanocobalamin

# CRYSTICILLIN (Squibb)

*Trade name for* Procaine Pencicillin G

# CRYSTODIGIN (Lilly)

*Trade name for* Digoxin

# CRYSTOIDS (Merck)

*Trade name for* Hexylresorcinol

# CRYSTOSERPINE (Smith Dorsey)

*Trade name for* Reserpine

# CUMERTILIN (Endo)

*Trade name for* Mercunalin

# CUMOPYRAN (Abbott)

*Trade name for* Cyclocumaryl

# CUPREX (Merck)

*Trade name for* Copper Compound

# CYANOCOBALAMIN

*Synonym* Vitamin B<sub>12</sub>  
*Trade names* Berybigen (Upjohn) Betalin 12 (Lilly) Bevatine 12 (Dorsey) Bevidox (Abbott) Bopar (Armour) Crystamin (Armour) Doctan (Walker) Dodecavine (U S Vitamin) Dodekroid (Riker) Plecyanin 12 (Plessner) Redisol (Merck) Rubramin (Squibb) Svitobex (Parke Davis V Tral (Fint Eaton) and others  
*Administration* Intramuscular  
*Dosage form* Vials of many sizes from 15 to 1 000 mcg per ml

# CYCLAINE (Merck)

*Trade name for* Hexylcaine HCl

# CYCLAMATE CALCIUM

*Trade name* Sucaryl Calcium (Abbott)  
*Administration* Oral  
*Dosage form* Solution 150 mg per ml

# CYCLAMATE SODIUM

*Trade name* Sucaryl Sodium (Abbott)  
*Administration* Oral  
*Dosage forms* Tablet 125 mg solution 150 mg per ml

# CYCLAMYCIN (Wyeth)

*Trade name for* Tricetyloleandomycin

# CYCLANDELATE

*Trade name* Cyclospasmol (Ives Cameron)  
*Administration* Oral  
*Dosage form* Tablet 100 mg

# CYCLIZINE

*Trade name* Marezine (Burroughs Wellcome)  
*Administration* Oral rectal  
*Dosage forms* Tablet 50 mg suppository 50 mg

# CYCLIZINE HCl

*Trade name* Marezine HCl (Burroughs Wellcome)  
*Administration* Oral subcutaneous  
*Dosage forms* Tablet 50 mg solution 50 mg per ml

# CYCLIZINE LACTATE

*Trade name* Marezine Lactate (Burroughs Wellcome)  
*Administration* Intramuscular  
*Dosage form* Ampule, 50 mg per ml

# CYCLOBARBITAL CALCIUM

*Trade name* Phanodorn Calcium (Winthrop)  
*Administration* Oral  
*Dosage form* Tablet 0.2 Gm

# CYCLOCUMAROL

*Trade name* Cumopyran (Abbott)  
*Administration* Oral  
*Dosage form* Tablets 25 50 mg

# CYCLOGYL HCl (Schiefelin)

*Trade name for* Cyclopentolate HCl

# CYCLOMETHACAINE

*Trade name* Surfacaine (Lilly)  
*Administration* Topical  
*Dosage forms* A variety of forms

# CYCLOPAL (Upjohn)

*Trade name for* Cyclopentylallylbarbituric Acid

# CYCLOPENTAMINE HCl

*Trade name* Clopane (Lilly)  
*Administration* Intranasal intramuscular  
*Dosage forms* Ampule, 25 mg in 1 ml solutions 0.5 and 1.0%

# CYCLOPENTENYLALLYLBARBITURIC ACID

*Trade name* Cyclopal (Upjohn)  
*Administration* Oral  
*Dosage form* Capsules 50 and 150 mg



**DESERPIDINE**

*Trade name* Harmony (Abbott)  
*Administration* Oral  
*Dosage form* Tablets, 0.1, 0.25, 1.0 mg

**DESICCATED BILE**

*Trade name* Desicol (Parke, Davis)  
*Administration* Oral  
*Dosage form* Capsule, 0.325 Gm

**DESICOL (Parke, Davis)**

*Trade name* for Desiccated Bile

**DESIVER (U S Vitamin)**

*Trade name* for Vitamin B Complex

**DESLANOSIDE**

*Trade name* Cedilanid D (Sandoz)  
*Administration* Intravenous intramuscular  
*Dosage form* Ampules, 2 ml containing 0.4 mg, 4 ml containing 0.8 mg

**DESOXYCORTICOSTERONE ACETATE**

*Trade names* Cortate (Schering), Cortinaq (Central), Decortin (Schieffelin), Decosterone (Barry), Descotone (Merck), Doca Acetate (Organon), Percorten (Ciba), Steraq (Ascher)

*Administration* Intramuscular, subcutaneous  
*Dosage form* Ampule, in oil or aqueous suspension, 5 mg per ml

**DESOXYEPHEDRINE (Upjohn)**

*Trade name* for Methamphetamine HCl

**d DESOXYEPHEDRINE HCl**

Synonym for Methamphetamine HCl

**dl DESOXYEPHEDRINE HCl**

*Trade names* Detrex (Mallard), Oxyfed (Colc), Methamph (Rorer), Premodrin (Premo), Normadrine (VanPelt & Brown)

*Administration* Oral  
*Dosage form* Tablets, 5-10 mg

**DESOXYN (Abbott)**

*Trade name* for Methamphetamine HCl

**DESYPHED (Winthrop)**

*Trade name* for Methamphetamine HCl

**DETERGENT CLEANSERS**

Acidolate (White), Almay Liquid Cleanser (Almay), Aquaphor (Duke), Aveeno Skin Cleanser (Fougera), Dermolate (White), Domolene (Dome), Lowila (Westwood), Mul Sol (Waynor), Nivea Cream (Duke), Nivea Skin Oil (Duke), pHisoderm (Winthrop)

**DETREX (Mallard)**

*Trade name* for dl Desoxyephedrine HCl

**DFVEGAN (Winthrop)**

*Trade name* of preparation containing principally Acetylaminohydroxyphenylarsonic Acid

*Administration* Intravaginal  
*Dosage forms* Powder, 0.25 Gm suppository, 0.25 Gm of active arsenical

**DEXAMETHASONE**

*Trade names* Decadron (Merck), Deronil (Schering), Gammacorten (Ciba)  
*Administration* Oral  
*Dosage form* Tablet, 0.75 mg

**DEAMBROMPHENIRAMINE MALEATE**

*Trade name* Disomer (White)  
*Administration* Oral  
*Dosage forms* Tablet, 2 mg sustained action tablet, 4, 6 mg syrup, 0.4 mg per ml

**DEXEDRINE SO, (Smith, Kline & French)**

*Trade name* for Dextro Amphetamine SO

**DEXOVAL (Vale)**

*Trade name* for Methamphetamine HCl

**DEXSTIM (Central)**

*Trade name* for Methamphetamine HCl

**DEXTRAN**

*Trade names* Expandex (CSC), Gentrin (Baxter), Plavolex (Wyeth)  
*Administration* Intravenous  
*Dosage forms* Bottles, 6 and 12% solutions

**DEXTRAN SO,**

Not available on commercial drug market

**DEXATRO AMPHETAMINE SO,**

*Trade names* d Amfetazol (Pitman Moore), Amphex (Algro), Dexedrine SO, (Smith, Kline & French)

*Administration* Oral  
*Dosage form* Tablets, 2.5, 5, and 10 mg

**DEXTRO CHLORPHENIRAMINE MALEATE**

*Trade name* Polaramine (Schering)  
*Administration* Oral  
*Dosage forms* Tablet, 2 mg, Repetab 6 mg

**DEXTROMETHORPHAN HBr**

*Trade names* Dornethan (Smith Dorsey), Romilar HBr (Roche)  
*Administration* Oral  
*Dosage forms* Tablet, 10 mg, syrup, 2.5 mg per ml

**DEXTRO PROPOXYPHENE HCl**

*Trade name* Darvon (Lilly)  
*Administration* Oral  
*Dosage forms* Tablets 30 and 60 mg

## DRUG INDEX

**DECAPRYN (Merrell)**

Trade name for Desoxyamine Succinate

**DFCHOLIN (Ames)**

Trade name for Dehydrocholic Acid

**DFCHOLIN SODIUM (Ames)**

Trade name for Sodium Dehydrocholate

**DECIOMYCIN (Lederle)**

Trade name for Demethylchlortetracycline

**DFCORTIN (Schieffelin)**

Trade name for Desoxycorticosterone Acetate

**DEHYDROCHOLIC ACID**

Trade names: Cholan DH (Maltbie) Decholin (Ames), Procholon (Squibb)

Administration Oral

Dosage form Tablet 0.25 Gm

**DELALUTIN (Squibb)**

Trade name for Progesterone

**DELATESTRYL (Squibb)**

Trade name for Testosterone Enanthate

**DELESTROGEN (Squibb)**

Trade name for Estradiol Valerate

**DELTA CORTFF (Upjohn)**

Trade name for Prednisolone

**DELTALIN (Lilly)**

Trade name for Calciferol

**DELTAMIDE (Armour)**

Trade name for Quadri Sulfas Mixture

**DELTAONE (Upjohn)**

Trade name for Prednisone

**DFLTRA (Merck)**

Trade name for Prednisone

**DELVEX (Lilly)**

Trade name for Dithiazanine I

**DELVINAL (Merck)**

Trade name for Vinbarbital Sodium

**DEMECARIUM**

Trade name Humorsol (Merck)

Administration Topical

Dosage form Dropper, 0.25% solution

**DEMECOLGIN**

Not available on commercial drug market

**DFMFROL HCl (Winthrop)**

Trade name for Meperidine HCl

**DEMETHYLCHLORTETRACYCLINE**

Trade name Declomycin (Lederle)

Administration Oral

Dosage form Capsule, 150 mg

**DFNYL (Prenco)**

Trade name for Diphenylhydantoin Sodium

**DFPO ACTH (Upjohn)**

Trade name for Corticotropin

**DEPO CEROCILLIN CHLOROPROCAINE (Upjohn)**

Trade name for Chloroprocaine Penicillin O

**DFPO ESTRADIOL**

Trade name for Estradiol Cyclopentylpropionate

**DEPO HEPARIN (Upjohn)**

Trade name for Heparin Sodium

**DEPO PENICILLIN (Upjohn)**

Trade name for Procaine Penicillin G

**DEPO TESTOSTERONE (Upjohn)**

Trade name for Testosterone Cyclopentylpropionate

**DEPROPANEX (Merck)**

Trade name for Pancreatic Extract

Administration Parenteral

**DERATOL (Brewer)**

Trade name for Calciferol

**DERMA PACK SUN SCREEN (Doak)**

Para aminobenzoic Acid cake

**DERMATONE SOAP (Chicago Pharmacal)**

Phenol soap

**DFRMOLATE (White)**

Detergent cleanser

**DERONIL (Schering)**

Trade name for Dexamethasone

**DFS (Grant)**

Trade name for Diethylstilbestrol

**DFSAMINE (Starr)**

Trade name for Methamphetamine HCl

**DESCOSTERONE (Barry)**

Trade name for Desoxycorticosterone Acetate

**DESCOTONE (Merck)**

Trade name for Desoxycorticosterone Acetate

**DESENEK (Wallace & Tiernan)**

Trade name for Undecylenic Acid

**DICODID (Bilhuber Knoll)**

Trade name for Dihydrocodeinone Bitartrate

**DICUMAROL (Various Manufacturers)**

Trade name for Bishydroxycoumarin

**DICURIN PROCAINE (Lilly)**

Trade name for Merethoxyl ne Procaïne

**DICYCLOMINE HCl**

Trade name Bentyl HCl (Merrell)

Administration Oral intramuscular

Dosage forms Capsule, 10 mg, syrup about 2 mg per ml, ampule, 10 mg per ml

**DIENESTROL**

Trade name Restrol (Central)

Administration Oral, subcutaneous, intramuscular

Dosage forms Tablets, 0.1, 0.5, 1.0, 1.5, and 5.0 mg vial, 5 mg per ml

**DITHOXYN**

Trade name Intracaine HCl (Philadelphia Ampoule)

Administration Parenteral, topical

Dosage forms Ampule, 1 Gm ointments, 2%, 5%

**DIETHYLCARBAMAZINE**

Synonyms Banocide, Caricide

Trade name Hetrazan (Lederle)

Administration Oral

Dosage forms Tablet, 50 mg, syrup, 30 mg per ml

**DIETHYL ETHER**

Synonym for Ether

**DIETHYL PROPANEDIOL**

Trade name Prenderol (Squibb)

Administration Oral

Dosage form Tablet, 0.5 Gm

**DIETHYLPROPION**

Trade names Tenuate (Merrell), Tepanil (National)

Administration Oral

Dosage form Tablet, 25 mg

**DIETHYLSTILBESTROL**

Synonym Stilbestrol

Trade names Bio des (Grant), DES (Grant), Stilbetin (Squibb), and others

Administration Oral intramuscular, rectal

Dosage forms Tablets, 10 mg to 100 mg suppositories 0.1 to 0.5 mg, ampule, 25 mg per ml

**DITHYLSTILBESTROL DIPALMITATE**

Trade name Stilpalmitate (Abbott)

Administration Intramuscular

Dosage form Ampule containing 7 or 14 mg in 1 ml of oil

**DIETHYLSTILBESTROL DIPROPIONATE**

Trade name

Administration

Dosage form Ampules, 0.5, 1.0, and 5.0 mg per ml in oil

**DITHYLSTILBESTROL DIPROPIONATE**

Administration Intramuscular

Dosage form Ampules, 0.5, 1.0, and 5.0 mg per ml in oil

**DIFUSIN (Ortho)**

Trade name for Hyaluronidase

**DIGALEN (Roche)**

Trade name for Partially Purified Digitalis Preparation

**DIGALLOL TRIOLEATE LIQUID**

Trade name Saf Tan (Texas Pharmacal)

Administration Topical

Dosage form As such

**DIGICARDIUM (Rorer)**

Trade name for Partially Purified Digitalis Preparation

**DIGIFOLIN (Ciba)**

Trade name for Partially Purified Digitalis Preparation

**DIGIFORTIS (Parke, Davis)**

Trade name for Partially Purified Digitalis Preparation

**DIGIGLUSIN (Lilly)**

Trade name for Partially Purified Digitalis Preparation

**DIGILANID (Sandoz)**

Administration Oral, rectal intravenous intramuscular

Dosage forms Tablet 0.33 mg suppository, 0.5 mg, vials, 30 and 90 ml, 0.33 mg per ml, ampules 2 and 4 ml, 0.2 mg per ml

**DIGISEALS (Harvey)**

Trade name for Crude Digitalis Leaf

**DIGISIDIN (Winthrop)**

Trade name for Digitoxin

**DIGITALIN POTENT (Merck)**

Trade name for Partially Purified Digitalis Preparation

**DIGITALIN NATIVELLI (Varick)**

Trade name for Digitoxin

**DIGITALIS LEAF**

Trade names Dig seals (Harvey), Digitora (Upjohn)

Administration Oral rectal

Dosage forms Tablets and capsules 0.5 and 1.0 Cat Unit, tincture, 1 Cat Unit per ml

**DEXTROSE**

*Synonym* Glucose

*Administration* Intravenous

*Dosage forms* 5 10 20 and 50% solutions in ampules

**DEXTROSE AND SODIUM GLUCONATE INJECTION**

*Administration* Intravenous subcutaneous

*Dosage forms* A variety of combinations

**DFP**

*Synonym* for Isoflurophate

**DIABINESE (Pfizer)**

*Trade name* for Chlorpropamide

**DIACHYLON OINTMENT (Ulmer)**

*Trade name* for Lead Oleate Ointment

**DIAFEN (Schenley)**

*Trade name* for Diphenylpyraline HCl

**DIAGNEX (Squibb)**

*Trade name* for Quinine Carbacrylic Resin

**DIAGNEX BLUE (Squibb)**

*Trade name* for Azures

**DIAL (Ciba)**

*Trade name* for Allobarbitol

**DIAL SOAP (Armour)**

Hexachlorophene soap

**DIA MER-SULFONAMIDES**

*Sy*

*Ti*

*Ac*

*Dosage forms* Tablets 0.3 0.5 Gm solutions

**DIAMINIDE (Merck)**

*Trade name* for Pyrilamine Maleate

**DIAMOX (Lederle)**

*Trade name* for Acetazolamide

**DIAMTHAZOLF HCl**

*Trade name* Asterol (Roche)

*Dosage forms* Ointment tincture powder 5%

**DIASONE SODIUM (Abbott)**

*Trade name* for Sulfoxone Sodium

**DIASTASE**

*Trade name* Taka Diastase (Parke, Davis)

*Administration* Oral

*Dosage forms* Capsule 0.16 Gm tablet 0.16 Gm liquid about 100 mg per ml

**DIATRINE HCl (Warner)**

*Trade name* for Methaphenilene HCl

**DIATRIZOATE METHYLGLUCAMINE**

*Trade name* Cardografin (Squibb)

*Administration* Intravenous

*Dosage form* Ampule 85%

**DIATRIZOATE SODIUM**

*Trade name* Hypaque Sodium (Winthrop)

*Administration* Intravenous

*Dosage form* Ampule 50%

**DIATRIZOATES SODIUM AND METHYLGLUCAMINE**

*Trade name* Renografin (Squibb)

*Administration* Intravenous

*Dosage form* Ampules 30 60 76%

**DIAZO OXO NORLEUCINE**

*Synonym* DON

Not available on the commercial drug market

**DIBENZYLINE (Smith Kline & French)**

*Trade name* for Phenoxybenzamine HCl

**DIBROMSALICYLALDEHYDE**

*Trade name* Dallyde (Hynson)

*Administration* Topical

*Dosage forms* Solution 0.5% ointment and powder 2%

**DIBUCAINE HCl**

*Trade name* Nupercaine HCl (Ciba)

*Administration* Parenteral topical

*Dosage forms* A variety of forms

**DIBULINE SO<sub>4</sub> (Merck)**

*Trade name* for Dibutolne SO

**DIBUTOLINE SO**

*Trade name* Dibuline SO (Merck)

*Administration* Intramuscular subcutaneous

*Dosage form* Ampule 25 mg per ml

**DICALCIUM PO**

*Administration* Oral

*Dosage form* Tablet 0.5 Gm

**DICHLORPHENAMIDE**

*Trade name* Darvonide (Merck)

*Administration* Oral

*Dosage form* Tablet 50 mg

**DIODOHYDROXYQUINOLIN**

Synonym for Dihydroxyquin

**DILABII SODIUM** (Breon)

Trade name for Sodium Dehydrocholate

**DILANTIN SODIUM** (Parke, Davis)

Trade name for Diphenylhydantoin Sodium

**DII AUDID HCl** (Bilhuber Knoll)

Trade name for Dihydromorphinone HCl

**DIMENFORMON** (Organon)

Trade name for Estradiol

**DIMENFORMON BENZOATE** (Organon)

Trade name for Estradiol Benzoate

**DIMENFORMON DIPROPIONATE** (Organon)

Trade name for Estradiol Dipropionate

**DIMENHYDRINATE**

Trade name Dramamine (Searle)

Administration Oral, rectal, intramuscular, intravenous

Dosage forms Tablet, 50 mg, liquid, 3 mg per ml, suppository, 100 mg, ampule, 50 mg per ml

**DIMERCAPROL**

Synonym BAL

Administration Intramuscular

Dosage form Ampule, 4.5 ml containing 150 mg in oil

**DIMETANT** (Robins)

Trade name for Parabromdylamine Maleate

**DIMETHISOQUIN HCl**

Trade name Quotane HCl (Smith, Kline & French)

Administration Topical

Dosage forms Ointment, lotion, 0.5%

**DIMETHOXANATE HCl**

Trade name Cothra (Ayerst)

Administration Oral

Dosage form Syrup, 5 mg per ml

**DIMETHYLANE** (National)

Trade name for Promoxoline

**DIMETHYL TUBOCURARINE Cl**

Trade name Mecostrin Cl (Squibb)

Administration Intravenous

Dosage form Vial, 1 mg per ml

**DIMETHYL TUBOCURARINE I**

Trade name Metubine I (Lilly)

Administration Intravenous

Dosage form Ampule, 0.5 and 1.0 mg per ml

**DIMOTHYN** (Flint, Eaton)

Trade name for Dihydroxy Aluminum Amino acetate

**DINACRIN** (Winthrop)

Trade name for Isoniazid

(Squibb), Regutol (Pharmacs)

Administration Oral

Dosage forms Capsules, 50 mg, liquid, 10 mg per ml, tablets, 50 and 100 mg

**DIDOQUIN** (Searle)

Trade name for Dihydroxyquin

**DIODRAST** (Winthrop)

Trade name for Iodopyracet

**DIOGYN** (Pfizer)

Trade name for Estradiol

**DIOGYN B** (Pfizer)

Trade name for Estradiol Benzoate

**DIOGYN F** (Pfizer)

Trade name for Ethinyl Estradiol

**DIOGYNETS** (Pfizer)

Trade name for Estradiol

**DIOLANDRONE** (Carnrick)

Trade name for Methandriol

**DIOLOSTENT**

Synonym for Methandriol

**DIOLOXOL** (Carnrick)

Trade name for Mephensesin

**DIONOSII** (Glaxo)

Trade name for Propyl iodine

**DIOTHANE HCl** (Merrell)

Trade name for Dipiperdon HCl

**DIOVAC** (Gray)

Trade name for Diocetyl Sodium Sulfosuccinate

**DIOXYLINE**

Trade name Paveril (Lilly)

Administration Oral

Dosage form Tablets, 100 and 200 mg

**DI PARALENT HCl** (Abbott)

Trade name for Chlorcyclizine HCl

**DIPAXIN** (Upjohn)

Trade name for Diphenadone



**D O F (Breon)**

Trade name for Methamphetamine HCl

**DOLITRONE (Merrell)**

Not available on the commercial drug market

**DOIOPHINE HCl (Lilly)**

Trade name for Methadone HCl

**DOMF PASTT (Dome)**

Zinc Oxide paste

**DOMIBORO (Dome)**

Trade name for Aluminum Acetate Solution

**DOMICONE (Dome)**

Silicone protective cream

**DOMIPHEN Br**

Trade name Bradosol Br (Ciba)

Administration Topical

Dosage form Lozenge 15 mg with 25 mg Benzocaine

**DOMOLENE (Dome)**

Detergent cleanser

**DON**

Synonym for DULO Oxo Norleucine

**DORAXAMIN (Dorsey)**

Trade name for Dihydroxy Aluminum Aminoacetate

**DORBANE (Schenley)**

Trade name for Dihydroxyanthraquinone

**DORIDEN (Ciba)**

Trade name for Glutethimide

**DORMETHAN (Smith Dorsey)**

Trade name for Dextromethorphan Br

**DORMIN (Dormin)**

Trade name for Methapyrilene HCl

**DORMISON (Schering)**

Trade name for Methylparafynol

**DORNAVAC (Merck)**

Trade name for Pancreatic Dornase

**DORSACAINE HCl (Dorsey)**

Trade name for Benoxinate HCl

**DORSAPHYLLIN (Dorsey)**

Trade name for Theophylline Sodium Glycinate

**DORSULFAS (Smith Dorsey)**

Trade name for Acet Diamer Sulfonamides

**DORYL (Merck)**

Trade name for Carbachol

**DOVE SOAP (Lever)**

Superfatted soap

**DOXICAL (Lloyd)**

Trade name for Calcium Dioctyl Sulfosuccinate

**DOXINATE (Lloyd)**

Trade name for Dioctyl Sodium Sulfosuccinate

**DOXOL (Blair)**

Trade name for Dioctyl Sodium Sulfosuccinate

**DOXYFED (Raymer)**

Trade name for Methamphetamine HCl

**DOXYLAMINE SUCGINATE**

Trade name Decapryn (Merrell)

Administration Oral

Dosage forms Tablets, 125 and 25 mg  
syrup 125 mg per ml**DRAMAMINE (Searle)**

Trade name for Dimenhydrinate

**DRAMICILLIN (White)**

Trade name for Potassium Penicillin

**DRINALFA (Squibb)**

Trade name for Methamphetamine HCl

**DRISDOL (Winthrop)**

Trade name for Calciferol

**DROPCILLIN (White)**

Trade name for Potassium Penicillin G

**DROSTENF (Ascher)**

Trade name for Methandriol

**DROXOLAN (Breon)**

Trade name for Dihydroxycholanic Acid

**DULCOLAX (Geigy)**

Trade name for Bisacodyl

**DUOGRAFIN (Squibb)**

Trade name for Methylglucamine D atrizoate and Iodipamide

**DUO STREP (Merck)**

Trade name for Streptoduoctin

**DUO-SULFANYL (Arlington)**

Trade name for Diamer Sulfonamides

**DIPERODON HCl**

*Trade name* Dothine HCl (Merrell)  
*Administration* Topical  
*Dosage forms* A variety of forms

**DIPHASOL TESTOSTERONE (Kremers Urban)**

*Trade name* for Testosterone

**DIPHENANIL METHYLSULFATE**

*Trade name* Prantal Methylsulfate (Schering)  
*Administration* Oral subcutaneous intramuscular topical  
*Dosage forms* Tablet 100 mg ampule 25 mg per ml cream 20 mg per Gm

**DIPHENADIONE**

*Trade name* D pax n (Upjohn)  
*Administration* Oral  
*Dosage form* Tablets 1 and 5 mg

**DIPHENAN (Burroughs Wellcome)**

*Trade name* for Benzylphenylcarbamate

**DIPHENHYDRAMINE HCl**

*Trade name* Benadryl (Parke Davis)  
*Administration* Oral parenteral topical  
*Dosage forms* Capsule 50 mg fluid 25 mg per ml vials 10 mg per ml

**DIPHENTOIN (Massengill)**

*Trade name* for Diphenylhydantoin Sodium

**DIPHENYLHYDANTOIN SODIUM**

*Synonym* Phenyton  
*Trade names* Denyl (Premo) Dilantin Sodium (Parke Davis) Diphentoin (Massengill) and others  
*Administration* Oral  
*Dosage form* Capsule 100 mg

**DIPHENYLPYRALINE HCl**

*Trade names* Difen (Schenley) H spril (Smith Kline & French)  
*Administration* Oral  
*Dosage form* Tablet 2 mg

**DIPYRONE**

*Trade names* Methampyrone (Testagar) Narone (Ulmer) Nariate (Harvey), Novaldin (Winthrop)  
*Administration* Oral intramuscular subcutaneous  
*Dosage forms* Tablet 0.3 Gm ampule 0.5 Gm per ml

**DIRNATE**

Not available on commercial drug market

**DISIPAL (Riker)**

*Trade name* for Orphenadrine HCl

**DISOMER (White)**

*Trade name* for Dexbrompheniramine Maleate

**DISTREPTOCIN SO (Lilly)**

*Trade name* for Streptoduocin

**DISTRYCIN (Squibb)**

*Trade name* for Streptoduocin

**DISULFIRAM**

*Trade name* Antabuse (Ayerst)  
*Administration* Oral  
*Dosage form* Tablet 0.5 Gm

**DISULFYN (Rorer)**

*Trade name* for Dia Mer Sulfonamides

**DITHIAZAMINE I**

*Trade names* Abminthic (Pfizer), Delvex (Lilly), Telmid (Lilly)  
*Administration* Oral  
*Dosage forms* Tablets 50 100 and 200 mg

**DITUBIN (Schering)**

*Trade name* for Isoniazid

**DIUCARDYN (Ayerst)**

*Trade name* for Mercaptopurine

**DIUMFRIN (C. D. Smith)**

*Trade name* for Mercurophylline

**DIURETIN (Bilhuber Knoll)**

*Trade name* for Theobromine and Sodium Salicylate

**DIURIL (Merck)**

*Trade name* for Chlorothiazide

**DIURIL SODIUM (Merck)**

*Trade name* for Chlorothiazide Sodium

**DIURNAL-PENICILLIN (Upjohn)**

*Trade name* for Procaine Penicillin G

**DIVINYL OXIDE**

*Synonym* for Vinyl Ether

**DOCA ACETATE (Organon)**

*Trade name* for Desovycort corticosterone Acetate

**DOCIBIN (Walker)**

*Trade name* for Cyanocobalamin

**DODECAVITE (U. S. Vitamin)**

*Trade name* for Cyanocobalamin

**DODEKROID (Riker)**

*Trade name* for Cyanocobalamin



**ENZEON (Breco)**

Trade name for Chymotrypsin

**EPHEDRINE**

Trade name Manadrin (Endo)

Administration Topical

Dosage form Aqueous or oily 1% solution

**EPHEDRINE HCl**

Synonym Racephedrine HCl

Trade names Efedron HCl (Hart), Ephedronin (Merck)

Administration Intramuscular or subcutaneous

Dosage forms Tablets, 30, 60 mg, ampule, 50 mg per ml

**EPHEDRINE SO.**

Trade name Isfedrol (Blue Line)

Administration Oral, parenteral

Dosage forms Tablet, 25 mg, ampule, 25 mg

**I-EPHENAMINE PENICILLIN G**

Trade name Compenamine (CSC)

Administration Intramuscular

Dosage form Ampule, 300,000 units per ml

**EPHETONIN (Merck)**

Trade name for Ephedrine HCl

**EPHYNAL (Roche)**

Trade name for Tocopherols, Mixed

**EPINEPHRINE**

Trade name Adrenalin (Parke, Davis)

Administration Parenteral

Dosage form Ampule, 1 500, in oil

**EPINEPHRINE BITARTRATE**

Trade name Suprarenin (Winthrop)

Administration Parenteral

Dosage forms Ampules, 1 500 in oil and 1 1,000 in saline, bottles, 10 ml of 1 1,000

**EPINEPHRINE HCl**

Trade names Adrin (Merck), Adrenalin HCl (Parke, Davis), Episcorb (Paschall), Supranephrin (Rorer), Sus-Phrine (Brewer), Vasodrine (Premo)

Administration Subcutaneous, intravenous, intracardiac, inhalation

Dosage forms Ampule, vial, 1 1,000, 1 2,500, 1 10,000

**EPINEPHRINE PO.**

Trade name Phosfo-Nefrin (Schueffelin)

Administration Subcutaneous

Dosage form Solution, 1 1,000

**EPISCORB (Paschall)**

Trade name for Epinephrine HCl

**EPOXYMETHAMINE Br**

Synonym for Methscopolamine Br

**EPROLIN (Lilly)**

Trade name for Tocopherols, Mixed

**FPSILAN (Warren-Teed)**

Trade name for Tocopherols, Mixed

**FPSOM SALTS**Synonym for Magnesium SO<sub>4</sub>**FQUANIL (Wyeth)**

Trade name for Meprobamate

**EQUINE GONADOTROPIN**

Trade names Equinex (Ayerst), Gonadogen (Upjohn)

Administration Intramuscular

Dosage forms Ampules of varying dosage

**FQUINEX (Ayerst)**

Trade name for Equine Gonadotropin

**EQUIPHYSIN (Harvey)**

Trade name for Pituitary Gonadotropin

**ERGOMAR (Nordson)**

Trade name for Ergotamine Tartrate

**ERGOMETRINE MALEATE**

Synonym for Ergonovine Maleate

**ERGONOVINE MALEATE**

Synonyms Ergometrine, Ergostetrine, Ergotocine

Trade name Ergotrate Maleate (Lilly)

Administration Oral, intravenous, intramuscular

Dosage forms Tablet, 0.2 mg, ampule, 0.2 mg per ml

**ERGONOVINE TARTRATE**

Trade name Basergin (Sandoz)

Administration Oral, intramuscular, intravenous, subcutaneous

Dosage forms Ampule, 0.2 mg per ml, tablet, 0.25 mg

**ERGOSTETRINE**

Synonym for Ergonovine

**ERGOT**

Trade name Ergotole (Merck)

Administration Oral, intramuscular

Dosage forms Extract, fluidextract

**ERGOTAMINE TARTRATE**

Trade names Ergomar (Nordson), Gynergen (Sandoz)

Administration Oral, subcutaneous, intramuscular

Dosage forms Tablet, 1 mg, ampule, 0.5 mg per ml

# DRUG INDEX

## **DUOZINE (Abbott)**

Trade name for Dia Mer Sulfonamides

## **DURABOLIN (Organon)**

Trade name for Nandrolone Phenpropionate

## **DURACILLIN (Lilly)**

Trade name for Procaine Penicillin G

## **DYCLONE (Pitman Moore)**

Trade name for Dyclonine HCl

## **DYCLONINE HCl**

Trade name Dyclone (Pitman Moore)

Administration Topical

Dosage forms Cream 1% solution 0.5%

## **DYLEPHRIN (Irwin Neisler)**

Aerosol spray Epinephrine HCl 2.5% Atropine SO 0.5%

## **ECHOTHIOPHATE**

Synonym Phospholine I

Not available on commercial drug market

## **ECOFROL (Breon)**

Trade name for Tocopherols Mixed

## **FCOLID Cl (Ciba)**

Trade name for Chlorisondamine Cl

## **LCOTRIN (Smith Kline & French)**

Trade name for Acetylsalicylic Acid

## **ECTYLURFA**

Trade name Nostyn (Ames)

Administration Oral

Dosage form Tablet 0.3 Gm

## **EDATHAMIL CALCIUM DISODIUM**

Synonyms EDTA Calcium Disodium Chelate

Trade names Versenate Calcium Disodium (Riker)

Administration Intravenous

Dosage form Ampule 200 mg per ml

## **EDATHAMIL DISODIUM**

Trade names Endrate (Abbott) Sodium Versenate (Riker)

Administration Intravenous

Dosage form Ampule 3 Gm in 10 ml

## **EDIOL (Schenley)**

Trade name for Fat Emulsion Oral

## **EDROPHONIUM Cl**

Trade name Tensilon Cl (Roche)

Administration Intravenous

Dosage form Ampule 10 mg per ml

## **EFEDRON HCl (Hart)**

Trade name for Ephedrine HCl

## **EFROXINE (Maltbie)**

Trade name for Methamphetamine HCl

## **ELATFRIN**

Administration Oral

Dosage form As such

## **FLIPTEN**

Not available on commercial drug market

## **ELKOSIN (Ciba)**

Trade name for Sulfisomidine

## **ELORINE SO (Lilly)**

Trade name for Tricyclamol SO

## **EMETINE BISMUTH I**

Administration Subcutaneous intramuscular

Dosage forms Various forms

## **EMETINE HCl**

Administration Subcutaneous intramuscular

Dosage forms Various forms

## **FMETROL (Winney)**

Trade name for Phosphorated Carbohydrate Solution

## **FMULSION BASE (Vimay)**

Ointment base

## **FNDOTHYRIN (Harrower)**

Trade name for Thyroglobulin

## **ENDRATE (Abbott)**

Trade name for Edathamil Disodium

## **ENELONE (Arlington)**

Trade name for Pregnenolone

## **ENKIDE (Brewer)**

Trade name for Potassium I

## **ENOVID (Searle)**

Trade name for Norethynodrel

## **ENTEROVIOFORM (Ciba)**

Trade name for Iodochlorhydroxyquin

## **ENTODON (Winthrop)**

Trade name for Propofol

## **ENTROMONE (Endo)**

Trade name for Chorionic Gonadotropin

## **ENTSUFON**

Trade name pilsoderm (Winthrop)

Administration Topical

Dosage form As such

## **ENZACTIN (Ayerst)**

Trade name for Triacetin

**ESTRIFOL (Premo)**

Trade name for Estrogenic Substances, Conjugated

**ESTRIOL**

Trade name Theclol (Parke, Davis)

Administration Oral

Dosage form Capsule, 0.24 mg

**ESTROGENIC SUBSTANCES, CONJUGATED**

Trade names Amnestrogen (Squibb), Conestron (Wyeth), Estrifol (Premo), Hormosteril (Miller), Menogen (Lilly), Premarin (Ayerst)

Administration Oral

Dosage forms Tablets, 0.3, 0.6, 1.25, and 2.5 mg liquid, 0.16 mg per ml

**ESTRONE**

Trade names Amniotin (Squibb), Estru-

**ESTRUGENONE (Kremers Urban)**

Trade name for Estrone

**ESTRUSOL (C. D. Smith)**

Trade name for Estrone

**ETALATE (Parke, Davis)**

Trade name for Ethylamine Oleate

**ETAMON Cl (Parke, Davis)**

Trade name for Tetraethylammonium Cl

**ETHAVERINE HCl**

Administration Oral, intravenous

Dosage forms Tablet, 32 mg, ampule, 20 mg per ml

**ETHICHLORVYNOL**

Trade name Placidyl (Abbott)

Administration Oral

Dosage form Capsules 100, 200, and 500 mg

**ETHIFR**

Synonyms Ethyl Ether, Diethyl Ether

Administration Inhalation

Dosage form Containers as such

**ETHINAMATE**

Trade name Valmid (Lilly)

Administration Oral

Dosage form Tablet 0.5 Gm

**ETHINORAL (C. D. Smith)**

Trade name for Ethinyl Estradiol

**ETHINYL ESTRADIOL**

Trade names Diogyn E (Pfizer), Esteed (Warren Teed), Estinyl (Schering), Ethinoral (C. D. Smith), Eticylol (Ciba), Inestra (Merck), Lynoral (Organon), Oradiol (VanPelt & Brown), Orestralyn (McNeil)

Administration Oral

Dosage forms Tablets, 0.01, 0.02, 0.05, 0.5 mg liquid, 0.004, 0.0075 mg per ml

**ETHIODOL (Fougera)**

Trade name for Ethyl Ester Iodinated Poppy Seed Oil

**ETHISTERONE**

Trade names Lutocylol (Ciba), Ora Lutin (Parke Davis), Pranone (Schering), Progestoral (Organon), Proluton C (Schering), Trostinone (Abbott), and others

Administration Oral, buccal

Dosage form Tablets, 5, 10, 25 mg

**ETHOHEPTAZINE CITRATE**

Trade name Zactane (Wyeth)

Administration Oral

Dosage form Tablet, 75 mg

**ETHOHEXADIOL**

Administration Topical

Dosage form As such

**ETHOPROPAZINE HCl**

Trade name Parsidol (Warner Chilcott)

Administration Oral

Dosage form Tablets, 10, 50, and 100 mg

**ETHOTOIN**

Trade name Peganone (Abbott)

Administration Oral

Dosage form Tablets, 0.25 and 0.5 Gm

**ETHOXAZENE**

Trade name Serenium (Squibb)

Administration Oral

Dosage form Tablet, 100 mg

**ETHOXZOLAMIDE**

Trade name Cardase (Upjohn)

Administration Oral

Dosage form Tablet, 125 mg

**ETHYLAMINE OLFATE**

Trade name Etalate (Parke, Davis)

Administration Intravenous

Dosage form Ampule, 5%

**ETHYL AMINO BENZOATE**

Trade names Anesthesin (Abbott), Benzocaine (Merck)

Dosage forms Various forms and concentrations from 1 to 20% available

## DRUG INDEX

## FRGOTOCINE

Synonym for Ergonovine

## ERGOTOLE (Merck)

Trade name for Ergot Extract

## ERGOTRATF MALFATE (Lilly)

Trade name for Ergonovine Maleate

## ERTRON (Whittier)

Trade name for Calciferol

## ERYTHRITYL TETRANITRATE

Trade name Cardlate (Burroughs Wellcome) Erythrol Tetranitrate (Merck)

Administration Oral

Dosage form Tablets 15 and 30 mg

## ERYTHROCIN (Abbott)

Trade name for Erythromycin

## ERYTHROCIN LACTOBIONATE (Abbott)

Trade name for Erythromycin Lactobionate

## ERYTHROCIN STEARATE (Abbott)

Trade name for Erythromycin Stearate

## ERYTHROL TETRANITRATE (Merck)

Trade name for Erythryl Tetranitrate

## ERYTHROMYCIN

Trade name Erythrocin (Abbott) Erythromycin (Lilly)

Administration Oral topical

Dosage form Tablets 100 and 200 mg

## ERYTHROMYCIN LACTOBIONATE

Trade name Erythrocin Lactobionate (Abbott)

Administration Parenteral topical

Dosage form Ampule 30 mg per ml

## ERYTHROMYCIN PROPIONATE

Trade name Erosone (Lilly)

Administration Oral

Dosage form Tablets 125 and 250 mg

## ERYTHROMYCIN STEARATE

Trade name Erythrocin Stearate (Abbott)

Administration Oral

Dosage form Tablets 100 50 mg

## ESCHATIN (Parke Davis)

Trade name for Adrenal Cortex Extract

## ESERINE SALICYLATE

Synonym for Physostigmine

## ESIDRIN (Ciba)

Trade name for Hydrochlorothiazide

## ESKACILLIN (Smith Kline &amp; French)

Trade name for Procaine Penicillin G

## ESKADIAMER (Smith Kline &amp; French)

Trade name for Diamer Sulfonamides

## FSKASERP (Smith Kline &amp; French)

Trade name for Reserpine

## ESOMID CL (Ciba)

Trade name for Hexamethonium Cl

## ESORB (Wyeth)

Trade name for Tocopherols Mixed

## ESTEED (Warren Teed)

Trade name for Ethinyl Estradiol

## ESTINYL (Schering)

Trade name for Ethinyl Estradiol

## ESTRADIOL

Trade names Aquadrol (National Drug)

Aquol (Estro) Drogyn (Pfizer) Drogyns

(Pfizer) Dmenformon (Organon) Estrad

dine (Rorer) Ovocyl (Ciba) Progynon

(Schering)

Administration Oral vaginal intramuscular

Dosage forms Tablets 0.1 0.2 0.5 mg

pellet 25 mg vials 0.25 1.0 mg per ml

## ESTRADIOL BENZOATE

Trade names Dmenformon Benzoate (Or

ganon) Drogyn B (Pfizer) Ovocyl (Ben

zoate (Ciba) Progynon B (Schering)

Solestro (Merck)

Administration Intramuscular

Dosage forms Ampules 0.166 0.33 1.66

and 2.0 mg per ml n o l

## ESTRADIOL CYCLOPENTYLPROPIO

NATE

Trade name Depo-Estradiol (Upjohn)

Administration Intramuscular

Dosage form Vials 1 and 5 mg per ml

## ESTRADIOL DIPROPIONATE

Trade names Dmenformon Dpropionate

## ESTRADIOL VALERATE

Trade name Delestrogen (Squibb)

Administration Intramuscular

Dosage form Vials 10 mg per ml

## ESTRADURIN (Ayerst)

Trade name for Polyestradiol PO

## ESTRALDINE (Rorer)

Trade name for Estradiol

## ESTRALDINE (Rorer)

Trade name for Estradiol

## ESTRATE (Lakeside)

Trade name for Alphaestradiol Triacetate

**FERRIC OXIDES**

Used in Neocalamine and other protectives

**FERROCHOLINATE**

Synonym Iron Choline Citrate

Trade names Chel Iron (Kinney), Ferrolip (Flint, Eaton)

Administration Oral

Dosage forms Tablet 1 Gm (120 mg Fe)  
syrup 16 mg Fe per ml

**FERROLIP (Flint, Eaton)**

Trade name for Ferrocholine

**FERRONORD (Nordmark)**

Trade name for Aminoacetic Ferrous SO<sub>4</sub> Complex

**FERROPYRIN (Bilhuber Knoll)**

Trade name for Phenylmethylpyrazolon Ferric Cl

**FERROUS CO<sub>3</sub>**

Trade name Fecarb (Ayerst)

Administration Oral

Dosage form Tablet, 200 mg

**FERROUS FUMARATE**

Trade names Firon (Beard), Fumeron (Standex), Toleron (Mallinckrodt)

Administration Oral

Dosage form Tablets, 200 and 350 mg

**FERROUS GLUCONATE**

Trade names Fergon (Winthrop) Irox (Cole), Nionate (Nion)

Administration Oral

Dosage forms Tablets, 0.16 and 0.32 Gm  
elixir 60 mg per ml

**FERROUS LACTATE**

Administration Oral

Dosage form As prescribed

**FERROUS SO<sub>4</sub>**

Trade names Feosol (Smith, Kline & French) Ferralyn (Lannett), Sulferrous (Chicago)

Administration Oral

Dosage forms Tablets capsules, 0.2 and 0.3 Gm

**FIBRIN FOAM**

Administration Topical

Dosage form As such

**FIBRINOGEN (BOVINE)**

Trade name Fibrigen (Merrell)

Administration Oral

Dosage form Vial 1.5% fibrinogen and 0.5% cephalin

**FIBRINOGEN (HUMAN)**

Trade name Parenogen (Cutter)

Administration Intravenous

Dosage form Vial, 1 Gm

**FIBROGEN (Merrell)**

Trade name for Fibrinogen (Bovine)

**FIBROLASIN, HUMAN**

Trade name Actase (Ortho)

Administration Intravenous

Dosage form Vial, 50,000 units

**FIRON (Beard)**

Trade name for Ferrous Fumarate

**FLAVAXIN (Winthrop)**

Trade name for Riboflavin

**FLANEDIL (Lederle)**

Trade name for Gallamine Triethiodide

**FLEET ENEMA (Fleet)**

Trade name for Sodium PO<sub>4</sub> solution

**FLEXIN (McNeil)**

Trade name for Zoxazolamine

**FLO CILLIN (Bristol)**

Trade name for Procaine Penicillin G

**FLORANTYRONE**

Trade name Zanol (Searle)

Administration Oral

Dosage form Tablet, 250 mg

**FLORAQUIN (Searle)**

Trade name for Diodoquin

**FLORINEF (Squibb)**

Trade name for Fludrocortisone Acetate

**FLOROPRYL (Merck)**

Trade name for Isoflurophate

**FLUDROCORTISONE ACETATE**

Synonym Fluorohydrocortisone Acetate

Trade names Alflorone (Merck), F Cortef (Upjohn), Flornef (Squibb)

Administration Oral, topical

Dosage forms Tablets, 0.1, 1.0 mg ointment, lotion 0.05, 0.1, 0.2%

**FLUMETHIAZIDE**

Trade name Ademol (Squibb)

Administration Oral

Dosage form Tablet, 500 mg

**FLUORESCCEIN SODIUM**

Administration Topical

Dosage form Solution 2%

**ETHYL BISCUONACETATE**

*Trade name* Tromexan Ethyl Acetate (Geigy)

*Administration* Oral

*Dosage form* Tablets scored 150 and 300 mg

**ETHYL CHLORIDE**

*Administration* Inhalation

*Dosage form* Spray bottles as such

**ETHYLDIMETHYLANMONIUM Br**

*Trade name* Ambutoonium Br (Wyeth)

*Administration* Oral

*Dosage form* Tablet 10 mg

**ETHYLENE**

*Administration* Inhalation

*Dosage form* Cylinders as such

**ETHYLEPHEDRINE HCl**

*Trade name* Nethamine HCl (McNeil)

*Administration* Oral

*Dosage form* Capsule 25 mg tablet 50 mg

**ETHYL ESTER IODINATED POPPY SEED OIL**

*Trade name* Ethiodol (Fougera)

*Administration* Instillation

*Dosage form* Ampule as such

**ETHYL ETHER**

Synonym for Ether

**ETHYL IODOPHENYLUNDECYLATE**

Synonym for Iophendylate

**ETHYLNOREPINEPHRINE HCl**

*Trade name* Butanefrine HCl (Winthrop)

Bronkophrine HCl (Breon)

*Administration* Subcutaneous intramuscular

*Dosage form* Vial 2 mg per ml

**ETIOLOL (Ciba)**

*Trade name* for Ethinyl Estradiol

**L-TOPLEX (U S Vitamin)**

*Trade name* for Tocopherols Mixed

**EUCALYPTOL**

*Administration* Topical

*Dosage form* As such

**EUCATROPINE HCl**

*Trade name* Euphthalmine HCl (Warner Chilcott)

*Administration* Topical

*Dosage form* As such

**EUPHTHALMINE HCl (Warner Chilcott)**

*Trade name* for Eucatropine HCl

**FUQUININE**

Synonym for Quinine Ethylcarbonate

**FURAX (Geigy)**

*Trade name* for Crothamiton

**EURESOL (Bibbier Knoll)**

*Trade name* for Resorcinol Monoacetate

**FVANS BLUE**

*Administration* Intravenous

*Dosage form* Ampule 0.5% further diluted

**EVIPAL SODIUM (Winthrop)**

*Trade name* for Hexobarbital Sodium

**EVRONAL SODIUM (Evron)**

*Trade name* for Secobarbital Sodium

**EXORBIN (Ayerst)**

*Trade name* for Polyamine Methylene Resin

**EXPANDEX (CSC)**

*Trade name* for Dextran

**FACTOR T**

Not available on the commercial drug market

**FAT EMULSION ORAL**

*Trade name* Ediol (Schenley)

*Administration* Oral

*Dosage form* Emulsion 50% fat 12.5% sucrose

**F CORTEF (Upjohn)**

*Trade name* for Fludrocortisone Acetate

**FECARB (Ayerst)**

*Trade name* for Ferrous CO<sub>3</sub>

**FEDU**

*Designation* for Fleet Enema Disposable Unit

**FEMERGIN**

Synonym for Ergotamine Tartrate

**FENDON (American Pharmaceutical)**

*Trade name* for Acetaminophen

**FFOSOL (Smith Kline & French)**

*Trade name* for Ferrous SO

**FERGON (Winthrop)**

*Trade name* for Ferrous Gluconate

**FERRALYN (Lanett)**

*Trade name* for Ferrous SO

**FERRIC GLYCEROPHOSPHATE**

*Administration* Oral

*Dosage form* As prescribed

**FERRIC HYPOPHOSPHATE**

*Administration* Oral

*Dosage form* As prescribed

**GALLAMINE TRIETHIODIDE***Trade name* Flaxedil (Lederle)*Administration* Intravenous*Dosage form* Vial, 20 mg per ml**GALLOGEN (Massengill)***Trade name for* p-Tolylmethylcarbinol Monod-camphorate Diethanolamine**GALLOTANNIC ACID***Synonym for* Tannic Acid**GAMMA BENZENE HEXACHLORIDE***Trade names* Gexane (Strassenburgh), Kwell (Reed & Cunnick)*Administration* Topical*Dosage forms* Ointment and liquid, 1%**GAMMACORTEN (Ciba)***Trade name for* Dexamethasone**GAMOPHEN (Ethicon)***Trade name for* Hexachlorophene**GAMOPHEN SURGICAL SOAP (Ethicon)***Hexachlorophene soap***GANTRISIN (Roche)***Trade name for* Sulfisoxazole**GANTRISIN ACETYL (Roche)***Trade name for* Acetyl Sulfisoxazole**GANTRISIN DIETHANOLAMINE (Roche)***Trade name for* Sulfisoxazole Diethanolamine**GASTRIC MUCIN***Administration* Oral*Dosage form* As such**GASTROGRAFIN (Squibb)***Trade name for* Methylglucamine Diatrizoate**GASTULORIC (Watren-Teed)***Trade name for* Glutamic Acid HCl**GELATIN SOLUTION, PURIFIED***Synonym* Oxypolygelatin*Trade name* Plazmoid (Upjohn)*Administration* Intravenous*Dosage form* Bottle, 50 mg per ml**GELATIN SPONGE, ABSORBABLE***Trade name* Gelfoam (Upjohn)*Administration* Topical*Dosage forms* Powder, sponges, compressed sponges, packs, cones of various sizes**GELUSIL (Warner Chilcott)***Trade name for* Magnesium Trisilicate*Aluminum Hydroxide***GEMONIL (Abbott)***Trade name for* Metharbital**GFNTERSAL (Ortho)***Trade name for* Methylosaniline**GFNTIAN***Administration* Oral*Dosage forms* As such, elixir, extract, compound tincture**GENTIAN VIOLET***Synonym for* Methylosaniline Cl**GENTRAN (Baxter)***Trade name for* Dextran**GESTASOL (National)***Trade name for* Chorionic Gonadotropin**GEXANT (Strassenburgh)***Trade name for* Gamma Benzene Hexachloride**GINGER***Administration* Oral*Dosage form* Fluidextract**GITALIGIN (White)***Trade name for* Gitalin**GITALIN***Trade name* Gitalgin (White)*Administration* Oral*Dosage form* Tablet, 0.5 mg**GLARUBIN (Massengill)***Trade name for* Glaucarubin**GLAUBER'S SALT***Synonym for* Sodium Sulfate**GLAUCARUBIN***Trade name* Glarubin (Massengill)*Administration* Oral*Dosage form* Tablet, 50 mg**GLOBULIN INSULIN WITH ZINC***Synonym for* Globulin Zinc Insulin**GLOBULIN ZINC INSULIN***Synonym* Globulin Insulin with Zinc*Administration* Subcutaneous*Dosage form* Vials, 40 and 80 units per**GLUCOPHYLLINE (Abbott)***Trade name for* Theophylline Methyl

**FLUOROHYDROCORTISONE ACETATE**

Synonym for Fludrocortisone Acetate

**FLUOROMETHOLONE**

Trade name Oxalone

Administration Topical

Dosage form Cream 0.025%

**FLUOTHANE (Ayerst)**

Trade name for Halothane

**FLUOXYMESTERONE**

Trade names Halotest n (Upjohn) Ultan  
dren (Ciba)

Administration Oral

Dosage forms Tablets 2 and 5 mg

**FLUPHENAZINE DIHYDROCHLORIDE**

Trade names Permutil (White) Prolixin  
(Squibb)

Administration Oral

Dosage form Tablets 0.25, 1, 2.5, and 5 mg

**FOLATE SODIUM**

Trade name Folvite Sodium (Lederle)

Administration Parenteral

Dosage form Aq. sol. 15 mg per ml

**FOLIC ACID**

Trade name Folvite (Lederle)

Administration Oral intramuscular

Dosage forms Tablets, 5, 10 and 20 mg  
ampule 15 mg per ml

**FOLLUTEIN (Squibb)**

Trade name for Chorionic Gonadotropin

**FOLVITE (Lederle)**

Trade name for Folic Acid

**FOLVITE SODIUM (Lederle)**

Trade name for Folate Sodium

**FORTHANE (Lilly)**

Trade name for Methylhexamine

**FOSTEX CREAM SHAMPOO (Fostex)**

Antifungal medicated shampoo

**FOWLER'S SOLUTION**

Synonym for Potassium Arsenite Solution

**FOXALIN (Grant)**

Trade name for Digitoxin

**FRENQUEL (Merrell)**

Trade name for Azacyclonol HCl

**FRUCTOSE**

Synonym Levulose

Trade name Levugen (Mead Johnson)

Administration Intravenous

Dosage form Ampules, 10%

**FUADIN (Winthrop)**

Trade name for Stibophen

**FUGILLIN (Upjohn)**

Trade name for Fumagillin

**FULVICIN (Schering)**

Trade name for Griseofulvin

**FUMAGILLIN**

Trade names Fum di (Abbott) Fugilin  
(Upjohn)

Administration Oral

Dosage form Tablet 10 mg

**FUMERON (Standex)**

Trade name for Ferrous Fumarate

**FUMIDIL (Abbott)**

Trade name for Fumagillin

**FUNGACETIN (Harvey)**

Trade name for Triacetin

**FUNGIZONE (Squibb)**

Trade name for Amphotericin B

**FURADANTIN (Eaton)**

Trade name for Nitrofurantoin

**FURALTADONE**

Trade name Altafur (Eaton)

Administration Oral

Dosage form Tablets, 50 and 250 mg

**FURASTOR (Eaton)**

Trade name for Nitrofurzuryl Methyl Ether

**FURAZOLIDONE**

Trade names Furoxone (Eaton), Tricofuron  
(Eaton)

Administration Intravaginal oral

Dosage forms Powder 0.1% suppository  
0.25% tablet 100 mg solution 10 mg  
per ml

**FURMETHIDE I (Smith, Kline & French)**

Trade name for Furtrethonium I

**FUROXONE (Eaton)**

Trade name with Furazolidine

**FURTRETHONIUM I**

Trade name Furmethide I (Smith Kline &  
French)

Administration Subcutaneous, oral

Dosage forms Tablet 10 mg ampule, 5 mg  
per ml

**GALACTOSE**

Administration Oral

Dosage form As such



**GUANIDINE HCl***Administration* Oral*Dosage form* Tablet, 125 mg**GYNERGEN (Sandoz)**

Trade name for Ergotamine Tartrate

**HALAZONE***Administration* Topical*Dosage form* Tablet, 4 mg to be dissolved**HALIVER OIL**

Mixture of Vitamins A and D

**HALOTESTIN (Upjohn)**

Trade name for Fluoxymesterone

**HALOTHANE***Trade name* Fluothane (Ayerst)*Administration* Inhalation*Dosage form* Volatile liquid as such**HARMONYL (Abbott)**

Trade name for Deserpidine

**HARTMAN'S SOLUTION**

Synonym for Lactated Ringer's Solution

**HEART MUSCLE EXTRACT***Trade name* Cardiomone (Endo), Myocardone (Chemico)**HEDULIN (Walker)**

Trade name for Phenindione

**HEMO-PAK (Johnson & Johnson)**

Trade name for Cellulose Oxidized

**HEPARIN POTASSIUM***Trade name* Clarin (Leeming)*Administration* Sublingual*Dosage form* Tablet, 50 mg**HEPARIN SODIUM***Trade names* Depo-Heparin (Upjohn), Liquacemin Sodium (Organon), Panheprin (Abbott)*Administration* Subcutaneous intravenous*Dosage form* Vials, 10, 50, 100, 200 mg per ml**HEPTABARBITAL***Trade name* Medomin (Geigy)*Administration* Oral*Dosage form* Tablets, 50 and 100 mg**HEPTOBEE (Endo)**

Trade name for Vitamin B Complex

**HEROIN**

Synonym for Diacetylmorphine

Not legally available in this country for any purpose

**HESPERIDIN METHYL CHALCONE***Synonym* Vitamin P*Trade name* Pev Gram (Ingram)*Administration* Oral*Dosage form* Capsule, 50 mg**HETRAZAN (Lederle)**

Trade name for Diethylcarbamazine

**HEXA BETALIN (Lilly)**

Trade name for Pyridoxine HCl

**HEXACHLOROPHENE***Trade names* Gamphen (Ethicon), Hex O

San (Retort), phisollex (Winthrop),

Surgicene (Central)

*Dosage forms* Usually in soap and other preparations, 0.5 to 3.0%**HEXADIMETHIRIN Br***Trade name* Polybrene (Abbott)*Administration* Intravenous*Dosage form* Ampule, 10 mg in 10 ml**HEXAFLUORODIETHYL ETHER***Synonym* Indokon

Not available on commercial drug market

**HEXAMETHONIUM Br***Trade name* Bistrium Br (Squibb)*Administration* Subcutaneous intramuscular intravenous*Dosage form* Vial 25 mg per ml**HEXAMETHONIUM Cl***Trade names* Bistrium Cl (Squibb), Esom d

Cl (Ciba), Hexameton Cl (Burroughs Wellcome), Methium Cl (Warner Chilcott)

*Administration* Oral, subcutaneous, intramuscular, intravenous*Dosage forms* Tablet, 0.25 Gm vials 25 and 100 mg per ml**HEXAMETON Cl (Burroughs Wellcome)**

Trade name for Hexamethonium Cl

**HEXAVIBEX (Parke Davis)**

Trade name for Pyridoxine HCl

**HEXESTROL***Administration* Oral, intramuscular*Dosage forms* Tablets 1 and 30 mg, vials, 1 and 5 mg per ml**HEXETIDINE***Trade name* Sterisil (Warner Chilcott)*Administration* Intravaginal*Dosage form* Gel, 0.1%**HEXOBARBITAL***Trade name* Evipal (Winthrop)*Administration* Oral*Dosage form* Tablet, 250 mg

**GLUCOSAMINE**

*Trade name* Cosa (Pfizer)

*Used with* ant biotics

**GLUCOSE**

*Synonym* Dextrose

*Administration* Intravenous

*Dosage forms* Ampules containing 5 10 20 and 50% solutions

**GLUCOSULFONE SODIUM**

*Trade name* Prom n (Parke Davis)

*Administration* Intravenous

*Dosage form* Ampule 0.4 Gm per ml

**GLUCURONE (Reed & Carnrick)**

*Trade name for* Glucuronolactone

**GLUCURONOLACTONE**

*Trade name* Glucurone (Reed & Carnrick)

*Administration* Oral

*Dosage form* Tablet 0.5 Gm

**GLUSATE (United Labs)**

*Trade name for* Glutamic Acid

**GLUSIDE**

*Synonym for* Saccharin

**GLUTAMIC ACID**

*Trade name* Glusate (United Labs)

*Administration* Oral

*Dosage form* Tablets 0.3 and 0.5 Gm

**GLUTAMIC ACID HCl**

*Trade names* Acidor de (Abbott) Acido-

thyn (Flint Eaton), Acidulin (Lilly)

Aclor (Cole), Gastuloric (Warren Teed)

Glutan HCl (Lederle) Hydronic (Up-

john) Munamuc (Pitman Moore)

*Administration* Oral

*Dosage form* Capsule 0.3 Gm

**GLUTAN HCl (Lederle)**

*Trade name for* Glutamic Acid HCl

**GLUTAVENE (Gray)**

*Trade name for* Sodium Glutamate

**GLUTETHIMIDE**

*Trade name* Doriden (Ciba)

*Administration* Tablets 125 250 500 mg

**GLYCERYL GUAIACOLATE**

*Trade name* Robutussin (Robins)

*Administration* Oral

*Dosage form* Syrup 20 mg per ml

*Remarks* Available only as a mixture with 0.2 mg Desoxyephedrine HCl per ml

**GLYCERYL TRIACETATE**

*Synonym for* Triacetin

**GLYCERYL TRINITRATE**

*Synonym* Nitroglycerin

*Trade name* Nitroglyn (Key)

*Administration* Sublingual

*Dosage forms* Tablets various sizes

**GLYCINE**

*Synonym for* Aminoacetic Acid

**GLYCOBIARSOL**

*Trade names* Amoebicon (C.M.C.) Broxo-

lin (Breon) Milubis (Winthrop)

*Administration* Topical intravaginal

*Dosage forms* Tablet 0.5 Gm suppository

0.25 Gm

**GLYSENNID (Sandoz)**

*Trade name for* Sennosides A and B

**GLYTHEONATE (Patch)**

*Trade name for* Theophylline Sodium Glycinate

**GOLD SODIUM THIOMALATE**

*Trade name* Myochrysine (Merck)

*Administration* Intramuscular

*Dosage form* Ampules 10 25 50 and 100 mg

**GOLD SODIUM THIOSULFATE**

*Synonym* Sodium Aurothiosulfate

*Administration* Intravenous intramuscular

*Dosage form* Ampules 10 25 50 and 100 mg

**GONADOGEN (Upjohn)**

*Trade name for* Equine Gonadotropin

**GONADOTRONE (Miller)**

*Trade name for* Pituitary Gonadotropin

**GRAMICIDIN**

*Trade name* Gramoderm (Schering)

*Administration* Topical

*Dosage form* Ointment 0.25 mg per Gm

**GRAMODERM (Schering)**

*Trade name of* Gramicidin

**GRIFULVIN (McNeil)**

*Trade name for* Griseofulvin

**GRISEOFULVIN**

*Trade names* Fulvicin (Schering) Grifulvin (McNeil)

*Administration* Oral

*Dosage form* Tablet 250 mg

**GROWTH HORMONE**

*Synonym for* Chorionic Gonadotropin

**GUANATOL HCl (Lilly)**

*Trade name for* Chloroguanide HCl

**HYDRALAZINE HCl***Trade name* Apresoline (Ciba)*Administration* Oral, intramuscular, intravenous*Dosage forms* Tablets, 10, 25, 50, 100 mg, ampule, 20 mg per ml**HYDRIODIC ACID***Administration* Oral*Dosage form* Syrup**HYDRIONIC (Upjohn)***Trade name for* Glutamic Acid HCl**HYDROCHLORIC ACID***Administration* Oral*Dosage form* Diluted, 10% of free acid**HYDROCHLOROTHIAZIDE***Trade names* Esidrix (Ciba), HydroDiuril (Merck), Oretic (Abbott)*Administration* Oral*Dosage form* Tablets, 25 and 50 mg**HYDROCORTAMATE HCl***Trade name* Magnacort (Pfizer)*Administration* Topical*Dosage form* Ointment, 0.5%**HYDROCORTISONE***Synonym* Compound F*Trade names* Cort-Dome (Dome), Cortef (Upjohn), Cortril (Pfizer), Hydrocortone (Merck), Otosone-F (Broemmel)*Administration* Oral, topical, intravenous*Dosage forms* Tablets 5, 10 and 25 mg, ampule, 5 mg per ml, various ointments and topical lotions**HYDROCORTISONE ACETATE***Trade names* Cortef Acetate (Upjohn), Cortril Acetate (Pfizer), Hydrocortone Acetate (Merck), Isopto Hydrocortisone (Alcon Labs)*Administration* Oral, topical, intra articular*Dosage forms* Tablet, 10 mg, ointments, 0.5, 1.0, 2.5% vial, 25 mg per ml**HYDROCORTISONE SUCCINATE***Trade name* Solu Cortef (Upjohn)*Administration* Intravenous*Dosage form* Vial, 100 mg**HYDROCORTONE (Merck)***Trade name for* Hydrocortisone**HYDROCORTONE ACETATE (Merck)***Trade name for* Hydrocortisone Acetate**HYDRODIURIL (Merck)***Trade name for* Hydrochlorothiazide**HYDROFLUMETHIAZIDE***Trade name* Saluron (Bristol)*Administration* Oral*Dosage form* Tablet, 50 mg**HYDROGEN PEROXIDE***Administration* Topical*Dosage form* Solution, 3%**HYDROLOSE (Upjohn)***Trade name for* Methylcellulose**HYDROUS WOOL FAT***Synonym* Lanolin*Trade name* Lamo (Tailby Nason)*Administration* Topical*Dosage forms* As such and in ointments**HYDROXYAMPHETAMINE HBr***Trade name* Paredrine HBr (Smith, Kline & French)*Administration* Oral, topical*Dosage forms* Tablet, 20 mg; solution, 1%**HYDROXYCHLOROQUINE SO<sub>4</sub>***Trade name* Plaquenil SO<sub>4</sub> (Winthrop)*Administration* Oral*Dosage form* Tablet, 200 mg**HYDROXY-DIHODOBENZYL-CYCLO-  
HEXANE CARBOXYLIC ACID***Trade name* Monophen (Bell Craig)*Administration* Oral*Dosage form* Capsule, 0.5 Gm**HYDROXYDIONE***Trade name* Viadril (Pfizer)*Administration* Intravenous*Dosage form* Ampule, 1 Gm**HYDROXYMERCURI O NITROPHENO-  
LATE***Trade name* Mercuriofen (Merck)*Administration* Topical*Dosage form* As such**HYDROXYPROGESTERONE ACETATE***Trade name* Prodox (Upjohn)*Administration* Oral*Dosage form* Tablets, 25, 50 mg**HYDROXYSTILBAMIDINE ISETHIO-  
NATE***Administration* Parenteral*Dosage form* Powder, 125 mg**HYDROXYZINE HCl***Trade names* Atarax (Roerig), Vistaril (Pfizer)*Administration* Oral*Dosage form* Tablets, 10 and 25 mg

**HEXOBARBITAL SODIUM**

*Trade names* Evipal Sodium (Winthrop)  
Somnalert (Warren Teed)  
*Administration* Intravenous  
*Dosage form* Ampules 1 and 5 Gm

**HEXOCYCLIUM METHYLSULFATE**

*Trade name* Tral (Abbott)  
*Administration* Oral  
*Dosage form* Tablet, 25 mg

**HEX O SAN (Retort)**

*Trade name* for Hexachlorophene

**HEX O SAN SURGICAL SOAP (Retort)**

Hexachlorophene soap

**HEXYLCAINE HCl**

*Trade name* Cyclaine (Merck)  
*Administration* Topical, local  
*Dosage forms* Topical 5% infiltration, 2%

**HEXYLRESORCINOL**

*Trade names* Caprokol (Merck) Crystoids (Merck)  
*Administration* Oral  
*Dosage forms* Capsule, 0.15 Gm in olive oil pills 0.1 0.2 Gm

**HIBICON (Lederle)**

*Trade name* for Benzchlorpropamide

**HIPPURAN (Mallinckrodt)**

*Trade name* for Iodohippurate Sodium

**HISPRIL (Smith Kline & French)**

*Trade name* for D phenylpyraline HCl

**HISTADYL (Lilly)**

*Trade name* for Methapyrilene HCl

**HISTALOG (Lilly)**

*Trade name* for Bitazole HCl

**HISTAMINASE**

*Trade name* Torantil (Winthrop)  
*Administration* Oral  
*Dosage form* Tablets 10 and 20 units

**HISTAMINE PO.**

*Administration* Subcutaneous  
*Dosage forms* Available in tablets and ampules usually from 0.5 to 2 mg

**HISTAN (Sherman)**

*Trade name* for Pyrilamine Maleate

**HISTIONEX (Strassenburgh)**

*Trade name* for Phenyltoloxamine Resin Complex

**HN,**

Common designation for Mechloroethamine

**HOLOCAINE HCl**

Synonym for Phenacaine HCl

**HOMATROPINE METHYLBROMIDE**

*Trade names* Mesopin (Endo), Novatrin (Campbell)  
*Administration* Oral, subcutaneous, intramuscular  
*Dosage forms* Tablets 25 and 50 mg ampule, 5 mg per ml

**HORMESTERAL (Miller)**

*Trade name* for Estrogenic Substances Conjugated

**HUMORSOL (Merck)**

*Trade name* for Demecarium Br

**HYALURONIDASE**

*Trade names* Alidase (Searle), Diffusin (Ortho), Hyazyme (Abbott) Infiltrase Armour, Wydase (Wyeth)  
*Administration* Subcutaneous  
*Dosage form* Ampule 150 U

**HYAZIME (Abbott)**

*Trade name* for Hyaluronidase

**HYCODAN BITARTRATE (Endo)**

*Trade name* for Dihydrocodeinone Bitartrate

**HYDELTRA (Merck)**

*Trade name* for Prednisolone

**HYDELTRASOL (Merck)**

*Trade name* for Prednisolone 21 PO.

**HYDELTRA TBA (Merck)**

*Trade name* for Prednisolone Butylacetate

**HYDERGINE (Sandoz)**

*Trade name* for Dihydroergocornine, Dihydroergocristine Dihydroergokryptine Mixture

**HYDRABAMINE PENICILLIN G**

*Trade name* Compocillin (Abbott)  
*Administration* Oral  
*Dosage form* Suspension, 60,000 units per ml.

**HYDRABAMINE PENICILLIN V**

Synonym for Hydrabamine Phenoxymethyl Penicillin

**HYDRABAMINE PHENOXYMETHYL PENICILLIN**

Synonym Hydrabamine Penicillin V  
*Trade name* Compocillin V (Abbott)  
*Administration* Oral  
*Dosage forms* Tablets, 125 and 250 mg suspension, 35 mg per ml

**INSOLUBLE LIVER FRACTION**

Synonym for Liver Fraction 2

**INSULIN**

Trade name *letin* (Lilly)

Administration Subcutaneous

Dosage form Vials, 40, 80, 100 units per ml

**INTOCOSTRIN (Squibb)**

Trade name for *Chondodendron tomentosum*

**INTRACAIN HCl (Philadelphia Ampule)**

Trade name for Diethoxyn

**INTRAHEPTOL (Lederle)**

Trade name for Liver Concentrate

**INTRINASE (Upjohn)**

Trade name for Intrinsic Factor with Vitamin B<sub>12</sub>

**INTRINSIC FACTOR**

Available on commercial drug market only in combination with Vitamin B<sub>12</sub>

**INTRINSIC FACTOR WITH VITAMIN B<sub>12</sub>**

Trade names *Bevidoral* (Abbott), *Bevitab* (Chicago), *Bifactor* (Organon), *Biopar* (Armour), *Biopar Forte* (Armour), *Intrinase* (Upjohn)

Administration Oral

Dosage form Tablets, of varying potency, ranging about 0.5 unit Intrinsic Factor and 25 mcg Vitamin B<sub>12</sub>

**INVERSINE (Merck)**

Trade name for Mecamylamine

**IODEIKON (Mallinckrodt)**

Trade name for Iodophthalein Sodium

**IODINATED GLYCEROL**

Trade name *Organdin* (Wampole)

Administration Oral

Dosage forms Solution, 25 mg Iodine per ml tablet, 15 mg Iodine

**IODINE**

Administration Topical

Dosage forms Various concentrations and physical forms are available

**IODIPAMIDE METHYLGLUCAMINE**

Trade name *Cholografin Methylglucamine* (Squibb)

Administration Intravenous

**IODIZED OIL**

Trade name *Lipiodol* (Foug)

Administration Instillation

Dosage form Ampules, 10 iodine

**IODOPHOSPHONIC ACID**

Trade name *Prinodax* (Scher)

Administration Oral

Dosage form Tablet, 0.5 Gm

**IODO BISMUTHATE OF C**

Administration Intramuscula

Dosage form Ampule, 50 mg

**IODOBASSID**

Trade name *Lipiodine* (Cib)

Administration Oral

Dosage form Tablet, 0.3 Gm

**IODOCHLORHYDROXYQU**

Trade names *Vioform* (Ciba form (Ciba)

Administration Oral, intrava

Dosage forms Tablet, 0.25 Gr 0.25 Gm, powder, 25%

**IODOCHLOROL (Searle)**

Trade name for Chloriodized

**IODOPANOIC ACID**

Synonym for Iopanoic Acid

**IODOPHTHALEIN SODIUM**

Synonyms *Tetraiodophenolph* um, and many others

Trade names *Iodeikon* (Mallin phen (Picker), *Stupolac* (Bu come)

Administration Oral, intraveno

Dosage form As such

**IODOPYRACET**

Trade name *Diodrast* (Winth

Administration Intravenous, re

Dosage form Solutions, 35 and

**IONAMIN (Strassenburgh)**

Trade name for Phenyl Tet Resin

**HYDROXYZINE PAMOATE**

*Trade name* Vistaril (Pfizer)  
*Administration* Oral parenteral  
*Dosage forms* Capsules, 25, 50, 100 mg  
 vials, 25 mg per ml

**HYFLAVIN (Endo)**

*Trade name* for Riboflavin Methylol

**HYKINONE (Abbott)**

*Trade name* for Menadione Sodium Bisulfite

**HYMORPHAN HCl (Endo)**

*Trade name* for Dihydromorphinone HCl

**HYOSCINE**

Synonym for Scopolamine

**HYOSCINE HBr**

Synonym for Scopolamine HBr

**HYOSCINE METHYLBROMIDE**

Synonym for Methscopolamine HBr

**IHYOSCYAMINE HBr**

*Administration* Oral  
*Dosage forms* Tablets of various sizes

**HYPaque SODIUM (Winthrop)**

*Trade name* for Diatrizoate Sodium

**HYPO**

Synonym for Sodium Thiosulfate

**HYTAKEROL (Winthrop)**

*Trade name* for Dihydrotestosterone

**I131**

Synonym for Sodium Radio-Iodide

**I132**

Synonym for Radio Iodine<sup>132</sup>

**I133**

Synonym for Radio Iodine<sup>133</sup>

**ICHTHALBIN (Bilhuber Knoll)**

*Trade name* for Ichthyol Albuminate

**ICHTHAMMOL**

*Administration* Topical  
*Dosage forms* Various 5 to 20%

**ICHTHYOL ALBUMINATE**

*Trade name* Ichthalbin (Bilhuber Knoll)  
*Administration* Oral, topical  
*Dosage form* Tablet 0.3 Gm

**ILETIN (Lilly)**

*Trade name* for Insulin

**ILIDAR (Roche)**

*Trade name* for Azapetine PO<sub>4</sub>

**ILOPAN (Warren Teed)**

*Trade name* for Pantothenyl Alcohol

**ILOSENE (Lilly)**

*Trade name* for Erythromycin Propionate

**ILOTICIN (Lilly)**

*Trade name* for Erythromycin

**IMFERON (Lakeside)**

*Trade name* for Iron Dextran

**IMIDAZOLE**

*Trade name* Carbinazole (Denver)  
 Not available on commercial drug market

**IMIPRAMINE HCl**

*Trade name* Tofranil (Geigy)  
*Administration* Oral, intramuscular  
*Dosage forms* Tablet, 25 mg ampule 12.5 mg per ml

**INDIGO CARMINE**

Synonym for Sodium Indigotindisulfonate

**INDOKON**

Synonym for Hexafluoroethyl Ether

**INDON (Parke, Davis)**

*Trade name* for Phenindione

**INESTRA (Merck)**

*Trade name* for Ethinyl Estradiol

**INFILTRASE (Armour)**

*Trade name* for Hyaluronidase

**INFUNDIN (Burrroughs Wellcome)**

*Trade name* for Pituitary Extract (Posterior)

**INH (Lilly)**

*Trade name* for Isoniazid

**INHISTON (Union)**

*Trade name* for Pheniramine Maleate

**INOSITOL**

*Administration* Oral  
*Dosage forms* Tablet and capsule 0.5 Gm

**INOSITOL HEXANITRATE**

*Trade name* Tolanate (CSC)  
*Administration* Oral  
*Dosage form* Tablet, 10 mg

**INOSITOL HEXAPHOSPHATE**

*Trade name* Calciphos (Bilhuber Knoll)  
*Administration* Oral  
*Dosage form* Tablet, 0.4 Gm.

**ISONIAZID**

*Synonym* Isonicotinic Acid Hydrazide  
*Trade names* Armazide (Armour), Cotina zin (Pfizer), Dinacrin (Winthrop), Ditubin (Schering), INH (Ili), Isolin (Abbott), Niadrin (Endo), Niconyl (Parke Davis), Nicozide (Premo), Nydrazid (Squibb), Pyridin (Nepera), Rimifon (Roche), Tisin (Arlington) Tyvid (Merrell), and others  
*Administration* Oral intramuscular  
*Dosage forms* Various forms

**ISONICOTINIC ACID HYDRAZIDE**

*Synonym* for Isoniazid

**ISONIPFCAINE**

*Synonym* for Meperidine

**ISONORIN SO. (C. D. Smith)**

*Trade name* for Isoproterenol SO

**ISO PAR (Medical Chem)**

*Trade name* for Coparaffinate

**ISOPHAN INSULIN**

*Synonym* NPH Insulin  
*Trade name* NPHletin (Lilly)  
*Administration* Subcutaneous  
*Dosage forms* Various concentrations

**ISOPROPAIDE I**

*Trade name* Darbid (Smith Kline & French)  
*Administration* Oral  
*Dosage form* Tablet, 5 mg

**ISOPROPYL ALCOHOL**

*Administration* Topical  
*Dosage form* Solutions 70 to 80%

**ISOPROTFRENOL HCl**

— — — — —

*Administration* Sublingual inhalation  
*Dosage forms* Tablet, 5, 10, 15 mg, solution 1:100, 1:200

**ISOPROTERENOL SO.**

*Trade names* Isonorin SO. (Smith, Carroll, Dunham), Norisodrine SO. (Abbott)  
*Administration* Inhalation sublingual  
*Dosage forms* Powder, 25%, solution, 1% tablet, 10 mg

**ISOPTO CORTISONE (Alcon)**

*Trade name* for Cortisone Acetate

**ISOPTO HYDROCORTISONE (Alcon)**

*Trade name* for Hydrocortisone Acetate

**ISORDIL (Ives)**

*Trade name* for Isosorbide Dinitrate

**ISOSORBIDE DINITRATE**

*Trade name* Isordil (Ives)  
*Administration* Oral  
*Dosage form* Tablet, 10 mg

**ISOTHIPENDYL HCl**

*Trade name* Theruhistin (Ayerst)  
*Administration* Oral  
*Dosage forms* Tablet, 4 mg sustained action tablet 12 mg, syrup, 0.4 mg per ml

**ISOTONIC SOLUTION OF THREE CHLORIDES**

*Synonym* for Ringer's Solution

**ISOXSUPRINE HCl**

*Trade name* Vasodilan (Mead Johnson)  
*Administration* Oral, intramuscular  
*Dosage forms* Tablet, 10 mg, ampule, 5 mg per ml

**ISTIZIN (Winthrop)**

*Trade name* for Dihydroxyanthraquinone

**ISUPREL HCl (Winthrop)**

*Trade name* for Isoproterenol HCl

**ITRUMIL SODIUM (Ciba)**

*Trade name* for Iothouracil Sodium

**JALAP**

*Administration* Oral  
*Dosage form* As such

**JUNIPER TAR**

*Synonym* Cade Oil  
*Administration* Topical  
*Dosage form* Various, 1 to 20%

**KADALEX (Don Baxter)**

*Trade name* for Potassium Cl in Dextrose

**KALPIN (Wallace)**

*Trade name* for Sodium and Calcium Alginate

**KANAMYCIN SO.**

*Trade name* Kantrex (Bristol)  
*Administration* Oral intramuscular  
*Dosage forms* Capsule 0.5 Gm vials, 0.25 and 0.33 Gm per ml

**KANTREX (Bristol)**

*Trade name* for Kanamycin SO.

**KAON (Warren Teed)**

*Trade name* for Potassium Gluconate

**KAOPECTATE (Upjohn)**

*Trade name* for a mixture of Kaolin and Pectin

**IOPANOIC ACID**

*Synonym* Iodopanoic Acid  
*Trade name* Telapaque (Winthrop)  
*Administration* Oral  
*Dosage form* Tablet, 0.5 Gm

**IOPHENDYLATE**

*Synonym* Ethyl Iodophenylundecylate  
*Trade names* Mulsopaque (Lafayette), Pantopaque (Lafayette)  
*Administration* Parenteral  
*Dosage form* As such, 50% emulsion

**IOPHENOXIC ACID**

*Trade name* Teridax (Schering)  
*Administration* Oral  
*Dosage form* Tablet, 0.75 Gm

**IOTHIOURACIL SODIUM**

*Trade name* Itriumil Sodium (Ciba)  
*Administration* Oral  
*Dosage form* Tablet, 50 mg

**IFECAC**

*Administration* Oral  
*Dosage forms* As such, fluid extract, syrup

**IPRAL SODIUM (Squibb)**

*Trade name* for Probarbital Sodium

**IPRONIAZID**

*Trade name* Marsilid (Roche)  
*Administration* Oral  
*Dosage form* Tablets, 10, 25, 50 mg

**IRON AND AMMONIUM CITRATE**

*Administration* Oral, intramuscular  
*Dosage forms* Capsule, 0.5 Gm; vial, 50 mg

**IRON AND BILE SALTS**

*Trade name* Bilon (Lilly)  
*Administration* Oral  
*Dosage form* Tablets, 0.16, 0.3 Gm

**IRON CACODYLATE**

*Synonym* for Ferric Cacodylate

**IRON CARBOHYDRATE COMPLEX**

*Trade name* Astrafer (Astra)  
*Administration* Intravenous  
*Dosage form* Solution, 20 mg iron per ml

**IRON CHOLINE CITRATE**

*Synonym* for Ferrocholine

**IRON HYDROXIDE, COLLOIDAL**

*Administration* Oral  
*Dosage form* Tablet, 75 mg

**IRON OXIDES**

*Synonym* for Ferric Oxides

**IRON-DEXTRAN**

*Trade name* Imferon (Lakeside)  
*Administration* Intramuscular  
*Dosage form* Ampule, 50 mg per ml

**IRON (Cole)**

*Trade name* for Ferrous Gluconate

**ISOBARB (U. S. Standard)**

*Trade name* for Pentobarbital Sodium

**ISOBORNYL THIOCYANOACETATE**

*Trade name* Bornate (Wyeth)  
*Administration* Topical  
*Dosage form* Emulsion, 5%

**ISOCARBOXAZID**

*Trade name* Marplan Br (Roche)  
*Administration* Oral  
*Dosage form* Tablets, 5 and 10 mg

**ISOCRIN (Warner-Chilcott)**

*Trade name* for Diacetylthioproxyphenylisatin

**ISODINE (Isodine)**

*Trade name* for Potassium-Iodine

**ISOEPHEDRINE HCl**

*Synonym* Pseudoephedrine HCl  
*Trade name* Sudafed (Burroughs Wellcome)  
*Administration* Oral  
*Dosage form* Tablet, 32 mg

**ISOFEDROL (Blue Line)**

*Trade name* for Ephedrine SO<sub>4</sub>

**ISOFLUOROPHATE**

*Synonym* DFP  
*Trade name* Floropryl (Merck)  
*Administration* Topical  
*Dosage forms* Solution, 0.1%, ointment, 0.025%

**ISO-IODEKON (Mallinckrodt)**

*Trade name* for Phenethiothalein Sodium

**ISOLYN (Abbott)**

*Trade name* for Isontund

**ISOMETH (Lloyd)**

*Trade name* for Isomethoprene Tartrate

**ISOMETHPTENE HCl**

*Trade name* Isometh (Lloyd)  
*Administration* Intravenous, subcutaneous  
*Dosage form* Vial, 100 mg per ml

**ISOMETHPTENE TARTRATE**

*Trade name* Isometh (Lloyd)  
*Administration* Intravenous, subcutaneous  
*Dosage form* Vial, 100 mg per ml



**LANOXIN** (Burroughs Wellcome)

Trade name for Digoxin

**LAURON** (Endo)

Trade name for Aurothioglycanide

**LIADOLATE**

Trade name Diachylon Ointment (Ulmer)

Administration Topical

Dosage form Ointment 50%

**LEFETHIN**

Administration Oral

Dosage form As such

**LEDERPLEX** (Lederle)

Trade name for Vitamin B Complex

**LENGALLOL** (Bulbular Knoll)

Trade name for Acetpyrogall

**LENTE ILFTIN** (Lilly)

Trade name for Lente Insulin

**LENTE INSULIN**

Trade name Lente Insulin (Lilly)

Administration Subcutaneous

Dosage form Vials 40 and 80 units per ml

**LENTOPEN** (Wyeth)

Trade name for Procaine Penicillin G

**LEFRITINE HCl** (Merck)

Trade name for Anleridine HCl

**LEFRITINE PO<sub>4</sub>** (Merck)

Trade name for Anleridine PO

**LESCOPINF Br** (Lincoln)

Trade name for Methscopolamine Br

**LFTHIDRONE** (Burroughs Wellcome)

Trade name for Nalorphine HBr

**LFUCOVORIN** (Lederle)

Trade name for Citrovorum Factor

**LFUKERAN** (Burroughs Wellcome)

Trade name for Chlorambucil

**LFVALLORPHAN TARTRATE**

Trade name Loflan (Roche)

Administration Parenteral

Dosage form Vial 1 mg per ml

**LFVARTERENOL BITARTRATE**

Trade name Levophed

Administration Intravenous

Dosage form Solution 1:1000

**LEVO DROMORAN TARTRATE** (Roche)

Trade name for Levorphan Tartrate

**LEVOHYOSCYAMINE SO**

Trade names Levisin SO (Kremers Urban)

Levanex (Kremers Urban)

Administration Oral

Dosage form Tablet 0.25 mg

**LEVONOR** (Nordmark)

Trade name for 1 Amphetamine Alginat

**LEVOPHED** (Winthrop)

Trade name for Levarterenol Bitartrate

**LEVO PROPOXYPHENT**

Not yet available on commercial drug market

**LEVORPHAN TARTRATE**

Trade name Levo Dromoran Tartrate (Roche)

Administration Oral subcutaneous

Dosage forms Tablet 2 mg ampule 2 mg per ml

**LEVISIN SO<sub>4</sub>** (Kremers Urban)

Trade name for Levohyoscyamine SO

**LEVUSINEX** (Kremers Urban)

Trade name for Levohyoscyamine SO

**LEVUGEN** (Mead Johnson)

Trade name for Levulose

**LEVULOSE**

Synonym for Fructose

**LIDOCAINE HCl**

Trade name Xylocaine HCl (Astra)

Administration Topical and parenteral

Dosage forms A variety of forms

**LIFEBUOY SOAP** (Lever)

Tetramethyl Thauram Disulfide soap

**LINAMPHETA** (Lincoln)

Trade name for Amphetamine SO

**INIT** (Corn Products)

Trade name for Starch

**LIOTHYRONINE SODIUM**

Synonym L Triiodothyronine

Trade names Cytomel (Smith Kline &amp; French) Trionine (Roche)

Administration Oral

Dosage form Tablets 5, 25 and 50 mcg

**LIPIODOL** (Fougere)

Trade name for Iodized Oil

**LIPID ADRENAL CORTEX**

Administration Intramuscular

Dosage form Ampule equivalent of 1 mg Hydrocortisone per ml

# DRUG INDEX

861

- KAPPADIONE** (Lilly)  
Trade name for Menadiol Sodium PO<sub>4</sub>
- KAPPAXIN** (Winthrop)  
Trade name for Menadione
- KAPRYLEX** (Strasensburgh)  
Trade name for Resin Caprylate
- KATONIUM** (Winthrop)  
Trade name for Styronate Resins
- KAYNALAT** (Winthrop)  
Trade name for Sodium Polystyrene Sulfonate
- KAYKLOT** (Raymer)  
Trade name for Menadione
- KAYQUINONE** (Abbott)  
Trade name for Menadione
- KEMADRIN** (Burroughs Wellcome)  
Trade name for Procyclidine HCl
- KENACORT** (Squibb)  
Trade name for Triamcinolone
- KENALOG** (Squibb)  
Trade name for Triamcinolone Acetonide
- KERAPHEN** (Packer)  
Trade name for Iodophthalain Sodium
- KETACHOL** (Searle)  
Trade name for Bile Extractives
- KY SERPINE** (Key)  
Trade name for Reserpine
- KELISFM** (Massengill)  
Trade name for Vitamin material
- KELIV**  
Trade name for Vitamin
- KAMIN** (Merrell)  
Trade name for Oxalic and Malonic Acid
- KUCOID** (Panray)  
Trade name for Alseroxylon
- KLOT** (Cole)  
Trade name for Menadione
- KREAMS A and D** (Dome)  
Soluble Tar preparation 2%
- KONAKION** (Roche)  
Trade name for Phytonadione
- KONDREXUL** (Patch)  
Trade name for Petrolatum
- KONOGEN** (Lilly)  
Trade name for Estrogenic Substances Conjugated
- KONSYL** (Burton Parsons)  
Trade name for Plantago Concentrate
- KOROTRIN** (Winthrop)  
Trade name for Chorionic Gonadotropin
- KUTROL** (Parke Davis)  
Trade name for Uroenterone
- KWELL** (Reed & Carnrick)  
Trade name for Gamma Benzene Hexachloride
- KYNEX** (Lederle)  
Trade name for Sulfamethoxypyridazine
- KYNEX ACETYL** (Lederle)  
Trade name for Sulfamethoxypyridazine Acetyl
- LACHESINE**  
Not available on the commercial drug market
- LACTATED RINGER'S SOLUTION**  
Synonym: Hartman's Solution  
Administration: Intravenous, subcutaneous  
Dosage form: Ampules and bottles as such
- LACTOFLAVIN**  
Synonym for Riboflavin
- LACTOSE**  
Available in the form of Alpha Lactose
- LA FORMULA** (Burton Parsons)  
Trade name for Plantago Concentrate
- LAMO** (Tailby Nason)  
Trade name for Lanolin
- LANATOSIDE C**  
Trade name: Cedriland Salts  
Administration: Oral, intramuscular, intravenous  
Dosage forms: Tablet 0.5 mg, ampules 2 mg per ml
- LANOLIN**  
Synonym for Hydrous Wool Fat

**LUTEIN (Hynson)**

Trade name for Corpus Luteum

**LUTEOTROPHIN (Squibb)**

Trade name for Prolactin

**LUTOCYLIN (Ciba)**

Trade name for Progesterone

**LUTOCYLOL (Ciba)**

Trade name for Ethisterone

**LUTREXIN (Hynson)**

Trade name for Lututrin

**LUTROMONE (Endo)**

Trade name for Progesterone

**LUTUTRIN**

Trade name Lutrexin (Hynson)

Administration Oral

Dosage form Tablet, 1,000 units

**LYNORAL (Organon)**

Trade name for Ethinyl Estradiol

**LYOCYTE (Merck)**Trade name for Red Blood Cells, Human  
Dried**MAALOX (Rorer)**Trade name for Magnesium and Aluminum  
Hydroxide Mixture**MAADRIBON (Roche)**

Trade name for Sulfadimethoxine

**MAADRIQID (Roche)**

Trade name for Sulfadimethoxine

**MAFENIDE HCl**

Trade name Sulfamylon HCl (Winthrop)

Administration Topical

Dosage form Solution, 5%

**MAGMASIL (Leeming)**

Trade name for Magnesium Trisilicate

**MAGNACORT (Pfizer)**

Trade name for Hydrocortamate HCl

**MAGNAMYCIN (Pfizer)**

Trade name for Carbomycin

**MAGNEPHYLLINE (Sherman)**

Trade name for Magnesium Theophylline

**MAGNESIA MAGMA**

Synonym for Magnesium Hydroxide

**MAGNESIUM AND ALUMINUM  
HYDROXIDE MIXTURE**Trade names Aludrox (Wyeth), Maalox  
(Rorer)

Administration Oral

Dosage forms Suspension, tablet

**MAGNESIUM CO<sub>3</sub>**

Administration Oral

Dosage form As such

**MAGNESIUM CITRATE**

Administration Oral

Dosage form Solution, 6%

**MAGNESIUM GLUCONATE**Trade names Almora (Durst), Menesia  
(Pitman-Moore)

Administration Oral

Dosage form Tablet, 0.5 Gm

**MAGNESIUM HYDROXIDE**Synonyms Magnesia Magma, Milk of Mag-  
nesiaDosage forms As such, suspension, 7.5%,  
tablet, 0.3 Gm**MAGNESIUM OXIDE**

Administration Oral, topical

Dosage form As such

**MAGNESIUM PO<sub>4</sub>**

Administration Oral

Dosage form As such

**MAGNESIUM SO<sub>4</sub>**

Synonym Epsom salts

Administration Oral

Dosage form Crystals

**MAGNESIUM THEOPHYLLINE**

Trade name Magnephylline (Sherman)

Administration Oral

Dosage form Tablets, 0.1 Gm

**MAGNESIUM TRISILICATE**Trade names Magmasil (Leeming), Trine-  
sium (Abbott), Tri Sil (Warren Teed)

Administration Oral

Dosage forms Tablet, 0.5 Gm, as such, sus-  
pensions of various concentrations**MAGNESIUM TRISILICATE AND  
ALUMINUM HYDROXIDE**Trade names Gelusil (Warner Chilcott),  
A M T (Wyeth), Magsal (Endo), Milk of  
Trisium (Abbott), Tri Creamalate (Win-  
throp), Trisogel (Lilly)

Administration Oral

Dosage forms Tablet, 0.5 Gm, suspensions  
of various concentrations

# DRUG INDEX

- LIPO BISMOL** (Parke, Davis)  
Trade name for Bismuth Octyloxyacetate
- LIPO DIAZINE** (Donley Evans)  
Trade name for Sulfadiazine
- LIPOGANTRISIN** (Roche)  
Trade name for Acetyl Sulfisoxazole
- LIPOIODINE** (Ciba)  
Trade name for Iodobrassid
- LIPO LUTIN** (Parke Davis)  
Trade name for Progesterone
- LIPO TRIAZINE** (Donley Evans)  
Trade name for Meth Dia Mer Sulfonamides
- LIQUAEMIN SODIUM** (Organon)  
Trade name for Heparin Sodium
- LIQUAMAR** (Organon)  
Trade name for Phenprocoumon
- LIQUIPRIN** (Johnson & Johnson)  
Trade name for Salicylamide
- LITHIUM ANTIMONY THIOALATE**  
Synonym Anthionaline  
Administration Parenteral  
Dosage form Ampule, 60 mg per ml
- LIVER CONCENTRATE**  
Trade name Intraheptol (Lederle)  
Administration Intravenous  
Dosage form Vial 1 ml equals 33.3 Gm liver
- LIVER DESICCATED**  
Administration Oral  
Dosage form Capsule, 0.5 Gm
- LIVER EXTRACT, ORAL**  
Administration Oral  
Dosage forms Powder, about 15 Gm per unit liquid, 45 ml per unit
- LIVER FRACTION 1**  
Synonym Soluble Liver Fraction
- LIVER FRACTION 2**  
Synonym Insoluble Liver Fraction  
Administration Oral
- LIVER INJECTION, CRUDE**  
Trade name Campolon (Winthrop)  
Administration Intramuscular  
Dosage form Ampule, 2 units per ml
- LIVER INJECTION, PURIFIED**  
Trade names Pernaemon (Organon), Reticulogen (Lilly)  
Administration Intramuscular  
Dosage form Vials, equivalent of 10 and 20 mg Vitamin B<sub>12</sub> per ml
- LOBELIN** (Bischoff)  
Trade name for Alpha Lobelin HCl
- LOBELINE** (Sandoz)  
Trade name for Alpha Lobeline HCl
- LORFAN TARTRATE** (Roche)  
Trade name for Levallorphan Tartrate
- LORINAL** (Arnar Stone)  
Trade name for Chloral Hydrate
- LOTIO ALBA**  
Synonym for White Lotion
- LOTUSATE** (Winthrop)  
Trade name for Talbutal
- LOWILA** (Westwood)  
Detergent cleanser
- LUASMIN** (Brewer)  
Each capsule or tablet contains Theophylline Sodium Acetate 0.7 Gm Ephedrine SO 30 mg Phenobarbital Sodium 30 mg
- LUBRIDERM** (Texas Pharmacal)  
Lanolin emulsion
- LUCORTEUM** (Merck)  
Trade name for Progesterone
- LUGOLS SOLUTION**  
Synonym for Strong Iodine Solution
- LULLAMIN** (Reed & Carnrick)  
Trade name for Methapyrilene HCl
- LUMINAL** (Winthrop)  
Trade name for Phenobarbital
- LUMINAL SODIUM** (Winthrop)  
Trade name for Phenobarbital Sodium
- LUNAR CAUSTIC**  
Synonym for Silver NO<sub>3</sub>
- LUNARGEN** (Lilly)  
Trade name for Silver Protein, M11
- LUNOSOL** (Hille)  
Trade name for Silver Cl, Colloidal

**MELLARIL (Sandoz)**

Trade name for Thioridazine HCl

**MELOXINE (Upjohn)**

Trade name for Methoxsalen

**MELOZETS (Merck)**

Trade name for Methylcellulose

**MENADIOL SODIUM PO.**

Trade names Kappadione (Lilly), Synkayvite (Roche) Thylokay (Squibb)

Administration Oral, parenteral

Dosage forms Tablet, 5 mg, ampules, 1, 2.5, 5, 10, 37.5, and 75 mg per ml

**MENADIONE**

Synonym Vitamin K Synthetic

Trade names Kappaxin (Winthrop), Kayklot (Raymer), Kayquinone (Abbott), Kolklot (Cole)

Administration Oral, intramuscular

Dosage forms Tablets, 1, 2 mg, ampules containing 2 to 4 mg in oil

**MENADIOL SODIUM BISULFITE**

Trade name Ilykinone (Abbott)

Administration Intramuscular

Dosage form Ampule, 4 mg per ml

**MFNESIA (Pitman Moore)**

Trade name for Magnesium Gluconate

**MINTHOL**

Administration Topical

Dosage forms Various, 0.1 to 1%

**MEONINE (Wyeth)**

Trade name for Methionine

**MEPACRINE HCl**

Synonym for Quinacrine HCl

**MEPAZINE ACETATE**

Trade name Pacatal Acetate (Warner Chilcott)

Administration Intramuscular intravenous

Dosage form Vial, 25 mg per ml

**MEPAZINE HCl**

Synonym Pecazine

Trade name Pacatal HCl (Warner Chilcott)

Administration Oral, intramuscular

Dosage forms Tablets, 25, 50 mg, ampule, 25 mg per ml

**MEPFNZOLATE METHYLBROMIDE**

Trade name Cantil (Lakeside)

Administration Oral

Dosage form Tablet, 25 mg

**MFPERIDINE HCl**

Synonyms Isonipercaine, Pethidine

Trade name Demerol HCl (Winthrop)

Administration Oral, subcutaneous, intramuscular, intravenous

Dosage forms Tablets, 50, 100 mg, ampule, 50 mg per ml, elixir, 10 mg per ml

**MEPHENFSIN**

Trade names Daserol (Evron), Dioloxol (Carunick), Mepherol (Bryant), Mephson (Tutag), Myanesin (Biorganic), Myoxane (Ascher), Oranixon (Organon), Prolax (Cole), S nan (Warren Teed), Thoxidol (Normand), Tolhart (Hart), Tolosate (Brewer), Tolserol (Squibb), Tolulox (Miller), and many others

Administration Oral

Dosage forms Tablets, 100, 250, and 500 mg

**MEPHENFSIN CARBAMATE**

Trade name Tolseram (Squibb)

Administration Oral

Dosage form Tablet, 0.5 Gm

**MEPHENTHRINE SO.**

Trade name Wyamine (Wyeth)

Administration Intranasal, intravenous, intramuscular, oral

Dosage forms Inhaler, 250 mg solution 15 mg per ml tablets, 12.5 and 25 mg

**MFPHEROL (Bryant)**

Trade name for Mephenesin

**MEPHOBARBITAL**

Trade name Mebaral (Winthrop)

Administration Oral

Dosage form Tablets, 30, 50, 100, and 200 mg

**MFPHSON (Tutag)**

Trade name for Mephenesin

**MEPHYTON (Merck)**

Trade name for Phytonadione

**MFPPIPERPHENIDOL Br**

Trade name Darzine Br (Merck)

Administration Oral

Dosage form Tablets, 50 and 100 mg

**MEPRANE DIPROPIONATE (Reed & Carnrick)**

Trade name for Promesthrol Dipropionate

**MEPROBIAMATE**

Trade names Equanil (Wyeth) Meprospan (Wallace), Miltown (Wallace)

Administration Oral

Dosage forms Tablet and capsule, 200 and 400 mg

## DRUG INDEX

**MAGSAL (Endo)**

Trade name for Magnesium Trisilicate and Aluminum Hydroxide

**MALESTRONE (Kirk)**

Trade name for Testosterone

**MALLOPHONE (Mallinckrodt)**

Trade name for Phenylazo-diamino pyridine HCl

**MANADRIK (Endo)**

Trade name for Ephedrine

**MANDELAMINE (Nepera)**

Trade name for Methenamine Mandelate

**MANDELIC ACID**

*Administration* Oral

*Dosage form* As such

**MANICOLE (Cole)**

Trade name for Mannitol Hexantrate

**MANNITOL**

*Administration* Intravenous

*Dosage form* Ampule 25%

**MANNITOL HEXANITRATE**

*Trade names* Manicole (Cole) Maxitrate (Strassenburgh) Nitranitol (Merrell)

*Administration* Oral

*Dosage form* Tablet 30 mg

**MANVENE (Searle)**

Trade name for Mytatinene oil

**MAPHARSEN (Parke Davis)**

Trade name for Oxophenarsine HCl

**MARCUMAR (Roche)**

Trade name for Phenprocoumon

**MAREZINE (Burroughs Wellcome)**

Trade name for Cyclizine

**MARFZINE HCl (Burroughs Wellcome)**

Trade name for Cyclizine HCl

**MAREZINE LACTATE (Burroughs Wellcome)**

Trade name for Cyclizine Lactate

**MARPLAN Br (Roche)**

Trade name for Isocarboxazid

**MARSILID (Roche)**

Trade name for Iproniazid

**MASENATE (Schieffelin)**

Trade name for Testosterone Propionate

**MASENONE (Schieffelin)**

Trade name for Methyltestosterone

**MATROMYCIN (Pfizer)**

Trade name for Oleandomycin PO<sub>4</sub>

**MAXITATE (Strassenburgh)**

Trade name for Mannitol Hexantrate

**MAXUKAL (Breon)**

Trade name for Calcium Kinase Gluconate

**MAZON (Belmont)**

Coal tar soap

**MEBARAL (Winthrop)**

Trade name for Mephobarbital

**MECAMYLAMINE**

*Trade name* Inversine (Merck)

*Administration* Oral

*Dosage form* Tablets 2.5 and 10 mg

**MECHLORETHAMINE HCl**

*Synonym* HN<sub>2</sub>

*Trade names* Mustargen HCl (Merck)

*Carbolyne* HCl (Merck)

*Administration* Intravenous

*Dosage form* Vial 10 mg

**MECHOLYL Br (Merck)**

Trade name for Methacholine Br

**MECHOLYL Cl (Merck)**

Trade name for Methacholine Cl

**MECLIZINE HCl**

*Synonym* Postafene

*Trade names* Bonamine (Pfizer) Bonine (Pfizer)

*Administration* Oral

*Dosage form* Tablet 25 mg

**MECOSTRIN Cl (Squibb)**

Trade name for Dimethyl Tubocurarine Cl

**MEDIHALER NITRO (Riker)**

Trade name for Octyl Nitrite

**MEDINAL (Warner Chilcott)**

Trade name for Barbitol Sodium

**MEDOMIN (Geigy)**

Trade name for Heptabarbital

**MEDROL (Upjohn)**

Trade name for Methylprednisolone

**MEGINIDE (Abbott)**

Trade name for Bemegride

**MELAMINE**

*Synonym* for Triethylene Melamine

**MERTESTATE (Breon)**

Trade name for Testosterone

**MFRTHIOLATE (Lilly)**

Trade name for Thimerosal

**MERTHYLINE (Drug Products)**

Trade name for Mercurophylline

**MERYTHROL (Chemico)**

Trade name for Salicylophenylformic Acid

**MESANTOIN (Sandoz)**

Trade name for Methylphenylethylhydantoin

**MESOPIN (Endo)**

Trade name for Homatropine Methylbromide

**MESTILBOL**

Trade name Monomestrol (Wallace &amp; Tiernan)

Administration Oral, intramuscular  
Dosage forms Tablets, 0.25, 0.5, 1, 2.5 mg, ampules, 10, 25 mg in 1 ml of oil**MESTINON Br (Roche)**

Trade name for Pyridostigmine Br

**METACRESYL ACETATE**

Trade name Cresatin (Merck)

Administration Topical  
Dosage form Ointment, 80%**METADEE (Merck)**

Trade name for Calciferol

**METAMINE (Leeming)**

Trade name for Aminotrate

**METAMUCIL (Searle)**

Trade name for Psyllium

**METANDREN (Ciba)**

Trade name for Methyltestosterone

**METAPHEN (Abbott)**

Trade name for Nitromersol

**METARAMINOL BITARTRATE**Trade name Aramine Bitartrate (Merck)  
Administration Intranasal, intravenous, intramuscular  
Dosage form Solutions, 0.25 and 1.0%**METHACHOLINE Br**

Trade name Mecholyl Br (Merck)

Administration Oral  
Dosage form Tablet, 0.2 Gm**METHACHOLINE Cl**Trade name Mecholyl Cl (Merck)  
Administration Oral, subcutaneous, ion transfer  
Dosage forms Powder, ampule, 25 mg**METHADONE HCl**

Synonym Amidone HCl

Trade names Adanon HCl (Winthrop), Althos (Wyeth), Dolophine HCl (Lilly)  
Administration Oral, subcutaneous, intravenous

Dosage forms 2.5, 5.0, 7.5, and 10 mg, ampules, 5 and 10 mg per ml

**METHADRINE HCl (Burroughs Wellcome)**

Trade name for Methamphetamine HCl

**METHAFURYLENE FUMARATE**

Trade name Foramalim (Eaton)

Administration Oral  
Dosage form Tablet, 50 mg**METHALLATAL**

Trade name Mosidal (Abbott)

Administration Oral  
Dosage form Tablet, 150 mg**METHALLENESTRIL**

Trade name Vallestrel (Searle)

Administration Oral  
Dosage form Tablet, 3 mg**METHA-MERDIAZINE (McNeil)**

Trade name for Meth Dia Mer-Sulfonamides

**METHAMOCTOL**

Trade name Aranthal (Bilhuber Knoll)

Administration Oral, intravenous  
Dosage forms Tablet, 130 mg, ampule, 100 mg per ml**METHAMPHIN (Rorer)**

Trade name for Methamphetamine HCl

**METHAMPYRONE (Testagar)**

Trade name for Dipyrone

**METHANDRIOL**Synonyms Diolostene, Methylandrostenediol  
Trade names Androdiol (Carnrick), Diolandrone (Carnrick), Drostone (Ascher), Methostan (Schering), Nabadiol (Breon), Neostene (Miller), Stenediol (Organon)  
Administration Oral, intramuscular, sublingual, buccal  
Dosage forms Tablets, 10 and 25 mg, vials, 25 and 50 mg per ml

**MEPROSPAN (Wallace)**

Trade name (long acting) for Meprobamate

**MFRATRAN (Merrell)**

Trade name for Pipradrol HCl

**MERBAK (Schieffelin)**

Trade name for Acetomicrotol

**MERBROMIN**

Trade name Mercurochrome (Hynson)

Dosage forms As such, tablet, 0.3 Gm solution 2%

**MERCAPTOMERIN**

Trade name Diucardyn (Ayerst) Thiomerin (Wyeth)

Administration Subcutaneous intramuscular

Dosage form Vials 10 and 30 ml

**MERCAPTOPURINE**

Trade name Purinethol (Burroughs Wellcome)

Administration Oral

Dosage form Tablet 50 mg

**MERCOCREOLS**

Trade name Mercresin (Upjohn)

Administration Topical

Dosage form Tincture 0.2%

**MIFRCODINONE (Merrell)**

Trade name for Dihydrocodeinone Bitartrate

**MIFRCRESIN (Upjohn)**

Trade name for Mercocresols

**MIFRCUMATILIN**

Trade name Cumertulin (Endo)

Administration Oral intramuscular

Dosage forms Tablets vials 1 2 10 ml

**MERCUPURIN (Campbell)**

Original trade name for Mercurophylline

**MIFRCURASCORB (Funk)**

Trade name for mixture of Mercurophylline and Ascorbic Acid

**MIFRCURIAL OINTMENT MILD**

Synonym Blue Ointment

Administration Topical

Dosage form Ointment 10%

**MERCURIC Cl**

Synonyms Corrosive Sublimate B chloride of Mercury

Dosage form As such

**MIFRCURIC OXIDE, RED**

Administration Topical

Dosage form Ointment, 5 to 10%

**MERCURIC OXIDE, YELLOW**

Administration Topical

Dosage forms Ointment, 1%

**MERCURITAL**

Not available on commercial drug market

**MERCUROCHROME (Hynson)**

Trade name for Merbromin

**MERCUROPHEN (Merck)**

Trade name for Hydroxymercurio-o-nitrophenolate

**MIFRCUROPHYLLIN DU (Kremers Urban)**

Trade name for Mercurophylline

**MIFRCUROPHYLLINE**

Trade names Diamerlin (C. D. Smith)

Mercurascorb (Funk) Mercupurin (Campbell)

Mercurophyllin DU (Kremers Urban)

Mercuzanthin (Campbell), Merthyl line (Drug Products)

Administration Oral intramuscular

Dosage forms Tablet, 74 mg vial, 2 ml

**MIFRCUROUS Cl**

Synonym for Mild Mercurous Cl

**MERCUZANTHIN (Campbell)**

Trade name for Mercurophylline

**MIFR DIAZINE (McNeil)**

Trade name for Dia Mer Sulfonamides

**MERETHONYLINE PROCAINE**

Trade name Dectin Procaine (Lilly)

Administration Intramuscular

Dosage form Vials 2 and 10 ml

**MIFRGAMATE**

Not available on commercial drug market

**MERPHENYL BORATE (Hamilton)**

Trade name for Phenylmercuric Borate

**MERPHENYL NO<sub>2</sub> (Hamilton)**

Trade name for Phenylmercuric NO<sub>2</sub>

**MERPURATE**

Not available on commercial drug market

**MERSALYL AND THEOPHYLLINE**

Trade names Mersalyn (Kirk) Salyrgan

theophylline (Winthrop) Theomersyl which contains the sodium ethinate of theophylline (Central)

Administration Intramuscular

Dosage form Vial, 2 ml

**MERSALYN (Kirk)**

Trade name for Mersalyl and Theophylline



**METHOXYLENF (McNeil)**

Trade name for Methapyrilene HCl

**METHOXYPHENAMINE HCl**

Trade name Orthoxine HCl (Upjohn)

Administration Oral

Dosage form Tablet 100 mg

**METHOXYPRIMAZINE MALEATE**

Trade name Tentone (Lederle)

Administration Oral

Dosage forms Tablets, 10, 25, 50 mg

**METHSCOPOLAMINE Br**

Synonyms Hyoscine Methylbromide, Scopolamine Methylbromide, Epoxymethamine Br

Trade names Lescopine Br (Lincoln), Pammine (Upjohn), Proscamide (Miller)

Administration Oral

Dosage forms Tablet, 2.5 mg capsule, 7.5 mg

**METHSCOPOLAMINE NO<sub>2</sub>**

Trade name Skopolate (Strassenburgh)

Administration Oral, subcutaneous, intramuscular

Dosage forms Tablet, 2 mg ampule, 2 mg per ml

**METHSUXIMIDE**

Trade name Celontin (Parke, Davis)

Administration Oral

Dosage form Capsule, 0.3 Gm

**METHYLAMINOHFPTANF HCl**

Trade name Oenethyl HCl

Administration Intravenous

Dosage form Solution 50 mg per ml

**METHYLANDROSTENEDIOL**

Synonym for Methandroliol

**METHYL ATROPINE NO<sub>2</sub>**

Trade name Metropine (Strassenburgh)

Administration Oral subcutaneous, intramuscular

Dosage forms Tablet, 1 mg, elixir, 0.25 mg per ml ampule, 2 mg per ml

**METHYLCELLULOSE**

Trade names Cellothyl (Warner Chilcott), Cologel (Lilly), Hydrolase (Upjohn),

Melozets (Merck), Methylose (Rowell), Premocel (Premo) Syneclose (Blue Line)

Administration Oral

Dosage forms Various forms

**METHYL CYCLOHEXENYL METHYL-PARABITURIC ACID**

Trade name Sombulex (Schenley)

Administration Oral

Dosage form Tablet, 0.25 Gm

**METHYLNE BLUE**

Administration Intravenous

Dosage form Vial, 60 ml 2% solution

**METHYLERGONOVINE TARTRATE**

Trade name Methergine Tartrate (Sandoz)

Administration Oral, intravenous, intramuscular

Dosage forms Ampule, 0.2 mg per ml fluid, 0.25 mg per ml, tablet, 0.25 mg

**METHYLGLUCAMINE DIATRIZOATE**

Trade names Cardiografin (Squibb), Gas trografen (Squibb), Renografin (Squibb)

Remarks Radiopaque material used in differing concentrations and routes for intravenous urography, venography, and car diography, and for gastrointestinal visualization

**METHYLGLUCAMINE DIATRIZOATE AND IODIPAMIDE**

Trade name Duografin (Squibb)

Administration Intravenous

Dosage form Vial, 50% solution

**METHYLHEXAMINE**

Trade name Forthane (Lilly)

Administration Intranasal

Dosage form Inhaler

**6 METHYLMERCAPTOPYRINE**

Not available on the commercial drug market

**METHYLOSE (Rowell)**

Trade name for Methylcellulose

**METHYLPARAFYNOL**

Trade name Dormison (Schering)

Administration Oral

Dosage form Capsules, 0.25 and 0.5 Gm

**METHYLPHENIDATE HCl**

Trade name Ritalin HCl (Ciba)

Administration Oral

Dosage form Tablets, 5, 10, and 20 mg

**METHYLPHENYLETHYLHYDANTOIN**

Synonym Phenantoin

Trade name Mesantoin (Sandoz)

Administration Oral

Dosage form Tablet, 100 mg

**METHYLPHENYLSUCCINIMIDE**

Synonym Phensuximide

Trade name Milontin (Parke, Davis)

Administration Oral

Dosage form Capsule, 0.5 Gm

**METHYLPREDNISOLONE**

Trade name Medrol (Upjohn)

Administration Oral

Dosage form Tablet, 4 mg

**METHANTHELINE Br**

*Trade name* Banthine Br (Scarle)  
*Administration* Oral, intramuscular, intra-  
 venous  
*Dosage forms* Tablet, 50 mg, ampule, 50 mg

**METHAPHENILENE HCl**

*Trade name* Diatrine HCl (Warner)  
*Administration* Oral  
*Dosage form* Tablet, 50 mg

**METHAPYRILENE**

Sold over the counter under a variety of trade  
 names Dormin, Lullam n, Nytol Sleep-  
 Fze Somnicaps, etc.

**METHAPYRILENE HCl**

*Synonym* Phenylpyrazine  
*Trade names* Cohist ne (Pitman Moore),  
 Dormin (Dormin), Histadyl (Lilly), Lul-  
 lamin (Reed & Carnrick) Methoxylene  
 (McNeil), Semkon (Massengill), Somni-  
 caps (Am Pharm), Thénylene (Abbott),  
 and many others  
*Administration* Oral topical subcutaneous  
 intramuscular  
*Dosage forms* Tablets 25 50 and 100 mg  
 solutions, 1, 2, and 5% ointment, 5%

**METHARBITAL**

*Trade name* Gemonil (Abbott)  
*Administration* Oral  
*Dosage form* Tablet 100 mg

**METHAZOLAMIDE**

*Trade name* Neptazane (Lederle)  
*Administration* Oral  
*Dosage form* Tablet, 50 mg

**METH DIA MER-SULFONAMIDES**

*Synonym* Sulfamethazine Sulfadiazine Sulfa-  
 merazine Mixture  
*Trade names* Lupo Triazine (Donley Evans),  
 Metha merdazine (McNeil), Neotrizine  
 (Lilly) Sulfa triazine (Thompson), Sul-  
 fonsol (National) Sulfose (Wyeth) Ter-  
 sonyl (Squibb) Trifonamide (Van Pelt &  
 Brown), Trionamide (Flint Eaton), Tri-  
 pazine (Eaton), Trisem (Massengill), Tri-  
 Sulfameth (Arlington), Trisulfazine (Gen-  
 tral) Truozone (Abbott)  
*Administration* Oral  
*Dosage forms* Tablets 0.3, 0.5 Gm, fluids  
 of various strengths

**METHIDILAZINE**

*Trade name* Tacaryl (Mead Johnson)  
*Administration* Oral  
*Dosage form* Tablets, 4 8 mg

**METHEDRINE HCl (Burroughs Wellcome)**

*Trade name* for Methamphetamine HCl

**METHENAMINE**

*Trade names* Urtone (Parke, Davis),  
 Urotropin (Warner Chilcott)  
*Administration* Oral  
*Dosage form* Tablets, 0.3 and 0.5 Gm

**METHENAMINE MANDELATE**

*Trade name* Mandelamine (Nepera)  
*Administration* Oral  
*Dosage form* Tablet, 0.25 Gm

**METHERGINE TARTRATE (Sandoz)**

*Trade name* for Methylegonovine Tartrate

**METHIACIL (Schwartz)**

*Trade name* for Methylthiouracil

**METHIMAZOLE**

*Trade name* Tapazole (Lilly)  
*Administration* Oral  
*Dosage form* Tablets 5 and 10 mg

**METHIODAL SODIUM**

*Trade name* Skodan Sodium (Winthrop)  
*Administration* Intravenous and retrograde  
*Dosage forms* Tablets, 1 Gm powder solu-  
 tion, 40%

**METHIONINE**

*Trade name* Meonine (Wyeth)  
*Administration* Oral and intravenous  
*Dosage forms* Tablet, 0.5 Gm capsule, 0.2  
 Gm crystals

**METHITURAL SODIUM**

*Trade name* Neraval Sodium (Schering)  
*Administration* Intravenous  
*Dosage form* Ampule, 1 2, 5 Gm

**METHIUM Cl**

*Trade name* for Hexamethonium Cl

**METHOCARBAMOL**

*Trade name* Robavon (Robins)  
*Administration* Oral  
*Dosage form* Tablet, 0.5 Gm

**METHOSTAN (Schering)**

*Trade name* for Methandriol

**METHOTREXATE (Lederle)**

*Trade name* for Amethopterin

**METHOXAMINE HCl**

*Trade name* Vasoxyl (Burroughs Wellcome)  
*Administration* Intramuscular, intravenous  
*Dosage form* Solution 20 mg per ml

**METHOXSALEN**

*Trade names* Meloxine (Upjohn), Oxor-  
 alen (Elder)  
*Administration* Topical oral  
*Dosage forms* Tablet, 10 mg lotion 1%

**MONOBENZONE***Trade name* Benoquin (Elder)*Administration* Topical*Dosage forms* Ointment, 20% lotion 5%**MONOBROMOSALICYL ALCOHOL***Trade name* Bromsalizol (Hynson)*Administration* Oral intramuscular*Dosage forms* Tablet, 0.3 Gm vial 40 mg per ml**MONOCAINE HCl (Novocol)***Trade name* for Butethamine HCl**MONOCILLIN (Schenley)***Trade name* for Procaine Penicillin G**MONODRAL Br (Winthrop)***Trade name* for Penthienate Br**MONOMESTROL (Wallace & Tiernan)***Trade name* for Mestibol**MONOPHEN (Bell Craig)***Trade name* for Hydroxy-diiodobenzyl cyclohexane Carboxylic Acid**MONOTHEAMIN (Lilly)***Trade name* for Theophylline Monoethanol amine**MONOVACHLOROSENE***Trade name* Chlorpactin (Guardian)*Administration* Topical*Dosage form* As such**MORNIDINE (Searle)***Trade name* for Pipamizine**MORPHINE HCl***Administration* Oral parenteral*Dosage forms* Various forms**MORPHINE SO***Administration* Oral*Dosage forms* Various forms**MORPHOLINYLETHYLMORPHINE***Synonym* Pholcodine

Not available on the commercial drug market

**MORUSUL (Endo)***Trade name* for Sodium Morrhuate**MOSIDAL (Abbott)***Trade name* for Methallatal**MUCILOSE (Winthrop)***Trade name* for Psyllium**MUCIN ALUMINUM HYDROXIDE MAGNESIUM TRISILICATE MIXTURE***Trade name* Mucotin (Harrower)*Administration* Oral*Dosage form* Tablet 0.9 Gm**MUCOTIN (Harrower)***Trade name* for Mucin Aluminum Hydroxide Magnesium Trisilicate Mixture**MUI-SOL (Waynor)***Detergent cleanser***MULSOPAQUE (Lafayette)***Trade name* for Iophendylate**MULTIFUGE CITRATE (Blue Line)***Trade name* for Piperazine Citrate**MURACIL (Organon)***Trade name* for Methylthiouracil**MUREL (Ayerst)***Trade name* for Valerhamate Br**MURIAMIC (Pitman Moore)***Trade name* for Glutamic Acid HCl**MUSTARGEN HCl (Merck)***Trade name* for Mechlorethamine HCl**MYANESIN (Bjorgane)***Trade name* for Mephenezin**MYB DEN (Buschoff)***Trade name* for Adenosine Monophosphate**MYCIFRADIN SO (Upjohn)***Trade name* for Neomycin SO**MYCOSTATIN (Squibb)***Trade name* for Nystatin**MYLERAN (Burroughs Wellcome)***Trade name* for Busulfan**MYOCARDONE (Chemical)***Trade name* for Heart Muscle Extract**MYOCHRYSINE (Merck)***Trade name* for Gold Sodium Thiomalate**MYOFLEX (Warren Teed)***Trade name* for Triethanolamine Salicylate**MYOXANE (Ascher)***Trade name* for Mephenezin**MYSOLIN (Ayerst)***Trade name* for Primidone

**METHYLOSANILIN CI**

Synonym Gentian Violet  
Trade name Gentersil (Ortho)  
Administration Topical  
Dosage forms Many forms

**METHYLSALICYLATE**

Synonym Oil of Wintergreen  
Administration Topical  
Dosage form As such

**METHYLTESTOSTERONE**

Trade names Andrometh (Central) Mestone (Schiffelin), Metandren (Libby), Neo Homoreol (M) (Organon) Oreton M (Schering) Synandren (Phar) Synandrolabs (Pfizer)  
Administration Oral, sublingual  
Dosage form Tablets, 10 and 25 mg

**METHYLTHIOURACIL**

Trade names Methicil (Schwartz), Muralil (Organon), Thimicil (Physicians)  
Administration Oral  
Dosage forms Tablet 50 mg

**METHYPRYLON**

Trade name Soludar (Roche)  
Administration Oral  
Dosage forms Tablets 50 and 200 mg capsule, 400 mg elixir 12.5 mg per ml

**METICORTFLOX (Schering)**

Trade name for Prednisolone

**METICORTELOX SOLUBLE (Schering)**

Trade name for Prednisolone Sodium Hemisuccinate

**METICORTEN (Schering)**

Trade name for Prednisone

**METIDERM AFROSOL (Schering)**

Trade name for Prednisolone

**METOPON HCl**

Administration Oral  
Dosage form Capsule 3 mg

**METRAZOL (Bilhuber Knoll)**

Trade name for Pentyl metetrazol

**METROPINE (Strassenburgh)**

Trade name for Methyl Atropine NO

**METUBINE I (Jilly)**

Trade name for Dimethyl Tubocurarine I

**METYLINF HCl (Jilly)**

Trade name for Piperocaine HCl

**MICOFUR (Eaton)**

Trade name for Nifuroxime

**MIDICEL (Parke, Davis)**

Trade name for Sulfamethoxypyridazine

**MIGESTERONE (Durst)**

Trade name for Progesterone

**MIKEDIMIDE (Panray)**

Trade name for Bemegride

**MILD MERCUROS CI**

Synonym Mercurous Cl  
Administration Oral  
Dosage form Tablet, 10 mg

**MILIBIS (Winthrop)**

Trade name for Glycoluarsol

**MILK OF MAGNESTA**

Synonym for Magnesium Hydroxide

**MILK OF TRINESIUM (Abbott)**

Trade name for Magnesium Trisilicate and Aluminum Hydroxide

**MILK SUGAR**

Synonym for Lactose

**MILONTIN (Parke, Davis)**

Trade name for Methylphenylsuccinamide

**MILTOWN (Wallace)**

Trade name for Meproamate

**MINERAL OIL**

Synonym for Petrolatum

**MINTACOL**

Not available on the commercial drug market

**MIOKON (Mallinckrodt)**

Trade name for Sodium Dipropionamidotriiodobenzoate

**MIRADON (Schering)**

Trade name for Anisindione

**MODFRIL (Pfizer)**

Trade name for Rescinnamine

**MOFBIQUIN (C.M.C.)**

Trade name for Duodohydroxyquin

**MOLOFAC (Squibb)**

Trade name for Diethyl Sodium Succinate

**MONACETIN**

Not readily available on commercial drug market

**MONITAN (Ivet Cameron)**

Trade name for Polysorbate 80

**NFOHETRAMINE (Nepera)**

Trade name for Thonzylamine HCl

**NFO HOMIBRFOI (Organon)**

Trade name for Testosterone Propionate

**NFO HOMIBRFOI (F) (Organon)**

Trade name for Testosterone

**NFO HOMIBRFOI (M) (Organon)**

Trade name for Methyltestosterone

**NFOHYDRIN (Lakeside)**

Trade name for Chlormerodrin

**NFO IOPAN (Schering)**

Trade name for Sodium Iodomethamate

**NEOLIN (Lilly)**

Trade name for Benzathine Penicillin G

**NEOMYCIN SO**

Trade name Mycfradin SO (Upjohn)

Administration Topical oral intramuscular

Dosage forms As such tablet 0.5 Gm.  
ampule 0.5 Gm**NFOVAL (Abbott)**

Trade name for Butethal

**NFOPRONTOSIL (Winthrop)**

Trade name for Azosulfamide

**NEO SILAOL (Parke Davis)**

Trade name for Silver J Colloidal

**NEOSTAM (Burroughs Wellcome)**

Trade name for St. Lamine Glucose

**NFOSTFNF (Miller)**

Trade name for Methandriol

**NEOSTIGMINE Br**

Trade name Prostigmin Br (Roche)

Administration Oral ophthalmic

Dosage forms Tablet, 15 mg solution 5%

**NFOSTIGMINE METHYLSULFATE**

Trade name Prostigmin Methylsulfate (Roche)

Administration Subcutaneous intramuscular

Dosage form Ampules 0.25, 0.5, and 1.0 mg per ml

**NFO SYNTPHRINE HCl (Winthrop)**

Trade name for Phenylephrine HCl

**NFOTRIZINE (Lilly)****NFIHFNALIN (Leeming)**Each tablet contains Isoproterenol 10 mg  
Theophylline, 130 mg Ephedrine SO 25 mg  
Phenobarbital 8 mg**NFTAZANE**

Trade name for Methazolamide

**NFRAMI SODIUM (Schering)**

Trade name for Methitalur Sodium

**NESACAINF HCl (Maltbie)**

Trade name for Chloroprocaine HCl

**NETHAMINE HCl (Merrell)**

Trade name for Ethylephedrine HCl

**NFUTRAPFN (Schenley)**

Trade name for Penicillinase

**NEUTRAZYME (Smith Dorsey)**

Trade name for Sodium Lauryl SO

**NIACIN**

Synonym for Nicotinic Acid

**NIACINAMIDE**

Synonym for Nicotinamide

**NIADRIN (Endo)**

Trade name for Isoniazid

**NIALAMIDE**

Trade name Niamid (Pfizer)

Administration Oral

Dosage form Tablets, 25 100 mg

**NIAMID (Pfizer)**

Trade name for Nialamide

**NICONYL (Parke Davis)**

Trade name for Isoniazid

**NICOTINAMIDE**

Synonym Niacinamide

Administration Oral parenteral

Dosage forms Tablets 25 50 and 100 mg  
ampules 10 50 and 100 mg per ml**NICOTINIC ACID**

Synonym Niacin

Administration Oral parenteral

Dosage form Tablets 25 50 and 100 mg

**NICOZIDE (Premo)**

Trade name for Isoniazid

**NIFUROXIME**

Trade name Micofur (Eaton)

Administration Intravaginal

Dosage forms Powders solutions and sup

**MYSTECLIN (Squibb)**

Trade name for Tetracycline and Nystatin

**MYSTECLIN V (Squibb)**

Trade name for Tetracycline PO Complex and Nystatin Mixture

**MYTELASE Cl (Winthrop)**

Trade name for Amibenonum Cl

**NABADIAL (Breon)**

Trade name for Methandrolo

**NAEPAIN HCl**

Trade name Amylsine HCl (Novorol)

Administration Topical

Dosage form Solution 4%

**NA GENT (Raymer)**

Trade name for Sodium Gentisate

**NAIR (Wallace)**

Proprietary depilatory

**NALLINE HCl (Merck)**

Trade name for Nalorphine HCl

**NALORPHINE HCl**

Trade names Lethidrone (Burroughs Wellcome) Nalline (Merck)

Administration Intravenous, intramuscular

Dosage form Ampules 1 and 2 ml containing 5 mg per ml

**NANDROLONE PHENPROPIONATE**

Trade name Durabolin (Organon)

Administration Subcutaneous intramuscular

Dosage form Ampule 25 mg per ml

**NAPENTAL (Massengill)**

Trade name for Pentobarbital Sodium

**NAPHAZOLINE HCl**

Trade name Privine HCl (Ciba)

Administration Intranasal conjunctival

Dosage form Solutions 0.05 and 0.1%

**NAPRYLATE (Strassenburgh)**

Trade name for Caprylic Compound

**NARCOTINE**

Synonym for Noscipone

**NARDIL (Warner-Chilcott)**

Trade name for Phenelzine Dihydrochloride

**NARONE (Ulmer)**

Trade name for Dipyrene

**NARTATE (Harvey)**

Trade name for Dipyrene

**NATOLONE (National)**

Trade name for Pregnenolone

**NATRASCORB (U S Vitamin)**

Trade name for Ascorbate Sodium

**NATRINIL (National Drug)**

Trade name for Carboxylic Resin

**NAUGAINE (Taylor)**

Trade name for Chlorocaine HCl

**NEBS (Norwich)**

Trade name for Acetaminophen

**NEBU PREL (Mahon)**

Trade name for Isoproterenol and Phenylephrine Mixture

**NECTADON (Merck)**

Trade name for Noscipone

**NEGATAN (Lilly)**

Trade name for Negatol

**NEGATOL**

Trade name Negatan (Lilly)

Administration Intravaginal

Dosage forms Solution 45% suppository 5%

**NEKO GERMICIDAL SOAP (Parke Davis)**

Mercuric Iodide soap

**NEMBUTAL (Abbott)**

Trade name for Pentobarbital Sodium

**NEO A\* FIL (Texas Pharmacal)**

Digallol Trileate Cream

**NEO ANTERGAN (Merck)**

Trade name for Pyrimamine Maleate

**NEOANTIMOSAN**

Synonym for Stibophen

**NEOATOPHAN**

Synonym for Neocinchophen

**NEOBASE (Burroughs Wellcome)**

Trade name for O/W emulsion base

**NEO CALGLUCON (Sandoz)**

Trade name for Calcium Gluconogalactoglucuronate

**NEOCINCHOPHEN**

Synonym Neocatophan

Trade name Tolysin (Lederle)

Administration Oral

Dosage form Tablets 0.2 and 0.3 Gm

**NOVATRIN (Campbell)**

Trade name for Homatropine Methylbromide

**NOVOBIOCIN SODIUM**

Trade name Albamycin Sodium (Upjohn),

Cathomycin Sodium (Merck)

Administration Oral

Dosage form Capsule, 250 mg

**NOVOCAIN (Winthrop)**

Trade name for Procaine HCl

**NPH ILFTIN (Lilly)**

Trade name for Isophane Insulin

**NPH INSULIN**

Synonym for Isophane Insulin

**NUJOL (Esso)**

Trade name for Petrolatum

**NU KOL-TAR (Benet)**

Crude Coal Tar

**NUMORPHAN HCl (Endo)**

Trade name for Oxymorphone

**NUPERCAINF HCl (Ciba)**

Trade name for Dibucaine HCl

**NUPORALS (Ciba)**

Trade name for Dibucaine HCl

**NYDRAZID (Squibb)**

Trade name for Isoniazid

**NYLIDRIN HCl**

Trade name Arlidin (Arlington)

Administration Oral, subcutaneous intra muscular

Dosage forms Tablet 6 mg, ampule, 5 mg per ml

**NYLOXIN (Hynson)**

Trade name for Cobra Venom Preparation

**NYSTATIN**

Trade name Mycostatin (Squibb)

Administration Oral

Dosage form Tablet 500 000 units

**NYTOL**

Trade name for Methapyrilene

**OBSTETRICAL PITUITRIN (Parke, Davis)**

Trade name for Posterior Lobe Pituitary Extract

**OCTIN HCl (Bilhuber Knoll)**

Trade name for Isometheptene

**OCTRITE (Hynson)**

Trade name for Octyl Nitrite

**OCTYL NITRITF**

Trade names Medihaler Nitro (Riker)

Octrite (Hynson)

Administration Inhalation

Dosage form Inhaler containing 2 ml

**OFNFTHYL HCl (Bilhuber Knoll)**

Trade name for Methylaminoheptane HCl

**OIL OF WINTERGREEN**

Synonym for Methylsalicylate

**OILATUM (Stiefel)**

Superfatted soap

**OLEANDOMYCIN PO,**

Trade name Matromycin (Pfizer)

Administration Oral intravenous

Dosage form Capsule, 250 mg ampule 500 mg

Remarks Sold and dispensed largely in a mixture with Tetracycline under the proprietary name of Sigmamycin

**OLFOVITAMIN A**

Synonym Vitamin A

Trade names Afaxin (Winthrop), Apexol (Roerig), and many others

Administration Oral intramuscular

Dosage forms Capsules and containers of 25 to 100 000 units, ampules 25 000, 50 000 100 000 units per ml

**OMNOPON**

Synonym for Pantopon (Roche)

**OPHTHAINE (Squibb)**

Trade name for Proparacaine HCl

**OPIUM**

Administration Oral

Dosage forms Camphorated Tr (Paregoric), Deodorized Tr

**ORABILEX (Fougera)**

Trade name for Bunamiodyl

**ORADIOL (VanPelt & Brown)**

Trade name for Ethinyl Estradiol

**ORA LUTIN (Parke, Davis)**

Trade name for Ethisterone

**ORANIXON (Organon)**

Trade name for Mephesisin

**ORAPEN (Schenley)**

Trade name for Potassium Penicillin G

**NIKETHAMIDE**

*Trade names* Coramine (Liba) Nikethyl (Abbott)  
*Administration* Intravenous  
*Dosage form* Ampules 250 mg per ml

**NIKETHYL (Abbott)**

Trade name for Nikethamide

**NILEVAR (Searle)**

Trade name for Norethandroloxe

**NILODIN**

Synonym for M rac 1 D

**NIONATE (Nion)**

Trade name for Ferrous Chlorate

**NISENTIL HCl (Roche)**

Trade name for Alphenidone HCl

**NISULFAZOLE (Breon)**

Trade name for p-Nitrosulfathiazole

**NITRANTOL (Mettell)**

Trade name for Mannitol Hexantrate

**NITRFTAMIN (Squibb)**

Trade name for Aminotrate

**NITRIC ACID**

*Administration* Topical  
*Dosage form* Fuming acid

**NITROFURANTOIN**

*Trade name* Furadantin (Eaton)  
*Administration* Oral intravenous drip  
*Dosage form* Tablets 50 mg

**NITROGEN MUSTARD**

Synonym for group of drugs which includes Mechlorethamine

**NITROGLYCERIN**

Synonym for Glyceryl Trinitrate

**NITROGLYN (Key)**

Delayed release tablet 2.5 to 5 mg of Glyceryl Trinitrate

**NITROVERSOL**

*Trade name* Metaphen (Abbott)  
*Administration* Topical  
*Dosage forms* Solution 0.5 0 0.01  
0.033% ointure 0.5%

**NITROTALANS (Maney)**

Trade name for Pentyrrythanol Tetranitrate

**p-NITROSULFATHIAZOLE**

*Trade name* Nisulfazole (Breon)  
*Administration* Intrarectal  
*Dosage form* Suspension 10%

**NITROUS OXIDE**

*Administration* Inhalation  
*Dosage form* Cylinders as such

**NIVEA CREAM (Duke)**

Detergent cleanser

**NIVEA SKIN OIL (Duke)**

Detergent cleanser

**NOCTEC (Squibb)**

Trade name for Chloral Hydrate

**NOLUDAR (Roche)**

Trade name for Methiprylon

**NORFTHANDROLOXE**

*Trade name* Nilevar (Searle)  
*Administration* Oral  
*Dosage form* Tablet 10 mg

**NORETHANDRONE**

*Trade name* Noluton (Parke Davis)  
*Administration* Oral  
*Dosage form* Tablet 5 mg

**NORFTHANDROFI**

*Trade name* Enovid (Searle)  
*Administration* Oral  
*Dosage form* Tablet 10 mg

**NORFLEX (Riker)**

Trade name for Orphenadrine Chloride

**NORISODRINE SO (Abbott)**

Trade name for Isoproterenol SO

**NORLUTIN (Parke Davis)**

Trade name for Norethandrone

**NORMADRINE (VanPelt & Brown)**

Trade name for Methamphetamine HCl

**NORMAL HUMAN PLASMA**

*Administration* Intravenous  
*Dosage form* As such or for reconstitution

**NORODIN (Endo)**

Trade name for Methylamphetamine HCl

**NOSCAPINE**

Synonym Narcotine  
*Trade name* Nectadon (Merck)  
*Administration* Oral  
*Dosage form* As such

**NOSTYN (Ames)**

Trade name for Fcetylurea

**NOVALDIN (Winthrop)**

Trade name for Dipyrone



**OXYQUINOLINE SO.***Trade name* Chinosol (Jewell)*Administration* Topical*Dosage form* As such**OXYTETRACYCLINE***Trade names* Terrabon (Pfizer), Terramycin (Pfizer)*Administration* Oral, topical*Dosage forms* Capsules, 50, 100 mg, solution troches, 15 mg aerosol, 50 mg per ml**OXYTETRACYCLINE HCl***Trade name* Terramycin HCl (Pfizer)*Administration* Oral, parenteral, topical*Dosage forms* Solution, elixirs, drops, ointments of several concentrations**OXYTOCIN***Trade name* Pitocin (Parke, Davis)*Administration* Intramuscular, subcutaneous*Dosage form* Ampule, 10 units per ml**p<sub>32</sub>**

Synonym for Sodium Radio-Phosphate

**PABA SODIUM**

Synonym for Sodium Para aminobenzoate

**PACATAL ACETATE (Warner-Chilcott)**

Trade name for Mepazine Acetate

**PACATAL HCl (Warner-Chilcott)**

Trade name for Mepazine HCl

**PACKER'S TAR SHAMPOO (Packer)**

Tar shampoo

**PACKER'S TAR SOAP (Packer)**

Pine tar soap

**PADUTIN (Winthrop)**

Trade name for Pancreatic Gland Extract

*Administration* Parenteral**PAGITANE HCl (Lilly)**

Trade name for Cycrimine HCl

**PALUDRINE HCl (Ayerst)**

Trade name for Chloroguanide HCl

**PAM**

Synonym for Pyridine Aldoximine Methiodine

**PAMAQUINE NAPHTHOATE**

Synonym Plasmoquine

*Trade name* Plasmochin Naphthoate (Winthrop)*Administration* Oral*Dosage form* Tablets, 20 and 40 mg**PAMINE Br (Upjohn)**

Trade name for Methscopolamine Br

**PAMISYL (Parke, Davis)**

Trade name for Aminosalicic Acid

**PAMISYL SODIUM (Parke, Davis)**

Trade name for Sodium Aminosalicylate

**PANALBA (Upjohn)**

Trade name for mixture of Tetracycline PO, and Novobiocin Sodium

**PANCREATIC DORNASE***Trade name* Dornavac (Merck)*Administration* Inhalation*Dosage form* Vial, when reconstituted 50,000 U per ml**PANCREATIN***Trade names* Amylgestin (McNeil), Panopsin (Harrower), Viokase (Vio-Bin)*Administration* Oral*Dosage forms* A variety of forms and sizes**PANHEPRIN (Abbott)**

Trade name for Heparin Sodium

**PANMYCIN (Upjohn)**

Trade name for Tetracycline

**PANMYCIN HCl (Upjohn)**

Trade name for Tetracycline HCl

**PANMYCIN PO, (Upjohn)**

Trade name for Tetracycline PO, Complex

**PANOPSIN (Harrower)**

Trade name for Pancreatin

**PANPARNIT (Geigy)**

Trade name for Caramiphen HCl

**PANRONE (Panray)**

Trade name for Amithiozone

**PANTHOLIN (Lilly)**

Trade name for Pantothenic Acid

**PANTOPAQUE (Lafayette)**

Trade name for Iophendylate

**PANTOPIUM**

Synonym for Pantopon (Roche)

**PANTOPON (Roche)**

Proprietary mixture of opium alkaloids, principally morphine

Synonyms Omnopon, Pantopium

*Administration* Oral, subcutaneous*Dosage forms* Tablets, approximately 10, 20 mg, ampule, approximately 20 mg per ml

**ORESTRALYN (McNeil)**

Trade name for Ethinyl Estradiol

**ORETIC (Abbott)**

Trade name for Hydrochlorothiazide

**ORETON (Schering)**

Trade name for Testosterone Propionate

**ORFTON F (Schering)**

Trade name for Testosterone

**ORETON M (Schering)**

Trade name for Methyltestosterone

**ORGANIDIN (Wampole)**

Trade name for Iodinated Glycerol

**ORINASE (Upjohn)**

Trade name for Tolbutamide

**ORPHENADRINE CITRATE**

Trade name Norflex (Riker)

Administration Oral

Dosage form Tablet 100 mg

**ORPHENADRINE HCl**

Trade name Ds-pal (Riker)

Administration Oral

Dosage form Tablet 50 mg

**ORTHOXINE HCl (Upjohn)**

Trade name for Methoxyphenamine HCl

**OSTFASIN (Wyeth)**

Trade name for Trimethidinum Methosulfate

**OTOSONE F (Broemmel)**

Trade name for Hydrocortisone

**OTRIVIN (Ciba)**

Trade name for Xylometazoline HCl

**OUABAIN**

Administration Intravenous intramuscular

Dosage form Ampules of various sizes

**OVOCLIN (Ciba)**

Trade name for Estradiol

**OVOCLIN BENZOATE (Ciba)**

Trade name for Estradiol Benzoate

**OVOCLIN DIPROPIONATE (Ciba)**

Trade name for Estradiol Dipropionate

**O/W EMULSION BASE**

Synonym for Oil in Water emulsion base

**ON BILE EXTRACT**

Trade names Bicol (McNeil), Bilein (Abbott)

Administration Oral

Dosage form Tablets of various sizes

**OXALIC AND MALONIC ACID MIXTURE**

Trade name Koagamin (Chatham)

Administration Parenteral

Dosage form Vial 10 ml.

**OXANAMIDE**

Trade name Quiaclin (Merrell)

Administration Oral

Dosage form Tablet, 400 mg

**OXOPHENARSINE HCl**

Trade name Mapharsen (Parke Davis)

Administration Intravenous

Dosage form Ampules 40 60 mg, 0.6 Gm

**OXSORALEN (Elder)**

Trade name for Methoxsalen

**OXTRIPHYLLINE**

Synonym Choline Theophyllinate

Trade name Cholecyl (Nepera)

Administration Oral

Dosage form Tablets 0.1 Gm, 0.2 Gm

**OXUCIDE (Breon)**

Trade name for Piperazine Citrate

**OXYCEL (Parke Davis)**

Trade name for Cellulose Oxidized

**OXYFED (Cole)**

Trade name for Methamphetamine HCl

**OXYGEN**

Administration Inhalation

Dosage forms Under pressure in tanks or metal bottles

**OXYL-IODIDE (Lilly)**

Trade name for Cinchophen Hydriodide

**OXYLON (Upjohn)**

Trade name for Fluorometholone

**OXYMORPHONE**

Trade name Numorphan HCl (Endo)

Administration Parenteral rectal

Dosage forms Ampules 1 2, and 10 ml suppositories 2 and 5 mg

**OXYPHENCYCLIMINE HCl**

Trade name Dancron (Pfizer)

Administration Oral

Dosage form Tablet 10 mg

**OXYPHENONIUM Br**

Trade name Antrenyl Br (Ciba)

Administration Oral

Dosage forms Tablet 5 mg syrup about 1 mg per ml.

**OXYPOLYGELATIN SOLUTION**

Synonym for Gelatin Solution, Purified

**PASEM SODIUM** (Massengill)

Trade name for Sodium Aminosalicylate

**PASKIUM** (Glenwood)

Trade name for Potassium Aminosalicylate

**PASKATT** (Lilly)

Trade name for Potassium Aminosalicylate

**PATHILON** (Lederle)

Trade name for Tridihexethide

**PAVATRINE** (Searle)

Trade name for Aminocarbofluorene

**PAVRIL** (Lilly)

Trade name for Dioxylene

**PFGAZINE**

Synonym for Mepazine

**PECTIN***Administration* Oral*Dosage form* As such but mainly in mixtures**PFGANONE** (Abbott)

Trade name for Ethotoin

**PELLETIERINE TANNATE***Trade name* Punicine Tannate (N Y Quinine)*Administration* Oral*Dosage form* Capsule, 0.25 Gm**PELLEX** (Pellex)

Calcium Hydroxide thioglycolic acid

**PEMOPHYLLIN** (Pitman Moore)

Trade name for Theophylline Sodium Glycinate

**PENALEV** (Merck)

Trade name for Potassium Penicillin G

**PENASOID** (Parke Davis)

Trade name for Potassium Penicillin G

**PENDIOMIDE** (Ciba)

Trade name for Azamethonium Br

**PEN G CAP** (Upjohn)

Trade name for Procaine Penicillin G

**PNICILLIN V**

Synonym for Phenoxymethyl Penicillin

**PENICILLINASE***Trade name* Neutrapen (Schenley)*Administration* Intravenous*Dosage form* Vial, 800 000 units**PENTAERYTHRITOL CHLORAL****PENTAERYTHRITOL TETRANITR***Trade names* Angicap (Pro-Acet), talans (Maney) Pentritol (Evron), trate (Warner Chilcott)*Administration* Oral*Dosage forms* Tablets 10 and 20 mg sustained release tablet 30 mg**PENTAL** (VanPelt & Brown)

Trade name for Pentobarbital Sodium

**PENTAQUINF PO***Administration* Oral*Dosage form* Tablet 13.3 mg**PENTHIFNATE Br***Trade name* Monodral Br (Winthrop)*Administration* Oral*Dosage form* Capsule, 5 mg**PENTIDS** (Squibb)

Trade name for Potassium Penicillin G

**PENTOBARBITAL SODIUM***Trade names* Isobarb (U S Standards), Napental (Massengill), Nembutal (Abbott), Pental (VanPelt & Brown)*Administration* Oral, rectal intravenous*Dosage forms* Capsules 30 50 100 mg, elixir, 3 mg per ml suppositories 30 130, and 200 mg, 0.25 and 0.5 Gm t d luted, vial 50 mg per ml**PENTOLINIUM***Trade name* Ansolysen (Wyeth)*Administration* Oral*Dosage form* Tablets 20 40, and 100**PENTOTHAL SODIUM** (Abbott)

Trade name for Thopental Sodium

**PENTRITOL** (Evron)

Trade name for Pentaerythritol Tetranitrate in sustained release form

**PENTYLENETETRAZOL***Trade names* Cardiazol (Bilhuber Knoll), Metrazol (Bilhuber Knoll)*Administration* Intravenous*Dosage form* Ampules 1 and 3 ml containing 0.1 Gm per ml**PENVEF** (Wyeth)

Trade name for Phenoxymethyl Penicillin

**PENVEE K** (Wyeth)

Trade name for Potassium Penicillin

**PENVEE L-A** (Wyeth)

Trade name for Phenoxymethyl Penicillin

**PERANDREN** (Ciba)

Trade name for Testosterone Propionate

**PANTOTHENIC ACID**

*Trade name* Ilopan (Warren-Teed), Panthol n (Lilly)  
*Administration* Oral  
*Dosage form* Tablet, 10 mg

**PANTOTHENYL ALCOHOL**

*Trade name* Ilopan (Warren Teed)  
*Administration* Intramuscular  
*Dosage form* 250 mg per ml

**PAPAVERINE**

*Administration* Oral  
*Dosage forms* Tablets 0.03 0.06 0.1 and 0.2 Gm

**PAPAVERINE HCl**

*Administration* Intravenous  
*Dosage form* Ampule 30 mg per ml

**PAPAYA ENZYME**

*Trade name* Caroid (Am Ferment)  
*Administration* Oral  
*Dosage forms* As such tablet 100 mg

**PARA AMINOSALICYLIC ACID**

Synonym for Aminosalicyl c Acid

**PARABROMDYLAMINE MALEATE**

*Trade name* Dimetane (Robins)  
*Administration* Oral  
*Dosage forms* Tablet, 4 mg elixir 0.4 mg per ml Extentabs, 12 mg

**PARACARBINOXAMINE MALEATE**

*Trade name* Clisip Maleate (McNeil)  
*Administration* Oral  
*Dosage forms* Tablet 4 mg fluid 1.25 mg per ml

**PARACODIN (Bilbuber Knoll)**

*Trade name* for Dihydrocodeine Bitartrate

**PARACORT (Parke Davis)**

*Trade name* for Prednisone

**PARACORTOL (Parke, Davis)**

*Trade name* for Prednisolone

**PARADIONE (Abbott)**

*Trade name* for Paramethadione

**PARAFLEX (McNeil)**

*Trade name* for Chlorzoxazone

**PARALDHYDE**

*Administration* Oral rectal intramuscular intravenous  
*Dosage form* As such

**PARAMETHADIONE**

*Trade name* Paradione (Abbott)  
*Administration* Oral  
*Dosage forms* Capsules, 150 and 300 mg solution, 0.3 Gm per ml

**PARAMINYL (Burlington)**

*Trade name* for Pyrilamine Maleate

**PARANITROSULFATHIAZOLE**

*Trade name* Nisulfazole (Breon)  
*Administration* Rectal  
*Dosage form* Suspension 10%

**PARA PAS (Gold Leaf)**

*Trade name* for Aminosalicyl c Acid

**PARASAL (Panray)**

*Trade name* for Aminosalicyl c Acid

**PARASAL CALCIUM (Panray)**

*Trade name* for Calcium Aminosalicylate

**PARASAL SODIUM (Panray)**

*Trade name* for Sodium Aminosalicylate

**PARATHYROID EXTRACT**

*Trade name* Paroidin (Parke Davis)  
*Administration* Subcutaneous intramuscular  
*Dosage form* Ampule 100 units per ml

**PARAZINE CITRATE (Tutag)**

*Trade name* for Piperazine Citrate

**PARFDRIN HBr (Smith Kline & French)**

*Trade name* for Hydroxylan phetamine HBr

**PAREGORIC**

*Opium preparation*

**PARENOGEN (Cutter)**

*Trade name* for Fibrinogen (Human)

**PARENTRACIN (C.S.C.)**

*Trade name* for Bacitracin

**PARNZYME (National)**

*Trade name* for Trypsin

**PARODYNE**

Synonym for Antipyrine

**PAROIDIN (Parke Davis)**

*Trade name* for Parathyroid Extract

**PARSIDOL (Warner Chilcott)**

*Trade name* for Ethopropazine HCl

**PASARA SODIUM (Smith Dorsey)**

*Trade name* for Sodium Aminosalicylate

**PHENINDAMINE TARTRATE***Trade name* Thephorin (Roche)*Administration* Oral topical*Dosage forms* Tablet, 10 mg syrup about 2 mg per ml lotion 2% ointment 5%**PHENINDIONE***Trade names* Danilone (Schieffelin) Hedu*In* (Walker) Indon (Parke Davis)*Administration* Oral*Dosage form* Tablet 50 mg**PHENIRAMINE MALEATE***Synonym* Prophepyridamine Maleate*Trade names* Inhiston (Union) Trimeton (Schering)*Administration* Oral*Dosage forms* Tablets 25 mg elixir about 2 mg per ml**PHENMETRAZINE HCl***Trade name* Preludin (Geigy)*Administration* Oral*Dosage form* Tablet 25 mg**PHENOBARBITAL***Trade name* Luminal Sodium (Winthrop)*Administration* Oral*Dosage form* Tablets 15 30 and 100 mg**PHENOBARBITAL SODIUM***Trade name* Luminal Sodium (Winthrop)*Administration* Oral rectal intravenous in intramuscular*Dosage forms* Ampules containing 0.13, 0.16 and 0.3 Gm in solution and as a powder tablets 65 and 100 mg**PHENOL***Synonym* Carbolic Acid*Administration* Topical*Dosage forms* Various forms**PHENOL RED***Synonym for* Phenolsulfonphthalein**PHENOLOR** (Squibb)*Trade name for* Cresol**PHENOLPHTHALEIN***Trade names* Too large a number to list*Administration* Oral*Dosage forms* A large variety of forms**PHENOLSULFONPHTHALEIN***Synonym* Phenol Red P S P*Administration* Intravenous intramuscular*Dosage form* Ampule 6 mg per ml**PHENOXENE** (Pitman Moore)*Trade name for* Chlorphenoxamine HCl**PHENOXYBENZAMINE HCl***Trade name* D benzyl ne (Smith Kline & French)*Administration* Oral*Dosage form* Capsule 10 mg**PHENOXYMETHYL HYDRAZAMINE PENICILLIN***Trade name* Compoicillin V (Abbott)*Administration* Oral*Dosage form* Suspension 60 000 units per ml**PHENOXYMETHYL PENICILLIN***Synonym* Penicillin V*Trade name* Pen Vee L V (Wyeth) V Cillin (Lilly)*Administration* Oral*Dosage form* Tablets 200 000 and 500 000 units**PHENOXYMETHYL POTASSIUM PENICILLIN***Synonym for* Potassium Penicillin V**PHENPROCOUNON***Trade names* Liquamar (Organon) Marcumar (Roche)*Administration* Oral*Dosage form* Tablet 3 mg**PHENPROPANIDE**

Not available on the commercial drug market

**PHENSUXIMIDE***Synonym for* Methylphenylsuccinimide**PHENTETIOTHALEIN SODIUM***Trade name* Iso-Iodoion (Mallinckrodt)*Administration* Intravenous*Dosage form* Ampule 2.5 Gm**PHENTOLAMINE HCl***Trade name* Regitine HCl (Ciba)*Administration* Oral*Dosage form* Tablet 50 mg**PHENTOLAMINE METHANESULFONATE***Trade name* Regitine Methanesulfonate (Ciba)*Administration* Intravenous intramuscular*Dosage form* Ampule 5 mg**PHENURONE** (Abbott)*Trade name for* Phenacetamide**PHENYLAZO DIAMINO PYRIDINE HCl***Trade names* Azodyne (Stuart) Mallophone (Mallinckrodt) Pyridum (Merck)*Administration* Oral topical*Dosage forms* Tablet 100 mg solution 10 mg per ml

**PFRANDREN PHENYLACETATE** (Ciba)  
Trade name for Testosterone Phenylacetate

**PERAZIL** (Burroughs Wellcome)  
Trade name for Chlorcyclizine HCl

**PFCORTEN** (Ciba)  
Trade name for Desoxycorticosterone Acetate

**PERFECTOCHOL** (Lafayette)  
Trade name for Iodoalphion c Acid

**PFRICLOR** (Ives Cameron)  
Trade name for Petrichloral

**PFRIN** (Endo)  
Trade name for Piperazine Calcium Edathymate

**PFRISTALTIN** (Ciba)  
Trade name for Cascara Sagrada

**PFRISTIM** (Mead Johnson)  
Trade name for Extract of Cascara Sagrada

**PERITRATF** (Warner Chilcott)  
Trade name for Pentaerythritol Tetranitrate

**PERMAPEN** (Eli Lilly)  
Trade name for Benzathine Penicillin G

**PERMITIL** (White)  
Trade name for Fluphenazine D hydrochloride

**PFRNAEMON** (Organon)  
Trade name for Liver Injection Purified

**PERPHENAZINE**  
Trade name Trilafon (Schering)  
Administration Oral  
Dosage forms Tablets, 2, 4, 8 and 16 mg  
syrup 0.4 mg per ml

**PETHIDINE**  
Synonym for Meperidine

**PETRICHLORAL**  
Trade name Periclor  
Administration Oral  
Dosage form Capsule 0.3 Gm

**PETROLATUM**  
Synonym Mineral oil  
Trade names Albolene (McKesson & Robbins) Kondremul (Patch) Nujol (Fisso) Petronol (Lilly)  
Administration Oral  
Dosage form As such

**PFTRONOL** (Lilly)  
Trade name for Petrolatum

**PHANODORN CALCIUM** (Winthrop)  
Trade name for Cyclobarbital Calcium

**PHEMER NITE** (Massengill)  
Trade name for Phenylmercuric NO

**PHEMEROL Cl** (Parke Davis)  
Trade name for Benzethonium Cl

**PHENACAINE HCl**  
Synonym Holocaine HCl  
Administration Topical  
Dosage form Ointment 2%

**PHENACEMIDE**  
Trade name Phenurone (Abbott)  
Administration Oral  
Dosage form Tablets 0.3 and 0.5 Gm

**PHENACETIN**  
Synonym for Acetophenetidin

**PHENAGLYCODOL**  
Trade name Ultram (Lilly)  
Administration Oral  
Dosage form Tablet 0.3 Gm

**PHEMANTOIN**  
Synonym for Methylphenylethylhydantoin

**PHENARSONE**  
Trade name Aldarson (Abbott)  
Administration Intravaginal  
Dosage forms Ampule 1 Gm powder suppository 0.5 Gm

**PHENARSONF SULFONYLATE**  
Trade name Aldarson (Abbott)  
Administration Intravenous  
Dosage form Ampule 1 Gm

**PHENAZON**  
Synonym for Antipyrine

**PHENFLZINE DIHYDROGEN SO**  
Trade name Nardil (Warner Chilcott)  
Administration Oral  
Dosage form Tablet 15 mg

**PHENFRGAN** (Wyeth)  
Trade name for Promethazine HCl

**PHENETAL**  
Trade name Salophen (Winthrop)  
Administration Oral  
Dosage form Tablet 0.3 Gm

**PHENFORMIN**  
Trade name DBI (L. S. Vitamin)  
Administration Oral  
Dosage form Tablet, 25 mg

**PHYTONADIONE**

*Synonym* Vitamin K<sub>1</sub>  
*Trade names* Mephyton (Merck), Konakion (Roche)  
*Administration* Intravenous, oral  
*Dosage forms* Ampule, 50 mg per ml, tablet, 5 mg

**PICRAGOL (Wyeth)**

*Trade name* for Silver Picrate

**PICRIC ACID**

*Administration* Topical  
*Dosage form* Various concentrations

**PICROTOXIN**

*Administration* Intravenous  
*Dosage form* Ampules, 1 and 20 ml containing 3 mg per ml

**PIG BILE EXTRACT**

*Administration* Oral  
*Dosage form* Tablet, 0.25 Gm

**PILOCARPINE HCl**

*Administration* Subcutaneous  
*Dosage form* 15 mg hypo tablets

**PIPADONE**

*Synonym* for Dipiprnone

**PIPAMAZINE**

*Trade name* Morindine (Searle)  
*Administration* Oral intravenous  
*Dosage forms* Tablet, 5 mg, ampule, 5 mg

**PIPANOL (Winthrop)**

*Trade name* for Trihexyphenidyl HCl

**PIPENZOLATE METHYLBROMIDE**

*Trade name* Pipital (Lakeside)  
*Administration* Oral  
*Dosage form* Tablet 5 mg

**PIPERATE (Lincoln)**

*Trade name* for Piperazine Tartrate

**PIPERAZATE (Leeming)**

*Trade name* for Piperazine PO.

**PIPERAZINE CALCIUM EDATHAMIL**

*Trade name* Perin (Endo)  
*Administration* Oral  
*Dosage form* 100 mg per ml

**PIPERAZINE CITRATE**

*Trade names* Antepar Citrate (Burroughs Wellcome), Multifuge Citrate (Blue Line), Oxicide (Breon), Parazine Citrate (Tutag), Pipizan Citrate (Merck)  
*Administration* Oral  
*Dosage forms* A variety of forms

**PIPERAZINE ESTRONE SO.**

*Trade name* Sulestrex Piperazine (Abbott)  
*Administration* Oral  
*Dosage forms* Tablets, 0.75, 1.5, and 3 mg, elixir, 0.3 mg per ml

**PIPERAZINE GLUCONATE**

*Trade name* Vermizine (Chicago)  
*Administration* Oral  
*Dosage form* Syrup, 100 mg per ml

**PIPERAZINE HEXAHYDRATE**

*Trade name* Anthalazine (Bowman)  
*Administration* Oral  
*Dosage form* Solution, 100 mg per ml

**PIPERAZINE PO.**

*Trade name* Piperazate (Leeming)  
*Administration* Oral  
*Dosage form* Wafer, 500 mg

**PIPERAZINE TARTRATE**

*Trade name* Piperate (Lincoln)  
*Administration* Oral  
*Dosage form* Solution, 100 mg per ml

**PIPRIDOLATE HCl**

*Trade name* Dactil (Lakeside)  
*Administration* Oral  
*Dosage form* Capsule, 50 mg

**PIPERILATE HCl**

*Trade name* Sycotrol (Reed & Carnrick)  
*Administration* Oral  
*Dosage form* Tablet, 3 mg

**PIPEROCAINE HCl**

*Trade name* Metycaine HCl (Lilly)  
*Administration* Topical, parenteral  
*Dosage forms* A variety of forms

**PIPFROXAN HCl**

*Trade name* Benodaine HCl (Merck)  
*Administration* Intravenous  
*Dosage form* Ampule, 20 mg per ml

**PIPIZAN CITRATE (Merck)**

*Trade name* for Piperazine Citrate

**PIPRADROL HCl**

*Trade name* Meratran (Merrell)  
*Administration* Oral  
*Dosage form* Tablets, 1.0, 2.5 mg

**PIPTAL (Lakeside)**

*Trade name* for PIPENZOLATE Methylbromide

**PIROMEN (Travenol)**

*Trade name* for Pseudomonas Polysaccharides

**PITOCIN (Parke, Davis)**

*Trade name* for Oxytocin

**PHENYL BUTAZONE**

*Trade name* Butazolidin (Geigy)  
*Administration* Oral  
*Dosage form* Tablets 100 and 200 mg

**PHENYLDIMETHYLPYRAZOLOX  
FERRIC CL**

*Trade name* Ferropyrin (B. I. Huber Knoll)  
*Administration* Topical  
*Dosage forms* Powder 15% solution 20%

**PHENYLEPHRINE HCl**

*Trade names* Almetrin (Meyer) Neo-Synephrine HCl (Winthrop) Succraphen (Smith Dorsey)  
*Administration* Oral intranasal intramuscular, intravenous  
*Dosage forms* Capsules 10 25 mg elixir 1 mg per ml topical preparations various ampules 2 and 10 mg per ml

**β PHENYLISOPROPYL HYDRAZINE**

*Trade name* Catron (Lakeside)  
*Administration* Oral  
*Dosage form* Tablets 3 and 6 mg

**PHENYLMERCURIC BORATE**

*Trade name* Merphenyl Borate (Hamilton)  
*Dosage form* Tincture 0.2%

**PHENYLMERCURIC NO**

*Trade names* Merphenyl N (Hamilton) Phenmerute (Massengill) and others  
*Dosage forms* Many forms

**PHENYLONE**

Synonym for Antipyrine

**PHENYLPROPANOLAMINE HCl**

*Trade name* Propadrine HCl (Merck)  
*Administration* Oral intranasal  
*Dosage forms* Capsules 25 50 mg solutions 1 and 3%

**PHENYLPROPYLMETHYLAMINE HCl**

*Trade name* Vonedrine (Merrell)  
*Administration* Inhalation topical  
*Dosage forms* Inhaler 250 mg solution 2.8%

**PHENYL-TERT BUTYLAMINE RESIN**

*Trade name* Ionamin (Strassenburgh)  
*Administration* Oral  
*Dosage form* Capsules 15 and 30 mg

**PHENYLTOLANAMINE DIHYDROGEN CITRATE**

*Trade name* Bristamin (Bristol)  
*Administration* Oral  
*Dosage form* Tablet 25 mg

**PHENYLTOLANAMINE RESIN COMPLEX**

*Trade name* Histonex (Strassenburgh)  
*Administration* Oral  
*Dosage form* Capsules 25 50 mg

**PHENYTOIN**

Synonym for Diphenylhydantoin Sodium

**PHETHENYLATE SODIUM**

*Trade name* Thiutoin (Lilly)  
*Administration* Oral  
*Dosage form* Capsules 0.12 and 0.24 Gm

**PHISODERM (Winthrop)**

*Trade name* for Entsofen

**PHISOHEX (Winthrop)**

*Trade name* for Hexachlorophene Soap

**PHOBIN (Lloyd)**

*Trade name* for Benactyzine HCl

**PHOLCODINE**

Synonym for Morpholinylethylmorphine

**PHOSFONEFRIN (Schieffelin)**

*Trade name* for Epinephrine PO

**PHOSPHALIFL (Wyeth)**

*Trade name* for Aluminum Hydroxide Gel

**PHOSPHOLINE I**

Synonym for Erchothophate  
 Not available on the commercial drug market

**PHOSPHORATED CARBOHYDRATE SOLUTION**

*Trade name* Emetrol (Kinney)  
*Administration* Oral  
*Dosage form* Solution as such

**PHOSPHORIC ACID**

*Administration* Oral  
*Dosage form* Solution 10%

**PHTHALYLSULFACETAMIDE**

*Trade names* Talsuln (Squibb) Thalarid (Schering), Thalul (Masseneill)  
*Administration* Oral  
*Dosage form* Tablet 0.5 Gm

**PHTHALYLSULFATHIAZOL**

*Trade name* Sulfathiazole (Merck)  
*Administration* Oral  
*Dosage form* Tablet 0.5 Gm

**PHYLICIN (B. I. Huber Knoll)**

*Trade name* for Theophylline Calcium Salt

**PHYSOSTIGMINE SULFATE**

Synonym for Eserine Sulfate  
*Administration* Topical (ophthalmic), subcutaneous  
*Dosage forms* Ampule 2 mg per ml powder



**PHYTONADIONE***Synonym* Vitamin K<sub>1</sub>*Trade names* Mephyton (Merck), Konakion (Roche)*Administration* Intravenous, oral*Dosage forms* Ampule, 50 mg per ml, tablet, 5 mg**PICRAGOL (Wyeth)***Trade name* for Silver Picrate**PICRIC ACID***Administration* Topical*Dosage form* Various concentrations**PICROTOXIN***Administration* Intravenous*Dosage form* Ampules, 1 and 20 ml containing 3 mg per ml**PIG BILE EXTRACT***Administration* Oral*Dosage form* Tablet, 0.25 Gm**PILOCARPINE HCl***Administration* Subcutaneous*Dosage form* 15 mg hypo tablets**PIPADONE***Synonym* for Dipipanone**PIPAMAZINE***Trade name* Mornidine (Searle)*Administration* Oral, intravenous*Dosage forms* Tablet, 5 mg, ampule, 5 mg**PIPANOL (Winthrop)***Trade name* for Trihexyphenidyl HCl**PIPENZOLATE METHYLBROMIDE***Trade name* Pipital (Lakeside)*Administration* Oral*Dosage form* Tablet 5 mg**PIPERATE (Lincoln)***Trade name* for Piperazine Tartrate**PIPERAZATE (Leeming)***Trade name* for Piperazine PO<sub>4</sub>**PIPERAZINE CALCIUM EDATHAMIL***Trade name* Penn (Endo)*Administration* Oral*Dosage form* 100 mg per ml**PIPERAZINE CITRATE***Trade names* Antepar Citrate (Burroughs Wellcome), Multifuge Citrate (Blue Line), Oxucide (Breon), Parazine Citrate (Tutag), Pipizan Citrate (Merck)*Administration* Oral*Dosage forms* A variety of forms**PIPERAZINE ESTRONE SO<sub>4</sub>***Trade name* Sulestrex Piperazine (Abbott)*Administration* Oral*Dosage forms* Tablets, 0.75, 1.5, and 3.0 mg; elixir, 0.3 mg per ml**PIPERAZINE GLUCONATE***Trade name* Vermizine (Chicago)*Administration* Oral*Dosage form* Syrup, 100 mg per ml**PIPERAZINE HEXAHYDRATE***Trade name* Anthalazine (Bowman)*Administration* Oral*Dosage form* Solution, 100 mg per ml**PIPERAZINE PO<sub>4</sub>***Trade name* Piperazate (Leeming)*Administration* Oral*Dosage form* Wafer, 500 mg**PIPERAZINE TARTRATE***Trade name* Piperate (Lincoln)*Administration* Oral*Dosage form* Solution, 100 mg per ml**PIPERIDOLATE HCl***Trade name* Dactil (Lakeside)*Administration* Oral*Dosage form* Capsule, 50 mg**PIPERILATE HCl***Trade name* Sycotrol (Reed & Carnrick)*Administration* Oral*Dosage form* Tablet, 3 mg**PIPEROCAINE HCl***Trade name* Metycaine HCl (Lilly)*Administration* Topical, parenteral*Dosage forms* A variety of forms**PIPEROXAN HCl***Trade name* Benodaine HCl (Merck)*Administration* Intravenous*Dosage form* Ampule, 20 mg per ml**PIPIZAN CITRATE (Merck)***Trade name* for Piperazine Citrate**PIPRADROL HCl***Trade name* Meratran (Merrell)*Administration* Oral*Dosage form* Tablets, 10, 25 mg**PIPTAL (Lakeside)***Trade name* for Pípenzolate Methylbromide**PIROMEN (Travenol)***Trade name* for Pseudomonas Polysaccharides**PITOCIN (Parke, Davis)***Trade name* for Oxytocin

**PITRESSIN (Parke Davis)**

Trade name for Vasopressin

**PITRESSIN TANNATE (Parke Davis)**

Trade name for Vasopressin Tannate

**PITUITARY EXTRACT (POSTERIOR)**

Synonyms Pituitary Obstetrical Pituitary Surgical

Trade names Infundin (Burroughs Wellcome) Pituitrin (Parke Davis)

Administration Intramuscular subcutaneous

Dosage form Ampules 5 and 10 units per ml

**PITUITARY GONADOTROPIN**

Trade names Equiphysin (Harvey) Gonadotrone (Miller)

Administration Subcutaneous intramuscular

Dosage forms Ampule varying dosages

**PITUITRIN (Parke Davis)**

Trade name for Pituitary Extract (Posterior)

**PLACIDYL (Abbott)**

Trade name for Ethchlorvynol

**PLANTAGO**

Trade names I A Formula (Burton Parsons) Konsyl (Burton Parsons)

Administration Oral

Dosage forms A variety of forms

**PLAQUENIL SO.**

Trade name for Hydroxychloroquine SO

**PLASMOCHIN NAPHTHOATE (Winthrop)**

Trade name for Pamaquine Naphthoate

**PLASMOQUINE**

Synonym for Pamaquine Naphthoate

**PLAVOLEX (Wyeth)**

Trade name for Dextran

**PLAZMOID (Upjohn)**

Trade name for Gelatin Solution Purified

**PLECYAMIN 12 (Plessner)**

Trade name for Cyanocobalamin

**PM 396**

Synonym for Methsuximide

**PODOPHYLLIN**

Administration Topical

Dosage form Ointment, 25%

**POLARAMINE (Schering)**

Trade name for Dextro-chlorpheniramine

**POLOXALCOL**

Trade name Polykol (Upjohn)

Administration Oral

Dosage form Liquid 200 mg per ml

**POLYAMINE METHYLENE RESIN**

Trade names Exorbin (Wyeth) Res nate (National) Busex (Columbus)

Administration Oral

Dosage form Tablet 0.25 Gm

**POLYBRENE (Abbott)**

Trade name for Hexad methrine Br

**POLYCYCLINE (Bristol)**

Trade name for Tetracycline

**POLYCYCLINE HCl (Bristol)**

Trade name for Tetracycline HCl

**POLYESTRADIOL PO**

Trade name Estradurin (Wyeth)

Administration Intramuscular

Dosage form Vial 40 mg

**POLYETHYLENE GLYCOLS**

Carbowax 400 Carbowax 1000 Carbowax 1500 Carbowax 1510 Carbowax 4000 (all Carbowax and Carbowax)

**POLYKOL (Upjohn)**

Trade name for Poloxalcol

**POLYMYXIN B SO.**

Trade name Aerosporin (Burroughs Wellcome)

Administration Oral intramuscular intrathecal topical

Dosage forms Vials 200 000 and 500 000 units tablet 500 000 units

**POLYOXYETHYLENE 20**

Synonym for Polysorbate 80

**POLYSORB HYDRATE (Fougera)**

Trade name for Sorbitan Sesquioleate Emulsion

**POLYSORBATE 20**

Synonyms Sorbitan Monolaurate Tween 20 Emulsifier

**POLYSORBATE 80**

Synonyms Polyoxyethylene 20, Sorbitan Mono-oleate Tween 80

Trade names Monitan (Ives Cameron) Sorlate (Abbott)

**POLYVINYLPIRROLIDONE**

Trade name PVP Macrose (Schenley)

Administration Intravenous

Dosage form Bottle, 3.5%

**PONTOCAINE HCl (Winthrop)**

Trade name for Tetracaine HCl

**POQUIL (Parke, Davis)**

Trade name for Pyriminium Cl

**POSTAFENE**

Synonym for Meclizine HCl

**POSTERIOR LOBE PITUITARY EXTRACT**

Trade names Obstetrical Pituitrin (Parke, Davis), Surgical Pituitrin (Parke, Davis)

Administration Subcutaneous, intramuscular

Dosage form Ampule, 10, 20 units per ml

**POTASSIC SALINE**

Synonym for Darrow's Solution

**POTASSIUM ACETATE**

Administration Intravenous, oral

Dosage form Ampule and powder

**POTASSIUM AMINOSALICYLATE**

Synonym Potassium Para aminosalicylate

Trade names Paskalium (Glenwood), Paskate (Lilly)

Dosage forms Tablet, 0.5 Gm, powder

**POTASSIUM AND SODIUM CHLORIDE WITH SODIUM LACTATE SOLUTION**

Synonym for Darrow's Solution (Modified)

**POTASSIUM ARSENITE**

Synonym Fowler's Solution

Administration Oral

Dosage form Solution, 1%

**POTASSIUM BICARBONATE**

Administration Oral

Dosage form Powder

**POTASSIUM CITRATE**

Administration Oral

Dosage forms Various solutions

**POTASSIUM Cl**

Administration Oral, intravenous

Dosage forms Crystals, ampules of varying concentration, often concentrated as 175 mEq per ml to be diluted at least 50 times in infusion fluid

**POTASSIUM Cl IN DEXTROSE**

Trade name Kadalex (Don Baxter)

Administration Intravenous

Dosage form Bottle, 0.2% in 5% dextrose

**POTASSIUM GLUCONATE**

Trade name Kaon (Warren Teed)

Administration Oral

Dosage form Elixir, 50 mg potassium per ml

**POTASSIUM I**

Trade name Enkide (Brewer)

Administration Oral

Dosage forms A large variety of forms

**POTASSIUM PARA-AMINOSALICYLATE**

Synonym for Potassium Aminosalicylate

**POTASSIUM PFNICILLIN**

Available in ointments

**POTASSIUM PFNICILLIN G**

Trade names Dramcillin (White), Drop-

" " " " " " " " " " " "

" " " " " " " " " " " "

Administration Oral, parenteral

Dosage forms A large variety of forms

**POTASSIUM PENICILLIN O**

Trade name Cer-O Cillin Potassium (Upjohn)

Administration Oral, topical, parenteral

Dosage forms Tablet, 100,000 units, troche, 5,000 units, ampule, 200,000 units per ml

**POTASSIUM PFNICILLIN V**

Synonym for Phenoxymethyl Potassium Penicillin

**POTASSIUM PERMANGANATE**

Administration Lavage

Dosage forms Tablets and crystals

**POTASSIUM PHENOXYMETHYL PENICILLIN**

Synonym Potassium Penicillin V

Trade name Compoicillin-VK Potassium (Abbott)

Administration Oral

Dosage forms Tablets, 125 and 250 mg, granules for solution

**POTASSIUM PO.**

Administration Intravenous

Dosage form Ampule

**POTASSIUM THIOCYANATE**

Administration Oral

Dosage form Tablet, 0.2 Gm

**POVAN (Parke, Davis)**

Trade name for Pyriminium Pamoate

**POVIDONE IODINE COMPLEX**

Trade names Betadine (Carbin &amp; Conwell), Isodine (Isodine)

Dosage form 1% to be diluted

**PRAGMATAR (Smith, Kline & French)**

Tar sulfur salicylic acid ointment

**PITRESSIN (Parke Davis)**

Trade name for Vasopressin

**PITRESSIN TANNATE (Parke, Davis)**

Trade name for Vasopressin Tannate

**PITUITARY EXTRACT (POSTERIOR)**

*Synonyms* Pituitary, Obstetrical Pituitary Surgical

*Trade names* Infundin (Burroughs Well come), Pituitrin (Parke, Davis)

*Administration* Intramuscular subcutaneous  
*Dosage form* Ampules, 5 and 10 units per ml

**PITUITARY GONADOTROPIN**

*Trade names* Equophysin (Harvey), Gonadotrone (Miller)

*Administration* Subcutaneous intramuscular  
*Dosage forms* Ampule varying dosages

**PITUITRIN (Parke Davis)**

Trade name for Pituitary Extract (Posterior)

**PLACIDYL (Abbott)**

Trade name for Ethchlorvynol

**PLANTAGO**

*Trade names* L. A. Formula (Burton Parsons), Konsyl (Burton Parsons)

*Administration* Oral  
*Dosage forms* A variety of forms

**PLAQUENIL SO.**

Trade name for Hydroxychloroquine SO.

**PLASMOCHIN NAPHTHOATE (Winthrop)**

Trade name for Pamaquine Naphthoate

**PLASMOQUINE**

Synonym for Pamaquine Naphthoate

**PLAVOLEX (Wyeth)**

Trade name for Dextran

**PLAZMOID (Upjohn)**

Trade name for Gelatin Solution Purified

**PLECYAMIN 12 (Plessner)**

Trade name for Cyanocobalamin

**PM 396**

Synonym for Methsuximide

**PODOPHYLLIN**

*Administration* Topical  
*Dosage form* Ointment, 25%

**POLARAMINE (Schering)**

Trade name for Dextro-chlorpheniramine

**POLOXALKOL**

*Trade name* Polykol (Upjohn)

*Administration* Oral

*Dosage form* Liquid, 200 mg per ml

**POLYAMINE METHYLENE RESIN**

*Trade names* Exorbin (Ayerst), Resinat (National), Basec (Columbus)

*Administration* Oral

*Dosage form* Tablet 0.25 Gm

**POLYBRENE (Abbott)**

Trade name for Hexad methrine Br

**POLYCYCLINE (Bristol)**

Trade name for Tetracycline

**POLYCYCLINE HCl (Bristol)**

Trade name for Tetracycline HCl

**POLYESTRADIOL PO.**

*Trade name* Estradurin (Ayerst)

*Administration* Intramuscular

*Dosage form* Vial, 40 mg

**POLYETHYLENE GLYCOLS**

Carbowax 400 Carbowax 1000, Carbowax 1500 Carbowax 1540 Carbowax 4000, (all Carbide and Carbon)

**POLYKOL (Upjohn)**

Trade name for Poloxalkol

**POLYMYXIN B SO.**

*Trade name* Actosporin (Burroughs Well come)

*Administration* Oral, intramuscular intrathecal topical

*Dosage forms* Vials 200,000 and 500,000 units tablet 500,000 units

**POLYOXYETHYLENE 20**

Synonym for Polysorbate 80

**POLYSORB HYDRATE (Fougera)**

Trade name for Sorbitan Sesquioleate Emulsion

**POLYSORBATE 20**

*Synonyms* Sorbitan Monolaurate, Tween 20 Emulsifier

**POLYSORBATE 80**

*Synonyms* Polyoxyethylene 20, Sorbitan Mono-oleate Tween 80

*Trade names* Monitan (Ives Cameron), Sorlate (Abbott)

**POLYVINYLPIRROLIDONE**

*Trade name* PVP Macrose (Schenley)

*Administration* Intravenous

*Dosage form* Bottle, 3.5%

**PROCAINE BUTYRATE**

*Trade name* Probutylin (Rorer)  
*Administration* Oral  
*Dosage forms* Capsules, 0.3 Gm elixir, 100 mg per ml

**PROCAINE HCl**

*Trade name* Novocain (Winthrop)  
*Administration* Parenteral  
*Dosage forms* A variety of concentrations

**PROCAINE PENICILLIN G**

*Trade names* Abbocillin (Abbott), Com pen (C S C), Crysticillin (Squibb), Depo

lin (Wyeth)  
*Administration* Oral parenteral  
*Dosage forms* A wide variety of forms

**PROCHLORPERAZINE DIMALEATE**

*Trade name* Compazine (Smith, Kline & French)  
*Administration* Oral, rectal, intramuscular  
*Dosage forms* Tablets, 5 mg, 10 mg, 25 mg, syrup suppositories, 5 mg, 25 mg, ampule, 10 mg (as ethanedisulfonate)

**PROCHOLON (Squibb)**

*Trade name* for Dehydrocholic Acid

**PROCYCLIDINE HCl**

*Trade name* Hemadrin (Burroughs Wellcome)  
*Administration* Oral  
*Dosage form* Tablet, 5 mg

**PRODOX (Upjohn)**

*Trade name* for Hydroxyprogesterone Acetate

**PROGESTERONE**

*Trade names* Colprosterone (Ayerst), Delalutin (Squibb), Lipo Lutin (Parke, Davis), Lucortum (Merck), Lutocylin (Ciba), Lutromone (Endo), Migesterone (Durst), Progestin (Organon), Proluton (Schering), Syngesterone (Pfizer) and many others  
*Administration* Intramuscular, sublingual, oral  
*Dosage forms* Ampules, 10, 25 mg per ml in oil and aqueous suspension tablets, 10, 25 mg

**PROGESTIN (Organon)**

*Trade name* for Progesterone

**PROGESTONE (Carnrick)**

*Trade name* for Corpus Luteum

**PROGESTORAL (Organon)**

*Trade name* for Ethisterone

**PROGUANIL HCl**

*Synonym* for Chloroguanide HCl

**PROGYNON (Schering)**

*Trade name* for Estradiol

**PROGYNON B (Schering)**

*Trade name* for Estradiol Benzoate

**PROGYNON DP (Schering)**

*Trade name* for Estradiol Dipropionate

**PROLACTIN**

*Trade name* Luteotrophin (Squibb)  
*Administration* Intramuscular and subcutaneous  
*Dosage form* Ampule to be diluted to 40 units per ml

**PROLAX (Cole)**

*Trade name* for Mephesisin

**PROLININ (Squibb)**

*Trade name* for Fluphenazine Dihydrochloride

**PROLOID (Warner Chilcott)**

*Trade name* for Thyroglobulin

**PROLUTON (Schering)**

*Trade name* for Progesterone

**PROLUTON C (Schering)**

*Trade name* for Ethisterone

**PROVIACETIN (Parke, Davis)**

*Trade name* for Acetosulfone

**PROMAZINE HCl**

*Trade name* Sparine (Wyeth)  
*Administration* Oral intravenous, intramuscular  
*Dosage forms* Tablets, 25 50 100 mg, vial, 50 mg per ml

**PROMETHAZINE HCl**

*Trade name* Phenergan (Wyeth)  
*Administration* Oral and topical  
*Dosage forms* Tablet, 12.5 mg, syrup 1.25 mg per ml cream, 2%

**PROMETHESTROL DIPROPIONATE**

*Trade name* Meprane Dipropionate (Reed & Carnrick)  
*Administration* Oral  
*Dosage form* Tablet, 1 mg

**PROMIN (Parke, Davis)**

*Trade name* for Glucosulfone Sodium

**PROMIZOLE (Parke, Davis)**

*Trade name* for Thiazolsulfone

**PRAMOXINE HCl**

*Trade name* Tronothane (Abbott)  
*Administration* Topical  
*Dosage forms* Solution lot on cream 1%

**PRANONE (Schering)**

*Trade name for* Ethisterone

**PRANTAL METHYLSULFATE (Schering)**

*Trade name for* D phenamil Methylsulfate

**PREDNIS (Arlington)**

*Trade name for* Prednisolone

**PREDNISOLONE**

*Trade names* Co-Hydeltra (Merck) Delta Cortel (Upjohn) Hydeltrol (Merck) Metacortolone (Schering) Paracortol (Parke Davis) Prednis (Arlington) Sterane (Pfizer) Sterolone (Rowell)  
*Administration* Oral topical  
*Dosage forms* Tablet 5 mg spray 50 mg

**PREDNISOLONE ACETATE**

*Trade name* Sterane Intramuscular (Pfizer)  
*Administration* Intramuscular  
*Dosage form* Vial 5 mg per ml

**PREDNISOLONE BUTYLACETATE**

*Trade name* Hydeltrol TBA (Merck)  
*Administration* Into tissue or joints  
*Dosage form* Ampule 20 mg per ml

**PREDNISOLONE 21 PO**

*Trade name* Hydeltrol (Merck)  
*Administration* Topical  
*Dosage form* Solution 0.5%

**PREDNISOLONE SODIUM HEMISUCCINATE**

*Trade name* Metacortolone Soluble (Schering)  
*Administration* Intravenous intramuscular  
*Dosage form* Vial 150 mg

**PREDNISONE**

*Trade names* Deltalone (Upjohn) Delta (Merck) Metacortin (Schering) Paracort (Parke Davis)  
*Administration* Oral  
*Dosage form* Tablet 5 mg

**PREGNEOLONE**

*Trade names* Arthenolone (Ayerst) Enelone (Funk) Natolone (National) Prenolon (Schering) Sharmane (Merck)  
*Administration* Oral intramuscular  
*Dosage forms* Tablet 100 mg vial 100 mg per ml

**PREGNYL (Organon)**

*Trade name for* Chorionic Gonadotropin

**PRELUDIN (Geigy)**

*Trade name for* Phenmetrazine HCl

**PRFMARIN (Ayerst)**

*Trade name for* Estrogenic Substances Conjugated

**PREMOCEL (Premo)**

*Trade name for* Methylcellulose

**PREMODRIN (Premo)**

*Trade name for* Methamphetamine HCl

**PRENDEROL (Squibb)**

*Trade name for* Diethyl Propionol

**PRENOLON (Schering)**

*Trade name for* Pregnenolone

**PRIMAQUINE PO**

*Administration* Oral  
*Dosage form* Tablet 15 mg as base

**PRIMIDONE**

*Trade name* Mysoline (Ayerst)  
*Administration* Oral  
*Dosage form* Tablet 0.25 Gm

**PRIODAX (Schering)**

*Trade name for* Iodoaliphonic Acid

**PRISCOLINE (Ciba)**

*Trade name for* Tolazoline HCl

**PRIVINE HCl (Ciba)**

*Trade name for* Naphazoline HCl

**PROBANTHINE Br (Searle)**

*Trade name for* Propantheline Br

**PROBARBITAL CALCIUM**

*Trade name* Ipral Calcium (Squibb)  
*Administration* Oral  
*Dosage form* Tablets 50 130 mg

**PROBENECID**

*Trade name* Benemid (Merck)  
*Administration* Oral  
*Dosage form* Tablet 0.5 Gm

**PROBUTYLIN (Rorer)**

*Trade name for* Procaine Butyrate

**PROCAINE AMIDE**

*Trade name* Pronestyl (Squibb)  
*Administration* Oral intravenous  
*Dosage forms* Capsule 0.25 Gm ampule 100 mg per ml

**PROCAINE AMIDE HCl**

*Trade name* Pronestyl HCl (Squibb)  
*Administration* Oral intravenous  
*Dosage forms* Capsule 0.25 Gm vial 100 mg per ml

**PTEROYL TRIGLUTAMATE SODIUM***Trade name* Teropterin (Lederle)*Administration* Intramuscular, intravenous*Dosage form* Ampule, 10 mg per ml**PUNICINE TANNATE (N.Y. Quinine)***Trade name* for Pelletierine Tannate**PURINETHOL (Burroughs Wellcome)***Trade name* for Mercaptopurine**PURODIGIN (Wyeth)***Trade name* for Digitoxin**PVP-MACROSE (Schenley)***Trade name* for Polyvinylpyrrolidone**PYDIRONE (Breon)***Preparation* of Dipyrone**PYMAFFD (Lloyd)***Trade name* for Pyrilamine Maleate**PYOKTANIN (Merck)***Trade name* for Methylosaniline Cl**PYRA-MALEATE (VanPelt & Brown)***Trade name* for Pyrilamine Maleate**PYRAMIDON (Winthrop)***Trade name* for Aminopyrine**PYRATHIAZINE HCl***Trade name* Pyrrolazote (Upjohn)*Administration* Oral*Dosage forms* Tablets, 25, 50, and 100 mg, elixir, 2.5 mg per ml**PYRAZINAMIDE (Merck)***Trade name* for Pyrazinoic Acid Amide**PYRAZINOIC ACID AMIDE***Trade names* Aldinamide (Lederle), Pyrazinamide (Merck)*Administration* Oral*Dosage form* Tablet, 0.5 Gm**PYRAZOLINE***Synonym* for Antipyrine**PYRETHRUM***Administration* Oral*Dosage forms* Various forms**PYRIBENZAMINE (Ciba)***Trade name* for Tripelecnamine HCl**PYRICIDIN (Nepera)***Trade name* for Isoniazid**PYRIDINE ALDOXIMINE METHIOD***Synonym* PAM

Not available on commercial drug market

**PYRIDIUM (Merck)***Trade name* for Phenylazo-diamino pyridine HCl**PYRIDOSTIGMIN Br***Trade name* Mestinon Br (Roche)*Administration* Oral*Dosage form* Tablet, 60 mg**PYRIDOXINE HCl***Synonym* Vitamin B<sub>6</sub>*Trade names* Beadox (Premo), Hexa Bet (Lilly), Hexavibex (Parke, Davis)*Administration* Oral, intravenous*Dosage forms* Tablets, 10, 25, 50 mg, solutions, 25, 50, 100 mg per ml**PYRILAMINE MALEATE***Trade names* Anthist (Lipton), Diamin (Merck), Copsamine (Durst), Hist (Sherman), Neo-Antergan (Merck), Paminyl (Buffington), Pymafed (Lloyd), Pyra Maleate (VanPelt & Brown), Rstamin (Strasbourg), Stangen (Phicians Drug), Statamin (Bowman), Theren (Rorer), and many others*Administration* Oral*Dosage forms* Various forms**PYRIMETHAMINE***Trade name* Daraprim (Burroughs Wellcome)*Administration* Oral*Dosage form* Tablet, 25 mg**PYROGALLIC ACID***Synonym* Pyrogallol*Dosage form* Ointment, 2 to 10%**PYROGALLOL***Synonym* for Pyrogallic Acid**PYRONIL (Lilly)***Trade name* for Pytrobutamine PO,**PYROBUTAMINE PO,***Trade name* Pyronil (Lilly)*Administration* Oral*Dosage form* Tablet, 15 mg**PYRROLAZOTE (Upjohn)***Trade name* for Pyrathiazine HCl**PYRVINIUM Cl***Trade names* Poquil (Parke, Davis), Valquin (Parke, Davis)*Administration* Oral*Dosage form* Suspension, 5 mg per ml

# DRUG INDEX

## PROMOXOLANE

Trade name Dimethylene (National)  
Administration Oral  
Dosage form Capsule, 0.25 Gm

## PROVISTYL (Squibb)

Trade name for Procaine Amide

## PROVISTYL HCl (Squibb)

Trade name for Procaine Amide HCl

## PROPADRINE HCl (Merck)

Trade name for Phenylpropinolamine HCl

## PROPANTHELINE Br

Trade name Pro-Banthine Br (Searle)  
Administration Oral intravenous intramuscular  
Dosage form Tablet, 15 mg ampule 30 mg

## PROPARACAINE HCl

Trade name Ophthaine (Squibb)  
Administration Topical  
Dosage form Solution 5 mg per ml

## PROPISA (Merck)

Trade name for Aminosalicyclic Acid

## PROPIHEXYPYRIDAMINE MALEATE

Synonym for Pheniramine Maleate

## PROPIODAL

Trade name Entodon (Winthrop)  
Administration Parenteral  
Dosage form Ampule 118 mg Iodine per ml

## PROPIOV GEL (Wyeth)

Trade name for Propionate Compound

## PROPIONATE CAPRYLATE COMPOUND

Trade name Sopronol (Wyeth)  
Dosage forms Ointment 30% powder and solution 25%

## PROPIONATE COMPOUND

Trade name Propion Gel (Wyeth)  
Administration Topical  
Dosage form Gel 20%

## PROPOXYCAINE HCl

Trade name Blockain (Breon)  
Administration Parenteral  
Dosage form Ampule 5 mg per ml

## PROPYLHEXEDRINE

Trade name Benzedrex  
Administration Inhalation  
Dosage form Inhaler 250 mg

## PROPYLIODINE

Trade name Donosil (Glaxo)  
Administration Intrabronchial  
Dosage forms Vials aqueous suspension (50%) with sodium carboxymethylcellulose only suspension (60%)

## PROPYLTHIOURACIL

Administration Oral  
Dosage form Tablets, 25 and 50 mg

## PROSCOMIDE (Miller)

Trade name for Methscopolamine Br

## PROSTIGMIN Br (Roche)

Trade name for Neostigmine Br

## PROSTIGMIN METHYLSULFATE (Roche)

Trade name for Neostigmine Methylsulfate

## PROTAMINE SO

Administration Intravenous  
Dosage form Ampule 10 mg per ml

## PROTAMINE ZINC AND ILETIN (Lilly)

Trade name for Protamine Zinc Insulin

## PROTAMINE ZINC INSULIN

Synonym PZI  
Trade name Protamine Zinc and Iletin (Lilly)  
Administration Subcutaneous  
Dosage form Vials 40 and 80 units per ml

## PROTHYRIN

Trade name Thyroactin (Winthrop)  
Administration Oral  
Dosage form Tablet 25 mg

## PROTOVERATRINES A AND B

Trade names Provel (Lilly) Veralba (Pitman Moore) and others especially in mixtures  
Administration Oral intramuscular intravenous  
Dosage forms Tablets 0.2 and 0.5 mg vial 0.2 mg per ml

## PROVELL (Lilly)

Trade name for Protoveratrines A and B

## PROVITAMIN A

Synonym for Carotene

## PSEUDOEPHEDRINE HCl

Synonym for Isoephedrine HCl

## PSEUDOMONAS POLYSACCHARIDES

Trade name Piromen (Travenol)  
Administration Intramuscular  
Dosage form Vial, 4 and 10 mcg per ml

## PSP

Synonym for Phenolsulfonphthalein

## PSYLLIUM

Trade names Metamucil (Searle) Mucilose (Winthrop) Serutan (Pharm Inc)  
Administration Oral  
Dosage forms As such or with dextrose



**RAPHETAMINE PO<sub>1</sub>** (Strassenburgh)Trade name for Amphetamine PO<sub>1</sub>**RASPBFRIN** (Miller)

Trade name for Salicylamide

**RAUDIXIN** (Squibb)Trade name for *Rauwolfia serpentina***RAUREN** (Maney)

Trade name for Reserpine

**RAURINE** (Lloyd)

Trade name for Reserpine

**RAU-SED** (Squibb)

Trade name for Reserpine

**RAU-TAB** (National)

Trade name for Alseroxylon

**RAUTENSIN** (Smith-Dorsey)

Trade name for Alseroxylon

**RAUWILOID** (Riker)

Trade name for Alseroxylon

**RAUWISTAN** (Thompson)Trade name for *Rauwolfia serpentina***RAUWOLFIA SERPENTINA**Trade name for *Rauwolfia serpentina***RED BLOOD CELLS, HUMAN DRIFT**

Trade name Lycopse (Merck)

Administration Topical

Dosage form Powder, as such

**REDISOL** (Merck)

Trade name for Cyanocobalamin

**REGITINE HCl** (Ciba)

Trade name for Phentolamine HCl

**REGITINE METHANESULFONATE**  
(Ciba)

Trade name for Phentolamine Methanesulfonate

**REGUTOL** (Pharmaco)

Trade name for Dioctyl Sodium Sulfosuccinate

**RELA** (Schering)

Trade name for Carisoprodol

**RELAXIN**

Trade names Cervilaxin (National), Relaxin (Warner Chilcott)

Administration Parenteral

Dosage form Ampule, 20 mg per ml

**RELEASIN** (Warner-Chilcott)

Trade name for Relaxin

**RENCAL** (Squibb)

Trade name for Sodium Phytate

**RENNIN**

Administration Oral

Dosage form As such

**RENOGRAFIN** (Squibb)

Trade name for Diatrizoates, Sodium and Methylglucamine

**RENTAMIN** (Strassenburgh)

Trade name for Pyrilamine Maleate

**RESCINNAMINE**

Trade name Modern (Pfizer)

Administration Oral

Dosage form Tablets, 0.25 and 0.5 mg

**RESERCFN** (Central)

Trade name for Reserpine

**RESERPINE**

Trade names Crystoserpine (Smith Dorsey), Eskaserp (Smith, Kline & French), Key-Serpine (Key), Rauren (Maney), Raurine (Lloyd), Rau-Sed (Squibb), Resercen (Central), Reserpoid (Upjohn), Roxinoid (Merck), Sandril (Lilly), Serfin (Parke, Davis), Serpanray (Panray), Serpasil (Riker), (Vita-hera)

s, 0.1  
per ml**RESERPOID** (Upjohn)

Trade name for Reserpine

**RESIN CAPRYLATE**

Trade name Kaprylex (Strassenburgh)

Administration Oral

Dosage form Capsule, 250 mg

**RESINAT** (National)

Trade name for Polyamine Methylene Resin

**RESISTAB** (Bristol-Meyers)

Trade name for Thonzylamine HCl

**RESODFC** (Smith, Kline & French)

Trade name for Carboxylic Resin

**RESORCIN**

Synonym for Resorcinol

**RESORCINOL**

Administration Topical

Dosage forms Various forms

# **PYRVINIUM PAMOATE**

*Trade name* Povan (Parke Davis)

*Administration* Oral

*Dosage form* Suspension 10 mg base per ml

# **PZA**

Synonym for Pyrazinamide

# **PZI**

Synonym for Protamine Zinc Insulin

# **QUADRINAL (Bilhuber Knoll)**

Each tablet contains Ephedrine HCl 25 mg  
Phenobarbital 25 mg Theophylline cal-  
cium Salicylate 0.13 Gm Potassium Io-  
dide 0.3 Gm

# **QUADRI SULFA MIXTURE**

*Trade name* Deltamide (Armour)

*Administration* Oral

*Dosage forms* Tablet 0.5 Gm fluid 100  
mg per ml

*Remarks* Mixture of Sulfadiazine Sulf-  
amerazine Sulfamethazine, Sulfacetamide

# **QUASSIA**

*Administration* Oral

*Dosage form* As such

# **QUELICIN Cl (Abbott)**

Trade name for Succinylcholine Cl

# **QUERCETIN**

*Trade name* Quertine (Abbott)

*Administration* Oral

*Dosage form* Tablets 10 and 20 mg

# **QUERTINE (Abbott)**

Trade name for Quercetin

# **QUIACTIN (Merrell)**

Trade name for Oxanamide

# **QUINACRINE HCl**

Synonym Mepacrine

*Trade name* Atabrine HCl (Winthrop)

*Administration* Oral

*Dosage form* Tablet, 100 mg

# **QUINAGLUTE (Wyann)**

Trade name for Quinidine Gluconate

# **QUINICARDINE (Varick)**

Trade name for Quinidine SO

# **QUINIDINE GLUCONATE**

*Trade name* Quinaglute (Wyann)

*Administration* Oral intramuscular

*Dosage forms* Tablet, 325 mg ampule 80  
mg per ml

# **QUINIDINE HCl**

*Administration* Intramuscular

*Dosage form* Ampule, 5 ml containing 0.6  
Gm

# **QUINIDINE SO**

*Trade name* Quinocardine (Varick)

*Administration* Oral intramuscular

*Dosage forms* Tablets capsules, 0.1 and 0.2  
Gm ampules containing 0.2 mg dissolved  
in Propylene Glycol

# **QUININE**

*Administration* Oral

*Dosage forms* Various forms

# **QUININE AND UREA HCl**

*Administration* Intravenous

*Dosage form* Ampule, 50 mg per ml

# **QUININE DIHYDROCHLORIDE**

*Administration* Intravenous intramuscular

*Dosage forms* Ampules of varying size

# **QUININE ETHYLCARBONATE**

Synonym Euquinine

*Administration* Oral

*Dosage forms* A variety of forms

# **QUINOXYL (Burroughs Wellcome)**

Trade name for Chinolofon

# **QUOTANE HCl (Smith Kline & French)**

Trade name for Dimethisoquin HCl

# **RABELLON (Merck)**

Trade name for mixture containing Hyoscy-  
amine HBr 0.45 mg Atropine SO, 0.04  
mg Scopolamine HBr 0.01 mg per tablet

# **RACEPHEDRINE HCl**

Synonym Ephedrine HCl

# **RACHOMATE (Abbott)**

Trade name for Sodium Radiochromate

# **RADIOACTIVE THORIUM**

*Trade name* Thorium X (Fleischman Burd)

*Dosage forms* Ointment alcohol lacquer

# **RADIO GOLD COLLOID**

Synonym Au<sup>199</sup> Aurcolloid

*Administration* Intravenous

*Dosage forms* Solutions, 20-40 millicuries  
per ml

# **RADIO IODINATED SERUM ALBUMIN (HUMAN)**

*Trade name* Risa (Abbott)

*Administration* Intravenous

*Dosage form* Vials 1 or more millicuries

# **RADIO IODINE<sup>131</sup>**

Synonym I<sup>131</sup>

Not available on the commercial drug market

# **RAPACODIN (Bilhuber Knoll)**

Trade name for Dihydrocodeine Bitartrate

**SAL ETHYL CARBONATE** (Parke, Davis)  
Trade name for Carbethyl Salicylate

**SALICIM** (Irwin Neisler)  
Trade name for Salicylamide

### **SALICYLAMIDE**

*Trade names* Amid Sal (Glenwood), Liquiprin (Johnson & Johnson), Raspberin (Miller) Salamide (Columbus), Salicim (Irwin Neisler) Salrin (Warren Teed)  
*Administration* Oral  
*Dosage form* Tablets 0.3 and 0.6 Gm

### **SALICYLANILIDE**

*Trade names* Antadol (Rorer), Salinidol (Doak)  
*Administration* Topical  
*Dosage form* Ointment 4.5%

### **SALICYLAZOSULFAPYRIDINE**

*Trade name* Azulidine (Pharmacia)  
*Administration* Oral  
*Dosage form* Tablet 0.5 Gm

### **SALICYLIC ACID**

*Administration* Topical  
*Dosage forms* Various forms

### **SALICYLOPHENYLFORMIC ACID**

*Trade name* Merythrol (Chemico)  
*Administration* Topical  
*Dosage forms* Solution, 0.1, 0.04% tincture, 0.033%

### **SALINE NORMAL**

Synonym for Sodium Cl Solution Isotonic

### **SALINIDOL** (Doak)

Trade name for Salicylanilide

### **SALOPHEN** (Winthrop)

Trade name for Phenetsal

### **SALRIN** (Warren Teed)

Trade name for Salicylamide

### **SALUNDEK** (Wallace & Tiernan)

Trade name for Zincchlorundesal

### **SALURON** (Bristol)

Trade name for Hydroflumethiazide

### **SALYRGAN THEOPHYLLINE** (Winthrop)

Trade name for Mersalyl and Theophylline

### **SANDOPTAL** (Sandoz)

Trade name for Allylbarbital

### **SANDRIL** (Lilly)

Trade name for Reserpine

### **SANTONIN**

*Administration* Oral  
*Dosage form* As such

### **SASS** (Abbott)

Trade name for Cholesterol Lowering Factor

### **SCARLETT RFD**

*Administration* Topical  
*Dosage form* Ointment 5%

### **SCILLARFEN** (Sandoz)

*Administration* Oral  
*Dosage forms* Tablet 0.8 mg solution 0.8 mg per ml

### **SCILLARFEN B** (Sandoz)

*Administration* Intravenous  
*Dosage form* Ampules 0.5 mg in 1 ml

### **SCOPOLAMINE**

*Synonym* Hyoscine  
*Administration* Oral subcutaneous intravenous  
*Dosage form* A variety of forms

### **SCOPOLAMINE HBr**

*Synonym* Hyoscine HBr  
*Administration* Oral subcutaneous  
*Dosage forms* Tablets 0.3 and 0.6 mg ampules 0.4 and 0.65 mg per ml

### **SCOPOLAMINE METHYLBROMIDE**

Synonym for Methscopolamine Br

### **SEBIZON** (Schering)

Proprietary lotion containing Sulfacetamide

### **SFECOBARBITAL SODIUM**

*Trade name* Evronal Sodium (Evron)  
*Secondal Sodium* (Lilly)  
*Administration* Oral rectal intravenous  
*Dosage forms* Capsules, tablets 30 50 100 mg suppositories 65 130, 200 mg ampules 0.25 0.5 Gm to be diluted

### **SECONAL SODIUM** (Lilly)

Trade name for Secobarbital Sodium

### **SEDAMYL** (Schenley)

Trade name for Acetyl bromdiethylacetylcarbamid

### **SEDULON** (Roche)

Trade name for Dihyprylone

### **SFELSUN SULFIDE SUSPENSION** (Abbott)

Selenium Sulfide shampoo

### **SFMIKON** (Massengill)

Trade name for Methapyrilene HCl

### **SEMI LENTE ILETIN** (Lilly)

Trade name for Semulente Insulin

**RESORCINOL MONOACETATE**

*Trade name* Euresol (B. I. Huber Knoll)

*Administration* Topical

*Dosage forms* Various forms

**RESTROL (Central)**

*Trade name* for Dienestrol

**RETICULOGFN (Lilly)**

*Trade name* for Laver Injection Purified

Contains small amount of Thiamine Cl

**RETROGRAFIN (Squibb)**

*Trade name* for Sodium and Methylglucamine D-atrizoate with Neomycin

**REXAUURUM (Kahlenberg)**

*Trade name* for Colloidal Gold

**RGENE (Cutter)**

*Trade name* for L-Arginine HCl

**RHUBARB**

*Administration* Oral

*Dosage form* Extract

**RIASOL (Shield)**

Phenol mercury soap

**RIBOFLAVIN**

*Synonyms* Lactoflavin Vitamin B<sub>2</sub> Vitamin G

*Trade name* Flavaxin (Winthrop)

*Administration* Oral parenteral

*Dosage forms* Tablets 1.5 and 10 mg  
ampule 5 mg

**RIBOFLAVIN METHYLOL**

*Trade name* Hyflavin (Endo)

*Administration* Intravenous intramuscular

*Dosage form* Vials 10 mg per ml

**RICINOLEIC ACID**

*Trade name* Aci-Jel (Ortho)

*Administration* Topical

*Dosage form* Gel

**RIMIFON (Roche)**

*Trade name* for Isoniazid

**RINGER'S SOLUTION**

*Synonym* Isotonic Solution of Three Chlorides

*Administration* Intravenous subcutaneous

*Dosage form* Bottles as such

**RIOGON (Breon)**

*Trade name* for Chorionic Gonadotropin

**RISA (Abbott)**

*Trade name* for Radio Iodinated Serum Albumin (Human)

**RISTOCETIN**

*Trade name* Spontin (Abbott)

*Administration* Intravenous

*Dosage form* Vial 500 mg

**RITALIN HCl (Ciba)**

*Trade name* for Methylphenidate HCl

**ROBALATE (Robins)**

*Trade name* for Dihydroxy Aluminum Ammonium acetate

**ROBAXIN (Robins)**

*Trade name* for Methocarbamol

**ROBITUSSIN (Robins)**

*Trade name* for Glyceryl Guaiacolate

**ROCCAL (Winthrop)**

*Trade name* for Benzalkonium Cl

**ROLICTON (Searle)**

*Trade name* for Amometradine

**ROMILAR HBr (Roche)**

*Trade name* for Dextromethorphan HBr

**RONIACOL (Roche)**

*Trade name* for Beta pyridyl-carbinol

**ROSE BENGAL**

Not readily available on commercial drug market

**ROTENONE**

*Administration* Topical

*Dosage forms* Various forms and concentrations are available

**ROXINOID (Merck)**

*Trade name* for Reserpine

**RUBRAMIN (Squibb)**

*Trade name* for Cyanocobalamin

**RUTIN**

*Synonym* Vitamin P Factor

*Administration* Oral

*Dosage form* Tablets 20 50 100 100 mg

**SAFF (Abbott)**

*Trade name* for Safflower Oil

**SAFFLOWER OIL**

*Trade name* Saff (Abbott)

*Administration* Oral

*Dosage form* Emulsion

**SAFTAN (Texas Pharmacal)**

*Trade name* for D-gallic Trioleate Liquid

**SALAMIDE (Columbus)**

*Trade name* for Salicylamide

**SINTROM (Geigy)**

Trade name for Acenocoumarol

**SITOSTEROLS**

Trade name Cytellin (Iilly)

Administration Oral

Dosage form Suspension, 20%

**SKIN FILM (Dome)**

Water soluble barrier to irritant oils

**SKIODAN SODIUM (Winthrop)**

Trade name for Methiodal Sodium

**SKOIFX (Williams)**

Propylene Glycol and Para aminobenzoic acid liquid

**SKOPOLATF (Strassenburgh)**

Trade name for Methscopolamine NO<sub>2</sub>

**SLFFP EZF**

Trade name for Methapyrilene

**SODIUM ACETRIZOATE**

Trade names Thuxokon (Mallinckrodt), Urokon Sodium (Mallinckrodt)

Administration Intravenous

Dosage form Ampules, 30%, 50%

**SODIUM p-AMINOHIPPURATE**

Administration Intravenous

Dosage form Ampule, 200 mg per ml

**SODIUM AMINOPTEROYLGLUTAMATE**

Trade name Aminopterin Sodium (Eederle)

Administration Oral

Dosage form Tablet, 0.5 mg

**SODIUM AMINOSALICYLATE**

Synonym Sodium Para aminosalicylate

Trade names Pamisyl Sodium (Parke, Davis), Pasara Sodium (Smith Dorsey), Pasem Sodium (Massengill), Parasal Sodium (Panray)

Administration Oral

Dosage form Tablet 0.5 Gm

**SODIUM AND CALCIUM ALGINATE**

Trade name Kalpin (Wallace)

Administration Oral

Dosage form As such

**SODIUM AND METHYLGLUCAMINE DIACETYLAMINOTRIHODOBENZOATES**

Trade name Gastrografin (Squibb)

Administration Oral

Dosage form Solution, 76%

**SODIUM AND METHYLGLUCAMINE DIATRIZOATES WITH NEOMYCIN**

Trade name Retrografin (Squibb)

Administration Intra ureteral

Dosage form 300 mg per ml w/ 25 mg per ml Neomycin

**SODIUM AND POTASSIUM GLUTAMATES**

Trade name Glutavene K (Gray)

Administration Intravenous

Dosage form Vial, 25%

**SODIUM BENZOATE**

Administration Intravenous

Dosage form Ampule, 88.5 mg per ml

**SODIUM BICARBONATE**

Administration Oral, intravenous

Dosage forms Tablets of various sizes ampules, isotonic (1.3%), hypertonic (7.5%)

**SODIUM BIPHOSPHATE**

Synonym Sodium PO<sub>4</sub> Acid

Administration Oral

Dosage form Tablet, 0.3 Gm

**SODIUM BISMUTH THIOLYCOLLATE**

Trade name Thio-Bismol (Parke, Davis)

Administration Intramuscular

Dosage form Ampule, 0.2 Gm

**SODIUM CACODYLATE**

Administration Subcutaneous, intravenous intramuscular

Dosage form Ampules, 0.05, 0.065, 0.1, 0.13, 0.2, 0.25, and 0.5 Gm per ml

**SODIUM CAPRYLATE**

Administration Topical

Dosage forms As such, solution 20%

**SODIUM CITRATE**

Administration Oral

Dosage form Powder

**SODIUM CI SOLUTION, HYPERTONIC**

Administration Intravenous

Dosage form Ampules, 2 to 5%

**SODIUM CI SOLUTION, HYPOTONIC**

Administration Intravenous

Dosage form Ampule, 0.425% in 2.5% Dextrose

**SODIUM CI SOLUTION, ISOTONIC**

Synonym Normal saline

Administration Intravenous

Dosage form Bottles of various sizes

**SODIUM DEHYDROCHOLATE**

Trade names Decholin Sodium (Ames),

Dilabil Sodium (Breon)

Administration Intravenous

Dosage form Ampule, 200 mg per ml

**SODIUM DIPROPIONAMIDO TRIHODO**

alt)

intra-arterial

30 ml

50 ml

**SEMILENTE INSULIN**

*Trade name* Semi Lente Insulin (Lilly)  
*Administration* Subcutaneous  
*Dosage forms* Vials 40 U per ml 80 U per ml

**SEMOXYDRINE (Massengill)**

*Trade name for* Methamphetamine HCl

**SENNA**

*Trade name* Senokot (Purdue)  
*Administration* Oral  
*Dosage forms* Tablet 225 mg as such

**SENNOSIDES A AND B**

*Trade name* Glysennid (Sandoz)  
*Administration* Oral  
*Dosage form* Tablet 12 mg

**SENOKOT (Purdue)**

*Trade name for* Senna

**SERENIUM (Squibb)**

*Trade name for* Ethoxazone

**SERFIN (Parke Davis)**

*Trade name for* Reserpine

**SEROMYCIN (Lilly)**

*Trade name for* Cycloserine

**SERPANRAY (Panray)**

*Trade name for* Reserpine

**SERPASIL (Ciba)**

*Trade name for* Reserpine

**SERPATE (Vale)**

*Trade name for* Reserpine

**SERPHLOID (Aiker)**

*Trade name for* Reserpine

**SERPINE (Pitman Moore)**

*Trade name for* Reserpine

**SERPIVITE (Vitarine)**

*Trade name for* Reserpine

**SERPOID (Canfield)**

*Trade name for* Reserpine

**SERUTAN (Pharm Inc)**

*Trade name for* Pyllium

**SERYNL**

*Synonym for* Azaserine

**SHARMONE (Merk)**

*Trade name for* Pregnenolone

**SIGMAMYCIN (Pfizer)**

*Trade name for mixture of* Tetracycline and Oleandomycin PO<sub>4</sub>

**SIGNEMYCIN V (Pfizer)**

*Trade name for mixture of* Tetracycline PO<sub>4</sub>, buffered and Oleandomycin PO<sub>4</sub>

**SILICONE PROTECTIVE CREAMS**

*Covicone* (Abbott) *Domicone* (Dome), *Silicote* (Amar Stone)

**SILICOTE (Amar-Stone)**

Silicone protective cream

**SILVER CI COLLOIDAL**

*Trade name* Lunasol (Hile)  
*Dosage forms* Solution 10% ointment 10%

**SILVER I COLLOIDAL**

*Trade name* Neo Silvol (Parke Davis)  
*Dosage forms* Capsules approximately 0.4 Gm solutions and suppositories

**SILVER NO.**

*Synonym* Lunar Capsule  
*Dosage form* As such fused sticks

**SILVER PICRATE**

*Trade name* Picragol (Wyeth)  
*Administration* Intravaginal  
*Dosage forms* Powder 50 mg suppositories 0.065 and 0.13 Gm

**SILVER POTASSIUM CYANIDE POTASSIUM CHOLEATE**

*Trade name* Silvogon (Bischoff)  
*Administration* Topical  
*Dosage forms* As such tablet 26 mg

**SILVER PROTEIN, MILD**

*Trade names* Argyrol (Barnes), Lunargen (Lilly) Silvol (Parke, Davis)  
*Administration* Topical  
*Dosage forms* Many forms

**SILVOGON (Bischoff)**

*Trade name for* Silver Potassium Cyanide Potassium Choleate

**SILVOL (Parke Davis)**

*Trade name for* Silver Protein Mild

**SINAN (Warren Teed)**

*Trade name for* Mephensetin

**SINAXAR (Armour)**

*Trade name for* Styramate

**SINGOSERP (Ciba)**

*Trade name for* Syrosingopine

**SINOGRAPHIN (Squibb)**

*A mixture of* Renografin (Squibb) and Cholografin (Squibb)

**SODIUM SO.***Synonym* Glauber's Salt*Administration* Oral*Dosage form* Crystals effervescent salts**SODIUM SUCCINATE***Synonym* Sodium Succinate Hexahydrate*Trade name* Soduxin (Brewer)*Administration* Intravenous*Dosage form* Ampule, 2 ml., 300 mg. per ml**SODIUM TETRADECYL SO***Trade name* Sotradecol Sodium (Wallace & Tiernan)*Administration* Intravenous*Dosage form* Vials, 1, 3, and 5%**SODIUM THIOSULFATE***Synonym* Sodium Hyposulfite, Hypo*Administration* Intravenous*Dosage form* Ampules 0.5 to 10 Gm**SODIUM VERSEDATE (Riker)***Trade name* for Edathamil Disodium**SODUXIN (Brewer)***Trade name* for Sodium Succinate**SOFTRAN (Stuart)***Trade name* for Buclizine HCl**SOLACTHYL (Squibb)***Trade name* for Corticotropin**SOLAR CREAM (Doak)***Para aminobenzoic acid and Titanium Dioxide cream***SOLESTRO (Merck)***Trade name* for Estradiol Benzoate**SOLGANAL (Schering)***Trade name* for Aurothioglucose**SOLUBLE LIVER FRACTION***Synonym* for Liver Fraction 1**SOLU CORTFF (Upjohn)***Trade name* for Hydrocortisone Succinate**SOLUTHRICIN (Merck)***Trade name* for Tyrothricin**SOLU ZYME (Upjohn)***Trade name* for Vitamin B Complex**SOMA (Wallace)***Trade name* for Carisoprodol**SOMATOTROPIN***Synonym* for Chorionic Gonadotropin**SOMBULEX (Schenley)***Trade name* for Methyl Cyclohexenyl Methyl barbituric Acid**SOMNALERT (Warren Teed)***Trade name* for Hexobarbital**SOMNICAPS (Am Pharm)***Trade name* for Methapyrilene HCl**SOMNOS (Merck)***Trade name* for Chloral Hydrate**SOPRONOL (Wyeth)***Trade name* for Propionate Caprylate Compound**SORBITAN MONOLAUROATE***Synonym* for Polysorbate 20**SORBITAN MONO OLEATE***Synonym* for Polysorbate 80**SORBITAN SESQUIOLEATE***Trade name* Polysorb Hydrate (Fougera)**SORICIN (Merrell)***Trade name* for Sodium Ricinoleate**SORLATE (Abbott)***Trade name* for Polysorbate 80**SOTRADECOL SODIUM (Wallace & Tiernan)***Trade name* for Sodium Tetradecyl SO**SOYALOID (Dome)***Trade name* for Colloids of Soya Beans**SPARINE (Wyeth)***Trade name* for Promazine HCl**SPIRODON (Cutter)***Trade name* for Tetrantoin**SPONTIN (Abbott)***Trade name* for Ristocetin**STABISOL (Squibb)***Trade name* for Bismuth Subsalicylate**STANGEN (Physicians Drug)***Trade name* for Pyrilamine Maleate**STANOLONE***Trade name* Adrolone (National)*Administration* Intramuscular*Dosage form* Vial 50 mg. per ml**STATICIN (Merck)***Trade name* for Caronamide

**SODIUM GENTISATE**

*Trade name* Na Gent (Raymer)  
*Administration* Oral  
*Dosage form* Tablet, 0.3 Gm

**SODIUM GLUTAMATE**

*Trade name* Glutavene (Gray)  
*Administration* Intravenous  
*Dosage form* Vial, 25%

**SODIUM HYPOSULFITE**

Synonym for Sodium Thiosulfate

**SODIUM INDIGOTINDISULFONATE**

*Synonym* Indigo Carmine  
*Administration* Intravenous, intramuscular, and subcutaneous  
*Dosage form* Ampule 8 mg per ml

**SODIUM I**

*Administration* Intravenous  
*Dosage form* Ampules of various sizes

**SODIUM IODOMETHAMATE**

*Trade name* Neo-Iopax (Schering)  
*Administration* Intravenous and retrograde  
*Dosage forms* Solutions, 50 and 75%

**SODIUM LACTATE**

*Administration* Intravenous, subcutaneous  
*Dosage form* Bottles, 1% molar and molar to be diluted

**SODIUM LAURYL SO.**

*Trade name* Neutrazyme (Smith Dorsey)  
*Administration* Rectal  
*Dosage form* Suppository, 100 mg

**SODIUM LEVOthyroxine**

*Trade name* Synthroid Sodium (Travenol)  
*Administration* Oral  
*Dosage form* Tablets, 0.1 and 0.2 mg

**SODIUM LIOTHYRONINE**

Synonym for Liothyronine Sodium

**SODIUM MORRHUATE**

*Trade name* Morusul (Endo)  
*Administration* Intravenous  
*Dosage form* Vial, 5% with Sulfadiazine

**SODIUM NITRITE**

*Administration* Intravenous  
*Dosage form* Tablet or powder

**SODIUM PARA-AMINOBENZOATE**

*Synonym* PABA Sodium  
*Administration* Oral  
*Dosage form* Tablet, 0.5 Gm

**SODIUM PARA-AMINOSALICYLATE**

Synonym for Sodium Aminosalicylate

**SODIUM PENICILLIN**

Available in troches for topical use

**SODIUM PENICILLIN G**

*Administration* Parenteral, topical  
*Dosage forms* A variety of forms

**SODIUM PERBORATE**

*Dosage form* As such

**SODIUM PEROXIDE**

*Dosage form* As such

**SODIUM PHYTATE**

*Trade name* Rencal (Squibb)  
*Administration* Rectal  
Not on commercial drug market

**SODIUM PO.**

*Trade name* Clyserol (Clyserol), Fleet Enema (Fleet), Travad (Travenol)  
*Administration* Oral rectal  
*Dosage forms* As such, and 20% solutions

**SODIUM PO., ACID**

Synonym for Sodium Biphosphate

**SODIUM POLYSTYRENE SULFONATE**

*Trade name* Kayexalate (Winthrop)  
*Administration* Oral  
*Dosage form* Powder, as such

**SODIUM PSYLLIATE**

*Trade name* Sylnasol (Searle)  
*Administration* Intravenous  
*Dosage form* Ampule, 5%

**SODIUM RADIO CHROMATE**

*Trade name* Rachomate (Abbott)  
*Administration* Intravenous  
*Dosage form* Solution which is mixed with blood before injection

**SODIUM RADIO IODIDE**

*Synonym* I<sup>131</sup>  
*Administration* Oral intravenous  
*Dosage forms* Capsules, solution

**SODIUM RADIO PHOSPHATE**

*Synonym* P<sup>32</sup>  
*Administration* Oral, intravenous  
*Dosage form* Solution

**SODIUM RICINOLEATE**

*Trade name* Sorcin (Merrell)  
*Administration* Intravenous  
*Dosage form* Ampule, 2% solution

**SODIUM SALICYLATE**

*Administration* Oral  
*Dosage form* Tablet, 0.3 Gm usually enteric-coated



**STRYGIN (Squibb)**

Trade name for Streptomycin SO

**STYPTICIN (Merck)**

Trade name for Cotinine Cl

**STYLVEN (Burroughs Wellcome)**

Trade name for Venom, Russell Viper

**STYRAMATE**

Trade name Sinaxar (Armour)

Administration Oral

Dosage form Tablet, 200 mg

**STYRONATE RESINS**

Trade name Katonium (Winthrop)

Administration Oral

Dosage form Powder, 15 Gm

**SUAVITIL (Merck)**

Trade name for Benaetazine HCl

**SUCARYL CALCIUM (Abbott)**

Trade name for Cyclamate Calcium

**SUCARYL SODIUM (Abbott)**

Trade name for Cyclamate Sodium

**SUCCINYLCHOLINE Cl**

Trade names Anectine Cl (Burroughs Wellcome), Quelicin Cl (Abbott), Succostrin (Squibb), Suxinyl (Fougera)

Administration Intravenous

Dosage form Solutions, 20, 50 mg per ml

**SUCCINYL SULFATHIAZOLE**

Trade name Sulfasuxidine (Merck)

Administration Oral

Dosage form Tablet, 0.5 Gm

**SUCOSTRIN Cl (Squibb)**

Trade name for Succinylcholine Cl

**SUCRAPHEN (Smith Dorsey)**

Trade name for Phenylephrine HCl

**SUCROSE DEHYDRATING AGENT**

Administration Intravenous

Dosage form Ampule 0.5 Gm per ml

**SUDAFED (Burroughs Wellcome)**

Trade name for Isophedrine HCl

**SUGRACILLIN (Upjohn)**

Trade name for Potassium Penicillin G

**SULAMYD (Schering)**

Trade name for Sulfacetamide

**SULAMYD SODIUM (Schering)**

Trade name for Sulfacetamide Sodium

**SULFSTREX PIPERAZINE (Abbott)**

Trade name for Piperazine Estrone SO

**SULFACETAMIDE**Trade names Sulamyd (Schering), Urosul  
fon (C.M.C.)

Administration Oral

Dosage form Tablet, 0.5 Gm

**SULFACETAMIDE SODIUM**Trade names Sebizon (Schering), Sulamyd  
Sodium (Schering)

Administration Topical

Dosage forms Ointments, 10% solution  
30%**SULFACETAMIDE-SULFADIAZINE****SULFAMERAZINE MIXTURE**

Synonym for Acet Dia Mer Sulfonamides

**SULFADIAZINE**Trade names Cremodiazine (Merck), Lipo  
Diazine (Donley Evans)

Administration Oral

Dosage form Tablet 0.5 Gm

**SULFADIAZINE SODIUM**

Administration Intravenous

Dosage form Solution 50 mg per ml

**SULFADIAZINE-SULFAMERAZINE MIXTURE**

Synonym for Dia Mer Sulfonamides

**SULFADIMER (Pitman Moore)**

Trade name for Dia Mer Sulfonamides

**SULFADIMETHOXINE**Trade names Madnbon (Roche) Madn  
qid (Roche)

Administration Oral

Dosage forms Tablet 0.5 Gm, capsule, 125  
mg, suspension 125 mg per ml**SULFATHIADOL**Trade name Sul Spanson (Smith Kline &  
French)

Administration Oral

Dosage forms Tablet 0.5 Gm sustained  
release tablet 650 mg suspension 130  
mg per ml**SULFAGUANIDINE**

Administration Oral

Dosage form Tablet 0.5 Gm

**SULFAMERAZINE**

Administration Oral

Dosage form Tablet 0.5 Gm

**SULFAMERAZINE SODIUM**

Administration Intravenous

Dosage form Solution 50 mg per ml

# DRUG INDEX

**STATOMIN** (Bowman)  
Trade name for Pyrilamine Maleate

**STEARODINE** (Parke Davis)  
Trade name for Calcium Iodostearate

**STECLIN** (Squibb)  
Trade name for Tetracycline HCl

**STELAZINE** (Smith Kline & French)  
Trade name for Trifluoperazine

**STENEDIOL** (Organon)  
Trade name for Methandriol

**STERANE** (Pfizer)  
Trade name for Prednisolone

**STERANE INTRAMUSCULAR** (Pfizer)  
Trade name for Prednisolone Acetate

**STERAQ** (Ascher)  
Trade name for Desoxycorticosterone Acetate

**STERISIL** (Warner Chilcott)  
Trade name for Hexetidine

**STEROLONE** (Rowell)  
Trade name for Prednisolone

**STEROSAN** (Gergy)  
Trade name for Chlorquinaldol

**STIBAMINE GLUCOSIDE**  
Trade name Neostam (Burroughs Wellcome)  
Administration Intramuscular intravenous  
Dosage form Ampule 1 Gm

**STIBOPHEN**  
Synonym Neoantimonan  
Trade name Fuadin (Winthrop)  
Administration Intramuscular  
Dosage form Ampule 8.5 mg as Antimony per ml

**STIGMONENE Br** (Warner Chilcott)  
Trade name for Benzpyriminium Br

**STILBAMIDINE ISETHIONATE**  
Administration Intravenous  
Dosage form Ampule 150 mg

**STILBESTROL**  
Synonym for Diethylstilbestrol

**TILBETIN** (Squibb)  
Trade name for Diethylstilbestrol

**TILPALMITATE** (Abbott)  
Trade name for Diethylstilbestrol Dipalmitate

**STILPHOSTROL** (Ames)  
Trade name for Diethylstilbestrol phosphate

**STIPOLAC** (Burroughs Wellcome)  
Trade name for Iodophthalcin Sodium

**STOMACH POWDERED**  
Trade name Ventricul n (Parke Davis)  
Administration Oral  
Dosage form As such

**STRAMONIUM**  
Administration Oral  
Dosage forms Capsules extracts tincture fluidextracts

**STREPTODUOGIN**  
Trade names Combistrep (Pfizer) Distrep  
tocin SO<sub>2</sub> (Lilly), Districin (Squibb),  
Duo Strep (Merck)  
Equal parts of Streptomycin and Dihydro  
streptomycin Sulfates  
Administration Intramuscular  
Dosage form Ampules 1 and 5 Gm

**STREPTOKINASE STREPTODORNASE**  
Trade name Varidase (Lederle)  
Administration Topical  
Dosage form Vial 100 000 units Strep o  
kinase 25 000 units Streptodornase

**STREPTOMYCIN CALCIUM CI**  
Administration Intramuscular  
Dosage form Vials 1 and 5 Gm for dilution

**STREPTOMYCIN SO<sub>2</sub>**  
Trade name Strycin (Squibb)  
Administration Intramuscular  
Dosage form Vials equivalent of 10 and  
50 Gm base

**STRONG IODINE SOLUTION**  
Synonym Lugol's Solution  
Administration Oral  
Dosage form Diluted

**STRONTIUM LACTATE**  
Trade name Strontolac (Wyeth)  
Administration Oral  
Dosage form Capsule 0.7 Gm

**STRONTOLAC** (Wyeth)  
Trade name for Strontium Lactate

**STROPHANTHIN**  
Available in hypodermic tablets of 0.3 and  
0.6 mg for intravenous injection

**STRYCHNINE** as such and salts  
Administration Oral, subcutaneous  
Dosage forms Various forms

**SURFACINE (Lilly)**

Trade name for Cyclomethicone

**SURGICAL PITUITRIN (Parke Davis)**

Trade name for Posterior Lobe Pituitary Extract

**SURGICEN (Central)**

Trade name for Hexachlorophene

**SURITAL SODIUM (Parke Davis)**

Trade name for Thiamylal Sodium

**SUSPHRINE (Brewer)**

Trade name for Epinephrine HCl

**SUVREN (Ayerst)**

Trade name for Captodiamine HCl

**SUXINYL (Fougera)**

Trade name for Succinylcholine Cl

**SYCOTROL (Reed & Carnrick)**

Trade name for Penicillate HCl

**SYLVSOL (Searle)**

Trade name for Sodium Psylliate

**SYMPATOL (Winthrop)**

Trade name for Sympetidine Tartrate

**SYNANDRETS (Pfizer)**

Trade name for Methyltestosterone

**SYNANDROL (Pfizer)**

Trade name for Testosterone Propionate

**SYNANDROL-F (Pfizer)**

Trade name for Testosterone

**SYNANDROTABS (Pfizer)**

Trade name for Methyltestosterone

**SYNATAN (Irwin Neisler)**

Trade name for Tanphetamine Hydrochloride

**SYNCELOSE (Blue Line)**

Trade name for Methylcellulose

**SYNCURINE (Burroughs Wellcome)**

Trade name for Decamethonium Bromide

**SYNDROX (McNeil)**

Trade name for Methamphetamine HCl

**SYNEPHRINE TARTRATE**

Trade name Sympatol (Winthrop)

Administration Oral subcutaneous

Dosage forms Tablet 0.1 Gm ampule 60 mg per ml

**SYNERONE (Pitman Moore)**

Trade name for Testosterone Propionate

**SYNGESTERONE (Pfizer)**

Trade name for Progesterone

**SYNGESTROTABS (Pfizer)**

Trade name for Ethisterone

**SYNKAMIN (Parke Davis)**

Trade name for Amino Methyl Naphthol HCl

**SYNKAVITE (Roche)**

Trade name for Menadiol Sodium Phosphate

**SYNPHYLLATE (Central)**

Trade name for Theophylline Sodium Glycinate

**SYNTETRIN (Bristol)**

Trade name for Tetracycline (Pyridine methyl)

**SYNTHROID SODIUM (Travenol)**

Trade name for Sodium Levothyroxine

**SYNTROPAN (Roche)**

Trade name for Amprotropine Phosphate

**SYROSINGOPINE**

Trade name Singoserp (Ciba)

Administration Oral

Dosage form Tablet 1 mg

**SYTOBEX (Parke Davis)**

Trade name for Cyanocobalamin

**TACARYL (Mead Johnson)**

Trade name for Methdilazine

**TACE (Merrell)**

Trade name for Chlorotrianene

**TAGATHEN (Led-rie)**

Trade name for Chlorothien Citrate

**TAKA DIASTASE (Parke Davis)**

Trade name for Diastase

**TALBUTAL**

Trade name Lotusate (Winthrop)

Administration Oral

Dosage form Tablets 30, 50 and 120 mg

**TALC**

Synonym Talcum

Dosage form As such

**TALCUM**

Synonym for Talc

# DRUG INDEX

## SULFAMETHAZINE

Administration Oral  
Dosage form Tablet 0.5 Gm

## SULFAMETHAZINE SULFADIAZINE SULFAMERAZINE MIXTURE

Synonym for Meth Dia Mer Sulfonamides

## SULFAMETHIZOLE

Trade names Thiosulfil (Ayerst) Urosulfin  
(Nepera)  
Administration Oral  
Dosage forms Tablet 0.25 Gm suspens on  
50 mg per ml

## SULFAMETHOXYPIRIDAZINE

Trade name Kynex (Lederle) Midicel  
(Parke Davis)  
Administration Oral  
Dosage form Tablet 0.5 Gm

## SULFAMETHOXYPIRIDAZINE ACETYL

Trade name Kynex Acetyl (Lederle)  
Administration Oral  
Dosage form Suspension 25 mg per ml

## SULFAMYLOX HCl (Winthrop)

Trade name for Mafen de HCl

## SULFANILAMIDE

Administration Oral top cal  
Dosage forms Tablet 0.5 Gm powder

## SULFAPYRIDINE

Administration Oral  
Dosage form Tablet 0.5 Gm

## SULFASUXIDINE (Merck)

Trade name for Succinylsulfathazole

## SULFATHALIDINE (Merck)

Trade name for Phthalylsulfathiazole

## SULFATHIAZOLE

Administration Oral topical  
Dosage forms Tablets 0.5 Gm and a va  
riety of forms

## SULFATHIAZOLE-SULFADIAZINE SULFAMERAZINE MIXTURE

Synonym for Thia Dia Mer-Sulfonamides

## SULFA TRI AZINE (Thompson)

Trade name for Meth Dia Mer Sulfonamides

## SULFERROUS (Chicago)

Trade name for Ferrous SO

## SULFINPYRAZONE

Trade name Anturan (Geigy)  
Administration Oral  
Dosage form Tablet 100 mg

## SULFISOMIDINE

Trade name Elkosin (Ciba)  
Administration Oral  
Dosage forms Tablet 0.5 Gm susp  
approximately 60 mg per ml

## SULFISOXAZOLF

Trade name Gantrisin (Roche)  
Administration Oral  
Dosage forms Tablet 0.5 Gm solution  
mg per ml

## SULFISOXAZOLE DIETHANOLAMINE

Trade name Gantrisin Diethanolamine  
(Roche)  
Administration Topical  
Dosage form Solution 4%

## SULFOBROMOPHTHALEIN SODIUM

Trade name Bromsulphalein (Hynson)  
Administration Intravenous  
Dosage form Ampule 50 mg per ml

## SULFONAMIDES DUPLEX (Lilly)

Trade name for Dia Mer Sulfonamides

## SULFONSOL (National)

Trade name for Meth Dia Mer Sulfonamides

## SULFOSE (Wyeth)

Trade name for Meth Dia Mer Sulfonamides

## SULFOXONE SODIUM

Trade name Diasone Sodium (Abbott)  
Administration Oral  
Dosage form Tablet 0.33 Gm

## SULSPANSION (Smith Kline & French)

Trade name for Sulfathiazole

## SUMYCIN (Squibb)

Trade name for Tetracycline PO Complex

## SUPERFATTED SOAPS

Almay Superfatted Soap (Almay) Basic Soap  
(Duke) Dove Soap (Lever) Olatum  
(Steifell)

## SUPERNONE

Trade name Alevaire (Winthrop)  
Administration Inhalation  
Dosage form Nebula 0.125%

## SUPRANEPHRIN (Rorer)

Trade name for Epinephrine HCl

## SUPRARENIN (Winthrop)

Trade name for Epinephrine Bitartrate

## SUR BEX (Abbott)

Trade name for Vitamin B C

## TESTOSTERONE

*Trade names* Androlin (Lincoln), Andro-naq (Central), Andrusol (C. D. Smith), Aqua Testosterone (Endocrine), Diphaseol Testosterone (Kremers Urban), Malestrone (Kirk), Mertestate (Brecon), Neo-Hom-breol (F) (Organon), Oreton F (Schering), Synandrol F (Pfizer), Testandrone (Carnrick), Testobase (Merk), Testo-steroid (Sherman), Testrone (Miller), Testryl (Squibb)

*Administration* Buccal sublingual, intramuscular

*Dosage forms* Tablets, 3, 5, and 6 mg, vials 25 and 50 mg per ml

## TESTOSTERONE CYCLOPENTYLPROPIONATE

*Trade name* Depo Testosterone (Upjohn)

*Administration* Intramuscular

*Dosage form* Vials, 50, 100 mg per ml

## TESTOSTERONE ENANTHATE

*Trade name* Delatestryl (Squibb)

*Administration* Intramuscular

*Dosage form* Ampule, 200 mg per ml

## TESTOSTERONE PHENYLACETATE

*Trade name* Perandren Phenylacetate (Ciba)

*Administration* Intramuscular

*Dosage form* Vial, 50 mg per ml

## TESTOSTERONE PROPIONATE

*Trade names* Androlin in Oil (Lincoln), Andronate (Central), Andrusol P (C. D. Smith), Neo-Hom-breol (F) (Organon), Oreton F (Schering), Synandrol F (Pfizer), Testandrone (Carnrick), Testobase (Merk), Testo-steroid (Sherman), Testrone (Miller), Testryl (Squibb)

*Administration* Intramuscular

*Dosage form* Vials, 10, 25, 50, 100 mg per ml

## TESTOSTERONE (Miller)

*Trade name* for Testosterone

## TESTRYL (Squibb)

*Trade name* for Testosterone

## TFTRABON (Pfizer)

*Trade name* for Tetracycline HCl

## TETRACAINE HCl

*Synonym* Amethocaine HCl

*Trade name* Pontocaine HCl (Winthrop)

*Administration* Topical parenteral

*Dosage forms* A large variety of forms

## TETRACHLOROETHYLENE

*Administration* Oral

*Dosage form* Capsules, 0.2, 1.0, 2.5 ml

## TFTRACYCLINE

*Trade names* Achromycin (Lederle), Panmycin (Upjohn), Polycycline (Bristol), Tetracycline (Roerig)

*Administration* Oral

*Dosage forms* Capsules, tablets, 50, 100, 250 mg

## TETRACYCLINE HCl

*Trade names* Achromycin HCl (Lederle), Panmycin HCl (Upjohn), Polycycline HCl (Bristol), Steclin (Squibb), Tetrabon (Pfizer), Tetracycline HCl (Roerig)

*Administration* Oral, parenteral, topical

*Dosage forms* A variety of forms

## TETRACYCLINE N-(PYRROLIDINO METHYL)

*Trade name* Syntetris (Bristol)

*Administration* Intravenous intramuscular

*Dosage form* Vials 150, 350 mg

## TETRACYCLINE PO, BUFFERED

*Trade names* Achromycin V (Lederle), Tetracycline V (Pfizer)

*Administration* Oral

*Dosage form* Capsules, 50, 100, 250 mg

## TETRACYCLINE PO, COMPLEX

*Trade names* Panmycin PO, (Upjohn), Sumycin (Squibb), Tetrex (Bristol)

*Administration* Oral

*Dosage form* Capsules, 50, 100, 250 mg

## TFTRACYN (Roerig)

*Trade name* for Tetracycline

## TFTRACYN HCl (Roerig)

*Trade name* for Tetracycline HCl

## TETRACYN V (Pfizer)

*Trade name* for Tetracycline PO, Buffered

## TETRAETHYLAMMONIUM Cl

*Synonym* TEA

*Trade name* Etamon (Parke Davis)

*Administration* Intravenous, intramuscular

*Dosage form* Vial 100 mg per ml

## TFTRAHYDROZOLINE HCl

*Trade name* Tyzine (Pfizer), Visine (Pfizer)

*Administration* Intranasal topical

*Dosage form* Solution 0.1%, 0.05%

## TETRAIODOPHENOLPHTHALEIN SODIUM

*Synonym* for Iodophthalein Sodium

## TFTRANTOIN

*Trade name* Spirodon (Cutter)

Not available on the commercial drug market

**TALSUTIN (Squibb)**

Trade name for Phthalylsulfacetam de

**TANNIC ACID**

*Synonym* Gallotannic Acid

*Administration* Topical oral by lavage

*Dosage form* Powder, glycerite and ointment

**TANPHETAMINE PROTOCOLLOID**

*Trade name* Synatan (Irwin Neisser)

*Administration* Oral

*Dosage form* Tablet 17.5 mg (equivalent to 5.25 mg Amphetamine)

**TAO (Roerig)**

Trade name for Triacetyloleandomycin

**TAPAZOLE (Lilly)**

Trade name for Methimazole

**TARBONIS (Reed & Carnrick)**

Proprietary Tar extract 5%

**TARCORTIN (Reed & Carnrick)**

Trade name for preparation containing Hydrocortisone 0.5% in Tarbonis

**TEA**

Synonym for Tetraethylammonium Cl

**TEDRAL (Warner Chilcott)**

Each tablet contains Theophylline 0.13 Gm, Ephedrine HCl 24 mg, Phenobarbital 8 mg

**TELDRI (Smith Kline & French)**

Trade name for Chlorpheniramine Maleate

**TELEPAQUE (Winthrop)**

Trade name for Iopanoic Acid

**TELMID (Lilly)**

Trade name for D-thuizanine I

**TEMI**

Synonym for Triethylene Melamine

**TEMARIL (Smith Kline & French)**

Trade name for Trimeprazine Tartrate

**TEMIPOSIL (Lederle)**

Trade name for Coated Calcium Carbimide

**TEMPRA (Mead Johnson)**

Trade name for Acetaminophen

**TFNSILON Cl (Roche)**

Trade name for Edrophonium Cl

**TENTONE (Lederle)**

Trade name for Methoxypromazine Maleate

**TENUATE (Merrell)**

Trade name for Diethylpropion

**TEPANIL (National)**

Trade name for Diethylpropion

**TFRFONYL (Squibb)**

Trade name for Meth D a Mer Sulfonamides

**TERGEMIST (Abbott)**

Trade name for Tergitol 08 and Potassium I

**TERGITOL 08 (Abbott)**

Detergent

**TERIDAX (Schering)**

Trade name for Iophenoxic Acid

**TEROPTERIN (Lederle)**

Trade name for Pteroyl Triglutamate Sodium

**TERPIN HYDRATE**

*Administration* Oral

*Dosage form* Elixir

**TERRABON (Pfizer)**

Trade name for Oxytetracycline

**TERRA CORTIL (Pfizer)**

Proprietary ointment containing Hydrocortisone 1% and Terramycin 3%

**TERRAMYCIN (Pfizer)**

Trade name for Oxytetracycline

**TERRAMYCIN HCl (Pfizer)**

Trade name for Oxytetracycline HCl

**TERSASEPTIC (Doak)**

Hexachlorophene soap

**TERTIASUL (Rorer)**

Trade name for Acet Dia Mer Sulfonamides

**TESSALON (Ciba)**

Trade name for Benzonatate

**TESTANDRONE (Carnrick)**

Trade name for Testosterone

**TESTOBASE (Merck)**

Trade name for Testosterone

**TESTODET (Merck)**

Trade name for Testosterone Propionate

**TESTOSTEROID (Sherman)**

Trade name for Testosterone

**THIOPHORIN (Roche)**

Trade name for Phenindamine Tartrate

**THIRUHISTIN (Ayerst)**

Trade name for Isothipendyl HCl

**THIOSODATE (Brewer)**

Trade name for Theobromine and Sodium Acetate

**THIVETIN**

Not available on the commercial drug market

**THIA-DIA MER SULFONAMIDES**

Synonym Sulfathiazole Sulfadiazine Sulfamerazine Mixture

Trade name Thi Di Mer (Pitman Moore)

Administration Oral

Dosage form Tablet, 0.5 Gm

**THIAMINE HCl**Synonym Vitamin B<sub>1</sub>

Trade names Betalin S (Lilly), Betaxin (Winthrop), Thiamintol (Rorer), Thibex (Brewer), and many others

Administration Oral, parenteral

Dosage forms Tablets of many sizes, ampules, 1 ml containing 10, 50, or 100 mg

**THIAMINTOL (Rorer)**Trade name for Vitamin B<sub>1</sub>**THIAMYLAL SODIUM**

Trade name Surital Sodium (Parke, Davis)

Administration Intravenous, rectal

Dosage forms Vials, 0.2, 0.3, 0.5, 1.0, 5.0, 10 Gm nonsterile for rectal, 1.5, 3.0 Gm

**THIANTOIN (Lilly)**

Trade name for Phethenylate Sodium

**THIAZOLSULFONE**

Trade name Promizole (Parke, Davis)

Administration Oral

Dosage form Tablet, 0.5 Gm

**THIBEX (Brewer)**Trade name for Vitamin B<sub>1</sub>**THI DI MFR (Pitman Moore)**

Trade name for Thi Di Mer Sulfonamides

**THIMECIL (Physicians)**

Trade name for Methylthiouracil

**THIMFROSAL**

Trade name Merthiolate (Lilly)

Administration Topical

Dosage forms A variety of forms

**THIO BISMOL (Parke, Davis)**

Trade name for Sodium Bismuth Thioglycolate

**THIOCARBARSONE (Lilly)**

Trade name for Carbamidophenyl di(carboxymethylthio) Arsenite

**6-THIOGUANINE**

Not available on the commercial drug market

**THIONFRIN (Wyeth)**

Trade name for Mercaptomerin

**THIOPENTAL SODIUM**

Trade name Pentothal Sodium (Abbott)

Administration Intravenous, rectal

Dosage forms Ampules, 0.5, 1.0 Gm, nonsterile for rectal, 1.5, 3.0 Gm

**THIOPERAZINE**

Synonym Vontil

Not on commercial drug market

**THIOPROPAZATE HCl**

Trade name Dartal HCl (Searle)

Administration Oral

Dosage form Tablets, 5 and 10 mg

**THIORIDAZINE HCl**

Trade name Mellaril (Sandoz)

Administration Oral

Dosage form Tablets 10, 25, 100 mg

**THIOSEMICARBAZONE**

Synonym for Amithiozone

**THIOSULFIL (Ayerst)**

Trade name for Sulfamethizole

**THIO-TFPA**

Synonym for Triethylene Thiophosphoramide

**THIXOKON (Mallinckrodt)**

Trade name for Sodium Acetrizonte

**THIOZYLAMINE HCl**

Trade names Anahist (Anahist), Neohetramine (Nepara), Resistab (Bristol Meyers)

Administration Oral, topical

Dosage forms Tablets 25, 50, 100 mg, syrup, 6.25 mg per ml, cream, 25%

**THORAZINE (Smith, Kline & French)**

Trade name for Chlorpromazine HCl

**THORIUM DIOXIDE**

Trade names Thorotrast (Testagar), Umbrathor (Heyden)

Administration Intravenous, intra arterial, oral, rectal, urethral

Dosage form Ampule 25%

**THORIUM X (Fleischman, Burd)**

Trade name for Radioactive Thorium

**THOROTRAST (Testagar)**

Trade name for Thorium D oxide

**TETREX (Bristol)**

Trade name for Tetracycline PO Complex

**THALAMYD (Schering)**

Trade name for Phthalylsulfacetamide

**THALISUL (Massengill)**

Trade name for Phthalylsulfacetamide

**THEELIN (Parke Davis)**

Trade name for Estrone

**THEEOL (Parke Davis)**

Trade name for Estrone

**THELESTRIN (Carnrick)**

Trade name for Estrone

**THENFADIL HCl (Winthrop)**

Trade name for Thenyldiamine HCl

**THENYLDIAMINE HCl**

Trade name Thenfadi (Winthrop)

Administration Oral

Dosage form Tablet 15 30 mg

**THENYLENE (Abbott)**

Trade name for Methapyrilene HCl

**THENYLPYRAMINE**

Synonym for Methapyrilene

**THEOBROMINE AND SODIUM ACETATE**

Trade name Thesodate (Brewer)

Administration Oral

Dosage form Tablets 0.25 and 0.5 Gm

**THEOBROMINE AND SODIUM SALICYLATE**

Trade name Diuretin (Bilhuber Knoll)

Administration Oral

Dosage form Tablet 0.5 Gm

**THEOBROMINE CALCIUM SALICYLATE**

Trade names Phyllicin (Bilhuber Knoll)

Theocalcin (Bilhuber Knoll)

Administration Oral

Dosage form Tablets 0.3 and 0.5 Gm

**THEOCALCIN (Bilhuber Knoll)**

Trade name for Theobromine Calcium Salicylate

**THEOCIN (Winthrop)**

Trade name for Theophylline

**THEOCIN SOLUBLE (Winthrop)**

Trade name for Theophylline and Sodium Acetate

**THEOGLYCINATE (Brayten)**

Trade name for Theophylline Sodium Glycinate

**THEOMERSYL (Central)**

Trade name for Mersalyl with Theophylline Sodium Glycinate

**THEOPHYLLINE**

Trade name Theocin (Winthrop)

Administration Oral

Dosage form Tablets 0.1 and 0.2 Gm

**THEOPHYLLINE AND SODIUM ACETATE**

Trade name Theocin Soluble (Winthrop)

Administration Oral

Dosage form Tablet (coated), 0.2 Gm

**THEOPHYLLINE CALCIUM SALICYLATE**

Trade name Phyllicin (Bilhuber Knoll)

Administration Oral

Dosage form Tablet 0.6 Gm

**THEOPHYLLINE ETHYLENEDIAMINE**

Synonym for Aminophylline

**THEOPHYLLINE ISOPROPANOLAMINE**

Trade name Theopropanol (National Drug)

Administration Oral intramuscular intravenous

Dosage forms Tablets 0.1 and 0.2 Gm  
vials for intramuscular injection, 2 ml containing 0.5 Gm for intravenous injection 10 ml containing 0.25 Gm

**THEOPHYLLINE METHYLGLUCAMINE**

Trade name Glucophylline (Abbott)

Administration Oral rectal parenteral

Dosage forms Tablets enteric-coated 0.15 and 0.3 Gm suppository 0.5 Gm intramuscular injection 0.73 Gm in 2 ml intravenous injection 0.37 Gm in 10 ml

**THEOPHYLLINE MONOETHANOLAMINE**

Trade name Glysmathane (Fleet) Monotheamin (Lilly)

Administration Oral, intravenous rectal

Dosage forms Tablet 0.2 Gm ampule, 25 mg per ml squeeze bottle, 625 mg

**THEOPHYLLINE SODIUM GLYCINATE**

Trade names Dorsoaphyllin (Dorsey) Pemo-

Gm in 20 ml

**THEOPROPANOL (Roche)**

Trade name for Theophylline Isopropanolamine



**TOLFRON (Mallinckrodt)**

Trade name for Ferrous Fumarate

**TOLHART (Hart)**

Trade name for Mephenesin

**TOLONIUM Cl***Synonym* Toluidine Blue*Trade name* Blutene Cl (Abbott)*Administration* Oral*Dosage form* Tablet, 100 mg**TOLOSATE (Brewer)**

Trade name for Mephenesin

**TOLPAL (Philadelphia)**

Trade name for Tolazoline HCl

**TOLSERAM (Squibb)**

Trade name for Mephenesin Carbamate

**TOLSEROL (Squibb)**

Trade name for Mephenesin

**TOLUIDINE BLUE***Synonym* for Tolonium Cl**TOLULOX (Miller)**

Trade name for Mephenesin

**p-TOLYLMETHYL-CARBINOL MONO-d-CAMPHORATE DIETHANOLAMINE***Trade name* Gallogen (Massengill)*Administration* Oral*Dosage form* Tablet, 75 mg**TOLYSIN (Lederle)**

Trade name for Neocinchophen

**TOPITRACIN (C.S.C.)**

Trade name for Bacitracin

**TOPOCIDE (Lilly)**

Trade name for emulsion containing Benzyl Benzoate, DDT, and Ethyl Aminobenzoate

**TORANTIL (Winthrop)**

Trade name for Histaminase

**TORYN (Smith, Kline & French)**

Trade name for Caramphen Ethanedisulfonate

**TOTAQUINE***Administration* Oral*Dosage forms* A variety of forms**TRAL (Abbott)**

Trade name for Hexocyclium Methylsulfate

**TRANCOPAL (Winthrop)**

Trade name for Chloremezanone

**TRASENTINE (Ciba)**

Trade name for Adiphenine HCl

**TRAVAD (Travenol)**Trade name for Sodium PO<sub>4</sub> solution**TRAVERT (Baxter)**

Trade name for Invert Sugar

**TRETHYLENE (Davis, Rose)**

Trade name for Trichloroethylene

**TRIACETIN***Synonym* Glyceryl Triacetate*Trade names* Enzactin (Ayerst), Fungacetin (Harvey)*Dosage forms* Ointment, 0.5 to 10%**TRIACETYLOLEANDOMYCIN***Trade names* Cyclamycin (Wyeth), Tao (Roerg)*Administration* Oral*Dosage forms* Capsules, 125 and 250 mg, suspension, 25 mg per ml**TRIACETYL PYROGALLOL***Synonym* for Acetpyrogall**TRIAMCINOLONE***Trade names* Aristocort (Lederle), Kenacort (Squibb)*Administration* Oral*Dosage form* Tablets, 2 and 4 mg**TRIAMCINOLONE ACETONIDE***Trade name* Kenalog (Squibb)*Administration* Topical*Dosage forms* Cream, lotion, ointment, 0.1%**TRIBROMOETHANOL***Trade name* Avertin (Winthrop)*Administration* Rectal*Dosage form* Solution, 2.5% with Amylene Hydrate**TRIBURON (Roche)**

Trade name for Triclobisonium Cl

**TRICHLOROACETIC ACID***Administration* Topical*Dosage forms* Crystals or highly concentrated solutions**TRICHLOROETHYLENE***Trade names* Chlorylen (Schering), Trethylene (Davis, Rose), Trilene (Ayerst)*Administration* Inhalation*Dosage form* Container, as such**TRICLOBISONIUM Cl***Trade name* Triburon (Roche)*Administration* Topical*Dosage forms* Ointment, 0.1%, cream, 0.1%

**THOXIDIL (Normand)**

Trade name for Mephene s n

**THROMBIN**

*Administration* Topical oral

*Dosage form* Vials 1 000 5 000 and 10 000 units to be diluted to 1 000 units per ml

**THROMBOL (Merck)**

Trade name for Thromboplastin

**THROMBOPLASTIN**

*Synonym* Brain Extract Solution

*Trade name* Thrombol (Merck)

*Administration* Topical oral subcutaneous intravenous

*Dosage form* Vial 20 ml

**THROMBOPLASTIN SUSPENSION**

*Trade name* Thrombol (Merck)

*Administration* Topical subcutaneous

*Dosage form* Vial 20 ml

**THYLOGEN (Rorer)**

Trade name for Pyrilamine Maleate

**THYLOKAY (Squibb)**

Trade name for Menad ol Sodium PO

**THYMOL**

*Administration* Topical

*Dosage forms* Various forms

**THYMOL I**

*Trade name* Aristol (Merck)

*Administration* Topical

*Dosage form* As such

**THYRACTIN (Winthrop)**

Trade name for Prothyryn

**THYRAR (Armour)**

Trade name for Thyro d

**THYROGLOBULIN**

*Trade names* Endothyryn (Harrower) Proloid (Warner Chilcott)

*Administration* Oral

*Dosage forms* Tablets 16 32 65 100 375 mg powder

**THYROID**

*Trade name* Thyrar (Armour)

*Administration* Oral

*Dosage forms* Tablets 15 30 60 120 mg

**THYROPROTEIN**

*Administration* Subcutaneous

*Dosage form* Ampule 13 mg per ml

**THYROTROPIN**

*Trade name* Thytropar (Armour)

*Administration* Intramuscular subcutaneous

*Dosage* Vial 10 U S P units

**THYROXIN**

*Administration* Intravenous

*Dosage form* Ampule 100 mg

**THYTROPAR (Armour)**

Trade name for Thyrotrop n

**TIBIONE (Schenley)**

Trade name for Amthiozone

**TIGAN (Roche)**

Trade name for Tr methobenzamide HCl

**TISIN (Arlington)**

Trade name for Isoniazid

**TITANIUM DIOXIDE**

*Administration* Topical

*Dosage forms* Up to 25% in powders creams and emulsions

**TITRALAC (Schenley)**

Trade name for Aminoacetic Acid and Calcium Carbonate

**TOCLASE (Pfizer)**

Trade name for Carbetapentane Citrate

**TOCOPHEREX (Squibb)**

Trade name for Tocopherols Mixed

**TOCOPHEROLS MIXED**

*Synonym* Vitamin E

*Trade names* Cotopherol (Endo) Ecofrol (Breon), Ephynal (Roche) Eprolin (Lilly) Epsilan (Warren Teed) Esorb (Wyeth) E Toplex (U S Vitamin), Tocopherex (Squibb) Tocophrin (Barry) Tofaxin (Winthrop) and many others

*Dosage form* Many forms

**TOCOPHRIN (Barry)**

Trade name for Tocopherols Mixed

**TOFAXIN (Winthrop)**

Trade name for Tocopherols Mixed

**TOFRANIL (Geigy)**

Trade name for Imipramine HCl

**TOLANATE (C.S.C.)**

Trade name for Inositol Hexanitrate

**TOLAZOLINE HCl**

*Trade names* Pristoline (Ciba) Tolpal (Philadelphia)

*Administration* Oral subcutaneous intramuscular intravenous

*Dosage forms* Tablet 26 mg elixir 6 mg per ml vial 25 mg per ml

**TOLBUTAMIDE**

*Trade name* Orinase (Upjohn)

*Administration* Oral

*Dosage form* Tablet 05 Gm

**TRIPROLIDINE HCl**

*Trade name* Actidil (Burroughs Wellcome)  
*Administration* Oral  
*Dosage forms* Tablet, 2.5 mg, syrup, 0.25 mg per ml

**TRISEM (Massengill)**

*Trade name for* Meth Dia Mer Sulfonamides

**TRI-SIL (Warren Teed)**

*Trade name for* Magnesium Trisilicate

**TRISOCEL (Lilly)**

*Trade name for* Magnesium Trisilicate and Aluminum Hydroxide

**TRI SULFAMETH (Arlington)**

*Trade name for* Meth Dia Mer Sulfonamides

**TRISULFAZINE (Central)**

*Trade name for* Meth Dia Mer Sulfonamides

**TRITHIONE (Ortho)**

*Trade name for* Aminotrolole

**TRIZIL (Central)**

*Trade name for* Acet Dia Mer Sulfonamides

**TROMEXAN ETHYL ACETATE (Geigy)**

*Trade name for* Ethyl Biscoumacetate

**TROXOTHANE (Abbott)**

*Trade name for* Pramoxine HCl

**TROSINONE (Abbott)**

*Trade name for* Ethisterone

**TRUOZINE (Abbott)**

*Trade name for* Meth Dia Mer Sulfonamides

**TRYPSIN**

*Trade names* Paryzyme (National), Tryptar (Armour)  
*Administration* Inhalation, parenteral  
*Dosage forms* Aerosol, 10 mg per ml vials  
 5 mg per ml in oil, 5 mg per ml

**TRYPTAR (Armour)**

*Trade name for* Trypsin

**TSPA**

*Synonym for* Triethylene Thiophosphoramide

**TUBADIL (Endo)**

*Trade name for* Tubocurarine Cl

**TUBARINE (Burroughs Wellcome)**

*Trade name for* Tubocurarine Cl

**TUBARINE Cl (Burroughs Wellcome)**

*Trade name for* Tubocurarine Cl

**TUBOCURARINE Cl**

*Trade names* Tubadil (Endo), Tubarin (Burroughs Wellcome)  
*Administration* Intramuscular, intravenous  
*Dosage form* Solutions, 3, 15, 30 mg per ml

**d TUBOCURARINE Cl**

*Synonym for* Tubocurarine Cl

**TURPENTINE OIL**

*Administration* Oral  
*Dosage form* As such

**TUSSIONIX (Stravenburgh)**

*Mixture of* Phenyltoloxamine and Dihydrocodemone

**TWFFN 20**

*Synonym for* Polysorbate 20

**TWFEN 80**

*Synonym for* Polysorbate 80

**TYLENOL (McNeil)**

*Trade name for* Acetaminophen

**TYROTHRICIN**

*Trade name* Soluthricin (Merck)  
*Administration* Topical  
*Dosage form* Solutions, 0.5, 2.5 mg per ml

**TYVID (Merrell)**

*Trade name for* Isoniazid

**TYZINE (Pfizer)**

*Trade name for* Tetrahydrozoline HCl

**ULTANDREN (Ciba)**

*Trade name for* Fluoxymesterone

**ULTRA LENTE ILETIN (Lilly)**

*Trade name for* Ultralente Insulin

**ULTRALENTE INSULIN**

*Trade name* Ultra Lente Iletin (Lilly)  
*Administration* Subcutaneous  
*Dosage forms* Vials, 40 U per ml, 80 U per ml

**ULTRAN (Lilly)**

*Trade name for* Phenaglycodel

**UMBRATHOR (Heyden)**

*Trade name for* Thorium Dioxide

**UNDECYLENIC ACID**

*Trade name* Desenex (Wallace & Tiernan)  
*Administration* Oral  
*Dosage form* Solution, 10%

**UNDESOL (Veltex)**

*Trade name for* Zincundecate

**UNIDIGIN (Merrell)**

*Trade name for* Digtoxin

- TRICOFURON (Laton)**  
Trade name for Furazolidone
- TRICOLOID SO (Burroughs Wellcome)**  
Trade name for Tricyclamol SO.
- TRICOMBISUL (Schering)**  
Trade name for Acet Dia Mer Sulfonamides
- TRI CREAMALATE (Winthrop)**  
Trade name for Magnesium Trisilicate and Alumnum Hydroxide
- TRICYCLAMOL SO**  
Trade names Elorine SO (Lilly) Tricoloid (Burroughs Wellcome)  
Administration Oral  
Dosage form Capsule 25 mg
- TRIDIHETHIDE**  
Trade name Pathilon (Lederle)  
Administration Oral  
Dosage form Tablet 25 mg
- TRIDIONE (Abbott)**  
Trade name for Trimethadione
- TRIFTHANOLAMINE**  
Emulsifier
- TRIETHANOLAMINE SALICYLATE**  
Trade name Myoflex Creme (Warren Teed)  
Dosage form Cream 10%
- TRIETHYLENE MELAMINE**  
Synonym TEM  
Administration Oral  
Dosage form Tablets 1 and 5 mg
- TRIETHYLENE THIOPHOSPHORAMIDE**  
Synonyms TSPA Thio-TEPA  
Not available on commercial drug market
- TRIFLUOPERAZINE**  
Trade name Stelazine (Smith Kline & French)  
Administration Oral  
Dosage form Tablet 1 mg
- TRIFLUPROMAZINE HCl**  
Trade name Vespryn (Squibb)  
Administration Oral  
Dosage form Tablets 10 25 and 50 mg
- TRIFONAMIDE (VanPelt & Brown)**  
Trade name for Meth Dia Mer Sulfonamides
- TRIMETHADIONE**  
Trade name Tridione (Abbott)  
Administration Oral  
Dosage forms Capsule 0.3 Gm tablet 150 mg solution about 30 mg per ml
- TRIMETHAPHAN CAMPHORSULFONATE**  
Trade name Arfonad (Roche)  
Administration Intravenous drip  
Dosage form Ampule 50 mg per ml
- TRIMETHIDINIUM METHOSULFATE**  
Trade name Ostensin (Wyeth)  
Administration Oral  
Dosage form Tablets 20 40 mg
- TRIMETHOBENZAMIDE HCl**  
Trade name Tigan (Roche)  
Administration Oral rectal intramuscular  
Dosage forms Capsule 100 mg pediatric suppositories 200 mg ampule 100 mg per ml
- TRIMETHYLENE**  
Synonym for Cyclopropane
- TRIMETON (Schering)**  
Trade name for Pheniramine Maleate
- TRINESIUM (Abbott)**  
Trade name for Magnesium Trisilicate
- TRIONAMIDE (Flint Faton)**  
Trade name for Meth Dia Mer Sulfonamides
- TRIONINE (Roche)**  
Trade name for Liothyronine
- TRIPAZINE (Eaton)**  
Trade name for Meth Dia Mer Sulfonamides
- TRIPLENNAMINE HCl**  
Trade name Pyrbenzamine (Ciba)  
Administration Oral topical  
Dosage forms Tablets 25 50 mg fluid equivalent of 5 mg per ml ointment 20 mg per Gm cream, 20 mg per ml
- TRIMETHADIONE**  
Trade name Tridione (Abbott)  
Administration Oral  
Dosage forms Capsule 0.3 Gm tablet 150 mg solution about 30 mg per ml
- TRIMETHAPHAN CAMPHORSULFONATE**  
Trade name Arfonad (Roche)  
Administration Intravenous drip  
Dosage form Ampule 50 mg per ml
- TRIMETHIDINIUM METHOSULFATE**  
Trade name Ostensin (Wyeth)  
Administration Oral  
Dosage form Tablets 20 40 mg
- TRIMETHOBENZAMIDE HCl**  
Trade name Tigan (Roche)  
Administration Oral rectal intramuscular  
Dosage forms Capsule 100 mg pediatric suppositories 200 mg ampule 100 mg per ml
- TRIMETHYLENE**  
Synonym for Cyclopropane
- TRIMETON (Schering)**  
Trade name for Pheniramine Maleate
- TRINESIUM (Abbott)**  
Trade name for Magnesium Trisilicate
- TRIONAMIDE (Flint Faton)**  
Trade name for Meth Dia Mer Sulfonamides
- TRIONINE (Roche)**  
Trade name for Liothyronine
- TRIPAZINE (Eaton)**  
Trade name for Meth Dia Mer Sulfonamides
- TRIPLENNAMINE HCl**  
Trade name Pyrbenzamine (Ciba)  
Administration Oral topical  
Dosage forms Tablets 25 50 mg fluid equivalent of 5 mg per ml ointment 20 mg per Gm cream, 20 mg per ml

**VERSENATE, CALCIUM DISODIUM**  
(Riker)

Trade name for Edathamil Calcium Disodium

**VESPRIN** (Squibb)

Trade name for Trifluoromazine HCl

**VIADRIL** (Pfizer)Trade name for Hydroxydione**VIBAZINE HCl** (Pfizer)

Trade name for Bucizine HCl

**VICIN** (Brewer)

Trade name for Ascorbic Acid

**VINACTANE SO<sub>2</sub>** (Ciba)Trade name for Viomycin SO<sub>2</sub>**VINBARBITAL SODIUM**

Trade name Delvinal (Merck)

Administration Oral

Dosage form Capsules, 30, 100, and 200 mg

**VINETHENE** (Merck)

Trade name for Vinyl Ether

**VINOBEL** (Merrell)

Trade name for Belladonna Extract

**VINYL ETHER**

Synonym Divinyl Oxide

Trade name Vinethene (Merck)

Administration Inhalation

Dosage form Bottles, as such

**VIOGIN** (Pfizer)Trade name for Viomycin SO<sub>2</sub>**VIOFORM** (Ciba)

Trade name for Iodochlorhydroxyquin

**VIOKAS** (VioBin)

Trade name for Pancreas

**VIOMYCIN SO<sub>2</sub>**Trade names Vinactane SO<sub>2</sub> (Ciba), Viocin (Pfizer)

Administration Intramuscular

Dosage form Ampule 1 Gm

**VIOSTEROL**

Synonym for Calciferol

**VISAMMIN**

Synonym Khellin

Trade names Amminin (National Drug), Khelisem (Massengill)

Administration Oral

Dosage form Tablets 10, 20, and 25 mg

**VISINE** (Pfizer)

Trade name for Tetrahydrozoline HCl

**VISTARIL** (Pfizer)

Trade name for Hydroxyzine Pamoate

**VITADFX B** (Cutter)

Trade name for Vitamin B Complex

**VITAMIN A**

Synonym for Oleovitamin A

**VITAMIN A, WATER MISCIBLE**

Trade names Acon (Endo), Aquasol (U S Vitamin), and many others

Administration Oral intramuscular

Dosage form Solution, 25,000 U per ml

**VITAMIN B**

Synonym for Thiamine HCl

**VITAMIN B<sub>2</sub>**

Synonym for Riboflavin

**VITAMIN B<sub>6</sub>**

Synonym for Pyridoxine HCl

**VITAMIN B<sub>12</sub>**

Synonym for Cyanocobalamin

**VITAMIN B COMPLEX**

Nonproprietary preparations Brewer's Yeast, Yeast Concentrate

Trade names Beta Concernin (Merrell), Betalin (Lilly), Betaplexin (Winthrop), Desiver (U S Vitamin), Heptobee (Endo), Lederplex (Lederle), Solu Zyme (Upjohn), Sur Bex (Abbott), Vitadex B (Cutter), and many others

Administration Oral parenteral

Dosage forms A large variety of forms

**VITAMIN C**

Synonym for Ascorbic Acid

**VITAMIN D<sub>3</sub>**

Synonym for Calciferol

**VITAMIN E**

Synonym for Tocopherols Mixed

**VITAMIN G**

Synonym for Riboflavin

**VITAMIN K**

Synonym for Menadiolone

**VITAMIN K, SYNTHETIC**

Synonym for Menadione

**VITAMIN K<sub>1</sub>**

Synonym for Phytonadione

**VITAMIN P**

Synonym for Hesperidin Methyl Chalcone

# DRUG INDEX

**UNITENSEN** (Irwin Neusler)  
Trade name for Cryptenamine

**UNITENSEN TANNATE** (Irwin Neusler)  
Trade name for Cryptenamine Tannate

**UREA**  
Synonym Carbamide  
Administration Oral  
Dosage form Solution various concentrations

**URECHOLINF Cl** (Merck)  
Trade name for Bethanechol Cl

**URETHAN**  
Synonym Ethyl Carbamate  
Administration Oral  
Dosage form Tablet 0.3 Gm

**URGININ**  
Administration Oral  
Dosage form Tablet 0.5 mg

**URITONE** (Parke Davis)  
Trade name for Methenamine

**UROENTERONE**  
Trade name Kutrol (Parke Davis)  
Administration Oral  
Dosage form Capsule 75 mg

**UROKOV SODIUM** (Mallinckrodt)  
Trade name for Sodium Acetizoate

**UROSULFIN** (Nepera)  
Trade name for Sulfamethazole

**UROSULFON** (CMC)  
Trade name for Sulfacetamide

**UROTROPIN** (Warner Chilcott)  
Trade name for Methenamine

**VALETHAMATE Br**  
Trade name Murel (Ayerst)  
Administration Oral intravenous intramuscular  
Dosage forms Tablet 10 mg vial 10 mg per ml

**VALLESTRIL** (Searle)  
Trade name for Methallenestril

**VALMID** (Lilly)  
Trade name for Ethinamate

**VANCOCIN** (Lilly)  
Trade name for Vancomycin

**VANCOMYCIN**  
Trade name Vancocin (Lilly)  
Administration Intravenous  
Dosage form Ampule 500 mg

**VANOGE** (VanPelt & Brown)  
Trade name for Aluminum Hydroxide

**VANQUIN** (Parke Davis)  
Trade name for Pyriminium Cl

**VANZOATE** (VanPelt & Brown)  
Trade name for Benzyl Benzoate

**VAPONEFRIN**  
Trade name for Epinephrine HCl (2.25% solution in a nebulizer)

**VARIDASE** (Lederle)  
Trade name for Streptokinase Streptodornase

**VASCULAT**  
Not available on the commercial drug market

**VASODILAN** (Mead Johnson)  
Trade name for Isosuprine

**VASODRINE** (Premo)  
Trade name for Epinephrine HCl

**VASOPRESSIN**  
Trade name Pitressin (Parke Davis)  
Administration Intramuscular subcutaneous  
Dosage form Vial 20 Pressor units per ml

**VASOPRESSIN TANNATE**  
Trade name Pitressin Tannate  
Administration Intramuscular  
Dosage form Ampule 5 units per ml in oil

**VASOXYL** (Burroughs Wellcome)  
Trade name for Methoxamine HCl

**V CILLIN** (Lilly)  
Trade name for Phenoxymethyl Penicillin

**VENOM RUSSELL VIPER**  
Trade name Styppen (Burroughs Wellcome)  
Administration Topical  
Dosage form Vial as such for solution

**VENTRICULIN** (Parke Davis)  
Trade name for Stomach Powdered

**VERALBA** (Pitman Moore)  
Trade name for Protoveratrine A and B

**VERILOID** (Riker)  
Trade name for Alkavir

**VERITOL**  
Not available on the commercial drug market

**VERMIZINE** (Chicago)  
Trade name for Piperazine Gluconate

**VERONAL**  
Synonym for Barbitol



# DRUG INDEX

## VITAMIN P FACTOR

Synonym Rutin  
Administration Oral  
Dosage form Tablets 20 50 100 250 mg

## VITRAL (Flint, Eaton)

Trade name for Cyanocobalamin

## VLEM DOME POWDER PACKETS (Dome)

Calcium polysulfide calcium thiosulfate sul  
fur powder

## VONEDRINE (Merrell)

Trade name for Phenylpropylmethylamine  
HCl

## VONTIL

Synonym for Thioprazine

## WARCOUNIN (Harvey)

Trade name for Warfarin Sodium

## WARFARIN SODIUM

Trade names Coumadin Sodium (Endo)  
Warcoumin (Harvey)  
Administration Oral intravenous  
Dosage forms Tablets 5, 10, 25 mg am  
pule 7.5 mg per ml

## WHITE LOTION

Synonym Lotio Alba  
Administration Topical  
Dosage forms Suspension zinc oxide and  
sulfurated potash, 4%

## WHITE PRECIPITATE

Synonym for Ammoniated Mercury

## WILD CHERRY

Administration Oral  
Dosage form Syrup

## WYAMINE (Wyeth)

Trade name for Mephentermine SO<sub>4</sub>

## WYCILLIN (Wyeth)

Trade name for Procaine Penicillin G

## WYDASE (Wyeth)

Trade name for Hyaluronidase

## WYNESTROV (Wyeth)

Trade name for Estrone

## AEROFORM (Merco)

Trade name for Bismuth Tribromophenate

## XYLOCAINE HCl (Astra)

Trade name for Lidocaine HCl

## XYLOMETAZOLINE HCl

Trade name Otrivan (Ciba)  
Administration Topical  
Dosage form Solution 0.1 and 0.05%

## YATREN

Synonym for Chinoson

## YEAST CONCENTRATE

Synonym for Vitamin B Complex

## YODOXIN

Trade name for Diiodohydroxyquin

## ZACTANE (Wyeth)

Trade name for Ethioheptazine Citrate

## ZACTIRIN (Wyeth)

Trade name for mixture of Aspirin and  
Ethioheptazine

## ZANCHOL (Searle)

Trade name for Flortantzone

## ZEPHIRAN Cl (Winthrop)

Trade name for Benzalkonium Cl

## ZETAR EMULSION (Dermik)

Crude Coal Tar

## ZETAR SHAMPOO (Dermik)

Tar shampoo

## ZINC INSULIN CRYSTALLINE

Administration Subcutaneous  
Dosage form Vials, 40 and 80 units per ml

## ZINC OXIDE

Administration Topical  
Dosage forms Various forms

## ZINC PEROXIDE

Administration Topical  
Dosage form Suspension 40%

## ZINC SO<sub>4</sub>

Administration Topical  
Dosage form Solution 1 to 4%

## ZINC STEARATE

Administration Topical  
Dosage form Powder about 15%

## ZINCHLORUNDESAL

Trade name Salundek (Wallace & Tiernan)  
Administration Topical  
Dosage form Ointment 20%

## ZINCUNDEGATE

Trade name Undesol (Veltex)  
Administration Topical  
Dosage form Ointment 50%

## ZOXAZOLAMINE

Trade name Flexin (McNeil)  
Administration Oral  
Dosage form Tablet, 250 mg



- Addictive analgesics, 212-238  
for relief of pain, design for use of, 232-238
- Addison's disease, diagnosis and therapy, 576-577
- Adenoiditis and nasopharyngitis, therapy, 718
- Adenoma parathyroid, 574
- Administration of drugs to children, methods, 50  
of narcotics, optimal mode, 234
- Adrenal cortex, diseases of, 575-580  
hyperfunction of, 577-580  
corticoids (*see* Adrenal steroids Adrenocorticosteroids)
- glands, 574-580  
disorders of, diagnostic use of ACTH for, 558  
therapeutic effects of ACTH on, 557  
insufficiency, diagnosis and therapy, 576-577  
medulla abnormality, 574  
steroids (*see also* Adrenocorticosteroids)  
in acute leukemia in children, 606-607  
in arthritis, clinical application, 591  
pharmacologic considerations, 591-596  
and rheumatic fever, mechanism of action, 595  
in carcinoma of breast, 622  
in chronic lymphocytic leukemia, 616  
in connective tissue disorders, 599  
contraindications to, 597  
drugs of, 597  
in Hodgkin's disease, 618  
intra-articular administration, 598  
mechanism of action on leukemic cells, 607  
in multiple myeloma, 620  
for rheumatic disorders, clinical applications, 591  
in rheumatoid arthritis, design for use of, 597-598  
supportive value in advanced cancer, 626  
untoward effects, 595, 596  
use of, 597
- Adrenalectomy for breast cancer, maintenance therapy following, 622  
for Cushing's syndrome, pre- and post-operative management, 578
- Adrenalin for nosebleed, 723, 724  
as vasoconstrictor in otolaryngology, 724
- Adrenergic agents for allergic disorders, 522-526  
table of, 523  
blocking agents in glaucoma, 707  
as miotics, 702  
in peripheral vascular diseases, 484, 491
- Adrenocorticosteroids (*see also* Adrenal steroids)  
for alkali poisoning, 786  
in allergic disease, 540-542  
for cardiovascular shock in poisoning, 784  
for microbial infections, 168, 169  
in pruritus systemic administration of, 758
- Adrenocorticotrophic hormone, 557-559
- Adrenocorticotropin in long term steroid therapy, 597
- Adrenogenital syndrome in newborn infant, 579
- Adrenogenitalism, hyperadrenocorticism with, 578-579
- Adrenosem for hemorrhage, 658
- Adsorbents as antidiarrheal agents, 373  
for irritable colon, 371
- Aerobacter aerogenes, urologic infection by, treatment, 697
- Aerosol mists, drug administration by, 45
- Aerosols for elimination of bronchial secretions, 531-533  
steroid in allergic disease, 542
- Aerosporin, clinical use and toxicity, 152  
side effects, 162
- Afferent neurogenic arcs mediating cough reflex, 497
- Afibrinogenemia, therapy of, 647
- Agranulocytosis antibiotics in, 641  
clinical considerations, 631
- AHG in hemophilia, 645-646
- Airsickness, drugs for, 318  
incidence of, 314
- Airway, establishing and maintaining, in poisoning, 783
- Albamylin, clinical use, 153  
in urology, 696, 697
- for pain relief, 455  
in preoperative preparation of patients skin, 136
- Alcoholic beverages as stimulants and digestants, 377
- Alcoholism, antialcoholic drugs and, 551  
stimulant drugs in treatment, 182
- Aldosterone, action and use of, 575
- Alevoire in bronchial drainage, 533
- Alkali poisoning, treatment, 786  
therapy of metabolic acidosis, 784
- Alkalinizers, urinary, pharmacologic considerations, 692  
purpose of, 691
- Alkaloid poisoning, treatment, 786
- Alkaloids, belladonna, 354-355
- Alkalosis, metabolic, 63  
therapy, 67  
respiratory, therapy, 67  
solutions for therapy, 78
- Alkylating agents, polyfunctional, in breast cancer, 622  
in carcinoma of lung, 624  
of ovary, 624  
in choriocarcinoma, 623  
in chronic myelocytic leukemia, 613-614  
in Hodgkin's disease, 617-618  
in miscellaneous forms of cancer, 625  
in regional chemotherapy in cancer, 626
- Allergic disorders adrenergic agents employed in, table, 523  
antihistamines in, 534-536  
classification table, 518  
clinical considerations, 517-518  
corticotropin and corticosteroids in, 538-543  
environmental control of, 520

# INDEX

A\* F1 771

A

Abdominal examination purging in preparation for 363  
management of 205

Abort on causes and treatment 677 679  
habitual 678  
prevention of progesterone therapy 678  
679

Absorption of drugs aspects of 27 28  
delayed 49

oral of drugs factors influence 41 44  
Abstinence syndrome 231

Acetaminophen desensitization for use of 210  
poisoning treatment under Methemoglobinemia c poisoning 789

toxic reactions to 209  
Acetazolamide as diuretic 98  
n pulmonary disease 87

for epilepsy 90  
for glaucoma 89 707 708  
for refractory edema of heart disease 8

toxic reactions to 99  
Acetophenetidin desensitization for use of 210  
for fever 351

for pain control 708  
poisoning treatment (under Methemoglobinemia c poisoning) 789

toxic reactions to 209  
Acetate in angiocardography 797

Acetyl strophanthin 407  
in desensitization tolerance test 401

Acetylcholine poisoning treatment (under Cholinergic compounds) 786

acetylcholine 104  
acetylsalicylic acid (see Aspirin)  
chlorhydrate, synergistic gastric analysis 803 803

dosage and doses 786  
d base balance adjustment therapy for 77 78

analgesics in 61  
disturbance method of diagnosis of 80  
restoration of 66-67

quilibrium in children disturbances n  
and drug selection 51  
urinary clinical application and  
pharmacologic considerations 691

Acidosis diabetic insulin for 550 553  
metabolic 63  
therapy of 67

respiratory therapy of 67  
solutions for therapy of 77

agents used in 729-731  
miscellaneous measures of control 731  
scurvy treatment 731

Acetazone chloride n preoperative preparation of patients 138

Acetazolamide 487  
Acromegaly therapy for 567

ACTH n acute leukemia n children 607  
n allergic disease 338 339 510  
arthritis clinical application 591

pharmacologic considerations 591 596  
n connective tissue disorders 600  
control of adrenal cortex by 375

and cortisone for nephrotic syndrome 88  
for refractory edema of heart disease 87  
n diagnosis of Cushing's syndrome 578

diagnostic use of 557 558  
n differentiation  
secondary between primary and  
576 hypoadrenocorticism

for eye infections 712  
n diphtheria 642  
thrombocytopenic purpura

for itching system administration of 758  
for lupus erythematosus 734  
for pemphigus 733

n rheumatic fever 599  
therapeutic use 557  
for uremia 772

Acetaminophen n pulmonary metastases from  
Wilms' tumor n children 626  
Action curve of pharmacologic explanation  
of 27 28

Acute pain treatment of 235 736  
Adams Stokes syndrome 412  
Isuprel n 416

Adenon pharmacology of 273  
Addiction cathartics 361  
relief of 368

codeine due to cough medication 500  
to hypnotics 290  
narcotics 230 237  
treatment 232  
pharmacologic abstinence syndrome 231

Analgesics add et ve—Cont d  
 field of usefulness 717  
 for general nary pa n 697  
 optimal dose 733  
 mode of administration 734  
 overdosage 28 730  
 for severe chronic pain lesion for us  
 of 737  
 tolerance to 230  
 definition of 07  
 dosage in pain control 07  
 nonaddictive 207 711  
 effects of 09  
 new rational basis for 710  
 ophthalmology 706  
 otolaryngology 721  
 selection of governed by quality and in  
 tensity of pain 207

Anaphylactic shock epinephrine for 574  
 Anapylactoid reactions summary of therapy  
 516

Androgens for anginal pain 433  
 carcinoma of breast 670 671  
 for dysmenorrhea 480  
 effect on blood cholesterol 519  
 for fertility in female 581  
 for hypogonadism with testicular failure  
 585  
 for infertility in male 587  
 for loss of libido in male 586  
 for menopause 581  
 production of 575  
 side effects in women 721  
 to suppress ovulation 680

Ante-auto-immune hemolytic therapy 610  
 711  
 deficiency clinical considerations 630  
 hemolytic clinical considerations 630  
 hypoplastic therapy 610  
 iron deficiency treatment with iron prep  
 arations 636 637  
 kinds of clinical considerations 629  
 macrocytic folate acid in 639  
 pernicious vitamin B in 115 116 638  
 739  
 of pregnancy management of 665  
 production of 71

Anesthesia cardac arrhythmias during 413  
 general (see also Anesthetics general)  
 design for use of drugs for 750  
 rational basis for new drugs for 251  
 local (see also Anesthetics local)  
 in suppression of cough 505  
 obstetric 669 670  
 regional 253  
 retrobulbar in ophthalmology 706  
 skeletal block 670  
 secondary agents for 249 250  
 definition and clinical and pharma  
 cological considerations 246  
 rational basis for new drugs for 251  
 spinal clinical applications 253 254  
 vasopressor agents with 477

ANALGESICS  
 nonvolatile agents for 248  
 rational basis for new drugs for 251

Anesthesia surgical—Cont d  
 volatile vapors for 246 717  
 topical of eardrum 727  
 of larynx 727 723  
 of nose and paranasal sinuses 722  
 of trachea 723

Anesthetics choice of 244 760  
 general choice of 244 251  
 clinical applications and pharmacolog  
 ical considerations 244 246  
 in otolaryngology 721  
 local choice of 252 260  
 clinical applications 257 254  
 as cough suppressants 505  
 duration of action 755  
 effects of 754 256  
 intensity of effect 255  
 new rational basis for 760  
 in ophthalmology 706  
 toxic reactions to 755  
 topical in otolaryngology 721 723

Angina decubitus 475  
 mercurial diuretics for 87

Anginal pain mechanism of 473  
 in miscellaneous cardiac disturbances 475  
 in respiratory disturbances 425  
 syndrome rational basis for new drugs for  
 431  
 sex categories of 424 426

Angiocardography radiopaque iodides in  
 797

Angioedema antihistamines 535  
 of larynx epinephrine for 574  
 pathogenesis 519  
 summary of therapy 516

ANALGESICS  
 721

Animals laboratory experiments on basis to  
 progress in therapeutics 24

Anion exchange resins as antacids 359

Anorexants choice of 341 350  
 effectiveness of 344  
 new need for 350  
 pharmacological considerations 313 345  
 side effects 346 347  
 use of 349

Anorexic drugs 341 350

Ansolyzen for hypertension 457

Antabuse for alcoholism 551

Antacids choice of 357 361  
 design for use of 359 360  
 freely absorbable 358  
 new rational basis for 360  
 pharmacological considerations 357  
 poorly absorbable 358 359

Antazolic (Antistene) in eye infections 714

Anterior pituitary disturbances 567 565  
 hormones 556 561

Anthelmintic therapy 383 390

Anthelmintics purging preparatory to use  
 of 363

Anthralin ointment for fungous infections of  
 skin 748  
 for psoriasis 763

Antacne agents 729 731

- Allergic disorders—Cont d  
   hyposensitization therapy, 521  
   new drugs, rational basis for 546  
   pathogenesis 518 519  
   pharmacologic management 520 545  
   therapy discussion and summary 545 547  
   physiologic and pharmacologic considerations 518 519  
   symptomatic management with pharmacologic agents 522 545  
   types of and agents for their control summary 546  
   phenomena definition 516  
   reactions to drugs explanation of 27  
   histamine in, 519  
   rhinitis acute corticosteroids for 720  
   Allergies (see also Allergic)  
   drugs used for choice of 516 547  
   mechanism of 517  
   Allergy to antibacterial agents 159  
   definition of term 516  
   Alpha lactose tablets for vaginal trichomoniasis, 686  
   Alphaprodine pharmacology and dosage 222  
   poisoning, treatment (under Narcotics) 786  
   for posttraumatic pain 236  
   Aluminum chloride for hyperhidrosis 755  
   hydroxide as antidote in acid poisoning 786  
   for hypoparathyroidism, 573  
   monostearate, procaine penicillin in 145  
   salts as gastric antacids 358  
   Amanita toxins poisoning by treatment 786  
   Amebae examination of stools for, purging preparatory to 363  
   Amebiasis, 379 382  
   chronic treatment 381  
   complications of treatment, 380  
   metastatic, treatment 381  
   Amebic abscess of liver, treatment 381  
   dysentery acute, treatment, 380  
   hepatitis, diffus, 382  
   Amenorrhea and delayed menstruation therapy 580 582  
   kinds of, 681  
   primary etiology and treatment 681  
   secondary, etiology and treatment 682  
   induced by endometriosis therapy, 680  
   Amethopterin in acute leukemia in children 608 609  
   in young adults, 612  
   in choriocarcinoma, 623  
   in chronic myelocytic leukemia 615  
   toxic manifestations of 608 609  
   Amidone as antitussive agent 501  
   pharmacology of 223  
   amine oxidase inhibitors 186  
   dosage 188  
   amino acryl amides as local anesthetics 257  
   aminodrox, 530  
   aminophylline for bronchospasm 528  
   as coronary artery dilator 432  
   as diuretic 93  
   methods of administration, 528 529  
   anal, untoward effects 530  
   refractory edema of heart disease 87  
   therapy in children, dangers of, 530  
   Aminopterin in acute leukemia of children 609  
   for psoriasis, 760  
   Aminopyrine, design for use of, 210  
   Amino uracil diuretics 99  
   Amuthiozone 157  
   Ammoniated mercury in bleaching of skin 731 732  
   ointment for fungous infections of skin, 747  
   in ophthalmology, 709  
   Ammonium chloride as diuretic 92  
   for refractory edema of heart disease 87  
   solution for alkalosis 78  
   as urinary acidifier 691  
   salts in management of cough 507  
   Amnesia definition and clinical and pharmacologic considerations 245  
   design for use of drugs for, 251  
   nonvolatile agents for 249  
   rational basis for new drugs for 251  
   stimulants for 184  
   volatile vapors and gases of no value for 249  
   Amobarbital (Amytal) as anticonvulsive in poisoning 782  
   Amphetamine for barbiturate depression 782  
   as central stimulant 186  
   dosage 188  
   forms of for obesity 347  
   in management of behavioral problems in children 181  
   poisoning treatment 786  
   for relief of pain 240  
   Amphetamine like drugs as anorexiants 345  
   348  
   Amyl nitrite action of as coronary artery dilator 427  
   poisoning treatment (under Methemoglobinemic poisoning) 786  
   in treatment of cyanide poisoning, 787  
   use of, 429  
   Amytal sodium as anticonvulsive in poisoning, 782  
   for eclamptic seizures 676  
   for psychoses 179  
   for sedation in pregnancy 664  
   Anabolic steroids 587  
   Anal lesions catharsis in presence of 362 369  
   Analeptics use of 781  
   Analgesia definition, and clinical and pharmacologic considerations 245  
   design for use of drugs for, 250  
   in labor 667 669  
   mechanism of 208  
   nonvolatile agents for, 249  
   rational basis for new drugs for 251  
   by reversal of pain mechanism 241 242  
   spinal clinical applications 253 254  
   volatile vapors for 248  
   Analgesic block regional 212  
   Analgens action of, 207  
   addictive for amnesia 249  
   classes of 212  
   contraindicated for chronic pain, 236  
   for control of pain 212 238  
   design for use of, 232 238  
   new rational basis for, 238



- Antialcoholic drugs and alcoholism 551  
 Antiallergic agents choice of, 516-517  
   new rational basis for, 546  
   symptomatic management with 522 545  
   therapy for vertigo 370  
 Antiarthritic agents choice of 589 603  
   design for use of 596 601  
   of doubtful utility, 592  
 Antibacterial agents, choice of 141 162  
   side reactions 158 162  
   effects of local antiseptics 129 140  
   therapy in children narrow margin for  
     error in 51  
   superinfection as hazard 158  
 Antibiotics for acne 730  
   in aeranulocytosis 641  
   antifungal oral griseofulvin 747 748 749  
   bacteriostatic and bactericidal activity of  
     169  
   broad spectrum superinfection following  
     158  
   combined with hydrocortisone for eczema  
     745  
   for contaminated ocular field 715  
   discussion of 141  
   in ear diseases 716 718  
   for eye infections 714 715  
   in general use 142 143  
   in lacrimal infections, 711  
   lozenges for stomatitis 770  
   in mastoiditis 718  
   for microbial disease 165 166  
   mode of action of 142  
   narrow spectrum uses of 149  
   new rational basis for 698  
   in ophthalmology penetration of 708  
   in otitis media 717  
   in otolaryngology 716 719  
   pharmacologic considerations 174 176  
   as prophylactic in poisoning 783  
   in prophylaxis of infections 170 171  
   of intraocular infection table 710  
   for pyoderma ointments 765 766  
   selection of 142  
   solubility problems of 45  
   specific design for use in infections 169  
   in therapy of intraocular infections table  
     711  
   three phases of therapy 692  
   in urology, 694 696  
   for virus infections 171, 172  
 Antibodies nature and mechanisms of 518  
   519  
 Anticholinergic drugs in allergic disease 527  
   choice of 352 356  
   for chronic inflammatory diseases of in  
     testes 371  
   design for use of 355  
   dosage 355 356  
   for hyperhidrosis side effects 756  
   for irritable colon, 371  
   new rational basis for, 356  
   for pain relief 241  
   pharmacologic considerations 351  
   side effects 354 356  
   synthetic 355  
   untoward reactions 528  
   in urology design for use of 690  
   coagulant of choice 655
- Anticoagulants definition 649  
   discussion of 650 656  
   dosage schedule for 657  
   hypothrombin inducing drugs as 655  
   new rational basis for 656-657  
   theoretically ideal features of 651  
   two types of 651 652  
 Anticonvulsants choice of 293 304  
   design for use in control of epilepsy 29  
     304  
   fate of in body 300  
   new need for 304  
   nonsedative ideal requirements of 296  
   pharmacologic requirements of 297  
   in poisoning 782  
   structural relationships between 299  
   structure and general properties of 298  
   toxicity of 300  
 Antidiabetic drugs oral 553 554  
   design for use of 374  
   new rational basis for 375  
   pharmacologic considerations 373  
 Antidotes poison 785 791  
   to toxicity of mercurial diuretics 94  
 Antieczematous agents 736 745  
 Antiemetic agents choice of 324 339  
   clinical applications 330 338  
   development of 325  
   for nausea and vomiting of pregnancy  
     336 337  
   new 338  
   evaluation of 339  
   pharmacologic considerations 324 330  
   for prevention of postoperative vomiting  
     334 335  
   for radiation sickness 333  
   side effects of 329 330  
   summary of therapeutic use of 338  
   therapy recommendations for 338  
 Antifungal agents in dermatology 747 750  
 Antigens nature and mechanisms of 518  
   519  
 Antihemophilic globulin in hemophilia 645  
   646 657  
 Antihistamines as antiemetic agents 326 327  
   as antitussive agents 509  
   common agents in clinical practice 536  
   development and classification 531  
   in eye infections clinical use 713 714  
   for insomnia 291  
   in pruritus 759  
   in symptomatic therapy of allergic states  
     534 536  
   as tranquilizers 262  
   untoward effects 535  
   for urticaria 77  
   for vertigo 317 370  
 Antihypertensive agents choice of 437 457  
 Anti-infective agents choice of 141 162  
 Anti-inflammatory agents in ophthalmology,  
   708 710  
 Antilouse drugs 751  
 Antimalarials in lupus erythematosus 753,  
   754  
 Antimony poisoning, treatment (under Heavy  
   metals), 786  
 preparations for schistosomiasis 389

- Benzonic acid esters as local anesthetics*, 256  
 and *salicylic acid ointment as keratolytic*, 752  
   *tincture of, for fungous infections*, 748
- Benzonate as cough suppressant*, 504
- Benzyl alcohol for topical block*, 259  
   *benzoate chlorophenothane lotion for infestations*, 751
- Bephenium salts for hookworm infection*, 383
- Berberi, thurmine deficiency disease*, 112
- Best drug, how to select*, 36-38
- Betazole, stimulus to gastric secretion of hydrochloric acid*, 802
- Bethanechol as miotic*, 702  
   *for postoperative gastric distention*, 375, 377  
   *in test of pancreatic secretion*, 804
- Bias as problem in drug evaluation*, 32
- Bicarbonate buffer system*, 57, 62
- Bicillin*, 144
- Biguanides for diabetes*, 553, 554
- Biliary tract, effect of morphine on*, 215
- Bilirubin in test of excretory function of liver*, 805
- Biologic compared with absolute potency and dosage*, 30
- Biotin*, 116
- Biphetamine resin for obesity*, 317
- Birth control*, 687-688
- Bisacodyl for constipation in pregnancy*, 666  
   *as laxative agent*, 370
- Bismuth poisoning, treatment (under Heavy metals)*, 786
- Bladder cystography*, 809
- Bleaches*, 731-732
- Bleeding, estrogenic, in menopause*, 685  
   *in pregnancy, and prevention of abortion*, 678  
   *uterine, excessive, hormonal therapy*, 582  
   *interspersed with amenorrhea*, 682
- Blepharitis, marginal, therapy*, 710
- Blocking antibody*, 521
- Blocks nerve, clinical applications*, 252-254
- Blood, alterations in respiratory function of*, 64  
   *cholesterol, agents effective in alteration of*, 549-550  
   *clotting mechanism, effects of heparin on*, 652  
   *coagulation, choice of drugs affecting*, 649-661  
   *counts, white cell, during antithyroid therapy*, 570  
   *disorders, choice of drugs for*, 629-648  
   *loss excessive anemia due to, clinical considerations*, 630  
   *replacement fluids*, 68-71  
   *pH, measurement of, to diagnose acid base imbalance*, 80  
   *and plasma substitutes, rational basis for*, 83  
   *pressure, elevation and reduction, cerebral hemodynamic response to*, 460-463  
   *high (see Hypertension)*  
   *increase of, purpose of vasoconstrictor drugs*, 458  
   *low diastolic, anginal pain due to*, 425
- Blood pressure—Cont'd*  
   *readings, in hypertensive disease*, 445  
   *response to chlorpromazine preoperatively*, 335  
   *to norepinephrine as contrasted to epinephrine*, 459  
   *pressures, procedures for differential diagnosis of pheochromocytoma and hypertension according to*, 799, 800  
   *salicylate in, test in diagnosis of poison ing.*, 777  
   *transfusion, replacement, in treatment of poisoning*, 791-792  
   *transfusions, renal hemodynamic response to*, 465  
   *in treatment of hematologic disorders*, 636  
   *whole, as replacement fluid*, 68
- Body fluids, abnormalities of*, 58-64  
   *compartments and volume of*, 54  
   *composition of*, 55  
   *disturbances in*, 60-64  
   *dynamics of*, 56-58
- Bonadonin for nausea and vomiting of pregnancy*, 336
- Bonain's solution as anesthetic to eardrum*, 722
- to prevent nausea and vomiting with drug administration*, 331
- Bone marrow defects, anemia due to, clinical considerations*, 630  
   *failure, therapy*, 640
- Boot, zinc gelatin, for itching of legs*, 758
- Boric acid in ophthalmology*, 700, 709
- Brain, conduction of pain from periphery to*, 198
- Brand names of drugs, meaning and importance of*, 40
- Breast, carcinoma of, clinical considerations*, 620-622  
   *engorgement, postpartum, hormonal therapy*, 584
- Bretylum tosylate for hypertension*, 452
- Bromide, disadvantages of*, 284  
   *intoxication, diuretics for*, 89  
   *poisoning, treatment*, 786
- Bromsulphalein in test of excretory function of liver*, 805
- Bronchopneumonia for allergic disorders*, 524
- Buerger's disease*, 488
- Buffer systems of body fluids*, 57

Atropine as anticholinergic agent 355  
in cardiac arrhythmias 420  
effect on blood pressure and pulse during intravenous infusion of methoxamine 473  
for motion sickness 316  
as mydriatic 704  
design for use of 705  
for pain relief 241  
in treatment of poisoning by cholinergic compounds 786 787  
for vertigo dosage 370  
Au<sup>198</sup> for pleural effusion and ascites in cancer 626  
Aural vertigo recurrent etiology 319  
Auricular contractions premature clinical considerations 408  
fibrillation clinical considerations 409 410  
digoxin for 417  
heart failure and digitalis for 394  
flutter clinical considerations 409  
ouabain for 417  
tachycardia clinical considerations 409  
digitalis for 394  
Auriculoventricular dissociation clinical considerations 410  
Aurothoglucose n uveitis 709  
Autoimmune hemolytic anemia therapy 640 641  
Autonomic drugs in ophthalmology classification of table 704  
for vertigo 320  
nervous system diagram of 483  
Avenae oatmeal bath for eczema 737  
Average dose definition of 30  
Avertin for amnesia 249  
for analgesia 249  
for secondary anesthesia 250  
for surgical anesthesia 248  
Azacyclonol uses of 270  
Azapetine action of 484  
in occlusive vascular disease 489  
in peripheral vascular disease administration 491  
Azaserine in acute leukemia in children 606  
dosage 611  
toxic effects 611  
Azotemia as side effect of ganglionic blocking agents 451  
Azures in tubeless gastric analysis 803

B

Bacitracin derivation clinical application and toxicity 148 149  
side effects 161  
in urology 696  
Bacteria on skin destruction of 130 131  
of patient preoperative removal of 135-139  
Bacterial infections choice of agents for 141 162  
prophylaxis of 170 171  
Bactericidal drugs new rational basis for 176  
Bacteriostatic effects of sulfonamides 174  
of various antibiotics 174 175  
BAL as antidote in metal poisoning 788 789

Balance of evidence in drug evaluation 35 36 37  
ionic therapy for adjustment of 73 77  
Balanced solutions potassium for replacement therapy 75  
saline for expansion of interstitial fluid volume 71  
Balantidosis treatment 389  
Banthine as anticholinergic agent dosage 355  
for bronchospasm 577  
for hyperhidrosis 756  
as mydriatic 705  
in urology 690 691  
Barbiturate poisoning treatment 781 782  
Barbiturates for insomnia 290  
for relief of pain 239  
as sedatives 270 271 285  
in treatment of insomnia with bronchial asthma 537  
Barium salts poisoning by treatment 786  
Bayer 600 as motile 701 702  
Bedridden patients design for use of cathartics 368 369  
management of constipation in 362 368  
Bedwetting in children stimulants in treatment of 181  
Behavioral problems in children stimulants in treatment of 181  
Belladonna alkaloids for motion sickness 316  
with phenobarbital for morning sickness 664  
tincture as anticholinergic agent 354  
for ptalism in pregnancy 667  
Bell's palsy corticosteroids 721  
Bemegride for barbiturate depression 782  
Benactyzine uses of 270  
Benadryl for allergic symptoms in urography 808  
as antiemetic 376  
in eye infections 714

Benodane in diagnosis of pheochromocytoma 801  
Benzoquin ointment for bleaching skin 73  
Benoxinate as ocular anesthetic 706  
Benzalkonium chloride as hand disinfectant 134  
for eye infections 712  
in ophthalmology 699  
Benzedrex inhaler 725  
Benzedrine as anorectic 346 347  
for barbiturate depression 782  
as mydriatic 705  
poisoning treatment (under Amphetamine) 786  
for relief of pain 240  
Benzocaine as topical anesthetic 256  
Benzodoxane in diagnosis of pheochromocytoma 574  
test in distinction between pheochromocytoma and hypertension, 801



- Castor oil, 366  
as cathartic prior to abdominal x rays, 369
- Castration combined with estrogen therapy in prostate cancer, 622
- Catecholamines, urinary excretion, in diagnosis of pheochromocytoma, 801
- Cathartics, addition to, 361  
relief of, 368  
basis of action of, 364  
choice of, 361-370  
dangers in use of, 365  
design for use of, 368  
increasing bulk of stools, 366  
irritant, 365-367  
mild, use in constipation due to miscellaneous causes, 364
- Caudal block, agents for, relative merits of, 259  
clinical applications, 253
- Causalgia, management of pain of, 203
- phenoxybenzamine for, 489
- Caustic burns of esophagus, corticosteroids for, 721  
soda poisoning, treatment (under Alkali), 786
- Caustics, 735
- Cauterizing agents 735
- Cautery chemical, for nosebleed, 723
- Cavtine in bronchial asthma 525
- CCl<sub>4</sub> for alcoholism 551
- Cedilanid 404
- Cedilanid D, 404
- Central depressants for motion sickness 317  
effects of muscle relaxants, 308  
nervous system, action of morphine on, 213, 214  
depressants in glaucoma, 707  
depression due to poison, treatment 781 782  
effects of anoxiants on, 345, 346  
of Demerol on 220
- stimulation by drugs sensitivity of children to, 48  
reaction to local anesthesia, 255  
sedation for cardiac arrhythmias, 414  
for obesity, 349  
stimulants for motion sickness, 317
- Centrally acting agents in vascular disturbances, 483 490  
antitussive agents 498 505
- Cerebral complications of hypertension, 442  
hemodynamic effects of blood pressure elevation and reduction, 460-463  
oxygen metabolism response to blood pressure elevation with vasopressor agents, 462
- Charcoal, activated, in treatment of thallium poisoning, 791
- Chelating agents for cardiac arrhythmias due to digitalis overdosage, 420  
for digitalis intoxication, 414
- Chemical cautery for nosebleed, 723
- detergents in preoperative preparation of patient's skin, 138  
and physical considerations in choice of drugs, 40 46  
poisoning (see Poisoning)  
relationships of drugs to clinical use, nature of, 25
- Chemosurgery for scarring in acne, 731
- Chemotherapeutic agents in cancer, general considerations 604 605  
new, rational basis for, 698  
in urology, 693-694
- Chemotherapy in cancer, future of, 627  
of eye infections, 714-715  
in lung cancer, indication for, 624  
in otolaryngology, reasons for failure of 716  
regional, in cancer 626  
three phases of, 692  
of urosepsis, design for, 696 697
- Chiari Frommel syndrome, therapy of, 563
- Child spacing, 687
- Children, acute leukemia in, clinical considerations, 605-612  
behavioral problems in, stimulants in treatment of, 181  
choice of drugs for, 47-53  
dosage of drugs, calculation of, 52  
growth, influences of drugs on 49  
response to disease consideration of in selection of drugs, 51  
silicilate poisoning in, 209
- pharmacologic considerations, 175  
in rickettsial infections, 172, 176  
side effects of, 161  
in urology, 696 697
- Chlorate poisoning treatment (under Methemoglobinemic poisoning), 786
- Chloride, extracellular, analysis of, 61  
and sodium excesses, relation to volume changes 63  
therapy for 82
- Chlorisondamine for hypertension 449 452
- Chlormerodrin for mercurial diuresis 95
- Chloroform for analgesia, 248  
for surgical anesthesia 246
- Chloromycetin (see Chloramphenicol)
- Chloroprocaine as local anesthetic, 257  
in nerve blocks, 258, 259
- 6 Chloropurine in acute leukemia in older adults, 612

- Bulk producers for obesity 349  
 Bulbous dermatoses agents used in 732 735  
 Burns caused by esophagus corticosteroids for 791  
 Buro Sol Powder for eczema 737  
 Burows solution for eczema 737  
 for pyoderma 765  
 Busulfan in chronic myelocytic leukemia 614  
 n polycythemia vera 644 615  
 Butabarbital as sedative 271  
 Butacaine (Butyn) as ocular anesthetic 706  
 Butazolidin for arthritis dosage 598  
 in ophthalmology 709  
 for rheumatoid arthritis dosage 598  
 toxic reactions to 210  
 Butethamine as local anesthetic 257  
 for local infiltration on 258  
 for nerve blocks 258 259
- C
- Cadmium poisoning treatment (under Heavy metals) 788  
 Caffeine as central stimulant 188  
 dosage 190  
 for stimulation of respiratory center 194  
 for tension headaches 183  
 Calciferol for hypoparathyroidism 57  
 Calcification mechanism of 190  
 Calcitonin due to hypervitaminosis D 120  
 Calcium carbonate for replacement therapy 76  
 chelators as arterial dilators 433  
 chlorides for replacement therapy 76  
 deficiency therapy for 76  
 sodium arsenate in treatment of lead poisoning 769  
 excretion in urinary sodium acid phosphate reduction of 691  
 gluconate for erythema multiforme bullosum 735  
 for hyperparathyroidism 574  
 for replacement therapy 76  
 lactate for hypoparathyroidism 572  
 for replacement therapy 76  
 phosphate for replacement therapy 76  
 salts for allergic disease 544  
 as gastric antacids 359  
 utilization of dosage in children 52  
 rhenic agents for obesity 348 349  
 r (see also Carcinoma)  
 all endocrine choice of drugs for 604  
 628  
 motherapeutic agents in general considerations 604 605  
 and procedures of recent interest 627  
 estrogens discussed on 685  
 of chemotherapy 697  
 ilaneous forms in clinical considerations 625 676  
 management of 205 206  
 state in clinical considerations 696 697  
 627  
 chemotherapy 696  
 ed forms of treatment warning  
 against 697  
 albicans infections agents used in 747 749 750
- Candace's diagnosis and treatment 685  
 Capomate for asthma 544  
 Capsules and tablets oral absorption of 47  
 Caramphen as antitussive agent 501  
 Carbachol as motor 701 70  
 Carbarone for amebic dysentery 380  
 for balant disease 383  
 for trichomoniasis 387  
 Carbazochrome for hemorrhage 658  
 Carbetapentane as antitussive agent 503  
 Carbomycin bacteriaspectrum 150  
 side reactions 161  
 Carbon dioxide combining power of plasma estimate of 80  
 content of blood rising alkal therapy 784  
 nhalation management of cough 509  
 Carbon anhydrase inhibitors 98 99  
 in glaucoma 707 708  
 to increase salt excretion 73  
 side effects 708  
 Carchol in as motor 707  
 Carcinoma (see also cancer)  
 of breast clinical considerations 690 697  
 of lung clinical considerations 693 694  
 of ovarian clinical considerations 694  
 of thyroid clinical considerations 694 695  
 Cardiac 530  
 Cardiac in glaucoma 707  
 Cardiac (see also Heart)  
 arrhythmias choice of drugs for 406 423  
 in clinical considerations 407 414  
 design for use of drugs in 421  
 details for 394  
 due to digitalis overdosage clinical considerations 413  
 potassium for 420  
 dosage of drugs 42  
 due to elevated blood pressure by vasoconstrictor agents 467 469  
 for treatment 421  
 due to intoxications 417  
 paroxysmal therapy 42  
 pharmacologic basis of therapy 414 417  
 Pronestyl in 419  
 prophylaxis versus treatment 407  
 quindin for 418 419  
 rational basis of new drugs for 429  
 undetermined nature clinical considerations 408  
 arous preparations for 417 421  
 automatic depression and stimulation of 415  
 complications of hypertension 447  
 dpressant quindin as 418  
 effects of isopropyl or agents 467 470  
 of creatinine 450  
 output effect of vasopressor agents on 469  
 Cardiazol as central stimulant dosage 190  
 Carfogen shock vasopressor agents for clinical use 475  
 (rdio) as ulcer effects of an phetamine like drugs 346 347  
 of morphine 315  
 Carisoprodol 269  
 Carotene 119  
 Carotene 119  
 Carotene 119  
 Cascara sagrada 367

- Citrated calcium carbimide for alcoholism, 551
- Citrovorum factor in macrocytic anemia, 639
- Climacteric, female (*see* Menopause) male, 586
- Climatotherapy of allergic disease, 545
- Clinical evaluation of drugs, principles, 31-36  
states commonly associated with ion defects, 62-64  
utility of drugs bearing of experimental data on, 23
- Clot formation, coagulation promoting agents for, 659-660
- Clotting, blood, mechanism of, 650
- Clysmathane for bronchial asthma, 529
- Coagulants definition 649
- Coagulation, blood, agents promoting, 657-659  
choice of drugs affecting, 649-661  
defects, stages of, 632  
therapy, 633  
mechanism of 650
- Coagulation promoting agents which result in clot formation, 659-660
- Coal tar preparations for chronic eczema 738, 739  
combined with hydrocortisone for eczema, 745
- Cobalt in therapy of anemia, 638
- Cobra venom for chronic pain, evaluation of, 242
- Cocaine as local anesthetic, 256  
mud for topical anesthesia of nose, 722  
as mydriatic 705  
as topical anesthetic, 260  
for nose and throat 722  
as vasoconstrictor in otolaryngology, 725
- Codeine addiction, 500  
compared with morphine, 217-218  
as cough suppressant, 500  
dosage, 511  
for diarrhea dosage 374  
in otolaryngology 721  
for pain relief, dosage, 217, 218  
parenteral administration of, 218  
pharmacology of, 217  
poisoning, treatment (*under* Narcotics), 789  
for postpartum patient, 668  
as sedative in bronchial asthma, 537
- Colace enema, 368
- Colchicine analogues in chronic myelocytic leukemia, 615  
in gout and gouty arthritis, dosage, 600  
in gouty arthritis, 590, 593  
historical background, 589
- Colitis, mucous, anticholinergic drugs in therapy of, 353  
therapy, 371  
ulcerative, therapy, 371
- Collagen disorders, ACTH in, 557  
new drugs for, rational basis for, 602  
steroids for, 592  
unusual, steroids for, 599
- Collection of data for clinical evaluation of drug, 34
- Colloid pattern, alterations in, 64  
solutions, nonprotein, 69
- Colloidal fluids for restoration of low blood volume, 68
- Coma, hepatic, purging in, 363
- Compartments, fluid, of body, 54
- Compazine (*see also* Prochlorperazine)  
for manic depressive psychoses, 274  
for nausea and vomiting, dosage of, 327  
of pregnancy, 337
- Composition of body fluids, 55  
disturbances in, 60-61
- Compound E (*see* Cortisone)
- Compound F (*see* Hydrocortisone)
- Compound 1080 (fluoroacetate), poisoning by, treatment, 788
- Conception, prevention of, 687, 688
- Conduction time of heart, effect of digitalis on, 395
- Condylomata acuminata, treatment, 687
- Conjunctiva, instillation of drops, 700
- Conjunctivitis, allergic, summary of therapy, 546  
therapy, 710
- Connective tissue disorders, unusual, adrenal steroids in, 599
- Constipation in bedridden patients, management of, 362, 368  
chronic, due to cathartic addiction, 361  
due to ganglionic blocking agents, 451  
in pregnancy, management, 666
- Contraceptives, 687, 688  
oral, 688
- Contraction of heart, influence of digitalis on, 395
- Contractions, premature auricular, clinical considerations, 408  
ventricular, premature, 411
- Contrast media in cystography, 809  
for excretory pyelography, 808  
in nephrography, 809  
in renal arteriography or aortography, 809  
in retrograde urography, 809
- Controls, appropriate, in clinical evaluation of drugs, 33
- Convallaria, 405
- Convulsions due to poisoning, treatment, 782
- Corneal baths for administration of drugs 700  
diseases of unknown etiology, trial therapy, 708  
infections, therapy, 710
- Cornstarch baths for eczema, 737
- Coronary artery dilators, basis of therapy with, 426-427  
choice of, 423-435  
clinical applications, 424-426  
dangers inherent in, 427  
design for use of, 434  
pharmacodynamic actions, 426-427  
various drugs, 427-434  
disease as complication of hypertension, 442  
spasm, nitrites in relief of pain of 424  
insufficiency, relief of pain of, 425  
occlusion, use of coronary dilators in, 424
- Cortical hormones, 575
- Corticoids, ACTH combined with, therapeutic use, 557

- Chloroquine for amebic abscess of liver, 381  
 dysentery 381  
 for giardiasis, 382  
 phosphate tablets for chronic discoid lupus erythematosus, 753  
 as sun screen, 771
- Chlorothiazide as diuretic, discussion of 100 101  
 for hypertension, 447 453 455  
 drug of choice 455  
 in toxemias of pregnancy, 675
- Chlorotrianisene for ovarian failure 581
- Chlorpromazine as antidote in amphetamine poisoning 786  
 as antiemetic, 327  
 with Devedrine for hang-over 182  
 for pharmacologic depression, 183  
 dosage, 283 284  
 effects of, 266 267  
 in glaucoma, 707  
 for involuntary psychoses, 275  
 for nausea and vomiting in alcoholic patients, 331  
 due to drugs 330, 331  
 due to infections and toxicoses 332 333  
 of pregnancy, 336, 337  
 for pain, indications and contraindications 240  
 preoperative use, blood pressure response to 335  
 in prevention of postoperative vomiting 334 335  
 for psychosomatic conditions, 279  
 for radiation sickness 333  
 and secobarbital antiemetic effect compared 332  
 side effects, 280 282, 329, 330  
 for toxic states, 280  
 as tranquilizer, discussion of 273
- Chlorpromide for diabetes 553 554
- Chlortetracycline, administration and clinical uses 146 147
- Choice of anesthetics, 244 260  
 of anorexants 341 350  
 of antacids, 357 361  
 of antiallergic agents 516 547  
 of antiarthritic agents, 589 603  
 of antibacterial agents 141 162  
 of anticonvulsants, 293 304  
 of antidiarrheal agents 370 375  
 of antiemetic agents 324 339  
 of antitussive agents, 493 514  
 between forms of same drug, 44 46  
 of cathartics, 361 370  
 of coronary artery dilators 423 435  
 of dermatologic drugs 726-773  
 of diagnostic agents 795 811  
 of digitalis materials 392 406  
 of diuretics 85 104  
 of drugs affecting blood coagulation, 649 661  
 for cancer and allied diseases 604 628  
 for cardiac arrhythmias 406 423  
 for children 47 53  
 for disturbances in equilibrium 311 322  
 in endocrine dysfunction, 555 588  
 for gastrointestinal disturbances 352 378  
 for heart diseases, 392 435

- Choice of drugs—Cont'd  
 for hematologic disorders, 629 648  
 for hypertension, 437-457  
 for infectious diseases 270 290  
 for local anesthetic agents 23 39  
 for treatment of poisoning 774 794  
 for tuberculosis 157  
 for viral spirochetal and rickettsial infections 164 177  
 of gastrointestinal stimulants and digestants 375 378  
 of hypnotics 287 292  
 of local antiseptics, 129 140  
 of ophthalmic drugs 699 715  
 of otolaryngologic drugs 716 725  
 of pain relieving drugs, 196 247  
 of placebos 38 39  
 of sedatives and tranquilizers in general medical practice 262 272  
 for psychiatric disorders 273 286  
 of skeletal muscle relaxants 306 310  
 of stimulants of mental and physical activity 178 190  
 to vital medullary centers 192 195  
 of urologic drugs 689 698  
 of vasoconstrictor drugs for hypotension and shock 458 479  
 of vasodilator drugs for treatment of peripheral vascular disturbances 481-492
- Cholangiography intravenous 806  
 oral 805 806
- Choleleryl, 530
- Cholesterol blood agents effective in alteration of 549 550  
 conversion to hydrocortisone 575
- Choline ineffective in atherosclerosis 551  
 theophyllinate as diuretic 93
- Cholinergic drugs dosages of 376 377  
 mode of action 689  
 in nonobstructive urinary retention 690  
 pharmacologic considerations 376 689  
 poisoning by treatment 786  
 for supraventricular tachycardias 415  
 toxicity and contraindications 690  
 untoward effects 377
- Cholografin in intravenous cholangiography 806
- Choriocarcinoma clinical considerations 673
- Chorionic gonadotropin, therapeutic and diagnostic uses 559 560
- Chromophobic tumor therapy 562
- Chronic pain treatment 236 238
- Chrysarobin for psoriasis 762
- Ciguolin paste for psoriasis 763
- Circulation, support of in treatment of narcotic poisoning, 229  
 time, tests for, 799
- Circulatory collapse following local anesthesia 255  
 insufficiency, peripheral, pain due to management of 204
- Cirrhotic edema diuresis of 88

- Delayed absorption dosage forms 47  
 drug actions intermediary processes 78  
 Delestrogen for ovarian failure 581  
 Delta steroids in treatment of pemphigus 733  
 Delix as antihelminthic 385  
 for trichuriasis 386  
 Demecoln in chronic myelocytic leukemia 615  
 Demerol (*see also* Meperidine)  
 as antitussive agent 501  
 for bronchial relaxation 537  
 compared with morphine and codeine 770  
 dosage 771  
 effects on central nervous system 770  
 gastrointestinal effects of 771  
 for genitourinary pain 697  
 in otolaryngology 771  
 pharmacology of 770 771  
 side effects 771 538  
 Demeton poisoning treatment (*under* Cholinergic compounds) 786  
 Demulcents and emollients in dermatology 746 747  
 management of cough 505  
 Depo-Estradol for ovarian failure 581  
 Depressants central for motion sickness 317  
 poisoning by treatment of 781  
 Depression of cardiac automaticity 415  
 central nervous system due to poisoning treatment 781 782  
 of conduct on details in 417  
 of medullary function rational basis for new drugs to counteract 194  
 mental due to reserpine 782  
 pharmacologic stimulants in treatment of 18  
 Dermabrasion of face for acne scars 731  
 Dermatoceneatous agents for 736 745  
 herpiform treatment 734  
 seborrheic agents for 766 769  
 Dermatologic disorders, incidence of 778  
 drugs choice of 776 773  
 radiation for eczema 736  
 reactions to Thorazine 281  
 Dermatophytes infections of glabrous skin by agents for 747 749  
 Dermatoses bullosa agents used in 732 735  
 Deronil (*see* Dexamethasone)  
 Desenex for dermatophytosis of feet 748  
 Deserpine 763  
 Deslanoside 404  
 Deoxycorticosterone acetate (DCA) 576  
 triphenylacetate (DCTPA) for Addison's disease 577  
 Desquamating agents 751 752  
 Detergent aerosols for removal of bronchial secretions 533  
 Detergents chemical in preoperative preparation of patients skin 138  
 as ophthalmic chemicals 699  
 Dexamethasone in allergic disease 547  
 for eye infections 712 713  
 in nephritis 733  
 for rheumatoid arthritis 591  
 Dexedrine for barbiturate depression 782  
 for behavioral problems in children 181  
 188  
 Dexedrine—Continued  
 and chlorpromazine combination in treatment of pharmacologic depression 183  
 for geriatric problems 187  
 for hangover 187  
 for neurologic disorders 187  
 for neurotic symptoms 180  
 for obesity 347  
 drug of choice 349  
 as stimulant 181  
 poisoning treatment (*under* Amphetamines) 786  
 for premenstrual tension 185  
 Dextran as plasma substitute 69  
 sulfate as anticoagulant 653  
 Dextroamphetamine (*see* Dexedrine)  
 propoxyphene pharmacologic contraindications 211  
 Dextromethorphan as antitussive agent  
 Dextrose solutions as replacement fluids  
 DFP (diisopropyl fluorophosphate) for coma 03  
 as motor 707  
 poisoning treatment (*under* Cholinergic compounds) 786  
 Diabetes and epilepsy incidence and treatment compared 793  
 insulin plus 565 566  
 mellitus varieties of insulin for 55  
 Diabetes for diabetes 553 554  
 Dacrylon ointment as keratolytic 757  
 Dacrylon tubeless gastric analysis 80  
 Diagnostic agents choice of 795 811  
 to distinguish between pheochromocytoma and hypertension 799  
 in gastrointestinal disease 807 806  
 in gynecology 807  
 in ophthalmology 810 811  
 for urologic disorders 807 810  
 tests dangers 795 796  
 in heart disease 796 799  
 Dialysis peritoneal for refractory edema heart disease 88  
 Diamox (*see* Acetazolamide)  
 Diarrhea anticholinergic drugs in therapy 353  
 as cause of ondefects 67  
 choice of agents for 370 375  
 chronic need for drugs for 370  
 functional therapy of 371  
 infectious operations in therapy of 377  
 postantibiotic therapy 377  
 postgastrectomy and postgastroenterostomy therapy 377  
 as side effect of tetracyclines 160  
 therapy 374  
 Diatrizoate in angiocardiology 797  
 Diabenamine as motor 70  
 Dibenzyl action of 484  
 for delayed wound healing 490  
 in occlusal vascular disease 489  
 in peripheral vascular disease administration 491  
 Dibucaine as local anesthetic 757  
 as ocular anesthetic 706  
 Diodol as cough suppressant 500

# INDEX

## Cort coids—Cont d

for adrenogenital syndrome in newborn infant 579

for diabetes insipidus 566

for hyperadrenocorticism with adrenogenitalism 579

in rheumatic disorders untoward effects, 595 596

for thyroiditis 572

Corticosteroids for acute disseminated lupus erythematosus 574

for adrenal insufficiency 576 577

in allergic disease 538 539, 540

in angioneurotic edema 721

in autoimmune hemolytic anemia 640 641

in Bell's palsy 721

for caustic burns of esophagus 721

contraindications to 598

effects on blood, 636

for erythema multiforme 721

in hematologic disorders 631 636

for hemolytic anemia 630

in hypoplastic anemia or bone marrow failure, 640

for idiopathic thrombocytopenic purpura 631 642 643

for microbial infections 168 169

for midline lethal granuloma 721

in otolaryngology 720

for pemphigus 732 733

for sarcoidosis 766

side effects 636

for status asthmaticus 721

topical proprietary table 740 744

for urticaria 772

in vascular purpuras 643

Corticotropin (see ACTH)

Cortisone and ACTH for nephrotic syndrome 88

for refractory edema of heart disease 87

in acute leukemia in children 607

after adrenalectomy or hypophysectomy in breast cancer 622

in arthritis clinical application 591

pharmacologic features 595

in Cushing's syndrome 578

for eye infections 712

in idiopathic thrombocytopenic purpura 642

in lung cancer 624

untoward effects 595 596

Coughers as antitussive agent 505

Cotton packs in eyes placing of 700

Cottonseed oil enema 368

Cough choice of drugs for 493 514

etiology factors of 494

harmful aspects of 495

impulses causing 496

incidence of 494

mechanism 495 496

paroxysmal 496

pharmacologic agents in management of 498 510 (see also Antitussives)

phases of 495

protective nature of 493

reflex afferent neurogenic arcs mediating 496 497

regulation of 496

remedy definition 498

Coumarin drugs as anticoagulants 656

and heparin therapy combined, 656

Cramps, night relief of 308

Cranioopharyngeoma therapy of 567

Cresatin as fungicide in ear 720

Cretinism congenital thyroid therapy 569

Crotamiton cream for infestations 751

Cryptorchidism therapy 559 560

Crystalloids solutions of in blood replacement therapy 70

Cumetol n for mercurial diuresis, 96

Curare for dysmenorrhea 309

as muscle relaxant 308

route of administration 309

Curariform agents in glaucoma 707

Curve of action of drug explanation of, 27

Cushing's syndrome ACTH in diagnosis of, 558

diagnosis and treatment 578

Cyanide poisoning treatment 787

Cyanocobalamin in hematologic disorders 631

Cyclazine (see also Marezine)

is antiemetic 376

for motion sickness 318

dosage 370

Cyclopentolate (Cyclospil) as miotic 705

Cycloplegics 704

with sympathomimetic agents in glaucoma 705

Cyclopropane for analgesia 218

for surgical anesthesia 247

Cycloserine side effects 162

in tuberculosis 150

in urology 694 695

Cystitis in puerperium management of 664

Cystography 809

Cytomel 568

for obesity 348

Cytopenic disorders clinical considerations 629 631

## D

Dainite 530

Darane in glaucoma 707

Daraprim in diagnosis of ureitis 811

in treatment of ureitis 715

Darenth n for hypertension 459

Darrow's solution for potassium deficiency 75

Darvon pharmacologic considerations 211

DBI for diabetes 553 554

Deafness drugs for 723

Deanol as central stimulant 187 190

Death due to local anesthesia 255

Decadron (see Dexamethasone)

Decholin 377

to determine circulation time 799

Decongestants in otolaryngology 724

Deficiency anemias clinical considerations 670

Dehydrating agents in therapy of vertigo 319 321

Dehydration dynamics of 59

estimate of degree of 79

Dehydrochloric acid 377

Delalutin for amenorrhea 581

Diuresis—Cont'd  
   chlorothiazide for, 100 101  
   design for, 102-104  
   diuretic action of digitalis, 396  
   agents, 73  
   therapy, dangers of, 90  
   edema reduction by, 66  
   pharmacologic basis of, 90  
   Diuretics, choice of, 85-104  
   combinations of, use of, 102  
   discussion of, 90-102  
   dosage, 104  
   under investigation, 102  
   in glaucoma, 707  
   mercurial, discussion of, 93 96  
   new, rational basis for, 101  
   sensitivity to, 798  
   Diuretic as diuretic, discussion of, 100-101  
   for hypertension, 453-455  
   Dizziness, causes of, 311  
   as side effect of ganglionic blocking agents, 452  
   Dolophine as antitussive agent, 501  
   pharmacology of, 223-224  
   Domeboro Powder or Tabs for eczema, 737  
   DOV for pyoderma, 765  
   in acute leukemia in children, 611  
   in carcinoma of breast, 622  
   Doriden for insomnia, 291  
   Dormison for insomnia, 291  
   Dorsacaine as ocular anesthetic, 706  
   Doryl as miotic, 701, 702  
   Dosage of analgesics, factors influencing, 233  
   appropriate in clinical evaluation of drug, 33  
   considerations in children, 52  
   of digitalis, 399 402  
   forms of drugs for oral absorption, 42  
   improper, as reason for therapeutic failure, 29  
   schedule, success of drug due to, 30  
   Dose, average, definition of, 30  
   Double blind technique in drug evaluation, 32  
   Drimamine as antiemetic, 326  
   for nausea and vomiting of pregnancy, 336, 337  
   for prevention of nausea and vomiting with drug administration, 331  
   of postoperative vomiting, 334, 335  
   for radiation sickness, 333  
   for vertigo, 318, 320  
   Dromoran poisoning, treatment (under Narcotics), 789  
   ops for conjunctiva, instillation, 700  
   Drug administration, hypotension associated with, vasopressor agents in therapy of, 476  
   abstention, 231  
   sensitivity tests in heart disease, 798-799  
   tolerance, 230  
   s, absorption of, 27-28  
   osol mists as method of administration of, 45  
   gic reactions, 159  
   explanation of, 27  
   resic (see Analgesics)  
   exigent, 341-350

Drugs—Cont'd  
   brand names, meaning and importance of, 40  
   for cardiac arrhythmias, choice of, 4  
   for children, administration of, 50  
   choice of, 47 53  
   curve of action of, 27-28  
   delayed action, intermediary processes of, 29-31  
   dosage, 29-31  
   forms of, 42  
   effects in children, difficulty of evaluation of, 49  
   elimination of, 28  
   enteric coated and other delayed absorption dosage forms, 42  
   epilepsy treated with, 293 297  
   evaluation of, bias as problem in, 32  
   collection of data, 34  
   interpretation of data, 35 36, 37  
   placebo in, 38  
   principles, 31-36  
   statistics, 35  
   forms of same, choice between, 44-46  
   for fluid balance control, investigations of, 83  
   for gastrointestinal disturbances, choice of, 352-378  
   for heart diseases, choice of, 392-435  
   for hypertension, choice of, 437-457  
   immaturity and response to, 47-49  
   for intestinal parasitism, choice of, 379 390  
   nonaddictive, for pain relief, 207-211  
   nonanalgesic, for relief of pain, 238 241  
   for nutritional disorders, choice of, 106 128  
   oral absorption of, factors influencing 41-44  
   for pain relief, choice of, 196 242  
   patterns of action, 25 29  
   physical and chemical considerations in choice of, 40-46  
   potency of, meaning of, 26  
   principles of choice of, 23-39  
   salts, choice of, 44  
   sedative and hypnotic, depression caused by overdosage of, treatment, 182-183  
   selection of best for purpose, 36-38  
   solubility of, importance of, 45  
   stimulant of mental and physical activity, 178 190  
   to vital medullary centers, choice of, 192-195  
   structure activity relationships, 25  
   therapeutic ratio of, 29  
   toxic reactions, explanations of, 26  
   tuberculostatic, discussion and dosage, 155-157  
   vasoconstrictor, choice of, 458 479  
   for viral infections, new, rational basis for, 176  
   spirochetal, and rickettsial infections, choice of, 164-177  
   vitamins as, 121, 125-126  
   Dulcolax as laxative agent 370  
   Duodenal ulcer, therapy of, 352  
   Durabolin, 587  
   Dwarfism, pituitary, therapy of, 563  
   Dyclonine (Dyclone) for analgesia of throat and oral cavity, 721  
   as topical anesthetic for oral lesions 722





- Epinephrine—Cont'd  
 for stimulation of cardiac automaticity, 416  
 for urticaria, 772, 773  
 as vasoconstrictor in otolaryngology, 721  
 for vertigo, dosage, 320  
 Equanil for neurotic patients, 282  
 Equilibrium, disturbances in, choice of agents  
   for, 311-322  
   design for use of agents for, 319-321  
   rational basis for new drugs for, 321-322  
 Equinex, 561  
 Ergonovine maleate in labor, 671-672  
   stress test in heart disease, 797-798  
 Ergot alkaloids in obstetrics, 671-672  
 Ergotamine for migraine headache, 242  
 Error, narrow margin for, in drug selection  
   in children, 51  
 Eruptions, eczematous acute, treatment, 736-738  
 Erythema multiforme bullosum, treatment, 735  
   corticosteroids for, 721  
 Erythromycin, administration and clinical  
   use, 150  
   with Gantrisin for intraocular infections,  
     side reactions, 161  
     in urology, 695, 697  
 Escherichia coli, urologic infection by, treat-  
   ment, 696  
 Eserine as miotic, 702  
 Esophagitis, peptic, antacids for, 357  
 Esophagus, caustic burns of, corticosteroids  
   for, 721  
 Esters as local anesthetics, 256  
 Estradiol for breast cancer, 621  
   engorgement post partum, 584  
   for dysmenorrhea, 583  
   for gigantism in female, 564  
   for ovarian failure, 581  
 Estrogens for acne, 730  
   and cancer, discussion, 685  
   in carcinoma of breast, 621  
   and castration in prostate cancer, 622  
   for dysmenorrhea, 583, 680  
   effect on blood cholesterol, 549  
   for gigantism, 564-565  
   for menopause, 581  
   for ovarian failure, 581  
   for postmenopausal or senile vaginitis, 687  
   for primary amenorrhea, 681  
   production of, 575  
   for secondary amenorrhea, 682  
   in therapy of menopause, 684, 685  
   for uterine bleeding, 659  
 Estimation in diagnosis of pheochromocytoma,  
   800  
 Ethchlorvynol, 271  
 Ethinyl estradiol in breast cancer  
   for gigantism in female, 564  
   in prostate cancer, 623  
 Ethisterone for amenorrhea, 581  
 Ethioheptazine, 211  
 Ethyl alcohol as hand disinfectant,  
   for pain relief, 239  
   in preoperative preparation of  
     skin, 136  
   aminobenzoate for topical block, 26  
   chloride for analgesia, 248  
   for secondary anesthesia, 250  
   for surgical anesthesia, 247  
 Ethylene for surgical anesthesia, 247  
 Eurax for infestations, 751  
 Evaluation of drug effects in children,  
   difficulty of, 49  
   of drugs (see Drugs, evaluation)  
 Exchange resins, discussion of, 96-98  
 transfusion in treatment of poisoning,  
 Excretory function of liver, tests, 804-805  
 Exophthalmos, therapy, 569, 570  
 Expansion of interstitial (extracellular) fluid  
   volume, 71  
   of vascular fluid volume, agents for, 68-71  
 Expectorants (see also Antitussive agents)  
   definition and use of term, 498, 506  
   for elimination of bronchial secretions, 531  
   in management of cough, 506  
   physiologic effect, 511  
   "stimulant," in management of cough, 508  
 Experimental data, bearing on clinical utility  
   of drugs, 23  
 Extent of absorption of drug, 28  
 External forces, resolution of, in clinical eval-  
   uation of drugs, 31  
 Extracardiac diseases, anginal pain in, 426  
 Extracellular fluid volume, agents for ex-  
   pansion of, 71  
   decrease in, 58-59  
   increase in, 60  
 Eyelid, inflammations, therapy, 710  
 Eyes application of drugs, 700  
   choice of drugs for, 699-715  
   diseases of, vitamin A in treatment, 110  
   effects of ganglionic blocking agents on,  
     451, 452
- F
- Face and trunk, seborrhea of, mercury con-  
   taining regimen for, 768  
   sulfur-containing regimen for, 767  
 Failure, heart, diuretics for, 86  
   left- and right heart, digitalis for, 393  
 Fat soluble vitamins, 110-112  
 Feet, hyperhidrosis of, medicated foot pow-  
   der for, 755  
 Ferrous gluconate in iron deficiency anemia,  
   637  
   sulfate in iron deficiency anemia, 637  
   with molybdenum oxide for anemia of  
     pregnancy, 665  
   poisoning, treatment, 788  
 Fever, action of salicylates in, 592  
   antipyretic agents and, 551  
   in micro-

# INDEX

- Dylephr n in allerg c d sease 524 527  
 Dynamics of body fluids 56 58  
 Dysentery ameb c acute treatment of 380  
 Dysmenorrhea curare for 309  
 primary therapy 679 680  
 secondary cause 679  
 therapy 680  
 treatment 583  
 Dyspepsia functional therapy 375  
 Dyspnea obstructive emphysema for 528  
 Eltophyllin for 530  
 Dysthythmia of testes anticholinergic  
 drugs and 354  
 Dystonia treatment 308
- ## E
- Ear diseases of antibiotic therapy 716 718  
 fungal drugs n 719 720  
 ring n therapy 724  
 Eardrum topical anesthesia of 720  
 Echothiophate for glaucoma 703  
 as m o t e 702  
 Eclampsia a management of 676  
 pre eclampsia and 674  
 prevention of 675  
 signs and symptoms 676  
 Ecold for hypertens on 457  
 Etilurea as tranquilizer 271  
 Eczema baths for 737  
 chronic treatment 738 739  
 shake lotions for 737 738  
 Eczematous conditions agents for 736-745  
 Edatham calcium disodium (EDTA) n  
 treatment of lead poisoning 789  
 Edema, angioneurotic corticosteroids for 721  
 causes and reduction of 65 66  
 c rhote d ures s of 88  
 of heart disease d ures s for 85 87  
 mucosal n allergic disorders relief of 527  
 526 528  
 of pregnancy d ures s of 89  
 Electrocardiograph c changes during intra  
 venous infusion of methoxamine  
 474  
 Electrolyte balance effect of acetazolamide  
 on 98  
 of exchange resins on 97  
 derangements exchange resins for 89  
 disturbances d ures s reactions 94  
 excess therapy for control of 87  
 and fluid loss due to catharsis 365  
 replacement therapy design for 78 83  
 p ttern alteration n 61  
 of plasma normal 79  
 patients of body fluids normal 55  
 Electrolyte plasma gravimetric concentra  
 tions of converted to combining  
 equivalents 80  
 Electroshock therapy Thorazine with n  
 manic states 275  
 Elimination of drugs eliminated by immaturity  
 48  
 p ocesses of 28  
 Eltophyllin for bronchospasm 330  
 Elixations solution for potassium depletion  
 75  
 Filonin in urology 693
- Embolism etiology and treatment  
 Emergency kit for treatment of  
 797  
 Emesis drug induced 330 337  
 effect of morphine on 214  
 in poisoning 780  
 in treatment of supraventricular  
 arrhythmias 415  
 Emetic agents mode of action of  
 325  
 Emetine for amebic abscess of liver 380  
 dysentery 380  
 bismuth oxide 381  
 Emollients and demulcents in derma  
 746 747  
 Emotionally stimulating for 184 18  
 support of patient in prevention of abo  
 679  
 Encephalopathy hypertensive 442  
 Endocrine dysfunction choice of drugs  
 555 588  
 Endolymphatic hydrops etiology 312  
 Eneina action of 364  
 Adrenastron of 365  
 kinds of 367 368  
 Endo d for gigantism in female 564  
 oral progesterone for amenorrhea 581  
 ENP (ethyl p n trophenyl thionobenzene pho  
 phonate) poisoning treatment  
 (under Cholinergic compounds)  
 786  
 Enteric-coated and other delayed absorption  
 dosage forms 42  
 Enteric regulation therapy 371  
 Enterobiasis treatment, 384  
 Enterocolitis pseudomembranous therapy  
 372  
 Enuresis, in children stimulants n treatment  
 of 181  
 Environmental control of allergy 520  
 Enzyme therapy for bronchial drainage 533  
 Enzymes n glaucoma 707  
 Ephedrine n allergy disease 525 526  
 replaced by Isuprel n heart disease 420  
 as vasoconstrictor n otolaryngology 724  
 Epidural block agents for relative merits  
 559  
 clinical applications 253  
 Epilepsy acetazolamide for 90  
 comparison of methods of treatment 294  
 design for use of drugs in control of 299  
 304  
 Dexedrine for 187  
 and diabetes incidence and treatment com  
 pared 293  
 nitrous oxide or narcosis treatment 307  
 new drugs for rational basis for 301  
 optimum medication for rapid determina  
 tion of 307 303  
 treatment with drugs 293 297  
 types of attacks effect of various medica  
 tions on 296  
 Epinephrine for allergic disorders 522 524  
 for heart block 419  
 and norepinephrine contrast n blood  
 pressure response to  
 for nosebleed 722  
 in ph

Gentian violet n fungous growths of oral cavity 770  
 for non lase 686 750  
 Cervical problems st mulants n manage ment of 181  
 Germ plas defect e al ort ons due to 677  
 Girdass treatment 38  
 Gtant sm stero d therapy of 561 565  
 Girl n 403  
 Cland(s) adrenal 574 580  
 parathyro d 572 574  
 p tu tary 556 566  
 thyro d 566 572  
 Claucoma acetazolam de for 89  
 acute and chro n c therapy 707  
 hypotens e ocul r drugs n 707 708  
 pro ocat e tests for 811  
 secondary mot es n 703  
 Glob n no l f e d human as pl sma s bst tute 69  
 z n nsul n 557  
 Clo rular fltration rate ner ase due to asoconstr ctor lugs 467 470  
 471  
 Glu oco r co ds for Addison s d sease 577  
 Glucose blood nsul ns effect e n regulat on of 55 553  
 Glucuron de conjugat on 49  
 Glutame antagon sts n acute leukem a n ch ldren 611  
 Cluteth m de 271  
 for nsom a 291  
 Glyceryl gua acolate as ant tuss e agent 508  
 tr n trate 429  
 po son ng treatment (unde Methemo glob nem c po on ng) 789  
 Cold po son ng treatment (under Heavy metals) 788  
 rad oact ve for pleural effus on and asc tes n cancer, 626  
 sal s n rheumato d arthr ts 597 596  
 dangers of 596  
 des gn for use of 598  
 sod um th osulfate n ophthalmology 709  
 Conadyl dysfunct on n female 580 584  
 fa lure n female and n male 561  
 Gonadotrop c hormone 559 561  
 for sexual precoc ty 580  
 Gonads fe male 580 584  
 male 585 587  
 Gonorrheal vag n ts ant bot c therapy 686  
 Cout (see also Arthr ts) and gouty arthr ts drugs of cho ce n 600  
 601 602  
 new drugs for rat onal bas s for 602  
 therapy 607 603  
 604  
 605  
 606  
 607  
 608  
 609  
 610  
 611  
 612  
 613  
 614  
 615  
 616  
 617  
 618  
 619  
 620  
 621  
 622  
 623  
 624  
 625  
 626  
 627  
 628  
 629  
 630  
 631  
 632  
 633  
 634  
 635  
 636  
 637  
 638  
 639  
 640  
 641  
 642  
 643  
 644  
 645  
 646  
 647  
 648  
 649  
 650  
 651  
 652  
 653  
 654  
 655  
 656  
 657  
 658  
 659  
 660  
 661  
 662  
 663  
 664  
 665  
 666  
 667  
 668  
 669  
 670  
 671  
 672  
 673  
 674  
 675  
 676  
 677  
 678  
 679  
 680  
 681  
 682  
 683  
 684  
 685  
 686  
 687  
 688  
 689  
 690  
 691  
 692  
 693  
 694  
 695  
 696  
 697  
 698  
 699  
 700  
 701  
 702  
 703  
 704  
 705  
 706  
 707  
 708  
 709  
 710  
 711  
 712  
 713  
 714  
 715  
 716  
 717  
 718  
 719  
 720  
 721  
 722  
 723  
 724  
 725  
 726  
 727  
 728  
 729  
 730  
 731  
 732  
 733  
 734  
 735  
 736  
 737  
 738  
 739  
 740  
 741  
 742  
 743  
 744  
 745  
 746  
 747  
 748  
 749  
 750  
 751  
 752  
 753  
 754  
 755  
 756  
 757  
 758  
 759  
 760  
 761  
 762  
 763  
 764  
 765  
 766  
 767  
 768  
 769  
 770  
 771  
 772  
 773  
 774  
 775  
 776  
 777  
 778  
 779  
 780  
 781  
 782  
 783  
 784  
 785  
 786  
 787  
 788  
 789  
 790  
 791  
 792  
 793  
 794  
 795  
 796  
 797  
 798  
 799  
 800  
 801  
 802  
 803  
 804  
 805  
 806  
 807  
 808  
 809  
 810  
 811  
 812  
 813  
 814  
 815  
 816  
 817  
 818  
 819  
 820  
 821  
 822  
 823  
 824  
 825  
 826  
 827  
 828  
 829  
 830  
 831  
 832  
 833  
 834  
 835  
 836  
 837  
 838  
 839  
 840  
 841  
 842  
 843  
 844  
 845  
 846  
 847  
 848  
 849  
 850  
 851  
 852  
 853  
 854  
 855  
 856  
 857  
 858  
 859  
 860  
 861  
 862  
 863  
 864  
 865  
 866  
 867  
 868  
 869  
 870  
 871  
 872  
 873  
 874  
 875  
 876  
 877  
 878  
 879  
 880  
 881  
 882  
 883  
 884  
 885  
 886  
 887  
 888  
 889  
 890  
 891  
 892  
 893  
 894  
 895  
 896  
 897  
 898  
 899  
 900  
 901  
 902  
 903  
 904  
 905  
 906  
 907  
 908  
 909  
 910  
 911  
 912  
 913  
 914  
 915  
 916  
 917  
 918  
 919  
 920  
 921  
 922  
 923  
 924  
 925  
 926  
 927  
 928  
 929  
 930  
 931  
 932  
 933  
 934  
 935  
 936  
 937  
 938  
 939  
 940  
 941  
 942  
 943  
 944  
 945  
 946  
 947  
 948  
 949  
 950  
 951  
 952  
 953  
 954  
 955  
 956  
 957  
 958  
 959  
 960  
 961  
 962  
 963  
 964  
 965  
 966  
 967  
 968  
 969  
 970  
 971  
 972  
 973  
 974  
 975  
 976  
 977  
 978  
 979  
 980  
 981  
 982  
 983  
 984  
 985  
 986  
 987  
 988  
 989  
 990  
 991  
 992  
 993  
 994  
 995  
 996  
 997  
 998  
 999  
 1000



- Hypaque in angiocardiology, 797  
 Hyperadrenocorticism with adrenogenitalism, 578 579  
   etiology, 577  
 Hypercholesterolemia, treatment with estrogen, 550  
 Hyperfunction of intestines, anticholinergic drugs for, 354  
 Hyperhidrosis agents used for, 731-736  
 Hyperlipemia agents effective in therapy of, 550  
   familial, 550  
 Hyperparathyroidism, diagnosis, 573  
   therapy, 574  
 Hyperpigmentation of skin, bleaching of, 731  
 Hyperpotassemia, exchange resins for, 89  
 Hypersensitivity, use of term, 516 (see also Allergy)  
 Hypertension, arteriosclerotic, 437, 439  
   choice of drugs in treatment, 437-437  
   classification of primary forms, 440-441  
   secondary forms, 439  
   complications, 442 443  
   control of symptoms, 443  
   curable forms, 437 439  
   drugs in treatment, design for use of, 455  
   new rational basis for, 456  
   pharmacologic considerations, 444  
   essential, 440, 441  
   established with complications in target organs, 442  
   established, without complications, 438  
   malignant, 443  
   mild and extremely labile, 438  
   nephritic, acute, as form of, 439  
   objective of treatment, 444  
   in obstetrics, evaluation of patient, 676  
   management, 677  
   and pheochromocytoma, procedures for differential diagnosis, 799 801  
   prognosis factors in, 438  
   renal, 443  
   suppressive treatment justification for, 444  
   sympathetic blockade, 450-453  
   toxaemia of pregnancy as form of, 439  
   treatment regimens, heroic, 450 453  
   mild, 445 447  
   potent, 447, 450  
   various drugs, 445 453  
 Hypertensive vascular and renal diseases in pregnancy, 675  
   medical management, 569 570  
   radioactive iodine therapy, 569  
   surgical treatment preparation for, 571  
 Hypertonic enema, 367  
   saline solutions for sodium depletion, 74  
   sodium bicarbonate and lactate solutions for acidosis, 77  
   solutions for replacement of electrolytes, 72  
 Hypertrochosis, agents used for, 771  
 Hypervitaminosis A, 119  
 Hypnotics, addiction to, 290  
   agents used as, 290 291  
   choice of, 287 292  
   depression due to overdosage of, treatment, 182 183  
   Hypnotics--Cont d  
   mechanism of action, 288  
   method of inducing sleep with, 291  
   pharmacologic considerations, 288-290  
   and sedatives for relief of pain, 238 241  
   Hypnotic upper gastrointestinal segment therapy, 375  
 Hypoadrenocorticism, diagnosis and therapy, 576 577  
   primary and secondary, ACTH in differentiation of, 558, 576  
   Hypofibrinogenemia, fibrinogen in, 617  
   Hypogonadism, chorionic gonadotropin for, 559 560  
   with testicular failure, androgen therapy, 585  
 Hypoparathyroidism, diagnosis and therapy, 572  
   Hypophysectomy for breast cancer, maintenance therapy following, 622  
   Hypoplastic anemia, therapy, 610  
   Hypopotassemia, exchange resins for, 89  
   Hypoprothrombinemia, acquired, vitamin K in, 646  
   drugs producing contraindications to, 655  
   Hypoprothrombin inducing drug, 654, 655, 656  
   Hyposensitization therapy of allergy, 521  
   Hypotension associated with drug administration treatment, 476  
   due to cardiac disease, therapy with vasopressor agents, 475  
   postural caused by Thorazine, 281  
   and shock, choice of vasoconstrictor drugs for, 458 479  
   due to severe infectious, vasopressor agents in, 476  
   surgical, treatment of, 476  
   Hypotensive ocular drugs, 706 708  
   Hypothrombin induction and heparin therapy combined, 655  
   Hypothyroidism, 566-569  
   etiology, 566  
   laboratory evaluation and diagnosis, 567  
   primary and secondary, differentiation, 567  
   therapeutic agents, 567 568  
   Hypotonic saline solution with dextrose for sodium depletion, 74  
   Hysterosalpingography, agents used for, 807  
   Hytakerol for hypoparathyroidism, 572  
  
 I  
   I in carcinoma of thyroid, 625  
   in hyperthyroidism, 569, 571  
   Idiopathic thrombocytopenic purpura, clinical considerations, 631  
   therapy, 642 643  
   Idioventricular rhythms, clinical considerations, 410 412  
   Ileus obstruction with, as side effect of ganglionic blocking agents, 451  
   Ilidar, action of, 484  
   in peripheral vascular disease, administration, 491  
   Ilosone in urology, 693, 697  
   Imbalance, fluid, estimate of, 78 80  
   plan of therapy, 81

morrhoids, catharsis in presence of, 362

553

PTP (hexaethyl tetraphosphate) poison-

exadimethrine bromide, heparin antagonist  
of choice, 653

examethonium in glaucoma 707

for hypertension, 448 452

in peripheral vascular disease, administra-

tion 490

for necrosis 384

of

574,

in management of pain, 242

in peripheral vascular disease 492

as stimulus to gastric secretion of hydro-

chloric acid 802

as vasodilator, 484

odgkin's disease clinical considerations, 617

619

olocaine as ocular anesthetic, 706

574

of frigidity in female, 584

pituitary conditions requiring, 562 565

of uterine bleeding, 582

hormone(s) adrenal steroid (see Adrenal

steroids)

adrenocorticotrophic, 557 559

androgenic in carcinoma of breast, 620

choice of, 555 588

estrogenic in carcinoma of breast 211

in fluid balance control 83

in glaucoma 707

gonadotropic, 559 561

Hormone(s)—Cont'd

growth, 556

pituitary (see also ACTH)

ancillary aids to effectiveness of 566

anterior, 556 561

posterior, 556, 565

administration, 565

defects of 565 566

purposes of, 555

steroid (see also Adrenal steroids)

in allergic disease, 538 543

untoward effects, 542 543

in therapy of dysmenorrhea, 680

of menopause, 684 685

of primary amenorrhea 681

of secondary amenorrhea 682

thyroid, 566, 567

thyrotropic 557

Humidification in facilitation of bronchial

drainage 531, 532

in management of cough 508

Hyaluronidase in glaucoma, 707

Hycodan as cough suppressant 500

Hydantoin for epilepsy, 300, 301

Hydeltrasol in bronchial asthma 541

Hydergine for vertigo, dosage 320

Hydralazine for hypertension 447

Hydrochloric acid, significance in gastric

analysis 802

574

for Addison's disease 577

in allergic disease 541

with antibiotics for seborrhea, 768

in arthritis 591

for cardiovascular shock due to poisoning,

784

in Cushing's syndrome 578

in eczema preparations 739 740 745

effect upon fever in mumps orchitis with

relief of pain, 170

in external otitis, 720

for eye infections 712

formation of 575

for itching 758

tablets in dermatitis herpetiformis, 733

for pemphigus 733

topical with coal tar for eczema, 745

untoward effects 595, 596

Hydrocyanic acid poisoning, treatment (under

Cyanide), 787

574

574

574

574

574

574

574

574

574

574

574

574

574

574

574

574

574

rop-

- Isocarboxazid for anginal pain, 431  
 dosage, 188  
 Isoflurophate as miotic, 701, 702  
 Isolation perfusion technique in cancer, 627  
 Isoniazid (isonicotinic acid hydrazide), side effects, 162  
 in treatment of tuberculosis, 156  
 for tuberculous eye infection, 712  
 Isophane insulin 552, 553  
 Isopropyl alcohol as hand disinfectant, 134  
 in preoperative preparation of patient's skin, 136  
 isonicotinic acid hydrazide (see Isoniazid)  
 Isoproterenol in allergic disease, 524-525  
 in heart block 419  
 Isotonic dextrose solution as replacement fluid 72  
 saline solution for sodium depletion, 74  
 sodium bicarbonate and sodium lactate solutions for acidosis, 77  
 solutions as replacement fluid, 71  
 Isuprel in Adams Stokes syndrome, 416  
 in heart block 412, 419  
 for stimulation of cardiac automaticity, 416  
 of conduction, 416  
 for ventricular asystole, 412  
 Itching (see also Pruritus)  
 agents against, 757-760  
 of ear canal ointment for, prescription, 717
- ## J
- Jaundice as side effect of chlorpromazine (Thorazine), 280, 330
- ## K
- Kanamycin 151  
 sulfate in urology, 695  
 Kantrex, 151  
 in urology 695  
 kaon in adrenal disease, 577, 578  
 arell diet 91  
 Kempner diet, 91  
 rice diet for hypertension, 445  
 analog for dermatologic therapy, 739  
 keratolytics, 751-752  
 in pityriasis rosea, 757  
 Kellin as coronary artery dilator, 432  
 Kellin "artificial," in removal of dialyzable toxins from body, 791  
 in treatment of poisoning, 785  
 function as cause of ion defects 63  
 Kobergrade urography 809  
 typhoid vaccine in intractable broncho-spasm, 544  
 for eczema 739  
 clinical use, 155  
 ology 693
- ## L
- analgesia during, 667-669  
 ne in, 671, 672  
 sedation in, 673  
 relaxants in, 673-674  
 data, bearing on clinical utility of drugs 23  
 function of 311  
 edema, cause, 312  
 relation to motion sickness, 314
- Lachesine as mydriatic, 704  
 Lacrimal infections, therapy, 711-712  
 Lactated Ringer's solution for expansion of interstitial fluid volume, 72  
 Lanatoside C, 404  
 Linoxin, 404  
 Laryngitis, inflammatory, 719  
 Larynx, topical anesthesia of, 722-723  
 and trachea diseases of, therapy, 719  
 Iassar's paste in vaginal trichomoniasis, 686  
 Lavage, gastric, in poisoning, 780-781  
 Laxatives (see also Cathartics)  
 to prevent ileus with use of ganglionic blocking agents, 451  
 Lead oleate plaster as keratolytic, 752  
 poisoning, EDTA in treatment of, 789  
 Left sided heart failure, diuretics for, 86  
 Leg cramps in pregnancy, management 666  
 Lente insulins, 552, 553  
 Lertine, dosage, 223  
 pharmacology and side effects 222  
 Leucovorin as preventive of toxic effects of amethopterin, 609  
 Leukemia, acute, in children, clinical considerations, 605 612  
 drugs of choice, 606 611  
 in older adults, treatment, 612  
 in young adults, treatment, 611  
 chronic lymphocytic, clinical considerations, 615 617  
 myelocytic, clinical considerations, 612-615  
 monocytic, clinical considerations 617  
 Leukeran in carcinoma of ovary, 624  
 in chronic lymphocytic leukemia, 616  
 Leukopenia as side effect of Thorazine, 281  
 Leukopenias, clinical considerations, 631  
 Levallorphan, comparison with nalorphine, 226  
 for narcotic depression, 782, 789, 790  
 pharmacologic effects and clinical uses and dosage, 227  
 in treatment of acute narcotic poisoning, 229  
 Levarterenol as short acting vasoconstrictor, intravenous infusion of, 471  
 Levo Dromoran pharmacology, 224 225  
 Levo-iso-methadone as analgesic, 224  
 Levonor for obesity, 347  
 Levophed (see Norepinephrine)  
 Levo-propoxyphene as antitussive agent, 504  
 Levorphan as antitussive agent, 499  
 pharmacology, 224-225  
 Libido, loss of, in female, hormonal therapy, 584  
 in male, 585  
 Lichen planus, agents used in, 753  
 Lichenified eczemas, treatment, 738 739  
 Lidocaine for analgesia of throat and oral cavity, 721  
 in glaucoma, 707  
 as local anesthetic, 257  
 for local infiltration, 258  
 for nerve blocks, 258, 259, 260  
 as retrobulbar, anesthetic, 706  
 as topical anesthetic in otolaryngology, 722  
 Liothyronine with antithyroid therapy for thyroid enlargement, 570  
 in hypothyroidism, 568  
 for obesity, 348

iron n iron deficiency anemia dosage 637  
ramne hydrochloride as central stimulant 187 190  
atunty effect on response to drugs 47-49  
nt nence overflow with urinary retention therapy 690

arterial n children narrow margin for error n treatment of 51  
ho ce of agents for 141 162  
neous n dermatology agents for 747 750  
f lids conjunct a cornea and lacrimal apparatus 710 715  
rophylaxis by antibiotics 170 171  
yogen c of sk n agents for 764 766  
vere hypotension and shock due to treatment of 476  
ral sp rochetal and r cketts al cho ce of drugs for 164 177  
ert lly male therapy 587  
estat ons agents used n 751  
litrat on local agents for relat e merits 257  
cl n cal appl cat on 257  
lammat on of eyel d therapy 710  
animat ons of lacr mal gland therapy 711 712  
cular agents for 708 710  
ammatory d sease of n est ne danger of cathart cs n 365  
us ons ntra enous precautions 81  
II (see Ison az d)

med cat on for nfluence of pat ents act ty and att tude on 288  
nature of 287  
rat onal bas s for new drugs for 29  
ul n cho ce of for d abet c pat ent 553  
effect on hyperl pem a, 550  
regular effects of 552 553  
ar etes of for d abet es 552 553  
ens e or narcos s treatment of ep lepsy 302  
ternal homeo tas s cho ce of agents to ad just and ma nta n 54 84  
d sturbances 58 64  
n ch ldren drug select on and 51  
ters tal flu d volume agents for expan sion of 71  
for reduct on of 72 73  
tertr g nous areas pre ent on of sk n nfect ons n 748  
test nal d sorders cho ce of drugs for 357 378  
flukes nfect on by treatment 390  
nflammat on and obstruct on danger of ca hart cs n 365  
paras tsm cho ce of drugs for 379 390  
rat onal bas s for drug therapy of 390

Intestines chron c nflammatory d seases of therapy 371  
d sturbed funct on of two types ant

Intramuscular adm n strat on of d gital s 398  
of muscle relaxants 309  
of narcot cs ad antages of 234  
Intraocular nfect ons ant b ot cs n 714 715  
prophylax s of table 710  
therapy table 711  
penetrat on of drugs methods to enhance 700  
pressure (see Glaucoma)  
Intra enous adm n strat on of d gital s 398  
of mephenes n as muscle relaxant 309  
of narcot cs nd cat ons for 234

rad opaque n ang ocard ography 797  
Iod ne for cauterizat on of corneal ulcers 709  
as d nfectant n preoperat e preparat on of pat ents sk n 137 138  
for fungous nfect ons of sk n 747  
po son ng an dotes 789  
rad oact e n carc noma of thyro d 625  
n hyperth ro d sm 569 571  
Iod pam de n ntra enous cholang ography 806  
Iodoalpn on c ac d n oral cholecys ography 806  
Iodomethamate n ang ocard ography 797  
Iodopyracet n ang ocard ography 797  
Ionam n for obes ty 348  
Ionephr n n allerg d sease 576  
Ion c balance therapy for adjustment of 73 77  
Ions defects of cl n cal states assoc ated w th 67 64  
spec fic abnormal tes of es mate of 79  
important 61

dosage 188  
tox ty of 156  
Iron for anemia, 636 637  
of pregnancy 665  
metabol sm 634  
po son ng treatment (under Ferrous sul fate) 788  
s de effects of 634  
Iron dex ran for anemia of pregnancy 665  
n iron deficiency anemia dosage 637  
Irrad at on for mens rual d sturbances 683  
Irritab lly of nt est nes crease by cathart cs, 364  
Ir table colon therapy of 371  
Ischem a during vascular surgery hypotens on due to vasopressor agents for 477



- phenitrimine for cardiac arrhythmias, 407
- Mephobarbital as sedative, 271
- Meprobamate in allergic disease, 538
- for insomnia, 291
- as muscle relaxant, oral use of, 309
- for neurotic patients, 282
- side effects of, 283
- as tranquilizer, 268 269
- Meratran as central stimulant, 187, 189
- Merbromin in ophthalmology, 709
- Mercaptopurin for mercurial diuresis, 96
- Mercaptopurine in acute leukemia in chil-  
dren 606
- dosage, 610
- in older adults, 612
- in young adults 612
- in chronic myelocytic leukemia, 614
- in monocytic leukemia, 617
- Mercurial diuretics, administration, 95
- discussion, 93 96
- effectiveness of, 103
- to increase salt excretion, 73
- in left-sided heart failure, 86
- reactions to, 93 94
- oils for psoriasis, 763
- Mercurial as oral diuretic, 95
- Mercurochrome in ophthalmology, 709
- Mercury compounds organic, in ophthalmol-  
ogy, 709
- poisoning treatment, 789
- preparations as bleaches, 731
- resistance factor in mercurial diuresis, 95
- Mercury-containing regimens for scalp and  
dermatitis, 768
- for face and trunk in seborrheic  
dermatitis, 95
- Mertiolate as oral diuretic, 709
- Mesantoin in ophthalmology, 709
- Mesantoin for epilepsy, 300, 301
- toxic reactions, 27
- ketabolic acidosis, 63
- in poisoning treatment, 784
- therapy 67
- alkalosis, 63
- therapy, 67
- abolism disorders of, choice of drugs in,  
519 554
- is, heavy poisoning with, treatment, 788
- 789
- mucil, dosage, 366
- then in ophthalmology, 709
- aminol, administration of, 478, 479
- radiogenic shock 475
- ypotension due to drug administration,  
476
- ager-acting vasoconstrictor, 471
- iacodynamics of, 473
- ynamic effect of, 464, 465, 466, 467
- line for abdominal distention, 375,  
377
- osis of pheochromocytoma, 574
- c, 702
- s, treatment (under Cholinergic  
compounds), 786
- pancreatic secretion, 804
- administration and dosage, 224
- ive agent, 501
- with morphine, 223
- s, 668
- Methadone—Cont'd
- poisoning, treatment (under Narcotic  
789
- Methallenestrol for ovarian failure, 581
- Methamocet in heart disease, 405
- Methamphetamine as adjunct in psychiatry  
interview, 184
- as central stimulant, 186
- dosage, 188
- for obesity, 347
- poisoning, treatment (under Ampheta-  
mine), 786
- Methandrol for dysmenorrhea, 583
- for endocrine problems in male, 587
- Methantheline in allergic disease, 527
- as anticholinergic agent, dosage, 355
- as mydriatic, 705
- for urinary frequency in elderly women,  
691
- for vesical spasm, 690
- Methazolamide as diuretic, 99
- Methemoglobinemia in diagnosis of poisoning,  
777
- Methemoglobinemic poisoning, treatment, 789
- Methenamine mandelate as anti infective  
agent in urology, 694
- in urinary infections, acidity of urine and,  
691
- Methimazole in carcinoma of thyroid, 625
- for hyperthyroidism, 570
- Methionine ineffective in atherosclerosis 551
- Methotrexate in acute leukemia in children,  
608 609
- in chonocarcinoma, 623
- intravenous infusion of, cardiac effects of,  
473, 474
- Methoxamine as longer-acting vasoconstrictor,  
471
- renal vasoconstrictive effect of, 463
- as vasoconstrictor, evaluation of, 473
- Methoxsalen for repigmentation, 756, 757
- as sun screen, 771
- Methylcellulose for obesity, 349
- Methylene blue in treatment of methemo-  
globinemic poisoning, 789
- Methylergonovine tartrate, action and uses of,  
673
- Methylparafynol for insomnia, 291
- Methylphenidate in alcoholism, 162
- as central stimulant, dosage, 189
- Methylprednisolone in allergic disease, 542
- for eye infections, 712, 713
- in pemphigus, 733
- Methyltestosterone in carcinoma of breast,  
621
- for dysmenorrhea, 583
- for hypogonadism with testicular failure,  
585
- for infertility in male, 587
- Methylpyrrol for insomnia, 291
- as sedative-type tranquilizer, 271
- Metopon, pharmacology of, 219
- Metrazol for barbiturate depression, 782
- as central stimulant, dosage, 190
- in management of genatric problems, 182
- Metycaine as local anesthetic, 256
- for local infiltration, 257
- as ocular anesthetic, 706

Lipotropic agents and atherosclerosis 549  
551  
Liquid and solid dosage forms pharmacology  
availability of 42  
Liver amebic abscess of treatment 381  
excretory function tests 804 805  
extracts in pernicious anemia 638  
Loading tests of liver function 804

to raise blood pressure in patients  
pharmacology 776  
Lubrication of anal canal by cathartics 364  
Lucanthone hydrochloride for schistosomiasis  
389  
Lugol's solution for exophthalmos 570  
for surgical preparation of thyrotoxic patient 571  
Luminal (see Phenobarbital)  
Lung carcinoma clinical considerations 623  
624  
Lungs function of 493  
Lupus erythematosus agents used in 753 754  
Lye poisoning treatment (under Alkalies) 786  
Lymphocytic leukemia chronic clinical considerations 615 617  
Lymphoma 372  
Lymphopathic venereum sulfonamides and  
nitrofurantoin for 171  
Lymphostasis clinical considerations 619

## M

Macrocytic anemia folic acid in 639

Mandelic acid in urinary infections acidity  
of urine and 691  
Mandelic depressive psychoses chlorpromazine  
for 274  
stimulants in treatment of 179  
Marengon as antiemetic 36  
for control of vomiting in pediatric infections  
and toxemia 33

Marrow defects anemia due to clinical considerations 630

Marsalid for anal pain 431  
as central stimulant 187  
dosage 188  
Mastitis resulting from otitis media therapy 718  
7  
Mecholyl for abdominal distention 375 377  
as motile 707  
poisoning treatment (under Cholinergic  
compounds) 789  
in test of pancreatic secretion 804  
Meclizine as antiemetic 776  
for motion sickness 318  
dosage 370  
Medications for insomnia patients attitudes  
toward 288  
Medrol in allergic disease 542  
for eye infections 717 713  
in pemphigus 733  
Medroxyprogesterone for gynecological female  
564  
Medullary centers vital choice of stimulants  
to 19 195  
function abnormality of 574  
depression of rational basis for new  
drugs to counteract 194  
stimulants design for use of 194  
pharmacologic considerations 191  
Megrimide for barbiturate depression 78  
Melanosis col 367  
Menadione sodium diphosphate for hemorrhage  
dosage 658  
Menadione sodium bisulfite for hemorrhage  
dosage 658  
Menarche age of 580  
Menstrual disease treatment of pharmacologic  
considerations 315  
syndrome etiology 312  
Menopause duration of treatment 684 685  
general considerations 683  
hormone therapy 684  
preparation for 684  
surgical treatment of 684  
symptoms 683  
syndrome stimulants in management of  
185  
treatment 583 584 683 685  
variants after symptoms and treatment  
687  
Menstrual disturbances 680 683  
Menstruation delayed amenorrhea and therapy  
580 587  
establishment of 680  
painful therapy 679 680  
physiology of 681  
Mental and physical activity stimulation of  
choice of drugs for 178 190  
Meperidine as anesthetic agent 501  
in obstetrics 669  
poisoning treatment (under Narcotics) 789  
Mephentermine as forerunner of tranquilizers  
267  
intravenous and oral as muscle relaxant  
309



- M crobal d seases cho ce of drugs for 164  
 177  
 M croorgan sms effects of ant b o t c s on 169  
 on sk n removal of 130 131  
 M crosporium fung nfect ons of scalp caused  
 by agents for 749  
 M ct ne as oral d uret c 99  
 M d cel cl n cal use 155  
 in urology 693  
 M dl ne lethal granuloma cort costero ds for  
 721  
 M gra ne headache  
 apy 90  
 ant retent onal ther  
 ergotam ne for 24  
 st mulants for 184  
 M ked m de for barb turate depre s on 787  
 M lk of magnes a as laxat c 366  
 M lont n for ep lepsy 301 302  
 M ltown for neuro c pat en s 28  
 relat on to muscle relaxants 306  
 M neral ol as cathart c n presence of anal  
 les ons 369  
 as lavat e agent 366  
 M ntacol as mot c 701 70  
 M ot c s 701 704  
 cl n cal appl cat ons 701 703  
 d sad antages 701  
 n glaucoma 703  
 mode of act on 701  
 se eral drugs 702  
 n strab smus 704  
 M rac l D for sch stosom as s 389  
 M olmen premens rual therapy 583  
 Monam ne ox dase nh b ors for ang nal pr n  
 431  
 Mon l al nfect ons of sk n and na ls agents  
 for 750  
 Mon l as s d agnos s and treatment 685  
 Monoca ne as local anes het c 257  
 for lo al nfiltrat on 258  
 for nerve blocks 258 259  
 Monochloracet c ac d solu on as cauter z ng  
 agent 735  
 Monoeyt c le kem a cl n cal cons derat ons  
 617  
 Mood effect of op a es on 213  
 Morn ng s ckness management of 664  
 Morph ne absorpt on late and xcret on  
 216  
 analges c act on of 213  
 as ant tuss c agent 499  
 ard u ascular effects of 215  
 compared w h code ne 217 218  
 w th le orphan 225  
 w h meper d ne 220  
 w th nethadone 3  
 ontr nd cat ed n bronch al asthma 537  
 dosage of 216 217  
 effect on b lary tract 215  
 on cen ral nervous sys em 213 214  
 on gastro ntest nal tract 215  
 on gen tounary tract 215  
 for gen tour nary pa n 697  
 in labor 668  
 optimal dose 233  
 overdosage 228  
 parameters of analges c act on 214  
 pharmacolog c act on of 213 217
- Morph ne—Cont d  
 po son ng treatment (under Narc  
 789  
 for se ere nosebleed 723  
 sulfate for acu e d arrhea dosage 374  
 Morphol nylethylmorph ne as cough sup  
 sant 501  
 Morphologic arterial occlu e d sease  
 489  
 Mot on s ckness 313 314  
 ant h stam nes for 318 320  
 treatment of pharmacolog c cons de  
 t ons 315  
 Mouth les ons of agents used for 769 770  
 Mouthwash ant sept c solu on for stom  
 t t s 770  
 Mucoly c agents n bronch al dra nge 53  
 Mucosal astringents as ant d arrheal agents  
 373  
 for rr table colon 371  
 edema n allerg c d sorders rel ef of 572  
 576 578  
 Mucous col t s therapy of 371  
 Multiple myeloma cl n cal cons derat ons  
 619 620  
 Mumps orch t s rel ef by h drocort sone 170  
 Muscle relaxants cl ncal areas of usefulness  
 308  
 routes of adm n strat on 309  
 skeletal 241  
 cho ce of 306 310  
 smoo h 241  
 spasm or spl nt ng rel ef of 307  
 use of relaxants for 308  
 Musculoskeletal pa n managen ent of O t  
 Mu hrooms tox c po son ng by treatme t  
 786  
 Mustard as emet c n po so ng 780  
 Mustargen ( ee N rogen mustard)  
 Mycostat n ( ee Nystat n)  
 Mydr as s purpose of 704  
 Mydriat cs 704 705  
 des gn for use of 705  
 n d agnos s of glaucoma 810  
 untoward effects 705  
 Myelocyt c leukem a chron c cl n cal con  
 s derat ons 612 615  
 Myelo d metaplas a cl n cal cons derat ons  
 637  
 Myeloprolifera e d sorders cl n cal con  
 s derat ons 631 632  
 M leran n chron c myelocyt c leukem a 614  
 n polycythem a vera 614 615  
 M ocard al automat c ty effect of d g tal s on  
 396  
 hypox a therapy 426  
 nfaret on hypotens on due to therapy w th  
 vasopressor agen s 475  
 use of coronary d lators n 424  
 M ochrys ne for rheumat d arthrit s 597  
 Myofasc al pa n syndromes w th trigger  
 mechan sms management 204  
 Myoneural junct on effect of curare on 308
- N  
 Nails fungous infect ons of griseofulvin for  
 747 748 749  
 therapy 749

- Ointments for ocular infections, 713  
and solutions in ophthalmology, methods of application, 700  
Oleandomycin, clinical use, 152  
lack of side effects, 161  
Oleoresin of aspidium for tapeworm infection, 388  
Omeprazole, 785  
omission, treatment (under Cholinergic compounds), 786  
Operation, disinfection of hands for, 131-135  
field of antiseptics for disinfection of, 135-139  
Ophthalmic drugs, choice of, 699-715  
preparations, local, 699-700  
Ophthalmology, autonomic drugs used in table, 704  
diagnostic agents of choice, 810-811  
Opiates, absorption, fate, and excretion, 216  
analgesic effects, 213-214  
as antidiarrheal agents, 373, 374  
as cause of vomiting, mechanism of, 330  
central nervous system effects, 213, 214  
clinical applications, 238  
for diarrhea of chronic inflammatory diseases of intestines, 372  
of irritable colon, 371  
pharmacologic aspects, 213-220  
Opioids, pharmacology of, 220-225  
Opium alkaloids as cough suppressants, 498-500  
derivatives and substitutes in labor, 667-669  
history, 212  
tincture, camphorated (paregoric), for diarrhea, 374  
deodorized, for diarrhea, dosage, 374  
Optimal dose of narcotic in pain management, 233  
mode of administration of narcotics, 234  
Opium medication, rapid determination of, in epilepsy, 302, 303  
Oral absorption of drugs, factors influencing, 41-44  
administration of drugs to children, 50  
ammonium chloride for alkalosis, 78  
cavity, diseases of, throat lozenge contraindicated, 719  
fungus growths, drugs for, 720  
contraceptives, 688  
diuretics, 100-101, 103  
effectiveness of, 95  
penicillin, 144  
progesterone in amenorrhea, 581  
route of administration of analgesics, advantages of, 234  
sodium bicarbonate for acidosis, 77  
use of muscle relaxants, 309  
Organic gold and mercury compounds in ophthalmology, 709  
nitrate, 430  
Orinase for diabetes, 553  
Osmosis of body fluids, 56  
Osmotic abnormalities, estimate of, 79  
diuretics, 92  
Otolaryngologic disorders, antibiotics in, 716-719  
choice of drugs for, 716-725  
Otolaryngology, postoperative medication, 724  
vasoconstrictors in, 724  
Ouabain, 402-403  
for auricular flutter, 409  
dosage, 400  
for heart disease, action of, 405  
to increase vagal tone, 417  
Ovarian failure, estrogens for, 581  
Ovary, carcinoma of, clinical considerations, 624  
Overdigitalization, arrhythmias due to, 413  
Overdosage of sedative and hypnotic drugs, treatment of depression due to, 182-183  
Ovulation, inhibition by oral progestin, 688  
Ovulatory failure, therapy, 582  
Oxalate poisoning, treatment, 790  
Oxanamide as tranquilizer, 271  
Oxoralen for repigmentation, 756, 757  
as sun screen, 771  
Oxycel for clot formation, 659  
Oxygen in combination with carbon dioxide in cough management, 509  
in poisoning, use of, 783  
Oxyphenonium for bronchospasm, 527  
Oxyphenyl isopropylmethylamine as mydriatic, 705  
Oxypolygelatin as plasma substitute, 69  
Oxytetracycline, administration and clinical uses, 146-147  
for urinary tract infections in pregnancy, 665  
Oxytocic drugs in obstetrics, 670-673  
synthetic, 673  
Oxytocin isolation and synthesis of, 673  
P  
P<sup>12</sup> in chronic myelocytic leukemia, 615  
in differential diagnosis of intraocular malignancy, 811  
in hematologic disorders, 635  
in polycythemia vera, 644, 645  
in thrombocythemia, 631  
Para, acute, treatment of, 235-236  
analgesic mechanism of, 423  
in miscellaneous disturbances, 425  
prevention and relief of, design for use of dilators for, 434  
caused by peripheral vascular insufficiency, management of, 204  
characteristics of, 199

## Nitrites—Cont d

- for pain relief 242
  - in coronary artery spasm, 424
  - in peripheral vascular disease 485
- poisoning with treatment (under Methemoglobinemic poisoning) 789
- rapid acting 429
- for relief of acute anginal pain summary 431
- in treatment of cyanide poisoning 787
- Nitrobenzene poisoning treatment (under Methemoglobinemic poisoning) 789
- Nitrofurantoin in urology, 693
- Nitrofurazone for eye infections 712
- Nitroscin mustard in carcinoma of breast 622
  - of lung 624
  - of ovary 624
  - in choriocarcinoma 673
  - in Hodgkin's disease 617 618
  - in intractable bronchospasm 544
  - in miscellaneous forms of cancer 625
  - in regional chemotherapy of cancer 626
- Nitroglycerin action of as coronary artery dilator 427
  - in peripheral vascular disease 485
  - pharmacologic use 429 430
- Nitromersol in ophthalmology 709
- Nitrous oxide for analgesia 249
  - for surgical anesthesia 247
- Nocardia brasiliensis infections griseofulvin in 747
- Nodal tachycardia clinical considerations 409
- Noludar for insomnia, 291
  - as sedative type tranquilizer 271
- Nonaddictive analgesics 207 211
  - drugs new rational basis for 210
- Nonnarcotic antitussives 502 505
- Norpinephrine administration of 478
  - in cardiogenic shock, 475
  - combined with phenylephrine use of 479
  - and epinephrine contrast in blood pressure response to, 459
  - for hypotension and shock due to severe infections 476
  - in obstetrics 674
  - renal dynamic effect of 464 465 467 468 469
    - response to 472
    - for severe reaction in urography 808
    - for shock due to poisoning 784
  - as short acting vasoconstrictor intravenous infusion of 471
  - for vascular collapse with infection 168
- Norethandrolone for endocrine problems in male 587
  - for gynecomastia in male 586
- Norethindrone for amenorrhea 581
  - for gigantism in female 564
- Norethynodrel for amenorrhea 581
  - for gigantism in female 564
- Norlutin for amenorrhea 581
  - for gigantism in female 564
- 19 Norsteroids for dysmenorrhea 583
  - for galactorrhea 563
  - for gigantism 564
  - as oral contraceptives 688
- Nocapone as antitussive agent 503

- Nose application of topical anesthetic, 722
  - and paranasal sinuses, diseases of therapy 718
  - topical anesthesia of, 722
- in intraocular infections 715
- side reactions 161
- in urology, 696 697
- Novocain (*see* Procaine)
- Noxious stimulation pain reactions to 199
- NPH insulin 552 553
- Nupercaine as local anesthetic 257
  - in obstetrics 670
  - as ocular anesthetic 706
- Nuporal for stomatitis 770
- Nutrients essential factors influencing requirements of 107
- Nutrition correction of faults of, in treatment of secondary amenorrhea, 682
  - factors influencing 106 109
  - in pregnancy importance of 663 664
- Nutritional disorders choice of drugs for 106 128
  - therapy rational basis for new drugs for 126
- Nylidrin in occlusive vascular disease 489
  - in peripheral vascular disease administration 491
  - as vasodilator, 485
- Nystatin in ear drops and ointments 720
  - in fungous growths in oral cavity 720
  - for moniliasis 686 750
  - side reactions 161
  - in urology 696

## O

- Obesity psychologic factors in 342
  - relief of drugs for 341 350
  - stimulants in treatment of 180
  - therapy for factors involved 343
- Obstetrics anesthesia in 669 670
  - and gynecology choice of drugs in 669 688
    - hypertension in evaluation and management of patient 676
    - oxytocic drugs in 670-673
    - special considerations of drug effects in 662
- Obstruction with ileus as side effect of ganglionic blocking agents 451
- Occlusion arterial treatment 486
  - coronary dilators for relief of pain 424
- Occlusive arterial disease, morphologic 487 489
- contaminated antibiotic therapy 715
- Ointment, antipruritic for external otitis, prescription 717

- Pentobarbital—Cont'd**  
 for pain relief, 239  
 sodium for insomnia, 290, 291
- Pentolinium** for hypertension, 448, 452  
 in peripheral vascular disease, administration, 491
- Pentothal** (*see* Thiopental)
- Pentylenetetrazol** for barbiturate depression, 782  
 as central stimulant, 188  
*dosage*, 190  
 as medullary stimulant, 193, 194
- Peptic esophagitis**, antacids for, 357  
 ulcer, antacids for, 357, 359-360  
 therapy of, 352, 353
- Pernarteritis nodosa**, summary of therapy, 516
- Peripheral nerve block**, agents for, relative merits, 258  
 clinical applications, 253  
 origin of pain, 198  
 resistance, effects of vasopressor agents on, 470  
 vascular disease, administration of drugs in, 490-492  
 choice of vasodilator drugs for, 481-492  
 diagnosis of, 485  
 insufficiency pain due to, management of, 204
- Peripherally acting antitussive agents**, 505-510
- Peritoneal dialysis** for refractory edema of heart disease, 88
- Pernicious anemia**, oral therapy of, 638  
 summary of therapy, 639  
 vitamin B<sub>12</sub> in, 638-639
- Perphenazine** as antiemetic, 328  
 effects of, 267
- Pharmaceutical manufacturer**, importance to physician in choice of drugs, 40, 44
- Pharmacologic actions of drugs**, analysis in animals, 24  
 addiction, 231  
 depression, stimulants in treatment of, 182  
 information essential to choice of drugs, 23-31
- Pharynx**, diseases of, therapy, 718  
 infections of, treated by sprays and 'paints', 720
- Phemerol** in ophthalmology, 699
- Phenacaine** as ocular anesthetic, 706
- Phenacetin** poisoning, treatment (*under* Methemoglobinemic poisoning), 789
- Phenaglycodol** as tranquilizer, 268-269
- Phenazone**, design for use of, 210
- Phenelzine dihydrogen sulfate** for anginal pain, 431  
*dosage*, 189
- Phenergan** (*see* Promethazine)
- Phenformin** for diabetes, 553, 554
- Phenmetrazine** for obesity, 347
- Phenobarbital** as anticonvulsive in poisoning, 782  
 with belladonna for morning sickness, 664  
 for epilepsy, 300, 301  
 for insomnia, 290  
 as sedative, 270, 271
- Phenol**, liquefied, as cauterizing agent, 735  
 poisoning, treatment, 790
- Phenolsulfonphthalein (P S P)** test, 810
- Phenothiazines**, action and effects, 266  
 as antiemetics, 267, 326-328  
 newer, general comments, 328-329  
 for relief of pain, 240  
 as tranquilizers, 262  
 uses of, 267
- Phenoxybenzamine**, action of, 484  
 for causalgia, 489  
 for delayed wound healing, 490  
 in occlusive vascular disease, 489  
 in peripheral vascular disease, administration, 491
- Phentolamine**, actions of, 484  
 in diagnosis of pheochromocytoma, 574, 799, 800, 801  
 in peripheral vascular disease, administration, 491
- Phenylbutazone** for arthritis, clinical application, 590  
 pharmacologic considerations, 593  
 in gouty arthritis, dosage, 600  
 in ophthalmology, 709  
 for rheumatoid arthritis, dosage, 598  
 toxic reactions, 210
- Phenylbutylamine resin** for obesity, 348
- Phenylephrine**, administration of, 478, 479  
 in allergic disease, 524, 526  
 in cardiogenic shock, 475  
 hydrochloride for shock due to poisoning, 784  
 for hypotension associated with drug administration, 476  
 as longer acting vasoconstrictor, 471  
 as nosedrop, 724  
 pharmacodynamics of, 473
- β-Phenylisopropyl hydrazine** for anginal pain, 431  
 . . . . . 526
- Phenytol** in narcosis treatment of epilepsy, 303
- Pheochromocytoma**, diagnosis of, 574  
 and hypertension procedures for differential diagnosis, 799-801
- pHisoHex** as hand disinfectant, 133  
 in preoperative preparation of patient's skin, 136
- Pholcodine** as antitussive agent, 500, 501
- Phosphate**, organic poisoning by, treatment (*under* Cholinergic compounds), 786
- Phosphates**, polymeric, poisoning by, treatment, 790
- Phospholine iodide** for glaucoma, 703  
 as miotic, 702
- Phosphorus** poisoning, treatment, 790
- Physical and chemical considerations in choice of drugs**, 40-46  
 and mental activity, stimulation of, choice of drugs for, 178-190
- Physician and anticoagulant drugs**, 649, 650, 651  
*attitude of, in clinical evaluation of drugs*, 32

## Paras—Cont'd

- chronic intractable determining best drug for 237
- optimal dosage of drug for 237
- treatment of 236 238
- control methods of 200 209
- nonaddictive analgesics for 207 211
- coronary action of nitrates relief of 477
- diagnosis of cause by history and physical examination 201
- differentiation of types of 200
- drugs for relief during labor dangers of 667
- genourinary analgesics for 697
- head management of 204
- intensity factors influencing 199 200
- influence of on optimal dose of narcotic 233
- intractable of cancer management of 206
- of malignancy management of 205 206
- management procedures of 201 209
- mechanism analgesia by reversal of 241 242
- of musculoskeletal origin management of 203
- nature of 196 200
- perception of 197
- effects of opiates on 214
- peripheral origin of 198
- postoperative treatment of 235
- posttraumatic treatment of 235
- process concepts of 197
- reaction to 197
- relief addictive analgesics for design for use of 237 238
- alcohol for 239
- choice of drugs for 196 242
- mechanism of drug action of 208
- new narcotics for rational basis for 238
- nonanalgesic drugs for 238 241
- placebos for 240 241
- sedatives and hypnotics for 238 241
- thoracic management of 205
- aspects of principles of control 207 206
- visceral treatment of 205 236
- Paras throat 720
- Pamph for bronchospasm 527
- Pancreatic deficiency therapy 376
- extracts as digestants 377
- secretion tests of 803 804
- Pancreatic acute antacid for 357
- therapy by anticholinergic drugs 353
- Panhypopituitarism 561
- Pantopon as antitussive agent 499
- pharmacology of 419
- poisoning treatment (under Narcotics) 789
- Pantothenic acid 116
- Papaverine as arterial dilator 431
- as asodilator 485
- Paralobarbital as acid esters as local anesthetic 256 257
- Paralobarbital
  - treatment of tuberculosis 156
- Paralobarbital as analgesic 216
- Paralobarbital for epilepsy 300 301

## Paras—Cont'd

- Parasitism, intestinal, choice of drugs for 379 390
- rational basis for drug therapy of 390
- Parasympathetic system drugs acting on table 701
- Parasympatholytic drugs for motion sickness 316
- Parathion poisoning treatment (under Cholinergic compounds) 786
- Parathormone 572 573
- Parathormone
  - clinical applications 253
- Pareidolic diagnosis of glaucoma 810 811
- Pareidolic for diarrhea 374
- Parenteral administration of drugs to children 50
- of fluids 81
- Parkinsonism, Dextroamphetamine and pargol for 187
- treatment 307
- Pathology as anticholinergic agent dosage 355
- Patient as appropriate subject for drug evaluation 33
- Patient's experience in evaluation of drug 34
- Patterns of drug action 25 29
- Pavlovian as arterial dilator 433
- Pediatric doses calculation of 57
- Pedicular gamma benzene hexachloride ointment for 751
- Peeling agents 751 752
- Pellagra treatment 113
- Pemphigus treatment 732 733
- Pencil as agent of choice in certain diseases 143
- allergic and other reactions to 160
- aqueous soluble 145
- forms of 143 145
- G 143
- procaine 144
- oral 144
- pharmacologic action as antimicrobial agent 174
- prevention of syphilis 170
- for pyoderma 766
- salts solubility of 45
- side reactions 175
- and streptomycin in intraocular infections 714
- therapy of syphilis 177 173
- in urinary infections acidity of urine and 691
- in urology 694
- loss of effectiveness 692
- V 144
- in urology 694
- Penobarbital as an convulsant in poisoning 782
- for cardiac arrhythmias 414



- Posttraumatic pain, management of, 235  
 Postvagotomy and postgastrectomy diarrhea, therapy, 372  
 Potash, caustic, poisoning by, treatment (*under* Alkali), 786  
 Potassium acetate and citrate as urinary alkalinizers, 692  
   replacement therapy, 75  
   bromate and chlorate poisoning, treatment (*under* Methemoglobinemic poisoning), 789  
   chloride for replacement therapy, 74  
   in treatment of thallium poisoning, 791  
   depletion therapy for, 74  
   for digitalis induced arrhythmias, 420  
   excess, relation to volume changes, 63  
   therapy for control of, 82  
   extracellular analysis of, 61  
   hydroxide poisoning, treatment (*under* Alkali), 786  
   iodide in management of cough, 507  
   permanganate in alkaloid poisoning, 786  
   baths for pyodermas, 765  
   tablets for eczema, 737  
   phosphate for replacement therapy, 75  
   replacement, oral, 75  
   in therapy of asthma, 544  
 Potency as basis of choice of drug, 30  
   of drug, meaning of, 26  
 Povon 385  
 Povidone iodine in preoperative preparation of patient's skin, 138  
 Pragmatar for seborrhea, 767  
 Prantal in allergic disease, 527  
 Precordial pain, hypertensive, 442  
 Prednisolone in allergic disease, 541, 542  
   in eczema preparations, 743  
   for eye infections, 712, 713  
   for pemphigus, 733  
   for rheumatoid arthritis, 597  
   untoward effects, 595, 596  
 Prednisone in acute leukemia in children, 606  
   in older adults, 612  
   in young adults, 611  
   in allergic disease, 541, 542  
   for arthritis, 591  
   in autoimmune hemolytic anemia, 640, 641  
   in carcinoma of breast, 622  
   of ovary, 624  
   in chronic lymphocytic leukemia, 616  
   myelocytic leukemia, 615  
   for exophthalmos, 570  
   for eye infections, 712, 713  
   in hematologic disorders, 634  
   in hemolytic anemia complicating Hodgkin's disease, 618  
   in hypoplastic anemia or bone marrow failure, 640  
   in idiopathic thrombocytopenic purpura, 642, 643  
   in intractable bronchospasm, 544  
   in lymphosarcoma, 619  
   in multiple myeloma, 620  
   in pemphigus, 733  
   in prostate cancer, 623  
   in rheumatic fever, 599  
   for rheumatoid arthritis, 597  
   for thyroiditis, 572  
 Prednisone—Cont'd  
   untoward effects, 595, 596  
   in unusual connective tissue disorders, 600  
   in vascular purpura, 643  
 Pre-eclampsia and eclampsia, 674  
   management, 675, 676  
 Pregnancy, anemia of, management, 665  
   anesthesia in, 669, 670  
   bleeding in, and prevention of abortion, 678  
   edema of, diuresis of, 89  
   nausea and vomiting of, antiemetic agents for, 336, 337  
   Dexedrine and chlorpromazine combination in management of, 185  
   normal, drug administration during, 663, 674  
   principles of, 663  
   preventive medicine in, 663  
   response to drugs during, 662  
   specific difficulties, 664, 667  
   syphilis in, penicillin therapy, 173  
   toxemias of, 674, 677  
 Pregnant mare's serum for male infertility, 587  
 Preludin for obesity, 347  
   as stimulant in obesity, 181  
 Premature contractions, auricular, clinical considerations, 408  
   ventricular, 411  
 Premenstrual molimen, therapy, 583  
   tension, Dexedrine in treatment of, 185  
   diuresis for, 90  
 Prenatal care, 663  
 Prescriptions in dermatology, importance of, 728  
 Pressure, intraocular (*see* Glaucoma)  
 Principles of choice of drugs, 23, 39  
   in evaluation of drugs, 31, 36  
 Priodax in oral cholecystography, 806  
 for tapeworm infection in children, 389  
 Prisolone, actions of, 484  
   in diagnosis of glaucoma, 811  
   as miotic, 703  
   in peripheral vascular disease, administration, 491  
 Privine as mydriatic, 705  
   as vasoconstrictor in otolaryngology, 724  
 Pro-Banthine as anticholinergic agent, dosage, 355  
   for hyperhidrosis, 756  
 Probenecid in gout and gouty arthritis, 600  
   for gouty arthritis, 591, 593, 594  
   toxicity, 594  
   as uricosuric agent, 590, 594  
 Procaine amide in cardiac arrhythmias, 419  
   in glaucoma, 707  
   intravenous, for management of pain, 242  
   for local infiltration anesthesia, 252, 256, 257  
   for nerve blocks, 258, 259  
 penicillin G, 144  
   in aluminum monostearate, 145  
   as retrobulbar anesthetic, 706  
 Prochlorperazine as antiemetic, 327  
   effects of, 267  
   for nausea and vomiting of pregnancy, 337  
   side effects, 327  
   for strongyloidiasis, 386

Cont'd  
 n management of chronic pain, 237  
 scription for hypertension, 444  
 saline solution for eczema 736  
 ine for glaucoma, 703  
 c, 702  
 one for hemorrhage from lack of  
 vitamin K, 658  
 for barbiturate depression, 781  
 lary stimulant 193 194  
 romoting agents 756 757  
 e for glaucoma 703  
 c 702  
 g, treatment (under Cholinergic  
 compounds), 786  
 ary retention 690  
 as analgesic 224  
 . . . . . 204  
 . . . . .  
 dosage 189  
 e as local anesthetic, 256  
 l infiltration 257  
 e blocks, 258, 259, 260  
 r anesthetic 706  
 in diagnosis of pheochromocytoma  
 801  
 as central stimulant, dosage 189  
 agement of behavioral problems in  
 children 181  
 riatric problems, 182  
 ment of neurologic disorders 182  
 n intractable bronchospasm 514  
 labor 672 673  
 therapy of diabetes insipidus 565  
 566  
 urine concentration test 810  
 defects posterior 565 566  
 ances anterior 562 565  
 m, therapy, 563  
 s posterior in obstetrics 672  
 556-566  
 adrenal glands interrelationship, 575  
 of, 556  
 ions of 556  
 thyroid gland physiologic interrela-  
 tionships 566  
 nes anterior 556 561  
 als in obstetrics, 672 673  
 rosea, agents used in 757  
 benactyzine and hydroxyzine as  
 270  
 of 38 39  
 y of antitussive drugs compared with,  
 512, 513  
 ef of pain, mode of action and use,  
 240 241  
 study of anorexians, 314  
 for insomnia 291  
 administration in hemophilia, 616  
 ood substitutes rational basis for 83  
 lytes, gravimetric concentrations of  
 converted to combining equiva-  
 lents 80  
 l electrolyte pattern of, 79  
 lacement fluid, 68  
 utes, 68  
 planing" of face for acne scars, 731

Platelet count effect of prednisone on, 642,  
 613  
 . . . . .  
 . . . . .  
 Podophyllum resin as cauterizing agent 735  
 Poison artificial removal from body 791 792  
 container importance of obtaining 775 776  
 elimination by purging, 363  
 removal of, 777, 780  
 Poisoning acidosis due to, treatment 784  
 airway important to treatment, 783  
 antidotes, 785 791  
 approach to management of, 774  
 barbiturate, treatment, 781 782  
 convulsions due to, treatment, 782  
 by depressants treatment 781 782  
 diagnosis clinical 776  
 laboratory 777  
 obtaining container, 775  
 searching locale 776  
 differential diagnosis, clinical signs in,  
 table 778 779  
 emergency kit for treatment 792  
 gastric lavage in diagnosis 776  
 hemodialysis in treatment, 791  
 narcotic, acute, 228 230  
 treatment 782, 789, 790  
 renal failure due to therapy 785  
 replacement transfusion in treatment 791  
 792  
 respiratory problems in, 782 783  
 salicylate, in children 209  
 shock in treatment 783 784  
 treatment, choice of drugs for, 774 794  
 emesis 780  
 removal of poison from body, 777, 780  
 specific measures, 785 791  
 supportive measures, 781 785  
 Polar bear liver vitamin A in, 119  
 Polycythemia, production of, 64  
 vera, clinical considerations, 631  
 therapy, 644 645  
 Polyfunctional alkylating agents (*see* Alkylat-  
 ing agents)  
 Polyglucin blood or plasma substitute 70  
 Polymyxin B, clinical use and toxicity, 152  
 side effects 162  
 in urology, 696, 697  
 Polyvinylpyrrolidone (PVP) as plasma sub-  
 stitute 70  
 and sodium acetate in hysterosalpingog-  
 raphy 807  
 Pontocaine (*see* Tetracaine)  
 . . . . .  
 . . . . .  
 Postmenopausal vaginitis symptoms and  
 treatment 687  
 Postoperative medication in otolaryngology  
 724  
 pain, management of, 235  
 vomiting, causes of and antiemetic agents  
 for, 331-336  
 Postpartum breast engorgement, hormonal  
 therapy, 584

- Quinidine for cardiac arrhythmias, 408, 409,  
410, 411, 418-419  
hypersensitivity test, 798  
preparations, 418  
Quinine as muscle relaxant, 308  
Quinolines combined with hydrocortisone for  
eczema, 745  
as local anesthetics, 257  
in lupus erythematosus, 753  
Quinolor Ointment, Compound, for acne, 730

## R

- Radiation, dermatologic, for eczema, 736  
in management of cough, 510  
sickness treated by antiemetic agents, 333  
therapy of acromegaly, 562  
Radioactive gold for pleural effusion and  
ascites in cancer, 626  
iodine with antithyroid therapy in surgical  
preparation of thyrotoxic patient,  
571  
in carcinoma of thyroid, 625  
therapy of hyperthyroidism, 569  
isotopes in differential diagnosis of intra-  
ocular malignancy, 811  
phosphorus in chronic myelocytic leu-  
kemia, 615  
Radiopaque iodides in angiocardiology,  
797  
Radio phosphate in hematologic disorders,  
635  
in polycythemia vera, 611, 615  
Rat bite fever, penicillin or tetracycline for,  
174  
Rate of absorption of drug, 27  
Rauwolfia materials, 263-266  
preparations, complications caused by, 282  
in peripheral vascular disease, 490  
as tranquilizers, discussion of, 273  
serpentina, as tranquilizer, 262  
in treatment of hypertension, 446  
Raynaud's disease, etiology and treatment,  
486-487  
Reactions, untoward, of drugs, categories of,  
26  
Rectal administration of digitalis, 398  
of drugs to children, 50  
Reduction of interstitial or intracellular  
volume agents for, 72-73  
Reflex sympathetic dystrophies, management  
of pain of, 203  
Refractory edema of heart disease, diuretics  
for, 87  
Regional analgesic block, 242  
anesthesia, 253  
chemotherapy in cancer, 626  
Regitine, actions of, 484  
in diagnosis of pheochromocytoma, 574,  
799, 800, 801  
Relapsing fever, tetracycline for, 174  
Relaxants, skeletal muscle, choice of, 306 310  
uterine, 673 674  
Relaxin in obstetrics, 674  
Releasein in obstetrics, 674  
Renal arteriography or aortography, 809  
complications of hypertension, 442  
effects of ganglionic blocking agents, 451  
failure due to poisoning, therapy, 785

## Renal—Cont'd

- function, improvement due to vasopressor  
agents, 466, 467, 470  
tests, 810  
hemodynamic responses to vasopressor  
agents, 463-467, 516  
hypertension 443  
parenchyma, nephrography, 808  
response to norepinephrine, 472  
and vascular diseases, hypertensive, in  
pregnancy, 675  
Renografin as contrast medium in excretory  
pyelography, 808  
Repigmentation, agents for, 756, 757  
Replacement therapy, fluid, 65  
transfusion in treatment of poisoning, 791  
792  
Rescinnamine, 263  
Reserpine, absorption of, 263  
complications caused by, 282  
dosage, 265, 283  
effects of, 264  
for exophthalmos, 570  
mental depression from, 265  
mode of action, 263  
parenteral, in treatment of hypertension,  
446  
uses of, 266  
Resins, exchange, discussion of, 96-98  
for anesthetic adjuvants 89  
Respiration, artificial, 194  
effect of morphine on, 214  
Respiratory acidosis, therapy, 67  
alkalosis, therapy, 67  
disease, etiology, 493  
disturbances, anginal pain in, 425  
function of blood, alterations in, 64  
problems in poisoning, 782-783  
stimulants clinical applications of, 192  
system allergic disorders of, 517  
tract fluid, effect of antitussives on, 497,  
506  
Retention enemas, 368  
of urine, nonobstructive, cholinergic drugs  
in 690  
Retrobulbar anesthesia in ophthalmology, 706  
Retrograde urography, 809  
Reversal of pain mechanism, analgesia by,  
241 242  
Rheumatic disorders, salicylates in, 590  
steroids in, 591  
actions, 595  
fever, adrenal steroids and ACTH for, 591,  
592  
corticotropin in, design for use of, 599  
etiology, 590  
new drugs for, rational basis for, 602  
salicylates in, design for use of, 599  
pharmacologic action, 593  
Rheumatoid arthritis (see Arthritis, rheu-  
matoid)  
Rhinitis, allergic, acute, corticosteroids for,  
720  
pathogenesis, 517, 519  
summary of therapy, 546  
treatment, 718

- Progestrone for amenorrhea 581  
n glaucoma 707  
for secondary amenorrhoea 682  
and testosterone for excess uterine bleeding 582  
for therapy of abortion on 678 679  
Progesterone oral as contraceptive 688  
Progestogens production of 575  
Promacetin tablets n dermatitis herpetiformis 734  
Promazine effects of 267  
for pain relief 240  
Promethazine as an emetic 376  
in eye infections 714  
for motion sickness dosage 30  
n obstetrics 669  
for pain relief 240  
as tranquilizer 262  
for vertigo 318  
Propofol for cardiac arrhythmias 407 408  
409 410 411 419  
Propafenone for obesity 347  
Propanolol as anticholinergic agent dosage 355  
for urinary frequency in elderly women 691  
Proparacaine as ocular anesthetic 706  
Prophylaxis of bacterial infections antibiotic for 170 171  
of intraocular infection 710  
and therapy of intraocular infections antibiotic n 714 715  
Propionyl in urology 695  
Propylhexedrine nasal 725  
Propylthiouracil for anginal syndrome 439  
for hyperthyroidism 570  
Prostate cancer clinical considerations 629  
673  
Prostagnin as anti-inflammatory 70  
for postoperative abdominal distention 375  
376  
Protamine zinc insulin 559 553  
Protein solutions as plasma substitutes 69  
Proteolytic enzymes n bronchial drainage 333  
Proctus vulgaris urologic infection by treatment 697  
Prothrombin deficiency vitamin K n 646  
Provera for amenorrhoea 581  
for giantism n female 564  
Pruritus causes 757  
systemic management 758 760  
treatment 757 760  
Prussic acid poisoning treatment (under Cyanide) 787  
Pseudoephedrine vascular constrictors n 643  
  
Psittacosis antibiotic therapy of 171  
Psoriasis local external treatment 760 61  
64  
systemic treatment 760  
triamecinolone for 591  
Psychiatric disorders sedatives and tranquilizers for choice of 273 786
- Psychiatric—Cont'd  
interventions stimulants as adjunct in 181  
use of barbiturates 285  
of sedatives 284 786  
Psychic complications of reserpine 289  
of Thorazine 781  
forces resolutions of clinical evaluation of drugs 31  
urinary retention therapy 690  
Psychogenic cough 513  
Psychologic reaction to physiologic states stimulants management of 184 185  
Psychoneuroses tranquilizers for 778  
Psychoses functional stimulants n treatment of 179  
n olutional Thorazine for 75  
Psychosomatic conditions chlorpromazine for 79  
headache management of 704  
  
edema n poisoning treatment of 783  
Purgative intestinal design for use of cathartics n 369 370  
ndations for 363  
prior to abdominal x rays 369  
Purine analogues n acute leukemia n children 605 606  
dosage 610  
n chronic myelocytic leukemia 614  
Purmethol in acute leukemia n children 606  
dosage 610  
n chronic myelocytic leukemia 614  
Purpura drop the thrombocytopenic clinical considerations 631  
therapy 647 643  
ascular corticosteroids in 643  
Pyelitis cystitis and during pregnancy 664  
Pyelography excretory contrast media for 808  
Pyelonephritis with hypertension therapy 443  
Pyeloureteritis during pregnancy management of 665  
Pyoderms agents used n 764 766  
Pyrazinamide n treatment of tuberculosis 157  
Pyrexia for arthritis 589 59  
  
therapy 114  
Pyrimethamine for urethritis 715  
Pyrimidine-dione diuretics 99  
Pyrimidine fluorinated n cancer 67  
Pyridines for enterobiasis 381 385  
PZI insulin 559 553
- Q  
Q fever untreated course of 166  
Quinine for giardiasis, 382  
hydrochloride tablets for chronic discoid lupus erythematosus 753  
for tapeworm infection 387

- Sensitivity of children to drugs, 48  
of method in clinical evaluation of drugs, 35
- Seromycin, side effects, 162
- Seryl, in acute leukemia in children, 606  
dosage, 611
- Sex steroids, 575
- Sexual precocity, 580
- Shampoos for seborrheic dermatitis, 766
- Sheehan's syndrome, therapy, 563
- Shock, dynamics of, 59  
hypotension and, choice of vasoconstrictor drugs for, 458-479  
due to severe infections, vasopressor agents in, 476  
normovolemic, renal hemodynamic response to norepinephrine in, 468, 469  
in poisoning, treatment of, 783-784  
vasopressor agents for, 458
- Sigamycin for staphylococcal infections, 152
- Sigmol enema, 367
- Silver nitrate for nosebleed, 723  
for stomatitis, 770
- Sinus arrhythmia, 408  
tachycardia, clinical considerations, 409
- Sinusitis, therapy, 718
- Site of absorption of drug, 28
- Sitosterol ineffective in atherosclerosis, 551
- Skeletal muscle relaxants, 241  
choice of, 306-310
- Skin diseases, choice of drugs for, 726-773  
disinfection, 130-131  
dry, emollients and demulcents for, 746-747  
glabrous, infections by dermatophytes and *Candida*, 747-750  
hyperpigmented, bleaching of, 731  
infections, pyogenic, agents used in, 764-766  
of patient, preoperative disinfection of, 135-139  
in psoriasis, therapy, 760-764  
reactions to sedatives, 289  
tests in avoidance of reactions to mercurial diuretics, 94  
uniqueness of, 726
- Skiodon as contrast medium in retrograde urography, 809
- Sleep disorder, nature of, 287
- Sleeping medications, reactions to, 289
- Smoker's cough, 513
- Smoking contraindicated in laryngitis, 719
- Smooth muscle relaxants, 241
- Soap as antiseptic, 132  
in preoperative preparation of patient's skin, 136  
sensitivity, agents used in, 769
- Soaps, antiseptic, for superficial pyoderma, 765  
germicidal, for control of hyperhidrosis, 755
- Soapsuds enema, 367
- Sodium acetate and polyvinylpyrrolidone in hysterosalpingography, 807  
acid phosphate in prevention of urinary stones, 691
- Sodium—Cont'd  
Amytal for psychoses, 179  
bicarbonate for acidosis, 77  
as alkalinizing solution, 784  
for indigestion, 357, 358  
as urinary alkalinizer, 692
- bromate and chlorate poisoning, treatment (*under* Methemoglobinemic poisoning), 789
- chloride, dextrose and, as replacement fluid, 72  
solutions for blood volume replacement, 70
- citrate as urinary alkalinizer, 692
- dehydrocholate to determine circulation time, 799
- depletion, therapy for, 74
- excess, and chloride excess, relation to volume changes, 63  
therapy for, 82
- extracellular, analysis of, 61
- fluorescein in diagnosis of eye disorders, 810, 811
- fluoride poisoning, treatment (*under* Fluoride), 788
- fluoroacetate poisoning, treatment (*under* Fluoroacetate), 788
- hexametaphosphate poisoning, treatment (*under* Phosphates, polymers), 790
- hydroxide poisoning, treatment (*under* Alkali), 786
- iodide as contrast medium in cystography, 809
- lactate for acidosis, 77  
as alkalinizing solution, 784  
for cardiac arrhythmias, 420  
as urinary alkalinizer, 692
- levothyroxine, 568
- morrhuate for varicosities, 660
- nitrite, 430  
poisoning, treatment (*under* Methemoglobinemic poisoning), 789  
in treatment of cyanide poisoning, 787  
phosphate as purgative, 366  
psyllate for varicosities, 660
- Solganal for rheumatoid arthritis, 592
- Solid and liquid dosage forms, physiologic availability of, 42
- Solubility of drugs, importance of, 45
- Solu-Cortef in acute leukemia in children, 607
- Solutions and ointments in ophthalmology, methods of application, 700
- Soma, 269
- Somatotropic hormone, 556
- Sopronol for dermatophytosis of feet, 748
- Southey tubes for refractory edema of heart disease, 88

# INDEX

- Rhythm, disturbances in (*see* Cardiac arrhythmias)
- Riasol for psoriasis 763
- Riboflavin deficiency treatment 112
- Ricinoleic acid gel for moniliasis 685
- Rickets treatment by vitamin D 110
- Rickettsial infections, antibiotics in therapy of 172 176
- choice of drugs for 164
- Right sided heart failure diuretics for 86
- Rigidity muscle muscle relaxants for 307
- Ringers solution for expansion of interstitial fluid volume 71
- Ringings in ear therapy 724
- Ristocetin use of 153
- Ritalin dosage 189
- Robitussin as antitussive agent 508
- Rohibon as oral diuretic 99
- Romilar as antitussive agent 502
- Rose bengal in diagnosis of eye disorders 810 811
- in test of excretory function of liver 805
- Rubber gloves hand disinfection and 132
- Russell viper venom for clot formation 660
- Rutin to promote coagulation 659
- S
- Saddle block anesthesia in obstetrics 670
- Salicylates action of 591 591
- for arthritis clinical application 589 590
- design for use of 596
- pharmacologic considerations 592 593
- for fever 551
- in gout and gouty arthritis 601
- intoxication treatment 781
- in pain control 208 209 210
- in rheumatic fever design for use of 599
- toxic reactions to 209
- in urine and blood tests in diagnosis of poisoning 777
- Salicylic acid and benzoic acid tincture of for fungous infections 748
- in keratolytic preparations 757
- for psoriasis of scalp 761 762
- Saline cathartics 366
- solutions isotonic as replacement fluid 1
- for sodium depletion 74
- Salt as emetic in poisoning 780
- excretion agents for increase of 73
- removal from gastrointestinal tract 73
- replacement oral 74
- restriction of urea by 91
- Salt losing syndrome in newborn infant 579
- Salts choice of forms of 44
- inorganic as gastric antacids 358 359
- Salundek ointment for fungous infections 748 749
- Salvagen with theophylline in glaucoma 707
- Sarcoidosis agents used in 766
- Sarabes gamma benzene hexachloride ointment for 751
- Salp fungous infections of griseofulvin for 747 748
- Sarby mycotic infections of therapy 749
- Schistosomiasis treatment 389
- Schizophrenia, acute, treatment 275
- chronic treatment, 276
- stimulants in treatment 179
- tranquilizers for 275 278
- treatment in hospital 276
- Scillaren 401
- B 401
- Sclerosing agents for varicosities 660
- Scopolamine for motion sickness 316
- dosage 320
- as mydriatic 704
- in obstetrical analgesia 669
- for relief of pain 240
- Scrubs preoperative with alcohol 131
- with soap, 132
- Scurvy ascorbic acid treatment 117
- Seasickness drugs for 318
- incidence of 314
- Sebizon for seborrhea of scalp 767
- Seborrhea and seborrheic dermatitis agents for 766 769
- Sebulex as shampoo for seborrhea of scalp, 767
- Secobarbital (Seconal) and chlorpromazine antiemetic effect compared, 332
- for pain relief 239
- for severe apprehension in urography 808
- sodium for insomnia, 290 291
- Secondary anesthesia (*see* Anesthesia second ary)
- Secretin in test of pancreatic secretion 801
- Secretions bronchial removal, 531 534
- respiratory expulsion by cough 497
- Sedation (*see* also Amnesia)
- central for cardiac arrhythmias 414
- for obesity 319
- as side effect of antihistamine therapy 535
- systemic in labor 673
- in therapy of bronchial asthma 536 538
- of hypertension 445
- for vertigo 370
- Sedatives barbiturates as 270 271
- dangers of 289
- depression due to overdosage of treatment 187 183
- in eclampsia 676
- and hypnotics for relief of pain 238 241
- for pruritus reasons for failure of 759
- for psychiatric conditions 281 286
- and tranquilizers in general medical practice choice of 262 272
- for psychiatric disorders, choice of 273 286
- for urticaria 772
- Seizures epileptic control by drugs 299 301
- Selection of best drug 36-38
- of drugs for children factors in 47 57
- Selenium sulfide suspension as shampoo for seborrhea of scalp 767
- Selsun suspension as shampoo for seborrhea of scalp 767
- Semilente insulin 552
- Serle and arteriosclerotic states tranquilizers for 279
- vaginitis symptoms and treatment 687
- Senna compound powder, 367
- Sensitivities (*see* Allergy)

## Sulfonamides—Cont'd

- in dermatitis herpetiformis, 734
- in ophthalmology, penetration of, 708
- in otitis media, 717
- in otolaryngology, 719
- in prophylaxis of intraocular infection, table, 710
- side effects, 174, 693
- in urology, 693
- for virus infections, 171, 172
- Sulfones in treatment of tuberculosis, 157
- Sulfonyleureas for diabetes, 553
- Sulfoxone sodium tablets in dermatitis herpetiformis, 734
- Sulfur and resorcinol for acne, 729
- Sulfur-containing regimen for face and trunk in seborrheic dermatitis, 767
- for scalp in seborrheic dermatitis, 766
- Sul-Spanion in urology, 693
- Sun protective measures ("sun screens"), 771
- Superinfection, hazard of antibacterial therapy, 158
- Supraventricular rhythms, clinical considerations, 408
- Surgical anesthesia, 244, 246, 251
- hypotension, treatment of, 476
- Sweating as cause of ion defects, 62
- excessive, agents used for, 751-756
- Sympathetic blockade in therapy of hypertension, 450-453
- nervous system, depression of, by drugs, 483-484
- Sympathicotonia, therapy of, 487
- Sympatholytic drugs for motion sickness, 317
- Sympathomimetic agents for allergic disorders, 522-526
- in ophthalmology, clinical value, 705
- amines as anorexants, 345-348
- as central stimulants, 186
- dosage, 188
- in heart disease, 405
- as vasomotor stimulants, 193
- Symptomatic management of allergic disorders with pharmacologic agents, 522-545
- Synthroid, 568
- Syphilis, prophylaxis by penicillin, 170
- treatment by penicillin, 172-173
- Syrosingopine, 263, 265
- Systemic therapy, place in dermatology, 727
- Systox poisoning, treatment (*under* Cholinergic compounds), 786

## T

- Tablets and capsules, oral absorption of, 42
- Tace for ovarian failure, 581
- Tachycardia, auricular, clinical considerations, 409
- nodal, 409
- sinus, clinical considerations, 409
- ventricular, clinical considerations, 411
- Tapazole in carcinoma of thyroid, 625
- for hyperthyroidism, 570
- Tapeworm infection, treatment, 387-389
- Tap-water enema, 367
- Tar applications for psoriasis, 762-763
- combined with hydrocortisone and/or quinolines for seborrhea, 768

## Tar—Cont'd

- preparations combined with hydrocortisone for eczema, 745
- for eczema, 738, 739
- shampoos in psoriasis of scalp, 761
- Tarbois Cream for eczema, 739
- Tartar emetic for schistosomiasis, 389
- Telepaque in oral cholecystography, 806
- TEM in carcinoma of ovary, 624
- in chronic lymphocytic leukemia, 615
- myelocytic leukemia, 614
- in Hodgkin's disease, 618
- Temarl for pruritus, 759
- Temperature graph in prevention of conception, 687
- Temposil for alcoholism, 551
- Ten eighty, poisoning by, treatment (*under* Fluoracetate), 788
- Tension headache, stimulants in treatment of, 183
- Tenuate, 348
- Tepanil, 348
- Testosterone for breast engorgement post partum, 584
- for male infertility, 587
- and progesterone for excessive uterine bleeding, 582
- propionate for carcinoma of breast, 621
- for testicular failure, 585
- Tests of concentrating power of gall bladder, 805-806
- diagnostic, dangers, 795-796
- in heart disease, 796-799
- digitalis tolerance, 401, 798
- drug sensitivity, in heart disease, 798-799
- of excretory function of liver, 804-805
- renal function, 810
- stress, ergonovine, in heart disease, 797-798
- Tetracaine as local anesthetic, 257
- for nerve blocks, 258-259, 260
- as ocular anesthetic, 706
- for topical anesthesia of larynx, 722, 723
- of nose and throat, 722
- Tetrachloroethylene for hookworm infection, 383
- Tetracycline for acne, 730
- administration and clinical uses, 146-147
- in agranulocytosis, 642
- allergic and other reactions to, 160
- for amebic dysentery, 380
- in intraocular infections, 715
- pharmacologic considerations, 175
- solubility, 45
- toxic effects, 175
- for trichomoniasis, 382
- in urology, 695, 697
- for viral and rickettsial infections, 171, 172, 176

- Sparine for manic depressive psychoses 274  
for pain relief 240
- Spasm anticholinergic drugs in therapy of 353  
of coronary artery nitrites in relief of pain of 424  
muscle relief of 307  
use of relaxants for 308
- Spastic disorders Dexedrine and pipradrol in treatment of 182
- Spastic muscle relaxants for relief of 307
- Spermatogenesis 560  
androgens for 587
- Spermicidal preparations in prevention of concepton 688
- Spinal analgesia clinical applications 253  
vasopressor agents with 477
- Sprochetal infections choice of drugs for 164
- Spramycin 153  
side effects 162
- Splenectomy in idiopathic thrombocytopenic purpura 612  
splinting muscle relief of 307
- Spontin use of 153
- Spray throat for laryngitis 719
- Sprays nose and throat use of 720
- Sprue 372
- Sputum types of 497
- Squill 404
- Starch bath for eczema 737  
solution in iodine poisoning 789
- Statistical significance of data in drug evaluation 35
- Status asthmaticus corticosteroids for 721
- Steam inhalation for laryngitis 719
- Stenedol 587
- Steroids for acromegaly 567  
adrenal (see Adrenal steroids)  
aerosolized in allergic disease 541  
in allergic disease 540 512  
for amenorrhea 581  
anabolic 587  
for breast engorgement post partum 584  
for dysmenorrhea 680  
for eye infections 71 713  
for gigantism 561 565  
for hypogonadism with testicular failure 585  
local use in eye untoward effects 713  
in ophthalmology 708  
oral in pemphigus 732 733  
see 575
- Solubility problems of 45
- Topical for dermatologic therapy 739 745  
untoward effects 517 543  
or uterine bleeding 587
- Trojan cream for seborrhea 768
- Treatment or cream for eczema 739
- Testol for dysmenorrhea 583  
ovary failure 581  
prostate cancer 673
- Ulinic expectorants 508
- Ulinic as adjunct in psychiatric interview 184
- Ulinic nervous system for vertigo, 317
- Stimulants—Cont d  
clinical applications 178 185  
for emotional states 181 185  
gastrointestinal choice of 375 378  
design for use of 377  
new rational basis for 377  
of mental and physical activity choice 178 190  
new rational basis for development of 191  
pharmacologic considerations 185  
respiratory 197  
vasomotor 197  
to vital medullary centers choice of 197 195
- Stimulation of cardiac automaticity 415  
of conduct on 416
- Stomatitis agents used in 769 770
- Stones urinary sodium acid phosphate in prevention of 691
- Strabismus myotics in 704
- Streptodornase and streptokinase for debridement 661
- Streptokinase production and use of 660-661
- Streptomycin administration clinical indications and dosage 145 146  
allergic and other reactions to 160  
and penicillin in intraocular infections 714  
in urology 691 697
- Stress test ergonovine in heart disease 797 798
- Stronglydosis treatment 385
- Strophanthin 403
- Structure activity relationships of drugs 25
- Styphen poisoning treatment 790
- Styphen for clot formation 660
- Subarachnoid block agents for relative merits of 259  
clinical application 253 254
- Subconjunctival injections 700
- Subcutaneous route of administration of narcotics 234
- Suicide attempts with barbiturates 290
- Sulfadiazine use of 155
- Sulfadimethoxine in urology 693
- Sulfathiazole use of 155
- Sulfamerazine use of 155
- Sulfamethoxypyridazine clinical use 155  
in urology 693
- Sulfapyridine for dermatitis herpetiformis 734  
use of 155
- Sulfonpyrazole caution in use of 601  
side effects 591  
as uricosuric agent 591
- Sulfisomidine in urology 693
- Sulfisoxazole for urinary tract infections 155  
in pregnancy 665
- Sulfobromophthalein in test of excretory function of liver 805
- Sulfonamides allergic and other reactions to 159  
antimicrobial action of 174  
choice of 155  
clinical use 154





- Tetraethylammonium chloride for hyperten-  
 sion 448  
 in diagnosis of pheochromocytoma 800  
 Tetrahydrozoline in allergic disease 576  
 Thallium poisoning treatment 791  
 Theophylline in bronchial asthma 58531  
 new salts of for allergic disorders 530  
 Therapeutic ratios as indicator of drug safety  
 and utility 29  
 Thelvetin 403  
 Thiamine deficiency treatment of 112  
 Thiazide derivatives diuretic action of 73  
 Thimerosal in ophthalmology 709  
 Thio-barbiturates for amnesia 249  
 for analgesia 249  
 for secondary anesthesia 250  
 for surgical anesthesia 248  
 Thio-phenol in glaucoma 707  
 sodium for amnesia 251  
 as anticonvulsant poisoning 787  
 for surgical anesthesia 248  
 Thiorazepam as antiemetic agent 318  
 effects of 267  
 Thionidazepam as tranquilizer 268  
 Thiosemicarbazone 157  
 Thioracis for analgesic syndrome 43  
 Thioracis as contrast medium in urethro-  
 graphy 810  
 Thoracic pain management of 05  
 Thorax for pharmacologic depression 183  
 Throat (see Chlorpromazine)  
 Throat application of topical anesthetic 72  
 lozenge contraindicated 719  
 spray in laryngitis 719  
 sprays and patients use of 70  
 Thrombin (bovine) for clot formation 659  
 Thromboangiitis obliterans 488  
 Thrombocytopenia clinical considerations 631  
 Thrombocytopenia clinical considerations  
 631  
 corticosteroids in 647 613  
 Thromboplastin formation of 650  
 Thrombotic arterial etiology and treatment  
 486  
 Thyroglobulin 568  
 Thyroid extract therapeutic use 567 568  
 gland 566 577  
 carcinoma of clinical considerations 64  
 decreased activity hypothyroidism 566  
 increased activity (hyperthyroidism)  
 569 571  
 interrelationship with pituitary gland  
 566  
 hormone effect on blood cholesterol 549  
 alterations for obesity 318  
 preparations general considerations and  
 comparative activity 568  
 in therapy of carcinoma of thyroid 65  
 tolerance of child to 569  
 diets substitute and acute treatment  
 571  
 oxycort patient preparation for surgery  
 571  
 oxycort cardiac arrhythmias asso-  
 ciated with, 413  
 oxycort hormone 55  
 effect on thyroid gland 566
- Tigan 330  
 Tinnitus therapy 724  
 Tissue changes in all regulatory mechanisms of  
 extracts as arterial dilators 433  
 reactivity in allergic disease modification  
 with corticosteroids and corti-  
 costeroids 518 513  
 Toluene as antitussive agent 503  
 Toltril as central stimulant, 187 190  
 Tolazoline actions of 181  
 in diagnosis of glaucoma 811  
 as miotic 703  
 in occlusive vascular disease 489  
 in peripheral arterial disease adminis-  
 tration 491  
 Tolbutamide for diabetes 553  
 Tolerance to hypnotics occurrence of 290  
 to narcotics 230  
 to nitrites 477 478  
 Tonsillitis therapy 718  
 Topical application of drugs place in derma-  
 tology 77  
 block agents for relative merits 259  
 in clinical applications 54  
 corticosteroid preparations propriety  
 table 740 744  
 Torsion as antitussive agent 504  
 Toxemia of pregnancy 64 677  
 duration of 89  
 hypertension in 439 443  
 treatment 675 67  
 Toxemia for 450  
 Tox reactions to drugs sensitivity of child  
 to local anesthetics 55  
 states tranquilizers for 280  
 Toxicity a uterine complication of narcotic  
 therapy 77 730  
 of legals 396-39  
 of drugs explanation of 6  
 Trachea larynx and diseases of therapy 719  
 topical anesthesia of 723  
 Trahon sulfonamide and tetracycline for  
 1
- Tranquilizers 73 81  
 agents and dosages 63  
 in allergic disease 518  
 history of 83  
 compared to barbiturates in psychi-  
 atry 85  
 dosage 83  
 duration of treatment 281  
 in glaucoma 07  
 mode of action 79 8  
 for neurotic disorders efficacy of 8  
 for obesity 449  
 popularity of 63  
 in pruritus 59  
 for psychoneuroses 78  
 relation to muscle relaxants, 10  
 to psychotherapy 773  
 for schizophrenia 275 8  
 effects of 77  
 and sedatives in general medical practice  
 choice of 26 7  
 for psychiatric disorders choice of 773  
 side effects 780 8

Vitamins clinical applications of, 109-118  
 deficiencies, difficulties in clinical diagnosis  
     and treatment of, 108  
     study of new drugs for, 127  
     description of, table, 122-124  
     design for use of, 121, 125  
     as drugs principles of use, 125-126  
     fat soluble, 110-112  
     pharmacologic considerations, 118-121  
     place in therapy, 106  
     sources of, 121  
     structure and functions of, 109  
     for vertigo, 318-321  
     water-soluble, 112-118

Vlem-Dome Powder Packets for acne, 730

Vlemminckx' solution for acne, 730

Vlemminckx' solution for acne, 730

Vlemminckx' solution for acne, 730

Vlemminckx' solution for acne, 730

Vlemminckx' solution for acne, 730

Vlemminckx' solution for acne, 730

Vlemminckx' solution for acne, 730

Vlemminckx' solution for acne, 730

Vlemminckx' solution for acne, 730

Vlemminckx' solution for acne, 730

Vlemminckx' solution for acne, 730

Vlemminckx' solution for acne, 730

Vlemminckx' solution for acne, 730

Vlemminckx' solution for acne, 730

Vlemminckx' solution for acne, 730

Vlemminckx' solution for acne, 730

Vlemminckx' solution for acne, 730

Vlemminckx' solution for acne, 730

Vlemminckx' solution for acne, 730

Vlemminckx' solution for acne, 730

Vlemminckx' solution for acne, 730

Vlemminckx' solution for acne, 730

Vlemminckx' solution for acne, 730

Vlemminckx' solution for acne, 730

Vlemminckx' solution for acne, 730

Vlemminckx' solution for acne, 730

Vlemminckx' solution for acne, 730

Vlemminckx' solution for acne, 730

Vlemminckx' solution for acne, 730

Vlemminckx' solution for acne, 730

Vlemminckx' solution for acne, 730

Vlemminckx' solution for acne, 730

Vlemminckx' solution for acne, 730

Vlemminckx' solution for acne, 730

Vlemminckx' solution for acne, 730

Vlemminckx' solution for acne, 730

Vlemminckx' solution for acne, 730

Vlemminckx' solution for acne, 730

Vlemminckx' solution for acne, 730

Vlemminckx' solution for acne, 730

Vlemminckx' solution for acne, 730

Vlemminckx' solution for acne, 730

Vlemminckx' solution for acne, 730

Vlemminckx' solution for acne, 730

as cause of ion defects, 62

due to digitalis, 396, 397

mechanism of, 324

postoperative causes of and antiemetic  
 agents for, 334-336

Vontil as antiemetic agent, 338

Von Willebrand's disease, corticosteroids in,  
 644

## W

Warfarin poisoning, treatment, 787, 791  
 sodium administration and onset of action,  
 655

coumarin derivative of choice, 652, 655

Water diuresis to increase salt excretion, 73  
 as diuretic, 91

Water—Cont'd

loss, dynamics of, 59

in poisoning, replacement of, 785

Water-soluble vitamins, 112-118

Weight reduction in therapy of hypertension,  
 446

Weil's disease, penicillin or tetracycline for,  
 173

Wetting agents for removal of bronchial secre-  
 tions, 533

Whipple's disease, 772

Whitfield's ointment, modified, for fungous  
 infections, 749

..

..

Whole blood as replacement fluid, 68

"Withdrawal syndrome" after steroid therapy,  
 543

Wound healing, delayed, phenoxylbenzamine  
 for, 490

Wounds, antiseptics in, use of, 139

## X

Xanthine derivatives in bronchial asthma,  
 528-531

as coronary artery dilators, 432

for pain relief, 242

diuretics, 92-93

Xylocaine (*see also* Lidocaine)

as local anesthetic, 257

for local infiltration, 258

as retrobulbar anesthetic, 706

## Z

Zactinn, 211

Zephiran as hand disinfectant, 134

in ophthalmology, 699-700

in preoperative preparation of patient's skin,  
 137

Zinc compounds in ophthalmology, 709

gelatin boot for itching of legs, 758

Zoxazolamine as uricosuric drug, 601

- Vagolytic agents in cardiac arrhythmias 420  
 Vagomimetic drugs for supraventricular tachycardia 415  
 Vallestril for ovarian failure 581  
 Valmidol for insomnia 291  
 Vancocin in urology 695  
   use of 153  
 Vancomycin side effects 169  
   in urology 695  
   use of 153  
 Vaponefrin in allergic disease 524  
 Vapors volatile for analgesia 248  
   for surgical anesthesia 246  
 Vascular collapse with hypotension in severe infection treatment of 168  
   defect clinical considerations 639  
   disturbances peripheral choice of vasodilator drugs for 481-492  
   fluid volume agents for expansion of 68-71  
   occlusion acute narcotics for 712  
   purpura corticosteroids 643  
   and renal diseases hypertensive pregnancy 673  
 Vasoconstrictor drugs in allergic disorders 522-531  
   for hypotension and shock choice of 458-479  
   in otolaryngology 724-725  
   site of action of 459  
   mechanisms cerebral and peripheral comparison of 461  
 Vasodilators in allergic disorders relief of 529  
   due to reaction 118  
 Vasodilator drugs clinical considerations and use of 485-490  
   coronary choice of 493-495  
   dangers of 489  
   in occlusive vascular disease 489  
   pharmacologic considerations 482-485  
   in therapy of arterial thrombosis 486  
   of hypertension 446  
   of peripheral vascular disease choice of 481-492  
   uses and limitations of 481  
 Vasomotor stimulants clinical applications of 199  
 Vasopressor agents administration of 478-479  
   cardiac effects of 467-470  
   in cardiogenic shock 475  
   cerebral hemodynamic response to 463-465  
   choice of 458-479  
   for hypotension associated with drug administration 476  
   long acting administration of 478  
   new evaluation of 479  
   pharmacologic considerations 458  
   renal hemodynamic response to 463-465  
   for shock due to poisoning 781  
   with sympathomimetics 477  
 Vasospastic conditions vasodilator drugs in 486-487  
 Vasoxylin renal vasoconstrictor effect of 463  
   as vasoconstrictor 471  
 Venesection in polycythemia vera 644  
 Venous thrombosis and thrombophlebitis treatment 490  
 Ventilation in treatment of narcotic poisoning 229  
 Ventricular arrhythmias digitalis contraindicated 418  
   side effects 450  
 Veratrum mydraticum 705  
 Vertigo causes of 311  
   without deafness 313  
   designed for use of drugs 319-321  
   other than motion sickness treatment of pharmacologic considerations 315  
   rational basis for new drugs for 321-322  
   recurrent aural etiology 312  
   surgery for 319  
   treated by combination of drugs 321  
   types of 312  
 Vexcal spasm, methanthelene for 690  
 Vexprin as antemetic 378  
 Vestibular neurons 313  
   stimulation relation to motion sickness 314  
 Vexadril 748  
 Vexyl ether for analgesia 248  
   for secondary anesthesia 250  
   for surgical anesthesia 247  
 Vexform cream for seborrhea 768  
   ointment or cream combined with hydrocortisone for eczema 715  
   for eczema 739  
 Vexkase as digestant 377  
 Vexomycin side effects 16  
   use of 154  
 Vexus infections antibiotics in prophylaxis of 171  
   in therapy of 171-172-176  
   choice of drugs for 164  
   rational basis for new drugs for 176  
 Vexsamin as coronary artery dilator 439  
 Vexsical pain management 705  
   treatment 736  
 Vexsamin A deficiency treatment of 110  
   pharmacologic and pathologic actions of 119  
 B<sub>6</sub> role in therapy 114  
 B deficiency treatment of 115  
   in diet 126  
   and folate acid relationship in hematopoiesis 639  
   hematologic disorders 634  
   in pernicious anemia 638-639  
 C to promote coagulation 659  
   treatment of scurvy 117  
 D deficiency treatment of 110  
   in toxication 120  
 D for hypoparathyroidism 579  
 E for anginal syndrome 433  
   deficiency treatment of 111  
 K deficiency 658  
   treatment of 111  
   in hematologic disorders 635  
   preparation of choice 658  
   in prothrombin deficiency 646  
 K as antagonist to anticoagulants 651  
 K S (II) 177